Cervicovaginal	O
foetal	B-GENE
fibronectin	I-GENE
in	O
the	O
prediction	O
of	O
preterm	O
labour	O
in	O
a	O
low-risk	O
population	O
.	O

Varicella-zoster	B-GENE
virus	I-GENE
(	I-GENE
VZV	I-GENE
)	I-GENE
glycoprotein	I-GENE
gI	I-GENE
is	O
a	O
type	B-GENE
1	I-GENE
transmembrane	I-GENE
glycoprotein	I-GENE
which	O
is	O
one	O
component	O
of	O
the	O
heterodimeric	O
gE	B-GENE
:	O
gI	B-GENE
Fc	I-GENE
receptor	I-GENE
complex	O
.	O

A	O
segment	O
of	O
mRNA	O
encoding	O
the	O
leader	O
peptide	O
of	O
the	O
CPA1	B-GENE
gene	I-GENE
confers	O
repression	O
by	O
arginine	O
on	O
a	O
heterologous	O
yeast	O
gene	O
transcript	O
.	O

In	O
addition	O
,	O
lexical	O
priming	O
was	O
examined	O
by	O
presenting	O
an	O
identity	O
prime	O
earlier	O
in	O
the	O
text	O
.	O

Lower	O
extremity	O
weight	O
bearing	O
under	O
various	O
standing	O
conditions	O
in	O
independently	O
ambulatory	O
patients	O
with	O
hemiparesis	O
.	O

Insulin-like	B-GENE
growth	I-GENE
factor	I-GENE
1	I-GENE
(	O
IGF-1	B-GENE
)	O
in	O
burn	O
patients	O
.	O

This	O
approach	O
enables	O
the	O
sources	O
of	O
error	O
in	O
the	O
calculation	O
of	O
nutrient	O
utilization	O
to	O
be	O
readily	O
identified	O
,	O
and	O
their	O
effect	O
on	O
precision	O
to	O
be	O
assessed	O
in	O
different	O
nutritional	O
and	O
metabolic	O
states	O
.	O

We	O
identify	O
the	O
"M	O
region"	O
of	O
the	O
muscle-specific	B-GENE
Xenopus	I-GENE
cardiac	I-GENE
actin	I-GENE
gene	I-GENE
promoter	I-GENE
from	O
-282	O
to	O
-348	O
as	O
necessary	O
for	O
the	O
embryonic	O
expression	O
of	O
a	O
cardiac	B-GENE
actin-beta-globin	I-GENE
reporter	I-GENE
gene	I-GENE
injected	O
into	O
fertilized	O
eggs	O
.	O

We	O
found	O
that	O
120	O
bp	O
of	O
the	O
enhancer's	O
transcriptional	O
core	O
becomes	O
DNase	B-GENE
I	I-GENE
hypersensitive	O
early	O
in	O
B-cell	O
development	O
.	O

Biochemical	O
experiments	O
have	O
shown	O
that	O
CopG	B-GENE
co-operatively	O
associates	O
to	O
its	O
target	O
DNA	O
at	O
low	O
protein	O
:	O
DNA	O
ratios	O
,	O
completely	O
protecting	O
four	O
helical	O
turns	O
on	O
the	O
same	O
face	O
of	O
the	O
double	O
helix	O
in	O
both	O
directions	O
from	O
the	O
inverted	O
repeat	O
that	O
constitutes	O
the	O
CopG	B-GENE
primary	O
target	O
.	O

3	O
.	O

Competition	O
needs	O
to	O
be	O
better	O
studied	O
,	O
since	O
in	O
Central	O
America	O
and	O
Caribean	O
islands	O
this	O
kind	O
of	O
study	O
has	O
favored	O
the	O
biological	O
control	O
of	O
planorbid	O
species	O
.	O

Echocardiography	O
revealed	O
right	O
ventricular	O
diastolic	O
collapse	O
(	O
RVDC	O
)	O
without	O
physical	O
signs	O
of	O
cardiac	O
tamponade	O
.	O

Structure	O
and	O
expression	O
of	O
a	O
gene	O
from	O
Arabidopsis	O
thaliana	O
encoding	O
a	O
protein	O
related	O
to	O
SNF1	B-GENE
protein	B-GENE
kinase	I-GENE
.	O

Our	O
results	O
indicate	O
that	O
the	O
retroplasmid	O
reverse	B-GENE
transcriptase	I-GENE
is	O
uniquely	O
adapted	O
to	O
initiate	O
cDNA	O
synthesis	O
by	O
recognizing	O
a	O
3'	O
CCA	O
sequence	O
.	O

TNF-alpha	B-GENE
exposure	O
markedly	O
increased	O
activity	O
of	O
several	O
RNA-binding	O
proteins	O
,	O
especially	O
a	O
novel	O
Mr	O
50	O
,	O
000-55	O
,	O
000	O
RNA-binding	O
protein	O
.	O

The	O
LMW	B-GENE
FGF-2	I-GENE
up-regulated	O
the	O
PKC	B-GENE
epsilon	I-GENE
levels	O
by	O
1	O
.	O
6-fold	O
;	O
by	O
contrast	O
the	O
HMW	B-GENE
isoform	I-GENE
down-regulated	O
the	O
level	O
of	O
this	O
PKC	B-GENE
isotype	I-GENE
by	O
about	O
3-fold	O
and	O
increased	O
the	O
amount	O
of	O
PKC	B-GENE
delta	I-GENE
by	O
1	O
.	O
7-fold	O
.	O

Urine	O
samples	O
collected	O
after	O
the	O
administration	O
of	O
these	O
supplements	O
can	O
test	O
positive	O
.	O

In	O
the	O
ultramarathon	O
runner	O
the	O
testosterone	O
levels	O
sharply	O
rose	O
at	O
the	O
beginning	O
of	O
the	O
training	O
session	O
(	O
from	O
the	O
7	O
,	O
20	O
ng	O
/	O
ml	O
to	O
11	O
,	O
50	O
ng	O
/	O
ml	O
after	O
20'	O
training	O
)	O
,	O
and	O
subsequently	O
decrease	O
after	O
3	O
hours	O
(	O
9	O
,	O
20	O
ng	O
/	O
ml	O
)	O
and	O
at	O
the	O
end	O
of	O
the	O
6	O
hours	O
training	O
(	O
4	O
,	O
60	O
ng	O
/	O
ml	O
)	O
.	O

A	O
significant	O
direct	O
relationship	O
was	O
observed	O
between	O
the	O
percent	O
area	O
density	O
of	O
smooth	O
muscle	O
and	O
the	O
percent	O
change	O
in	O
peak	O
urinary	O
flow	O
rate	O
.	O

60th	O
birthday	O
of	O
colonel	O
prof	O
.	O
e	O
.	O
cerny	O
m	O
.	O
d	O
.	O

In	O
a	O
previous	O
study	O
(	O
Brandl	O
,	O
C	O
.	O

Thrombolysis	O
was	O
followed	O
by	O
a	O
similar	O
increase	O
of	O
platelet	O
activity	O
with	O
maximal	O
values	O
reached	O
at	O
the	O
3rd	O
hour	O
in	O
both	O
groups	O
(	O
196	O
+	O
/	O
-	O
43	O
IU	O
/	O
ml	O
in	O
Group	O
1	O
and	O
192	O
+	O
/	O
-	O
39	O
in	O
Group	O
2	O
:	O
p	O
<	O
001versus	O
baseline	O
and	O
p	O
NS	O
between	O
the	O
groups	O
)	O
.	O

The	O
latter	O
was	O
determined	O
as	O
follows	O
:	O
Type	O
I-solid	O
tumor	O
tissue	O
without	O
significant	O
peripheral	O
isolated	O
tumor	O
cells	O
;	O
Type	O
II-solid	O
tumor	O
tissue	O
associated	O
with	O
peripheral	O
isolated	O
tumor	O
cells	O
;	O
Type	O
III-isolated	O
tumor	O
cells	O
only	O
.	O

Comparison	O
of	O
the	O
nucleotide	O
sequences	O
between	O
the	O
human	O
and	O
bovine	O
DNA	O
showed	O
that	O
the	O
sequence	O
similarity	O
extended	O
2400	O
bp	O
downstream	O
from	O
the	O
coding	O
region	O
.	O

Periodic	O
breathing	O
and	O
apnea	O
in	O
preterm	O
infants	O
.	O

Antivitamin	O
K	O
agents	O
.	O

Simultaneously	O
a	O
greater	O
NA	O
was	O
found	O
with	O
no	O
change	O
in	O
plasma	O
epinephrine	O
response	O
.	O

The	O
behavior	O
of	O
different	O
types	O
of	O
polytetrafluoroethylene	O
(	O
PTFE	O
)	O
prostheses	O
in	O
the	O
reparative	O
scarring	O
process	O
of	O
abdominal	O
wall	O
defects	O
.	O

IX	O
.	O

The	O
murine	B-GENE
Mov-34	I-GENE
gene	I-GENE
:	O
full-length	O
cDNA	O
and	O
genomic	O
organization	O
.	O

Among	O
the	O
mixed	O
race	O
persons	O
one	O
Chukcha-Eskimo	O
had	O
AS	O
,	O
one	O
Eskimo-Russian	O
had	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
.	O

To	O
examine	O
the	O
basis	O
for	O
the	O
apparent	O
differences	O
in	O
postsegregational	O
killing	O
between	O
the	O
two	O
E	O
.	O
coli	O
strains	O
,	O
transformation	O
assays	O
were	O
carried	O
out	O
to	O
determine	O
the	O
relative	O
sensitivities	O
of	O
the	O
strains	O
to	O
the	O
ParE	B-GENE
toxin	I-GENE
protein	I-GENE
.	O

The	O
mHIF-1	B-GENE
alpha	I-GENE
structural	I-GENE
gene	I-GENE
is	O
composed	O
of	O
15	O
exons	O
.	O

Variability	O
within	O
Down's	O
syndrome	O
(	O
trisomy-21	O
)	O
:	O
empirically	O
observed	O
sex	O
differences	O
in	O
IQs	O
.	O

The	O
participants	O
were	O
homosexual	O
men	O
in	O
hepatitis	O
B	O
vaccine	O
trials	O
in	O
Amsterdam	O
(	O
n	O
=	O
74	O
)	O
,	O
New	O
York	O
City	O
(	O
n	O
=	O
120	O
)	O
,	O
and	O
San	O
Francisco	O
(	O
n	O
=	O
168	O
)	O
.	O

Very	O
small	O
deletions	O
within	O
the	O
conserved	O
region	O
completely	O
abolished	O
transforming	O
activity	O
of	O
dbl	B-GENE
,	O
while	O
extensive	O
deletion	O
outside	O
of	O
this	O
region	O
had	O
no	O
effect	O
.	O

Studies	O
on	O
the	O
organic	O
matrix	O
of	O
human	O
ear	O
ossicles	O
.	O

These	O
differences	O
are	O
smaller	O
than	O
those	O
described	O
in	O
standard	O
textbooks	O
.	O

The	O
algorithm	O
also	O
limited	O
TG	O
to	O
20	O
and	O
64%	O
,	O
apoB	B-GENE
to	O
6	O
and	O
20%	O
,	O
and	O
Lp	B-GENE
(	I-GENE
a	I-GENE
)	I-GENE
to	O
15	O
and	O
56%	O
,	O
of	O
low-	O
and	O
high-risk	O
groups	O
,	O
respectively	O
.	O

Like	O
other	O
members	O
of	O
this	O
family	O
,	O
the	O
AP-4	B-GENE
HLH	B-GENE
motif	I-GENE
and	O
the	O
adjacent	O
basic	O
domain	O
are	O
necessary	O
and	O
sufficient	O
to	O
confer	O
site-specific	O
DNA	O
binding	O
.	O

Following	O
the	O
patients	O
during	O
a	O
course	O
of	O
therapy	O
with	O
a	O
selective	O
vasodilator	O
calcium	O
antagonist	O
,	O
the	O
beta-adrenergic	O
reflex	O
vasodilation	O
became	O
substantially	O
attenuated	O
but	O
was	O
preserved	O
during	O
a	O
placebo	O
course	O
of	O
therapy	O
.	O

Two	O
members	O
of	O
the	O
Cbl	B-GENE
family	I-GENE
have	O
since	O
been	O
defined	O
in	O
mammals	O
(	O
c-Cbl	B-GENE
and	O
Cbl-b	B-GENE
)	O
,	O
one	O
in	O
C	O
.	O
elegans	O
(	O
Sli-1	B-GENE
)	O
and	O
one	O
in	O
Drosophila	O
(	O
D-Cbl	B-GENE
)	O
.	O

Fourteen	O
healthy	O
male	O
volunteers	O
completed	O
the	O
study	O
.	O

Comparisons	O
of	O
the	O
four	O
operon	O
control	O
regions	O
studied	O
indicate	O
that	O
the	O
NarL	B-GENE
heptamers	I-GENE
are	O
arranged	O
with	O
diverse	O
orientations	O
and	O
spacing	O
.	O

Hybridization	O
of	O
plasmid-transformed	O
Escherichia	O
coli	O
RR1	O
colonies	O
with	O
32P-labeled	O
viral	O
genome	O
RNAs	O
demonstrated	O
the	O
presence	O
of	O
DNA	O
clones	O
representative	O
of	O
each	O
of	O
the	O
10	O
reovirus	O
RNAs	O
and	O
10	O
of	O
the	O
11	O
constituent	O
segments	O
of	O
the	O
rotavirus	O
genome	O
.	O

Sci	O
.	O

The	O
secondary	O
,	O
but	O
not	O
the	O
primary	O
,	O
antibody	O
responses	O
of	O
male	O
C57Bl	O
/	O
6	O
mice	O
were	O
higher	O
among	O
mice	O
housed	O
alone	O
compared	O
to	O
mice	O
housed	O
in	O
groups	O
;	O
differences	O
were	O
observed	O
for	O
both	O
IgM	B-GENE
and	O
IgG	B-GENE
anti-KLH	I-GENE
antibodies	I-GENE
.	O

TaV	O
particles	O
have	O
a	O
buoyant	O
density	O
of	O
1	O
.	O
296	O
g	O
/	O
cm3	O
in	O
CsCl	O
and	O
consist	O
of	O
two	O
capsid	O
proteins	O
of	O
56	O
and	O
6	O
kDa	O
.	O

Demonstration	O
of	O
tissue	O
lesions	O
after	O
intramuscular	O
injection	O
by	O
determination	O
of	O
creatine	B-GENE
kinase	I-GENE
in	O
blood	O
.	O

These	O
six	O
amino	O
acids	O
are	O
part	O
of	O
an	O
amphipathic	O
helix	O
that	O
is	O
highly	O
conserved	O
among	O
nuclear	B-GENE
hormone	I-GENE
receptors	I-GENE
and	O
contains	O
the	O
core	O
domain	O
of	O
the	O
ligand-dependent	O
transactivation	O
function	O
,	O
AF-2	B-GENE
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
control	O
hypertension	O
and	O
keep	O
appropriate	O
renal	O
blood	O
flow	O
during	O
living	O
renal	O
transplantation	O
surgery	O
.	O

Neither	O
mutant	O
exhibited	O
derepression	O
of	O
the	O
silent	B-GENE
mating	I-GENE
type	I-GENE
loci	I-GENE
.	O

Transcriptional	O
activation	O
of	O
the	O
chicken	B-GENE
lysozyme	I-GENE
gene	I-GENE
by	O
NF-kappa	B-GENE
Bp65	I-GENE
(	O
RelA	B-GENE
)	O
and	O
c-Rel	B-GENE
,	O
but	O
not	O
by	O
NF-kappa	B-GENE
Bp50	I-GENE
.	O

Current	O
diagnostic	O
uses	O
of	O
computerized	O
tomography	O
in	O
clinical	O
medicine	O
.	O

59	O
cases	O
of	O
surgically	O
resectable	O
cancers	O
(	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
N0	O
,	O
N1	O
)	O
had	O
a	O
minimum	O
followup	O
of	O
two	O
years	O
(	O
average	O
4	O
years	O
+	O
/	O
-	O
3	O
months	O
)	O
.	O

Re-examining	O
methylbenzene	O
(	O
toluene	O
)	O
as	O
a	O
treatment	O
for	O
Ancylostomum	O
caninum	O
.	O

Mean	O
fluorosis	O
scores	O
,	O
however	O
,	O
were	O
similar	O
.	O

The	O
subgroup	O
innervating	O
the	O
medial	O
rectus	O
lies	O
exclusively	O
along	O
the	O
medial	O
face	O
of	O
the	O
oculomotor	O
nucleus	O
,	O
with	O
no	O
aberrant	O
neurons	O
in	O
the	O
medial	O
longitudinal	O
fasciculus	O
,	O
as	O
have	O
been	O
found	O
in	O
other	O
mammals	O
.	O

Responsiveness	O
to	O
beta-2	O
agonist	O
therapy	O
was	O
retained	O
with	O
both	O
agents	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

POU-domain	B-GENE
proteins	I-GENE
,	O
such	O
as	O
the	O
pituitary-specific	B-GENE
factor	I-GENE
Pit-1	I-GENE
,	O
are	O
members	O
of	O
the	O
homeodomain	B-GENE
family	I-GENE
of	O
proteins	O
which	O
are	O
important	O
in	O
development	O
and	O
homeostasis	O
,	O
acting	O
constitutively	O
or	O
in	O
response	O
to	O
signal-transduction	O
pathways	O
to	O
either	O
repress	O
or	O
activate	O
the	O
expression	O
of	O
specific	O
genes	O
.	O

The	O
TCF-1	B-GENE
alpha	I-GENE
binding	I-GENE
site	I-GENE
was	O
also	O
required	O
for	O
TCR	B-GENE
alpha	I-GENE
enhancer	I-GENE
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	O
but	O
not	O
HeLa	O
cells	O
,	O
confirming	O
that	O
TCF-1	B-GENE
alpha	I-GENE
is	O
a	O
T-cell-specific	B-GENE
transcription	I-GENE
factor	I-GENE
.	O

The	O
interleukin	B-GENE
2	I-GENE
receptor	I-GENE
alpha-chain	I-GENE
(	O
IL-2R	B-GENE
alpha	I-GENE
)	O
gene	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Prediction	O
of	O
the	O
times	O
of	O
sandfly	O
development	O
.	O

A	O
mixture	O
of	O
human	B-GENE
albumin	I-GENE
5%	O
and	O
hydroxy-ethyl-starch	O
was	O
used	O
as	O
a	O
solution	O
for	O
dilution	O
.	O

The	O
localization	O
of	O
this	O
proteoglycan	B-GENE
locus	I-GENE
in	O
the	O
human	O
genome	O
and	O
the	O
availability	O
of	O
new	O
RFLPs	O
provide	O
the	O
tools	O
for	O
future	O
studies	O
of	O
human	O
diseases	O
where	O
the	O
HSPG2	B-GENE
proteoglycan	I-GENE
gene	I-GENE
is	O
suspected	O
to	O
be	O
involved	O
.	O

Several	O
7SL	B-GENE
RNA-encoding	I-GENE
sequences	I-GENE
and	O
various	O
intergenic	O
spacers	O
were	O
amplified	O
from	O
the	O
individual	O
HindIII	B-GENE
fragments	I-GENE
of	O
about	O
1	O
.	O
3	O
and	O
2	O
.	O
8	O
kb	O
.	O

Tctex-1	B-GENE
binding	O
required	O
the	O
first	O
19	O
amino	O
acids	O
of	O
Fyn	B-GENE
and	O
integrity	O
of	O
two	O
lysine	O
residues	O
within	O
this	O
sequence	O
that	O
were	O
previously	O
shown	O
to	O
be	O
important	O
for	O
Fyn	B-GENE
interactions	O
with	O
the	O
immunoreceptor	B-GENE
tyrosine-based	I-GENE
activation	I-GENE
motifs	I-GENE
(	O
ITAMs	B-GENE
)	O
of	O
lymphocyte	B-GENE
Ag	I-GENE
receptors	I-GENE
.	O

Hydroxypropyl	O
methacrylate	O
,	O
a	O
new	O
water-miscible	O
embedding	O
medium	O
for	O
electron	O
microscopy	O
.	O

Significant	O
correlations	O
between	O
mental	O
status	O
as	O
measured	O
by	O
the	O
Mini-Mental	O
State	O
Examination	O
and	O
NA	O
/	O
mI	O
,	O
mI	O
/	O
Cr	O
and	O
NA	O
were	O
found	O
.	O

Treatment	O
for	O
this	O
condition	O
often	O
involves	O
use	O
of	O
a	O
wax	O
softening	O
or	O
dispersing	O
agent	O
(	O
cerumenolytic	O
)	O
before	O
syringing	O
.	O

Like	O
humans	O
,	O
the	O
PITSLRE	B-GENE
PK	I-GENE
genes	I-GENE
in	I-GENE
chickens	I-GENE
must	O
be	O
closely	O
linked	O
,	O
based	O
on	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
localization	O
of	O
these	O
genes	O
to	O
a	O
single	O
chicken	O
microchromosome	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
kinetics	O
of	O
erythropoietin	B-GENE
(	O
EPO	B-GENE
)	O
production	O
and	O
address	O
the	O
pathogenesis	O
of	O
anemia	O
of	O
prematurity	O
,	O
we	O
measured	O
EPO	B-GENE
levels	O
in	O
infants	O
during	O
the	O
first	O
year	O
of	O
life	O
.	O

Protein	B-GENE
kinases	I-GENE
play	O
pivotal	O
roles	O
in	O
the	O
control	O
of	O
many	O
cellular	O
processes	O
.	O

In	O
the	O
former	O
cells	O
,	O
ets-2	B-GENE
was	O
a	O
CSF-1	B-GENE
immediate-early	B-GENE
response	I-GENE
gene	I-GENE
,	O
and	O
phosphorylated	O
ets-2	B-GENE
was	O
detected	O
after	O
2	O
to	O
4	O
h	O
,	O
coincident	O
with	O
expression	O
of	O
ets-2	B-GENE
protein	I-GENE
.	O

In	O
particular	O
,	O
unc-86	B-GENE
encodes	O
a	O
POU-type	B-GENE
homeodomain	I-GENE
protein	I-GENE
needed	O
for	O
the	O
production	O
of	O
the	O
touch	O
cells	O
,	O
while	O
mec-3	B-GENE
encodes	O
a	O
LIM-type	B-GENE
homeodomain	I-GENE
protein	I-GENE
needed	O
for	O
the	O
differentiation	O
of	O
the	O
touch	O
cells	O
.	O

Mutation	O
analysis	O
implicated	O
multiple	O
segments	O
of	O
the	O
5'	O
untranslated	O
region	O
as	O
contributing	O
to	O
the	O
inhibitory	O
effect	O
.	O

Pathology	O
of	O
neuritis	O
caudae	O
equinae	O
in	O
the	O
horse	O
.	O

Two	O
new	O
glucosidase	B-GENE
inhibitors	O
(	O
BAY	O
m	O
1099	O
and	O
BAY	O
o	O
1248	O
)	O
were	O
studied	O
in	O
volunteers	O
and	O
type	O
II	O
diabetics	O
under	O
various	O
conditions	O
.	O

The	O
characteristics	O
of	O
the	O
VirD1	O
/	O
VirD2-mediated	O
cleavage	O
reaction	O
strongly	O
resemble	O
those	O
observed	O
with	O
relaxosomes	O
of	O
IncP	O
plasmids	O
involved	O
in	O
initiation	O
of	O
transfer	O
DNA	O
replication	O
during	O
bacterial	O
conjugation	O
.	O

To	O
define	O
the	O
number	O
and	O
nature	O
of	O
the	O
E6	B-GENE
and	O
E7	B-GENE
gene	I-GENE
products	O
expressed	O
in	O
BPV-1-transformed	O
cells	O
,	O
we	O
performed	O
immunoprecipitation	O
experiments	O
with	O
antisera	O
raised	O
to	O
bacterially	O
expressed	O
BPV-1	B-GENE
E6	I-GENE
and	O
E7	B-GENE
fusion	I-GENE
proteins	I-GENE
.	O

These	O
results	O
suggest	O
that	O
UBP41	B-GENE
may	O
play	O
an	O
important	O
role	O
in	O
the	O
recycling	O
of	O
ubiquitin	B-GENE
by	O
hydrolysis	O
of	O
branched	B-GENE
poly-ubiquitin	I-GENE
chains	I-GENE
generated	O
by	O
the	O
action	O
of	O
26	B-GENE
S	I-GENE
proteasome	I-GENE
on	O
poly-ubiquitinated	O
protein	O
substrates	O
,	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
free	O
ubiquitin	B-GENE
from	O
linear	B-GENE
poly-ubiquitin	I-GENE
chains	I-GENE
and	O
of	O
certain	O
ribosomal	O
proteins	O
from	O
ubiquitin	B-GENE
fusion	I-GENE
proteins	I-GENE
.	O

Results	O
of	O
the	O
ECAT	O
Angina	O
Pectoris	O
Study	O
Group	O
.	O

Conversely	O
,	O
activation	O
of	O
Oct-3	B-GENE
/	I-GENE
4	I-GENE
promoter	I-GENE
by	O
RAR	B-GENE
:	O
RXR	B-GENE
heterodimers	I-GENE
was	O
completely	O
abolished	O
by	O
EAR-3	B-GENE
/	I-GENE
COUP-TFI	I-GENE
and	O
by	O
ARP-1	B-GENE
/	I-GENE
COUP-TFII	I-GENE
.	O

At	O
both	O
water	O
temperatures	O
,	O
VO2	O
increased	O
linearly	O
with	O
increasing	O
swimming	O
velocity	O
.	O

To	O
see	O
if	O
a	O
pulse	O
oximeter	O
can	O
monitor	O
the	O
fetus	O
during	O
labour	O
we	O
recruited	O
100	O
Caucasian	O
women	O
in	O
normal	O
uncomplicated	O
labour	O
.	O

In	O
adult	O
tissues	O
,	O
it	O
was	O
less	O
restricted	O
,	O
indicating	O
that	O
RAFTK	B-GENE
expression	O
is	O
developmentally	O
up-regulated	O
.	O

A	O
cytosolic	O
variant	O
of	O
the	O
protein	O
underwent	O
efficient	O
transphosphorylation	O
,	O
yet	O
failed	O
to	O
activate	O
appreciably	O
either	O
p70	B-GENE
(	I-GENE
S6k	I-GENE
)	I-GENE
or	O
MAP	B-GENE
kinase	I-GENE
following	O
treatment	O
with	O
FK1012	O
.	O

Recent	O
studies	O
have	O
shown	O
the	O
rat	O
larynx	O
to	O
be	O
an	O
important	O
organ	O
in	O
the	O
evaluation	O
of	O
irritancy	O
of	O
inhaled	O
materials	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Rat7p	B-GENE
/	I-GENE
Nup159p	I-GENE
is	O
anchored	O
within	O
the	O
NPC	B-GENE
through	O
its	O
coiled-coil	O
region	O
and	O
adjacent	O
sequences	O
.	O

The	O
experiment	O
results	O
showed	O
:	O
(	O
i	O
)	O
not	O
only	O
1O2	O
,	O
but	O
also	O
free	O
radicals	O
(	O
O2-	O
.	O
.	O
OH	O
and	O
YHPD-	O
.	O
)	O
can	O
be	O
formed	O
by	O
the	O
aid	O
of	O
YHPD	O
;	O
and	O
(	O
ii	O
)	O
as	O
to	O
the	O
ability	O
of	O
producing	O
1O2	O
,	O
YHPD	O
less	O
than	O
BHPD	O
,	O
while	O
for	O
generating	O
O2-	O
.	O
and	O
.	O
OH	O
,	O
YHPD	O
greater	O
than	O
BHPD	O
.	O

There	O
is	O
now	O
a	O
significative	O
difference	O
between	O
age	O
group	O
1-5	O
and	O
the	O
others	O
(	O
p	O
Less	O
Than	O
0	O
,	O
02	O
)	O
.	O

Role	O
of	O
histoclinical	O
studies	O
in	O
the	O
prophylaxis	O
of	O
spontaneous	O
abortions	O
.	O

Our	O
results	O
indicate	O
that	O
RA-mediated	O
repression	O
of	O
the	O
hMGP	B-GENE
gene	I-GENE
is	O
due	O
to	O
binding	O
of	O
liganded	O
RAR	B-GENE
/	I-GENE
RXR	I-GENE
to	O
a	O
novel	O
negative	O
RA	B-GENE
response	I-GENE
element	I-GENE
.	O

The	O
mean	O
waiting	O
time	O
to	O
receive	O
the	O
pancreas	O
transplant	O
was	O
244	O
days	O
for	O
SPK	O
and	O
167	O
days	O
for	O
PAK	O
recipients	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

An	O
AP-1	B-GENE
binding	I-GENE
sequence	I-GENE
is	O
essential	O
for	O
regulation	O
of	O
the	O
human	B-GENE
alpha2	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
collagen	I-GENE
(	O
COL1A2	B-GENE
)	O
promoter	O
activity	O
by	O
transforming	B-GENE
growth	I-GENE
factor-beta	I-GENE
.	O

The	O
prevalence	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
relatively	O
low	O
in	O
childhood	O
,	O
with	O
anti-HCV	O
prevalence	O
rates	O
of	O
0	O
.	O
1-0	O
.	O
4%	O
in	O
the	O
Western	O
world	O
.	O

Hybridization	O
of	O
a	O
probe	O
from	O
this	O
region	O
to	O
electrophoretic	O
blots	O
of	O
RNAs	O
from	O
different	O
human	O
tissues	O
showed	O
a	O
predominant	O
2	O
.	O
8-kilobase	O
(	O
kb	O
)	O
message	O
accompanied	O
by	O
weaker	O
bands	O
4	O
.	O
1	O
and	O
2	O
.	O
1	O
kb	O
in	O
size	O
.	O

Both	O
strains	O
grew	O
very	O
poorly	O
,	O
or	O
not	O
at	O
all	O
,	O
on	O
nonfermentable	O
carbon	O
sources	O
and	O
exhibited	O
,	O
at	O
most	O
,	O
only	O
5%	O
of	O
wild-type	B-GENE
ubiquinol-cytochrome	I-GENE
c	I-GENE
oxidoreductase	I-GENE
activity	O
.	O

Consciousness	O
is	O
connected	O
with	O
attention	O
,	O
working	O
memory	O
and	O
perception	O
.	O

SIT	B-GENE
(	O
SHP2-interacting	B-GENE
transmembrane	I-GENE
adaptor	I-GENE
protein	I-GENE
)	O
is	O
a	O
recently	O
identified	O
transmembrane	O
adaptor	O
protein	O
,	O
which	O
is	O
expressed	O
in	O
lymphocytes	O
.	O

Certain	O
transcript	O
patterns	O
in	O
Epifagus	O
plastids	O
are	O
highly	O
complex	O
and	O
similar	O
to	O
those	O
of	O
tobacco	O
operons	O
.	O

The	O
putative	O
immunity	O
protein	O
was	O
detected	O
among	O
the	O
[	O
35S	O
]	O
methionine-labelled	O
proteins	O
produced	O
by	O
minicells	O
carrying	O
cni	B-GENE
cloned	O
under	O
lac	B-GENE
promoter	I-GENE
control	O
,	O
and	O
when	O
the	O
gene	O
was	O
subcloned	O
into	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
a	O
bacteriophage	O
T7	O
promoter	O
.	O

This	O
region	O
includes	O
verA	B-GENE
,	O
a	O
structural	O
gene	O
previously	O
shown	O
to	O
be	O
required	O
for	O
ST	B-GENE
biosynthesis	O
,	O
and	O
24	O
additional	O
closely	O
spaced	O
transcripts	O
ranging	O
in	O
size	O
from	O
0	O
.	O
6	O
to	O
7	O
.	O
2	O
kb	O
that	O
are	O
coordinately	O
induced	O
only	O
under	O
ST-producing	O
conditions	O
.	O

In	O
transformed	O
E	O
.	O
coli	O
,	O
constitutive	B-GENE
CAT	I-GENE
expression	O
is	O
maintained	O
when	O
as	O
little	O
as	O
0	O
.	O
3	O
kilobase	O
of	O
DNA	O
from	O
the	O
3'	O
end	O
of	O
the	O
1	O
.	O
6-kilobase	O
segment	O
is	O
inserted	O
in	O
the	O
correct	O
orientation	O
in	O
front	O
of	O
the	O
CAT	B-GENE
gene	I-GENE
.	O

Comparison	O
of	O
sequences	O
of	O
ovine	O
and	O
bovine	O
,	O
rat	O
and	O
guinea-pig	B-GENE
alpha	I-GENE
s1-casein	I-GENE
mRNAs	I-GENE
has	O
revealed	O
a	O
greater	O
homology	O
in	O
the	O
3'	O
and	O
especially	O
5'	O
non	O
coding	O
regions	O
.	O

The	O
determination	O
of	O
physical	O
performance	O
capacity	O
was	O
based	O
on	O
W170	O
,	O
W85%	O
and	O
on	O
predicted	O
VO2	O
max	O
measured	O
with	O
continuously	O
increasing	O
work	O
load	O
on	O
a	O
bicycle	O
ergometer	O
.	O

The	O
effects	O
of	O
a	O
1-	O
or	O
24-hour	O
pretreatment	O
regimen	O
with	O
monophosphoryl	O
lipid	O
A	O
(	O
MLA	O
,	O
35	O
micrograms	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
on	O
myocardial	O
stunning	O
produced	O
by	O
repetitive	O
coronary	O
occlusions	O
were	O
studied	O
in	O
barbital-anesthetized	O
dogs	O
.	O

The	O
spermicide	O
nonoxynol-9	O
is	O
a	O
member	O
of	O
a	O
homologous	O
series	O
of	O
alkylphenol-ethoxylates	O
(	O
polyethoxyethanols	O
)	O
of	O
general	O
formula	O
C9H19-C6H6-O-	O
(	O
CH2CH2O	O
)	O
n-1	O
CH2CH2OH	O
.	O

According	O
to	O
their	O
functional	O
properties	O
the	O
latter	O
neurons	O
were	O
subdivided	O
into	O
:	O
(	O
a	O
)	O
neurons	O
responding	O
to	O
stimuli	O
near	O
the	O
eyes	O
;	O
(	O
b	O
)	O
neurons	O
triggered	O
by	O
complex	O
visual	O
stimuli	O
;	O
(	O
c	O
)	O
neurons	O
inhibited	O
by	O
visual	O
stimuli	O
.	O

To	O
our	O
knowledge	O
,	O
type	O
IV	O
renal	O
tubular	O
acidosis	O
has	O
not	O
been	O
reported	O
previously	O
in	O
association	O
with	O
Alport's	O
syndrome	O
in	O
an	O
adult	O
patient	O
.	O

Observers	O
with	O
brain	O
injury	O
and	O
control	O
participants	O
performed	O
a	O
vigilance	O
task	O
during	O
which	O
they	O
received	O
periodic	O
whiffs	O
of	O
unscented	O
air	O
or	O
air	O
scented	O
with	O
peppermint	O
.	O

To	O
explore	O
the	O
functional	O
relationship	O
between	O
c-fos	B-GENE
and	O
Rb	B-GENE
,	O
a	O
eukaryotic	O
expression	O
plasmid	O
was	O
constructed	O
containing	O
the	O
c-fos	B-GENE
gene	I-GENE
under	O
control	O
of	O
the	O
SV40	O
promoter	O
complex	O
.	O

The	O
neuroleptic-induced	O
increase	O
in	O
central	O
DA	O
turnover	O
(	O
an	O
indicator	O
for	O
the	O
degree	O
of	O
DA	B-GENE
receptor	I-GENE
blocking	O
)	O
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
therapeutic	O
effect	O
of	O
neuroleptics	O
and	O
the	O
development	O
of	O
hypokinetic-rigid	O
symptoms	O
.	O

Effects	O
of	O
Trypanosoma	O
vivax	O
on	O
pregnancy	O
of	O
Yankasa	O
sheep	O
and	O
the	O
results	O
of	O
homidum	O
chloride	O
chemotherapy	O
.	O

The	O
two	O
main	O
experimental	O
variables	O
were	O
the	O
attended	O
hemifield	O
(	O
left	O
or	O
right	O
)	O
and	O
the	O
proportion	O
of	O
trials	O
requiring	O
a	O
shift	O
within	O
that	O
hemifield	O
(	O
20%	O
or	O
80%	O
)	O
.	O

155	O
aa	O
,	O
shares	O
78%	O
identity	O
with	O
the	O
analogous	O
region	O
of	O
Xenopus	O
laevis	O
FGF3	B-GENE
and	O
72%	O
identity	O
with	O
the	O
product	O
of	O
the	O
more	O
distantly	O
related	O
human	O
gene	O
.	O

J	O
.	O

Removal	O
of	O
all	O
core	B-GENE
histone	I-GENE
tail	O
domains	O
by	O
limited	O
trypsin	B-GENE
proteolysis	O
or	O
acetylation	O
of	O
the	O
core	B-GENE
histone	I-GENE
tails	O
significantly	O
relieves	O
this	O
inhibition	O
and	O
allows	O
TFIIIA	B-GENE
to	O
exhibit	O
high-affinity	O
binding	O
to	O
nucleosomal	O
DNA	O
.	O

Agonist-induced	B-GENE
receptor	I-GENE
internalization	O
,	O
determined	O
as	O
the	O
percent	O
of	O
total	O
[	O
125I	O
]	O
Tyr0-oCRF	B-GENE
bound	O
located	O
in	O
the	O
acid-resistant	O
fraction	O
of	O
transfected	O
Cos	O
7	O
cells	O
,	O
increased	O
with	O
time	O
(	O
0-60	O
min	O
at	O
37	O
degrees	O
C	O
)	O
for	O
both	O
wild-type	O
and	O
variant	O
oCRF1	B-GENE
.	O

Pharmacology	O
studies	O
with	O
potassium	O
chloride	O
and	O
acetylcholine	O
suggest	O
that	O
raveron	O
acts	O
as	O
a	O
calcium	O
antagonist	O
by	O
blocking	O
the	O
influx	O
of	O
extracellular	O
calcium	O
.	O

Surprisingly	O
,	O
Northern	O
(	O
RNA	O
)	O
blot	O
analysis	O
and	O
reverse	O
transcriptase-PCRs	O
performed	O
after	O
transfection	O
of	O
COS-7	O
or	O
HeLa	O
cells	O
with	O
these	O
viral	O
RNAs	O
revealed	O
that	O
Y88S	B-GENE
and	O
Y88L	B-GENE
RNAs	I-GENE
replicated	O
at	O
only	O
very	O
low	O
levels	O
.	O

Comparison	O
of	O
the	O
genomic	O
DNA	O
sequence	O
with	O
that	O
of	O
the	O
four	O
different	O
mRNAs	O
indicates	O
that	O
these	O
transcripts	O
are	O
produced	O
by	O
alternative	O
splicing	O
of	O
the	O
murine	O
pre-mRNA	O
according	O
to	O
a	O
cassette	O
model	O
.	O

The	O
STAT	B-GENE
protein	I-GENE
accumulation	O
resulting	O
from	O
C	B-GENE
/	I-GENE
EBP	I-GENE
expression	O
was	O
tightly	O
coupled	O
to	O
the	O
morphological	O
conversion	O
of	O
fibroblasts	O
to	O
adipocytes	O
and	O
represents	O
an	O
expression	O
profile	O
identical	O
to	O
that	O
reported	O
for	O
mature	O
adipocytes	O
in	O
vivo	O
.	O

To	O
illustrate	O
its	O
performance	O
,	O
measurements	O
of	O
photoluminescence	O
in	O
GaAs	O
/	O
AlGaAs	O
heterostructures	O
are	O
presented	O
.	O

RNA	B-GENE
polymerase	I-GENE
bound	O
to	O
the	O
+10A	B-GENE
promoter	I-GENE
partially	O
protects	O
a	O
20	O
base-pair	O
sequence	O
from	O
DNase	B-GENE
I	I-GENE
digestion	O
upstream	O
of	O
the	O
start	O
site	O
.	O

Further	O
,	O
the	O
ability	O
of	O
recombinant	B-GENE
beta	I-GENE
and	I-GENE
/	I-GENE
or	I-GENE
gamma	I-GENE
chains	I-GENE
to	O
function	O
in	O
defined	O
biochemical	O
assays	O
of	O
beta	B-GENE
gamma	I-GENE
activity	O
was	O
assessed	O
for	O
membrane	O
extracts	O
and	O
supernatant	O
fractions	O
from	O
infected	O
Sf9	O
cells	O
.	O

TRAF2	B-GENE
is	O
known	O
to	O
associate	O
with	O
TRADD	B-GENE
,	O
and	O
expression	O
of	O
a	O
dominant-negative	O
N-terminal	O
deletion	O
TRAF2	B-GENE
mutant	I-GENE
was	O
found	O
to	O
partially	O
inhibit	O
LMP1-induced	O
JNK	B-GENE
activation	O
in	O
293	O
cells	O
.	O

A	O
portion	O
of	O
Region	O
II	O
also	O
resembles	O
part	O
of	O
the	O
human	O
c-jun	B-GENE
oncoprotein's	O
leucine	O
zipper	O
,	O
which	O
in	O
turn	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
the	O
heterodimerization	O
site	O
between	O
the	O
jun	B-GENE
and	O
fos	B-GENE
oncoproteins	I-GENE
.	O

Buflomedil	O
(	O
i	O
.	O
v	O
.	O
)	O
induced	O
a	O
dose-dependent	O
increase	O
of	O
cardiac	O
output	O
at	O
0	O
.	O
16-0	O
.	O
64	O
mg	O
/	O
kg	O
,	O
biphasic	O
changes	O
at	O
1	O
.	O
28	O
and	O
2	O
.	O
56	O
mg	O
/	O
kg	O
and	O
a	O
marked	O
decrease	O
and	O
subsequent	O
slight	O
increase	O
at	O
a	O
large	O
dose	O
of	O
5	O
.	O
12	O
mg	O
/	O
kg	O
.	O

These	O
results	O
indicate	O
that	O
both	O
naturally	O
acquired	O
and	O
passive	O
(	O
modified	O
immune	O
serum	O
globulin	O
)	O
antibodies	O
to	O
type	B-GENE
III	I-GENE
group	I-GENE
B	I-GENE
Streptococcus	I-GENE
antigen	I-GENE
are	O
partially	O
protective	O
against	O
intra-amniotic	O
infection	O
.	O

The	O
rates	O
of	O
total	O
energy	O
use	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
39	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
vs	O
35	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
3	O
kJ	O
X	O
min-1	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
significantly	O
higher	O
at	O
-10	O
degrees	O
C	O
than	O
at	O
22	O
degrees	O
C	O
.	O

In	O
addition	O
to	O
the	O
protein-tyrosine	B-GENE
kinase	I-GENE
domain	I-GENE
,	O
p56lck	B-GENE
possesses	O
Src	B-GENE
homology	I-GENE
2	I-GENE
and	I-GENE
3	I-GENE
(	O
SH2	B-GENE
and	O
SH3	B-GENE
)	O
domains	O
as	O
well	O
as	O
a	O
unique	O
N-terminal	O
region	O
.	O

Each	O
binding	O
site	O
,	O
however	O
,	O
was	O
different	O
in	O
its	O
preference	O
for	O
binding	O
partners	O
.	O

An	O
ASIC-chip	O
for	O
stereoscopic	O
depth	O
analysis	O
in	O
video-real-time	O
based	O
on	O
visual	O
cortical	O
cell	O
behavior	O
.	O

Picture	O
the	O
smell	O
.	O

We	O
have	O
isolated	O
a	O
cDNA	O
encoding	O
human	B-GENE
MEKK3	I-GENE
.	O

Human	B-GENE
acid	I-GENE
ceramidase	I-GENE
(	I-GENE
(	I-GENE
AC	I-GENE
)	I-GENE
N-acylsphingosine	I-GENE
amidohydrolase	I-GENE
,	O
EC	B-GENE
3	I-GENE
.	I-GENE
5	I-GENE
.	O

Mutagenesis	O
of	O
SNT1	B-GENE
(	I-GENE
IRS	I-GENE
)	I-GENE
CX	I-GENE
identified	O
three	O
classes	O
of	O
effector	O
motifs	O
within	O
SNT	B-GENE
critical	O
for	O
both	O
sustained	O
ERK	B-GENE
activation	O
and	O
neuronal	O
differentiation	O
:	O
1	O
)	O
four	O
phosphotyrosine	O
motifs	O
that	O
mediate	O
recruitment	O
of	O
Grb2	B-GENE
,	O
2	O
)	O
two	O
phosphotyrosine	O
motifs	O
that	O
mediate	O
recruitment	O
of	O
Shp2	B-GENE
,	O
and	O
3	O
)	O
a	O
C-terminal	O
motif	O
that	O
functions	O
by	O
helping	O
to	O
recruit	O
Sos	B-GENE
.	O

Indium-111	O
leukocyte	O
imaging	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

The	O
potential	O
impact	O
of	O
using	O
a	O
rapid	O
diagnostic	O
test	O
(	O
Strep	O
A	O
OIA	O
)	O
on	O
detection	O
and	O
treatment	O
of	O
group	O
A	O
beta-hemolytic	O
streptococcal	O
(	O
GABHS	O
)	O
pharyngitis	O
in	O
a	O
large-volume	O
pediatric	O
and	O
adolescent	O
clinic	O
was	O
examined	O
.	O

The	O
only	O
isolate	O
of	O
Aeromonas	O
hydrophila	O
produced	O
cytotoxic	O
enterotoxin	B-GENE
and	O
was	O
invasive	O
.	O

On	O
Days	O
1	O
and	O
14	O
,	O
most	O
young	O
and	O
elderly	O
subjects	O
exhibited	O
monoexponential	O
decline	O
in	O
bevantolol	O
plasma	O
concentrations	O
after	O
absorption	O
phase	O
.	O

Although	O
the	O
mechanism	O
of	O
action	O
of	O
ICRF-159	O
and	O
187	O
has	O
not	O
been	O
clearly	O
defined	O
,	O
it	O
is	O
evident	O
from	O
both	O
preclinical	O
and	O
early	O
clinical	O
studies	O
that	O
these	O
compounds	O
are	O
of	O
interest	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
KRAB	B-GENE
domain	I-GENE
present	O
in	O
the	O
non-finger	O
region	O
of	O
many	O
ZFP	B-GENE
genes	I-GENE
quenches	O
transcription	O
possibly	O
due	O
to	O
specific	O
protein-protein	O
interactions	O
between	O
the	O
KRAB-A	B-GENE
domain	I-GENE
and	O
components	O
of	O
the	O
proximal	O
transcriptional	O
apparatus	O
.	O

A	O
new	O
variant	O
of	O
the	O
EMG-BFB	O
method	O
(	O
multichannel	O
)	O
is	O
offered	O
which	O
has	O
made	O
it	O
possible	O
to	O
use	O
the	O
method	O
not	O
only	O
for	O
training	O
weakened	O
muscles	O
and	O
reducing	O
spasticity	O
in	O
their	O
antagonists	O
but	O
also	O
for	O
improving	O
motor	O
coordination	O
.	O

We	O
investigated	O
the	O
incidence	O
of	O
congenital	O
color	O
deficiency	O
among	O
Koreans	O
by	O
the	O
use	O
of	O
H-R-R	O
pseudoisochromatic	O
plates	O
.	O

We	O
suggest	O
that	O
sensitivity	O
to	O
photoperiod	O
in	O
pallid	O
bats	O
,	O
as	O
in	O
several	O
other	O
mammals	O
,	O
is	O
mediated	O
by	O
the	O
pineal	O
gland	O
.	O

The	O
debate	O
over	O
electives--1899	O
.	O

This	O
report	O
presents	O
an	O
analysis	O
of	O
the	O
vocal	O
repertoire	O
of	O
howler	O
monkeys	O
(	O
Alouatta	O
palliata	O
)	O
observed	O
during	O
a	O
field	O
study	O
in	O
southwestern	O
Panama	O
.	O

Additionally	O
,	O
deletion	O
analysis	O
of	O
the	O
UCP2	B-GENE
promoter-PLAP	I-GENE
constructs	I-GENE
indicated	O
that	O
the	O
minimal	O
region	O
exhibiting	O
the	O
promoter	O
activity	O
was	O
located	O
between	O
nt	O
-33	O
and	O
+100	O
,	O
and	O
that	O
a	O
strong	O
enhancer	O
was	O
present	O
within	O
601	O
bp	O
of	O
the	O
5'-promoter	O
region	O
.	O

The	O
sequence	O
analysis	O
of	O
both	O
products	O
of	O
individual	O
phi	O
80	O
site-specific	O
recombination	O
events	O
in	O
vivo	O
shows	O
that	O
recombination	O
with	O
a	O
secondary	O
attachment	O
(	O
att	O
)	O
site	O
generates	O
several	O
different	O
novel	O
joints	O
at	O
the	O
mismatched	O
position	O
:	O
one	O
recombination	O
event	O
resulted	O
in	O
a	O
single	O
base-pair	O
deletion	O
and	O
two	O
other	O
recombination	O
events	O
resulted	O
in	O
two	O
different	O
single	O
base-pair	O
substitutions	O
.	O

Epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
transcriptionally	O
up-regulates	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
expression	O
in	O
human	O
glioblastoma	O
cells	O
via	O
a	O
pathway	O
involving	O
phosphatidylinositol	B-GENE
3'-kinase	I-GENE
and	O
distinct	O
from	O
that	O
induced	O
by	O
hypoxia	O
.	O

A	O
candidate	O
gene	O
for	O
Bcg	B-GENE
,	O
designated	O
natural	B-GENE
resistance-associated	I-GENE
macrophage	I-GENE
protein	I-GENE
(	O
Nramp	B-GENE
)	O
,	O
has	O
been	O
isolated	O
and	O
shown	O
to	O
encode	O
a	O
novel	O
macrophage-specific	O
membrane	O
protein	O
,	O
which	O
is	O
altered	O
in	O
susceptible	O
animals	O
.	O

The	O
triple	O
combination	O
of	O
nizatidine	O
,	O
clarithromycin	O
,	O
and	O
bismuth	O
subcitrate	O
resulted	O
in	O
an	O
ulcer	O
healing	O
rate	O
of	O
98%	O
and	O
an	O
H	O
.	O
pylori	O
eradication	O
rate	O
of	O
90%	O
.	O

Connector	B-GENE
enhancer	I-GENE
of	I-GENE
KSR	I-GENE
(	O
CNK	B-GENE
)	O
is	O
a	O
multidomain	O
protein	O
required	O
for	O
RAS	B-GENE
signaling	O
.	O

Continued	O
absorption	O
of	O
amino	O
acids	O
by	O
the	O
NBB	O
carrier	O
(	O
for	O
neutral	O
amino	O
acids	O
)	O
,	O
the	O
Y+	O
system	O
(	O
for	O
dibasic	O
amino	O
acids	O
)	O
,	O
and	O
the	O
PHE	O
carrier	O
were	O
operative	O
even	O
during	O
the	O
actively	O
purging	O
stage	O
of	O
watery	O
diarrhoea	O
due	O
to	O
cholera	O
.	O

Weaned	O
rats	O
were	O
fed	O
a	O
normal	O
diet	O
or	O
a	O
low-protein	O
,	O
low-energy	O
diet	O
,	O
and	O
injected	O
with	O
saline	O
or	O
thyroxine	O
(	O
5	O
micrograms	O
/	O
100	O
g	O
BW	O
)	O
for	O
22	O
days	O
.	O

They	O
also	O
occur	O
in	O
similar	O
locations	O
in	O
the	O
promoters	O
of	O
several	O
other	O
ribosomal	B-GENE
protein	I-GENE
genes	I-GENE
.	O

In	O
the	O
present	O
work	O
,	O
the	O
complete	O
genome	O
sequences	O
of	O
Pyrococcus	O
horikoshii	O
and	O
Pyrococcus	O
abyssi	O
,	O
two	O
species	O
in	O
a	O
genus	O
of	O
hyperthermophilic	O
archaeon	O
(	O
archaebacterium	O
)	O
,	O
were	O
compared	O
to	O
detect	O
large	O
genome	O
polymorphisms	O
linked	O
with	O
restriction-modification	B-GENE
gene	I-GENE
homologs	I-GENE
.	O

For	O
the	O
first	O
group	O
,	O
the	O
maximal	O
decrease	O
in	O
plasma	O
potassium	O
elicited	O
by	O
salbutamol	O
was	O
0	O
.	O
80	O
+	O
/	O
-	O
0	O
.	O
19	O
,	O
0	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
22	O
,	O
and	O
0	O
.	O
78	O
+	O
/	O
-	O
0	O
.	O
46	O
mmol	O
/	O
l	O
,	O
and	O
for	O
the	O
second	O
group	O
,	O
maximal	O
decrement	O
was	O
1	O
.	O
31	O
+	O
/	O
-	O
0	O
.	O
37	O
,	O
0	O
.	O
70	O
+	O
/	O
-	O
0	O
.	O
24	O
,	O
and	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
17	O
mmol	O
/	O
l	O
for	O
the	O
iv	O
,	O
po	O
,	O
and	O
it	O
routes	O
,	O
respectively	O
.	O

A	O
similar	O
chimera	O
was	O
assembled	O
from	O
the	O
two	O
halves	O
of	O
the	O
molecule	O
expressed	O
separately	O
in	O
different	O
bacteria	O
and	O
refolded	O
together	O
.	O

The	O
lemdr1	B-GENE
gene	I-GENE
was	O
cloned	O
in	O
the	O
expression	O
vector	O
pALTNEO	O
and	O
transfected	O
into	O
wild-type	O
L	O
.	O
enriettii	O
and	O
the	O
resulting	O
transfected	O
cells	O
were	O
resistant	O
to	O
vinblastine	O
but	O
at	O
lower	O
levels	O
than	O
in	O
the	O
selected	O
mutant	O
cells	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
is	O
78	O
.	O
0%	O
identical	O
to	O
the	O
cytoplasmic	B-GENE
dynein	I-GENE
heavy	I-GENE
chain	I-GENE
of	I-GENE
Neurospora	I-GENE
crassa	I-GENE
,	O
70	O
.	O
2%	O
identical	O
to	O
that	O
of	O
Aspergillus	O
nidulans	O
and	O
24	O
.	O
8%	O
identical	O
to	O
that	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

Dose	O
standardisation	O
of	O
botulinum	B-GENE
toxin	I-GENE
.	O

These	O
cells	O
produced	O
P2Y	B-GENE
(	I-GENE
11	I-GENE
)	I-GENE
mRNA	I-GENE
during	O
culture	O
.	O

In	O
contrast	O
,	O
an	O
amino-terminal	O
fragment	O
containing	O
the	O
C	B-GENE
/	I-GENE
H1	I-GENE
domain	I-GENE
was	O
sufficient	O
for	O
coactivation	O
of	O
Zta	B-GENE
transcription	O
and	O
viral	O
reactivation	O
function	O
.	O

The	O
pathogenesis	O
of	O
Dupuytren's	O
contracture	O
.	O

The	O
uptake	O
of	O
fluorine-18	O
fluorodeoxyglucose	O
(	O
F-18	O
FDG	O
)	O
by	O
a	O
malignant	O
tumor	O
depends	O
on	O
the	O
blood	O
glucose	O
level	O
.	O

The	O
inhibition	O
of	O
StAR	B-GENE
gene	I-GENE
transcription	O
by	O
DAX-1	B-GENE
was	O
dose-dependent	O
reducing	O
transcription	O
to	O
6%	O
of	O
control	O
levels	O
.	O

Mibefradil	O
(	O
Ro	O
40-5967	O
)	O
is	O
a	O
novel	O
calcium	O
antagonist	O
from	O
a	O
new	O
chemical	O
class	O
and	O
is	O
the	O
first	O
that	O
selectively	O
blocks	O
the	O
T-type	O
calcium	O
channel	O
.	O

These	O
results	O
suggest	O
that	O
5	O
KE	O
X	O
3	O
/	O
W	O
may	O
be	O
the	O
optimal	O
regimen	O
to	O
augment	O
the	O
antitumor	O
immunity	O
of	O
RNL	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
silymarin	O
may	O
exert	O
a	O
strong	O
anticarcinogenic	O
effect	O
against	O
PCA	O
and	O
that	O
this	O
effect	O
is	O
likely	O
to	O
involve	O
impairment	O
of	O
erbB1-SHC-mediated	O
signaling	O
pathway	O
,	O
induction	O
of	O
CDKIs	B-GENE
,	O
and	O
a	O
resultant	O
G1	O
arrest	O
.	O

Articles	O
addressing	O
valvular	O
heart	O
disease	O
or	O
heart	O
failure	O
secondary	O
to	O
acute	O
myocardial	O
infarction	O
or	O
Chagas'	O
disease	O
were	O
excluded	O
.	O

We	O
further	O
show	O
that	O
proteolytic	O
targeting	O
by	O
calpain	B-GENE
II	I-GENE
and	O
the	O
proteasome	O
involves	O
different	O
structural	O
elements	O
of	O
YY1	B-GENE
.	O

These	O
findings	O
suggest	O
that	O
a	O
range	O
of	O
microenvironmental	O
conditions	O
exist	O
within	O
purified	O
water	O
systems	O
,	O
leading	O
to	O
variable	O
populations	O
of	O
bacteria	O
.	O

Like	O
their	O
yeast	O
counterpart	O
,	O
the	O
mouse	O
GCN2	B-GENE
isoforms	O
contain	O
HisRS-related	B-GENE
sequences	I-GENE
juxtaposed	O
to	O
the	O
kinase	O
catalytic	O
domain	O
.	O

Vitamin	O
D3	O
plus	O
nicotine	O
treatment	O
produced	O
parallel	O
increases	O
in	O
cardiac	O
mass	O
and	O
elastic	O
modulus	O
,	O
with	O
a	O
significant	O
correlation	O
between	O
the	O
two	O
.	O

Microvessels	O
were	O
counted	O
in	O
a	O
x200	O
field	O
(	O
0	O
.	O
754	O
mm2	O
)	O
in	O
the	O
area	O
of	O
maximal	O
angiogenesis	O
.	O

In	O
endemic	O
BL	O
,	O
the	O
RB2	B-GENE
/	I-GENE
p130	I-GENE
gene	I-GENE
is	O
mutated	O
in	O
most	O
of	O
the	O
cases	O
,	O
and	O
the	O
protein	O
is	O
restricted	O
to	O
the	O
cytoplasm	O
.	O

French	O
bean	O
contains	O
a	O
small	O
family	O
of	O
genes	B-GENE
encoding	I-GENE
PAL	I-GENE
and	O
two	O
of	O
these	O
genes	O
,	O
PAL2	B-GENE
and	O
PAL3	B-GENE
,	O
have	O
been	O
shown	O
to	O
be	O
differentially	O
expressed	O
at	O
the	O
mRNA	O
level	O
in	O
bean	O
tissues	O
.	O

The	O
avian	O
cellular	O
homolog	O
of	O
the	O
oncogene	B-GENE
jun	I-GENE
.	O

The	O
availability	O
of	O
cryoprecipitate	O
and	O
DDAVP	O
offers	O
an	O
alternative	O
and	O
effective	O
treatment	O
for	O
the	O
temporary	O
reversal	O
of	O
uremic	O
bleeding	O
in	O
patients	O
who	O
require	O
urgent	O
invasive	O
procedures	O
.	O

The	O
intranodal	O
mesothelial	O
cells	O
occupied	O
the	O
sinusoids	O
of	O
the	O
lymph	O
nodes	O
and	O
were	O
initially	O
suspected	O
of	O
being	O
metastatic	O
from	O
the	O
ovarian	O
tumor	O
in	O
each	O
case	O
.	O

A	O
total	O
of	O
7	O
(	O
4	O
males	O
and	O
3	O
females	O
)	O
patients	O
were	O
included	O
in	O
this	O
retrospective	O
study	O
to	O
determine	O
the	O
sensitivity	O
of	O
radioimmunoscintigraphy	O
with	O
I-131	O
labeled	O
anti	O
CEA	B-GENE
/	I-GENE
CA	I-GENE
19-9	O
monoclonal	O
antibodies	O
.	O

Patients	O
with	O
detectable	O
serum	O
TNF	B-GENE
levels	O
had	O
significantly	O
lower	O
serum	O
T3	O
concentrations	O
compared	O
to	O
those	O
with	O
undetectable	O
levels	O
[	O
1	O
.	O
072	O
+	O
/	O
-	O
0	O
.	O
588	O
vs	O
.	O

We	O
find	O
that	O
the	O
measured	O
Nusselt	O
number	O
decreased	O
about	O
20%	O
over	O
the	O
range	O
of	O
Pr	O
spanned	O
in	O
the	O
experiment	O
.	O

Sodium	O
dodecyl	O
sulphate-induced	O
cleavage	O
by	O
eukaryotic	B-GENE
topoisomerase	I-GENE
I	I-GENE
is	O
known	O
to	O
yield	O
enzyme	O
covalently	O
attached	O
to	O
the	O
3'	O
cut	O
end	O
of	O
the	O
DNA	O
.	O

To	O
identify	O
some	O
of	O
the	O
genes	O
expressed	O
in	O
LPS-activated	O
coelomocytes	O
,	O
we	O
sequenced	O
randomly	O
chosen	O
clones	O
from	O
a	O
directionally	O
constructed	O
cDNA	O
library	O
to	O
produce	O
a	O
set	O
of	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
.	O

Adding	O
10	O
mmol	O
SDS	O
/	O
l	O
led	O
to	O
transient	O
inhibition	O
of	O
acidification	O
,	O
metal	O
solubilization	O
and	O
sulfur	O
oxidation	O
.	O

Overexpression	O
of	O
CARP	B-GENE
in	O
cardiomyocytes	O
suppresses	O
cardiac	B-GENE
troponin	I-GENE
C	I-GENE
and	O
atrial	B-GENE
natriuretic	I-GENE
factor	I-GENE
transcription	O
.	O

It	O
contained	O
seven	O
extra	O
amino	O
acids	O
of	O
FVVLNLQ	B-GENE
;	O
this	O
short	O
stretch	O
of	O
extra	O
sequence	O
was	O
found	O
between	O
Gln	O
(	O
421	O
)	O
and	O
Phe	O
(	O
422	O
)	O
within	O
the	O
SET	B-GENE
(	O
Suvar3-9	B-GENE
,	I-GENE
Enhancer-of-zeste	I-GENE
,	I-GENE
Trithorax	I-GENE
)	O
interacting	O
domain	O
(	O
SID	B-GENE
)	O
of	O
rMTM	B-GENE
.	O

Therapeutic	O
use	O
of	O
continuous	O
subcutaneous	O
infusion	O
of	O
recombinant	B-GENE
human	I-GENE
erythropoietin	I-GENE
in	O
malnourished	O
predialysis	O
anemic	O
patients	O
with	O
diabetic	O
nephropathy	O
.	O

Circulating	O
platelets	O
may	O
be	O
activated	O
by	O
exposed	O
triple-helical	O
collagen	B-GENE
in	O
atherosclerotic	O
lesions	O
in	O
Mg-deficient	O
ruminants	O
.	O

Elevated	O
maternal	B-GENE
alpha	I-GENE
fetoproteins	I-GENE
and	O
oligoamnios	O
:	O
fetal	O
prognosis	O
.	O

These	O
analyses	O
demonstrate	O
that	O
the	O
dUTPase	B-GENE
isoforms	O
are	O
encoded	O
by	O
the	O
same	O
gene	O
with	O
isoform-specific	O
transcripts	O
arising	O
through	O
the	O
use	O
of	O
alternative	O
5'	O
exons	O
.	O

Overexpression	O
of	O
the	O
bZip	O
interaction	O
domain	O
of	O
CBP	B-GENE
specifically	O
abolishes	O
the	O
positive	O
cross	O
talk	O
between	O
TR	B-GENE
and	O
p45	B-GENE
/	I-GENE
NF-E2	I-GENE
.	O

Of	O
these	O
179	O
samples	O
,	O
Mobiluncus	O
SP	O
was	O
observed	O
in	O
35	O
(	O
19	O
.	O
6%	O
)	O
using	O
Gram	O
staining	O
and	O
in	O
18	O
(	O
10	O
.	O
1%	O
)	O
this	O
microorganism	O
was	O
isolated	O
in	O
agar	O
RLK	O
and	O
anaerobic	O
atmosphere	O
.	O

The	O
phi	B-GENE
AP3	I-GENE
factor	I-GENE
is	O
a	O
nuclear	O
phosphoprotein	O
;	O
the	O
extent	O
of	O
its	O
phosphorylation	O
is	O
regulated	O
during	O
the	O
cell	O
cycle	O
.	O

As	O
the	O
half-life	O
of	O
the	O
compound	O
did	O
never	O
exceed	O
8-9	O
h	O
,	O
the	O
data	O
do	O
not	O
support	O
any	O
change	O
of	O
pidotimod	O
administration	O
schedule	O
(	O
every	O
24-12	O
h	O
)	O
.	O

Studies	O
also	O
have	O
alluded	O
to	O
a	O
relationship	O
between	O
the	O
MSMR	O
cyst	O
and	O
certain	O
signs	O
or	O
symptoms	O
of	O
disease	O
.	O

One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA-3	B-GENE
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	O
lymphocytes	O
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
replication	O
.	O

There	O
were	O
minimal	O
negative	O
effects	O
on	O
hematological	O
parameters	O
,	O
acid-base	O
status	O
,	O
and	O
blood	O
gases	O
.	O

A	O
crucial	O
transcription	O
factor	O
in	O
this	O
process	O
is	O
STAT6	B-GENE
,	O
which	O
binds	O
to	O
a	O
specific	O
DNA	O
element	O
upon	O
cytokine	O
activation	O
.	O

Using	O
Ki-ras-transformed	O
3T3	O
cells	O
as	O
a	O
model	O
system	O
,	O
we	O
show	O
that	O
both	O
RA	O
and	O
the	O
'dissociating'	O
retinoids	O
inhibit	O
anchorage-independent	O
cell	O
proliferation	O
,	O
suggesting	O
that	O
retinoid-induced	O
growth	O
inhibition	O
may	O
be	O
related	O
to	O
AP1	B-GENE
transrepression	O
.	O

Ovarian	O
tumors	O
in	O
pregnancy	O
.	O

Altogether	O
,	O
our	O
results	O
indicate	O
that	O
the	O
transcriptional	O
activity	O
of	O
Cut	B-GENE
proteins	I-GENE
is	O
modulated	O
by	O
PKC	B-GENE
.	O

References	O
for	O
occupational	O
fitness	O
of	O
adolescents	O
with	O
diseases	O
of	O
the	O
respiratory	O
tract	O
and	O
lungs	O
.	O

Lysosomal	O
enzymes	O
that	O
degrade	O
cartilage	O
are	O
released	O
.	O

We	O
have	O
previously	O
mapped	O
the	O
defect	O
in	O
RIIIS	O
/	O
J	O
to	O
distal	O
mouse	O
Chr	O
11	O
,	O
distinct	O
from	O
the	O
Vwf	B-GENE
locus	I-GENE
on	O
Chr	O
6	O
.	O

Plasma	B-GENE
renin	I-GENE
activity	O
rose	O
and	O
the	O
plasma	O
aldosterone	O
level	O
fell	O
after	O
taking	O
lisinopril	O
.	O

In	O
addition	O
a	O
significant	O
Treatment	O
X	O
Strain	O
interaction	O
was	O
due	O
to	O
the	O
larger	O
defecation	O
numbers	O
displayed	O
by	O
the	O
taurine-injected	O
MR	O
rats	O
relative	O
to	O
the	O
saline-injected	O
MR	O
rats	O
.	O

Retroviral	O
transduction	O
of	O
T	B-GENE
/	I-GENE
T	I-GENE
(	I-GENE
L	I-GENE
)	I-GENE
causes	O
a	O
rapidly	O
fatal	O
myeloproliferative	O
disease	O
in	O
a	O
murine	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
model	O
,	O
whereas	O
T	B-GENE
/	I-GENE
T	I-GENE
(	I-GENE
F	I-GENE
)	I-GENE
causes	O
a	O
long-latency	O
,	O
pre-B-cell	O
lymphoblastic	O
lymphoma	O
.	O

Typical	O
configurations	O
of	O
psychosocial	O
stress	O
factors	O
of	O
psychiatrically	O
conspicuous	O
children	O
and	O
adolescents	O
.	O

The	O
mutant	O
allele	O
of	O
the	O
alpha	B-GENE
1-tubulin	I-GENE
gene	I-GENE
was	O
designated	O
tua1-1	B-GENE
.	O

Treatment	O
includes	O
both	O
medical	O
and	O
surgical	O
options	O
,	O
with	O
medical	O
therapy	O
further	O
subclassified	O
into	O
pharmacologic	O
and	O
pneumatic	O
dilation	O
.	O

Similarly	O
approximately	O
300	O
bp	O
of	O
sequence	O
downstream	O
of	O
the	O
translation	O
terminator	O
TGA	O
of	O
the	O
beta-tubulin	B-GENE
2	I-GENE
(	O
BTU2	B-GENE
)	O
gene	O
could	O
substitute	O
for	O
the	O
3'	O
region	O
of	O
the	O
H4-I	B-GENE
gene	I-GENE
.	O

The	O
gene	O
was	O
uniquely	O
mapped	O
with	O
odds	O
>	O
1	O
,	O
000	O
:	O
1	O
on	O
chromosome	O
3p	O
in	O
Centre	O
d'Etude	O
du	O
Polymorphisme	O
Humain	O
pedigrees	O
.	O

Furthermore	O
,	O
the	O
soluble	O
forms	O
of	O
ATF6	B-GENE
and	O
the	O
G13	B-GENE
gene	I-GENE
product	I-GENE
are	O
unable	O
to	O
bind	O
to	O
several	O
point	O
mutants	O
of	O
the	O
cis-acting	O
ER	B-GENE
stress	I-GENE
response	I-GENE
element	I-GENE
in	O
vitro	O
that	O
hardly	O
respond	O
to	O
ER	O
stress	O
in	O
vivo	O
.	O

A	O
retrospective	O
study	O
of	O
banked	O
sera	O
from	O
19	O
cats	O
with	O
the	O
eosinophilic	O
granuloma	O
complex	O
revealed	O
that	O
68%	O
of	O
affected	O
cats	O
had	O
circulating	O
antibodies	O
to	O
components	O
of	O
normal	O
cat	O
epithelium	O
.	O

Elimination	O
of	O
natural	O
antibodies	O
in	O
discordant	O
xenografts	O
.	O

The	O
first	O
one	O
is	O
a	O
TPA-responsive	B-GENE
element	I-GENE
that	O
controls	O
the	O
base-line	O
ST3	B-GENE
promoter	I-GENE
activity	O
but	O
is	O
not	O
required	O
for	O
its	O
activation	O
.	O

Cyclic	B-GENE
AMP-dependent	I-GENE
protein	I-GENE
kinase	I-GENE
binding	O
to	O
A-kinase	B-GENE
anchoring	O
proteins	O
in	O
living	O
cells	O
by	O
fluorescence	O
resonance	O
energy	O
transfer	O
of	O
green	O
fluorescent	O
protein	O
fusion	O
proteins	O
.	O

RESULTS	O
:	O
In	O
the	O
pregnant	O
group	O
,	O
serum	O
PP14	B-GENE
concentrations	O
were	O
markedly	O
increased	O
after	O
ET	O
,	O
and	O
a	O
significant	O
difference	O
between	O
the	O
pregnant	O
group	O
and	O
the	O
nonpregnant	O
group	O
was	O
observed	O
8	O
days	O
following	O
ET	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Paf1p	B-GENE
may	O
therefore	O
be	O
required	O
for	O
both	O
positive	O
and	O
negative	O
regulation	O
of	O
subsets	O
of	O
yeast	O
genes	O
.	O

The	O
sign	O
of	O
Leser-Trelat	O
:	O
does	O
it	O
exist	O
?	O
The	O
sign	O
of	O
Leser-Trelat	O
is	O
usually	O
regarded	O
as	O
a	O
reliable	O
cutaneous	O
marker	O
of	O
internal	O
malignancy	O
.	O

We	O
have	O
initiated	O
studies	O
to	O
identify	O
candidate	O
signal	O
transducers	O
that	O
associate	O
with	O
the	O
cytosolic	O
domain	O
(	O
cd	O
)	O
of	O
the	O
IL-1R	B-GENE
.	O

To	O
test	O
whether	O
or	O
not	O
SOCS-3	B-GENE
also	O
binds	O
to	O
the	O
IGFIR	B-GENE
,	O
we	O
cloned	O
human	B-GENE
SOCS-3	I-GENE
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
from	O
human	O
skeletal	O
muscle	O
mRNA	O
.	O

The	O
CD4	B-GENE
count	O
at	O
which	O
remission	O
occurs	O
may	O
reflect	O
severe	O
immunodeficiency	O
such	O
that	O
risk	O
for	O
AIDS-related	O
infection	O
is	O
high	O
.	O

Platelet	O
counts	O
and	O
function	O
as	O
well	O
as	O
fibrinogen	B-GENE
and	O
von	B-GENE
Willebrand	I-GENE
factor	I-GENE
(	O
vWF	B-GENE
)	O
levels	O
were	O
determined	O
in	O
each	O
sample	O
.	O

Developmental	O
toxicity	O
of	O
the	O
class	O
III	O
antiarrhythmic	O
agent	O
almokalant	O
in	O
mice	O
.	O

The	O
absence	O
of	O
other	O
regions	O
of	O
hybridization	O
suggests	O
that	O
there	O
are	O
no	O
closely	O
related	O
sequences	O
(	O
e	O
.	O
g	O
.	O
,	O
reverse	O
transcribed	O
pseudogenes	O
)	O
scattered	O
throughout	O
the	O
genome	O
and	O
that	O
if	O
there	O
are	O
closely	O
related	O
genes	O
,	O
they	O
must	O
be	O
clustered	O
near	O
GSTT2	B-GENE
.	O

Recent	O
advances	O
have	O
shown	O
that	O
volatile	O
sulfur	O
is	O
a	O
result	O
of	O
ecological	O
interactions	O
and	O
transformation	O
processes	O
through	O
planktonic	O
food	O
webs	O
.	O

Cdk2	B-GENE
and	O
MAPK	B-GENE
precipitates	O
from	O
untreated	O
tumor	O
lysates	O
phosphorylated	O
recombinant	B-GENE
wild-type	I-GENE
p27	I-GENE
but	O
not	O
the	O
T187A	O
mutant	O
in	O
vitro	O
.	O

Ribonuclease	B-GENE
protection	O
assays	O
revealed	O
that	O
hmg1	B-GENE
and	O
hmg2	B-GENE
are	O
differentially	O
expressed	O
in	O
a	O
developmentally-	O
and	O
spatially-modulated	O
manner	O
during	O
morphogenesis	O
of	O
specialized	O
terpenoid-containing	O
pigment	O
glands	O
in	O
embryos	O
.	O

SERS	O
spectra	O
were	O
obtained	O
by	O
vacuum	O
evaporation	O
and	O
casting	O
of	O
p-NTP	O
onto	O
silver	O
island	O
films	O
,	O
and	O
also	O
from	O
colloidal	O
silver	O
solutions	O
.	O

From	O
these	O
results	O
,	O
it	O
is	O
concluded	O
that	O
EDLF	O
has	O
clear	O
vasoconstrictor	O
properties	O
which	O
are	O
not	O
due	O
to	O
adrenergic	O
or	O
calcium	O
entry	O
mechanisms	O
and	O
that	O
there	O
are	O
differences	O
in	O
the	O
vasoconstrictor	O
effects	O
of	O
EDLFs	O
with	O
respect	O
to	O
different	O
vascular	O
beds	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Dbf8p	B-GENE
plays	O
an	O
essential	O
role	O
in	O
chromosome	O
segregation	O
.	O

The	O
HOI	O
induced	O
a	O
nearly	O
fourfold	O
increase	O
in	O
ANF	B-GENE
in	O
the	O
elderly	O
,	O
whereas	O
that	O
for	O
the	O
young	O
was	O
threefold	O
.	O

The	O
sequence	O
data	O
now	O
permit	O
a	O
detailed	O
interpretation	O
of	O
the	O
X-ray	O
crystallographic	O
structure	O
of	O
the	O
enzyme	O
and	O
the	O
cloning	O
and	O
expression	O
of	O
the	O
clostridial	O
gene	O
will	O
facilitate	O
site-directed	O
mutagenesis	O
.	O

Dissolution	O
of	O
the	O
Pt-30%Ir	O
microelectrode	O
tip	O
was	O
observed	O
by	O
scanning	O
electron	O
microscopy	O
at	O
charge	O
densities	O
as	O
low	O
as	O
200	O
microC	O
/	O
cm2	O
X	O
ph	O
(	O
1	O
A	O
/	O
cm2	O
)	O
,	O
whereas	O
erosion	O
of	O
activated	O
iridium	O
microelectrodes	O
occurred	O
only	O
at	O
the	O
highest	O
charge	O
and	O
current	O
densities	O
(	O
3200	O
microC	O
/	O
cm2	O
X	O
ph	O
,	O
16	O
A	O
/	O
cm2	O
)	O
.	O

The	O
steepness	O
of	O
the	O
standard	O
O2	O
dissociation	O
curve	O
becomes	O
greater	O
during	O
the	O
training	O
period	O
(	O
increase	O
in	O
Hill's	O
n	O
from	O
2	O
.	O
68	O
+	O
/	O
-	O
0	O
.	O
10	O
to	O
2	O
.	O
96	O
+	O
/	O
-	O
0	O
.	O
15	O
)	O
.	O

Subcutaneous	O
administration	O
of	O
the	O
somatostatin	B-GENE
analogue	O
,	O
octreotide	O
,	O
100	O
micrograms	O
thrice	O
daily	O
,	O
resulted	O
in	O
a	O
sustained	O
improvement	O
in	O
diarrhoea	O
and	O
disappearance	O
of	O
faecal	O
incontinence	O
without	O
reducing	O
calcitonin	B-GENE
levels	O
.	O

The	O
fracture	O
groups	O
were	O
significantly	O
older	O
and	O
had	O
more	O
years	O
since	O
menopause	O
than	O
the	O
control	O
groups	O
.	O

Total	O
serum	O
calcium	O
was	O
7	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dl	O
,	O
whereas	O
ionized	O
calcium	O
was	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
dl	O
,	O
phosphorus	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
dl	O
,	O
and	O
alkaline	B-GENE
phosphatase	I-GENE
149	O
+	O
/	O
-	O
48	O
.	O
6	O
U	O
/	O
liter	O
.	O

CONCLUSION	O
:	O
TNF	B-GENE
alpha	I-GENE
,	O
TGF	B-GENE
beta	I-GENE
,	O
PDGF	B-GENE
and	O
IL-1beta	B-GENE
increased	O
LDLr	B-GENE
gene	I-GENE
expression	O
by	O
increasing	O
sterol-independent	O
and	O
mitogenesis-independent	O
gene	O
transcription	O
.	O

Cell	O
viability	O
and	O
lysosomal	O
enzymes	O
.	O

Automatic	O
view	O
box	O
.	O

Reporter	O
constructs	O
function	O
in	O
a	O
parallel	O
manner	O
,	O
demonstrating	O
the	O
key	O
role	O
of	O
the	O
AhR	B-GENE
in	O
constitutive	O
as	O
well	O
as	O
TCDD-induced	O
expression	O
of	O
Cyp1B1	B-GENE
in	O
mouse	O
embryo	O
fibroblasts	O
.	O

At	O
baseline	O
,	O
serum	O
levels	O
of	O
lycopene	O
and	O
FLOP	O
were	O
abnormally	O
high	O
and	O
serum	O
FLOP	O
was	O
correlated	O
significantly	O
with	O
plasma	O
cyclosporine	O
levels	O
(	O
r	O
=	O
0	O
.	O
646	O
,	O
p	O
=	O
0	O
.	O
016	O
)	O
.	O

2	O
.	O
numerous	O
narrow	O
shunt	O
vessels	O
departing	O
continuously	O
from	O
the	O
primary	O
arteries	O
to	O
feed	O
a	O
secondary	O
arterial	O
system	O
which	O
parallels	O
the	O
primary	O
one	O
.	O

Pmt2	B-GENE
is	O
a	O
member	O
of	O
a	O
six-protein	O
family	O
in	O
yeast	O
that	O
catalyzes	O
the	O
first	O
step	O
in	O
O	O
mannosylation	O
of	O
target	O
proteins	O
.	O

Promoter	O
activity	O
was	O
high	O
in	O
cell	O
lines	O
that	O
expressed	O
high	O
levels	O
of	O
endogenous	O
D3	B-GENE
mRNA	I-GENE
,	O
as	O
indicated	O
by	O
Northern	O
blot	O
analyses	O
,	O
and	O
was	O
significantly	O
reduced	O
when	O
the	O
promoter	O
was	O
truncated	O
to	O
-122	O
bp	O
.	O

Sequencing	O
analysis	O
has	O
shown	O
that	O
each	O
rap1t	B-GENE
allele	I-GENE
contains	O
a	O
nonsense	O
mutation	O
within	O
a	O
discrete	O
region	O
between	O
amino	O
acids	O
663	O
and	O
684	O
.	O

This	O
protein	O
is	O
present	O
in	O
both	O
HeLa	O
nuclear	O
extracts	O
and	O
S100	O
extracts	O
but	O
absent	O
from	O
SR	B-GENE
protein	I-GENE
preparations	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
a	O
classical	O
SR	B-GENE
protein	I-GENE
.	O

Finally	O
a	O
10-nucleotide	O
region	O
flanking	O
the	O
exon	O
4	O
protein-binding	O
site	O
is	O
homologous	O
to	O
instability	O
elements	O
within	O
five	O
other	O
transcripts	O
,	O
suggesting	O
that	O
a	O
common	O
coding	O
region	O
determinant	O
may	O
exist	O
.	O

Alternating	O
proline	O
/	O
alanine	O
sequence	O
of	O
beta	B-GENE
B1	I-GENE
subunit	I-GENE
originates	O
from	O
a	O
repetitive	O
DNA	O
sequence	O
.	O

The	O
distribution	O
and	O
organization	O
of	O
projections	O
from	O
the	O
spinal	O
cervical	O
enlargement	O
to	O
subnucleus	O
reticularis	O
dorsalis	O
(	O
SRD	O
)	O
and	O
the	O
neighbouring	O
Cuneate	O
nucleus	O
(	O
Cu	O
)	O
area	O
was	O
studied	O
in	O
the	O
rat	O
by	O
using	O
microinjections	O
of	O
Phaseolus	B-GENE
vulgaris	I-GENE
leucoagglutinin	I-GENE
(	O
PHA-L	B-GENE
)	O
into	O
different	O
laminae	O
around	O
the	O
C7	O
level	O
.	O

Retreatment	O
of	O
these	O
2	O
dogs	O
resulted	O
in	O
a	O
similar	O
,	O
but	O
blunted	O
,	O
response	O
to	O
human	B-GENE
immunoglobulin	I-GENE
.	O

Cloning	O
and	O
sequence	O
analyses	O
revealed	O
a	O
second	O
cDNA	O
with	O
a	O
95-nt	O
deletion	O
in	O
the	O
region	O
coding	O
for	O
the	O
putative	O
second	O
intracellular	O
loop	O
and	O
the	O
fourth	O
transmembrane	O
domain	O
of	O
the	O
5-HT2C-R	B-GENE
.	O

The	O
relative	O
toxicity	O
of	O
nickel	O
oxide	O
(	O
NiO	O
)	O
,	O
nickel	O
sulfate	O
hexahydrate	O
(	O
NiSO4	O
.	O
6H2O	O
)	O
,	O
and	O
nickel	O
subsulfide	O
(	O
Ni3S2	O
)	O
was	O
studied	O
in	O
F344	O
/	O
N	O
rats	O
and	O
B6C3F1	O
mice	O
after	O
inhalation	O
exposure	O
for	O
6	O
hr	O
/	O
day	O
,	O
5	O
days	O
/	O
week	O
,	O
for	O
13	O
weeks	O
.	O

In	O
the	O
region	O
Walgau	O
with	O
mixed	O
industrial-rural	O
population	O
an	O
iodine	O
deficiency	O
I	O
was	O
found	O
in	O
81%	O
and	O
an	O
iodine	O
deficiency	O
II	O
in	O
45%	O
.	O

We	O
propose	O
that	O
plasmids	O
of	O
the	O
pLS1	O
family	O
(	O
pE194	O
,	O
pADB201	O
,	O
and	O
pLB4	O
)	O
share	O
functional	O
and	O
structural	O
characteristics	O
for	O
the	O
regulation	O
of	O
their	O
copy	O
numbers	O
.	O

Reye's	O
syndrome	O
:	O
reports	O
of	O
7	O
cases	O
in	O
the	O
period	O
1982-1987	O
.	O

The	O
new	O
FIGO	O
definition	O
of	O
cervical	O
cancer	O
stage	O
IA	O
:	O
a	O
critique	O
.	O

In	O
one	O
of	O
these	O
tumors	O
the	O
observed	O
rearrangement	O
was	O
not	O
due	O
to	O
the	O
insertion	O
of	O
an	O
intact	O
MoMuLV	O
provirus	O
.	O

Among	O
six	O
different	O
library	O
isolates	O
containing	O
6	B-GENE
.	I-GENE
5-	I-GENE
to	I-GENE
7-kb	I-GENE
IAP	I-GENE
units	I-GENE
,	O
some	O
restriction	O
sites	O
were	O
highly	O
conserved	O
whereas	O
others	O
varied	O
in	O
both	O
occurrence	O
and	O
position	O
.	O

Immunochemotherapy	O
with	O
schizophyllan	O
(	O
SPG	O
)	O
combined	O
with	O
chemotherapeutic	O
agents	O
was	O
evaluated	O
in	O
two	O
syngeneic	O
tumor-C3H	O
/	O
He	O
mouse	O
systems	O
.	O

Mutation	O
of	O
the	O
octamer	O
element	O
also	O
significantly	O
reduced	O
the	O
ability	O
of	O
HDAC1	B-GENE
to	O
confer	O
repression	O
of	O
inducible	O
HLA-DRA	B-GENE
promoter	I-GENE
activation	O
.	O

Outflow	O
obstruction	O
of	O
pancreatic	O
juice	O
,	O
i	O
.	O
e	O
.	O
,	O
"relative	O
stenosis	O
of	O
the	O
minor	O
papilla	O
,	O
"	O
was	O
considered	O
to	O
be	O
present	O
in	O
the	O
patients	O
with	O
type	O
II	O
papilla	O
,	O
and	O
,	O
therefore	O
,	O
the	O
patients	O
with	O
type	O
II	O
papilla	O
might	O
suffer	O
from	O
acute	O
pancreatitis	O
resulting	O
from	O
poor	O
drainage	O
of	O
pancreatic	O
juice	O
and	O
excessive	O
pressure	O
in	O
the	O
dorsal	O
duct	O
.	O

Natl	O
.	O

Pharmacological	O
and	O
pharmacokinetic	O
characteristics	O
of	O
the	O
non-ionic	O
monomeric	O
X-ray	O
contrast	O
agent	O
iopromide	O
(	O
Ultravist	O
,	O
CAS	O
73334-07-3	O
)	O
were	O
evaluated	O
in	O
preclinical	O
studies	O
.	O

The	O
membrane-distal	O
cytoplasmic	O
region	O
of	O
human	B-GENE
granulocyte	I-GENE
colony-stimulating	I-GENE
factor	I-GENE
receptor	I-GENE
is	O
required	O
for	O
STAT3	B-GENE
but	O
not	O
STAT1	B-GENE
homodimer	I-GENE
formation	O
.	O

The	O
mean	O
value	O
of	O
the	O
CD79b	B-GENE
to	O
the	O
CD79b	B-GENE
internally	O
deleted	O
ratio	O
was	O
0	O
.	O
64	O
+	O
/	O
-	O
0	O
.	O
20	O
SD	O
in	O
normal	O
donors	O
and	O
0	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
27	O
SD	O
in	O
B-CLL	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

Amino	O
acid	O
sequence	O
of	O
one	O
human	O
liver	O
clone	O
(	O
HL-14	O
)	O
was	O
identical	O
to	O
the	O
rabbit	B-GENE
skeletal	I-GENE
muscle	I-GENE
phosphatase	I-GENE
2A	I-GENE
cDNA	I-GENE
(	O
with	O
97%	O
nucleotide	O
identity	O
)	O
.	O

Factor	B-GENE
XI	I-GENE
deficiency	O
is	O
a	O
rare	O
hereditary	O
bleeding	O
disorder	O
affecting	O
the	O
intrinsic	O
pathway	O
.	O

The	O
effect	O
of	O
ibopamine	O
and	O
furosemide	O
in	O
130	O
patients	O
with	O
NYHA	O
Class	O
I	O
and	O
II	O
heart	O
failure	O
were	O
studied	O
in	O
a	O
parallel	O
,	O
double-blind	O
,	O
randomized	O
placebo-controlled	O
multi-centre	O
trial	O
.	O

The	O
assembly	O
of	O
sequence	O
ready	O
,	O
high-resolution	O
physical	O
maps	O
and	O
construction	O
of	O
minimally	O
overlapping	O
contigs	O
for	O
the	O
human	O
as	O
well	O
as	O
model	O
genomes	O
requires	O
accurate	O
determination	O
of	O
the	O
extent	O
of	O
overlap	O
between	O
adjacent	O
clones	O
as	O
well	O
as	O
their	O
relative	O
orientation	O
.	O

The	O
SSB-poly	O
(	O
dT	O
)	O
affinity	O
is	O
too	O
high	O
to	O
measure	O
in	O
buffers	O
containing	O
even	O
5	O
M	O
NaCl	O
;	O
however	O
,	O
in	O
1	O
.	O
8-2	O
.	O
5	O
M	O
NaBr	O
,	O
we	O
measure	O
alpha	O
log	O
Kobsd	O
/	O
alpha	O
log	O
[	O
NaBr	O
]	O
=	O
-5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
,	O
with	O
a	O
lower	O
value	O
of	O
omega	O
T	O
/	O
O	O
=	O
130	O
+	O
/	O
-	O
70	O
.	O

Selenium	O
is	O
an	O
essential	O
element	O
for	O
humans	O
,	O
animals	O
and	O
some	O
species	O
of	O
microorganisms	O
.	O

Consistent	O
with	O
this	O
,	O
we	O
show	O
that	O
peptides	O
representing	O
docking	O
sites	O
within	O
the	O
target	O
substrates	O
Elk-1	B-GENE
and	O
p90	B-GENE
(	I-GENE
rsk	I-GENE
)	I-GENE
inhibit	O
ERK-dependent	O
activation	O
of	O
MKP-3	B-GENE
.	O

Acute	O
type	O
A	O
hepatitis	O
in	O
three	O
patients	O
with	O
chronic	O
HBV	O
infection	O
.	O

A	O
potential	O
TATA	O
box	O
is	O
located	O
29	O
base	O
pairs	O
upstream	O
of	O
the	O
first	O
transcription	O
initiation	O
site	O
.	O

Use	O
of	O
radioactive	O
isotopes	O
in	O
the	O
chemistry	O
of	O
proteins	O
.	O

Mutations	O
at	O
two	O
neighboring	O
sites	O
,	O
serine	O
242	O
and	O
threonine	O
255	O
,	O
exacerbated	O
the	O
effect	O
.	O

Preface	O
.	O

Light	O
microscopical	O
and	O
routine	O
immunohistochemical	O
studies	O
of	O
a	O
cervical	O
neoplasm	O
in	O
a	O
32	O
year	O
old	O
woman	O
initially	O
suggested	O
a	O
histiocytic	O
lymphoma	O
,	O
but	O
histochemical	O
staining	O
for	O
chloroacetate	B-GENE
esterase	I-GENE
established	O
the	O
correct	O
diagnosis	O
.	O

All	O
of	O
the	O
newly	O
acquired	O
proviruses	O
identified	O
in	O
mosaic	O
founder	O
SWR	B-GENE
/	I-GENE
J-RF	I-GENE
/	I-GENE
J	I-GENE
mice	O
that	O
could	O
be	O
transmitted	O
through	O
the	O
germ	O
line	O
were	O
also	O
present	O
in	O
somatic	O
tissues	O
,	O
demonstrating	O
that	O
viral	O
integration	O
occurred	O
before	O
the	O
germ	O
line	O
was	O
set	O
aside	O
from	O
the	O
somatic	O
lineages	O
.	O

Autoionization	O
rates	O
and	O
energy	O
levels	O
of	O
triplet	O
nf	O
,	O
v	O
=	O
1	O
Rydberg	O
states	O
of	O
H2	O
.	O

At	O
20	O
days	O
(	O
D	O
)	O
and	O
at	O
3	O
months	O
post-TBI	O
,	O
irradiated	O
rats	O
had	O
a	O
significantly	O
lower	O
percentage	O
of	O
avoidance	O
than	O
controls	O
but	O
no	O
statistical	O
difference	O
was	O
found	O
at	O
5	O
months	O
post-TBI	O
.	O
b	O
/	O
Two-way	O
avoidance	O
test	O
:	O
this	O
test	O
was	O
performed	O
only	O
after	O
TBI	O
.	O

Monitoring	O
changes	O
in	O
the	O
heart	O
rate	O
of	O
the	O
premature	O
fetus	O
during	O
tocolysis	O
with	O
the	O
beta-adrenomimetics	O
partusisten	O
and	O
Pre-par	O
.	O

Thin-layer	O
chromatographic	O
methods	O
were	O
up-dated	O
for	O
pharmacokinetic	O
studies	O
of	O
imipramine	O
in	O
plasma	O
and	O
urine	O
.	O

This	O
study	O
was	O
designed	O
to	O
compare	O
the	O
efficacy	O
of	O
efegatran	O
plus	O
streptokinase	B-GENE
versus	O
heparin	O
plus	O
accelerated	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
TPA	B-GENE
)	O
in	O
coronary	O
reperfusion	O
in	O
acute	O
MI	O
.	O

Based	O
on	O
the	O
current	O
literature	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
toxicity	O
of	O
OA	O
indicate	O
three	O
major	O
effects	O
:	O
(	O
1	O
)	O
inhibition	O
of	O
mitochondrial	O
respiration	O
correlated	O
with	O
a	O
depletion	O
of	O
ATP	O
;	O
(	O
2	O
)	O
inhibition	O
of	O
tRNA-synthetase	B-GENE
accompanied	O
by	O
a	O
reduced	O
protein	O
synthesis	O
;	O
and	O
(	O
3	O
)	O
enhanced	O
lipid	O
peroxidation	O
.	O

And	O
,	O
most	O
importantly	O
,	O
reconstitution	O
of	O
a	O
consensus	B-GENE
CRE	I-GENE
,	O
within	O
the	O
21-bp	O
enhancers	O
increases	O
binding	O
of	O
CREB	B-GENE
/	I-GENE
ATF	I-GENE
proteins	I-GENE
but	O
abrogates	O
basal	O
repression	O
of	O
LTR-directed	O
transcription	O
in	O
vitro	O
.	O

The	O
cause	O
of	O
death	O
is	O
often	O
quite	O
apparent	O
from	O
the	O
pathological	O
and	O
toxicological	O
findings	O
;	O
however	O
,	O
the	O
manner	O
of	O
death	O
often	O
gives	O
the	O
examining	O
official	O
some	O
difficulty	O
.	O

In	O
doses	O
of	O
0	O
.	O
03-0	O
.	O
3	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
,	O
SG-75	O
did	O
not	O
significantly	O
affect	O
pulse	O
pressure	O
,	O
heart	O
rate	O
,	O
aortic	O
blood	O
flow	O
,	O
left	O
ventricular	O
pressure	O
(	O
LVP	O
)	O
and	O
LVdP	O
/	O
dt	O
max	O
.	O

The	O
RNA	O
aptamer	O
contains	O
three	O
stems	O
separated	O
by	O
a	O
pair	O
of	O
two-base	O
bulges	O
,	O
and	O
adopts	O
an	O
unanticipated	O
fold	O
in	O
which	O
both	O
junctional	O
sites	O
are	O
anchored	O
through	O
base	O
triple	O
formation	O
.	O

Phase	O
II	O
study	O
of	O
VP-16	O
(	O
capsule	O
)	O
in	O
solid	O
tumors	O
.	O

These	O
results	O
suggest	O
that	O
leader-mRNA	O
fusion	O
in	O
coronavirus	O
transcription	O
does	O
not	O
require	O
direct	O
RNA-RNA	O
interaction	O
between	O
complementary	O
sequences	O
.	O

Activation	O
of	O
nuclear	B-GENE
factor	I-GENE
(	I-GENE
NF	I-GENE
)	I-GENE
-kappaB	I-GENE
and	O
subsequent	O
proinflammatory	O
gene	O
expression	O
in	O
human	O
airway	O
epithelial	O
cells	O
can	O
be	O
evoked	O
by	O
oxidative	O
stress	O
.	O

A	O
cAMP-responsive	B-GENE
element-like	I-GENE
(	O
CRE-like	B-GENE
,	O
TGACGTGA	B-GENE
)	O
promoter	O
sequence	O
and	O
a	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
signaling	O
pathway	O
are	O
involved	O
in	O
this	O
induction	O
,	O
and	O
activation	O
of	O
both	O
CRE	B-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
and	O
activating	B-GENE
transcription	I-GENE
factor-2	I-GENE
(	O
ATF-2	B-GENE
)	O
is	O
required	O
in	O
the	O
above	O
process	O
.	O

These	O
data	O
suggest	O
that	O
a	O
major	O
part	O
of	O
the	O
reduction	O
in	O
food	O
intake	O
in	O
hyperphagic	O
rats	O
eating	O
a	O
quinine-adulterated	O
diet	O
is	O
due	O
to	O
postingestional	O
events	O
.	O

Similarly	O
,	O
we	O
examined	O
whether	O
the	O
ELK1	B-GENE
,	O
SAP1a	B-GENE
,	O
FLI1	B-GENE
,	O
EWS-FLI1	B-GENE
,	O
ETS1	B-GENE
,	O
ETS2	B-GENE
,	O
PEA3	B-GENE
and	O
PU	B-GENE
.	I-GENE
1	I-GENE
proteins	I-GENE
can	O
form	O
ternary	O
complexes	O
with	O
SRF	B-GENE
on	O
the	O
Egr1	B-GENE
SREI	B-GENE
and	I-GENE
II	I-GENE
.	O

In	O
Arabidopsis	O
,	O
the	O
induction	O
of	O
a	O
dehydration-responsive	B-GENE
gene	I-GENE
,	O
rd22	B-GENE
,	O
is	O
mediated	O
by	O
abscisic	O
acid	O
(	O
ABA	O
)	O
and	O
requires	O
protein	O
biosynthesis	O
for	O
ABA-dependent	B-GENE
gene	I-GENE
expression	O
.	O

Like	O
the	O
elicitors	O
of	O
the	O
hypersensitive	O
reaction	O
(	O
HR	O
)	O
produced	O
by	O
E	O
.	O
chrysanthemi	O
(	O
HarpinEch	O
)	O
and	O
E	O
.	O
amylovora	O
(	O
HarpinEa	O
)	O
,	O
the	O
deduced	O
36-kDa	O
protein	O
does	O
not	O
possess	O
a	O
typical	O
signal	O
sequence	O
,	O
but	O
it	O
contains	O
a	O
putative	O
membrane-spanning	O
domain	O
.	O

During	O
skeletal	O
muscle	O
development	O
,	O
different	O
types	O
of	O
muscle	O
fibers	O
are	O
generated	O
,	O
which	O
express	O
different	O
combinations	O
of	O
muscle-specific	O
gene	O
products	O
.	O

This	O
resulted	O
in	O
a	O
complete	O
inhibition	O
of	O
Site-1	O
cleavage	O
that	O
was	O
restored	O
by	O
concomitant	O
overexpression	O
of	O
full-length	O
SCAP	B-GENE
.	O

Elimination	O
of	O
Haemophilus	O
influenzae	O
type	O
b	O
meningitis	O
after	O
introduction	O
of	O
vaccination	O
.	O

MK-801	O
administration	O
resulted	O
in	O
a	O
biphasic	O
response	O
in	O
seizure	O
latency	O
.	O

The	O
functional	O
homology	O
of	O
Cwg2	B-GENE
with	O
Cdc43	B-GENE
,	O
which	O
has	O
been	O
implicated	O
in	O
the	O
control	O
of	O
cell	O
polarity	O
,	O
suggests	O
a	O
link	O
between	O
two	O
morphogenetic	O
events	O
such	O
as	O
establishment	O
of	O
cell	O
polarity	O
and	O
cell	O
wall	O
biosynthesis	O
.	O

Using	O
anchored	O
PCR	O
,	O
a	O
VL	B-GENE
element	I-GENE
rearranged	O
to	O
CL2	B-GENE
was	O
isolated	O
.	O

The	O
Schistosoma	B-GENE
mansoni	I-GENE
homologue	I-GENE
(	O
SmSmad2	B-GENE
)	O
was	O
overexpressed	O
in	O
bacteria	O
as	O
a	O
Sj26-GST	B-GENE
fusion	I-GENE
protein	I-GENE
and	O
used	O
to	O
raise	O
specific	O
antibodies	O
.	O

In	O
addition	O
,	O
5'	O
deletions	O
removing	O
all	O
but	O
34	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
point	O
retained	O
greater	O
than	O
90%	O
promoter	O
activity	O
,	O
suggesting	O
that	O
the	O
-35	O
hexamer	O
was	O
not	O
essential	O
for	O
promoter	O
activity	O
.	O

This	O
loss	O
was	O
independent	O
of	O
drug	O
concentration	O
and	O
a	O
correction	O
factor	O
was	O
employed	O
to	O
calculate	O
the	O
true	O
free	O
diazepam	O
concentration	O
.	O

Coexposure	O
to	O
FP	O
also	O
resulted	O
in	O
a	O
more	O
pronounced	O
and	O
sustained	O
activation	O
of	O
the	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
kinase	I-GENE
/	I-GENE
extracellular	I-GENE
signal-regulated	I-GENE
protein	I-GENE
kinase	I-GENE
cascade	O
after	O
PMA	O
treatment	O
,	O
although	O
disruption	O
of	O
this	O
pathway	O
by	O
the	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
kinase	I-GENE
1	I-GENE
inhibitor	O
U0126	O
did	O
not	O
prevent	O
potentiation	O
of	O
apoptosis	O
.	O

Indeed	O
,	O
it	O
is	O
shown	O
that	O
it	O
mediates	O
the	O
formation	O
of	O
disulfide-linked	O
homodimers	O
and	O
that	O
the	O
formation	O
of	O
homo-	O
and	O
heterodimers	O
are	O
mutually	O
excluded	O
.	O

We	O
enrolled	O
253	O
HIV-antibody	B-GENE
positive	O
heroin	O
addicts	O
without	O
HIV-related	O
disease	O
(	O
n	O
=	O
81	O
)	O
or	O
with	O
persistent	O
generalized	O
lymphadenopathy	O
(	O
n	O
=	O
172	O
)	O
in	O
a	O
prospective	O
study	O
to	O
evaluate	O
clinical	O
progression	O
to	O
AIDS	O
related	O
complex	O
(	O
ARC	O
)	O
or	O
AIDS	O
and	O
to	O
identify	O
factors	O
of	O
possible	O
prognostic	O
relevance	O
.	O

Functional	O
tests	O
using	O
a	O
reporter	O
gene	O
,	O
containing	O
Stat5-binding	B-GENE
elements	I-GENE
,	O
confirmed	O
that	O
while	O
the	O
variant	O
form	O
was	O
inactive	O
by	O
itself	O
,	O
it	O
could	O
inhibit	O
the	O
function	O
of	O
the	O
full-length	O
receptor	O
.	O

The	O
monkey	B-GENE
LHR	I-GENE
cDNA	I-GENE
displayed	O
83-94%	O
overall	O
sequence	O
homology	O
with	O
the	O
other	O
mammalian	B-GENE
LHR	I-GENE
cDNAs	I-GENE
.	O

In	O
hypertensive	O
nephrosclerosis	O
,	O
therapy	O
containing	O
an	O
ACEI	O
alone	O
or	O
in	O
combination	O
significantly	O
reduces	O
the	O
incidence	O
of	O
renal	O
events	O
.	O

Removal	O
of	O
beta	B-GENE
2-microglobulin	I-GENE
by	O
hemodialysis	O
and	O
hemofiltration	O
:	O
a	O
four	O
year	O
follow	O
up	O
.	O

Most	O
of	O
the	O
patients	O
presented	O
with	O
Transient	O
Ischemic	O
Attacks	O
(	O
64%	O
)	O
or	O
Reversible	O
Ischemic	O
Neurologic	O
Deficits	O
(	O
19%	O
)	O
.	O

Another	O
segment	O
of	O
CRL3	B-GENE
(	O
-296	O
to	O
-184	O
)	O
,	O
also	O
displaying	O
enhancer	O
function	O
,	O
contained	O
tandem	O
repeated	O
sequences	O
(	O
DR-A1	B-GENE
and	O
DR-A2	B-GENE
)	O
.	O

In	O
Klinefelter's	O
syndrome	O
(	O
47XXY	O
)	O
,	O
serum	O
testosterone	O
levels	O
are	O
at	O
the	O
lower	O
end	O
of	O
the	O
normal	O
range	O
and	O
dihydrotestosterone	O
levels	O
are	O
low	O
.	O

Whereas	O
the	O
muscle	O
isoform	O
consists	O
of	O
997	O
amino	O
acids	O
and	O
terminates	O
with	O
the	O
sequence	B-GENE
Ala-Ile-Leu-Glu	I-GENE
,	O
the	O
second	O
isoform	O
is	O
1043	O
amino	O
acids	O
in	O
length	O
due	O
to	O
the	O
replacement	O
of	O
these	O
last	O
4	O
amino	O
acids	O
with	O
a	O
50-amino	O
acid	O
sequence	O
that	O
contains	O
a	O
potential	O
transmembrane	O
domain	O
followed	O
by	O
a	O
consensus	O
sequence	O
for	O
an	O
N-linked	O
glycosylation	O
site	O
.	O

Homology	O
with	O
the	O
human	O
protein	O
is	O
only	O
34%	O
in	O
the	O
tandem	O
repeat	O
domain	O
,	O
mainly	O
showing	O
conservation	O
of	O
serines	O
and	O
threonines	O
,	O
presumed	O
sites	O
of	O
O-linked	O
carbohydrate	O
attachment	O
.	O

Efficacy	O
of	O
a	O
three-	O
versus	O
a	O
five-week	O
alcohol	O
treatment	O
program	O
.	O

An	O
overexpression	O
of	O
the	O
betaAPP	B-GENE
gene	I-GENE
in	O
certain	O
areas	O
of	O
the	O
AD	O
brain	O
has	O
been	O
suggested	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
neuropathology	O
of	O
AD	O
.	O

Widening	O
of	O
the	O
abdominal	O
aortic	O
wall	O
on	O
an	O
ultrasound	O
examination	O
was	O
the	O
key	O
to	O
the	O
incidental	O
diagnosis	O
of	O
a	O
clinically	O
unsuspected	O
type	O
B	O
dissection	O
.	O

Activity	O
of	O
acid	B-GENE
hydrolases	I-GENE
of	O
peripheral	O
blood	O
leukocytes	O
in	O
focal	O
and	O
segmental	O
pneumonia	O
in	O
children	O
.	O

These	O
techniques	O
have	O
been	O
used	O
by	O
many	O
people	O
for	O
many	O
years	O
and	O
no	O
claim	O
is	O
being	O
made	O
for	O
any	O
innovation	O
in	O
this	O
regard	O
.	O

In	O
conclusion	O
,	O
primary	O
chemotherapy	O
based	O
on	O
high	O
dose	O
MTX	O
and	O
ara-C	O
is	O
highly	O
efficient	O
in	O
PCNSL	O
.	O

His	O
HC	B-GENE
II	I-GENE
activity	O
and	O
antigen	O
levels	O
were	O
49%	O
and	O
50%	O
,	O
respectively	O
,	O
and	O
his	O
daughter	O
also	O
showed	O
similar	O
low	O
levels	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
four	O
distinct	O
E2F	B-GENE
complexes	I-GENE
present	O
in	O
aged	O
and	O
senescent	O
normal	O
,	O
human	O
diploid	O
fibroblasts	O
.	O

Our	O
results	O
show	O
that	O
,	O
from	O
a	O
thermodynamical	O
standpoint	O
,	O
melatonin	O
may	O
directly	O
scavenge	O
hydroxyl	O
radicals	O
both	O
in	O
vacuum	O
and	O
in	O
aqueous	O
solution	O
.	O

Selected	O
topics	O
in	O
pediatric	O
ultrasonography--1992	O
.	O

We	O
report	O
here	O
on	O
the	O
molecular	O
nature	O
of	O
an	O
EMS-induced	O
mutant	O
,	O
mn1-89	B-GENE
,	O
a	O
leaky	O
semidominant	O
allele	O
of	O
the	O
Miniature1	B-GENE
(	O
Mn1	B-GENE
)	O
seed	O
locus	O
that	O
encodes	O
a	O
seed-specific	B-GENE
cell	I-GENE
wall	I-GENE
invertase	I-GENE
,	O
INCW2	B-GENE
.	O

These	O
data	O
indicate	O
that	O
although	O
218leu	O
retains	O
normal	O
transactivation	O
activity	O
on	O
a	O
p53	B-GENE
promoter	I-GENE
in	O
yeast	O
at	O
physiological	O
temperatures	O
,	O
it	O
is	O
not	O
capable	O
of	O
normal	O
p53	B-GENE
function	O
in	O
the	O
presence	O
of	O
a	O
248trp	B-GENE
allele	I-GENE
in	O
SNU-C5	O
cells	O
.	O

Increase	O
in	O
urinary	O
calcium	O
and	O
oxalate	O
after	O
fructose	O
infusion	O
.	O

These	O
results	O
would	O
suggest	O
that	O
a	O
high	O
UV	O
sensitivity	O
is	O
associated	O
with	O
high	O
phaeomelanin	O
and	O
low	O
eumelanin	O
levels	O
,	O
and	O
point	O
to	O
the	O
eumelanin	O
/	O
phaeomelanin	O
ratio	O
as	O
a	O
novel	O
chemical	O
parameter	O
that	O
could	O
be	O
used	O
for	O
predicting	O
individuals	O
at	O
high	O
risk	O
for	O
skin	O
cancer	O
and	O
melanoma	O
.	O

METHODS	O
:	O
This	O
retrospective	O
review	O
comprised	O
2711	O
eyes	O
that	O
had	O
LASIK	O
between	O
September	O
1996	O
and	O
September	O
1999	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
spindle	O
pole	O
body	O
duplication	O
gene	B-GENE
MPS1	I-GENE
is	O
part	O
of	O
a	O
mitotic	O
checkpoint	O
.	O

These	O
features	O
were	O
considered	O
consistent	O
with	O
a	O
diagnosis	O
of	O
Rothmund-Thomson	O
syndrome	O
.	O

Transfection	O
analyses	O
indicated	O
that	O
the	O
expression	O
of	O
Tbxas1	B-GENE
is	O
controlled	O
by	O
a	O
short	O
(	O
70-bp	O
)	O
positive	O
regulatory	O
sequence	O
and	O
several	O
upstream	O
repressive	O
elements	O
.	O

Clinical	O
aspects	O
and	O
therapy	O
.	O

Effect	O
of	O
variations	O
in	O
time	O
interval	O
between	O
treatment	O
with	O
BCG	O
and	O
quartz	O
dust	O
on	O
translocation	O
of	O
quartz	O
dust	O
from	O
the	O
lungs	O
to	O
their	O
regional	O
lymph	O
nodes	O
.	O

To	O
the	O
problem	O
of	O
the	O
stimulation	O
of	O
the	O
growth	O
of	O
transplantable	O
tumors	O
of	O
animals	O
previously	O
treated	O
with	O
antineoplastic	O
antibiotics	O
.	O

Despite	O
the	O
absence	O
of	O
exercise-induced	O
asthma	O
(	O
EIA	O
)	O
while	O
breathing	O
WH	O
air	O
,	O
asthmatic	O
patients	O
still	O
had	O
significantly	O
higher	O
mean	O
GH	O
increments	O
than	O
normal	O
subjects	O
(	O
9	O
.	O
2	O
vs	O
2	O
.	O
3	O
ng	O
/	O
ml	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
cut-off	O
percentage	O
positivity	O
value	O
was	O
established	O
using	O
500	O
brucellosis-positive	O
and	O
500	O
brucellosis-negative	O
serum	O
samples	O
,	O
confirmed	O
with	O
reference	O
to	O
the	O
sample	O
data	O
using	O
the	O
indirect	O
ELISA	O
kit	O
.	O

As	O
a	O
sequence-specific	O
DNA	O
binding	O
transcription	O
factor	O
,	O
p53	B-GENE
specifically	O
binds	O
to	O
a	O
20-bp	B-GENE
consensus	I-GENE
motif	I-GENE
5'-PuPuPuC	I-GENE
(	I-GENE
A	I-GENE
/	I-GENE
T	I-GENE
)	I-GENE
(	I-GENE
T	I-GENE
/	I-GENE
A	I-GENE
)	I-GENE
GPyPyPyPuPuPuC	I-GENE
(	I-GENE
A	I-GENE
/	I-GENE
T	I-GENE
)	I-GENE
(	I-GENE
T	I-GENE
/	I-GENE
A	I-GENE
)	I-GENE
GPyPyPy-3'	I-GENE
.	O

Airflow	O
was	O
measured	O
with	O
a	O
custom-designed	O
turbine	O
and	O
a	O
45-ft	O
.	O
-long	O
cable	O
to	O
reach	O
the	O
volume-measuring	O
module	O
.	O

Viral	O
RNA	O
,	O
molecularly	O
cloned	O
proviral	O
DNA	O
,	O
and	O
virus-specific	O
protein	O
of	O
avian	O
retrovirus	O
MH2	O
were	O
analyzed	O
.	O

To	O
study	O
the	O
mechanisms	O
as	O
well	O
as	O
magnitude	O
of	O
the	O
transmembrane	O
transfer	O
of	O
bacterial	O
products	O
from	O
the	O
dialysate	O
,	O
we	O
developed	O
a	O
computerized	O
in	O
vitro	O
dialysis	O
model	O
which	O
provides	O
continuous	O
pressure	O
recording	O
from	O
the	O
arterial	O
,	O
venous	O
,	O
dialysate	O
inflow	O
and	O
outflow	O
ports	O
.	O

Mutations	O
in	O
the	O
RP2	B-GENE
locus	I-GENE
at	I-GENE
Xp11	I-GENE
.	I-GENE
3	I-GENE
were	O
found	O
in	O
a	O
further	O
10-20%	O
of	O
XLRP	O
patients	O
,	O
as	O
predicted	O
from	O
linkage	O
studies	O
.	O

There	O
was	O
a	O
close	O
correlation	O
between	O
plasma	O
clearance	O
of	O
NT	O
by	O
10-hydroxylation	O
and	O
the	O
D	O
metabolic	O
ratio	O
(	O
D	O
/	O
4-OH-D	O
in	O
urine	O
)	O
in	O
the	O
Ghanaians	O
(	O
rs	O
=	O
-0	O
.	O
95	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
Swedes	O
(	O
rs	O
=	O
-0	O
.	O
84	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

METHODS	O
:	O
We	O
studied	O
20	O
symptomatic	O
patients	O
with	O
HOCM	O
(	O
12	O
men	O
)	O
,	O
mean	O
age	O
52	O
+	O
/	O
-	O
17	O
years	O
,	O
before	O
and	O
after	O
septal	O
reduction	O
using	O
echocardiography	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
.	O

The	O
intensity	O
of	O
the	O
SSTEs	O
is	O
an	O
order	O
of	O
magnitude	O
larger	O
than	O
that	O
of	O
the	O
MSEs	O
and	O
determines	O
the	O
signal	O
contrast	O
if	O
both	O
effects	O
are	O
selected	O
simultaneously	O
.	O

The	O
limit	O
between	O
the	O
cecum	O
and	O
the	O
ascending	O
colon	O
was	O
externally	O
marked	O
by	O
the	O
sulcus	O
cecocolicus	O
dorsalis	O
and	O
ventralis	O
.	O

Special	O
issues	O
devoted	O
to	O
the	O
biosynthesis	O
of	O
woody	O
plant	O
biopolymers	O
and	O
related	O
substances	O
.	O

Interestingly	O
,	O
Csx	B-GENE
/	I-GENE
Nkx2	I-GENE
.	O

Consequently	O
,	O
it	O
is	O
not	O
known	O
how	O
knee	O
loading	O
changes	O
following	O
ACL	O
transection	O
,	O
and	O
how	O
it	O
contributes	O
to	O
cartilage	O
degeneration	O
.	O

Increased	O
PTHRP	B-GENE
production	O
by	O
a	O
tyrosine	B-GENE
kinase	I-GENE
oncogene	I-GENE
,	O
Tpr-Met	B-GENE
:	O
role	O
of	O
the	O
Ras	B-GENE
signaling	O
pathway	O
.	O

The	O
95%	O
confidence	O
values	O
(	O
2SD	O
)	O
for	O
the	O
change	O
in	O
Ros	O
required	O
to	O
exclude	O
natural	O
variability	O
were	O
0	O
.	O
39	O
,	O
0	O
.	O
50	O
and	O
0	O
.	O
53	O
cmH2O	O
l-1	O
s	O
,	O
respectively	O
.	O

Expression	O
of	O
the	O
proapoptotic	B-GENE
protein	I-GENE
Bax	I-GENE
under	O
the	O
control	O
of	O
a	O
GAL10	B-GENE
promoter	I-GENE
in	O
Saccharomyces	O
cerevisiae	O
resulted	O
in	O
galactose-inducible	O
cell	O
death	O
.	O

TSA	O
treatment	O
,	O
however	O
,	O
did	O
not	O
detectably	O
alter	O
enhancer	O
factor	O
binding	O
or	O
the	O
positioning	O
of	O
nuc-1	B-GENE
on	O
the	O
majority	O
of	O
the	O
chromatin	O
templates	O
indicating	O
that	O
protein	O
acetylation	O
and	O
chromatin	O
remodeling	O
may	O
be	O
limiting	O
steps	O
that	O
occur	O
only	O
on	O
transcriptionally	O
competent	O
templates	O
,	O
or	O
that	O
remodeling	O
of	O
nuc-1	B-GENE
requires	O
additional	O
factors	O
.	O

I	O
.	O

We	O
analyzed	O
the	O
modular	O
organization	O
of	O
DNA	B-GENE
polymerase	I-GENE
beta	I-GENE
and	O
found	O
that	O
residues	O
making	O
contact	O
with	O
DNA	O
phosphates	O
were	O
localized	O
to	O
five	O
modules	O
.	O

The	O
effects	O
initiated	O
from	O
the	O
nucleus	O
accumbens	O
septi	O
were	O
most	O
marked	O
.	O

Using	O
various	O
techniques	O
,	O
we	O
have	O
undertaken	O
a	O
systematic	O
analysis	O
of	O
the	O
natural	O
TATA-less	O
human	B-GENE
DNA	I-GENE
polymerase	I-GENE
beta	I-GENE
(	O
beta-pol	B-GENE
)	O
gene	O
promoter	O
.	O

The	O
incidence	O
of	O
hepatitis	B-GENE
B	I-GENE
antigen	I-GENE
following	O
transfusion	O
was	O
about	O
2	O
.	O
8	O
per	O
cent	O
.	O

Molecular	O
neurochemistry	O
of	O
addictive	O
drugs	O
.	O

Radiolabelled	O
palmitate	O
was	O
not	O
incorporated	O
into	O
the	O
mutated	O
protein	O
,	O
showing	O
that	O
lipid	O
modification	O
occurs	O
at	O
the	O
Cys-22	O
residue	O
.	O

METHODS	O
:	O
Fibrotic	O
changes	O
involving	O
bone	O
marrow	O
were	O
evaluated	O
histologically	O
semiquantitatively	O
using	O
reticulin	O
fiber	O
impregnation	O
(	O
method	O
of	O
Gomori	O
)	O
.	O

LPO	O
and	O
SOD	B-GENE
levels	O
were	O
measured	O
at	O
five	O
points	O
before	O
and	O
during	O
the	O
operation	O
.	O

Acute	O
experiments	O
on	O
nembutal-anesthetized	O
cats	O
(	O
50	O
mg	O
/	O
kg	O
)	O
were	O
employed	O
to	O
investigate	O
the	O
effect	O
of	O
1	O
T	O
pulsating	O
magnetic	O
field	O
(	O
PMF	O
)	O
on	O
neuromuscular	O
system	O
of	O
the	O
leg	O
.	O

In	O
contrast	O
,	O
2	O
,	O
397	O
(	O
74%	O
)	O
had	O
one	O
or	O
more	O
risk	O
factors	O
(	O
not	O
low	O
risk	O
)	O
;	O
of	O
these	O
,	O
5	O
.	O
3%	O
died	O
in	O
6	O
weeks	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Activation	O
of	O
alpha	B-GENE
4	I-GENE
beta	I-GENE
1	I-GENE
with	O
TS2	B-GENE
/	I-GENE
16	I-GENE
inhibited	O
the	O
cytoplasmic	O
protrusions	O
and	O
cell	O
migration	O
but	O
did	O
not	O
affect	O
the	O
pattern	O
of	O
phosphorylation	O
.	O

Mitomycin-C	O
can	O
cause	O
severe	O
necrosis	O
and	O
ulceration	O
when	O
extravasated	O
inadvertently	O
into	O
skin	O
and	O
soft	O
tissues	O
following	O
IV	O
drug	O
administration	O
.	O

The	O
transposon-inactivated	O
gene	O
,	O
designated	O
pilP	B-GENE
,	O
is	O
525	O
bp	O
long	O
,	O
potentially	O
encoding	O
a	O
19	O
.	O
1-kDa	O
protein	O
precursor	O
that	O
contains	O
a	O
typical	O
membrane	O
lipoprotein	O
leader	O
sequence	O
.	O

Isolation	O
of	O
Aeromonas	O
from	O
faeces	O
.	O

The	O
seco-steroid	O
hormone	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
is	O
known	O
to	O
induce	O
the	O
expression	O
of	O
a	O
calcium	O
binding	O
protein	O
termed	O
calbindin-D28K	B-GENE
in	O
a	O
variety	O
of	O
target	O
tissues	O
.	O

In	O
all	O
cases	O
the	O
antigenemia	O
was	O
transient	O
and	O
cleared	O
by	O
28th	O
day	O
post-vaccination	O
.	O

The	O
interferon	B-GENE
(	O
IFN	B-GENE
)	O
-induced	O
double-stranded	B-GENE
RNA	I-GENE
(	I-GENE
dsRNA	I-GENE
)	I-GENE
-activated	I-GENE
Ser	I-GENE
/	I-GENE
Thr	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
PKR	B-GENE
)	O
plays	O
a	O
role	O
in	O
the	O
antiviral	O
and	O
antiproliferative	O
effects	O
of	O
IFN	B-GENE
.	O

Differential	O
association	O
of	O
products	O
of	O
alternative	O
transcripts	O
of	O
the	O
candidate	O
tumor	B-GENE
suppressor	I-GENE
ING1	I-GENE
with	O
the	O
mSin3	B-GENE
/	I-GENE
HDAC1	I-GENE
transcriptional	I-GENE
corepressor	I-GENE
complex	I-GENE
.	O

Identical	O
components	O
of	O
yeast	O
transcription	B-GENE
factor	I-GENE
IIIB	I-GENE
are	O
required	O
and	O
sufficient	O
for	O
transcription	O
of	O
TATA	O
box-containing	O
and	O
TATA-less	O
genes	O
.	O

DNA-binding	O
activity	O
was	O
not	O
increased	O
by	O
the	O
addition	O
of	O
forskolin	O
to	O
thecal	O
or	O
luteal	O
cells	O
.	O

Badcock	O
and	O
Westheimer	O
(	O
Spatial	O
Vision	O
1	O
(	O
1	O
)	O
,	O
3-11	O
,	O
1985	O
)	O
showed	O
that	O
a	O
thin	O
vertical	O
line	O
induces	O
nearby	O
zones	O
of	O
attraction	O
and	O
repulsion	O
;	O
this	O
study	O
extends	O
those	O
results	O
by	O
more	O
closely	O
examining	O
the	O
horizontal	O
and	O
vertical	O
extents	O
of	O
the	O
repulsion	O
zone	O
and	O
by	O
using	O
an	O
illusory	O
contour	O
to	O
induce	O
repulsion	O
.	O

Forty-one	O
ASA	O
physical	O
status	O
I	O
or	O
II	O
adult	O
patients	O
undergoing	O
a	O
variety	O
of	O
1-1	O
.	O
5	O
h	O
surgical	O
procedures	O
were	O
randomly	O
allocated	O
to	O
receive	O
CCA	O
with	O
desflurane	O
or	O
isoflurane	O
with	O
ventilation	O
being	O
either	O
spontaneous	O
or	O
controlled	O
.	O

The	O
codon	O
usage	O
is	O
particularly	O
marked	O
for	O
the	O
gag	B-GENE
,	O
pol	B-GENE
,	O
and	O
env	B-GENE
genes	I-GENE
.	O

Premature	O
initiation	O
of	O
mitosis	O
in	O
yeast	O
lacking	O
RCC1	B-GENE
or	O
an	O
interacting	O
GTPase	B-GENE
.	O

Position-independent	O
expression	O
of	O
a	O
human	B-GENE
nerve	I-GENE
growth	I-GENE
factor-luciferase	I-GENE
reporter	I-GENE
gene	I-GENE
cloned	O
on	O
a	O
yeast	O
artificial	O
chromosome	O
vector	O
.	O

Judicious	O
use	O
of	O
laboratory	O
testing	O
,	O
including	O
monitoring	O
of	O
CD4	B-GENE
cell	O
counts	O
,	O
is	O
recommended	O
.	O

Plasma	O
Al	O
was	O
obtained	O
during	O
each	O
baseline	O
and	O
drug	O
course	O
.	O

The	O
exploratory	O
behaviour	O
in	O
normal	O
and	O
aggressive	O
mice	O
.	O

31	O
,	O
1997	O
,	O
40	O
patients	O
had	O
died	O
(	O
35	O
in	O
the	O
ERA-II	O
group	O
and	O
5	O
in	O
the	O
ERA-III	O
group	O
)	O
,	O
for	O
a	O
crude	O
mortality	O
rate	O
of	O
8	O
.	O
0%	O
.	O

The	O
relatively	O
scanty	O
number	O
of	O
examples	O
,	O
which	O
could	O
be	O
justified	O
by	O
the	O
variety	O
and	O
complexity	O
of	O
combined	O
exposure	O
,	O
allows	O
to	O
conclude	O
that	O
life-style	O
factors	O
have	O
considerable	O
influence	O
on	O
interindividual	O
differences	O
in	O
susceptibility	O
to	O
xenobiotics	O
toxicity	O
.	O

However	O
,	O
the	O
action	O
of	O
each	O
cognate	O
ligand	O
and	O
the	O
accessory	O
cellular	O
factors	O
that	O
can	O
differentially	O
regulate	O
the	O
transcriptional	O
responses	O
of	O
a	O
heterodimer-DNA	O
complex	O
are	O
not	O
well	O
understood	O
.	O

REM	O
dream	O
content	O
was	O
scored	O
for	O
categories	O
suggesting	O
the	O
predominant	O
influence	O
of	O
the	O
left	O
hemisphere	O
,	O
e	O
.	O
g	O
.	O
,	O
good	O
ego	O
functioning	O
,	O
verbalization	O
,	O
or	O
the	O
right	O
hemisphere	O
,	O
e	O
.	O
g	O
.	O
,	O
music	O
,	O
spatial	O
salience	O
,	O
bizarreness	O
.	O

We	O
suggest	O
that	O
FlgN	B-GENE
and	O
FliT	B-GENE
are	O
substrate-specific	O
flagellar	O
chaperones	O
that	O
prevent	O
oligomerization	O
of	O
the	O
HAPs	B-GENE
by	O
binding	O
to	O
their	O
helical	O
domains	O
before	O
export	O
.	O

LY290181	O
appears	O
to	O
inhibit	O
uPA	B-GENE
promoter	I-GENE
activation	O
by	O
blocking	O
phorbol	O
ester-stimulated	O
binding	O
of	O
nuclear	O
proteins	O
to	O
the	O
uPA	B-GENE
PEA3	B-GENE
/	I-GENE
12-0-tetradecanoylphorbol	I-GENE
13-acetate	I-GENE
responsive	I-GENE
element	I-GENE
(	O
TRE	B-GENE
)	O
.	O

Forty-five	O
cases	O
were	O
surgically	O
by	O
direct	O
approach	O
to	O
the	O
tumour	O
,	O
while	O
two	O
cases	O
were	O
treated	O
only	O
with	O
a	O
shunt	O
.	O

In	O
line	O
with	O
the	O
small	O
values	O
for	O
QS	O
/	O
QC	O
,	O
our	O
results	O
further	O
indicate	O
that	O
even	O
large	O
,	O
well-perfused	O
,	O
occluded	O
air	O
spaces	O
in	O
the	O
lung	O
will	O
hardly	O
affect	O
the	O
recovered	O
ventilation	O
/	O
perfusion	O
distribution	O
obtained	O
from	O
inert	O
gas	O
data	O
when	O
CDCSF6	O
exceeds	O
0	O
.	O
1	O
ml	O
.	O
min-1	O
.	O
mmHg-1	O
.	O

All	O
13	O
patients	O
showed	O
endoscopic	O
evidence	O
of	O
oesophagitis	O
,	O
moderate	O
in	O
4	O
and	O
severe	O
in	O
9	O
.	O

A	O
transformation-competent	O
mutant	O
,	O
like	O
the	O
wild-type	B-GENE
E5	I-GENE
protein	I-GENE
,	O
bound	O
the	O
receptor	O
and	O
induced	O
receptor	O
tyrosine	O
phosphorylation	O
and	O
down-regulation	O
.	O

The	O
location	O
of	O
the	O
IBS	O
within	O
the	O
catB	B-GENE
structural	I-GENE
gene	I-GENE
,	O
the	O
cooperativity	O
observed	O
in	O
footprinting	O
studies	O
and	O
phasing	O
studies	O
suggest	O
that	O
the	O
IBS	O
participates	O
in	O
the	O
interaction	O
of	O
CatR	B-GENE
with	O
the	O
upstream	O
binding	O
sites	O
by	O
looping	O
out	O
the	O
intervening	O
DNA	O
.	O

The	O
initial	O
inpatient	O
experience	O
for	O
individuals	O
with	O
HIV-related	O
TB	O
may	O
be	O
pivotal	O
to	O
the	O
acceptance	O
of	O
and	O
participation	O
in	O
ongoing	O
TB	O
care	O
.	O

T	O
.	O
,	O
Patel	O
,	O
S	O
.	O

DNA	O
sequence	O
analysis	O
showed	O
that	O
the	O
gene	O
was	O
525	O
bp	O
long	O
and	O
encoded	O
a	O
175-amino-acid	O
protein	O
with	O
a	O
molecular	O
weight	O
of	O
19	O
,	O
094	O
containing	O
a	O
21-residue	O
typical	O
lipoprotein	O
signal	O
peptide	O
and	O
consensus	O
prolipoprotein	O
processing	O
site	O
.	O

Zn	B-GENE
(	I-GENE
II	I-GENE
)	I-GENE
coordination	I-GENE
domain	I-GENE
mutants	I-GENE
of	I-GENE
T4	I-GENE
gene	I-GENE
32	I-GENE
protein	I-GENE
.	O

All	O
of	O
the	O
indigo-producing	O
bacteria	O
had	O
an	O
indoxyl	B-GENE
phosphatase	I-GENE
with	O
a	O
pI	O
of	O
6	O
.	O
4	O
.	O

Xylose-	O
and	O
arabinose-containing	O
polymers	O
were	O
better	O
digested	O
than	O
was	O
cellulose	B-GENE
for	O
both	O
breads	O
.	O

Saturable	O
spermidine	O
transport	O
in	O
stk2	B-GENE
:	O
:	O
lacZ	B-GENE
mutants	I-GENE
had	O
an	O
approximately	O
fivefold-lower	O
affinity	O
and	O
twofold-lower	O
Vmax	O
than	O
in	O
the	O
parental	O
strain	O
.	O

Unlike	O
other	O
progenitor	O
cells	O
of	O
the	O
brain	O
,	O
SVZa	O
progenitor	O
cells	O
have	O
the	O
capacity	O
to	O
divide	O
even	O
though	O
they	O
express	O
a	O
neuronal	O
phenotype	O
.	O

The	O
decrease	O
of	O
TNF	B-GENE
receptors	I-GENE
by	O
IL-4	B-GENE
was	O
accompanied	O
by	O
down-regulation	O
of	O
TNF-induced	O
activities	O
,	O
including	O
cytotoxicity	O
,	O
caspase-3	B-GENE
activation	O
,	O
NF-kappaB	B-GENE
and	O
AP-1	B-GENE
activation	O
,	O
and	O
c-Jun	B-GENE
N-terminal	I-GENE
kinase	I-GENE
induction	O
.	O

Here	O
we	O
report	O
on	O
the	O
isolation	O
of	O
ICK2	B-GENE
,	O
and	O
show	O
that	O
it	O
interacts	O
with	O
Cdc2aAt	B-GENE
,	O
but	O
not	O
with	O
a	O
second	O
CDK	B-GENE
from	I-GENE
Arabidopsis	I-GENE
,	O
Cdc2bAt	B-GENE
.	O

Rac	B-GENE
causes	O
uncapping	O
of	O
actin	B-GENE
filaments	I-GENE
(	O
F-actin	B-GENE
)	O
at	O
the	O
plus-ends	O
,	O
through	O
phosphatidylinositol	O
4	O
,	O
5	O
bisphosphate	O
(	O
PIP2	O
)	O
,	O
and	O
eventually	O
induces	O
membrane	O
ruffling	O
.	O

Assays	O
of	O
total	O
cholesterol	O
as	O
well	O
as	O
the	O
HDL	B-GENE
,	O
HDL2	B-GENE
,	O
LDL	B-GENE
,	O
triglycerides	O
,	O
endothelin-1	B-GENE
,	O
lipoprotein	B-GENE
(	I-GENE
a	I-GENE
)	I-GENE
,	O
estradiol	O
and	O
FSH	B-GENE
were	O
also	O
obtained	O
at	O
baseline	O
before	O
receiving	O
ERT	O
and	O
after	O
3	O
months	O
of	O
ERT	O
.	O

These	O
transcripts	O
have	O
a	O
unique	O
5'untranslated	O
region	O
and	O
NH2-terminal	O
sequence	O
and	O
encode	O
a	O
predicted	O
protein	O
of	O
121	O
kD	O
.	O

Trinipatch	O
is	O
a	O
small	O
,	O
transparent	O
,	O
matricial	O
,	O
monolayer	O
patch	O
with	O
an	O
absorption	O
promoter	O
,	O
marketed	O
in	O
two	O
dose-strengths	O
(	O
5	O
mg	O
/	O
24	O
h	O
and	O
10	O
mg	O
/	O
24	O
h	O
)	O
by	O
Laboratoires	O
Synthelabo	O
.	O

CONCLUSION	O
:	O
Some	O
Gulf	O
War	O
veterans	O
may	O
have	O
delayed	O
,	O
chronic	O
neurotoxic	O
syndromes	O
from	O
wartime	O
exposure	O
to	O
combinations	O
of	O
chemicals	O
that	O
inhibit	O
butyrylcholinesterase	B-GENE
and	O
neuropathy	B-GENE
target	I-GENE
esterase	I-GENE
.	O

The	O
activity	O
of	O
6-fluoroquinolones	O
and	O
their	O
nonfluorinated	O
derivatives	O
is	O
compared	O
in	O
general	O
.	O

Lars	O
has	O
AIDS--a	O
more	O
dignified	O
life	O
with	O
care	O
at	O
home	O
.	O

Transcriptional	O
regulators	O
utilizing	O
the	O
POU	B-GENE
domain	I-GENE
DNA-binding	O
motif	O
have	O
been	O
shown	O
to	O
form	O
multi-protein	O
complexes	O
dependent	O
on	O
the	O
POU	B-GENE
domain	I-GENE
itself	O
and	O
its	O
flexible	O
recognition	O
of	O
various	O
octamer	O
sequence	O
elements	O
.	O

These	O
elements	O
comprise	O
a	O
binding	O
site	O
for	O
Krox	B-GENE
proteins	I-GENE
,	O
one	O
for	O
nuclear	B-GENE
factor	I-GENE
1	I-GENE
,	O
an	O
octamer	O
motif	O
that	O
binds	O
POU-homeodomain	B-GENE
proteins	I-GENE
,	O
and	O
a	O
novel	O
TN	B-GENE
control	I-GENE
element	I-GENE
.	O

In	O
this	O
study	O
the	O
splenectomized	O
captive	O
born	O
cynomolgus	O
appeared	O
to	O
be	O
capable	O
of	O
supplementing	O
rhesus	O
as	O
an	O
antimalarial	O
drug	O
testing	O
model	O
.	O

It	O
has	O
been	O
calculated	O
that	O
600	O
,	O
000	O
new	O
cases	O
of	O
lung	O
cancer	O
occur	O
worldwide	O
every	O
year	O
,	O
most	O
of	O
them	O
due	O
to	O
smoking	O
.	O

In	O
this	O
manuscript	O
we	O
demonstrate	O
that	O
two	O
tandem	B-GENE
Ets	I-GENE
sites	I-GENE
in	O
the	O
mouse	B-GENE
GL	I-GENE
alpha	I-GENE
promoter	I-GENE
bind	O
the	O
transcription	B-GENE
factors	I-GENE
Elf-1	I-GENE
and	O
PU	B-GENE
.	I-GENE
1	I-GENE
,	O
and	O
that	O
the	O
3'	O
site	O
is	O
essential	O
for	O
expression	O
of	O
a	O
luciferase	B-GENE
reporter	I-GENE
gene	I-GENE
driven	O
by	O
the	O
GL	B-GENE
alpha	I-GENE
promoter	I-GENE
.	O

The	O
mean	O
total	O
white	O
cell	O
count	O
increased	O
from	O
a	O
baseline	O
of	O
11	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
(	O
SD	O
2	O
.	O
3	O
)	O
to	O
16	O
.	O
2	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
(	O
SD	O
4	O
.	O
6	O
)	O
on	O
day	O
1	O
,	O
normalising	O
thereafter	O
.	O

The	O
level	O
of	O
serum	B-GENE
creatine	I-GENE
kinase	I-GENE
was	O
significantly	O
high	O
2	O
days	O
after	O
ESWIB	O
,	O
but	O
it	O
recovered	O
in	O
a	O
week	O
.	O

The	O
results	O
show	O
that	O
nerve	O
and	O
roots	O
differ	O
considerably	O
both	O
in	O
the	O
force	O
they	O
sustain	O
before	O
failure	O
and	O
in	O
the	O
other	O
biomechanics	O
they	O
exhibit	O
.	O

FLP	B-GENE
and	O
Cre	B-GENE
recombinase	I-GENE
function	O
in	O
Xenopus	O
embryos	O
.	O

We	O
detected	O
no	O
effect	O
of	O
deleting	O
YCL024W	B-GENE
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
deletion	O
of	O
GIN4	B-GENE
.	O

Recombinant	B-GENE
AROM-p64	I-GENE
displayed	O
high	O
binding	O
to	O
single-stranded	O
DNA	O
and	O
poly	O
(	O
A	O
)	O
homopolymers	O
suggesting	O
that	O
this	O
protein	O
could	O
play	O
a	O
role	O
in	O
mRNA	O
maturation	O
/	O
metabolism	O
.	O

In	O
our	O
studies	O
,	O
we	O
utilized	O
HIV-1	O
HXB2	B-GENE
and	O
HIV-1	O
Z2Z6	B-GENE
core	I-GENE
enhancers	I-GENE
because	O
the	O
Z2Z6	O
strain	O
has	O
a	O
single	O
point	O
mutation	O
flanking	O
the	O
right	O
ETS-binding	B-GENE
site	I-GENE
.	O

Four	O
short	O
nucleotide	O
sequences	O
(	O
boxes	B-GENE
I	I-GENE
to	I-GENE
IV	I-GENE
)	O
contribute	O
to	O
the	O
light	O
responsiveness	O
of	O
the	O
parsley	B-GENE
chalcone	I-GENE
synthase	I-GENE
promoter	I-GENE
.	O

ZEBRA	B-GENE
and	O
cellular	O
AP-1	B-GENE
bZip	I-GENE
activators	I-GENE
,	O
such	O
as	O
c-Fos	B-GENE
,	O
have	O
homologous	O
DNA-binding	O
domains	O
,	O
and	O
their	O
DNA-binding	O
specificities	O
overlap	O
.	O

Drug	O
effect	O
,	O
measured	O
as	O
postural	O
sway	O
,	O
was	O
also	O
similar	O
in	O
the	O
patients	O
with	O
cirrhosis	O
and	O
control	O
subjects	O
;	O
therefore	O
the	O
ratio	O
of	O
effect	O
area	O
under	O
the	O
curve	O
to	O
concentration	O
area	O
under	O
the	O
curve	O
,	O
a	O
measure	O
of	O
sensitivity	O
,	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
patients	O
with	O
cirrhosis	O
and	O
the	O
control	O
subjects	O
.	O

Damage	O
to	O
the	O
BBB	O
was	O
judged	O
by	O
extravasation	O
of	O
Evans	O
Blue	O
(	O
EB	O
)	O
dye	O
,	O
which	O
was	O
administered	O
either	O
2	O
,	O
3	O
,	O
24	O
or	O
48	O
h	O
after	O
onset	O
of	O
MCAo	O
.	O

At	O
the	O
carboxyl	O
terminus	O
,	O
deletion	O
as	O
far	O
as	O
residue	O
388	O
did	O
not	O
affect	O
in	O
vitro	O
TRF	B-GENE
.	I-GENE
C	I-GENE
assembly	O
,	O
although	O
trans-activating	O
activity	O
was	O
abolished	O
.	O

The	O
procedure	O
facilitated	O
the	O
retention	O
of	O
a	O
mandibular	O
molar	O
with	O
a	O
Class	O
III	O
FI	O
in	O
a	O
manner	O
acceptable	O
to	O
both	O
the	O
patient	O
and	O
the	O
clinician	O
.	O

Histological	O
signs	O
of	O
the	O
flare-up	O
reaction	O
were	O
already	O
present	O
at	O
6	O
hr	O
after	O
i	O
.	O
v	O
.	O
challenge	O
and	O
lasted	O
for	O
at	O
least	O
4	O
days	O
.	O

Moxidectin	O
(	O
at	O
3	O
times	O
the	O
therapeutic	O
dose	O
)	O
did	O
not	O
have	O
deleterious	O
effects	O
on	O
cow	O
reproductive	O
performance	O
as	O
examined	O
(	O
eg	O
,	O
at	O
folliculogenesis	O
,	O
ovulation	O
,	O
and	O
the	O
early	O
embryonic	O
phase	O
of	O
development	O
)	O
.	O

To	O
this	O
end	O
,	O
an	O
expression	O
cassette	O
consisting	O
of	O
the	O
gene	O
for	O
a	O
green	B-GENE
fluorescent	I-GENE
protein	I-GENE
(	O
GFP	B-GENE
)	O
flanked	O
at	O
its	O
3'	O
end	O
by	O
EAV-specific	O
transcription-regulating	O
sequences	O
was	O
constructed	O
.	O

Promoter	O
recognition	O
algorithms	O
identified	O
divergent	O
promoter	O
elements	O
within	O
the	O
CpG	O
island	O
,	O
which	O
lies	O
between	O
the	O
ATM	B-GENE
and	O
E14	B-GENE
/	I-GENE
NPAT	I-GENE
genes	I-GENE
,	O
and	O
provide	O
evidence	O
for	O
a	O
putative	O
second	O
ATM	B-GENE
promoter	I-GENE
located	O
within	O
intron	O
3	O
,	O
immediately	O
upstream	O
of	O
the	O
first	O
coding	O
exon	O
.	O

A	O
retrospective	O
epidemiological	O
study	O
is	O
reported	O
concerning	O
burn	O
injuries	O
in	O
775	O
children	O
hospitalized	O
at	O
the	O
unit	O
of	O
burn	O
care	O
of	O
Casablanca	O
between	O
1985	O
and	O
1993	O
.	O

Thus	O
,	O
SAG	B-GENE
appears	O
to	O
control	O
cell	O
cycle	O
progression	O
in	O
yeast	O
by	O
promoting	O
ubiquitination	O
and	O
degradation	O
of	O
cell	O
cycle	O
regulatory	O
proteins	O
.	O

The	O
main	O
issues	O
are	O
the	O
need	O
to	O
explain	O
a	O
number	O
of	O
still	O
unknown	O
mechanisms	O
,	O
to	O
determine	O
which	O
"natural	O
diet"	O
carries	O
the	O
minimum	O
coronary	O
risk	O
and	O
whether	O
"new"	O
foods	O
produced	O
by	O
modern	O
technology	O
are	O
really	O
needed	O
to	O
contrast	O
this	O
epidemic	O
.	O

BACKGROUND	O
:	O
Diazepam	O
,	O
one	O
of	O
the	O
benzodiazepine	O
group	O
of	O
tranquilizers	O
,	O
is	O
used	O
as	O
an	O
adjunctive	O
drug	O
for	O
sedation	O
and	O
for	O
relief	O
of	O
anxiety	O
in	O
the	O
treatment	O
of	O
epilepsy	O
.	O

Hippocampal	O
stimulation	O
overlapping	O
conditioned	O
stimulus	O
preexposure	O
produced	O
attenuation	O
of	O
latent	O
inhibition	O
,	O
as	O
did	O
stimulation	O
presented	O
during	O
conditioning	O
after	O
preexposure	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
thrombin-stimulated	O
vascular	O
smooth	O
muscle	O
proliferation	O
is	O
delayed	O
and	O
requires	O
the	O
de	O
novo	O
expression	O
of	O
one	O
or	O
more	O
autocrine	O
mitogens	O
.	O

However	O
,	O
five	O
new	O
mutation	O
sites	O
(	O
S61	B-GENE
,	O
SL1	B-GENE
,	O
S29	B-GENE
,	O
SL11	B-GENE
,	O
SL196	B-GENE
and	O
SL126	B-GENE
)	O
are	O
unique	O
to	O
the	O
nrdB	B-GENE
intron	O
and	O
disrupt	O
self-splicing	O
.	O

The	O
murine	O
chromosomal	O
locations	O
of	O
the	O
five	O
NMDA	B-GENE
receptor	I-GENE
channel	I-GENE
subunits	I-GENE
,	O
the	O
epsilon	B-GENE
1	I-GENE
(	O
Grin2a	B-GENE
)	O
,	O
epsilon	B-GENE
2	I-GENE
(	O
Grin2b	B-GENE
)	O
,	O
epsilon	B-GENE
3	I-GENE
(	O
Grin2c	B-GENE
)	O
,	O
epsilon	B-GENE
4	I-GENE
(	O
Grin2d	B-GENE
)	O
and	O
zeta	B-GENE
1	I-GENE
(	O
Grinl	B-GENE
)	O
subunits	O
,	O
were	O
determined	O
using	O
an	O
interspecific	O
backcross	O
mapping	O
panel	O
derived	O
from	O
crosses	O
of	O
[	O
(	O
C57BL	O
/	O
6JxM	O
.	O
spretus	O
)	O
F1xC57BL	O
/	O
6J	O
]	O
mice	O
.	O

Surprisingly	O
,	O
however	O
,	O
TCR-mediated	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	B-GENE
C	I-GENE
gamma	I-GENE
1	I-GENE
remains	O
intact	O
in	O
the	O
Jurkat	O
cells	O
expressing	O
the	O
A2	B-GENE
/	I-GENE
HCP	I-GENE
chimera	O
.	O

Serum	B-GENE
creatine	I-GENE
kinase	I-GENE
(	O
SCK	B-GENE
)	O
was	O
measured	O
in	O
ten	O
subjects	O
in	O
the	O
laboratory	O
before	O
and	O
after	O
the	O
performance	O
of	O
bicycle	O
ergometry	O
and	O
a	O
lifting	O
task	O
.	O

N	O
.	O
,	O
and	O
Fanning	O
,	O
E	O
.	O

This	O
indicates	O
that	O
under	O
certain	O
experimental	O
conditions	O
cdc2	B-GENE
/	I-GENE
p58	I-GENE
and	O
cdc2	B-GENE
/	I-GENE
p62	I-GENE
may	O
express	O
some	O
differences	O
in	O
their	O
catalytic	O
activity	O
.	O

Plasma	B-GENE
histaminase	I-GENE
in	O
patients	O
of	O
bronchial	O
asthma	O
and	O
the	O
effect	O
of	O
prednisolone	O
administration	O
on	O
it	O
.	O

40	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
1	O
mg	O
/	O
l	O
(	O
SD	O
)	O
vs	O
31	O
.	O
2	O
+	O
/	O
-	O
8	O
.	O
0	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
beta	O
2m	O
was	O
not	O
significantly	O
higher	O
in	O
patients	O
with	O
bone	O
cysts	O
(	O
37	O
.	O
7	O
+	O
/	O
-	O
11	O
.	O
4	O
mg	O
/	O
l	O
vs	O
37	O
.	O
0	O
+	O
/	O
-	O
10	O
.	O
0	O
)	O
,	O
but	O
median	O
duration	O
of	O
dialysis	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
longer	O
in	O
patients	O
with	O
bone	O
cysts	O
(	O
90	O
vs	O
57	O
months	O
)	O
.	O
beta	B-GENE
2m	I-GENE
was	O
lower	O
in	O
patients	O
maintained	O
on	O
dialysis	O
for	O
less	O
than	O
1	O
year	O
and	O
whose	O
residual	O
urine	O
volume	O
was	O
greater	O
than	O
0	O
.	O
1	O
litre	O
per	O
day	O
.	O

The	O
susceptibility	O
of	O
Aspergillus	O
fumigatus	O
to	O
mulundocandin	O
,	O
an	O
echinocandin-like	O
compound	O
,	O
and	O
other	O
antifungal	O
agents	O
was	O
assessed	O
by	O
the	O
National	O
Committee	O
for	O
Clinical	O
Laboratory	O
Standards	O
(	O
NCCLS	O
)	O
M38-P	O
method	O
,	O
a	O
2	O
,	O
3-bis	O
(	O
2-methoxy-4-nitro-5-sulfophenyl	O
)	O
-5-	O
[	O
(	O
phenyl-amino	O
)	O
carbonyl	O
]	O
-2H-tetrazolium	O
hydroxide	O
(	O
XTT	O
)	O
-based	O
colorimetric	O
assay	O
,	O
and	O
determination	O
of	O
morphologic	O
alterations	O
by	O
microscopy	O
.	O

The	O
authors	O
report	O
a	O
case	O
in	O
which	O
stereotactic	O
irrigation	O
of	O
a	O
brain	O
cyst	O
was	O
temporally	O
associated	O
with	O
respiratory	O
distress	O
.	O

Number	O
of	O
patients	O
infected	O
with	O
nontuberculous	O
mycobacteria	O
(	O
NTM	O
)	O
is	O
increasing	O
world-wide	O
in	O
recent	O
years	O
.	O

An	O
F222W	B-GENE
:	I-GENE
W21F	I-GENE
rGST	I-GENE
A1-1	I-GENE
double	I-GENE
mutant	I-GENE
provides	O
a	O
direct	O
fluorescence	O
probe	O
of	O
changes	O
in	O
the	O
environment	O
of	O
the	O
C-terminal	O
residue	O
.	O

Comparison	O
of	O
the	O
plant	B-GENE
nuclear	I-GENE
tRNA	I-GENE
3'	I-GENE
processing	I-GENE
enzyme	I-GENE
with	O
the	O
plant	O
mitochondrial	O
one	O
suggests	O
that	O
both	O
activities	O
are	O
different	O
enzymes	O
.	O

DtxR	B-GENE
is	O
an	O
iron-dependent	O
sequence-specific	O
DNA-binding	O
protein	O
that	O
binds	O
to	O
the	O
tox	B-GENE
operator	I-GENE
,	O
an	O
inverted-repeat	O
nucleotide	O
sequence	O
located	O
upstream	O
from	O
the	O
diphtheria	B-GENE
toxin	I-GENE
gene	I-GENE
.	O

Cerebral125	B-GENE
albumin	I-GENE
was	O
increased	O
to	O
similar	O
proportions	O
in	O
those	O
groups	O
submitted	O
to	O
hyperosmolality	O
.	O

Laboratory	O
studies	O
using	O
Ca45	O
labeled	O
teeth	O
and	O
biologically	O
stained	O
teeth	O
confirmed	O
that	O
the	O
dentifrice	O
did	O
not	O
decalcify	O
enamel	O
or	O
bleach	O
teeth	O
.	O

Autonomic	O
dysfunctions	O
were	O
restricted	O
to	O
tonic	O
pupils	O
.	O

Results	O
from	O
the	O
mechanism	O
study	O
have	O
revealed	O
that	O
YY1	B-GENE
is	O
able	O
to	O
inhibit	O
transactivation	O
mediated	O
by	O
either	O
AP1	B-GENE
or	O
the	O
Sp1-related	B-GENE
protein	I-GENE
,	O
and	O
YY1	B-GENE
suppressive	O
activity	O
is	O
DNA	O
binding	O
dependent	O
.	O

The	O
men	O
self-selected	O
a	O
prescribed	O
diet	O
at	O
home	O
emphasizing	O
saturated	O
fat	O
as	O
the	O
visible	O
fat	O
for	O
1	O
week	O
.	O

By	O
analyzing	O
the	O
RanGAP	B-GENE
activity	O
of	O
a	O
series	O
of	O
recombinantly	O
expressed	O
rna1p	B-GENE
mutant	I-GENE
derivatives	O
,	O
we	O
show	O
that	O
the	O
highly	O
acidic	O
sequence	O
in	O
the	O
C-terminal	O
domain	O
of	O
both	O
yeast	O
proteins	O
is	O
indispensable	O
for	O
activating	O
Ran-mediated	O
GTP	O
hydrolysis	O
.	O

One	O
patients	O
had	O
plasma	B-GENE
C-peptide	I-GENE
greater	O
than	O
3	O
pM	O
and	O
was	O
therefore	O
excluded	O
from	O
analysis	O
.	O

NF-kappa	B-GENE
B	I-GENE
p65	B-GENE
,	O
p50	B-GENE
,	O
and	O
Rel	B-GENE
functionally	O
synergize	O
with	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
,	O
C	B-GENE
/	I-GENE
EBP	I-GENE
beta	I-GENE
,	O
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
delta	I-GENE
.	O

Cryoglobulinemia	O
in	O
Raynaud's	O
syndrome	O
.	O

Freezing	O
of	O
plasma	O
to	O
obtain	O
better	O
yield	O
of	O
factor	B-GENE
VIII	I-GENE
:	O
C	O
.	O

A	O
polymorphic	O
dinucleotide	O
(	O
GT	O
/	O
CA	O
)	O
n	O
repeat	O
contained	O
in	O
the	O
NHE5	O
cosmid	O
was	O
identified	O
and	O
developed	O
into	O
a	O
microsatellite	O
PCR	O
marker	O
.	O

In	O
the	O
VA-SMV	O
mode	O
,	O
the	O
connection	O
was	O
made	O
with	O
valved	O
conduits	O
from	O
the	O
LV	O
apex	O
(	O
inflow	O
)	O
to	O
the	O
ascending	O
aorta	O
(	O
outflow	O
)	O
(	O
n	O
=	O
11	O
)	O
or	O
to	O
the	O
DAo	O
(	O
n	O
=	O
12	O
)	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
a	O
simple	O
two-step	O
strategy	O
was	O
devised	O
by	O
which	O
essential	O
cis-acting	O
sites	O
like	O
the	O
a	O
sequence	O
can	O
be	O
readily	O
deleted	O
from	O
their	O
natural	O
loci	O
in	O
large	O
viral	O
DNA	O
genomes	O
.	O

The	O
reduction	O
in	O
saturated	O
fatty	O
acids	O
intake	O
led	O
to	O
modest	O
(	O
but	O
in	O
group	O
1	O
significant	O
)	O
0	O
.	O
15	O
mmol	O
/	O
l	O
(	O
2	O
.	O
5%	O
)	O
reduction	O
in	O
total	O
serum	O
cholesterol	O
level	O
.	O

We	O
cloned	O
a	O
DNA	O
fragment	O
encoding	O
the	O
N-terminal	O
part	O
of	O
a	O
protein	O
with	O
significant	O
similarity	O
to	O
members	O
of	O
the	O
LysR	B-GENE
family	I-GENE
of	I-GENE
transcriptional	I-GENE
regulators	I-GENE
(	O
LTTRs	B-GENE
)	O
.	O

Advances	O
in	O
hemophilia	O
treatment	O
:	O
a	O
hepatitis-safe	O
factor	B-GENE
VIII	I-GENE
concentrate	O
.	O

The	O
records	O
from	O
1948	O
through	O
1967	O
of	O
344	O
previously	O
untreated	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
supraglottic	O
larynx	O
and	O
hypopharynx	O
who	O
had	O
clinically	O
positive	O
cervical	O
lymph	O
node	O
metastases	O
staged	O
N1	O
,	O
N2A	O
,	O
or	O
N2B	O
,	O
and	O
whose	O
initial	O
neck	O
treatment	O
consisted	O
of	O
external	O
radiation	O
therapy	O
alone	O
were	O
reviewed	O
.	O

A	O
comparative	O
analysis	O
of	O
the	O
reported	O
MOCT-associated	O
malignant	O
melanomas	O
emphasizes	O
the	O
singularity	O
of	O
our	O
case	O
in	O
the	O
amelanotic	O
character	O
of	O
the	O
melanoma	O
,	O
its	O
lymphotropism	O
and	O
the	O
coexistence	O
of	O
invasive	O
squamous	O
cell	O
carcinoma	O
.	O

The	O
remaining	O
RAD+	B-GENE
cells	O
progressed	O
to	O
form	O
microcolonies	O
(	O
<	O
30	O
cells	O
)	O
containing	O
aberrantly	O
shaped	O
inviable	O
cells	O
.	O

Increasing	O
the	O
phosphorus	O
content	O
of	O
the	O
diet	O
improved	O
the	O
reabsorption	O
of	O
calcium	O
and	O
magnesium	O
.	O

Characterization	O
of	O
an	O
EcR	B-GENE
/	I-GENE
USP	I-GENE
heterodimer	I-GENE
target	I-GENE
site	I-GENE
that	O
mediates	O
ecdysone	O
responsiveness	O
of	O
the	O
Drosophila	B-GENE
Lsp-2	I-GENE
gene	I-GENE
.	O

Drug	O
inhibition	O
of	O
whole	O
blood	O
aspirin	B-GENE
esterase	I-GENE
.	O

The	O
actuarial	O
local	O
control	O
rates	O
at	O
10	O
years	O
for	O
the	O
three	O
treatment	O
groups	O
were	O
as	O
follows	O
:	O
subtotal	O
excision	O
alone	O
,	O
18%	O
;	O
subtotal	O
excision	O
plus	O
postoperative	O
radiation	O
therapy	O
,	O
82%	O
;	O
and	O
total	O
excision	O
alone	O
,	O
77%	O
.	O

It	O
is	O
related	O
to	O
a	O
variety	O
of	O
mammalian	O
Golgi-associated	O
proteins	O
and	O
to	O
the	O
yeast	O
Uso1p	B-GENE
,	O
an	O
essential	O
protein	O
involved	O
in	O
docking	O
of	O
endoplasmic	O
reticulum-derived	O
vesicles	O
to	O
the	O
cis-Golgi	O
.	O

We	O
found	O
three	O
out	O
of	O
four	O
original	O
(	O
Volkan's	O
)	O
groups	O
of	O
linking	O
objects	O
,	O
but	O
also	O
an	O
additional	O
one	O
,	O
hitherto	O
undescribed	O
,	O
comprising	O
objects	O
used	O
for	O
designing	O
a	O
memorial	O
shrine	O
to	O
the	O
deceased	O
.	O

To	O
examine	O
whether	O
thiamine	O
(	O
vitamin	O
B1	O
)	O
deficiency	O
is	O
associated	O
with	O
recurrent	O
aphthous	O
stomatitis	O
,	O
we	O
studied	O
vitamin	O
B1	O
levels	O
in	O
70	O
patients	O
with	O
recurrent	O
aphthous	O
stomatitis	O
and	O
in	O
50	O
members	O
of	O
a	O
control	O
group	O
.	O

The	O
upstream	O
delta-alpha	O
breakpoint	O
is	O
flanked	O
by	O
the	O
direct	O
repeats	O
of	O
the	O
acceptor	O
splice	O
site	O
,	O
whereas	O
the	O
down-stream	O
alpha-delta	O
breakpoint	O
is	O
located	O
in	O
the	O
adjacent	O
intron	O
.	O

Like	O
Epo	B-GENE
,	O
HNF-4	B-GENE
is	O
expressed	O
in	O
kidney	O
,	O
liver	O
,	O
and	O
Hep3B	O
cells	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

The	O
centromeric	O
YAC	O
contig	O
,	O
which	O
consists	O
of	O
23	O
overlapping	O
YACs	O
and	O
orders	O
19	O
sequence-tagged	O
sites	O
(	O
STSs	O
)	O
,	O
covers	O
a	O
minimum	O
of	O
2	O
.	O
2	O
Mb	O
and	O
spans	O
the	O
Ewing	O
sarcoma	O
breakpoint	O
.	O
c-ets	B-GENE
1	I-GENE
and	O
Fli-1	B-GENE
,	O
two	O
members	O
of	O
the	O
ets	B-GENE
family	I-GENE
,	O
have	O
been	O
linked	O
within	O
400	O
kb	O
of	O
intervening	O
DNA	O
within	O
this	O
contig	O
,	O
which	O
also	O
comprises	O
a	O
polymorphic	O
microsatellite	O
,	O
D11S912	B-GENE
(	I-GENE
CA	I-GENE
)	I-GENE
n	I-GENE
,	O
which	O
we	O
have	O
localized	O
within	O
the	O
Fli-1	B-GENE
gene	I-GENE
.	O

Null	O
alleles	O
of	O
SAS4	B-GENE
and	O
SAS5	B-GENE
bypassed	O
the	O
role	O
of	O
the	O
Abf1p	B-GENE
binding	I-GENE
site	I-GENE
of	O
the	O
HMR-E	B-GENE
silencer	I-GENE
but	O
not	O
the	O
role	O
of	O
the	O
ACS	B-GENE
or	O
Rap1p	B-GENE
binding	I-GENE
site	I-GENE
.	O

For	O
signal	O
durations	O
less	O
than	O
10	O
ms	O
,	O
however	O
,	O
the	O
SoNo	O
and	O
S	O
pi	O
No	O
threshold	O
functions	O
converged	O
and	O
the	O
masking-level	O
difference	O
decreased	O
.	O

The	O
initial	O
patients	O
treated	O
with	O
AZQ	O
and	O
mitroxantrone	O
experienced	O
prolonged	O
bone	O
marrow	O
suppression	O
and	O
,	O
therefore	O
,	O
subsequent	O
cohorts	O
were	O
treated	O
with	O
G-CSF	B-GENE
,	O
5	O
micrograms	O
/	O
kg	O
,	O
beginning	O
the	O
day	O
after	O
completion	O
of	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
.	O

The	O
basal	O
promoter	O
strength	O
of	O
constructs	O
that	O
contained	O
deletions	O
in	O
the	O
U5	B-GENE
region	I-GENE
of	O
the	O
LTR	B-GENE
was	O
analyzed	O
by	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
assays	O
following	O
transfection	O
of	O
HeLa	O
cells	O
or	O
Jurkat	O
T-cells	O
in	O
the	O
presence	O
or	O
absence	O
of	O
viral	O
transactivator	O
tax	B-GENE
protein	O
.	O

In	O
Schizosaccharomyces	O
pombe	O
,	O
the	O
activity	O
of	O
the	O
M-phase-inducing	O
Cdc2	B-GENE
/	I-GENE
Cdc13	I-GENE
cyclin-dependent	I-GENE
kinase	I-GENE
is	O
inhibited	O
by	O
Wee1	B-GENE
and	O
Mik1	B-GENE
tyrosine	B-GENE
kinases	I-GENE
,	O
and	O
activated	O
by	O
Cdc25	B-GENE
and	O
Pyp3	B-GENE
tyrosine	B-GENE
phosphatases	I-GENE
.	O

Measurement	O
of	O
the	O
time	O
constant	O
of	O
VO2	O
and	O
oxygen	O
pulse	O
during	O
constant	O
work	O
rate	O
exercise	O
are	O
useful	O
for	O
the	O
objective	O
evaluation	O
of	O
the	O
training	O
effect	O
of	O
patients	O
with	O
COPD	O
.	O

By	O
order	O
of	O
decreasing	O
rate	O
,	O
finger	O
flexors	O
,	O
jaw	O
,	O
crossed	O
adductors	O
,	O
and	O
triceps	O
reflexes	O
were	O
less	O
frequently	O
elicited	O
in	O
both	O
groups	O
.	O

The	O
direct	O
effects	O
of	O
transmitter	O
release	O
were	O
(	O
a	O
)	O
an	O
early	O
fall	O
in	O
MAP	O
followed	O
by	O
a	O
late	O
pressor	O
effect	O
;	O
and	O
(	O
b	O
)	O
an	O
early	O
bradycardia	O
followed	O
by	O
a	O
late	O
tachycardia	O
.	O

66	O
:	O
469-479	O
,	O
1992	O
)	O
.	O

A	O
724-bp	O
segment	O
of	O
the	O
5'-flanking	O
region	O
consisting	O
of	O
the	O
proximal	O
E-box	O
flanked	O
upstream	O
by	O
a	O
mammalian-specific	O
352-bp	O
region	O
was	O
sufficient	O
for	O
maximal	O
transcriptional	O
activation	O
in	O
postconfluent	O
BC3H1	O
myoblasts	O
.	O

Arachnoid	O
cyst	O
.	O

Glutathione	B-GENE
peroxidase	I-GENE
in	O
human	O
red	O
cells	O
in	O
health	O
and	O
disease	O
.	O

It	O
encodes	O
a	O
protein	O
with	O
three	O
zinc	O
fingers	O
similar	O
to	O
those	O
of	O
the	O
transcription	B-GENE
factor	I-GENE
Sp1	I-GENE
.	O

Liver	O
regional	O
blood	O
volume	O
(	O
LRBV	O
)	O
is	O
altered	O
by	O
several	O
disease	O
states	O
and	O
various	O
drugs	O
.	O

The	O
ESEM	O
differs	O
from	O
conventional	O
SEM	O
in	O
that	O
no	O
sample	O
preparation	O
is	O
needed	O
,	O
eliminating	O
artifactual	O
changes	O
.	O

Enhancers	O
containing	O
disrupted	O
Ets-1	B-GENE
binding	I-GENE
sites	I-GENE
were	O
tested	O
in	O
transient	O
expression	O
assays	O
in	O
the	O
murine	O
T-cell	O
line	O
EL4	O
.	O
E1	O
;	O
alterations	O
in	O
the	O
LVb	B-GENE
element	I-GENE
affected	O
constitutive	O
enhancer	O
activity	O
,	O
while	O
mutation	O
of	O
either	O
the	O
LVb	B-GENE
or	O
LVc	B-GENE
element	I-GENE
disrupted	O
phorbol	O
ester-induced	O
enhancer	O
activity	O
.	O

The	O
presence	O
of	O
truncated	O
receptor	O
isoforms	O
in	O
diverse	O
species	O
suggests	O
that	O
these	O
proteins	O
may	O
have	O
important	O
functional	O
roles	O
in	O
regulating	O
EGFR	B-GENE
activity	O
.	O

The	O
results	O
confirm	O
and	O
extend	O
previous	O
work	O
by	O
other	O
researchers	O
.	O

In	O
the	O
final	O
model	O
,	O
grade	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
,	O
peritoneal	O
cytologic	O
results	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
,	O
progesterone	B-GENE
receptor	I-GENE
status	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
age	O
as	O
a	O
continuous	O
variable	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
were	O
most	O
closely	O
associated	O
with	O
disease-free	O
survival	O
.	O

The	O
lack	O
of	O
change	O
in	O
the	O
ratio	O
of	O
the	O
two	O
spliced	O
products	O
expressed	O
from	O
either	O
the	O
normal	O
or	O
the	O
5'-rearranged	B-GENE
myb	I-GENE
further	O
indicates	O
that	O
the	O
insertion	O
of	O
the	O
unique	O
121	O
amino	O
acids	O
in	O
the	O
larger	O
myb	B-GENE
transcripts	I-GENE
is	O
not	O
a	O
consequence	O
of	O
tumor-specific	O
activation	O
of	O
the	O
mouse	B-GENE
myb	I-GENE
oncogene	I-GENE
.	O

Removal	O
of	O
beta	B-GENE
2-microglobulin	I-GENE
by	O
hemodialysis	O
and	O
hemofiltration	O
:	O
a	O
four	O
year	O
follow	O
up	O
.	O

A	O
single	O
MEF-2	B-GENE
site	I-GENE
is	O
a	O
major	O
positive	O
regulatory	O
element	O
required	O
for	O
transcription	O
of	O
the	O
muscle-specific	O
subunit	O
of	O
the	O
human	B-GENE
phosphoglycerate	I-GENE
mutase	I-GENE
gene	I-GENE
in	O
skeletal	O
and	O
cardiac	O
muscle	O
cells	O
.	O

The	O
statistical	O
analysis	O
consist	O
of	O
the	O
F	O
test	O
followed	O
by	O
Snedecor	O
's	O
contrast	O
test	O
.	O

In	O
conclusion	O
,	O
USPIO-enhanced	O
MRI	O
data	O
were	O
capable	O
to	O
characterize	O
tumor	O
microvessel	O
properties	O
in	O
this	O
breast	O
cancer	O
model	O
:	O
microvascular	O
permeability	O
(	O
determined	O
using	O
USPIO	O
)	O
correlated	O
significantly	O
with	O
tumor	O
grade	O
.	O

Furthermore	O
,	O
the	O
PH	B-GENE
and	O
PTB	O
domains	O
are	O
highly	O
homologous	O
(	O
at	O
least	O
40%	O
identical	O
)	O
to	O
those	O
found	O
in	O
insulin	B-GENE
receptor	I-GENE
substrates	I-GENE
1	I-GENE
,	I-GENE
2	I-GENE
,	I-GENE
and	I-GENE
3	I-GENE
(	O
IRS-1	B-GENE
,	O
IRS-2	B-GENE
,	O
and	O
IRS-3	B-GENE
)	O
.	O

The	O
authors	O
describe	O
the	O
technique	O
of	O
transverse	O
axial	O
tomography	O
of	O
the	O
spine	O
and	O
give	O
a	O
detailed	O
description	O
of	O
the	O
axial	O
anatomy	O
of	O
the	O
normal	O
lumbar	O
spine	O
from	O
L-4	O
to	O
the	O
sacrum	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
the	O
protein	O
that	O
binds	O
to	O
enhancer	B-GENE
site	I-GENE
III	I-GENE
.	O

Foxp1	B-GENE
and	O
Foxp2	B-GENE
are	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
lung	O
as	O
early	O
as	O
E12	O
.	O
5	O
of	O
mouse	O
development	O
with	O
Foxp2	B-GENE
expression	O
restricted	O
to	O
the	O
airway	O
epithelium	O
.	O

In	O
the	O
unclipped	O
group	O
arterial	O
pressure	O
decreased	O
50	O
mmHg	O
to	O
normal	O
by	O
24	O
h	O
and	O
was	O
associated	O
with	O
increased	O
diuresis	O
and	O
a	O
small	O
decrease	O
in	O
blood	O
volume	O
(	O
9	O
.	O
8%	O
)	O
.	O

The	O
mean	O
times	O
to	O
detection	O
of	O
all	O
mycobacteria	O
with	O
BACTEC	O
9000	O
MB	O
and	O
BACTEC	O
460	O
TB	O
were	O
similar	O
(	O
10	O
.	O
3	O
and	O
10	O
.	O
0	O
days	O
,	O
respectively	O
)	O
.	O

The	O
alpha	B-GENE
inhibin	I-GENE
promoter	I-GENE
containing	O
a	O
mutated	O
CRE	B-GENE
was	O
not	O
regulated	O
by	O
forskolin	O
in	O
granulosa	O
cells	O
and	O
did	O
not	O
bind	O
the	O
CREB	B-GENE
protein	I-GENE
.	O

We	O
show	O
also	O
that	O
RA	O
represses	O
the	O
transcriptional	O
activity	O
of	O
a	O
reporter	O
gene	O
containing	O
a	O
TPA	B-GENE
responding	O
AP1	B-GENE
binding	I-GENE
site	I-GENE
driving	O
the	O
HSV	B-GENE
tk	I-GENE
promoter	I-GENE
.	O

We	O
also	O
compared	O
the	O
sequence	O
with	O
the	O
partly	O
homologous	O
products	O
of	O
the	O
S	O
.	O
cerevisiae	O
genes	O
TPS2	B-GENE
and	O
TSL1	B-GENE
which	O
code	O
for	O
the	O
larger	O
subunits	O
of	O
the	O
trehalose	B-GENE
synthase	I-GENE
complex	I-GENE
and	O
with	O
a	O
TSL1	B-GENE
homologue	I-GENE
,	O
TPS3	B-GENE
,	O
of	O
unknown	O
function	O
.	O

Seventy-two	O
hours	O
after	O
administration	O
of	O
vitamin	O
K1	O
,	O
plasma	O
concentrations	O
of	O
the	O
vitamin	O
were	O
not	O
different	O
from	O
normal	O
.	O

Methanesulfonyl	O
fluoride	O
(	O
MSF	O
)	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
safety	O
and	O
efficacy	O
in	O
the	O
treatment	O
of	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
type	O
.	O

FDA	O
regulations	O
for	O
growth	B-GENE
factors	I-GENE
and	O
related	O
products	O
.	O

Six	O
distinct	O
Ets	B-GENE
mRNAs	I-GENE
were	O
identified	O
:	O
Ets2	B-GENE
,	O
Fli1	B-GENE
,	O
GABPalpha	B-GENE
,	O
SAP1	B-GENE
,	O
Elk1	B-GENE
,	O
and	O
PE1	B-GENE
.	O

The	O
histidine-tagged	O
gene	O
,	O
rpoCHIS	B-GENE
,	O
was	O
used	O
to	O
replace	O
the	O
wild-type	O
allele	O
in	O
the	O
chromosome	O
of	O
S	O
.	O
coelicolor	O
and	O
S	O
.	O
lividans	O
.	O

Identification	O
of	O
a	O
spliced	O
gene	O
from	O
Kaposi's	O
sarcoma-associated	O
herpesvirus	O
encoding	O
a	O
protein	O
with	O
similarities	O
to	O
latent	B-GENE
membrane	I-GENE
proteins	I-GENE
1	I-GENE
and	I-GENE
2A	I-GENE
of	I-GENE
Epstein-Barr	I-GENE
virus	I-GENE
.	O

To	O
identify	O
these	O
sites	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
3T3-L1	O
adipocyte	B-GENE
insulin	I-GENE
receptor	I-GENE
of	O
the	O
mouse	O
was	O
determined	O
.	O

Wild	B-GENE
type	I-GENE
HA-p190	I-GENE
induced	O
a	O
phenotype	O
of	O
rounded	O
cells	O
with	O
long	O
,	O
beaded	O
extensions	O
similar	O
to	O
that	O
seen	O
when	O
Rho	B-GENE
function	O
is	O
disrupted	O
by	O
ADP-ribosylation	O
.	O

Following	O
2	O
.	O
5	O
Gy	O
,	O
HbO2	B-GENE
changes	O
were	O
minimal	O
.	O

In	O
summary	O
,	O
the	O
data	O
establish	O
that	O
the	O
previously	O
reported	O
human	B-GENE
MAdCAM-1	I-GENE
cDNA	I-GENE
does	O
indeed	O
encode	O
the	O
human	O
homologue	O
of	O
mouse	B-GENE
MAdCAM-1	I-GENE
,	O
despite	O
gross	O
dissimilarities	O
in	O
the	O
MAdCAM-1	B-GENE
C-terminal	O
structures	O
.	O

Upstream	O
of	O
the	O
dra	B-GENE
gene	I-GENE
an	O
open	O
reading	O
frame	O
of	O
313	O
amino	O
acids	O
was	O
identified	O
.	O

Chemical	O
uptake	O
into	O
human	O
stratum	O
corneum	O
in	O
vivo	O
from	O
volatile	O
and	O
non-volatile	O
solvents	O
.	O

Diet	O
therapy	O
with	O
soy	O
proteins	O
for	O
chronic	O
stomach	O
ulcers	O
.	O

This	O
may	O
result	O
in	O
more	O
reabsorption	O
and	O
hence	O
reduced	O
renal	O
clearance	O
.	O

In	O
patients	O
who	O
had	O
received	O
no	O
previous	O
drug	O
treatment	O
,	O
log	O
baseline	O
plasma	B-GENE
renin	I-GENE
activity	O
and	O
change	O
in	O
mean	O
blood	O
pressure	O
after	O
SQ	O
20881	O
correlated	O
significantly	O
(	O
r	O
=	O
0	O
.	O
651	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

We	O
conclude	O
that	O
sequences	O
outside	O
of	O
the	O
hLEF	B-GENE
HMG	I-GENE
box	I-GENE
mediate	O
cell-	O
and	O
context-specific	O
activation	O
of	O
the	O
TCR	B-GENE
alpha	I-GENE
enhancer	I-GENE
and	O
may	O
facilitate	O
interactions	O
between	O
hLEF	B-GENE
and	O
other	O
T-cell-specific	O
factors	O
recruited	O
to	O
the	O
enhancer	O
.	O

More	O
mRNA	O
corresponding	O
to	O
nagB	B-GENE
and	O
nagA	B-GENE
is	O
detected	O
than	O
that	O
corresponding	O
to	O
the	O
distal	O
genes	O
,	O
nagC	B-GENE
and	O
nagD	B-GENE
.	O

However	O
,	O
its	O
participation	O
in	O
collagen	B-GENE
binding	O
has	O
not	O
been	O
shown	O
.	O

Development	O
of	O
a	O
provisional	O
information-retrieval	O
descriptor	O
language	O
for	O
"Roentgenology	O
and	O
Medical	O
Radiology"	O
for	O
use	O
in	O
the	O
Medinform	O
system	O
.	O

The	O
sequenced	O
genomic	O
region	O
thus	O
accounts	O
for	O
essentially	O
all	O
of	O
the	O
longest	O
known	O
transcript	O
(	O
4	O
.	O
5	O
kb	O
)	O
,	O
although	O
the	O
precise	O
ends	O
of	O
this	O
transcript	O
have	O
not	O
been	O
defined	O
.	O

Neonatal	O
Chagas	O
disease	O
:	O
laboratory	O
diagnosis	O
during	O
the	O
first	O
year	O
of	O
life	O
.	O

This	O
study	O
evaluates	O
the	O
feasibility	O
of	O
indirect	O
mesenteric	O
lymphangiography	O
as	O
a	O
colonoscopic	O
technique	O
in	O
a	O
canine	O
model	O
.	O

The	O
gonadotrope-specific	O
and	O
regulated	O
expression	O
of	O
the	O
GnRH	B-GENE
receptor	I-GENE
(	O
GnRH-R	B-GENE
)	O
gene	O
is	O
dependent	O
on	O
multiple	O
transcription	O
factors	O
that	O
interact	O
with	O
the	O
noncanonical	B-GENE
GnRH-R	I-GENE
activating	I-GENE
sequence	I-GENE
(	O
GRAS	B-GENE
)	O
,	O
the	O
activator	B-GENE
protein-1	I-GENE
(	O
AP-1	B-GENE
)	O
element	O
,	O
and	O
the	O
steroidogenic	B-GENE
factor-1	I-GENE
(	O
SF-1	B-GENE
)	O
binding	O
site	O
.	O

FK506	O
is	O
10-	O
to	O
100-fold	O
more	O
potent	O
than	O
cyclosporin	O
A	O
in	O
preventing	O
organ	O
rejection	O
and	O
in	O
toxicity	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	O
acid	O
sequences	O
with	O
protein	O
sequences	O
of	O
T	O
.	O
pyriformis	O
H2As	B-GENE
showed	O
only	O
two	O
and	O
three	O
differences	O
respectively	O
,	O
in	O
a	O
total	O
of	O
137	O
amino	O
acids	O
for	O
H2A1	B-GENE
,	O
and	O
132	O
amino	O
acids	O
for	O
H2A2	B-GENE
,	O
indicating	O
the	O
two	O
genes	O
arose	O
before	O
the	O
divergence	O
of	O
these	O
two	O
species	O
.	O

Anecdotal	O
observations	O
scattered	O
throughout	O
the	O
literature	O
have	O
often	O
provided	O
clues	O
to	O
underlying	O
variations	O
in	O
humans'	O
ability	O
to	O
handle	O
dietary	O
chemicals	O
.	O

Fewer	O
recombination	O
events	O
are	O
detected	O
in	O
four	O
different	O
B	O
and	O
T	O
cell	O
lines	O
that	O
do	O
not	O
undergo	O
switch	O
recombination	O
of	O
their	O
endogenous	O
genes	O
.	O

These	O
observations	O
establish	O
that	O
RsmC	B-GENE
negatively	O
regulates	O
rsmB	B-GENE
transcription	O
but	O
positively	O
affects	O
RsmA	B-GENE
production	O
.	O

The	O
relations	O
among	O
various	O
negative	O
emotional	O
and	O
behavioral	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
,	O
aggression	O
,	O
anxiety	O
,	O
undercompliance	O
,	O
depressive	O
mood	O
)	O
and	O
adjustment	O
were	O
examined	O
through	O
use	O
of	O
data	O
from	O
the	O
31-year-old	O
New	O
York	O
Longitudinal	O
Study	O
.	O

This	O
was	O
most	O
pronounced	O
during	O
the	O
initial	O
phase	O
of	O
Erk	B-GENE
activation	O
.	O

Institution	O
of	O
both	O
intravenous	O
and	O
intracisternal	O
administration	O
of	O
amphotericin	O
B	O
and	O
possibly	O
concomitant	O
intravenous	O
administration	O
of	O
dexamethasone	O
may	O
be	O
warranted	O
in	O
situations	O
in	O
which	O
the	O
association	O
of	O
C	O
.	O
immitis	O
with	O
CNS	O
vasculitis	O
or	O
encephalitis	O
appears	O
likely	O
before	O
serologic	O
or	O
cultural	O
confirmation	O
of	O
C	O
.	O
immitis	O
infection	O
involving	O
the	O
CNS	O
is	O
available	O
.	O

Increasing	O
mean	O
arterial	O
pressure	O
by	O
phenylephrine	O
infusion	O
to	O
levels	O
much	O
greater	O
than	O
produced	O
by	O
NMA	O
and	O
NNA	O
caused	O
only	O
small	O
reductions	O
in	O
cardiac	O
output	O
.	O

The	O
nucleotide	O
sequence	O
of	O
22	O
,	O
846	O
bp	O
of	O
the	O
left	O
arm	O
of	O
chromosome	O
IV	O
is	O
described	O
.	O

The	O
application	O
of	O
these	O
microelectrodes	O
to	O
the	O
measurement	O
of	O
rapid	O
,	O
transient	O
changes	O
in	O
retinal	O
[	O
K+	O
]	O
o	O
is	O
presented	O
.	O

From	O
all	O
clinically	O
important	O
yeasts	O
species	O
,	O
a	O
total	O
of	O
96%	O
were	O
identified	O
by	O
ATB	O
method	O
according	O
to	O
conventional	O
methods	O
.	O

To	O
account	O
for	O
this	O
observation	O
,	O
other	O
possible	O
causes	O
include	O
increased	O
CSF	O
pulsation	O
in	O
children	O
creating	O
motion	O
artifact	O
,	O
changes	O
in	O
arterial	O
oxygen	O
concentration	O
intrinsic	O
to	O
propofol	O
or	O
related	O
to	O
the	O
supplemental	O
oxygen	O
normally	O
administered	O
,	O
or	O
changes	O
in	O
CSF	O
protein	O
levels	O
related	O
to	O
propofol	O
binding	O
to	O
proteins	O
for	O
uptake	O
into	O
CSF	O
.	O

A	O
gas-liquid	O
chromatographic	O
method	O
for	O
the	O
determination	O
of	O
p-chlorophenoxyisobutyric	O
(	O
CPIB	O
)	O
acid	O
in	O
blood	O
plasma	O
is	O
described	O
.	O

The	O
fatigue	O
exercise	O
showed	O
relatively	O
high	O
blood	O
lactate	O
concentration	O
[	O
12	O
.	O
5	O
(	O
SD	O
2	O
.	O
6	O
)	O
mmol	O
x	O
l	O
(	O
-1	O
)	O
]	O
and	O
an	O
increase	O
of	O
serum	B-GENE
creatine	I-GENE
kinase	I-GENE
(	O
CK	B-GENE
)	O
activity	O
delayed	O
by	O
2	O
days	O
[	O
540	O
(	O
SD	O
407	O
)	O
U	O
x	O
l	O
(	O
-1	O
)	O
]	O
.	O

However	O
,	O
the	O
presence	O
of	O
effacement	O
seems	O
to	O
be	O
a	O
more	O
reliable	O
and	O
practical	O
parameter	O
that	O
will	O
be	O
preferred	O
in	O
that	O
prediction	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
NGF	B-GENE
in	O
regulating	O
gene	O
transcription	O
in	O
PC12	O
and	O
INS-1	O
cells	O
,	O
in	O
order	O
to	O
define	O
if	O
there	O
are	O
NGF-regulated	O
genes	O
per	O
se	O
.	O

Chloroplast	B-GENE
mutator	I-GENE
(	O
chm	B-GENE
)	O
of	O
Arabidopsis	O
is	O
a	O
recessive	O
nuclear	O
mutation	O
that	O
causes	O
green	O
and	O
white	O
variegation	O
in	O
leaves	O
and	O
is	O
inherited	O
in	O
a	O
non-Mendelian	O
fashion	O
.	O

In	O
three	O
of	O
the	O
seven	O
,	O
inhalation	O
of	O
2	O
ml	O
normal	O
saline	O
produced	O
FEV1	O
falls	O
of	O
25%	O
to	O
30%	O
,	O
but	O
these	O
falls	O
were	O
not	O
as	O
great	O
as	O
each	O
subject's	O
reactions	O
to	O
the	O
test	O
solutions	O
.	O

As	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
analysis	O
and	O
supershift	O
experiments	O
,	O
FIRE1	B-GENE
,	O
located	O
between	O
-516	O
and	O
-498	O
,	O
is	O
responsible	O
for	O
binding	O
NF-Y	B-GENE
.	O

The	O
less-polar	O
mycolic	O
acid-containing	O
Rhodococcus	O
species	O
showed	O
chromatographic	O
patterns	O
that	O
partially	O
overlapped	O
(	O
in	O
elution	O
times	O
)	O
the	O
patterns	O
of	O
Nocardia	O
asteroides	O
,	O
N	O
.	O
otitidiscaviarum	O
,	O
and	O
N	O
.	O
brasiliensis	O
,	O
but	O
the	O
larger	O
number	O
of	O
peaks	O
in	O
the	O
last	O
species	O
made	O
separation	O
between	O
the	O
genera	O
possible	O
.	O

Electrophile	B-GENE
Response	I-GENE
Elements	I-GENE
(	O
EpREs	B-GENE
)	O
,	O
located	O
in	O
5'-flanking	O
sequences	O
of	O
both	O
the	O
GCSh	B-GENE
and	O
GCSl	B-GENE
subunit	I-GENE
genes	I-GENE
,	O
are	O
hypothesized	O
to	O
at	O
least	O
partially	O
mediate	O
gene	O
induction	O
following	O
xenobiotic	O
exposure	O
.	O

Extreme	O
potency	O
of	O
botulinum	B-GENE
toxin	I-GENE
.	O

It	O
appears	O
that	O
the	O
pulmonary	O
gas	O
exchange	O
parenchyma	O
of	O
these	O
smallest	O
mammals	O
is	O
well	O
suited	O
to	O
supply	O
the	O
organism	O
with	O
the	O
comparatively	O
high	O
levels	O
of	O
O2	O
required	O
by	O
the	O
high	O
metabolic	O
rates	O
,	O
exhibiting	O
a	O
structural	O
adaptation	O
of	O
the	O
lung	O
to	O
higher	O
VO2	O
.	O

The	O
development	O
and	O
histostructural	O
organization	O
of	O
intrahepatic	O
biliary	O
ducts	O
were	O
studied	O
on	O
a	O
human	O
embryofetal	O
material	O
6	O
to	O
32	O
weeks	O
old	O
.	O

Labile	O
LTR-binding	B-GENE
proteins	I-GENE
appear	O
to	O
be	O
essential	O
for	O
c-myc	B-GENE
hyperexpression	O
,	O
since	O
both	O
LTR-enhanced	O
transcription	O
and	O
the	O
activities	O
of	O
LTR-binding	B-GENE
proteins	I-GENE
are	O
specifically	O
decreased	O
after	O
inhibition	O
of	O
protein	O
synthesis	O
(	O
A	O
.	O

Age	O
at	O
POI	O
and	O
asymptote	O
were	O
achieved	O
later	O
for	O
Line	O
RBC2	O
than	O
for	O
Line	O
F	O
.	O

Disorders	O
of	O
platelet	O
function	O
in	O
chronic	O
myeloid	O
leukemias	O
.	O

Hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
was	O
detected	O
in	O
2	O
patients	O
,	O
with	O
negative	O
hepatitis	B-GENE
C	I-GENE
virus	I-GENE
antibody	I-GENE
.	O

Clinical	O
and	O
angiographic	O
examinations	O
in	O
occlusion	O
disease	O
of	O
the	O
great	O
intestinal	O
arteries	O
.	O

Prevention	O
,	O
differential	O
diagnosis	O
and	O
therapy	O
of	O
travel	O
diarrhea	O
.	O

CONCLUSIONS	O
:	O
Two	O
consecutive	O
sets	O
of	O
transrectal	O
ultrasound	O
guided	O
sextant	O
biopsies	O
of	O
the	O
prostate	O
performed	O
in	O
a	O
single	O
office	O
visit	O
represent	O
a	O
cost-effective	O
biopsy	O
strategy	O
for	O
men	O
presenting	O
with	O
an	O
abnormal	O
digital	O
rectal	O
examination	O
and	O
/	O
or	O
elevated	O
serum	B-GENE
PSA	I-GENE
.	O

We	O
compare	O
the	O
results	O
of	O
this	O
algorithm	O
with	O
the	O
results	O
obtained	O
with	O
two	O
other	O
algorithms	O
,	O
the	O
optimal	O
algorithm	O
for	O
monochannel	O
nonoverlapping	O
noise	O
and	O
the	O
optimal	O
algorithm	O
for	O
multichannel	O
additive	O
noise	O
,	O
and	O
we	O
show	O
that	O
in	O
both	O
cases	O
improvement	O
can	O
be	O
obtained	O
.	O

A	O
safe	O
and	O
simple	O
system	O
for	O
the	O
detection	O
of	O
sudden	O
infant	O
death	O
syndrome	O
(	O
SIDS	O
)	O
is	O
proposed	O
.	O

Transactivation	O
of	O
naturally	O
occurring	O
HIV-1	O
long	O
terminal	O
repeats	O
by	O
the	O
JNK	B-GENE
signaling	O
pathway	O
.	O

Histological	O
examination	O
revealed	O
a	O
small	O
simple	O
renal	O
cyst	O
associated	O
with	O
renal	O
cell	O
carcinoma	O
.	O

Those	O
dosages	O
that	O
inhibited	O
mean	O
NTE	B-GENE
activity	O
in	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
72%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
66%	O
of	O
control	O
values	O
within	O
44	O
hr	O
postexposure	O
produced	O
marked	O
spinal	O
cord	O
pathology	O
14	O
days	O
postexposure	O
in	O
greater	O
than	O
or	O
equal	O
to	O
90%	O
of	O
similarly	O
dosed	O
animals	O
.	O

RESULTS	O
:	O
An	O
herpetic	O
seroconversion	O
is	O
observed	O
with	O
presence	O
of	O
type	O
I	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
I	O
)	O
nucleic	O
acids	O
in	O
the	O
recipient's	O
aqueous	O
humor	O
.	O

Plasma	O
NE	O
was	O
also	O
low	O
in	O
the	O
anephric	O
group	O
(	O
289	O
mg	O
/	O
liter	O
+	O
/	O
-	O
126	O
(	O
1	O
SD	O
)	O
vs	O
612	O
+	O
/	O
-	O
189	O
,	O
P	O
=	O
0	O
.	O
033	O
,	O
resting	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
gene	O
homologous	O
to	O
the	O
Escherichia	B-GENE
coli	I-GENE
dnaA	I-GENE
gene	I-GENE
was	O
isolated	O
from	O
Pseudomonas	O
putida	O
and	O
its	O
transcription	O
was	O
investigated	O
in	O
E	O
.	O
coli	O
as	O
well	O
as	O
in	O
P	O
.	O
putida	O
.	O

CONCLUSION	O
:	O
More	O
than	O
50%	O
of	O
patients	O
with	O
perennial	O
rhinitis	O
and	O
CRS	O
do	O
not	O
improve	O
after	O
surgery	O
,	O
a	O
response	O
that	O
may	O
be	O
predicted	O
by	O
more	O
cells	O
expressing	O
IL-5	B-GENE
mRNA	I-GENE
in	O
the	O
ethmoid	O
sinuses	O
.	O

Concussion	O
of	O
the	O
spinal	O
cord	O
.	O

Relatively	O
large	O
DNA	O
rearrangements	O
spanning	O
the	O
region	O
with	O
tandem	O
direct	O
repeats	O
encoding	O
the	O
carboxy-terminal	B-GENE
histone	I-GENE
H1-like	I-GENE
structure	I-GENE
of	O
AlgP	B-GENE
were	O
detected	O
in	O
several	O
strains	O
upon	O
conversion	O
from	O
the	O
mucoid	O
to	O
the	O
nonmucoid	O
phenotype	O
.	O

This	O
approach	O
places	O
gHoxb-1	B-GENE
into	O
the	O
normal	O
embryonic	O
spatiotemporal	O
context	O
in	O
which	O
lab	O
acts	O
.	O

IVOX	O
was	O
named	O
as	O
an	O
acronym	O
for	O
intravascular	O
oxygenator	O
.	O

EGFR	B-GENE
levels	O
were	O
found	O
to	O
be	O
elevated	O
5-	O
,	O
3	O
.	O

However	O
,	O
serial	O
passages	O
of	O
fetal	O
lamb	O
kidney	O
(	O
FLK	O
)	O
cells	O
,	O
which	O
are	O
sensitive	O
to	O
infection	O
with	O
BLV	O
,	O
after	O
transient	O
transfection	O
revealed	O
that	O
mutation	O
of	O
a	O
second	O
tyrosine	O
residue	O
in	O
the	O
N-terminal	O
motif	O
completely	O
prevented	O
the	O
propagation	O
of	O
the	O
virus	O
.	O

Serum	O
levels	O
of	O
IgG	B-GENE
and	O
IgM	B-GENE
were	O
also	O
raised	O
,	O
but	O
contrary	O
to	O
the	O
findings	O
of	O
other	O
observers	O
IgA	B-GENE
levels	O
were	O
normal	O
.	O

The	O
performance	O
of	O
three	O
commonly	O
used	O
chemical	O
cartridge	O
respirators	O
for	O
SO2	O
was	O
measured	O
under	O
working	O
conditions	O
in	O
a	O
copper	O
smelter	O
.	O

The	O
promoter	O
region	O
(	O
P1	O
)	O
corresponding	O
to	O
the	O
main	O
group	O
of	O
transcription	O
initiation	O
sites	O
is	O
devoid	O
of	O
TATA	O
and	O
CAAT	O
boxes	O
but	O
has	O
putative	O
binding	O
sites	O
for	O
the	O
transcription	B-GENE
factor	I-GENE
SP1	I-GENE
and	O
is	O
embedded	O
in	O
a	O
large	O
G	O
+	O
C-rich	O
domain	O
of	O
a	O
CpG	O
island	O
,	O
features	O
shared	O
by	O
the	O
promoters	O
of	O
constitutively	O
expressed	O
housekeeping	O
genes	O
.	O

We	O
find	O
that	O
our	O
response	O
function	O
is	O
well	O
approximated	O
by	O
the	O
GSER	O
only	O
within	O
a	O
particular	O
frequency	O
range	O
determined	O
by	O
the	O
material	O
parameters	O
of	O
both	O
the	O
bead	O
and	O
the	O
network	O
.	O

THE	O
SCALING	O
OF	O
SONG	O
FREQUENCY	O
IN	O
CICADAS	O
.	O

HIV	O
infectiousness	O
and	O
the	O
AIDS	O
epidemic	O
.	O

Endocytosis	O
and	O
lysosomal	O
targeting	O
of	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptors	I-GENE
are	O
mediated	O
by	O
distinct	O
sequences	O
independent	O
of	O
the	O
tyrosine	B-GENE
kinase	I-GENE
domain	I-GENE
.	O

Expansins	B-GENE
are	O
a	O
family	O
of	O
proteins	O
that	O
catalyse	O
long-term	O
extension	O
of	O
isolated	O
plant	O
cell	O
walls	O
due	O
to	O
an	O
as	O
yet	O
unknown	O
biochemical	O
mechanism	O
.	O

The	O
patterns	O
of	O
early	O
mRNA	O
and	O
protein	O
expression	O
in	O
these	O
seven	O
mutants	O
were	O
examined	O
,	O
and	O
it	O
was	O
found	O
that	O
mutation	O
of	O
the	O
T'	B-GENE
(	I-GENE
135	I-GENE
)	I-GENE
acceptor	I-GENE
site	I-GENE
resulted	O
in	O
the	O
utilization	O
of	O
cryptic	O
splice	O
sites	O
and	O
the	O
generation	O
of	O
new	O
T'	B-GENE
species	I-GENE
.	O

Problems	O
common	O
to	O
pediatrics	O
and	O
anesthesiology	O
.	O

Shc	B-GENE
stimulates	O
Ras	B-GENE
/	I-GENE
mitogen-activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAPK	B-GENE
)	O
through	O
forming	O
a	O
complex	O
with	O
Grb2	B-GENE
at	O
the	O
phosphorylated	O
tyrosine	O
(	O
Y	O
)	O
residue	O
317	O
.	O

Cholangiography	O
was	O
performed	O
in	O
all	O
cases	O
and	O
classified	O
by	O
a	O
scoring	O
system	O
specifically	O
developed	O
for	O
pediatric	O
patients	O
.	O

Frog	O
type	O
I	O
(	O
Ft	O
I	O
)	O
and	O
frog	O
type	O
II	O
(	O
Ft	O
II	O
)	O
slowly	O
adapting	O
(	O
SA	O
)	O
units	O
produced	O
spikes	O
only	O
at	O
the	O
indentation	O
phase	O
,	O
and	O
the	O
threshold	O
response	O
phase	O
(	O
TRP	O
)	O
,	O
i	O
.	O
e	O
.	O
.	O
the	O
phase	O
of	O
the	O
first	O
spike	O
was	O
for	O
ca	O
.	O

We	O
describe	O
here	O
a	O
Drosophila	B-GENE
melanogaster	I-GENE
FAK	I-GENE
homologue	I-GENE
,	O
DFak56	B-GENE
,	O
which	O
maps	O
to	O
band	O
56D	O
on	O
the	O
right	O
arm	O
of	O
the	O
second	O
chromosome	O
.	O

Chem	O
.	O

A	O
single	O
N-glycosylation	O
site	O
present	O
in	O
chicken	B-GENE
gp42	I-GENE
is	O
conserved	O
among	O
all	O
five	O
of	O
these	O
proteins	O
:	O
carbohydrate	O
analysis	O
of	O
gp42	B-GENE
revealed	O
the	O
presence	O
of	O
a	O
complex	O
type	O
glycan	O
chain	O
at	O
this	O
site	O
.	O

Different	O
doses	O
of	O
15-methyl-PGF2	O
alpha	O
(	O
0	O
.	O
125-10	O
mg	O
)	O
were	O
used	O
to	O
induce	O
luteolysis	O
and	O
oestrus	O
in	O
7	O
heifers	O
with	O
28	O
treatments	O
on	O
day	O
8-12	O
of	O
the	O
oestrous	O
cycle	O
.	O

BSE	O
and	O
farmworkers	O
.	O

The	O
distribution	O
of	O
the	O
sites	O
of	O
recombinational	O
resolution	O
is	O
inversely	O
correlated	O
with	O
that	O
of	O
the	O
gradient	O
of	O
sequence	O
divergence	O
,	O
with	O
only	O
approximately	O
7%	O
of	O
the	O
X	O
recombinants	O
resolved	O
within	O
the	O
3'	O
third	O
of	O
the	O
X	O
blocks	O
where	O
two	O
diverged	O
Alu	B-GENE
family	I-GENE
repeats	I-GENE
reside	O
.	O

A	O
pre-boutonniere	O
deformity	O
was	O
simulated	O
by	O
dividing	O
the	O
central	O
slip	O
.	O

First	O
,	O
human	O
erythroid	O
K562	O
cells	O
stably	O
integrated	O
with	O
various	O
HS-40	B-GENE
mutants	I-GENE
cis	O
linked	O
to	O
a	O
human	B-GENE
alpha-globin	I-GENE
promoter-growth	I-GENE
hormone	I-GENE
hybrid	I-GENE
gene	I-GENE
were	O
analyzed	O
by	O
genomic	O
footprinting	O
and	O
expression	O
analysis	O
.	O

Electron	O
microscopic	O
picture	O
of	O
the	O
cerebral	O
cortex	O
in	O
rats	O
cooled	O
to	O
22	O
degrees	O
C	O
.	O

Enterococcus	O
faecium	O
strains	O
with	O
vanA-mediated	O
glycopeptide	O
resistance	O
were	O
isolated	O
by	O
enrichment	O
culture	O
from	O
the	O
intestines	O
and	O
feces	O
of	O
several	O
animal	O
species	O
,	O
mainly	O
horses	O
and	O
dogs	O
(	O
8%	O
positive	O
)	O
,	O
chickens	O
(	O
7%	O
positive	O
)	O
,	O
and	O
pigs	O
(	O
6%	O
positive	O
)	O
.	O

Poly	O
(	O
dT	O
)	O
and	O
denatured	O
calf	O
thymus	O
DNA	O
were	O
more	O
effective	O
than	O
were	O
other	O
polynucleotides	O
tested	O
in	O
promoting	O
accumulation	O
of	O
19	O
HDP*	B-GENE
;	O
(	O
dT	O
)	O
8	O
was	O
as	O
effective	O
as	O
were	O
longer	O
molecules	O
of	O
(	O
dT	O
)	O
n	O
,	O
but	O
(	O
dT	O
)	O
4	O
and	O
(	O
dT	O
)	O
6	O
were	O
much	O
less	O
effective	O
,	O
indicating	O
that	O
the	O
binding	O
site	O
involved	O
in	O
19	O
HDP*	B-GENE
accumulation	O
covered	O
between	O
6	O
and	O
8	O
residues	O
of	O
(	O
dT	O
)	O
n	O
.	O

Studies	O
on	O
powdered	O
preparations	O
.	O

Ultraviolet	O
light-induced	O
kinin	B-GENE
formation	O
in	O
human	O
skin	O
.	O

Effect	O
of	O
bromazepam	O
on	O
growth	B-GENE
hormone	I-GENE
and	O
prolactin	B-GENE
secretion	O
in	O
normal	O
subjects	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
cloned	O
a	O
region	O
that	O
complements	O
the	O
exoenzyme	O
S-deficient	O
phenotype	O
of	O
strain	O
388	O
exs1	B-GENE
:	O
:	O
Tn1	B-GENE
,	O
a	O
chromosomal	B-GENE
Tn1	I-GENE
insertional	I-GENE
mutation	I-GENE
.	O

Cytoprotection	O
with	O
amifostine	O
in	O
radiotherapy	O
or	O
radio-chemotherapy	O
of	O
head	O
and	O
neck	O
tumors	O
.	O

The	O
BAL	O
concentrations	O
of	O
the	O
nine	O
cytokines	O
evaluated	O
for	O
the	O
more	O
and	O
less	O
affected	O
lungs	O
were	O
compared	O
:	O
interleukin-6	B-GENE
(	O
IL-6	B-GENE
)	O
,	O
IL-8	B-GENE
,	O
IL-12	B-GENE
,	O
tumor	B-GENE
necrosis	I-GENE
factor-alpha	I-GENE
(	O
TNF-alpha	B-GENE
)	O
,	O
and	O
interferon	B-GENE
gamma	I-GENE
(	O
IFN-gamma	B-GENE
)	O
showed	O
significant	O
differences	O
(	O
p	O
ranged	O
between	O
0	O
.	O

Comparison	O
of	O
the	O
cDNA-predicted	O
avian	B-GENE
TnIcardiac	I-GENE
amino	I-GENE
acid	I-GENE
sequences	I-GENE
with	O
known	O
TnI	B-GENE
sequences	I-GENE
indicated	O
1	O
)	O
that	O
the	O
presence	O
of	O
an	O
N-terminal	O
extension	O
sequence	O
carrying	O
a	O
dual	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
phosphorylation	O
target	O
site	O
and	O
an	O
adjacent	O
proline-rich	O
segment	O
is	O
an	O
ancient	O
cardiac-specific	O
feature	O
of	O
TnI	B-GENE
which	O
has	O
been	O
conserved	O
since	O
the	O
bird	O
/	O
mammal	O
divergence	O
,	O
2	O
)	O
that	O
features	O
of	O
the	O
near-N-terminal	O
troponin	B-GENE
C	I-GENE
(	O
TnC	B-GENE
)	O
-binding	O
site	O
sequence	O
suggest	O
isoform-specific	O
adaptation	O
of	O
TnI	B-GENE
and	O
TnC	B-GENE
,	O
and	O
3	O
)	O
that	O
the	O
avian	O
TnIcardiac	B-GENE
internal	O
actin	B-GENE
/	I-GENE
TnC-binding	I-GENE
,	I-GENE
actomyosin-inhibitory	I-GENE
,	I-GENE
domain	I-GENE
shows	O
significant	O
sequence	O
divergence	O
from	O
mammalian	B-GENE
TnIcardiac	I-GENE
sequences	I-GENE
,	O
including	O
the	O
absence	O
of	O
a	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
target	O
site	O
which	O
is	O
a	O
cardiac-specific	O
feature	O
of	O
TnI	B-GENE
in	O
mammals	O
.	O

Certain	O
spt10	B-GENE
spontaneous	O
alleles	O
are	O
good	O
suppressors	O
but	O
have	O
a	O
normal	O
growth	O
rate	O
,	O
suggesting	O
that	O
the	O
SPT10	B-GENE
protein	I-GENE
may	O
have	O
two	O
distinct	O
functions	O
.	O

Genomic	O
libraries	O
were	O
stored	O
as	O
frozen	O
cultures	O
in	O
a	O
96-well	O
format	O
,	O
each	O
well	O
containing	O
approximately	O
300-600	O
colonies	O
(	O
12	O
plates	O
for	O
small	O
library	O
,	O
four	O
for	O
medium-size	O
library	O
and	O
four	O
for	O
large	O
library	O
)	O
.	O

In	O
summary	O
,	O
the	O
efficacies	O
of	O
adjuvant	O
carboplatin	O
and	O
of	O
abdominal	O
radiotherapy	O
seem	O
to	O
be	O
identical	O
.	O

Immobilized	O
dimers	O
of	O
N-cadherin-Fc	B-GENE
chimera	I-GENE
mimic	O
cadherin-mediated	O
cell	O
contact	O
formation	O
:	O
contribution	O
of	O
both	O
outside-in	O
and	O
inside-out	O
signals	O
.	O

In	O
contrast	O
,	O
gel	O
mobility	O
shift	O
experiments	O
have	O
failed	O
to	O
reveal	O
that	O
HAP2	B-GENE
or	O
HAP3	B-GENE
binds	O
to	O
domain	O
1	O
or	O
that	O
hap3	B-GENE
mutations	O
affect	O
the	O
complexes	O
bound	O
to	O
it	O
.	O

The	O
PDH	B-GENE
complex-encoding	I-GENE
genes	I-GENE
were	O
identified	O
by	O
hybridization	O
experiments	O
and	O
sequence	O
analysis	O
in	O
two	O
separate	O
gene	O
regions	O
in	O
the	O
genome	O
of	O
Z	O
.	O
mobilis	O
.	O

None	O
of	O
the	O
patients	O
was	O
obese	O
.	O

Sensory	O
evoked	O
field	O
potentials	O
were	O
recorded	O
from	O
the	O
mesencephalic	O
reticular	O
formation	O
(	O
MRF	O
)	O
,	O
central	O
gray	O
(	O
CG	O
)	O
and	O
somatosensory	O
cortex	O
(	O
SCX	O
)	O
,	O
following	O
incremental	O
doses	O
of	O
halothane	O
in	O
freely-moving	O
rats	O
.	O

Mucosal	O
application	O
of	O
NCX-4016	O
,	O
however	O
,	O
did	O
not	O
cause	O
PD	O
reduction	O
and	O
luminal	O
H+	O
loss	O
,	O
but	O
produced	O
a	O
marked	O
hyperemia	O
,	O
resulting	O
in	O
no	O
damage	O
in	O
the	O
stomach	O
of	O
both	O
normal	O
and	O
STZ-diabetic	O
rats	O
.	O

A	O
role	O
for	O
glycogen	B-GENE
synthase	I-GENE
kinase-3	I-GENE
in	O
the	O
control	O
of	O
gene	O
expression	O
.	O

CONCLUSION	O
:	O
Our	O
study	O
shows	O
that	O
(	O
1	O
)	O
total	O
body	O
BMD	O
and	O
femoral	O
neck	O
BMD	O
were	O
significantly	O
higher	O
in	O
the	O
study	O
group	O
that	O
performed	O
weight-bearing	O
exercises	O
than	O
in	O
control	O
subjects	O
,	O
(	O
2	O
)	O
swimming	O
exercise	O
had	O
no	O
effect	O
on	O
BMD	O
,	O
and	O
(	O
3	O
)	O
although	O
swimming	O
is	O
not	O
a	O
bone-building	O
exercise	O
,	O
it	O
can	O
significantly	O
improve	O
shoulder	O
,	O
back	O
,	O
and	O
grip	O
muscle	O
strength	O
.	O

Adjuvant	O
therapy	O
for	O
colon	O
cancer	O
Surgery	O
alone	O
may	O
fail	O
to	O
cure	O
a	O
considerable	O
number	O
of	O
locally	O
advanced	O
colon	O
cancers	O
.	O

Several	O
particular	O
features	O
of	O
this	O
polypeptide	O
fragment	O
from	O
the	O
hamster	B-GENE
lysyl-tRNA	I-GENE
synthetase	I-GENE
suggest	O
that	O
it	O
is	O
implicated	O
in	O
the	O
assembly	O
of	O
that	O
enzyme	O
within	O
the	O
multisynthetase	O
complex	O
.	O

Identification	O
of	O
an	O
AfsA	B-GENE
homologue	I-GENE
(	O
BarX	B-GENE
)	O
from	O
Streptomyces	O
virginiae	O
as	O
a	O
pleiotropic	O
regulator	O
controlling	O
autoregulator	O
biosynthesis	O
,	O
virginiamycin	O
biosynthesis	O
and	O
virginiamycin	O
M1	O
resistance	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
was	O
highly	O
conserved	O
across	O
the	O
wide	O
range	O
of	O
eukaryotes	O
(	O
vertebrates	O
,	O
invertebrates	O
,	O
fungi	O
,	O
plants	O
and	O
protozoa	O
)	O
in	O
which	O
this	O
gene	O
has	O
now	O
been	O
identified	O
.	O

We	O
observed	O
NP	B-GENE
/	I-GENE
NMP4	I-GENE
/	I-GENE
CIZ	I-GENE
expression	O
in	O
osteocytes	O
,	O
osteoblasts	O
,	O
and	O
chondrocytes	O
in	O
rat	O
bone	O
.	O

Southwestern	O
blot	O
analysis	O
demonstrated	O
that	O
this	O
phosphoprotein	O
can	O
bind	O
the	O
kappa	B-GENE
B	I-GENE
element	I-GENE
directly	O
and	O
specifically	O
.	O

The	O
therapeutic	O
action	O
of	O
cyclosporin	O
A	O
(	O
Sandimmun	O
)	O
:	O
its	O
application	O
in	O
rheumatoid	O
arthritis	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
GLC	O
of	O
short	O
chain	O
fatty	O
acids	O
produced	O
on	O
agar	O
medium	O
by	O
anaerobes	O
,	O
combined	O
with	O
simple	O
tests	O
such	O
as	O
Gram's	O
stain	O
and	O
colonial	O
morphology	O
,	O
may	O
allow	O
fir	O
direct	O
presumptive	O
genus	O
identification	O
from	O
an	O
initial	O
pure	O
agar	O
culture	O
.	O

Moreover	O
,	O
the	O
mass	O
estimated	O
with	O
the	O
QCM	O
response	O
through	O
the	O
Sauerbrey	O
equation	O
and	O
the	O
mass	O
which	O
can	O
be	O
measured	O
thanks	O
to	O
other	O
analytical	O
techniques	O
,	O
in	O
our	O
case	O
an	O
enzymatic	O
assay	O
,	O
are	O
different	O
:	O
the	O
deposited	O
mass	O
is	O
generally	O
overestimated	O
by	O
the	O
QCM	O
.	O

The	O
Wnt	B-GENE
signaling	O
pathway	O
functions	O
reiteratively	O
during	O
animal	O
development	O
to	O
control	O
cell	O
fate	O
decisions	O
.	O

The	O
relationship	O
of	O
human	O
umbilical	O
arterial	O
and	O
venous	O
plasma	O
levels	O
of	O
corticosteroids	O
to	O
gestational	O
age	O
.	O

Oseltamivir	O
(	O
GS4104	O
)	O
,	O
which	O
can	O
be	O
administered	O
orally	O
,	O
is	O
the	O
prodrug	O
of	O
GS4071	O
,	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
influenzavirus	B-GENE
neuraminidases	I-GENE
.	O

BACKGROUND	O
:	O
Defensins	B-GENE
,	O
also	O
known	O
as	O
human	B-GENE
neutrophil	I-GENE
peptides	I-GENE
,	O
are	O
antimicrobial	O
peptides	O
present	O
in	O
the	O
azurophil	O
granules	O
of	O
neutrophils	O
.	O

We	O
also	O
show	O
by	O
immunogold	O
electron	O
microscopy	O
immunocytochemistry	O
that	O
amphiphysin	B-GENE
I	I-GENE
is	O
localized	O
in	O
the	O
nerve	O
terminal	O
cytomatrix	O
and	O
is	O
partially	O
associated	O
with	O
endocytic	O
intermediates	O
.	O

The	O
human	B-GENE
gp39	I-GENE
promoter	I-GENE
.	O

The	O
metabolic	O
clearance	O
rate	O
of	O
progesterone	O
was	O
295	O
+	O
/	O
-	O
49	O
(	O
S	O
.	O
E	O
.	O
)	O
1	O
/	O
day	O
.	O

The	O
SCMV	B-GENE
SNE	I-GENE
sites	I-GENE
contain	O
potential	O
overlapping	O
core	O
recognition	O
binding	O
motifs	O
for	O
SRF	B-GENE
,	O
Rel	B-GENE
/	I-GENE
NFkappaB	I-GENE
,	O
ETS	B-GENE
,	O
and	O
YY1	B-GENE
class	I-GENE
transcription	I-GENE
factors	I-GENE
but	O
fail	O
to	O
respond	O
to	O
either	O
serum	O
or	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
.	O

Disulfiram	O
and	O
the	O
drug-induced	O
effects	O
on	O
motility	O
.	O

Resistance	O
training	O
shifts	O
the	O
power	O
curve	O
in	O
a	O
positive	O
direction	O
when	O
the	O
measurements	O
are	O
determined	O
with	O
absolute	O
loads	O
,	O
but	O
the	O
increased	O
power	O
may	O
not	O
be	O
transferred	O
to	O
an	O
absolute	O
performance	O
task	O
like	O
the	O
SSP	O
.	O

The	O
authors	O
concluded	O
that	O
ultrasonic	O
Doppler-cardiography	O
can	O
be	O
used	O
for	O
measuring	O
the	O
relative	O
changes	O
in	O
the	O
stroke	O
volume	O
.	O

The	O
c-Ets-1	B-GENE
oncoprotein	I-GENE
is	O
a	O
transcription	O
activator	O
that	O
specifically	O
binds	O
to	O
DNA	O
.	O

Internally	O
oriented	O
patients'	O
scores	O
on	O
Rotter's	O
Internal-External	O
Locus	O
of	O
Control	O
Scale	O
remained	O
the	O
same	O
over	O
treatment	O
but	O
those	O
of	O
externally	O
oriented	O
patients	O
shifted	O
toward	O
greater	O
internal	O
control	O
.	O

Percent	O
identities	O
of	O
the	O
mouse	B-GENE
PP2	I-GENE
to	O
mouse	B-GENE
Y1	I-GENE
,	O
mouse	B-GENE
Y4	I-GENE
/	I-GENE
PP1	I-GENE
and	O
human	B-GENE
Y2	I-GENE
receptors	I-GENE
are	O
53	O
,	O
42	O
,	O
and	O
31	O
,	O
respectively	O
.	O

ZK7	B-GENE
and	O
HZF16	B-GENE
genes	I-GENE
appear	O
to	O
be	O
the	O
splice	O
variants	O
transcribed	O
from	O
the	O
same	O
gene	O
.	O

Evidence	O
for	O
two	O
distinctive	O
clinical	O
,	O
epidemiological	O
,	O
and	O
immunological	O
types	O
of	O
infection	O
.	O

Positional	O
cloning	O
has	O
already	O
produced	O
the	O
sequences	O
of	O
more	O
than	O
70	O
human	O
genes	O
associated	O
with	O
specific	O
diseases	O
.	O

15	O
,	O
2500-2508	O
;	O
O'Neill	O
,	O
T	O
.	O

Serum	O
lipid	O
changes	O
during	O
pregnancy	O
due	O
to	O
oral	O
calcium	O
administration	O
.	O

The	O
protein	O
is	O
composed	O
of	O
two	O
major	O
domains	O
separated	O
by	O
a	O
hydrophobic	O
linker	O
region	O
of	O
20	O
amino	O
acid	O
residues	O
.	O

MEK	B-GENE
itself	O
is	O
activated	O
via	O
serine	O
phosphorylation	O
by	O
upstream	B-GENE
activator	I-GENE
kinases	I-GENE
,	O
including	O
c-raf	B-GENE
,	O
mos	B-GENE
and	O
MEK	B-GENE
kinase	I-GENE
.	O

A	O
protein	O
lacking	O
the	O
SH2	B-GENE
and	O
RING	O
finger	O
domains	O
has	O
no	O
activity	O
,	O
but	O
a	O
chimeric	O
protein	O
with	O
the	O
SH2	B-GENE
and	O
RING	O
finger	O
domains	O
of	O
SLI-1	B-GENE
replaced	O
by	O
the	O
equivalent	O
domains	O
of	O
c-Cbl	B-GENE
has	O
activity	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
MEMA	B-GENE
protein	I-GENE
is	O
identical	O
with	O
a	O
160	B-GENE
kDa	I-GENE
nuclear	I-GENE
'domain	I-GENE
rich	I-GENE
in	I-GENE
serines'	I-GENE
(	I-GENE
DRS	I-GENE
)	I-GENE
protein	I-GENE
occurring	O
free	O
in	O
the	O
nucleoplasm	O
and	O
in	O
U2-ribonucleoprotein	B-GENE
structures	I-GENE
.	O

The	O
central	O
globular	O
domain	O
is	O
highly	O
similar	O
to	O
those	O
regions	O
from	O
other	O
H1	B-GENE
molecules	I-GENE
,	O
and	O
the	O
carboxyl-terminal	O
domain	O
contains	O
a	O
repeating	O
hexapeptide	O
motif	O
,	O
variants	O
of	O
which	O
are	O
conserved	O
among	O
H1	B-GENE
molecules	I-GENE
.	O

Neither	O
side	O
effect	O
nor	O
abnormal	O
laboratory	O
findings	O
due	O
to	O
this	O
drug	O
were	O
observed	O
.	O

One	O
group	O
(	O
n	O
=	O
9	O
)	O
was	O
premedicated	O
with	O
midazolam	O
,	O
0	O
.	O
1	O
mg	O
kg-1	O
,	O
and	O
atropine	O
0	O
.	O
2-0	O
.	O
4	O
mg	O
i	O
.	O
m	O
.	O

No	O
evidence	O
for	O
the	O
presence	O
of	O
introns	O
within	O
the	O
acvA	B-GENE
gene	I-GENE
has	O
been	O
found	O
.	O

The	O
effects	O
of	O
tap	O
(	O
TW	O
)	O
or	O
carbonated	O
(	O
CW	O
)	O
water	O
on	O
arterial	O
pH	O
,	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PCO2	O
)	O
and	O
plasma	O
lactate	O
were	O
determined	O
in	O
heat-stressed	O
broilers	O
.	O

Weak	O
promoter	O
activity	O
was	O
observed	O
for	O
the	O
promoter	O
of	O
the	O
C1	B-GENE
and	I-GENE
C2	I-GENE
ORFs	I-GENE
(	O
C1-C2	B-GENE
gene	I-GENE
)	O
and	O
for	O
the	O
promoter	O
of	O
the	O
V1	B-GENE
ORF	I-GENE
.	O

These	O
results	O
strongly	O
suggested	O
that	O
similar	O
,	O
if	O
not	O
identical	O
,	O
the	O
CArG	B-GENE
box	I-GENE
binding	I-GENE
proteins	I-GENE
interact	O
with	O
the	O
functionally	O
different	O
promoter	O
element	O
in	O
the	O
VLC1	B-GENE
,	O
cardiac	B-GENE
alpha-actin	I-GENE
,	O
and	O
c-fos	B-GENE
genes	I-GENE
.	O

The	O
ORFII	B-GENE
gene	I-GENE
product	I-GENE
is	O
targeted	O
to	O
the	O
chloroplast	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
data	O
indicating	O
the	O
presence	O
of	O
PMSR	B-GENE
activity	O
in	O
the	O
chloroplast	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
response	O
rates	O
and	O
toxicity	O
of	O
two	O
regimens	O
containing	O
granulocyte-macrophage-colony	B-GENE
stimulating	I-GENE
factor	I-GENE
(	O
GM-CSF	B-GENE
)	O
in	O
combination	O
with	O
interleukin-2	B-GENE
(	O
IL-2	B-GENE
)	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O

(	O
1998	O
)	O
J	O
.	O

For	O
this	O
purpose	O
,	O
a	O
simple	O
respiration-control	O
device	O
has	O
been	O
developed	O
that	O
enables	O
the	O
patient	O
to	O
monitor	O
breath-holding	O
during	O
successive	O
scans	O
.	O

Additional	O
education	O
and	O
research	O
is	O
needed	O
to	O
provide	O
further	O
direction	O
for	O
intervention	O
and	O
incorporation	O
into	O
practice	O
.	O

The	O
438	B-GENE
bp	I-GENE
EcoRI	I-GENE
fragment	I-GENE
,	O
which	O
was	O
detected	O
by	O
Southern	O
hybridization	O
,	O
reveals	O
an	O
open	O
reading	O
frame	O
which	O
encodes	O
a	O
protein	O
of	O
103	O
amino	O
acids	O
.	O

In	O
the	O
meantime	O
,	O
one	O
has	O
succeeded	O
to	O
establish	O
the	O
deammonification	O
processes	O
in	O
a	O
continuous	O
flow	O
moving-bed	O
pilot	O
plant	O
.	O

Restoration	O
of	O
impaired	O
immune	O
functions	O
in	O
aging	O
animals	O
.	O

While	O
this	O
Saccharomyces	O
cerevisiae	O
SIN4	B-GENE
gene	I-GENE
product	I-GENE
is	O
a	O
component	O
of	O
a	O
mediator	O
complex	O
associated	O
with	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
,	O
various	O
studies	O
suggest	O
the	O
involvement	O
of	O
Sin4	B-GENE
in	O
the	O
alteration	O
of	O
higher-order	O
chromatin	O
structure	O
.	O

A	O
high-resolution	O
restriction	O
map	O
of	O
over	O
200	O
kb	O
of	O
contiguous	O
DNA	O
containing	O
N-myc	B-GENE
has	O
been	O
generated	O
by	O
subcloning	O
YACs	O
into	O
cosmids	O
.	O

While	O
the	O
latter	O
corresponded	O
to	O
a	O
protein	O
of	O
824	O
amino	O
acids	O
,	O
an	O
upstream	O
open	O
reading	O
frame	O
(	O
uORF	O
)	O
within	O
the	O
5'	O
leader	O
could	O
potentially	O
encode	O
a	O
54	O
amino	O
acid	O
peptide	O
.	O

In	O
summary	O
,	O
the	O
no-adverse-effect-level	O
for	O
this	O
study	O
was	O
determined	O
to	O
be	O
1000	O
ppm	O
,	O
based	O
on	O
decreased	O
weight	O
gain	O
in	O
female	O
rats	O
,	O
and	O
on	O
slight	O
organ	O
weight	O
changes	O
in	O
both	O
sexes	O
at	O
3000	O
ppm	O
.	O

A	O
secondary	O
spread	O
of	O
an	O
imported	O
methicillin-resistant	O
Staphylococcus	O
aureus	O
strain	O
(	O
MRSA	O
)	O
to	O
two	O
other	O
patients	O
occurred	O
within	O
a	O
Danish	O
surgical	O
ward	O
in	O
spite	O
of	O
isolation	O
of	O
a	O
multitraumatized	O
index-patient	O
immediately	O
after	O
arrival	O
from	O
a	O
hospital	O
in	O
the	O
Mediterranean	O
area	O
.	O

The	O
FMN	O
moiety	O
but	O
not	O
the	O
[	O
3Fe-4S	O
]	O
cluster	O
of	O
the	O
subunit	O
appears	O
to	O
participate	O
in	O
this	O
reaction	O
.	O

It	O
thus	O
appears	O
that	O
MAPK	B-GENE
functions	O
in	O
meiotic	O
maturation	O
by	O
preventing	O
unfertilized	O
eggs	O
from	O
proceeding	O
into	O
parthenogenetic	O
development	O
.	O

Tolterodine	O
users	O
were	O
7	O
.	O
5	O
times	O
more	O
likely	O
to	O
have	O
received	O
another	O
spasmolytic	O
drug	O
(	O
RR	O
7	O
.	O
5	O
,	O
95%	O
CI	O
4	O
.	O
8	O
to	O
11	O
.	O
9	O
)	O
.	O

Effect	O
of	O
immune	O
lymphocytes	O
and	O
of	O
rabbit-anti-lymphocyte	B-GENE
globulin	I-GENE
(	O
RAMLG	B-GENE
)	O
on	O
infected	O
macrophages	O
exposed	O
to	O
increased	O
incubation	O
temperature	O
in	O
vitro	O
.	O

The	O
Menopause-Rating-Scale	O
(	O
MRS	O
I	O
)	O
was	O
used	O
in	O
clinical	O
practice	O
since	O
1992	O
.	O

CONCLUSION	O
:	O
Patients	O
wit	O
clinically	O
palpable	O
neck	O
disease	O
(	O
N1-3	O
)	O
,	O
histological	O
evidence	O
of	O
metastatic	O
nodal	O
disease	O
,	O
extracapsular	O
spread	O
,	O
and	O
three	O
or	O
more	O
positive	O
lymph	O
nodes	O
are	O
at	O
greater	O
risk	O
of	O
developing	O
failure	O
at	O
distant	O
sites	O
.	O

Cardiac	O
disease	O
was	O
not	O
detected	O
with	O
M-mode	O
,	O
2-dimensional	O
real-time	O
or	O
pulsed-wave	O
Doppler	O
echocardiography	O
.	O

Bupropion	O
to	O
aid	O
smoking	O
cessation	O
.	O

One	O
extract	O
with	O
the	O
lowest	O
PCA	O
content	O
was	O
non-carcinogenic	O
.	O

The	O
derivatives	O
of	O
the	O
latter	O
two	O
cell	O
lines	O
showed	O
increased	O
expression	O
of	O
the	O
p27Kip1	B-GENE
protein	I-GENE
and	O
inhibition	O
of	O
cell	O
growth	O
.	O

Interestingly	O
,	O
the	O
interaction	O
of	O
ZAP-70	B-GENE
with	O
the	O
motif	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
both	O
ZAP-70	B-GENE
SH2	B-GENE
domains	I-GENE
and	O
both	O
of	O
the	O
tyrosine	O
residues	O
in	O
the	O
motif	O
,	O
suggesting	O
that	O
ZAP-70	B-GENE
interacts	O
with	O
two	O
phosphotyrosine	O
residues	O
and	O
that	O
the	O
binding	O
of	O
the	O
two	O
SH2	B-GENE
domains	I-GENE
is	O
cooperative	O
.	O

The	O
baroreflex	O
latency	O
(	O
from	O
the	O
ECG	O
R-wave	O
to	O
the	O
integrated	O
MSNA	O
burst	O
peak	O
)	O
was	O
constant	O
at	O
approximately	O
1	O
.	O
20	O
s	O
during	O
sleep	O
,	O
suggesting	O
that	O
pulse-synchronicity	O
was	O
maintained	O
.	O

One	O
CKD	O
patient's	O
journey	O
.	O

The	O
mode	O
of	O
resistance	O
to	O
quinupristin	O
/	O
dalfopristin	O
was	O
not	O
evident	O
(	O
sat	O
A-negative	O
by	O
PCR	O
)	O
;	O
and	O
these	O
cases	O
illustrate	O
the	O
existence	O
of	O
streptogramin-resistant	O
isolates	O
before	O
the	O
introduction	O
of	O
this	O
antimicrobial	O
class	O
into	O
human	O
clinical	O
practice	O
.	O

The	O
conservation	O
of	O
both	O
the	O
G-box	O
and	O
H-box	O
in	O
different	O
CHS	B-GENE
promoters	I-GENE
emphasizes	O
their	O
importance	O
as	O
regulatory	O
motifs	O
.	O

In	O
the	O
past	O
decade	O
,	O
there	O
have	O
been	O
enormous	O
advances	O
in	O
the	O
use	O
of	O
Bayesian	O
methodology	O
for	O
analysis	O
of	O
epidemiologic	O
data	O
,	O
and	O
there	O
are	O
now	O
many	O
practical	O
advantages	O
to	O
the	O
Bayesian	O
approach	O
.	O

Binding	O
affinities	O
of	O
different	O
nucleotide	O
mono-	O
,	O
di-	O
and	O
triphosphates	O
and	O
non-hydrolyzable	O
analogs	O
indicate	O
that	O
the	O
beta-phosphate	O
moiety	O
is	O
required	O
for	O
substrate	O
binding	O
.	O

The	O
LTR-binding	O
activities	O
of	O
VBP	B-GENE
,	O
a1	B-GENE
/	I-GENE
EBP	I-GENE
,	O
and	O
B-cell	O
nuclear	O
extract	O
protein	O
were	O
compared	O
and	O
mapped	O
by	O
gel	O
shift	O
,	O
DNase	B-GENE
I	I-GENE
footprinting	O
,	O
and	O
methylation	O
interference	O
assays	O
.	O

The	O
importance	O
of	O
temporal	O
factors	O
on	O
the	O
presence	O
and	O
severity	O
of	O
ethanol	O
withdrawal	O
signs	O
in	O
the	O
rat	O
was	O
quantified	O
using	O
rating	O
scale	O
,	O
tremor	O
,	O
and	O
acoustic	O
startle	O
paradigms	O
.	O

In	O
this	O
study	O
26	O
patients	O
(	O
20	O
females	O
and	O
6	O
males	O
)	O
were	O
evaluated	O
.	O

BACKGROUND	O
AND	O
DESIGN	O
:	O
Fifty-nine	O
melanocytic	O
nevi	O
with	O
eccentric	O
foci	O
of	O
hyperpigmentation	O
(	O
"small	O
dark	O
dots"	O
)	O
that	O
measured	O
primarily	O
1	O
to	O
2	O
mm	O
in	O
diameter	O
were	O
prospectively	O
examined	O
to	O
determine	O
the	O
histologic	O
correlates	O
of	O
the	O
dark	O
dots	O
.	O

Phosphocreatine	O
hydrolysis	O
during	O
submaximal	O
exercise	O
:	O
the	O
effect	O
of	O
FIO2	O
.	O

Present	O
results	O
reveal	O
a	O
frequency-dependent	O
inhibition	O
of	O
ganglionic	O
transmission	O
by	O
diltiazem	O
,	O
and	O
suggest	O
that	O
diltiazem	O
may	O
depress	O
excessive	O
sympathetic	O
activity	O
without	O
affecting	O
normal	O
ganglionic	O
transmission	O
.	O

Thus	O
,	O
quantitative	O
analysis	O
of	O
thallium-201	O
uptake	O
and	O
washout	O
provided	O
objective	O
evidence	O
for	O
improved	O
myocardial	O
perfusion	O
after	O
coronary	O
angioplasty	O
.	O

However	O
,	O
artificially	O
ventilated	O
rats	O
,	O
pretreated	O
with	O
MK-801	O
,	O
were	O
more	O
sensitive	O
(	O
lethal	O
cocaine	O
dose	O
,	O
76	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
0	O
mg	O
/	O
kg	O
,	O
n	O
=	O
5	O
)	O
than	O
vehicle	O
pretreated	O
rats	O
(	O
129	O
.	O
4	O
+	O
/	O
-	O
15	O
.	O
8	O
mg	O
/	O
kg	O
,	O
n	O
=	O
6	O
)	O
,	O
indicating	O
that	O
MK-801	O
may	O
increase	O
both	O
the	O
respiratory	O
and	O
the	O
cardiac	O
toxicity	O
of	O
cocaine	O
in	O
urethane	O
anesthetized	O
rats	O
.	O

However	O
,	O
overexpression	O
of	O
both	O
the	O
STE4	B-GENE
and	O
STE18	B-GENE
proteins	I-GENE
did	O
not	O
generate	O
a	O
stronger	O
pheromone	O
response	O
than	O
overexpression	O
of	O
STE4	B-GENE
in	O
the	O
presence	O
of	O
wild-type	O
levels	O
of	O
STE18	B-GENE
.	O

In	O
a	O
gel	O
retardation	O
assay	O
using	O
HepG2	O
nuclear	O
extracts	O
,	O
the	O
5'	O
flanking	O
sequence	O
from	O
-74	O
to	O
-46	O
showed	O
a	O
shifted	O
band	O
.	O

In	O
an	O
attempt	O
to	O
reduce	O
the	O
incidence	O
of	O
NSAID-induced	O
gastrointestinal	O
lesions	O
,	O
the	O
following	O
approaches	O
have	O
been	O
proposed	O
:	O
(	O
i	O
)	O
use	O
of	O
the	O
prostaglandin	O
analogue	O
misoprostol	O
,	O
which	O
is	O
an	O
antiulcer	O
drug	O
which	O
has	O
been	O
proven	O
to	O
be	O
as	O
effective	O
in	O
the	O
prevention	O
of	O
NSAID-induced	O
gastric	O
and	O
duodenal	O
ulcers	O
as	O
in	O
the	O
reduction	O
of	O
serious	O
upper	O
gastrointestinal	O
complications	O
;	O
(	O
ii	O
)	O
histamine	B-GENE
H2	I-GENE
receptor	I-GENE
antagonists	O
(	O
H2	O
antagonists	O
)	O
,	O
e	O
.	O
g	O
.	O
ranitidine	O
,	O
cimetidine	O
and	O
famotidine	O
,	O
which	O
are	O
useful	O
in	O
the	O
prevention	O
of	O
NSAID-induced	O
duodenal	O
ulcers	O
during	O
long	O
term	O
treatment	O
,	O
but	O
not	O
in	O
the	O
prevention	O
of	O
NSAID-induced	O
gastric	O
ulcers	O
;	O
(	O
iii	O
)	O
proton	O
pump	O
inhibitors	O
,	O
e	O
.	O
g	O
omeprazole	O
,	O
and	O
pantoprazole	O
,	O
whose	O
efficacy	O
in	O
preventing	O
NSAID-associated	O
ulcers	O
has	O
been	O
recently	O
demonstrated	O
;	O
and	O
(	O
iv	O
)	O
barrier	O
agents	O
,	O
e	O
.	O
g	O
.	O
sucralfate	O
,	O
which	O
cannot	O
be	O
recommended	O
as	O
prophylactic	O
agents	O
to	O
prevent	O
NSAID-induced	O
gastropathy	O
.	O

SRC-1	B-GENE
can	O
relieve	O
the	O
NF-kappaB-mediated	O
repression	O
of	O
GR	B-GENE
activity	O
.	O

Two	O
other	O
patients	O
underwent	O
PRFR	O
.	O

Biol	O
.	O

Thin	O
melanomas	O
can	O
metastasize	O
and	O
be	O
lethal	O
.	O

The	O
chromosomal	O
localization	O
on	O
distal	O
chromosome	O
7	O
places	O
it	O
in	O
a	O
cluster	O
of	O
imprinted	O
genes	O
,	O
flanked	O
by	O
the	O
previously	O
described	O
Tapa1	B-GENE
and	O
Kcnq1	B-GENE
genes	I-GENE
.	O

Consistent	O
with	O
this	O
interpretation	O
,	O
a	O
mutant	O
form	O
of	O
XRN1	B-GENE
,	O
which	O
encodes	O
a	O
5'-3'	O
exonuclease	O
,	O
was	O
identified	O
as	O
an	O
extragenic	O
suppressor	O
that	O
increases	O
the	O
half-life	O
of	O
rhis4	B-GENE
mRNA	I-GENE
,	O
leading	O
to	O
a	O
10-fold	O
increase	O
in	O
steady-state	O
mRNA	O
levels	O
compared	O
to	O
the	O
wild-type	B-GENE
HIS4	I-GENE
mRNA	I-GENE
level	O
.	O

Chlamydia	O
trachomatis	O
and	O
Chlamydia	O
psittaci	O
were	O
not	O
affected	O
by	O
methanol	O
fixation	O
.	O

Topological	O
and	O
Mutational	O
Analysis	O
of	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
Ste14p	I-GENE
,	O
Founding	O
Member	O
of	O
the	O
Isoprenylcysteine	B-GENE
Carboxyl	I-GENE
Methyltransferase	I-GENE
Family	I-GENE
.	O

The	O
pexB	B-GENE
upstream	I-GENE
region	I-GENE
contained	O
245	O
nucleotides	O
within	O
which	O
sequences	O
approximating	O
the	O
consensus	O
for	O
cyclic	B-GENE
AMP	I-GENE
receptor	I-GENE
protein	I-GENE
and	O
integration	B-GENE
host	I-GENE
factor	I-GENE
binding	I-GENE
sites	I-GENE
were	O
discernible	O
.	O

Transient	O
transfections	O
of	O
a	O
construct	O
expressing	O
the	O
RNA	O
transcript	O
defined	O
by	O
clone	O
B1	O
.	O
1	O
into	O
D17	O
cells	O
led	O
to	O
the	O
expression	O
of	O
an	O
Env	B-GENE
/	I-GENE
Mlvi-4	I-GENE
fusion	I-GENE
protein	I-GENE
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
33	O
kDa	O
.	O

This	O
study	O
suggests	O
that	O
PSP	O
is	O
more	O
common	O
than	O
previously	O
considered	O
,	O
is	O
commonly	O
misdiagnosed	O
and	O
that	O
the	O
majority	O
of	O
cases	O
are	O
not	O
initially	O
referred	O
to	O
neurologists	O
.	O

While	O
TGF-beta1	B-GENE
does	O
not	O
alter	O
the	O
mitogen-induced	O
expression	O
and	O
abundance	O
of	O
G1	O
phase	O
cyclin	B-GENE
D1	I-GENE
and	O
cdks	B-GENE
4	I-GENE
and	I-GENE
2	I-GENE
in	O
MCs	O
,	O
it	O
inhibits	O
cyclin	B-GENE
E-cdk	I-GENE
2	I-GENE
activity	O
,	O
thus	O
preventing	O
mitogen-elicited	O
phosphorylation	O
and	O
inactivation	O
of	O
pRb	B-GENE
in	O
G1	O
phase	O
and	O
transition	O
to	O
S	O
phase	O
.	O

The	O
application	O
of	O
the	O
biotechnology	O
at	O
the	O
plants	O
for	O
treatment	O
of	O
the	O
surface	O
storm	O
waters	O
from	O
the	O
industrial	O
zone	O
Telychka	O
of	O
the	O
city	O
of	O
Kyiv	O
has	O
allowed	O
the	O
content	O
of	O
petroleum	O
in	O
water	O
dropped	O
to	O
the	O
Dnieper	O
to	O
be	O
constantly	O
reduced	O
50-100	O
times	O
.	O

Structural	O
organization	O
and	O
expression	O
of	O
the	O
mouse	B-GENE
estrogen	I-GENE
receptor	I-GENE
.	O

These	O
data	O
suggest	O
that	O
dopaminergic	O
regulation	O
of	O
adrenal	O
zona	O
glomerulosa	O
corticosteroid	O
and	O
renal	B-GENE
renin	I-GENE
secretion	O
is	O
absent	O
in	O
patients	O
with	O
high	O
spinal	O
cord	O
transections	O
,	O
suggesting	O
that	O
intact	O
neural	O
pathways	O
from	O
the	O
central	O
nervous	O
system	O
are	O
necessary	O
for	O
metoclopramide	O
stimulation	O
of	O
aldosterone	O
and	O
renin	B-GENE
secretion	O
in	O
men	O
.	O

Thus	O
,	O
VF	O
resistant	O
to	O
defibrillation	O
is	O
not	O
necessarily	O
associated	O
with	O
both	O
toxic	O
plasma	O
drug	O
level	O
and	O
remarkably	O
decreased	O
conduction	O
.	O

Wegener's	O
granulomatosis	O

Comparison	O
of	O
elastase-1	B-GENE
with	O
amylase	B-GENE
,	O
lipase	B-GENE
,	O
and	O
trypsin-like	O
immunoreactivity	O
in	O
the	O
diagnosis	O
of	O
acute	O
pancreatitis	O
.	O

The	O
Sox	B-GENE
gene	I-GENE
family	I-GENE
(	O
Sry	B-GENE
like	O
HMG	B-GENE
box	I-GENE
gene	I-GENE
)	O
is	O
characterised	O
by	O
a	O
conserved	O
DNA	O
sequence	O
encoding	O
a	O
domain	O
of	O
approximately	O
80	O
amino	O
acids	O
which	O
is	O
responsible	O
for	O
sequence	O
specific	O
DNA	O
binding	O
.	O

The	O
dose	O
was	O
50	O
Gy	O
/	O
20	O
fractions	O
/	O
5	O
weeks	O
.	O

Vasoactive	B-GENE
intestinal	I-GENE
peptide	I-GENE
and	O
pituitary	B-GENE
adenylate	I-GENE
cyclase-activating	I-GENE
polypeptide	I-GENE
inhibit	O
nuclear	B-GENE
factor-kappa	I-GENE
B-dependent	I-GENE
gene	I-GENE
activation	O
at	O
multiple	O
levels	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
.	O

Homozygous	O
protein	B-GENE
C	I-GENE
(	O
PC	B-GENE
)	O
deficiency	O
is	O
reported	O
in	O
two	O
siblings	O
(	O
girl	O
and	O
boy	O
)	O
who	O
received	O
their	O
proper	O
diagnoses	O
at	O
the	O
ages	O
of	O
7	O
4	O
/	O
12	O
and	O
1	O
3	O
/	O
12	O
years	O
respectively	O
.	O

A	O
subsequent	O
screen	O
for	O
the	O
loss	O
of	O
the	O
positively	O
selectable	O
target	O
locus	O
marker	O
detects	O
the	O
desired	O
replacement	O
at	O
modest	O
frequency	O
(	O
>	O
2%	O
)	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
forkhead	B-GENE
homologue	I-GENE
in	I-GENE
rhabdomyosarcoma	I-GENE
(	O
FKHR	B-GENE
)	O
,	O
a	O
recently	O
described	O
member	O
of	O
the	O
hepatocyte	B-GENE
nuclear	I-GENE
factor	I-GENE
3	I-GENE
/	I-GENE
forkhead	I-GENE
homeotic	I-GENE
gene	I-GENE
family	O
,	O
as	O
a	O
nuclear	B-GENE
hormone	I-GENE
receptor	I-GENE
(	O
NR	B-GENE
)	O
intermediary	O
protein	O
.	O

Ultrastructural	O
and	O
morphometric	O
study	O
of	O
the	O
myeloid	O
parenchyma	O
cells	O
of	O
mice	O
prior	O
and	O
after	O
X-ray	O
exposure	O
.	O

Cloning	O
of	O
higher	B-GENE
plant	I-GENE
omega-3	I-GENE
fatty	I-GENE
acid	I-GENE
desaturases	I-GENE
.	O

To	O
determine	O
the	O
true	O
molecular	O
identity	O
of	O
SFD	B-GENE
,	O
both	O
the	O
50-	O
and	O
57-kDa	O
polypeptides	O
were	O
directly	O
sequenced	O
.	O

Synchronous	O
extracts	O
showed	O
no	O
significant	O
migration	O
inhibition	O
in	O
allogeneic	O
assays	O
.	O

In	O
order	O
to	O
decipher	O
the	O
pathway	O
that	O
leads	O
to	O
Hox	B-GENE
gene	I-GENE
induction	O
,	O
we	O
have	O
investigated	O
whether	O
a	O
Hox	B-GENE
gene	I-GENE
regulator	O
,	O
the	O
leucine	O
zipper	O
transcription	O
factor	O
MafB	B-GENE
/	I-GENE
Kr	I-GENE
,	O
is	O
itself	O
transcriptionally	O
regulated	O
by	O
the	O
environmental	O
signals	O
.	O

Eight	O
cats	O
infected	O
with	O
H	O
.	O
pylori	O
were	O
used	O
in	O
the	O
study	O
.	O

However	O
,	O
subcutaneously	O
administered	O
pneumococci	O
gave	O
a	O
lower	O
mortality	O
than	O
pneumococci	O
given	O
intravenously	O
or	O
intraperitoneally	O
.	O

Their	O
mean	O
IOP	O
was	O
15	O
.	O
3	O
(	O
SD	O
3	O
.	O
7	O
)	O
mmHg	O
prior	O
to	O
induction	O
of	O
anesthesia	O
,	O
13	O
.	O
5	O
(	O
SD	O
3	O
.	O
5	O
)	O
mmHg	O
after	O
loss	O
of	O
eyelash	O
reflex	O
following	O
injection	O
of	O
methohexitone	O
,	O
16	O
.	O
1	O
(	O
SD	O
2	O
.	O
4	O
)	O
mmHg	O
after	O
cessation	O
of	O
muscle	O
fasciculations	O
induced	O
by	O
suxamethonium	O
,	O
19	O
.	O
2	O
(	O
SD	O
5	O
.	O
6	O
)	O
mmHg	O
after	O
cessation	O
of	O
convulsion	O
and	O
15	O
.	O
5	O
(	O
SD	O
4	O
.	O
4	O
)	O
mmHg	O
following	O
resumption	O
of	O
regular	O
spontaneous	O
respiration	O
.	O

The	O
ligand	O
for	O
RXR	B-GENE
,	O
9-cis	O
retinoic	O
acid	O
,	O
has	O
the	O
opposite	O
effect	O
of	O
destabilizing	O
the	O
heterodimeric-DNA	O
complex	O
.	O

The	O
majority	O
of	O
PI	B-GENE
kinase	I-GENE
activity	O
appeared	O
to	O
be	O
cbl-associated	O
after	O
PRL	B-GENE
stimulation	O
.	O

Current	O
world	O
literature	O
.	O

Defects	O
of	O
fibrillin	B-GENE
(	O
FBN1	B-GENE
)	O
,	O
a	O
glycoprotein	O
component	O
of	O
the	O
extracellular	O
microfibril	O
,	O
cause	O
Marfan	O
syndrome	O
.	O

The	O
substrates	O
for	O
glycan	O
synthesis	O
in	O
the	O
lumen	O
of	O
the	O
Golgi	O
are	O
nucleotide	O
sugars	O
that	O
must	O
be	O
transported	O
from	O
the	O
cytosol	O
by	O
specific	O
membrane-bound	O
transporters	O
.	O

DNA	O
binding	O
and	O
glutathione	B-GENE
S-transferase	I-GENE
pull-down	O
assays	O
demonstrate	O
that	O
binding	O
requires	O
Elk-1	B-GENE
(	I-GENE
1-212	I-GENE
)	I-GENE
but	O
not	O
the	O
C-terminal	O
transactivation	O
domain	O
.	O

(	O
1994	O
,	O
Hum	O
.	O

The	O
synergistic	O
effect	O
due	O
to	O
the	O
5'-3'	O
cooperation	O
was	O
at	O
least	O
fourfold	O
greater	O
than	O
the	O
sum	O
of	O
the	O
contributions	O
of	O
the	O
individual	O
UTRs	O
.	O

At	O
Cabras	O
(	O
Oristano	O
)	O
,	O
a	O
town	O
characterized	O
by	O
a	O
high	O
incidence	O
of	O
thalassaemia	O
and	O
G6PD	B-GENE
deficiency	O
less	O
than	O
half	O
the	O
people	O
between	O
18	O
and	O
35	O
have	O
a	O
fair	O
knowledge	O
of	O
genetic	O
diseases	O
and	O
of	O
their	O
prevention	O
.	O

These	O
motifs	O
include	O
a	O
Chi	B-GENE
motif	I-GENE
and	O
a	O
Chi-like	B-GENE
element	I-GENE
previously	O
found	O
in	O
the	O
recombination	O
hotspot	O
region	O
of	O
the	O
Bcl-2	B-GENE
proto-oncogene	I-GENE
and	O
close	O
to	O
chromosomal	O
breakpoints	O
in	O
T-ALL	O
lines	O
.	O

16	O
subjects	O
were	O
repatch	O
tested	O
to	O
ethylmercury	O
chloride	O
(	O
EtHgCl	O
)	O
and	O
to	O
solutions	O
containing	O
EtHgCl	O
mixed	O
with	O
L-cysteine	O
and	O
glutathione	O
,	O
respectively	O
.	O

Adhesion	O
,	O
phagocytosis	O
,	O
chemotactic	O
and	O
random	O
migration	O
,	O
nitroblue	O
tetrazolium	O
dye	O
reduction	O
of	O
peritoneal	O
exudate	O
neutrophils	O
and	O
macrophages	O
,	O
fibrinogen	B-GENE
level	O
,	O
gelation	O
of	O
soluble	O
fibrin	B-GENE
and	O
serial	O
dilution	O
protamine	O
sulfate	O
test	O
were	O
investigated	O
in	O
115	O
New	O
Zealand	O
white	O
rabbits	O
with	O
experimentally	O
induced	O
Shwartzman	O
phenomenon	O
in	O
the	O
colon	O
,	O
and	O
in	O
control	O
animals	O
.	O

Corticosteroid	O
therapy	O
is	O
known	O
to	O
be	O
hazardous	O
in	O
patients	O
with	O
occult	O
infection	O
but	O
the	O
mechanism	O
by	O
which	O
the	O
host	O
parasite	O
relationship	O
is	O
altered	O
by	O
steroids	O
is	O
not	O
known	O
.	O
We	O
have	O
used	O
an	O
intestinal	O
protozoal	O
parasite	O
,	O
Giardia	O
muris	O
,	O
to	O
examine	O
the	O
effects	O
of	O
corticosteroids	O
on	O
the	O
number	O
of	O
parasites	O
in	O
the	O
intestine	O
in	O
the	O
course	O
of	O
a	O
primary	O
infection	O
.	O

Each	O
recombinant	O
product	O
was	O
a	O
fusion	O
protein	O
with	O
a	O
B	B-GENE
domain	I-GENE
of	O
Staphylococcal	B-GENE
protein	I-GENE
A	I-GENE
(	O
SPA	B-GENE
)	O
.	O

The	O
C5	B-GENE
alpha-chain	I-GENE
was	O
encoded	O
by	O
49	O
kilobases	O
containing	O
26	O
exons	O
;	O
the	O
beta-chain	O
was	O
encoded	O
by	O
29	O
kilobases	O
containing	O
16	O
exons	O
.	O

METHODS	O
:	O
Four	O
hundred	O
fifty	O
patients	O
with	O
the	O
diagnosis	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oral	O
cavity	O
received	O
their	O
primary	O
treatment	O
at	O
Roswell	O
Park	O
Cancer	O
Center	O
(	O
RPCI	O
)	O
from	O
1971	O
to	O
1991	O
.	O

Eighty	O
patients	O
presenting	O
to	O
HGGM	O
with	O
non-Hodgkin's	O
lymphomas	O
between	O
1962	O
and	O
1986	O
,	O
were	O
reviewed	O
.	O

In	O
contrast	O
,	O
dig1	B-GENE
dig2	B-GENE
cells	O
constitutively	O
invade	O
agar	O
medium	O
,	O
whereas	O
a	O
dig1	B-GENE
dig2	B-GENE
ste12	B-GENE
triple	O
mutant	O
does	O
not	O
,	O
indicating	O
that	O
Dig1	B-GENE
and	O
Dig2	B-GENE
share	O
a	O
role	O
in	O
negatively	O
regulating	O
the	O
invasive	O
growth	O
pathway	O
.	O

During	O
presentation	O
of	O
happy	O
facial	O
expressions	O
,	O
we	O
detected	O
a	O
signal	O
increase	O
predominantly	O
in	O
the	O
left	O
anterior	O
cingulate	O
gyrus	O
,	O
bilateral	O
posterior	O
cingulate	O
gyri	O
,	O
medial	O
frontal	O
cortex	O
and	O
right	O
supramarginal	O
gyrus	O
,	O
brain	O
regions	O
previously	O
implicated	O
in	O
visuospatial	O
and	O
emotion	O
processing	O
tasks	O
.	O

In	O
contrast	O
to	O
behavioral	O
deviation	O
(	O
the	O
avoidance	O
conditioning	O
lost	O
)	O
,	O
the	O
haloperidol	O
intrastriatal	O
microinjections	O
did	O
not	O
affect	O
the	O
DA	O
synaptic	O
level	O
in	O
rostral	O
neostriatum	O
.	O

Considerably	O
high	O
levels	O
of	O
IgE	B-GENE
antibodies	I-GENE
was	O
also	O
established	O
while	O
other	O
pollens	O
did	O
not	O
show	O
such	O
correspondence	O
.	O

Coexpression	O
of	O
mouse	O
PKR	B-GENE
(	I-GENE
1-515	I-GENE
)	I-GENE
WT	I-GENE
as	O
a	O
Gal4	B-GENE
DNA-binding	O
domain	O
fusion	O
with	O
either	O
the	O
catalytic-deficient	O
human	O
PKR	B-GENE
(	I-GENE
1-551	I-GENE
)	I-GENE
K296R	O
mutant	O
,	O
the	O
RNA-binding-deficient	O
human	O
PKR	B-GENE
(	I-GENE
1-551	I-GENE
)	I-GENE
K64E	I-GENE
/	I-GENE
K296R	I-GENE
double	O
mutant	O
,	O
or	O
wild-type	O
mouse	O
PKR	B-GENE
(	I-GENE
1-515	I-GENE
)	I-GENE
WT	I-GENE
as	O
full-length	O
PKR-Gal4	B-GENE
activation	O
domain	O
fusions	O
resulted	O
in	O
activation	O
of	O
the	O
HIS3	B-GENE
and	O
lacZ	B-GENE
reporters	O
.	O

Overexpression	O
of	O
either	O
DAP-1	B-GENE
or	O
sentrin	B-GENE
causes	O
apoptosis	O
of	O
TNF-sensitive	O
L929	O
fibroblast	O
cell	O
line	O
,	O
as	O
well	O
as	O
TNF-resistant	O
osteosarcoma	O
cell	O
line	O
,	O
U2OS	O
.	O

An	O
association	O
between	O
hSIE	B-GENE
and	O
Stat-3	B-GENE
after	O
MHC-I	B-GENE
ligation	O
was	O
directly	O
demonstrated	O
by	O
precipitating	O
Stat-3	B-GENE
from	O
nuclear	O
extracts	O
with	O
biotinylated	O
hSIE	B-GENE
probe	O
and	O
avidin-coupled	O
agarose	O
.	O

The	O
mechanism	O
by	O
which	O
large	O
molecules	O
,	O
such	O
as	O
the	O
diphosphonate	O
99mTc-labeled	O
EHDP	O
or	O
99mTc-labeled	O
pyrophosphate	O
,	O
pass	O
through	O
capillaries	O
in	O
bone	O
is	O
by	O
passive	O
diffusion	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
from	O
rat	O
brain	O
and	O
human	O
liver	O
encoding	O
a	O
putative	O
isoform	O
of	O
the	O
Na	B-GENE
,	I-GENE
K-ATPase	I-GENE
beta	I-GENE
subunit	I-GENE
.	O

I	O
.	O

Src	B-GENE
activation	O
induced	O
by	O
FGF1	B-GENE
was	O
blocked	O
by	O
the	O
SH2	B-GENE
domain	I-GENE
of	O
Src	B-GENE
and	O
PP2	B-GENE
,	O
a	O
specific	O
inhibitor	O
of	O
Src	B-GENE
.	O

In	O
a	O
third	O
experiment	O
,	O
crossover	O
AM	O
between	O
dissimilar	O
textures	O
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
that	O
the	O
more	O
salient	O
textures	O
carried	O
the	O
AM	O
.	O

Muscle	O
action	O
potential	O
and	O
masticatory	O
rhythm	O
of	O
anterior	O
temporal	O
and	O
masseter	O
muscles	O
in	O
children	O
and	O
adults	O
.	O

Chemical	O
constituents	O
of	O
the	O
gentianaceae	O
V	O
:	O
tetraoxygenated	O
xanthones	O
of	O
Swertia	O
chirata	O
Buch	O
.	O
-Ham	O
.	O

However	O
,	O
although	O
deletion	O
of	O
Fp1	B-GENE
in	O
the	O
hCRBP1	B-GENE
gene	I-GENE
yielded	O
increased	O
CAT	B-GENE
activity	O
,	O
pointing	O
toward	O
a	O
negative	O
regulatory	O
function	O
exerted	O
by	O
this	O
element	O
,	O
its	O
insertion	O
upstream	O
of	O
the	O
p12	B-GENE
basal	I-GENE
promoter	I-GENE
results	O
in	O
an	O
impressive	O
positive	O
stimulation	O
of	O
CAT	B-GENE
gene	I-GENE
expression	O
.	O

Mutational	O
analyses	O
have	O
demonstrated	O
the	O
importance	O
of	O
sequences	O
within	O
the	O
327	O
bp	O
segment	O
that	O
contain	O
a	O
putative	O
cyclic	B-GENE
AMP	I-GENE
responsive	I-GENE
element	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
binding	O
site	O
for	O
TGF-beta	B-GENE
1	I-GENE
and	O
PMA	O
responsiveness	O
and	O
putative	O
PU-1	B-GENE
and	O
Sp1	B-GENE
binding	I-GENE
sites	I-GENE
for	O
basal	O
promoter	O
activity	O
.	O

Response	O
durations	O
were	O
short	O
.	O

Thus	O
,	O
Xlim-1	B-GENE
not	O
only	O
contains	O
a	O
unique	O
tyrosine-rich	O
activation	O
domain	O
but	O
also	O
contains	O
a	O
negative	O
regulatory	O
domain	O
in	O
CT239-403	B-GENE
,	O
suggesting	O
a	O
complex	O
regulatory	O
mechanism	O
underlying	O
the	O
transcriptional	O
activity	O
of	O
Xlim-1	B-GENE
in	O
the	O
organizer	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
exhibited	O
70%	O
identity	O
to	O
that	O
of	O
Bacillus	B-GENE
stearothermophilus	I-GENE
TyrTS	I-GENE
and	O
55%	O
identity	O
to	O
that	O
of	O
E	B-GENE
.	I-GENE
coli	I-GENE
TyrTS	I-GENE
,	O
while	O
identity	O
to	O
a	O
second	O
cryptic	O
B	B-GENE
.	I-GENE
subtilis	I-GENE
TyrTS	I-GENE
gene	I-GENE
,	O
designated	O
tyrZ	B-GENE
,	O
was	O
only	O
27%	O
.	O

Behaviorally	O
,	O
a	O
pain-tolerant	O
group	O
(	O
PT	O
=	O
29	O
Ss	O
)	O
tolerated	O
the	O
entire	O
3-min	O
test	O
(	O
means	O
=	O
180	O
+	O
/	O
-	O
0	O
sec	O
)	O
,	O
while	O
a	O
pain-sensitive	O
group	O
(	O
PS	O
=	O
13	O
Ss	O
)	O
averaged	O
only	O
50	O
.	O
31	O
+	O
/	O
-	O
20	O
.	O
81	O
sec	O
of	O
the	O
cold-pressor	O
test	O
(	O
t	O
=	O
16	O
.	O
75	O
,	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
,	O
replicating	O
our	O
earlier	O
studies	O
.	O

Sequence	O
conservation	O
is	O
greatest	O
for	O
residues	O
located	O
near	O
the	O
active	O
centers	O
of	O
the	O
exo	B-GENE
and	O
pol	B-GENE
domains	I-GENE
of	O
the	O
E	B-GENE
.	I-GENE
coli	I-GENE
DNA	I-GENE
polymerase	I-GENE
I	I-GENE
structure	O
.	O

This	O
study	O
compared	O
the	O
gross	O
and	O
fine	O
motor	O
performance	O
of	O
14	O
traumatically	O
brain-injured	O
children	O
(	O
five	O
to	O
15	O
years	O
old	O
,	O
with	O
loss	O
of	O
consciousness	O
for	O
at	O
least	O
24	O
hours	O
)	O
to	O
14	O
normal	O
children	O
group	O
matched	O
for	O
age	O
and	O
sex	O
.	O

The	O
plateau	O
MO2	O
value	O
was	O
that	O
predicted	O
by	O
allometric	O
relation	O
.	O

One	O
was	O
allowed	O
fresh	O
drinking	O
water	O
ad	O
libitum	O
whilst	O
the	O
other	O
received	O
Aludrox	O
in	O
their	O
drinking	O
water	O
.	O

Although	O
the	O
gene	O
is	O
substantially	O
smaller	O
than	O
the	O
human	O
genes	O
for	O
other	O
mitochondrial	O
enzymes	O
,	O
its	O
intron	O
/	O
exon	O
organization	O
is	O
very	O
similar	O
,	O
especially	O
to	O
that	O
of	O
P450scc	B-GENE
.	O

This	O
and	O
previous	O
results	O
suggest	O
that	O
the	O
CRE	B-GENE
and	O
Sp1	B-GENE
site	I-GENE
may	O
synergistically	O
activate	O
TH	B-GENE
transcription	O
in	O
a	O
promoter	O
context-dependent	O
manner	O
.	O

The	O
same	O
rhythmic	O
structure	O
enables	O
a	O
prediction	O
to	O
be	O
made	O
concerning	O
when	O
vowels	O
of	O
stressed	O
syllables	O
will	O
be	O
auditorily	O
perceived	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
function	O
of	O
the	O
hypothalamic-pituitary-thyroid	O
(	O
HPT	O
)	O
-axis	O
in	O
unipolar	O
depression	O
,	O
the	O
authors	O
measured	O
basal	O
0800h	O
plasma	O
levels	O
of	O
free	O
thyroxine	O
(	O
FT4	O
)	O
,	O
free	O
triiodothyronine	O
(	O
FT3	O
)	O
,	O
and	O
thyroid	B-GENE
stimulating	I-GENE
hormone	I-GENE
(	O
TSH	B-GENE
)	O
by	O
means	O
of	O
the	O
new	O
,	O
ultrasensitive	O
assays	O
(	O
TSH-IRMA	O
)	O
in	O
69	O
healthy	O
controls	O
,	O
62	O
minor	O
,	O
101	O
simple	O
major	O
,	O
and	O
57	O
melancholic	O
depressed	O
subjects	O
.	O

We	O
have	O
previously	O
shown	O
that	O
LBP-1	B-GENE
represses	O
HIV-1	O
transcription	O
by	O
inhibiting	O
the	O
binding	O
of	O
TFIID	B-GENE
to	O
the	O
TATA	O
box	O
.	O

Leptinaemia	O
does	O
not	O
correlate	O
with	O
the	O
actual	O
or	O
mean	O
blood	O
pressure	O
reading	O
nor	O
with	O
stage	O
of	O
hypertension	O
according	O
to	O
the	O
WHO	O
classification	O
.	O

Hex	B-GENE
is	O
expressed	O
in	O
the	O
developing	O
liver	O
coincident	O
with	O
the	O
forkhead	B-GENE
/	I-GENE
winged	I-GENE
helix	I-GENE
transcription	I-GENE
factor	I-GENE
,	O
Hepatocyte	B-GENE
Nuclear	I-GENE
Factor	I-GENE
3beta	I-GENE
(	O
HNF3beta	B-GENE
)	O
.	O

The	O
SEN1	B-GENE
gene	I-GENE
corresponds	O
to	O
a	O
6	O
,	O
336-bp	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
2	O
,	O
112-amino-acid	O
protein	O
(	O
molecular	O
mass	O
,	O
239	O
kDa	O
)	O
.	O

In	O
contrast	O
,	O
transcription	O
initiating	O
from	O
opuE	B-GENE
P-1	I-GENE
(	O
sigma	B-GENE
A	I-GENE
)	O
rose	O
in	O
proportion	O
to	O
the	O
external	O
osmolarity	O
and	O
was	O
maintained	O
at	O
high	O
levels	O
.	O

A	O
synthetic	O
oligonucleotide	O
containing	O
the	O
SRE	B-GENE
sequence	I-GENE
from	O
the	O
mouse	B-GENE
c-fos	I-GENE
gene	I-GENE
promoter	I-GENE
(	O
-299	O
to	O
-322	O
)	O
was	O
radioactively	O
labeled	O
,	O
used	O
as	O
a	O
probe	O
for	O
the	O
mobility	O
shift	O
assay	O
and	O
Southwestern	O
(	O
DNA-protein	O
)	O
blotting	O
,	O
and	O
also	O
used	O
for	O
sequence-specific	O
affinity	O
chromatography	O
.	O

As	O
extensively	O
examined	O
with	O
the	O
myogenin	B-GENE
promoter	I-GENE
,	O
presence	O
of	O
one	O
or	O
multiple	O
copies	O
of	O
Me	B-GENE
in	O
the	O
vectors	O
elevated	O
the	O
expression	O
activity	O
in	O
myotubes	O
by	O
4	O
.	O
5-	O
to	O
19-fold	O
over	O
those	O
without	O
Me	B-GENE
,	O
but	O
not	O
significantly	O
in	O
myoblasts	O
.	O

The	O
proteins	O
differ	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
21-amino-acid	O
sequence	O
located	O
24	O
amino	O
acids	O
C	O
terminal	O
of	O
the	O
translational	O
initiation	O
codon	O
.	O

Subunit	O
composition	O
and	O
domain	O
structure	O
of	O
the	O
Spo0A	B-GENE
sporulation	I-GENE
transcription	I-GENE
factor	I-GENE
of	I-GENE
Bacillus	I-GENE
subtilis	I-GENE
.	O

Cytosolic	B-GENE
acetyl-CoA	I-GENE
synthetase	I-GENE
(	O
AceCS1	B-GENE
)	O
activates	O
acetate	O
to	O
supply	O
the	O
cells	O
with	O
acetyl-CoA	O
for	O
lipid	O
synthesis	O
.	O

Previous	O
experience	O
and	O
contextual	O
cues	O
are	O
essential	O
elements	O
in	O
the	O
generation	O
of	O
a	O
subjective	O
prediction	O
.	O

Increases	O
in	O
the	O
perfusate	O
PCO2	O
but	O
not	O
in	O
the	O
perfusate	O
H+	O
were	O
highly	O
correlated	O
with	O
decreases	O
in	O
both	O
myocardial	O
contractility	O
and	O
oxygen	O
consumption	O
(	O
r2	O
=	O
.	O
88	O
)	O
.	O

Although	O
previous	O
data	O
have	O
suggested	O
that	O
Rev	B-GENE
uses	O
the	O
same	O
export	O
pathway	O
as	O
uracil-rich	B-GENE
small	I-GENE
nuclear	I-GENE
RNAs	I-GENE
and	O
5S	B-GENE
ribosomal	I-GENE
RNA	I-GENE
,	O
the	O
CTE	B-GENE
seems	O
to	O
interact	O
with	O
evolutionarily	O
conserved	O
factors	O
that	O
are	O
essential	O
for	O
cellular	O
mRNA	O
export	O
.	O

These	O
exons	O
were	O
identified	O
by	O
cloning	O
and	O
sequencing	O
cDNAs	O
obtained	O
by	O
polymerase	B-GENE
chain	O
reaction	O
amplification	O
of	O
a	O
fibroblast	O
cDNA	O
library	O
.	O

Analysis	O
of	O
the	O
sequences	O
with	O
the	O
BLAST	O
and	O
GRAIL	O
programs	O
provided	O
additional	O
independent	O
evidence	O
that	O
15	O
of	O
these	O
17	O
clones	O
contain	O
coding	O
sequences	O
and	O
that	O
nine	O
other	O
clones	O
are	O
likely	O
to	O
contain	O
sequences	O
coding	O
for	O
portions	O
of	O
new	O
genes	O
.	O

Consanguinity	O
and	O
migration	O
in	O
the	O
marriages	O
of	O
the	O
region	O
of	O
Nunoa	O
,	O
Santiago	O
,	O
1850-1960	O
.	O

Approximately	O
50%	O
of	O
the	O
residues	O
are	O
conserved	O
among	O
all	O
three	O
sequences	O
,	O
yet	O
all	O
three	O
viruses	O
have	O
retained	O
response	O
elements	O
for	O
glucocorticoids	O
,	O
two	O
positionally	O
conserved	O
CCAAT	O
boxes	O
,	O
and	O
positionally	O
conserved	O
TATA	O
boxes	O
.	O

TMBr-1	B-GENE
is	O
identical	O
to	O
striated	B-GENE
muscle	I-GENE
alpha-tropomyosin	I-GENE
from	O
amino	O
acids	O
1	O
through	O
258	O
but	O
contains	O
a	O
novel	O
COOH-terminal	O
region	O
from	O
amino	O
acids	O
259	O
through	O
281	O
.	O

Most	O
of	O
the	O
prepeptide	O
portion	O
of	O
the	O
precursor	O
polypeptide	O
is	O
encoded	O
by	O
the	O
next	O
three	O
exons	O
,	O
and	O
the	O
mature	O
form	O
of	O
IL-1	B-GENE
alpha	I-GENE
is	O
encoded	O
by	O
the	O
remaining	O
three	O
exons	O
.	O

The	O
assessment	O
using	O
7	O
H	O
9	O
liquid	O
medium	O
by	O
the	O
former	O
author	O
demonstrated	O
the	O
potent	O
activities	O
of	O
both	O
CS-940*	O
and	O
sparfloxacin	O
(	O
SPFX	O
)	O
,	O
followed	O
by	O
AM-1155*	O
,	O
ciprofloxacin	O
(	O
CPFX	O
)	O
,	O
levofloxacin	O
(	O
LVFX	O
)	O
,	O
OPC-17116*	O
,	O
NM-394*	O
in	O
sequence	O
.	O

Its	O
expression	O
pattern	O
is	O
representative	O
of	O
many	O
B	O
cell-specific	O
proteins	O
,	O
which	O
are	O
essential	O
for	O
B	O
cell	O
development	O
and	O
activation	O
but	O
are	O
down-regulated	O
after	O
B	O
cells	O
become	O
terminally	O
differentiated	O
plasma	O
cells	O
.	O

The	O
implications	O
for	O
estimates	O
of	O
cortical	O
magnification	O
and	O
possible	O
differences	O
in	O
the	O
specializations	O
of	O
foveal	O
and	O
peripheral	O
vision	O
are	O
discussed	O
.	O

Pargyline	O
,	O
a	O
monoamine	B-GENE
oxidase	I-GENE
inhibitor	O
,	O
reduces	O
peak	O
3	O
transiently	O
(	O
max	O
.	O

The	O
stoichiometry	O
of	O
the	O
complexes	O
formed	O
with	O
the	O
dodeca-satellite	B-GENE
C	I-GENE
strand	I-GENE
suggests	O
that	O
,	O
in	O
DDP1	B-GENE
,	O
the	O
15	O
consecutive	O
KH	B-GENE
domains	I-GENE
are	O
organized	O
such	O
that	O
they	O
define	O
two	O
nucleic	O
acid	O
binding	O
surfaces	O
.	O

CONCLUSIONS	O
:	O
In	O
addition	O
to	O
the	O
superiority	O
of	O
octafluoropropane-filled	O
microspheres	O
to	O
air-filled	O
microspheres	O
for	O
LV	O
opacification	O
,	O
the	O
efficacy	O
of	O
OCTA	O
is	O
relatively	O
unaffected	O
by	O
impaired	O
LV	O
function	O
and	O
is	O
less	O
susceptible	O
to	O
the	O
effects	O
of	O
poor	O
echogenicity	O
than	O
AIR	O
.	O

Overexpression	O
of	O
BAG-1	B-GENE
also	O
protected	O
certain	O
cell	O
lines	O
from	O
heat	O
shock-induced	O
cell	O
death	O
.	O

Thus	O
,	O
VDR	B-GENE
acts	O
selectively	O
on	O
the	O
two	O
components	O
required	O
for	O
activation	O
of	O
this	O
promoter	O
/	O
enhancer	O
:	O
it	O
competes	O
with	O
NFAT1	B-GENE
for	O
binding	O
to	O
the	O
composite	O
site	O
,	O
positioning	O
itself	O
adjacent	O
to	O
Jun-Fos	B-GENE
on	O
the	O
DNA	O
.	O

The	O
nucleosomal	O
response	O
associated	O
with	O
immediate-early	B-GENE
gene	I-GENE
induction	O
is	O
mediated	O
via	O
alternative	O
MAP	B-GENE
kinase	I-GENE
cascades	I-GENE
:	O
MSK1	B-GENE
as	O
a	O
potential	O
histone	B-GENE
H3	I-GENE
/	I-GENE
HMG-14	I-GENE
kinase	I-GENE
.	O

More	O
importantly	O
,	O
this	O
fusion	O
converted	O
a	O
less	O
effective	O
vaccine	O
into	O
one	O
with	O
significant	O
potency	O
against	O
established	O
E7-expressing	O
metastatic	O
tumors	O
.	O

Its	O
organization	O
and	O
regulation	O
indicate	O
that	O
the	O
S	B-GENE
.	I-GENE
pombe	I-GENE
URA1	I-GENE
gene	I-GENE
product	I-GENE
appears	O
very	O
similar	O
to	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
URA2	I-GENE
gene	I-GENE
product	I-GENE
.	O

Elimination	O
of	O
ETH1	B-GENE
in	O
apn1	B-GENE
strains	O
also	O
increased	O
spontaneous	O
mutation	O
rates	O
9-	O
or	O
31-fold	O
compared	O
to	O
the	O
wild	O
type	O
as	O
determined	O
by	O
reversion	O
to	O
adenine	O
or	O
lysine	O
prototrophy	O
,	O
respectively	O
.	O

The	O
MCAD	B-GENE
nuclear	I-GENE
receptor	I-GENE
response	I-GENE
element	I-GENE
1	I-GENE
(	O
NRRE-1	B-GENE
)	O
interacts	O
in	O
vitro	O
with	O
ERR	B-GENE
alpha	I-GENE
expressed	O
in	O
COS-7	O
cells	O
.	O

Fulminant	O
hepatitis	O
A	O
in	O
chronic	O
HBV	O
carrier	O
.	O

Srb10	B-GENE
is	O
a	O
physiological	O
regulator	O
of	O
Gcn4	B-GENE
stability	O
because	O
both	O
phosphorylation	O
and	O
turnover	O
of	O
Gcn4	B-GENE
are	O
diminished	O
in	O
srb10	B-GENE
mutants	I-GENE
.	O

An	O
apparent	O
N-terminal	O
transit	O
peptide	O
in	O
the	O
coding	O
region	O
and	O
a	O
3'	O
poly	O
(	O
A	O
)	O
tail	O
exist	O
in	O
the	O
cDNA	O
clone	O
indicated	O
that	O
this	O
chloroplast	O
protein	O
as	O
nuclear	O
encoded	O
.	O

These	O
sites	O
are	O
also	O
potential	O
keratan	O
sulfate	O
attachment	O
sites	O
.	O

The	O
concept	O
of	O
"structural	O
identifiability"	O
is	O
employed	O
in	O
this	O
analysis	O
to	O
determine	O
which	O
model	O
parameters	O
can	O
be	O
and	O
which	O
cannot	O
be	O
determined	O
"uniquely"	O
from	O
given	O
input-output	O
data	O
;	O
a	O
step-by-step	O
procedure	O
based	O
on	O
an	O
extension	O
of	O
this	O
concept	O
is	O
presented	O
for	O
adapting	O
the	O
overall	O
approach	O
to	O
the	O
experimental	O
design	O
problem	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
these	O
clones	O
encode	O
two	O
distinct	O
forms	O
of	O
translocase	B-GENE
.	O

Protamine	B-GENE
and	O
heparin	O
doses	O
,	O
their	O
sum	O
(	O
Sigma-dose	O
)	O
and	O
differential	O
(	O
Delta-dose	O
)	O
doses	O
,	O
and	O
activated	O
clotting	O
times	O
were	O
tabulated	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
cell-specific	O
suppression	O
of	O
RA-stimulated	O
zif268	B-GENE
gene	I-GENE
expression	O
can	O
be	O
attributed	O
to	O
a	O
29	O
base	O
pair	O
nucleotide	O
sequence	O
,	O
located	O
downstream	O
of	O
the	O
RA-responsive	B-GENE
region	I-GENE
in	O
the	O
zif268	B-GENE
gene	I-GENE
.	O

This	O
structure	O
of	O
cucumisin	B-GENE
suggests	O
that	O
it	O
is	O
probably	O
synthesized	O
as	O
an	O
inactive	O
precursor	O
.	O

Identification	O
and	O
estimation	O
of	O
monosaccharides	O
and	O
disaccharides	O
in	O
urine	O
by	O
gas-liquid	O
chromatography	O
.	O

In	O
the	O
current	O
model	O
,	O
Wingless	B-GENE
/	I-GENE
Wnt	I-GENE
signal	O
stabilizes	O
Armadillo	B-GENE
/	I-GENE
beta-catenin	I-GENE
,	O
which	O
then	O
accumulates	O
in	O
nuclei	O
and	O
binds	O
TCF	B-GENE
/	I-GENE
LEF	I-GENE
family	I-GENE
proteins	I-GENE
,	O
forming	O
bipartite	O
transcription	O
factors	O
which	O
activate	O
transcription	O
of	O
Wingless	B-GENE
/	I-GENE
Wnt	I-GENE
responsive	I-GENE
genes	I-GENE
.	O

In	O
DNA	O
strand	O
exchange	O
reactions	O
using	O
oligonucleotides	O
,	O
we	O
found	O
that	O
Rec2	B-GENE
exhibited	O
a	O
pairing	O
bias	O
that	O
is	O
opposite	O
that	O
of	O
RecA	B-GENE
.	O

The	O
ability	O
of	O
U6-U57	B-GENE
mutants	I-GENE
to	O
influence	O
the	O
fidelity	O
of	O
both	O
branch	O
site	O
and	O
3'	O
splice	O
site	O
recognition	O
suggests	O
that	O
this	O
nucleotide	O
may	O
participate	O
in	O
the	O
formation	O
of	O
the	O
active	O
site	O
(	O
s	O
)	O
of	O
the	O
spliceosome	O
.	O

Endorphins	B-GENE
and	O
legal	O
issues	O
.	O

Human	O
brain	O
cDNA	O
library	O
screening	O
and	O
5'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
yielded	O
full-length	B-GENE
DENTT	I-GENE
cDNA	I-GENE
containing	O
an	O
1899-bp	O
open	O
reading	O
frame	O
encoding	O
a	O
predicted	O
633-amino-acid	O
protein	O
with	O
four	O
potential	O
nuclear	O
localization	O
signals	O
(	O
NLSs	O
)	O
and	O
two	O
coiled-coil	O
regions	O
.	O

The	O
orientations	O
of	O
the	O
contact	O
surfaces	O
and	O
their	O
locations	O
relative	O
to	O
the	O
object's	O
center	O
of	O
mass	O
were	O
varied	O
.	O

The	O
carboxyl-terminal	O
portion	O
of	O
UKLF	B-GENE
contains	O
three	O
zinc	O
fingers	O
of	O
the	O
Cys2-His2	O
type	O
and	O
binds	O
in	O
vitro	O
to	O
the	O
CACCC	B-GENE
motif	I-GENE
of	O
the	O
beta-globin	B-GENE
promoter	I-GENE
and	O
to	O
the	O
Sp1	B-GENE
recognition	I-GENE
sequence	I-GENE
.	O

Since	O
myoglobin	B-GENE
is	O
co-extracted	O
with	O
the	O
hemoglobin	B-GENE
,	O
the	O
2	O
heme	O
pigments	O
are	O
separated	O
in	O
one	O
portion	O
of	O
the	O
extract	O
by	O
precipitating	O
the	O
hemoglobin	B-GENE
in	O
an	O
85%	O
(	O
NH4	O
)	O
2SO4	O
solution	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
murine	B-GENE
beta	I-GENE
(	I-GENE
3	I-GENE
)	I-GENE
integrin	I-GENE
gene	I-GENE
promoter	O
:	O
identification	O
of	O
an	O
interleukin-4	B-GENE
responsive	I-GENE
element	I-GENE
and	O
regulation	O
by	O
STAT-6	B-GENE
.	O

Polarised	O
expression	O
of	O
human	O
intestinal	O
N-benzoyl-L-tyrosyl-p-aminobenzoic	B-GENE
acid	I-GENE
hydrolase	I-GENE
(	O
human	B-GENE
meprin	I-GENE
)	O
alpha	O
and	O
beta	O
subunits	O
in	O
Madin-Darby	O
canine	O
kidney	O
cells	O
.	O

ME1a1	B-GENE
,	O
a	O
16-base-pair	O
nuclear	O
factor	O
binding	O
site	O
residing	O
between	O
the	O
c-MYC	B-GENE
P1	I-GENE
and	I-GENE
P2	I-GENE
transcription	I-GENE
initiation	I-GENE
sites	I-GENE
,	O
is	O
required	O
for	O
P2	B-GENE
activity	O
.	O

Protein	B-GENE
tyrosine	I-GENE
kinases	I-GENE
(	O
PTKs	B-GENE
)	O
are	O
implicated	O
in	O
the	O
control	O
of	O
cell	O
growth	O
by	O
virtue	O
of	O
their	O
frequent	O
appearance	O
as	O
products	O
of	O
retroviral	O
oncogenes	O
,	O
as	O
intracellular	O
signal	O
transducers	O
,	O
and	O
as	O
growth	B-GENE
factor	I-GENE
receptors	I-GENE
or	O
components	O
thereof	O
.	O

Experiments	O
with	O
epitope-tagged	O
proteins	O
show	O
that	O
UEV1A	B-GENE
is	O
a	O
nuclear	O
protein	O
,	O
whereas	O
both	O
Kua	B-GENE
and	O
Kua-UEV	B-GENE
localize	O
to	O
cytoplasmic	O
structures	O
,	O
indicating	O
that	O
the	O
Kua	B-GENE
domain	I-GENE
determines	O
the	O
cytoplasmic	O
localization	O
of	O
Kua-UEV	B-GENE
.	O

Abnormal	O
technetium	O
Tc	O
99m	O
medronate	O
scans	O
in	O
patients	O
with	O
previously	O
undiagnosed	O
polyarthralgias	O
suggested	O
inflammatory	O
arthropathy	O
and	O
influenced	O
management	O
decisions	O
with	O
favorable	O
therapeutic	O
outcomes	O
.	O

However	O
,	O
regional	O
MVO2	O
increased	O
to	O
about	O
the	O
same	O
extent	O
in	O
the	O
CFX	O
(	O
from	O
6	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
12	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
ml	O
O2	O
.	O
min-1	O
times	O
100	O
g-1	O
)	O
and	O
the	O
LAD	O
region	O
(	O
from	O
7	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
6	O
to	O
14	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
3	O
ml	O
O2	O
.	O
min-1	O
times	O
100	O
g-1	O
)	O
.	O

Among	O
the	O
patients	O
grades	O
1-2-3	O
,	O
81%	O
had	O
a	O
good	O
out	O
come	O
without	O
any	O
neurological	O
abnormality	O
,	O
among	O
the	O
patients	O
graded	O
4-5	O
,	O
only	O
27%	O
had	O
a	O
fair	O
out	O
come	O
.	O

1st	O
data	O
on	O
the	O
immunosuppressive	O
therapy	O
of	O
scleroderma	O
.	O

Sulphur	O
amino	O
acids	O
(	O
g	O
/	O
16	O
g	O
N	O
)	O
were	O
higher	O
in	O
the	O
isolates	O
than	O
in	O
the	O
flours	O
.	O

These	O
components	O
both	O
had	O
a	O
median	O
R2	O
of	O
0	O
.	O
84	O
,	O
compared	O
to	O
median	O
R2s	O
ranging	O
from	O
0	O
.	O
37	O
to	O
0	O
.	O
83	O
for	O
five	O
commonly	O
used	O
ad	O
hoc	O
EEG	O
components	O
.	O

By	O
DNase	B-GENE
I	I-GENE
footprint	O
analysis	O
of	O
the	O
PNR	B-GENE
element	I-GENE
,	O
a	O
palindrome	O
of	O
two	O
high-affinity	O
Ets-binding	B-GENE
sites	I-GENE
(	O
CTTCCCTGGAAG	B-GENE
)	O
was	O
identified	O
.	O

Toxicity	O
during	O
the	O
therapeutic	O
period	O
was	O
not	O
significant	O
in	O
the	O
study	O
group	O
compared	O
with	O
the	O
historical	O
control	O
,	O
treated	O
with	O
the	O
same	O
regimen	O
without	O
G-CSF	B-GENE
.	O

Transcripts	O
from	O
a	O
second	O
POU-domain	B-GENE
gene	I-GENE
,	O
Oct-25	B-GENE
,	O
were	O
present	O
at	O
low	O
levels	O
in	O
oocytes	O
and	O
early	O
embryos	O
and	O
were	O
dramatically	O
upregulated	O
during	O
early	O
gastrulation	O
.	O

Moreover	O
,	O
exons	O
2a	O
and	O
2b	O
share	O
the	O
same	O
5'	O
sequence	O
but	O
differ	O
from	O
each	O
other	O
by	O
the	O
use	O
of	O
two	O
distinct	O
donor	O
splice	O
sites	O
171	O
bp	O
apart	O
in	O
the	O
gene	O
.	O

Discrimination	O
between	O
HIV-1	O
and	O
HIV-2	O
showed	O
evidence	O
for	O
the	O
presence	O
of	O
HIV-1	O
only	O
.	O

The	O
functional	O
mature	O
domain	O
of	O
pediocin	B-GENE
AcH	I-GENE
(	I-GENE
Lys+1	I-GENE
to	I-GENE
Cys+44	I-GENE
)	I-GENE
is	O
targeted	O
into	O
the	O
E	O
.	O
coli	O
sec	O
machinery	O
and	O
secreted	O
to	O
the	O
periplasm	O
in	O
active	O
form	O
when	O
fused	O
in	O
frame	O
to	O
the	O
COOH	O
terminus	O
of	O
the	O
secretory	B-GENE
protein	I-GENE
maltose-binding	I-GENE
protein	I-GENE
(	O
MBP	B-GENE
)	O
.	O

In	O
yeast	O
,	O
the	O
products	O
of	O
the	O
UPF1	B-GENE
and	O
UPF3	B-GENE
genes	I-GENE
are	O
required	O
for	O
this	O
decay	O
pathway	O
,	O
and	O
in	O
this	O
report	O
we	O
focus	O
on	O
the	O
identification	O
and	O
characterization	O
of	O
additional	O
factors	O
required	O
for	O
rapid	O
decay	O
of	O
nonsense-containing	O
mRNAs	O
.	O

Unified	O
theory	O
of	O
segregated-stack	O
organic	O
charge-transfer	O
solids	O
:	O
Magnetic	O
properties	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
dominant	O
negative	O
forms	O
of	O
Rac	B-GENE
and	O
Cdc42	B-GENE
or	O
of	O
the	O
Rho	B-GENE
inhibitor	O
C3	B-GENE
transferase	I-GENE
blocked	O
serum-induced	O
DNA	O
synthesis	O
.	O

In	O
gel	O
retardation	O
assays	O
,	O
an	O
RCS	O
cell-specific	O
protein	O
and	O
another	O
closely	O
related	O
protein	O
expressed	O
only	O
in	O
RCS	O
cells	O
and	O
primary	O
chondrocytes	O
bound	O
to	O
a	O
10-bp	O
sequence	O
within	O
the	O
18-mer	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

It	O
is	O
surprising	O
that	O
dnaE173	O
,	O
a	O
potent	O
mutator	O
mutation	O
specific	O
for	O
sequence	O
substitution	O
as	O
well	O
as	O
single-base	O
frameshift	O
,	O
did	O
not	O
enhance	O
the	O
frequency	O
of	O
the	O
hot-spot	O
frameshift	O
mutation	O
.	O

However	O
,	O
the	O
relative	O
positions	O
of	O
the	O
VV	O
genes	O
(	O
genus	O
Orthopoxvirus	O
)	O
are	O
different	O
than	O
those	O
of	O
the	O
corresponding	O
ORFs	O
in	O
SFV	O
(	O
genus	O
Leporipoxvirus	O
)	O
,	O
indicating	O
complex	O
rearrangements	O
of	O
DNA	O
in	O
the	O
genome	O
of	O
one	O
or	O
both	O
of	O
these	O
viruses	O
subsequent	O
to	O
their	O
divergence	O
from	O
a	O
common	O
ancestor	O
.	O

CONCLUSION	O
:	O
There	O
are	O
no	O
differences	O
in	O
the	O
measurement	O
data	O
derived	O
from	O
this	O
method	O
and	O
actual	O
measurement	O
data	O
from	O
an	O
object	O
created	O
by	O
the	O
computer-aided	O
dental	O
design	O
program	O
.	O

Ki-ras	B-GENE
and	O
p53	B-GENE
mutations	I-GENE
in	O
pancreatic	O
ductal	O
adenocarcinoma	O
.	O

Eleven	O
healthy	O
,	O
normotensive	O
males	O
undergoing	O
routine	O
restorative	O
dental	O
care	O
were	O
evaluated	O
during	O
treatment	O
for	O
possible	O
hemodynamic	O
alterations	O
in	O
response	O
to	O
potential	O
sympathetic	O
nervous	O
system	O
stimulation	O
.	O

CSR	O
is	O
directed	O
to	O
specific	O
heavy	O
chain	O
isotypes	O
by	O
cytokines	O
and	O
B	O
cell	O
activators	O
that	O
induce	O
transcription	O
from	O
the	O
unrearranged	O
,	O
or	O
germline	O
(	O
GL	O
)	O
,	O
C	O
(	O
H	O
)	O
region	O
genes	O
.	O

As	O
predicted	O
by	O
the	O
Wing	O
and	O
Kristofferson	O
model	O
,	O
the	O
durations	O
of	O
successive	O
ISIs	O
tended	O
to	O
be	O
negatively	O
correlated	O
.	O

Based	O
on	O
sequence	O
homology	O
,	O
the	O
genes	O
were	O
identified	O
as	O
TEF	B-GENE
,	O
encoding	O
translation	B-GENE
elongation	I-GENE
factor-1	I-GENE
alpha	I-GENE
and	O
RPS7	B-GENE
,	O
encoding	O
ribosomal	B-GENE
protein	I-GENE
S7	O
.	O

Symptomatic	O
hyperventilators	O
had	O
a	O
larger	O
number	O
of	O
sighs	O
and	O
abnormally	O
wide	O
fluctuations	O
in	O
baseline	O
for	O
inspiratory	O
time	O
,	O
expiratory	O
time	O
,	O
and	O
PETCO2	O
.	O

As	O
the	O
high-affinity	O
Mg2+	O
binding	O
sites	O
are	O
filled	O
,	O
the	O
primer	O
terminus	O
migrates	O
from	O
the	O
exonuclease	B-GENE
site	I-GENE
to	O
a	O
highly	O
based	O
stacked	O
polymerase	B-GENE
active	I-GENE
site	I-GENE
.	O

A	O
population	O
pharmacokinetic	O
study	O
of	O
cyclosporin	O
in	O
organ	O
transplant	O
patients	O
,	O
including	O
elderly	O
allograft	O
recipients	O
up	O
to	O
75	O
years	O
of	O
age	O
,	O
did	O
not	O
identify	O
age	O
as	O
a	O
covariable	O
influencing	O
cyclosporin	O
pharmacokinetics	O
.	O

The	O
same	O
response	O
occurs	O
whether	O
acrylamide	O
is	O
given	O
immediately	O
after	O
nerve	O
ligation	O
or	O
1	O
week	O
later	O
.	O

This	O
strategy	O
was	O
used	O
to	O
place	O
both	O
the	O
Tn903	B-GENE
neo	I-GENE
gene	I-GENE
and	O
the	O
Rhodosporidium	B-GENE
toruloides	I-GENE
phenylalanine	I-GENE
ammonia	I-GENE
lyase	I-GENE
(	O
PAL	B-GENE
)	O
-encoding	O
gene	O
under	O
the	O
transcriptional	O
control	O
of	O
pPGK	B-GENE
:	O
:	O
REP2	B-GENE
.	O

Early	O
heparin	O
therapy	O
in	O
60	O
children	O
with	O
acute	O
meningococcemia	O
.	O

The	O
highest	O
decrease	O
in	O
mutagenic	O
activity	O
was	O
observed	O
when	O
enzymatic	O
bleaching	O
was	O
used	O
together	O
with	O
chlorine	O
.	O

Regarding	O
gestational	O
risk	O
,	O
3	O
,	O
243	O
drugs	O
used	O
(	O
34%	O
)	O
belonged	O
to	O
category	O
A	O
risk	O
,	O
1	O
,	O
923	O
(	O
22	O
.	O
6%	O
)	O
to	O
category	O
B	O
,	O
3	O
,	O
798	O
(	O
39	O
.	O
7%	O
)	O
to	O
category	O
C	O
,	O
289	O
(	O
3	O
.	O
0%	O
)	O
to	O
category	O
D	O
,	O
and	O
55	O
(	O
0	O
.	O
6%	O
)	O
to	O
category	O
X	O
.	O

These	O
same	O
regions	O
showed	O
remarkable	O
homology	O
to	O
two	O
invertebrate	O
proteins	O
,	O
CNC	B-GENE
and	O
skin-1	B-GENE
,	O
postulated	O
to	O
regulate	O
embryonic	O
development	O
in	O
Drosophila	O
melanogaster	O
and	O
Caenorhabditis	O
elegans	O
,	O
respectively	O
.	O

Using	O
a	O
MOS-Hypersil	O
reversed-phase	O
column	O
with	O
a	O
phosphate	O
buffer--acetonitrile	O
mobile	O
phase	O
,	O
baseline	O
separation	O
of	O
antipyrine	O
,	O
its	O
metabolites	O
3-hydroxymethylantipyrine	O
,	O
norantipyrine	O
and	O
4-hydroxyantipyrine	O
,	O
and	O
the	O
internal	O
standard	O
,	O
phenacetin	O
,	O
was	O
achieved	O
within	O
6	O
min	O
.	O

The	O
other	O
element	O
bound	O
RBP-J	B-GENE
kappa	I-GENE
with	O
low	O
affinity	O
.	O

Copyright	O
2001	O
S	O
.	O

In	O
addition	O
,	O
on	O
the	O
Cohler's	O
maternal	O
scale	O
,	O
Korean	O
mothers	O
were	O
found	O
to	O
view	O
their	O
infants	O
as	O
more	O
passive	O
and	O
dependent	O
than	O
American	O
mothers	O
did	O
(	O
P	O
less	O
than	O
0	O
.	O
00	O
)	O
.	O

A	O
2	O
years	O
and	O
9	O
months	O
old	O
female	O
patient	O
,	O
with	O
the	O
diagnosis	O
of	O
Weaver	O
syndrome	O
is	O
reported	O
.	O

Actins	B-GENE
show	O
two	O
different	O
forms	O
of	O
N-terminal	O
processing	O
dependent	O
on	O
their	O
N-terminal	O
sequence	O
.	O

Ex	O
vivo	O
MAO	B-GENE
inhibition	O
data	O
indicated	O
DPGPEA	O
to	O
be	O
an	O
inhibitor	O
of	O
MAO-B	B-GENE
,	O
although	O
the	O
effect	O
was	O
much	O
weaker	O
than	O
seen	O
with	O
tranylcypromine	O
or	O
pargyline	O
.	O

For	O
this	O
purpose	O
,	O
the	O
writhing	O
test	O
,	O
capsaicin	O
and	O
formalin	O
induced-pain	O
in	O
mice	O
were	O
used	O
.	O

Brain	O
pH	O
following	O
3	O
h	O
of	O
cerebral	O
focal	O
ischemia	O
changed	O
from	O
a	O
normal	O
value	O
of	O
7	O
.	O
0	O
to	O
6	O
.	O
5	O
and	O
6	O
.	O
2	O
in	O
animals	O
studied	O
under	O
barbiturate	O
and	O
halothane	O
anesthesia	O
,	O
respectively	O
.	O

The	O
CHARGE	O
association	O
is	O
a	O
collection	O
of	O
multisystem	O
congenital	O
anomalies	O
including	O
choanal	O
atresia	O
.	O

No	O
specific	O
subgroup	O
of	O
clients	O
benefited	O
more	O
from	O
URD	O
,	O
although	O
a	O
prospective	O
study	O
employing	O
random	O
assignment	O
might	O
be	O
more	O
successful	O
in	O
identifying	O
such	O
a	O
group	O
.	O

Because	O
of	O
this	O
latter	O
phenomenon	O
,	O
we	O
were	O
able	O
to	O
identify	O
a	O
particular	O
cysteine	O
motif	O
that	O
was	O
repeated	O
multiple	O
times	O
in	O
Dfurin2	B-GENE
but	O
present	O
only	O
twice	O
in	O
mammalian	B-GENE
furin	I-GENE
.	O

We	O
have	O
synthesized	O
[	O
7	O
,	O
7-2H2	O
]	O
-19-OHA	O
with	O
high	O
deuterium	O
content	O
and	O
,	O
together	O
with	O
[	O
7	O
,	O
7-2H2	O
]	O
A	O
and	O
[	O
9	O
,	O
11-2H2	O
]	O
estrone	O
(	O
E1	O
)	O
,	O
have	O
developed	O
a	O
quantitative	O
assay	O
of	O
serum	O
level	O
19-OHA	O
,	O
A	O
,	O
and	O
E1	O
using	O
the	O
gas	O
chromatography	O
/	O
mass	O
spectrometry-mass	O
fragmentography	O
method	O
to	O
monitor	O
individual	O
subjects	O
throughout	O
pregnancy	O
.	O

The	O
human	B-GENE
purH	I-GENE
cDNA	I-GENE
is	O
1776	O
base	O
pairs	O
in	O
length	O
encoding	O
for	O
a	O
591-amino	O
acid	O
polypeptic	O
(	O
Mr	O
=	O
64	O
,	O
425	O
)	O
.	O

Incorporation	O
of	O
0	O
.	O
1	O
or	O
0	O
.	O
2	O
M	O
sodium	O
dihydrogen	O
phosphate	O
in	O
the	O
sugar	O
solutions	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
shelf-life	O
of	O
diltiazem	O
.	O

Moloney	O
murine	O
leukemia	O
virus	O
(	O
MMLV	O
)	O
-derived	O
pUCMoTiN-based	O
retroviral	O
vectors	O
were	O
engineered	O
to	O
allow	O
constitutive	O
and	O
Tat	B-GENE
(	O
trans-activator	B-GENE
of	I-GENE
transcription	I-GENE
)	O
-inducible	O
expression	O
of	O
five	O
hammerhead	B-GENE
ribozymes	I-GENE
targeted	O
against	O
highly	O
conserved	O
sequences	O
within	O
the	O
group	B-GENE
antigen	I-GENE
(	O
Gag	B-GENE
)	O
,	O
protease	B-GENE
(	O
Pro	B-GENE
)	O
,	O
reverse	B-GENE
transcriptase	I-GENE
(	O
RT	B-GENE
)	O
,	O
tat	B-GENE
,	O
and	O
envelope	B-GENE
(	O
Env	B-GENE
)	O
coding	O
regions	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
RNA	O
.	O

Spleen	O
weight	O
in	O
rats	O
during	O
tumour	O
growth	O
and	O
in	O
homograft	O
rejection	O
.	O

We	O
have	O
found	O
out	O
that	O
one-year-old	O
carps	O
are	O
extremely	O
sensitive	O
to	O
ichthiomycin	O
in	O
concentrations	O
between	O
25-125	O
micrograms	O
/	O
dm3	O
.	O

Remarkably	O
,	O
U21	B-GENE
contains	O
a	O
long	O
stretch	O
(	O
13	O
nt	O
.	O
)	O
of	O
complementarity	O
to	O
a	O
highly	O
conserved	O
sequence	O
in	O
28S	B-GENE
rRNA	I-GENE
.	O

The	O
humanized	B-GENE
LL2	I-GENE
(	O
hLL2	B-GENE
)	O
,	O
lacking	O
light	B-GENE
chain	I-GENE
variable	I-GENE
region	I-GENE
glycosylation	O
,	O
exhibited	O
immunoreactivities	O
that	O
were	O
comparable	O
to	O
that	O
of	O
chimeric	B-GENE
LL2	I-GENE
(	O
cLL2	B-GENE
)	O
,	O
which	O
was	O
shown	O
previously	O
to	O
have	O
antigen-binding	O
properties	O
similar	O
to	O
its	O
murine	O
counterpart	O
,	O
suggesting	O
that	O
the	O
VK-appended	O
oligosaccharides	O
found	O
in	O
mLL2	B-GENE
are	O
not	O
necessary	O
for	O
antigen	O
binding	O
.	O

Once	O
HIT	O
II	O
is	O
suspected	O
,	O
heparin	O
(	O
and	O
low-molecular-weight	O
heparins	O
)	O
should	O
be	O
stopped	O
immediately	O
.	O

Whereas	O
creatine	B-GENE
kinase	I-GENE
activity	O
declined	O
exponentially	O
from	O
a	O
single	O
peak	O
,	O
myoglobin	B-GENE
appeared	O
in	O
multiple	O
episodes	O
inadequately	O
represented	O
by	O
a	O
single	O
peak	O
value	O
and	O
having	O
no	O
clear	O
clinical	O
correlation	O
.	O

Twelve	O
genomic	O
fragments	O
containing	O
novel	O
response	O
elements	O
are	O
described	O
,	O
and	O
the	O
transcription	O
unit	O
associated	O
with	O
one	O
of	O
them	O
,	O
NN-84AG	B-GENE
,	O
was	O
characterized	O
in	O
detail	O
.	O

Analysis	O
of	O
the	O
consensus	O
binding	O
sequence	O
and	O
the	O
DNA-binding	O
domain	O
of	O
ZF5	B-GENE
.	O

Sequencing	O
of	O
the	O
TP53	B-GENE
transcripts	I-GENE
from	O
exons	O
2	O
to	O
10	O
,	O
however	O
,	O
did	O
not	O
reveal	O
mutations	O
of	O
the	O
remaining	O
allele	O
in	O
any	O
of	O
these	O
tumors	O
.	O

Pneumothorax	O
following	O
lung	O
abscess	O
in	O
the	O
renal	O
transplant	O
patient	O
.	O

The	O
iterative	O
method	O
proposed	O
by	O
Bengtsson	O
[	O
Appl	O
.	O

CONCLUSION	O
:	O
The	O
alpha2-adrenergic	O
antagonist	O
idazoxan	O
increases	O
glucose-induced	O
sympathetic	O
activity	O
but	O
not	O
energy	O
expenditure	O
in	O
obese	O
subjects	O
.	O

These	O
losses	O
account	O
for	O
the	O
resistance	O
of	O
EDS-IV	O
collagen	B-GENE
to	O
cyanogen	O
bromide	O
and	O
mammalian	B-GENE
collagenase	I-GENE
digestion	O
.	O

Relations	O
between	O
cellular	O
electrical	O
activity	O
and	O
cardiac	O
mechanical	O
activity	O
in	O
man	O
,	O
the	O
dog	O
and	O
the	O
rabbit	O
.	O

Expression	O
of	O
p130	B-GENE
(	I-GENE
Cas	I-GENE
)	I-GENE
(	O
Cas	B-GENE
)	O
,	O
a	O
major	O
binding	O
protein	O
for	O
the	O
Crk	B-GENE
SH2-domain	B-GENE
,	O
also	O
induced	O
JNK	B-GENE
activation	O
,	O
which	O
was	O
blocked	O
by	O
the	O
SH2-mutant	B-GENE
of	O
Crk	B-GENE
.	O

Skeletal	B-GENE
muscle	I-GENE
metaboreceptor	I-GENE
responses	O
are	O
impaired	O
in	O
heart	O
failure	O
.	O

The	O
purified	O
recombinant	O
protein	O
was	O
assayed	O
for	O
its	O
enzyme	O
activity	O
by	O
monitoring	O
transfer	O
of	O
[	O
3H	O
]	O
methyl	O
groups	O
from	O
the	O
substrate	O
DNA	O
to	O
the	O
MGMT	B-GENE
protein	I-GENE
;	O
the	O
activity	O
was	O
found	O
to	O
be	O
stable	O
at	O
90	O
degrees	O
C	O
for	O
at	O
least	O
30	O
min	O
.	O

This	O
interaction	O
involved	O
the	O
SH3	B-GENE
region	I-GENE
of	O
p50	B-GENE
(	I-GENE
csk	I-GENE
)	I-GENE
and	O
a	O
proline-rich	O
region	O
(	O
PPPLPERTPESFVLADM	B-GENE
)	O
outside	O
the	O
catalytic	O
region	O
of	O
PTP-PEST	B-GENE
.	O

SETTING--Delhi	O
,	O
urban	O
India	O
,	O
1985-6	O
.	O

The	O
mean	O
(	O
+	O
/	O
-	O
sd	O
)	O
intra-vesicular	O
pressure	O
(	O
IVP	O
)	O
and	O
maximal	O
urethral	O
closure	O
pressures	O
(	O
MUCP	O
)	O
were	O
10	O
.	O
3	O
(	O
+	O
/	O
-	O
1	O
.	O
7	O
)	O
and	O
129	O
.	O
8	O
(	O
+	O
/	O
-	O
19	O
.	O
6	O
)	O
cmH2O	O
,	O
respectively	O
,	O
and	O
the	O
ratio	O
between	O
MUCP	O
and	O
IVP	O
was	O
13	O
.	O
2	O
(	O
+	O
/	O
-	O
2	O
.	O
5	O
)	O
.	O

Data	O
from	O
in	O
vitro	O
splicing	O
assays	O
,	O
UV	O
crosslinking	O
and	O
RNA-binding	O
competition	O
experiments	O
indicates	O
a	O
strong	O
correlation	O
between	O
the	O
binding	O
affinities	O
of	O
PSI	B-GENE
for	O
the	O
SELEX	O
sequences	O
and	O
their	O
ability	O
to	O
modulate	O
splicing	O
of	O
P	B-GENE
element	I-GENE
IVS3	I-GENE
in	O
vitro	O
.	O

Use	O
of	O
subcutaneous	O
deferoxamine	O
in	O
a	O
child	O
with	O
hemochromatosis	O
associated	O
with	O
congenital	O
dyserythropoietic	O
anemia	O
,	O
type	O
I	O
.	O

The	O
primary	O
CT	O
findings	O
were	O
misinterpreted	O
as	O
a	O
brain	O
infarct	O
or	O
possibly	O
a	O
tumour	O
.	O

If	O
hnRNP	B-GENE
K	I-GENE
is	O
a	O
transcription	O
factor	O
,	O
then	O
interactions	O
with	O
the	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
transcription	O
apparatus	O
are	O
predicted	O
.	O

Methyl	O
formate	O
was	O
used	O
as	O
the	O
solvent	O
of	O
biodegradable	O
oligoesters	O
for	O
the	O
fabrication	O
of	O
microspheres	O
with	O
encapsulated	O
bovine	B-GENE
serum	I-GENE
albumin	I-GENE
(	O
BSA	B-GENE
)	O
.	O

We	O
report	O
here	O
that	O
constitutively	O
active	O
Mek1	B-GENE
could	O
activate	O
p96h2bk	B-GENE
in	O
the	O
absence	O
of	O
oncogenic	B-GENE
Ras	I-GENE
.	O

Botulinum	B-GENE
toxin	I-GENE
A	I-GENE
in	O
the	O
treatment	O
of	O
hemiplegic	O
spastic	O
foot	O
drop--clinical	O
and	O
functional	O
outcomes	O
.	O

Mutational	O
analysis	O
of	O
the	O
P2-proximal	B-GENE
CTCF	I-GENE
binding	I-GENE
site	I-GENE
and	O
transient-cotransfection	O
experiments	O
demonstrate	O
that	O
CTCF	B-GENE
is	O
a	O
transcriptional	O
repressor	O
of	O
the	O
human	B-GENE
c-myc	I-GENE
gene	I-GENE
.	O

To	O
determine	O
whether	O
the	O
excess	O
prevalence	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
in	O
US	O
black	O
and	O
Hispanic	O
homosexual	O
men	O
relative	O
to	O
white	O
men	O
can	O
be	O
explained	O
by	O
differences	O
in	O
sociodemographic	O
factors	O
,	O
history	O
of	O
sexually	O
transmitted	O
diseases	O
,	O
or	O
sexual	O
and	O
drug-use	O
behaviors	O
,	O
the	O
authors	O
conducted	O
a	O
cross-sectional	O
analysis	O
of	O
baseline	O
HIV-1	O
seroprevalence	O
and	O
HIV-1	O
risk	O
factors	O
among	O
4	O
,	O
475	O
non-Hispanic	O
white	O
,	O
234	O
Hispanic	O
white	O
,	O
and	O
194	O
black	O
homosexual	O
men	O
from	O
four	O
centers	O
in	O
the	O
United	O
States	O
(	O
Baltimore	O
/	O
Washington	O
,	O
DC	O
,	O
Pittsburgh	O
,	O
Chicago	O
,	O
and	O
Los	O
Angeles	O
)	O
.	O

Antibodies	O
raised	O
against	O
a	O
bacterially	O
produced	O
beta	B-GENE
gal-trk	I-GENE
receptor	I-GENE
kinase	I-GENE
fusion	I-GENE
protein	I-GENE
recognized	O
a	O
44	O
kd	O
phosphoprotein	O
phosphorylated	O
on	O
serine	O
,	O
threonine	O
and	O
tyrosine	O
in	O
extracts	O
of	O
trk-2h	B-GENE
transformed	O
NIH3T3	O
cells	O
.	O

Potscoital	O
test	O
.	O

Fibular	O
dimelia	O
with	O
deficiency	O
of	O
the	O
tibia	O
.	O

Thus	O
,	O
although	O
p28	B-GENE
may	O
play	O
only	O
a	O
limited	O
role	O
during	O
the	O
early	O
embryonic	O
cleavages	O
,	O
it	O
may	O
function	O
later	O
in	O
development	O
to	O
establish	O
a	O
somatic	O
type	O
of	O
cell	O
cycle	O
.	O

In	O
Denmark	O
only	O
1-3	O
cases	O
of	O
transfusion-associated	O
hepatitis	O
NANB	O
(	O
TAH-NANB	O
)	O
are	O
registered	O
annually	O
or	O
about	O
1	O
case	O
per	O
100	O
,	O
000	O
units	O
transfused	O
.	O

These	O
indications	O
of	O
deregulated	O
signalling	O
in	O
the	O
absence	O
of	O
tyrosine	O
118	O
were	O
substantiated	O
by	O
sustained	O
activation	O
of	O
STAT3	B-GENE
.	O

Interestingly	O
,	O
this	O
mutant	O
cell	O
line	O
lacks	O
expression	O
of	O
the	O
IKK	B-GENE
regulatory	I-GENE
protein	I-GENE
,	O
IKKgamma	B-GENE
.	O

Membrane-bound	O
Steel	B-GENE
factor	I-GENE
induces	O
more	O
persistent	O
tyrosine	B-GENE
kinase	I-GENE
activation	O
and	O
longer	O
life	O
span	O
of	O
c-kit	B-GENE
gene-encoded	O
protein	O
than	O
its	O
soluble	O
form	O
.	O

Replacement	B-GENE
variant	I-GENE
histone	I-GENE
genes	I-GENE
contain	O
intervening	O
sequences	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
GluR2	B-GENE
gene	I-GENE
:	O
neural-specific	O
expression	O
,	O
multiple	O
promoters	O
,	O
and	O
regulatory	O
elements	O
.	O

Determination	O
of	O
lead	O
in	O
blood	O
.	O

The	O
central	O
(	O
R	O
)	O
domain	O
is	O
responsible	O
for	O
receptor-binding	O
activity	O
whereas	O
the	O
N-terminal	O
(	O
T	O
)	O
domain	O
mediates	O
translocation	O
,	O
the	O
process	O
by	O
which	O
the	O
C-terminal	O
cytotoxic	O
domain	O
is	O
transported	O
from	O
the	O
receptor	O
to	O
the	O
site	O
of	O
its	O
cytotoxicity	O
.	O

To	O
determine	O
whether	O
interaction	O
of	O
arsenite	O
with	O
the	O
hormone-binding	O
domain	O
results	O
in	O
receptor	O
activation	O
,	O
COS-1	O
cells	O
were	O
transiently	O
cotransfected	O
with	O
the	O
chimeric	B-GENE
receptors	I-GENE
GAL-ER	I-GENE
,	O
which	O
contains	O
the	O
hormone-binding	O
domain	O
of	O
ERalpha	B-GENE
and	O
the	O
DNA-binding	O
domain	O
of	O
the	O
transcription	O
factor	O
GAL4	B-GENE
,	O
and	O
a	O
GAL4-responsive	O
CAT	B-GENE
reporter	I-GENE
gene	I-GENE
.	O

The	O
JHRLSS	O
has	O
been	O
used	O
in	O
prior	O
studies	O
to	O
assess	O
RLS	O
severity	O
,	O
but	O
has	O
not	O
previously	O
been	O
validated	O
in	O
relation	O
to	O
direct	O
measures	O
of	O
the	O
morbidity	O
associated	O
with	O
RLS	O
.	O

VP-16	O
,	O
ifosfamide	O
and	O
cisplatin	O
(	O
VIP	O
)	O
for	O
extensive	O
small	O
cell	O
lung	O
cancer	O
.	O

Measurements	O
were	O
compared	O
with	O
two	O
computerised	O
treatment	O
planning	O
systems--Theraplan	O
VO5B	O
and	O
ADAC	O
Pinnacle3	O
V4	O
.	O
0b	O
.	O

The	O
experimentally	O
mapped	O
regions	O
of	O
RPB5	B-GENE
involved	O
in	O
these	O
interactions	O
correspond	O
to	O
distinct	O
and	O
surface-exposed	O
alpha-helical	O
structures	O
.	O

The	O
role	O
of	O
daunorubicin	O
in	O
induction	O
therapy	O
for	O
adult	O
acute	O
myeloid	O
leukemia	O
.	O

These	O
data	O
suggest	O
that	O
hypocitraturia	O
in	O
type	O
I	O
renal	O
tubular	O
acidosis	O
may	O
be	O
due	O
to	O
a	O
defect	O
in	O
proximal	O
tubule	O
function	O
.	O

Each	O
expressed	O
domain	O
,	O
as	O
well	O
as	O
FKBP-33	B-GENE
itself	O
,	O
possesses	O
peptidyl-prolyl	B-GENE
cis-trans	I-GENE
isomerase	I-GENE
activity	O
,	O
though	O
with	O
much	O
lower	O
specific	O
activities	O
than	O
FKBP-12	B-GENE
.	O

5-	O
(	O
Dimethylaminopropyl	O
)	O
-19	O
,	O
11-dihydro-5H-benzo	O
[	O
2	O
,	O
3	O
]	O
pyrido	O
[	O
6	O
,	O
7-b	O
]	O
azepine	O
.	O

The	O
induction	O
of	O
RNKP-1	B-GENE
expression	O
in	O
the	O
Con	O
A-cultured	O
spleen	O
cells	O
is	O
accompanied	O
by	O
increases	O
in	O
both	O
NK	O
and	O
lymphokine-activated	O
killer	O
lymphocyte	O
activities	O
.	O

Cephradine	O
250	O
mg	O
at	O
night	O
for	O
12	O
months	O
was	O
given	O
as	O
a	O
prophylactic	O
measure	O
to	O
33	O
female	O
patients	O
of	O
mean	O
age	O
41	O
.	O
6	O
years	O
,	O
who	O
had	O
a	O
history	O
in	O
the	O
preceding	O
12	O
months	O
of	O
between	O
three	O
and	O
24	O
(	O
median	O
=	O
7	O
)	O
episodes	O
of	O
frequency	O
and	O
/	O
or	O
dysuria	O
.	O

Sterile	O
mutants	O
of	O
Saccharomyces	O
cerevisiae	O
were	O
isolated	O
from	O
alpha	O
*	O
cells	O
having	O
the	O
a	B-GENE
/	I-GENE
alpha	I-GENE
aar1-6	I-GENE
genotype	O
(	O
exhibiting	O
alpha	O
mating	O
ability	O
and	O
weak	O
a	O
mating	O
ability	O
as	O
a	O
result	O
of	O
a	O
defect	O
in	O
a1-alpha	B-GENE
2	I-GENE
repression	O
)	O
.	O

Four	O
cases	O
of	O
synovial	O
chondromatosis	O
are	O
presented	O
.	O

We	O
report	O
here	O
that	O
out	O
of	O
the	O
major	O
pro-inflammatory	O
cytokines	O
examined	O
,	O
IL-1alpha	B-GENE
,	O
IL-1beta	B-GENE
,	O
TNF-alpha	B-GENE
and	O
IL-6	B-GENE
,	O
only	O
IL-6	B-GENE
was	O
generated	O
and	O
secreted	O
in	O
PKCeta	O
-expressing	O
cells	O
without	O
any	O
additional	O
inducer	O
in	O
serum-supplemented	O
cultures	O
(	O
10%	O
FCS	O
)	O
.	O

Twenty-nine	O
days	O
after	O
injection	O
of	O
5	O
.	O
8	O
mCi	O
of	O
Tc-99m	O
,	O
which	O
gives	O
28	O
rads	O
to	O
the	O
testis	O
,	O
the	O
number	O
of	O
sperm	O
hads	O
decreased	O
to	O
70%	O
of	O
control	O
.	O

Fluorometric	O
methods	O
can	O
also	O
provide	O
information	O
about	O
porphyrin	O
binding	O
sites	O
that	O
is	O
useful	O
in	O
understanding	O
porphyrin	O
transport	O
and	O
clearance	O
.	O

Homozygous	O
individuals	O
usually	O
develop	O
purpura	O
fulminans	O
as	O
newborns	O
;	O
heterozygous	O
protein	O
C-deficient	O
individuals	O
are	O
at	O
increased	O
risk	O
for	O
venous	O
thrombosis	O
and	O
pulmonary	O
embolism	O
.	O

DAF16	B-GENE
is	O
known	O
to	O
be	O
a	O
component	O
of	O
a	O
signaling	O
pathway	O
that	O
has	O
been	O
partially	O
dissected	O
genetically	O
and	O
includes	O
homologues	O
of	O
the	O
insulin	B-GENE
/	I-GENE
IGF-1	I-GENE
receptor	I-GENE
,	O
PtdIns	B-GENE
3-kinase	I-GENE
and	O
PKB	B-GENE
.	O

The	O
prevalence	O
of	O
CPAF	O
was	O
similar	O
in	O
type	O
1	O
and	O
type	O
2	O
diabetes	O
,	O
was	O
greater	O
in	O
women	O
than	O
in	O
men	O
,	O
and	O
was	O
significantly	O
greater	O
after	O
repeated	O
administrations	O
than	O
after	O
one	O
single	O
administration	O
of	O
chlorpropamide	O
.	O

The	O
identification	O
of	O
viable	O
myocardium	O
with	O
both	O
99mTc-tetrofosmin	O
and	O
201Tl	O
can	O
be	O
greatly	O
enhanced	O
to	O
a	O
similar	O
degree	O
if	O
the	O
severity	O
of	O
reduction	O
in	O
activity	O
within	O
nonreversible	O
defects	O
is	O
considered	O
.	O

Molecular	O
analysis	O
of	O
a	O
novel	O
schizosaccharomyces	O
pombe	O
gene	O
containing	O
two	O
RNP	B-GENE
consensus-sequence	I-GENE
RNA-binding	I-GENE
domains	I-GENE
.	O

Interestingly	O
,	O
a	O
decreased	O
transcription	O
from	O
the	O
endogenous	O
c-Myb	B-GENE
promoter	I-GENE
was	O
observed	O
in	O
several	O
HTLV-I	O
transformed	O
T-cell	O
lines	O
.	O

The	O
role	O
of	O
pharmacological	O
profiling	O
in	O
safety	O
assessment	O
.	O

The	O
tumor-suppressor	B-GENE
protein	I-GENE
p53	I-GENE
is	O
involved	O
in	O
maintaining	O
genomic	O
stability	O
.	O

Catch-up	O
growth	O
and	O
craniofacial	O
dimensions	O
following	O
administration	O
of	O
the	O
antineoplastic	O
agent	O
vincristine	O
to	O
young	O
rats	O
.	O

Previous	O
experimental	O
evidence	O
had	O
indicated	O
that	O
Reg1	B-GENE
might	O
target	O
Glc7	B-GENE
to	O
nuclear	O
substrates	O
such	O
as	O
the	O
Snf1	B-GENE
kinase	I-GENE
complex	I-GENE
.	O

The	O
main	O
causes	O
of	O
liver	O
disease	O
in	O
the	O
patients	O
with	O
HCC	O
were	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
(	O
77%	O
)	O
,	O
alcohol	O
abuse	O
(	O
73%	O
)	O
,	O
and	O
the	O
combination	O
of	O
HCV	O
and	O
alcohol	O
abuse	O
(	O
50%	O
)	O
.	O

Recommendations	O
to	O
deal	O
with	O
these	O
and	O
related	O
issues	O
are	O
presented	O
.	O

The	O
changes	O
after	O
treatment	O
were	O
observed	O
chiefly	O
by	O
electromyography	O
while	O
sensory	O
and	O
motor	O
improvement	O
were	O
also	O
recorded	O
as	O
auxiliary	O
indicators	O
.	O

Specific	O
class	B-GENE
I	I-GENE
and	I-GENE
II	I-GENE
histone	I-GENE
deacetylases	I-GENE
(	O
HDACs	B-GENE
)	O
interact	O
in	O
vivo	O
with	O
BCoR	B-GENE
,	O
suggesting	O
that	O
BCoR	B-GENE
may	O
functionally	O
link	O
these	O
two	O
classes	O
of	O
HDACs	B-GENE
.	O

Preliminary	O
report	O
.	O

Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	B-GENE
region	I-GENE
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

Localization	O
of	O
the	O
brachial	O
plexus	O
with	O
the	O
nerve	O
stimulator	O
is	O
equally	O
effective	O
at	O
the	O
interscalene	O
,	O
supraclavicular	O
,	O
and	O
axillary	O
sites	O
.	O

Although	O
the	O
OC	B-GENE
promoter	I-GENE
is	O
activated	O
in	O
a	O
C	O
terminus	O
dependent	O
manner	O
,	O
the	O
MDR	B-GENE
,	O
LTR	O
and	O
BSP	B-GENE
promoters	I-GENE
are	O
repressed	O
by	O
three	O
distinct	O
mechanisms	O
,	O
either	O
independent	O
of	O
or	O
involving	O
the	O
AML	B-GENE
C	I-GENE
terminus	I-GENE
,	O
or	O
requiring	O
only	O
the	O
conserved	O
C-terminal	B-GENE
pentapeptide	I-GENE
VWRPY	I-GENE
.	O

We	O
critically	O
assess	O
current	O
systematic	O
uncertainties	O
and	O
determine	O
the	O
primordial	O
Li	O
abundance	O
within	O
new	O
,	O
much	O
tighter	O
limits	O
:	O
&parl0	O
;	O
Li&solm0	O
;	O
H&parr0	O
;	O
p	O
=	O
1	O
.	O
23+0	O
.	O
68-0	O
.	O
32x10-10	O
.	O

In	O
64%	O
a	O
small	O
cardiac	O
vein	O
does	O
not	O
exist	O
,	O
but	O
its	O
origin	O
,	O
the	O
right	O
marginal	O
vein	O
,	O
joins	O
the	O
system	O
of	O
anterior	O
cardiac	O
veins	O
.	O

These	O
results	O
indicate	O
that	O
the	O
cis-regulatory	O
elements	O
required	O
for	O
developmental	O
control	O
of	O
the	O
HaG3-A	B-GENE
helianthinin	I-GENE
gene	I-GENE
are	O
located	O
in	O
a	O
2	O
.	O
4	O
kb	O
upstream	O
region	O
of	O
this	O
gene	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
yeast	B-GENE
PHO8	I-GENE
promoter	I-GENE
in	O
comparison	O
to	O
the	O
coregulated	O
PHO5	B-GENE
promoter	I-GENE
.	O

The	O
trk-2h	B-GENE
oncogene	I-GENE
,	O
isolated	O
from	O
the	O
human	O
breast	O
carcinoma	O
cell	O
line	O
MDA-MB	O
231	O
by	O
genomic	O
DNA-transfection	O
into	O
NIH3T3	O
cells	O
,	O
consists	O
of	O
the	O
trk	B-GENE
proto-oncogene	I-GENE
receptor	I-GENE
kinase	I-GENE
domain	I-GENE
fused	O
to	O
a	O
N-terminal	O
41	O
amino	O
acid	O
activating	O
sequence	O
(	O
Kozma	O
,	O
S	O
.	O
C	O
.	O
,	O
Redmond	O
,	O
S	O
.	O
M	O
.	O
S	O
.	O
,	O
Xiao-Chang	O
,	O
F	O
.	O
,	O
Saurer	O
,	O
S	O
.	O
M	O
.	O
,	O
Groner	O
,	O
B	O
.	O
and	O
Hynes	O
,	O
N	O
.	O
E	O
.	O

Substrates	O
include	O
the	O
p21	B-GENE
(	I-GENE
ras	I-GENE
)	I-GENE
proteins	I-GENE
,	O
nuclear	B-GENE
lamins	I-GENE
,	O
and	O
a	O
series	O
of	O
retinal	O
proteins	O
.	O

Transcription	O
of	O
the	O
metH	B-GENE
gene	I-GENE
in	I-GENE
Salmonella	I-GENE
typhimurium	I-GENE
and	I-GENE
Escherichia	I-GENE
coli	I-GENE
is	O
positively	O
regulated	O
by	O
the	O
metR	B-GENE
gene	I-GENE
product	I-GENE
,	O
a	O
DNA	O
binding	O
protein	O
.	O

Morphine-dependent	O
and	O
control	O
rats	O
in	O
an	O
oral	O
free-choice	O
protocol	O
were	O
treated	O
with	O
gamma-vinyl	O
GABA	O
(	O
GVG	O
)	O
,	O
60	O
,	O
120	O
and	O
240	O
mg	O
/	O
kg	O
IP	O
,	O
for	O
3	O
days	O
over	O
three	O
successive	O
periods	O
.	O

Approximately	O
20%	O
of	O
ALCLs	O
that	O
express	O
ALK	B-GENE
do	O
not	O
contain	O
the	O
t	O
(	O
2	O
;	O
5	O
)	O
,	O
suggesting	O
that	O
other	O
genetic	O
abnormalities	O
can	O
result	O
in	O
aberrant	O
ALK	B-GENE
expression	O
.	O

Furthermore	O
,	O
loss	O
of	O
methylation	O
also	O
greatly	O
reduced	O
the	O
association	O
of	O
another	O
yeast	B-GENE
B-type	I-GENE
subunit	I-GENE
,	O
Rts1p	B-GENE
.	O

Cytogenetic	O
and	O
molecular	O
characterization	O
of	O
random	O
chromosomal	O
rearrangements	O
activating	O
the	O
drug	O
resistance	O
gene	O
,	O
MDR1	B-GENE
/	I-GENE
P-glycoprotein	I-GENE
,	O
in	O
drug-selected	O
cell	O
lines	O
and	O
patients	O
with	O
drug	O
refractory	O
ALL	O
.	O

The	O
husband	O
in	O
one	O
of	O
the	O
married	O
couples	O
was	O
treated	O
for	O
hepatitis	O
of	O
unidentified	O
etiology	O
in	O
an	O
Infectology	O
Department	O
four	O
years	O
ago	O
.	O

These	O
genetic	O
alterations	O
do	O
not	O
affect	O
synthesis	O
of	O
the	O
major	O
c-myc	B-GENE
protein	I-GENE
,	O
p64	B-GENE
,	O
which	O
is	O
initiated	O
from	O
the	O
first	O
AUG	O
codon	O
in	O
exon	O
2	O
.	O

Its	O
application	O
in	O
Madagascar	O
:	O
advantages	O
and	O
disadvantages	O
.	O

This	O
paper	O
describes	O
the	O
results	O
of	O
an	O
initial	O
study	O
on	O
the	O
application	O
of	O
linear	O
solvation	O
energy	O
relationships	O
(	O
LSERs	O
)	O
to	O
the	O
prediction	O
of	O
internal	O
standard	O
compounds	O
in	O
reversed-phase	O
liquid	O
chromatographic	O
(	O
RPLC	O
)	O
method	O
development	O
.	O

What's	O
new	O
in	O
gynecologic	O
and	O
obstetrical	O
surgery	O
.	O

Treatment	O
with	O
heparin	O
,	O
plasminogen	B-GENE
activators	O
and	O
fibrinogenolytic	O
agents	O
was	O
disappointing	O
although	O
renal	O
function	O
has	O
stabilized	O
in	O
one	O
patient	O
on	O
long	O
term	O
oral	O
anticoagulant	O
therapy	O
.	O

M	O
.	O

There	O
was	O
a	O
weak	O
significant	O
correlation	O
between	O
TGF	B-GENE
beta	I-GENE
1	I-GENE
levels	O
and	O
normal	O
cell	O
radiosensitivity	O
(	O
lymphocyte	O
SF2	O
)	O
.	O

We	O
now	O
provide	O
evidence	O
for	O
physical	O
and	O
functional	O
interaction	O
between	O
Doa4	B-GENE
and	O
the	O
proteasome	O
.	O

We	O
describe	O
a	O
genetic	O
system	O
for	O
further	O
characterizing	O
the	O
role	O
of	O
the	O
extreme	O
C-terminus	O
of	O
the	O
beta	O
subunit	O
of	O
E	B-GENE
.	I-GENE
coli	I-GENE
RNA	I-GENE
polymerase	I-GENE
.	O

The	O
single	O
site	O
of	O
glycosylation	O
is	O
located	O
near	O
the	O
C-terminus	O
in	O
the	O
N-glycosylation	B-GENE
sequon	I-GENE
-Asn-Cys-Ser-	I-GENE
in	O
which	O
Cys	O
forms	O
part	O
of	O
a	O
disulphide	O
bridge	O
.	O

P	O
.	O

Mental	O
rotation	O
of	O
paired	O
figures	O
engendered	O
activation	O
in	O
the	O
left	O
superior	O
parietal	O
lobule	O
and	O
the	O
right	O
frontal	O
medial	O
gyrus	O
.	O

When	O
combined	O
with	O
independent	O
activating	O
mutations	O
in	O
the	O
c-abl	B-GENE
kinase	I-GENE
domain	I-GENE
or	O
NH2-terminus	O
,	O
the	O
G128R	B-GENE
mutation	O
blocked	O
transformation	O
by	O
the	O
double	O
mutant	O
,	O
suggesting	O
that	O
the	O
G128R	B-GENE
mutant	I-GENE
was	O
unable	O
to	O
transform	O
cells	O
for	O
trivial	O
reasons	O
.	O

The	O
csbA	B-GENE
fusion	I-GENE
was	O
maximally	O
expressed	O
during	O
early	O
stationary	O
phase	O
in	O
cells	O
grown	O
in	O
Luria	O
broth	O
containing	O
5%	O
glucose	O
and	O
0	O
.	O
2%	O
glutamine	O
.	O

9	O
.	O
7	O
(	O
95%	O
CI	O
:	O
9	O
.	O
6-9	O
.	O
7	O
)	O
micromol	O
/	O
L	O
among	O
women	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

A	O
single	O
protease-resistant	O
structure	O
formed	O
by	O
the	O
entirety	O
of	O
both	O
PDZ	B-GENE
repeats	I-GENE
1	I-GENE
and	I-GENE
2	I-GENE
(	O
PDZ1-2	B-GENE
)	O
contains	O
the	O
protein	B-GENE
4	I-GENE
.	I-GENE
1-binding	I-GENE
site	I-GENE
.	O

All	O
other	O
changes	O
at	O
the	O
3-	O
,	O
5-	O
,	O
and	O
6-positions	O
,	O
as	O
well	O
as	O
the	O
replacement	O
of	O
the	O
phenyl	O
group	O
at	O
position	O
2	O
,	O
caused	O
a	O
marked	O
decrease	O
of	O
activity	O
.	O

Thomas'	O
Hospital	O
solution	O
(	O
with	O
95%	O
O2	O
:	O
5%	O
CO2	O
)	O
can	O
meet	O
the	O
metabolic	O
demand	O
of	O
the	O
ischaemic	O
myocardium	O
and	O
thus	O
increase	O
the	O
safe	O
duration	O
of	O
cardiac	O
arrest	O
.	O

The	O
cleavage	O
dipeptides	O
of	O
C1YVV	B-GENE
NIa	I-GENE
protease	I-GENE
are	O
Q	B-GENE
(	I-GENE
E	I-GENE
)	I-GENE
/	I-GENE
S	I-GENE
(	I-GENE
A	I-GENE
,	I-GENE
G	I-GENE
)	I-GENE
.	O

Using	O
mouse-human	O
somatic	O
hybrids	O
and	O
FISH	O
analysis	O
,	O
the	O
PE-2	B-GENE
gene	I-GENE
is	O
localized	O
to	O
human	O
chromosome	O
19q13	O
.	O
2	O
,	O
a	O
region	O
involved	O
in	O
translocations	O
and	O
deletions	O
in	O
leukemias	O
and	O
several	O
solid	O
tumors	O
,	O
suggesting	O
that	O
this	O
novel	O
ETS	B-GENE
factor	I-GENE
may	O
play	O
a	O
role	O
in	O
carcinogenesis	O
.	O

Maximum	O
number	O
of	O
strains	O
(	O
39	O
.	O
1%	O
)	O
were	O
resistant	O
in	O
S	O
.	O
bareilly	O
serotype	O
,	O
followed	O
by	O
S	O
.	O
typhimurium	O
(	O
21	O
.	O
7%	O
)	O
and	O
least	O
in	O
S	O
.	O
typhi	O
(	O
17	O
.	O
4%	O
)	O
.	O

Use	O
of	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
in	O
cattle	O
breeding	O
.	O

Interestingly	O
,	O
these	O
response	O
elements	O
display	O
dramatically	O
reduced	O
affinity	O
for	O
retinoic	B-GENE
acid	I-GENE
receptor-retinoid-X	I-GENE
receptor	I-GENE
heterodimers	I-GENE
.	O

Mutations	O
within	O
the	O
C	O
terminus	O
of	O
c-fos	B-GENE
at	O
serine	O
residues	O
that	O
are	O
phosphorylation	O
targets	O
for	O
growth	B-GENE
factors	I-GENE
and	O
MAP	B-GENE
kinase	I-GENE
completely	O
abrogate	O
transactivation	O
and	O
block	O
potentiation	O
by	O
MAP	B-GENE
kinase	I-GENE
.	O

Efficacy	O
and	O
field	O
evaluation	O
of	O
Bacillus	O
thuringiensis	O
(	O
H-14	O
)	O
and	O
B	O
.	O
sphaericus	O
against	O
floodwater	O
mosquitoes	O
in	O
California	O
.	O

The	O
range	O
of	O
200	O
000-300	O
000	O
spermatozoa	O
/	O
microl	O
appeared	O
to	O
be	O
a	O
reasonable	O
compromise	O
for	O
both	O
criteria	O
.	O

The	O
characterized	O
Aplysia	B-GENE
Afurin2	I-GENE
is	O
a	O
candidate	O
PC	B-GENE
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
processing	O
of	O
egg-laying	B-GENE
hormone	I-GENE
(	O
ELH	B-GENE
)	O
-related	O
precursors	O
in	O
the	O
secretory	O
cells	O
of	O
the	O
atrial	O
gland	O
.	O

A	O
role	O
for	O
RalGDS	B-GENE
and	O
a	O
novel	O
Ras	B-GENE
effector	O
in	O
the	O
Ras-mediated	O
inhibition	O
of	O
skeletal	O
myogenesis	O
.	O

Analyses	O
of	O
hGMR	B-GENE
beta	I-GENE
subunit	I-GENE
mutants	I-GENE
revealed	O
two	O
cytoplasmic	O
regions	O
involved	O
in	O
activation	O
of	O
the	O
c-myc	B-GENE
promoter	I-GENE
,	O
one	O
is	O
essential	O
and	O
the	O
other	O
is	O
dispensable	O
but	O
enhances	O
the	O
activity	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
scanthrough	O
translation	O
,	O
where	O
the	O
initiating	O
AUG	O
of	O
a	O
primary	O
open	O
reading	O
frame	O
is	O
bypassed	O
,	O
is	O
most	O
likely	O
to	O
account	O
for	O
the	O
presentation	O
of	O
cryptic	O
epitopes	O
from	O
alternative	O
reading	O
frames	O
within	O
the	O
influenza	B-GENE
A	I-GENE
PR	I-GENE
/	I-GENE
8	I-GENE
/	I-GENE
34	I-GENE
nucleoprotein	I-GENE
gene	I-GENE
.	O

Lowering	O
of	O
the	O
renal	O
blood	O
flow	O
alters	O
the	O
glomerular	O
and	O
tubular	O
excretion	O
processes	O
.	O

We	O
find	O
that	O
BCL-6	B-GENE
POZ	B-GENE
domain	I-GENE
mutations	O
that	O
disrupt	O
the	O
interaction	O
with	O
N-CoR	B-GENE
and	O
SMRT	B-GENE
no	O
longer	O
repress	O
transcription	O
.	O

Maternal	O
p	O
,	O
p'DDE	O
and	O
beta-HCH	O
levels	O
were	O
also	O
associated	O
with	O
newborn	O
levels	O
,	O
but	O
levels	O
of	O
PCBs	O
were	O
not	O
.	O

Children	O
who	O
developed	O
lower	O
respiratory	O
tract	O
infections	O
or	O
PCP	O
had	O
increased	O
rates	O
of	O
decline	O
of	O
CD4	B-GENE
cell	O
counts	O
during	O
the	O
first	O
6	O
months	O
of	O
life	O
.	O

Selective	O
stimulation	O
of	O
central	O
alpha-autoreceptors	B-GENE
following	O
treatment	O
with	O
alpha-methyldopa	O
and	O
FLA	O
136	O
.	O

OBJECTIVE	O
:	O
Our	O
goal	O
was	O
to	O
determine	O
whether	O
chlamydia-infected	O
women	O
have	O
a	O
higher	O
rate	O
of	O
febrile	O
complications	O
after	O
postpartum	O
tubal	O
ligation	O
.	O

The	O
pre-mRNA	O
splicing	O
factor	O
U2AF	B-GENE
(	O
U2	B-GENE
small	I-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
particle	I-GENE
[	I-GENE
snRNP	I-GENE
]	I-GENE
auxiliary	I-GENE
factor	I-GENE
)	O
plays	O
a	O
critical	O
role	O
in	O
3'	O
splice	O
site	O
selection	O
.	O

The	O
Euglena	B-GENE
ribosomal	I-GENE
protein	I-GENE
gene	I-GENE
cluster	I-GENE
resembles	O
the	O
S-10	B-GENE
ribosomal	I-GENE
protein	I-GENE
operon	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
in	O
gene	O
organization	O
and	O
follows	O
the	O
exact	O
linear	O
order	O
of	O
the	O
analogous	O
genes	O
in	O
the	O
tobacco	O
and	O
liverwort	O
chloroplast	O
genomes	O
.	O

The	O
linear	O
plasmid	O
pCLU1	O
from	O
the	O
yeast	O
Kluyveromyces	O
lactis	O
normally	O
replicates	O
in	O
the	O
cytoplasm	O
,	O
with	O
the	O
aid	O
of	O
the	O
helper	O
linear	O
plasmid	O
pGKL2	O
,	O
using	O
terminal	B-GENE
protein	I-GENE
(	O
TP	B-GENE
)	O
as	O
a	O
primer	O
.	O

A	O
high-efficiency	O
cross-flow	O
micronebulizer	O
interface	O
for	O
capillary	O
electrophoresis	O
and	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
.	O

This	O
hypothesis	O
is	O
consistent	O
with	O
the	O
occurrence	O
of	O
PEA3	B-GENE
binding	I-GENE
sites	I-GENE
in	O
the	O
PEA3	B-GENE
promoter	I-GENE
and	O
with	O
the	O
ability	O
of	O
PEA3	B-GENE
to	O
transactivate	O
this	O
promoter	O
.	O

DMCM	O
also	O
permits	O
extension	O
of	O
the	O
possibilities	O
of	O
obtaining	O
and	O
transplanting	O
donor	O
organs	O
.	O

The	O
sequences	O
showed	O
extensive	O
homologies	O
with	O
squalene	B-GENE
synthase	I-GENE
genes	I-GENE
and	O
enzymes	O
from	O
a	O
number	O
of	O
other	O
organisms	O
and	O
extreme	O
amino	O
acid	O
conservation	O
within	O
the	O
binding	O
and	O
catalytic	O
domains	O
.	O

When	O
10	O
fields	O
were	O
analysed	O
,	O
a	O
strong	O
relationship	O
was	O
found	O
between	O
the	O
presence	O
of	O
bacteria	O
on	O
Gram	O
staining	O
and	O
the	O
final	O
diagnosis	O
of	O
VAP	O
(	O
for	O
PSB	O
and	O
PTC	O
respectively	O
:	O
sensitivity	O
74	O
and	O
81%	O
,	O
specificity	O
94	O
and	O
100%	O
,	O
positive	O
predictive	O
value	O
91	O
and	O
100%	O
,	O
negative	O
predictive	O
value	O
82	O
and	O
88%	O
)	O
.	O

They	O
correspond	O
to	O
nucleotides	O
equivalent	O
to	O
base-pair	O
C1-G72	O
and	O
discriminator	O
base	O
A73	O
in	O
the	O
amino	O
acid-acceptor	O
branch	O
of	O
the	O
molecule	O
.	O

As	O
a	O
reflection	O
of	O
uncertainties	O
in	O
the	O
estimates	O
for	O
individual	O
sources	O
,	O
the	O
90th	O
percentiles	O
of	O
PCDD	O
/	O
F	O
releases	O
for	O
1999	O
ranged	O
up	O
to	O
4	O
.	O
1	O
g	O
I-TEQ	O
/	O
y	O
.	O

The	O
evaluation	O
was	O
performed	O
using	O
a	O
retrospective	O
study	O
design	O
with	O
newborn	O
blood	O
samples	O
from	O
three	O
screening	O
centres	O
.	O

Two	O
distinct	O
Salmonella	B-GENE
fimbrins	I-GENE
,	O
AgfA	B-GENE
and	O
SefA	B-GENE
,	O
comprising	O
thin	O
aggregative	O
fimbriae	O
SEF17	B-GENE
and	O
SEF14	B-GENE
,	O
respectively	O
,	O
were	O
each	O
genetically	O
engineered	O
to	O
carry	O
PT3	B-GENE
,	O
an	O
alpha-helical	O
16-amino	O
acid	O
Leishmania	O
T-cell	O
epitope	O
derived	O
from	O
the	O
metalloprotease	B-GENE
gp63	B-GENE
.	O

The	O
MRS	O
II	O
meets	O
a	O
high	O
methodological	O
standard	O
as	O
an	O
instrument	O
standardized	O
in	O
the	O
population	O
.	O

Duration	O
of	O
remission	O
in	O
advanced	O
gastric	O
cancer	O
patients	O
responding	O
to	O
sequential	O
dose	O
of	O
MTX	O
and	O
5-FU	O
.	O

Northern	O
analysis	O
indicated	O
differential	O
expression	O
by	O
tissue	O
with	O
highest	O
expression	O
in	O
the	O
heart	O
.	O

These	O
data	O
show	O
that	O
the	O
spv	B-GENE
virulence	I-GENE
genes	I-GENE
belong	O
simultaneously	O
to	O
several	O
regulons	O
in	O
the	O
cell	O
,	O
raising	O
the	O
possibility	O
that	O
spv	B-GENE
expression	O
can	O
be	O
fine-tuned	O
in	O
response	O
to	O
multiple	O
environmental	O
inputs	O
.	O

Clb2	B-GENE
/	I-GENE
Cdc28	I-GENE
kinase	I-GENE
is	O
not	O
required	O
for	O
the	O
repression	O
of	O
MCB-binding	B-GENE
factor	I-GENE
transcriptional	O
activity	O
in	O
G2	O
and	O
M	O
phase	O
.	O

Cbf3	B-GENE
contains	O
three	O
proteins	O
,	O
Cbf3a	B-GENE
,	O
Cbf3b	B-GENE
and	O
Cbf3c	B-GENE
.	O

The	O
results	O
of	O
induced	O
coexpression	O
were	O
also	O
supported	O
by	O
rapid	O
generation	O
of	O
FeLV	O
recombinants	O
when	O
FeLV-C	O
was	O
used	O
to	O
infect	O
the	O
feline	O
3201B	O
cell	O
line	O
that	O
constitutively	O
expresses	O
high	O
levels	O
of	O
endogenous	O
FeLV-specific	O
mRNAs	O
.	O

COGLAB	O
includes	O
measures	O
of	O
preattentional	O
,	O
attentional	O
,	O
conceptual	O
,	O
and	O
psychomotor	O
performance	O
.	O

We	O
discuss	O
these	O
results	O
in	O
terms	O
of	O
the	O
influence	O
that	O
time	O
and	O
nutritional	O
constraints	O
have	O
on	O
odonate	O
development	O
patterns	O
and	O
fitness	O
.	O

Within	O
each	O
lobe	O
,	O
the	O
PA	O
dispersion	O
was	O
up	O
to	O
10	O
cmH2O	O
at	O
CFV	O
of	O
90	O
l	O
/	O
min	O
;	O
when	O
flow	O
decreased	O
,	O
PA	O
at	O
all	O
sites	O
decreased	O
,	O
as	O
did	O
the	O
intralobar	O
dispersion	O
.	O

N	O
.	O
van	O
Hoek	O
,	O
and	O
M	O
.	O

Use	O
of	O
serum	O
thyroglobulin	B-GENE
determination	O
in	O
the	O
follow-up	O
of	O
differentiated	O
carcinomas	O
of	O
the	O
thyroid	O
.	O

Large	O
and	O
small	O
medullary	O
lesions	O
inhibited	O
the	O
occurrence	O
of	O
target	O
fibres	O
in	O
the	O
tenotomized	O
muscles	O
,	O
the	O
smallest	O
one	O
being	O
neurolysis	O
of	O
the	O
dorsal	O
roots	O
.	O

No	O
such	O
benefits	O
were	O
seen	O
for	O
children	O
with	O
CD4+	B-GENE
counts	O
below	O
0	O
.	O
2	O
x	O
10	O
(	O
9	O
)	O
per	O
liter	O
at	O
entry	O
.	O

Pyk2	B-GENE
phosphorylation	O
increased	O
upon	O
adherence	O
of	O
FLG	O
29	O
.	O
1	O
cells	O
to	O
fibronectin	B-GENE
and	O
to	O
ST2	O
stromal	O
cells	O
.	O

Supplementing	O
a	O
soybean	O
protein	O
and	O
sucrose-based	O
diet	O
with	O
levels	O
of	O
2	O
.	O
2	O
,	O
11	O
,	O
and	O
55	O
ppm	O
of	O
the	O
antibiotic	O
,	O
from	O
the	O
two	O
sources	O
each	O
with	O
two	O
different	O
purities	O
,	O
improved	O
weight	O
gain	O
of	O
chicks	O
an	O
average	O
of	O
23%	O
and	O
improved	O
feed	O
efficiency	O
an	O
average	O
of	O
13%	O
at	O
the	O
higher	O
levels	O
(	O
all	O
P	O
less	O
than	O
.	O
01	O
)	O
.	O

Mutagenesis	O
of	O
IM1	B-GENE
enhances	O
the	O
ability	O
of	O
c-Fos	B-GENE
to	O
activate	O
an	O
AP1	B-GENE
bearing	I-GENE
promoter	I-GENE
.	O

Hypothermia	O
After	O
Cardiac	O
Arrest	O
(	O
HACA	O
)	O
Study	O
Group	O
.	O

Intrathecal	O
acetyl	B-GENE
cholinesterase	I-GENE
inhibitors	O
produce	O
analgesia	O
that	O
is	O
synergistic	O
with	O
morphine	O
and	O
clonidine	O
in	O
rats	O
.	O

The	O
bZP2	B-GENE
cDNA	I-GENE
(	I-GENE
115-1914	I-GENE
nt	I-GENE
,	I-GENE
1	I-GENE
.	I-GENE
8	I-GENE
kb	I-GENE
)	I-GENE
,	O
excluding	O
sequences	O
coding	O
for	O
N-terminal	O
signal	O
sequence	O
and	O
C-terminal	O
transmembranelike	O
domain	O
,	O
was	O
PCR	O
amplified	O
and	O
Sac1-Sal1	B-GENE
restricted	I-GENE
fragment	I-GENE
cloned	O
in	O
frame	O
downstream	O
of	O
the	O
T5	O
promoter	O
under	O
the	O
lac	B-GENE
operator	I-GENE
control	O
in	O
a	O
pQE-30	O
vector	O
.	O

Combining	O
multiple	O
laboratory	O
studies	O
may	O
be	O
of	O
value	O
in	O
predetermining	O
the	O
eventual	O
outcome	O
in	O
near-drowning	O
.	O

STUDY	O
DESIGN	O
.	O

A	O
tobacco	O
homologue	O
(	O
trolC	B-GENE
)	O
of	O
the	O
rolC	B-GENE
gene	I-GENE
of	I-GENE
the	I-GENE
Agrobacterium	I-GENE
rhizogenes	I-GENE
Ri-plasmid	I-GENE
was	O
cloned	O
and	O
sequenced	O
from	O
Nicotiana	O
tabacum	O
L	O
.	O
cv	O
.	O

Sternocleidomastoid	O
,	O
neck	O
or	O
facial	O
muscles	O
wasting	O
were	O
also	O
found	O
in	O
three	O
cases	O
.	O

The	O
first	O
hypothesis	O
was	O
supported	O
in	O
the	O
sense	O
that	O
stimulus	O
differences	O
might	O
affect	O
behaviour	O
even	O
without	O
their	O
successful	O
attentive	O
processing	O
in	O
normal	O
participants	O
.	O

The	O
prescription	O
for	O
apoplexy	O
includes	O
C1-7	O
,	O
T1-9	O
and	O
L2-4	O
.	O

The	O
expression	O
of	O
the	O
putative	O
operon	O
bglPH	B-GENE
of	O
Bacillus	O
subtilis	O
was	O
studied	O
by	O
using	O
bglP'-lacZ	B-GENE
transcriptional	I-GENE
fusions	I-GENE
.	O

The	O
correlation	O
between	O
PaCO2	O
and	O
PtcO2	O
in	O
RDS	O
was	O
insufficient	O
to	O
make	O
clinical	O
judgement	O
.	O

A	O
series	O
of	O
amino	O
terminal	O
deletion	O
mutants	O
(	O
d10	O
,	O
d20	O
,	O
d27	O
,	O
d31	O
,	O
d40	O
,	O
d44	O
,	O
and	O
d73	O
)	O
were	O
compared	O
for	O
processing	O
,	O
cell	O
surface	O
expression	O
,	O
and	O
maintenance	O
of	O
their	O
biological	O
attributes	O
by	O
recombinant	O
expression	O
of	O
mutant	O
genes	O
using	O
a	O
plasmid	O
vector	O
(	O
pcDL-SR	O
alpha-296	O
)	O
in	O
CV-1	O
and	O
HeLa	O
cells	O
.	O

Cloning	O
and	O
characterization	O
of	O
human	B-GENE
Lnk	I-GENE
,	O
an	O
adaptor	O
protein	O
with	O
pleckstrin	B-GENE
homology	O
and	O
Src	B-GENE
homology	I-GENE
2	I-GENE
domains	I-GENE
that	O
can	O
inhibit	O
T	O
cell	O
activation	O
.	O

As	O
a	O
result	O
,	O
beta-apo-8'-carotenoic	O
acid	O
ethyl	O
ester	O
(	O
apo-EE	O
)	O
was	O
used	O
as	O
a	O
reference	O
standard	O
in	O
Experiments	O
4	O
to	O
6	O
.	O

Nevertheless	O
,	O
in	O
view	O
of	O
the	O
potential	O
transmission	O
rates	O
of	O
HGV	O
and	O
the	O
lack	O
of	O
effective	O
immunization	O
,	O
HGV	O
should	O
be	O
regarded	O
as	O
a	O
potential	O
occupational	O
hazard	O
for	O
medical	O
and	O
dental	O
staff	O
.	O

Disruption	O
of	O
any	O
one	O
of	O
the	O
four	O
genes	O
encoding	O
the	O
newly	O
identified	O
SRP	B-GENE
proteins	I-GENE
results	O
in	O
slow	O
cell	O
growth	O
and	O
inefficient	O
protein	O
translocation	O
across	O
the	O
ER	O
membrane	O
.	O

We	O
derive	O
joint	O
probability	O
density	O
distributions	O
for	O
three	O
key	O
uncertain	O
properties	O
of	O
the	O
climate	O
system	O
,	O
using	O
an	O
optimal	O
fingerprinting	O
approach	O
to	O
compare	O
simulations	O
of	O
an	O
intermediate	O
complexity	O
climate	O
model	O
with	O
three	O
distinct	O
diagnostics	O
of	O
recent	O
climate	O
observations	O
.	O

An	O
increase	O
in	O
the	O
level	O
of	O
serum	O
enzymes	O
,	O
such	O
as	O
aspartate	B-GENE
transaminase	I-GENE
,	O
alkaline	B-GENE
phosphatase	I-GENE
,	O
creatine	B-GENE
phosphokinase	I-GENE
,	O
lactate	B-GENE
dehydrogenase	I-GENE
after	O
D	O
.	O
russelli	O
venom	O
injection	O
in	O
albino	O
rats	O
is	O
indicative	O
of	O
cell	O
or	O
tissue	O
damage	O
.	O

Among	O
a	O
population	O
of	O
18	O
,	O
175	O
children	O
below	O
7	O
years	O
of	O
age	O
in	O
medium	O
sized	O
towns	O
and	O
rural	O
areas	O
in	O
south-western	O
Germany	O
552	O
(	O
3	O
.	O
03%	O
)	O
cases	O
of	O
croup	O
were	O
registered	O
during	O
a	O
12	O
months	O
period	O
in	O
1984-85	O
by	O
their	O
physicians	O
.	O

The	O
7-day	O
treatment	O
resulted	O
in	O
a	O
decrease	O
in	O
mitochondrial	O
uptake	O
of	O
Rh123	O
and	O
an	O
increase	O
in	O
NAO	O
uptake	O
.	O

Primer	O
extension	O
and	O
mung	B-GENE
bean	I-GENE
and	I-GENE
S1	I-GENE
nuclease	I-GENE
mapping	O
indicated	O
multiple	O
transcription	O
initiation	O
sites	O
and	O
were	O
consistent	O
with	O
Northern	O
analyses	O
.	O

GCN4	B-GENE
encodes	O
a	O
transcriptional	O
activator	O
of	O
amino	O
acid	O
biosynthetic	O
genes	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
progress	O
of	O
morphological	O
research	O
on	O
the	O
parabrachial	O
nucleus	O
.	O

The	O
cysteine-rich	O
region	O
of	O
raf-1	B-GENE
kinase	I-GENE
contains	O
zinc	O
,	O
translocates	O
to	O
liposomes	O
,	O
and	O
is	O
adjacent	O
to	O
a	O
segment	O
that	O
binds	O
GTP-ras	B-GENE
.	O

The	O
CBF1	B-GENE
site	I-GENE
within	O
HS2	B-GENE
resides	O
near	O
sites	O
for	O
hematopoietic	O
regulators	O
such	O
as	O
GATA-1	B-GENE
,	O
NF-E2	B-GENE
,	O
and	O
TAL1	B-GENE
.	O

Here	O
we	O
provide	O
the	O
first	O
evidence	O
for	O
the	O
involvement	O
of	O
GCN1-GCN2	B-GENE
interaction	O
in	O
activation	O
of	O
GCN2	B-GENE
per	O
se	O
.	O

The	O
results	O
of	O
these	O
experiments	O
indicate	O
that	O
at	O
least	O
two	O
upstream	O
activator	O
sequences	O
(	O
UAS	O
)	O
mediate	O
maximum	O
induction	O
by	O
galactose	O
.	O

In	O
a	O
second	O
series	O
of	O
experiments	O
,	O
the	O
efficacy	O
of	O
PDC	O
/	O
HDC	O
Ac	O
was	O
evaluated	O
in	O
both	O
single	O
and	O
multiple	O
dose	O
regiments	O
.	O

Significant	O
correlations	O
existed	O
between	O
FEV1	O
and	O
the	O
corresponding	O
values	O
of	O
Raw	O
,	O
MEF50	O
and	O
MEF25	O
,	O
although	O
there	O
were	O
considerable	O
individual	O
differences	O
between	O
test	O
results	O
.	O

The	O
liver	O
in	O
the	O
severely	O
ill	O
.	O

20%	O
of	O
total	O
HSL	B-GENE
transcripts	I-GENE
in	O
human	O
subcutaneous	O
adipocytes	O
.	O

Western	O
analyses	O
with	O
antisera	O
raised	O
against	O
Lu-ECAM-1	B-GENE
peptides	I-GENE
show	O
that	O
the	O
N-terminal	O
region	O
of	O
the	O
predicted	O
open	O
reading	O
frame	O
is	O
present	O
only	O
in	O
the	O
larger	O
size	O
proteins	O
(	O
i	O
.	O
e	O
.	O

Intrastriatal	O
grafts	O
of	O
nigral	O
and	O
adrenal	O
tissues	O
have	O
been	O
found	O
to	O
be	O
effective	O
in	O
alleviating	O
many	O
of	O
the	O
simple	O
motor	O
and	O
sensorimotor	O
deficits	O
associated	O
with	O
lesions	O
of	O
the	O
nigrostriatal	O
dopamine	O
system	O
.	O

In	O
contrast	O
,	O
the	O
action	O
of	O
GLP-1	B-GENE
at	O
the	O
CRE	B-GENE
was	O
not	O
blocked	O
by	O
cotransfection	O
with	O
M1-CREB	B-GENE
,	O
an	O
isoform	O
that	O
lacks	O
a	O
consensus	O
serine	O
residue	O
serving	O
as	O
substrate	O
for	O
PKA-mediated	O
phosphorylation	O
.	O

Post-operative	O
functional	O
outcome	O
is	O
related	O
to	O
pre-operative	O
functional	O
status	O
.	O

The	O
cleavage	O
of	O
Fak	B-GENE
by	O
caspases	B-GENE
may	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
execution	O
of	O
the	O
suicide	O
program	O
by	O
disabling	O
the	O
anti-apoptotic	O
function	O
of	O
Fak	B-GENE
.	O

As	O
authorized	O
by	O
the	O
World	O
Health	O
Organization	O
29th	O
Expert	O
Committee	O
on	O
Biological	O
Standardization	O
,	O
the	O
preparation	O
of	O
human	B-GENE
prolactin	I-GENE
in	O
ampoules	O
coded	O
75	O
/	O
504	O
has	O
been	O
established	O
as	O
the	O
International	O
Reference	O
Preparation	O
(	O
IRP	O
)	O
of	O
human	B-GENE
prolactin	I-GENE
for	O
immunoassay	O
.	O

Many	O
of	O
these	O
landfill	O
operations	O
were	O
undertaken	O
in	O
the	O
early	O
1950s	O
and	O
1960s	O
,	O
when	O
knowledge	O
regarding	O
the	O
safe	O
and	O
prolonged	O
containment	O
of	O
the	O
waste	O
buried	O
was	O
nonexistent	O
or	O
minimal	O
at	O
best	O
.	O

The	O
SH2	B-GENE
and	O
SH3	B-GENE
domains	I-GENE
of	O
pp60src	B-GENE
direct	O
stable	O
association	O
with	O
tyrosine	O
phosphorylated	O
proteins	O
p130	B-GENE
and	O
p110	B-GENE
.	O

The	O
use	O
of	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
resulted	O
in	O
significant	O
improvements	O
in	O
the	O
treatment	O
of	O
HIV	O
infection	O
,	O
including	O
a	O
decrease	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
several	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
-related	O
malignancies	O
.	O

A	O
particularly	O
striking	O
HpaII	B-GENE
tiny	O
fragment	O
island	O
,	O
extending	O
over	O
nearly	O
2	O
,	O
000	O
base	O
pairs	O
,	O
surrounds	O
the	O
USF2	B-GENE
translation	I-GENE
initiation	I-GENE
site	I-GENE
.	O

Our	O
results	O
implicate	O
TGF-beta	B-GENE
RII	I-GENE
as	O
a	O
direct	O
target	O
of	O
EWS-FLI1	B-GENE
.	O

It	O
was	O
possible	O
to	O
classify	O
the	O
animals	O
into	O
high	O
and	O
low	O
responders	O
according	O
to	O
the	O
pattern	O
of	O
humoral	O
immune	O
response	O
.	O

Requirements	O
for	O
the	O
nuclear-cytoplasmic	O
translocation	O
of	O
infected-cell	B-GENE
protein	I-GENE
0	I-GENE
of	O
herpes	O
simplex	O
virus	O
1	O
.	O

Localization	O
of	O
67	O
exons	O
on	O
a	O
YAC	O
contig	O
spanning	O
1	O
.	O
5	O
Mb	O
around	O
the	O
multidrug	B-GENE
resistance	I-GENE
gene	I-GENE
region	I-GENE
of	O
human	O
chromosome	O
7q21	O
.	O
1	O
.	O

The	O
role	O
of	O
'scientific	O
psychiatry'	O
in	O
understanding	O
patients	O
with	O
chronic	O
schizophrenia	O
or	O
severe	O
personality	O
disorder	O
.	O

The	O
genes	O
encoding	O
(	B-GENE
2Fe-2S	I-GENE
)	I-GENE
plant-like	I-GENE
ferredoxins	I-GENE
were	O
studied	O
in	O
the	O
widely	O
used	O
cyanobacterium	O
Synechocystis	O
PCC6803	O
.	O

PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
bony	O
anchorage	O
of	O
a	O
new	O
implant	O
(	O
orderly	O
wired	O
surface	O
effect	O
with	O
alloy	O
Ti	O
Al	O
Va	O
and	O
ordered	O
pores	O
of	O
488	O
mu	O
)	O
.	O

Transfer	B-GENE
RNA	I-GENE
genes	I-GENE
from	I-GENE
Dictyostelium	I-GENE
discoideum	I-GENE
are	O
frequently	O
associated	O
with	O
repetitive	O
elements	O
and	O
contain	O
consensus	O
boxes	O
in	O
their	O
5'	O
and	O
3'-flanking	O
regions	O
.	O

Ultrastructural	O
studies	O
of	O
retinopathy	O
of	O
premature	O
infants	O
.	O

The	O
present	O
studies	O
compare	O
the	O
biochemical	O
characteristics	O
,	O
Kanagawa	O
hemolysin	O
reactions	O
,	O
and	O
plasmid	O
profiles	O
of	O
13	O
patient	O
and	O
221	O
environmental	O
isolates	O
of	O
the	O
organism	O
.	O

A	O
preliminary	O
study	O
of	O
vincristine	O
,	O
methotrexate	O
,	O
and	O
prednisolone	O
(	O
VM*P	O
)	O
combination	O
chemotherapy	O
for	O
advanced	O
adult	O
non-Hodgkin's	O
lymphoma	O
.	O

Accurate	O
pathologic	O
staging	O
identifies	O
patients	O
who	O
are	O
potentially	O
curable	O
with	O
radiotherapy	O
.	O

In	O
addition	O
,	O
C	B-GENE
/	I-GENE
EBP	I-GENE
beta	I-GENE
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
gamma	I-GENE
readily	O
heterodimerize	O
with	O
each	O
other	O
as	O
well	O
as	O
with	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
.	O

Intraoperative	O
measurement	O
of	O
activated	O
partial	O
thromboplastin	B-GENE
time	O
and	O
prothrombin	B-GENE
time	O
with	O
a	O
new	O
compact	O
monitor	O
.	O

The	O
pattern	O
of	O
RNase	B-GENE
E	I-GENE
digestion	O
of	O
finP305	B-GENE
RNA	I-GENE
differed	O
from	O
FinP	B-GENE
,	O
and	O
GST-FinO	B-GENE
did	O
not	O
protect	O
finP305	B-GENE
RNA	I-GENE
from	O
cleavage	O
in	O
vitro	O
.	O

During	O
exercise	O
K+	O
is	O
released	O
from	O
contracting	O
muscle	O
and	O
plasma	O
K+	O
concentration	O
rises	O
.	O

Second	O
,	O
the	O
membrane	O
expression	O
of	O
alpha	O
and	O
beta	O
subunits	O
was	O
mimicked	O
by	O
cholesterol	O
and	O
17-ketocholesterol	O
,	O
both	O
of	O
which	O
inhibit	O
HMG-CoA	B-GENE
reductase	I-GENE
.	O

In	O
vitro	O
affinity	O
analyses	O
demonstrated	O
that	O
recombinant	O
130-kD	O
protein	O
directly	O
interacts	O
with	O
ZO-1	B-GENE
and	O
the	O
cytoplasmic	O
domain	O
of	O
occludin	B-GENE
,	O
but	O
not	O
with	O
ZO-2	B-GENE
.	O

Clinical	O
differentiation	O
of	O
patients	O
with	O
mild	O
diplegic	O
cerebral	O
palsy	O
(	O
CP	O
)	O
and	O
idiopathic	O
toe	O
walking	O
(	O
ITW	O
)	O
can	O
be	O
difficult	O
.	O

Next	O
,	O
we	O
stably	O
overexpressed	O
wild-type	B-GENE
Shc	I-GENE
or	O
Y317F	B-GENE
mutant	I-GENE
Shc	I-GENE
into	O
HIRc	O
cells	O
.	O

CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
the	O
LysU	B-GENE
crystal	O
structure	O
with	O
the	O
structures	O
of	O
seryl-	B-GENE
and	I-GENE
aspartyl-tRNA	I-GENE
synthetases	I-GENE
enables	O
a	O
conserved	O
core	O
to	O
be	O
identified	O
.	O

Quantitative	O
analysis	O
of	O
the	O
coronary	O
stenosis	O
was	O
assessed	O
before	O
and	O
after	O
PTCA	O
,	O
and	O
the	O
dilatation	O
resulted	O
in	O
an	O
increase	O
in	O
minimal	O
luminal	O
cross-sectional	O
area	O
from	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
8	O
to	O
2	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
2	O
mm2	O
.	O

Thirty-two	O
rats	O
were	O
divided	O
into	O
four	O
groups	O
.	O

Mice	O
homozygous	O
for	O
the	O
dlg	B-GENE
mutation	O
exhibit	O
growth	O
retardation	O
in	O
utero	O
,	O
have	O
hypoplasia	O
of	O
the	O
premaxilla	O
and	O
mandible	O
,	O
have	O
a	O
cleft	O
secondary	O
palate	O
,	O
and	O
die	O
perinatally	O
.	O

Here	O
we	O
focused	O
on	O
the	O
role	O
of	O
the	O
5'	O
proximal	O
regulatory	O
cassette	O
(	O
-190	O
;	O
+53	O
bp	O
)	O
of	O
the	O
rat	B-GENE
enkephalin	I-GENE
(	O
rENK	B-GENE
)	O
gene	O
in	O
the	O
developmental	O
regulation	O
of	O
the	O
enkephalin	B-GENE
phenotype	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
gene	O
predicts	O
a	O
polypeptide	O
of	O
215	O
amino	O
acids	O
(	O
25	O
.	O
2	O
kDa	O
)	O
with	O
two	O
putative	O
membrane-spanning	O
domains	O
.	O

Quantum-statistical	O
theory	O
of	O
high-field	O
transport	O
phenomena	O
.	O

Depletion	O
of	O
dopamine	O
in	O
the	O
nucleus	O
accumbens	O
led	O
to	O
a	O
dramatic	O
shift	O
in	O
behavior	O
in	O
which	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
lever	O
pressing	O
but	O
a	O
significant	O
increase	O
in	O
consumption	O
of	O
lab	O
chow	O
.	O

The	O
two	O
genes	O
code	O
for	O
polypeptides	B-GENE
of	I-GENE
420	I-GENE
amino	I-GENE
acids	I-GENE
(	I-GENE
M	I-GENE
.	I-GENE
HgiCI	I-GENE
)	I-GENE
and	O
345	B-GENE
amino	I-GENE
acids	I-GENE
(	I-GENE
R	I-GENE
.	I-GENE
HgiCI	I-GENE
)	I-GENE
.	O

Glucose-6-phosphate	B-GENE
dehydrogenase	I-GENE
(	O
G-6-PD	B-GENE
)	O
deficiency	O
in	O
the	O
newborn	O
.	O

Angiography	O
of	O
aneurysmal	O
bone	O
cyst	O
.	O

The	O
two	O
mouse	O
lines	O
carrying	O
the	O
unfragmented	O
Hnf3g-lacZ	B-GENE
YAC	I-GENE
showed	O
tissue-specific	O
,	O
copy	O
number-dependent	O
and	O
position-independent	O
expression	O
,	O
proving	O
that	O
170	O
kb	O
of	O
the	O
Hnf3g	B-GENE
locus	O
contain	O
all	O
elements	O
important	O
in	O
the	O
regulation	O
of	O
Hnf3g	B-GENE
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
structural	O
organization	O
of	O
a	O
vertebrate	O
gene	O
encoding	O
an	O
integral	O
membrane	O
protein	O
of	O
the	O
nuclear	O
envelope	O
that	O
may	O
be	O
a	O
member	O
of	O
a	O
family	O
of	O
polypeptides	O
conserved	O
in	O
evolution	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
spleen	O
necrosis	O
virus	O
(	O
SNV	O
)	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
are	O
associated	O
with	O
Rex	O
/	O
Rex-responsive	O
element-independent	O
expression	O
of	O
bovine	O
leukemia	O
virus	O
RNA	O
and	O
supports	O
the	O
hypothesis	O
that	O
SNV	O
RNA	O
contains	O
a	O
cis-acting	O
element	O
that	O
interacts	O
with	O
cellular	B-GENE
Rex-like	I-GENE
proteins	I-GENE
.	O

After	O
successful	O
subtotal	O
parathyroidectomy	O
,	O
evident	O
by	O
the	O
decrease	O
of	O
serum	O
iPTH	B-GENE
levels	O
,	O
both	O
the	O
CL	O
of	O
group	O
2	O
PMNs	O
and	O
the	O
ability	O
of	O
group	O
2	O
sera	O
to	O
induce	O
augmented	O
CL	O
in	O
normal	O
PMNs	O
decreased	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

Current	O
status	O
of	O
chemotherapy	O
for	O
Hodgkin's	O
disease	O
.	O

AIMS	O
/	O
METHODS	O
:	O
Reticuloendothelial	O
system	O
function	O
,	O
as	O
assessed	O
by	O
clearance	O
of	O
radiolabelled	O
bacteria	O
,	O
was	O
evaluated	O
in	O
acute	O
liver	O
injury	O
induced	O
by	O
D-galactosamine	O
in	O
rats	O
,	O
and	O
compared	O
with	O
that	O
after	O
70%	O
liver	O
resection	O
model	O
.	O

Lethal	O
Tachmalcor	O
(	O
4-	O
(	O
3'-diethylamino-2'-hydroxypropyl	O
)	O
-ajmaline	O
)	O
poisoning	O
in	O
childhood	O
.	O

IgG	B-GENE
levels	O
of	O
1	O
/	O
100	O
were	O
present	O
in	O
only	O
four	O
out	O
of	O
ten	O
samples	O
obtained	O
150	O
days	O
after	O
the	O
clinical	O
onset	O
.	O

RNase	B-GENE
protection	O
and	O
primer	O
extension	O
assays	O
confirmed	O
that	O
the	O
5'	O
non-coding	O
exon	O
is	O
included	O
in	O
the	O
DDT1	O
aFGF	B-GENE
mRNA	I-GENE
and	O
that	O
a	O
major	O
transcription	O
start	O
site	O
is	O
approximately	O
136	O
bp	O
upstream	O
of	O
the	O
5'	O
non-coding	O
splice	O
junction	O
of	O
this	O
exon	O
.	O

Cytoskeletal	O
polarization	O
of	O
T	O
cells	O
is	O
regulated	O
by	O
an	O
immunoreceptor	O
tyrosine-based	O
activation	O
motif-dependent	O
mechanism	O
.	O

Functional	O
effects	O
following	O
subacute	O
administration	O
.	O

(	O
1988	O
)	O
J	O
.	O

The	O
effect	O
of	O
acetazolamide	O
(	O
ACZ	O
)	O
on	O
HCO3-	O
and	O
Cl-	O
activities	O
in	O
inner	O
ear	O
fluid	O
was	O
investigated	O
by	O
ion-selective	O
microelectrode	O
methods	O
.	O

Eukaryotic	B-GENE
initiation	I-GENE
factor	I-GENE
3	I-GENE
(	O
eIF3	B-GENE
)	O
is	O
a	O
large	O
multisubunit	O
complex	O
that	O
stabilizes	O
the	O
ternary	O
complex	O
,	O
eIF2	B-GENE
x	O
GTP	B-GENE
x	O
tRNA	B-GENE
(	I-GENE
Met	I-GENE
)	I-GENE
i	I-GENE
and	O
promotes	O
mRNA	O
binding	O
to	O
the	O
40	B-GENE
S	I-GENE
ribosomal	I-GENE
subunit	I-GENE
.	O
eIF3	B-GENE
also	O
functions	O
as	O
a	O
ribosome	O
subunit	O
anti-association	O
factor	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
isotretinoin	O
on	O
HDL	B-GENE
,	O
we	O
measured	O
HDL-C	B-GENE
,	O
HDL	B-GENE
phospholipids	O
(	O
HDL-PL	B-GENE
)	O
,	O
apoprotein	B-GENE
A1	I-GENE
(	O
apo	B-GENE
A-1	I-GENE
)	O
,	O
and	O
HDL-C	B-GENE
subfractions	O
(	O
HDL2-C	B-GENE
and	O
HDL3-C	B-GENE
)	O
in	O
24	O
healthy	O
,	O
male	O
patients	O
receiving	O
a	O
16-week	O
course	O
of	O
isotretinoin	O
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
treatment	O
of	O
severe	O
acne	O
vulgaris	O
.	O

The	O
expression	O
of	O
the	O
pilin	B-GENE
gene	I-GENE
,	O
tcpA	B-GENE
,	O
is	O
dependent	O
upon	O
ToxR	B-GENE
and	O
upon	O
ToxT	B-GENE
.	O

These	O
results	O
indicate	O
that	O
patients	O
who	O
undergo	O
postoperative	O
irradiation	O
for	O
low	O
grade	O
spinal	O
astrocytomas	O
and	O
localized	O
spinal	O
ependymomas	O
achieve	O
excellent	O
survival	O
.	O

A	O
one-week	O
ulcer	O
therapy	O
with	O
atropine	O
and	O
Vikalin	O
(	O
Roter	O
)	O
led	O
to	O
a	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
reduction	O
of	O
the	O
nocturnal	O
proteolytic	O
activity	O
.	O

This	O
GAP	B-GENE
activity	O
was	O
observed	O
in	O
3T3-L1	O
adipocyte	O
lysates	O
,	O
and	O
was	O
able	O
to	O
accelerate	O
the	O
hydrolysis	O
of	O
the	O
[	O
alpha-32P	O
]	O
GTP	O
bound	O
to	O
GST-Rab4	B-GENE
into	O
[	O
alpha-32P	O
]	O
GDP	O
.	O

NF-kappa	B-GENE
B	I-GENE
/	I-GENE
Rel	I-GENE
transcription	I-GENE
factors	I-GENE
participate	O
in	O
the	O
activation	O
of	O
numerous	O
genes	O
involved	O
in	O
immune	O
regulation	O
/	O
inflammation	O
including	O
cytokines	O
,	O
cell	O
surface	O
receptors	O
,	O
adhesion	O
molecules	O
,	O
and	O
acute	O
phase	O
proteins	O
.	O

S	O
.	O
,	O
Kim	O
,	O
S	O
.	O

The	O
predicted	O
protein	O
,	O
Seb1p	B-GENE
,	O
consists	O
of	O
82	O
amino	O
acids	O
and	O
contains	O
one	O
potential	O
membrane-spanning	O
region	O
at	O
the	O
C-terminus	O
but	O
no	O
N-terminal	O
signal	O
sequence	O
.	O

Droperidol-induced	O
extrapyramidal	O
symptoms	O
in	O
an	O
adolescent	O
following	O
strabismus	O
surgery	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
the	O
expression	O
of	O
LIMK-1	B-GENE
mRNA	I-GENE
predominantly	O
in	O
the	O
brain	O
and	O
the	O
expression	O
of	O
LIMK-2	B-GENE
mRNA	I-GENE
in	O
various	O
tissues	O
in	O
the	O
rat	O
.	O

Cyclin-dependent	B-GENE
kinase-2	I-GENE
(	O
Cdk2	B-GENE
)	O
forms	O
an	O
inactive	O
complex	O
with	O
cyclin	B-GENE
D1	I-GENE
since	O
Cdk2	B-GENE
associated	O
with	O
cyclin	B-GENE
D1	I-GENE
is	O
not	O
phosphorylated	O
by	O
Cdk7-cyclin-H	B-GENE
.	O

The	O
sixth	O
nucleotide	O
was	O
bulged	O
out	O
to	O
allow	O
stacking	O
of	O
this	O
U	O
.	O
G	O
pair	O
on	O
the	O
adjacent	O
helical	O
region	O
.	O

I	O
propose	O
that	O
their	O
gene	O
products	O
bind	O
to	O
the	O
chromatin	O
to	O
establish	O
or	O
maintain	O
a	O
proper	O
higher	O
order	O
structure	O
as	O
a	O
prerequisite	O
for	O
a	O
regulated	O
gene	O
expression	O
.	O

The	O
invasive	O
pattern	O
of	O
squamous	O
cell	O
carcinoma	O
in	O
the	O
mandibular	O
gingiva	O
.	O

Paraneoplastic	O
rheumatic	O
syndromes	O
.	O

The	O
distribution	O
of	O
the	O
various	O
repeats	O
suggests	O
its	O
organization	O
is	O
similar	O
to	O
the	O
beta-heterochromatic	O
regions	O
near	O
the	O
base	O
of	O
the	O
major	O
chromosome	O
arms	O
.	O

In	O
the	O
present	O
report	O
,	O
66	O
hemochromatosis	O
families	O
yielding	O
151	O
hemochromatosis	O
chromosomes	O
and	O
182	O
normal	O
chromosomes	O
were	O
RFLP-typed	O
with	O
a	O
battery	O
of	O
probes	O
,	O
including	O
two	O
newly	O
derived	O
polymorphic	O
markers	O
from	O
the	O
6	O
.	O
7	O
and	O
HLA-F	B-GENE
loci	I-GENE
located	O
150	O
and	O
250	O
kb	O
telomeric	O
to	O
HLA-A	B-GENE
,	O
respectively	O
.	O

The	O
p34	B-GENE
.	I-GENE
8	I-GENE
gene	I-GENE
has	O
a	O
strong	O
codon	O
usage	O
bias	O
which	O
is	O
strikingly	O
different	O
from	O
that	O
of	O
the	O
polyhedrin	B-GENE
gene	I-GENE
.	O

There	O
was	O
an	O
increase	O
in	O
protein	O
binding	O
onto	O
this	O
element	O
only	O
after	O
peptide	O
treatment	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
1	O
)	O
to	O
examine	O
the	O
effect	O
of	O
high	O
intensity	O
,	O
low	O
frequency	O
transcutaneous	O
electrical	O
nerve	O
stimulation	O
at	O
auricular	O
acupuncture	O
points	O
on	O
experimental	O
pain	O
threshold	O
measured	O
at	O
the	O
wrist	O
and	O
2	O
)	O
to	O
determine	O
the	O
changes	O
in	O
effect	O
over	O
time	O
.	O

The	O
chloramphenicol-resistance	B-GENE
transposon	I-GENE
Tn4451	B-GENE
undergoes	O
precise	O
conjugative	O
deletion	O
from	O
its	O
parent	O
plasmid	O
plP401	O
in	O
Clostridium	O
perfringens	O
and	O
precise	O
spontaneous	O
excision	O
from	O
multicopy	O
plasmids	O
in	O
Escherichia	O
coli	O
.	O

These	O
temperature-	O
and	O
cold-sensitive	O
strains	O
were	O
used	O
to	O
prepare	O
extracts	O
deficient	O
in	O
BRF1	B-GENE
activity	O
and	O
were	O
tested	O
for	O
transcriptional	O
activity	O
by	O
RNA	B-GENE
polymerases	I-GENE
I	I-GENE
,	I-GENE
II	I-GENE
,	I-GENE
and	I-GENE
III	I-GENE
in	O
vitro	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
GATA-5	B-GENE
performs	O
a	O
unique	O
temporally	O
and	O
spatially	O
restricted	O
function	O
in	O
the	O
embryonic	O
heart	O
and	O
lung	O
.	O

Mesial	O
temporal	O
sclerosis	O
.	O

The	O
Cili-2	B-GENE
sequences	I-GENE
possess	O
similarity	O
to	O
the	O
RNaseH	B-GENE
domain	I-GENE
of	O
Lian-Aa1	B-GENE
,	O
a	O
mosquito	O
non-LTR	O
retrotransposon	O
.	O

Whole	O
bowel	O
irrigation	O
is	O
a	O
recently	O
described	O
technique	O
to	O
enhance	O
the	O
passage	O
of	O
drugs	O
already	O
beyond	O
the	O
pylorus	O
.	O

Experiments	O
showed	O
that	O
temporary	O
arrest	O
of	O
pulmonary	O
circulation	O
under	O
conditions	O
of	O
extracorporeal	O
circulation	O
is	O
attended	O
by	O
the	O
development	O
of	O
ischemia	O
of	O
the	O
respiratory	O
pulmonary	O
tissue	O
.	O

Heterogeneous	B-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
(	I-GENE
hnRNP	I-GENE
)	I-GENE
core	I-GENE
protein	I-GENE
A1	I-GENE
is	O
a	O
major	O
component	O
of	O
mammalian	B-GENE
hnRNP	I-GENE
40	I-GENE
S	I-GENE
particles	I-GENE
.	O

Monkeys	O
were	O
evaluated	O
before	O
and	O
after	O
unilateral	O
and	O
serial	O
bilateral	O
removal	O
of	O
superior	O
temporal	O
cortex	O
.	O

Yeast	B-GENE
U1	I-GENE
snRNP	I-GENE
is	O
considerably	O
more	O
complex	O
than	O
its	O
metazoan	O
counterpart	O
,	O
which	O
suggests	O
possible	O
differences	O
between	O
yeast	O
and	O
metazoa	O
in	O
early	O
splicing	O
events	O
.	O

Plasma	O
CCK	B-GENE
levels	O
were	O
determined	O
at	O
regular	O
intervals	O
.	O

In	O
addition	O
,	O
stonin	B-GENE
2	I-GENE
binds	O
to	O
the	O
C2B	B-GENE
domains	I-GENE
of	O
synaptotagmins	B-GENE
I	I-GENE
and	I-GENE
II	O
.	O

12	O
healthy	O
women	O
(	O
age	O
18-38	O
years	O
)	O
were	O
examined	O
using	O
the	O
2-hour's	O
method	O
of	O
passive	O
leg	O
rising	O
(	O
PLR	O
)	O
in	O
follicular	O
(	O
FP	O
)	O
and	O
luteal	O
(	O
LP	O
)	O
phases	O
of	O
normal	O
ovulatory	O
cycle	O
.	O

E1A	B-GENE
represses	O
apolipoprotein	B-GENE
AI	I-GENE
enhancer	I-GENE
activity	O
in	O
liver	O
cells	O
through	O
a	O
pRb-	O
and	O
CBP-independent	O
pathway	O
.	O

RESULTS	O
:	O
Circulating	O
leptin	B-GENE
concentrations	O
in	O
AN	O
were	O
3	O
.	O
5+	O
/	O
-0	O
.	O
5	O
versus	O
7	O
.	O
6+	O
/	O
-1	O
.	O
2	O
ng	O
/	O
ml	O
in	O
control	O
subjects	O
.	O

In	O
addition	O
,	O
two	O
internal	O
promoters	O
,	O
PmiaA	B-GENE
and	O
P1hfq	B-GENE
were	O
identified	O
and	O
mapped	O
to	O
201	O
and	O
837	O
nucleotides	O
upstream	O
from	O
the	O
respective	O
translation	O
start	O
sites	O
.	O

George	O
T	O
.	O

Effects	O
of	O
alcoholism	O
on	O
the	O
family	O
.	O

These	O
results	O
were	O
superior	O
to	O
those	O
in	O
24	O
patients	O
with	O
conventional	O
end-to-end	O
sutures	O
on	O
clinical	O
testing	O
.	O

These	O
results	O
indicate	O
that	O
virulence-associated	O
genes	O
and	O
their	O
overall	O
chromosomal	O
arrangement	O
are	O
relatively	O
well	O
conserved	O
between	O
B	O
.	O
henselae	O
and	O
other	O
gram-negative	O
bacteria	O
such	O
as	O
A	O
.	O
tumefaciens	O
.	O

Effect	O
of	O
triftazin	O
and	O
aminazin	O
on	O
hippocampal	O
bioelectric	O
activity	O
.	O

TBPf	O
is	O
defined	O
as	O
a	O
quotient	O
of	O
the	O
difference	O
of	O
the	O
first	O
and	O
the	O
second	O
measurement	O
:	O
TBPf	O
=	O
(	O
P1	O
-	O
P2	O
)	O
/	O
(	O
A1	O
-	O
A2	O
)	O
.	O

Comparison	O
of	O
remnant-like	O
lipoprotein	O
particles	O
in	O
postmenopausal	O
women	O
with	O
and	O
without	O
coronary	O
artery	O
disease	O
and	O
in	O
men	O
with	O
coronary	O
artery	O
disease	O
.	O

One	O
phage	O
clone	O
contains	O
a	O
junction	O
between	O
alpha	O
satellite	O
DNA	O
and	O
a	O
novel	O
low-copy	O
repeated	O
sequence	O
.	O

The	O
yeast	B-GENE
MMS2	I-GENE
gene	I-GENE
was	O
cloned	O
by	O
its	O
ability	O
to	O
complement	O
the	O
methyl	O
methanesulfonate	O
sensitivity	O
of	O
the	O
mms2-1	B-GENE
mutant	I-GENE
and	O
was	O
later	O
shown	O
to	O
be	O
involved	O
in	O
DNA	O
post-replication	O
repair	O
.	O

Biopsies	O
of	O
the	O
jejunal	O
mucosa	O
have	O
shown	O
abnormal	O
enzyme	O
activity	O
or	O
deficiencies	O
in	O
transport	O
mechanisms	O
.	O

In	O
the	O
controls	O
,	O
it	O
was	O
found	O
that	O
all	O
right-handed	O
and	O
10	O
out	O
of	O
14	O
left-handed	O
control	O
subjects	O
showed	O
a	O
right	O
VHF	O
(	O
i	O
.	O
e	O
.	O
,	O
left	O
hemisphere	O
)	O
advantage	O
.	O

Genes	O
belonging	O
to	O
the	O
ras	B-GENE
superfamily	I-GENE
encode	O
low-molecular-weight	B-GENE
GTP	I-GENE
/	I-GENE
GDP-binding	I-GENE
proteins	I-GENE
that	O
are	O
highly	O
conserved	O
in	O
wide	O
variety	O
of	O
organisms	O
.	O

Four	O
forms	O
of	O
salmonellosis	O
were	O
recognised	O
in	O
feedlots	O
and	O
during	O
transport	O
by	O
sea	O
:	O
septicaemic	O
,	O
and	O
acute	O
,	O
subacute	O
and	O
chronic	O
enteric	O
.	O

A	O
cDNA	O
encoding	O
a	O
MYC-related	B-GENE
DNA	I-GENE
binding	I-GENE
protein	I-GENE
was	O
isolated	O
by	O
DNA-ligand	O
binding	O
screening	O
,	O
using	O
the	O
67-bp	O
region	O
as	O
a	O
probe	O
,	O
and	O
designated	O
rd22BP1	B-GENE
.	O

Two	O
phosphopeptides	O
,	O
identified	O
as	O
RS-	B-GENE
[	I-GENE
32P	I-GENE
]	I-GENE
SGASGLLTSEHHSR	I-GENE
and	O
S-	B-GENE
[	I-GENE
32P	I-GENE
]	I-GENE
SGASGLLTSEHHSR	I-GENE
,	O
were	O
obtained	O
after	O
stoichiometric	O
phosphorylation	O
and	O
trypsinization	O
of	O
the	O
peptide	O
.	O

DESIGN	O
:	O
Prospective	O
cohort	O
study	O
with	O
a	O
20	O
y	O
follow-up	O
period	O
,	O
the	O
First	O
National	O
Health	O
and	O
Examination	O
Survey	O
(	O
NHANES	O
1	O
)	O
Epidemiologic	O
Follow-up	O
Study	O
(	O
NHEFS	O
)	O
.	O

We	O
present	O
the	O
preliminary	O
results	O
obtained	O
on	O
36	O
patients	O
which	O
were	O
followed	O
for	O
a	O
mean	O
period	O
of	O
12	O
months	O
.	O

Moreover	O
,	O
expression	O
of	O
CBF1	B-GENE
in	O
yeast	O
was	O
found	O
to	O
activate	O
transcription	O
of	O
reporter	O
genes	O
containing	O
the	O
C-repeat	B-GENE
/	I-GENE
DRE	I-GENE
as	O
an	O
upstream	O
activator	O
sequence	O
but	O
not	O
mutant	O
versions	O
of	O
the	O
DNA	O
element	O
.	O

The	O
computer-programmed	O
cytocentrifuge	O
is	O
currently	O
most	O
popular	O
.	O

Levels	O
of	O
TSG-14	B-GENE
protein	I-GENE
(	O
also	O
termed	O
PTX-3	B-GENE
)	O
become	O
elevated	O
in	O
the	O
serum	O
of	O
mice	O
and	O
humans	O
after	O
injection	O
with	O
bacterial	O
lipopolysaccharide	O
,	O
but	O
in	O
contrast	O
to	O
conventional	O
acute	O
phase	O
proteins	O
,	O
the	O
bulk	O
of	O
TSG-14	B-GENE
synthesis	O
in	O
the	O
intact	O
organism	O
occurs	O
outside	O
the	O
liver	O
.	O

OBJECTIVE	O
:	O
To	O
compare	O
pregnancy	O
complications	O
in	O
women	O
having	O
genetic	O
amniocentesis	O
at	O
11-14	O
weeks	O
versus	O
those	O
undergoing	O
amniocentesis	O
at	O
16-19	O
weeks'	O
gestation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
F-wave	O
may	O
be	O
elicited	O
in	O
motoneuron	O
of	O
different	O
depolarization	O
threshold	O
but	O
primarily	O
in	O
larger	O
and	O
faster	O
nerve	O
fibers	O
,	O
with	O
a	O
lower	O
threshold	O
of	O
depolarization	O
.	O

Microcirculatory	O
oxygenation	O
and	O
shunting	O
in	O
sepsis	O
and	O
shock	O
.	O

Thus	O
,	O
the	O
characterization	O
of	O
the	O
promoter	O
region	O
should	O
help	O
to	O
define	O
regulatory	O
elements	O
that	O
control	O
neuron-specific	O
and	O
developmental	O
expression	O
of	O
the	O
MAP1B	B-GENE
gene	I-GENE
.	O

The	O
induced	O
respiratory	O
burst	O
was	O
investigated	O
by	O
the	O
intracellular	O
oxidative	O
transformation	O
of	O
dihydrorhodamine	O
123	O
to	O
the	O
fluorescent	O
dye	O
rhodamine	O
123	O
via	O
flow	O
cytometry	O
.	O

Transfection	O
of	O
non-deleted	O
expression	O
vector	O
into	O
NIH3T3	O
cells	O
results	O
in	O
acquisition	O
of	O
focus-forming	O
activity	O
while	O
a	O
deleted	O
form	O
of	O
expression	O
vector	O
fails	O
to	O
show	O
this	O
activity	O
even	O
in	O
the	O
presence	O
of	O
basic	B-GENE
FGF	I-GENE
.	O

The	O
results	O
suggest	O
that	O
the	O
bulbospinal	O
micturition	O
reflex	O
evoked	O
by	O
bladder	O
filling	O
and	O
L-dopa	O
involves	O
a	O
descending	O
pathway	O
where	O
transmission	O
is	O
partly	O
mediated	O
by	O
spinal	B-GENE
alpha	I-GENE
1-adrenoceptors	I-GENE
.	O

Although	O
isl-1	B-GENE
binds	O
to	O
both	O
the	O
insulin	B-GENE
and	O
amylin	B-GENE
gene	I-GENE
promoter	I-GENE
elements	I-GENE
in	O
vitro	O
,	O
these	O
sequences	O
display	O
marked	O
differences	O
in	O
their	O
relative	O
transcriptional	O
properties	O
when	O
ligated	O
adjacent	O
to	O
a	O
heterologous	O
promoter	O
and	O
transfected	O
into	O
InR1	O
-G9	O
islet	O
cells	O
.	O

RESULTS	O
:	O
The	O
subjects	O
in	O
the	O
augmented	O
feedback	O
group	O
significantly	O
reduced	O
their	O
peak	O
vertical	O
ground	O
reaction	O
force	O
in	O
both	O
post-test	O
conditions	O
(	O
2-minute	O
post-test	O
reduction	O
,	O
0	O
.	O
85+	O
/	O
-0	O
.	O
62	O
;	O
1-week	O
post-test	O
reduction	O
,	O
0	O
.	O
74+	O
/	O
-0	O
.	O
58	O
)	O
as	O
compared	O
to	O
the	O
sensory	O
,	O
control	O
I	O
,	O
and	O
control	O
II	O
feedback	O
groups	O
.	O

Study	O
of	O
antinuclear	B-GENE
autoantibodies	I-GENE
by	O
immunofluorescence	O
technic	O
in	O
collagen	B-GENE
diseases	O
.	O

PNT	O
,	O
ADD	O
and	O
BSS	O
in	O
the	O
initial	O
stage	O
of	O
kindling	O
,	O
kindling	O
rate	O
for	O
the	O
stage-3	O
and	O
-5	O
seizures	O
,	O
seizure	O
parameters	O
at	O
the	O
first	O
stage-3	O
and	O
-5	O
were	O
recorded	O
and	O
compared	O
to	O
the	O
values	O
of	O
saline-treated	O
,	O
control	O
group	O
.	O

Effects	O
of	O
negative	O
pleural	O
pressure	O
on	O
left	O
ventricular	O
hemodynamics	O
.	O

These	O
data	O
indicate	O
that	O
RNK-Met-1	B-GENE
is	O
a	O
serine	B-GENE
protease	I-GENE
with	O
unique	O
activity	O
that	O
is	O
expressed	O
in	O
the	O
granules	O
of	O
large	O
granular	O
lymphocytes	O
.	O

No	O
effect	O
of	O
the	O
intervention	O
on	O
depression	O
scores	O
was	O
found	O
.	O

Ruddell	O
,	O
M	O
.	O

Rigid	O
point	O
feature	O
registration	O
using	O
mutual	O
information	O
.	O

Together	O
,	O
these	O
results	O
identify	O
HPK1	B-GENE
as	O
a	O
new	O
component	O
of	O
TCR	B-GENE
signaling	O
.	O

Nine	O
cases	O
of	O
GBS	O
and	O
five	O
of	O
TM	O
reported	O
to	O
the	O
active	O
AFP	O
surveillance	O
were	O
not	O
found	O
in	O
the	O
hospital	O
searches	O
.	O

The	O
B-oligomer	O
of	O
pertussis	B-GENE
toxin	I-GENE
deactivates	O
CC	B-GENE
chemokine	I-GENE
receptor	I-GENE
5	I-GENE
and	O
blocks	O
entry	O
of	O
M-tropic	O
HIV-1	O
strains	O
.	O

The	O
mass-specific	O
resting	O
minute	O
ventilation	O
(	O
E	O
)	O
and	O
the	O
ventilatory	O
equivalent	O
(	O
E	O
/	O
(	O
O	O
(	O
2	O
)	O
)	O
)	O
were	O
approximately	O
the	O
same	O
at	O
the	O
two	O
ages	O
,	O
with	O
a	O
breathing	O
pattern	O
significantly	O
deeper	O
and	O
slower	O
at	O
day	O
1	O
.	O

Forty	O
4-month	O
old	O
SD	O
female	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
,	O
namely	O
sham	O
operation	O
,	O
bilateral	O
ovariectomy	O
,	O
ovariectomy	O
plus	O
supplementary	O
ethinyl	O
estradiol	O
(	O
0	O
.	O
2	O
microgram	O
/	O
100	O
g	O
B	O
.	O

The	O
different	O
holoenzyme	B-GENE
RNA	I-GENE
polymerases	I-GENE
generated	O
upon	O
reconstituting	O
these	O
mutants	O
independently	O
with	O
core	B-GENE
RNA	I-GENE
polymerase	I-GENE
(	O
alpha2beta	B-GENE
beta'	I-GENE
)	O
have	O
shown	O
reduced	O
transcriptional	O
activity	O
in	O
comparison	O
to	O
the	O
enzyme	O
containing	O
wild-type	B-GENE
sigma	I-GENE
factor	I-GENE
.	O

Thyrotropin-releasing	O
hormone-induced	O
contraction	O
of	O
urethral	O
and	O
vaginal	O
muscle	O
.	O

Contacts	O
between	O
Bacillus	O
subtilis	O
catabolite	O
regulatory	O
protein	O
CcpA	B-GENE
and	O
amyO	B-GENE
target	O
site	O
.	O

Thus	O
,	O
the	O
tri-snRNP-specific	B-GENE
27K	I-GENE
protein	I-GENE
could	O
potentially	O
be	O
involved	O
in	O
SR	B-GENE
protein-mediated	O
protein	O
/	O
protein	O
interactions	O
and	O
,	O
additionally	O
,	O
its	O
phosphorylation	O
state	O
could	O
modulate	O
pre-mRNA	O
splicing	O
.	O

Tcn1p	B-GENE
/	I-GENE
Crz1p	I-GENE
,	O
a	O
calcineurin-dependent	O
transcription	O
factor	O
that	O
differentially	O
regulates	O
gene	O
expression	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

A	O
comparison	O
of	O
the	O
Flavobacterium	O
glycosylasparaginase	B-GENE
with	O
a	O
mammalian	O
glycosylasparaginase	B-GENE
revealed	O
30%	O
structural	O
identity	O
and	O
60%	O
overall	O
similarity	O
between	O
the	O
prokaryotic	O
and	O
eukaryotic	O
forms	O
of	O
the	O
enzyme	O
.	O

This	O
region	O
,	O
however	O
,	O
contains	O
a	O
CCAATC	O
box	O
in	O
the	O
reverse	O
complement	O
and	O
several	O
GC	O
boxes	O
that	O
are	O
recognition	O
sites	O
for	O
SP1	B-GENE
.	O

Furthermore	O
,	O
the	O
amount	O
of	O
tRNA	B-GENE
(	I-GENE
3Lys	I-GENE
)	I-GENE
that	O
was	O
placed	O
onto	O
viral	O
RNA	O
in	O
mutated	O
viruses	O
was	O
significantly	O
less	O
than	O
that	O
placed	O
in	O
the	O
wild-type	O
virus	O
.	O

All	O
62	O
isolates	O
were	O
resistant	O
to	O
lincomycin	O
,	O
colistin	O
,	O
nystatin	O
,	O
amphotericin	O
B	O
,	O
trimethoprim	O
lactate	O
,	O
polymyxin	O
B	O
,	O
and	O
anisomycin	O
.	O

However	O
,	O
in	O
a	O
new	O
experiment	O
in	O
which	O
the	O
deletion	O
task	O
was	O
presented	O
as	O
a	O
puppet	O
game	O
,	O
and	O
with	O
pretraining	O
and	O
selection	O
on	O
vowel	O
deletion	O
,	O
a	O
significantly	O
higher	O
level	O
of	O
success	O
was	O
achieved	O
by	O
the	O
children	O
working	O
with	O
the	O
CVCC	O
material	O
.	O

These	O
results	O
indicate	O
that	O
significant	O
pulmonary	O
metabolism	O
of	O
5-HT	O
followed	O
by	O
efflux	O
of	O
5-HIAA	O
into	O
venous	O
output	O
occurs	O
during	O
single-pass	O
circulation	O
.	O

Thirty	O
seven	O
patients	O
(	O
amitriptyline	O
n	O
=	O
16	O
,	O
moclobemide	O
n	O
=	O
21	O
)	O
completed	O
the	O
six	O
week	O
protocol	O
,	O
which	O
was	O
conducted	O
under	O
double	O
blind	O
conditions	O
.	O

Evidence	O
for	O
the	O
promoting	O
role	O
of	O
the	O
intra-uterine	B-GENE
kinin	I-GENE
release	O
in	O
the	O
development	O
of	O
late	O
hypertonic	O
saline-induced	O
abortion	O
.	O

Cross-linking	O
FcalphaR	B-GENE
on	O
wt-ITAM	B-GENE
or	O
IIA-ITAM	B-GENE
cells	O
triggered	O
equivalent	O
PI	O
3-kinase-dependent	O
activation	O
of	O
PKBalpha	B-GENE
.	O

Characterization	O
of	O
a	O
human	B-GENE
alternatively	I-GENE
spliced	I-GENE
truncated	I-GENE
reduced	I-GENE
folate	I-GENE
carrier	I-GENE
increasing	O
folate	O
accumulation	O
in	O
parental	O
leukemia	O
cells	O
.	O

We	O
conclude	O
that	O
cephalothin	O
clearance	O
of	O
S	O
.	O
aureus	O
from	O
a	O
site	O
accessible	O
to	O
phagocytes	O
was	O
delayed	O
when	O
compared	O
to	O
a	O
phagocyte-inaccessible	O
site	O
.	O

Recently	O
,	O
we	O
discovered	O
that	O
alanine	O
substitutions	O
of	O
the	O
active	O
center	O
cleft	O
residues	O
significantly	O
impair	O
the	O
depurinating	O
and	O
ribosome	O
inhibitory	O
activity	O
of	O
PAP	B-GENE
.	O

The	O
decrements	O
in	O
cerebrovascular	O
resistance	O
induced	O
by	O
hexamethonium	O
,	O
in	O
mm	O
Hg	O
ml	O
(	O
-1	O
)	O
.	O
min	O
(	O
-1	O
)	O
,	O
were	O
:	O
under	O
control	O
.	O

The	O
resulting	O
integrated	O
physical	O
,	O
genetic	O
,	O
and	O
cytogenetic	O
map	O
constitutes	O
a	O
resource	O
for	O
the	O
characterization	O
of	O
genes	O
that	O
may	O
be	O
involved	O
in	O
the	O
WAGR	O
syndrome	O
.	O

Umweltchem	O
.	O

In	O
Experiment	O
2	O
,	O
we	O
again	O
used	O
classification	O
,	O
but	O
the	O
fixed	O
standard	O
75	O
was	O
not	O
at	O
the	O
center	O
of	O
the	O
range	O
of	O
target	O
numbers	O
(	O
20	O
,	O
21	O
,	O
.	O
.	O
.	O

Leukemia	O
in	O
twins	O
:	O
world-wide	O
review	O
of	O
clinical	O
cases	O
.	O

The	O
TUP1	B-GENE
gene	I-GENE
was	O
isolated	O
in	O
a	O
screen	O
for	O
genes	O
that	O
regulate	O
mating	O
type	O
(	O
V	O
.	O
L	O
.	O

The	O
Caenorhabditis	B-GENE
elegans	I-GENE
death	I-GENE
susceptibility	I-GENE
gene	I-GENE
,	O
ced-3	B-GENE
,	O
has	O
a	O
number	O
of	O
homologs	O
in	O
vertebrate	O
species	O
,	O
including	O
interleukin-1	B-GENE
beta	I-GENE
(	I-GENE
IL-1	I-GENE
beta	I-GENE
)	I-GENE
-converting	I-GENE
enzyme	I-GENE
(	O
ICE	B-GENE
)	O
,	O
Ich-1long	B-GENE
,	O
and	O
CPP32	B-GENE
.	O

RPS14	B-GENE
introns	O
3	O
and	O
4	O
both	O
contain	O
Alu	B-GENE
sequences	I-GENE
.	O

Transcription	O
factors	O
of	O
the	O
Stat	B-GENE
family	I-GENE
are	O
controlled	O
by	O
protein	B-GENE
kinases	I-GENE
.	O

A	O
novel	O
,	O
testis-specific	B-GENE
mRNA	I-GENE
transcript	I-GENE
encoding	O
an	O
NH2-terminal	B-GENE
truncated	I-GENE
nitric-oxide	I-GENE
synthase	I-GENE
.	O
mRNA	O
diversity	O
represents	O
a	O
major	O
theme	O
of	O
neuronal	B-GENE
nitric-oxide	I-GENE
synthase	I-GENE
(	O
nNOS	B-GENE
)	O
gene	O
expression	O
in	O
somatic	O
cells	O
/	O
tissues	O
.	O

The	O
isoform	O
,	O
designated	O
HDAC9a	B-GENE
,	O
is	O
132	O
aa	O
shorter	O
at	O
the	O
C	O
terminus	O
than	O
HDAC9	B-GENE
.	O

The	O
ESEG's	O
are	O
a	O
direct	O
result	O
of	O
the	O
NEXT	O
study	O
.	O

Body	O
temperature	O
and	O
overall	O
conductance	O
in	O
the	O
cold	O
appear	O
to	O
be	O
more	O
variable	O
in	O
P	O
.	O
s	O
.	O
campbelli	O
than	O
in	O
nominative	O
sp	O
.	O

After	O
6	O
months	O
,	O
definite	O
improvement	O
in	O
strength	O
occurred	O
in	O
4	O
of	O
7	O
carnitine-treated	O
patients	O
and	O
in	O
none	O
of	O
7	O
controls	O
.	O

Fifty-seven	O
patients	O
aged	O
<	O
55	O
years	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
in	O
second	O
or	O
third	O
bone	O
marrow	O
(	O
BM	O
)	O
relapse	O
or	O
refractory	O
to	O
first-line	O
therapy	O
were	O
enrolled	O
in	O
an	O
Italian	O
cooperative	O
study	O
.	O

After	O
gamma-irradiation	O
,	O
the	O
majority	O
of	O
F9	O
cells	O
undergo	O
apoptosis	O
implying	O
that	O
wt-p53	B-GENE
likely	O
triggers	O
pro-apoptotic	O
gene	O
expression	O
in	O
DNA	O
damaged	O
cells	O
.	O

While	O
fusion	O
to	O
the	O
N-terminus	O
required	O
a	O
linker	O
to	O
become	O
surface	O
accessible	O
,	O
both	O
fusion	O
to	O
the	O
N-terminus	O
and	O
to	O
the	O
C-terminus	O
was	O
compatible	O
with	O
particle	O
assembly	O
and	O
preserved	O
the	O
native	O
antigenicity	O
and	O
immunogenicity	O
of	O
HBcAg	B-GENE
.	O

Studies	O
have	O
substantiated	O
the	O
involvement	O
of	O
numerous	O
loci	O
on	O
certain	O
chromosomes	O
;	O
in	O
excess	O
of	O
10	O
chromosomes	O
are	O
thought	O
to	O
be	O
involved	O
.	O

Grade	O
3	O
mucositis	O
was	O
reported	O
in	O
1	O
patient	O
.	O

Multiparous	O
women	O
presented	O
higher	O
BMI	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
PBF	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
compared	O
with	O
primi-	O
and	O
nulliparous	O
groups	O
.	O

Isolation	O
by	O
PCR	O
of	O
a	O
cDNA	O
clone	O
from	O
pea	O
petals	O
with	O
similarity	O
to	O
petunia	O
and	O
wheat	B-GENE
zinc	I-GENE
finger	I-GENE
proteins	I-GENE
.	O

Gastritis	O
score	O
was	O
significantly	O
lower	O
in	O
nodminus	O
sign	O
/	O
CagAminus	O
signchildren	O
than	O
in	O
nod+	O
/	O
CagAminus	O
sign	O
(	O
p	O
=	O
.	O
004	O
)	O
,	O
nodminus	O
sign	O
/	O
CagA+	O
(	O
p	O
=	O
.	O
002	O
)	O
and	O
nod+	O
/	O
CagA+	O
(	O
p	O
<	O
.	O
001	O
)	O
,	O
both	O
in	O
the	O
antrum	O
and	O
corpus	O
.	O

We	O
found	O
no	O
correlation	O
between	O
plasma	O
COP	O
and	O
body	O
weight	O
at	O
the	O
same	O
age	O
(	O
r2	O
=	O
0	O
.	O
05	O
,	O
P	O
=	O
0	O
.	O
155	O
)	O
.	O

The	O
227-to-239	O
region	O
blocked	O
ADR1	B-GENE
activity	O
independently	O
of	O
the	O
TAD	B-GENE
present	O
on	O
ADR1	B-GENE
,	O
ADR1	B-GENE
DNA	O
binding	O
,	O
and	O
specific	O
ADH2	B-GENE
promoter	I-GENE
sequences	I-GENE
.	O

A	O
polypeptide	O
chain	O
of	O
34	O
residues	O
of	O
the	O
deduced	O
yeast	O
amino	O
acid	O
sequence	O
closely	O
resembles	O
a	O
peptide	O
sequence	O
at	O
the	O
ADP	O
binding	O
site	O
of	O
bovine	B-GENE
muscle	I-GENE
pyruvate	I-GENE
kinase	I-GENE
.	O

The	O
enzymic	O
hydrolysis	O
of	O
urea	O
produces	O
ammonia	O
which	O
causes	O
a	O
vivid	O
yellow	O
to	O
purple	O
colour	O
change	O
in	O
the	O
pH	O
indicator	O
.	O

ZIOS	O
was	O
significantly	O
more	O
sensitive	O
than	O
all	O
subsequent	O
methods	O
,	O
and	O
Ptc	O
,	O
O2	O
was	O
significantly	O
more	O
sensitive	O
than	O
FEV1	O
.	O

In	O
contrast	O
,	O
the	O
MAN	O
showed	O
a	O
unimodal	O
,	O
skewed	O
distribution	O
,	O
with	O
a	O
range	O
from	O
approximately	O
1	O
to	O
14	O
micron	O
and	O
a	O
maximum	O
at	O
3-4	O
micron	O
.	O

Nuclear	B-GENE
hormone	I-GENE
receptors	I-GENE
(	O
NRs	B-GENE
)	O
are	O
ligand-inducible	O
transcription	O
factors	O
that	O
mediate	O
critical	O
functions	O
in	O
many	O
species	O
.	O

OBJECTIVES	O
:	O
The	O
objective	O
of	O
this	O
review	O
was	O
to	O
assess	O
the	O
effects	O
of	O
prophylactic	O
prostaglandin	O
use	O
in	O
the	O
third	O
stage	O
of	O
labour	O
.	O

Ethylene	O
is	O
involved	O
in	O
endosperm	O
rupture	O
and	O
high-level	O
betaGLU	B-GENE
I	I-GENE
expression	O
;	O
but	O
,	O
it	O
does	O
not	O
affect	O
the	O
spatial	O
and	O
temporal	O
pattern	O
of	O
betaGLU	B-GENE
I	I-GENE
expression	O
.	O

The	O
presence	O
of	O
visna-maedi	O
in	O
Italy	O
is	O
reported	O
for	O
the	O
first	O
time	O
.	O

Derivatives	O
of	O
fluorene	O
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor-suppressor	B-GENE
protein	I-GENE
pRb	I-GENE
,	O
the	O
G1	B-GENE
cyclins	I-GENE
,	O
the	O
cyclin-dependent	B-GENE
kinases	I-GENE
,	O
and	O
their	O
inhibitors	O
.	O

Fast	O
continuous	O
expansion	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
the	O
GA-binding	B-GENE
protein	I-GENE
(	O
GABP	B-GENE
)	O
to	O
ets	B-GENE
sequence	I-GENE
motifs	I-GENE
within	O
each	O
repeated	O
unit	O
is	O
required	O
for	O
transcriptional	O
activation	O
of	O
the	O
COXIV	B-GENE
promoter	I-GENE
.	O

(	O
1997	O
)	O
Science	O
275	O
,	O
1927-1930	O
)	O
.	O

No	O
patient	O
with	O
bradyarrhythmia	O
-related	O
SCD	O
had	O
manifest	O
atrioventricular	O
block	O
or	O
bundle	O
branch	O
block	O
.	O

Overall	O
,	O
these	O
findings	O
demonstrate	O
that	O
mutations	O
E768D	O
and	O
V804L	O
are	O
gain-of-function	O
mutations	O
that	O
confer	O
to	O
the	O
long	B-GENE
RET	I-GENE
isoform	I-GENE
the	O
capacity	O
to	O
exert	O
a	O
biological	O
effect	O
,	O
although	O
these	O
mutations	O
are	O
more	O
weakly	O
activating	O
than	O
the	O
MEN2A	B-GENE
and	O
MEN2B	B-GENE
mutations	O
.	O

Several	O
of	O
the	O
exon	O
boundaries	O
correspond	O
to	O
the	O
boundaries	O
of	O
functional	O
domains	O
in	O
the	O
p55	B-GENE
protein	I-GENE
.	O

HS	O
inducibility	O
required	O
the	O
HSE	B-GENE
which	O
was	O
bound	O
by	O
HS	B-GENE
transcription	I-GENE
factor-1	I-GENE
(	I-GENE
HSF-1	I-GENE
)	I-GENE
present	O
in	O
extracts	O
prepared	O
from	O
cells	O
exposed	O
to	O
HS	O
.	O

Comprehensive	O
care	O
of	O
the	O
patient	O
exposed	O
to	O
a	O
human	O
teratogen	O
may	O
also	O
include	O
discussion	O
of	O
prenatal	O
diagnostic	O
procedures	O
and	O
other	O
pregnancy	O
management	O
options	O
.	O

The	O
avidin-biotin	B-GENE
complex	I-GENE
peroxidase	I-GENE
(	O
ABC-P	B-GENE
)	O
method	O
was	O
used	O
to	O
detect	O
Mycobacterium	O
bovis	O
,	O
and	O
the	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
by	O
the	O
Ziehl-Neelsen	O
(	O
ZN	O
)	O
technique	O
.	O

Therefore	O
,	O
both	O
the	O
Chilean	O
and	O
the	O
Japanese	O
samples	O
collected	O
in	O
high-risk	O
areas	O
showed	O
higher	O
mutagenic	O
rates	O
than	O
the	O
Japanese	O
ones	O
in	O
a	O
low-risk	O
area	O
,	O
with	O
a	O
statistical	O
significance	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
chi-square	O
test	O
)	O
.	O

Counter-current	O
heat	O
exchange	O
in	O
the	O
respiratory	O
passages	O
:	O
effect	O
on	O
water	O
and	O
heat	O
balance	O
.	O

Both	O
mutant	O
receptors	O
were	O
expressed	O
on	O
the	O
cell	O
surface	O
and	O
bound	O
insulin	B-GENE
normally	O
,	O
but	O
showed	O
markedly	O
impaired	O
autophosphorylation	O
in	O
response	O
to	O
insulin	B-GENE
.	O

Marked	O
sedative	O
activity	O
was	O
observed	O
with	O
9-methoxy-5-phenylpyrrolo	O
[	O
2	O
,	O
1-d	O
]	O
[	O
1	O
,	O
5	O
]	O
benzothiazepin-6	O
,	O
6-dioxide	O
(	O
NF19	O
)	O
and	O
9-chloro-5-p-nitrophenylpyrrolo	O
[	O
2	O
,	O
1-d	O
]	O
[	O
1	O
,	O
5	O
]	O
benzothiazepin-6	O
,	O
6-dioxide	O
(	O
NF20	O
)	O
.	O

A	O
second	O
,	O
novel	O
C	B-GENE
subunit	I-GENE
(	O
CeCAT	B-GENE
alpha'	I-GENE
,	O
374	O
residues	O
)	O
has	O
a	O
unique	O
56-residue	O
carboxyl-terminal	O
region	O
that	O
is	O
generated	O
by	O
the	O
alternative	O
splicing	O
of	O
the	O
C	B-GENE
pre-mRNA	I-GENE
.	O

The	O
mouse	O
extracellular	B-GENE
signal-regulated	I-GENE
kinase	I-GENE
2	I-GENE
gene	I-GENE
.	O

Interaction	O
of	O
H-2Eb	B-GENE
with	O
an	O
IAP	B-GENE
retrotransposon	I-GENE
in	O
the	O
A20	O
/	O
2J	O
B	O
cell	O
lymphoma	O
.	O

The	O
Lp	B-GENE
mouse	I-GENE
mutant	I-GENE
provides	O
a	O
model	O
for	O
the	O
severe	O
human	O
neural	O
tube	O
defect	O
(	O
NTD	O
)	O
,	O
cranio-rachischisis	O
.	O

These	O
effects	O
were	O
not	O
seen	O
with	O
SHIP2	B-GENE
possessing	O
a	O
mutation	O
in	O
the	O
SH2	B-GENE
domain	I-GENE
(	O
R47G	B-GENE
)	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
vitamin	B-GENE
D	I-GENE
response	I-GENE
element	I-GENE
(	O
VDRE	B-GENE
)	O
in	O
the	O
promoter	O
of	O
c-fos	B-GENE
.	O

Plasma	O
concentrations	O
of	O
atracurium	O
and	O
laudanosine	O
were	O
0	O
.	O
73-3	O
.	O
11	O
micrograms	O
ml-1	O
and	O
0	O
.	O
48-8	O
.	O
65	O
micrograms	O
ml-1	O
,	O
respectively	O
;	O
CSF	O
concentration	O
of	O
laudanosine	O
was	O
70-440	O
ng	O
ml-1	O
.	O

These	O
findings	O
suggest	O
that	O
intraarterial	O
neoadjuvant	O
chemotherapy	O
should	O
be	O
effective	O
on	O
advanced	O
cervical	O
cancer	O
.	O

Distinguishing	O
roles	O
of	O
the	O
membrane-cytoskeleton	O
and	O
cadherin	B-GENE
mediated	O
cell-cell	O
adhesion	O
in	O
generating	O
different	O
Na+	B-GENE
,	I-GENE
K	I-GENE
(	I-GENE
+	I-GENE
)	I-GENE
-ATPase	I-GENE
distributions	O
in	O
polarized	O
epithelia	O
.	O

These	O
results	O
suggest	O
that	O
gluconeogenic	O
genes	O
are	O
derepressed	O
upon	O
binding	O
of	O
Cat8p	B-GENE
,	O
whose	O
synthesis	O
depends	O
on	O
the	O
release	O
of	O
Cat4p	B-GENE
(	O
Mig1p	B-GENE
)	O
from	O
the	O
CAT8	B-GENE
promoter	I-GENE
.	O

We	O
failed	O
to	O
find	O
these	O
data	O
to	O
be	O
useful	O
in	O
predicting	O
the	O
time	O
of	O
onset	O
of	O
initial	O
seizures	O
after	O
acute	O
ischemic	O
stroke	O
and	O
recurrence	O
.	O

The	O
interaction	O
of	O
AF-1	B-GENE
with	O
proteins	O
that	O
regulate	O
distinct	O
steps	O
of	O
transcription	O
may	O
provide	O
a	O
mechanism	O
for	O
synergistic	O
activation	O
of	O
gene	O
expression	O
by	O
AF-1	B-GENE
.	O

The	O
N-terminal	O
portion	O
of	O
Notch	B-GENE
(	I-GENE
IC	I-GENE
)	I-GENE
inhibited	O
p50	B-GENE
DNA	O
binding	O
and	O
interacted	O
specifically	O
with	O
p50	B-GENE
subunit	I-GENE
,	O
not	O
p65	B-GENE
of	O
NF-kappaB	B-GENE
.	O

2	O
cases	O
of	O
type	O
II	O
tyrosinosis	O
(	O
Richner-Hanhart	O
syndrome	O
)	O
.	O

Expression	O
of	O
the	O
human	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
(	I-GENE
TCR	I-GENE
)	I-GENE
alpha	I-GENE
gene	I-GENE
is	O
regulated	O
by	O
a	O
T	O
cell-specific	O
transcriptional	O
enhancer	O
that	O
is	O
located	O
4	O
.	O
5	O
kilobases	O
(	O
kb	O
)	O
3'	O
to	O
the	O
C	B-GENE
alpha	I-GENE
gene	I-GENE
segment	I-GENE
.	O

Each	O
group	O
received	O
15	O
ml	O
/	O
kg	O
of	O
either	O
6%	O
pentafraction	O
,	O
6%	O
pentastarch	O
,	O
or	O
plasma	O
followed	O
two	O
hours	O
later	O
by	O
1	O
.	O
5	O
micrograms	O
/	O
kg	O
/	O
0	O
.	O
5	O
hr	O
E	O
.	O

Infectious	O
mutant	O
virus	O
progeny	O
was	O
obtained	O
only	O
on	O
complementing	O
gK-expressing	O
cells	O
,	O
suggesting	O
that	O
gK	B-GENE
has	O
an	O
important	O
function	O
in	O
the	O
replication	O
cycle	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
in	O
the	O
region	O
of	O
the	O
specificity	O
pocket	O
is	O
similar	O
to	O
that	O
of	O
S	B-GENE
.	I-GENE
griseus	I-GENE
proteases	I-GENE
A	I-GENE
,	I-GENE
B	I-GENE
,	I-GENE
and	I-GENE
C	O
.	O

The	O
prevalence	O
and	O
incidence	O
of	O
human	O
immunodeficiency	O
virus	O
types	O
1	O
and	O
2	O
(	O
HIV-1	O
,	O
HIV-2	O
)	O
,	O
human	O
T-lymphotropic	O
virus	O
types	O
I	O
and	O
II	O
(	O
HTLV-I	O
/	O
II	O
)	O
,	O
and	O
syphilitic	O
infections	O
and	O
the	O
association	O
between	O
these	O
infections	O
were	O
determined	O
in	O
a	O
cohort	O
of	O
police	O
officers	O
in	O
Guinea-Bissau	O
.	O

As	O
expected	O
,	O
the	O
heparin	O
did	O
produce	O
increased	O
recalcification	O
times	O
and	O
the	O
development	O
of	O
occasional	O
subcutaneous	O
hematomas	O
.	O

The	O
partial	O
ORF	O
was	O
found	O
to	O
be	O
identical	O
to	O
the	O
C	O
terminus	O
of	O
HrpJ2	B-GENE
.	O

Expression	O
of	O
thiamin	B-GENE
biosynthetic	I-GENE
genes	I-GENE
(	O
thiCOGE	B-GENE
)	O
and	O
production	O
of	O
symbiotic	B-GENE
terminal	I-GENE
oxidase	I-GENE
cbb3	I-GENE
in	O
Rhizobium	O
etli	O
.	O

In	O
this	O
regard	O
,	O
we	O
have	O
recently	O
observed	O
that	O
a	O
constitutively	O
active	O
G	B-GENE
protein-coupled	I-GENE
receptor	I-GENE
(	O
GPCR	B-GENE
)	O
encoded	O
by	O
the	O
Kaposi's	O
sarcoma-associated	O
herpes	O
virus	O
(	O
KSHV	O
)	O
/	O
human	O
herpes	O
virus	O
8	O
is	O
oncogenic	O
and	O
stimulates	O
angiogenesis	O
by	O
increasing	O
the	O
secretion	O
of	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
(	O
VEGF	B-GENE
)	O
,	O
which	O
is	O
a	O
key	O
angiogenic	O
stimulator	O
and	O
a	O
critical	O
mitogen	O
for	O
the	O
development	O
of	O
Kaposi's	O
sarcoma	O
.	O

Selected	O
topics	O
in	O
laboratory	O
animal	O
medicine	O
.	O

II	O
.	O

These	O
results	O
suggest	O
that	O
leader-mRNA	O
fusion	O
in	O
coronavirus	O
transcription	O
does	O
not	O
require	O
direct	O
RNA-RNA	O
interaction	O
between	O
complementary	O
sequences	O
.	O

These	O
regions	O
may	O
be	O
differentially	O
involved	O
in	O
tissue-specificity	O
,	O
and	O
/	O
or	O
circadian	O
regulation	O
,	O
of	O
the	O
human	B-GENE
hPer1	I-GENE
gene	I-GENE
transcription	O
.	O

Polyclonal	O
antiserum	O
generated	O
to	O
the	O
fusion	O
protein	O
was	O
capable	O
of	O
detecting	O
42-	O
and	O
46-kilodalton	O
polypeptides	O
from	O
virus	O
particles	O
;	O
both	O
polypeptides	O
were	O
also	O
shown	O
to	O
contain	O
HBsAg	B-GENE
determinants	I-GENE
.	O

The	O
LA	O
50s	O
derived	O
from	O
this	O
combined	O
data	O
when	O
compared	O
with	O
our	O
earlier	O
series	O
from	O
1965	O
to	O
1970	O
also	O
did	O
not	O
show	O
a	O
significant	O
change	O
in	O
mortality	O
.	O

The	O
amount	O
of	O
drained	O
effusion	O
was	O
measured	O
,	O
and	O
fluid	O
was	O
sent	O
for	O
diagnostic	O
assessment	O
.	O

Since	O
sildenafil	O
came	O
on	O
the	O
market	O
,	O
it	O
seems	O
that	O
the	O
place	O
of	O
MUSE	O
is	O
reduced	O
because	O
comparative	O
studies	O
give	O
better	O
results	O
for	O
sildenafil	O
than	O
MUSE	O
(	O
70%	O
vs	O
40%	O
)	O
and	O
of	O
course	O
with	O
a	O
better	O
acceptance	O
.	O

Asymptomatic	O
bacteriospermia	O
and	O
fertility	O
.	O

There	O
was	O
no	O
difference	O
in	O
plasma	O
concentrations	O
of	O
PGI2	O
(	O
figure	O
4	O
)	O
and	O
TxA2	O
in	O
patients	O
with	O
normal	O
blood	O
pressure	O
,	O
mild	O
preeclampsia	O
and	O
hypotension	O
,	O
whereas	O
in	O
severe	O
preeclampsia	O
,	O
the	O
plasma	O
concentration	O
of	O
PGI2	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
of	O
TxA2	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Labial	O
bar	O
.	O

Reperfusion	O
with	O
normal	O
blood	O
in	O
the	O
beating	O
,	O
working	O
hearts	O
caused	O
extensive	O
structural	O
damage	O
,	O
reduced	O
reflow	O
,	O
and	O
failed	O
to	O
restore	O
contractility	O
in	O
any	O
instance	O
(	O
-27%	O
systolic	O
shortening	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

By	O
sequence	O
comparison	O
,	O
42	O
blocks	O
of	O
homology	O
are	O
defined	O
in	O
the	O
5'-terminal	O
region	O
,	O
of	O
which	O
36	O
appear	O
in	O
the	O
CpG	O
island	O
and	O
contain	O
numerous	O
conserved	O
CpG	O
dinucleotides	O
.	O

GCD10	B-GENE
was	O
first	O
identified	O
genetically	O
as	O
a	O
translational	O
repressor	O
of	O
GCN4	B-GENE
.	O

Analysis	O
of	O
a	O
Mac1p	B-GENE
mutant	I-GENE
,	O
refractile	O
for	O
copper-dependent	O
repression	O
of	O
the	O
Cu	B-GENE
(	I-GENE
I	I-GENE
)	I-GENE
transport	I-GENE
genes	I-GENE
,	O
showed	O
an	O
aberrant	O
pattern	O
of	O
CUP1	B-GENE
expression	O
and	O
copper	O
sensitivity	O
.	O

French	O
,	O
M	O
.	O

Stromelysin-1	B-GENE
,	O
matrix	B-GENE
metalloproteinase-3	I-GENE
(	O
MMP-3	B-GENE
)	O
,	O
is	O
an	O
important	O
endopeptidase	B-GENE
selectively	O
expressed	O
by	O
somatic	O
cells	O
in	O
organ	O
tissues	O
.	O

Ficat	O
and	O
Bizou's	O
condylar	O
depth	O
index	O
and	O
the	O
condylar-joint	O
surface	O
angle	O
of	O
Brattstrom	O
are	O
recommended	O
as	O
especially	O
suitable	O
methods	O
of	O
measurement	O
.	O

A	O
soap	O
and	O
water	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
solution	O
effectively	O
decontaminated	O
powdered	O
stratum	O
corneum	O
.	O

Each	O
repeat	O
consists	O
of	O
12	O
nt	O
,	O
coding	O
for	O
the	O
reiterated	O
sequence	O
,	O
K	B-GENE
/	I-GENE
NPAG	I-GENE
.	O

Purification	O
of	O
MvaT	B-GENE
enriched	O
for	O
two	O
polypeptides	O
of	O
approximate	O
molecular	O
mass	O
15	O
kDa	O
and	O
16	O
kDa	O
,	O
designated	O
P15	B-GENE
and	O
P16	B-GENE
.	O

The	O
Asian	O
mouse	O
Mus	O
castaneus	O
is	O
resistant	O
to	O
infection	O
by	O
the	O
polytropic	O
mink	O
cell	O
focus-inducing	O
(	O
MCF	O
)	O
subgroup	O
of	O
murine	O
leukemia	O
viruses	O
(	O
MuLVs	O
)	O
.	O

AB004534	B-GENE
.	O

The	O
10	O
kDa	O
polypeptide	O
was	O
phosphorylated	O
in	O
vitro	O
by	O
incubating	O
wheat	O
etioplast	O
membranes	O
with	O
[	O
gamma	O
32P	O
]	O
ATP	O
.	O

The	O
RMRI	O
was	O
tested	O
for	O
interrater	O
reliability	O
using	O
three	O
simulated	O
and	O
10	O
actual	O
patients	O
.	O

The	O
rat	O
incisor	O
is	O
an	O
excellent	O
model	O
system	O
in	O
which	O
to	O
study	O
amelgenesis	O
.	O

Haploid	O
cells	O
of	O
mating	O
type	O
A	O
of	O
the	O
basidiomycetous	O
yeast	O
Rhodosporidium	O
toruloides	O
secrete	O
a	O
mating	O
pheromone	O
,	O
rhodotorucine	B-GENE
A	I-GENE
,	O
which	O
is	O
an	O
undecapeptide	O
containing	O
S-farnesyl	O
cysteine	O
at	O
its	O
carboxy	O
terminus	O
.	O

The	O
FBF	O
questionnaire	O
did	O
not	O
highlight	O
a	O
characteristic	O
basic	O
symptoms	O
profile	O
of	O
schizoaffective	O
disorder	O
,	O
when	O
compared	O
with	O
bipolar	O
affective	O
disorder	O
and	O
schizophrenia	O
.	O

Magnetic	O
trapping	O
of	O
spin-polarized	O
atomic	O
hydrogen	O
.	O

The	O
transcription	O
and	O
alternative	O
splicing	O
of	O
human	B-GENE
ORL1	I-GENE
and	O
GAIP	B-GENE
are	O
cell-type	O
specific	O
.	O

In	O
the	O
single	O
case	O
the	O
restoration	O
of	O
a	O
structured	O
daily	O
routine	O
represents	O
the	O
presupposition	O
for	O
a	O
cognitive	O
therapy	O
.	O

Exercise	O
training	O
has	O
become	O
increasingly	O
important	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
patients	O
.	O

BACKGROUND	O
:	O
Chronic	O
alcohol	O
consumption	O
has	O
been	O
demonstrated	O
to	O
be	O
deleterious	O
to	O
bone	O
health	O
.	O

The	O
similar	O
phenotypes	O
of	O
bur6	B-GENE
and	O
bur3	B-GENE
(	O
mot1	B-GENE
)	O
mutations	O
suggest	O
that	O
Bur6p	B-GENE
and	O
Mot1p	B-GENE
have	O
related	O
,	O
but	O
not	O
identical	O
,	O
functions	O
in	O
modulating	O
the	O
activity	O
of	O
the	O
general	O
transcription	O
machinery	O
in	O
vivo	O
.	O

Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
plysS	O
,	O
harbouring	O
a	O
recombinant	O
plasmid	O
containing	O
the	O
catalase-peroxidase	B-GENE
gene	I-GENE
,	O
produced	O
a	O
large	O
amount	O
of	O
proteins	O
that	O
co-migrated	O
on	O
SDS	O
/	O
PAGE	O
with	O
the	O
native	O
enzyme	O
.	O

Uracil	B-GENE
DNA	I-GENE
glycosylase	I-GENE
catalyzes	O
the	O
initial	O
step	O
in	O
the	O
repair	O
pathway	O
that	O
removes	O
potentially	O
mutagenic	O
uracil	O
from	O
duplex	O
DNA	O
.	O

Disruption	O
of	O
re-replication	O
control	O
by	O
overexpression	O
of	O
human	B-GENE
ORC1	I-GENE
in	O
fission	O
yeast	O
.	O

Whereas	O
Smad2	B-GENE
was	O
rapidly	O
phosphorylated	O
by	O
TGF-beta	B-GENE
and	O
involved	O
in	O
the	O
initial	O
activation	O
of	O
Agc	B-GENE
expression	O
in	O
confluent	O
cells	O
,	O
Smad2	B-GENE
activation	O
was	O
not	O
required	O
for	O
maintaining	O
the	O
high	O
level	O
of	O
Agc	B-GENE
expression	O
.	O

DATA	O
SOURCES	O
:	O
Epidemiologic	O
studies	O
,	O
research	O
studies	O
,	O
review	O
articles	O
,	O
and	O
government	O
reports	O
pertaining	O
to	O
epidemiology	O
of	O
lung	O
cancer	O
.	O

Both	O
alleles	O
are	O
functionally	O
expressed	O
and	O
are	O
distributed	O
within	O
CD4+	B-GENE
/	I-GENE
CD8+	I-GENE
T	O
cell	O
subsets	O
.	O

The	O
Italian	O
Lung	O
Cancer	O
Task	O
Force	O
(	O
FONICAP	O
)	O
.	O

These	O
show	O
that	O
the	O
collagen	B-GENE
in	O
this	O
tissue	O
is	O
modified	O
compared	O
with	O
that	O
in	O
tendon	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
VirD2	B-GENE
omega	I-GENE
domain	I-GENE
is	O
important	O
for	O
efficient	O
T-DNA	O
integration	O
.	O

The	O
spontaneous	O
mutation	O
blocking	O
pca	B-GENE
gene	I-GENE
expression	O
was	O
located	O
in	O
the	O
promoter	O
for	O
the	O
pca	B-GENE
operon	I-GENE
.	O

The	O
binding	O
specificity	O
of	O
this	O
protein	O
was	O
compared	O
to	O
that	O
of	O
human	B-GENE
E2F	I-GENE
using	O
a	O
number	O
of	O
mutant	B-GENE
E2F	I-GENE
sites	I-GENE
as	O
competitors	O
.	O

These	O
case	O
reports	O
provide	O
further	O
evidence	O
that	O
LiCO3	O
can	O
be	O
a	O
useful	O
medication	O
in	O
the	O
treatment	O
of	O
aggressive	O
behavior	O
and	O
affective	O
instability	O
after	O
brain	O
injury	O
,	O
but	O
that	O
it	O
has	O
significant	O
potential	O
for	O
neurotoxicity	O
in	O
this	O
population	O
,	O
particularly	O
when	O
used	O
in	O
conjunction	O
with	O
neuroleptic	O
agents	O
.	O

We	O
also	O
isolated	O
two	O
alternatively	O
spliced	O
forms	O
of	O
human	B-GENE
CD6	I-GENE
cDNA	I-GENE
lacking	O
sequences	O
encoding	O
membrane-proximal	O
regions	O
of	O
the	O
cytoplasmic	O
domain	O
which	O
maintain	O
the	O
same	O
reading	O
frame	O
as	O
CD6-PB1	B-GENE
.	O

Eight	O
CAD	O
patients	O
who	O
were	O
matched	O
to	O
the	O
treated	O
patients	O
for	O
age	O
(	O
+	O
/	O
-3	O
years	O
)	O
,	O
baseline	O
low	B-GENE
density	I-GENE
lipoprotein	I-GENE
(	O
+	O
/	O
-5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
triglycerides	O
(	O
+	O
/	O
-50	O
mg	O
/	O
dL	O
)	O
but	O
who	O
had	O
never	O
been	O
treated	O
with	O
lipid-lowering	O
drugs	O
were	O
selected	O
as	O
controls	O
.	O

Judge	O
OKs	O
docs'	O
bid	O
for	O
Chicago	O
hospital	O
.	O

The	O
characterization	O
of	O
the	O
promoter	O
region	O
indicated	O
that	O
three	O
distinct	O
regulatory	O
elements	O
corresponding	O
to	O
an	O
AP-1	B-GENE
binding	I-GENE
site	I-GENE
(	O
or	O
TRE	B-GENE
)	O
,	O
a	O
PRDII	B-GENE
/	I-GENE
kappaB	I-GENE
domain	I-GENE
,	O
and	O
a	O
CAAT	O
box	O
are	O
involved	O
in	O
the	O
activation	O
by	O
pp60	B-GENE
(	I-GENE
v-	I-GENE
)	I-GENE
src	I-GENE
.	O

The	O
-64	O
/	O
-37	O
region	O
interacted	O
with	O
purified	O
Sp1	B-GENE
and	O
an	O
unidentified	O
protein	O
(	O
s	O
)	O
,	O
proximal	B-GENE
regulatory	I-GENE
factor	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
I	I-GENE
(	O
PRF-I	B-GENE
)	O
.	O

Although	O
most	O
SH2-pTyr	B-GENE
interactions	O
occur	O
between	O
two	O
different	O
types	O
of	O
molecules	O
,	O
some	O
appear	O
to	O
involve	O
only	O
a	O
single	O
molecular	O
type	O
.	O

From	O
an	O
RNK-16	O
lambda-gt11	O
library	O
,	O
we	O
have	O
isolated	O
and	O
sequenced	O
a	O
novel	O
cDNA	O
rat	B-GENE
NK	I-GENE
cell	I-GENE
protease	I-GENE
1	I-GENE
(	O
RNKP-1	B-GENE
)	O
that	O
has	O
characteristics	O
unique	O
to	O
serine	B-GENE
proteases	I-GENE
.	O

Similarly	O
,	O
in	O
mammalian	O
cells	O
PBP74	B-GENE
is	O
synthesized	O
as	O
a	O
pre-protein	O
that	O
requires	O
membrane	O
potential-dependent	O
import	O
into	O
mitochondria	O
for	O
its	O
maturation	O
.	O

The	O
M	B-GENE
reading	I-GENE
frame	I-GENE
differed	O
from	O
the	O
reported	O
sequence	O
by	O
a	O
single	O
nucleotide	O
corresponding	O
to	O
a	O
conservative	O
lysine	O
to	O
arginine	O
amino	O
acid	O
substitution	O
near	O
the	O
carboxy-terminus	O
conserved	O
among	O
the	O
M	B-GENE
proteins	I-GENE
of	O
paramyxoviruses	O
.	O

Occupational	O
exposure	O
to	O
hepatitis	O
B	O
virus	O
and	O
human	O
immunodeficiency	O
virus	O
:	O
a	O
comparative	O
risk	O
analysis	O
.	O

Although	O
it	O
is	O
well	O
known	O
that	O
calcium	O
channel	O
blockers	O
can	O
influence	O
contraction	O
of	O
vascular	O
smooth	O
muscle	O
,	O
there	O
is	O
less	O
knowledge	O
on	O
its	O
effect	O
on	O
excitation	O
contraction	O
coupling	O
in	O
the	O
endocrine	O
glands	O
and	O
more	O
specifically	O
on	O
insulin	B-GENE
and	O
glucagon	O
release	O
.	O

There	O
were	O
no	O
instances	O
of	O
major	O
flap	O
necrosis	O
although	O
two	O
flaps	O
showed	O
tip	O
ischaemia	O
.	O

Clinical	O
applications	O
of	O
inhibition	O
of	O
beta-adrenergic	B-GENE
receptors	I-GENE
with	O
propranolol	O
.	O

Improved	O
methods	O
have	O
been	O
developed	O
for	O
maintaining	O
and	O
breeding	O
the	O
neotropical	O
short-tailed	O
fruit	O
bat	O
,	O
Carollia	O
perspicillata	O
,	O
in	O
an	O
easily-reproduced	O
,	O
laboratory	O
setting	O
.	O

The	O
intensity	O
of	O
myocardial	O
uptake	O
of	O
Tc-99m-PYP	O
in	O
patients	O
with	O
echocardiographic	O
left	O
ventricular	O
hypertrophy	O
and	O
/	O
or	O
highly	O
refractile	O
myocardial	O
echoes	O
,	O
so-called	O
granular	O
sparkling	O
appearance	O
(	O
GS	O
)	O
was	O
slightly	O
greater	O
than	O
that	O
in	O
patients	O
with	O
neither	O
myocardial	O
hypertrophy	O
nor	O
GS	O
.	O

The	O
only	O
predictor	O
of	O
response	O
to	O
tacrolimus	O
was	O
a	O
previous	O
response	O
to	O
cyclosporin	O
and	O
prednisone	O
,	O
either	O
as	O
a	O
complete	O
or	O
partial	O
remission	O
(	O
remission	O
rate	O
75%	O
vs	O
15	O
.	O
3	O
;	O
P	O
=	O
0	O
.	O
036	O
)	O
.	O

Three	O
group	O
1	O
patients	O
developed	O
CMV	O
disease	O
;	O
1	O
group	O
2	O
patient	O
developed	O
CMV	O
hepatitis	O
.	O

CAL	O
gain	O
amounted	O
to	O
4	O
.	O
2+	O
/	O
-1	O
.	O
3	O
mm	O
,	O
60%	O
of	O
the	O
defects	O
showing	O
CAL	O
gain	O
>	O
or	O
=	O
4	O
mm	O
.	O

After	O
clofelin	O
administration	O
the	O
autoregulation	O
borders	O
shifted	O
to	O
the	O
right	O
i	O
.	O
e	O
.	O
towards	O
higher	O
AP	O
levels	O
.	O

Persistent	O
acantholytic	O
dermatosis	O
with	O
increased	O
light	O
sensitivity	O
.	O

In	O
fact	O
,	O
SPT	B-GENE
activity	O
in	O
the	O
fly	O
expressing	O
epitope-tagged	O
Lace	B-GENE
was	O
absorbed	O
by	O
epitope-specific	O
antibody	O
.	O

The	O
length	O
scales	O
of	O
the	O
turbulence	O
were	O
also	O
estimated	O
:	O
at	O
a	O
Reynolds	O
number	O
near	O
4	O
,	O
000	O
the	O
macroscale	O
is	O
about	O
1	O
.	O
25	O
mm	O
,	O
the	O
Taylor	O
microscale	O
is	O
about	O
0	O
.	O
85	O
mm	O
,	O
and	O
the	O
Kolmogoroff	O
scale	O
is	O
near	O
0	O
.	O
075	O
mm	O
.	O

C	O
.	O

DESIGN	O
:	O
Prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
trial	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
signal	O
transduction	O
pathways	O
that	O
are	O
involved	O
in	O
OM-induced	O
LDLR	B-GENE
transcription	O
.	O

The	O
hexanucleotide	B-GENE
5'-TGTCCT-3'	I-GENE
,	O
thought	O
to	O
be	O
important	O
for	O
GRE	B-GENE
activity	O
,	O
not	O
only	O
was	O
found	O
in	O
this	O
sequence	O
and	O
in	O
the	O
5'-flanking	O
region	O
,	O
but	O
also	O
was	O
present	O
twice	O
in	O
the	O
3'	O
end	O
of	O
the	O
gene	O
that	O
did	O
not	O
show	O
specific	O
receptor	O
binding	O
.	O

The	O
term	O
endovascular	O
papillary	O
haemangioma	O
is	O
suggested	O
.	O

Mutations	O
at	O
the	O
extreme	O
C-terminus	O
of	O
EIAV	B-GENE
Tat	I-GENE
impaired	O
both	O
RNA	O
binding	O
and	O
activation	O
domain	O
functions	O
,	O
suggesting	O
effects	O
on	O
secondary	O
or	O
tertiary	O
structure	O
.	O

Repeated	O
efforts	O
to	O
isolate	O
recombinant	O
baculoviruses	O
containing	O
a	O
wild-type	B-GENE
kinase	I-GENE
failed	O
,	O
whereas	O
recombinants	O
expressing	O
a	O
nonfunctional	O
kinase	B-GENE
with	O
a	O
catalytic	O
domain	B-GENE
II	I-GENE
mutation	O
were	O
readily	O
isolated	O
.	O

Elementary	O
visual	O
hallucinations	O
in	O
migraine	O
and	O
epilepsy	O
.	O

RT-PCR	O
was	O
performed	O
using	O
previously	O
reported	O
degenerate	O
oligonucleotide	O
primers	O
to	O
the	O
ligand	O
binding	O
domain	O
(	O
LBD	O
)	O
of	O
known	O
beta	B-GENE
integrin	I-GENE
subunits	I-GENE
and	O
Bge	B-GENE
cDNA	I-GENE
.	O

Chronic	O
administration	O
of	O
sodium	O
cyanate	O
decreases	O
O2	O
extraction	O
ratio	O
in	O
dogs	O
.	O

Efficient	O
phosphorylation	O
of	O
BRDG1	B-GENE
by	O
Tec	B-GENE
required	O
the	O
PH	B-GENE
and	O
SH2	B-GENE
domains	I-GENE
as	O
well	O
as	O
the	O
kinase	O
domain	O
of	O
the	O
latter	O
.	O

Evidence-based	O
care	O
:	O
a	O
new	O
formula	O
for	O
an	O
old	O
problem	O
?	O

With	O
this	O
GH	B-GENE
and	O
estrogen	O
treatment	O
regimen	O
,	O
most	O
girls	O
with	O
TS	O
can	O
grow	O
and	O
develop	O
much	O
more	O
in	O
conformity	O
with	O
their	O
healthy	O
peers	O
.	O

After	O
acclimation	O
,	O
resting	O
supine	O
and	O
sitting	O
DPB	O
decreased	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
by	O
6	O
and	O
9	O
mmHg	O
,	O
respectively	O
.	O

METHODS	O
:	O
DSF	O
was	O
instilled	O
in	O
one	O
eye	O
chosen	O
at	O
random	O
and	O
CF	O
in	O
the	O
fellow	O
eye	O
of	O
13	O
normal	O
subjects	O
and	O
in	O
13	O
patients	O
with	O
KCS	O
.	O

With	O
regard	O
to	O
nonhematologic	O
toxicities	O
,	O
diarrhea	O
,	O
infection	O
and	O
elevated	O
serum	B-GENE
alkaline	I-GENE
phosphatase	I-GENE
of	O
grade	O
3	O
or	O
over	O
were	O
observed	O
in	O
2%	O
of	O
cycles	O
,	O
but	O
were	O
tolerable	O
and	O
reversible	O
.	O

Tests	O
showed	O
that	O
an	O
overall	O
impression	O
of	O
the	O
force	O
applied	O
could	O
be	O
obtained	O
from	O
a	O
laboratory	O
simulation	O
,	O
but	O
that	O
clearing	O
cement	O
and	O
testing	O
cement	O
were	O
not	O
modelled	O
by	O
this	O
method	O
.	O

These	O
lesions	O
were	O
asymptomatic	O
,	O
but	O
both	O
were	O
characterized	O
clinically	O
by	O
central	O
ulceration	O
.	O

In	O
addition	O
,	O
double	O
mutants	O
with	O
either	O
dim1-delta	B-GENE
or	O
dim2-1	B-GENE
and	O
the	O
endocytosis	O
mutants	B-GENE
end4-1	I-GENE
or	O
act1-1	B-GENE
displayed	O
synthetic	O
growth	O
defects	O
,	O
indicating	O
that	O
the	O
DIM	B-GENE
gene	I-GENE
products	I-GENE
function	O
in	O
a	O
common	O
or	O
parallel	O
endocytic	O
pathway	O
.	O

35	O
patients	O
with	O
acute	O
arterial	O
occlusions	O
[	O
27	O
]	O
and	O
graft	O
thromboses	O
[	O
8	O
]	O
,	O
responsible	O
for	O
severe	O
and	O
recent	O
ischemia	O
,	O
were	O
treated	O
by	O
fibrinolytic	O
therapy	O
(	O
Urokinase	B-GENE
:	O
1	O
000	O
units	O
/	O
kg	O
/	O
hour	O
,	O
and	O
Lys	O
Plasminogen	B-GENE
)	O
.	O

Moreover	O
,	O
it	O
is	O
the	O
assumptions	O
behind	O
steady-state	O
O2	O
uptake	O
that	O
do	O
not	O
permit	O
proper	O
interpretation	O
of	O
energy	O
expenditure	O
during	O
EPOC	O
;	O
1	O
l	O
O2	O
not	O
=	O
20	O
.	O
9	O
kJ	O
.	O

An	O
examination	O
of	O
the	O
properties	O
of	O
sequences	O
surrounding	O
ARS1	B-GENE
left	O
open	O
the	O
possibility	O
that	O
ABFI	B-GENE
enhances	O
the	O
initiation	O
of	O
DNA	O
replication	O
at	O
ARS1	B-GENE
by	O
transcriptional	O
activation	O
.	O

The	O
intron	O
is	O
capable	O
of	O
splicing	O
despite	O
the	O
fact	O
that	O
both	O
the	O
EBS1	B-GENE
/	I-GENE
IBS1	I-GENE
and	O
the	O
EBS2	B-GENE
/	I-GENE
IBS2	I-GENE
sequence	I-GENE
motifs	I-GENE
,	O
thought	O
to	O
be	O
necessary	O
for	O
correct	O
splicing	O
,	O
extend	O
over	O
5	O
instead	O
of	O
6	O
bp	O
.	O

From	O
day	O
10	O
,	O
a	O
significant	O
increase	O
in	O
platelet	O
count	O
was	O
observed	O
in	O
eight	O
of	O
the	O
ten	O
patients	O
treated	O
with	O
heparin	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
with	O
return	O
to	O
the	O
initial	O
value	O
after	O
heparin	O
cessation	O
in	O
six	O
of	O
the	O
responders	O
.	O

The	O
association	O
of	O
p255	B-GENE
with	O
splicing	O
complexes	O
is	O
suggested	O
by	O
the	O
finding	O
that	O
mAb	B-GENE
CC3	I-GENE
can	O
inhibit	O
in	O
vitro	O
splicing	O
and	O
immunoprecipitate	O
pre-messenger	O
RNA	O
and	O
splicing	O
products	O
.	O

In	O
rats	O
anaesthetized	O
with	O
+-chloralose	O
the	O
changes	O
in	O
extracellular	O
pH	O
and	O
K+	O
in	O
spinal	O
cord	O
dorsal	O
horn	O
were	O
studied	O
using	O
pH	O
and	O
K+	O
ion-selective	O
electrodes	O
.	O

Rather	O
,	O
usp	B-GENE
is	O
required	O
in	O
late	O
third	O
instar	O
larvae	O
for	O
appropriate	O
developmental	O
and	O
transcriptional	O
responses	O
to	O
the	O
ecdysone	O
pulse	O
that	O
triggers	O
puparium	O
formation	O
.	O

The	O
majority	O
of	O
MRF	O
units	O
were	O
behaviorally	O
incongruent	O
;	O
in	O
the	O
most	O
frequently	O
observed	O
case	O
,	O
their	O
activity	O
failed	O
to	O
change	O
reliably	O
when	O
behavior	O
habituated	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
either	O
the	O
fatty	O
acid	O
composition	O
of	O
biliary	O
lecithin	O
or	O
in	O
the	O
bile	O
acid	O
composition	O
of	O
bile	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
investigate	O
whether	O
constitutive	B-GENE
NF-kappaB	I-GENE
activity	O
in	O
chronically	O
HIV-1-infected	O
promonocytic	O
U937	O
(	O
U9-IIIB	O
)	O
and	O
myeloblastic	O
PLB-985	O
(	O
PLB-IIIB	O
)	O
cells	O
affects	O
apoptotic	O
signaling	O
.	O

Survey	O
on	O
antibody	O
against	O
egg	O
drop	O
syndrome-1976	O
virus	O
among	O
chicken	O
flocks	O
in	O
Japan	O
.	O

We	O
present	O
evidence	O
that	O
the	O
upstream	O
open	O
reading	O
frame	O
(	O
uORF	O
)	O
represses	O
the	O
translation	O
of	O
the	O
downstream	O
major	O
open	O
reading	O
frame	O
(	O
mORF	O
)	O
.	O

In	O
EEG	O
only	O
single	O
slow	O
waves	O
above	O
left	O
temporal	O
region	O
were	O
revealed	O
.	O

No	O
increased	O
tumor-related	O
mortality	O
was	O
observed	O
after	O
a	O
mean	O
follow-up	O
of	O
44	O
months	O
.	O

In	O
Rat-1a	O
cells	O
the	O
expression	O
of	O
human	B-GENE
c-jun	I-GENE
mRNA	I-GENE
was	O
associated	O
with	O
the	O
ability	O
to	O
clone	O
in	O
soft	O
agarose	O
and	O
form	O
tumors	O
in	O
nude	O
mice	O
.	O

Carbonic	B-GENE
anhydrase	I-GENE
V	I-GENE
(	O
CA	B-GENE
V	I-GENE
)	O
is	O
expressed	O
in	O
mitochondrial	O
matrix	O
in	O
liver	O
and	O
several	O
other	O
tissues	O
.	O

Metabolism	O
of	O
calcium	O
and	O
vitamin	O
D3	O
in	O
patients	O
with	O
acute	O
tubulointerstitial	O
nephritis	O
:	O
a	O
study	O
of	O
41	O
patients	O
with	O
nephropathia	O
epidemica	O
.	O

OBJECTIVES	O
:	O
The	O
objective	O
of	O
this	O
review	O
was	O
to	O
compare	O
the	O
effectiveness	O
,	O
safety	O
and	O
acceptability	O
of	O
the	O
diaphragm	O
with	O
and	O
without	O
spermicide	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
A	O
64-year-old	O
woman	O
with	O
confirmed	O
AV	O
nodal	O
reentrant	O
tachycardia	O
underwent	O
a	O
successful	O
"slow	O
pathway"	O
AV	O
modification	O
with	O
a	O
single	O
radiofrequency	O
application	O
.	O

In	O
3	O
treatments	O
the	O
diet	O
was	O
supplemented	O
with	O
0	O
,	O
100	O
and	O
150	O
mg	O
probiotic	O
/	O
kg	O
food	O
.	O

We	O
show	O
that	O
stimulation	O
of	O
resting	O
splenic	O
B	O
cells	O
with	O
CD40L-expressing	O
Sf9	O
cells	O
induces	O
germ-line	O
gamma	B-GENE
1	I-GENE
and	O
epsilon	B-GENE
transcripts	I-GENE
independently	O
of	O
cytokines	O
.	O

Routine	O
blood	O
examination	O
showed	O
leukocytosis	O
,	O
thrombocytopenia	O
,	O
positive	O
CRP	B-GENE
,	O
and	O
elevated	O
myocardial	O
enzymes	O
.	O

We	O
propose	O
that	O
refeeding	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
activation	O
of	O
certain	O
viral	O
infections	O
previously	O
suppressed	O
by	O
famine	O
.	O

Survival	O
after	O
development	O
of	O
symptomatic	O
infection	O
(	O
P-2	O
)	O
did	O
not	O
differ	O
by	O
transmission	O
mode	O
.	O

Most	O
other	O
end	O
points	O
were	O
highly	O
significant	O
,	O
and	O
death	O
,	O
which	O
was	O
monitored	O
across	O
the	O
U	O
.	O
S	O
.	O
program	O
,	O
was	O
different	O
with	O
p	O
<	O
0	O
.	O
0001	O
.	O

Constipation	O
is	O
not	O
a	O
risk	O
factor	O
for	O
hemorrhoids	O
:	O
a	O
case-control	O
study	O
of	O
potential	O
etiological	O
agents	O
.	O

Mutational	O
analysis	O
of	O
chromosomal	O
segment	O
64AB	O
,	O
a	O
region	O
containing	O
the	O
glutamic	B-GENE
acid	I-GENE
decarboxylase	I-GENE
gene	I-GENE
.	O

Substitution	O
of	O
the	O
DR1	B-GENE
beta	I-GENE
chain	I-GENE
with	O
H-2E	B-GENE
beta	I-GENE
k	I-GENE
led	O
to	O
a	O
dramatic	O
loss	O
of	O
recognition	O
;	O
alpha	O
chain	O
substitution	O
had	O
a	O
less	O
marked	O
effect	O
.	O

In	O
contrast	O
to	O
the	O
selective	O
expression	O
of	O
the	O
receptor	O
,	O
FL	B-GENE
expression	O
was	O
detected	O
in	O
90-100%	O
of	O
the	O
various	O
cell	O
types	O
of	O
leukemia	O
cell	O
lines	O
from	O
all	O
hematopoietic	O
cell	O
lineages	O
.	O

Antibodies	O
to	O
the	O
human	B-GENE
PTS1R	I-GENE
recognize	O
this	O
protein	O
in	O
human	O
,	O
monkey	O
,	O
rat	O
,	O
and	O
hamster	O
cells	O
.	O

The	O
combination	O
of	O
Pitx2	B-GENE
and	O
another	O
homeodomain	B-GENE
protein	I-GENE
,	O
Pit-1	B-GENE
,	O
yielded	O
a	O
synergistic	O
55-fold	O
activation	O
of	O
the	O
prolactin	B-GENE
promoter	I-GENE
in	O
transfection	O
assays	O
.	O

Consistent	O
with	O
the	O
specificity	O
observed	O
for	O
the	O
interaction	O
of	O
DmCKIIalpha	B-GENE
with	O
these	O
bHLH	B-GENE
proteins	I-GENE
,	O
sequence	O
alignment	O
suggests	O
that	O
only	O
m5	B-GENE
,	O
m7	B-GENE
,	O
and	O
m8	B-GENE
contain	O
a	O
consensus	O
site	O
for	O
phosphorylation	O
by	O
CKII	B-GENE
within	O
a	O
subdomain	O
unique	O
to	O
these	O
three	O
proteins	O
.	O

The	O
transcription	O
start	O
point	O
of	O
the	O
proximal	O
promoter	O
aligns	O
to	O
that	O
of	O
mouse	B-GENE
promoter	I-GENE
P3	I-GENE
and	O
lies	O
within	O
a	O
conserved	O
region	O
of	O
sequence	O
.	O

METHODS	O
:	O
One	O
hundred	O
fourteen	O
consecutive	O
patients	O
(	O
mean	O
age	O
61	O
years	O
)	O
with	O
focal	O
pancreatic	O
masses	O
,	O
detected	O
on	O
CT	O
,	O
underwent	O
EUS-FNA	O
by	O
using	O
a	O
linear-array	O
echoendoscope	O
and	O
22-gauge	O
needles	O
.	O

The	O
phosphorylation	O
efficiency	O
is	O
improved	O
by	O
increasing	O
the	O
number	O
of	O
N-terminal	O
arginine	O
residues	O
and	O
by	O
moving	O
the	O
arginyl	O
cluster	O
one	O
residue	O
further	O
away	O
from	O
the	O
serine	O
,	O
the	O
nonapeptide	B-GENE
(	I-GENE
Arg	I-GENE
)	I-GENE
4-Ala-Ala-Ser-Val-Ala	I-GENE
being	O
the	O
best	O
substrate	O
among	O
all	O
the	O
short	O
peptides	O
tested	O
(	O
Km	O
=	O
15	O
microM	O
)	O
.	O

Here	O
is	O
presented	O
the	O
monitoring	O
of	O
the	O
accidental	O
spill	O
on	O
vertical	O
distribution	O
of	O
heavy	O
metals	O
in	O
the	O
estuarine	O
sediments	O
.	O

A	O
mutant	O
in	O
the	O
AAV	O
terminal	O
resolution	O
site	O
(	O
trs	O
)	O
was	O
defective	O
for	O
DNA	O
replication	O
in	O
the	O
in	O
vitro	O
assay	O
.	O

Analysis	O
of	O
homologous	O
DNA	O
sequences	O
within	O
the	O
first	O
intron	O
of	O
the	O
mouse	B-GENE
and	I-GENE
human	I-GENE
mts1	I-GENE
genes	I-GENE
:	O
kB-like	B-GENE
site	I-GENE
and	O
microsatellite	O
DNA	O
.	O

The	O
medium	O
chains	O
of	O
these	O
complexes	O
,	O
mu1	B-GENE
and	O
mu2	B-GENE
,	O
have	O
been	O
implicated	O
in	O
two	O
types	O
of	O
interaction	O
:	O
assembly	O
with	O
the	O
beta1	B-GENE
and	I-GENE
beta2	I-GENE
chains	I-GENE
of	O
the	O
corresponding	O
complexes	O
and	O
recognition	O
of	O
tyrosine-based	O
sorting	O
signals	O
.	O

The	O
promoter	O
was	O
stimulated	O
8-20-fold	O
by	O
phorbol	O
esters	O
accounting	O
for	O
the	O
previously	O
observed	O
transcriptional	O
activation	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
beta	I-GENE
.	O

The	O
rats	O
were	O
used	O
for	O
the	O
study	O
of	O
the	O
effects	O
of	O
sepsis	O
on	O
the	O
utilization	O
of	O
exogenous	O
fat	O
emulsion	O
.	O

Its	O
interaction	O
with	O
RFX5	B-GENE
and	O
RFXAP	B-GENE
is	O
essential	O
for	O
binding	O
of	O
the	O
RFX	B-GENE
complex	I-GENE
to	O
MHC-II	B-GENE
promoters	I-GENE
.	O

In	O
CV-1	O
cells	O
,	O
cotransfection	O
of	O
the	O
retinoid	B-GENE
and	I-GENE
estrogen	I-GENE
receptors	I-GENE
led	O
to	O
mutual	O
inhibition	O
of	O
the	O
other's	O
activity	O
,	O
while	O
an	O
RA-dependent	O
inhibition	O
of	O
ER	B-GENE
activity	O
was	O
observed	O
in	O
breast	O
cancer	O
cells	O
.	O

Thirty	O
minutes	O
of	O
supine	O
restraint	O
decreased	O
DOPAC	O
concentrations	O
in	O
the	O
median	O
eminence	O
of	O
female	O
rats	O
that	O
were	O
not	O
exposed	O
to	O
ether	O
,	O
and	O
brief	O
exposure	O
to	O
ether	O
enhanced	O
this	O
effect	O
.	O

Constrictive	O
pericarditis	O
and	O
pleuropulmonary	O
disease	O
linked	O
to	O
ergot	O
dopamine	O
agonist	O
therapy	O
(	O
cabergoline	O
)	O
for	O
Parkinson's	O
disease	O
.	O

The	O
first	O
follow-up	O
was	O
at	O
a	O
nearly	O
constant	O
interval	O
of	O
5	O
.	O
1	O
years	O
in	O
Caerphilly	O
and	O
3	O
.	O
2	O
years	O
in	O
Speedwell	O
;	O
251	O
major	O
IHD	O
events	O
had	O
occurred	O
.	O

A	O
transgenic	O
complementation	O
assay	O
was	O
used	O
to	O
test	O
whether	O
NIa	B-GENE
supplied	O
in	O
trans	O
could	O
rescue	O
amplification-defective	O
viral	O
genomes	O
encoding	O
altered	O
NIa	B-GENE
proteins	I-GENE
.	O

Chirality-glass	O
and	O
spin-glass	O
correlations	O
in	O
the	O
two-dimensional	O
random-bond	O
XY	O
model	O
.	O

Initial	O
results	O
indicate	O
that	O
this	O
23S	B-GENE
pre-rRNA	I-GENE
is	O
the	O
same	O
as	O
the	O
species	O
detected	O
on	O
depletion	O
of	O
the	O
small	B-GENE
nucleolar	I-GENE
RNA-associated	I-GENE
proteins	I-GENE
NOP1	B-GENE
and	O
GAR1	B-GENE
and	O
in	O
an	O
snr10	B-GENE
mutant	I-GENE
strain	O
.	O

Complementary	O
DNAs	O
encompassing	O
the	O
coat	B-GENE
protein	I-GENE
coding	O
and	O
adjacent	O
regions	O
of	O
Agropyron	O
mosaic	O
virus	O
(	O
AgMV	O
)	O
and	O
Hordeum	O
mosaic	O
virus	O
(	O
HoMV	O
)	O
were	O
cloned	O
and	O
sequenced	O
.	O

To	O
understand	O
further	O
the	O
expression	O
and	O
regulation	O
of	O
the	O
V1aR	B-GENE
,	O
we	O
now	O
describe	O
the	O
genomic	O
characteristics	O
,	O
tissue	O
expression	O
,	O
chromosomal	O
localization	O
,	O
and	O
regional	O
mapping	O
of	O
the	O
human	B-GENE
V1aR	I-GENE
gene	I-GENE
,	O
AVPR1A	B-GENE
.	O

Vaccinia	O
virus-expressed	O
,	O
purified	O
full-length	B-GENE
HPV-16	I-GENE
and	I-GENE
BPV-1	I-GENE
E2	I-GENE
proteins	I-GENE
bound	O
a	O
consensus	O
E2	B-GENE
site	I-GENE
with	O
high	O
specific	O
affinities	O
(	O
Kd	O
=	O
approximately	O
10	O
(	O
-9	O
)	O
M	O
)	O
and	O
stimulated	O
in	O
vitro	O
transcription	O
up	O
to	O
six-	O
to	O
eightfold	O
.	O

Genes	O
for	O
ocs	B-GENE
element	I-GENE
binding	I-GENE
factors	I-GENE
(	O
OBFs	B-GENE
)	O
,	O
belonging	O
to	O
a	O
specific	O
class	O
of	O
basic-region	B-GENE
leucine	I-GENE
zipper	I-GENE
(	I-GENE
bZIP	I-GENE
)	I-GENE
transcription	I-GENE
factors	I-GENE
,	O
have	O
been	O
isolated	O
in	O
a	O
number	O
of	O
plants	O
.	O

Interestingly	O
,	O
highly	O
charged	O
residues	O
were	O
abundantly	O
possessed	O
in	O
the	O
carboxy-terminal	O
part	O
of	O
the	O
MDV2	B-GENE
UL10	I-GENE
protein	I-GENE
.	O

By	O
using	O
lambda	O
gt11	O
expression	O
cloning	O
with	O
oligonucleotides	O
corresponding	O
to	O
the	O
human	O
immunodeficiency	O
virus	O
1	O
TATA	O
element	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
cellular	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
123	O
kDa	O
that	O
we	O
designate	O
TATA	B-GENE
element	I-GENE
modulatory	I-GENE
factor	I-GENE
(	O
TMF	B-GENE
)	O
.	O

We	O
show	O
here	O
that	O
RA	O
and	O
E1A	B-GENE
induce	O
phosphorylation	O
of	O
the	O
E1A-associated	B-GENE
300	I-GENE
kDa	I-GENE
protein	I-GENE
(	O
p300	B-GENE
)	O
during	O
the	O
differentiation	O
of	O
F9	O
cells	O
.	O

Pathophysiology	O
of	O
bone	O
loss	O
in	O
castrated	O
animals	O
.	O

A	O
strong	O
correlation	O
exists	O
between	O
the	O
numbers	O
of	O
CFU-GM	O
transfused	O
and	O
the	O
rate	O
of	O
granulocytes	O
and	O
platelets	O
recovery	O
.	O

Because	O
of	O
serious	O
infections	O
(	O
fever	O
larger	O
than	O
or	O
equal	O
to	O
101	O
degrees	O
F	O
.	O
granulocytes	O
less	O
than	O
1	O
,	O
000	O
/	O
mm	O
,	O
3	O
and	O
hospitalization	O
)	O
and	O
1	O
drug	O
death	O
in	O
the	O
first	O
4	O
patients	O
,	O
oral	O
calcium	O
leucovorin	O
,	O
20	O
to	O
30	O
mg	O
/	O
m2	O
orally	O
,	O
was	O
given	O
2	O
days	O
after	O
methotrexate	O
in	O
subsequent	O
treatment	O
cycles	O
.	O

Of	O
the	O
six	O
cases	O
of	O
malignant	O
polyposis	O
,	O
none	O
were	O
identified	O
using	O
CT	O
,	O
and	O
only	O
two	O
were	O
diagnosed	O
by	O
small	O
bowel	O
follow-through	O
.	O

Successful	O
interaction	O
of	O
ARF	B-GENE
and	O
PKC-alpha	B-GENE
with	O
PLD1	B-GENE
was	O
not	O
achieved	O
,	O
but	O
a	O
C-terminal	O
fragment	O
of	O
human	B-GENE
PLD1	I-GENE
(	O
denoted	O
"D4"	O
)	O
interacted	O
with	O
the	O
active	O
mutant	O
of	O
RhoA	B-GENE
,	O
RhoAVal-14	B-GENE
.	O

Repetitive	O
sequences	O
are	O
present	O
in	O
at	O
least	O
three	O
introns	O
of	O
the	O
cytochrome	B-GENE
P-450PBc2	I-GENE
gene	I-GENE
,	O
but	O
not	O
in	O
exons	O
or	O
the	O
5'-flanking	O
region	O
.	O

(	O
GUT	O
)	O
Sera	O
of	O
30	O
montoux	O
negative	O
healthy	O
adults	O
(	O
age	O
/	O
sex	O
matched	O
)	O
were	O
taken	O
as	O
control	O
by	O
detecting	O
IgG	B-GENE
anti	I-GENE
bodies	I-GENE
to	O
A60	B-GENE
antigen	I-GENE
.	O

Using	O
immunolocalization	O
,	O
we	O
observe	O
that	O
ACE3	B-GENE
,	O
a	O
440-bp	O
chorion	O
element	O
that	O
contains	O
information	O
sufficient	O
to	O
drive	O
amplification	O
,	O
directs	O
DmORC	O
localization	O
in	O
follicle	O
cells	O
.	O

E2F	B-GENE
activity	O
is	O
regulated	O
in	O
part	O
by	O
the	O
retinoblastoma	B-GENE
family	I-GENE
of	I-GENE
tumor	I-GENE
suppressor	I-GENE
proteins	I-GENE
.	O

The	O
rate-decreasing	O
effects	O
of	O
morphine	O
and	O
U50488	O
were	O
reversed	O
completely	O
by	O
a	O
0	O
.	O
01	O
and	O
1	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
of	O
naloxone	O
,	O
respectively	O
.	O

Demonstration	O
of	O
fine	O
structure	O
of	O
the	O
guinea	O
pig	O
organ	O
of	O
Corti	O
after	O
electron	O
microscopic	O
silver	O
staining	O
.	O

A	O
cDNA	O
encoding	O
the	O
NF-4FB	B-GENE
enhancer	I-GENE
binding	I-GENE
protein	I-GENE
has	O
been	O
cloned	O
by	O
screening	O
a	O
lambda	O
gt11	O
cDNA	O
library	O
with	O
a	O
rabiolabelled	O
oligonucleotide	O
corresponding	O
to	O
the	O
NF-4FB	B-GENE
recognition	I-GENE
sequence	I-GENE
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
correlate	O
the	O
responsiveness	O
to	O
bronchoprovocation	O
with	O
methacholine	O
in	O
subjects	O
a	O
with	O
allergic	O
rhinitis	O
during	O
and	O
out	O
of	O
the	O
pollen	O
season	O
with	O
total	O
serum	O
IgE	B-GENE
and	O
blood	O
eosinophils	O
.	O

The	O
Siglecs	B-GENE
are	O
a	O
subfamily	O
of	O
I-type	B-GENE
lectins	I-GENE
(	O
immunoglobulin	B-GENE
superfamily	I-GENE
proteins	I-GENE
that	O
bind	O
sugars	O
)	O
that	O
specifically	O
recognize	O
sialic	O
acids	O
.	O

The	O
interaction	O
between	O
piroxicam	O
and	O
poloxamer	O
was	O
studied	O
by	O
x-ray	O
diffractometry	O
(	O
XRD	O
)	O
,	O
infrared	O
(	O
IR	O
)	O
spectroscopy	O
and	O
differential	O
thermal	O
analysis	O
(	O
DTA	O
)	O
with	O
a	O
solid	O
dispersion	O
,	O
coprecipitate	O
,	O
or	O
physical	O
mixture	O
.	O

Immunelectrophoretic	O
pattern	O
of	O
Wassermann	O
reagin	O
and	O
comparison	O
of	O
the	O
appearance	O
time	O
between	O
RPCF	B-GENE
and	O
FTA	B-GENE
antibodies	I-GENE
.	O

Reactive	O
lymphoid	O
hyperplasia	O
was	O
found	O
in	O
15	O
cases	O
,	O
2	O
cases	O
had	O
angiofollicular	O
lymphoid	O
hyperplasia	O
or	O
Castleman's	O
disease	O
,	O
atypical	O
lymphoid	O
hyperplasia	O
suggestive	O
of	O
malignant	O
lymphoma	O
was	O
observed	O
in	O
3	O
cases	O
,	O
and	O
malignant	O
lymphoma	O
was	O
diagnosed	O
in	O
the	O
remaining	O
4	O
cases	O
.	O

In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
mechanism	O
underlying	O
Ras	B-GENE
activation	O
upon	O
stimulation	O
of	O
these	O
two	O
types	O
of	O
receptors	O
in	O
hematopoietic	O
cells	O
.	O

The	O
distribution	O
phase	O
is	O
followed	O
by	O
an	O
elimination	O
phase	O
with	O
a	O
much	O
longer	O
half-life	O
(	O
mean	O
value	O
375	O
min	O
)	O
and	O
a	O
volume	O
of	O
distribution	O
of	O
approximately	O
200-400	O
l	O
.	O

OKA	O
and	O
calyculin	O
A	O
do	O
not	O
decrease	O
OCFRE	B-GENE
DNA-protein	O
interactions	O
,	O
suggesting	O
that	O
important	O
protein-protein	O
interactions	O
are	O
phosphatase	O
regulated	O
.	O

In	O
addition	O
,	O
media	O
containing	O
F	B-GENE
beta	I-GENE
alpha	I-GENE
/	I-GENE
CG	I-GENE
beta	I-GENE
displayed	O
high-affinity	O
binding	O
to	O
both	O
CG	B-GENE
and	O
FSH	B-GENE
receptors	I-GENE
.	O

Antisense	O
transcription	O
of	O
a	O
murine	B-GENE
FGFR-3	I-GENE
psuedogene	I-GENE
during	O
fetal	O
developement	O
.	O

Within	O
the	O
Strep	O
.	O
mutans	O
group	O
there	O
was	O
a	O
highly-significant	O
difference	O
between	O
Strep	O
.	O
mutans	O
/	O
Strep	O
.	O
cricetus	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
with	O
respect	O
to	O
mean	O
clump	O
size	O
.	O

Here	O
we	O
review	O
progress	O
to	O
date	O
in	O
this	O
area	O
.	O

Both	O
BG	O
and	O
IRI	B-GENE
concentrations	O
during	O
the	O
OGTT	O
were	O
the	O
lowest	O
in	O
body	O
builders	O
,	O
medium	O
in	O
controls	O
,	O
and	O
the	O
highest	O
in	O
obese	O
men	O
.	O

Hypersplenism	O
.	O

We	O
report	O
the	O
construction	O
of	O
an	O
approximately	O
1	O
.	O
7-Mb	O
sequence-ready	O
YAC	O
/	O
BAC	O
clone	O
contig	O
of	O
8p22-p23	O
.	O

In	O
the	O
ePTFE	O
specimens	O
,	O
tissue	O
coverage	O
had	O
increased	O
.	O

A	O
decrease	O
of	O
the	O
lysozyme	B-GENE
activity	O
coincided	O
with	O
the	O
clinical	O
improvement	O
of	O
the	O
bacterial	O
meningitis	O
.	O

In	O
this	O
study	O
,	O
we	O
elucidate	O
signaling	O
pathways	O
induced	O
by	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
with	O
hypericin	O
.	O

In	O
situ	O
copper-phenanthroline	O
footprinting	O
of	O
individual	O
gel	O
shift	O
assembly	O
intermediates	O
shows	O
that	O
on	O
the	O
302-nucleotide	O
G4oric	O
,	O
the	O
first	O
two	O
SSB	B-GENE
tetramers	I-GENE
assemble	O
at	O
random	O
,	O
but	O
the	O
addition	O
of	O
more	O
SSB	B-GENE
tetramers	I-GENE
results	O
in	O
formation	O
of	O
a	O
unique	O
structure	O
.	O

The	O
distribution	O
of	O
patients	O
was	O
as	O
follows	O
:	O
group	O
1--complex	O
gamma-therapy	O
(	O
55	O
cases	O
)	O
,	O
group	O
2--complex	O
gamma-therapy	O
plus	O
iliac	O
lymphadenectomy	O
(	O
50	O
cases	O
)	O
and	O
group	O
3--complex	O
radiation	O
treatment	O
with	O
megavolt	O
bremsstrahlung	O
beam	O
from	O
the	O
luc	O
type	O
installation	O
and	O
iliac	O
lymphadenectomy	O
(	O
50	O
cases	O
)	O
.	O

Cellular	B-GENE
Csk	I-GENE
was	O
associated	O
with	O
several	O
phosphoproteins	O
,	O
some	O
of	O
which	O
were	O
interacting	O
with	O
the	O
Csk	B-GENE
SH2	B-GENE
domain	I-GENE
.	O

Previous	O
studies	O
characterized	O
a	O
cytokine-inducible	O
,	O
functional	O
nuclear	B-GENE
factor	I-GENE
(	I-GENE
NF	I-GENE
)	I-GENE
-kappaB	I-GENE
consensus	I-GENE
element	I-GENE
in	O
the	O
immediate	O
5'	O
regulatory	O
region	O
of	O
the	O
MGSA	B-GENE
/	I-GENE
GRO-alpha	I-GENE
gene	I-GENE
at	O
-78	O
bp	O
.	O

Enhancer	O
activity	O
requires	O
both	O
the	O
AP-1	B-GENE
site	I-GENE
and	O
these	O
adjacent	O
sequences	O
.	O

A	O
significant	O
association	O
between	O
a	O
family	O
history	O
and	O
a	O
higher	O
urinary	O
pH	O
was	O
observed	O
among	O
the	O
female	O
calcium	O
stone	O
patients	O
.	O

Successful	O
treatment	O
of	O
candidiasis	O
with	O
transfer	O
factor	O
.	O

Disturbances	O
of	O
placental	O
maturation	O
,	O
2	O
.	O

Between	O
acoR	B-GENE
and	O
acoXABC	B-GENE
,	O
two	O
different	O
types	O
of	O
sequences	O
with	O
dual	O
rotational	O
symmetry	O
[	O
CAC-	O
(	O
N11	O
to	O
N18	O
)	O
-GTG	O
and	O
TGT-	O
(	O
N10	O
to	O
N14	O
)	O
-ACA	O
]	O
were	O
found	O
;	O
these	O
sequences	O
are	O
similar	O
to	O
NtrC	B-GENE
and	O
NifA	B-GENE
upstream	I-GENE
activator	I-GENE
sequences	I-GENE
,	O
respectively	O
.	O

Workload	O
,	O
UAPs	O
,	O
and	O
you	O
.	O

This	O
unique	O
location	O
of	O
cavernous	O
malformation	O
is	O
associated	O
with	O
a	O
risk	O
of	O
permanent	O
loss	O
of	O
the	O
vision	O
.	O

Results	O
for	O
men	O
who	O
drank	O
up	O
to	O
two	O
drinks	O
per	O
day	O
suggest	O
that	O
if	O
the	O
dependence	O
criteria	O
were	O
invalid	O
,	O
reductions	O
in	O
the	O
prevalence	O
of	O
specific	O
indicators	O
of	O
alcohol	O
dependence	O
would	O
range	O
from	O
0	O
.	O
3%	O
to	O
5	O
.	O
2%	O
.	O

The	O
complete	O
response	O
(	O
CR	O
)	O
rate	O
was	O
34%	O
in	O
the	O
CODE	O
with	O
rhG-CSF	B-GENE
group	O
and	O
23%	O
in	O
the	O
CODE	O
alone	O
group	O
;	O
the	O
median	O
survival	O
was	O
59	O
and	O
32	O
weeks	O
,	O
respectively	O
,	O
in	O
these	O
groups	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

The	O
data	O
further	O
indicate	O
that	O
the	O
IL-7R	B-GENE
alpha	I-GENE
chains	I-GENE
are	O
directly	O
involved	O
in	O
the	O
activation	O
of	O
JAKs	B-GENE
and	O
STATs	B-GENE
and	O
have	O
a	O
major	O
role	O
in	O
proliferative	O
signaling	O
in	O
precursor	O
B	O
cells	O
.	O

Chromatin	O
repression	O
of	O
these	O
replacement	O
genes	O
would	O
be	O
avoided	O
,	O
consistent	O
with	O
the	O
high	O
,	O
constitutive	O
expression	O
of	O
replacement	O
H3	B-GENE
histone	I-GENE
genes	I-GENE
in	O
plants	O
.	O

The	O
mutants	O
were	O
obtained	O
by	O
substitution	O
into	O
a	O
molecular	O
clone	O
of	O
M-MuLV	O
DNA	O
by	O
DNA	O
from	O
two	O
acutely	O
transforming	O
viruses	O
,	O
Ableson	O
MuLV	O
(	O
Ab-MuLV	O
)	O
and	O
Moloney	O
murine	O
sarcoma	O
virus	O
(	O
M-MSV	O
)	O
.	O

Plasmids	O
pAMS12	O
,	O
pAMS13	O
and	O
pAMS14	O
were	O
transformed	O
into	O
a	O
laboratory	O
strain	O
of	O
Saccharomyces	O
cerevisiae	O
,	O
whereas	O
pAMS15	O
was	O
stably	O
introduced	O
into	O
two	O
commercial	O
wine	O
yeast	O
strains	O
.	O

Within	O
Stage	O
IA	O
,	O
141	O
patients	O
had	O
well	O
differentiated	O
tumor	O
(	O
G1	O
)	O
,	O
20	O
had	O
moderately	O
well	O
differentiated	O
tumor	O
(	O
G2	O
)	O
,	O
and	O
12	O
patients	O
had	O
poorly	O
differentiated	O
(	O
G3	O
)	O
.	O

Complete	O
recovery	O
of	O
liver	O
function	O
after	O
this	O
surgery	O
tended	O
to	O
be	O
slow	O
.	O

USF	B-GENE
synthesized	O
in	O
an	O
in	O
vitro	O
transcription	O
and	O
translation	O
system	O
also	O
binds	O
to	O
the	O
ADH	B-GENE
promoter	I-GENE
as	O
well	O
as	O
to	O
the	O
MLP	O
.	O

In	O
lean	O
mice	O
,	O
the	O
fat	O
/	O
water	O
intensity	O
ratio	O
was	O
about	O
1	O
:	O
4	O
,	O
about	O
half	O
that	O
in	O
normal	O
mice	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
The	O
authors	O
analyzed	O
41	O
persons	O
formerly	O
submitted	O
to	O
surgery	O
(	O
after	O
8	O
years	O
and	O
4	O
months	O
,	O
as	O
a	O
mean	O
)	O
,	O
31	O
to	O
highly	O
selective	O
vagotomy	O
,	O
and	O
10	O
to	O
truncal	O
or	O
selective	O
vagotomy	O
plus	O
gastroduodenal	O
drainage	O
.	O

Ultimate	O
strengthes	O
seem	O
to	O
be	O
reached	O
for	O
cast	O
cobalt	O
alloys	O
,	O
whereas	O
titanium	O
alloys	O
,	O
such	O
as	O
Ta	O
6	O
V	O
,	O
present	O
very	O
high	O
fatigue	O
limit	O
under	O
corrosion	O
.	O

Low-grade	O
gastric	O
MALT	O
lymphoma	O
and	O
helicobacter	O
heilmannii	O
(	O
Gastrospirillum	O
hominis	O
.	O

NOT4	B-GENE
interacts	O
with	O
NOT1	B-GENE
and	O
NOT3	B-GENE
in	O
the	O
two-hybrid	O
assay	O
,	O
and	O
overexpression	O
of	O
NOT3	B-GENE
or	O
NOT4	B-GENE
suppresses	O
not1	B-GENE
and	O
not2	B-GENE
mutations	O
.	O

Six	O
patients	O
with	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
-associated	O
myelopathy	O
(	O
HAM	O
)	O
were	O
studied	O
by	O
electrophysiologic	O
methods	O
.	O

The	O
naltrexone	O
/	O
lofexidine	O
combination	O
was	O
associated	O
with	O
a	O
more	O
rapid	O
resolution	O
of	O
the	O
opiate	O
withdrawal	O
syndrome	O
than	O
a	O
7-day	O
lofexidine-only	O
treatment	O
schedule	O
,	O
without	O
substantial	O
increases	O
in	O
withdrawal	O
symptoms	O
or	O
hypotensive	O
side-effects	O
.	O

PBSX	O
is	O
induced	O
by	O
agents	O
which	O
elicit	O
the	O
SOS	O
response	O
.	O

Regulation	O
of	O
embryonic	O
growth	O
and	O
lysosomal	O
targeting	O
by	O
the	O
imprinted	O
Igf2	B-GENE
/	I-GENE
Mpr	I-GENE
gene	I-GENE
.	O

Five	O
control	O
subjects	O
with	O
COPD	O
,	O
who	O
performed	O
the	O
same	O
sequence	O
of	O
tests	O
without	O
breathing	O
30%	O
O2	O
,	O
showed	O
no	O
change	O
in	O
flow	O
rates	O
or	O
density	O
dependence	O
.	O

The	O
protein	O
was	O
associated	O
with	O
purified	O
vaccinia	O
virus	O
particles	O
and	O
with	O
membranes	O
of	O
immature	O
and	O
mature	O
virions	O
that	O
were	O
visualized	O
by	O
electron	O
microscopy	O
of	O
infected	O
cells	O
.	O

Both	O
factors	O
demonstrated	O
significant	O
correlations	O
with	O
rCBF	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
and	O
frontal	O
polar	O
cortex	O
while	O
for	O
each	O
factor	O
there	O
were	O
also	O
unique	O
patterns	O
of	O
correlations	O
with	O
posterior	O
brain	O
regions	O
.	O

Sudomoina	O
,	O
A	O
.	O

An	O
exon	O
that	O
prevents	O
transport	O
of	O
a	O
mature	O
mRNA	O
.	O

The	O
results	O
revealed	O
increased	O
blood	O
lead	O
level	O
associated	O
with	O
decreased	O
blood	B-GENE
haemoglobin	I-GENE
and	O
increased	O
urinary	O
excretion	O
of	O
delta	O
amino	O
levulinic	O
acid	O
.	O

An	O
in	O
vivo	O
ZAP-70	B-GENE
substrate	O
,	O
SLP-76	B-GENE
,	O
implicated	O
in	O
Erk	B-GENE
activation	O
,	O
also	O
became	O
rapidly	O
tyrosine-phosphorylated	O
in	O
Jurkat	O
cells	O
,	O
but	O
not	O
in	O
P116	O
cells	O
,	O
upon	O
treatment	O
with	O
H2O2	O
.	O

Promoter	O
activity	O
was	O
dose-dependently	O
inhibited	O
by	O
cotransfection	O
with	O
either	O
ras	B-GENE
or	O
mos	B-GENE
oncogenes	I-GENE
,	O
but	O
oncogene	O
inhibition	O
was	O
reversed	O
and	O
the	O
overall	O
activity	O
increased	O
when	O
cells	O
were	O
treated	O
with	O
the	O
MAP	B-GENE
kinase	I-GENE
kinase	I-GENE
(	O
MKK	B-GENE
)	O
inhibitor	O
PD98059	O
.	O

Bone	O
and	O
bones	O
.	O

In	O
earlier	O
studies	O
we	O
identified	O
several	O
regulatory	O
elements	O
that	O
control	O
transcriptional	O
activation	O
and	O
aerobic	O
repression	O
of	O
one	O
of	O
these	O
genes	O
,	O
COX5b	B-GENE
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
a	O
soluble	O
form	O
of	O
ERp57	B-GENE
/	I-GENE
GRP58	I-GENE
by	O
Western	O
blotting	O
and	O
biosynthetic	O
labeling	O
.	O

The	O
models	O
accurately	O
localized	O
the	O
common	O
boundaries	O
between	O
the	O
PBB	O
and	O
CN	O
.	O

This	O
experiment	O
was	O
conducted	O
to	O
determine	O
if	O
the	O
sex	O
or	O
actual	O
egg	O
production	O
was	O
the	O
important	O
factor	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Respiratory	O
adaptation	O
to	O
chronic	O
hypoxia	O
in	O
newborn	O
rats	O
.	O

Collectively	O
,	O
these	O
and	O
previously	O
published	O
data	O
suggest	O
a	O
model	O
where	O
NS1	B-GENE
recruits	O
eIF4GI	B-GENE
specifically	O
to	O
the	O
5'	O
untranslated	O
region	O
(	O
5'	O
UTR	O
)	O
of	O
the	O
viral	O
mRNA	O
,	O
allowing	O
for	O
the	O
preferential	O
translation	O
of	O
the	O
influenza	O
virus	O
messengers	O
.	O

Today	O
there	O
is	O
no	O
doubt	O
that	O
elevated	O
plasma	O
cholesterol	O
levels	O
should	O
be	O
lowered	O
first	O
by	O
dietary	O
modification	O
even	O
in	O
early	O
childhood	O
,	O
beginning	O
at	O
the	O
age	O
of	O
two	O
years	O
.	O

HEED	B-GENE
was	O
found	O
to	O
bind	O
to	O
MA	B-GENE
protein	I-GENE
in	O
vitro	O
,	O
as	O
efficiently	O
as	O
in	O
vivo	O
in	O
yeast	O
cells	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
the	O
ACE	B-GENE
inhibitor	O
perindopril	O
(	O
and	O
the	O
diuretic	O
indapamide	O
for	O
those	O
with	O
no	O
definite	O
indication	O
for	O
or	O
contraindication	O
to	O
treatment	O
with	O
a	O
diuretic	O
)	O
or	O
matching	O
placebo	O
(	O
s	O
)	O
.	O

I	O
.	O

Northern	O
analysis	O
of	O
RNA	O
samples	O
isolated	O
from	O
ammonium-grown	O
cultures	O
of	O
the	O
ntcA	B-GENE
mutant	I-GENE
showed	O
reduced	O
amounts	O
of	O
glnA	B-GENE
message	I-GENE
and	O
the	O
absence	O
of	O
a	O
1	O
.	O
7-kb	O
transcript	O
.	O

RVR	B-GENE
'loss	O
of	O
function'	O
studies	O
by	O
constitutive	O
over-expression	O
of	O
a	O
dominant	O
negative	O
RVR	B-GENE
delta	I-GENE
E	I-GENE
resulted	O
in	O
increased	O
levels	O
of	O
p21Cip1	B-GENE
/	I-GENE
Waf1	I-GENE
and	O
myogenin	B-GENE
mRNAs	I-GENE
after	O
serum	O
withdrawal	O
.	O

Consistent	O
with	O
this	O
,	O
purified	O
Dlk	B-GENE
phosphorylated	O
core	O
histones	B-GENE
H3	I-GENE
,	O
H2A	B-GENE
and	O
H4	B-GENE
as	O
exogenous	O
substrates	O
and	O
endogenous	O
histone	B-GENE
H3	I-GENE
in	O
kinase	O
assays	O
with	O
nuclear	O
extracts	O
.	O

The	O
effects	O
of	O
taloximine	O
and	O
aminophylline	O
on	O
isolated	O
human	O
smooth	O
muscle	O
.	O

In	O
a	O
highly	O
select	O
group	O
of	O
stable	O
hypertensive	O
patients	O
,	O
we	O
have	O
assessed	O
the	O
strength	O
of	O
association	O
between	O
various	O
blood	O
pressure	O
measurements	O
(	O
24	O
h	O
average	O
automated	O
ambulatory	O
blood	O
pressure	O
,	O
4	O
h	O
automated	O
ambulatory	O
morning	O
average	O
blood	O
pressure	O
,	O
multiple	O
office	O
visit	O
average	O
blood	O
pressure	O
,	O
and	O
a	O
single	O
office	O
visit	O
average	O
blood	O
pressure	O
)	O
and	O
various	O
echocardiographic	O
indices	O
of	O
hypertensive	O
cardiac	O
target	O
organ	O
damage	O
(	O
left	O
atrial	O
diameter	O
,	O
left	O
ventricular	O
end	O
diastolic	O
diameter	O
,	O
posterior	O
wall	O
thickness	O
,	O
combined	O
wall	O
thickness	O
,	O
relative	O
wall	O
thickness	O
,	O
left	O
ventricular	O
mass	O
and	O
mass	O
index	O
,	O
and	O
combined	O
wall	O
thickness	O
/	O
left	O
ventricular	O
diastolic	O
diameter	O
ratio	O
)	O
.	O

The	O
structural	O
gene	O
encoding	O
the	O
novel	O
lantibiotic	O
epilancin	B-GENE
K7	I-GENE
from	O
Staphylococcus	O
epidermidis	O
K7	O
was	O
cloned	O
and	O
its	O
nucleotide	O
sequence	O
was	O
determined	O
.	O

Overexpression	O
of	O
H411	B-GENE
cDNA	I-GENE
in	O
the	O
RAW	O
264	O
.	O
7	O
macrophage	O
cell	O
line	O
promoted	O
an	O
increased	O
growth	O
rate	O
,	O
suggesting	O
that	O
expression	O
of	O
H411	B-GENE
is	O
part	O
of	O
the	O
proliferative	O
cell	O
response	O
to	O
LPS	O
.	O

Number	O
and	O
size	O
of	O
the	O
myelin	O
structures	O
in	O
the	O
pneumocytes	O
typ	O
II	O
increased	O
simultaneously	O
.	O

cDNA	O
and	O
structural	O
organization	O
of	O
the	O
gene	B-GENE
Pole1	I-GENE
for	O
the	O
mouse	B-GENE
DNA	I-GENE
polymerase	I-GENE
epsilon	I-GENE
catalytic	I-GENE
subunit	I-GENE
.	O

A	O
transcription	O
factor	O
exclusion	O
assay	O
was	O
used	O
to	O
show	O
that	O
the	O
PCF1	B-GENE
mutation	I-GENE
affects	O
two	O
distinct	O
stages	O
in	O
transcription	O
:	O
one	O
prior	O
to	O
and	O
one	O
after	O
stable	O
complex	O
formation	O
;	O
and	O
that	O
these	O
effects	O
are	O
mediated	O
by	O
a	O
component	O
of	O
the	O
stable	O
complex	O
.	O

Efficacy	O
was	O
determined	O
by	O
responses	O
to	O
question	O
3	O
(	O
ability	O
to	O
achieve	O
an	O
erection	O
)	O
and	O
question	O
4	O
(	O
ability	O
to	O
maintain	O
an	O
erection	O
)	O
of	O
the	O
15-item	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
.	O

The	O
1489-base	O
pair	O
EFIA	B-GENE
cDNA	O
encodes	O
a	O
322-amino	O
acid	O
protein	O
which	O
is	O
nearly	O
identical	O
to	O
two	O
previously	O
described	O
human	O
DNA	O
binding	O
proteins	O
.	O

PRL	B-GENE
receptor	I-GENE
also	O
activates	O
SHP-2	B-GENE
,	O
a	O
cytosolic	B-GENE
tyrosine	I-GENE
phosphatase	I-GENE
.	O

Thirty-one	O
age-matched	O
,	O
conscious	O
,	O
virgin	O
,	O
male	O
Sprague-Dawley	O
rats	O
and	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHRs	O
)	O
were	O
individually	O
injected	O
with	O
a	O
single	O
subcutaneous	O
dose	O
of	O
85	O
mg	O
/	O
kg	O
dl-isoproterenol	O
to	O
determine	O
the	O
degree	O
and	O
time	O
course	O
of	O
drug-induced	O
cardiac	O
failure	O
and	O
functional	O
recovery	O
.	O

Termination	O
of	O
induced	O
VT	O
on	O
the	O
first	O
attempt	O
was	O
comparable	O
with	O
BV	O
pacing	O
(	O
87	O
.	O
4%	O
)	O
versus	O
RV	O
pacing	O
(	O
89	O
.	O
6%	O
)	O
.	O

We	O
mapped	O
two	O
overlapping	O
expressed	O
sequence	O
tag	O
clones	O
within	O
a	O
genomic	O
contig	O
on	O
human	O
chromosome	O
5	O
,	O
band	O
q31	O
.	O

60	O
patients	O
were	O
entered	O
into	O
a	O
randomised	O
study	O
comparing	O
vindesine	O
(	O
3	O
mg	O
/	O
m2	O
/	O
week	O
)	O
plus	O
interferon-alpha	B-GENE
2b	I-GENE
(	O
6	O
U	O
/	O
m2	O
3	O
times	O
per	O
week	O
)	O
to	O
vindesine	O
alone	O
or	O
to	O
interferon	B-GENE
alone	O
for	O
the	O
treatment	O
of	O
metastatic	O
malignant	O
melanoma	O
.	O

However	O
,	O
mutations	O
in	O
the	O
HNF-4	B-GENE
binding	I-GENE
site	I-GENE
on	O
element	B-GENE
CIIB	I-GENE
and	O
inhibition	O
of	O
HNF-4	B-GENE
synthesis	O
in	O
HepG2	O
cells	O
by	O
antisense	O
HNF-4	B-GENE
constructs	I-GENE
decreased	O
the	O
apoCII	B-GENE
promoter	I-GENE
activity	O
to	O
25-40%	O
of	O
the	O
control	O
,	O
indicating	O
that	O
HNF-4	B-GENE
is	O
a	O
positive	O
regulator	O
of	O
the	O
apoCII	B-GENE
gene	I-GENE
.	O

Our	O
results	O
indicate	O
that	O
D	B-GENE
(	I-GENE
4	I-GENE
)	I-GENE
and	O
D	B-GENE
(	I-GENE
2L	I-GENE
)	I-GENE
receptors	I-GENE
activate	O
the	O
ERK	B-GENE
kinase	I-GENE
cascade	O
by	O
first	O
mobilizing	O
signaling	O
by	O
the	O
PDGF	B-GENE
receptor	I-GENE
,	O
followed	O
by	O
the	O
subsequent	O
activation	O
of	O
ERK1	B-GENE
/	I-GENE
2	I-GENE
by	O
pathways	O
associated	O
with	O
this	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
.	O

The	O
effects	O
of	O
anabolic	O
implants	O
on	O
rate	O
,	O
composition	O
and	O
energetic	O
efficiency	O
of	O
growth	O
were	O
determined	O
in	O
steers	O
fed	O
diets	O
varying	O
in	O
forage	O
and	O
grain	O
content	O
.	O

The	O
results	O
of	O
the	O
lab	O
and	O
field	O
tests	O
yielded	O
high	O
levels	O
of	O
infestation	O
in	O
larvae	O
with	O
values	O
ranging	O
from	O
90	O
to	O
100%	O
and	O
from	O
85	O
to	O
95%	O
,	O
respectively	O
.	O

The	O
FAS	B-GENE
promoter	I-GENE
was	O
up-regulated	O
by	O
insulin	B-GENE
through	O
the	O
proximal	O
insulin	B-GENE
response	I-GENE
sequence	I-GENE
containing	O
an	O
E-box	O
motif	O
at	O
the	O
-65-base	O
pair	O
position	O
.	O

In	O
cell	O
lines	O
transformed	O
by	O
BCR	B-GENE
/	I-GENE
ABL	I-GENE
,	O
CRKL	B-GENE
was	O
tyrosine	O
phosphorylated	O
,	O
while	O
CRK	B-GENE
was	O
not	O
.	O

The	O
two-hybrid	O
assay	O
was	O
then	O
performed	O
using	O
full-length	O
genes	O
of	O
CI	B-GENE
,	O
HC-Pro	B-GENE
,	O
P1	B-GENE
,	O
P3	B-GENE
,	O
and	O
CP	B-GENE
,	O
but	O
no	O
heterologous	O
interactions	O
were	O
detected	O
.	O

The	O
nucleolin	B-GENE
gene	I-GENE
extends	O
over	O
9000	O
base-pairs	O
and	O
is	O
split	O
into	O
14	O
exons	O
that	O
encode	O
the	O
706	O
amino	O
acid	O
residues	O
of	O
the	O
protein	O
.	O

The	O
absolute	O
configuration	O
at	O
C-2	O
in	O
monocrotalic	O
acid	O
.	O

With	O
the	O
exception	O
of	O
mutants	O
that	O
remove	O
the	O
membrane	O
anchor	O
domain	O
,	O
all	O
of	O
the	O
mutant	O
glycoproteins	O
retained	O
the	O
ability	O
to	O
cause	O
fusion	O
of	O
CD4-bearing	O
cells	O
.	O

We	O
also	O
present	O
evidence	O
that	O
human	B-GENE
HYAL1	I-GENE
is	O
identical	O
to	O
an	O
uncharacterized	O
gene	O
positionally	O
cloned	O
by	O
others	O
from	O
chromosome	O
3p21	O
.	O
3	O
that	O
is	O
homozygously	O
deleted	O
in	O
several	O
small-cell	O
lung	O
carcinoma	O
cell	O
lines	O
.	O

Furthermore	O
,	O
strains	O
with	O
mutant	B-GENE
RPM1	I-GENE
genes	I-GENE
also	O
accumulate	O
precursor	B-GENE
Rpm1r	I-GENE
,	O
suggesting	O
that	O
mutations	O
in	O
either	O
gene	O
can	O
lead	O
to	O
similar	O
biogenesis	O
defects	O
.	O

Isolated	O
Systolic	O
Hypertension	O
:	O
An	O
Update	O
.	O

STK	O
/	O
RON-expressing	O
Ba	O
/	O
F3	O
pro-B	O
cells	O
(	O
BaF	O
/	O
STK	O
)	O
exhibited	O
MSP-dependent	O
growth	O
,	O
whereas	O
STK	B-GENE
/	I-GENE
RON-expressing	O
mouse	O
erythroleukaemia	O
cells	O
(	O
MEL	O
/	O
STK	B-GENE
)	O
displayed	O
MSP-induced	O
apoptosis	O
.	O

Also	O
,	O
the	O
BALB	B-GENE
/	I-GENE
c	I-GENE
gene	I-GENE
contains	O
a	O
single	O
substitution	O
in	O
a	O
conserved	O
octamer	O
sequence	O
approximately	O
equal	O
to	O
100	O
nucleotides	O
upstream	O
of	O
the	O
coding	O
region	O
,	O
which	O
could	O
affect	O
its	O
expression	O
.	O

Immunological	O
testing	O
was	O
performed	O
on	O
all	O
brewery	O
workers	O
and	O
some	O
control	O
volunteers	O
using	O
skin	O
prick	O
testing	O
with	O
hops	O
,	O
barley	O
,	O
and	O
yeast	O
antigens	O
as	O
well	O
as	O
other	O
nonoccupational	O
allergens	O
,	O
and	O
by	O
determining	O
total	O
serum	B-GENE
IgE	I-GENE
levels	O
.	O

Purified	O
CarP	B-GENE
binds	O
in	O
vitro	O
to	O
the	O
carAB	B-GENE
control	I-GENE
region	I-GENE
and	O
protects	O
against	O
DNase	B-GENE
I	I-GENE
two	O
approximately	O
25	O
bp	O
long	O
stretches	O
,	O
one	O
of	O
which	O
is	O
located	O
just	O
downstream	O
of	O
the	O
GATC	B-GENE
sequence	I-GENE
.	O

An	O
intact	O
neurovascular	O
supply	O
is	O
essential	O
for	O
the	O
viability	O
of	O
a	O
muscle	O
flap	O
.	O

Prevention	O
of	O
maternal	O
Rh	O
sensitization	O
:	O
anti-Rh	B-GENE
immune	I-GENE
globulin	I-GENE
.	O

The	O
pCMBS-reactive	O
sulfhydryl	O
groups	O
were	O
located	O
exclusively	O
in	O
the	O
exofacial	O
half	O
of	O
the	O
plasma	O
membrane	O
and	O
,	O
when	O
presented	O
in	O
a	O
helical	O
model	O
,	O
lie	O
along	O
one	O
side	O
of	O
the	O
helices	O
.	O

These	O
mutations	O
alter	O
two	O
regions	O
of	O
GAL4	B-GENE
protein	I-GENE
:	O
the	O
DNA	O
binding	O
domain	O
,	O
and	O
the	O
transcription	O
activation	O
domain	O
.	O

However	O
,	O
deletions	O
of	O
the	O
C	O
terminal	O
11	O
or	O
14	O
amino	O
acids	O
had	O
more	O
substantial	O
effects	O
.	O

In	O
the	O
local	O
geomagnetic	O
field	O
,	O
the	O
animals	O
preferred	O
the	O
SE-sector	O
.	O

It	O
contains	O
a	O
5'-noncoding	O
region	O
(	O
NCR	O
)	O
of	O
73	O
nucleotides	O
,	O
five	O
open	O
reading	O
frames	O
(	O
ORFs	O
1	O
to	O
5	O
)	O
which	O
encode	O
proteins	O
with	O
M	O
(	O
r	O
)	O
160	B-GENE
kDa	I-GENE
RNA-dependent	I-GENE
RNA	I-GENE
polymerase	I-GENE
(	I-GENE
ORF1	I-GENE
)	I-GENE
,	O
26	B-GENE
kDa	I-GENE
movement	I-GENE
protein	I-GENE
1	I-GENE
(	I-GENE
ORF2	I-GENE
)	I-GENE
,	O
13	B-GENE
kDa	I-GENE
movement	I-GENE
protein	I-GENE
2	I-GENE
(	I-GENE
ORF3	I-GENE
)	I-GENE
,	O
10	B-GENE
kDa	I-GENE
movement	I-GENE
protein	I-GENE
3	I-GENE
(	I-GENE
ORF4	I-GENE
)	I-GENE
,	O
24	B-GENE
kDa	I-GENE
coat	I-GENE
protein	I-GENE
(	I-GENE
OFR5	I-GENE
)	I-GENE
,	O
and	O
a	O
3'	O
NCR	O
of	O
76	O
nucleotides	O
.	O

Audiological	O
findings	O
in	O
pregnancy	O
.	O

Hemodynamic	O
assessment	O
was	O
obtained	O
before	O
and	O
following	O
administration	O
of	O
digoxin	O
10	O
micrograms	O
/	O
kg	O
IV	O
or	O
dopamine	O
,	O
5	O
to	O
12	O
micrograms	O
/	O
kg	O
/	O
min	O
IV	O
.	O

Both	O
groups	O
were	O
subjected	O
to	O
tests	O
of	O
delayed	O
hypersensitivity	O
with	O
Candidin	O
,	O
Trycophytin	O
and	O
Tuberculin	O
.	O

Notably	O
,	O
these	O
residues	O
are	O
located	O
in	O
different	O
domains	O
.	O

The	O
human	O
U4	B-GENE
/	I-GENE
U6	I-GENE
snRNP	I-GENE
contains	O
60	O
and	O
90kD	O
proteins	O
that	O
are	O
structurally	O
homologous	O
to	O
the	O
yeast	O
splicing	O
factors	O
Prp4p	B-GENE
and	O
Prp3p	B-GENE
.	O

The	O
diagnostic	O
accuracy	O
of	O
serum	O
PE-1	B-GENE
was	O
0	O
.	O
80	O
,	O
and	O
that	O
of	O
amylase	B-GENE
0	O
.	O
97	O
.	O

Six	O
healthy	O
male	O
subjects	O
received	O
single	O
oral	O
doses	O
of	O
regular	O
release	O
(	O
RR	O
)	O
quinidine	O
sulfate	O
,	O
sustained	O
release	O
(	O
SR	O
)	O
quinidine	O
bisulfate	O
and	O
the	O
same	O
dose	O
of	O
the	O
SR	O
product	O
with	O
food	O
(	O
SR-F	O
)	O
.	O

We	O
discuss	O
the	O
results	O
in	O
relation	O
to	O
previous	O
systems	O
for	O
parcellating	O
the	O
posterior	O
ectosylvian	O
gyrus	O
of	O
the	O
cat	O
and	O
consider	O
the	O
possibility	O
that	O
divisions	O
of	O
the	O
feline	O
posterior	O
ectosylvian	O
gyrus	O
correspond	O
directly	O
to	O
areas	O
making	O
up	O
the	O
superior	O
temporal	O
gyrus	O
in	O
primates	O
.	O

The	O
results	O
indicate	O
that	O
anthraquinone	O
sennoside	O
B	O
and	O
rhein	O
are	O
weakly	O
genotoxic	O
.	O

Studies	O
of	O
biochemical	O
and	O
morphological	O
changes	O
(	O
between	O
normal	O
and	O
treated	O
animals	O
)	O
show	O
that	O
chrysotile	O
induces	O
an	O
increase	O
in	O
the	O
lung	O
free	O
cell	O
population	O
and	O
pulmonary	O
surfactant	O
levels	O
.	O

The	O
motility	O
of	O
sperm	O
,	O
except	O
for	O
those	O
adjacent	O
to	O
both	O
electrodes	O
,	O
did	O
not	O
change	O
after	O
stimulation	O
for	O
60s	O
,	O
despite	O
a	O
high	O
electrical	O
energy	O
.	O

11-Aminoundecanoyl-SK-NH2	O
and	O
11-aminoundecanoyl-SH-NH2	O
establish	O
that	O
a	O
simple	O
alkyl	O
backbone	O
can	O
maintain	O
an	O
appropriate	O
distance	O
between	O
three	O
elements	O
critical	O
for	O
recognition	O
by	O
the	O
fungal	O
enzyme's	O
peptide-binding	O
site	O
:	O
a	O
simple	O
omega-terminal	O
amino	O
group	O
,	O
a	O
beta-hydroxyl	O
,	O
and	O
an	O
epsilon-amino	O
group	O
or	O
an	O
imidazole	O
.	O

Homo-oligomerisation	O
and	O
nuclear	O
localisation	O
of	O
mouse	B-GENE
histone	I-GENE
deacetylase	I-GENE
1	O
.	O

Phorbol	O
esters	O
stimulated	O
phosphorylation	O
of	O
CSK	B-GENE
35H	I-GENE
proteins	I-GENE
,	O
thus	O
emphasizing	O
that	O
sequences	O
isolated	O
according	O
to	O
PKC	B-GENE
binding	O
activity	O
in	O
vitro	O
are	O
also	O
PKC	B-GENE
substrates	O
in	O
vivo	O
.	O

Serodiagnosis	O
of	O
ectromelia	O
in	O
laboratory	O
mice	O
.	O

TBP	B-GENE
can	O
be	O
phosphorylated	O
in	O
vitro	O
by	O
extracts	O
of	O
U937	O
cells	O
or	O
by	O
bacterially	O
expressed	O
activated	O
ERK2	B-GENE
;	O
the	O
phosphorylation	O
sites	O
were	O
mapped	O
to	O
ERK	B-GENE
kinase	I-GENE
consensus	I-GENE
sites	I-GENE
in	O
the	O
TBP	B-GENE
amino-terminal	I-GENE
domain	I-GENE
.	O

Sodium-taurocholate-induced	O
acute	O
necrotizing	O
pancreatitis	O
does	O
not	O
affect	O
jejunal	O
oxygenation	O
in	O
pigs	O
.	O

Laser	O
ablation	O
has	O
been	O
employed	O
as	O
a	O
therapeutic	O
measure	O
for	O
chronic	O
pulmonary	O
emphysema	O
.	O

This	O
differential	O
sensitivity	O
to	O
DB	O
,	O
as	O
measured	O
by	O
a	O
lower	O
concentration	O
of	O
DB	O
which	O
caused	O
loss	O
of	O
righting	O
in	O
LS	O
,	O
was	O
accompanied	O
by	O
an	O
equal	O
rate	O
of	O
water-soluble	O
barbiturate	O
brain	O
distribution	O
and	O
elimination	O
in	O
the	O
two	O
lines	O
.	O

In	O
the	O
SPK	O
and	O
PTA	O
category	O
,	O
anti-T-cell	O
therapy	O
significantly	O
lowered	O
the	O
risk	O
of	O
graft	O
loss	O
.	O

Smoking	O
was	O
regarded	O
as	O
the	O
major	O
contribution	O
to	O
pulmonary	O
dysfunction	O
.	O

Deletion	O
analysis	O
showed	O
that	O
the	O
-321	O
/	O
+41	O
sequence	O
was	O
sufficient	O
for	O
both	O
the	O
constitutive	O
promoter	O
activity	O
and	O
auto-activation	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
identified	O
the	O
interaction	O
of	O
C	B-GENE
/	I-GENE
EBPs	I-GENE
and	O
Sp1	B-GENE
to	O
this	O
region	O
.	O

A	O
reduction	O
of	O
the	O
aspartate	B-GENE
aminotransferase	I-GENE
activity	O
was	O
observed	O
from	O
800	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
/	O
d	O
onwards	O
.	O

Through	O
two	O
novel	O
mechanisms	O
,	O
Arf	B-GENE
inhibits	O
the	O
oncoprotein	B-GENE
Hdm2	I-GENE
,	O
a	O
negative	O
regulator	O
of	O
p53	B-GENE
.	O

Incidence	O
correlated	O
with	O
the	O
grade	O
of	O
oral	O
hygiene	O
und	O
periodontal	O
disease	O
.	O

On	O
the	O
basis	O
of	O
its	O
bZIP	B-GENE
structural	O
homology	O
,	O
meq	B-GENE
is	O
perhaps	O
the	O
only	O
member	O
of	O
the	O
jun-fos	B-GENE
gene	I-GENE
family	I-GENE
completely	O
viral	O
in	O
origin	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-GENE
in	O
the	O
GM-CSF	B-GENE
promoter	I-GENE
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-GENE
isoforms	I-GENE
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

FAK	B-GENE
localizes	O
to	O
sites	O
of	O
transmembrane	B-GENE
integrin	I-GENE
receptor	I-GENE
clustering	O
and	O
facilitates	O
intracellular	O
signaling	O
events	O
.	O

In	O
concert	O
with	O
the	O
coactivator	O
CREB	B-GENE
binding	I-GENE
protein	I-GENE
/	I-GENE
p300	I-GENE
,	O
which	O
interacts	O
with	O
GABPalpha	B-GENE
,	O
the	O
binding	O
of	O
GABPalpha	B-GENE
and	I-GENE
-beta	I-GENE
to	O
the	O
dyad	O
symmetry	O
element	O
controls	O
the	O
induction	O
of	O
IL-16	B-GENE
promoter	I-GENE
in	O
T	O
cells	O
.	O

DNase	B-GENE
I	I-GENE
footprinting	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
PBP	B-GENE
binds	O
to	O
the	O
half-site	O
of	O
each	O
palindrome	O
with	O
the	O
core	B-GENE
recognition	I-GENE
sequence	I-GENE
TGGGAG	I-GENE
.	O

You	O
make	O
the	O
diagnosis	O
.	O

In	O
hemodialyzed	O
patients	O
(	O
Epo	B-GENE
and	O
Non-Epo	O
group	O
)	O
leptin	B-GENE
levels	O
were	O
significantly	O
higher	O
when	O
compared	O
to	O
CAPD	O
patients	O
(	O
Epo	B-GENE
and	O
Non-Epo	O
group	O
,	O
respectively	O
)	O
.	O

Osteogenesis	O
imperfecta	O
.	O

This	O
region	O
of	O
60	O
amino	O
acids	O
may	O
be	O
involved	O
in	O
coiled-coil	O
interactions	O
similar	O
to	O
those	O
that	O
facilitate	O
the	O
filament	O
formation	O
in	O
the	O
rod	O
region	O
.	O

Detection	O
of	O
hemophilia	O
A	O
carriers	O
.	O

DNase	B-GENE
I	I-GENE
footprinting	O
and	O
electrophoretic	O
mobility	O
shift	O
analyses	O
revealed	O
two	O
hepatocyte	B-GENE
nuclear	I-GENE
factor-1	I-GENE
(	O
HNF1	B-GENE
)	O
,	O
three	O
CCAAT	B-GENE
/	I-GENE
enhancer-binding	I-GENE
protein	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
)	O
,	O
and	O
one	O
consensus	O
palindromic	O
thyroid	B-GENE
hormone	I-GENE
response	I-GENE
elements	I-GENE
within	O
the	O
first	O
215	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
the	O
promoter	O
sequence	O
of	O
rat	B-GENE
Std	I-GENE
.	O

GR63178A	O
is	O
a	O
water-soluble	O
analogue	O
of	O
mitoquidone	O
,	O
a	O
pentacyclic	O
pyrroloquinone	O
.	O

Identification	O
of	O
a	O
proline-rich	O
sequence	O
in	O
the	O
CD2	B-GENE
cytoplasmic	I-GENE
domain	I-GENE
critical	O
for	O
regulation	O
of	O
integrin-mediated	O
adhesion	O
and	O
activation	O
of	O
phosphoinositide	B-GENE
3-kinase	I-GENE
.	O

16	O
women	O
were	O
treated	O
with	O
methadone	O
to	O
prevent	O
withdrawal	O
symptoms	O
.	O

Galphaq	B-GENE
,	O
Galpha12	B-GENE
,	O
and	O
Galpha13	B-GENE
,	O
but	O
not	O
Galphai	B-GENE
,	O
activate	O
SRF	B-GENE
through	O
RhoA	B-GENE
.	O

Fundus	O
changes	O
in	O
(	O
type	O
II	O
)	O
mesangiocapillary	O
glomerulonephritis	O
simulating	O
drusen	O
:	O
a	O
histopathological	O
report	O
.	O

The	O
malate	B-GENE
synthase	I-GENE
gene	I-GENE
,	O
MLS1	B-GENE
,	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
is	O
transcriptionally	O
regulated	O
by	O
the	O
carbon	O
source	O
in	O
the	O
growth	O
medium	O
.	O

OBJECTIVE	O
:	O
To	O
follow-up	O
prospectively	O
patients	O
with	O
arthritis	O
after	O
infection	O
with	O
beta-haemolytic	O
streptococci	O
of	O
Lancefield	O
group	O
A	O
(	O
beta	O
HSA	O
)	O
,	O
with	O
emphasis	O
on	O
clinical	O
characteristics	O
and	O
serological	O
features	O
.	O

Gemfibrozil	O
in	O
hyperlipidaemic	O
patients	O
with	O
peripheral	O
arterial	O
disease	O
:	O
some	O
undiscovered	O
actions	O
.	O

Mucin	B-GENE
gene	I-GENE
expression	O
has	O
been	O
shown	O
to	O
be	O
altered	O
in	O
many	O
intestinal	O
diseases	O
and	O
especially	O
cancers	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
results	O
support	O
earlier	O
reports	O
that	O
collagenase	B-GENE
inhibitors	O
are	O
useful	O
in	O
controlling	O
blister	O
formation	O
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

Framingham	O
Type	O
A	O
behavior	O
was	O
positively	O
associated	O
with	O
diastolic	O
blood	O
pressure	O
(	O
r	O
=	O
0	O
.	O
17	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
among	O
the	O
women	O
.	O

The	O
neglect	O
of	O
Richards's	O
theory	O
demonstrates	O
the	O
range	O
of	O
factors	O
,	O
other	O
than	O
the	O
strictly	O
scientific	O
,	O
which	O
can	O
be	O
important	O
in	O
determining	O
the	O
influence	O
or	O
otherwise	O
of	O
a	O
psychological	O
theory	O
.	O

C	B-GENE
/	I-GENE
EBP	I-GENE
beta	I-GENE
V	I-GENE
>	O
A	O
selectively	O
binds	O
only	O
the	O
subset	O
of	O
C	B-GENE
/	I-GENE
EBP	I-GENE
sites	I-GENE
that	O
are	O
also	O
DBP	B-GENE
sites	I-GENE
,	O
both	O
as	O
oligonucleotides	O
and	O
within	O
the	O
natural	O
contexts	O
of	O
the	O
albumin	B-GENE
and	O
cholesterol	B-GENE
hydroxylase	I-GENE
promoters	I-GENE
.	O

The	O
nucleotide	O
(	O
nt	O
)	O
sequences	O
of	O
the	O
exons	O
,	O
exon	O
/	O
intron	O
boundaries	O
and	O
5'-	O
and	O
3'-untranslated	O
regions	O
were	O
determined	O
.	O

The	O
first	O
algorithm	O
,	O
FOREPROJ	O
,	O
is	O
a	O
fast-forward	O
projection	O
algorithm	O
that	O
allows	O
calculation	O
of	O
the	O
3-D	O
attenuation	O
correction	O
factors	O
(	O
ACF's	O
)	O
directly	O
from	O
a	O
two-dimensional	O
(	O
2-D	O
)	O
transmission	O
scan	O
,	O
without	O
first	O
reconstructing	O
the	O
attenuation	O
map	O
and	O
then	O
performing	O
a	O
3-D	O
forward	O
projection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
reproducibility	O
of	O
a	O
number	O
of	O
simplified	O
clearance	O
methods	O
using	O
chromium-51	O
ethylenediamine	O
tetraacetic	O
acid	O
(	O
51Cr-EDTA	O
)	O
and	O
to	O
compare	O
these	O
with	O
the	O
multiple	O
blood	O
sample	O
technique	O
.	O

Site-directed	O
mutagenesis	O
of	O
CAR	B-GENE
revealed	O
that	O
CAR	B-GENE
residues	I-GENE
Leu73	I-GENE
and	I-GENE
Lys121	I-GENE
and	I-GENE
/	I-GENE
or	I-GENE
Lys123	I-GENE
are	O
critical	O
contact	O
residues	O
,	O
with	O
Tyr80	O
and	O
Tyr83	O
being	O
peripherally	O
involved	O
in	O
the	O
binding	O
interaction	O
with	O
the	O
Ad5	O
,	O
Ad9	O
,	O
Ad12	O
,	O
and	O
Ad41L	O
fiber	O
knobs	O
.	O

The	O
Prolactin	B-GENE
levels	O
were	O
within	O
the	O
physiological	O
norms	O
;	O
the	O
responses	O
to	O
TRH	B-GENE
were	O
normal	O
,	O
and	O
elevated	O
only	O
in	O
a	O
few	O
cases	O
.	O

To	O
investigate	O
the	O
activity	O
of	O
TCF11	B-GENE
through	O
this	O
selected	O
site	O
,	O
both	O
alone	O
and	O
in	O
the	O
presence	O
of	O
MafG	B-GENE
,	O
we	O
have	O
used	O
a	O
transient	O
transfection	O
assay	O
.	O

Interleukin-1	B-GENE
levels	O
remained	O
low	O
throughout	O
the	O
course	O
.	O

This	O
dominant-negative	O
effect	O
of	O
FRNK	B-GENE
was	O
reversed	O
by	O
a	O
point	O
mutation	O
(	O
Leu-1034	O
to	O
Ser	O
)	O
which	O
prevented	O
FRNK	B-GENE
localization	O
to	O
focal	O
contact	O
sites	O
.	O

In	O
ten	O
other	O
experiments	O
(	O
5	O
experimental	O
and	O
5	O
control	O
rats	O
)	O
99mTc-sulfur	O
colloid	O
was	O
injected	O
intravenously	O
.	O

Additionally	O
,	O
the	O
mouse	O
promoter	O
contains	O
22	O
copies	O
of	O
a	O
CT	B-GENE
dinucleotide	I-GENE
repeat	I-GENE
sequence	I-GENE
located	O
approximately	O
155	O
bp	O
5'	O
to	O
exon	O
1	O
.	O

Expression	O
of	O
various	O
FAK	B-GENE
mutants	I-GENE
in	O
the	O
FAK-	O
cells	O
showed	O
that	O
FAK	B-GENE
kinase	I-GENE
activity	O
,	O
the	O
Tyr-397	B-GENE
/	I-GENE
SH2	I-GENE
domain	I-GENE
binding	I-GENE
site	I-GENE
,	O
and	O
the	O
first	O
proline-rich	O
SH3	B-GENE
binding	I-GENE
region	I-GENE
in	O
the	O
FAK	B-GENE
C-terminal	I-GENE
domain	I-GENE
were	O
individually	O
needed	O
to	O
promote	O
full	O
FAK-mediated	O
FAK-	O
cell	O
migration	O
to	O
FN	B-GENE
whereas	O
direct	O
paxillin	B-GENE
binding	O
to	O
FAK	B-GENE
was	O
not	O
required	O
.	O

In	O
contrast	O
,	O
over-expression	O
of	O
RAR	B-GENE
beta	I-GENE
only	O
poorly	O
restored	O
differentiation	O
,	O
although	O
it	O
could	O
replace	O
RAR	B-GENE
gamma	I-GENE
for	O
the	O
activation	O
of	O
target	O
genes	O
.	O

CONCLUSION	O
:	O
Human	O
preterm	O
birth	O
is	O
associated	O
with	O
significantly	O
lower	O
progesterone	O
/	O
17	O
beta-estradiol	O
ratios	O
than	O
those	O
of	O
women	O
with	O
preterm	O
labor	O
delivered	O
at	O
term	O
.	O

Thus	O
,	O
two	O
very	O
different	O
regulatory	O
elements	O
are	O
used	O
to	O
mediate	O
estrogen	O
induction	O
of	O
related	O
genes	O
in	O
chickens	O
and	O
amphibians	O
.	O

Specifically	O
,	O
by	O
oligonucleotide-directed	O
site-specific	O
mutagenesis	O
,	O
we	O
demonstrate	O
that	O
of	O
10	O
cysteine	O
residues	O
in	O
the	O
ORF4	O
polypeptide	O
,	O
only	O
C-421	O
and	O
C-426	O
are	O
essential	O
for	O
transactivator	O
function	O
and	O
suggest	O
that	O
these	O
cysteine	O
residues	O
may	O
participate	O
in	O
critical	O
protein-protein	O
interactions	O
rather	O
than	O
protein-nucleic	O
acid	O
interactions	O
to	O
mediate	O
ORF4	O
inducibility	O
.	O

The	O
ratio	O
of	O
P-31	O
NMR-S	O
derived	O
inorganic	O
phosphates	O
[	O
Pi	O
]	O
to	O
phosphocreatine	O
[	O
PCr	O
]	O
was	O
significantly	O
greater	O
at	O
rest	O
in	O
LVH	O
baboons	O
[	O
0	O
.	O
53	O
+	O
/	O
-	O
0	O
.	O
06	O
versus	O
controls	O
=	O
0	O
.	O
41	O
+	O
/	O
-	O
0	O
.	O
17	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
]	O
.	O

The	O
effect	O
of	O
these	O
cell	O
cycle	O
regulators	O
is	O
not	O
specific	O
to	O
the	O
rap1s	B-GENE
or	O
hmr	B-GENE
delta	I-GENE
A	I-GENE
mutation	I-GENE
,	O
since	O
swi6	B-GENE
,	O
swi4	B-GENE
,	O
and	O
clb5	B-GENE
mutations	I-GENE
also	O
suppress	O
mutations	O
in	O
SIR1	B-GENE
,	O
another	O
gene	O
implicated	O
in	O
the	O
establishment	O
of	O
silencing	O
.	O

Some	O
of	O
the	O
peptide	B-GENE
:	I-GENE
MBP	I-GENE
fusions	I-GENE
were	O
also	O
analyzed	O
using	O
surface	O
plasmon	O
resonance	O
.	O

3	O
.	O

METHODS	O
:	O
We	O
studied	O
the	O
clinical	O
benefit	O
of	O
depth-dependent	O
RR	O
,	O
nonuniform	O
AC	O
using	O
a	O
scanning	O
line	O
source	O
,	O
and	O
scatter	O
correction	O
(	O
photon	O
energy	O
recovery	O
[	O
PER	O
]	O
)	O
compared	O
with	O
filtered	O
backprojection	O
alone	O
.	O

All	O
89	O
participating	O
household	O
members	O
were	O
anti-HIV	O
seronegative	O
,	O
and	O
78	O
who	O
were	O
tested	O
were	O
serum	B-GENE
p24	I-GENE
antigen	I-GENE
negative	O
.	O

In	O
contrast	O
,	O
a	O
Maf-related	B-GENE
protein	I-GENE
,	O
Nrl	B-GENE
,	O
completely	O
mimicked	O
c-Maf	B-GENE
actions	O
.	O

TRAF2	B-GENE
is	O
a	O
potent	O
activator	O
of	O
a	O
95-kDa	B-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
termed	O
germinal	B-GENE
center	I-GENE
kinase	I-GENE
related	I-GENE
(	O
GCKR	B-GENE
,	O
also	O
referred	O
to	O
as	O
KHS1	B-GENE
)	O
,	O
which	O
signals	O
activation	O
of	O
the	O
SAPK	B-GENE
pathway	O
.	O

Clinical	O
and	O
epidemiological	O
characteristics	O
of	O
oral	O
squamous	O
cell	O
carcinoma	O
in	O
women	O
BACKGROUND	O
:	O
Squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
of	O
the	O
oral	O
cavity	O
occurs	O
mainly	O
in	O
the	O
male	O
population	O
.	O

The	O
TraD	B-GENE
protein	I-GENE
(	I-GENE
83	I-GENE
,	I-GENE
899	I-GENE
Da	I-GENE
)	I-GENE
contains	O
three	O
hydrophobic	O
regions	O
,	O
of	O
which	O
two	O
are	O
located	O
near	O
the	O
amino-terminal	O
region	O
.	O

Responses	O
to	O
brainstem	O
of	O
nuclei	O
medialis	O
dorsalis	O
,	O
lateralis	O
posterior	O
were	O
of	O
considerably	O
longer	O
latency	O
.	O

Human	O
ZFM1	B-GENE
protein	I-GENE
is	O
a	O
transcriptional	O
repressor	O
that	O
interacts	O
with	O
the	O
transcription	B-GENE
activation	I-GENE
domain	I-GENE
of	I-GENE
stage-specific	I-GENE
activator	I-GENE
protein	I-GENE
.	O

Reaction	O
times	O
to	O
tachistoscopically	O
presented	O
stimuli	O
in	O
diabetics	O
.	O

Following	O
the	O
satisfactory	O
results	O
and	O
taking	O
into	O
account	O
that	O
the	O
complications	O
had	O
reduced	O
to	O
a	O
very	O
low	O
rate	O
(	O
in	O
2	O
cases	O
lead	O
tip	O
displacement	O
and	O
pouch	O
haematoma	O
occurred	O
respectively	O
)	O
,	O
the	O
Authors	O
consider	O
the	O
adopted	O
method	O
an	O
useful	O
approach	O
for	O
PMK	O
implantation	O
particularly	O
when	O
the	O
use	O
of	O
the	O
vena	O
cephalica	O
is	O
deemed	O
impossible	O
.	O

In	O
patients	O
with	O
type	O
IA	O
maple	O
syrup	O
urine	O
disease	O
,	O
the	O
E1alpha	B-GENE
subunit	I-GENE
is	O
affected	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
E1	B-GENE
and	O
branched-chain	B-GENE
ketoacid	I-GENE
dehydrogenase	I-GENE
catalytic	O
activities	O
.	O

Postcoital	O
contraception	O
:	O
a	O
family	O
planning	O
study	O
.	O

These	O
data	O
indicate	O
that	O
the	O
largest	O
subunit	O
of	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
and	O
TFIIB	B-GENE
are	O
important	O
determinants	O
of	O
transcription	O
start	O
site	O
selection	O
in	O
S	O
.	O
cerevisiae	O
and	O
suggest	O
that	O
this	O
function	O
might	O
be	O
conferred	O
by	O
interaction	O
between	O
these	O
two	O
proteins	O
.	O

Two	O
patients	O
with	O
recurrent	O
tumors	O
had	O
high	O
S-phase	O
fractions	O
both	O
on	O
the	O
first	O
resected	O
specimens	O
and	O
at	O
the	O
time	O
of	O
the	O
second	O
operation	O
.	O

SIN-1	O
had	O
no	O
influence	O
on	O
either	O
the	O
ischemic	O
parameters	O
in	O
the	O
surface	O
electrocardiogram	O
(	O
ECG	O
)	O
or	O
the	O
intracoronary	O
ECG	O
.	O

Human	O
isoforms	O
,	O
designated	O
1	O
to	O
4	O
,	O
differ	O
from	O
each	O
other	O
by	O
the	O
start	O
codon	O
used	O
.	O

No	O
relevant	O
changes	O
in	O
heart	O
rate	O
,	O
body	O
weight	O
,	O
and	O
plasma	O
levels	O
of	O
renin	B-GENE
activity	O
and	O
aldosterone	O
concentration	O
were	O
observed	O
.	O

The	O
orf61	B-GENE
gene	I-GENE
product	I-GENE
,	O
when	O
expressed	O
from	O
an	O
exogenous	O
promoter	O
,	O
inhibited	O
int-mediated	O
integration	O
at	O
the	O
chromosomal	B-GENE
attB	I-GENE
site	I-GENE
.	O

Surgical	O
treatment	O
of	O
pathologic	O
scars	O
of	O
myocardial	O
infarct	O
.	O

Hybrid	O
female	O
mice	O
(	O
C57BL	O
x	O
CBA	O
)	O
were	O
paired	O
with	O
breeder	O
males	O
(	O
CD-1	O
)	O
and	O
LNG	O
pellets	O
were	O
implanted	O
on	O
day	O
0	O
,	O
the	O
day	O
on	O
which	O
copulation	O
plugs	O
were	O
found	O
,	O
or	O
on	O
day	O
2	O
or	O
day	O
3	O
in	O
the	O
postcoital	O
period	O
.	O

Temafloxacin	O
400	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
administered	O
orally	O
for	O
28	O
days	O
represents	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
chronic	O
bacterial	O
prostatitis	O
.	O

The	O
currently	O
proposed	O
extended	O
arch	O
repair	O
should	O
be	O
reserved	O
for	O
the	O
small	O
group	O
of	O
infants	O
with	O
transverse	O
aortic	O
arch	O
to	O
ascending	O
aorta	O
diameter	O
ratios	O
(	O
arch	O
indices	O
)	O
of	O
less	O
than	O
0	O
.	O
25	O
.	O

Low	O
MAO	B-GENE
subjects	O
showed	O
a	O
pattern	O
of	O
higher	O
scores	O
in	O
KSP	O
Impulsiveness	O
,	O
EPQ	O
Neuroticism	O
,	O
and	O
KSP	O
Somatic	O
Anxiety	O
and	O
Irritability	O
and	O
lower	O
scores	O
in	O
KSP	O
Socialization	O
,	O
in	O
line	O
with	O
personality	O
profiles	O
found	O
in	O
alcoholics	O
,	O
psychopaths	O
,	O
and	O
suicide	O
attempters	O
who	O
also	O
tend	O
to	O
have	O
low	O
platelet	O
MAO	B-GENE
activity	O
.	O

It	O
brings	O
about	O
fatigue	O
,	O
negative	O
moods	O
,	O
and	O
impaired	O
health	O
,	O
sleep	O
,	O
safety	O
,	O
and	O
working	O
capacity	O
.	O

Next	O
,	O
we	O
show	O
that	O
two	O
EMS-induced	O
mutations	O
,	O
previously	O
shown	O
to	O
interact	O
genetically	O
with	O
zipper	B-GENE
(	I-GENE
Ebr	I-GENE
)	I-GENE
,	O
disrupt	O
the	O
RhoA	B-GENE
locus	I-GENE
.	O

HSF	B-GENE
binds	O
DNA	O
as	O
a	O
trimer	O
,	O
and	O
additional	O
trimers	O
can	O
bind	O
DNA	O
co-operatively	O
.	O

Apart	O
from	O
antimicrobial	O
properties	O
,	O
recent	O
data	O
indicate	O
that	O
PMN	O
also	O
exert	O
anti-inflammatory	O
effects	O
by	O
stimulation	O
and	O
release	O
of	O
cytokine	O
antagonists	O
such	O
as	O
interleukin-1	B-GENE
receptor	I-GENE
antagonist	I-GENE
(	O
IL-1ra	B-GENE
)	O
.	O

Mouse	B-GENE
Impact	I-GENE
is	O
a	O
paternally	O
expressed	O
gene	O
encoding	O
an	O
evolutionarily	O
conserved	O
protein	O
of	O
unknown	O
function	O
.	O

BACKGROUND	O
:	O
Mitosis	O
is	O
regulated	O
by	O
MPF	B-GENE
(	O
maturation	B-GENE
promoting	I-GENE
factor	I-GENE
)	O
,	O
the	O
active	O
form	O
of	O
Cdc2	B-GENE
/	I-GENE
28-cyclin	I-GENE
B	I-GENE
complexes	I-GENE
.	O

We	O
report	O
an	O
example	O
of	O
an	O
MDV-transformed	O
T-lymphoblastoid	O
cell	O
line	O
(	O
T9	O
)	O
expressing	O
high	O
levels	O
of	O
a	O
truncated	B-GENE
C-MYB	I-GENE
protein	I-GENE
as	O
a	O
result	O
of	O
RAV	O
integration	O
within	O
one	O
c-myb	B-GENE
allele	I-GENE
.	O

The	O
interaction	O
of	O
caffeine	O
,	O
theophylline	O
and	O
theobromine	O
with	O
monoamine	B-GENE
oxidase	I-GENE
inhibitors	O
.	O

However	O
,	O
parallax	O
measurements	O
showed	O
that	O
at	O
150K	O
,	O
collapse	O
of	O
Epon	O
sections	O
does	O
not	O
take	O
place	O
.	O

To	O
gain	O
an	O
understanding	O
of	O
the	O
mGSTM2	B-GENE
regulation	O
,	O
we	O
have	O
also	O
cloned	O
and	O
analyzed	O
its	O
promoter	O
region	O
.	O

Mutations	O
in	O
three	O
loci	O
(	O
SIC1	B-GENE
,	O
SWI5	B-GENE
,	O
and	O
RIC3	B-GENE
)	O
were	O
identified	O
.	O

Therefore	O
,	O
mechanisms	O
that	O
control	O
activation	O
of	O
the	O
MAP	B-GENE
kinase	I-GENE
cascade	I-GENE
temporally	O
and	O
spatially	O
may	O
be	O
important	O
for	O
specification	O
of	O
cellular	O
responses	O
.	O

None	O
had	O
a	O
past	O
history	O
of	O
opportunistic	O
infections	O
;	O
neither	O
did	O
any	O
have	O
lymphopenia	O
.	O

EMSA	O
competition	O
experiments	O
showed	O
that	O
mutations	O
within	O
the	O
direct	O
repeats	O
failed	O
to	O
compete	O
for	O
binding	O
of	O
the	O
nuclear	O
proteins	O
to	O
labeled	O
wild	O
type	O
oligonucleotide	O
.	O

In	O
H4IIE	O
rat	O
hepatoma	O
cells	O
,	O
glucocorticoids	O
,	O
retinoic	O
acid	O
and	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
increase	O
PEPCK	B-GENE
gene	I-GENE
transcription	O
whereas	O
insulin	B-GENE
and	O
phorbol	O
esters	O
have	O
the	O
opposite	O
effect	O
.	O

Until	O
such	O
investigations	O
are	O
performed	O
,	O
we	O
conclude	O
that	O
the	O
role	O
for	O
adjuvant	O
treatment	O
is	O
questionable	O
and	O
that	O
TME	O
surgery	O
is	O
preferred	O
as	O
the	O
treatment	O
option	O
for	O
Stage	O
T1-T3	O
rectal	O
cancers	O
.	O

It	O
was	O
established	O
that	O
intrathecal	O
or	O
intraperitoneal	O
PTFL	O
,	O
elevated	O
the	O
nociceptive	O
threshold	O
for	O
mechanical	O
stimuli	O
in	O
the	O
formalin	O
test	O
in	O
rats	O
.	O

The	O
E1	B-GENE
nuclear	I-GENE
transport	I-GENE
motif	I-GENE
is	O
highly	O
conserved	O
in	O
the	O
animal	O
and	O
human	O
papillomaviruses	O
and	O
is	O
encoded	O
in	O
a	O
similar	O
region	O
in	O
the	O
related	O
E1	B-GENE
genes	I-GENE
.	O

Rapid	O
evolution	O
of	O
the	O
DNA-binding	O
site	O
in	O
LAGLIDADG	B-GENE
homing	I-GENE
endonucleases	I-GENE
.	O

The	O
gene	O
is	O
contained	O
within	O
a	O
1	B-GENE
.	I-GENE
8-kilobase	I-GENE
AccI-EcoRI	I-GENE
restriction	I-GENE
fragment	I-GENE
mapping	O
at	O
map	O
coordinates	O
0	O
.	O
136	O
to	O
0	O
.	O
148	O
in	O
the	O
UL	B-GENE
region	I-GENE
of	O
the	O
EHV-1	O
genome	O
and	O
is	O
transcribed	O
from	O
right	O
to	O
left	O
.	O

Alternatively	O
processed	O
isoforms	O
of	O
cellular	B-GENE
nucleic	I-GENE
acid-binding	I-GENE
protein	I-GENE
interact	O
with	O
a	O
suppressor	O
region	O
of	O
the	O
human	B-GENE
beta-myosin	I-GENE
heavy	I-GENE
chain	I-GENE
gene	I-GENE
.	O

Improvement	O
of	O
the	O
polypyrimidine	O
tract	O
also	O
increased	O
the	O
splicing	O
efficiency	O
,	O
but	O
to	O
a	O
degree	O
slightly	O
less	O
than	O
that	O
obtained	O
with	O
the	O
branchpoint	O
mutation	O
.	O

Thus	O
,	O
the	O
predicted	O
CD30v	B-GENE
protein	I-GENE
retains	O
most	O
of	O
the	O
cytoplasmic	O
region	O
,	O
but	O
lacks	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
.	O

To	O
evaluate	O
whether	O
the	O
human	O
gene	O
is	O
also	O
a	O
target	O
of	O
thyroid	O
hormone	O
we	O
have	O
searched	O
for	O
T3-responsive	B-GENE
elements	I-GENE
in	O
NRGN	B-GENE
cloned	O
genomic	O
fragments	O
spanning	O
the	O
whole	O
gene	O
.	O

Validity	O
of	O
immunohistology	O
and	O
in	O
situ	O
hybridization	O
in	O
the	O
differential	O
diagnosis	O
of	O
cytomegalovirus	O
pneumonia	O
and	O
idiopathic	O
interstitial	O
pneumonia	O
after	O
allogenic	O
bone	O
marrow	O
transplantation	O
.	O

This	O
work	O
,	O
therefore	O
,	O
also	O
emphasizes	O
the	O
importance	O
of	O
careful	O
choice	O
of	O
oligonucleotide	O
and	O
cDNA	O
probes	O
to	O
study	O
PKC	B-GENE
zeta	I-GENE
mRNA	I-GENE
.	O

A	O
prospective	O
observational	O
study	O
was	O
conducted	O
to	O
identify	O
early	O
indicators	O
of	O
acute	O
dengue	O
virus	O
infection	O
.	O

The	O
homeobox	B-GENE
gene	I-GENE
ATK1	I-GENE
of	O
Arabidopsis	O
thaliana	O
is	O
expressed	O
in	O
the	O
shoot	O
apex	O
of	O
the	O
seedling	O
and	O
in	O
flowers	O
and	O
inflorescence	O
stems	O
of	O
mature	O
plants	O
.	O

From	O
the	O
Icelandic	O
Red	O
Cross	O
activities	O
.	O

Since	O
glutathione	B-GENE
peroxidase	I-GENE
(	O
GPX	B-GENE
)	O
and	O
superoxide	B-GENE
dismutase	I-GENE
(	O
SOD	B-GENE
)	O
play	O
a	O
significant	O
role	O
in	O
erythrocyte	O
antioxidative	O
defence	O
,	O
it	O
is	O
very	O
important	O
to	O
determine	O
their	O
activity	O
in	O
occupationally	O
exposed	O
workers	O
.	O

Oligosynaptic	O
EPSP	O
components	O
were	O
consistently	O
modulated	O
only	O
in	O
the	O
superficial	O
peroneal	O
responses	O
in	O
flexor	O
motoneurons	O
,	O
which	O
exhibited	O
enhanced	O
amplitude	O
during	O
the	O
flexion	O
phase	O
.	O

Like	O
the	O
consensus	B-GENE
mammalian	I-GENE
LHbeta	I-GENE
gene	I-GENE
,	O
the	O
5'-flanking	O
region	O
of	O
the	O
gpLH	B-GENE
/	I-GENE
CGbeta	I-GENE
gene	I-GENE
contains	O
a	O
single	O
TATA	O
sequence	O
37	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
codon	O
.	O

Marrow	O
cell	O
necrosis	O
in	O
anorexia	O
nervosa	O
and	O
involuntary	O
starvation	O
.	O

Blood	O
pressure	O
in	O
children	O
.	O

Because	O
the	O
hcf109	B-GENE
locus	I-GENE
was	O
mapped	O
at	O
a	O
distance	O
<	O
0	O
.	O
1	O
centimorgans	O
from	O
the	O
phytochrome	B-GENE
C	I-GENE
gene	I-GENE
,	O
its	O
molecular	O
characterization	O
by	O
positional	O
cloning	O
is	O
possible	O
.	O

Despite	O
this	O
there	O
was	O
no	O
difference	O
in	O
the	O
intubating	O
conditions	O
at	O
one	O
minute	O
with	O
25	O
excellent	O
/	O
5	O
good	O
in	O
the	O
suxamethonium	O
group	O
and	O
27	O
excellent	O
/	O
3	O
good	O
in	O
the	O
rocuronium	O
group	O
.	O

However	O
,	O
by	O
an	O
NS35-specific	B-GENE
RNA	I-GENE
capture	O
assay	O
,	O
the	O
multimers	O
were	O
shown	O
to	O
possess	O
the	O
RNA-binding	O
activity	O
previously	O
demonstrated	O
for	O
NS35	B-GENE
.	O

This	O
molecule	O
,	O
wH22xeGFP	B-GENE
,	O
consists	O
of	O
the	O
entire	B-GENE
humanized	I-GENE
anti-FcgammaRI	I-GENE
mAb	I-GENE
H22	B-GENE
with	O
eGFP	B-GENE
genetically	O
fused	O
to	O
the	O
C-terminal	O
end	O
of	O
each	O
CH3	B-GENE
domain	I-GENE
.	O
wH22xeGFP	B-GENE
binds	O
within	O
the	O
ligand-binding	O
region	O
by	O
its	O
Fc	B-GENE
end	O
,	O
as	O
well	O
as	O
outside	O
the	O
ligand-binding	O
region	O
by	O
its	O
Fab	B-GENE
ends	O
,	O
thereby	O
cross-linking	O
FcgammaRI	B-GENE
.	O

In	O
contrast	O
,	O
the	O
distribution	O
of	O
endocytic	O
markers	O
is	O
not	O
affected	O
.	O

For	O
example	O
,	O
introduction	O
of	O
immunogenic	O
and	O
purification	O
tag	O
sequences	O
into	O
the	O
C-terminal	O
coding	O
region	O
significantly	O
decreased	O
bop	B-GENE
gene	I-GENE
mRNA	I-GENE
and	O
protein	O
accumulation	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
carboxyl	O
terminus	O
of	O
CFTR	B-GENE
contains	O
a	O
tyrosine-based	O
internalization	O
signal	O
that	O
interacts	O
with	O
the	O
endocytic	O
adaptor	O
complex	O
AP-2	B-GENE
to	O
facilitate	O
efficient	O
entry	O
of	O
CFTR	B-GENE
into	O
clathrin-coated	O
vesicles	O
.	O

After	O
treatment	O
with	O
tunicamycin	O
,	O
the	O
transfectants	O
secreted	O
unglycosylated	O
18-kDa	O
polypeptides	O
which	O
could	O
also	O
bind	O
IgE	B-GENE
.	O

Fisher's	O
exact	O
test	O
or	O
Pearson's	O
chi2	O
test	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

RNP1	B-GENE
,	O
a	O
new	O
ribonucleoprotein	O
gene	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

RESULTS	O
:	O
Basal	O
plasma	B-GENE
IGF-I	I-GENE
levels	O
as	O
well	O
as	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
were	O
lower	O
in	O
amenorrheic	O
patients	O
than	O
in	O
healthy	O
controls	O
.	O

Studies	O
on	O
Coxsackie	O
B	O
Type	O
5	O
virus	O
infections	O
.	O

Polymerase	O
chain	O
reaction	O
analysis	O
of	O
ETS1	B-GENE
cDNA	I-GENE
identified	O
several	O
amplified	O
products	O
,	O
indicating	O
alternative	O
splicing	O
.	O

Platelet-derived	O
growth	O
factor-dependent	O
activation	O
of	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
is	O
regulated	O
by	O
receptor	O
binding	O
of	O
SH2-domain-containing	B-GENE
proteins	I-GENE
which	O
influence	O
Ras	B-GENE
activity	O
.	O

APC-resistance	O
was	O
determined	O
with	O
a	O
functional	O
method	O
with	O
high	O
sensitivity	O
and	O
specificity	O
for	O
the	O
factor	B-GENE
V	I-GENE
Leiden	O
mutation	O
.	O

The	O
activity	O
of	O
the	O
coat	B-GENE
protein	I-GENE
promoter	I-GENE
of	O
chloris	O
striate	O
mosaic	O
virus	O
is	O
enhanced	O
by	O
its	O
own	O
and	O
C1-C2	B-GENE
gene	I-GENE
products	I-GENE
.	O

The	O
ether	O
phospholipid	O
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine	O
(	O
ET-18-OCH3	O
;	O
edelfosine	O
)	O
is	O
a	O
potent	O
inducer	O
of	O
apoptosis	O
in	O
human	O
tumor	O
cells	O
.	O

The	O
factor	O
structure	O
of	O
"schizotypal'	O
traits	O
:	O
a	O
large	O
replication	O
study	O
.	O

Resistance	O
to	O
the	O
simulated	O
physiologic	O
environment	O
was	O
tested	O
by	O
measured	O
retention	O
of	O
mechanical	O
properties	O
after	O
immersion	O
times	O
in	O
pseudo-extracellular	O
fluid	O
(	O
PECF	O
)	O
at	O
37	O
degrees	O
C	O
for	O
as	O
long	O
as	O
three	O
years	O
.	O

In	O
the	O
absence	O
of	O
other	O
stabilizers	O
,	O
increased	O
sucrose	O
can	O
provide	O
increased	O
thermoresistance	O
to	O
the	O
virus	O
in	O
2	O
.	O
5%	O
albumin	B-GENE
.	O

We	O
found	O
that	O
lung	O
cancer	O
tissues	O
of	O
positive	O
67Ga	O
scan	O
expressed	O
TFR	B-GENE
,	O
but	O
those	O
of	O
a	O
negative	O
scan	O
did	O
not	O
.	O

The	O
results	O
of	O
replicase	B-GENE
assays	O
performed	O
with	O
mutant	B-GENE
VP2	I-GENE
containing	O
a	O
deletion	O
in	O
its	O
RNA-binding	O
domain	O
suggests	O
that	O
the	O
essential	O
role	O
for	O
VP2	B-GENE
in	O
replication	O
is	O
linked	O
to	O
the	O
protein's	O
ability	O
to	O
bind	O
the	O
mRNA	O
template	O
for	O
minus-strand	O
synthesis	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
TS	O
and	O
the	O
PTS	O
.	O

Recurrent	O
arterial	O
thrombotic	O
disease	O
on	O
young	O
onset	O
and	O
protein	B-GENE
S	I-GENE
deficiency	O
.	O

Three	O
mutants	O
(	O
pms1	B-GENE
,	O
pms2	B-GENE
and	O
pms3	B-GENE
)	O
isolated	O
earlier	O
from	O
MW104-1B	O
were	O
shown	O
to	O
correct	O
in	O
vitro	O
constructed	O
plasmids	O
with	O
defined	O
DNA	O
mismatches	O
(	O
G	O
/	O
T	O
,	O
A	O
/	O
C	O
,	O
G	O
/	O
G	O
,	O
etc	O
.	O
)	O
poorly	O
(	O
Kramer	O
et	O
al	O
.	O
,	O
1989a	O
)	O
.	O

Hemolytic	O
jaundice	O
due	O
to	O
G6PD	B-GENE
deficiency	O
causing	O
kernicterus	O
in	O
a	O
female	O
newborn	O
.	O

The	O
presence	O
of	O
locus-specific	O
residues	O
throughout	O
the	O
entire	O
promoter	O
region	O
strongly	O
suggests	O
that	O
the	O
various	O
HLA	B-GENE
class	I-GENE
I	I-GENE
loci	I-GENE
are	O
differentially	O
regulated	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Computer	O
assisted	O
mapping	O
in	O
quantitative	O
analysis	O
of	O
cerebral	O
positron	O
emission	O
tomograms	O
.	O

Animal	O
studies	O
showed	O
that	O
beam	O
equalization	O
significantly	O
improved	O
fluoroscopic	O
and	O
angiographic	O
image	O
quality	O
.	O

Maternal	O
lactation	O
.	O

In	O
mouse	O
,	O
Mmip1	B-GENE
(	O
Mad	B-GENE
member	I-GENE
interacting	I-GENE
protein	I-GENE
1	I-GENE
)	O
and	O
Smc3	B-GENE
share	O
99%	O
sequence	O
identity	O
and	O
are	O
products	O
of	O
the	O
same	O
gene	O
.	O

Intracellular	O
pH	O
,	O
H	O
ion	O
flux	O
and	O
H	O
ion	O
permeability	O
coefficient	O
in	O
bullfrog	O
toe	O
muscle	O
.	O

The	O
variability	O
is	O
most	O
likely	O
a	O
result	O
of	O
alternative	O
splicing	O
of	O
exons	O
from	O
the	O
primary	O
elastin	B-GENE
transcripts	I-GENE
.	O

Identification	O
of	O
the	O
plakoglobin-binding	O
domain	O
in	O
desmoglein	B-GENE
and	O
its	O
role	O
in	O
plaque	O
assembly	O
and	O
intermediate	O
filament	O
anchorage	O
.	O

Analysis	O
of	O
the	O
promoter	O
sequence	O
revealed	O
the	O
presence	O
of	O
a	O
major	O
transcriptional	O
start	O
site	O
,	O
a	O
canonical	O
TATA	O
box	O
and	O
putative	O
cis	O
regulatory	O
elements	O
for	O
pituitary	O
specific	O
expression	O
as	O
well	O
as	O
an	O
E-responsive	B-GENE
element	I-GENE
.	O

We	O
previously	O
showed	O
that	O
the	O
upstream	B-GENE
promoter	I-GENE
element	I-GENE
of	O
the	O
yeast	B-GENE
RP39A	I-GENE
gene	I-GENE
consists	O
of	O
these	O
identical	O
sequence	O
motifs	O
.	O

The	O
roles	O
of	O
phorbol	O
esters	O
and	O
cyclic	O
AMP	O
in	O
mediating	O
the	O
GnRH	B-GENE
response	O
were	O
also	O
investigated	O
.	O

Clinical	O
and	O
haematological	O
signs	O
are	O
not	O
specific	O
in	O
this	O
setting	O
,	O
and	O
the	O
diagnosis	O
relies	O
on	O
histological	O
features	O
,	O
mainly	O
bone	O
marrow	O
examination	O
.	O

In	O
conclusion	O
,	O
the	O
disposition	O
of	O
venlafaxine	O
and	O
O-desmethylvenlafaxine	O
is	O
markedly	O
altered	O
in	O
renal	O
disease	O
;	O
therefore	O
dosage	O
adjustment	O
is	O
warranted	O
for	O
patients	O
with	O
creatinine	O
clearance	O
values	O
below	O
30	O
ml	O
/	O
min	O
.	O

The	O
prevalence	O
of	O
tobacco	O
dependence	O
diagnosed	O
according	O
to	O
the	O
ICD-10	O
criteria	O
was	O
higher	O
in	O
alcohol-dependent	O
individuals	O
(	O
58	O
.	O
1%	O
)	O
than	O
in	O
nondrinkers	O
or	O
social	O
drinkers	O
(	O
12	O
.	O
8%	O
)	O
.	O

The	O
carboxyl-terminal	O
transactivation	O
domain	O
of	O
heat	B-GENE
shock	I-GENE
factor	I-GENE
1	I-GENE
is	O
negatively	O
regulated	O
and	O
stress	O
responsive	O
.	O

Three	O
new	O
aromatase	B-GENE
inhibitors	O
have	O
recently	O
completed	O
phase	O
III	O
evaluation	O
as	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
in	O
post-menopausal	O
women	O
whose	O
disease	O
has	O
progressed	O
despite	O
tamoxifen	O
therapy	O
:	O
anastrozole	O
(	O
ARIMIDEX	O
,	O
Zeneca	O
)	O
,	O
letrozole	O
(	O
FEMARA	O
,	O
Novartis	O
)	O
and	O
vorozole	O
(	O
RIVIZOR	O
,	O
Janssen	O
)	O
.	O

The	O
recognition	O
specificity	O
of	O
the	O
p55	B-GENE
PDZ	B-GENE
domain	I-GENE
appears	O
to	O
be	O
unique	O
,	O
since	O
the	O
three	O
PDZ	B-GENE
domains	I-GENE
of	O
hDlg	B-GENE
(	O
human	O
lymphocyte	O
homologue	O
of	O
the	O
Drosophila	B-GENE
discs	I-GENE
large	I-GENE
tumor	I-GENE
suppressor	I-GENE
)	O
do	O
not	O
bind	O
the	O
cytoplasmic	O
domain	O
of	O
glycophorin	B-GENE
C	I-GENE
.	O

Tolerance	O
in	O
renal	O
transplantation	O
after	O
allogeneic	O
bone	O
marrow	O
transplantation-6-year	O
follow-up	O
.	O

The	O
Fas	B-GENE
receptor	I-GENE
mediates	O
a	O
signalling	O
cascade	O
resulting	O
in	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
within	O
hours	O
of	O
receptor	O
cross-linking	O
.	O

Moreover	O
,	O
it	O
also	O
discusses	O
the	O
effects	O
of	O
antihypertensive	O
drugs	O
currently	O
regarded	O
as	O
first-choice	O
agents	O
,	O
i	O
.	O
e	O
.	O
calcium	O
antagonists	O
and	O
the	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitors	O
,	O
on	O
intrarenal	O
hemodynamics	O
.	O

Regulation	O
of	O
laminin	B-GENE
beta2	I-GENE
chain	I-GENE
gene	I-GENE
expression	O
in	O
human	O
cancer	O
cell	O
lines	O
.	O

Lesion	O
diameters	O
of	O
greater	O
than	O
20	O
mm	O
and	O
the	O
large	O
sessile-type	O
configurations	O
were	O
factors	O
that	O
were	O
associated	O
with	O
incomplete	O
removal	O
.	O

Effect	O
of	O
intraventricular	O
administration	O
of	O
streptolysin	B-GENE
O	I-GENE
on	O
the	O
electroencephalogram	O
of	O
rabbits	O
.	O

Thus	O
,	O
diamide	O
treatment	O
of	O
nuclear	O
extracts	O
strongly	O
reduces	O
the	O
binding	O
of	O
NFI	B-GENE
proteins	I-GENE
,	O
and	O
the	O
addition	O
of	O
higher	O
concentrations	O
of	O
dithiothreitol	O
to	O
nuclear	O
extracts	O
from	O
TG-treated	O
cells	O
restores	O
NFI-DNA	B-GENE
binding	O
to	O
levels	O
in	O
extracts	O
from	O
untreated	O
cells	O
.	O

Subjects	O
were	O
16	O
male	O
chronic	O
schizophrenics	O
consisting	O
of	O
8	O
DST	O
suppressors	O
and	O
8	O
nonsuppressors	O
.	O

In	O
these	O
cells	O
,	O
E2	B-GENE
proteins	I-GENE
had	O
little	O
or	O
no	O
stimulatory	O
effect	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
HPV-11	B-GENE
enhancer-SV40	I-GENE
promoter	I-GENE
.	O

Constructs	O
designed	O
and	O
expressed	O
were	O
E2L1	B-GENE
(	I-GENE
1-98	I-GENE
)	I-GENE
,	O
E2L1	B-GENE
.	I-GENE
H1	I-GENE
(	I-GENE
1-128	I-GENE
)	I-GENE
,	O
E2L2	B-GENE
(	I-GENE
120-233	I-GENE
)	I-GENE
,	O
E2H1	B-GENE
.	I-GENE
L2	I-GENE
(	I-GENE
98-233	I-GENE
)	I-GENE
,	O
and	O
E2L1	B-GENE
.	I-GENE
H1	I-GENE
.	I-GENE
L2	I-GENE
(	I-GENE
1-233	I-GENE
)	I-GENE
,	O
where	O
numbers	O
in	O
parentheses	O
give	O
the	O
amino	O
acid	O
sequence	O
for	O
the	O
portions	O
of	O
the	O
E2	B-GENE
component	O
incorporated	O
into	O
a	O
construct	O
.	O

633+	O
/	O
-258	O
aggregates	O
/	O
ml	O
at	O
0	O
rpm	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Deglycosylation	O
with	O
endoglycosidase	B-GENE
H	I-GENE
showed	O
that	O
the	O
mutant	O
receptors	O
had	O
mainly	O
high-mannose	O
oligosaccharide	O
chains	O
.	O

Pulmonary	O
arterial	O
pressure	O
and	O
structure	O
in	O
the	O
patas	O
monkey	O
after	O
prolonged	O
administration	O
of	O
aminorex	O
fumarate	O
.	O

This	O
multiple-electrode	O
array	O
for	O
round	O
window	O
cochlear	O
implantation	O
is	O
a	O
robust	O
,	O
reliable	O
system	O
for	O
inserting	O
20	O
mm	O
along	O
the	O
scala	O
tympani	O
with	O
a	O
minimum	O
of	O
trauma	O
and	O
can	O
provide	O
for	O
bipolar	O
stimulation	O
.	O

Although	O
there	O
is	O
little	O
evidence	O
that	O
diet	O
composition	O
plays	O
a	O
clinically	O
important	O
role	O
in	O
the	O
absorption	O
or	O
expenditure	O
of	O
energy	O
,	O
it	O
does	O
appear	O
to	O
play	O
a	O
role	O
in	O
food	O
intake	O
.	O

This	O
observation	O
calls	O
for	O
careful	O
monitoring	O
of	O
calcium	O
and	O
alkaline	B-GENE
phosphatase	I-GENE
values	O
and	O
possible	O
adjustments	O
of	O
vitamin	O
D	O
intake	O
when	O
fortifiers	O
are	O
used	O
for	O
extended	O
periods	O
.	O

Interference	O
with	O
rheumatoid	B-GENE
factor	I-GENE
was	O
only	O
observed	O
in	O
the	O
ELISA	O
enzygnost	O
if	O
sera	O
were	O
not	O
pretreated	O
with	O
latex	O
adsorbents	O
.	O

A	O
comparison	O
of	O
the	O
promoters	O
for	O
muMIP-1	B-GENE
beta	I-GENE
and	O
muMIP-1	B-GENE
alpha	I-GENE
reveals	O
a	O
conserved	O
CK-1	B-GENE
element	I-GENE
,	O
but	O
transient	O
expression	O
studies	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
with	O
proximal	O
fragments	O
of	O
either	O
the	O
muMIP-1	B-GENE
beta	I-GENE
or	O
the	O
muMIP-1	B-GENE
alpha	I-GENE
5'	I-GENE
promoter	I-GENE
fused	O
to	O
a	O
human	B-GENE
growth	I-GENE
hormone	I-GENE
reporter	I-GENE
gene	I-GENE
link	O
LPS-inducibility	O
in	O
both	O
to	O
promoter	O
segments	O
near	O
to	O
,	O
but	O
not	O
identical	O
with	O
,	O
the	O
consensus	B-GENE
CK-1	I-GENE
sequence	I-GENE
.	O

Cardiac	O
markers	O
troponin	B-GENE
T	I-GENE
,	O
CK-MB	B-GENE
mass	O
and	O
myoglobin	B-GENE
were	O
helpful	O
in	O
the	O
differential	O
diagnosis	O
of	O
chest	O
pain	O
,	O
even	O
when	O
the	O
ECG	O
was	O
unremarkable	O
or	O
nonspecific	O
.	O

We	O
have	O
determined	O
that	O
the	O
mutants	O
define	O
two	O
complementation	O
groups	O
,	O
designated	O
cgs1+	B-GENE
and	O
cgs2+	B-GENE
(	O
continues	O
to	O
grow	O
in	O
stationary	O
)	O
.	O

The	O
ectopic	O
expression	O
of	O
Oct-3	B-GENE
/	I-GENE
4	I-GENE
in	O
hybrid	O
cells	O
under	O
a	O
constitutive	O
promoter	O
is	O
sufficient	O
for	O
transcriptional	O
activation	O
of	O
an	O
octamer-dependent	O
promoter	O
.	O

The	O
accumulation	O
of	O
both	O
LHA4	B-GENE
and	O
LHA2	B-GENE
mRNAs	I-GENE
is	O
induced	O
by	O
the	O
addition	O
of	O
exogenous	O
sugars	O
and	O
this	O
induction	O
appears	O
to	O
be	O
dependent	O
on	O
sugar	O
uptake	O
and	O
metabolism	O
,	O
because	O
mannitol	O
and	O
3-O-methylglucose	O
do	O
not	O
stimulate	O
mRNA	O
accumulation	O
.	O

A	O
further	O
study	O
on	O
plasminogen	B-GENE
activator	I-GENE
release	O
by	O
vasoactive	O
agents	O
in	O
the	O
isolated	O
perfused	O
dog	O
leg	O
.	O

Distal	O
lower	O
motor	O
neuron	O
syndrome	O
with	O
high-titer	O
serum	B-GENE
IgM	I-GENE
anti-GM1	I-GENE
antibodies	I-GENE
:	O
improvement	O
following	O
immunotherapy	O
with	O
monthly	O
plasma	O
exchange	O
and	O
intravenous	O
cyclophosphamide	O
.	O

Spfkh1	B-GENE
is	O
transcribed	O
in	O
one	O
open	O
reading	O
frame	O
that	O
contains	O
the	O
DNA	O
binding	O
domain	O
,	O
nuclear	O
localization	O
signal	O
and	O
transactivation	O
domain	O
.	O

Using	O
appropriate	O
synthetic	B-GENE
HSE	I-GENE
oligonucleotides	I-GENE
,	O
three	O
types	O
of	O
clones	O
with	O
potential	O
HSE	B-GENE
binding	I-GENE
domains	I-GENE
were	O
isolated	O
from	O
a	O
tomato	O
lambda	O
gt11	O
expression	O
library	O
by	O
DNA-ligand	O
screening	O
.	O

The	O
presence	O
of	O
such	O
a	O
putative	O
RNA-	O
binding	O
domain	O
suggests	O
a	O
mechanism	O
for	O
the	O
observed	O
autoregulation	O
of	O
bacteriophage	O
T4	B-GENE
DNA	I-GENE
polymerase	I-GENE
synthesis	O
by	O
binding	O
to	O
its	O
own	O
mRNA	O
.	O

Glutathione	B-GENE
S-transferase	I-GENE
(	O
GST	B-GENE
)	O
-E2F	B-GENE
and	O
GST-DP	B-GENE
fusion	I-GENE
proteins	I-GENE
were	O
found	O
to	O
cooperate	O
in	O
binding	O
to	O
the	O
three	O
E2F	B-GENE
sites	I-GENE
in	O
the	O
DNA	B-GENE
polymerase	I-GENE
alpha	I-GENE
gene	I-GENE
promoter	I-GENE
in	O
vitro	O
.	O

Influence	O
of	O
metoprolol	O
treatment	O
on	O
sympatho-adrenal	O
activation	O
of	O
fibrinolysis	O
.	O

Secondary	O
cleavage	O
of	O
RT	B-GENE
at	O
Trp-595-Tyr-596	B-GENE
of	I-GENE
Pol	I-GENE
yields	O
a	O
truncated	O
form	O
lacking	O
the	O
C-terminal	B-GENE
RNase	I-GENE
H	I-GENE
domain	I-GENE
.	O

Although	O
p48	B-GENE
gene	I-GENE
induction	O
is	O
dependent	O
on	O
STAT1	B-GENE
and	O
JAK1	B-GENE
,	O
activated	O
STAT1	B-GENE
does	O
not	O
bind	O
to	O
GATE	B-GENE
.	O

The	O
second	O
method	O
,	O
the	O
"macro"	O
assay	O
,	O
has	O
a	O
sensitivity	O
range	O
of	O
0	O
.	O
03-5	O
.	O
0	O
micrograms	O
phosphorus	O
with	O
100-500	O
microliters	O
HClO4	O
.	O

In	O
contrast	O
,	O
c-Src-derived	B-GENE
construct	I-GENE
(	O
a-Src	B-GENE
)	O
,	O
that	O
was	O
excluded	O
from	O
detergent-resistant	O
membranes	O
,	O
could	O
not	O
restore	O
the	O
series	O
of	O
phagocytosis	O
signaling	O
.	O

Ime1	B-GENE
plays	O
a	O
pivotal	O
role	O
in	O
the	O
initiation	O
of	O
meiosis	O
in	O
a	O
/	O
alpha	O
diploid	O
cells	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

Concentrations	O
of	O
N	O
(	O
O3-	O
)	O
-N	O
and	O
N	O
(	O
H3-	O
)	O
-N	O
at	O
Deoprayag	O
varied	O
from	O
0	O
.	O
30	O
to	O
0	O
.	O
50	O
and	O
0	O
.	O
02	O
to	O
0	O
.	O
12	O
mg	O
/	O
L	O
,	O
respectively	O
,	O
depending	O
on	O
season	O
.	O

To	O
characterize	O
this	O
effect	O
,	O
we	O
looked	O
for	O
targets	O
of	O
NS1	B-GENE
influenza	I-GENE
virus	I-GENE
protein	I-GENE
among	O
cellular	O
translation	O
factors	O
.	O

Innervation	O
of	O
the	O
ventral	O
diaphragm	O
of	O
the	O
locust	O
(	O
Locusta	O
migratoria	O
)	O
.	O

In	O
the	O
37	O
patients	O
without	O
lung	O
disease	O
respiratory	O
muscle	O
weakness	O
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
vital	O
capacity	O
,	O
total	O
lung	O
capacity	O
,	O
and	O
maximum	O
voluntary	O
ventilation	O
;	O
by	O
significant	O
increases	O
in	O
residual	O
volume	O
and	O
arterial	O
carbon	O
dioxide	O
tension	O
(	O
PaCO2	O
)	O
;	O
and	O
greater	O
likelihood	O
of	O
dependence	O
on	O
ventilators	O
,	O
atelectasis	O
,	O
and	O
pneumonia	O
.	O

Of	O
600	O
mediastinoscopies	O
carried	O
out	O
from	O
1966	O
to	O
1973	O
,	O
479	O
were	O
performed	O
to	O
assess	O
the	O
operability	O
of	O
a	O
pulmonary	O
carcinoma	O
.	O

These	O
data	O
provide	O
the	O
molecular	O
tools	O
for	O
the	O
final	O
identification	O
of	O
the	O
MKS	B-GENE
and	O
the	O
MUL	B-GENE
genes	I-GENE
.	O

Compared	O
to	O
those	O
with	O
normal	O
renal	O
functions	O
,	O
these	O
patients	O
were	O
older	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
,	O
had	O
significantly	O
elevated	O
blood	O
pressures	O
(	O
P	O
<	O
0	O
.	O
01	O
or	O
P	O
=	O
0	O
.	O
0001	O
)	O
,	O
and	O
in	O
the	O
case	O
of	O
Type	O
1	O
DM	O
,	O
with	O
a	O
higher	O
body	O
mass	O
index	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
and	O
waist-hip	O
ratio	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Implications	O
in	O
biomonitoring	O
of	O
the	O
observed	O
accumulation	O
patterns	O
,	O
especially	O
in	O
the	O
different	O
tissues	O
of	O
Posidonia	O
oceanica	O
,	O
are	O
discussed	O
.	O

T-cell	B-GENE
receptor	I-GENE
beta	I-GENE
(	O
TCR	B-GENE
beta	I-GENE
)	O
gene	O
rearrangements	O
occur	O
in	O
a	O
third	O
of	O
early	O
B-cell	O
acute	O
lymphoblastic	O
leukemias	O
(	O
ALLs	O
)	O
.	O

This	O
study	O
assesses	O
the	O
feasibility	O
and	O
toxicity	O
of	O
adoptive	O
immunotherapy	O
with	O
tumor	O
infiltrating	O
lymphocytes	O
and	O
recombinant	B-GENE
interleukin-2	I-GENE
in	O
29	O
patients	O
who	O
underwent	O
resection	O
for	O
stage	O
III	O
non-small-cell	O
lung	O
cancer	O
.	O

The	O
MXR	B-GENE
gene	I-GENE
encodes	O
a	O
half-transporter	O
and	O
the	O
absence	O
of	O
cytogenetic	O
evidence	O
of	O
coamplification	O
of	O
other	O
regions	O
suggests	O
that	O
a	O
partner	O
may	O
not	O
be	O
overexpressed	O
,	O
and	O
instead	O
the	O
MXR	B-GENE
half-transporter	I-GENE
homodimerizes	O
to	O
mediate	O
drug	O
transport	O
.	O

We	O
compared	O
the	O
parameters	O
pleural	B-GENE
adenosine	I-GENE
deaminase	I-GENE
(	O
PADA	B-GENE
,	O
determined	O
in	O
405	O
patients	O
)	O
,	O
the	O
PADA	B-GENE
/	I-GENE
serum	I-GENE
ADA	I-GENE
ratio	O
(	O
P	B-GENE
/	I-GENE
SADA	I-GENE
;	O
276	O
cases	O
)	O
,	O
pleural	B-GENE
lysozyme	I-GENE
(	O
PLYS	B-GENE
,	O
276	O
cases	O
)	O
,	O
the	O
PLYS	B-GENE
/	I-GENE
serum	I-GENE
LYS	I-GENE
ratio	O
(	O
P	B-GENE
/	I-GENE
SLYS	I-GENE
;	O
276	O
cases	O
)	O
,	O
and	O
pleural	B-GENE
interferon	I-GENE
gamma	I-GENE
(	O
IFN	B-GENE
,	O
145	O
cases	O
)	O
regarding	O
their	O
ability	O
to	O
differentiate	O
tuberculous	O
pleural	O
effusions	O
from	O
others	O
.	O

176	O
:	O
787-792	O
,	O
1992	O
;	O
M	O
.	O

An	O
immunologically	O
related	O
protein	O
was	O
detected	O
in	O
ribosome	O
and	O
membrane	O
fractions	O
of	O
mitochondria	O
from	O
Saccharomyces	O
cerevisiae	O
.	O

As	O
the	O
components	O
of	O
these	O
complexes	O
,	O
at	O
least	O
five	O
TRBPs	B-GENE
(	O
p30	B-GENE
,	O
p37	B-GENE
,	O
p46	B-GENE
,	O
p50	B-GENE
,	O
and	O
p56	B-GENE
)	O
showing	O
specific	O
binding	O
to	O
the	O
TAR	B-GENE
RNA	I-GENE
were	O
detected	O
in	O
the	O
uv	O
cross-linking	O
assay	O
.	O

Acute	O
stress	O
in	O
7	O
rats	O
also	O
increased	O
the	O
mean	O
amount	O
of	O
IL-6	B-GENE
released	O
in	O
the	O
urine	O
by	O
31	O
.	O
5%	O
from	O
775	O
.	O
9	O
+	O
/	O
-	O
69	O
.	O
2	O
to	O
1	O
,	O
021	O
.	O
1	O
+	O
/	O
-	O
93	O
.	O
3	O
pg	O
.	O
/	O
ml	O
.	O

All	O
of	O
the	O
basal	O
TPN	O
solutions	O
were	O
isonitrogenous	O
and	O
identical	O
in	O
nutrient	O
composition	O
,	O
except	O
for	O
the	O
difference	O
in	O
energy	O
level	O
,	O
which	O
was	O
adjusted	O
with	O
glucose	O
.	O

We	O
used	O
stored	O
plasma	O
samples	O
from	O
409	O
patients	O
in	O
the	O
National	O
Institute	O
of	O
Neurological	O
Diseases	O
and	O
Stroke	O
(	O
NINDS	O
)	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
t-PA	B-GENE
)	O
Stroke	O
Trial	O
to	O
examine	O
the	O
relationship	O
between	O
an	O
apolipoprotein	B-GENE
(	I-GENE
Apo	I-GENE
)	I-GENE
E2	I-GENE
or	O
an	O
Apo	B-GENE
E4	I-GENE
phenotype	O
and	O
a	O
favorable	O
outcome	O
3	O
months	O
after	O
stroke	O
,	O
the	O
risk	O
of	O
intracerebral	O
hemorrhage	O
,	O
and	O
the	O
response	O
to	O
intravenous	O
t-PA	B-GENE
therapy	O
.	O

The	O
introns	O
are	O
1	O
.	O
6-1	O
.	O
9	O
kbp	O
long	O
.	O

Relations	O
between	O
adrenergic	O
mechanisms	O
and	O
analgesic	O
effects	O
.	O

Here	O
we	O
demonstrate	O
that	O
native	B-GENE
MRCK	I-GENE
exists	O
in	O
high-molecular-weight	O
complexes	O
.	O

In	O
vitro	O
binding	O
studies	O
demonstrate	O
that	O
eIF-5A	B-GENE
is	O
required	O
for	O
efficient	O
interaction	O
of	O
Rev-NES	B-GENE
with	O
CRM1	B-GENE
/	I-GENE
exportin1	I-GENE
and	O
that	O
eIF-5A	B-GENE
interacts	O
with	O
the	O
nucleoporins	O
CAN	B-GENE
/	I-GENE
nup214	I-GENE
,	O
nup153	B-GENE
,	O
nup98	B-GENE
,	O
and	O
nup62	B-GENE
.	O

The	O
antihypertensive	O
effect	O
of	O
Estulic	O
has	O
been	O
examined	O
over	O
a	O
12-month	O
period	O
in	O
101	O
hypertensive	O
patients	O
.	O

The	O
thrombolytic	O
effects	O
of	O
native	O
tissue-type	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
AK-124	B-GENE
)	O
on	O
experimental	O
canine	O
coronary	O
thrombosis	O
.	O

Both	O
immunophilins	B-GENE
may	O
have	O
important	O
roles	O
in	O
receptor	O
assembly	O
and	O
may	O
represent	O
a	O
new	O
category	O
of	O
ligand-	O
and	O
calcium-dependent	O
modulators	O
of	O
protein	O
function	O
.	O

Substitutions	O
of	O
region	O
I	O
with	O
synthetic	O
sequences	O
showed	O
that	O
no	O
specific	O
sequence	O
but	O
rather	O
repeats	O
of	O
three	O
or	O
more	O
consecutive	O
adenines	O
or	O
thymines	O
,	O
without	O
interruption	O
by	O
guanine	O
or	O
cytosine	O
,	O
are	O
required	O
for	O
the	O
ARS	B-GENE
activity	O
.	O

The	O
coding	O
region	O
of	O
2385	O
nucleotides	O
corresponds	O
to	O
a	O
polypeptide	O
chain	O
of	O
795	O
amino	O
acids	O
,	O
giving	O
a	O
molecular	O
weight	O
of	O
91	O
,	O
555	O
for	O
the	O
hsp108	B-GENE
protein	I-GENE
.	O

Both	O
neural	O
and	O
hormonal	O
pathways	O
and	O
both	O
opiate	O
and	O
nonopiate	O
substances	O
play	O
roles	O
in	O
the	O
complex	O
modulation	O
of	O
pain	O
transmission	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
TtrA	B-GENE
contains	O
a	O
molybdopterin	O
guanine	O
dinucleotide	O
cofactor	O
and	O
a	O
[	O
4Fe-4S	O
]	O
cluster	O
,	O
that	O
TtrB	B-GENE
binds	O
four	O
[	O
4Fe-4S	O
]	O
clusters	O
,	O
and	O
that	O
TtrC	B-GENE
is	O
an	O
integral	O
membrane	O
protein	O
containing	O
a	O
quinol	O
oxidation	O
site	O
.	O

A	O
tyrosine-based	O
sorting	O
signal	O
in	O
the	O
beta2	B-GENE
integrin	I-GENE
cytoplasmic	I-GENE
domain	I-GENE
mediates	O
its	O
recycling	O
to	O
the	O
plasma	O
membrane	O
and	O
is	O
required	O
for	O
ligand-supported	O
migration	O
.	O

The	O
IE0	B-GENE
gene	I-GENE
product	O
also	O
transactivated	O
the	O
IE1	B-GENE
promoter	I-GENE
but	O
did	O
not	O
affect	O
expression	O
from	O
its	O
own	O
promoter	O
.	O

Variations	O
of	O
the	O
timing	O
of	O
deflections	O
in	O
the	O
His	O
bundle	O
recordings	O
.	O

The	O
probability	O
of	O
treatment	O
with	O
lamotrigine	O
being	O
maintained	O
for	O
six	O
months	O
was	O
86%	O
,	O
for	O
twelve	O
months	O
61%	O
and	O
for	O
three	O
years	O
31%	O
.	O

The	O
ventilation	O
did	O
not	O
increase	O
when	O
PACO2	O
was	O
increased	O
.	O

The	O
Arabidopsis	B-GENE
FAD7	I-GENE
gene	I-GENE
encodes	O
a	O
chloroplast	B-GENE
omega-3	I-GENE
fatty	I-GENE
acid	I-GENE
desaturase	I-GENE
that	O
catalyzes	O
the	O
desaturation	O
of	O
lipid-linked	O
dienoic	O
fatty	O
acids	O
(	O
18	O
:	O
2	O
and	O
16	O
:	O
2	O
)	O
.	O

Transient	O
overexpression	O
of	O
c-Jun	B-GENE
induced	O
tenascin-C	B-GENE
expression	O
in	O
primary	O
REF	O
and	O
in	O
FR3T3	O
,	O
an	O
established	O
fibroblast	O
cell	O
line	O
.	O

Dual	O
roles	O
of	O
p82	B-GENE
,	O
the	O
clam	O
CPEB	B-GENE
homolog	I-GENE
,	O
in	O
cytoplasmic	O
polyadenylation	O
and	O
translational	O
masking	O
.	O

Arterial	O
radioactivity	O
content	O
after	O
the	O
intravenous	O
administration	O
of	O
HMPAO	O
in	O
seven	O
human	O
subjects	O
was	O
analyzed	O
.	O

The	O
alterations	O
of	O
5-HT	O
and	O
5-HIAA	O
levels	O
in	O
several	O
regions	O
of	O
the	O
brain	O
under	O
the	O
conditions	O
examined	O
may	O
indicate	O
that	O
IDPN's	O
neurotoxicity	O
primarily	O
affects	O
5-HT-containing	O
neurones	O
.	O

The	O
recruitment	O
of	O
constitutively	O
phosphorylated	O
p185	B-GENE
(	I-GENE
neu	I-GENE
)	I-GENE
and	O
the	O
activated	O
mitogenic	O
pathway	O
proteins	O
to	O
this	O
membrane-microfilament	O
interaction	O
site	O
provides	O
a	O
physical	O
model	O
for	O
integrating	O
the	O
assembly	O
of	O
the	O
mitogenic	O
pathway	O
with	O
the	O
transmission	O
of	O
growth	B-GENE
factor	I-GENE
signal	O
to	O
the	O
cytoskeleton	O
.	O

The	O
outcome	O
of	O
the	O
optimization	O
of	O
the	O
seven-field	O
plan	O
prompted	O
an	O
investigation	O
into	O
the	O
best	O
results	O
that	O
could	O
be	O
achieved	O
by	O
an	O
"ideal"	O
conformal	O
radiotherapy	O
technique	O
.	O

The	O
site-directed	O
mutation	O
of	O
the	O
kappa	B-GENE
B	I-GENE
motif	I-GENE
in	O
IL-6	B-GENE
/	I-GENE
CAT	I-GENE
plasmid	O
resulted	O
in	O
the	O
complete	O
abrogation	O
of	O
IL-6	B-GENE
promoter	I-GENE
activity	O
in	O
these	O
cells	O
.	O

METHODS	O
:	O
P-selectin	B-GENE
expression	O
of	O
nonstimulated	O
and	O
ADP-stimulated	O
platelets	O
was	O
flow	O
cytometrically	O
measured	O
before	O
the	O
clopidogrel	O
loading	O
dose	O
and	O
on	O
3	O
consecutive	O
days	O
in	O
52	O
patients	O
with	O
coronary	O
artery	O
disease	O
:	O
21	O
patients	O
in	O
group	O
1	O
received	O
300	O
mg	O
of	O
clopidogrel	O
after	O
stent	O
implantation	O
and	O
11	O
patients	O
in	O
group	O
2	O
received	O
the	O
higher	O
450-mg	O
clopidogrel	O
loading	O
dose	O
followed	O
by	O
a	O
daily	O
dose	O
of	O
75	O
mg	O
of	O
clopidogrel	O
for	O
both	O
groups	O
.	O

The	O
mouse	B-GENE
beta	I-GENE
2-syntrophin	I-GENE
gene	I-GENE
(	O
>	O
33	O
kilobases	O
)	O
contains	O
seven	O
exons	O
,	O
all	O
of	O
which	O
have	O
homologues	O
at	O
the	O
corresponding	O
position	O
in	O
the	O
alpha	B-GENE
1-syntrophin	I-GENE
gene	I-GENE
.	O

Interestingly	O
,	O
the	O
avirulent	O
strain	O
H37Ra	O
showed	O
weak	O
hybridization	O
with	O
these	O
two	O
probes	O
,	O
suggesting	O
that	O
these	O
genes	O
might	O
have	O
been	O
deleted	O
in	O
the	O
avirulent	O
strain	O
or	O
are	O
present	O
in	O
limited	O
copy	O
numbers	O
as	O
opposed	O
to	O
those	O
in	O
the	O
virulent	O
strain	O
H37Rv	O
.	O

In	O
contrast	O
to	O
MPc3	B-GENE
,	O
data	O
indicate	O
that	O
the	O
Pc	B-GENE
protein	I-GENE
M33	B-GENE
does	O
not	O
interact	O
with	O
AF9	B-GENE
.	O

Expression	O
of	O
this	O
protein	O
in	O
E	O
.	O
coli	O
demonstrated	O
that	O
tyrosine	O
was	O
incorporated	O
during	O
suppression	O
and	O
that	O
yeast	B-GENE
cytoplasmic	I-GENE
TyrRS	I-GENE
activity	O
was	O
produced	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
the	O
Pseudomonas	B-GENE
putida	I-GENE
PpG7	I-GENE
salicylate	I-GENE
hydroxylase	I-GENE
gene	I-GENE
(	O
nahG	B-GENE
)	O
and	O
its	O
3'-flanking	O
region	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
PecS	B-GENE
attenuates	O
pelD	B-GENE
and	O
pelE	B-GENE
expression	O
rather	O
than	O
acting	O
as	O
a	O
true	O
repressor	O
like	O
KdgR	B-GENE
.	O

In	O
several	O
cell	O
lines	O
,	O
mTOR	B-GENE
or	O
its	O
downstream	O
targets	O
can	O
be	O
regulated	O
by	O
phosphatidylinositol	B-GENE
(	I-GENE
PI	I-GENE
)	I-GENE
3-kinase	I-GENE
;	O
protein	B-GENE
kinases	I-GENE
A	I-GENE
,	I-GENE
B	I-GENE
,	I-GENE
and	I-GENE
C	I-GENE
;	O
heterotrimeric	B-GENE
G-proteins	I-GENE
;	O
a	O
PD98059-sensitive	O
kinase	B-GENE
or	O
calcium	O
;	O
as	O
well	O
as	O
by	O
amino	O
acids	O
.	O

Sequences	O
downstream	O
of	O
the	O
two	O
human	B-GENE
CA	I-GENE
genes	I-GENE
,	O
possibly	O
containing	O
homologous	O
enhancer	O
elements	O
,	O
have	O
not	O
yet	O
been	O
reported	O
.	O

This	O
establishes	O
Rad3	B-GENE
/	I-GENE
Mec1	I-GENE
as	O
the	O
only	O
conserved	O
protein	O
which	O
is	O
required	O
for	O
all	O
the	O
DNA	O
structure	O
checkpoints	O
in	O
both	O
yeast	O
model	O
systems	O
.	O

However	O
,	O
plasmids	O
carrying	O
the	O
yeast	B-GENE
TyrRS	I-GENE
gene	I-GENE
could	O
not	O
be	O
stably	O
maintained	O
in	O
E	O
.	O
coli	O
.	O

16	O
percent	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
sustained	O
normalization	O
of	O
serum	B-GENE
alanine	I-GENE
aminotransferase	I-GENE
levels	O
(	O
41	O
percent	O
vs	O
.	O

The	O
sequence	O
was	O
determined	O
of	O
6493	O
nucleotides	O
encompassing	O
the	O
bet	B-GENE
genes	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
which	O
encode	O
the	O
osmoregulatory	O
choline-glycine	B-GENE
betaine	I-GENE
pathway	I-GENE
.	O

135	O
students	O
had	O
a	O
count	O
of	O
less	O
than	O
50	O
eggs	O
/	O
10	O
ml	O
.	O
urine	O
and	O
56	O
had	O
more	O
than	O
50	O
eggs	O
/	O
10	O
ml	O
.	O

Based	O
on	O
the	O
hypothesis	O
that	O
evolutionarily	O
conserved	O
regions	O
are	O
functionally	O
important	O
and	O
likely	O
to	O
interact	O
with	O
coactivators	O
,	O
we	O
compared	O
the	O
amino	O
acid	O
sequence	O
of	O
C	B-GENE
/	I-GENE
EBPalpha	I-GENE
from	O
different	O
species	O
(	O
frog	O
to	O
human	O
)	O
and	O
identified	O
four	O
highly	O
conserved	O
regions	O
(	O
CR1-CR4	B-GENE
)	O
within	O
the	O
transactivation	O
domain	O
.	O

Evidence	O
for	O
a	O
novel	O
MAPKKK-independent	O
pathway	O
controlling	O
the	O
stress	O
activated	O
Sty1	B-GENE
/	I-GENE
Spc1	I-GENE
MAP	I-GENE
kinase	I-GENE
in	O
fission	O
yeast	O
.	O

A	O
recombinant	O
derivative	O
harboring	O
the	O
pMJ101	O
replication	O
region	O
proved	O
to	O
be	O
compatible	O
with	O
pJM1	O
,	O
a	O
plasmid	O
containing	O
the	O
iron	O
acquisition	O
system	O
required	O
for	O
the	O
virulence	O
of	O
V	O
.	O
anguillarum	O
775	O
,	O
another	O
important	O
pathogen	O
that	O
causes	O
vibriosis	O
.	O

Five	O
of	O
these	O
have	O
ocular	O
or	O
oculocutaneous	O
albinism	O
.	O

NH3	O
and	O
NO	O
interaction	O
with	O
Si	O
(	O
100	O
)	O
-	O
(	O
2	O
x	O
1	O
)	O
surfaces	O
.	O

Normal	O
values	O
for	O
the	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
of	O
the	O
grey	O
(	O
Armenian	O
)	O
hamster	O
.	O

Lipoprotein	B-GENE
lipase	I-GENE
(	O
LPL	B-GENE
)	O
,	O
a	O
key	O
enzyme	O
in	O
normal	O
lipoprotein	O
metabolism	O
,	O
has	O
a	O
complex	O
pattern	O
of	O
regulation	O
and	O
tissue-specific	O
expression	O
.	O

Protein	O
electrophoresis	O
showed	O
decreased	O
albumin	B-GENE
levels	O
in	O
both	O
groups	O
,	O
with	O
lower	O
values	O
in	O
G2	O
.	O

A	O
xylE	B-GENE
transcriptional	I-GENE
fusion	I-GENE
to	O
the	O
putative	O
mxbD	B-GENE
promoter	I-GENE
showed	O
low-level	O
expression	O
in	O
wild-type	O
cells	O
grown	O
on	O
one-carbon	O
(	O
C1	O
)	O
compounds	O
and	O
no	O
detectable	O
expression	O
in	O
cells	O
grown	O
on	O
succinate	O
.	O

The	O
variable	O
phenotype	O
of	O
the	O
allotetraploids	O
could	O
not	O
be	O
explained	O
by	O
cytological	O
abnormalities	O
.	O

The	O
RNase	B-GENE
MRP	I-GENE
RNA	I-GENE
gene	I-GENE
was	O
deleted	O
by	O
insertional	O
replacement	O
and	O
found	O
to	O
be	O
essential	O
for	O
cellular	O
viability	O
,	O
indicating	O
a	O
critical	O
nuclear	O
role	O
for	O
RNase	B-GENE
MRP	I-GENE
.	O

Studies	O
on	O
the	O
method	O
of	O
size	O
reduction	O
of	O
medicinal	O
compounds	O
.	O

A	O
human	B-GENE
Raf-responsive	I-GENE
zinc-finger	I-GENE
protein	I-GENE
that	O
binds	O
to	O
divergent	O
sequences	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

One	O
of	O
these	O
small	B-GENE
inteins	I-GENE
might	O
be	O
inactive	O
or	O
a	O
"pseudo	B-GENE
intein	I-GENE
.	I-GENE
"	I-GENE
The	O
results	O
suggest	O
a	O
modular	O
architecture	O
for	O
inteins	B-GENE
,	O
clarify	O
their	O
origin	O
and	O
relationship	O
to	O
other	O
protein	O
families	O
,	O
and	O
extend	O
recent	O
experimental	O
findings	O
on	O
the	O
functional	O
roles	O
of	O
intein	B-GENE
N	I-GENE
,	I-GENE
C	I-GENE
,	I-GENE
and	I-GENE
EN	I-GENE
motifs	I-GENE
.	O

220	O
,	O
263-273	O
)	O
.	O

As	O
in	O
S	O
.	O
cerevisiae	O
,	O
the	O
sequence	O
of	O
rhp51+	B-GENE
showed	O
two	O
MluI	B-GENE
cell-cycle	I-GENE
boxes	I-GENE
and	O
a	O
putative	O
DNA	O
damage-responsive	O
element	O
in	O
its	O
upstream	O
region	O
.	O

There	O
was	O
no	O
competition	O
between	O
activin	B-GENE
A	I-GENE
and	O
OP-1	B-GENE
for	O
availability	O
of	O
Smad4	B-GENE
,	O
indicating	O
that	O
the	O
concentration	O
of	O
this	O
common	O
signal	O
transducer	O
is	O
not	O
limiting	O
for	O
generating	O
the	O
observed	O
biological	O
responses	O
.	O

Intra-articular	O
dislocation	O
of	O
the	O
patella	O
.	O

Pneumothorax	O
during	O
laparoscopic	O
dissection	O
of	O
the	O
diaphragmatic	O
hiatus	O
.	O

Dosage	O
in	O
both	O
cases	O
was	O
0	O
.	O
2	O
g	O
/	O
m2	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	B-GENE
sphingosine	I-GENE
kinase	I-GENE
.	O

Processing	O
of	O
the	O
polycistronic	O
precursor	O
requires	O
nucleases	B-GENE
also	O
involved	O
in	O
rRNA	B-GENE
processing	O
,	O
i	O
.	O
e	O
.	O
,	O
Rnt1p	B-GENE
and	O
Rat1p	B-GENE
.	O

Hyperactivation	O
of	O
Cdc2	B-GENE
in	O
fission	O
yeast	O
causes	O
cells	O
to	O
undergo	O
a	O
lethal	O
premature	O
mitosis	O
called	O
mitotic	O
catastrophe	O
.	O

Tissue-specific	O
expression	O
of	O
the	O
diazepam-binding	B-GENE
inhibitor	I-GENE
in	O
Drosophila	O
melanogaster	O
:	O
cloning	O
,	O
structure	O
,	O
and	O
localization	O
of	O
the	O
gene	O
.	O

Competition	O
analysis	O
by	O
gel	O
mobility	O
shift	O
electrophoresis	O
indicates	O
that	O
this	O
DNA-protein	O
interaction	O
is	O
novel	O
and	O
not	O
related	O
to	O
many	O
transcription	O
factors	O
previously	O
reported	O
.	O

Nevertheless	O
,	O
we	O
demonstrate	O
that	O
the	O
entire	O
three-component	O
yeast	O
capping	O
apparatus	O
,	O
consisting	O
of	O
RNA	B-GENE
5'-triphosphatase	I-GENE
(	O
Cet1p	B-GENE
)	O
,	O
RNA	B-GENE
guanylyltransferase	I-GENE
(	O
Ceg1p	B-GENE
)	O
,	O
and	O
Abd1p	B-GENE
could	O
be	O
replaced	O
in	O
vivo	O
by	O
the	O
two-component	O
mammalian	O
apparatus	O
consisting	O
of	O
a	O
bifunctional	O
triphosphatase-guanylyltransferase	B-GENE
Mce1p	I-GENE
and	O
the	O
methyltransferase	B-GENE
Hcm1	I-GENE
(	I-GENE
121-476	I-GENE
)	I-GENE
p	I-GENE
.	O

We	O
purified	O
a	O
Ca2+	B-GENE
/	I-GENE
calmodulin	I-GENE
(	I-GENE
CaM	I-GENE
)	I-GENE
-dependent	I-GENE
protein	I-GENE
kinase	I-GENE
(	I-GENE
CaM	I-GENE
kinase	I-GENE
)	I-GENE
from	I-GENE
the	I-GENE
yeast	I-GENE
Saccharomyces	I-GENE
cerevisiae	I-GENE
with	O
properties	O
similar	O
to	O
mammalian	B-GENE
type	I-GENE
II	I-GENE
CaM	I-GENE
kinases	I-GENE
.	O

The	O
247-kDa	O
complex	O
appears	O
to	O
contain	O
two	O
distinct	O
protein-DNA	O
complexes	O
of	O
approximately	O
232	O
and	O
256	O
kDa	O
and	O
represents	O
two	O
proteins	O
covalently	O
cross-linked	O
to	O
a	O
single	O
DRE	B-GENE
oligonucleotide	O
,	O
while	O
the	O
97	O
,	O
105	O
,	O
and	O
115-kDa	O
complexes	O
represent	O
single	O
protein-DRE	B-GENE
cross-links	O
.	O

Identification	O
of	O
a	O
promoter-specific	O
transactivation	O
domain	O
in	O
the	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
regulatory	I-GENE
protein	I-GENE
ICP4	I-GENE
.	O

In	O
insects	O
,	O
arylalkylamine	B-GENE
N-acetyltransferases	I-GENE
(	O
AANATs	B-GENE
)	O
have	O
been	O
implicated	O
in	O
several	O
physiological	O
processes	O
,	O
including	O
sclerotization	O
,	O
inactivation	O
of	O
certain	O
neurotransmitters	O
,	O
and	O
,	O
similar	O
to	O
the	O
function	O
in	O
vertebrates	O
,	O
catalysis	O
of	O
the	O
rate-limiting	O
step	O
in	O
melatonin	O
biosynthesis	O
.	O

Eliminating	O
any	O
subset	O
of	O
ASCUS	O
reduces	O
the	O
ASCUS	O
/	O
SIL	O
ratio	O
but	O
also	O
significantly	O
diminishes	O
the	O
sensitivity	O
of	O
the	O
Papanicolaou	O
test	O
.	O

The	O
enteric	O
route	O
is	O
the	O
principal	O
mode	O
of	O
transmission	O
for	O
hepatitis	O
A	O
,	O
but	O
maximal	O
levels	O
of	O
hepatitis	O
A	O
virus	O
excretion	O
occur	O
before	O
the	O
onset	O
of	O
jaundice	O
.	O

Km	O
values	O
for	O
ammonium	O
,	O
2-oxoglutarate	O
,	O
NADH	O
,	O
glutamate	O
and	O
NAD+	O
were	O
6	O
.	O
5	O
,	O
3	O
.	O
5	O
,	O
0	O
.	O
06	O
,	O
37	O
.	O
1	O
and	O
0	O
.	O
046	O
mM	O
,	O
respectively	O
.	O

ROS	B-GENE
x	O
SRC	B-GENE
(	O
R	B-GENE
)	O
contains	O
a	O
16-amino-acid	O
deletion	O
that	O
includes	O
the	O
3'	O
half	O
of	O
the	O
transmembrane	O
domain	O
of	O
ros	B-GENE
.	O

Unlike	O
the	O
typical	O
enhancer	O
element	O
,	O
this	O
region	O
functions	O
in	O
an	O
orientation-dependent	O
manner	O
.	O

We	O
present	O
this	O
case	O
because	O
of	O
the	O
rarity	O
of	O
left	O
ventricular	O
involvement	O
associated	O
with	O
ARVD	O
.	O

We	O
describe	O
a	O
novel	O
zinc	B-GENE
finger	I-GENE
protein	I-GENE
,	O
dsRBP-ZFa	B-GENE
,	O
isolated	O
by	O
screening	O
an	O
expression	O
library	O
with	O
dsRNA	O
.	O

With	O
respect	O
to	O
effective	O
diffusivity	O
of	O
platelets	O
(	O
De	O
)	O
and	O
the	O
surface	O
reactivity	O
constant	O
(	O
K	O
)	O
,	O
less	O
significant	O
differences	O
were	O
found	O
among	O
artificial	O
materials	O
.	O

Catch-up	O
growth	O
was	O
observed	O
only	O
for	O
a	O
12-month	O
period	O
in	O
4	O
children	O
with	O
a	O
bone	O
age	O
of	O
7	O
to	O
8	O
years	O
.	O

Am	O
.	O

The	O
frequency	O
of	O
PPNG	O
strains	O
increased	O
from	O
1	O
.	O
7%	O
in	O
1981	O
to	O
6	O
.	O
7%	O
in	O
1985	O
.	O

These	O
results	O
suggested	O
that	O
NfxB	B-GENE
negatively	O
autoregulates	O
the	O
expression	O
of	O
nfxB	B-GENE
itself	O
.	O

An	O
egg	O
protein	O
,	O
lysozyme	B-GENE
,	O
is	O
a	O
still	O
unlabeled	O
additive	O
currently	O
used	O
in	O
cheese	O
preparation	O
.	O

Component	O
P100	O
was	O
associated	O
with	O
a	O
frontal	O
negativity	O
of	O
similar	O
latency	O
favoring	O
the	O
hypothesis	O
of	O
a	O
dipolar	O
occipital	O
generator	O
.	O

W	O
.	O

No	O
direct	O
repeats	O
flank	O
the	O
pseudogene	O
in	O
the	O
U2	B-GENE
/	I-GENE
4	I-GENE
locus	I-GENE
.	O

Crossover	O
in	O
the	O
specific	O
heat	O
of	O
dilute	O
magnets	O
induced	O
by	O
critical	O
spin-wave	O
dynamics	O
.	O

The	O
effects	O
on	O
reflex	O
latencies	O
but	O
not	O
on	O
paCO2	O
or	O
pHa	O
were	O
blocked	O
by	O
naloxone	O
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
and	O
were	O
not	O
present	O
in	O
morphine-tolerant	O
animals	O
.	O

Pharmacologic	O
doses	O
of	O
vitamin	O
B6	O
administered	O
to	O
lactating	O
women	O
have	O
been	O
reported	O
to	O
suppress	O
plasma	B-GENE
prolactin	I-GENE
.	O

In	O
Group	O
V	O
,	O
the	O
salvaged	O
tissue	O
was	O
primarily	O
subepicardial	O
with	O
virtually	O
no	O
lateral	O
zone	O
of	O
salvaged	O
tissue	O
(	O
ratio	O
of	O
salvaged	O
subepicardium	O
to	O
salvaged	O
subendocardium	O
14	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
9	O
to	O
1	O
)	O
.	O

In	O
a	O
previous	O
interim	O
report	O
we	O
noted	O
more	O
prompt	O
resolution	O
of	O
dermatomal	O
signs	O
and	O
symptoms	O
with	O
acyclovir	O
treatment	O
.	O

In	O
cellular	O
supernatant	O
fraction	O
,	O
SHRSP	O
showed	O
a	O
decrease	O
of	O
magnesium	O
in	O
many	O
tissues	O
and	O
an	O
elevation	O
of	O
the	O
calcium	O
to	O
magnesium	O
ratio	O
when	O
compared	O
to	O
age-matched	O
WKY	O
and	O
SHRSR	O
.	O

Cloning	O
of	O
a	O
human	B-GENE
phosphoinositide	I-GENE
3-kinase	I-GENE
with	O
a	O
C2	B-GENE
domain	I-GENE
that	O
displays	O
reduced	O
sensitivity	O
to	O
the	O
inhibitor	O
wortmannin	O
.	O

Selective	O
bronchial	O
intubation	O
in	O
the	O
management	O
of	O
unilateral	O
pulmonary	O
interstitial	O
emphysema	O
.	O

Kidney	O
weight	O
and	O
kidney-to-body	O
weight	O
ratio	O
were	O
significantly	O
elevated	O
at	O
the	O
highest	O
dose	O
level	O
after	O
10	O
weeks	O
and	O
at	O
the	O
two	O
higher	O
dose	O
levels	O
after	O
15	O
weeks	O
of	O
exposure	O
.	O

However	O
,	O
inhibition	O
of	O
both	O
the	O
ERK	B-GENE
/	I-GENE
RSK	I-GENE
and	O
the	O
p38	B-GENE
/	I-GENE
MAPKAP	I-GENE
kinase	I-GENE
2	I-GENE
pathways	O
completely	O
abolished	O
NGF-induced	O
CREB	B-GENE
Ser-133	O
phosphorylation	O
.	O

Malaria	O
,	O
anaemia	O
,	O
and	O
HIV-1	O
transmission	O
in	O
central	O
Africa	O
.	O

Association	O
with	O
HL-A	B-GENE
W-27	I-GENE
.	O

Endonuclease	B-GENE
III	I-GENE
(	O
Nth	B-GENE
)	O
of	O
Escherichia	O
coli	O
is	O
a	O
DNA	B-GENE
glycosylase	I-GENE
essential	O
for	O
the	O
removal	O
of	O
oxidised	O
pyrimidine	O
base	O
residues	O
from	O
DNA	O
.	O

This	O
sequence	O
,	O
Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe	B-GENE
,	O
forms	O
part	O
of	O
the	O
B-loop	B-GENE
and	O
is	O
conserved	O
in	O
a	O
wide	O
variety	O
of	O
organisms	O
that	O
include	O
bacteria	O
,	O
algae	O
and	O
archeabacteria	O
.	O

Hierarchy	O
of	O
protein	B-GENE
tyrosine	I-GENE
kinases	I-GENE
in	O
interleukin-2	B-GENE
(	O
IL-2	B-GENE
)	O
signaling	O
:	O
activation	O
of	O
syk	B-GENE
depends	O
on	O
Jak3	B-GENE
;	O
however	O
,	O
neither	O
Syk	B-GENE
nor	O
Lck	B-GENE
is	O
required	O
for	O
IL-2-mediated	O
STAT	B-GENE
activation	O
.	O

Multifunctional	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
MFPK	B-GENE
)	O
phosphorylates	O
ATP-citrate	B-GENE
lyase	I-GENE
on	O
peptide	B-GENE
B	I-GENE
on	O
two	O
sites	O
,	O
BT	O
and	O
BS	O
,	O
on	O
threonine	O
and	O
serine	O
,	O
respectively	O
,	O
inhibitor	B-GENE
2	I-GENE
on	O
a	O
threonyl	O
residue	O
,	O
and	O
glycogen	B-GENE
synthase	I-GENE
at	O
sites	O
2	O
and	O
3	O
.	O

Prrp	B-GENE
can	O
also	O
associate	O
with	O
the	O
EVH1	B-GENE
domain	I-GENE
of	O
Mena	B-GENE
,	O
another	O
microfilament-associated	O
protein	O
.	O

The	O
full	O
length	O
cDNA	O
sequence	O
of	O
a	O
Type	B-GENE
I	I-GENE
transforming	I-GENE
growth	I-GENE
factor-beta	I-GENE
(	I-GENE
TGF-beta	I-GENE
)	I-GENE
receptor	I-GENE
has	O
been	O
isolated	O
from	O
the	O
filarial	O
parasitic	O
nematode	O
Brugia	O
pahangi	O
.	O

The	O
sample	O
includes	O
all	O
the	O
HIV-infected-patients	O
continuously	O
referred	O
to	O
the	O
Outpatient	O
Service	O
of	O
the	O
Infectious	O
Diseases	O
dept	O
.	O
of	O
Bologna's	O
"Ospedale	O
Maggiore"	O
General	O
Hospital	O
during	O
some	O
five	O
days	O
(	O
19-23rd	O
,	O
July	O
1993	O
)	O
.	O

Angiography	O
was	O
performed	O
following	O
the	O
rCBF	O
study	O
and	O
the	O
degree	O
of	O
vasospasm	O
was	O
measured	O
on	O
the	O
angiograms	O
.	O

Furthermore	O
,	O
no	O
transcripts	O
of	O
the	O
same	O
size	O
and	O
having	O
the	O
same	O
developmental	O
profile	O
as	O
those	O
generated	O
by	O
the	O
wild-type	B-GENE
E10	I-GENE
fragment	I-GENE
were	O
identified	O
by	O
probes	O
covering	O
the	O
remainder	O
of	O
the	O
cloned	O
region	O
.	O

We	O
discuss	O
the	O
need	O
to	O
use	O
animals	O
older	O
than	O
3	O
months	O
for	O
the	O
study	O
of	O
'adult'	O
regeneration	O
phenomena	O
since	O
3-month-old	O
rats	O
may	O
be	O
somewhat	O
immature	O
.	O

Sequence	O
analysis	O
of	O
reverse	O
transcribed	O
,	O
amplified	O
cDNA	O
generated	O
from	O
total	O
RNA	O
isolated	O
from	O
transfected	O
cells	O
demonstrated	O
the	O
presence	O
of	O
abnormally	O
spliced	O
products	O
containing	O
13	O
and	O
78	O
additional	O
bases	O
as	O
well	O
as	O
the	O
accumulation	O
of	O
unspliced	O
mRNA	O
.	O

Furthermore	O
,	O
a	O
p21X	B-GENE
protein	I-GENE
lacking	O
the	O
N-terminus	O
of	O
Rex1	B-GENE
was	O
expressed	O
at	O
high	O
levels	O
;	O
our	O
data	O
indicate	O
that	O
p21X	B-GENE
is	O
translated	O
from	O
the	O
1	O
.	O
6-kb	O
mRNA	O
which	O
is	O
derived	O
primarily	O
from	O
deleted	O
proviruses	O
.	O

Diet	O
and	O
atopic	O
eczema	O
.	O

High	O
values	O
of	O
both	O
retinol	O
and	O
beta-carotene	O
were	O
found	O
in	O
full	O
fat	O
cheeses	O
and	O
whipping	O
cream	O
:	O
from	O
179	O
.	O
0	O
(	O
cheese	O
,	O
Edam-type	O
)	O
to	O
318	O
.	O
7	O
micrograms	O
/	O
100	O
g	O
(	O
whipping	O
cream	O
)	O
and	O
from	O
86	O
.	O
7	O
(	O
cheese	O
,	O
Edam-type	O
)	O
to	O
186	O
.	O
5	O
micrograms	O
/	O
100	O
g	O
(	O
whipping	O
cream	O
)	O
for	O
all-trans	O
retinol	O
and	O
total	O
beta-carotene	O
,	O
respectively	O
.	O

Troubled	O
CareNetwork	O
gets	O
pact	O
from	O
largest	O
teacher	O
union	O
in	O
Wis	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
relationship	O
between	O
blood	O
flow	O
in	O
the	O
tumor	O
assessed	O
by	O
color	O
Doppler	O
ultrasound	O
,	O
microvessel	O
density	O
,	O
and	O
vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
levels	O
in	O
endometrial	O
carcinoma	O
.	O

Among	O
mucus-secreting	O
cells	O
,	O
the	O
gastric	O
gland	O
mucous	O
cells	O
,	O
Brunner's	O
glands	O
,	O
accessory	O
glands	O
of	O
pancreaticobiliary	O
tract	O
,	O
and	O
pancreatic	O
ducts	O
exhibiting	O
gastric	O
metaplasia	O
are	O
unique	O
in	O
that	O
they	O
express	O
class	B-GENE
III	I-GENE
mucin	I-GENE
identified	O
by	O
paradoxical	O
Con	B-GENE
A	I-GENE
staining	O
composed	O
of	O
periodate	O
oxidation	O
,	O
sodium	O
borohydride	O
reduction	O
,	O
Con	B-GENE
A	I-GENE
,	O
and	O
horseradish	B-GENE
peroxidase	I-GENE
reaction	O
.	O

Elevated	O
IOP	O
developed	O
in	O
35	O
patients	O
(	O
44	O
eyes	O
)	O
during	O
the	O
study	O
.	O

To	O
determine	O
the	O
function	O
of	O
VZV	B-GENE
gK	I-GENE
in	O
virus	O
growth	O
,	O
a	O
series	O
of	O
gK	B-GENE
deletion	I-GENE
mutants	I-GENE
were	O
constructed	O
with	O
VZV	O
cosmid	O
DNA	O
derived	O
from	O
the	O
Oka	O
strain	O
.	O

The	O
effect	O
of	O
independent	O
predictors	O
on	O
survival	O
was	O
examined	O
in	O
a	O
Cox	O
regression	O
model	O
with	O
adjustment	O
for	O
existing	O
illnesses	O
.	O

Ectopic	O
ACTH	B-GENE
syndrome	O
and	O
medullary	O
thyroid	O
carcinoma	O
.	O

We	O
observed	O
that	O
dephosphorylation	O
severely	O
inhibits	O
the	O
DNA-binding	O
ability	O
of	O
C	B-GENE
/	I-GENE
EBP-delta	I-GENE
and	O
its	O
transactivating	O
potential	O
increases	O
in	O
the	O
presence	O
of	O
cellular	O
phosphatase	B-GENE
inhibitors	O
,	O
such	O
as	O
okadaic	O
acid	O
and	O
sodium	O
orthovanadate	O
.	O

Furthermore	O
,	O
phosphatidylinositol	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
trisphosphate	O
specifically	O
stimulates	O
the	O
activity	O
of	O
ILK	B-GENE
in	O
vitro	O
,	O
and	O
in	O
addition	O
,	O
membrane	O
targetted	O
constitutively	O
active	O
Pi	B-GENE
(	I-GENE
3	I-GENE
)	I-GENE
K	I-GENE
activates	O
ILK	B-GENE
in	O
vivo	O
.	O

49	O
,	O
XXXXY	O
chromosome	O
anomaly	O
:	O
an	O
unusual	O
variant	O
of	O
Klinefelter's	O
syndrome	O
.	O

Propafenone	O
is	O
well	O
tolerated	O
in	O
the	O
majority	O
of	O
young	O
patients	O
.	O

Furthermore	O
,	O
our	O
novel	O
observation	O
that	O
expression	O
of	O
a	O
highly	O
activated	O
FGFR3	B-GENE
kinase	I-GENE
domain	I-GENE
is	O
able	O
to	O
morphologically	O
transform	O
fibroblasts	O
suggests	O
that	O
dysregulation	O
of	O
FGFR3	B-GENE
has	O
the	O
potential	O
to	O
play	O
a	O
role	O
in	O
human	O
neoplasia	O
.	O

Postdocs	O
face	O
hardship	O
across	O
mainland	O
Europe	O
.	O

C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
also	O
activates	O
the	O
promoter	O
of	O
the	O
rat	B-GENE
class-I	I-GENE
ADH	I-GENE
gene	I-GENE
in	O
a	O
sequence-specific	O
manner	O
[	O
Potter	O
et	O
al	O
.	O
,	O
Arch	O
.	O

An	O
experimental	O
long-term	O
study	O
.	O

XYL1	B-GENE
was	O
isolated	O
as	O
a	O
highly	O
expressed	O
fusion	O
clone	O
from	O
a	O
'lacZ	B-GENE
translational	O
fusion	O
library	O
.	O

Only	O
transcripts	O
specific	O
for	O
TSGF-2	B-GENE
are	O
detected	O
in	O
ovary	O
and	O
testes	O
tissues	O
of	O
adults	O
as	O
well	O
as	O
in	O
puparia	O
,	O
while	O
neither	O
gene	O
is	O
expressed	O
during	O
the	O
larval	O
developmental	O
stages	O
.	O

Using	O
RACE	O
techniques	O
we	O
have	O
cloned	O
and	O
sequenced	O
one	O
of	O
the	O
hamster	O
liver	O
3-hydroxy-hexobarbital	B-GENE
dehydrogenases	I-GENE
which	O
catalyze	O
not	O
only	O
cyclic	O
alcohols	O
but	O
also	O
17beta-hydroxy-steroids	O
and	O
3alpha-hydroxysteroids	O
.	O

Currently	O
,	O
the	O
clinical	O
use	O
of	O
5-aminolaevulinic	O
acid	O
(	O
ALA	O
)	O
induced	O
protoporphyrin	B-GENE
IX	I-GENE
(	O
PPIX	B-GENE
)	O
for	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
is	O
limited	O
by	O
the	O
maximum	O
tolerated	O
oral	O
ALA	O
dose	O
(	O
60	O
mg	O
/	O
kg	O
)	O
.	O

The	O
presence	O
of	O
an	O
unusual	O
transcript	O
possessing	O
IVS2C	B-GENE
beta	I-GENE
1	I-GENE
at	O
the	O
5'	O
terminus	O
suggests	O
that	O
cleavage	O
of	O
its	O
splice	O
acceptor	O
is	O
inefficient	O
or	O
negatively	O
regulated	O
.	O

We	O
found	O
sequences	O
related	O
to	O
this	O
insertion	O
in	O
wild-type	O
strains	O
of	O
N	O
.	O
crassa	O
and	O
other	O
Neurospora	O
species	O
.	O

The	O
altered	O
amino	O
acid	O
residues	O
of	O
the	O
seven	O
mutant	B-GENE
9ORF1	I-GENE
polypeptides	I-GENE
clustered	O
within	O
three	O
separate	O
regions	O
referred	O
to	O
as	O
region	O
I	O
(	O
residues	O
34	O
to	O
41	O
)	O
,	O
region	O
II	O
(	O
residues	O
89	O
to	O
91	O
)	O
,	O
and	O
C-terminal	O
region	O
III	O
(	O
residues	O
122	O
to	O
125	O
)	O
.	O

A	O
one	O
base	O
pair	O
mismatch	O
within	O
the	O
corresponding	O
region	O
of	O
the	O
CYP3A4	B-GENE
gene	I-GENE
was	O
sufficient	O
for	O
a	O
differential	O
enhancer	O
activity	O
.	O

The	O
recombinant	O
purified	O
protein	O
expressed	O
in	O
the	O
baculovirus	O
system	O
had	O
an	O
approximate	O
molecular	O
size	O
20	O
kDa	O
with	O
amino-terminal	B-GENE
sequence	I-GENE
of	I-GENE
AVQGP	I-GENE
.	O

During	O
the	O
2h	O
resuscitation	O
period	O
,	O
extracellular	O
aspartate	O
and	O
glutamate	O
concentrations	O
in	O
the	O
cerebral	O
striatum	O
were	O
higher	O
during	O
hypoxaemic	O
resuscitation	O
(	O
p	O
=	O
0	O
.	O
044	O
and	O
p	O
=	O
0	O
.	O
055	O
,	O
respectively	O
)	O
than	O
during	O
resuscitation	O
with	O
21%	O
O2	O
or	O
100%	O
O2	O
,	O
suggesting	O
an	O
unfavourable	O
accumulation	O
of	O
potent	O
excitotoxins	O
during	O
hypoxaemic	O
resuscitation	O
.	O

When	O
overexpressed	O
in	O
an	O
appropriate	O
cell	O
line	O
,	O
TAN-1C	B-GENE
prevented	O
kappa	O
B-dependent	O
transactivation	O
in	O
transient	O
reporter	O
gene	O
assays	O
in	O
a	O
fashion	O
similar	O
to	O
the	O
structurally	O
related	O
protein	O
,	O
Bcl-3	B-GENE
.	O

Ras-GRF1	B-GENE
transiently	O
expressed	O
with	O
v-Src	B-GENE
was	O
tyrosine-phosphorylated	O
and	O
showed	O
significant	O
GEF	B-GENE
activity	O
toward	O
Rac	B-GENE
,	O
but	O
not	O
Rho	B-GENE
and	O
Cdc42	B-GENE
,	O
which	O
was	O
comparable	O
with	O
that	O
induced	O
by	O
Gbetagamma	B-GENE
.	O

Protein	O
films	O
are	O
distinctly	O
different	O
in	O
mechanical	O
profiles	O
from	O
those	O
films	O
made	O
of	O
other	O
materials	O
.	O

The	O
5'	O
flanking	O
region	O
of	O
the	O
CD1	B-GENE
gene	I-GENE
contained	O
the	O
binding	O
motifs	O
for	O
two	O
cytokine-inducible	O
transcription	O
factors	O
,	O
NF-IL2-A	B-GENE
and	O
NF-IL6	B-GENE
.	O

This	O
,	O
together	O
with	O
the	O
data	O
obtained	O
with	O
haloperidol	O
,	O
suggests	O
that	O
a	O
minimal	O
increase	O
in	O
the	O
firing	O
rate	O
of	O
LC	O
cells	O
(	O
+140%	O
)	O
is	O
required	O
before	O
it	O
could	O
influence	O
the	O
turnover	O
of	O
NA	O
,	O
as	O
measured	O
by	O
DOPAC	O
changes	O
.	O

A	O
.	O

Replacement	O
of	O
the	O
CRE	B-GENE
with	O
a	O
second	O
copy	O
of	O
the	O
AP-1	B-GENE
site	I-GENE
results	O
in	O
a	O
level	O
of	O
transcriptional	O
activity	O
comparable	O
with	O
that	O
of	O
the	O
wild-type	O
sequence	O
,	O
but	O
replacement	O
of	O
the	O
AP-1	B-GENE
site	I-GENE
with	O
a	O
CRE	B-GENE
abolishes	O
activity	O
.	O

Silencing	O
can	O
be	O
restored	O
by	O
creation	O
of	O
a	O
telomere	O
at	O
13	O
kb	O
from	O
the	O
reporter	O
construct	O
,	O
or	O
by	O
insertion	O
of	O
340	O
bp	O
of	O
yeast	O
telomeric	O
repeat	O
sequence	O
at	O
this	O
site	O
without	O
chromosomal	O
truncation	O
.	O

In	O
mammals	O
,	O
the	O
transcriptional	O
repressors	O
in	O
the	O
Wnt	B-GENE
pathway	I-GENE
are	O
not	O
well	O
defined	O
.	O

They	O
were	O
found	O
to	O
be	O
seropositive	O
for	O
antibodies	O
to	O
hepatitis	O
C	O
virus	O
by	O
second-generation	O
testing	O
(	O
RIBA	O
2	O
,	O
Ortho	O
Diagnostic	O
Systems	O
Inc	O
,	O
Westwood	O
,	O
MA	O
)	O
.	O

Replacing	O
the	O
aspartic	O
acid	O
with	O
a	O
lysine	O
but	O
not	O
with	O
an	O
alanine	O
or	O
valine	O
residue	O
allowed	O
formation	O
of	O
disulfide-linked	O
dimers	O
.	O

Acute	O
effects	O
of	O
LI	O
160	O
(	O
extract	O
of	O
Hypericum	O
perforatum	O
,	O
St	O
John's	O
wort	O
)	O
and	O
two	O
of	O
its	O
constituents	O
on	O
neuroendocrine	O
responses	O
in	O
the	O
rat	O
.	O

Additional	O
studies	O
revealed	O
that	O
bovine	B-GENE
brain	I-GENE
Galpha	I-GENE
(	I-GENE
q	I-GENE
/	I-GENE
11	I-GENE
)	I-GENE
could	O
also	O
bind	O
to	O
an	O
N-terminal	O
construct	O
of	O
GRK2	B-GENE
,	O
while	O
no	O
binding	O
of	O
Galpha	B-GENE
(	I-GENE
q	I-GENE
/	I-GENE
11	I-GENE
)	I-GENE
,	O
Galpha	B-GENE
(	I-GENE
s	I-GENE
)	I-GENE
,	O
Galpha	B-GENE
(	I-GENE
i	I-GENE
)	I-GENE
,	O
or	O
Galpha	B-GENE
(	I-GENE
12	I-GENE
/	I-GENE
13	I-GENE
)	I-GENE
to	O
comparable	O
constructs	O
of	O
GRK5	B-GENE
or	O
GRK6	B-GENE
was	O
observed	O
.	O

Within	O
this	O
sequence	O
the	O
MSAS	B-GENE
gene	I-GENE
was	O
identified	O
as	O
a	O
5322-bp-long	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
protein	O
of	O
1774	O
amino	O
acids	O
and	O
190	O
,	O
731	O
Da	O
molecular	O
mass	O
.	O

These	O
introns	O
belong	O
to	O
the	O
class	O
of	O
nuclear	O
pre-mRNA	O
introns	O
and	O
contain	O
typical	O
5'-	O
and	O
3'-consensus	O
sequences	O
,	O
as	O
well	O
as	O
unique	O
features	O
.	O

Due	O
to	O
its	O
relatively	O
soluble	O
chemical	O
form	O
,	O
90Sr	O
was	O
rapidly	O
translocated	O
from	O
lung	O
to	O
bone	O
where	O
a	O
substantial	O
portion	O
was	O
retained	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

Patients	O
and	O
their	O
relatives	O
must	O
be	O
informed	O
about	O
the	O
available	O
effective	O
treatment	O
possibilities	O
and	O
about	O
the	O
right	O
moment	O
for	O
their	O
application	O
in	O
an	O
individual	O
patient	O
.	O

Initially	O
,	O
we	O
observed	O
that	O
unmutated	O
p53	B-GENE
is	O
strongly	O
expressed	O
in	O
premalignant	O
mammary	O
glands	O
and	O
in	O
mammary	O
tumors	O
derived	O
from	O
the	O
MMTV-c-myc	O
strain	O
.	O

Regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
measurements	O
and	O
psychiatric	O
ratings	O
were	O
performed	O
on	O
seven	O
schizophrenic	O
patients	O
(	O
mean	O
age	O
=	O
41	O
.	O
4	O
years	O
)	O
who	O
had	O
been	O
examined	O
18	O
years	O
previously	O
in	O
a	O
study	O
that	O
used	O
similar	O
psychiatric	O
ratings	O
and	O
a	O
comparable	O
rCBF	O
technique	O
.	O

The	O
Dox-A2	B-GENE
ORF	I-GENE
driven	O
by	O
the	O
TDH3	B-GENE
promoter	I-GENE
complemented	O
the	O
phenotype	O
of	O
a	O
strain	O
deleted	O
for	O
sun2	B-GENE
.	O

Examples	O
are	O
using	O
more	O
subjects	O
or	O
an	O
improved	O
research	O
design	O
,	O
developing	O
consensus	O
statements	O
or	O
using	O
meta-analysis	O
.	O

Eight	O
highly	O
trained	O
male	O
kayakers	O
were	O
studied	O
to	O
determine	O
the	O
relationship	O
between	O
critical	O
power	O
(	O
CP	O
)	O
and	O
the	O
onset	O
of	O
blood	O
lactate	O
accumulation	O
(	O
OBLA	O
)	O
.	O

The	O
presence	O
of	O
the	O
foreign	O
gene	O
was	O
confirmed	O
by	O
Southern	O
analysis	O
.	O

We	O
have	O
isolated	O
and	O
functionally	O
characterized	O
the	O
mouse	O
gene	O
for	O
the	O
C2	B-GENE
subunit	I-GENE
of	O
the	O
20S	B-GENE
proteasome	I-GENE
.	O

A	O
fluoroimmunoassay	O
for	O
the	O
determination	O
of	O
serum	O
of	O
plasma	O
levels	O
of	O
propranolol	O
was	O
developed	O
using	O
antibodies	O
to	O
propranolol	O
coupled	O
to	O
magnetizable	O
solid-phase	O
particles	O
and	O
fluorescein-labeled	O
propranolol	O
as	O
tracer	O
.	O

A	O
beta2	B-GENE
RARE	I-GENE
reporter	I-GENE
construct	I-GENE
in	O
which	O
the	O
methylation-susceptible	O
cytosines	O
in	O
the	O
sense	O
strand	O
were	O
replaced	O
by	O
thymine	O
displayed	O
marked	O
loss	O
of	O
activity	O
in	O
a	O
replicated	O
chromatin-dependent	O
manner	O
.	O

I	O
.	O

Effect	O
of	O
indomethacin	O
and	O
prostaglandin	O
F2	O
alpha	O
on	O
parturition	O
in	O
swine	O
.	O

The	O
subjects	O
received	O
a	O
single	O
500	O
mg	O
dose	O
of	O
acetaminophen	O
i	O
.	O
v	O
.	O
and	O
concentrations	O
in	O
plasma	O
were	O
measured	O
for	O
360	O
minutes	O
and	O
in	O
urine	O
for	O
24	O
h	O
in	O
order	O
to	O
estimate	O
the	O
production	O
of	O
metabolites	O
.	O

The	O
H-reflex	O
recovery	O
curve	O
was	O
obtained	O
after	O
stimulation	O
of	O
the	O
median	O
nerve	O
at	O
the	O
elbow	O
and	O
recording	O
from	O
the	O
flexor	O
carpi	O
radialis	O
.	O

The	O
experimental	O
results	O
showed	O
that	O
the	O
coagulation-electrooxidation	O
process	O
could	O
efficiently	O
remove	O
the	O
color	O
and	O
the	O
COD	O
from	O
the	O
simulated	O
dye	O
wastewater	O
.	O

The	O
predicted	O
L	B-GENE
mRNA	I-GENE
was	O
6398	O
nucleotides	O
long	O
and	O
contained	O
a	O
single	O
open	O
reading	O
frame	O
corresponding	O
to	O
an	O
L	B-GENE
protein	I-GENE
encompassing	I-GENE
2109	I-GENE
amino	I-GENE
acids	I-GENE
with	O
a	O
MW	O
of	O
241	O
,	O
546	O
.	O

The	O
kinetics	O
of	O
kinase	B-GENE
activity	O
within	O
these	O
complexes	O
compared	O
to	O
CheA	B-GENE
alone	O
indicate	O
approximately	O
a	O
50%	O
decrease	O
in	O
the	O
KM	O
for	O
ATP	O
and	O
a	O
100-fold	O
increase	O
in	O
the	O
Vmax	O
.	O

Thyrotropin-induced	O
expression	O
of	O
a	O
gene	O
for	O
a	O
ribosomal	O
protein	O
related	O
to	O
the	O
trk	B-GENE
oncogene	I-GENE
.	O

Gap	B-GENE
b3	I-GENE
consists	O
of	O
two	O
polypeptide	O
chains	O
(	O
Mr	O
=	O
110	O
,	O
000	O
and	O
30	O
,	O
000	O
)	O
,	O
which	O
seem	O
to	O
be	O
proteolytic	O
cleavage	O
products	O
connected	O
by	O
disulfide	O
bonds	O
from	O
a	O
precursor	O
protein	O
.	O

The	O
observed	O
sequence	O
variation	O
disrupts	O
the	O
first	O
ORF	O
in	O
many	O
Y's	B-GENE
while	O
most	O
of	O
the	O
second	O
ORF	O
including	O
the	O
putative	O
helicase	B-GENE
region	I-GENE
is	O
unaffected	O
.	O

Serum	O
IgG	B-GENE
was	O
initially	O
elevated	O
in	O
6	O
patients	O
.	O

The	O
cleavage	O
site	O
between	O
VPg	B-GENE
and	O
RNA	B-GENE
dependent	I-GENE
RNA	I-GENE
polymerase	I-GENE
was	O
predicted	O
to	O
be	O
E445-T446	O
based	O
on	O
the	O
amino	O
acid	O
sequence	O
analysis	O
of	O
the	O
polyprotein	O
from	O
different	O
sobemoviruses	O
.	O

Twenty-one	O
percent	O
of	O
these	O
patients	O
had	O
neurologic	O
disease	O
that	O
appeared	O
to	O
be	O
responsible	O
for	O
the	O
tinnitus	O
.	O

The	O
indoor	O
radon	O
concentration	O
in	O
the	O
summer	O
(	O
1990	O
)	O
period	O
ranged	O
between	O
8	O
and	O
81	O
Bq	O
m-3	O
,	O
while	O
in	O
the	O
winter	O
(	O
1989-1990	O
)	O
it	O
ranged	O
between	O
20	O
and	O
143	O
Bq	O
m-3	O
for	O
the	O
first	O
year	O
of	O
measurements	O
or	O
between	O
8	O
and	O
92	O
Bq	O
m-3	O
in	O
the	O
summer	O
(	O
1991	O
)	O
period	O
and	O
between	O
12	O
and	O
119	O
Bq	O
m-3	O
in	O
the	O
winter	O
(	O
1990-1991	O
)	O
for	O
the	O
second	O
year	O
of	O
measurements	O
.	O

The	O
model	O
is	O
able	O
to	O
anticipate	O
why	O
the	O
effect	O
of	O
water	O
fluoridation	O
on	O
caries	O
prevalence	O
is	O
most	O
pronounced	O
when	O
caries	O
is	O
diagnosed	O
at	O
cavity	O
level	O
.	O

Coronary	O
arteries--old	O
and	O
new	O
.	O

False	O
positive	O
PET	O
FDG	O
corresponded	O
to	O
lung	O
infection	O
,	O
degenerative	O
bone	O
disease	O
,	O
and	O
reconstruction	O
artifact	O
.	O

These	O
changes	O
were	O
the	O
result	O
of	O
a	O
decrease	O
in	O
afterload	O
:	O
mean	O
aortic	O
pressure	O
fell	O
from	O
85	O
+	O
/	O
-	O
11	O
.	O
8	O
to	O
68	O
+	O
/	O
-	O
19	O
.	O
6	O
mmHg	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
systemic	O
arterial	O
resistance	O
fell	O
from	O
2	O
886	O
+	O
/	O
-	O
745	O
to	O
2	O
010	O
+	O
/	O
-	O
610	O
dynes	O
/	O
cm-5	O
/	O
sec	O
/	O
m-2	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
ERSF	B-GENE
including	O
NF-Y	B-GENE
and	O
ATF6alpha	B-GENE
and	I-GENE
/	I-GENE
or	I-GENE
beta	I-GENE
and	O
capable	O
of	O
binding	O
to	O
ERSE	B-GENE
is	O
indeed	O
formed	O
when	O
the	O
cellular	O
UPR	B-GENE
is	O
activated	O
.	O

Demographic	O
and	O
clinical	O
data	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
339	O
healthy	O
age-matched	O
women	O
and	O
with	O
a	O
sample	O
of	O
224	O
women	O
with	O
wrist	O
fracture	O
.	O

The	O
gene	O
sequence	O
also	O
identified	O
a	O
340-nucleotide	O
RNA	O
in	O
total	O
yeast	O
RNA	O
and	O
in	O
purified	O
RNase	B-GENE
MRP	I-GENE
enzyme	I-GENE
preparations	O
.	O

Further	O
observations	O
on	O
resorption	O
in	O
guinea	O
pigs	O
following	O
injections	O
of	O
trypan	O
blue	O
.	O

The	O
murine	B-GENE
MHC	I-GENE
class	I-GENE
I	I-GENE
genes	I-GENE
,	O
H-2Dq	B-GENE
and	O
H-2Lq	B-GENE
,	O
are	O
strikingly	O
homologous	O
to	O
each	O
other	O
,	O
H-2Ld	B-GENE
,	O
and	O
two	O
genes	O
reported	O
to	O
encode	O
tumor-specific	B-GENE
antigens	I-GENE
.	O

The	O
introduction	O
of	O
an	O
acidic	O
residue	O
at	O
the	O
second	O
site	O
was	O
essential	O
for	O
suppression	O
of	O
the	O
Asn-285	O
mutation	O
because	O
Lys-220	O
and	O
Gln-220	O
second-site	O
mutants	O
of	O
the	O
Asn-285	O
mutant	O
showed	O
very	O
low	O
tetracycline	O
resistance	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
effects	O
of	O
antithrombotic	O
drugs	O
in	O
patients	O
with	O
left	O
ventricular	O
thrombi	O
:	O
assessment	O
with	O
indium-111	O
platelet	O
imaging	O
and	O
two-dimensional	O
echocardiography	O
.	O

To	O
identify	O
additional	O
non-Sir	B-GENE
factors	I-GENE
that	O
affect	O
rDNA	O
silencing	O
,	O
we	O
performed	O
a	O
genetic	O
screen	O
designed	O
to	O
isolate	O
mutations	O
which	O
alter	O
the	O
expression	O
of	O
reporter	O
genes	O
integrated	O
within	O
the	O
rDNA	O
.	O

Blood	O
flow	O
velocity	O
waveforms	O
were	O
recorded	O
by	O
pulsed	O
Doppler	O
examination	O
of	O
the	O
fetal	O
internal	O
carotid	O
and	O
middle	O
cerebral	O
arteries	O
using	O
the	O
established	O
transabdominal	O
route	O
as	O
well	O
as	O
a	O
new	O
transvaginal	O
approach	O
.	O

The	O
first	O
85	O
nt	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
mouse	B-GENE
desmin	I-GENE
gene	I-GENE
,	O
which	O
contain	O
an	O
E	O
box	O
(	O
E1	B-GENE
)	O
,	O
the	O
binding	O
site	O
of	O
the	O
helix-loop-helix	O
myogenic	O
regulators	O
,	O
are	O
sufficient	O
to	O
confer	O
low	O
level	O
muscle-specific	O
expression	O
.	O

The	O
first	O
involved	O
complementation	O
of	O
a	O
nonphotosynthetic	O
mutant	O
of	O
Chlamydomonas	O
,	O
CC-2341	O
(	O
ac-u-g-2	O
.	O
3	O
)	O
,	O
which	O
has	O
a	O
frameshift	O
mutation	O
in	O
the	O
psaB	B-GENE
gene	I-GENE
,	O
and	O
selection	O
of	O
photosynthetic	O
transformants	O
on	O
minimal	O
medium	O
.	O

Moreover	O
,	O
the	O
second	O
RCC1-like	B-GENE
motif	I-GENE
located	O
at	O
the	O
amino-terminus	O
of	O
p619	B-GENE
stimulates	O
guanine	O
nucleotide	O
exchange	O
on	O
ARF1	B-GENE
and	O
on	O
members	O
of	O
the	O
related	O
Rab	B-GENE
proteins	I-GENE
,	O
but	O
not	O
on	O
other	O
small	B-GENE
GTP	I-GENE
binding	I-GENE
proteins	I-GENE
such	O
as	O
Ran	B-GENE
or	O
R-Ras2	B-GENE
/	I-GENE
TC21	I-GENE
.	O

Subcloning	O
of	O
DNA	O
fragments	O
from	O
the	O
8	O
.	O
5-kilobase	O
(	O
kb	O
)	O
insert	O
of	O
pAVO4	O
defined	O
a	O
4-kb	O
DNA	O
fragment	O
which	O
contained	O
the	O
functional	B-GENE
FBP+	I-GENE
gene	I-GENE
and	O
its	O
regulatory	O
region	O
.	O

Spectroscopy	O
of	O
negative	O
ions	O
utilizing	O
multiphoton	O
detachment	O
in	O
a	O
Raman	O
coupling	O
regime	O
.	O

Bandshift	O
experiments	O
demonstrate	O
that	O
BmHR3A	B-GENE
binds	O
specifically	O
to	O
RORE	B-GENE
(	O
Retinoic	B-GENE
acid-related	I-GENE
Orphan	I-GENE
receptor	I-GENE
Response	I-GENE
Element	I-GENE
)	O
-like	O
sequences	O
in	O
the	O
promoters	O
of	O
both	O
genes	O
,	O
thus	O
suggesting	O
a	O
direct	O
role	O
for	O
BmHR3A	B-GENE
in	O
regulating	O
the	O
expression	O
of	O
BmGATAbeta	B-GENE
and	O
ESP	B-GENE
genes	I-GENE
during	O
vitellogenesis	O
.	O

Drugs	O
that	O
are	O
transformed	O
via	O
phase	O
II	O
reactions	O
usually	O
do	O
not	O
require	O
dosage	O
adjustment	O
.	O

100	O
years	O
of	O
dentistry	O
at	O
the	O
Friedrich	O
Schiller	O
University	O
in	O
Jena	O
.	O

Gamma	B-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
(	O
GGTP	B-GENE
)	O
activity	O
in	O
the	O
seminal	O
fluid	O
.	O

In	O
addition	O
to	O
that	O
,	O
she	O
received	O
hepatic	O
intra-arterial	O
infusion	O
of	O
levoforinate	O
(	O
l-LV	O
)	O
250	O
mg	O
and	O
5-fluorouracil	O
(	O
5-FU	O
)	O
500	O
mg	O
for	O
combined	O
multiple	O
hepatic	O
metastases	O
starting	O
on	O
postoperative	O
day	O
14	O
,	O
and	O
these	O
medications	O
were	O
administered	O
over	O
48	O
hours	O
once	O
weekly	O
by	O
infuser	O
pump	O
.	O

The	O
morphological	O
effects	O
of	O
two	O
snake	O
venoms	O
,	O
N	O
.	O
naja	O
and	O
A	O
.	O
piscivorus	O
,	O
and	O
of	O
the	O
Direct	B-GENE
Lytic	I-GENE
Factor	I-GENE
and	O
Phospholipase-A	B-GENE
,	O
compounds	O
purified	O
from	O
N	O
.	O
naja	O
crude	O
venom	O
,	O
were	O
investigated	O
on	O
lung	O
and	O
cremaster	O
vessels	O
of	O
rats	O
.	O

The	O
regional	O
blockade	O
of	O
H1R	B-GENE
was	O
observed	O
mainly	O
in	O
the	O
frontal	O
,	O
temporal	O
and	O
anterior	O
cingulate	O
cortices	O
,	O
and	O
the	O
intravenous	O
administration	O
of	O
d-chlorpheniramine	O
as	O
a	O
therapeutic	O
dose	O
(	O
2	O
mg	O
)	O
blocked	O
over	O
60%	O
of	O
H1R	B-GENE
in	O
the	O
frontal	O
cortices	O
.	O

The	O
frequency	O
of	O
positive	O
anti-GM1	B-GENE
antibody	I-GENE
titers	O
in	O
the	O
Guillain-Barre	O
syndrome	O
patients	O
with	O
PEN	O
19	O
isolates	O
was	O
higher	O
than	O
that	O
in	O
the	O
Guillain-Barre	O
syndrome	O
and	O
Fisher's	O
syndrome	O
patients	O
without	O
PEN	O
19	O
isolates	O
.	O

TG-day	O
and	O
TG-night	O
were	O
19	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
1%	O
,	O
26	O
.	O
6	O
+	O
/	O
-	O
5	O
.	O
3%	O
,	O
(	O
750	O
mm3	O
<	O
T	O
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	O
gene	O
constructs	O
to	O
examine	O
the	O
transcription	O
control	O
elements	O
in	O
the	O
5'	O
flanking	O
region	O
of	O
the	O
human	B-GENE
EpoR	I-GENE
gene	I-GENE
.	O

However	O
,	O
there	O
were	O
some	O
properties	O
of	O
Rak	B-GENE
that	O
are	O
distinct	O
from	O
Src-like	B-GENE
kinases	I-GENE
:	O
(	O
a	O
)	O
expression	O
of	O
Rak	B-GENE
was	O
predominantly	O
in	O
epithelial-derived	O
cell	O
lines	O
and	O
tissues	O
,	O
especially	O
normal	O
liver	O
and	O
kidney	O
,	O
and	O
cell	O
lines	O
of	O
breast	O
and	O
colon	O
origin	O
;	O
(	O
b	O
)	O
Rak	B-GENE
does	O
not	O
harbor	O
the	O
NH2-terminal	O
glycine	O
essential	O
for	O
myristylation	O
and	O
membrane	O
localization	O
;	O
and	O
(	O
c	O
)	O
Rak	B-GENE
possesses	O
a	O
putative	O
bipartite	O
nuclear	O
localization	O
signal	O
in	O
the	O
SH2	B-GENE
domain	I-GENE
,	O
and	O
subcellular	O
fractionation	O
studies	O
revealed	O
that	O
p54rak	B-GENE
resides	O
predominantly	O
in	O
the	O
nucleus	O
.	O

The	O
role	O
of	O
DNA	O
rearrangement	O
and	O
alternative	O
RNA	O
processing	O
in	O
the	O
expression	O
of	O
immunoglobulin	B-GENE
delta	I-GENE
genes	I-GENE
.	O

Genomic	O
and	O
functional	O
characterization	O
of	O
the	O
oas	B-GENE
gene	I-GENE
family	I-GENE
encoding	O
O-acetylserine	B-GENE
(	I-GENE
thiol	I-GENE
)	I-GENE
lyases	I-GENE
,	O
enzymes	O
catalyzing	O
the	O
final	O
step	O
in	O
cysteine	O
biosynthesis	O
in	O
Arabidopsis	O
thaliana	O
.	O

The	O
results	O
indicate	O
that	O
the	O
open-section	O
effect	O
decreases	O
the	O
torsional	O
stiffness	O
and	O
stress	O
concentration	O
effects	O
decrease	O
the	O
torsional	O
strength	O
of	O
a	O
long	O
bone	O
with	O
a	O
longitudinal	O
defect	O
.	O

Output	O
of	O
99mTcO-4	O
by	O
the	O
parotid	O
gland	O
closely	O
mimicked	O
fluctuations	O
in	O
parotid	O
saliva	O
flow	O
rate	O
.	O

Evaluating	O
dietary	O
department	O
management	O
.	O

A	O
review	O
of	O
studies	O
published	O
between	O
1983	O
and	O
1995	O
shows	O
that	O
there	O
are	O
some	O
common	O
factors	O
as	O
regards	O
the	O
psychological	O
distress	O
and	O
social	O
and	O
functional	O
limitations	O
this	O
group	O
of	O
patients	O
has	O
to	O
deal	O
with	O
.	O

Plasma	O
and	O
bladder	O
platinum	O
concentration	O
were	O
measured	O
following	O
intravesical	O
DDP	O
,	O
and	O
also	O
histopathological	O
examination	O
,	O
urinalysis	O
,	O
complete	O
blood	O
count	O
and	O
blood	O
chemistry	O
were	O
performed	O
in	O
order	O
to	O
know	O
the	O
toxicity	O
of	O
intravesical	O
DDP	O
.	O

The	O
cDNA	O
sequence	O
has	O
an	O
813-bp	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97	O
.	O
6%	O
identical	O
to	O
the	O
272	O
carboxy-terminal	O
amino	O
acids	O
of	O
the	O
human	B-GENE
ets-1	I-GENE
protein	I-GENE
.	O

Tetrad	O
analysis	O
and	O
mitotic	O
recombination	O
experiments	O
localized	O
the	O
PEP4	B-GENE
gene	I-GENE
proximal	O
to	O
GAL4	B-GENE
on	O
chromosome	O
XVI	O
.	O

These	O
results	O
support	O
the	O
view	O
that	O
clonidine	O
and	O
6-OHDA	O
,	O
but	O
not	O
alpha-MD	O
,	O
have	O
central	O
pressor	O
actions	O
in	O
the	O
rat	O
that	O
oppose	O
their	O
antihypertensive	O
action	O
.	O

Lauciello	O
describes	O
a	O
technique	O
for	O
the	O
placement	O
of	O
functionally	O
generated	O
amalgam	O
stops	O
as	O
restorations	O
within	O
mandibular	O
acrylic	O
teeth	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
major	B-GENE
IE	I-GENE
proteins	I-GENE
IE86	B-GENE
,	O
IE72	B-GENE
,	O
and	O
IE55	B-GENE
are	O
capable	O
of	O
trans-activating	O
the	O
HIV	O
LTR	O
in	O
a	O
T-cell	O
line	O
,	O
HUT-78	O
.	O

A	O
phylogenetic	O
analysis	O
with	O
the	O
TK	B-GENE
domains	I-GENE
from	O
these	O
sequences	O
and	O
a	O
fourth	O
,	O
from	O
a	O
novel	O
scavenger	B-GENE
RTK	I-GENE
(	O
all	O
domains	O
comprise	O
the	O
signature	O
for	O
the	O
TK	B-GENE
class	I-GENE
II	I-GENE
receptors	I-GENE
)	O
,	O
showed	O
that	O
they	O
are	O
distantly	O
related	O
to	O
the	O
insulin	B-GENE
and	O
insulin-like	B-GENE
receptors	I-GENE
.	O

Members	O
of	O
the	O
myocyte-specific	B-GENE
enhancer-binding	I-GENE
factor	I-GENE
2	I-GENE
(	O
MEF2	B-GENE
)	O
family	O
of	O
transcription	O
factors	O
bind	O
a	O
conserved	O
A	O
/	O
T-rich	O
sequence	O
in	O
the	O
control	O
regions	O
of	O
numerous	O
muscle-specific	O
genes	O
.	O

We	O
show	O
that	O
IL-6	B-GENE
activates	O
JRE-IL6	B-GENE
through	O
an	O
H7-sensitive	O
pathway	O
that	O
does	O
not	O
involve	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
,	O
cyclic	B-GENE
AMP-dependent	I-GENE
kinase	I-GENE
,	O
Ca	B-GENE
(	I-GENE
2+	I-GENE
)	I-GENE
-	I-GENE
or	I-GENE
calmodulin-dependent	I-GENE
kinases	I-GENE
,	O
Ras	B-GENE
,	O
Raf-1	B-GENE
,	O
or	O
NF-IL6	B-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
beta	I-GENE
)	O
.	O

Histological	O
analysis	O
showed	O
that	O
the	O
neuronal	O
loss	O
in	O
the	O
DHED-treated	O
group	O
was	O
notably	O
reduced	O
in	O
the	O
hippocampal	O
area	O
(	O
CA1	O
)	O
of	O
ischemic	O
rats	O
and	O
in	O
the	O
dentate	O
gyrus	O
and	O
hippocampal	O
area	O
(	O
CA1	O
and	O
CA3	O
)	O
of	O
EC-lesioned	O
rats	O
compared	O
with	O
the	O
nontreated	O
group	O
.	O

Expression	O
of	O
the	O
human	B-GENE
papillomavirus	I-GENE
type	I-GENE
11	I-GENE
E5A	I-GENE
protein	I-GENE
from	O
the	O
E1E4	B-GENE
,	I-GENE
E5	I-GENE
transcript	I-GENE
.	O

The	O
next	O
twenty	O
years	O
of	O
prevention	O
in	O
Indian	O
country	O
:	O
visionary	O
,	O
complex	O
,	O
and	O
practical	O
.	O

The	O
Jem	B-GENE
peptide	O
sequence	O
shows	O
a	O
'leucine-zipper'	O
dimerisation	O
motif	O
with	O
limited	O
homology	O
to	O
Fos	B-GENE
/	I-GENE
Jun	I-GENE
and	O
ATF	B-GENE
/	I-GENE
CREB	I-GENE
proteins	I-GENE
and	O
several	O
putative	O
phosphorylation	O
sites	O
.	O

We	O
have	O
utilized	O
the	O
human	B-GENE
4F2	I-GENE
heavy	I-GENE
chain	I-GENE
(	O
4F2HC	B-GENE
)	O
gene	O
as	O
a	O
model	O
system	O
in	O
studies	O
designed	O
to	O
elucidate	O
the	O
molecular	O
events	O
involved	O
in	O
regulating	O
inducible	O
gene	O
expression	O
during	O
normal	O
human	O
T-cell	O
activation	O
.	O

We	O
cloned	O
the	O
third	O
human	O
gene	O
for	O
the	O
LD78	B-GENE
,	O
termed	O
LD78	B-GENE
gamma	I-GENE
and	O
the	O
sequence	O
analysis	O
showed	O
that	O
it	O
is	O
a	O
5'-truncated	O
pseudogene	O
.	O

Moreover	O
,	O
the	O
reconstitution	O
of	O
eUSF	B-GENE
and	O
TFIID-depleted	O
transcription	O
complexes	O
with	O
purified	O
protein	O
fractions	O
demonstrate	O
that	O
not	O
only	O
TFIID	B-GENE
but	O
also	O
eUSF	B-GENE
essentially	O
participates	O
in	O
complex	O
formation	O
even	O
on	O
H5	B-GENE
promoter	I-GENE
mutations	O
lacking	O
the	O
TATA-box	O
.	O

Histamine	O
reactivity	O
had	O
returned	O
to	O
normal	O
in	O
half	O
the	O
workers	O
who	O
had	O
left	O
their	O
original	O
factories	O
,	O
but	O
in	O
only	O
one	O
worker	O
who	O
had	O
moved	O
within	O
her	O
original	O
factory	O
.	O

BIAcore	O
analysis	O
gave	O
a	O
Kaff	O
of	O
4	O
.	O
4	O
x	O
10	O
(	O
10	O
)	O
M-1	O
for	O
the	O
binding	O
of	O
N-A3	B-GENE
to	O
T84	B-GENE
.	I-GENE
1	I-GENE
and	O
2	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
M-1	O
for	O
the	O
binding	O
of	O
N-A3	B-GENE
to	O
T84	B-GENE
.	I-GENE
66	I-GENE
.	O

Together	O
these	O
data	O
imply	O
that	O
the	O
HFV	B-GENE
R	I-GENE
region	I-GENE
acts	O
in	O
the	O
nucleus	O
to	O
modify	O
the	O
cytoplasmic	O
fate	O
of	O
target	B-GENE
HFV	I-GENE
mRNA	I-GENE
.	O

Transcription	O
factor	O
recognition	O
surface	O
on	O
the	O
RNA	B-GENE
polymerase	I-GENE
alpha	I-GENE
subunit	I-GENE
is	O
involved	O
in	O
contact	O
with	O
the	O
DNA	O
enhancer	O
element	O
.	O

Rind	O
et	O
al	O
.	O
's	O
study's	O
main	O
conclusions	O
were	O
not	O
supported	O
by	O
the	O
original	O
data	O
.	O

Thus	O
,	O
transcriptional	O
regulation	O
,	O
splicing	O
,	O
kinase	O
interaction	O
sites	O
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
the	O
LMP2A	B-GENE
homologs	I-GENE
have	O
been	O
conserved	O
despite	O
significant	O
sequences	O
heterogeneity	O
in	O
the	O
preterminal	O
repeat	O
regions	O
of	O
these	O
human	O
and	O
nonhuman	O
primate	O
EBVs	O
.	O

These	O
results	O
indicate	O
the	O
presence	O
of	O
TATA-unified	O
transcription	O
systems	O
in	O
contemporary	O
eukaryotes	O
and	O
provide	O
insight	O
into	O
the	O
residual	O
need	O
for	O
TBP	B-GENE
by	O
all	O
three	O
Pols	B-GENE
in	O
other	O
eukaryotes	O
despite	O
a	O
lack	O
of	O
TATA	O
elements	O
in	O
their	O
promoters	O
.	O

The	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
RAD30	I-GENE
gene	I-GENE
,	O
a	O
homologue	B-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
dinB	I-GENE
and	O
umuC	B-GENE
,	O
is	O
DNA	O
damage	O
inducible	O
and	O
functions	O
in	O
a	O
novel	O
error-free	O
postreplication	O
repair	O
mechanism	O
.	O

Right	O
LHR	O
(	O
R-LHR	O
)	O
provided	O
the	O
best	O
interobserver	O
and	O
intraobserver	O
reproducibility	O
.	O

Two-Channel	O
Kondo	O
Lattice	O
:	O
An	O
Incoherent	O
Metal	O
.	O

A	O
limiting	O
factor	O
were	O
disturbances	O
in	O
the	O
system	O
of	O
energy	O
transport	O
(	O
creatine	O
phosphate	O
,	O
creatine	B-GENE
phosphokinase	I-GENE
)	O
and	O
of	O
the	O
calcium	O
pump	O
(	O
Ca++-ATPase	B-GENE
of	O
the	O
sarcoplasmic	O
reticulum	O
,	O
SPR	O
)	O
,	O
which	O
evidently	O
led	O
to	O
a	O
decrease	O
of	O
the	O
inotropic	O
properties	O
of	O
the	O
myocardium	O
at	O
70%	O
restriction	O
of	O
coronary	O
blood	O
flow	O
.	O

The	O
IC50	O
values	O
for	O
rat	O
and	O
dog	O
urinary	O
bladder	O
were	O
3	O
.	O
9	O
x	O
10	O
(	O
-6	O
)	O
M	O
and	O
3	O
.	O
8	O
x	O
10	O
(	O
-6	O
)	O
M	O
,	O
respectively	O
.	O

It	O
is	O
shown	O
that	O
the	O
(	O
G+C	O
)	O
-rich	O
element	O
of	O
the	O
aldolase	B-GENE
C	I-GENE
promoter	I-GENE
directs	O
transcription	O
in	O
neuronal	O
as	O
well	O
as	O
in	O
nonneuronal	O
cells	O
.	O

During	O
most	O
of	O
the	O
cell	O
cycle	O
,	O
separase	B-GENE
is	O
kept	O
inactive	O
by	O
binding	O
to	O
an	O
inhibitory	O
protein	O
called	O
securin	B-GENE
.	O

A	O
comparison	O
of	O
the	O
nucleotide	O
sequence	O
of	O
the	O
p54	B-GENE
gene	I-GENE
carried	O
by	O
two	O
virulent	O
ASFV	O
strains	O
(	O
E70	O
and	O
E75	O
)	O
with	O
that	O
obtained	O
from	O
virus	O
Ba71V	O
showed	O
100%	O
similarity	O
.	O

The	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type-1	I-GENE
(	I-GENE
HIV-1	I-GENE
)	I-GENE
Tat	I-GENE
protein	I-GENE
regulates	O
transcription	O
by	O
stimulating	O
RNA	B-GENE
polymerase	I-GENE
processivity	O
.	O

Statistics	O
of	O
the	O
past	O
5	O
years	O
.	O

TB	O
bone	O
area	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
height	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
years	O
in	O
present	O
colony	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
and	O
menses	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
predicted	O
TB	O
BMC	O
.	O

Cotransfection	O
of	O
the	O
coactivator	O
CREB-binding	B-GENE
protein	I-GENE
relieved	O
the	O
transcriptional	O
repression	O
of	O
PPARalphawt	B-GENE
by	O
PPARalphatr	B-GENE
,	O
suggesting	O
that	O
the	O
dominant	O
negative	O
effect	O
of	O
PPARalphatr	B-GENE
might	O
occur	O
through	O
competition	O
for	O
essential	O
coactivators	O
.	O

Looming	O
detectors	O
in	O
the	O
human	O
visual	O
pathway	O
.	O

In	O
contrast	O
,	O
exogenous	B-GENE
PTHrP1-34	I-GENE
and	I-GENE
1-86	I-GENE
peptides	I-GENE
did	O
not	O
significantly	O
affect	O
IL-8	B-GENE
production	O
;	O
moreover	O
,	O
PTHrP-neutralizing	B-GENE
antibodies	I-GENE
did	O
not	O
inhibit	O
the	O
production	O
of	O
IL-8	B-GENE
by	O
transfected	O
PTHrP	B-GENE
.	O

All	O
radiologists	O
using	O
the	O
machine	O
found	O
that	O
the	O
reporting	O
terminal	O
was	O
simple	O
to	O
operate	O
,	O
but	O
found	O
that	O
reporting	O
abnormalities	O
caused	O
an	O
increased	O
effort	O
and	O
took	O
a	O
longer	O
time	O
.	O

Results	O
:	O
Transpulmonary	O
passage	O
of	O
contrast	O
occurred	O
in	O
sufficient	O
amounts	O
to	O
enhance	O
the	O
intensity	O
of	O
the	O
Doppler	O
signal	O
significantly	O
,	O
but	O
the	O
duration	O
of	O
this	O
effect	O
was	O
short	O
.	O

Rams	O
were	O
weighed	O
and	O
testis	O
size	O
was	O
estimated	O
by	O
orchimetry	O
at	O
each	O
time	O
period	O
.	O

Although	O
the	O
terminase	B-GENE
apparently	O
interacts	O
with	O
this	O
gp20	B-GENE
portal	I-GENE
peptide	I-GENE
,	O
polyclonal	O
antibody	O
against	O
the	O
portal	O
peptide	O
appears	O
unable	O
to	O
access	O
it	O
in	O
the	O
native	O
structure	O
,	O
suggesting	O
intimate	O
association	O
of	O
gp20	B-GENE
and	O
gp17	B-GENE
possibly	O
internalizes	O
terminase	B-GENE
regions	I-GENE
within	O
the	O
portal	O
in	O
the	O
packasome	O
complex	O
.	O

Simulating	O
the	O
impact	O
during	O
human	O
jumping	O
by	O
means	O
of	O
a	O
4-degrees-of-freedom	O
model	O
.	O

We	O
report	O
a	O
prevalence	O
study	O
of	O
the	O
best	O
visual	O
acuity	O
in	O
the	O
affected	O
eye	O
of	O
100	O
selected	O
patients	O
with	O
herpetic	O
keratitis	O
seen	O
during	O
a	O
two-year	O
period	O
.	O

The	O
m7GpppN	O
cap	O
structure	O
of	O
eukaryotic	O
mRNA	O
is	O
formed	O
cotranscriptionally	O
by	O
the	O
sequential	O
action	O
of	O
three	O
enzymes	O
:	O
RNA	B-GENE
triphosphatase	I-GENE
,	O
RNA	B-GENE
guanylyltransferase	I-GENE
,	O
and	O
RNA	B-GENE
(	I-GENE
guanine-7	I-GENE
)	I-GENE
-methyltransferase	I-GENE
.	O

R	O
.	O
,	O
Fleischmann	O
,	O
R	O
.	O
,	O
Venter	O
,	O
J	O
.	O

In	O
addition	O
,	O
two-dimensional	O
nuclear	O
magnetic	O
resonance	O
studies	O
with	O
F17A	O
,	O
K13Q	O
,	O
F15Y	O
and	O
F27Y	O
revealed	O
that	O
the	O
mutants	O
have	O
the	O
same	O
overall	O
structure	O
as	O
the	O
wild-type	B-GENE
CspB	I-GENE
protein	I-GENE
.	O

The	O
extraction	O
recovery	O
of	O
Amphotericin	O
B	O
from	O
the	O
cerebrospinal	O
fluid	O
is	O
higher	O
than	O
90%	O
over	O
the	O
entire	O
linear	O
range	O
.	O

The	O
plexiform	O
neurofibroma	O
and	O
multiple	O
localized	O
neurofibromas	O
are	O
characteristic	O
of	O
NF1	B-GENE
.	O

In	O
addition	O
,	O
we	O
find	O
that	O
E2F-1	B-GENE
can	O
cause	O
apoptosis	O
in	O
p53-	B-GENE
/	I-GENE
-	I-GENE
tumour	O
cells	O
and	O
further	O
p300	B-GENE
,	O
which	O
also	O
functions	O
as	O
a	O
co-activator	O
for	O
the	O
E2F	B-GENE
/	I-GENE
DP	I-GENE
heterodimer	I-GENE
,	O
enhances	O
the	O
apoptotic	O
activity	O
of	O
E2F-1	B-GENE
.	O

Following	O
retransfusion	O
,	O
the	O
affected	O
epithelial	O
lining	O
appeared	O
greatly	O
distended	O
over	O
the	O
oedematous	O
lamina	O
propria	O
,	O
with	O
almost	O
complete	O
loss	O
of	O
structural	O
detail	O
.	O

Here	O
we	O
report	O
that	O
the	O
proline-rich	O
region	O
of	O
CAP	B-GENE
is	O
recognized	O
by	O
the	O
SH3	B-GENE
domains	I-GENE
of	O
several	O
proteins	O
,	O
including	O
the	O
yeast	B-GENE
actin-associated	I-GENE
protein	I-GENE
Abp1p	I-GENE
.	O

Molecular	O
cloning	O
of	O
a	O
P-type	B-GENE
ATPase	I-GENE
gene	I-GENE
from	O
the	O
cyanobacterium	O
Synechocystis	O
sp	O
.	O

The	O
prognosis	O
of	O
seven	O
patients	O
who	O
received	O
ABSCT	O
was	O
significantly	O
better	O
than	O
that	O
of	O
13	O
patients	O
who	O
received	O
conventional	O
therapy	O
alone	O
.	O

In	O
the	O
work	O
reported	O
here	O
,	O
we	O
used	O
peptide	O
mapping	O
,	O
mass	O
spectrometry	O
,	O
and	O
site-directed	O
mutagenesis	O
to	O
identify	O
two	O
sets	O
of	O
pAP	B-GENE
phosphorylation	O
sites	O
.	O

The	O
RAT3	B-GENE
gene	I-GENE
encodes	O
an	O
1157-amino	O
acid	O
protein	O
without	O
similarity	O
to	O
other	O
known	O
proteins	O
.	O

The	O
high	O
conservation	O
of	O
the	O
3'	O
terminus	O
suggests	O
that	O
this	O
region	O
directs	O
the	O
assembly	O
of	O
proteins	O
required	O
for	O
the	O
initiation	O
of	O
RNA	O
replication	O
.	O

Sixteen	O
patients	O
were	O
studied	O
within	O
24	O
hours	O
of	O
resuscitation	O
and	O
all	O
showed	O
depressed	O
right	O
ventricular	O
ejection	O
(	O
RVEF	O
)	O
and	O
/	O
or	O
an	O
increased	O
end-diastolic	O
volume	O
(	O
RVEDVI	O
)	O
.	O

This	O
is	O
predicted	O
to	O
encode	O
a	O
315-residue	O
protein	O
containing	O
seven	O
hydrophobic	O
helical	O
regions	O
and	O
a	O
17	O
amino	O
acid	O
motif	O
characteristic	O
of	O
the	O
R7G	B-GENE
family	I-GENE
of	O
G-protein	B-GENE
coupled	I-GENE
membrane-bound	I-GENE
receptors	I-GENE
.	O

In	O
10	O
control	O
sheep	O
mean	O
plasma	O
TXB2	O
concentration	O
increased	O
from	O
0	O
.	O
39	O
ng	O
/	O
ml	O
prebypass	O
to	O
about	O
1	O
.	O
1	O
ng	O
/	O
ml	O
at	O
8	O
and	O
16	O
min	O
of	O
bypass	O
.	O

J	O
.	O

The	O
distributed	O
current	O
density	O
J	O
is	O
calculated	O
within	O
the	O
volume	O
defined	O
by	O
the	O
motor	O
unit	O
.	O

The	O
PI3K_68D	B-GENE
cDNA	I-GENE
encodes	O
a	O
protein	O
of	O
210	O
kDa	O
,	O
which	O
lacks	O
sequences	O
implicated	O
in	O
linking	O
p110	O
PI	B-GENE
3-kinases	I-GENE
to	O
p85	B-GENE
adaptor	I-GENE
proteins	I-GENE
,	O
but	O
contains	O
an	O
amino-terminal	O
proline-rich	O
sequence	O
,	O
which	O
could	O
bind	O
to	O
SH3	B-GENE
domains	I-GENE
,	O
and	O
a	O
carboxy-terminal	O
C2	O
domain	O
.	O

Two	O
mutations	O
that	O
affect	O
larval	B-GENE
cuticle	I-GENE
protein	I-GENE
gene	I-GENE
expression	O
in	O
the	O
2	O
/	O
3	O
variant	O
Drosophila	O
melanogaster	O
strain	O
were	O
investigated	O
.	O

Nursing	O
of	O
patients	O
with	O
gynecological	O
diseases	O
.	O

Prominent	O
findings	O
were	O
chronic	O
pancreatitis	O
with	O
acinar	O
and	O
ductal	O
plugs	O
,	O
granulomatous	O
and	O
necrotizing	O
peripancreatic	O
steatitis	O
,	O
degenerative	O
myopathy	O
,	O
testicular	O
atrophy	O
,	O
candidiasis	O
and	O
bacterial	O
necrotizing	O
glossitis	O
.	O

Nipponbare	O
as	O
well	O
as	O
O	O
.	O
australiensis	O
.	O

We	O
show	O
that	O
the	O
Sm-binding	B-GENE
site	I-GENE
and	O
stem-loop	O
III	O
structures	O
are	O
necessary	O
for	O
correct	O
3'-end	O
formation	O
.	O

Relief	O
from	O
autoinhibition	O
and	O
a	O
subsequent	O
10-60-fold	O
increase	O
in	O
V	O
(	O
max	O
)	O
have	O
been	O
observed	O
upon	O
N-SH2	B-GENE
domain	I-GENE
engagement	O
by	O
a	O
specific	O
phosphotyrosyl	O
ligand	O
or	O
upon	O
deletion	O
of	O
the	O
SH2	B-GENE
domains	I-GENE
to	O
yield	O
the	O
catalytic	O
PTPase	B-GENE
domain	I-GENE
.	O

Viral	O
cell-to-cell	O
movement	O
of	O
PVX	B-GENE
CP	I-GENE
mutant	I-GENE
was	O
complemented	O
in	O
Nicotiana	O
tabacum	O
cv	O
.	O

The	O
percentage	O
RFR	O
reduction	O
at	O
the	O
end	O
of	O
CPB	O
showed	O
significant	O
correlation	O
with	O
1	O
)	O
CPB	O
duration	O
(	O
r	O
=	O
0	O
.	O
49	O
)	O
,	O
2	O
)	O
oxygen	O
flow	O
rate	O
index	O
(	O
OFRI	O
)	O
,	O
i	O
.	O
e	O
.	O
flow	O
/	O
min	O
in	O
the	O
bubble	O
oxygenator	O
/	O
m2	O
bsa	O
(	O
r	O
=	O
0	O
.	O
38	O
)	O
,	O
and	O
3	O
)	O
blood	O
flow	O
rate	O
index	O
(	O
BFRI	O
)	O
,	O
i	O
.	O
e	O
.	O
average	O
volume	O
of	O
blood	O
pumped	O
through	O
the	O
heart-lung	O
machine	O
/	O
min	O
CPB	O
time	O
/	O
m2	O
bsa	O
(	O
r	O
=	O
0	O
.	O
51	O
)	O
.	O

Risk	O
of	O
HTLV	O
infection	O
in	O
patients	O
on	O
haemodialysis	O
.	O

Unfolding	O
can	O
be	O
described	O
by	O
a	O
two-state	O
process	O
since	O
a	O
ratio	O
of	O
delta	O
Hcalorimetric	O
to	O
delta	O
Hvan't	O
Hoff	O
equals	O
0	O
.	O
96	O
.	O

A	O
proposal	O
of	O
50	O
performance	O
indicators	O
divided	O
into	O
five	O
different	O
groups	O
is	O
presented	O
here	O
,	O
namely	O
structural	O
indicators	O
,	O
operational	O
indicators	O
,	O
water	O
and	O
service	O
quality	O
indicators	O
,	O
personnel	O
indicators	O
and	O
economic	O
indicators	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
sodium	O
channel	O
blocking	O
drugs	O
selectively	O
prolong	O
the	O
late	O
potential	O
,	O
or	O
terminal	O
low	O
amplitude	O
signal	O
,	O
portion	O
of	O
the	O
signal-averaged	O
QRS	O
complex	O
and	O
that	O
prolongation	O
of	O
the	O
late	O
potential	O
would	O
correlate	O
with	O
slowing	O
of	O
ventricular	O
tachycardia	O
.	O

The	O
in	O
vitro	O
activity	O
of	O
mecillinam	O
and	O
amoxicillin	O
/	O
clavulanic	O
acid	O
against	O
Escherichia	O
coli	O
strains	O
producing	O
beta-lactamases	B-GENE
of	O
the	O
TEM-1	B-GENE
,	O
Oxa-1	B-GENE
and	O
chromosomal	O
type	O
were	O
studied	O
using	O
the	O
broth	O
and	O
agar	O
dilution	O
technique	O
.	O

The	O
cop	B-GENE
region	I-GENE
also	O
harbors	O
a	O
region	O
of	O
plasmid	O
incompatibility	O
,	O
inc	B-GENE
,	O
encompassing	O
a	O
stem-loop	O
structure	O
,	O
the	O
repA	B-GENE
promoter	I-GENE
,	O
Prep	B-GENE
,	O
as	O
well	O
as	O
two	O
distinct	O
RepA	B-GENE
binding	I-GENE
sites	I-GENE
,	O
BD-1	B-GENE
and	O
BD-2	B-GENE
.	O

IL-12	B-GENE
production	O
was	O
correlated	O
with	O
C3a	O
concentration	O
measured	O
at	O
the	O
outlet	O
of	O
hemodialyzer	O
after	O
15	O
min	O
of	O
dialysis	O
(	O
r	O
=	O
0	O
.	O
69	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Only	O
two	O
of	O
27	O
participants	O
(	O
7	O
.	O
4%	O
)	O
with	O
definite	O
POAG	O
had	O
been	O
previously	O
diagnosed	O
and	O
treated	O
,	O
and	O
66	O
.	O
7%	O
of	O
the	O
previously	O
undiagnosed	O
had	O
IOP	O
less	O
than	O
22	O
mmHg	O
.	O

DNA	O
sequence	O
analysis	O
reveals	O
that	O
the	O
gene	O
encodes	O
a	O
protein	O
highly	O
homologous	O
to	O
rat	B-GENE
CRP1	I-GENE
.	O

When	O
cysteine	O
is	O
scanned	O
through	O
the	O
helices	O
,	O
characteristic	O
repeating	O
patterns	O
of	O
solvent	O
exposure	O
and	O
burial	O
are	O
observed	O
.	O

Recombinant	O
expression	O
of	O
a	O
chimeric	O
EGFR	B-GENE
/	I-GENE
ErbB-3	I-GENE
receptor	I-GENE
in	O
NIH	O
3T3	O
fibroblasts	O
allowed	O
us	O
to	O
investigate	O
cytoplasmic	O
events	O
associated	O
with	O
ErbB-3	B-GENE
signal	O
transduction	O
upon	O
ligand	O
activation	O
.	O

Replicating	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
chromosomes	O
were	O
found	O
to	O
be	O
similar	O
to	O
other	O
eukaryotic	O
chromosomes	O
in	O
that	O
the	O
rate	O
and	O
extent	O
of	O
micrococcal	B-GENE
nuclease	I-GENE
(	O
MNase	B-GENE
)	O
digestion	O
were	O
greater	O
with	O
replicating	O
than	O
with	O
nonreplicating	O
mature	O
SV40	O
chromatin	O
.	O

One	O
gene	O
appears	O
ubiquitously	O
expressed	O
while	O
the	O
other	O
is	O
prominently	O
expressed	O
in	O
muscle	O
.	O

Recurrence	O
of	O
oxalate	O
deposition	O
in	O
a	O
renal	O
transplant	O
during	O
ciclosporin	O
A	O
therapy	O
.	O

As	O
retinoic	O
acid	O
and	O
thyroid	O
hormone	O
are	O
frequently	O
involved	O
in	O
developmental	O
regulatory	O
processes	O
,	O
it	O
is	O
possible	O
that	O
this	O
element	O
may	O
be	O
important	O
in	O
the	O
process	O
of	O
islet	O
cell	O
differentiation	O
.	O

We	O
have	O
shown	O
that	O
the	O
epidural	O
(	O
EPI	O
)	O
delivery	O
of	O
morphine	O
encapsulated	O
in	O
multivesicular	O
liposomes	O
(	O
DepoFoam	O
drug	O
delivery	O
system	O
)	O
produces	O
a	O
sustained	O
clearance	O
of	O
morphine	O
and	O
a	O
prolonged	O
analgesia	O
.	O

The	O
results	O
of	O
these	O
studies	O
support	O
a	O
model	O
in	O
which	O
VirB4	B-GENE
dimers	I-GENE
or	O
homomultimers	O
contribute	O
structural	O
information	O
for	O
the	O
assembly	O
of	O
a	O
transenvelope	O
channel	O
competent	O
for	O
bidirectional	O
DNA	O
transfer	O
,	O
whereas	O
an	O
ATP-dependent	O
activity	O
is	O
required	O
for	O
configuring	O
this	O
channel	O
as	O
a	O
dedicated	O
export	O
machine	O
.	O

The	O
C-terminal	B-GENE
Cdk2	I-GENE
truncations	O
,	O
however	O
,	O
were	O
non-functional	O
in	O
these	O
strains	O
and	O
thus	O
dependent	O
for	O
activity	O
on	O
the	O
pho85	B-GENE
coding	I-GENE
region	I-GENE
which	O
remained	O
in	O
the	O
mutant	B-GENE
pho85	I-GENE
:	O
:	O
HIS3	B-GENE
chromosomal	I-GENE
locus	I-GENE
.	O

It	O
is	O
concluded	O
that	O
haloperidol	O
selectively	O
reduced	O
the	O
animal's	O
capacity	O
to	O
'programme	O
non-stimulus	O
directed	O
motor	O
behaviour'	O
.	O

Sleep	O
was	O
determined	O
again	O
for	O
an	O
additional	O
3	O
days	O
and	O
6	O
hours	O
.	O

Histochemical	O
localization	O
of	O
GUS	B-GENE
revealed	O
promoter	O
function	O
in	O
leaf	O
epidermis	O
,	O
mesophyll	O
and	O
vascular	O
bundles	O
,	O
in	O
the	O
cortex	O
and	O
vascular	O
cylinder	O
of	O
the	O
root	O
.	O

We	O
show	O
here	O
that	O
the	O
in	O
vitro	O
transcription	O
extract	O
contains	O
a	O
binding	O
activity	O
that	O
is	O
specific	O
for	O
the	O
initiator	O
element	O
and	O
thus	O
may	O
participate	O
in	O
recruiting	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
to	O
the	O
SL	B-GENE
RNA	I-GENE
gene	I-GENE
promoter	I-GENE
.	O

The	O
inserted	O
region	O
,	O
which	O
represents	O
an	O
intron	O
in	O
brain	O
and	O
muscle	O
,	O
is	O
expressed	O
in	O
the	O
tumor	O
cell	O
lines	O
either	O
as	O
a	O
"readthrough"	O
form	O
or	O
with	O
78	O
residues	O
deleted	O
from	O
its	O
5'	O
end	O
.	O

Localization	O
of	O
the	O
insertion	O
locus	O
in	O
the	O
yeast	O
genome	O
and	O
complementation	O
studies	O
with	O
the	O
temperature-sensitive	O
mutant	O
indicate	O
that	O
the	O
two	O
mutations	O
are	O
allelic	O
.	O

The	O
conditions	O
for	O
obtaining	O
titanium	O
dioxide	O
from	O
the	O
substrates	O
titanium	O
tetrachloride	O
and	O
oxygen	O
and	O
applying	O
this	O
to	O
a	O
surgical	O
stainless	O
steel	O
of	O
the	O
type	O
316L	O
by	O
the	O
plasma	O
assisted	O
chemical	O
vapour	O
deposition	O
method	O
have	O
been	O
determined	O
.	O

The	O
growth	O
defect	O
of	O
a	O
reg1	B-GENE
reg2	B-GENE
double	I-GENE
mutant	I-GENE
is	O
alleviated	O
by	O
a	O
loss-of-function	O
mutation	O
in	O
the	O
SNF1-encoded	B-GENE
protein	I-GENE
kinase	I-GENE
.	O

When	O
combined	O
with	O
serum	O
ferritin	B-GENE
and	O
hemoglobin	B-GENE
determinations	O
,	O
the	O
serum	O
transferrin	B-GENE
receptor	I-GENE
assay	O
is	O
a	O
valuable	O
addition	O
in	O
epidemiologic	O
surveys	O
because	O
it	O
provides	O
a	O
quantitative	O
measure	O
of	O
functional	O
iron	O
deficiency	O
and	O
it	O
distinguishes	O
true	O
IDA	O
from	O
the	O
anemia	O
of	O
chronic	O
disease	O
.	O

The	O
MMPI-A	O
(	O
Butcher	O
et	O
al	O
.	O
,	O
1992	O
)	O
,	O
like	O
the	O
older	O
MMPI	O
(	O
Hathaway	O
&	O
McKinley	O
,	O
1983	O
)	O
,	O
distinguishes	O
between	O
anorexia	O
and	O
bulimia	O
.	O

In	O
this	O
study	O
,	O
to	O
characterize	O
the	O
gene	O
for	O
protein	B-GENE
Z	I-GENE
,	O
its	O
organization	O
and	O
structure	O
were	O
determined	O
by	O
a	O
combination	O
of	O
PCR	O
amplification	O
of	O
leukocyte	O
DNA	O
and	O
isolation	O
of	O
phage	O
clones	O
from	O
a	O
human	O
genomic	O
library	O
.	O

A	O
genomic	O
DNA	O
clone	O
encoding	O
oryzacystatin	B-GENE
(	O
Oc	B-GENE
)	O
,	O
a	O
cysteine	B-GENE
proteinase	I-GENE
inhibitor	I-GENE
(	O
cystatin	B-GENE
)	O
of	O
rice	O
,	O
was	O
isolated	O
from	O
a	O
lambda	O
EMBL3	O
phage	O
library	O
constructed	O
with	O
Sau3AI	B-GENE
partial	O
digests	O
of	O
rice	O
chromosomal	O
DNA	O
,	O
by	O
screening	O
with	O
an	O
oc	B-GENE
cDNA	I-GENE
as	O
a	O
probe	O
.	O

Surprisingly	O
,	O
the	O
RXR-specific	O
ligand	O
9-cis-retinoic	O
acid	O
induced	O
binding	O
of	O
SRC-1	B-GENE
to	O
the	O
RXR	B-GENE
component	I-GENE
of	O
the	O
TRE-bound	O
heterodimer	O
.	O

The	O
average	O
coefficients	O
of	O
correlation	O
were	O
0	O
.	O
9998	O
and	O
0	O
.	O
9993	O
for	O
the	O
QMF	O
and	O
the	O
QIT	O
system	O
,	O
respectively	O
.	O

The	O
results	O
imply	O
that	O
kindling	O
does	O
not	O
produce	O
its	O
facilitating	O
effect	O
on	O
acquisition	O
of	O
HPC	O
SS	O
by	O
removing	O
a	O
disruptive	O
effect	O
of	O
the	O
stimulation	O
.	O

When	O
RNA	O
encoding	O
the	O
tail	O
domain	O
of	O
desmoglein	B-GENE
was	O
coinjected	O
with	O
plakoglobin	B-GENE
RNA	I-GENE
,	O
both	O
the	O
dorsalizing	O
effect	O
and	O
nuclear	O
accumulation	O
of	O
plakoglobin	B-GENE
were	O
suppressed	O
.	O

Two	O
related	O
cDNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
that	O
recognize	O
the	O
XMyoDa	B-GENE
TATA	I-GENE
motif	I-GENE
.	O

Fluorimetric	O
determination	O
of	O
methylmercury	O
as	O
an	O
ion-association	O
complex	O
with	O
rhodamine	O
B	O
in	O
the	O
presence	O
of	O
iodide	O
.	O

Expression	O
from	O
this	O
element	O
is	O
regulated	O
by	O
a	O
heteromeric	O
protein	O
complex	O
containing	O
ubiquitous	O
(	O
i	O
.	O
e	O
.	O
the	O
E2A-	B-GENE
and	O
HEB-encoded	B-GENE
proteins	I-GENE
)	O
and	O
islet-enriched	O
members	O
of	O
the	O
bHLH	B-GENE
family	I-GENE
.	O

The	O
electromyographically	O
recorded	O
responses	O
consisted	O
of	O
an	O
early	O
R1	O
response	O
in	O
the	O
orbicularis	O
oculi	O
muscle	O
ipsilateral	O
to	O
the	O
side	O
of	O
stimulation	O
,	O
a	O
bilateral	O
late	O
response	O
(	O
ipsilateral	O
R2	O
and	O
contralateral	O
Rc	O
)	O
and	O
a	O
third	O
,	O
R3	O
response	O
,	O
in	O
the	O
ipsilateral	O
orbicularis	O
oculi	O
muscle	O
.	O

The	O
amplification	O
was	O
achieved	O
using	O
two	O
primers	O
which	O
correspond	O
to	O
TRH	B-GENE
progenitor	I-GENE
sequence	I-GENE
(	O
Lys	B-GENE
/	I-GENE
Arg-Arg-Gln-His-Pro-Gly-Lys	I-GENE
/	I-GENE
Arg-Arg	I-GENE
)	O
.	O

Pilot	O
study	O
of	O
blood	O
coagulation	O
in	O
gout	O
patients	O
.	O

The	O
well-known	O
Rel	B-GENE
/	I-GENE
NF-kappaB	I-GENE
family	I-GENE
of	O
vertebrate	O
transcription	O
factors	O
comprises	O
a	O
number	O
of	O
structurally	O
related	O
,	O
interacting	O
proteins	O
that	O
bind	O
DNA	O
as	O
dimers	O
and	O
whose	O
activity	O
is	O
regulated	O
by	O
subcellular	O
location	O
.	O

Contractile	O
responses	O
to	O
norepinephrine	O
,	O
serotonin	O
and	O
potassium	O
(	O
K+	O
)	O
and	O
relaxant	O
responses	O
to	O
isoproterenol	O
and	O
papaverine	O
were	O
studied	O
in	O
vitro	O
with	O
spirally	O
cut	O
thoracic	O
aortic	O
strips	O
from	O
aortic	O
coarcted	O
hypertensive	O
rats	O
(	O
AHR	O
)	O
2	O
,	O
6	O
,	O
14	O
and	O
28	O
days	O
postoperatively	O
and	O
compared	O
to	O
time-matched	O
,	O
sham-operated	O
normotensive	O
controls	O
.	O

Tristetraprolin	B-GENE
(	O
TTP	B-GENE
)	O
is	O
the	O
prototype	O
of	O
a	O
group	O
of	O
potential	O
transcription	O
factors	O
that	O
contain	O
two	O
or	O
more	O
unusual	O
CCCH	O
zinc	O
fingers	O
.	O

These	O
intron	O
chimeras	O
show	O
that	O
peripheral	O
sequences	O
and	O
the	O
elements	O
that	O
define	O
the	O
splice	O
sites	O
are	O
adequate	O
for	O
self-splicing	O
activity	O
but	O
that	O
the	O
central	O
portions	O
containing	O
the	O
catalytic	O
cores	O
of	O
ai4	B-GENE
and	O
bi4	B-GENE
are	O
deficient	O
;	O
these	O
cores	O
are	O
the	O
likely	O
targets	O
of	O
the	O
splicing	O
proteins	O
.	O

Km	O
and	O
Vmax	O
for	O
two	O
substrates	O
,	O
src-related	B-GENE
peptide	I-GENE
and	O
poly	O
(	O
Glu	O
,	O
Tyr	O
)	O
(	O
4	O
:	O
1	O
)	O
,	O
were	O
2	O
.	O
4	O
mM	O
and	O
2	O
.	O
5	O
mumol	O
min-1	O
mg-1	O
and	O
0	O
.	O
26	O
mM	O
and	O
1	O
.	O
2	O
mumol	O
min-1	O
mg-1	O
,	O
respectively	O
.	O

Human	B-GENE
ULK1	I-GENE
,	O
a	O
novel	O
serine	B-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
related	O
to	O
UNC-51	B-GENE
kinase	I-GENE
of	O
Caenorhabditis	O
elegans	O
:	O
cDNA	O
cloning	O
,	O
expression	O
,	O
and	O
chromosomal	O
assignment	O
.	O

Sulfhydryl	O
titration	O
with	O
iodoacetamide	O
,	O
monitored	O
by	O
quantitating	O
the	O
residual	O
thiols	O
after	O
reaction	O
with	O
a	O
maleimide	O
derivative	O
of	O
biotin	O
,	O
revealed	O
a	O
striking	O
difference	O
in	O
the	O
apparent	O
pK	O
(	O
a	O
)	O
values	O
of	O
the	O
cysteines	O
at	O
the	O
two	O
splice	O
junctions	O
.	O

High	O
plasma	O
concentrations	O
of	O
soluble	O
E-selectin	B-GENE
were	O
closely	O
associated	O
with	O
multiple-organ	O
dysfunction	O
and	O
death	O
.	O

In	O
such	O
a	O
manner	O
,	O
activated	O
PKR	B-GENE
inhibits	O
cell	O
growth	O
and	O
induces	O
apoptosis	O
,	O
whereas	O
disruption	O
of	O
normal	O
PKR	B-GENE
signaling	O
results	O
in	O
unregulated	O
cell	O
growth	O
.	O

When	O
a	O
tumour	O
is	O
present	O
nipple	O
discharge	O
is	O
of	O
little	O
importance	O
for	O
the	O
diagnosis	O
and	O
treatment	O
.	O

When	O
the	O
CO2	O
content	O
reached	O
9	O
Vol%	O
the	O
animals	O
became	O
apathic	O
and	O
lost	O
body	O
weight	O
.	O

The	O
results	O
demonstrate	O
that	O
(	O
i	O
)	O
no	O
intact	O
capsids	O
were	O
assembled	O
when	O
the	O
full-length	O
or	O
a	O
truncated	O
(	O
missing	O
the	O
C-terminal	O
65	O
amino	O
acids	O
)	O
UL80	B-GENE
.	I-GENE
5	I-GENE
protein	I-GENE
was	O
tested	O
;	O
(	O
ii	O
)	O
when	O
the	O
C-terminal	O
65	O
amino	O
acids	O
of	O
the	O
UL80	B-GENE
.	I-GENE
5	I-GENE
protein	I-GENE
were	O
replaced	O
with	O
the	O
C-terminal	O
25	O
amino	O
acids	O
of	O
the	O
UL26	B-GENE
.	I-GENE
5	I-GENE
protein	I-GENE
,	O
intact	O
capsids	O
were	O
made	O
and	O
direct	O
interaction	O
of	O
the	O
UL80	B-GENE
.	I-GENE
5	I-GENE
protein	I-GENE
with	O
VP5	B-GENE
was	O
detected	O
;	O
(	O
iii	O
)	O
assembly	O
of	O
intact	O
capsids	O
was	O
demonstrated	O
when	O
the	O
sequence	O
of	O
the	O
last	O
12	O
amino	O
acids	O
of	O
the	O
UL80	B-GENE
.	I-GENE
5	I-GENE
protein	I-GENE
was	O
changed	O
from	O
RRIFVA	B-GENE
ALNKLE	I-GENE
to	O
RRIFVAAMMKLE	B-GENE
;	O
(	O
iv	O
)	O
self-interaction	O
of	O
the	O
scaffold	O
proteins	O
is	O
mediated	O
by	O
sequences	O
N	O
terminal	O
to	O
the	O
maturation	O
cleavage	O
site	O
;	O
and	O
(	O
v	O
)	O
the	O
UL26	B-GENE
.	I-GENE
5	I-GENE
and	O
UL80	B-GENE
.	I-GENE
5	I-GENE
proteins	I-GENE
will	O
not	O
coassemble	O
into	O
scaffold	O
structures	O
.	O

Anti-nucleolin	B-GENE
mAb	I-GENE
was	O
used	O
to	O
confirm	O
the	O
antigenic	O
properties	O
of	O
this	O
p95	B-GENE
component	I-GENE
.	O

Sixty	O
days	O
after	O
the	O
intervention	O
,	O
twitch	O
and	O
tetanic	O
tensions	O
remained	O
dependent	O
upon	O
the	O
extracellular	O
Ca2+	O
concentration	O
(	O
[	O
Ca	O
]	O
o	O
)	O
both	O
in	O
groups	O
A	O
and	O
B	O
.	O

Methoxyflurane	O
and	O
renal	O
function	O
.	O

In	O
the	O
present	O
experiments	O
,	O
we	O
investigate	O
the	O
role	O
played	O
by	O
the	O
temporal	O
pattern	O
of	O
neural	O
activity	O
during	O
the	O
ontogeny	O
of	O
frequency	O
tuning	O
in	O
the	O
mouse	O
central	O
auditory	O
system	O
.	O

Because	O
the	O
mutant	O
defective	O
in	O
DNA	O
binding	O
also	O
fails	O
to	O
stimulate	O
Abf1	B-GENE
ARS1	B-GENE
DNA-binding	O
activity	O
,	O
our	O
results	O
suggest	O
that	O
Cdc6	B-GENE
DNA-binding	O
activity	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
initiation	O
of	O
DNA	O
replication	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
vacuolar	B-GENE
H	I-GENE
(	I-GENE
+	I-GENE
)	I-GENE
-ATPase	I-GENE
B2	I-GENE
subunit	I-GENE
gene	I-GENE
in	O
differentiating	O
THP-1	O
cells	O
.	O

Potential	O
treatments	O
include	O
dobutamine	O
,	O
KATP	O
channel	O
activators	O
,	O
and	O
21-aminosteroids	O
.	O

According	O
to	O
Sugiura's	O
classification	O
,	O
they	O
consisted	O
of	O
Type	O
Ia	O
in	O
63%	O
,	O
Type	O
Ib	O
in	O
11%	O
,	O
Type	O
II	O
in	O
11%	O
,	O
and	O
Type	O
III	O
in	O
16%	O
.	O

METHODS	O
:	O
In	O
the	O
current	O
study	O
the	O
authors	O
reported	O
on	O
PPB	O
cases	O
from	O
a	O
national	O
retrospective	O
search	O
performed	O
in	O
18	O
Italian	O
Associations	O
for	O
Pediatric	O
Hematology	O
and	O
Oncology	O
centers	O
.	O

D	O
.	O

These	O
results	O
indicate	O
that	O
HIV-1	O
Gag	B-GENE
sequences	I-GENE
can	O
influence	O
the	O
viral	O
PR-mediated	O
processing	O
of	O
the	O
MuLV	O
TM	B-GENE
Env	I-GENE
protein	I-GENE
p15	B-GENE
(	I-GENE
E	I-GENE
)	I-GENE
.	O

Consistent	O
with	O
its	O
role	O
in	O
p53	B-GENE
ubiquitination	O
,	O
mE6-AP	B-GENE
was	O
found	O
both	O
in	O
the	O
nucleus	O
and	O
cytosol	O
,	O
while	O
Nedd-4	B-GENE
was	O
found	O
only	O
in	O
the	O
cytosol	O
.	O

Tests	O
of	O
the	O
method	O
indicate	O
(	O
1	O
)	O
the	O
Mossbauer	O
source	O
can	O
be	O
placed	O
on	O
the	O
basilar	O
membrane	O
without	O
altering	O
the	O
signal-transmission	O
properties	O
of	O
the	O
cochlea	O
,	O
and	O
(	O
2	O
)	O
the	O
source	O
adheres	O
to	O
the	O
basilar	O
membrane	O
.	O

When	O
expressed	O
alone	O
in	O
test	O
cells	O
,	O
Atr-I	B-GENE
is	O
unable	O
to	O
bind	O
TGF-beta	B-GENE
,	O
activin	B-GENE
,	O
or	O
bone	B-GENE
morphogenetic	I-GENE
protein	I-GENE
2	I-GENE
.	O

One	O
of	O
these	O
elements	O
,	O
the	O
homeodomain-binding	B-GENE
element	I-GENE
,	O
was	O
identified	O
to	O
mediate	O
negative	O
regulation	O
.	O

The	O
mutations	O
did	O
not	O
affect	O
the	O
repression	O
of	O
CPA1	B-GENE
by	O
arginine	O
.	O

Increasing	O
the	O
extracellular	O
calcium	O
concentration	O
enhanced	O
detrusor	O
contractility	O
in	O
a	O
dose-dependent	O
manner	O
in	O
both	O
control	O
and	O
obstructed	O
bladders	O
.	O

These	O
six	O
districts	O
have	O
an	O
area	O
of	O
34	O
,	O
000	O
km2	O
and	O
hold	O
a	O
population	O
of	O
30	O
million	O
.	O

Anti-hepatitis	B-GENE
A	I-GENE
virus	O
(	O
HAV	O
)	O
titer	O
after	O
vaccination	O
was	O
measured	O
in	O
83	O
HIV-positive	O
and	O
39	O
HIV-negative	O
men	O
.	O

An	O
endometrial	O
luteal	O
phase	O
deficiency	O
was	O
detected	O
in	O
15	O
(	O
30%	O
)	O
of	O
aborting	O
patients	O
.	O

These	O
viruses	O
depend	O
on	O
the	O
host	O
cell	O
machinery	O
for	O
their	O
existence	O
,	O
and	O
interference	O
with	O
these	O
processes	O
typically	O
interferes	O
with	O
other	O
important	O
host	O
physiology	O
.	O

RNase	B-GENE
protection	O
analysis	O
of	O
two	O
rRNA	B-GENE
fragments	I-GENE
whose	O
genes	O
are	O
adjacent	O
provided	O
evidence	O
for	O
a	O
polycistronic	O
transcript	O
containing	O
sequences	O
from	O
both	O
,	O
as	O
well	O
as	O
separate	O
small	O
RNAs	O
.	O

A	O
38-year-old	O
woman	O
with	O
ulcerative	O
colitis	O
subsequently	O
developed	O
sarcoidosis	O
.	O

Patients	O
receiving	O
VPA	O
showed	O
differences	O
in	O
attention	O
,	O
visuomotor	O
performance	O
,	O
verbal	O
span	O
and	O
sensory	O
discrimination	O
tasks	O
at	O
T1	O
,	O
in	O
visuomotor	O
performance	O
at	O
T2	O
and	O
in	O
spatial	O
span	O
at	O
T3	O
,	O
whereas	O
no	O
differences	O
were	O
detected	O
at	O
T4	O
.	O

Recently	O
,	O
an	O
electrical-mechanical	O
analog	O
model	O
of	O
heat	O
flow	O
within	O
the	O
brain	O
has	O
been	O
developed	O
from	O
which	O
an	O
expression	O
for	O
CBF	O
has	O
been	O
derived	O
:	O
CBF	O
=	O
Cb	O
/	O
(	O
tau	O
rho	O
c	O
)	O
where	O
tau	O
is	O
the	O
thermal	O
decay	O
constant	O
,	O
rho	O
is	O
the	O
density	O
of	O
blood	O
,	O
and	O
c	O
is	O
its	O
specific	O
heat	O
.	O

It	O
is	O
suggested	O
that	O
a	O
raised	O
hydroxykynurenine	O
/	O
hydroxyanthranilic	O
acid	O
ratio	O
does	O
not	O
necessarily	O
indicate	O
vitamin	O
B6	O
deficiency	O
but	O
may	O
represent	O
a	O
nonspecific	O
response	O
of	O
tryptophan	O
metabolism	O
to	O
stress	O
.	O

"Complex	O
partial"	O
seizures	O
.	O

Acute	O
feasibility	O
and	O
safety	O
of	O
a	O
smoking	O
reduction	O
strategy	O
for	O
smokers	O
with	O
schizophrenia	O
.	O

RESULTS	O
:	O
A	O
novel	O
gene	O
was	O
cloned	O
.	O

To	O
compare	O
the	O
PAX3	B-GENE
and	O
putative	O
PAX3-FKHR	B-GENE
transactivation	I-GENE
domains	I-GENE
,	O
we	O
fused	O
C-terminal	O
test	O
fragments	O
to	O
the	O
heterologous	O
GAL4	B-GENE
DNA-binding	I-GENE
domain	I-GENE
and	O
tested	O
activation	O
of	O
a	O
reporter	O
gene	O
co-transfected	O
into	O
four	O
cell	O
types	O
.	O

A	O
single	O
amino	O
acid	O
change	O
in	O
the	O
CPY	B-GENE
vacuolar	I-GENE
sorting	I-GENE
signal	I-GENE
prevents	O
this	O
interaction	O
.	O

Removal	O
of	O
PDMP	O
from	O
the	O
cell	O
medium	O
resulted	O
in	O
reversal	O
of	O
the	O
cell	O
cycle	O
changes	O
,	O
with	O
cells	O
re-entering	O
the	O
S	O
phase	O
.	O

The	O
phosphotransferase	B-GENE
system	O
(	O
PTS	O
)	O
of	O
Streptomyces	O
coelicolor	O
identification	O
and	O
biochemical	O
analysis	O
of	O
a	O
histidine	B-GENE
phosphocarrier	I-GENE
protein	I-GENE
HPr	B-GENE
encoded	O
by	O
the	O
gene	O
ptsH	B-GENE
.	O

One	O
member	O
of	O
this	O
family	O
,	O
RFX1	B-GENE
,	O
is	O
a	O
transcription	O
factor	O
for	O
a	O
variety	O
of	O
viral	O
and	O
cellular	O
genes	O
.	O

Evaluation	O
of	O
desmopressin	O
for	O
dental	O
extractions	O
in	O
patients	O
with	O
hemostatic	O
disorders	O
.	O

Combination	O
of	O
3	O
multiple	O
primary	O
malignant	O
and	O
benign	O
tumors	O
of	O
the	O
breasts	O
and	O
uterus	O
.	O

RESULTS	O
:	O
The	O
standardised	O
mortality	O
ratio	O
(	O
SMR	O
)	O
for	O
all	O
malignant	O
neoplasms	O
was	O
94	O
(	O
95%	O
CI	O
74	O
to	O
118	O
)	O
.	O

Erythrocyte	O
AA	O
in	O
FO+EPO-supplemented	O
infants	O
remained	O
low	O
and	O
below	O
breast-	O
and	O
placebo	O
formula-fed	O
levels	O
.	O

A	O
semiautomatic	O
digital	O
system	O
(	O
Videoplan	O
2	O
)	O
was	O
used	O
.	O

On	O
histologic	O
examination	O
the	O
cuboidal	O
epithelium	O
of	O
the	O
mucous	O
membrane	O
was	O
found	O
to	O
be	O
changed	O
into	O
columnar	O
epithelium	O
,	O
with	O
uneven	O
distribution	O
of	O
enlarged	O
nuclei	O
in	O
the	O
vacuolized	O
cytoplasm	O
.	O

Swim-over	O
:	O
an	O
alternative	O
method	O
for	O
harvesting	O
motile	O
spermatozoa	O
.	O

The	O
rat	B-GENE
aldolase	I-GENE
C	I-GENE
gene	I-GENE
encodes	O
a	O
glycolytic	O
enzyme	O
strongly	O
expressed	O
in	O
adult	O
brain	O
.	O

The	O
human	O
cDNA	O
clone	O
NFBD1	O
(	O
previously	O
designated	O
KIAA0170	O
)	O
encodes	O
a	O
novel	O
protein	O
(	O
2089	O
amino	O
acids	O
in	O
length	O
;	O
calculated	O
molecular	O
mass	O
226	O
,	O
440	O
D	O
)	O
with	O
possible	O
BRCT	B-GENE
domains	I-GENE
at	O
its	O
carboxy	O
terminus	O
(	O
amino	O
acid	O
residues	O
1894-2089	O
)	O
.	O

The	O
effects	O
of	O
systemic	O
glucose	O
concentration	O
on	O
brain	O
metabolism	O
following	O
repeated	O
brain	O
ischemia	O
.	O

Mechanism	O
of	O
interferon	B-GENE
action	O
:	O
identification	O
of	O
essential	O
positions	O
within	O
the	O
novel	O
15-base-pair	B-GENE
KCS	I-GENE
element	I-GENE
required	O
for	O
transcriptional	O
activation	O
of	O
the	O
RNA-dependent	B-GENE
protein	I-GENE
kinase	I-GENE
pkr	I-GENE
gene	I-GENE
.	O

The	O
strategies	O
by	O
which	O
hepatitis	O
B	O
and	O
hepatitis	O
D	O
can	O
be	O
diminished	O
and	O
eventually	O
eliminated	O
are	O
:	O
immunization	O
,	O
measures	O
to	O
prevent	O
exposure	O
to	O
infective	O
blood	O
or	O
blood	O
derivatives	O
and	O
education	O
(	O
in	O
particular	O
awareness	O
that	O
hepatitis	O
B	O
is	O
a	O
sexually	O
transmitted	O
disease	O
)	O
.	O

A	O
single	O
five	O
minute	O
period	O
of	O
rapid	O
atrial	O
pacing	O
fails	O
to	O
limit	O
infarct	O
size	O
in	O
the	O
in	O
situ	O
rabbit	O
heart	O
.	O

Finally	O
,	O
three	O
new	O
missense	O
mutations	O
,	O
E138V	B-GENE
,	O
R254G	B-GENE
,	O
and	O
P362R	B-GENE
,	O
were	O
identified	O
in	O
the	O
human	B-GENE
AC	I-GENE
gene	I-GENE
from	O
FD	O
patients	O
.	O

Although	O
the	O
spatial	O
and	O
temporal	O
variability	O
of	O
LDF	O
signals	O
evoked	O
by	O
cerebrocortical	O
microflow	O
is	O
in	O
the	O
same	O
range	O
as	O
with	O
other	O
methods	O
and	O
in	O
other	O
organs	O
,	O
LDF	O
cerebrocortical	O
mapping	O
is	O
restricted	O
by	O
the	O
large	O
temporal	O
and	O
spatial	O
heterogeneity	O
of	O
the	O
cerebrocortical	O
vasculature	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
chlorphentermine	O
may	O
be	O
capable	O
of	O
producing	O
dual	O
stimulus	O
effects	O
in	O
animals	O
.	O

However	O
,	O
2	O
minimum	O
alveolar	O
concentration	O
anesthesia	O
did	O
significantly	O
decrease	O
the	O
calculated	O
VE	O
at	O
a	O
PCO2	O
of	O
60	O
mmHg	O
(	O
from	O
7	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
4	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
6	O
l	O
.	O
min-1	O
)	O
,	O
indicating	O
a	O
rightward	O
shift	O
in	O
the	O
response	O
relationship	O
.	O

Nuclease	B-GENE
probing	O
and	O
structure-directed	O
mutagenesis	O
revealed	O
that	O
the	O
105-nt	B-GENE
TE	I-GENE
(	O
TE105	B-GENE
)	O
forms	O
a	O
cruciform	O
secondary	O
structure	O
containing	O
four	O
helices	O
connected	O
by	O
single-stranded	O
regions	O
.	O

These	O
results	O
suggested	O
that	O
the	O
GG	O
motifs	O
contributed	O
to	O
the	O
cell-specific	O
transcription	O
of	O
the	O
human	B-GENE
insulin	I-GENE
gene	I-GENE
in	O
association	O
with	O
the	O
binding	O
of	O
the	O
sequence-specific	O
nuclear	O
factor	O
.	O

To	O
investigate	O
the	O
potential	O
role	O
of	O
SP1	B-GENE
,	O
we	O
examined	O
nuclear	O
extracts	O
from	O
HCMV-infected	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
differentiation	O
of	O
neoplastically	O
transformed	O
cells	O
does	O
not	O
repress	O
mitogenic	O
responsiveness	O
or	O
junB	B-GENE
or	O
c-fos	B-GENE
inducibility	O
.	O

Of	O
the	O
drugs	O
orally	O
administered	O
,	O
WR-168643	O
was	O
the	O
best	O
protector	O
with	O
a	O
DMF	O
of	O
1	O
.	O
51	O
.	O

Here	O
,	O
we	O
report	O
that	O
swa5-1	B-GENE
is	O
a	O
new	O
temperature-sensitive	O
allele	O
of	O
the	O
clathrin	B-GENE
heavy	I-GENE
chain	I-GENE
gene	I-GENE
(	O
chc1-5	B-GENE
)	O
,	O
which	O
carries	O
a	O
frameshift	O
mutation	O
near	O
the	O
3'	O
end	O
of	O
the	O
CHC1	B-GENE
open	O
reading	O
frame	O
.	O

Artificial	O
ventilation	O
was	O
conducted	O
using	O
a	O
tidal	O
volume	O
of	O
10	O
ml	O
X	O
kg-1	O
and	O
a	O
rate	O
of	O
10	O
to	O
12	O
c	O
X	O
min-1	O
.	O

Active	O
complexes	O
eluted	O
at	O
a	O
higher	O
molecular	O
weight	O
than	O
inactive	O
complexes	O
,	O
were	O
relatively	O
deficient	O
in	O
both	O
p21	B-GENE
and	O
p27	B-GENE
,	O
and	O
contained	O
Cdk2	B-GENE
with	O
increased	O
threonine	O
160	O
phosphorylation	O
,	O
consistent	O
with	O
a	O
mechanism	O
of	O
activation	O
of	O
cyclin	B-GENE
E-Cdk2	I-GENE
involving	O
both	O
reduced	O
CDK	B-GENE
inhibitor	O
association	O
and	O
CDK-activating	O
kinase-mediated	O
phosphorylation	O
of	O
Cdk2	B-GENE
.	O

Pancreaticoduodenal	O
lymph	O
node	O
enlargement	O
,	O
regardless	O
of	O
cause	O
,	O
has	O
been	O
a	O
source	O
of	O
imaging	O
confusion	O
because	O
of	O
its	O
propensity	O
to	O
mimic	O
pancreatic	O
malignancy	O
yet	O
not	O
cause	O
biliary	O
obstruction	O
.	O

The	O
5'-flanking	O
region	O
,	O
from	O
nucleotide	O
-837	O
to	O
-336	O
,	O
contains	O
TATA	O
and	O
inverted	O
CAAT	O
boxes	O
as	O
well	O
as	O
GATA-1	B-GENE
/	I-GENE
SP1	I-GENE
erythroid-specific	O
cis-acting	O
regulatory	O
elements	O
.	O

Mutation	O
of	O
KRKR	B-GENE
to	O
NGER	B-GENE
retains	O
MO15	B-GENE
in	O
the	O
cytoplasmic	O
compartment	O
,	O
whilst	O
the	O
wild-type	O
protein	O
is	O
detected	O
exclusively	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
when	O
combined	O
with	O
mitomycin	O
C	O
given	O
with	O
1	O
to	O
5-days	O
interval	O
,	O
the	O
concurrent	O
administration	O
of	O
SPG	O
prolonged	O
significantly	O
the	O
life-span	O
of	O
the	O
tumor-bearing	O
mice	O
.	O

The	O
equilibrium	O
phosphorus	O
content	O
(	O
EPC0	O
)	O
of	O
surface	O
soil	O
was	O
generally	O
higher	O
than	O
the	O
SRP	O
content	O
of	O
drainage	O
water	O
,	O
at	O
one	O
farm	O
by	O
1	O
order	O
of	O
magnitude	O
.	O

When	O
blood	O
samples	O
of	O
patients	O
with	O
hyperbilirubinemia	O
were	O
analyzed	O
,	O
direct	O
measurement	O
of	O
ZPP	O
by	O
this	O
fluorimeter	O
yielded	O
significantly	O
higher	O
levels	O
than	O
did	O
an	O
alternate	O
extraction	O
method	O
.	O

Transformation	O
blocks	O
differentiation-induced	O
inhibition	O
of	O
serum	B-GENE
response	I-GENE
factor	I-GENE
interactions	O
with	O
serum	B-GENE
response	I-GENE
elements	I-GENE
.	O

The	O
monoexponential	O
rate	O
of	O
clearance	O
of	O
tracer--obtained	O
from	O
the	O
portion	O
of	O
the	O
residue-detection	O
curve	O
reflecting	O
metabolism	O
of	O
fatty	O
acid	O
incorporated	O
into	O
neutral	O
lipids--correlated	O
directly	O
with	O
induced	O
changes	O
in	O
tension-time	O
index	O
after	O
injections	O
into	O
the	O
left	O
atrium	O
(	O
r	O
=	O
0	O
.	O
96	O
,	O
n	O
=	O
12	O
)	O
,	O
right	O
atrium	O
(	O
r	O
=	O
0	O
.	O
86	O
,	O
n	O
=	O
14	O
)	O
,	O
and	O
ear	O
vein	O
(	O
r	O
=	O
0	O
.	O
93	O
,	O
n	O
=	O
14	O
)	O
.	O

Using	O
a	O
previously	O
published	O
two-frequency	O
(	O
AC	O
excitation	O
)	O
three-electrode	O
method	O
,	O
the	O
admittance	O
locus	O
plot	O
(	O
ALP	O
)	O
in	O
the	O
low-frequency	O
region	O
(	O
<	O
1000	O
Hz	O
)	O
has	O
been	O
shown	O
to	O
be	O
very	O
well	O
approximated	O
by	O
a	O
straight	O
line	O
and	O
can	O
be	O
described	O
with	O
frequency-independent	O
parameters	O
;	O
phase	O
angle	O
alpha	O
pi	O
/	O
2	O
,	O
conductance	O
at	O
extrapolated	O
zero	O
frequency	O
G0	O
=	O
1	O
/	O
R0	O
,	O
and	O
ion	O
relaxation	O
time	O
tau	O
.	O

A	O
rather	O
similar	O
pattern	O
of	O
results	O
was	O
obtained	O
with	O
respect	O
to	O
LMP2B	B-GENE
mRNA	I-GENE
expression	O
,	O
such	O
transcripts	O
being	O
detectable	O
only	O
in	O
a	O
subset	O
of	O
tumors	O
,	O
and	O
then	O
at	O
apparently	O
low	O
levels	O
.	O

Temporal	O
relationships	O
and	O
the	O
development	O
phase	O
affected	O
.	O

To	O
dissect	O
these	O
mechanisms	O
,	O
wild-type	O
and	O
mutant	B-GENE
Raf-1	I-GENE
proteins	I-GENE
were	O
studied	O
in	O
an	O
in	O
vitro	O
system	O
with	O
purified	O
plasma	O
membranes	O
from	O
v-Ras-	O
and	O
v-Src-transformed	O
cells	O
(	O
transformed	O
membranes	O
)	O
.	O

The	O
influence	O
of	O
p53	B-GENE
on	O
cytokine-triggered	O
Janus	B-GENE
kinase-STAT	I-GENE
signaling	O
was	O
investigated	O
in	O
human	O
hepatoma	O
Hep3B	O
cell	O
lines	O
engineered	O
to	O
constitutively	O
express	O
the	O
temperature-sensitive	O
Val135	B-GENE
mutant	I-GENE
of	I-GENE
p53	I-GENE
.	O

Anatomy	O
of	O
the	O
uterine	O
artery	O
.	O

Neurofibromatosis	O
of	O
the	O
breast	O
in	O
a	O
patient	O
with	O
Morbus	O
von	O
Recklinghausen	O
.	O

Endovascular	O
aneurysm	O
repair	O
with	O
the	O
AneuRx	O
stent-graft	O
is	O
safe	O
,	O
but	O
is	O
it	O
effective	O
?	O

Vascular	B-GENE
endothelial	I-GENE
growth	I-GENE
factor	I-GENE
(	O
VEGF	B-GENE
)	O
,	O
a	O
potent	O
agonist	O
secreted	O
by	O
virtually	O
all	O
cells	O
,	O
controls	O
migration	O
and	O
division	O
of	O
vascular	O
endothelial	O
cells	O
.	O

This	O
caused	O
severe	O
cortical	O
damage	O
and	O
neuronal	O
loss	O
in	O
hippocampus	O
subfields	O
CA1	O
,	O
CA3	O
,	O
and	O
hilus	O
.	O

Only	O
the	O
3	O
.	O
0-kb	O
transcript	O
was	O
detected	O
in	O
adult	O
tissues	O
,	O
where	O
its	O
expression	O
was	O
restricted	O
almost	O
exclusively	O
to	O
the	O
central	O
nervous	O
system	O
.	O

A	O
third	O
prominent	O
component	O
of	O
apparent	O
molecular	O
mass	O
16	O
kDa	O
displayed	O
several	O
properties	O
,	O
including	O
ability	O
to	O
bind	O
45Ca2+	O
,	O
that	O
are	O
characteristic	O
of	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
of	O
mammalian	B-GENE
calcineurin	I-GENE
and	O
was	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
bovine	B-GENE
calcineurin	I-GENE
.	O

Escalation	O
to	O
180	O
mg	O
/	O
m2	O
was	O
to	O
be	O
carried	O
out	O
if	O
white	O
blood	O
cell	O
nadir	O
count	O
was	O
>	O
2	O
.	O
0	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
and	O
platelet	O
nadir	O
count	O
was	O
>	O
75	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
.	O

Change	O
in	O
plasma	B-GENE
cystyl	I-GENE
aminopeptidase	I-GENE
(	O
oxytocinase	B-GENE
)	O
between	O
30-34	O
weeks'	O
gestation	O
as	O
a	O
predictor	O
of	O
pregnancy-induced	O
hypertension	O
.	O

Preflight	O
,	O
inflight	O
,	O
and	O
postflight	O
exercise	O
response	O
tests	O
were	O
conducted	O
on	O
the	O
astronauts	O
of	O
the	O
second	O
Skylab	O
mission	O
(	O
Skylab	O
3	O
)	O
as	O
part	O
of	O
an	O
evaluation	O
of	O
physiological	O
adaptation	O
to	O
long-term	O
weightlessness	O
.	O

When	O
data	O
were	O
expressed	O
in	O
a	O
cumulative	O
manner	O
,	O
the	O
response	O
to	O
intravenous	O
adenosine	O
3	O
mg	O
,	O
6	O
mg	O
,	O
9	O
mg	O
and	O
12	O
mg	O
in	O
the	O
24	O
episodes	O
of	O
PSVT	O
were	O
5	O
episodes	O
(	O
21%	O
)	O
,	O
16	O
episodes	O
(	O
67%	O
)	O
,	O
20	O
episodes	O
(	O
83%	O
)	O
and	O
20	O
episodes	O
(	O
83%	O
)	O
respectively	O
.	O

Letter	O
:	O
Aryl	B-GENE
hydrocarbon	I-GENE
hydroxylase	I-GENE
and	O
smoking	O
.	O

Measurements	O
of	O
activity	O
with	O
the	O
radioprotective	O
chamber	O
VA-K-254	O
of	O
the	O
osimeter	O
VA-J18	O
.	O

Serial	O
followup	O
strength	O
data	O
for	O
2	O
patients	O
were	O
compared	O
to	O
change	O
in	O
creatinine	B-GENE
kinase	I-GENE
(	O
CK	B-GENE
)	O
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
forced	O
overexpression	O
of	O
the	O
wild	O
type	O
,	O
but	O
not	O
the	O
kinase-inactivated	O
mutant	O
of	O
nm23H1	B-GENE
,	O
converted	O
the	O
GDP-bound	O
forms	O
of	O
Rac1	B-GENE
,	O
Cdc42	B-GENE
,	O
and	O
RhoA	B-GENE
to	O
their	O
GTP-bound	O
forms	O
in	O
vitro	O
by	O
its	O
nucleoside	B-GENE
diphosphate	I-GENE
kinase	I-GENE
activity	O
,	O
but	O
nm23H1	B-GENE
alone	O
apparently	O
did	O
not	O
produce	O
the	O
GTP-bound	O
form	O
of	O
these	O
GTPases	B-GENE
in	O
vivo	O
.	O

Mobility	O
and	O
supershift	O
assays	O
demonstrated	O
that	O
upstream	B-GENE
stimulatory	I-GENE
factor	I-GENE
(	O
USF	B-GENE
)	O
and	O
Sp1	B-GENE
bind	O
to	O
the	O
former	O
elements	O
and	O
competition	O
experiments	O
confirmed	O
that	O
CREB	B-GENE
/	I-GENE
ATF	I-GENE
and	O
AP-1	B-GENE
bind	O
to	O
the	O
CRE	B-GENE
/	I-GENE
TRE	I-GENE
element	I-GENE
.	O

The	O
results	O
showed	O
that	O
MIP	O
,	O
MMIF	O
,	O
FIC	O
,	O
Wimax	O
,	O
P0	O
.	O
1	O
and	O
minute	O
ventilation	O
(	O
Vr	O
)	O
were	O
significantly	O
increased	O
after	O
administration	O
of	O
methylphenidatum	O
and	O
aminophylline	O
.	O

During	O
BH	O
the	O
ventilator	O
was	O
disconnected	O
and	O
a	O
bias	O
flow	O
of	O
50%	O
O2	O
at	O
4-5	O
l	O
/	O
min	O
was	O
delivered	O
through	O
the	O
side	O
ports	O
of	O
a	O
small	O
catheter	O
whose	O
tip	O
was	O
positioned	O
1	O
cm	O
cephalad	O
of	O
the	O
carina	O
.	O

Growth	B-GENE
factor	I-GENE
stimulation	O
of	O
cells	O
causes	O
the	O
phosphorylation	O
of	O
the	O
c-Myc	B-GENE
transcriptional	I-GENE
activation	I-GENE
domain	I-GENE
at	O
Ser62	O
within	O
a	O
proline-rich	O
region	O
that	O
is	O
highly	O
conserved	O
among	O
members	O
of	O
the	O
Myc	B-GENE
family	I-GENE
(	O
Alvarez	O
,	O
E	O
.	O
,	O
Northwood	O
,	O
I	O
.	O
C	O
.	O
,	O
Gonzalez	O
,	O
F	O
.	O

In	O
this	O
report	O
this	O
technique	O
was	O
applied	O
to	O
human	O
breast	O
carcinoma	O
MDA-MB231	O
cells	O
overexpressing	O
human	B-GENE
MPG	I-GENE
in	O
order	O
to	O
assess	O
whether	O
up-regulation	O
of	O
the	O
initial	O
step	O
in	O
BER	O
alters	O
the	O
activity	O
of	O
selected	O
other	O
BER	O
(	O
hOGG1	B-GENE
and	O
APE	B-GENE
/	I-GENE
ref-1	I-GENE
)	O
or	O
direct	O
reversal	O
(	O
MGMT	B-GENE
)	O
repair	O
activities	O
.	O

When	O
BFDS	O
was	O
taken	O
as	O
the	O
reference	O
,	O
W	O
/	O
A	O
Z	O
scores	O
showed	O
consistent	O
positive	O
increments	O
,	O
from	O
birth	O
in	O
girls	O
and	O
1	O
mo	O
in	O
boys	O
.	O

Plasmids	O
for	O
the	O
cloning	O
and	O
expression	O
of	O
full-length	O
double-stranded	O
cDNAs	O
under	O
control	O
of	O
the	O
SV40	B-GENE
early	I-GENE
or	I-GENE
late	I-GENE
gene	I-GENE
promoter	I-GENE
.	O

Regarding	O
"the	O
relation	O
between	O
sexual	O
orientation	O
and	O
penile	O
size	O
,	O
"	O
by	O
A	O
.	O

A	O
total	O
of	O
281	O
patients	O
were	O
divided	O
into	O
groups	O
according	O
to	O
their	O
clinical	O
diagnosis	O
and	O
were	O
examined	O
using	O
capnography	O
,	O
spirometry	O
and	O
blood-gas	O
analysis	O
.	O

A	O
substantial	O
fraction	O
of	O
Cbl	B-GENE
was	O
constitutively	O
associated	O
with	O
Grb2	B-GENE
and	O
this	O
interaction	O
was	O
mediated	O
by	O
Grb2	B-GENE
SH3	I-GENE
domains	I-GENE
.	O

The	O
AGM	B-GENE
and	I-GENE
NIH	I-GENE
/	I-GENE
Swiss	I-GENE
mouse	I-GENE
CCR5	I-GENE
proteins	I-GENE
are	O
97	O
.	O
7	O
to	O
98	O
.	O
3%	O
and	O
79	O
.	O
8%	O
identical	O
to	O
the	O
human	O
protein	O
,	O
respectively	O
.	O

Mutagenesis	O
of	O
the	O
CDE	B-GENE
/	I-GENE
CHR	I-GENE
elements	I-GENE
and	O
Sp1	B-GENE
sites	I-GENE
in	O
this	O
region	O
,	O
alone	O
or	O
in	O
combination	O
,	O
reduced	O
transcriptional	O
activity	O
by	O
40-60%	O
in	O
asynchronously	O
growing	O
cells	O
and	O
abolished	O
cell	O
cycle	O
periodicity	O
in	O
G2-M-synchronized	O
cells	O
.	O

All	O
our	O
patients	O
had	O
polyps	O
,	O
23	O
(	O
54%	O
)	O
had	O
asthma	O
,	O
12	O
(	O
27%	O
)	O
had	O
aspirin	O
sensitivity	O
,	O
20	O
(	O
65%	O
)	O
had	O
eosinophilia	O
,	O
and	O
9	O
(	O
69%	O
)	O
had	O
increased	O
total	O
IgE	B-GENE
levels	O
.	O

Differential	O
activation	O
of	O
the	O
extracellular	B-GENE
signal-regulated	I-GENE
kinase	I-GENE
,	O
Jun	B-GENE
kinase	I-GENE
and	O
Janus	B-GENE
kinase-Stat	I-GENE
pathways	O
by	O
oncostatin	O
M	O
and	O
basic	B-GENE
fibroblast	I-GENE
growth	I-GENE
factor	I-GENE
in	O
AIDS-derived	O
Kaposi's	O
sarcoma	O
cells	O
.	O

By	O
contrast	O
,	O
PvirE	B-GENE
or	O
Plac	B-GENE
promoter	I-GENE
constructs	I-GENE
yielded	O
functional	O
VirE2	B-GENE
only	O
if	O
virE1	B-GENE
was	O
coexpressed	O
with	O
virE2	B-GENE
.	O

PURPOSE	O
:	O
To	O
introduce	O
an	O
image	O
analysis	O
of	O
the	O
cornea	O
in	O
photorefractive	O
keratectomy	O
(	O
PRK	O
)	O
for	O
preoperative	O
and	O
early	O
postoperative	O
determination	O
of	O
changes	O
in	O
the	O
condition	O
of	O
the	O
cornea	O
.	O

Normal	O
alpha1	B-GENE
(	I-GENE
I	I-GENE
)	I-GENE
collagen	I-GENE
mRNA	I-GENE
showed	O
no	O
significant	O
reduction	O
when	O
AR	O
or	O
IR	O
was	O
expressed	O
from	O
the	O
pHbetaAPr-1-neo	O
vector	O
and	O
a	O
small	O
(	O
10-20%	O
)	O
but	O
significant	O
reduction	O
when	O
either	O
ribozyme	B-GENE
was	O
expressed	O
from	O
the	O
pCI	O
.	O
neo	O
vector	O
.	O

Patients	O
with	O
apparently	O
minor	O
CT	O
abnormalities	O
may	O
have	O
significant	O
epidural	O
disease	O
.	O

Diagnosis	O
:	O
progressive	O
multifocal	O
leukoencephalopathy	O
.	O

Transformed	O
cell	O
lines	O
expressing	O
solely	O
E1a	B-GENE
or	O
E1a	B-GENE
and	O
E1b	B-GENE
gene	I-GENE
products	I-GENE
derived	O
from	O
these	O
viruses	O
display	O
enhanced	O
anchorage-independent	O
growth	O
at	O
37	O
degrees	O
C	O
versus	O
32	O
degrees	O
C	O
and	O
display	O
a	O
cytoskeletal	O
architecture	O
resembling	O
untransformed	O
fibroblastic	O
CREF	O
cells	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
S	O
.	O
aureus	O
peptide	O
carrying	O
the	O
phosphoryl	O
group	O
was	O
found	O
to	O
be	O
Gln-Val-Val-Ser-Thr-Phe-Met-Gly-Asn-Gly-Leu-Ala-Ile-Pro-His-Gly-Thr-Asp-	B-GENE
Asp	I-GENE
.	O

PKC-gamma	B-GENE
,	O
which	O
is	O
not	O
present	O
in	O
keratinocytes	O
,	O
also	O
induces	O
involucrin	B-GENE
gene	I-GENE
expression	O
in	O
a	O
TPA-independent	O
manner	O
,	O
when	O
introduced	O
into	O
SVHK	O
cells	O
.	O

The	O
exogenous	O
fos	B-GENE
gene	I-GENE
was	O
rapidly	O
induced	O
to	O
maximal	O
levels	O
within	O
1-2	O
hr	O
of	O
estrogen	O
addition	O
.	O

In	O
addition	O
,	O
expected	O
decreases	O
in	O
ATIC	B-GENE
enzymatic	O
function	O
in	O
ATIC-ALK-containing	O
lymphomas	O
may	O
render	O
these	O
tumors	O
more	O
sensitive	O
to	O
antifolate	O
drugs	O
such	O
as	O
methotrexate	O
.	O

Examination	O
of	O
ANCA	O
is	O
not	O
only	O
a	O
significant	O
contribution	O
towards	O
a	O
more	O
accurate	O
diagnosis	O
of	O
renal	O
vasculitis	O
,	O
but	O
also	O
an	O
indicator	O
of	O
the	O
activity	O
of	O
the	O
disease	O
and	O
thus	O
of	O
the	O
effectiveness	O
of	O
immunosuppressive	O
treatment	O
.	O

NaeI	B-GENE
,	O
a	O
novel	O
DNA	B-GENE
endonuclease	I-GENE
,	O
shows	O
topoisomerase	B-GENE
and	O
recombinase	B-GENE
activities	O
when	O
a	O
Lys	O
residue	O
is	O
substituted	O
for	O
Leu	O
43	O
.	O

Expression	O
of	O
class	B-GENE
IV	I-GENE
ADH	I-GENE
mRNA	I-GENE
was	O
detected	O
in	O
human	O
stomach	O
but	O
not	O
liver	O
.	O

Within	O
the	O
3'	O
terminal	O
50	O
nucleotides	O
,	O
the	O
mouse	B-GENE
mt	I-GENE
12S	I-GENE
rRNA	I-GENE
contains	O
a	O
potential	O
10	O
bp	O
hairpin	O
structure	O
and	O
a	O
sequence	O
of	O
15	O
consecutive	O
nucleotides	O
common	O
to	O
the	O
RNA	O
of	O
the	O
small	O
ribosomal	O
subunit	O
in	O
all	O
systems	O
,	O
but	O
does	O
not	O
contain	O
the	O
mRNA	O
binding	O
site	O
(	O
ACCUCC	B-GENE
)	O
found	O
in	O
E	O
.	O
coli	O
and	O
corn	O
chloroplast	O
rRNAs	O
.	O

The	O
second	O
goal	O
was	O
to	O
ascertain	O
the	O
somatotopic	O
arrangement	O
of	O
the	O
GPi	O
in	O
PD	O
.	O

In	O
addition	O
to	O
its	O
effect	O
in	O
augmenting	O
the	O
neutrophil	O
response	O
to	O
eccentric	O
exercise	O
,	O
vitamin	O
E	O
causes	O
a	O
greater	O
increase	O
in	O
circulating	O
creatine	B-GENE
kinase	I-GENE
activity	O
,	O
perhaps	O
indicating	O
increased	O
skeletal	O
muscle	O
repair	O
.	O

The	O
NR2	O
hybrid	O
is	O
a	O
powerful	O
tool	O
for	O
the	O
mapping	O
of	O
new	O
probes	O
of	O
this	O
region	O
,	O
as	O
well	O
as	O
for	O
obtaining	O
new	O
informative	O
probes	O
specific	O
for	O
the	O
deletion	O
by	O
subtractive	O
cloning	O
of	O
the	O
region	O
.	O

The	O
sequence	O
similarity	O
has	O
suggested	O
that	O
SCG10	B-GENE
and	O
stathmin	B-GENE
have	O
been	O
derived	O
from	O
structurally	O
and	O
evolutionarily	O
related	O
genes	O
.	O

PSI-G	B-GENE
and	O
PSI-K	B-GENE
probably	O
have	O
evolved	O
from	O
a	O
gene	O
duplication	O
of	O
an	O
ancestral	O
gene	O
.	O

Each	O
sample	O
was	O
analysed	O
as	O
soon	O
as	O
possible	O
,	O
and	O
repeated	O
15	O
,	O
30	O
,	O
60	O
and	O
120	O
min	O
after	O
sampling	O
.	O

Chimaeric	B-GENE
VP16-E2	I-GENE
molecules	I-GENE
suggest	O
that	O
the	O
epithelial	O
specific	O
transcriptional	O
activation	O
of	O
the	O
BPV-4	O
LCR	O
promoter	O
is	O
mediated	O
by	O
the	O
E2	B-GENE
transactivation	I-GENE
domain	I-GENE
.	O

The	O
pigment	O
intensity	O
of	O
both	O
melanized	O
colonies	O
and	O
appressoria	O
of	O
CAL	O
transformants	O
was	O
weaker	O
than	O
that	O
of	O
the	O
wild	O
type	O
.	O

Mutations	O
in	O
the	O
alpha	B-GENE
and	I-GENE
sigma-70	I-GENE
subunits	I-GENE
of	I-GENE
RNA	I-GENE
polymerase	I-GENE
affect	O
expression	O
of	O
the	O
mer	B-GENE
operon	I-GENE
.	O

Heterogeneity	O
of	O
human	B-GENE
serum	I-GENE
albumin	I-GENE
.	O

Total	O
body	O
irradiation	O
was	O
delivered	O
according	O
to	O
a	O
hyperfractionated	O
scheme	O
of	O
12	O
fractions	O
given	O
three	O
per	O
day	O
5	O
hr	O
apart	O
for	O
4	O
days	O
.	O

This	O
300	O
bp	O
5'-upstream	O
sequence	O
of	O
K3	B-GENE
keratin	I-GENE
gene	I-GENE
,	O
which	O
can	O
function	O
in	O
vitro	O
as	O
a	O
keratinocyte-specific	O
promoter	O
,	O
contains	O
two	O
clusters	O
of	O
partially	O
overlapping	O
motifs	O
,	O
one	O
with	O
an	O
NFkB	B-GENE
consensus	O
sequence	O
and	O
another	O
with	O
a	O
GC	O
box	O
.	O

The	O
effect	O
of	O
feeding	O
patterns	O
on	O
fat	O
deposition	O
in	O
mice	O
.	O

A	O
mutant	O
form	O
of	O
Vps1p	B-GENE
lacking	O
the	O
entire	O
GTP-binding	O
domain	O
interfered	O
with	O
vacuolar	O
protein	O
sorting	O
in	O
wild-type	O
cells	O
.	O

Both	O
proprioceptive	O
and	O
electroreceptive	O
units	O
showed	O
a	O
progression	O
of	O
receptive	O
fields	O
from	O
anterior	O
to	O
posterior	O
body	O
in	O
the	O
rostral	O
to	O
caudal	O
direction	O
along	O
the	O
length	O
of	O
DGR	O
.	O

Molecular	O
identification	O
of	O
smg-4	B-GENE
,	O
required	O
for	O
mRNA	O
surveillance	O
in	O
C	O
.	O
elegans	O
.	O

Of	O
these	O
patients	O
,	O
46	O
,	O
164	O
were	O
placed	O
on	O
a	O
waiting	O
list	O
for	O
transplantation	O
,	O
23	O
,	O
275	O
of	O
whom	O
received	O
a	O
first	O
cadaveric	O
transplant	O
between	O
1991	O
and	O
1997	O
.	O

Radiotherapy	O
and	O
early	O
orchiectomy	O
in	O
stage	O
D1	O
prostatic	O
carcinoma	O
.	O

Interestingly	O
,	O
the	O
RNA	O
sequences	O
selected	O
by	O
the	O
mutated	O
zinc	B-GENE
knuckle	I-GENE
9G8	I-GENE
variant	I-GENE
are	O
efficiently	O
recognized	O
by	O
SRp20	B-GENE
,	O
in	O
agreement	O
with	O
the	O
fact	O
that	O
the	O
RBD	O
of	O
9G8	B-GENE
and	O
SRp20	B-GENE
are	O
similar	O
.	O

Krox-20	B-GENE
,	O
a	O
zinc	O
finger	O
gene	O
,	O
has	O
a	O
highly	O
conserved	O
pattern	O
of	O
expression	O
in	O
r3	B-GENE
and	O
r5	B-GENE
and	O
is	O
functionally	O
required	O
for	O
their	O
maintenance	O
in	O
mouse	O
embryos	O
.	O

These	O
results	O
illustrate	O
an	O
important	O
role	O
for	O
La	B-GENE
in	O
RNA	O
production	O
by	O
demonstrating	O
its	O
ability	O
to	O
clear	O
the	O
termination	O
sites	O
of	O
class	B-GENE
III	I-GENE
templates	I-GENE
,	O
thereby	O
promoting	O
efficient	O
use	O
of	O
transcription	O
complexes	O
by	O
pol	B-GENE
III	I-GENE
.	O

The	O
cytosolic	O
glutathione	B-GENE
S-transferases	I-GENE
(	O
GSTs	B-GENE
,	O
EC	O
2	O
.	O
5	O
.	O
1	O
.	O
18	O
)	O
are	O
a	O
superfamily	O
of	O
dimeric	O
isoenzymes	O
which	O
catalyze	O
the	O
conjugation	O
of	O
electrophilic	O
substrates	O
with	O
glutathione	O
.	O

The	O
patient	O
had	O
developed	O
left-sided	O
low-frequency	O
tremor	O
and	O
hemidystonia	O
after	O
a	O
severe	O
head	O
trauma	O
sustained	O
at	O
15	O
years	O
of	O
age	O
.	O

Full	O
thyroid	O
function	O
testing	O
was	O
performed	O
on	O
600	O
randomly	O
selected	O
samples	O
with	O
normal	O
TSH	B-GENE
values	O
and	O
also	O
on	O
subjects	O
with	O
abnormal	O
TSH	B-GENE
levels	O
.	O

17	O
.	O
5%	O
of	O
cycles	O
)	O
.	O

The	O
mei4+	B-GENE
gene	I-GENE
of	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
was	O
cloned	O
by	O
functional	O
complementation	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
two	O
genes	B-GENE
encoding	I-GENE
gp138	I-GENE
,	O
a	O
cell	O
surface	O
glycoprotein	O
involved	O
in	O
the	O
sexual	O
cell	O
fusion	O
of	O
Dictyostelium	O
discoideum	O
.	O

Routinely	O
collected	O
,	O
processed	O
and	O
stored	O
breast	O
cancer	O
tissue	O
blocks	O
recovered	O
from	O
the	O
archives	O
of	O
the	O
Pathology	O
laboratory	O
in	O
Dar	O
es	O
Salaam	O
after	O
storage	O
of	O
up	O
to	O
3	O
years	O
were	O
analysed	O
by	O
a	O
flow	O
cytometry	O
for	O
DNA	O
ploidy	O
and	O
S-phase	O
fraction	O
.	O

The	O
daily	O
administration	O
of	O
betamethasone	O
for	O
three	O
weeks	O
markedly	O
reduced	O
the	O
absorption	O
of	O
calcium	O
and	O
phosphate	O
as	O
well	O
as	O
the	O
growth	O
rate	O
.	O

Overall	O
prevalences	O
of	O
antibody	O
were	O
70	O
per	O
cent	O
in	O
cattle	O
,	O
67	O
per	O
cent	O
in	O
sheep	O
and	O
76	O
per	O
cent	O
in	O
goats	O
as	O
assessed	O
by	O
an	O
immunodiffusion	O
test	O
.	O

So	O
far	O
15	O
children	O
have	O
been	O
studied	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
metaphase	O
spreads	O
of	O
chromosome	O
8	O
,	O
containing	O
hybrid	O
cell	O
line	O
706-B6	O
clone	O
17	O
(	O
CL-17	O
)	O
with	O
cosmid	O
c101F1	O
,	O
placed	O
the	O
9804	B-GENE
gene	I-GENE
close	O
to	O
the	O
telomere	O
at	O
8q24	O
.	O
3	O
.	O

Typical	O
and	O
atypical	O
clinical	O
features	O
of	O
this	O
lacrimal	O
sac	O
cyst	O
are	O
emphasized	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
activated	O
GH	B-GENE
receptor	I-GENE
can	O
stimulate	O
Stat1	B-GENE
,	O
a	O
cytoplasmic	O
transcription	O
factor	O
that	O
becomes	O
tyrosine	O
phosphorylated	O
and	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
can	O
interact	O
with	O
specific	O
DNA	O
sequences	O
to	O
modulate	O
gene	O
expression	O
.	O

Different	O
sequence	O
elements	O
of	O
both	O
the	O
retroviral	O
vectors	O
and	O
the	O
c-myc	B-GENE
gene	I-GENE
recombined	O
during	O
genesis	O
of	O
highly	O
oncogenic	O
retroviruses	O
CMII	O
,	O
MC29	O
,	O
or	O
MH2	O
.	O

The	O
close	O
proximity	O
of	O
the	O
two	O
neuropeptide	B-GENE
Y	I-GENE
receptor	I-GENE
genes	I-GENE
suggests	O
that	O
they	O
have	O
evolved	O
from	O
a	O
gene	O
duplication	O
event	O
with	O
the	O
small	O
intron	O
interrupting	O
the	O
coding	O
sequence	O
of	O
the	O
y1	B-GENE
gene	I-GENE
being	O
converted	O
into	O
a	O
functional	O
sequence	O
within	O
the	O
y5	B-GENE
gene	I-GENE
,	O
while	O
the	O
reverse	O
complementary	O
sequence	O
was	O
utilized	O
as	O
an	O
alternatively	O
spliced	O
5'	O
exon	O
for	O
the	O
y1	B-GENE
gene	I-GENE
.	O

Effect	O
of	O
2-	O
(	O
p-chlorophenyl	O
)	O
cyclopropylamine	O
on	O
5-hydroxyindole	O
concentration	O
and	O
monoamine	B-GENE
oxidase	I-GENE
activity	O
in	O
rat	O
brain	O
.	O

Mutations	O
affecting	O
only	O
CD4	B-GENE
regulation	O
mapped	O
to	O
residues	O
previously	O
shown	O
to	O
mediate	O
the	O
binding	O
of	O
Nef	B-GENE
to	O
this	O
receptor	O
,	O
such	O
as	O
W57	O
and	O
L58	O
,	O
as	O
well	O
as	O
to	O
an	O
AP-recruiting	B-GENE
dileucine	I-GENE
motif	I-GENE
and	O
to	O
an	O
acidic	O
dipeptide	O
in	O
the	O
C-terminal	O
region	O
of	O
the	O
protein	O
.	O

Furthermore	O
,	O
we	O
notice	O
two	O
potential	O
consensus	O
motifs	O
which	O
are	O
also	O
found	O
in	O
corresponding	O
positions	O
in	O
the	O
genes	O
for	O
the	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
and	O
the	O
68-kDa	B-GENE
neurofilament	I-GENE
protein	I-GENE
.	O

Pathogens	O
(	O
Staphylococcus	O
aureus	O
or	O
Gram-negative	O
bacilli	O
)	O
were	O
isolated	O
from	O
only	O
one	O
member	O
of	O
staff	O
in	O
small	O
numbers	O
and	O
irregularly	O
and	O
rarely	O
in	O
large	O
numbers	O
from	O
patients	O
.	O

Mg-chelatase	B-GENE
of	O
tobacco	O
:	O
identification	O
of	O
a	O
Chl	B-GENE
D	I-GENE
cDNA	I-GENE
sequence	I-GENE
encoding	O
a	O
third	O
subunit	O
,	O
analysis	O
of	O
the	O
interaction	O
of	O
the	O
three	O
subunits	O
with	O
the	O
yeast	O
two-hybrid	O
system	O
,	O
and	O
reconstitution	O
of	O
the	O
enzyme	O
activity	O
by	O
co-expression	O
of	O
recombinant	B-GENE
CHL	I-GENE
D	I-GENE
,	O
CHL	B-GENE
H	I-GENE
and	O
CHL	B-GENE
I	I-GENE
.	O

The	O
nature	O
of	O
the	O
process	O
formed	O
by	O
the	O
successive	O
occurrences	O
of	O
this	O
arrhythmia	O
was	O
studied	O
in	O
8	O
patients	O
with	O
a	O
history	O
of	O
symptomatic	O
paroxysmal	O
AF	O
.	O

Interferon-alpha-induced	O
gene	O
expression	O
:	O
evidence	O
for	O
a	O
selective	O
effect	O
of	O
ouabain	O
on	O
activation	O
of	O
the	O
ISGF3	B-GENE
transcription	I-GENE
complex	I-GENE
.	O

Molecular	O
and	O
genetic	O
analysis	O
of	O
the	O
yeast	B-GENE
early	I-GENE
meiotic	I-GENE
recombination	I-GENE
genes	I-GENE
REC102	I-GENE
and	O
REC107	B-GENE
/	I-GENE
MER2	I-GENE
.	O

Antibodies	O
made	O
against	O
fusion	O
protein	O
produced	O
by	O
the	O
DP1A	B-GENE
clone	O
reacted	O
specifically	O
with	O
DP-I	B-GENE
and	I-GENE
-II	I-GENE
on	O
immunoblots	O
.	O

When	O
voltage-operated	O
Ca2+	O
channels	O
(	O
VOC	O
)	O
were	O
blocked	O
by	O
nifedipine	O
,	O
midazolam	O
,	O
in	O
concentrations	O
more	O
than	O
1	O
microM	O
,	O
attenuated	O
both	O
phasic	O
and	O
tonic	O
responses	O
.	O

Binding	O
of	O
U2	B-GENE
small	I-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
was	O
partially	O
inhibited	O
.	O

Hematology	O
problem	O
of	O
the	O
month	O
:	O
band	O
or	O
seg	O
?	O

Heme	B-GENE
oxygenase	I-GENE
1	I-GENE
is	O
an	O
essential	O
enzyme	O
in	O
heme	O
catabolism	O
that	O
cleaves	O
heme	O
to	O
form	O
biliverdin	O
,	O
iron	O
,	O
and	O
carbon	O
monoxide	O
.	O

The	O
characteristic	O
feature	O
of	O
liver	O
and	O
spleen	O
MP	O
function	O
in	O
patients	O
with	O
VHA	O
associated	O
with	O
HBsAg	B-GENE
carriership	O
consisted	O
in	O
the	O
lack	O
of	O
the	O
compensatory	O
reaction	O
on	O
the	O
part	O
of	O
spleen	O
MP	O
,	O
which	O
was	O
likely	O
to	O
be	O
connected	O
with	O
overstrain	O
of	O
long	O
standing	O
and	O
depletion	O
of	O
the	O
MP	O
system	O
due	O
to	O
permanent	O
antigenic	O
stimulation	O
of	O
HBsAg	B-GENE
.	O

Since	O
the	O
RINX	B-GENE
gene	I-GENE
is	O
likely	O
an	O
ortholog	O
of	O
the	O
goldfish	B-GENE
Vsx1	I-GENE
gene	I-GENE
,	O
it	O
has	O
been	O
named	O
VSX1	B-GENE
by	O
the	O
Human	O
Gene	O
Nomenclature	O
Committee	O
.	O

The	O
hepatitis	B-GENE
A	I-GENE
virus	I-GENE
antibody	I-GENE
(	O
anti-HAV	B-GENE
)	O
in	O
chronic	O
diffuse	O
liver	O
diseases	O
.	O

Nature	O
398	O
,	O
828-830	O
)	O
that	O
the	O
amino	O
acid	O
sequences	O
of	O
peptide	O
fragments	O
obtained	O
from	O
a	O
polypeptide	O
found	O
in	O
a	O
complex	O
of	O
proteins	O
that	O
alters	O
chromatin	O
structure	O
(	O
ARC	B-GENE
)	O
are	O
identical	O
to	O
portions	O
of	O
the	O
deduced	O
open	O
reading	O
frame	O
of	O
TIG-1	B-GENE
mRNA	I-GENE
.	O

Diazepam	O
(	O
3	O
mg	O
/	O
kg	O
)	O
generalized	O
to	O
Ro	O
11-6896	O
whereas	O
the	O
structurally	O
related	O
Ro	O
5-4864	O
(	O
3	O
mg	O
/	O
kg	O
and	O
30	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

Additional	O
factors	O
such	O
as	O
advanced	O
age	O
,	O
concomitant	O
use	O
of	O
corticosteroids	O
or	O
anticoagulants	O
,	O
prior	O
ulcer	O
complications	O
and	O
co-morbid	O
diseases	O
may	O
further	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

The	O
magnitude	O
of	O
the	O
early	O
response	O
was	O
241	O
+	O
/	O
-	O
51%	O
in	O
A	O
(	O
%	O
baseline	O
RL	O
;	O
mean	O
+	O
/	O
-	O
SE	O
)	O
,	O
and	O
significantly	O
less	O
in	O
B	O
(	O
119	O
+	O
/	O
-	O
7%	O
)	O
and	O
C	O
(	O
131	O
+	O
/	O
-	O
16%	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
the	O
eight	O
patients	O
with	O
persistent	O
generalized	O
lymph-adenopathy	O
(	O
PGL	O
)	O
and	O
nontender	O
,	O
nonenlarging	O
nodes	O
,	O
pathologic	O
analysis	O
revealed	O
lymphoid	O
hyperplasia	O
.	O

We	O
conclude	O
that	O
(	O
a	O
)	O
the	O
likelihood	O
of	O
detecting	O
carcinoma	O
or	O
atypical	O
hyperplasia	O
exclusively	O
in	O
the	O
adipose	O
tissue	O
component	O
of	O
grossly	O
benign	O
breast	O
biopsies	O
is	O
extremely	O
low	O
,	O
and	O
(	O
b	O
)	O
a	O
possible	O
cost-effective	O
method	O
of	O
sampling	O
grossly	O
benign	O
breast	O
biopsies	O
consists	O
of	O
initially	O
submitting	O
a	O
maximum	O
of	O
10	O
blocks	O
of	O
fibrous	O
parenchyma	O
for	O
each	O
case	O
,	O
then	O
examining	O
the	O
remaining	O
tissue	O
histologically	O
only	O
if	O
carcinoma	O
or	O
atypical	O
hyperplasia	O
is	O
found	O
among	O
these	O
blocks	O
.	O

Simian	O
parainfluenza	O
virus	O
5	O
(	O
SV5	O
)	O
is	O
a	O
prototype	O
of	O
the	O
Paramyxoviridae	O
family	O
of	O
nonsegmented	O
negative-sense	O
RNA	O
viruses	O
.	O

Nephrotoxicity	O
after	O
orthotopic	O
liver	O
transplantation	O
in	O
cyclosporin	O
A	O
and	O
FK	O
506-treated	O
patients	O
.	O

Despite	O
considerable	O
research	O
,	O
an	O
explanation	O
of	O
this	O
effect	O
has	O
been	O
elusive	O
.	O

The	O
standard	O
principles	O
of	O
surgical	O
management	O
must	O
be	O
adhered	O
to	O
when	O
using	O
Sandostatin	O
to	O
treat	O
patients	O
with	O
these	O
disorders	O
.	O

Polycythemia-1973	O
.	O

From	O
two	O
inhibitor	O
scaffolds	O
,	O
we	O
have	O
identified	O
potent	O
and	O
selective	O
inhibitors	O
for	O
sensitized	O
kinases	B-GENE
from	O
five	O
distinct	O
subfamilies	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
study	O
the	O
morphological	O
characteristics	O
of	O
the	O
fibrous	O
tissue	O
capsule	O
resulting	O
from	O
the	O
implantation	O
of	O
aluminum	O
calcium	O
phosphate	O
(	O
ALCAP	O
)	O
and	O
hydroxyapetite	O
(	O
HA	O
)	O
bioceramics	O
.	O

Biol	O
.	O

A	O
distinct	O
staining	O
pattern	O
for	O
the	O
N-utrophin	B-GENE
was	O
not	O
detectable	O
,	O
although	O
it	O
was	O
expected	O
to	O
localise	O
at	O
the	O
actin	B-GENE
stress	O
fibers	O
.	O

The	O
sequence	O
of	O
the	O
repressor	O
locus	O
,	O
c	O
,	O
of	O
the	O
Streptomyces	O
temperate	O
phage	O
,	O
phi	O
C31	O
,	O
was	O
shown	O
previously	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
74	O
kDa	O
protein	O
.	O

Introductory	O
remarks	O
.	O

Accumulated	O
evidence	O
indicates	O
that	O
,	O
upon	O
stimulation	O
with	O
interferon-gamma	B-GENE
(	O
IFN-gamma	B-GENE
)	O
,	O
three	O
beta-type	O
subunits	O
,	O
designated	O
LMP2	B-GENE
,	O
LMP7	B-GENE
,	O
and	O
PSMB10	B-GENE
,	O
are	O
incorporated	O
into	O
the	O
20S	B-GENE
proteasome	I-GENE
by	O
displacing	O
the	O
housekeeping	O
beta-type	O
subunits	O
designated	O
PSMB6	B-GENE
,	O
PSMB5	B-GENE
,	O
and	O
PSMB7	B-GENE
,	O
respectively	O
.	O

The	O
addition	O
of	O
zidovudine	O
did	O
not	O
influence	O
this	O
transfer	O
.	O

The	O
Dax-1	B-GENE
gene	I-GENE
encodes	O
a	O
protein	O
that	O
is	O
structurally	O
related	O
to	O
members	O
of	O
the	O
orphan	B-GENE
nuclear	I-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

Human	B-GENE
AP-2rep	I-GENE
repressed	O
both	O
reporter	O
expression	O
from	O
a	O
transiently	O
transfected	O
AP-2alpha	B-GENE
promoter	I-GENE
and	O
the	O
endogenous	O
AP-2alpha	B-GENE
gene	I-GENE
and	O
inversely	O
was	O
negatively	O
regulated	O
by	O
AP-2alpha	B-GENE
.	O

The	O
radial	O
forearm	O
flap	O
is	O
used	O
most	O
commonly	O
,	O
however	O
the	O
lateral	O
arm	O
flap	O
may	O
be	O
the	O
flap	O
of	O
choice	O
in	O
certain	O
situations	O
.	O

Similarly	O
,	O
the	O
N-terminal	O
cytoplasmic	O
domain	O
of	O
the	O
latent	B-GENE
membrane	I-GENE
protein	I-GENE
2A	I-GENE
(	O
LMP2A	B-GENE
)	O
of	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
contains	O
a	O
single	O
copy	O
of	O
the	O
Tyr-X-X-Leu	B-GENE
/	I-GENE
Ile-containing	I-GENE
motif	I-GENE
which	O
could	O
play	O
a	O
critical	O
role	O
in	O
B	O
cell	O
transformation	O
.	O

The	O
N-terminal	O
small	O
segment	O
of	O
yeast	B-GENE
TAF145	I-GENE
(	O
yTAF145	B-GENE
)	O
binds	O
to	O
TBP	B-GENE
and	O
thereby	O
inhibits	O
TBP	B-GENE
function	O
.	O

VEGF	B-GENE
promoter	I-GENE
activity	O
in	O
transient	O
transfections	O
was	O
decreased	O
by	O
either	O
pharmacological	O
or	O
genetic	O
inhibition	O
of	O
EGFR	B-GENE
,	O
Ras	B-GENE
,	O
or	O
phosphatidylinositol	B-GENE
3'-kinase	I-GENE
[	B-GENE
PI	I-GENE
(	I-GENE
3	I-GENE
)	I-GENE
kinase	I-GENE
]	I-GENE
.	O

A	O
murine	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
showing	O
homology	O
with	O
erythropoietin	B-GENE
receptor	I-GENE
(	O
EPOR	B-GENE
)	O
was	O
identified	O
in	O
the	O
EST	O
database	O
.	O

The	O
Schizosaccharomyces	B-GENE
pombe	I-GENE
rad1+	I-GENE
cell	I-GENE
cycle	I-GENE
checkpoint	I-GENE
control	I-GENE
gene	I-GENE
is	O
required	O
for	O
S-phase	O
and	O
G2	O
/	O
M	O
arrest	O
in	O
response	O
to	O
both	O
DNA	O
damage	O
and	O
incomplete	O
DNA	O
replication	O
.	O

The	O
mobility	O
of	O
the	O
upper	O
and	O
lower	O
premolars	O
under	O
load	O
was	O
investigated	O
in	O
relation	O
to	O
the	O
interproximal	O
contact	O
and	O
occlusal	O
facets	O
.	O

32Pi	O
labeling	O
or	O
isoelectric	O
focusing	O
analysis	O
of	O
eIF-2	B-GENE
alpha	I-GENE
from	O
conditional	O
casein	B-GENE
kinase	I-GENE
II	I-GENE
mutants	I-GENE
indicated	O
that	O
phosphorylation	O
of	O
eIF-2	B-GENE
alpha	I-GENE
is	O
abolished	O
or	O
dephosphorylated	O
forms	O
of	O
eIF-2	B-GENE
alpha	I-GENE
are	O
detected	O
when	O
these	O
strains	O
are	O
grown	O
at	O
the	O
restrictive	O
growth	O
conditions	O
.	O

Exons	O
A1a	O
and	O
A1b	O
are	O
separated	O
from	O
each	O
other	O
by	O
a	O
124-nucleotide	O
intron	O
.	O

Immunostaining	O
of	O
cells	O
transfected	O
with	O
these	O
constructs	O
revealed	O
that	O
both	O
the	O
myristoylated	O
and	O
nonmyristoylated	O
mutants	O
were	O
localized	O
in	O
nuclei	O
,	O
whereas	O
wild-type	B-GENE
PKC	I-GENE
alpha	I-GENE
was	O
primarily	O
cytoplasmic	O
and	O
perinuclear	O
.	O

Plasma	B-GENE
lecithin	I-GENE
/	I-GENE
cholesterol	I-GENE
acyltransferase	I-GENE
(	O
LCAT	B-GENE
)	O
activity	O
in	O
multiple-organ	O
donors	O
:	O
a	O
predictor	O
of	O
allograft	O
viability	O
in	O
clinical	O
liver	O
transplantation	O
.	O

Western	O
blot	O
analysis	O
of	O
various	O
bovine	O
tissues	O
with	O
human	O
NMT	B-GENE
peptide	I-GENE
antibody	I-GENE
indicated	O
a	O
common	O
prominent	O
immunoreactive	O
band	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
48	O
.	O
5-50	O
kDa	O
in	O
all	O
tissues	O
.	O

These	O
differences	O
involve	O
specific	O
hydrogen-bonding	O
interactions	O
between	O
the	O
protein	O
and	O
DNA	O
,	O
including	O
guanine	O
N7	O
sites	O
in	O
the	O
major	O
groove	O
of	O
DNA	O
,	O
and	O
alterations	O
in	O
DNA	O
phosphodiester	O
conformation	O
induced	O
by	O
protein	O
binding	O
.	O

Transient	O
transfection	O
assays	O
showed	O
that	O
site	O
A	O
is	O
necessary	O
and	O
sufficient	O
for	O
RXR	B-GENE
alpha-mediated	O
transactivation	O
of	O
the	O
apoAI	B-GENE
gene	I-GENE
basal	I-GENE
promoter	I-GENE
in	O
human	O
hepatoma	O
HepG2	O
cells	O
in	O
the	O
presence	O
of	O
RA	O
and	O
that	O
this	O
transactivation	O
is	O
abolished	O
by	O
increasing	O
amounts	O
of	O
cotransfected	O
ARP-1	B-GENE
.	O

This	O
structure	O
interconnects	O
specific	O
triplets	O
of	O
the	O
basal	O
bodies	O
with	O
the	O
microtubular	O
bundles	O
that	O
emerge	O
from	O
the	O
basal	O
apparatus	O
.	O

When	O
this	O
DNA	O
fragment	O
was	O
placed	O
upstream	O
of	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
reporter	O
gene	O
and	O
transfected	O
into	O
a	O
carp	O
CF	O
cell	O
line	O
,	O
it	O
could	O
drive	O
the	O
synthesis	O
of	O
CAT	B-GENE
enzyme	I-GENE
16	O
times	O
more	O
efficiently	O
than	O
the	O
promoterless	O
pCAT-Basic	B-GENE
.	O

A	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
d	O
,	O
l-baclofen	O
10	O
mg	O
/	O
kg	O
both	O
reduced	O
noradrenaline	O
(	O
NA	O
)	O
biosynthesis	O
in	O
vivo	O
(	O
31%	O
)	O
and	O
the	O
endogenous	O
concentration	O
of	O
normetanephrine	O
(	O
NMN	O
)	O
(	O
32%	O
)	O
and	O
increased	O
NA	O
levels	O
(	O
28%	O
)	O
.	O

The	O
case	O
for	O
neutrinos	O
from	O
SN	O
1987A	O
.	O

The	O
active	O
site	O
includes	O
the	O
acidic	O
triad	O
Asp53	O
(	O
the	O
site	O
of	O
phosphorylation	O
)	O
,	O
Asp10	O
and	O
Glu9	O
.	O

Furthermore	O
the	O
median	O
increase	O
in	O
cyclosporine	O
DR	O
/	O
C	O
(	O
SS	O
trough	O
)	O
was	O
18	O
l	O
h-1	O
(	O
-3	O
.	O
1	O
to	O
42	O
.	O
1	O
l	O
h-1	O
,	O
interquartile	O
range	O
)	O
.	O

These	O
results	O
show	O
that	O
the	O
CAAT-region	O
is	O
involved	O
in	O
upregulating	O
the	O
MDR1	B-GENE
promoter	I-GENE
in	O
HL60	O
/	O
VCR	O
cells	O
.	O

The	O
virus-associated	O
VAI	O
RNA	O
of	O
adenovirus	O
is	O
a	O
small	O
highly	O
structured	O
RNA	O
that	O
is	O
required	O
for	O
the	O
efficient	O
translation	O
of	O
cellular	O
and	O
viral	O
mRNAs	O
at	O
late	O
times	O
after	O
infection	O
.	O

Hyperthyroidism	O
.	O

While	O
interactions	O
of	O
WT	B-GENE
and	O
variant	O
TGF-alpha	B-GENE
with	O
the	O
ErbBs	B-GENE
all	O
result	O
in	O
ErbB2	B-GENE
activation	O
,	O
they	O
produce	O
different	O
biological	O
consequences	O
,	O
suggesting	O
that	O
the	O
various	O
TGF-alpha	B-GENE
precursors	I-GENE
differentially	O
modulate	O
ErbB	B-GENE
signaling	O
.	O

By	O
contrast	O
,	O
secretory	B-GENE
HI	I-GENE
antibodies	I-GENE
were	O
not	O
demonstrated	O
at	O
the	O
onset	O
of	O
illness	O
in	O
any	O
of	O
the	O
patients	O
,	O
but	O
their	O
formation	O
started	O
early	O
and	O
the	O
antibodies	O
reached	O
maximal	O
levels	O
about	O
10	O
days	O
after	O
onset	O
of	O
illness	O
.	O

Mammalian	B-GENE
ABPs	I-GENE
and	O
SHBGs	B-GENE
bind	O
sex	O
steroids	O
with	O
high	O
affinity	O
,	O
but	O
some	O
binding	O
properties	O
differ	O
among	O
species	O
.	O

PRDII-BF1-derived	B-GENE
cDNAs	I-GENE
did	O
not	O
result	O
in	O
stimulation	O
of	O
either	O
basal	O
or	O
tat-induced	O
activated	O
gene	O
expression	O
.	O

The	O
rCBF	O
ratio	O
was	O
mainly	O
reduced	O
in	O
frontal	O
lobes	O
(	O
65%	O
)	O
.	O

We	O
isolated	O
several	O
overlapping	O
A-phage	O
and	O
cosmid	O
clones	O
that	O
cover	O
more	O
than	O
100	O
kb	O
of	O
human	O
DNA	O
and	O
contained	O
the	O
entire	O
VDR	B-GENE
gene	I-GENE
.	O

The	O
treatment	O
group	O
also	O
showed	O
in	O
vivo	O
T-cell	O
activation	O
with	O
an	O
initial	O
lymphopenia	O
followed	O
by	O
a	O
rebound	O
lymphocytosis	O
and	O
upregulation	O
of	O
the	O
subset	O
markers	O
CD25	B-GENE
(	O
interleukin	B-GENE
2	I-GENE
receptor	I-GENE
)	O
and	O
CD45RO	B-GENE
(	O
T-memory	O
cells	O
)	O
.	O

Selected	O
parameters	O
:	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
arterial	O
blood	O
pressure	O
(	O
ABP	O
)	O
and	O
arterial	O
O2	O
saturation	O
(	O
SaO2	O
)	O
monitored	O
by	O
pulsoximetry	O
were	O
measured	O
during	O
the	O
procedure	O
.	O

Persistent	O
activation	O
of	O
mitogen-activated	B-GENE
protein	I-GENE
kinases	I-GENE
p42	I-GENE
and	O
p44	B-GENE
and	O
ets-2	B-GENE
phosphorylation	O
in	O
response	O
to	O
colony-stimulating	B-GENE
factor	I-GENE
1	I-GENE
/	I-GENE
c-fms	I-GENE
signaling	O
.	O

The	O
psychologic	O
factors	O
associated	O
wth	O
serious	O
illness	O
,	O
terminal	O
prognoses	O
,	O
and	O
dying	O
complicate	O
the	O
scenario	O
even	O
more	O
as	O
compared	O
with	O
that	O
of	O
nonmalignant	O
pain	O
.	O

It	O
is	O
transparent	O
,	O
cheap	O
to	O
be	O
made	O
,	O
and	O
easy	O
to	O
empty	O
and	O
was	O
tested	O
in	O
118	O
animals	O
for	O
two	O
and	O
four	O
weeks	O
.	O

Coenzyme	B-GENE
Q10	I-GENE
:	O
blood	O
levels	O
and	O
metabolic	O
demand	O
.	O

A	O
drug	O
with	O
ISA	O
"down	O
regulates"	O
beta	B-GENE
receptors	I-GENE
;	O
thus	O
,	O
when	O
the	O
drug	O
is	O
withdrawn	O
there	O
is	O
no	O
post-beta-blocking	O
drug	O
hypersensitivity	O
in	O
contrast	O
to	O
agents	O
without	O
ISA	O
.	O

The	O
workup	O
included	O
skin	O
tests	O
(	O
up	O
to	O
1	O
microgram	O
/	O
ml	O
,	O
Pharmacia	O
)	O
,	O
measurement	O
of	O
specific	O
serum	O
IgE	B-GENE
with	O
RAST-CAP	O
(	O
Pharmacia	O
)	O
,	O
and	O
CAST	O
with	O
three	O
concentrations	O
of	O
bee	O
(	O
Apis	O
mellifera	O
)	O
and	O
wasp	O
(	O
Vespula	O
spec	O
.	O
)	O
venom	O
(	O
Aquagen	O
ALK	O
)	O
.	O

A	O
position-independent	O
activation	O
domain	O
which	O
contained	O
conserved	O
regions	O
II	O
and	O
III	O
was	O
identified	O
at	O
the	O
carboxyl	O
terminus	O
of	O
the	O
HNF-3	B-GENE
beta	I-GENE
protein	I-GENE
(	O
amino	O
acids	O
361	O
to	O
458	O
)	O
.	O

Mutations	O
in	O
genes	O
encoding	O
PR65	B-GENE
/	I-GENE
A	I-GENE
subunits	I-GENE
have	O
been	O
identified	O
in	O
several	O
different	O
human	O
cancers	O
and	O
the	O
PP2A	B-GENE
inhibitor	O
,	O
termed	O
fostriecin	O
,	O
is	O
being	O
tested	O
as	O
an	O
anticancer	O
drug	O
.	O

In	O
contrast	O
to	O
the	O
wild-type	O
protein	O
,	O
expression	O
of	O
p45	B-GENE
NF-E2	I-GENE
lacking	O
this	O
activation	O
domain	O
in	O
an	O
NF-E2	B-GENE
null	O
cell	O
line	O
fails	O
to	O
support	O
enhancer-dependent	O
transcription	O
in	O
transient	O
assays	O
.	O

Similar	O
clinical	O
evaluation	O
of	O
an	O
obligate	O
carrier	O
revealed	O
no	O
ocular	O
abnormalities	O
.	O

The	O
present	O
study	O
reports	O
visual	O
evoked	O
potential	O
responses	O
to	O
pattern	O
reversal	O
(	O
VEP-P	O
)	O
in	O
ten	O
third	O
trimester	O
pregnant	O
women	O
and	O
changes	O
in	O
latency	O
of	O
NPN	O
complex	O
when	O
compared	O
with	O
these	O
responses	O
in	O
the	O
non	O
pregnant	O
state	O
.	O

Abrogation	O
of	O
p53	B-GENE
function	O
by	O
E6	B-GENE
resulted	O
in	O
an	O
increase	O
in	O
the	O
spontaneous	O
mutation	O
frequencies	O
at	O
the	O
heterozygous	O
thymidine	B-GENE
kinase	I-GENE
(	O
TK	B-GENE
)	O
locus	O
but	O
not	O
at	O
the	O
hemizygous	O
hypoxanthine	B-GENE
phosphoribosyl	I-GENE
transferase	I-GENE
(	O
HPRT	B-GENE
)	O
locus	O
.	O

55	O
+	O
/	O
-	O
11%	O
)	O
,	O
all	O
other	O
parameters	O
showed	O
a	O
significant	O
increase	O
:	O
RS	O
index	O
5	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
4	O
mVolt	O
to	O
6	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
7	O
mVolt	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
EDD	O
6	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
6	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
9	O
cm	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
HV	O
1017	O
+	O
/	O
-	O
151	O
ml	O
to	O
1099	O
+	O
/	O
-	O
261	O
ml	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
EDV	O
371	O
+	O
/	O
-	O
131	O
ml	O
to	O
441	O
+	O
/	O
-	O
175	O
ml	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
RBV	O
117	O
+	O
/	O
-	O
57	O
ml	O
to	O
151	O
+	O
/	O
-	O
77	O
ml	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Significant	O
immunoglobulinuria	O
developed	O
prior	O
to	O
the	O
development	O
of	O
azotemia	O
,	O
significantly	O
decreased	O
creatinine	O
clearance	O
,	O
significant	O
proteinuria	O
(	O
greater	O
than	O
or	O
equal	O
to	O
3+	O
dipstick	O
or	O
greater	O
than	O
or	O
equal	O
to	O
5	O
gm	O
per	O
24-hour	O
urine	O
collection	O
)	O
,	O
or	O
oliguria	O
.	O

ECM	O
disruption	O
in	O
Lytechinus	O
embryos	O
caused	O
a	O
relative	O
drop	O
in	O
USF	B-GENE
RNA	I-GENE
accumulation	O
levels	O
to	O
approximately	O
60%	O
of	O
control	O
embryos	O
,	O
while	O
LpS1	B-GENE
RNA	I-GENE
accumulation	O
levels	O
dropped	O
to	O
less	O
than	O
5%	O
.	O

Deep	O
tans	O
were	O
induced	O
over	O
the	O
backs	O
of	O
volunteers	O
with	O
repeated	O
exposure	O
to	O
longwave	O
ultraviolet	O
radiation	O
(	O
UV-A	O
)	O
.	O

Significance	O
of	O
the	O
pulmonary	O
gas	O
exchange	O
reaction	O
to	O
physical	O
loading	O
in	O
evaluating	O
the	O
effectiveness	O
of	O
mitral	O
commissurotomy	O
.	O

It	O
is	O
shown	O
that	O
the	O
displacement	O
distribution	O
measured	O
by	O
q-space	O
MRI	O
in	O
both	O
the	O
large	O
displacement	O
(	O
i	O
.	O
e	O
.	O
,	O
large	O
r	O
)	O
and	O
the	O
long-wavelength	O
(	O
i	O
.	O
e	O
.	O
,	O
small	O
q	O
)	O
limits	O
is	O
the	O
same	O
3D	O
Gaussian	O
displacement	O
distribution	O
assumed	O
in	O
DT-MRI	O
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
indicates	O
that	O
NF-IL-6	B-GENE
,	O
as	O
well	O
as	O
other	O
related	O
members	O
of	O
this	O
family	O
,	O
bind	O
specifically	O
to	O
the	O
NF-IL-6	B-GENE
site	O
in	O
the	O
IL-8	B-GENE
promoter	I-GENE
.	O

The	O
ICBF	O
in	O
the	O
ischaemic	O
cortex	O
revealed	O
a	O
graded	O
reduction	O
from	O
the	O
ischaemic	O
centre	O
to	O
the	O
surrounding	O
tissues	O
.	O

These	O
changes	O
at	O
the	O
site	O
of	O
injection	O
consist	O
of	O
a	O
focal	O
abnormality	O
characterized	O
by	O
a	O
slight	O
increase	O
in	O
signal	O
intensity	O
on	O
T1	O
weighted	O
images	O
and	O
markedly	O
increased	O
signal	O
intensity	O
on	O
T2	O
weighted	O
images	O
.	O

Copper	O
treatments	O
were	O
assigned	O
to	O
simulate	O
the	O
different	O
levels	O
of	O
copper	O
intake	O
that	O
might	O
result	O
from	O
differences	O
in	O
daily	O
feed	O
intake	O
similar	O
to	O
the	O
practice	O
followed	O
with	O
commercial	O
industry	O
.	O

3-	O
(	O
N-Alkyl-N-2-chloroethylaminomethyl	O
)	O
-5-	O
or	O
7-halogenobenzo	O
[	O
b	O
]	O
thiophen	O
hydrochlorides	O
.	O

Transcervical	O
amnioinfusion	O
.	O

A	O
computer	O
program	O
,	O
ACCESS-IAQ	O
,	O
is	O
developed	O
to	O
simulate	O
the	O
airflow	O
pattern	O
,	O
the	O
time	O
history	O
of	O
the	O
contaminant	O
concentrations	O
in	O
the	O
occupied	O
zone	O
,	O
and	O
the	O
inhalation	O
exposures	O
.	O

As	O
with	O
VP16	B-GENE
,	O
the	O
transactivation	O
function	O
of	O
Luman	B-GENE
is	O
also	O
regulated	O
by	O
HCF	B-GENE
.	O

Slowly	O
adapting	O
type	B-GENE
I	I-GENE
mechanoreceptor	I-GENE
discharge	O
as	O
a	O
function	O
of	O
dynamic	O
force	O
versus	O
dynamic	O
displacement	O
of	O
glabrous	O
skin	O
of	O
raccoon	O
and	O
squirrel	O
monkey	O
hand	O
.	O

Hypomagnesemia	O
was	O
due	O
to	O
magnesium	O
wasting	O
by	O
the	O
kidney	O
.	O

Interestingly	O
,	O
although	O
E	B-GENE
domains	I-GENE
of	O
these	O
two	O
receptors	O
are	O
much	O
less	O
conserved	O
,	O
replacement	O
of	O
this	O
domain	O
in	O
rtER	B-GENE
by	O
its	O
human	O
counterpart	O
resulted	O
in	O
higher	O
estradiol	O
sensitivity	O
but	O
no	O
increase	O
in	O
the	O
magnitude	O
of	O
transactivation	O
.	O

Propranolol	O
also	O
effectively	O
controlled	O
her	O
familial	O
tremor	O
.	O

From	O
sequence	O
alignments	O
with	O
phylogenetically	O
related	O
viruses	O
,	O
including	O
tymoviruses	O
,	O
we	O
predicted	O
that	O
p223	B-GENE
contained	O
a	O
papain-like	B-GENE
proteinase	I-GENE
domain	I-GENE
with	O
a	O
putative	O
catalytic	O
cysteine994	O
and	O
histidine1075	O
.	O

The	O
distribution	O
of	O
their	O
fibrinogen	B-GENE
levels	O
was	O
Gaussian	O
,	O
but	O
more	O
wide-based	O
than	O
the	O
distribution	O
of	O
our	O
normal	O
controls	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
demonstrate	O
that	O
in	O
certain	O
cases	O
of	O
expulsive	O
choroidal	O
hemorrhage	O
(	O
ECH	O
)	O
anatomical	O
success	O
and	O
useful	O
vision	O
can	O
be	O
obtained	O
with	O
repeated	O
vitreoretinal	O
surgery	O
.	O

17	O
volunteer	O
deaf	O
Ss	O
were	O
compared	O
with	O
18	O
volunteer	O
hearing	O
Ss	O
on	O
the	O
Stanford	O
Hypnotic	O
Clinical	O
Scale	O
(	O
SHCS	O
)	O
of	O
Morgan	O
and	O
J	O
.	O

1	O
The	O
effects	O
in	O
normal	O
subjects	O
of	O
a	O
single	O
oral	O
dose	O
of	O
Motival	O
(	O
one	O
tablet	O
,	O
containing	O
fluphenazine	O
0	O
.	O
5	O
mg	O
and	O
nortriptyline	O
10	O
mg	O
)	O
on	O
the	O
contingent	O
negative	O
variation	O
(	O
CNV	O
)	O
,	O
reaction	O
time	O
,	O
heart	O
rate	O
,	O
blood	O
pressure	O
and	O
self-rating	O
scales	O
for	O
alertness	O
,	O
anxiety	O
,	O
tension	O
,	O
detachment	O
and	O
depression	O
were	O
compared	O
with	O
those	O
of	O
diazepam	O
(	O
5	O
mg	O
and	O
7	O
.	O
5	O
mg	O
)	O
and	O
placebo	O
or	O
propranolol	O
(	O
60	O
mg	O
)	O
.	O

Summers	O
,	O
Virology	O
89	O
:	O
517-527	O
,	O
1978	O
)	O
.	O

Lens	B-GENE
aldose	I-GENE
reductase	I-GENE
in	O
diabetic	O
and	O
galactosemic	O
cataracts	O
.	O

This	O
DNA	O
motif	O
represents	O
a	O
novel	O
protein-binding	O
sequence	O
.	O

The	O
virus	O
encodes	O
a	O
40-kDa	O
protein	O
,	O
tax	B-GENE
,	O
that	O
is	O
important	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
.	O

[	B-GENE
Ala85	I-GENE
]	I-GENE
Dk	I-GENE
(	I-GENE
69-85	I-GENE
)	I-GENE
retains	O
full	O
biological	O
activity	O
.	O

Platelet	O
serotonin	O
(	O
5-HT	O
)	O
and	O
5-HT	B-GENE
releasing	I-GENE
factor	I-GENE
in	O
plasma	O
of	O
migrainous	O
patients	O
.	O

CONCLUSIONS	O
:	O
XCoe2	B-GENE
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
transcriptional	O
cascade	O
that	O
specifies	O
primary	O
neurons	O
in	O
Xenopus	O
embryos	O
:	O
by	O
maintaining	O
Delta-Notch	O
signalling	O
,	O
XCoe2	B-GENE
stabilises	O
the	O
higher	O
neural	O
potential	O
of	O
selected	O
progenitor	O
cells	O
that	O
express	O
X-ngnr-1	B-GENE
,	O
ensuring	O
the	O
transition	O
between	O
neural	O
competence	O
and	O
irreversible	O
commitment	O
to	O
a	O
neural	O
fate	O
;	O
and	O
it	O
promotes	O
neuronal	O
differentiation	O
by	O
activating	O
XNeuroD	B-GENE
expression	O
,	O
directly	O
or	O
indirectly	O
.	O

Strontium-90	O
was	O
inject	O
i	O
.	O
v	O
.	O
into	O
pregnant	O
rats	O
on	O
day	O
18	O
post	O
conception	O
(	O
p	O
.	O
c	O
.	O
)	O
.	O

Iodine	O
metabolism	O
in	O
chronic	O
thyroiditis	O
.	O

However	O
,	O
with	O
the	O
alpha1	O
antagonist	O
prazosin	O
(	O
5	O
x	O
10	O
(	O
-8	O
)	O
-5	O
x	O
10	O
(	O
-7	O
)	O
M	O
)	O
,	O
no	O
relaxation	O
occurred	O
.	O

RESULTS	O
:	O
At	O
latest	O
examination	O
,	O
mean	O
UPDRS	O
II	O
and	O
III	O
scores	O
had	O
improved	O
by	O
30%	O
(	O
on	O
stimulation	O
,	O
off	O
therapy	O
)	O
with	O
mean	O
50%	O
reduction	O
in	O
daily	O
off	O
time	O
.	O

A	O
phylogenetic	O
analysis	O
of	O
the	O
reverse	B-GENE
transcriptase	I-GENE
domain	I-GENE
confirms	O
our	O
differential	O
genetic	O
assessment	O
that	O
Cyclops	B-GENE
from	O
pea	O
is	O
a	O
novel	O
element	O
with	O
no	O
specific	O
relationship	O
to	O
the	O
previously	O
described	O
Gypsy-like	B-GENE
elements	I-GENE
from	O
plants	O
.	O

Instead	O
,	O
it	O
contained	O
two	O
tandem	O
kappaB	B-GENE
elements	I-GENE
and	O
a	O
variant	O
activating	B-GENE
transcription	I-GENE
factor	I-GENE
/	I-GENE
cAMP	I-GENE
response	I-GENE
element	I-GENE
site	O
,	O
which	O
closely	O
resembled	O
sites	O
in	O
the	O
E-selectin	B-GENE
gene	I-GENE
that	O
are	O
required	O
for	O
TNF-alpha-	O
or	O
LPS-inducible	O
expression	O
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

This	O
paper	O
describes	O
the	O
genomic	O
organization	O
of	O
mouse	O
gC1qBP	B-GENE
and	O
the	O
characterization	O
of	O
its	O
5'	O
flanking	O
region	O
.	O

PRL-1	B-GENE
is	O
able	O
to	O
dephosphorylate	O
phosphotyrosine	O
substrates	O
,	O
and	O
mutation	O
of	O
the	O
active-site	O
cysteine	O
residue	O
abolishes	O
this	O
activity	O
.	O

A	O
Chinese	O
(	O
HK	O
)	O
SF-36	O
survey	O
form	O
was	O
developed	O
by	O
an	O
iterative	O
translation	O
process	O
.	O

Infarct	O
regional	O
ejection	O
fraction	O
improved	O
by	O
10	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
1%	O
between	O
early	O
and	O
late	O
studies	O
when	O
the	O
infarct-related	O
artery	O
was	O
patent	O
and	O
by	O
4	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
4%	O
if	O
it	O
was	O
occluded	O
(	O
p	O
=	O
0	O
.	O
048	O
)	O
;	O
changes	O
in	O
global	O
and	O
noninfarct	O
regional	O
ejection	O
fraction	O
were	O
similar	O
irrespective	O
of	O
perfusion	O
status	O
.	O

The	O
activated	O
glucocorticoid	B-GENE
receptor	I-GENE
forms	O
a	O
complex	O
with	O
Stat5	B-GENE
and	O
enhances	O
Stat5-mediated	O
transcriptional	O
induction	O
.	O

This	O
partial	O
transection	O
could	O
permit	O
vasopressin	B-GENE
to	O
be	O
secreted	O
in	O
response	O
to	O
a	O
larger	O
rise	O
in	O
plasma	O
sodium	O
concentration	O
.	O

This	O
repressor	O
is	O
however	O
unlikely	O
to	O
mediate	O
spi	B-GENE
2	I-GENE
.	I-GENE
3	I-GENE
3'	I-GENE
UTR	I-GENE
silencer	I-GENE
action	O
since	O
it	O
was	O
not	O
detected	O
in	O
rat	O
hepatocytes	O
.	O

Abstracts	O
.	O

The	O
severity	O
of	O
pathologic	O
changes	O
increased	O
with	O
the	O
magnitude	O
of	O
percussion	O
.	O

ANIMALS	O
:	O
Fifty	O
dogs	O
with	O
naturally	O
developing	O
DM	O
.	O

Acute	O
pancreatitis	O
:	O
a	O
multisystem	O
disease	O
.	O

Interestingly	O
,	O
the	O
RXRalphaF318A	B-GENE
constitutive	O
activity	O
generated	O
within	O
heterodimers	O
in	O
the	O
presence	O
of	O
BMS614	O
requires	O
the	O
integrity	O
of	O
both	O
RXR	B-GENE
and	O
RAR	B-GENE
AF-2	B-GENE
domains	I-GENE
.	O

Fundamental	O
and	O
clinical	O
evaluation	O
of	O
equilibrium	O
dialysis--radioimmunoassay	O
system	O
for	O
measurement	O
of	O
serum	O
free	O
thyroxine	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
and	O
rank	O
the	O
frequency	O
of	O
self	O
reported	O
visual	O
disability	O
in	O
daily	O
tasks	O
performed	O
by	O
glaucoma	O
patients	O
;	O
to	O
examine	O
the	O
interrelation	O
between	O
disabilities	O
using	O
factor	O
analysis	O
;	O
to	O
study	O
the	O
relation	O
between	O
perceived	O
visual	O
difficulty	O
and	O
a	O
measure	O
of	O
the	O
severity	O
of	O
visual	O
field	O
loss	O
;	O
to	O
develop	O
a	O
glaucoma	O
specific	O
subgroup	O
of	O
questions	O
;	O
and	O
examine	O
the	O
validity	O
and	O
reliability	O
of	O
this	O
subgroup	O
of	O
questions	O
.	O

The	O
amino-terminal	O
third	O
of	O
the	O
protein	O
contains	O
a	O
high-mobility-group	B-GENE
motif	I-GENE
characteristic	O
of	O
DNA-binding	O
proteins	O
.	O

In	O
rlf2	B-GENE
mutants	I-GENE
,	O
telomeric	O
chromatin	O
is	O
perturbed	O
:	O
Telomeric	O
silencing	O
is	O
reduced	O
and	O
Rap1p	B-GENE
localization	O
is	O
altered	O
.	O

Solution	O
structure	O
and	O
mechanism	O
of	O
the	O
MutT	B-GENE
pyrophosphohydrolase	I-GENE
.	O

Among	O
the	O
H	B-GENE
/	I-GENE
ACA	I-GENE
snoRNAs	I-GENE
associated	O
with	O
Gar1p	B-GENE
,	O
one	O
can	O
distinguish	O
a	O
large	O
group	O
of	O
snoRNAs	B-GENE
that	O
are	O
not	O
essential	O
in	O
yeast	O
and	O
serve	O
as	O
guides	O
for	O
pseudouridine	O
synthesis	O
onto	O
the	O
pre-rRNA	B-GENE
molecule	I-GENE
.	O

Against	O
gram-positive	O
organisms	O
,	O
E-4767	O
and	O
E-5065	O
were	O
,	O
in	O
general	O
,	O
eight-	O
and	O
fourfold	O
more	O
active	O
than	O
tosufloxacin	O
,	O
which	O
is	O
the	O
most	O
potent	O
of	O
the	O
reference	O
compounds	O
.	O

A	O
significant	O
degree	O
of	O
homology	O
was	O
also	O
found	O
among	O
these	O
genes	O
and	O
the	O
Mtase	B-GENE
gene	I-GENE
of	O
related	O
phage	O
SPR	O
,	O
which	O
codes	O
for	O
an	O
enzyme	O
with	O
different	O
modification	O
specificity	O
.	O

These	O
results	O
suggest	O
that	O
NZ-107	O
may	O
be	O
a	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
bronchial	O
asthma	O
by	O
reducing	O
late-phase	O
airway	O
responses	O
and	O
airway	O
hyperreactivity	O
.	O

RESULTS	O
:	O
Of	O
the	O
patients	O
with	O
IS	O
,	O
67%	O
had	O
significantly	O
greater	O
values	O
of	O
directional	O
preponderance	O
on	O
the	O
OVAR	O
test	O
(	O
a	O
measure	O
of	O
otolith	O
system	O
imbalance	O
)	O
compared	O
with	O
control	O
subjects	O
.	O

Additional	O
deletion	O
mutations	O
revealed	O
a	O
new	O
,	O
67-amino-acid	O
functional	O
domain	O
within	O
the	O
proline-rich	O
region	O
of	O
SLP-76	B-GENE
,	O
which	O
we	O
have	O
termed	O
the	O
P-1	B-GENE
domain	I-GENE
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
has	O
the	O
greatest	O
homology	O
(	O
61%	O
)	O
to	O
the	O
green	B-GENE
alga	I-GENE
Scenedemus	I-GENE
obliquus	I-GENE
plastocyanin	I-GENE
.	O

The	O
viral	O
LTR	O
was	O
used	O
as	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
relationship	O
between	O
the	O
side	O
of	O
sinusitis	O
and	O
the	O
cleft	O
side	O
in	O
patients	O
with	O
unilateral	O
cleft	O
palate	O
.	O

When	O
nifA	B-GENE
mRNA	I-GENE
5'	O
start	O
points	O
were	O
mapped	O
by	O
primer	O
extension	O
,	O
both	O
a	O
minor	O
upstream	O
transcript	O
(	O
s	O
)	O
starting	O
45	O
bp	O
distal	O
to	O
the	O
anaerobox	O
and	O
a	O
major	O
downstream	O
transcript	O
starting	O
10	O
bp	O
distal	O
to	O
the	O
sigma	B-GENE
54	I-GENE
box	O
were	O
observed	O
.	O

The	O
sequence	O
of	O
monkey	B-GENE
opsin	I-GENE
closely	O
resembles	O
the	O
human	O
sequence	O
at	O
the	O
nucleotide	O
and	O
the	O
amino	O
acid	O
levels	O
,	O
with	O
the	O
latter	O
having	O
only	O
7	O
differences	O
out	O
of	O
348	O
residues	O
.	O

It	O
is	O
the	O
oxidation	O
peak	O
of	O
this	O
product	O
,	O
arising	O
in	O
acidic	O
media	O
at	O
0	O
.	O
42	O
V	O
,	O
which	O
was	O
analysed	O
using	O
DPV	O
,	O
again	O
following	O
the	O
accumulation	O
of	O
clenbuterol	O
at	O
the	O
Nafion-modified	O
CPE	O
.	O

Its	O
potential	O
as	O
a	O
diagnostic	O
tool	O
for	O
epidemiological	O
surveillance	O
was	O
assessed	O
in	O
comparison	O
with	O
three	O
other	O
diagnostic	O
tests	O
:	O
stool	O
examination	O
,	O
ELISA	O
with	O
soluble	B-GENE
egg	I-GENE
antigen	I-GENE
(	O
SEA	B-GENE
)	O
and	O
the	O
circumoval	O
precipitin	O
test	O
(	O
COPT	O
)	O
.	O

Albumin	B-GENE
expression	O
is	O
maintained	O
in	O
the	O
liver	O
by	O
a	O
combination	O
of	O
liver-enriched	O
transcription	O
factors	O
such	O
as	O
CAAT	B-GENE
enhancer-binding	I-GENE
protein	I-GENE
(	I-GENE
C	I-GENE
/	I-GENE
EBP	I-GENE
)	I-GENE
alpha	I-GENE
and	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
.	O

T2	O
cancers	O
should	O
not	O
be	O
excluded	O
from	O
the	O
benefit	O
of	O
preoperative	O
irradiation	O
.	O

Amounts	O
of	O
glucose	O
infused	O
during	O
the	O
last	O
20	O
min	O
of	O
each	O
2	O
hour	O
insulin	B-GENE
infusion	O
were	O
(	O
at	O
1	O
and	O
10	O
m	O
/	O
kg	O
/	O
min	O
respectively	O
)	O
:	O
before	O
treatment	O
(	O
K+	O
=	O
2	O
.	O
7	O
mmol	O
/	O
l	O
)	O
:	O
2	O
.	O
4	O
and	O
8	O
.	O
4	O
mg	O
/	O
kg	O
/	O
min	O
;	O
after	O
spironolactone	O
(	O
K+	O
=	O
3	O
.	O
9	O
mmol	O
/	O
l	O
)	O
:	O
3	O
.	O
3	O
and	O
15	O
.	O
4	O
mg	O
/	O
kg	O
/	O
min	O
;	O
after	O
indomethacine	O
(	O
K+	O
=	O
3	O
.	O
7	O
mmol	O
/	O
l	O
)	O
:	O
5	O
and	O
19	O
mg	O
/	O
kg	O
/	O
min	O
after	O
stopping	O
drugs	O
(	O
K+	O
=	O
2	O
.	O
9	O
mmol	O
/	O
l	O
)	O
:	O
2	O
.	O
5	O
and	O
5	O
.	O
3	O
mg	O
/	O
kg	O
/	O
min	O
.	O

A	O
gapped	O
search	O
with	O
the	O
C-terminal	O
region	O
of	O
CDED	B-GENE
/	I-GENE
LIOR	I-GENE
revealed	O
a	O
36-41%	O
similarity	O
to	O
several	O
proteins	O
related	O
to	O
signal	O
transduction	O
and	O
cell	O
replication	O
,	O
such	O
as	O
ORC1	B-GENE
and	O
KSR	B-GENE
.	O

Circulating	O
oxytocin	B-GENE
in	O
male	O
guinea	O
pigs	O
affected	O
by	O
the	O
female	O
cohabitation	O
and	O
reproductive	O
condition	O
.	O

Prophylactic	O
lymph	O
node	O
dissection	O
or	O
radiation	O
therapy	O
to	O
the	O
nodal	O
chain	O
may	O
decrease	O
local	O
recurrence	O
but	O
does	O
not	O
consistently	O
affect	O
overall	O
survival	O
.	O

The	O
COL7A1	B-GENE
gene	I-GENE
,	O
which	O
encodes	O
type	B-GENE
VII	I-GENE
collagen	I-GENE
,	O
has	O
been	O
implicated	O
as	O
a	O
candidate	O
gene	O
for	O
dominantly	O
and	O
recessively	O
inherited	O
forms	O
of	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

Cell	O
factor-mediated	O
regulatory	O
interactions	O
are	O
involved	O
in	O
regulating	O
the	O
restricted	O
expression	O
of	O
the	O
HCMV	B-GENE
major	I-GENE
immediate-early	I-GENE
(	I-GENE
IE	I-GENE
)	I-GENE
gene	I-GENE
(	O
J	O
.	O

AIMS	O
:	O
To	O
establish	O
a	O
baseline	O
and	O
intraindividual	O
fluctuations	O
of	O
the	O
tumour	O
markers	O
CEA	B-GENE
,	O
CA	B-GENE
50	I-GENE
and	O
CA	B-GENE
242	I-GENE
in	O
patients	O
cured	O
from	O
colorectal	O
cancer	O
,	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
serum	O
concentrations	O
and	O
intraindividual	O
fluctuations	O
do	O
not	O
differ	O
from	O
the	O
concentrations	O
in	O
cancer-free	O
individuals	O
.	O

Effects	O
of	O
thromboxane	B-GENE
synthetase	I-GENE
inhibition	O
on	O
postburn	O
mesenteric	O
vascular	O
resistance	O
and	O
the	O
rate	O
of	O
bacterial	O
translocation	O
in	O
a	O
chronic	O
porcine	O
model	O
.	O

Formation	O
of	O
hyphae	O
and	O
chlamydospores	O
by	O
Cryptococcus	O
laurentii	O
.	O

The	O
transforming	O
protein	O
of	O
Rous	O
sarcoma	O
virus	O
,	O
pp60v-src	B-GENE
,	O
and	O
its	O
normal	O
cellular	O
homolog	O
,	O
pp60c-src	B-GENE
,	O
differ	O
not	O
only	O
in	O
oncogenic	O
potential	O
but	O
also	O
in	O
their	O
subcellular	O
localization	O
and	O
cytoskeletal	O
binding	O
ability	O
.	O
pp60v-src	B-GENE
has	O
been	O
shown	O
to	O
stably	O
associate	O
with	O
a	O
detergent-insoluble	O
cytoskeletal	O
matrix	O
,	O
whereas	O
pp60c-src	B-GENE
does	O
not	O
.	O

DNA	O
from	O
PCR	O
was	O
labeled	O
and	O
used	O
to	O
isolate	O
several	O
lambda	O
gt11	O
cDNA	O
clones	O
,	O
including	O
one	O
full-length	O
one	O
(	O
Dd	B-GENE
kinase-2	I-GENE
)	O
.	O

The	O
importin	B-GENE
alpha	I-GENE
.	I-GENE
beta	I-GENE
heterodimer	I-GENE
mediates	O
nuclear	O
import	O
of	O
proteins	O
containing	O
classical	O
nuclear	O
localization	O
signals	O
.	O

Nineteen	O
patients	O
with	O
non-visualized	O
gallbladder	O
with	O
OCG	O
subsequently	O
had	O
Tc-99m-PyG	O
cholescintigraphy	O
performed	O
.	O

The	O
EC	O
(	O
50	O
)	O
for	O
suppression	O
of	O
long-term	O
memory	O
(	O
the	O
concentration	O
decreasing	O
memory	O
by	O
50%	O
)	O
of	O
fear	O
conditioning	O
to	O
context	O
was	O
2	O
.	O
00%	O
plus	O
/	O
minus	O
0	O
.	O
01%	O
(	O
mean	O
plus	O
/	O
minus	O
SEM	O
)	O
,	O
and	O
for	O
fear	O
conditioning	O
to	O
tone	O
was	O
3	O
.	O
45%	O
plus	O
/	O
minus	O
0	O
.	O
26%	O
,	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

OBJECTIVE	O
:	O
Although	O
the	O
preponderance	O
of	O
findings	O
offer	O
support	O
for	O
transient	O
(	O
where	O
is	O
it	O
?	O
)	O
as	O
opposed	O
to	O
sustained	O
(	O
what	O
is	O
it	O
?	O
)	O
deficit	O
,	O
a	O
need	O
remains	O
for	O
specific	O
depiction	O
of	O
the	O
deficit	O
.	O

E	O
.	O

Dietary	O
supplement	O
with	O
fish	O
oil	O
and	O
related	O
n-3	O
EFAs	O
has	O
been	O
used	O
to	O
study	O
their	O
antihypertensive	O
property	O
in	O
animals	O
and	O
humans	O
with	O
borderline	O
and	O
essential	O
hypertension	O
.	O

HCV	O
infection	O
acquired	O
during	O
or	O
after	O
BMT	O
caused	O
only	O
mild	O
acute	O
hepatitis	O
C	O
,	O
which	O
progressed	O
to	O
chronic	O
hepatitis	O
C	O
in	O
one	O
patient	O
surviving	O
10	O
years	O
after	O
BMT	O
.	O

Gel-shift	O
assays	O
with	O
nuclear	O
extracts	O
and	O
oligonucleotide	O
sequences	O
spanning	O
the	O
0	O
.	O
125-kb	O
promoter	O
region	O
detected	O
an	O
ETS-immunoreactive	O
complex	O
,	O
present	O
most	O
abundantly	O
in	O
cells	O
overexpressing	O
HER2	B-GENE
,	O
whose	O
high-affinity	O
binding	O
depended	O
on	O
the	O
GAGGAA	B-GENE
response	I-GENE
element	I-GENE
.	O

Northern	O
analyses	O
of	O
RNAs	O
from	O
mouse	O
tissues	O
and	O
cell	O
lines	O
indicated	O
that	O
p11	B-GENE
mRNA	I-GENE
levels	O
vary	O
widely	O
.	O

Further	O
research	O
is	O
required	O
to	O
better	O
measure	O
treatment	O
effects	O
,	O
modification	O
of	O
MS	O
natural	O
history	O
,	O
and	O
net	O
societal	O
costs	O
of	O
IFN	B-GENE
beta-1b	I-GENE
in	O
RRMS	O
.	O

If	O
delay	O
has	O
occurred	O
between	O
centrifugation	O
and	O
the	O
measurement	O
,	O
causing	O
substantial	O
loss	O
of	O
CO2	O
,	O
equilibration	O
of	O
the	O
sample	O
with	O
a	O
gas	O
mixture	O
corresponding	O
to	O
PCO2	O
=	O
5	O
.	O
3	O
kPa	O
prior	O
to	O
the	O
measurement	O
is	O
recommended	O
.	O

Magnetic	O
resonance	O
imaging	O
in	O
coccidioidal	O
arthritis	O
.	O

For	O
steers	O
the	O
urinary	O
N	O
values	O
were	O
403	O
and	O
295	O
mg	O
/	O
kg	O
W0	O
.	O
75	O
at	O
200	O
and	O
350	O
kg	O
live	O
weight	O
respectively	O
and	O
total	O
N	O
excretion	O
including	O
faecal	O
N	O
was	O
408	O
and	O
320	O
mg	O
/	O
kg	O
W0	O
.	O
75	O
.	O

Data	O
from	O
the	O
V-HeFT	O
II	O
show	O
that	O
at	O
2-year	O
follow-up	O
,	O
a	O
progressive	O
rise	O
of	O
plasma	O
norepinephrine	O
was	O
observed	O
in	O
both	O
treatment	O
arms	O
,	O
suggesting	O
that	O
disease	O
progresses	O
despite	O
treatment	O
with	O
either	O
an	O
angiotensin-converting	B-GENE
enzyme	I-GENE
inhibitor	O
,	O
enalapril	O
,	O
or	O
vasodilator	O
therapy	O
with	O
hydralazine	O
/	O
isosorbide	O
dinitrate	O
.	O

Diver	O
respiratory	O
responses	O
to	O
a	O
tunable	O
closed-circuit	O
breathing	O
apparatus	O
.	O

Phosphorylation	O
of	O
tyrosine	O
residues	O
in	O
the	O
kinase	B-GENE
domain	I-GENE
and	O
juxtamembrane	O
region	O
regulates	O
the	O
biological	O
and	O
catalytic	O
activities	O
of	O
Eph	B-GENE
receptors	I-GENE
.	O

The	O
indications	O
for	O
its	O
use	O
include	O
every	O
primary	O
and	O
secondary	O
rhinoplasty	O
candidate	O
unless	O
tip	O
grafts	O
are	O
going	O
to	O
be	O
under	O
tension	O
or	O
if	O
the	O
deformity	O
is	O
minor	O
.	O

The	O
effect	O
of	O
pure	O
natural	O
porcine	B-GENE
secretin	I-GENE
on	O
endocrine	O
and	O
exocrine	O
pancreatic	O
secretion	O
was	O
studied	O
in	O
the	O
totally	O
isolated	O
perfused	O
porcine	O
pancreas	O
.	O

Exogenous	O
LHRH	B-GENE
is	O
also	O
known	O
to	O
facilitate	O
mating	O
behavior	O
in	O
several	O
species	O
.	O

CONCLUSION	O
:	O
Chronic	O
administration	O
of	O
misoprostol	O
may	O
have	O
caused	O
a	O
negative	O
natriuretic	O
effect	O
in	O
cirrhotic	O
patients	O
with	O
ascites	O
.	O

The	O
in	O
vivo	O
profile	O
of	O
ZFH-2	B-GENE
in	O
the	O
larval	O
CNS	O
shows	O
intriguing	O
overlap	O
with	O
DDC	B-GENE
in	O
specific	O
serotonin	O
and	O
dopamine	O
neurons	O
.	O

Using	O
this	O
reporter	O
gene	O
system	O
,	O
we	O
previously	O
showed	O
that	O
EPO-induced	O
activation	O
of	O
the	O
c-fos	B-GENE
promoter	I-GENE
can	O
be	O
detected	O
rapidly	O
and	O
sensitively	O
as	O
an	O
elevation	O
of	O
cellular	B-GENE
luciferase	I-GENE
activity	O
.	O

Demonstration	O
of	O
the	O
agent	O
was	O
performed	O
from	O
the	O
6th	O
to	O
the	O
11th	O
day	O
p	O
.	O
i	O
.	O
by	O
direct	O
microscopic	O
methods	O
(	O
Stamp	O
and	O
auramine	O
staining	O
,	O
fluorescent	O
antibody	O
technique	O
)	O
;	O
the	O
Coxiella	O
content	O
was	O
determined	O
by	O
titration	O
in	O
embryonated	O
hen's	O
eggs	O
.	O

These	O
characteristic	O
structural	O
features	O
were	O
used	O
to	O
create	O
the	O
abbreviation	O
AZF1	B-GENE
(	O
Asparagine-rich	B-GENE
Zinc	I-GENE
Finger	I-GENE
protein	I-GENE
)	O
.	O

NMR	O
of	O
diffusing	O
atoms	O
in	O
a	O
periodic	O
porous	O
medium	O
in	O
the	O
presence	O
of	O
a	O
nonuniform	O
magnetic	O
field	O
.	O

Cost-effectiveness	O
of	O
interferon	B-GENE
beta-1b	I-GENE
in	O
slowing	O
multiple	O
sclerosis	O
disability	O
progression	O
.	O

Pseudosubstrate	O
(	O
19-36	O
)	O
,	O
derived	O
from	O
the	O
C-terminus	O
of	O
Ca-dependent	B-GENE
PKC	I-GENE
isotypes	I-GENE
,	O
inhibited	O
beta-PKC	B-GENE
but	O
not	O
nPKC	B-GENE
activity	O
using	O
either	O
Histone	B-GENE
IIIS	I-GENE
or	O
peptide	O
(	O
19-31	O
)	O
as	O
substrate	O
.	O

Sensing	O
with	O
chemically	O
and	O
biologically	O
modified	O
carbon	O
electrodes	O
.	O

Structure	O
,	O
promoter	O
analysis	O
and	O
chromosomal	O
assignment	O
of	O
the	O
human	B-GENE
APEX	I-GENE
gene	I-GENE
.	O

Upon	O
tyrosine	O
phosphorylation	O
at	O
the	O
ITIMs	O
,	O
these	O
molecules	O
recruit	O
SH2	B-GENE
domain-containing	O
phosphatases	B-GENE
such	O
as	O
SH2-containing	O
tyrosine	B-GENE
phosphatase-1	I-GENE
and	O
negatively	O
regulate	O
cell	O
activity	O
.	O

Homologous	O
recombination	O
between	O
the	O
Autographa	O
californica	O
nuclear	O
polyhedrosis	O
virus	O
(	O
AcNPV	O
)	O
genome	O
and	O
a	O
0	O
.	O
6-kbp-long	O
DNA	O
fragment	O
derived	O
from	O
the	O
putative	O
DNA	B-GENE
helicase	I-GENE
gene	I-GENE
of	I-GENE
Bombyx	I-GENE
mori	I-GENE
nuclear	I-GENE
polyhedrosis	I-GENE
virus	I-GENE
generates	O
eh2-AcNPV	O
,	O
an	O
expanded-host-range	O
AcNPV	O
mutant	O
(	O
S	O
.	O

The	O
transcriptional	O
activities	O
of	O
the	O
full-length	O
promoter	O
(	O
-295	O
to	O
+85	O
)	O
and	O
of	O
three	O
deletion	O
constructs	O
(	O
-197	O
,	O
-154	O
and	O
-74	O
to	O
+85	O
)	O
were	O
significantly	O
down-regulated	O
in	O
resistant	O
cells	O
.	O

Both	O
variants	O
display	O
the	O
seven-transmembrane	O
topology	O
that	O
is	O
typical	O
for	O
G	B-GENE
protein-coupled	I-GENE
receptors	I-GENE
.	O

This	O
region	O
does	O
not	O
contain	O
an	O
identifiable	O
TATA	O
element	O
,	O
indicating	O
that	O
transcription	O
of	O
the	O
glutaminase	B-GENE
gene	I-GENE
is	O
driven	O
by	O
a	O
TATA-less	O
promoter	O
.	O

Age	O
>	O
/	O
=	O
50	O
years	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
14	O
.	O
1	O
)	O
,	O
BMI	O
>	O
/	O
=	O
28	O
kg	O
/	O
m	O
(	O
2	O
)	O
(	O
OR	O
,	O
5	O
.	O
7	O
)	O
,	O
triglycerides	O
>	O
/	O
=	O
1	O
.	O
7	O
mmol	O
/	O
L	O
(	O
OR	O
,	O
5	O
)	O
,	O
and	O
alanine	B-GENE
aminotransferase	I-GENE
(	O
ALT	B-GENE
)	O
>	O
/	O
=	O
2N	O
(	O
OR	O
,	O
4	O
.	O
6	O
)	O
were	O
independently	O
associated	O
with	O
septal	O
fibrosis	O
.	O

XXI	O
.	O

They	O
generated	O
ca	O
.	O

Northern	O
blot	O
analyses	O
demonstrate	O
that	O
3	O
.	O
9-	O
and	O
5-kilobase	O
mRNAs	O
corresponding	O
to	O
the	O
cDNA	O
were	O
present	O
in	O
all	O
tissues	O
examined	O
,	O
suggesting	O
that	O
the	O
protein	O
it	O
encodes	O
performs	O
a	O
housekeeping	O
function	O
.	O

Furthermore	O
,	O
the	O
DNA	B-GENE
polymerase	I-GENE
II	I-GENE
complex	I-GENE
was	O
difficult	O
to	O
obtain	O
from	O
dpb2-1	B-GENE
mutant	O
cells	O
,	O
suggesting	O
that	O
a	O
stable	O
DNA	B-GENE
polymerase	I-GENE
II	I-GENE
complex	I-GENE
requires	O
DPB2	B-GENE
and	O
is	O
essential	O
for	O
chromosomal	O
replication	O
.	O

Linking	O
continuous	O
community-based	O
morbidity	O
recording	O
of	O
influenza-like	O
illness	O
(	O
ILI	O
)	O
with	O
virological	O
sampling	O
has	O
consistently	O
proved	O
its	O
value	O
as	O
one	O
of	O
the	O
earliest	O
indicators	O
of	O
circulating	O
influenza	O
activity	O
.	O

Levels	O
of	O
the	O
MEK	B-GENE
inhibitor	O
PD98059	O
that	O
block	O
EGF-induced	O
mitogenesis	O
and	O
MAP	B-GENE
kinase	I-GENE
phosphorylation	O
also	O
abrogate	O
EGF-induced	O
focal	O
adhesion	O
disassembly	O
and	O
cell	O
motility	O
.	O

IFI16	B-GENE
consists	O
of	O
ten	O
exons	O
and	O
nine	O
intervening	O
introns	O
spanning	O
at	O
least	O
28	O
kilobases	O
(	O
kb	O
)	O
of	O
DNA	O
.	O

Smoking	O
history	O
and	O
awake	O
oxygen	O
saturation	O
(	O
SaO2	O
)	O
was	O
recorded	O
in	O
all	O
of	O
them	O
.	O

In	O
a	O
heterologous	O
transcriptional	O
system	O
in	O
which	O
the	O
upstream	O
regions	O
of	O
oIFNtau	B-GENE
were	O
inserted	O
in	O
front	O
of	O
simian	B-GENE
virus	I-GENE
40	I-GENE
(	I-GENE
SV40	I-GENE
)	I-GENE
promoter	I-GENE
,	O
the	O
regions	O
between	O
bases	O
-654	O
and	O
-555	O
were	O
determined	O
as	O
being	O
the	O
enhancer	O
region	O
required	O
for	O
oIFNtau-SV40-CAT	B-GENE
transactivation	O
.	O

The	O
evidence	O
presented	O
here	O
suggests	O
that	O
the	O
p40	B-GENE
complex	I-GENE
is	O
a	O
ribonucleoprotein	O
complex	O
containing	O
L1Hs	B-GENE
RNA	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
and	O
that	O
protein-protein	O
interactions	O
in	O
which	O
alpha-helix	O
structures	O
participate	O
,	O
for	O
example	O
coiled-coils	O
,	O
may	O
occur	O
in	O
the	O
complex	O
.	O

However	O
,	O
the	O
elderly	O
group	O
showed	O
significantly	O
longer	O
mean	O
residence	O
times	O
(	O
MRTs	O
)	O
and	O
lower	O
plasma	O
clearance	O
of	O
lidocaine	O
during	O
the	O
period	O
compared	O
with	O
the	O
adult	O
group	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Two	O
major	O
and	O
one	O
minor	O
transcription	O
initiation	O
sites	O
were	O
assigned	O
to	O
positions	O
+1	O
and	O
+24	O
and	O
position	O
+14	O
,	O
respectively	O
,	O
by	O
a	O
combination	O
of	O
ribonuclease	B-GENE
protection	O
,	O
primer	O
extension	O
,	O
and	O
5'	O
RACE	O
analyses	O
.	O

Taking	O
into	O
consideration	O
weight	O
and	O
seasonal	O
changes	O
in	O
bone	O
mass	O
,	O
total	O
(	O
TBBMC	O
)	O
and	O
regional	O
body	O
bone	O
mineral	O
content	O
were	O
measured	O
in	O
38	O
women	O
treated	O
with	O
GnRH	B-GENE
agonists	O
for	O
6	O
months	O
for	O
endometriosis	O
or	O
leiomyomata	O
.	O

Time	O
to	O
progression	O
was	O
6	O
months	O
(	O
5-7	O
months	O
)	O
with	O
a	O
median	O
survival	O
from	O
registration	O
of	O
9	O
.	O
6	O
months	O
(	O
95%	O
CI	O
8-12	O
months	O
)	O
.	O

SCFFWD1	B-GENE
may	O
be	O
critical	O
for	O
tumor	O
development	O
and	O
suppression	O
through	O
regulation	O
of	O
beta-catenin	B-GENE
protein	I-GENE
stability	O
.	O

In	O
addition	O
to	O
the	O
previously	O
identified	O
and	O
characterized	O
attenuator	B-GENE
1	I-GENE
situated	O
93	O
nucleotides	O
downstream	O
from	O
the	O
major	O
late	O
transcription	O
start	O
site	O
,	O
a	O
second	O
attenuator	O
,	O
attenuator	B-GENE
2	I-GENE
,	O
situated	O
55	O
nucleotides	O
downstream	O
from	O
it	O
,	O
has	O
been	O
identified	O
.	O

A	O
long	O
follow-up	O
study	O
revealed	O
that	O
convalescent	O
stage	O
children	O
still	O
have	O
the	O
potency	O
to	O
have	O
an	O
immediate	O
type	O
hypersensitivity	O
reaction	O
on	O
exposure	O
to	O
mite	O
antigen	O
,	O
with	O
a	O
high	O
titer	O
of	O
mite	B-GENE
specific	I-GENE
IgE	I-GENE
in	O
their	O
sera	O
,	O
but	O
they	O
are	O
free	O
from	O
asthmatic	O
attacks	O
because	O
of	O
the	O
reduction	O
in	O
the	O
amount	O
of	O
mite	O
antigen	O
in	O
the	O
body	O
,	O
as	O
shown	O
by	O
the	O
reduction	O
in	O
the	O
amount	O
of	O
mite	B-GENE
specific	I-GENE
IgG	I-GENE
.	O

These	O
changes	O
weren't	O
so	O
significant	O
in	O
the	O
group	O
of	O
obese	O
children	O
who	O
didn't	O
lose	O
weight	O
.	O

USA	O
80	O
,	O
3618-3622	O
)	O
The	O
two	O
proteins	O
show	O
36%	O
identities	O
in	O
their	O
amino	O
acid	O
sequence	O
,	O
in	O
an	O
alignment	O
requiring	O
six	O
gaps	O
.	O

After	O
cells	O
were	O
stably	O
transfected	O
with	O
CIITA	B-GENE
,	O
endogenous	O
MHC	B-GENE
class	I-GENE
II	I-GENE
genes	I-GENE
were	O
constitutively	O
expressed	O
,	O
and	O
MHC	B-GENE
class	I-GENE
II	I-GENE
promoters	I-GENE
,	O
delivered	O
by	O
transfection	O
,	O
were	O
actively	O
transcribed	O
in	O
CIITA-expressing	O
cells	O
.	O

POU-specific	O
and	O
POU-homeo	B-GENE
domains	I-GENE
of	O
Oct3	B-GENE
were	O
produced	O
in	O
Echerichia	O
coli	O
for	O
characterization	O
of	O
DNA	O
binding	O
to	O
the	O
octamer	O
sequence	O
.	O

Bullous	O
angiolymphoid	O
hyperplasia	O
with	O
eosinophilia	O
.	O

No	O
title	O
available	O
.	O

Regulation	O
of	O
urokinase	B-GENE
plasminogen	I-GENE
activator	I-GENE
gene	I-GENE
transcription	O
in	O
the	O
RAW264	O
murine	O
macrophage	O
cell	O
line	O
by	O
macrophage	B-GENE
colony-stimulating	I-GENE
factor	I-GENE
(	O
CSF-1	B-GENE
)	O
is	O
dependent	O
upon	O
the	O
level	O
of	O
cell-surface	O
receptor	O
.	O

Polyclonal	O
antibodies	O
against	O
the	O
N-terminal	O
part	O
(	O
amino	O
acids	O
12-363	O
)	O
and	O
the	O
C-terminal	O
part	O
(	O
amino	O
acids	O
330-730	O
)	O
of	O
rainbow	B-GENE
trout	I-GENE
HIF-1alpha	I-GENE
protein	I-GENE
recognized	O
rainbow	B-GENE
trout	I-GENE
and	I-GENE
chinook	I-GENE
salmon	I-GENE
HIF-1alpha	I-GENE
protein	I-GENE
in	O
Western	O
blot	O
analysis	O
.	O

It	O
is	O
thus	O
one	O
of	O
the	O
key	O
enzymes	O
involved	O
in	O
the	O
triiodothyronine-mediated	O
control	O
of	O
growth	O
,	O
differentiation	O
and	O
basal	O
metabolism	O
in	O
vertebrates	O
.	O

Similarly	O
,	O
comparison	O
of	O
percentage	O
reductions	O
of	O
heart	O
rate	O
at	O
supine	O
,	O
sitting	O
and	O
exercise	O
by	O
repeated	O
measure	O
analysis	O
showed	O
the	O
Malays	O
to	O
have	O
significantly	O
higher	O
change	O
compared	O
to	O
the	O
Chinese	O
(	O
p	O
=	O
0	O
.	O
040	O
)	O
.	O

To	O
analyze	O
the	O
mechanism	O
of	O
fos	B-GENE
/	I-GENE
jun	I-GENE
activation	O
by	O
TCDD	O
we	O
have	O
used	O
electrophoretic	O
mobility	O
shift	O
and	O
transient	O
expression	O
assays	O
of	O
reporter	O
gene	O
constructs	O
containing	O
response	O
elements	O
for	O
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TRE	B-GENE
)	O
,	O
serum	O
(	O
SRE	B-GENE
)	O
,	O
cAMP	O
(	O
CRE	B-GENE
)	O
,	O
and	O
aromatic	O
hydrocarbons	O
(	O
AhRE	O
)	O
from	O
the	O
fos	B-GENE
and	O
jun	B-GENE
genes	I-GENE
fused	O
to	O
the	O
firefly	B-GENE
luciferase	I-GENE
gene	I-GENE
under	O
the	O
control	O
of	O
the	O
SV40	B-GENE
minimal	I-GENE
promoter	I-GENE
.	O

The	O
mysteries	O
of	O
geographic	O
variability	O
in	O
nonmelanoma	O
skin	O
cancer	O
incidence	O
.	O

The	O
two	O
different	O
phosphoforms	O
of	O
STAT5	B-GENE
have	O
identical	O
in	O
vitro	O
DNA	O
binding	O
specificity	O
and	O
reactivity	O
with	O
tyrosine	O
phosphopeptides	O
,	O
but	O
differ	O
in	O
their	O
cellular	O
localization	O
.	O

Changes	O
in	O
tissue	O
PCO2	O
were	O
less	O
dramatic	O
and	O
did	O
not	O
vary	O
significantly	O
from	O
those	O
recorded	O
in	O
venous	O
blood	O
.	O

To	O
improve	O
test	O
efficiency	O
,	O
we	O
modified	O
our	O
previously	O
introduced	O
contrast	O
/	O
color	O
card	O
test	O
by	O
including	O
a	O
patterned	O
test	O
stimulus	O
and	O
reducing	O
the	O
number	O
of	O
stimuli	O
in	O
both	O
experimental	O
phases	O
.	O

Sequence	O
comparisons	O
of	O
prokaryotic	B-GENE
RCR	I-GENE
initiators	I-GENE
has	O
revealed	O
a	O
set	O
of	O
three	O
common	O
motifs	O
,	O
two	O
of	O
which	O
,	O
a	O
putative	O
metal	O
coordination	O
site	O
and	O
a	O
downstream	O
active-site	O
tyrosine	O
motif	O
,	O
could	O
be	O
tentatively	O
identified	O
in	O
parvoviral	B-GENE
replicator	I-GENE
proteins	I-GENE
.	O

An	O
even	O
greater	O
inflammatory	O
response	O
was	O
observed	O
after	O
intratracheal	O
instillation	O
of	O
ufCB	O
,	O
but	O
not	O
after	O
CB	O
instillation	O
.	O

Validity	O
of	O
NIR	O
spectroscopy	O
for	O
quantitatively	O
measuring	O
muscle	O
oxidative	O
metabolic	O
rate	O
in	O
exercise	O
.	O

Ten	O
males	O
performed	O
both	O
test	O
conditions	O
and	O
oxygen	O
uptake	O
VO2	O
,	O
heart	O
rate	O
,	O
minute	O
ventilation	O
VE	O
,	O
perceived	O
exertion	O
and	O
spinal	O
shrinkage	O
were	O
recorded	O
.	O

A	O
major	O
mechanism	O
whereby	O
steroid	B-GENE
hydroxylase	I-GENE
gene	I-GENE
transcription	O
is	O
regulated	O
in	O
the	O
adrenal	O
cortex	O
requires	O
the	O
pituitary	O
peptide	O
hormone	O
,	O
ACTH	B-GENE
,	O
which	O
acts	O
via	O
cAMP	O
.	O

AF	B-GENE
showed	O
a	O
mixed	O
nuclear	O
/	O
cytoplasmic	O
pattern	O
of	O
expression	O
in	O
the	O
epithelial	O
,	O
endothelial	O
,	O
and	O
stromal	O
component	O
of	O
the	O
normal	O
breast	O
and	O
benign	O
lesions	O
,	O
whereas	O
an	O
impressive	O
loss	O
of	O
AF	B-GENE
expression	O
was	O
noted	O
in	O
in	O
situ	O
and	O
invasive	O
breast	O
cancer	O
and	O
tumoral	O
stroma	O
.	O

Based	O
on	O
213	O
determinations	O
,	O
the	O
control	O
mean	O
serum	B-GENE
CPK	I-GENE
activity	O
was	O
262	O
+	O
/	O
-	O
113	O
I	O
.	O
U	O
.	O
/	O
liter	O
.	O

In	O
vivo	O
,	O
selective	O
activation	O
of	O
SAPKs	B-GENE
stimulates	O
formation	O
of	O
the	O
ternary	O
complex	O
containing	O
Elk-1	B-GENE
,	O
serum	B-GENE
response	I-GENE
factor	I-GENE
and	O
the	O
serum	B-GENE
response	I-GENE
element	I-GENE
,	O
and	O
enhances	O
Elk-1-dependent	O
transcription	O
.	O

At	O
all	O
time-points	O
,	O
most	O
patients	O
(	O
>	O
/	O
=	O
87%	O
)	O
were	O
receiving	O
irbesartan	O
/	O
HCTZ	O
alone	O
.	O

A	O
leucine	O
zipper	O
domain	O
of	O
the	O
suppressor	B-GENE
of	I-GENE
Hairy-wing	I-GENE
protein	I-GENE
mediates	O
its	O
repressive	O
effect	O
on	O
enhancer	O
function	O
.	O

Analysis	O
of	O
the	O
inferred	O
1	B-GENE
,	I-GENE
859-residue	I-GENE
ama-1	I-GENE
product	I-GENE
showed	O
considerable	O
identity	O
with	O
the	O
largest	O
subunit	O
of	O
RNAP	B-GENE
II	I-GENE
from	O
other	O
organisms	O
,	O
including	O
the	O
presence	O
of	O
a	O
zinc	O
finger	O
motif	O
near	O
the	O
amino	O
terminus	O
,	O
and	O
a	O
carboxyl-terminal	O
domain	O
of	O
42	O
tandemly	O
reiterated	O
heptamers	O
with	O
the	O
consensus	O
Tyr	O
Ser	O
Pro	O
Thr	O
Ser	O
Pro	O
Ser	O
.	O

The	O
two	O
contiguous	O
IGF2	B-GENE
(	O
human	B-GENE
insulin-like	I-GENE
growth	I-GENE
factor	I-GENE
II	I-GENE
)	O
and	O
H19	B-GENE
genes	I-GENE
are	O
reciprocally	O
imprinted	O
in	O
both	O
human	O
and	O
mouse	O
.	O

The	O
requirement	O
of	O
3'	O
complementarity	O
for	O
a	O
ligation	O
reaction	O
is	O
reaffirmed	O
by	O
results	O
from	O
1	O
nt	O
insertions	O
on	O
either	O
the	O
3'-	O
or	O
5'-side	O
of	O
the	O
nick	O
.	O

In	O
serum-stimulated	O
cells	O
,	O
the	O
binding	O
of	O
NF-Y	B-GENE
/	I-GENE
CBF	I-GENE
to	O
TKC1	B-GENE
increased	O
gradually	O
,	O
reaching	O
a	O
plateau	O
at	O
the	O
S	O
phase	O
.	O

Data	O
are	O
presented	O
hinting	O
that	O
the	O
15	O
beta-hydroxy-	O
,	O
metabolite	O
of	O
CPA	O
may	O
actually	O
be	O
the	O
biologically	O
active	O
agent	O
.	O

A	O
sharp	O
outbreak	O
of	O
influenza	O
A	O
occurred	O
on	O
the	O
base	O
during	O
February	O
that	O
was	O
due	O
to	O
an	O
A	O
/	O
Texas	O
/	O
1	O
/	O
77-like	O
virus	O
,	O
a	O
variant	O
of	O
the	O
A	O
/	O
Victoria	O
/	O
3	O
/	O
75	O
prototpye	O
.	O

One	O
missense	O
allele	O
(	O
P236S	B-GENE
)	O
with	O
complete	O
loss	O
of	O
function	O
at	O
30	O
degreesC	O
and	O
four	O
missense	O
alleles	O
(	O
L173F	B-GENE
,	O
E225K	B-GENE
,	O
S269L	B-GENE
and	O
E274K	B-GENE
)	O
that	O
conferred	O
a	O
temperature	O
sensitive	O
phenotype	O
were	O
identified	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
xylitol	O
,	O
an	O
activator	O
of	O
the	O
pentose	O
phosphate	O
pathway	O
.	O

Pentane	O
and	O
ethane	O
,	O
which	O
arise	O
during	O
lipid	O
peroxidation	O
in	O
vivo	O
,	O
were	O
measured	O
by	O
gas	O
chromatography	O
in	O
breath	O
samples	O
of	O
rats	O
fed	O
for	O
8	O
weeks	O
a	O
vitamin	O
E-deficient	O
diet	O
to	O
which	O
had	O
been	O
added	O
0	O
,	O
11	O
,	O
or	O
40	O
IU	O
vitamin	O
E	O
acetate	O
per	O
kg	O
.	O

Here	O
we	O
have	O
determined	O
the	O
nucleotide	O
sequence	O
of	O
3	O
.	O
5	O
kb	O
from	O
the	O
3'	O
end	O
of	O
delta	B-GENE
gag	I-GENE
to	O
the	O
3'	O
end	O
of	O
molecularly	O
cloned	O
proviral	O
MH2	O
DNA	O
,	O
in	O
order	O
to	O
elucidate	O
the	O
genetic	O
structure	O
of	O
the	O
virus	O
and	O
to	O
compare	O
it	O
with	O
other	O
mht	B-GENE
-	O
and	O
myc-containing	O
oncogenic	O
viruses	O
as	O
well	O
as	O
with	O
the	O
chicken	B-GENE
proto-myc	I-GENE
gene	I-GENE
.	O

Concurrent	O
with	O
ligand-dependent	O
uptake	O
,	O
we	O
now	O
show	O
that	O
the	O
receptor	O
undergoes	O
ligand-induced	O
ubiquitination	O
,	O
suggesting	O
that	O
receptor	O
ubiquitination	O
may	O
function	O
in	O
the	O
ligand-dependent	O
endocytosis	O
of	O
the	O
a-factor	B-GENE
receptor	I-GENE
as	O
well	O
as	O
in	O
its	O
constitutive	O
endocytosis	O
.	O

Cleavage	O
and	O
DNA	O
joining	O
reactions	O
,	O
carried	O
out	O
by	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
(	I-GENE
HIV-1	I-GENE
)	I-GENE
integrase	I-GENE
,	O
are	O
necessary	O
to	O
effect	O
the	O
covalent	O
insertion	O
of	O
HIV-1	O
DNA	O
into	O
the	O
host	O
genome	O
.	O

Immunoprecipitation	O
experiments	O
using	O
DokR-specific	B-GENE
antibodies	I-GENE
revealed	O
an	O
interaction	O
between	O
endogenous	B-GENE
DokR	I-GENE
and	O
a	O
150-kDa	O
protein	O
that	O
is	O
tyrosine-phosphorylated	O
in	O
EGF-stimulated	O
BaF	O
/	O
3	O
cells	O
.	O

The	O
requirement	O
for	O
proteolytic	O
activity	O
of	O
both	O
FVIIa	B-GENE
and	O
FXa	B-GENE
suggests	O
that	O
protease-activated	O
receptors	O
may	O
be	O
involved	O
.	O

The	O
weight-bearing	O
surface	O
of	O
the	O
PE	O
head	O
became	O
smoother	O
with	O
time	O
after	O
THA	O
,	O
and	O
the	O
friction	O
coefficient	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
of	O
an	O
unused	O
PE	O
head	O
.	O

Collaborative	O
study	O
of	O
Japanese	O
Pharmacopoeia	O
Heparin	O
Sodium	O
Reference	O
Standard	O
.	O

The	O
cDNA	O
corresponding	O
to	O
the	O
FPS1	B-GENE
gene	I-GENE
was	O
isolated	O
by	O
functional	O
complementation	O
of	O
a	O
mutant	O
yeast	O
strain	O
defective	O
in	O
FPS	B-GENE
activity	O
(	O
Delourme	O
,	O
D	O
.	O
,	O
Lacroute	O
,	O
F	O
.	O
,	O
and	O
Karst	O
,	O
F	O
.	O

Pharmacokinetic	O
parameters	O
were	O
similar	O
to	O
values	O
given	O
in	O
the	O
literature	O
for	O
intravenous	O
(	O
IV	O
)	O
or	O
intraarterial	O
(	O
IA	O
)	O
bolus	O
MMC	O
injections	O
(	O
Tmax	O
=	O
7	O
.	O
0	O
min	O
following	O
the	O
beginning	O
of	O
MMC	O
infusion	O
,	O
Vss	O
=	O
0	O
.	O
57	O
1	O
/	O
kg	O
,	O
C1	O
=	O
8	O
.	O
9	O
ml	O
/	O
min	O
.	O
kg	O
,	O
T1	O
/	O
2	O
alpha	O
=	O
8	O
.	O
3	O
min	O
,	O
T1	O
/	O
2	O
beta	O
=	O
58	O
.	O
6	O
min	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
expression	O
of	O
TD-IkappaBalpha	B-GENE
blocked	O
phorbol	O
myristate	O
acetate-phytohemagglutinin	B-GENE
or	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha-induced	O
IkappaBalpha	B-GENE
gene	I-GENE
transcription	O
and	O
abolished	O
NF-kappaB	B-GENE
DNA	O
binding	O
activity	O
,	O
due	O
to	O
the	O
continued	O
cytoplasmic	O
sequestration	O
of	O
RelA	B-GENE
(	I-GENE
p65	I-GENE
)	I-GENE
by	O
TD-IkappaBalpha	B-GENE
.	O

A	O
second	O
promoter	O
activity	O
was	O
identified	O
in	O
the	O
region	O
between	O
the	O
two	O
major	O
transcriptional	O
start	O
sites	O
.	O

Unique	O
to	O
this	O
system	O
,	O
the	O
activity	O
of	O
TraR	B-GENE
is	O
negatively	O
modulated	O
by	O
an	O
antiactivator	O
called	O
TraM	B-GENE
.	O

Direct	O
and	O
inverted	O
repeat	O
elements	O
of	O
10	O
,	O
11	O
,	O
16	O
,	O
19	O
,	O
and	O
22	O
nucleotides	O
(	O
nt	O
)	O
flank	O
the	O
promoter	O
site	O
.	O

Single	O
tooth	O
replacement	O
with	O
the	O
aid	O
of	O
the	O
ITI	O
(	O
International	O
Team	O
fur	O
Implantologie	O
)	O
type	O
F	O
hollow-cylinder	O
implant	O
.	O

Interestingly	O
,	O
the	O
positions	O
of	O
these	O
introns	O
have	O
been	O
conserved	O
in	O
comparison	O
with	O
the	O
genes	O
of	O
two	O
other	O
transglutaminase-like	O
activities	O
described	O
in	O
the	O
literature	O
,	O
but	O
the	O
TGM1	B-GENE
gene	I-GENE
is	O
by	O
far	O
the	O
smallest	O
characterized	O
to	O
date	O
because	O
its	O
introns	O
are	O
relatively	O
smaller	O
.	O

Studies	O
on	O
swine	O
enteroviruses	O
.	O

In	O
addition	O
,	O
anti-phosphotyrosine	B-GENE
antibodies	I-GENE
immunoprecipitated	O
80K-H	B-GENE
from	O
cell	O
lysates	O
of	O
FGF-stimulated	O
but	O
not	O
from	O
control	O
fibroblasts	O
.	O

Splice	O
variations	O
in	O
genes	O
coding	O
for	O
the	O
transmembrane	B-GENE
FGF	I-GENE
receptor	I-GENE
(	O
FGFR	B-GENE
)	O
result	O
in	O
isoforms	O
that	O
vary	O
in	O
the	O
ectodomain	O
,	O
intracellular	O
juxtamembrane	O
domain	O
,	O
and	O
the	O
intracellular	B-GENE
kinase	I-GENE
domain	I-GENE
.	O

The	O
efficacy	O
of	O
quantitative	O
and	O
qualitative	O
chloride	O
titrators	O
in	O
the	O
estimation	O
of	O
human	O
salt	O
intake	O
.	O

During	O
the	O
period	O
from	O
May	O
to	O
August	O
,	O
1978	O
,	O
an	O
epidemic	O
of	O
hand	O
,	O
foot	O
and	O
mouth	O
disease	O
(	O
HFMD	O
)	O
occurred	O
in	O
Gifu	O
prefecture	O
.	O

The	O
design	O
principle	O
based	O
on	O
a	O
uniform	O
vibration	O
mode	O
is	O
presented	O
.	O

The	O
enzymatic	O
response	O
of	O
neutrophils	O
and	O
monocytes	O
was	O
similar	O
although	O
the	O
magnitude	O
of	O
the	O
NADPH	B-GENE
oxidase	I-GENE
activity	O
was	O
significantly	O
higher	O
in	O
neutrophils	O
than	O
in	O
monocytes	O
.	O

These	O
results	O
suggest	O
that	O
beta-1	B-GENE
may	O
act	O
as	O
a	O
tissue-specific	O
,	O
trans-acting	O
regulator	O
of	O
the	O
expression	O
of	O
the	O
beta-zein	B-GENE
gene	I-GENE
in	O
developing	O
maize	O
endosperm	O
.	O

Thus	O
,	O
through	O
a	O
change	O
in	O
conformation	O
upon	O
repair	O
of	O
the	O
6RG	O
lesion	O
,	O
MGMT	B-GENE
switches	O
from	O
a	O
DNA	O
repair	O
factor	O
to	O
a	O
transcription	O
regulator	O
(	O
R-MGMT	B-GENE
)	O
,	O
enabling	O
the	O
cell	O
to	O
sense	O
as	O
well	O
as	O
respond	O
to	O
mutagens	O
.	O

Mothers	O
with	O
severe	O
anatomical	O
abnormalities	O
,	O
who	O
are	O
HIV	O
positive	O
,	O
have	O
active	O
TB	O
or	O
whose	O
children	O
have	O
inherited	O
mono-	O
or	O
disaccharide	O
intolerances	O
should	O
not	O
breastfeed	O
.	O

Metal	O
coordination	O
compounds	O
of	O
thiabendazole	O
.	O

The	O
responsiveness	O
of	O
visual	O
cortex	O
(	O
VC	O
)	O
and	O
superior	O
colliculus	O
(	O
SC	O
)	O
was	O
simultaneously	O
compared	O
following	O
conditioning	O
"ON"	O
or	O
"OFF"	O
stimulation	O
,	O
in	O
the	O
rabbit	O
.	O

Existence	O
and	O
uniqueness	O
of	O
solutions	O
of	O
the	O
appropriate	O
boundary	O
value	O
problems	O
are	O
established	O
,	O
in	O
the	O
case	O
of	O
small	O
permeability	O
coefficients	O
and	O
transport	O
rates	O
,	O
or	O
large	O
diffusion	O
coefficients	O
and	O
small	O
resistance	O
to	O
flow	O
constants	O
.	O

The	O
neurohypophysial	O
vasopressin	B-GENE
and	O
oxytocin	B-GENE
content	O
was	O
bioassayed	O
by	O
pressor	O
effect	O
following	O
Dekanski	O
or	O
milk-ejection	O
activity	O
in	O
vitro	O
following	O
van	O
Dongen	O
and	O
Hays	O
,	O
respectively	O
.	O

MK-927	O
:	O
a	O
topically	O
active	O
ocular	O
hypotensive	O
carbonic	B-GENE
anhydrase	I-GENE
inhibitor	O
.	O

Because	O
of	O
differences	O
in	O
patient	O
characteristics	O
,	O
control	O
measurements	O
were	O
obtained	O
from	O
normal	O
muscle	O
in	O
all	O
patients	O
.	O

We	O
have	O
cloned	O
the	O
single-copy	O
gene	O
for	O
the	O
trans	B-GENE
-spliceosomal	I-GENE
U5	I-GENE
snRNA	I-GENE
from	O
the	O
trypanosomatid	O
species	O
Leptomonas	O
seymouri	O
,	O
using	O
U5	B-GENE
RNA	I-GENE
affinity	O
selection	O
and	O
cDNA	O
cloning	O
.	O

In	O
these	O
experiments	O
we	O
begin	O
to	O
study	O
the	O
potential	O
functions	O
of	O
the	O
alpha	B-GENE
7	I-GENE
cytoplasmic	I-GENE
domain	I-GENE
by	O
analyzing	O
homologies	O
between	O
the	O
rat	O
and	O
human	O
sequences	O
,	O
by	O
immunologic	O
studies	O
using	O
an	O
anti-cytoplasmic	O
domain	O
antiserum	O
,	O
and	O
by	O
identifying	O
two	O
alternate	O
forms	O
.	O

The	O
Mauriceville	O
and	O
Varkud	O
mitochondrial	O
plasmids	O
are	O
closely	O
related	O
,	O
closed-circular	O
DNAs	O
(	O
3	O
.	O
6	O
and	O
3	O
.	O
7	O
kb	O
,	O
respectively	O
)	O
that	O
have	O
characteristics	O
of	O
mtDNA	O
introns	O
and	O
retroid	O
elements	O
.	O

RESULTS	O
:	O
The	O
target	O
dose	O
was	O
comparable	O
in	O
the	O
3D-CRT	O
and	O
IMRT	O
plans	O
,	O
although	O
improvements	O
were	O
seen	O
when	O
seven	O
and	O
nine	O
IMRT	O
fields	O
were	O
used	O
.	O

[	O
Pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
during	O
10%	O
O2-PVR	O
during	O
21%	O
O2	O
/	O
PVR	O
during	O
21%	O
O2	O
]	O
x	O
100	O
was	O
termed	O
as	O
hypoxic	O
pulmonary	O
vasoconstriction	O
(	O
HPV	O
)	O
.	O

This	O
analysis	O
revealed	O
an	O
intact	O
gene	O
(	O
arg4	B-GENE
)	O
showing	O
a	O
high	O
degree	O
of	O
homology	O
with	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
CPA2	I-GENE
gene	I-GENE
encoding	O
the	O
large	O
subunit	O
of	O
carbamoyl-phosphate	B-GENE
synthetase	I-GENE
(	O
CPS-A	B-GENE
)	O
.	O

Diminished	O
forearm	O
arteriolar	O
dilator	O
capacity	O
produced	O
by	O
mineralocorticoid-induced	O
salt	O
retention	O
in	O
man	O
.	O

The	O
effects	O
of	O
dominant	O
interfering	O
forms	O
of	O
the	O
JNK	B-GENE
/	I-GENE
p38	I-GENE
signaling	O
pathway	O
demonstrate	O
that	O
activation	O
of	O
these	O
kinases	O
is	O
critical	O
for	O
cytokine-induced	O
E-selectin	B-GENE
gene	I-GENE
expression	O
.	O

During	O
flexion	O
whiplash	O
,	O
the	O
torque	O
at	O
the	O
occipital	O
condyle	O
reverses	O
its	O
direction	O
at	O
about	O
25	O
ms	O
after	O
impact	O
.	O

Mutations	O
of	O
the	O
RET	B-GENE
gene	I-GENE
,	O
encoding	O
a	O
receptor	B-GENE
tyrosine	I-GENE
kinase	I-GENE
,	O
have	O
been	O
associated	O
with	O
the	O
inherited	O
cancer	O
syndromes	O
MEN	O
2A	O
and	O
MEN	O
2B	O
.	O

Analyses	O
revealed	O
that	O
scale	O
matters	O
above	O
and	O
beyond	O
the	O
effect	O
of	O
quadrat	O
area	O
.	O

The	O
topology	O
and	O
chain	O
folding	O
of	O
the	O
beta	O
subunits	O
in	O
the	O
artifactual	O
beta	O
60	O
capsid	O
are	O
similar	O
to	O
the	O
native	B-GENE
alpha	I-GENE
3	I-GENE
beta	I-GENE
60	I-GENE
enzyme	I-GENE
.	O

Northern	O
blot	O
analysis	O
,	O
using	O
the	O
Ltp4-specific	O
probe	O
,	O
indicated	O
that	O
Xanthomonas	O
campestris	O
pv	O
.	O
translucens	O
induced	O
an	O
increase	O
over	O
basal	O
levels	O
of	O
Ltp4	B-GENE
mRNA	I-GENE
,	O
while	O
Pseudomonas	O
syringae	O
pv	O
.	O
japonica	O
caused	O
a	O
decrease	O
.	O

Together	O
,	O
these	O
data	O
identify	O
ERK2	B-GENE
as	O
a	O
specific	O
and	O
direct	O
target	O
of	O
HePTP	B-GENE
and	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
HePTP	B-GENE
negatively	O
regulates	O
ERK2	B-GENE
activity	O
as	O
part	O
of	O
a	O
feedback	O
mechanism	O
.	O

UV	O
cross-linking	O
experiments	O
demonstrated	O
that	O
HSV	O
infection	O
caused	O
enhanced	O
binding	O
of	O
protein	O
factors	O
,	O
including	O
the	O
64-kDa	B-GENE
component	I-GENE
of	I-GENE
cleavage	I-GENE
stimulation	I-GENE
factor	I-GENE
(	O
CstF	B-GENE
)	O
,	O
to	O
poly	O
(	O
A	O
)	O
site	O
RNAs	O
from	O
virus	O
genes	O
of	O
all	O
temporal	O
classes	O
and	O
that	O
this	O
enhanced	O
binding	O
required	O
expression	O
of	O
IE63	B-GENE
.	O

However	O
,	O
little	O
was	O
understood	O
about	O
the	O
normal	O
function	O
of	O
CREB-2	B-GENE
in	O
mammalian	O
development	O
or	O
organ	O
physiology	O
.	O

Follow-up	O
study	O
showed	O
85%	O
of	O
these	O
patients	O
with	O
effectiveness	O
.	O

In	O
order	O
to	O
gain	O
deeper	O
insight	O
into	O
the	O
role	O
of	O
the	O
amino-terminal	O
domain	O
of	O
the	O
p24	B-GENE
(	I-GENE
CA	I-GENE
)	I-GENE
protein	O
during	O
viral	O
replication	O
,	O
eight	O
highly	O
conserved	O
proline	O
residues	O
known	O
to	O
promote	O
turns	O
and	O
to	O
terminate	O
alpha-helices	O
within	O
the	O
p24	B-GENE
tertiary	O
structure	O
were	O
replaced	O
by	O
a	O
leucine	O
residue	O
(	O
P-position-L	O
)	O
.	O

However	O
,	O
when	O
directed	O
to	O
the	O
nucleosome	O
by	O
fusion	O
to	O
core	B-GENE
histone	I-GENE
H2A	I-GENE
or	O
H2B	B-GENE
,	O
the	O
non-histone	O
tail	O
forms	O
an	O
MCB	O
that	O
appears	O
identical	O
to	O
that	O
of	O
the	O
endogenous	O
protein	O
.	O

A	O
novel	O
growth-related	O
nuclear	O
protein	O
binds	O
and	O
inhibits	O
rat	O
aldolase	B-GENE
B	I-GENE
gene	I-GENE
promoter	O
.	O

The	O
investigation	O
was	O
apt	O
at	O
studying	O
the	O
relationship	O
between	O
urinary	O
metabolites	O
of	O
serotonin	O
and	O
catecholamine	O
(	O
5-HIAA	O
and	O
VMA	O
)	O
,	O
T-cells	O
(	O
OKT3+	B-GENE
)	O
,	O
T-helper	O
(	O
OKT4+	B-GENE
)	O
,	O
T-suppressor	O
(	O
OKT8+	B-GENE
)	O
and	O
B-cells	O
(	O
EAC-rosette	O
forming	O
cells	O
)	O
in	O
normal	O
(	O
10	O
subjects	O
,	O
1	O
female	O
,	O
9	O
male	O
,	O
age	O
21	O
+	O
/	O
-	O
5	O
years	O
)	O
and	O
stress	O
administered	O
subjects	O
(	O
20	O
subjects	O
,	O
3	O
female	O
,	O
17	O
male	O
,	O
age	O
20	O
+	O
/	O
-	O
4	O
years	O
)	O
.	O

During	O
the	O
following	O
pregnancy	O
ultrasonographic	O
studies	O
of	O
the	O
male	O
fetus	O
in	O
the	O
16th	O
week	O
of	O
gestation	O
revealed	O
severe	O
micrognathia	O
,	O
short	O
and	O
wide	O
thumbs	O
,	O
and	O
big	O
toes	O
,	O
and	O
bowed	O
tibiae	O
.	O

Bacteriostatic	O
and	O
bacteriacidal	O
activity	O
of	O
hydroxy-9	O
ellipticine	O
in	O
vitro	O
.	O

A	O
cDNA	O
clone	O
was	O
isolated	O
from	O
a	O
chicken	O
embryo	O
cDNA	O
library	O
employing	O
a	O
PCR-generated	O
radiolabeled	O
probe	O
specific	O
for	O
the	O
U3	B-GENE
region	I-GENE
of	O
the	O
Rous	O
sarcoma	O
virus	O
LTR	O
.	O

Finally	O
,	O
there	O
are	O
a	O
growing	O
number	O
of	O
arguments	O
favouring	O
the	O
use	O
of	O
ACE	B-GENE
inhibitors	O
very	O
early	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
.	O

5	O
micrograms	O
/	O
l	O
was	O
detected	O
in	O
urine	O
from	O
some	O
non-occupationally	O
exposed	O
persons	O
.	O

Lipiodol	O
was	O
covalently	O
conjugated	O
with	O
EDTB	O
.	O

Transfection	O
of	O
HepG2	O
and	O
SK-N-MC	O
cells	O
with	O
constructs	O
deleted	O
of	O
additional	O
5'-flanking	O
fragments	O
permitted	O
the	O
definition	O
of	O
a	O
minimal	O
200	O
bp	O
promoter	O
fragment	O
containing	O
the	O
pseudo-TATA	O
box	O
and	O
two	O
putative	O
SP1-binding	B-GENE
sites	I-GENE
.	O

Comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
shows	O
that	O
the	O
ZNF189	B-GENE
gene	I-GENE
spans	O
approximately	O
11	O
kb	O
and	O
is	O
organized	O
into	O
at	O
least	O
four	O
exons	O
,	O
the	O
large	O
3'-end	O
exon	O
coding	O
for	O
the	O
complete	O
zinc	O
finger	O
domain	O
and	O
the	O
3'	O
untranslated	O
region	O
.	O

86	O
:	O
3199-3203	O
)	O
or	O
G1	O
to	O
S	O
phase	O
(	O
Reilly	O
,	O
C	O
.	O

Mutations	O
truncating	O
as	O
many	O
as	O
143	O
C-terminal	O
residues	O
from	O
the	O
transcriptional	O
activator	O
encoded	O
by	O
the	O
areA	B-GENE
gene	I-GENE
,	O
mediating	O
nitrogen	O
metabolite	O
repression	O
in	O
Aspergillus	O
nidulans	O
,	O
do	O
not	O
significantly	O
reduce	O
the	O
ability	O
of	O
the	O
areA	B-GENE
product	I-GENE
to	O
activate	O
expression	O
of	O
most	O
genes	O
under	O
areA	B-GENE
control	O
.	O

However	O
,	O
we	O
identified	O
a	O
gene	O
between	O
the	O
MDV2	B-GENE
UL54	I-GENE
and	O
UL55	B-GENE
genes	I-GENE
with	O
homology	O
to	O
the	O
first	O
ORF	O
(	O
ORF-1	B-GENE
)	O
of	O
equine	O
herpesvirus	O
type	O
1	O
and	O
corresponding	O
gene	O
identified	O
in	O
pseudorabies	O
virus	O
.	O

Using	O
lectin-affinity	O
chromatography	O
,	O
discordance	O
between	O
the	O
pattern	O
of	O
O-glycosylation	O
of	O
SSBP	B-GENE
and	O
DSBP	B-GENE
was	O
demonstrated	O
.	O

The	O
first	O
case	O
of	O
HCV	O
seroconversion	O
in	O
Portugal	O
after	O
the	O
introduction	O
of	O
HCV	O
NAT	O
screening	O
.	O

Analysis	O
of	O
hematopoietic	B-GENE
growth	I-GENE
factor	I-GENE
prescriptions	O
in	O
19	O
french	O
cancer	O
centers	O
.	O

The	O
mechanism	O
underlying	O
such	O
analgesia	O
has	O
been	O
suggested	O
to	O
involve	O
the	O
interaction	O
between	O
the	O
two	O
separate	O
but	O
interconnected	O
motivational	O
systems	O
"defense"	O
and	O
"pain	O
.	O
"	O
To	O
determine	O
the	O
developmental	O
course	O
of	O
defense	O
and	O
nociception	O
,	O
these	O
processes	O
were	O
analyzed	O
during	O
early	O
ontogeny	O
in	O
rats	O
.	O

By	O
in	O
vitro	O
immunoprecipitations	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
identified	O
two	O
classes	O
of	O
high	O
affinity	O
Engrailed-binding	B-GENE
sites	I-GENE
upstream	O
of	O
each	O
of	O
the	O
two	O
polyhomeotic	O
transcription	O
units	O
.	O

From	O
our	O
ultrastructural	O
and	O
biochemical	O
studies	O
,	O
it	O
is	O
evident	O
that	O
Type	O
II	O
pneumocytes	O
are	O
an	O
early	O
target	O
of	O
radiation	O
and	O
the	O
release	O
of	O
surfactant	O
into	O
the	O
alveolus	O
shortly	O
after	O
exposure	O
persists	O
for	O
days	O
and	O
weeks	O
.	O

METHODS	O
:	O
Experiments	O
testing	O
the	O
new	O
catheter	O
and	O
comparing	O
it	O
to	O
the	O
existing	O
catheter	O
included	O
:	O
(	O
1	O
)	O
measurement	O
of	O
the	O
laser	O
output	O
beam	O
sizes	O
and	O
divergences	O
;	O
(	O
2	O
)	O
evaluation	O
of	O
particulate	O
matter	O
generation	O
during	O
ablation	O
of	O
atherosclerotic	O
tissue	O
;	O
(	O
3	O
)	O
measurement	O
of	O
ablation	O
hole	O
sizes	O
and	O
tissue	O
penetration	O
rates	O
;	O
(	O
4	O
)	O
histopathologic	O
examination	O
of	O
laser-induced	O
in	O
vivo	O
vessel	O
wall	O
injury	O
.	O

Treatment	O
of	O
suppurative	O
peritonitis	O
.	O

In	O
Experiment	O
2	O
scopolamine	O
hydrobromide	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
was	O
administered	O
1	O
h	O
before	O
each	O
electrical	O
stimulation	O
until	O
each	O
rat	O
showed	O
the	O
stage-3	O
seizure	O
.	O

In	O
the	O
clinical	O
study	O
,	O
the	O
defect	O
size	O
shown	O
by	O
BMIPP	O
imaging	O
was	O
greater	O
in	O
anterior	O
than	O
in	O
inferior	O
infarcts	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
correlated	O
well	O
with	O
the	O
risk	O
area	O
revealed	O
by	O
contrast	O
ventriculography	O
(	O
r	O
=	O
0	O
.	O
80	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
CONCLUSION	O
:	O
The	O
above	O
preliminary	O
data	O
,	O
admittedly	O
from	O
a	O
small	O
group	O
of	O
patients	O
,	O
suggest	O
that	O
tomographic	O
BMIPP	O
imaging	O
provides	O
an	O
accurate	O
quantification	O
of	O
defect	O
size	O
by	O
means	O
of	O
a	O
simple	O
threshold	O
technique	O
and	O
,	O
in	O
the	O
subacute	O
phase	O
,	O
permits	O
determination	O
of	O
the	O
amount	O
of	O
myocardium	O
at	O
risk	O
after	O
acute	O
myocardial	O
infarction	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
the	O
HA	B-GENE
gene	I-GENE
in	O
these	O
two	O
mutants	O
confirmed	O
the	O
HA-	B-GENE
phenotype	O
.	O

Characterization	O
of	O
FIII	B-GENE
/	I-GENE
YY1	I-GENE
,	O
a	O
Xenopus	O
laevis	O
conserved	O
zinc-finger	O
protein	O
binding	O
to	O
the	O
first	O
exon	O
of	O
L1	B-GENE
and	O
L14	B-GENE
ribosomal	I-GENE
protein	I-GENE
genes	I-GENE
.	O

This	O
binary	O
repeat	O
contains	O
repetitive	O
DNA	O
elements	O
that	O
include	O
LINES	O
,	O
SINES	O
,	O
medium	O
reiteration	O
frequency	O
repeats	O
,	O
and	O
a	O
transposon-like	O
element	O
.	O

Corticosteroid-mediated	O
transcriptional	O
inhibition	O
was	O
greater	O
for	O
MR	B-GENE
/	I-GENE
GR	I-GENE
in	O
combination	O
than	O
for	O
MR	B-GENE
or	O
GR	B-GENE
alone	O
.	O

The	O
other	O
model	O
was	O
a	O
continuous	O
exponential	O
plus	O
constant	O
of	O
the	O
form	O
La-	O
=	O
a	O
+	O
b	O
[	O
exp	O
(	O
cVO2	O
)	O
]	O
.	O

DESIGN--A	O
randomised	O
study	O
was	O
conducted	O
in	O
all	O
women	O
aged	O
50-70	O
years	O
who	O
were	O
eligible	O
for	O
breast	O
cancer	O
screening	O
and	O
living	O
in	O
the	O
city	O
of	O
Utrecht	O
.	O

Interestingly	O
,	O
dTFIIA-L	B-GENE
/	I-GENE
S	I-GENE
is	O
also	O
able	O
to	O
significantly	O
enhance	O
transcriptional	O
activation	O
by	O
upstream	O
transcription	O
factors	O
including	O
Sp1	B-GENE
,	O
VP16	B-GENE
,	O
and	O
NTF-1	B-GENE
.	O

A	O
"Level	O
A"	O
in	O
vitro	O
/	O
in	O
vivo	O
correlation	O
was	O
established	O
for	O
a	O
sustained	O
release	O
theophylline	O
(	O
CAS	O
58-55-9	O
)	O
preparation	O
(	O
Bronchoretard	O
)	O
under	O
investigation	O
.	O

The	O
most	O
frequent	O
risk	O
factor	O
for	O
ischaemic	O
was	O
hypertension	O
.	O

Prostate-specific	B-GENE
antigen	I-GENE
(	O
PSA	B-GENE
)	O
promoter-driven	O
androgen-inducible	O
expression	O
of	O
sodium	B-GENE
iodide	I-GENE
symporter	I-GENE
in	O
prostate	O
cancer	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
npm3	B-GENE
,	O
which	O
is	O
usually	O
coactivated	O
with	O
fgf8	B-GENE
by	O
MMTV	O
insertion	O
,	O
was	O
not	O
up-regulated	O
by	O
androgens	O
in	O
SC-3	O
cells	O
.	O

Prostaglandin	O
synthesis	O
inhibitors	O
have	O
been	O
shown	O
to	O
delay	O
healing	O
of	O
bone	O
and	O
this	O
has	O
led	O
to	O
limitations	O
on	O
their	O
use	O
clinically	O
in	O
some	O
situations	O
.	O

Here	O
we	O
show	O
that	O
independent	O
of	O
uncertainties	O
in	O
the	O
models	O
,	O
terrestrial	O
planets	O
with	O
dense	O
atmosphere	O
like	O
Venus	O
can	O
evolve	O
into	O
one	O
of	O
only	O
four	O
possible	O
rotation	O
states	O
.	O

Elimination	O
of	O
ETH1	B-GENE
in	O
apn1	B-GENE
strains	O
also	O
increased	O
spontaneous	O
mutation	O
rates	O
9-	O
or	O
31-fold	O
compared	O
to	O
the	O
wild	O
type	O
as	O
determined	O
by	O
reversion	O
to	O
adenine	O
or	O
lysine	O
prototrophy	O
,	O
respectively	O
.	O

In	O
flies	O
,	O
the	O
dShc	B-GENE
protein	I-GENE
physically	O
associates	O
with	O
the	O
activated	O
Drosophila	B-GENE
epidermal	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
homolog	I-GENE
(	O
DER	B-GENE
)	O
and	O
is	O
inducibly	O
phosphorylated	O
on	O
tyrosine	O
by	O
DER	B-GENE
.	O

FEV1	O
did	O
not	O
fall	O
significantly	O
in	O
patients	O
without	O
acute	O
or	O
chronic	O
GVHD	O
and	O
recovered	O
earlier	O
than	O
in	O
patients	O
without	O
posttransplant	O
pulmonary	O
infection	O
.	O

Helicobacter	O
pylori	O
and	O
stomach	O
diseases	O
:	O
from	O
clinical	O
point	O
of	O
view	O

Its	O
cognate	O
binding	O
protein	O
,	O
REST	B-GENE
/	I-GENE
NRSF	I-GENE
,	O
is	O
an	O
essential	O
transcription	O
factor	O
;	O
its	O
null	O
mutations	O
result	O
in	O
embryonic	O
lethality	O
,	O
and	O
its	O
dominant	O
negative	O
mutants	O
produce	O
aberrant	O
expression	O
of	O
neuron-specific	O
genes	O
.	O

These	O
two	O
repeat	O
motifs	O
are	O
organized	O
in	O
an	O
extremely	O
well-ordered	O
pattern	O
in	O
each	O
domain	O
,	O
which	O
suggests	O
that	O
SbHRGP3	B-GENE
belongs	O
to	O
a	O
new	O
group	O
of	O
proteins	O
having	O
the	O
repeat	O
motifs	O
of	O
two	O
distinct	O
groups	O
of	O
dicot	B-GENE
extensins	I-GENE
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
zinc	B-GENE
finger	I-GENE
protein	I-GENE
Gis1	I-GENE
acts	O
as	O
a	O
dosage-dependent	O
suppressor	O
of	O
the	O
rim15Delta	B-GENE
defect	O
in	O
nutrient	O
limitation-induced	O
transcriptional	O
derepression	O
of	O
SSA3	B-GENE
.	O

Rho	B-GENE
GDP	I-GENE
/	I-GENE
GTP	I-GENE
exchange	I-GENE
inhibitor	I-GENE
,	O
Rho	B-GENE
GDI	I-GENE
,	O
comigrated	O
with	O
Rac2	B-GENE
and	O
RhoA	B-GENE
,	O
but	O
not	O
Rac1	B-GENE
.	O

Angina	O
haemorrhagica	O
bullosa	O
causing	O
respiratory	O
obstruction	O
postoperatively	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
cloned	O
the	O
5'-flanking	O
region	O
of	O
the	O
human	B-GENE
nidogen	I-GENE
gene	I-GENE
.	O

Phagocytosis	O
of	O
tubercle	O
bacilli	O
by	O
macrophages	O
.	O

Acad	O
.	O

A	O
mutant	O
(	O
residues	O
1-332	O
)	O
showed	O
complete	O
Ca2+	O
/	O
CaM-dependent	O
activity	O
.	O

A	O
statistically	O
significant	O
improvement	O
due	O
to	O
the	O
administration	O
of	O
Bromergon	O
was	O
observed	O
in	O
symptoms	O
associated	O
with	O
overreactiveness	O
to	O
normal	O
prolactin	B-GENE
levels	O
,	O
i	O
.	O
e	O
.	O
abdominal	O
tension	O
,	O
edema	O
,	O
weight	O
gain	O
and	O
breast	O
tenderness	O
.	O

Structural	O
organization	O
and	O
developmental	O
expression	O
pattern	O
of	O
the	O
mouse	B-GENE
WD-repeat	I-GENE
gene	I-GENE
DMR-N9	I-GENE
immediately	O
upstream	O
of	O
the	O
myotonic	B-GENE
dystrophy	I-GENE
locus	I-GENE
.	O

Visual	O
averaged	O
evoked	O
responses	O
and	O
platelet	B-GENE
monoamine	I-GENE
oxidase	I-GENE
in	O
patients	O
suffering	O
from	O
alcoholism	O
.	O

Notice	O
of	O
retraction	O
.	O

Anisotropic	O
heat	O
transport	O
in	O
the	O
octylcyanobiphenyl	O
(	O
8CB	O
)	O
liquid	O
crystal	O
.	O

In	O
this	O
study	O
,	O
evidence	O
is	O
presented	O
that	O
temporally	O
and	O
spatially	O
specific	O
mef2	B-GENE
expression	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
cis-acting	O
regulatory	O
modules	O
that	O
are	O
responsive	O
to	O
different	O
genetic	O
signals	O
.	O

BACKGROUND	O
:	O
We	O
hypothesized	O
that	O
the	O
postoperative	O
serum	O
level	O
of	O
TA90-IC	B-GENE
,	O
an	O
immune	O
complex	O
of	O
a	O
90-kDa	O
tumor-associated	O
antigen	O
and	O
its	O
antibody	O
,	O
might	O
have	O
a	O
significant	O
correlation	O
with	O
recurrence	O
and	O
survival	O
in	O
patients	O
with	O
thick	O
primary	O
melanomas	O
.	O

Tolerance	O
test	O
of	O
HB	O
419	O
in	O
animal	O
experiments	O
.	O

The	O
present	O
data	O
also	O
demonstrate	O
that	O
ectopic	O
expression	O
of	O
blr1	B-GENE
increased	O
JNK	B-GENE
/	I-GENE
SAPK	I-GENE
activity	O
,	O
but	O
JNK	B-GENE
/	I-GENE
SAPK	B-GENE
activation	O
was	O
not	O
needed	O
for	O
accelerated	O
RA-induced	O
differentiation	O
and	O
growth	O
arrest	O
.	O

Structure	O
of	O
the	O
EMAPII	B-GENE
domain	I-GENE
of	O
human	B-GENE
aminoacyl-tRNA	I-GENE
synthetase	I-GENE
complex	I-GENE
reveals	O
evolutionary	O
dimer	O
mimicry	O
.	O

To	O
identify	O
nuclear	O
regulatory	O
factors	O
,	O
we	O
have	O
located	O
and	O
functionally	O
characterized	O
the	O
CCR5	B-GENE
gene	I-GENE
promoter	I-GENE
.	O

Effects	O
of	O
estradiol	O
on	O
worm	O
burden	O
and	O
peripheral	O
leukocytes	O
in	O
Parastrongylus	O
malaysiensis-infected	O
rats	O
.	O

The	O
protein	O
expressed	O
by	O
F2771	B-GENE
cDNA	I-GENE
in	O
transfected	O
COS	O
cells	O
is	O
localized	O
in	O
the	O
cytoplasm	O
.	O

No	O
mutations	O
were	O
found	O
in	O
follicular	O
adenomas	O
.	O

Pax-3	B-GENE
is	O
a	O
paired-type	B-GENE
homeobox	I-GENE
gene	I-GENE
that	O
is	O
specifically	O
expressed	O
in	O
the	O
dorsal	O
and	O
posterior	O
neural	O
tube	O
.	O

The	O
present	O
study	O
sought	O
to	O
develop	O
an	O
equation	O
to	O
estimate	O
VO2peak	O
in	O
peripheral	O
arterial	O
occlusive	O
disease	O
(	O
PAOD	O
)	O
patients	O
with	O
intermittent	O
claudication	O
and	O
to	O
determine	O
independent	O
predictors	O
of	O
VO2peak	O
in	O
this	O
population	O
.	O

The	O
predominant	O
sensitizing	O
allergens	O
in	O
Swedish	O
asthmatic	O
children	O
are	O
furred	O
pet	O
animals	O
.	O

There	O
were	O
45	O
to	O
56	O
nt	O
differences	O
between	O
the	O
virulent	O
and	O
avirulent	O
groups	O
while	O
there	O
were	O
6	O
to	O
14	O
nt	O
differences	O
among	O
four	O
avirulent	O
strains	O
.	O

These	O
data	O
demonstrate	O
that	O
DMVA	O
does	O
not	O
cause	O
more	O
myocardial	O
trauma	O
than	O
CPB	O
when	O
used	O
to	O
provide	O
resuscitative	O
circulatory	O
support	O
.	O

This	O
night-day	O
oscillation	O
is	O
driven	O
by	O
the	O
endogenous	O
clock	O
(	O
located	O
in	O
the	O
suprachiasmatic	O
nucleus	O
,	O
SCN	O
)	O
.	O

Magnetically	O
induced	O
optical	O
self-pulsing	O
in	O
a	O
nonlinear	O
resonator	O
.	O

Furthermore	O
,	O
transfection	O
of	O
cells	O
with	O
the	O
spacer-RING	O
domain	O
alone	O
suppressed	O
the	O
antiapoptotic	O
function	O
of	O
the	O
N-terminal	O
BIR	O
domain	O
of	O
c-IAP1	B-GENE
and	O
induced	O
apoptosis	O
.	O

Factors	O
associated	O
with	O
intrafamilial	O
transmission	O
of	O
hepatitis	O
B	O
virus	O
infection	O
in	O
Korea	O
.	O

N-terminal	O
sequence	O
analysis	O
and	O
NMR	O
measurements	O
revealed	O
that	O
this	O
fragment	O
originates	O
from	O
the	O
C-terminal	O
80	O
residues	O
of	O
MBF1	B-GENE
and	O
form	O
a	O
well	O
structured	O
C-terminal	O
domain	O
of	O
MBF1	B-GENE
,	O
MBF1CTD	B-GENE
.	O

Involvement	O
of	O
early	B-GENE
growth	I-GENE
response	I-GENE
factor	I-GENE
Egr-1	I-GENE
in	O
apolipoprotein	B-GENE
AI	I-GENE
gene	I-GENE
transcription	O
.	O

Eight	O
rabbits	O
were	O
exposed	O
to	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
4	O
mg	O
/	O
m3	O
Co2+	O
as	O
CoCl2	O
and	O
1	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
m3	O
Cr3+	O
as	O
Cr	O
(	O
NO3	O
)	O
3	O
(	O
group	O
Co	O
+	O
Cr	O
)	O
,	O
eight	O
to	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
m3	O
Co2+	O
(	O
group	O
Co	O
)	O
,	O
and	O
eight	O
to	O
filtered	O
air	O
(	O
control	O
group	O
)	O
,	O
for	O
4	O
months	O
,	O
5	O
days	O
/	O
week	O
,	O
and	O
6	O
hr	O
/	O
day	O
.	O

From	O
life-table	O
analyses	O
of	O
these	O
patients	O
,	O
we	O
estimated	O
that	O
the	O
incidence	O
of	O
secondary	O
chondrosarcoma	O
in	O
patients	O
who	O
have	O
Ollier	O
disease	O
is	O
about	O
25	O
per	O
cent	O
at	O
the	O
age	O
of	O
forty	O
years	O
,	O
and	O
that	O
malignant	O
degeneration	O
is	O
almost	O
a	O
certainty	O
in	O
patients	O
who	O
have	O
Maffucci	O
syndrome	O
.	O

Reagent	O
strips	O
are	O
frequently	O
used	O
in	O
the	O
practice	O
of	O
laboratory	O
medicine	O
as	O
well	O
as	O
outside	O
the	O
professional	O
laboratories	O
.	O

Having	O
an	O
LRR	B-GENE
domain	I-GENE
and	O
an	O
SH3-binding	B-GENE
domain	I-GENE
,	O
Acan125	B-GENE
and	O
the	O
C	O
.	O
elegans	O
homologue	O
define	O
a	O
novel	O
family	O
of	O
bifunctional	O
binding	O
proteins	O
.	O

The	O
newly	O
recognised	O
skeletogenital	O
syndrome	O
.	O

Valuing	O
families	O
:	O
social	O
work	O
practice	O
with	O
families	O
from	O
a	O
strengths	O
perspective	O
.	O

The	O
Psc2	B-GENE
cDNA	I-GENE
contained	O
an	O
open	O
reading	O
frame	O
homologous	O
to	O
CP2	B-GENE
family	I-GENE
proteins	I-GENE
.	O

These	O
data	O
show	O
that	O
PTH	B-GENE
and	O
cAMP	O
can	O
repress	O
collagen	B-GENE
promoter	I-GENE
activity	O
in	O
calvariae	O
from	O
transgenic	O
mice	O
,	O
suggesting	O
that	O
the	O
alpha	B-GENE
1	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
collagen	I-GENE
promoter	I-GENE
may	O
contain	O
cis	O
elements	O
down-stream	O
of	O
-2	O
.	O
3	O
kilobases	O
that	O
mediate	O
PTH	B-GENE
and	O
cAMP	O
repression	O
of	O
collagen	B-GENE
gene	I-GENE
expression	O
in	O
bone	O
.	O

Mean	O
corpuscular	B-GENE
hemoglobin	I-GENE
concentrations	O
remained	O
normal	O
for	O
48	O
h	O
and	O
then	O
decreased	O
in	O
both	O
groups	O
,	O
the	O
CO2	O
group	O
showing	O
the	O
larger	O
decrease	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
level	O
of	O
oxidative	O
stress	O
in	O
healthy	O
controls	O
(	O
CTL	O
)	O
compared	O
with	O
CRF	O
and	O
HD	O
patients	O
before	O
(	O
pre-HD	O
)	O
and	O
after	O
(	O
post-HD	O
)	O
the	O
dialysis	O
session	O
,	O
carried	O
out	O
on	O
a	O
high	O
biocompatible	O
polyacrylonitrile	O
membrane	O
AN69	O
.	O

Effects	O
of	O
methiothepin	O
and	O
lysergic	O
acid	O
diethylamide	O
on	O
serotonin	O
release	O
in	O
vitro	O
and	O
serotonin	O
synthesis	O
in	O
vivo	O
:	O
possible	O
relation	O
to	O
serotonin	B-GENE
autoreceptor	I-GENE
function	O
.	O

Rabbit	O
eyes	O
were	O
removed	O
and	O
held	O
in	O
temperature-regulated	O
chambers	O
and	O
irrigated	O
with	O
saline	O
.	O

In	O
contrast	O
to	O
the	O
myoD	B-GENE
promoter	I-GENE
,	O
the	O
myoD	B-GENE
enhancer	I-GENE
shows	O
striking	O
conservation	O
between	O
humans	O
and	O
mice	O
both	O
in	O
its	O
sequence	O
and	O
its	O
distal	O
position	O
.	O

Serum	B-GENE
beta	I-GENE
2-microglobulin	I-GENE
levels	O
(	O
beta-2-M	B-GENE
)	O
were	O
studied	O
in	O
150	O
drug	O
addicts	O
,	O
50	O
of	O
them	O
asymptomatic	O
carriers	O
of	O
anti	B-GENE
HIV-1	I-GENE
antibodies	I-GENE
,	O
50	O
symptomatic	O
carriers	O
with	O
persistent	O
generalized	O
lymphadenopathy	O
(	O
P	O
.	O
G	O
.	O
L	O
.	O
)	O
and	O
50	O
serum	O
negative	O
patients	O
who	O
had	O
been	O
living	O
in	O
a	O
closed	O
community	O
for	O
at	O
least	O
2	O
years	O
.	O

During	O
challenge	O
,	O
rebiopsy	O
was	O
done	O
when	O
reticulin	B-GENE
antibodies	I-GENE
turned	O
positive	O
(	O
mean	O
0	O
.	O
6	O
years	O
,	O
range	O
0	O
.	O
2-2	O
.	O
0	O
)	O
or	O
at	O
the	O
end	O
of	O
the	O
two	O
year	O
study	O
.	O

The	O
Bacillus	B-GENE
subtilis	I-GENE
phage	I-GENE
phi	I-GENE
105	I-GENE
repressor	I-GENE
,	O
a	O
lambda	B-GENE
repressor-like	O
transcriptional	O
regulatory	O
protein	B-GENE
,	O
was	O
overproduced	O
in	O
Escherichia	O
coli	O
and	O
purified	O
to	O
near	O
homogeneity	O
in	O
order	O
to	O
examine	O
its	O
in	O
vitro	O
DNA-binding	O
properties	O
.	O

The	O
present	O
study	O
examined	O
the	O
dependence	O
of	O
difference	O
tone	O
level	O
[	O
L	O
(	O
f2-f1	O
)	O
]	O
on	O
the	O
following	O
parameters	O
of	O
the	O
two-tone	O
input	O
:	O
f1	O
,	O
f2	O
/	O
f1	O
(	O
f2	O
greater	O
than	O
f1	O
)	O
,	O
L1	O
,	O
L2	O
,	O
and	O
L1	O
=	O
L2	O
.	O

We	O
now	O
show	O
that	O
regulation	O
of	O
flaN	B-GENE
transcription	O
in	O
vivo	O
depends	O
on	O
a	O
sigma	B-GENE
54	I-GENE
promoter	I-GENE
and	O
two	O
ftr	B-GENE
elements	I-GENE
located	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
at	O
+86	O
(	O
ftr2	B-GENE
)	O
and	O
+120	O
(	O
ftr3	B-GENE
)	O
.	O

Subsequently	O
,	O
we	O
show	O
that	O
the	O
reexpression	O
of	O
the	O
r-PTPeta	B-GENE
gene	I-GENE
in	O
highly	O
malignant	O
rat	O
thyroid	O
cells	O
transformed	O
by	O
retroviruses	O
carrying	O
the	O
v-mos	B-GENE
and	O
v-ras-Ki	B-GENE
oncogenes	I-GENE
suppresses	O
their	O
malignant	O
phenotype	O
.	O

Synovial	O
cysts	O
of	O
the	O
hip	O
joint	O
.	O

In	O
vitro	O
binding	O
studies	O
using	O
GST	B-GENE
fusion	O
proteins	O
and	O
yeast	O
extracts	O
defined	O
distinct	O
binding	O
sites	O
on	O
yAP180A	B-GENE
for	O
Pan1p	B-GENE
and	O
clathrin	B-GENE
.	O
yAP180	B-GENE
proteins	I-GENE
and	O
Pan1p	B-GENE
,	O
like	O
actin	B-GENE
,	O
localize	O
to	O
peripheral	O
patches	O
along	O
the	O
plasma	O
membrane	O
.	O

The	O
availability	O
of	O
potent	O
regulatory	O
DNA	O
cassettes	O
harboring	O
the	O
murine	B-GENE
D1A	I-GENE
gene	I-GENE
promoter	I-GENE
could	O
aid	O
testing	O
the	O
neuronal-specific	O
expression	O
of	O
transgenes	O
in	O
vivo	O
.	O

Autoradiographic	O
localisation	O
of	O
its	O
cellular	O
distribution	O
in	O
the	O
kidney	O
.	O

Syndromes	O
of	O
abnormal	O
fat	O
redistribution	O
and	O
metabolic	O
complications	O
in	O
HIV-infected	O
patients	O
.	O

We	O
have	O
identified	O
in	O
the	O
5'	O
untranslated	O
region	O
of	O
the	O
Drosophila	B-GENE
copia	I-GENE
retrotransposon	I-GENE
,	O
3'	O
to	O
the	O
left	O
LTR	O
,	O
a	O
sequence	O
for	O
transcriptional	O
regulation	O
by	O
homeoproteins	O
.	O

Effects	O
of	O
estrogen	O
and	O
glucocorticoids	O
on	O
the	O
adrenal	O
development	O
of	O
the	O
fetus	O
.	O

A	O
concentration	O
of	O
12	O
.	O
5	O
ppm	O
SO2	O
induced	O
a	O
decrease	O
from	O
baseline	O
values	O
of	O
approximately	O
80%	O
in	O
mean	O
MCA	O
and	O
of	O
roughly	O
70%	O
in	O
mean	O
CBF	O
.	O

CM	O
reduced	O
the	O
nuclear	O
binding	O
activity	O
of	O
transcription	B-GENE
factor	I-GENE
AP-1	I-GENE
.	O

The	O
SUP44	B-GENE
suppressor	I-GENE
mutation	I-GENE
occurs	O
near	O
a	O
region	O
of	O
the	O
protein	O
that	O
corresponds	O
to	O
the	O
known	O
positions	O
of	O
alterations	O
in	O
E	B-GENE
.	I-GENE
coli	I-GENE
S5	I-GENE
ram	I-GENE
mutations	I-GENE
.	O

The	O
DNA	O
sequence	O
encodes	O
a	O
protein	O
of	O
1520	O
amino	O
acids	O
with	O
sequence	O
homology	O
to	O
the	O
human	B-GENE
c-abl	I-GENE
proto-oncogene	I-GENE
product	I-GENE
,	O
beginning	O
at	O
the	O
amino	O
terminus	O
and	O
extending	O
656	O
amino	O
acids	O
through	O
the	O
region	O
essential	O
for	O
tyrosine	B-GENE
kinase	I-GENE
activity	O
.	O

The	O
expression	O
pattern	O
of	O
GL2	B-GENE
,	O
as	O
demonstrated	O
by	O
in	O
situ	O
hybridization	O
,	O
indicated	O
that	O
the	O
gene	O
is	O
expressed	O
in	O
trichome	O
progenitor	O
cells	O
and	O
at	O
stages	O
associated	O
with	O
trichome	O
development	O
.	O

The	O
amount	O
of	O
these	O
factors	O
was	O
reduced	O
in	O
GEO	O
cells	O
in	O
which	O
the	O
u-PAR	B-GENE
gene	I-GENE
is	O
only	O
weakly	O
transcriptionally	O
activated	O
.	O

Homozygous	O
mutant	O
mice	O
,	O
designated	O
Cux	B-GENE
/	I-GENE
CDPDeltaCR1	I-GENE
,	O
display	O
a	O
phenotype	O
characterized	O
by	O
curly	O
vibrissae	O
and	O
wavy	O
hair	O
.	O

In	O
the	O
3'	O
flanking	O
region	O
of	O
the	O
27	B-GENE
kDa	I-GENE
zein	I-GENE
gene	I-GENE
,	O
several	O
AATAAA-like	O
sequences	O
and	O
a	O
sequence	O
resembling	O
the	O
mammalian	O
GT-rich	O
sequence	O
are	O
present	O
around	O
the	O
polyadenylation	O
sites	O
.	O

Furthermore	O
it	O
was	O
suggested	O
that	O
FK506	O
plasma	O
levels	O
were	O
concerned	O
with	O
the	O
appearance	O
of	O
side	O
effect	O
.	O

CONCLUSION	O
:	O
SPT	O
is	O
more	O
useful	O
than	O
WST	O
in	O
differentiating	O
patients	O
predisposed	O
to	O
aspiration	O
.	O

The	O
qualitative	O
concentrations	O
of	O
HCG	B-GENE
had	O
a	O
sensitivity	O
of	O
37	O
.	O
5%	O
and	O
a	O
specificity	O
of	O
100%	O
.	O

Mapping	O
of	O
RNA-	O
temperature-sensitive	B-GENE
mutants	I-GENE
of	I-GENE
Sindbis	I-GENE
virus	I-GENE
:	I-GENE
complementation	I-GENE
group	I-GENE
F	I-GENE
mutants	I-GENE
have	O
lesions	O
in	O
nsP4	B-GENE
.	O

In	O
addition	O
to	O
a	O
previously	O
characterized	O
promoter	O
(	O
P1	B-GENE
)	O
,	O
we	O
now	O
show	O
the	O
existence	O
of	O
a	O
second	O
promoter	O
for	O
the	O
human	B-GENE
IL-5Ralpha	I-GENE
gene	I-GENE
.	O

Allergenic	O
activity	O
of	O
allergen	O
extract	O
Ambrosia	O
elatior	O
(	O
AE	O
)	O
was	O
tested	O
in	O
fifteen	O
volunteers	O
extremely	O
sensitive	O
to	O
the	O
allergen	O
.	O

This	O
approach	O
was	O
examined	O
utilizing	O
the	O
fetal	O
protein	O
,	O
HGB	B-GENE
F	I-GENE
.	O

Data	O
were	O
processed	O
with	O
a	O
semi-automatic	O
computer	O
program	O
which	O
develops	O
an	O
averaged-volume	O
curve	O
from	O
an	O
assigned	O
LV	O
region-of-interest	O
.	O

The	O
mouse	B-GENE
M-lysozyme	I-GENE
downstream	I-GENE
enhancer	I-GENE
has	O
been	O
previously	O
characterized	O
on	O
several	O
levels	O
of	O
gene	O
regulation	O
.	O

This	O
complex	O
interacts	O
at	O
the	O
GTPase	B-GENE
domain	I-GENE
in	O
the	O
large	B-GENE
subunit	I-GENE
rRNA	I-GENE
,	O
overlapping	O
the	O
binding	O
site	O
of	O
the	O
protein	B-GENE
L11-like	I-GENE
eukaryotic	I-GENE
counterpart	I-GENE
(	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
protein	I-GENE
L15	I-GENE
and	O
mammalian	B-GENE
protein	I-GENE
L12	I-GENE
)	O
.	O

Each	O
patient	O
had	O
measurable	O
LH	B-GENE
and	O
FSH	B-GENE
levels	O
,	O
with	O
pulsed	O
nocturnal	O
secretion	O
,	O
and	O
pubertal	O
LH	B-GENE
and	O
FSH	B-GENE
responses	O
to	O
LRH	B-GENE
.	O

Using	O
one	O
of	O
the	O
six	O
fragments	O
(	O
CPK3-8	B-GENE
)	O
,	O
we	O
isolated	O
a	O
2022	B-GENE
bp	I-GENE
cDNA	I-GENE
(	I-GENE
VrCDPK-1	I-GENE
)	I-GENE
from	O
a	O
Vigna	O
radiata	O
lambda	O
gt11	O
library	O
.	O

TIEG	B-GENE
expression	O
in	O
hFOB	O
cells	O
was	O
highly	O
induced	O
by	O
TGF-beta	B-GENE
and	O
bone	B-GENE
morphogenetic	I-GENE
protein-2	I-GENE
(	O
BMP-2	B-GENE
)	O
,	O
with	O
a	O
moderate	O
induction	O
by	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
(	O
EGF	B-GENE
)	O
,	O
but	O
no	O
induction	O
by	O
other	O
growth	O
factors	O
/	O
cytokines	O
was	O
observed	O
.	O

Introduction	O
of	O
v-fms	B-GENE
into	O
a	O
CSF-1	B-GENE
dependent	O
murine	O
macrophage	O
cell	O
line	O
induced	O
factor	O
independence	O
and	O
tumorigenicity	O
by	O
a	O
nonautocrine	O
mechanism	O
.	O

Eighteen	O
patients	O
were	O
untreated	O
,	O
and	O
8	O
had	O
been	O
given	O
previous	O
treatment	O
with	O
depot	O
testosterone	O
100	O
mg	O
intramuscularly	O
every	O
2-3	O
weeks	O
for	O
an	O
average	O
duration	O
of	O
4	O
.	O
7	O
years	O
.	O

We	O
tried	O
amphotericin	O
B	O
(	O
AmB	O
)	O
,	O
and	O
remission	O
of	O
the	O
tumor	O
was	O
obtained	O
.	O

Isolation	O
of	O
T	O
.	O
gambiense	O
strains	O
in	O
Zaire	O
and	O
their	O
adaptation	O
to	O
laboratory	O
animals	O
.	O

The	O
mRNA	O
identified	O
in	O
both	O
human	O
and	O
rat	O
cells	O
with	O
the	O
human	B-GENE
clathrin	I-GENE
clone	O
revealed	O
transcripts	O
of	O
approximately	O
6	O
.	O
5	O
kb	O
,	O
which	O
is	O
consistent	O
with	O
the	O
predicted	O
180	O
kDa	O
molecular	O
weight	O
of	O
the	O
clathrin	B-GENE
heavy	I-GENE
chain	I-GENE
.	O

Survival	O
of	O
111	O
Indium-labelled	O
autologous	O
platelets	O
was	O
studied	O
in	O
2	O
patients	O
after	O
correction	O
of	O
platelet	O
count	O
and	O
was	O
still	O
found	O
shortened	O
.	O

Analysis	O
of	O
mCTR	B-GENE
mRNAs	I-GENE
has	O
revealed	O
that	O
the	O
three	O
alternative	O
promoters	O
give	O
rise	O
to	O
at	O
least	O
seven	O
mCTR	B-GENE
isoforms	I-GENE
in	O
the	O
5'	O
region	O
of	O
the	O
gene	O
and	O
generate	O
5'-untranslated	O
regions	O
of	O
very	O
different	O
lengths	O
.	O

The	O
overall	O
incidence	O
of	O
SIDS	O
was	O
1	O
.	O
43	O
per	O
1	O
,	O
000	O
live	O
births	O
.	O

A	O
method	O
for	O
the	O
simultaneous	O
determination	O
of	O
de	O
(	O
N-methyl	O
)	O
-N-ethyl-8	O
,	O
9	O
-anhydroerythromycin	O
A	O
6	O
,	O
9-hemiacetal	O
(	O
EM523	O
,	O
I	O
)	O
and	O
its	O
three	O
metabolites	O
in	O
human	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
using	O
high-performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
with	O
chemiluminescence	O
(	O
CL	O
)	O
detection	O
.	O

Expression	O
of	O
the	O
CYP11A1	B-GENE
gene	I-GENE
is	O
increased	O
by	O
hormones	O
,	O
such	O
as	O
adrenocorticotropin	B-GENE
and	O
luteinizing	B-GENE
hormone	I-GENE
,	O
as	O
well	O
as	O
by	O
a	O
number	O
of	O
growth	B-GENE
factors	I-GENE
,	O
suggesting	O
that	O
its	O
promoter	O
may	O
contain	O
regulatory	O
elements	O
that	O
respond	O
to	O
multiple	O
signal	O
transduction	O
pathways	O
.	O

Deletion	O
analysis	O
of	O
the	O
ICL1	B-GENE
promoter	I-GENE
led	O
to	O
the	O
identification	O
of	O
an	O
upstream	O
activating	O
sequence	O
element	O
,	O
UASICL1	B-GENE
(	O
5'	B-GENE
CATTCATCCG	I-GENE
3'	I-GENE
)	O
,	O
necessary	O
and	O
sufficient	O
for	O
conferring	O
carbon	O
source-dependent	O
regulation	O
on	O
a	O
heterologous	O
reporter	O
gene	O
.	O

Cotransfections	O
with	O
ATF-2	B-GENE
and	O
HNF-4	B-GENE
expression	O
plasmids	O
resulted	O
in	O
additive	O
transactivation	O
of	O
the	O
apoCIII	B-GENE
promoter	I-GENE
.	O

Precision	O
measurement	O
of	O
the	O
pion	O
mass	O
difference	O
m	O
pi	O
--m	O
pi	O
0	O
.	O

Once	O
NGF	B-GENE
administration	O
is	O
proven	O
effective	O
it	O
will	O
be	O
possible	O
to	O
develop	O
alternative	O
ways	O
of	O
NGF	B-GENE
administration	O
.	O

Environmental	O
factors	O
were	O
more	O
important	O
in	O
the	O
older	O
cohorts	O
(	O
perhaps	O
because	O
of	O
less	O
reliable	O
recall	O
)	O
.	O

Two-dimensional	O
gel	O
electrophoresis	O
of	O
anti-p59fyn	B-GENE
immunoprecipitates	O
obtained	O
from	O
non-transformed	O
resting	O
human	O
T	O
lymphocytes	O
resulted	O
in	O
the	O
identification	O
of	O
an	O
oligomeric	O
protein	O
complex	O
which	O
is	O
constitutively	O
formed	O
between	O
Fyn	B-GENE
and	O
several	O
additional	O
phosphoproteins	O
(	O
pp43	B-GENE
,	O
pp72	B-GENE
,	O
pp85	B-GENE
,	O
the	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
Pyk2	B-GENE
,	O
as	O
well	O
as	O
the	O
two	O
recently	O
cloned	O
adaptor	O
proteins	O
,	O
SKAP55	B-GENE
and	O
SLAP-130	B-GENE
)	O
.	O

Sequence	O
analysis	O
of	O
the	O
zebrafish	B-GENE
egr1	I-GENE
coding	I-GENE
region	I-GENE
revealed	O
a	O
high	O
level	O
of	O
homology	O
to	O
the	O
mouse	O
,	O
rat	O
,	O
and	O
human	B-GENE
Egr1	I-GENE
genes	I-GENE
with	O
the	O
notable	O
exception	O
of	O
a	O
polymorphic	O
,	O
triplet	O
nucleotide	O
repeat	O
sequence	O
in	O
the	O
region	O
coding	O
for	O
the	O
amino	O
terminus	O
of	O
the	O
Egr1	B-GENE
protein	I-GENE
.	O

Pseudocontact	O
shifts	O
arise	O
from	O
the	O
isotropic	O
reorientational	O
average	O
of	O
the	O
dipolar	O
coupling	O
between	O
unpaired	O
electron	O
and	O
nuclei	O
,	O
in	O
the	O
presence	O
of	O
magnetic	O
susceptibility	O
anisotropy	O
.	O

However	O
,	O
no	O
studies	O
have	O
been	O
conducted	O
to	O
further	O
investigate	O
this	O
potentially	O
hazardous	O
effect	O
of	O
lidocaine	O
.	O

On	O
the	O
basis	O
of	O
these	O
unique	O
properties	O
,	O
the	O
newly	O
characterized	O
hemagglutinin	B-GENE
has	O
been	O
termed	O
Limulus	B-GENE
18K	I-GENE
agglutination-aggregation	I-GENE
factor	I-GENE
(	O
18K-LAF	B-GENE
)	O
.	O

Products	O
of	O
immune	O
cells	O
such	O
as	O
transfer	B-GENE
factor	I-GENE
and	O
lymphokines	O
form	O
the	O
third	O
and	O
possibly	O
most	O
important	O
group	O
of	O
immune-stimulating	O
agents	O
.	O

Its	O
clearance	O
has	O
been	O
found	O
to	O
be	O
decreased	O
(	O
typically	O
by	O
around	O
25%	O
,	O
but	O
often	O
by	O
far	O
more	O
)	O
by	O
erythromycin	O
,	O
troleandomycin	O
(	O
triacetyloleandomycin	O
)	O
,	O
roxithromycin	O
,	O
enoxacin	O
,	O
ciprofloxacin	O
,	O
pefloxacin	O
,	O
norfloxacin	O
,	O
ofloxacin	O
,	O
fluoroquinolone	O
T-3262	O
,	O
pipemidic	O
acid	O
,	O
cimetidine	O
,	O
etintidine	O
,	O
propranolol	O
,	O
verapamil	O
,	O
diltiazem	O
,	O
nifedipine	O
,	O
furosemide	O
(	O
frusemide	O
)	O
,	O
at	O
least	O
some	O
anovulent	O
agents	O
,	O
viloxazine	O
,	O
allopurinol	O
,	O
ticlopidine	O
,	O
idrocilamide	O
,	O
thiabendazole	O
,	O
disulfiram	O
,	O
influenza-	O
and	O
BCG-vaccination	O
,	O
interferon	B-GENE
,	O
and	O
caffeine	O
(	O
half-life	O
increase	O
)	O
.	O

Of	O
110	O
previously	O
untreated	O
patients	O
who	O
had	O
entered	O
the	O
study	O
of	O
protocol	O
TCL821	O
,	O
96	O
were	O
evaluable	O
.	O

Grippers	O
with	O
integrated	O
piezoresistive	O
force	O
sensors	O
and	O
with	O
attached	O
strain	O
gauges	O
have	O
been	O
reported	O
.	O

Advanced	O
adenoma	O
was	O
defined	O
as	O
an	O
adenoma	O
larger	O
than	O
10	O
mm	O
or	O
an	O
adenoma	O
of	O
any	O
size	O
with	O
villous	O
component	O
,	O
high-grade	O
dysplasia	O
or	O
invasive	O
carcinoma	O
.	O

Here	O
,	O
we	O
identified	O
three	O
cis-elements	O
required	O
for	O
replication	O
within	O
the	O
200	O
bp	O
promoter	O
,	O
using	O
autonomously	O
replicating	O
plasmids	O
carrying	O
various	O
mutations	O
and	O
deletions	O
.	O

Oligonucleotides	O
,	O
designed	O
on	O
the	O
basis	O
of	O
conserved	O
flanking	O
amino	O
acid	O
sequence	O
segments	O
within	O
the	O
catalytic	O
domain	O
of	O
eukaryotic	B-GENE
protein	I-GENE
kinase	I-GENE
C	I-GENE
(	B-GENE
PKC	I-GENE
)	I-GENE
proteins	I-GENE
,	O
were	O
used	O
as	O
primers	O
for	O
polymerase	O
chain	O
reactions	O
to	O
amplify	O
a	O
427-bp	O
chromosomal	O
DNA	O
fragment	O
from	O
the	O
filamentous	O
fungus	O
Trichoderma	O
reesei	O
.	O

Potentially	O
load-insensitive	O
measures	O
of	O
ventricular	O
performance	O
were	O
therefore	O
evaluated	O
in	O
10	O
open-	O
and	O
closed-chested	O
,	O
anesthetized	O
rabbits	O
.	O

Two	O
patients	O
were	O
treated	O
successfully	O
with	O
a	O
combination	O
of	O
metronidazole	O
(	O
a	O
tissue	O
amoebicide	O
)	O
and	O
diloxanide	O
(	O
a	O
lumenal	O
amoebicide	O
)	O
.	O

The	O
interindividual	O
variability	O
of	O
the	O
parameters	O
is	O
taken	O
into	O
consideration	O
by	O
interactively	O
determining	O
the	O
threshold	O
levels	O
.	O

Merlie	O
,	O
Cold	O
Spring	O
Harbor	O
Symp	O
.	O

Late	O
complications	O
of	O
catheterisation	O
for	O
intravenous	O
nutrition	O
[	O
letter	O
]	O
.	O

Toward	O
this	O
end	O
,	O
we	O
prepared	O
synthetic	O
proteins	O
with	O
either	O
the	O
catalytic	O
domain	O
of	O
FAP-1	B-GENE
(	I-GENE
C-terminal	I-GENE
399	I-GENE
amino	I-GENE
acids	I-GENE
)	I-GENE
or	O
its	O
inactive	O
form	O
(	O
Cys2408--	O
>	O
Ser	O
)	O
fused	O
to	O
glutathione-S-transferase	B-GENE
(	O
GST	B-GENE
)	O
.	O

To	O
investigate	O
the	O
mechanisms	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
retinoid	B-GENE
X	I-GENE
receptor	I-GENE
(	O
RXR	B-GENE
)	O
gene	O
expression	O
,	O
the	O
5'-flanking	O
region	O
of	O
the	O
human	B-GENE
RXRgamma2	I-GENE
isoform	I-GENE
was	O
characterized	O
.	O

The	O
E1	B-GENE
gene	I-GENE
is	O
located	O
within	O
the	O
first	O
intron	O
of	O
the	O
gene	O
for	O
RCC1	B-GENE
,	O
a	O
protein	O
that	O
regulates	O
onset	O
of	O
mitosis	O
.	O

Young	O
CD-1	O
mice	O
,	O
4	O
days	O
old	O
,	O
exposed	O
to	O
0	O
.	O
1%	O
nicotine	O
sulfate	O
on	O
gestational	O
days	O
6-20	O
were	O
compared	O
with	O
untreated	O
pups	O
of	O
the	O
same	O
age	O
to	O
determine	O
its	O
effect	O
on	O
the	O
development	O
of	O
mandibular	O
first	O
molars	O
.	O

Here	O
we	O
demonstrate	O
that	O
AML1a	B-GENE
,	O
which	O
solely	O
has	O
no	O
effects	O
as	O
a	O
transcriptional	O
regulator	O
,	O
dominantly	O
suppresses	O
transcriptional	O
activation	O
by	O
AML1b	B-GENE
,	O
and	O
that	O
AML1a	B-GENE
exhibits	O
the	O
higher	O
affinity	O
for	O
DNA-binding	O
than	O
AML1b	B-GENE
.	O

During	O
the	O
past	O
4	O
years	O
,	O
a	O
purposeful	O
search	O
was	O
made	O
for	O
electrocardiograms	O
with	O
documented	O
reversible	O
QRS	O
changes	O
associated	O
with	O
all	O
acute	O
injury	O
pattern	O
.	O

Four	O
patients	O
(	O
group	O
1	O
)	O
had	O
type	O
I	O
basement	O
membrane	O
nephropathy	O
,	O
characterized	O
by	O
marked	O
thickening	O
and	O
lamellation	O
of	O
the	O
basement	O
membrane	O
in	O
a	O
pattern	O
resembling	O
that	O
of	O
Alport's	O
syndrome	O
.	O

A	O
genetic	O
screen	O
in	O
yeast	O
has	O
allowed	O
us	O
to	O
identify	O
a	O
novel	O
transcriptional	O
factor	O
binding	O
to	O
the	O
GlRE	B-GENE
,	O
i	O
.	O
e	O
.	O
the	O
chicken	B-GENE
ovalbumin	I-GENE
upstream	I-GENE
promoter-transcription	I-GENE
factor	I-GENE
II	I-GENE
(	O
COUP-TFII	B-GENE
)	O
.	O

SAPK	B-GENE
/	I-GENE
JNK	I-GENE
activation	O
was	O
completely	O
abolished	O
in	O
the	O
absence	O
of	O
MKK7	B-GENE
,	O
even	O
though	O
expression	O
of	O
MKK4	B-GENE
was	O
strongly	O
upregulated	O
in	O
mkk7	B-GENE
(	I-GENE
-	I-GENE
/	I-GENE
-	I-GENE
)	I-GENE
mast	O
cell	O
lines	O
,	O
and	O
phosphorylation	O
of	O
MKK4	B-GENE
occurred	O
normally	O
in	O
response	O
to	O
multiple	O
stress	O
stimuli	O
.	O

In	O
a	O
PC12	O
cell	O
mutant	O
that	O
is	O
deficient	O
in	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
activity	O
(	O
AB	O
.	O
11	O
)	O
,	O
all	O
three	O
differentiating	O
agents	O
were	O
unable	O
to	O
down-regulate	O
nrg-1	B-GENE
mRNA	I-GENE
.	O

Thus	O
,	O
the	O
active-site	O
mutation	O
prevents	O
the	O
wild-type	O
processing	O
of	O
the	O
N-glycosylated	O
73-kDa	O
precursor	O
of	O
PrB	B-GENE
to	O
the	O
41	B-GENE
.	I-GENE
5	I-GENE
kDa	I-GENE
pro-PrB	I-GENE
in	O
the	O
endoplasmic	O
reticulum	O
.	O

99mTc-HMPAO	O
was	O
distributed	O
in	O
the	O
territories	O
of	O
the	O
ACA	O
and	O
MCA	O
in	O
the	O
two	O
patients	O
who	O
were	O
treated	O
with	O
intraarterial	O
infusion	O
of	O
papaverine	O
from	O
the	O
C4	O
segment	O
,	O
but	O
was	O
distributed	O
only	O
to	O
the	O
territory	O
of	O
the	O
ACA	O
in	O
four	O
patients	O
who	O
were	O
treated	O
with	O
intraarterial	O
infusion	O
of	O
papaverine	O
from	O
the	O
C1	O
segment	O
at	O
1	O
ml	O
/	O
min	O
.	O

The	O
diabetic	O
state	O
was	O
characterized	O
by	O
mild	O
insulin	B-GENE
deficiency	O
,	O
plasma	O
levels	O
being	O
73%	O
of	O
controls	O
,	O
and	O
mild	O
hyperglycemia	O
,	O
with	O
nonfasting	O
plasma	O
glucose	O
levels	O
of	O
1	O
.	O
5	O
times	O
normal	O
.	O

Acquired	O
antithrombin	B-GENE
deficiency	O
in	O
sepsis	O
.	O

Thrombolytic	O
therapy	O
in	O
spontaneous	O
coronary	O
artery	O
dissection	O
.	O

Structural	O
studies	O
have	O
shown	O
that	O
class	B-GENE
I	I-GENE
major	I-GENE
histocompatibility	I-GENE
complex	I-GENE
(	O
MHC	B-GENE
)	O
-restricted	O
peptide-specific	B-GENE
T	I-GENE
cell	I-GENE
receptor	I-GENE
(	I-GENE
TCR	I-GENE
)	I-GENE
-alpha	I-GENE
/	I-GENE
betas	I-GENE
make	O
multiple	O
contacts	O
with	O
the	O
alpha1	O
and	O
alpha2	O
helices	O
of	O
the	O
MHC	B-GENE
,	O
but	O
it	O
is	O
unclear	O
which	O
or	O
how	O
many	O
of	O
these	O
interactions	O
contribute	O
to	O
functional	O
binding	O
.	O

The	O
bearing	O
of	O
season	O
and	O
sequence	O
of	O
calving	O
on	O
frequency	O
of	O
male	O
,	O
female	O
and	O
total	O
calvings	O
in	O
Hariana	O
cows	O
.	O

Histological	O
evaluation	O
revealed	O
a	O
more	O
than	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
interepithelial	O
mononuclear	O
cells	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
while	O
the	O
number	O
of	O
epithelial	O
cells	O
/	O
100	O
microns	O
of	O
villous	O
mucosa	O
and	O
the	O
mean	O
height	O
of	O
the	O
epithelial	O
cells	O
were	O
comparable	O
in	O
both	O
groups	O
.	O

8%	O
(	O
95%	O
CI	O
,	O
21	O
.	O
3-44	O
.	O
3%	O
)	O
.	O

The	O
responsive	O
region	O
of	O
the	O
alpha	B-GENE
2	I-GENE
(	I-GENE
V	I-GENE
)	I-GENE
collagen	I-GENE
gene	I-GENE
was	O
localized	O
to	O
a	O
fragment	O
including	O
100	O
bp	O
of	O
basal	O
promoter	O
and	O
150	O
bp	O
of	O
exon	O
1	O
sequences	O
,	O
which	O
contained	O
two	O
CRE-like	B-GENE
elements	I-GENE
.	O

Various	O
mutant	B-GENE
HN	I-GENE
genes	I-GENE
were	O
constructed	O
to	O
examine	O
the	O
role	O
of	O
residues	O
flanking	O
the	O
signal-anchor	O
domain	O
,	O
including	O
the	O
cytoplasmic	O
tail	O
,	O
on	O
assembly	O
and	O
intracellular	O
transport	O
of	O
the	O
HN	B-GENE
glycoprotein	I-GENE
.	O

A	O
model	O
with	O
age	O
and	O
weight	O
described	O
the	O
best	O
fit	O
for	O
TBBMD	O
,	O
whereas	O
age	O
,	O
weight	O
,	O
and	O
height	O
described	O
the	O
best	O
fit	O
for	O
total	O
body	O
TBBMC	O
.	O

In	O
view	O
of	O
the	O
short	O
t1	O
/	O
2	O
,	O
we	O
used	O
three	O
doses	O
/	O
day	O
.	O

These	O
findings	O
suggest	O
a	O
novel	O
ankyrin-independent	O
role	O
for	O
LAD-1	B-GENE
related	O
to	O
FGFR	B-GENE
signaling	O
.	O

To	O
facilitate	O
the	O
investigation	O
of	O
parameters	O
that	O
govern	O
selective	O
export	O
in	O
adenovirus-infected	O
cells	O
,	O
we	O
constructed	O
a	O
marked	O
human	O
beta-actin	B-GENE
minigene	I-GENE
under	O
the	O
control	O
of	O
the	O
glucocorticoid-inducible	B-GENE
enhancer-promoter	I-GENE
of	O
mouse	O
mammary	O
tumor	O
virus	O
and	O
introduced	O
it	O
into	O
the	O
left	O
end	O
of	O
the	O
adenovirus	O
type	O
5	O
(	O
Ad5	O
)	O
genome	O
.	O

In	O
the	O
latter	O
category	O
particular	O
emphasis	O
is	O
being	O
placed	O
on	O
new	O
anthracycline	O
analogues	O
of	O
doxorubicin	O
and	O
analogues	O
of	O
cisplatinum	O
diammine	O
dichloride	O
.	O

A	O
human	B-GENE
SPT3-TAFII31-GCN5-L	I-GENE
acetylase	I-GENE
complex	I-GENE
distinct	O
from	O
transcription	B-GENE
factor	I-GENE
IID	I-GENE
.	O

It	O
is	O
possible	O
that	O
cyclic	O
variations	O
in	O
heme	O
turnover	O
are	O
related	O
to	O
changes	O
in	O
erythrocyte	O
characteristics	O
during	O
the	O
progesterone	O
phase	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
cDNA	O
that	O
encodes	O
a	O
new	O
member	O
of	O
the	O
GTPase-activating	B-GENE
protein	I-GENE
(	O
GAP	B-GENE
)	O
family	O
of	O
GTPase	B-GENE
regulators	O
.	O

In	O
addition	O
,	O
CaMig1	B-GENE
formed	O
specific	O
complexes	O
with	O
the	O
URS1	B-GENE
region	I-GENE
of	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
FBP1	I-GENE
gene	I-GENE
.	O

New	O
beta-blocking	O
drugs	O
have	O
been	O
introduced	O
which	O
may	O
prove	O
beneficial	O
in	O
certain	O
clinical	O
situations	O
since	O
they	O
exert	O
more	O
selective	O
blockade	O
of	O
the	O
cardiac	B-GENE
receptors	I-GENE
(	O
beta1	B-GENE
)	O
as	O
opposed	O
to	O
smooth	B-GENE
muscle	I-GENE
receptors	I-GENE
(	O
beta2	B-GENE
)	O
.	O

The	O
nucleotide	O
sequence	O
alignment	O
between	O
mouse	O
and	O
human	B-GENE
CA	I-GENE
IV	I-GENE
shows	O
69%	O
identity	O
in	O
the	O
coding	O
region	O
and	O
all	O
of	O
the	O
exon-intron	O
boundaries	O
are	O
conserved	O
,	O
as	O
are	O
the	O
sizes	O
of	O
the	O
introns	O
.	O

The	O
transcription	O
factor	O
Sp1	B-GENE
bound	O
to	O
eight	O
sites	O
,	O
as	O
demonstrated	O
by	O
footprinting	O
assays	O
and	O
gel	O
shift	O
analysis	O
with	O
purified	O
Sp1	B-GENE
.	O

Thus	O
,	O
a	O
negative	O
test	O
is	O
compatible	O
with	O
low	O
disease	O
activity	O
and	O
/	O
or	O
efficacy	O
of	O
calcium	O
antagonist	O
treatment	O
.	O

Structural	O
changes	O
in	O
the	O
C-terminus	O
of	O
Ca2+-bound	O
rat	B-GENE
S100B	I-GENE
(	O
beta	B-GENE
beta	I-GENE
)	O
upon	O
binding	O
to	O
a	O
peptide	O
derived	O
from	O
the	O
C-terminal	O
regulatory	O
domain	O
of	O
p53	B-GENE
.	O

Rapid	O
detection	O
of	O
radioisotopically	O
contaminated	O
test	O
serum	O
before	O
radioassay	O
of	O
vitamin	O
B12	O
.	O

These	O
disorders	O
include	O
low-back	O
pain	O
,	O
saddle	O
anesthesia	O
,	O
bilateral	O
sciatica	O
,	O
then	O
motor	O
weakness	O
of	O
the	O
lower	O
extremities	O
or	O
chronic	O
paraplegia	O
and	O
,	O
bladder	O
dysfunction	O
.	O

Weight	O
loss	O
reduces	O
arterial	O
pressure	O
by	O
a	O
decrease	O
in	O
intravascular	O
volume	O
and	O
cardiac	O
output	O
associated	O
with	O
a	O
fall	O
in	O
sympathetic	O
activity	O
.	O

A	O
promising	O
new	O
cement	O
,	O
4-META	O
/	O
MMA-TBB	O
opaque	O
resin	O
,	O
has	O
shown	O
remarkable	O
adhesive	O
properties	O
as	O
a	O
bone	O
cement	O
in	O
vivo	O
.	O

The	O
first	O
symptoms	O
of	O
enzootic	O
calcinosis	O
were	O
noted	O
in	O
March	O
1998	O
,	O
when	O
some	O
of	O
the	O
cows	O
developed	O
locomotor	O
abnormalities	O
.	O

Temperature-shift	O
experiments	O
using	O
synchronously	O
grown	O
cells	O
of	O
a	O
delta	B-GENE
top1	I-GENE
top2	B-GENE
temperature-sensitive	I-GENE
(	I-GENE
ts	I-GENE
)	I-GENE
double	I-GENE
mutant	I-GENE
and	O
its	O
isogenic	O
top2	B-GENE
ts	O
strain	O
show	O
that	O
,	O
whereas	O
mitotic	O
blocks	O
can	O
prevent	O
killing	O
of	O
the	O
top2	B-GENE
ts	I-GENE
mutant	I-GENE
at	O
a	O
nonpermissive	O
temperature	O
,	O
the	O
same	O
treatments	O
are	O
ineffective	O
in	O
preventing	O
cell	O
death	O
of	O
the	O
delta	B-GENE
top1	I-GENE
top2	B-GENE
ts	I-GENE
double	I-GENE
mutant	I-GENE
.	O

These	O
results	O
indicate	O
that	O
TGF-betaf	B-GENE
potentiates	O
the	O
c-fos	B-GENE
SRE	B-GENE
activated	O
by	O
PKC	B-GENE
through	O
the	O
SRF	B-GENE
binding	I-GENE
site	I-GENE
.	O

By	O
using	O
a	O
DNA	O
sequence	O
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	B-GENE
BCL-6	I-GENE
in	O
vitro	O
,	O
we	O
show	O
here	O
that	O
BCL-6	B-GENE
is	O
present	O
in	O
DNA-binding	O
complexes	O
in	O
nuclear	O
extracts	O
from	O
various	O
B-cell	O
lines	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
protein	O
product	O
of	O
the	O
ref-1	B-GENE
gene	I-GENE
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
Fos-Jun	B-GENE
heterodimers	I-GENE
,	O
Jun-Jun	B-GENE
homodimers	I-GENE
and	O
Hela	O
cell	O
AP-1	B-GENE
proteins	I-GENE
as	O
well	O
as	O
that	O
of	O
several	O
other	O
transcription	O
factors	O
including	O
NF-kappa	B-GENE
B	I-GENE
,	O
Myb	B-GENE
and	O
members	O
of	O
the	O
ATF	B-GENE
/	I-GENE
CREB	I-GENE
family	I-GENE
.	O

The	O
data	O
obtained	O
up	O
to	O
now	O
only	O
suggest	O
the	O
future	O
potentiality	O
of	O
Bestatin	O
treatment	O
for	O
these	O
types	O
of	O
malignancy	O
.	O

The	O
results	O
supported	O
the	O
therapeutic	O
principle	O
of	O
TCM	O
:	O
Treating	O
patients	O
according	O
to	O
their	O
pathophysiological	O
patterns	O
.	O

Ki-ras4BVal-12	B-GENE
transfectant	O
cells	O
expressed	O
2-fold	O
elevated	O
protein	O
levels	O
of	O
the	O
lysosomal	B-GENE
cysteine	I-GENE
protease	I-GENE
cathepsin	I-GENE
B	I-GENE
but	O
did	O
not	O
up-regulate	O
cathepsin	B-GENE
B	I-GENE
mRNA	I-GENE
expression	O
.	O

Fgd3	B-GENE
and	O
FGD1	B-GENE
share	O
a	O
high	O
degree	O
of	O
sequence	O
identity	O
that	O
spans	O
>	O
560	O
contiguous	O
amino	O
acid	O
residues	O
.	O

Conformational	O
studies	O
combining	O
secondary	O
structure	O
predictions	O
,	O
CD	O
and	O
NMR	O
spectroscopy	O
together	O
with	O
ELISA	O
assays	O
,	O
showed	O
that	O
the	O
greater	O
is	O
the	O
propensity	O
of	O
the	O
epitope	O
for	O
helix	O
formation	O
the	O
higher	O
is	O
the	O
recognition	O
by	O
anti-K159	B-GENE
.	O

Spores	O
from	O
Rhizopus	O
stolonifer	O
were	O
suspended	O
in	O
distilled	O
water	O
(	O
1	O
x	O
10	O
(	O
6	O
)	O
spores	O
/	O
mL	O
)	O
and	O
used	O
as	O
starter	O
.	O

Gene	B-GENE
1	I-GENE
has	O
been	O
completely	O
sequenced	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
sexually	O
transmitted	O
diseases	O
(	O
STD	O
)	O
control	O
program	O
for	O
female	O
sex	O
workers	O
(	O
FSW	O
)	O
in	O
Lima	O
,	O
Peru	O
,	O
provided	O
periodic	O
serological	O
tests	O
for	O
syphilis	O
and	O
cervical	O
smears	O
for	O
gonococci	O
,	O
but	O
not	O
medication	O
for	O
STD	O
or	O
condoms	O
.	O

Ciprofloxacin	O
:	O
an	O
overview	O
of	O
adverse	O
experiences	O
.	O

Persistence	O
of	O
toxaphene	O
in	O
treated	O
lakes	O
.	O

Nevertheless	O
cryopreservation	O
of	O
spermatozoa	O
in	O
a	O
medium	O
containing	O
neither	O
SP	O
nor	O
biological	O
substances	O
could	O
offer	O
an	O
acceptable	O
cryoprotection	O
of	O
spermatozoa	O
to	O
be	O
used	O
in	O
assisted	O
fertilization	O
procedures	O
,	O
especially	O
for	O
intracytoplasmic	O
sperm	O
injection	O
.	O

Comparison	O
of	O
three	O
different	O
preparations	O
of	O
disodium	O
cromoglycate	O
in	O
the	O
prevention	O
of	O
exercise-induced	O
bronchospasm	O
:	O
a	O
double-blind	O
study	O
.	O

Fenoldopam	O
,	O
a	O
dopamine	B-GENE
receptor	I-GENE
agonist	O
,	O
has	O
been	O
shown	O
,	O
in	O
animal	O
experiments	O
,	O
to	O
improve	O
renal	O
perfusion	O
.	O

Escherichia	O
coli	O
JRG582	O
is	O
an	O
ampD	B-GENE
ampE	B-GENE
deletion	O
derivative	O
of	O
strain	O
HfrH	O
and	O
accordingly	O
it	O
is	O
derepressed	O
for	O
expression	O
of	O
the	O
cloned	O
inducible	O
beta-lactamase	B-GENE
gene	I-GENE
of	O
Citrobacter	O
freundii	O
,	O
carried	O
on	O
plasmid	O
pNU305	O
.	O

Guinea	O
pigs	O
weighing	O
300	O
approximately	O
350	O
g	O
were	O
used	O
.	O

Alginate	B-GENE
biosynthesis	O
is	O
controlled	O
by	O
a	O
complex	O
regulatory	O
mechanism	O
.	O

In	O
visible	O
tumours	O
the	O
best	O
results	O
were	O
obtained	O
with	O
FB	O
(	O
85%	O
)	O
while	O
TBN	O
was	O
positive	O
in	O
65%	O
.	O

Molecules	O
of	O
NH3	O
are	O
capable	O
of	O
emitting	O
stimulated	O
radiation	O
(	O
MASER	O
)	O
.	O

A	O
simplified	O
thin-layer	O
chromatographic	O
determination	O
of	O
hippuric	O
acid	O
and	O
methylhippuric	O
acids	O
.	O

Mutations	O
in	O
the	O
nuclear	B-GENE
gene	I-GENE
CBP1	I-GENE
of	I-GENE
Saccharomyces	I-GENE
cerevisiae	I-GENE
result	O
in	O
degradation	O
of	O
mitochondrially	B-GENE
encoded	I-GENE
cytochrome	I-GENE
b	I-GENE
(	O
cob	B-GENE
)	O
RNA	O
;	O
thus	O
,	O
the	O
cells	O
are	O
unable	O
to	O
respire	O
.	O

Radiative	O
corrections	O
to	O
beta	O
decay	O
and	O
the	O
possibility	O
of	O
a	O
fourth	O
generation	O
.	O

Results	O
support	O
the	O
hypothesis	O
that	O
endogenous	B-GENE
corticotropin-releasing	I-GENE
factor	I-GENE
,	O
perhaps	O
acting	O
at	O
a	O
peripheral	O
binding	O
site	O
,	O
suppresses	O
the	O
active	O
behavioral	O
response	O
characteristic	O
of	O
pups	O
during	O
the	O
early	O
phase	O
of	O
isolation	O
in	O
novel	O
surroundings	O
.	O

TFEC	B-GENE
,	O
a	O
basic	B-GENE
helix-loop-helix	I-GENE
protein	I-GENE
,	O
forms	O
heterodimers	O
with	O
TFE3	B-GENE
and	O
inhibits	O
TFE3-dependent	O
transcription	O
activation	O
.	O

Ly-49	B-GENE
is	O
a	O
family	B-GENE
type	I-GENE
II	I-GENE
transmembrane	I-GENE
proteins	I-GENE
encoded	O
by	O
a	O
gene	O
cluster	O
on	O
murine	O
chromosome	O
6	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
crucial	O
role	O
of	O
the	O
mutations	O
activating	O
v-erbA	B-GENE
as	O
an	O
oncogene	O
is	O
to	O
'freeze'	O
c-ErbA	B-GENE
/	I-GENE
TRalpha	I-GENE
in	O
its	O
non-liganded	O
,	O
repressive	O
conformation	O
and	O
to	O
facilitate	O
its	O
overexpression	O
.	O

All	O
were	O
experienced	O
hearing	O
aid	O
users	O
who	O
wore	O
linear	O
Class	O
D	O
instruments	O
with	O
input	O
compression	O
limiting	O
at	O
the	O
time	O
of	O
their	O
enrollment	O
in	O
this	O
study	O
.	O

Adenyl	B-GENE
cyclase	I-GENE
activity	O
of	O
gastric	O
mucosa	O
in	O
patients	O
with	O
duodenal	O
ulcer	O
before	O
and	O
after	O
treatment	O
.	O

In	O
whole	O
sardine	O
,	O
domoic	O
acid	O
was	O
detected	O
in	O
levels	O
exceeding	O
sometimes	O
the	O
regulatory	O
limit	O
.	O

Comparison	O
of	O
beta	B-GENE
2-microglobulin	I-GENE
removal	O
using	O
the	O
same	O
polysulphone	O
membrane	O
for	O
haemodialysis	O
and	O
haemofiltration	O
shows	O
that	O
beta	B-GENE
2-microglobulin	I-GENE
is	O
more	O
effectively	O
removed	O
by	O
convection	O
than	O
by	O
diffusion	O
when	O
both	O
treatment	O
modes	O
are	O
matched	O
for	O
blood	O
flow	O
and	O
urea	O
clearance	O
.	O

The	O
mice	O
are	O
phenotypically	O
normal	O
and	O
do	O
not	O
develop	O
spontaneous	O
tumors	O
at	O
an	O
early	O
age	O
,	O
in	O
contrast	O
to	O
knock-out	O
(	O
p53	B-GENE
(	I-GENE
-	I-GENE
/	I-GENE
-	I-GENE
)	I-GENE
)	O
strains	O
with	O
a	O
defective	O
p53	B-GENE
gene	I-GENE
.	O

At	O
this	O
timepoint	O
,	O
many	O
leucocytes	O
in	O
the	O
ME	O
and	O
ET	O
mucosa	O
had	O
incorporated	O
BrdU	O
(	O
between	O
15	O
and	O
25%	O
within	O
the	O
subsets	O
)	O
.	O

The	O
cost	O
per	O
test	O
is	O
less	O
than	O
those	O
for	O
CC	O
,	O
kEIA	O
and	O
PACE2	O
.	O

Effect	O
of	O
succimer	O
on	O
the	O
intensity	O
of	O
tricarboxylic	B-GENE
acid	I-GENE
dehydrogenase	I-GENE
reactions	O
in	O
the	O
brain	O
of	O
rats	O
poisoned	O
with	O
mercuric	O
chloride	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
C-terminal	O
region	O
of	O
Crk	B-GENE
contains	O
negative	O
regulatory	O
elements	O
important	O
for	O
both	O
Abl	B-GENE
and	O
FAK	B-GENE
dependent	O
signal	O
pathways	O
,	O
and	O
offers	O
a	O
paradigm	O
for	O
an	O
autoinhibitory	O
region	O
in	O
the	O
SH3	B-GENE
linker	I-GENE
/	I-GENE
C-terminal	I-GENE
SH3	I-GENE
domain	I-GENE
.	O

Adriamycin	O
:	O
comparison	O
of	O
a	O
5-week	O
schedule	O
with	O
a	O
3-week	O
schedule	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O

In	O
contrast	O
,	O
mutations	O
affecting	O
the	O
other	O
two	O
Nim1p-related	B-GENE
kinases	I-GENE
in	O
S	O
.	O
cerevisiae	O
,	O
Hsl1p	B-GENE
and	O
Kcc4p	B-GENE
,	O
produce	O
no	O
detectable	O
effect	O
on	O
septin	B-GENE
organization	O
.	O

A	O
Drosophila	B-GENE
shc	I-GENE
gene	I-GENE
product	I-GENE
is	O
implicated	O
in	O
signaling	O
by	O
the	O
DER	B-GENE
receptor	I-GENE
tyrosine	I-GENE
kinase	I-GENE
.	O

Group	O
psychometric	O
functions	O
for	O
listeners	O
with	O
hearing	O
loss	O
do	O
not	O
show	O
a	O
decrease	O
in	O
performance	O
at	O
the	O
largest	O
values	O
of	O
delta	O
f	O
included	O
in	O
this	O
study	O
.	O

Thus	O
,	O
blocks	O
in	O
the	O
RARalpha-specific	O
pathway	O
of	O
retinoid-induced	O
differentiation	O
may	O
be	O
bypassed	O
during	O
retinoid	O
induction	O
of	O
FR-beta	B-GENE
expression	O
.	O

Once	O
the	O
proliferation	O
of	O
fibroblasts	O
and	O
collagen	B-GENE
synthesis	O
had	O
led	O
to	O
an	O
increase	O
of	O
mechanical	O
strength	O
,	O
no	O
negative	O
effect	O
on	O
wound	O
healing	O
could	O
be	O
detected	O
applying	O
the	O
same	O
chemotherapeutic	O
agents	O
.	O

In	O
10	O
pentobarbitalized	O
dogs	O
,	O
plasma	O
viscosity	O
(	O
Ep	O
)	O
was	O
raised	O
fourfold	O
while	O
apparent	O
blood	O
viscosity	O
(	O
Ea	O
)	O
increased	O
about	O
twofold	O
by	O
two	O
steps	O
of	O
exchange	O
transfusion	O
of	O
200	O
ml	O
of	O
plasma	O
with	O
plasma	O
containing	O
high	O
molecular	O
weight	O
dextran	O
(	O
mol	O
wt	O
500	O
,	O
000	O
,	O
20%	O
wt	O
/	O
vol	O
)	O
.	O

Hospital	O
hit	O
for	O
hiring	O
AHERF	O
physicians	O
.	O

After	O
overtraining	O
on	O
the	O
original	O
discrimination	O
,	O
the	O
controls	O
showed	O
the	O
normal	O
difficulty	O
in	O
learning	O
the	O
first	O
reversal	O
.	O

Interestingly	O
,	O
the	O
activity	O
of	O
IkappaB	B-GENE
kinase	I-GENE
(	O
IKK-beta	B-GENE
)	O
,	O
which	O
plays	O
an	O
essential	O
role	O
in	O
NF-kappaB	B-GENE
activation	O
through	O
IkappaB	B-GENE
phosphorylation	O
,	O
was	O
largely	O
enhanced	O
in	O
paclitaxel-treated	O
cells	O
,	O
detected	O
as	O
IkappaBalpha	B-GENE
phosphorylation	O
.	O

We	O
evaluated	O
regional	O
right	O
ventricular	O
wall	O
motion	O
during	O
systole	O
in	O
patients	O
with	O
surgically	O
repaired	O
tetralogy	O
of	O
Fallot	O
(	O
TOF	O
)	O
using	O
color	O
kinesis	O
imaging	O
.	O

The	O
effect	O
of	O
Rho	B-GENE
on	O
AP-1	B-GENE
is	O
independent	O
of	O
the	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
pathway	I-GENE
,	O
as	O
a	O
dominant-negative	B-GENE
MEK	I-GENE
and	O
a	O
MEK	B-GENE
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho-induced	B-GENE
AP-1	I-GENE
activity	O
.	O

The	O
mortality	O
rate	O
and	O
histopathological	O
features	O
of	O
Nocardia	O
asteroides	O
and	O
Nocardia	O
brasiliensis	O
infections	O
in	O
congenitally	O
athymic	O
(	O
nude	O
)	O
mice	O
of	O
ICR	O
and	O
C3H	O
/	O
eB	O
origins	O
were	O
quite	O
different	O
from	O
what	O
we	O
found	O
for	O
Swiss	O
white	O
mice	O
and	O
other	O
inbred	O
mouse	O
strains	O
(	O
namely	O
,	O
C57	O
/	O
BL	O
/	O
6J	O
,	O
New	O
Zealand	O
Black	O
,	O
BALB	O
/	O
c	O
,	O
CBA	O
/	O
LAC	O
,	O
and	O
C3H	O
/	O
eB	O
)	O
.	O

Influence	O
of	O
oil	O
emulsions	O
and	O
diphenyl	O
on	O
post-harvest	O
physiconutritional	O
changes	O
in	O
Kagzi	O
limes	O
(	O
Citrus	O
aurantifolia	O
)	O
was	O
studied	O
.	O

IFN-stimulated	B-GENE
gene	I-GENE
factor-3	I-GENE
and	O
STAT1	B-GENE
homodimers	I-GENE
formed	O
and	O
bound	O
an	O
IFN-stimulated	B-GENE
response	I-GENE
element	I-GENE
(	O
ISRE	B-GENE
)	O
and	O
gamma-activated	B-GENE
sequence	I-GENE
(	O
GAS	B-GENE
)	O
element	O
,	O
respectively	O
.	O

Re	O
:	O
A	O
modified	O
method	O
for	O
the	O
in	O
vivo	O
labeling	O
of	O
red	O
blood	O
cells	O
with	O
Tc-99m	O
.	O

ORF	B-GENE
M1	I-GENE
has	O
striking	O
homology	O
to	O
poxvirus	O
serpins	B-GENE
,	O
while	O
ORF	B-GENE
M11	I-GENE
encodes	O
a	O
potential	O
homolog	O
of	O
Bcl-2-like	B-GENE
molecules	I-GENE
encoded	O
by	O
other	O
gammaherpesviruses	O
(	O
gene	B-GENE
16	I-GENE
of	O
HVS	O
and	O
KSHV	O
and	O
the	O
BHRF1	B-GENE
gene	I-GENE
of	O
EBV	O
)	O
.	O

A	O
short	O
sequence	O
surrounding	O
the	O
major	O
JNK	B-GENE
phosphorylation	O
site	O
of	O
c-Jun	B-GENE
is	O
conserved	O
in	O
c-Fos	B-GENE
and	O
is	O
part	O
of	O
its	O
activation	O
domain	O
,	O
suggesting	O
that	O
c-Fos	B-GENE
may	O
be	O
similarly	O
regulated	O
.	O

Two	O
hundred	O
sixty-four	O
patients	O
scheduled	O
for	O
DCBM	O
were	O
randomized	O
to	O
receive	O
intravenously	O
geG	O
0	O
.	O
25	O
mg	O
(	O
geG-25	O
)	O
,	O
or	O
geG	O
0	O
.	O
5	O
mg	O
(	O
geG-50	O
)	O
,	O
or	O
HBB	O
20	O
mg	O
as	O
hypotonic	O
agent	O
.	O

Estrogen	O
replacement	O
,	O
either	O
as	O
17	O
beta-estradiol	O
or	O
beta-estradiol-3-benzoate	O
via	O
subcutaneous	O
Silastic	O
capsules	O
,	O
was	O
associated	O
with	O
elevated	O
rates	O
of	O
heat	O
production	O
and	O
dry	O
heat	O
loss	O
relative	O
to	O
untreated	O
ovariectomized	O
controls	O
.	O

Sodium	O
restriction	O
in	O
cardiac	O
failure	O
.	O

Rapamycin	O
(	O
FRAP	B-GENE
/	I-GENE
mTOR	I-GENE
inhibitor	O
)	O
blocked	O
4E-BP1	B-GENE
phosphorylation	O
causing	O
a	O
predominance	O
of	O
the	O
alpha	O
(	O
hypophosphorylated	O
)	O
band	O
.	O

CONTEXT	O
:	O
ThinPrep	O
,	O
AutoPap	O
,	O
and	O
Papnet	O
are	O
3	O
new	O
technologies	O
that	O
increase	O
the	O
sensitivity	O
and	O
cost	O
of	O
cervical	O
cancer	O
screening	O
.	O

A	O
unique	O
leucine-proline	B-GENE
repeat	I-GENE
element	I-GENE
found	O
N-terminal	O
to	O
the	O
DNA-binding	O
domain	O
of	O
EmBP-1	B-GENE
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
DNA-binding	O
or	O
dimerization	O
.	O

Endosonography	O
accurately	O
assessed	O
tumor	O
extension	O
in	O
two	O
T2	O
tumors	O
,	O
14	O
T3	O
tumors	O
,	O
and	O
seven	O
T4	O
tumors	O
.	O

The	O
PDE4A-subfamily-specific	B-GENE
linker	I-GENE
region	I-GENE
LR1	B-GENE
,	O
which	O
joins	O
UCR1	B-GENE
and	O
UCR2	B-GENE
,	O
is	O
encoded	O
by	O
two	O
exons	O
,	O
whereas	O
LR2	B-GENE
,	O
which	O
joins	O
UCR2	B-GENE
to	O
the	O
catalytic	O
unit	O
,	O
is	O
encoded	O
by	O
a	O
single	O
exon	O
.	O

Range	O
behavior	O
of	O
Hereford	O
,	O
Hereford	O
x	O
Holstein	O
and	O
Holstein	O
non-lactating	O
heifers	O
.	O

Forty-eight	O
pigs	O
were	O
removed	O
from	O
sows	O
at	O
1	O
d	O
of	O
age	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
treatments	O
:	O
1	O
)	O
control	O
with	O
lactose	O
as	O
the	O
carbohydrate	O
source	O
,	O
2	O
)	O
lactose	O
replaced	O
(	O
gram	O
for	O
gram	O
)	O
with	O
CSS	O
(	O
dextrose	O
equivalent	O
[	O
DE	O
]	O
-20	O
)	O
,	O
and	O
3	O
)	O
lactose	O
replaced	O
with	O
DE-42	O
.	O

Oxidative	O
degradation	O
of	O
adrenaline	O
solutions	O
:	O
study	O
of	O
the	O
intermediate	O
stages	O
and	O
their	O
analytic	O
value	O
for	O
the	O
control	O
of	O
this	O
solute	O
.	O

Forskolin	O
treatment	O
(	O
10	O
microM	O
)	O
of	O
the	O
transfected	O
cells	O
for	O
3--6	O
h	O
maximally	O
induced	O
luciferase	B-GENE
threefold	O
.	O

We	O
have	O
used	O
these	O
modified	O
assay	O
conditions	O
to	O
extend	O
studies	O
on	O
the	O
transposition	O
pathway	O
.	O

Thirty	O
Class	O
I	O
and	O
Class	O
II	O
recessions	O
in	O
30	O
patients	O
were	O
treated	O
with	O
a	O
modified	O
subepithelial	O
connective	O
tissue	O
graft	O
procedure	O
.	O

Two	O
classes	O
of	O
inactive	O
receptors	O
were	O
identified	O
:	O
one	O
in	O
which	O
both	O
transcriptional	O
activation	O
and	O
dimerization	O
were	O
compromised	O
and	O
a	O
second	O
in	O
which	O
only	O
transcriptional	O
activation	O
was	O
abolished	O
.	O

The	O
results	O
also	O
imply	O
that	O
the	O
absence	O
of	O
perforin	B-GENE
expression	O
in	O
non-cytotoxic	O
cells	O
may	O
be	O
due	O
to	O
the	O
suppression	O
of	O
the	O
induction	O
of	O
the	O
killer-cell-specific	O
trans-acting	O
factor	O
NF-P2	B-GENE
.	O

Vibrio	O
cholerae	O
O139	O
in	O
Calcutta	O
.	O

A	O
brief	O
account	O
of	O
the	O
1988	O
seminar	O
in	O
Shanghai	O
on	O
viral	O
hepatitis	O
A	O
.	O

To	O
characterize	O
the	O
expression	O
of	O
this	O
DNA	B-GENE
repair	I-GENE
enzyme	I-GENE
,	O
we	O
have	O
isolated	O
the	O
corresponding	O
genomic	O
clone	O
.	O

Serum	B-GENE
gamma	I-GENE
glutamyltransferase	I-GENE
in	O
the	O
diagnosis	O
of	O
liver	O
disease	O
in	O
cattle	O
.	O

Snail	O
mortality	O
did	O
not	O
differ	O
among	O
the	O
various	O
treatment	O
conditions	O
.	O

The	O
effect	O
of	O
a	O
constant	O
magnetic	O
field	O
on	O
the	O
phagocytic	O
activity	O
of	O
Paramecia	O
.	O

However	O
,	O
one	O
CAK-phosphorylated	O
phosphopeptide	O
comigrates	O
with	O
a	O
Cdc2-phosphorylated	O
phosphopeptide	O
previously	O
shown	O
to	O
be	O
mitosis-specific	O
,	O
suggesting	O
that	O
,	O
in	O
vitro	O
,	O
CAK	B-GENE
is	O
able	O
to	O
phosphorylate	O
at	O
least	O
one	O
site	O
that	O
is	O
also	O
phosphorylated	O
in	O
vivo	O
.	O

The	O
5-year	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
progression-free	O
survival	O
(	O
PFS	O
)	O
rates	O
were	O
58	O
.	O
9%	O
and	O
55	O
.	O
4%	O
for	O
arm	O
A	O
and	O
44	O
.	O
5%	O
and	O
41	O
.	O
3%	O
for	O
arm	O
B	O
(	O
P	O
=	O
.	O
007	O
and	O
P	O
=	O
.	O
02	O
)	O
,	O
respectively	O
.	O

The	O
JTc	O
delta	O
among	O
the	O
three	O
groups	O
did	O
not	O
differ	O
as	O
well	O
:	O
JTc	O
delta	O
of	O
the	O
VT	O
group	O
was	O
70	O
ms	O
+	O
/	O
-	O
30	O
ms	O
,	O
the	O
JTc	O
delta	O
of	O
the	O
PVC	O
group	O
was	O
60	O
msec	O
+	O
/	O
-	O
25	O
msec	O
,	O
and	O
the	O
JTc	O
delta	O
of	O
the	O
control	O
group	O
was	O
70	O
ms	O
+	O
/	O
-	O
30	O
ms	O
.	O

Overall	O
least-squares	O
means	O
for	O
uncooked	O
and	O
cooked	O
longissimus	O
muscle	O
and	O
subcutaneous	O
fat	O
were	O
63	O
.	O
32	O
,	O
80	O
.	O
27	O
and	O
98	O
.	O
90	O
mg	O
of	O
cholesterol	O
/	O
100	O
g	O
of	O
tissue	O
,	O
respectively	O
.	O

Sequence	O
analysis	O
of	O
the	O
isolated	O
genomic	O
clone	O
revealed	O
that	O
the	O
DNA	O
binding	O
domain	O
of	O
this	O
orphan	B-GENE
receptor	I-GENE
is	O
most	O
homologous	O
to	O
the	O
human	B-GENE
TR2	I-GENE
receptor	I-GENE
.	O

Interestingly	O
,	O
this	O
amino-terminal	O
determinant	O
appears	O
not	O
to	O
reside	O
in	O
the	O
HSV-alpha	O
TIF	B-GENE
,	O
which	O
displays	O
no	O
independent	O
amino-terminal	O
activity	O
.	O

UVA-induced	O
melanocytic	O
lesions	O
.	O

PFK-A	B-GENE
mRNA	O
was	O
more	O
abundantly	O
expressed	O
in	O
all	O
tissues	O
than	O
were	O
the	O
PFK-B	B-GENE
and	O
PFK-C	B-GENE
genes	I-GENE
.	O

The	O
hybrid	O
viruses	O
were	O
found	O
to	O
accumulate	O
to	O
high	O
levels	O
in	O
infected	O
plants	O
,	O
to	O
form	O
stable	O
virions	O
,	O
and	O
to	O
be	O
mechanically	O
transmissible	O
.	O

The	O
ORs	O
of	O
GC	O
,	O
adjusted	O
for	O
age	O
and	O
sex	O
,	O
varied	O
from	O
17	O
.	O
1	O
,	O
for	O
those	O
with	O
baseline	O
diagnoses	O
of	O
superficial	O
intestinal	O
metaplasia	O
(	O
IM	O
)	O
,	O
to	O
29	O
.	O
3	O
,	O
for	O
those	O
with	O
deep	O
IM	O
or	O
mild	O
dysplasia	O
(	O
DYS	O
)	O
or	O
IM	O
with	O
glandular	O
atrophy	O
and	O
neck	O
hyperplasia	O
,	O
to	O
104	O
.	O
2	O
,	O
for	O
those	O
with	O
moderate	O
or	O
severe	O
DYS	O
,	O
as	O
compared	O
with	O
subjects	O
with	O
superficial	O
gastritis	O
(	O
SG	O
)	O
or	O
chronic	O
atrophic	O
gastritis	O
(	O
CAG	O
)	O
at	O
baseline	O
.	O

Lesions	O
were	O
made	O
by	O
pressure	O
injection	O
of	O
kainic	O
acid	O
into	O
the	O
SOC	O
through	O
a	O
stereotaxically	O
positioned	O
glass	O
micropipette	O
.	O

Analysis	O
of	O
the	O
intact	O
hGH	B-GENE
gene	I-GENE
or	O
hGH	B-GENE
5'-flanking	I-GENE
DNA	I-GENE
(	I-GENE
5'-FR	I-GENE
)	I-GENE
coupled	O
to	O
the	O
hGh	B-GENE
cDNA	I-GENE
or	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
or	O
luciferase	B-GENE
genes	I-GENE
,	O
indicated	O
that	O
cAMP	O
primarily	O
stimulated	O
hGH	B-GENE
promoter	I-GENE
activity	O
.	O

Chemical	O
histologic	O
and	O
immunologic	O
responses	O
in	O
rats	O
to	O
CC1-4	O
by	O
different	O
routes	O
of	O
administration	O
.	O

Clone	O
39	O
was	O
a	O
homolog	O
of	O
CONSTANS	B-GENE
,	O
which	O
is	O
a	O
gene	O
involved	O
in	O
controlling	O
the	O
flowering	O
time	O
in	O
Arabidopsis	O
.	O

Here	O
we	O
describe	O
the	O
identification	O
and	O
characterization	O
of	O
several	O
Sp100	B-GENE
splice	I-GENE
variant	I-GENE
proteins	I-GENE
and	O
support	O
their	O
existence	O
by	O
elucidation	O
of	O
the	O
3'-end	O
of	O
the	O
Sp100	B-GENE
gene	I-GENE
.	O

Although	O
linker	O
regions	O
in	O
transcription	O
factors	O
are	O
known	O
to	O
modulate	O
DNA	O
binding	O
specificity	O
,	O
our	O
studies	O
suggest	O
that	O
the	O
human	B-GENE
HSF1	I-GENE
linker	O
plays	O
no	O
role	O
in	O
determining	O
HSF1	B-GENE
binding	O
preferences	O
in	O
vivo	O
but	O
is	O
a	O
critical	O
determinant	O
in	O
regulating	O
the	O
HSF1	B-GENE
monomer-trimer	I-GENE
equilibrium	O
.	O

They	O
also	O
negatively	O
modulate	O
the	O
PI	B-GENE
3-kinase	I-GENE
catalytic	O
activity	O
but	O
to	O
different	O
extents	O
,	O
dependent	O
on	O
the	O
unique	O
N-terminal	O
structure	O
of	O
each	O
isoform	O
.	O

We	O
conclude	O
that	O
the	O
'morning	O
dip'	O
observed	O
in	O
asthmatic	O
patients	O
cannot	O
simply	O
be	O
explained	O
by	O
changes	O
in	O
cell	O
receptor	O
number	O
or	O
affinity	O
,	O
as	O
our	O
results	O
suggest	O
that	O
both	O
groups	O
have	O
intact	O
beta-adrenoceptor	B-GENE
function	O
.	O

In	O
contrast	O
,	O
the	O
PPSF	O
+	O
DBP	O
side	O
showed	O
large	O
amounts	O
of	O
bone	O
formation	O
,	O
and	O
bone	O
almost	O
covered	O
the	O
implant	O
.	O

Clinicopathologic	O
studies	O
in	O
feminizing	O
tumors	O
of	O
the	O
ovary	O
.	O

A	O
case	O
of	O
a	O
dense	O
epidermoid	O
cyst	O
of	O
the	O
suprasellar	O
cistern	O
is	O
presented	O
.	O

The	O
divergence	O
in	O
primary	O
structure	O
between	O
the	O
sheep	O
CRF1	B-GENE
and	O
the	O
other	O
mammalian	B-GENE
CRF1s	I-GENE
is	O
primarily	O
localized	O
to	O
the	O
extracellular	O
amino	O
terminal	O
domain	O
of	O
the	O
receptor	O
(	O
18	O
of	O
22	O
divergent	O
residues	O
,	O
ovine	O
vs	O
human	B-GENE
CRF1	I-GENE
)	O
.	O

Localization	O
of	O
the	O
cytokine	B-GENE
response	I-GENE
element	I-GENE
by	O
5'-deletion	O
analysis	O
and	O
site-directed	O
mutagenesis	O
revealed	O
a	O
cis-acting	O
binding	O
site	O
for	O
activated	O
STAT	B-GENE
complexes	I-GENE
.	O

Comparison	O
of	O
human	B-GENE
and	I-GENE
murine	I-GENE
blk	I-GENE
sequences	I-GENE
indicated	O
that	O
they	O
share	O
86%	O
amino	O
acid	O
identity	O
,	O
the	O
most	O
conserved	O
region	O
being	O
the	O
catalytic	O
domain	O
(	O
93%	O
identity	O
)	O
.	O

An	O
experiment	O
on	O
the	O
return-of-fear	O
(	O
ROF	O
)	O
was	O
carried	O
out	O
on	O
40	O
snake-	O
or	O
spider-phobic	O
subjects	O
in	O
order	O
to	O
determine	O
whether	O
an	O
arousing	O
event	O
that	O
occurs	O
shortly	O
before	O
retest	O
influences	O
the	O
magnitude	O
of	O
the	O
ROF	O
.	O

Members	O
of	O
the	O
Ras	B-GENE
subfamily	I-GENE
of	O
small	B-GENE
GTP-binding	I-GENE
proteins	I-GENE
have	O
been	O
shown	O
to	O
be	O
promiscuous	O
towards	O
a	O
variety	O
of	O
putative	O
effector	O
molecules	O
such	O
as	O
the	O
protein	B-GENE
kinase	I-GENE
c-Raf	I-GENE
and	O
the	O
Ral-specific	B-GENE
guanine	I-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
(	O
Ral-GEF	B-GENE
)	O
.	O

Targeted	O
disruption	O
of	O
the	O
OGG1	B-GENE
gene	I-GENE
in	O
yeast	O
revealed	O
a	O
second	O
OG	B-GENE
glycosylase	I-GENE
/	I-GENE
lyase	I-GENE
protein	I-GENE
,	O
tentatively	O
named	O
Ogg2	B-GENE
,	O
which	O
differs	O
from	O
Ogg1	B-GENE
in	O
that	O
it	O
preferentially	O
acts	O
on	O
OG	O
:	O
G	O
.	O

Characterization	O
of	O
the	O
regulatory	O
regions	O
of	O
the	O
human	B-GENE
aromatase	I-GENE
(	O
P450arom	B-GENE
)	O
gene	O
involved	O
in	O
placenta-specific	O
expression	O
.	O

Ectopic	O
expression	O
of	O
Apo-3	B-GENE
in	O
HEK293	O
or	O
HeLa	O
cells	O
induced	O
marked	O
apoptosis	O
.	O

Here	O
we	O
report	O
the	O
complete	O
6-kilobase	O
cDNA	O
sequence	O
coding	O
for	O
a	O
chain	O
of	O
1775	O
amino	O
acids	O
,	O
as	O
well	O
as	O
the	O
genomic	O
structure	O
.	O

Regulation	O
of	O
RhoA	B-GENE
is	O
required	O
to	O
maintain	O
adhesion	O
in	O
stationary	O
cells	O
,	O
but	O
is	O
also	O
critical	O
for	O
cell	O
spreading	O
and	O
migration	O
[	O
3	O
]	O
.	O

Prolonged	O
heavy	O
work	O
effected	O
an	O
increase	O
of	O
10	O
.	O
3	O
plus	O
or	O
minus	O
0	O
.	O
9	O
mmHg	O
in	O
in	O
vivo	O
P50	O
(	O
7	O
.	O
30	O
PH-v	O
,	O
41	O
degrees	O
C-v	O
,	O
and	O
45	O
Pv-CO2	O
)	O
;	O
due	O
entirely	O
to	O
the	O
additive	O
effects	O
of	O
increased	O
venous	O
temperature	O
and	O
[	O
H+	O
]	O
.	O

DNase	B-GENE
I	I-GENE
footprinting	O
of	O
the	O
proximal	O
promoter	O
revealed	O
four	O
regions	O
of	O
protection	O
.	O

Atmospheric	O
benzene	O
,	O
urinary	O
muconic	O
acid	O
(	O
tt-MA	O
)	O
and	O
leukocyte	B-GENE
alkaline	I-GENE
phosphatase	I-GENE
activity	O
(	O
LAPA	O
)	O
were	O
evaluated	O
among	O
66	O
car	O
mechanics	O
,	O
34	O
road	O
tanker	O
drivers	O
,	O
and	O
28	O
nonexposed	O
workers	O
.	O

These	O
results	O
indicate	O
that	O
residue	O
266	O
serves	O
as	O
a	O
"protein	O
sensor"	O
of	O
altered	O
minor	O
groove	O
interactions	O
and	O
identifies	O
which	O
base	O
pair	O
interactions	O
are	O
altered	O
by	O
these	O
lesions	O
.	O

Supraventricular	O
arrhythmias--digoxin	O
and	O
quinidine	O
revisited	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
functional	O
role	O
of	O
the	O
other	O
MAP	B-GENE
kinases	I-GENE
in	O
PDGF-mediated	O
cellular	O
responses	O
.	O

Differentiating	O
among	O
renal	O
stones	O
.	O

Biological	O
action	O
and	O
kinetics	O
of	O
the	O
elimination	O
of	O
tritium	O
oxide	O
in	O
dogs	O
.	O

Chordoma	O
of	O
the	O
spinal	O
cord	O
in	O
a	O
F344	O
rat	O
.	O

Does	O
afferent	O
loop	O
syndrome	O
exist	O
?	O
It	O
is	O
the	O
author's	O
opinion	O
that	O
diagnosis	O
of	O
the	O
"adducent	O
loop	O
syndrome"	O
is	O
unlikely	O
to	O
be	O
correct	O
in	O
patients	O
subjected	O
to	O
Billroth-II	O
gastrectomy	O
.	O

The	O
active	O
derivatives	O
of	O
the	O
present	O
series	O
were	O
also	O
tested	O
for	O
their	O
analgesic	O
activity	O
against	O
aconitine-induced	O
writhing	O
in	O
albino	O
mice	O
and	O
ulcerogenic	O
activity	O
in	O
albino	O
rats	O
.	O

Disruption	O
of	O
the	O
HOG1	B-GENE
and	O
PBS2	B-GENE
genes	I-GENE
leads	O
to	O
a	O
dramatic	O
decrease	O
of	O
the	O
HSP12	B-GENE
inducibility	O
in	O
osmostressed	O
cells	O
,	O
whereas	O
overproduction	O
of	O
Hog1	B-GENE
produces	O
a	O
fivefold	O
increase	O
in	O
wild-type	O
induced	O
levels	O
upon	O
a	O
shift	O
to	O
a	O
high	O
salt	O
concentration	O
.	O

Human	B-GENE
Duo	I-GENE
contains	O
a	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
(	O
GEF	B-GENE
)	O
domain	O
that	O
is	O
likely	O
to	O
be	O
rac1-specific	O
,	O
a	O
pleckstrin	B-GENE
homology	I-GENE
(	O
PH	B-GENE
)	O
domain	O
and	O
spectrin-like	B-GENE
repeat	I-GENE
units	I-GENE
.	O

The	O
relations	O
between	O
type	O
A	O
behavior	O
,	O
clinically	O
relevant	O
behavior	O
,	O
academic	O
achievement	O
,	O
and	O
IQ	O
in	O
children	O
.	O

The	O
results	O
suggest	O
that	O
the	O
greater	O
estrogenic	O
influence	O
associated	O
with	O
the	O
ethinyl	O
estradiol-containing	O
OC	O
resulted	O
in	O
inhibition	O
of	O
coronary	O
artery	O
atherosclerosis	O
despite	O
a	O
pronounced	O
progestin-induced	O
lowering	O
of	O
plasma	O
HDL	O
cholesterol	O
concentration	O
and	O
,	O
further	O
,	O
that	O
hormonal	O
balance	O
may	O
have	O
a	O
marked	O
influence	O
on	O
the	O
relationship	O
between	O
plasma	O
lipids	O
and	O
atherogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
mammalian	O
cell-free	O
transcription	O
system	O
reconstituted	O
with	O
only	O
recombinant	O
proteins	O
and	O
epitope-tagged	O
multiprotein	O
complexes	O
.	O

We	O
specially	O
devised	O
3	O
types	O
of	O
turbo	O
pumps	O
,	O
a	O
centrifugal	O
pump	O
(	O
CFP	O
)	O
,	O
a	O
mixed	O
flow	O
pump	O
(	O
MFP	O
)	O
,	O
and	O
an	O
axial	O
flow	O
pump	O
(	O
AFP	O
)	O
,	O
and	O
analyzed	O
their	O
in	O
vitro	O
performance	O
.	O

Physical	O
analysis	O
maps	O
SAL6	B-GENE
to	O
chromosome	O
XVI	O
between	O
TPK2	B-GENE
and	O
spt14	B-GENE
.	O

Calcium	O
and	O
phosphorus	O
metabolism	O
in	O
chronic	O
uremia	O
.	O

Role	O
of	O
the	O
3'	O
untranslated	O
region	O
of	O
baculovirus	B-GENE
p10	I-GENE
mRNA	I-GENE
in	O
high-level	O
expression	O
of	O
foreign	O
genes	O
.	O

The	O
three	O
isoforms	O
purified	O
with	O
anti-FLAG	B-GENE
antibody	I-GENE
affinity	O
column	O
transferred	O
sulfate	O
to	O
heparan	O
sulfate	O
and	O
heparin	O
but	O
not	O
to	O
other	O
glycosaminoglycans	O
.	O

Cloning	O
and	O
expression	O
of	O
a	O
specific	O
human	B-GENE
alpha	I-GENE
1	I-GENE
,	I-GENE
2-mannosidase	I-GENE
that	O
trims	O
Man9GlcNAc2	O
to	O
Man8GlcNAc2	O
isomer	O
B	O
during	O
N-glycan	O
biosynthesis	O
.	O

Higher	O
fasting	O
serum	O
gastrin	B-GENE
concentration	O
(	O
102	O
.	O
0	O
+	O
/	O
-	O
21	O
.	O
1	O
vs	O
63	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
3	O
ng	O
.	O
l-1	O
)	O
,	O
and	O
greater	O
postprandial	O
gastrin	B-GENE
release	O
(	O
AUC0-120	O
:	O
16690	O
+	O
/	O
-	O
2648	O
vs	O
10654	O
+	O
/	O
-	O
1283	O
ng	O
.	O
l-1	O
min	O
)	O
were	O
observed	O
after	O
VTP-HM	O
than	O
after	O
VTP-Cas	O
.	O

Second	O
,	O
the	O
transcription	B-GENE
factor	I-GENE
Gal-ER	I-GENE
was	O
rendered	O
more	O
potent	O
and	O
less	O
susceptible	O
to	O
cell	O
type-specific	O
variation	O
by	O
fusing	O
the	O
strong	O
activating	O
domain	O
of	O
the	O
herpesvirus	B-GENE
protein	I-GENE
VP16	I-GENE
onto	O
its	O
C	O
terminus	O
.	O

A	O
progressive	O
growth	O
of	O
blood	O
erythrocyte	O
membrane	O
injury	O
has	O
been	O
demonstrated	O
after	O
rats	O
were	O
exposed	O
to	O
gamma-irradiaton	O
at	O
a	O
dose	O
of	O
100	O
to	O
500	O
Gy	O
.	O

VDR	B-GENE
/	I-GENE
RXR	I-GENE
bound	O
well	O
to	O
the	O
VDREs	B-GENE
and	O
to	O
DR4	B-GENE
and	O
DR5	B-GENE
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

We	O
describe	O
a	O
case	O
of	O
acetaminophen	O
overdose	O
that	O
was	O
treated	O
with	O
both	O
hemodialysis	O
(	O
HD	O
)	O
and	O
NAC	O
due	O
to	O
severe	O
intoxication	O
and	O
slow	O
drug	O
clearance	O
.	O

Acad	O
.	O

The	O
amplitudes	O
of	O
DPOAE	O
also	O
recovered	O
to	O
a	O
greater	O
extent	O
and	O
outer	O
hair	O
cell	O
losses	O
were	O
less	O
severe	O
in	O
the	O
R-PIA-treated	O
ears	O
.	O

Furthermore	O
,	O
beta	B-GENE
2-adrenoceptor	I-GENE
sensitivity	O
appears	O
to	O
be	O
unaltered	O
in	O
BHT	O
.	O

Fifty-eight	O
RMI's	O
occurred	O
in	O
the	O
placebo	O
group	O
as	O
compared	O
to	O
only	O
twenty	O
in	O
the	O
AC	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Nodal	O
domains	O
are	O
regions	O
where	O
a	O
function	O
has	O
definite	O
sign	O
.	O

HYPOTHESIS	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
oxidative	O
susceptibility	O
of	O
apolipoprotein	B-GENE
B-containing	I-GENE
lipoproteins	I-GENE
and	O
antioxidant	O
status	O
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
and	O
chronic	O
stable	O
angina	O
pectoris	O
.	O

Cost-effectiveness	O
analysis	O
provides	O
a	O
rational	O
means	O
of	O
allocating	O
limited	O
health	O
care	O
resources	O
by	O
allowing	O
the	O
comparison	O
of	O
the	O
costs	O
of	O
lipid-lowering	O
therapy	O
,	O
in	O
particular	O
,	O
therapy	O
with	O
beta-hydroxy-beta-methylglutaryl-CoA	B-GENE
(	I-GENE
coenzyme	I-GENE
A	I-GENE
)	I-GENE
reductase	I-GENE
inhibitors	O
(	O
statins	O
)	O
,	O
with	O
the	O
costs	O
of	O
atherosclerosis	O
that	O
could	O
be	O
prevented	O
by	O
lowering	O
cholesterol	O
.	O

Further	O
,	O
Ser	O
/	O
Thr	O
phosphorylation	O
of	O
downstream	O
molecules	O
Akt	B-GENE
and	O
p70	B-GENE
S6	I-GENE
kinase	I-GENE
was	O
inhibited	O
.	O

The	O
cloning	O
of	O
PTR2	B-GENE
represents	O
the	O
first	O
example	O
of	O
the	O
molecular	O
genetic	O
characterization	O
of	O
a	O
eucaryotic	O
peptide	O
transport	O
gene	O
.	O

These	O
include	O
the	O
CACCC	O
and	O
CAAT	O
motifs	O
.	O

Sixty-nine	O
(	O
44%	O
)	O
patients	O
were	O
administered	O
250	O
MBq	O
(	O
7	O
mCi	O
)	O
99Tcm-tetrofosmin	O
at	O
rest	O
followed	O
4	O
h	O
later	O
by	O
750	O
MBq	O
(	O
21	O
mCi	O
)	O
during	O
stress	O
(	O
the	O
1	O
day	O
protocol	O
)	O
,	O
whereas	O
88	O
(	O
56%	O
)	O
patients	O
had	O
rest	O
and	O
stress	O
imaging	O
studies	O
on	O
two	O
separate	O
days	O
,	O
receiving	O
a	O
500	O
MBq	O
(	O
14	O
mCi	O
)	O
dose	O
of	O
99Tcm-tetrofosmin	O
on	O
each	O
occasion	O
(	O
the	O
2	O
day	O
protocol	O
)	O
.	O

Liver	O
microsomes	O
of	O
the	O
shag	O
showed	O
smaller	O
than	O
8%	O
of	O
the	O
epoxide	B-GENE
hydrase	I-GENE
activity	O
and	O
smaller	O
than	O
14%	O
of	O
the	O
hydroxylating	O
capacity	O
of	O
liver	O
microsomes	O
from	O
the	O
rat	O
.	O

Deletion	O
analysis	O
of	O
rOC	B-GENE
promoter-chloramphenicol	I-GENE
acetyltransferase	I-GENE
constructs	I-GENE
demonstrates	O
that	O
an	O
AML-1-binding	B-GENE
sequence	I-GENE
within	O
the	O
proximal	O
promoter	O
(	O
-138	O
to	O
-130	O
nt	O
)	O
contributes	O
to	O
75%	O
of	O
the	O
level	O
of	O
osteocalcin	B-GENE
gene	I-GENE
expression	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
purified	O
RAG1	B-GENE
/	I-GENE
2	I-GENE
proteins	I-GENE
can	O
cleave	O
DNA	O
hairpins	O
in	O
vitro	O
,	O
but	O
the	O
same	O
activity	O
was	O
also	O
described	O
for	O
a	O
protein	O
complex	O
of	O
the	O
DNA	B-GENE
repair	I-GENE
proteins	I-GENE
Nbs1	I-GENE
/	I-GENE
Mre11	I-GENE
/	I-GENE
Rad50	I-GENE
.	O

Finally	O
,	O
the	O
stability	O
of	O
the	O
nucleotide	O
binding	O
function	O
of	O
the	O
two	O
proteins	O
is	O
similar	O
as	O
assessed	O
by	O
sensitivity	O
to	O
urea	O
.	O

Our	O
studies	O
extend	O
these	O
findings	O
and	O
show	O
that	O
the	O
E2	B-GENE
transactivation	I-GENE
gene	I-GENE
is	O
expressed	O
from	O
multiple	O
promoters	O
.	O

Expression	O
of	O
a	O
hybrid	O
protein	O
containing	O
the	O
cytoplasmic	O
C-terminal	O
half	O
of	O
UhpB	B-GENE
fused	O
to	O
glutathione	B-GENE
S-transferase	I-GENE
(	O
GST	B-GENE
)	O
also	O
interfered	O
with	O
Uhp	B-GENE
signaling	O
.	O

Morphological	O
and	O
functional	O
alterations	O
noted	O
after	O
baboon	O
renal	O
allotransplantation	O
.	O

The	O
sequence	O
of	O
the	O
HIR1	B-GENE
gene	I-GENE
predicts	O
an	O
88-kDa	O
protein	O
with	O
three	O
repeats	O
of	O
a	O
motif	O
found	O
in	O
the	O
G	B-GENE
beta	I-GENE
subunit	I-GENE
of	O
retinal	B-GENE
transducin	I-GENE
and	O
in	O
a	O
yeast	O
transcriptional	O
repressor	O
,	O
Tup1	B-GENE
.	O

65-kilodalton	O
protein	O
phosphorylated	O
by	O
interleukin	B-GENE
2	I-GENE
stimulation	O
bears	O
two	O
putative	O
actin-binding	B-GENE
sites	I-GENE
and	O
two	O
calcium-binding	O
sites	O
.	O

The	O
murine	B-GENE
mutation	I-GENE
dominant	I-GENE
white	I-GENE
spotting	I-GENE
(	O
W	B-GENE
)	O
is	O
in	O
the	O
proto-oncogene	O
,	O
c-kit	B-GENE
.	O

Protein	B-GENE
kinase	I-GENE
C	I-GENE
(	O
PKC	B-GENE
)	O
,	O
a	O
widely-distributed	O
enzyme	O
implicated	O
in	O
the	O
regulation	O
of	O
many	O
physiological	O
processes	O
,	O
consists	O
of	O
a	O
family	O
of	O
at	O
least	O
twelve	O
isoenzymes	O
which	O
differ	O
in	O
tissue	O
distribution	O
,	O
subcellular	O
localization	O
,	O
regulatory	O
properties	O
,	O
etc	O
.	O

Therefore	O
,	O
the	O
rbcL-rbcS	B-GENE
locus	I-GENE
seems	O
to	O
be	O
barely	O
expressed	O
under	O
a	O
standard	O
condition	O
for	O
photoautotrophic	O
growth	O
.	O

In	O
particular	O
,	O
the	O
S1'	B-GENE
specificity	I-GENE
site	I-GENE
is	O
a	O
deep	O
and	O
highly	O
hydrophobic	O
cavity	O
.	O

Pigs	O
were	O
switched	O
from	O
the	O
growing	O
to	O
the	O
finishing	O
diet	O
at	O
57	O
and	O
61	O
kg	O
in	O
Exp	O
.	O

In	O
broken	O
L-cell	O
membranes	O
expressing	O
wild	B-GENE
type	I-GENE
or	I-GENE
mutant	I-GENE
M6P	I-GENE
/	I-GENE
IGF	I-GENE
II	I-GENE
receptors	I-GENE
,	O
30	O
nM	O
IGF	B-GENE
II	I-GENE
also	O
failed	O
to	O
affect	O
the	O
pertussis	B-GENE
toxin	I-GENE
substrate	O
activity	O
.	O

NF-HB	B-GENE
(	O
BSAP	B-GENE
)	O
is	O
a	O
repressor	O
of	O
the	O
murine	B-GENE
immunoglobulin	I-GENE
heavy-chain	I-GENE
3'	I-GENE
alpha	I-GENE
enhancer	I-GENE
at	O
early	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

We	O
found	O
that	O
RhoA	B-GENE
can	O
initiate	O
a	O
linear	O
kinase	O
cascade	O
leading	O
to	O
the	O
activation	O
of	O
ERK6	B-GENE
(	O
p38	B-GENE
gamma	I-GENE
)	O
,	O
a	O
recently	O
identified	O
member	O
of	O
the	O
p38	B-GENE
family	I-GENE
of	O
MAPKs	B-GENE
.	O

Granulocyte	B-GENE
colony-stimulating	I-GENE
factor	I-GENE
(	O
G-CSF	B-GENE
)	O
administration	O
in	O
vivo	O
has	O
been	O
shown	O
to	O
improve	O
the	O
defence	O
mechanisms	O
against	O
infection	O
by	O
different	O
microbes	O
.	O

Exposure	O
to	O
higher	O
TPA	B-GENE
concentrations	O
decreased	O
the	O
content	O
of	O
these	O
transcripts	O
.	O

100	O
and	O
14	O
p	O
.	O

GN101	O
,	O
YC819-9	O
,	O
and	O
SB3	O
.	O

Another	O
common	O
mutation	O
involved	O
amino	O
acids	O
that	O
are	O
thought	O
to	O
make	O
specific	O
contacts	O
with	O
DNA	O
.	O

Patients	O
were	O
assessed	O
for	O
cardiac	O
MIBG	O
uptake	O
,	O
circulating	O
norepinephrine	O
concentration	O
,	O
LVEF	O
,	O
peak	O
Vo2	O
,	O
x-ray	O
cardiothoracic	O
ratio	O
,	O
M-mode	O
echographic	O
end-diastolic	O
diameter	O
and	O
right-sided	O
heart	O
catheterization	O
parameters	O
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
attP	B-GENE
,	O
attB	B-GENE
and	O
bacteria-prophage	O
junctions	O
attL	B-GENE
and	O
attR	B-GENE
showed	O
a	O
26	O
bp	O
common	O
core	O
sequence	O
,	O
where	O
recombination	O
takes	O
place	O
,	O
near	O
the	O
5'	O
end	O
of	O
the	O
integrase	B-GENE
gene	I-GENE
.	O

This	O
revealed	O
a	O
minimum	O
of	O
six	O
novel	O
OSBP-related	B-GENE
proteins	I-GENE
,	O
designated	O
ORP-1	B-GENE
to	O
ORP-6	B-GENE
.	O

Hp	O
positive	O
relatives	O
of	O
gastric	O
cancer	O
had	O
a	O
markedly	O
higher	O
prevalence	O
of	O
atrophy	O
than	O
those	O
with	O
Hp	O
negativity	O
without	O
cancer	O
relatives	O
(	O
29	O
vs	O
.	O

A	O
.	O
,	O
Swift	O
,	O
A	O
.	O

We	O
have	O
been	O
studying	O
the	O
interaction	O
of	O
the	O
oncogenic	O
human	O
polyomavirus	O
BK	O
(	O
BKV	O
)	O
with	O
the	O
tumor-suppressor	B-GENE
protein	I-GENE
p53	I-GENE
to	O
understand	O
the	O
biology	O
of	O
this	O
virus	O
as	O
well	O
as	O
to	O
understand	O
the	O
basic	O
mechanisms	O
of	O
p53	B-GENE
transactivation	O
.	O

The	O
pJR	O
vectors	O
differ	O
among	O
them	O
in	O
:	O
(	O
a	O
)	O
the	O
selectable	O
marker	O
(	O
Saccharomyces	O
cerevisiae	O
LEU	B-GENE
2	I-GENE
gene	I-GENE
,	O
which	O
complements	O
S	B-GENE
.	I-GENE
pombe	I-GENE
leu1-	I-GENE
gene	I-GENE
and	O
S	O
.	O
pombe	O
ura4+	B-GENE
and	O
his3+	B-GENE
genes	I-GENE
)	O
;	O
(	O
b	O
)	O
the	O
thiamine-repressible	O
nmt1	B-GENE
promoter	I-GENE
(	O
3X	O
,	O
41X	O
and	O
81X	O
with	O
extremely	O
high	O
,	O
moderate	O
or	O
low	O
transcription	O
efficiency	O
,	O
respectively	O
)	O
;	O
and	O
(	O
c	O
)	O
the	O
multiple	O
cloning	O
site	O
(	O
two	O
multiple	O
cloning	O
sites	O
,	O
with	O
12	O
restriction	O
sites	O
each	O
)	O
.	O

This	O
report	O
substantiates	O
that	O
at	O
least	O
two	O
of	O
the	O
18	O
kDa	O
hsps	B-GENE
in	O
maize	O
are	O
products	O
of	O
different	O
but	O
related	O
genes	O
.	O

The	O
novel	O
hematopoietic	B-GENE
growth	I-GENE
factor	I-GENE
FLT3	I-GENE
ligand	I-GENE
(	O
FL	B-GENE
)	O
is	O
the	O
cognate	O
ligand	O
for	O
the	O
FLT3	B-GENE
,	O
tyrosine	B-GENE
kinase	I-GENE
receptor	I-GENE
(	O
R	B-GENE
)	O
,	O
also	O
referred	O
to	O
as	O
FLK-2	B-GENE
and	O
STK-1	B-GENE
.	O

The	O
mucosal	O
defence	O
capacity	O
against	O
proteolytic	O
leukocyte	O
enzymes	O
.	O

The	O
Mif1	B-GENE
5'	I-GENE
flanking	I-GENE
region	I-GENE
contains	O
a	O
functional	O
ER	B-GENE
stress-responsive	I-GENE
element	I-GENE
which	O
is	O
sufficient	O
for	O
induction	O
by	O
tunicamycin	O
.	O

After	O
infection	O
of	O
293	O
cells	O
(	O
which	O
provide	O
complementary	O
E1a-E1b	B-GENE
functions	O
)	O
,	O
both	O
viruses	O
directed	O
equal	O
amounts	O
of	O
P	B-GENE
/	I-GENE
C-specific	I-GENE
mRNA	I-GENE
transcription	O
.	O

This	O
prospective	O
study	O
compared	O
the	O
measured	O
energy	O
expenditures	O
of	O
30	O
patients	O
using	O
indirect	O
calorimetry	O
with	O
their	O
predicted	O
basal	O
energy	O
expenditure	O
according	O
to	O
the	O
Harris-Benedict	O
equation	O
,	O
or	O
their	O
calculated	O
energy	O
expenditure	O
derived	O
from	O
basal	O
energy	O
expenditure	O
times	O
,	O
an	O
activity	O
factor	O
,	O
and	O
a	O
stress	O
factor	O
.	O

To	O
determine	O
what	O
role	O
eIF4E	B-GENE
might	O
play	O
in	O
c-myc	B-GENE
expression	O
,	O
the	O
c-myc	B-GENE
5'	I-GENE
untranslated	I-GENE
region	I-GENE
(	I-GENE
UTR	I-GENE
)	I-GENE
was	O
fused	O
in-frame	O
to	O
CAT	B-GENE
reporters	I-GENE
,	O
and	O
several	O
more	O
derivative	O
constructs	O
were	O
made	O
.	O

Such	O
a	O
change	O
may	O
involve	O
increased	O
mammary	O
utilization	O
of	O
pre-formed	O
long-chain	O
fatty	O
acid	O
and	O
increased	O
metabolism	O
of	O
glucose	O
via	O
glycolysis	O
.	O

Unaided	O
attempts	O
to	O
quit	O
smoking	O
are	O
generally	O
unsuccessful	O
.	O

Mycotoxins	B-GENE
in	O
feeds	O
and	O
foods	O
.	O

The	O
experiments	O
show	O
that	O
it	O
is	O
the	O
micromilieu	O
of	O
the	O
alveoli	O
and	O
the	O
condition	O
of	O
the	O
AM	O
(	O
certain	O
physiological	O
activation	O
states	O
,	O
such	O
as	O
phagocytic	O
activity	O
)	O
that	O
essentially	O
determine	O
the	O
degree	O
of	O
recovery	O
.	O

Comparative	O
studies	O
of	O
the	O
antithrombin	B-GENE
III	I-GENE
level	O
and	O
plasminogen	B-GENE
activator	I-GENE
activity	O
in	O
patients	O
with	O
thrombophlebitis	O
.	O

Thus	O
,	O
YMIP	B-GENE
is	O
a	O
functional	O
homolog	O
of	O
RMIP	B-GENE
and	O
represents	O
a	O
new	O
component	O
of	O
the	O
yeast	O
mitochondrial	O
import	O
machinery	O
.	O

METHODS	O
:	O
Forty-nine	O
cases	O
with	O
intrahepatic	O
multiple	O
nodules	O
of	O
HCC	O
,	O
by	O
gross	O
examination	O
,	O
among	O
184	O
consecutive	O
resected	O
HCCs	O
were	O
examined	O
clinicopathologically	O
.	O

Influence	O
of	O
cigarette	O
smoking	O
on	O
some	O
blood	O
coagulation	O
tests	O
.	O

During	O
the	O
program's	O
use	O
at	O
the	O
RSNA	O
meeting	O
,	O
the	O
program	O
selected	O
the	O
correct	O
diagnosis	O
in	O
the	O
top	O
five	O
22%	O
of	O
the	O
time	O
.	O

Mutation	O
of	O
Enh4	B-GENE
,	O
an	O
essential	O
GT-IIC-like	B-GENE
enhanson	I-GENE
in	O
the	O
context	O
of	O
the	O
intact	O
enhancer	O
,	O
abolishes	O
silencer	O
activity	O
,	O
and	O
multimerized	O
GT-IIC	B-GENE
enhansons	I-GENE
mimic	O
the	O
intact	O
CSEn	B-GENE
enhancer	I-GENE
/	I-GENE
silencer	I-GENE
activities	O
in	O
BeWo	O
and	O
GC	O
cells	O
,	O
respectively	O
.	O

The	O
complete	O
gene	O
organization	O
was	O
obtained	O
by	O
combining	O
the	O
results	O
of	O
the	O
sequence	O
of	O
these	O
clones	O
and	O
those	O
of	O
the	O
characterization	O
of	O
polymerase	B-GENE
chain	O
reaction-amplified	O
genomic	O
segments	O
.	O

The	O
dopamine	B-GENE
D4	I-GENE
receptor	I-GENE
as	O
well	O
as	O
many	O
other	O
catecholaminergic	B-GENE
receptors	I-GENE
contain	O
several	O
putative	O
SH3	B-GENE
binding	I-GENE
domains	I-GENE
.	O

These	O
data	O
indicate	O
that	O
activation	O
of	O
these	O
enzymes	O
is	O
not	O
sufficient	O
for	O
the	O
acute	O
stimulation	O
of	O
glucose	O
transport	O
.	O

EXAFS	O
measurements	O
around	O
the	O
Ge-K	O
edge	O
have	O
been	O
carried	O
out	O
for	O
liquid	O
Ge-Si	O
alloys	O
for	O
the	O
first	O
time	O
to	O
investigate	O
the	O
local	O
structure	O
around	O
a	O
Ge	O
atom	O
.	O

We	O
used	O
the	O
Toshiba	O
IIDR	O
system	O
,	O
which	O
is	O
composed	O
of	O
an	O
X-ray	O
TV	O
system	O
and	O
a	O
digital	O
image	O
managing	O
circuit	O
.	O

Dissociable	O
effects	O
of	O
lidocaine	O
inactivation	O
of	O
the	O
rostral	O
and	O
caudal	O
basolateral	O
amygdala	O
on	O
the	O
maintenance	O
and	O
reinstatement	O
of	O
cocaine-seeking	O
behavior	O
in	O
rats	O
.	O

Spontaneous	O
degradation	O
of	O
atracurium	O
in	O
plasma	O
is	O
the	O
major	O
route	O
of	O
elimination	O
in	O
man	O
and	O
contributes	O
to	O
a	O
short	O
elimination	O
half-life	O
(	O
approximatively	O
20	O
min	O
)	O
.	O

Wild-type	B-GENE
AT1A	I-GENE
receptors	I-GENE
,	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
rapidly	O
internalized	O
after	O
Ang	B-GENE
II	I-GENE
stimulation	O
[	O
t1	O
/	O
2	O
2	O
.	O
3	O
min	O
;	O
maximal	O
level	O
of	O
internalization	O
(	O
Ymax	O
)	O
78	O
.	O
2%	O
]	O
,	O
as	O
did	O
mutant	O
receptors	O
carrying	O
single	O
acidic	O
substitutions	O
(	O
T332E	O
,	O
t1	O
/	O
2	O
2	O
.	O
7	O
min	O
,	O
Ymax	O
76	O
.	O
3%	O
;	O
S335D	O
,	O
t1	O
/	O
2	O
2	O
.	O
4	O
min	O
,	O
Ymax	O
76	O
.	O
7%	O
;	O
T336E	O
,	O
t1	O
/	O
2	O
2	O
.	O
5	O
min	O
,	O
Ymax	O
78	O
.	O
2%	O
;	O
S338D	O
,	O
t1	O
/	O
2	O
2	O
.	O
6	O
min	O
,	O
Ymax	O
78	O
.	O
4%	O
)	O
.	O

Almost	O
complete	O
sequence	O
identity	O
was	O
found	O
between	O
the	O
3'	O
end	O
of	O
the	O
DXS6673E	B-GENE
gene	I-GENE
and	O
two	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
and	O
between	O
the	O
5'	O
end	O
of	O
the	O
DXS6673E	B-GENE
gene	I-GENE
and	O
a	O
third	O
EST	O
.	O

1	O
.	O

The	O
rate-limiting	O
step	O
for	O
telomerase	B-GENE
activity	O
seems	O
to	O
be	O
the	O
expression	O
of	O
the	O
catalytic	O
subunit	O
of	O
the	O
enzyme	O
,	O
encoded	O
by	O
the	O
human	B-GENE
telomerase	I-GENE
reverse	I-GENE
transcriptase	I-GENE
(	O
hTERT	B-GENE
)	O
gene	O
.	O

Characterization	O
of	O
the	O
5'-flanking	O
region	O
of	O
the	O
human	B-GENE
multidrug	I-GENE
resistance	I-GENE
protein	I-GENE
2	I-GENE
(	O
MRP2	B-GENE
)	O
gene	O
and	O
its	O
regulation	O
in	O
comparison	O
withthe	O
multidrug	B-GENE
resistance	I-GENE
protein	I-GENE
3	I-GENE
(	O
MRP3	B-GENE
)	O
gene	O
.	O

Epstein-Barr	B-GENE
virus	I-GENE
(	I-GENE
EBV	I-GENE
)	I-GENE
latent	I-GENE
membrane	I-GENE
protein	I-GENE
1	I-GENE
(	O
LMP1	B-GENE
)	O
is	O
essential	O
for	O
EBV-mediated	O
transformation	O
of	O
primary	O
B	O
lymphocytes	O
.	O

Regulation	O
of	O
parathyroid	B-GENE
hormone-related	I-GENE
protein	I-GENE
(	O
PTHrP	B-GENE
)	O
gene	O
expression	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
the	O
antagonistic	O
effects	O
of	O
CRP	B-GENE
and	O
KdgR	B-GENE
on	O
the	O
expression	O
of	O
the	O
pectinolysis	B-GENE
genes	I-GENE
occur	O
by	O
different	O
mechanisms	O
,	O
including	O
direct	O
competition	O
between	O
the	O
two	O
regulators	O
or	O
between	O
the	O
repressor	O
and	O
RNA	B-GENE
polymerase	I-GENE
for	O
the	O
occupation	O
of	O
a	O
common	O
DNA	O
region	O
on	O
the	O
target	O
genes	O
.	O

In	O
a	O
gntR	B-GENE
deletion	I-GENE
mutant	I-GENE
,	O
the	O
expression	O
of	O
a	O
chromosomal	B-GENE
gntT	I-GENE
:	I-GENE
:	I-GENE
lacZ	I-GENE
fusion	I-GENE
is	O
both	O
high	O
and	O
constitutive	O
,	O
confirming	O
that	O
GntR	B-GENE
is	O
the	O
negative	O
regulator	O
of	O
gntT	B-GENE
.	O

Consistent	O
with	O
the	O
protein	O
expression	O
data	O
,	O
V	B-GENE
beta	I-GENE
8	I-GENE
.	I-GENE
3	I-GENE
gene	I-GENE
transcripts	I-GENE
were	O
found	O
only	O
in	O
the	O
transgenic	O
lines	O
with	O
the	O
wild-type	O
promoter	O
.	O

These	O
synergistic	O
effects	O
were	O
strongly	O
Jem-1	B-GENE
dose-dependent	O
.	O

Their	O
afterglows	O
are	O
brighter	O
than	O
supernovae	O
and	O
therefore	O
are	O
called	O
hypernovae	O
.	O

AMDA	O
white	O
paper	O
identifies	O
ways	O
to	O
improve	O
pharmaceutical	O
care	O
in	O
SNFs	O
.	O

Compensatory	O
renal	O
hypertrophy	O
in	O
parabiotic	O
rats	O
.	O

Story	O
of	O
a	O
hospital	O
that	O
filmed	O
its	O
employee	O
orientation	O
program	O
.	O

An	O
activation-responsive	O
element	O
in	O
single	B-GENE
C	I-GENE
motif-1	I-GENE
/	I-GENE
lymphotactin	I-GENE
promoter	I-GENE
is	O
a	O
site	O
of	O
constitutive	O
and	O
inducible	O
DNA-protein	O
interactions	O
involving	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
.	O

TNF	O
Treatment	O
of	O
cell	O
activated	O
the	O
p38	B-GENE
MAP	I-GENE
kinase	I-GENE
pathway	O
,	O
as	O
revealed	O
by	O
increased	O
phosphorylation	O
of	O
p38	B-GENE
MAP	I-GENE
kinase	I-GENE
itself	O
,	O
activation	O
of	O
the	O
substrate	O
protein	O
MAPKAP	B-GENE
kinase-2	I-GENE
,	O
and	O
culminating	O
in	O
the	O
phosphorylation	O
of	O
the	O
heat	B-GENE
shock	I-GENE
protein	I-GENE
27	I-GENE
(	O
hsp27	B-GENE
)	O
.	O

Nernst--Planck	O
analog	O
equations	O
and	O
stationary	O
state	O
membrane	O
electric	O
potentials	O
.	O

Two	O
of	O
the	O
three	O
groups	O
were	O
administered	O
dauricine	O
,	O
as	O
a	O
new	O
calcium	O
channel	O
blocker	O
,	O
and	O
verapamil	O
,	O
as	O
a	O
generally	O
recognized	O
calcium	O
channel	O
blocker	O
,	O
respectively	O
,	O
from	O
15	O
minutes	O
pre-bypass	O
to	O
the	O
end	O
of	O
the	O
bypass	O
procedure	O
(	O
a	O
period	O
of	O
95	O
minutes	O
)	O
.	O

Contrary	O
to	O
1	O
,	O
8-dihydroxy-9-anthrone	O
,	O
1	O
,	O
8	O
,	O
9-triacetoxyanthracene	O
and	O
1	O
,	O
8-diacetoxy-9-anthrone	O
are	O
effective	O
against	O
psoriatic	O
lesions	O
without	O
accompanying	O
inflammations	O
of	O
the	O
skin	O
.	O

We	O
have	O
isolated	O
and	O
sequenced	O
the	O
gene	O
encoding	O
the	O
human	B-GENE
U1-70K	I-GENE
snRNP	I-GENE
protein	I-GENE
.	O

Underlying	O
the	O
clustering	O
of	O
these	O
risk	O
variables	O
were	O
three	O
factors	O
.	O

We	O
found	O
that	O
the	O
gene	O
segment	O
containing	O
the	O
mu	B-GENE
m	I-GENE
poly	I-GENE
(	I-GENE
A	I-GENE
)	I-GENE
signals	I-GENE
,	O
along	O
with	O
536	O
bp	O
of	O
downstream	O
flanking	O
sequence	O
,	O
acted	O
as	O
a	O
transcription	O
terminator	O
in	O
both	O
myeloma	O
cells	O
and	O
L	O
cell	O
fibroblasts	O
.	O

These	O
results	O
continue	O
to	O
support	O
the	O
hypothesis	O
that	O
HS2	B-GENE
,	O
HS3	B-GENE
,	O
and	O
HS4	B-GENE
act	O
as	O
a	O
single	O
,	O
integral	O
unit	O
to	O
regulate	O
human	B-GENE
globin	I-GENE
gene	I-GENE
transcription	O
as	O
a	O
holocomplex	O
,	O
but	O
they	O
can	O
also	O
be	O
interpreted	O
to	O
say	O
that	O
formation	O
of	O
a	O
DNase	B-GENE
I	I-GENE
hypersensitive	O
holocomplex	O
alone	O
is	O
not	O
sufficient	O
for	O
mediating	O
high-level	O
globin	B-GENE
gene	I-GENE
transcription	O
.	O

Ischemia	O
and	O
reperfusion	O
markedly	O
increased	O
the	O
release	O
of	O
6-keto-PGF1	B-GENE
alpha	I-GENE
and	O
TXB2	B-GENE
.	O

Prenatal	O
exposure	O
to	O
the	O
fungicide	O
dinocap	O
causes	O
behavioral	O
torticollis	O
,	O
ballooning	O
and	O
cleft	O
palate	O
in	O
mice	O
,	O
but	O
not	O
rats	O
or	O
hamsters	O
.	O

Calibration	O
and	O
a	O
correction	O
of	O
blood	O
O2	O
content	O
measured	O
by	O
Po2	O
and	O
CO	O
saturation	O
.	O

In	O
addition	O
,	O
we	O
observe	O
that	O
the	O
hUBF-promoter	B-GENE
interaction	O
is	O
highly	O
sensitive	O
to	O
the	O
antagonistic	O
effects	O
of	O
cisplatin-DNA	O
adducts	O
.	O

Using	O
the	O
two-hybrid	O
system	O
,	O
we	O
show	O
that	O
nonprenylated	O
Rac1	B-GENE
interacts	O
very	O
weakly	O
with	O
Rho-GDI	B-GENE
,	O
pointing	O
to	O
the	O
predominant	O
role	O
of	O
protein-isoprene	O
interaction	O
in	O
complex	O
formation	O
.	O

Tele-Talk	O
has	O
the	O
extra	O
capability	O
of	O
operating	O
in	O
live	O
conference	O
situations	O
using	O
microphone	O
input	O
.	O

This	O
open	O
reading	O
frame	O
was	O
confirmed	O
the	O
correct	O
one	O
by	O
direct	O
amino-terminal	O
sequence	O
analysis	O
of	O
the	O
overproduced	O
msgB	B-GENE
gene	I-GENE
product	I-GENE
.	O

Neither	O
ethanol	O
regimen	O
impaired	O
spontaneous	O
alternation	O
,	O
but	O
the	O
4	O
g	O
ethanol	O
.	O
kg-1	O
x	O
day-1	O
regimen	O
increased	O
the	O
percent	O
completed	O
trials	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
traI	B-GENE
structural	I-GENE
gene	I-GENE
and	O
application	O
of	O
purified	O
mutant	O
TraI	B-GENE
proteins	I-GENE
for	O
in	O
vitro	O
assays	O
served	O
to	O
evaluate	O
the	O
functional	O
importance	O
of	O
conserved	O
amino	O
acid	O
residues	O
.	O

This	O
indicates	O
that	O
the	O
mechanism	O
by	O
which	O
CX	O
blocks	O
rapid	O
degradation	O
of	O
tubulin	B-GENE
mRNA	I-GENE
in	O
vivo	O
is	O
not	O
simply	O
by	O
preventing	O
its	O
translation	O
and	O
suggests	O
the	O
involvement	O
of	O
an	O
altered	O
trans-factor	O
.	O

By	O
using	O
space-discrete	O
/	O
continuous	O
metapopulation	O
dynamic	O
models	O
and	O
computer	O
simulations	O
,	O
we	O
show	O
that	O
there	O
can	O
be	O
two	O
principally	O
different	O
regimes	O
of	O
metapopulation	O
dynamics	O
.	O

Activated	O
areas	O
have	O
been	O
identified	O
by	O
means	O
of	O
cross-correlation	O
analysis	O
.	O

The	O
protein	O
product	O
of	O
orfD	B-GENE
,	O
which	O
is	O
probably	O
a	O
new	O
tra	B-GENE
gene	I-GENE
(	O
named	O
traX	B-GENE
)	O
,	O
contains	O
65%	O
hydrophobic	O
amino	O
acids	O
,	O
especially	O
rich	O
in	O
alanine	O
and	O
leucine	O
.	O

Members	O
of	O
the	O
titin	B-GENE
/	I-GENE
myosin	I-GENE
light	I-GENE
chain	I-GENE
kinase	I-GENE
family	I-GENE
play	O
an	O
essential	O
role	O
in	O
the	O
organization	O
of	O
the	O
actin	O
/	O
myosin	O
cytoskeleton	O
,	O
especially	O
in	O
sarcomere	O
assembly	O
and	O
function	O
.	O

Purified	O
Hsk1	B-GENE
phosphorylates	O
the	O
Cdc19	B-GENE
(	O
Mcm2	B-GENE
)	O
subunit	O
of	O
the	O
six-member	B-GENE
minichromosome	I-GENE
maintenance	I-GENE
protein	I-GENE
complex	I-GENE
purified	O
from	O
fission	O
yeast	O
.	O

In	O
these	O
vectors	O
the	O
chimeric	O
long	O
terminal	O
repeat	O
(	O
chLTR	O
)	O
drives	O
the	O
expression	O
of	O
the	O
chloramphenicol	B-GENE
acetyl	I-GENE
transferase	I-GENE
(	O
CAT	B-GENE
)	O
reporter	O
gene	O
that	O
is	O
followed	O
by	O
an	O
internal	O
SV40	O
virus	O
early	O
region	O
promoter	O
linked	O
to	O
the	O
neomycin	B-GENE
phosphotransferase	I-GENE
II	I-GENE
(	O
NEO	B-GENE
)	O
gene	O
.	O

A	O
second	O
peptide	O
(	O
amino	O
acids	O
58-77	O
)	O
also	O
antagonized	O
p21-activity	O
,	O
but	O
this	O
peptide	O
did	O
not	O
affect	O
the	O
ability	O
of	O
p21	B-GENE
to	O
interact	O
with	O
cyclin	B-GENE
E	I-GENE
/	I-GENE
Cdk2	I-GENE
.	O

Some	O
reflexions	O
apropos	O
of	O
a	O
personal	O
statistical	O
study	O
of	O
513	O
arterial	O
embolisms	O
.	O

Mutational	O
analysis	O
of	O
mRNA	B-GENE
capping	I-GENE
enzyme	I-GENE
identifies	O
amino	O
acids	O
involved	O
in	O
GTP	O
binding	O
,	O
enzyme-guanylate	O
formation	O
,	O
and	O
GMP	O
transfer	O
to	O
RNA	O
.	O

Preferential	O
heterodimeric	O
parallel	O
coiled-coil	O
formation	O
by	O
synthetic	B-GENE
Max	I-GENE
and	O
c-Myc	B-GENE
leucine	I-GENE
zippers	I-GENE
:	O
a	O
description	O
of	O
putative	O
electrostatic	O
interactions	O
responsible	O
for	O
the	O
specificity	O
of	O
heterodimerization	O
.	O

For	O
oral	O
administration	O
,	O
AUC0-infinity	O
was	O
58	O
.	O
47	O
+	O
/	O
-	O
16	O
.	O
37	O
microg	O
x	O
h	O
/	O
ml	O
,	O
t1	O
/	O
2beta	O
was	O
18	O
.	O
39	O
+	O
/	O
-	O
0	O
.	O
06	O
hours	O
,	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
was	O
2	O
.	O
12	O
+	O
/	O
-	O
00	O
.	O
51	O
microg	O
/	O
ml	O
,	O
time	O
to	O
Cmax	O
was	O
2	O
.	O
20	O
+	O
/	O
-	O
2	O
.	O
17	O
hours	O
,	O
mean	O
absorption	O
time	O
was	O
2	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
51	O
hours	O
,	O
and	O
bioavailability	O
was	O
42	O
+	O
/	O
-	O
0	O
.	O
42%	O
.	O

Unlike	O
p59v-rel	B-GENE
,	O
which	O
is	O
a	O
nuclear	O
protein	O
in	O
CEF	O
,	O
indirect	O
immunofluorescence	O
showed	O
that	O
p68c-rel	B-GENE
in	O
JD214c-rel	O
infected	O
CEF	O
is	O
located	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
these	O
cells	O
,	O
even	O
though	O
the	O
sequence	O
of	O
p68c-rel	B-GENE
showed	O
that	O
it	O
contains	O
a	O
nuclear	O
localizing	O
sequence	O
identical	O
to	O
the	O
one	O
previously	O
identified	O
in	O
p59v-rel	B-GENE
.	O

In	O
addition	O
,	O
depletion	O
of	O
Oct-1	B-GENE
from	O
the	O
nuclear	O
extract	O
by	O
using	O
Oct-1-specific	O
antiserum	O
or	O
a	O
sequence-specific	O
DNA	O
affinity	O
resin	O
decreased	O
in	O
vitro	O
transcription	O
from	O
the	O
wild-type	O
MMTV	O
promoter	O
to	O
a	O
level	O
identical	O
to	O
that	O
obtained	O
from	O
a	O
promoter	O
in	O
which	O
all	O
three	O
octamer-related	O
sequences	O
were	O
mutated	O
.	O

Bacterially	O
expressed	O
protein	O
,	O
as	O
well	O
as	O
the	O
in	O
vitro	O
reticulocyte	O
lysate	O
translation	O
product	O
,	O
comigrated	O
with	O
the	O
purified	O
37-kDa	O
protein	O
on	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gels	O
.	O

Although	O
diagnostic	O
laparoscopy	O
is	O
still	O
considered	O
the	O
standard	O
reference	O
in	O
the	O
diagnosis	O
of	O
ectopic	O
pregnancy	O
(	O
EP	O
)	O
,	O
use	O
of	O
high-resolution	O
endovaginal	O
sonography	O
,	O
in	O
conjunction	O
with	O
qualitative	O
serum	O
assays	O
of	O
the	O
beta	O
subunit	O
of	O
human	B-GENE
chorionic	I-GENE
gonadotropin	I-GENE
(	O
beta-hCG	B-GENE
)	O
,	O
allows	O
detection	O
of	O
earlier	O
and	O
smaller	O
EPs	O
.	O

Proprotein	O
processing	O
occurs	O
intracellularly	O
.	O

In	O
this	O
report	O
,	O
almost	O
6	O
kb	O
of	O
DNA	O
sequence	O
is	O
presented	O
,	O
including	O
1251	O
bp	O
5'	O
to	O
the	O
gene	O
,	O
over	O
4	O
kb	O
of	O
exon	O
and	O
exon-intron	O
junctions	O
,	O
and	O
583	O
bp	O
3'	O
to	O
the	O
gene	O
.	O

Patients	O
with	O
low	O
probability	O
of	O
having	O
aluminum	O
overload	O
(	O
serum	O
iron	O
levels	O
<	O
40	O
micrograms	O
/	O
L	O
and	O
DAI	O
<	O
150	O
micrograms	O
/	O
L	O
)	O
had	O
significantly	O
higher	O
values	O
of	O
serum	O
iron	O
,	O
iron	O
transferrin	B-GENE
saturation	O
,	O
and	O
serum	B-GENE
ferritin	I-GENE
levels	O
compared	O
with	O
those	O
patients	O
with	O
a	O
high	O
probability	O
of	O
having	O
aluminum	O
overload	O
(	O
serum	O
aluminum	O
levels	O
>	O
40	O
micrograms	O
/	O
L	O
and	O
DAI	O
>	O
150	O
micrograms	O
/	O
L	O
)	O
.	O

It	O
has	O
a	O
grave	O
prognosis	O
with	O
>	O
70%	O
mortality	O
in	O
3	O
months	O
,	O
despite	O
mechanical	O
ventilation	O
.	O

In	O
calves	O
receiving	O
milk-substitute	O
diets	O
containing	O
80-260	O
g	O
DM	O
/	O
kg	O
,	O
milk	O
intakes	O
were	O
reduced	O
by	O
up	O
to	O
30%	O
on	O
the	O
1st	O
day	O
that	O
calves	O
were	O
fed	O
once	O
daily	O
instead	O
of	O
twice	O
daily	O
.	O

Our	O
results	O
suggest	O
that	O
Lrp	B-GENE
binds	O
a	O
central	O
palindromic	O
site	O
,	O
interacting	O
predominantly	O
with	O
the	O
major	O
groove	O
of	O
its	O
DNA	O
target	O
,	O
and	O
that	O
additional	O
dimers	O
bind	O
to	O
flanking	O
sites	O
to	O
form	O
a	O
nucleoprotein	O
activation	O
complex	O
.	O

In	O
vitro	O
expression	O
levels	O
of	O
the	O
different	O
plasmids	O
differed	O
by	O
as	O
much	O
as	O
tenfold	O
.	O

It	O
could	O
also	O
inhibit	O
C1q-dependent	O
haemolysis	O
of	O
both	O
IgG-	O
and	O
IgM-sensitized	O
erythrocytes	O
.	O

After	O
resection	O
of	O
the	O
proximal	O
fragment	O
,	O
all	O
scaphoid	O
contact	O
area	O
and	O
pressure	O
was	O
born	O
by	O
the	O
distal	O
scaphoid	O
fragment	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
association	O
between	O
complete	O
congenital	O
heart	O
block	O
(	O
CCHB	O
)	O
in	O
the	O
fetus	O
and	O
adult	O
disease	O
.	O

Polypyrimidine	O
and	O
ssDNA	O
binding	O
by	O
the	O
isolated	O
VH	B-GENE
domain	I-GENE
of	O
immunization-induced	O
anti-Z-DNA	B-GENE
Ab	I-GENE
resembles	O
the	O
activity	O
of	O
natural	O
autoantibodies	O
and	O
suggests	O
that	O
VH-dependent	O
binding	O
to	O
a	O
ligand	O
mimicked	O
by	O
polypyrimidines	O
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
selection	O
before	O
immunization	O
with	O
Z-DNA	O
.	O

Likewise	O
,	O
rad6-delta	B-GENE
reduces	O
silencing	O
of	O
the	O
telomere-located	B-GENE
RNAP	I-GENE
II-transcribed	I-GENE
genes	I-GENE
URA3	I-GENE
and	O
ADE2	B-GENE
.	O

In	O
this	O
report	O
we	O
studied	O
the	O
role	O
of	O
protein-tyrosine	B-GENE
phosphatase	I-GENE
SHP-2	B-GENE
in	O
ErbB-mediated	O
activation	O
of	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAPK	B-GENE
)	O
by	O
overexpressing	O
SHP-2	B-GENE
mutants	I-GENE
in	O
COS-7	O
cells	O
.	O

I	O
hypothesize	O
that	O
white	B-GENE
gene	I-GENE
expression	O
from	O
P	O
[	O
en	O
]	O
is	O
repressed	O
by	O
the	O
formation	O
of	O
a	O
protein	O
complex	O
which	O
is	O
initiated	O
at	O
the	O
engrailed	B-GENE
PS	I-GENE
sites	I-GENE
and	O
also	O
requires	O
interactions	O
with	O
flanking	O
genomic	O
DNA	O
.	O

Ninety-four	O
percent	O
of	O
the	O
EPs	O
were	O
tubal	O
,	O
and	O
90%	O
of	O
the	O
tubes	O
exhibited	O
some	O
pathologic	O
changes	O
,	O
including	O
chronic	O
salpingitis	O
(	O
49	O
.	O
5%	O
)	O
and	O
follicular	O
salpingitis	O
(	O
10%	O
)	O
,	O
among	O
others	O
.	O

A	O
comparison	O
of	O
the	O
clinical	O
profile	O
of	O
cavernous	O
malformations	O
with	O
and	O
without	O
associated	O
venous	O
malformations	O
.	O

These	O
genes	O
encode	O
a	O
tryptophanyl	B-GENE
tRNA	I-GENE
,	O
the	O
protein	B-GENE
translocase	I-GENE
component	O
SecE	B-GENE
,	O
the	O
antiterminator	B-GENE
protein	I-GENE
NusG	I-GENE
,	O
and	O
the	O
ribosomal	B-GENE
proteins	I-GENE
L11	I-GENE
and	I-GENE
L1	I-GENE
in	O
addition	O
to	O
PkwR	B-GENE
,	O
a	O
putative	O
regulatory	O
protein	O
of	O
the	O
LacI-GalR	B-GENE
family	I-GENE
.	O

The	O
Caenorhabditis	B-GENE
elegans	I-GENE
vitellogenin	I-GENE
genes	I-GENE
are	O
subject	O
to	O
sex-	O
,	O
stage-	O
,	O
and	O
tissue-specific	O
regulation	O
:	O
they	O
are	O
expressed	O
solely	O
in	O
the	O
adult	O
hermaphrodite	O
intestine	O
.	O

For	O
colostral	O
milk	O
there	O
was	O
a	O
significant	O
correlation	O
of	O
vitamin	O
K1	O
to	O
cholesterol	O
(	O
r	O
=	O
0	O
.	O
62	O
)	O
but	O
not	O
to	O
total	O
lipid	O
or	O
phospholipid	O
suggesting	O
a	O
role	O
for	O
cholesterol	O
in	O
the	O
secretion	O
of	O
vitamin	O
K1	O
into	O
colostral	O
milk	O
.	O

Hypercalcemia	O
associated	O
with	O
elevated	O
serum	B-GENE
PTH	I-GENE
concentration	O
indicating	O
primary	O
hyperparathyroidism	O
was	O
found	O
in	O
7	O
BC	O
patients	O
(	O
7%	O
)	O
and	O
in	O
none	O
of	O
healthy	O
women	O
or	O
patients	O
with	O
thyroid	O
cancer	O
.	O

Effect	O
of	O
heat	O
treatments	O
on	O
the	O
meltability	O
of	O
cheeses	O
.	O

Epidemiologic	O
evidence	O
indicates	O
that	O
estrogen	O
replacement	O
therapy	O
after	O
menopause	O
increases	O
breast	O
cancer	O
risk	O
.	O

In	O
8	O
healthy	O
volunteers	O
there	O
were	O
no	O
significant	O
differences	O
in	O
AUC	O
,	O
peak	O
plasma	O
concentrations	O
or	O
time	O
to	O
peak	O
concentration	O
when	O
OXC	O
was	O
administered	O
either	O
with	O
or	O
without	O
ERY	O
.	O

Salient	O
applications	O
of	O
PB-PK	O
modeling	O
to	O
toxicological	O
problems	O
are	O
illustrated	O
with	O
examples	O
.	O

Determination	O
of	O
20	O
alpha-hydroxy-9	O
beta	O
,	O
10	O
alpha-pregna-4	O
,	O
6-dien-3-one	O
in	O
plasma	O
by	O
selected	O
ion	O
monitoring	O
.	O

Metabolic	O
labeling	O
studies	O
in	O
S	O
.	O
cerevisiae	O
and	O
co-expression	O
of	O
nmt72p	B-GENE
with	O
several	O
protein	O
substrates	O
of	O
Nmt1p	B-GENE
in	O
Escherichia	O
coli	O
indicate	O
that	O
the	O
Leu99--	O
>	O
Pro	O
substitution	O
causes	O
a	O
reduction	O
in	O
the	O
acylation	O
of	O
some	O
but	O
not	O
all	O
protein	O
substrates	O
.	O

G-CSF	B-GENE
activates	O
multiple	O
signaling	O
molecules	O
,	O
including	O
the	O
JAK1	B-GENE
and	O
JAK2	B-GENE
kinases	I-GENE
and	O
the	O
STAT	B-GENE
transcription	O
factors	O
.	O

Schooling	O
is	O
found	O
to	O
be	O
related	O
to	O
good	O
health	O
even	O
after	O
controlling	O
for	O
differences	O
in	O
observable	O
health	O
inputs	O
.	O

The	O
reason	O
that	O
nitrous	O
oxide	O
does	O
not	O
produce	O
hydroxyl	O
radicals	O
readily	O
might	O
be	O
that	O
the	O
one-electron	O
reduction	O
proceeds	O
through	O
an	O
N2O-	O
intermediate	O
which	O
is	O
energetically	O
very	O
unfavourable	O
:	O
EO	O
(	O
N2O	O
/	O
N2O-	O
)	O
=	O
-1	O
.	O
1	O
V	O
.	O

Parkinsonian	O
patients	O
had	O
a	O
significantly	O
lower	O
prevalence	O
of	O
alcohol	O
use	O
.	O

There	O
was	O
evidence	O
of	O
attenuated	O
regression	O
slopes	O
relating	O
recalled	O
to	O
observed	O
portion	O
sizes	O
for	O
4	O
of	O
the	O
10	O
food	O
groups	O
;	O
adjusted	O
r2	O
values	O
for	O
the	O
recalled	O
portion	O
sizes	O
ranged	O
from	O
0	O
.	O
02	O
to	O
0	O
.	O
94	O
.	O

Retroviral	B-GENE
nucleocapsid	I-GENE
proteins	I-GENE
(	O
NCPs	B-GENE
)	O
are	O
CCHC-type	B-GENE
zinc	I-GENE
finger	I-GENE
proteins	I-GENE
that	O
mediate	O
virion	O
RNA	O
binding	O
activities	O
associated	O
with	O
retrovirus	O
assembly	O
and	O
genomic	O
RNA	O
encapsidation	O
.	O

Binding	O
of	O
serum	B-GENE
response	I-GENE
factor	I-GENE
to	O
CArG	B-GENE
box	I-GENE
sequences	I-GENE
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
restrict	O
gene	O
expression	O
to	O
arterial	O
smooth	O
muscle	O
cells	O
.	O

Acquired	O
bile	O
duct	O
blockage	O
:	O
entry	O
of	O
hepatobiliary	O
agent	O
into	O
an	O
intrahepatic	O
abscess	O
.	O

The	O
patients	O
were	O
divided	O
into	O
3	O
subgroups	O
:	O
1	O
)	O
13	O
N+	O
patients	O
with	O
multiple	O
hot	O
spots	O
(	O
greater	O
than	O
2	O
)	O
(	O
N+	O
IM	O
)	O
;	O
2	O
)	O
24	O
N+	O
patients	O
with	O
single	O
hot	O
spots	O
(	O
less	O
than	O
or	O
equal	O
to	O
2	O
)	O
(	O
N+	O
IS	O
)	O
;	O
3	O
)	O
12	O
N-	O
patients	O
with	O
single	O
hot	O
spots	O
(	O
less	O
than	O
or	O
equal	O
to	O
2	O
)	O
(	O
N-	O
IS	O
)	O
.	O

Carbon	O
catabolite	O
repression	O
of	O
the	O
gnt	B-GENE
operon	I-GENE
of	I-GENE
Bacillus	I-GENE
subtilis	I-GENE
is	O
mediated	O
by	O
the	O
catabolite	O
control	O
protein	O
CcpA	B-GENE
and	O
by	O
HPr	B-GENE
,	O
a	O
phosphocarrier	O
protein	O
of	O
the	O
phosphotransferase	B-GENE
system	I-GENE
.	O

The	O
frequency	O
of	O
integrations	O
that	O
led	O
to	O
transcription	O
of	O
the	O
lacZ	B-GENE
gene	I-GENE
was	O
estimated	O
to	O
be	O
0	O
.	O
5%	O
of	O
all	O
integrations	O
,	O
of	O
which	O
14%	O
were	O
downregulated	O
on	O
differentiation	O
of	O
32D	O
cells	O
towards	O
neutrophils	O
.	O

Interferon-alpha	B-GENE
treatment	O
of	O
posttransplant	O
lymphoproliferative	O
disorder	O
in	O
recipients	O
of	O
solid	O
organ	O
transplants	O
.	O

ATP-dependent	O
assembly	O
of	O
a	O
ternary	O
complex	O
consisting	O
of	O
a	O
DNA	O
mismatch	O
and	O
the	O
yeast	B-GENE
MSH2-MSH6	I-GENE
and	O
MLH1-PMS1	B-GENE
protein	I-GENE
complexes	I-GENE
.	O

Since	O
1967	O
at	O
the	O
times	O
of	O
their	O
biennial	O
ABCC	O
/	O
RERF	O
radiological	O
examinations	O
,	O
all	O
Adult	O
Health	O
Study	O
(	O
AHS	O
)	O
subjects	O
have	O
been	O
interviewed	O
to	O
determine	O
the	O
exposures	O
to	O
medical	O
x-rays	O
they	O
experienced	O
in	O
institutions	O
other	O
than	O
RERF	O
in	O
order	O
to	O
estimate	O
the	O
numbers	O
of	O
examinations	O
and	O
corresponding	O
doses	O
which	O
they	O
received	O
.	O

We	O
have	O
determined	O
that	O
these	O
nicks	O
occur	O
in	O
both	O
the	O
wild-type	O
and	O
the	O
mutant	O
sites	O
.	O

The	O
tumor	O
suppressor	O
and	O
transcriptional	O
factor	O
p53	B-GENE
is	O
a	O
phosphorylated	O
protein	O
.	O

Treatment	O
of	O
PCC4	O
.	O
aza1R	O
cells	O
with	O
an	O
RAR-selective	O
agonist	O
also	O
repressed	O
the	O
expression	O
of	O
EC-1	B-GENE
mRNA	I-GENE
while	O
treatment	O
with	O
an	O
RXR-selective	O
agonist	O
reduced	O
EC-1	B-GENE
expression	O
slightly	O
.	O

By	O
comparing	O
the	O
abundances	O
of	O
many	O
yeast	O
transcripts	O
in	O
isogenic	O
wild-type	O
and	O
paf1	B-GENE
mutant	I-GENE
strains	O
,	O
we	O
have	O
identified	O
genes	O
whose	O
expression	O
is	O
affected	O
by	O
PAF1	B-GENE
.	O

The	O
physical	O
characteristics	O
of	O
these	O
calls	O
vary	O
among	O
species	O
of	O
bat	O
,	O
and	O
variations	O
also	O
exist	O
in	O
the	O
timing	O
and	O
patterns	O
of	O
respiratory	O
muscle	O
recruitment	O
during	O
echolocation	O
.	O

Most	O
important	O
,	O
infection	O
of	O
the	O
cells	O
with	O
an	O
adenoviral	O
construct	O
expressing	O
this	O
mutant	O
inhibited	O
the	O
induction	O
of	O
VEGF	B-GENE
mRNA	I-GENE
under	O
conditions	O
that	O
mimic	O
hypoxia	O
.	O

A	O
constitutive	O
allele	O
of	O
GPA2	B-GENE
could	O
stimulate	O
growth	O
of	O
a	O
strain	O
lacking	O
both	O
RAS	B-GENE
genes	I-GENE
.	O

The	O
end-stage	O
or	O
involutional	O
phase	O
of	O
proliferative	O
diabetic	O
retinopathy	O
may	O
result	O
in	O
stabilization	O
of	O
vision	O
for	O
long	O
periods	O
of	O
time	O
.	O

We	O
have	O
previously	O
reported	O
that	O
expression	O
of	O
a	O
tumour	O
derived	O
brk	B-GENE
cDNA	I-GENE
in	O
mouse	O
embryonic	O
fibroblasts	O
and	O
human	O
mammary	O
epithelial	O
cells	O
supports	O
anchorage	O
independent	O
growth	O
,	O
and	O
in	O
the	O
latter	O
potentiates	O
the	O
mitogenic	O
response	O
to	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
.	O

A	O
total	O
of	O
26	O
BCG	O
strains	O
,	O
out	O
of	O
them	O
10	O
Czechoslovak	O
strains	O
(	O
2	O
lyophilized	O
cultures	O
of	O
BCG	O
of	O
different	O
batch	O
,	O
6	O
strains	O
isolated	O
from	O
abscesses	O
of	O
children	O
after	O
BCG-vaccination	O
and	O
2	O
strains	O
from	O
fatal	O
cases	O
after	O
BCG-vaccination	O
)	O
and	O
16	O
strains	O
obtained	O
from	O
foreign	O
laboratories	O
,	O
were	O
used	O
.	O

The	O
myeloproliferative	O
sarcoma	O
virus	O
(	O
MPSV	O
)	O
was	O
derived	O
by	O
passage	O
of	O
Moloney	O
sarcoma	O
virus	O
(	O
Mo-MuSV	O
)	O
in	O
adult	O
mice	O
.	O

Re	O
:	O
"Assessing	O
the	O
direction	O
of	O
causality	O
in	O
cross-sectional	O
studies"	O
.	O

Standard	O
curve	O
correlation	O
coefficients	O
of	O
0	O
.	O
995	O
or	O
greater	O
were	O
obtained	O
during	O
validation	O
experiments	O
and	O
analysis	O
of	O
study	O
samples	O
.	O

Echosismography	O
enables	O
to	O
improve	O
the	O
diagnosis	O
when	O
compared	O
with	O
classical	O
sonography	O
in	O
about	O
20%	O
of	O
cases	O
.	O

The	O
serine	B-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
Raf-1	I-GENE
functions	O
downstream	O
of	O
Rats	B-GENE
in	O
a	O
signal	O
transduction	O
cascade	O
which	O
transmits	O
mitogenic	O
stimuli	O
from	O
the	O
plasma	O
membrane	O
to	O
the	O
nucleus	O
.	O

Furthermore	O
,	O
the	O
over-replication	O
phenotype	O
produced	O
by	O
this	O
mutant	B-GENE
p65cdc18	I-GENE
is	O
resistant	O
to	O
increased	O
mitotic	O
cyclin	B-GENE
/	I-GENE
CDK	I-GENE
activity	O
,	O
a	O
known	O
inhibitor	O
of	O
over-replication	O
.	O

Benefits	O
of	O
obtaining	O
board	O
certification	O
in	O
pharmacotherapy	O
.	O

For	O
various	O
dog	O
vessels	O
in	O
vivo	O
,	O
Q	O
/	O
Dk	O
ranged	O
from	O
0	O
.	O
15	O
to	O
47	O
X	O
10	O
(	O
5	O
)	O
Torr	O
/	O
cm2	O
.	O

Plate	O
luting	O
,	O
a	O
technique	O
that	O
uses	O
polymethylmethacrylate	O
(	O
PMMA	O
)	O
interposed	O
between	O
the	O
plate	O
and	O
the	O
bone	O
,	O
as	O
well	O
as	O
between	O
the	O
screw	O
heads	O
and	O
the	O
plate	O
,	O
to	O
improve	O
the	O
stability	O
of	O
internal	O
fixation	O
was	O
tested	O
in	O
vitro	O
using	O
20	O
paired	O
equine	O
third	O
metacarpal	O
bones	O
with	O
mid-diaphyseal	O
osteotomies	O
plated	O
with	O
six-hole	O
broad	O
ASIF	O
compression	O
plates	O
.	O

Our	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
MMF	O
on	O
in	O
vivo	O
bone	O
mineral	O
metabolism	O
.	O

These	O
data	O
suggest	O
that	O
these	O
sequences	O
located	O
immediately	O
3'	O
to	O
the	O
breakpoint	O
of	O
the	O
HPFH-3	B-GENE
deletion	I-GENE
,	O
exhibit	O
both	O
the	O
structure	O
and	O
the	O
function	O
of	O
an	O
enhancer	O
,	O
and	O
can	O
modify	O
the	O
developmental	O
specificity	O
of	O
the	O
fetal	B-GENE
gamma-globin	I-GENE
genes	I-GENE
,	O
resulting	O
in	O
their	O
continued	O
expression	O
during	O
adult	O
life	O
.	O

CONCLUSIONS	O
:	O
While	O
INR	O
correction	O
may	O
be	O
achieved	O
by	O
all	O
the	O
above	O
methods	O
,	O
that	O
relating	O
log	O
reference	O
INR	O
to	O
log	O
local	O
prothrombin	B-GENE
time	O
by	O
linear	O
regression	O
analysis	O
is	O
the	O
simplest	O
to	O
perform	O
.	O

Sensory	O
kindling	O
:	O
implications	O
for	O
development	O
of	O
sensory	O
prostheses	O
.	O

A	O
rapid	O
fluorimetric	O
procedure	O
for	O
the	O
determination	O
of	O
the	O
fungicide	O
5-fluorocytosine	O
in	O
serum	O
is	O
described	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
effects	O
of	O
Msx2	B-GENE
expression	O
on	O
OC	B-GENE
promoter	I-GENE
activation	O
(	O
luciferase	B-GENE
reporter	I-GENE
)	O
by	O
FGF2	B-GENE
/	I-GENE
FSK	I-GENE
and	O
calcitriol	O
in	O
MC3T3-E1	O
osteoblasts	O
.	O

Human	B-GENE
neuronal	I-GENE
Elav-like	I-GENE
proteins	I-GENE
contain	O
three	O
RNP-type	B-GENE
RNA	I-GENE
recognition	I-GENE
motifs	I-GENE
(	O
RRMs	B-GENE
)	O
.	O

Liquid	O
chromatographic	O
method	O
for	O
analysis	O
of	O
all-rac-alpha-tocopheryl	O
acetate	O
and	O
retinyl	O
palmitate	O
in	O
milk-based	O
infant	O
formula	O
using	O
matrix	O
solid-phase	O
dispersion	O
.	O

Interestingly	O
,	O
internal	O
and	O
5'	O
deletions	O
revealed	O
tha	O
the	O
distal	O
promoter	O
was	O
not	O
required	O
for	O
full	O
transcriptional	O
activity	O
and	O
that	O
the	O
first	O
631	O
base	O
pairs	O
of	O
WNT-5A	B-GENE
harbored	O
the	O
strongest	O
promoter	O
activity	O
.	O

Truncated	O
forms	O
of	O
a	O
novel	O
yeast	O
protein	O
suppress	O
the	O
lethality	O
of	O
a	O
G	B-GENE
protein	I-GENE
alpha	I-GENE
subunit	I-GENE
deficiency	O
by	O
interacting	O
with	O
the	O
beta	O
subunit	O
.	O

Thus	O
,	O
BALB	O
/	O
c	O
mice	O
appear	O
to	O
be	O
the	O
most	O
appropriate	O
strain	O
of	O
mice	O
to	O
perform	O
studies	O
on	O
the	O
possible	O
connection	O
between	O
infection	O
with	O
T	O
.	O
canis	O
and	O
allergic	O
asthma	O
.	O

These	O
studies	O
demonstrate	O
that	O
site-specific	O
recognition	O
of	O
the	O
bxd	B-GENE
PRE	I-GENE
by	O
d	O
(	O
GA	O
)	O
(	O
n	O
)	O
repeat	O
binding	O
activities	O
mediates	O
PcG-dependent	O
silencing	O
.	O

We	O
studied	O
the	O
effect	O
of	O
skinfold	O
thickness	O
on	O
the	O
correlation	O
between	O
serum	O
total	O
bilirubin	O
level	O
and	O
transcutaneous	O
bilirubin	O
(	O
TcB	O
)	O
readings	O
.	O

Binding	O
affinities	O
of	O
these	O
recombinant	O
phages	O
as	O
determined	O
by	O
the	O
retention	O
of	O
these	O
phages	O
by	O
a	O
His-tag	O
immobilized	O
gp17	B-GENE
column	O
,	O
and	O
by	O
co-immunoprecipitation	O
with	O
purified	O
terminase	B-GENE
supported	O
the	O
specific	O
nature	O
of	O
the	O
portal	B-GENE
protein	I-GENE
and	O
terminase	B-GENE
interaction	I-GENE
sites	I-GENE
.	O

During	O
the	O
following	O
9	O
1	O
/	O
2	O
years	O
three	O
sequential	O
liver	O
biopsies	O
were	O
performed	O
.	O

Toward	O
absolute	O
methods	O
in	O
clinical	O
chemistry	O
:	O
application	O
of	O
mass	O
fragmentography	O
to	O
high-accuracy	O
analyses	O
.	O

Psychiatric	O
disorders	O
in	O
children	O
and	O
adolescents	O
carry	O
considerable	O
morbidity	O
,	O
impede	O
development	O
,	O
and	O
carry	O
a	O
significant	O
mortality	O
by	O
suicide	O
.	O

Functional	O
characterization	O
of	O
a	O
fraction	O
identified	O
by	O
its	O
activity	O
in	O
a	O
second	O
template	O
rescue	O
assay	O
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
of	O
MdPin1	B-GENE
,	O
a	O
Pin1	B-GENE
homologue	O
from	O
the	O
plant	O
species	O
apple	O
(	O
Malus	O
domestica	O
)	O
and	O
show	O
that	O
it	O
has	O
the	O
same	O
phosphorylation-specific	O
substrate	O
specificity	O
and	O
can	O
be	O
inhibited	O
by	O
juglone	O
in	O
vitro	O
,	O
as	O
is	O
the	O
case	O
for	O
Pin1	B-GENE
.	O

Commun	O
.	O

Teratological	O
study	O
of	O
etoperidone	O
in	O
the	O
rat	O
and	O
rabbit	O
.	O

(	O
3	O
)	O
This	O
effect	O
occurs	O
without	O
removing	O
TRs	B-GENE
from	O
the	O
TRE	B-GENE
.	O

A	O
Y	B-GENE
.	I-GENE
lipolytica	I-GENE
Kar2p	I-GENE
mutant	I-GENE
was	O
isolated	O
that	O
restored	O
interaction	O
with	O
an	O
Sls1p	B-GENE
mutant	I-GENE
,	O
suggesting	O
that	O
the	O
interaction	O
with	O
Sls1p	B-GENE
could	O
be	O
nucleotide	O
and	O
/	O
or	O
conformation	O
dependent	O
.	O

Nine	O
animals	O
served	O
as	O
control	O
animals	O
,	O
whereas	O
20	O
animals	O
received	O
a	O
focal	O
arachnoid	O
scar	O
at	O
C1-C2	O
,	O
which	O
was	O
produced	O
by	O
placement	O
of	O
a	O
kaolin-soaked	O
fibrin	B-GENE
sponge	O
on	O
the	O
posterior	O
surface	O
of	O
the	O
spinal	O
cord	O
.	O

High	O
ATP	O
/	O
GTP	O
ratios	O
promoted	O
initiation	O
of	O
RNA	O
primer	O
synthesis	O
at	O
3'-dCTTT	B-GENE
sites	I-GENE
,	O
whereas	O
low	O
ATP	O
/	O
GTP	O
ratios	O
promoted	O
initiation	O
at	O
3'-dCCC	B-GENE
sites	I-GENE
.	O

Two	O
predominant	O
effects	O
were	O
noted	O
:	O
(	O
i	O
)	O
the	O
Xaa	O
residue	O
in	O
the	O
dual	B-GENE
phosphorylation	I-GENE
motif	I-GENE
Thr-Xaa-Tyr	I-GENE
as	O
well	O
as	O
the	O
length	O
of	O
L12	O
influence	O
p38	B-GENE
substrate	O
specificity	O
,	O
and	O
(	O
ii	O
)	O
the	O
length	O
of	O
L12	O
plays	O
a	O
major	O
role	O
in	O
controlling	O
autophosphorylation	O
.	O

This	O
L-myc	B-GENE
sequence	I-GENE
is	O
amplified	O
10-20-fold	O
in	O
four	O
SCLC	O
cell	O
line	O
DNAs	O
and	O
in	O
one	O
SCLC	O
tumour	O
specimen	O
taken	O
directly	O
from	O
a	O
patient	O
.	O

We	O
have	O
previously	O
reported	O
reduced	O
levels	O
of	O
choline	B-GENE
acetyltransferase	I-GENE
activity	O
in	O
the	O
cerebral	O
cortex	O
of	O
patients	O
who	O
died	O
after	O
a	O
head	O
injury	O
,	O
demonstrating	O
that	O
there	O
is	O
a	O
loss	O
of	O
cortical	O
cholinergic	O
innervation	O
.	O

Significant	O
increases	O
in	O
mean	O
serum	O
E2	O
concentration	O
(	O
100	O
to	O
150	O
pg	O
/	O
ml	O
)	O
were	O
noted	O
at	O
6	O
and	O
8	O
hours	O
after	O
administration	O
on	O
day	O
1	O
and	O
at	O
8	O
hours	O
on	O
day	O
4	O
.	O

Paleoceanographic	O
data	O
from	O
the	O
Laurentian	O
Fan	O
,	O
used	O
as	O
a	O
proxy	O
for	O
sea	O
surface	O
temperature	O
,	O
reveal	O
that	O
surface	O
slope	O
waters	O
north	O
of	O
the	O
Gulf	O
Stream	O
experienced	O
warming	O
during	O
the	O
Little	O
Ice	O
Age	O
of	O
the	O
16th	O
to	O
19th	O
centuries	O
and	O
support	O
the	O
notion	O
of	O
an	O
NAO-driven	O
coupled	O
system	O
.	O

Six	O
putative	O
MDV	O
genome	O
products	O
,	O
including	O
one	O
Rep	B-GENE
and	O
five	O
non-Rep	O
proteins	O
,	O
show	O
high	O
(	O
70	O
.	O
4-90	O
.	O
9%	O
)	O
amino	O
acid	O
identity	O
to	O
the	O
corresponding	O
six	O
FBNYV	B-GENE
proteins	I-GENE
,	O
whereas	O
two	O
other	O
Rep	B-GENE
proteins	I-GENE
encoded	O
by	O
MDV-C2	B-GENE
and	O
C3	B-GENE
are	O
82	O
.	O
3%	O
and	O
73	O
.	O
0%	O
identical	O
to	O
those	O
encoded	O
by	O
SCSV-C2	B-GENE
and	O
C6	B-GENE
,	O
respectively	O
.	O

We	O
investigated	O
the	O
smoking	O
habits	O
of	O
relapsers	O
1	O
year	O
after	O
quitting	O
in	O
a	O
smoking	O
cessation	O
trial	O
using	O
nicotine	O
or	O
placebo	O
patches	O
.	O

While	O
determination	O
of	O
the	O
protein	O
content	O
of	O
the	O
formulae	O
gave	O
no	O
valid	O
information	O
,	O
RAST	O
/	O
EAST	O
inhibition	O
was	O
highest	O
for	O
cow's	O
milk	O
,	O
followed	O
by	O
the	O
partially	O
hydrolysed	O
whey	O
formula	O
,	O
partially	O
hydrolysed	O
whey	O
/	O
casein	O
formula	O
,	O
soy	B-GENE
/	I-GENE
pork	I-GENE
collagen	I-GENE
formula	O
,	O
and	O
the	O
amino	O
acid	O
formula	O
.	O

Transcriptional	O
regulation	O
of	O
SUP35	B-GENE
and	O
SUP45	B-GENE
in	I-GENE
Saccharomyces	I-GENE
cerevisiae	I-GENE
.	O

The	O
clinical	O
relevance	O
of	O
these	O
findings	O
is	O
strengthened	O
by	O
the	O
observation	O
that	O
similar	O
results	O
were	O
obtained	O
when	O
P	O
.	O
HCl	O
was	O
given	O
by	O
the	O
intravenous	O
route	O
.	O

RESULTS	O
:	O
Looking	O
at	O
the	O
question	O
of	O
its	O
benefits	O
,	O
we	O
were	O
unable	O
to	O
find	O
any	O
methodologically	O
sound	O
studies	O
that	O
have	O
shown	O
efficacy	O
for	O
EMDR	O
in	O
eating	O
disorders	O
,	O
or	O
,	O
indeed	O
,	O
any	O
psychiatric	O
disorder	O
.	O

The	O
2	O
kb	O
of	O
5'-flanking	O
region	O
and	O
the	O
1	O
.	O
1	O
kb	O
of	O
the	O
entire	O
sGTH	B-GENE
alpha	I-GENE
subunit	I-GENE
coding	O
region	O
were	O
sequenced	O
from	O
the	O
genomic	O
clone	O
,	O
sGTH	B-GENE
alpha-G1	I-GENE
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
of	O
bovine	B-GENE
and	I-GENE
rat	I-GENE
GHF-1	I-GENE
cDNA	I-GENE
clones	O
.	O

These	O
data	O
demonstrate	O
that	O
paxillin	B-GENE
localizes	O
to	O
focal	O
adhesions	O
independent	O
of	O
interactions	O
with	O
vinculin	B-GENE
and	O
/	O
or	O
FAK	B-GENE
,	O
and	O
represents	O
the	O
first	O
definitive	O
demonstration	O
of	O
LIM	B-GENE
domains	I-GENE
functioning	O
as	O
a	O
primary	O
determinant	O
of	O
protein	O
subcellular	O
localization	O
to	O
focal	O
adhesions	O
.	O

Systematic	O
functional	O
analysis	O
of	O
V1a	B-GENE
/	I-GENE
V2	I-GENE
hybrid	I-GENE
receptors	I-GENE
showed	O
that	O
the	O
second	O
intracellular	O
loop	O
of	O
the	O
V1a	B-GENE
receptor	I-GENE
is	O
required	O
and	O
sufficient	O
for	O
efficient	O
coupling	O
to	O
Gq	B-GENE
/	I-GENE
11	I-GENE
,	O
whereas	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
V2	B-GENE
receptor	I-GENE
is	O
required	O
and	O
sufficient	O
for	O
coupling	O
to	O
Gs	B-GENE
.	O

Both	O
NUP98-HOXA9	B-GENE
chimeras	I-GENE
transformed	O
NIH	O
3T3	O
fibroblasts	O
,	O
and	O
this	O
transformation	O
required	O
the	O
HOXA9	B-GENE
domains	I-GENE
for	O
DNA	O
binding	O
and	O
PBX	B-GENE
interaction	O
.	O

KFC	B-GENE
,	O
a	O
Ste20-like	B-GENE
kinase	I-GENE
with	O
mitogenic	O
potential	O
and	O
capability	O
to	O
activate	O
the	O
SAPK	B-GENE
/	I-GENE
JNK	I-GENE
pathway	I-GENE
.	O

One	O
RNA	O
construct	O
which	O
consisted	O
of	O
112	O
nucleotides	O
(	O
nt	O
)	O
from	O
nt	O
639	O
to	O
nt	O
750	O
formed	O
a	O
heterodimeric	O
complex	O
with	O
the	O
RNA	O
which	O
consisted	O
of	O
200	O
nucleotides	O
from	O
nt	O
551	O
to	O
nt	O
750	O
.	O

Cytogenetic	O
analysis	O
of	O
LOH	O
mutants	O
by	O
chromosome	O
painting	O
indicated	O
a	O
mosaic	O
of	O
chromosomal	O
aberrations	O
involving	O
chromosome	O
17	O
,	O
in	O
which	O
partial	O
chromosome	O
deletions	O
,	O
amplifications	O
,	O
and	O
multiple	O
translocations	O
appeared	O
heterogeneously	O
in	O
a	O
single	O
mutant	O
.	O

In	O
addition	O
,	O
a	O
potent	O
splicing	O
enhancer	O
sequence	O
isolated	O
in	O
the	O
selection	O
specifically	O
binds	O
a	O
20-kDa	B-GENE
SR	I-GENE
protein	I-GENE
.	O

A	O
dose-dependent	O
fall	O
in	O
GABA	O
content	O
was	O
observed	O
;	O
GABA	O
decrease	O
was	O
evident	O
15	O
min	O
after	O
the	O
administration	O
,	O
reached	O
its	O
nadir	O
at	O
60	O
min	O
and	O
disappeared	O
at	O
120	O
minutes	O
.	O

Within	O
their	O
polypeptide	O
chain	O
,	O
they	O
all	O
contain	O
those	O
conserved	O
features	O
that	O
define	O
a	O
plant	O
CDPK	B-GENE
;	O
kinase	B-GENE
catalytic	I-GENE
sequences	I-GENE
are	O
linked	O
to	O
a	O
calmodulin-like	B-GENE
regulatory	I-GENE
domain	I-GENE
through	O
a	O
junction	O
region	O
.	O

RESULTS	O
:	O
The	O
parameters	O
SF2	O
and	O
plating	O
efficiency	O
were	O
stable	O
throughout	O
the	O
4-year	O
test	O
period	O
.	O

Involvement	O
of	O
AP-2	B-GENE
in	O
regulation	O
of	O
the	O
R-FABP	B-GENE
gene	I-GENE
in	O
the	O
developing	O
chick	O
retina	O
.	O

Two	O
studies	O
assessed	O
two	O
types	O
of	O
reliability	O
of	O
the	O
student	O
Jenkins	O
Activity	O
Survey	O
(	O
JAS	O
;	O
a	O
questionnaire	O
measure	O
of	O
Type	O
A	O
behavior	O
)	O
.	O

Two-way	O
analysis	O
of	O
variance	O
was	O
used	O
to	O
determine	O
whether	O
composite	O
knowledge	O
score	O
differed	O
among	O
patient	O
groups	O
.	O

We	O
have	O
shown	O
previously	O
that	O
in	O
contrast	O
to	O
other	O
extracellular	O
matrix	O
molecules	O
pepsin-solubilized	O
collagen	B-GENE
VI	I-GENE
(	O
CVI	B-GENE
)	O
can	O
stimulate	O
DNA	O
synthesis	O
of	O
various	O
mesenchymal	O
cell	O
types	O
,	O
apparently	O
independent	O
of	O
integrin-mediated	O
signal	O
transduction	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
encoding	O
a	O
putative	O
cytokine	O
which	O
is	O
induced	O
by	O
stimulation	O
via	O
the	O
CD2	B-GENE
structure	I-GENE
on	O
human	O
T	O
lymphocytes	O
.	O

In	O
the	O
studies	O
reported	O
here	O
,	O
the	O
5'-flanking	O
region	O
of	O
the	O
human	B-GENE
gp130	I-GENE
gene	I-GENE
was	O
isolated	O
and	O
the	O
transcription	O
initiation	O
sites	O
were	O
mapped	O
.	O

Preimmune	B-GENE
IgG	I-GENE
,	O
anti-GalT	B-GENE
Fab	I-GENE
fragments	I-GENE
,	O
irrelevant	O
polymers	O
and	O
monomeric	O
N-acetylglucosamine	O
had	O
no	O
effect	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
cDNA	O
encoding	O
a	O
bacteriophage-type	B-GENE
RNA	I-GENE
polymerase	I-GENE
from	O
the	O
higher	O
plant	O
Chenopodium	O
album	O
.	O

Female	O
but	O
not	O
male	O
mortalities	O
were	O
significantly	O
higher	O
for	O
cake-fed	O
rats	O
than	O
for	O
those	O
fed	O
diet	O
41B	O
.	O

Genomic	O
DNA	O
hybridization	O
suggests	O
that	O
SpSHR2	B-GENE
is	O
a	O
single-copy	O
gene	O
in	O
the	O
S	O
.	O
purpuratus	O
genome	O
.	O

Its	O
transcription	O
in	O
vitro	O
by	O
pol	B-GENE
III	I-GENE
requires	O
the	O
same	O
factors	O
as	O
the	O
U6	B-GENE
gene	I-GENE
with	O
the	O
major	O
exception	O
that	O
the	O
modified	O
TATA-box	O
of	O
this	O
construct	O
only	O
interacts	O
with	O
a	O
TATA-binding	B-GENE
protein	I-GENE
(	O
TBP	B-GENE
)	O
mutant	O
(	O
TBP-DR2	B-GENE
)	O
but	O
not	O
with	O
TBP	B-GENE
wild-type	I-GENE
(	O
TBPwt	B-GENE
)	O
.	O

How	O
do	O
graduates	O
of	O
different	O
types	O
of	O
programs	O
perform	O
on	O
state	O
boards	O
?	O

Interdomain	O
signaling	O
in	O
a	O
two-domain	O
fragment	O
of	O
the	O
human	B-GENE
glucocorticoid	I-GENE
receptor	I-GENE
.	O

Teratological	O
studies	O
on	O
SF-837	O
.	O

Our	O
laboratory	O
and	O
others	O
have	O
shown	O
alternative	O
splicing	O
of	O
up	O
to	O
ten	O
exons	O
at	O
a	O
discrete	O
extracellular	O
site	O
to	O
be	O
primarily	O
responsible	O
for	O
the	O
generation	O
of	O
CD44	B-GENE
variant	I-GENE
(	O
CD44v	B-GENE
)	O
isoforms	O
.	O

She	O
has	O
since	O
developed	O
a	O
positive	O
anti-cardiolipin	B-GENE
antibody	I-GENE
but	O
does	O
not	O
meet	O
diagnostic	O
criteria	O
for	O
systemic	O
lupus	O
erythematosis	O
.	O
Conclusion	O
:	O
The	O
presence	O
of	O
known	O
autoimmune	O
disease	O
in	O
a	O
woman	O
with	O
POF	O
should	O
not	O
dissuade	O
the	O
clinician	O
from	O
evaluating	O
for	O
a	O
potential	O
genetic	O
cause	O
.	O

Forced	O
expression	O
of	O
BZAP45	B-GENE
strongly	O
stimulates	O
H4	B-GENE
promoter	I-GENE
(	O
nt	O
-215	O
to	O
-1	O
)	O
/	B-GENE
CAT	I-GENE
reporter	I-GENE
gene	I-GENE
activity	O
.	O

This	O
up-grading	O
of	O
the	O
final	O
score	O
by	O
the	O
CA	O
component	O
is	O
greater	O
(	O
3-8%	O
)	O
in	O
the	O
less	O
able	O
students	O
with	O
scores	O
below	O
the	O
mean	O
level	O
.	O

The	O
ORF	O
was	O
analyzed	O
for	O
secondary	O
structural	O
features	O
,	O
and	O
the	O
sequence	O
data	O
bases	O
were	O
searched	O
for	O
homologies	O
.	O

The	O
[	O
18F	O
]	O
FMISO	O
TMRR	O
is	O
a	O
simple	O
and	O
clinically	O
useful	O
index	O
for	O
detecting	O
tumour	O
hypoxia	O
in	O
NPC	O
.	O

The	O
transcripts	O
were	O
equally	O
active	O
with	O
or	O
without	O
a	O
5'	O
methylated	O
capstructure	O
as	O
expected	O
,	O
since	O
EMCV-RNA	O
is	O
one	O
of	O
the	O
mRNAs	O
capable	O
of	O
internal	O
initiation	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
group	O
;	O
Control	O
group	O
A	O
in	O
which	O
a	O
hot-water	O
circulating	O
system	O
was	O
used	O
and	O
group	O
B	O
in	O
which	O
a	O
transtracheal	O
heating	O
and	O
humidification	O
system	O
by	O
ANAMED	O
HUMITUBE	O
was	O
used	O
,	O
during	O
gastric	O
cancer	O
operation	O
.	O

The	O
equilibrium	O
dissociation	O
binding	O
constant	O
for	O
the	O
interaction	O
of	O
TnrA	B-GENE
with	O
the	O
nrgAB	B-GENE
promoter	I-GENE
fragment	I-GENE
was	O
7	O
.	O
7	O
nM	O
under	O
the	O
conditions	O
used	O
here	O
.	O

Tissue-specific	O
expression	O
of	O
the	O
tmy-1	B-GENE
gene	I-GENE
was	O
determined	O
by	O
microinjection	O
of	O
a	O
promoter	B-GENE
/	I-GENE
lacZ	I-GENE
fusion	I-GENE
gene	I-GENE
and	O
with	O
immunohistochemistry	O
by	O
using	O
affinity-purified	O
tissue-specific	B-GENE
anti-tropomyosins	I-GENE
.	O

Radiolabeled	O
recombinant	B-GENE
TARC	I-GENE
specifically	O
bound	O
to	O
T	O
cell	O
lines	O
and	O
peripheral	O
T	O
cells	O
but	O
not	O
to	O
monocytes	O
or	O
granulocytes	O
.	O

Intravenous	O
versus	O
oral	O
administration	O
of	O
amitriptyline	O
in	O
patients	O
with	O
major	O
depression	O
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	B-GENE
factor	I-GENE
expression	O
is	O
that	O
several	O
GATA	B-GENE
proteins	I-GENE
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA-binding	O
site	O
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

Calcitriol	O
therapy	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
serum	O
iPTH	B-GENE
levels	O
(	O
701	O
+	O
/	O
-	O
103	O
.	O
9	O
vs	O
.	O

In	O
most	O
subjects	O
,	O
markers	O
of	O
bone	O
formation	O
and	O
resorption	O
were	O
normal	O
.	O

Nevertheless	O
,	O
inactivation	O
of	O
the	O
cyclin	B-GENE
E-Cdk2	I-GENE
complex	I-GENE
in	O
response	O
to	O
mitogen	O
starvation	O
occurs	O
normally	O
in	O
MEFs	O
that	O
have	O
a	O
homozygous	O
deletion	O
of	O
the	O
p27	B-GENE
gene	I-GENE
.	O

Moreover	O
,	O
this	O
enhancement	O
of	O
transcriptional	O
activation	O
by	O
COUP-TFI	B-GENE
requires	O
specifically	O
the	O
AF-1	B-GENE
transactivation	O
function	O
of	O
ER	B-GENE
and	O
can	O
be	O
observed	O
in	O
the	O
presence	O
of	O
E2	O
or	O
4-hydroxytamoxifen	O
but	O
not	O
ICI	O
164384	O
.	O

A	O
pharmacokinetic	O
study	O
of	O
apalcillin	O
was	O
performed	O
in	O
12	O
patients	O
in	O
an	O
intensive-care	O
unit	O
.	O

Autoimmune	O
manipulation	O
aids	O
juvenile	O
diabetes	O
management	O
.	O

Effect	O
of	O
indoramin	O
in	O
small	O
doses	O
on	O
the	O
central	O
vasomotor	O
loci	O
has	O
been	O
studied	O
in	O
chloralose	O
anesthetized	O
cats	O
by	O
localizing	O
it	O
to	O
the	O
central	O
sites	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
spo20	B-GENE
(	I-GENE
+	I-GENE
)	I-GENE
gene	I-GENE
product	I-GENE
is	O
structurally	O
homologous	O
to	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
Sec14	I-GENE
,	O
the	O
major	O
phosphatidylinositol	O
transfer	O
protein	O
of	O
budding	O
yeast	O
.	O

Baseline	O
electrocorticography	O
over	O
the	O
surface	O
of	O
the	O
temporal	O
lobe	O
and	O
depth	O
electrode	O
recordings	O
in	O
the	O
amygdala	O
and	O
hippocampus	O
were	O
obtained	O
,	O
followed	O
by	O
10	O
min	O
of	O
recording	O
before	O
and	O
after	O
the	O
i	O
.	O
v	O
.	O
administration	O
of	O
both	O
alfentanil	O
50	O
microg	O
/	O
kg	O
and	O
fentanyl	O
10	O
microg	O
/	O
kg	O
.	O

Although	O
elevated	O
serum	O
levels	O
of	O
antibodies	O
to	O
the	O
nicotinic	B-GENE
acetylcholine	I-GENE
receptor	I-GENE
(	O
nAChR	B-GENE
)	O
have	O
been	O
reported	O
in	O
neuroleptic	O
treated	O
patients	O
with	O
tardive	O
dyskinesia	O
,	O
such	O
antibodies	O
have	O
not	O
been	O
determined	O
in	O
comparable	O
nondyskinetic	O
patients	O
.	O

VII	O
.	O

Recently	O
,	O
a	O
mutation	O
in	O
the	O
amino-terminus	O
of	O
IB1	B-GENE
was	O
associated	O
with	O
diabetes	O
.	O

In	O
budding	O
yeast	O
,	O
the	O
protein	O
Skp1p	B-GENE
,	O
the	O
cullin-family	B-GENE
member	I-GENE
Cdc53p	B-GENE
,	O
and	O
the	O
F-box	B-GENE
/	I-GENE
WD-repeat	I-GENE
protein	I-GENE
Cdc4p	B-GENE
form	O
the	O
SCFCdc4p	B-GENE
ubiquitin	B-GENE
ligase	B-GENE
complex	I-GENE
,	O
which	O
targets	O
the	O
cyclin-dependent	B-GENE
kinase	I-GENE
(	O
Cdk	B-GENE
)	O
inhibitor	O
Sic1p	B-GENE
for	O
proteolysis	O
[	O
3	O
]	O
[	O
4	O
]	O
[	O
5	O
]	O
[	O
6	O
]	O
[	O
7	O
]	O
[	O
8	O
]	O
.	O

We	O
show	O
that	O
p73	B-GENE
can	O
transcriptionally	O
inhibit	O
a	O
number	O
of	O
cellular	O
and	O
viral	O
promoters	O
.	O

Induced	O
expression	O
of	O
Rnd3	B-GENE
is	O
associated	O
with	O
transformation	O
of	O
polarized	O
epithelial	O
cells	O
by	O
the	O
Raf-MEK-extracellular	B-GENE
signal-regulated	I-GENE
kinase	I-GENE
pathway	I-GENE
.	O

How	O
does	O
a	O
nurse	O
go	O
about	O
maintaining	O
her	O
level	O
of	O
competence	O
when	O
she	O
is	O
one	O
of	O
the	O
few	O
local	O
practitioners	O
in	O
her	O
field	O
?	O
Vancouver	O
sex	O
therapist	O
Bianca	O
Rucker	O
is	O
doing	O
it	O
by	O
cultivating	O
a	O
network	O
of	O
colleagues	O
and	O
mentors	O
in	O
related	O
fields	O
both	O
at	O
home	O
and	O
across	O
the	O
continent	O
.	O

In	O
addition	O
,	O
benzocaine	O
and	O
2-phenoxyethanol	O
depressed	O
complement	O
activity	O
and	O
phagocytosis	O
,	O
while	O
MS222	O
and	O
quinaldine	O
sulphate	O
did	O
not	O
.	O

(	O
1992	O
)	O
J	O
.	O

Expression	O
of	O
neuronal	O
traits	O
in	O
pancreatic	O
beta	O
cells	O
.	O

All	O
four	O
domains	O
were	O
linked	O
via	O
proline-threonine-rich	O
peptides	O
.	O

Both	O
genes	O
comprise	O
three	O
exons	O
,	O
two	O
introns	O
and	O
an	O
unusually	O
long	O
3'-untranslated	O
region	O
(	O
3	O
.	O
2	O
kilobase	O
pairs	O
)	O
,	O
specificying	O
a	O
mRNA	O
of	O
approximately	O
4	O
.	O
1	O
kilobases	O
.	O

Convulsive	O
seizure	O
during	O
a	O
treatment	O
with	O
interferon	B-GENE
alpha	I-GENE
for	O
chronic	O
viral	O
hepatitis	O
C	O
.	O

The	O
ratio	O
of	O
the	O
activity	O
of	O
arogenate	B-GENE
dehydrogenase	I-GENE
to	O
that	O
of	O
prephenate	B-GENE
dehydrogenase	I-GENE
(	O
approximately	O
3	O
:	O
1	O
)	O
remained	O
constant	O
throughout	O
purification	O
,	O
and	O
the	O
two	O
activities	O
were	O
therefore	O
inseparable	O
.	O

Pathogenetic	O
relationships	O
between	O
renal	O
tubular	O
acidosis	O
and	O
sodium	O
metabolism	O
alterations	O
in	O
liver	O
cirrhosis	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
the	O
urinary	O
porphyrin	B-GENE
excretion	O
and	O
the	O
porphyrin	B-GENE
content	O
in	O
lijver	O
and	O
skin	O
were	O
diminished	O
in	O
HCB-CQ-treated	O
animals	O
by	O
about	O
50%	O
compared	O
to	O
the	O
HCB	O
controls	O
.	O

YAC	O
and	O
cosmid	O
contigs	O
spanning	O
the	O
Batten	B-GENE
disease	I-GENE
(	I-GENE
CLN3	I-GENE
)	I-GENE
region	I-GENE
at	O
16p12	O
.	O
1-p11	O
.	O
2	O
.	O

Hu-Met-1	B-GENE
mRNA	I-GENE
expression	O
in	O
a	O
small	O
number	O
of	O
human	O
T	O
cell	O
tumor	O
lines	O
did	O
not	O
correlate	O
with	O
any	O
particular	O
phenotype	O
or	O
stage	O
of	O
development	O
.	O

Identification	O
of	O
dynein	B-GENE
heavy	I-GENE
chain	I-GENE
genes	I-GENE
expressed	O
in	O
human	O
and	O
mouse	O
testis	O
:	O
chromosomal	O
localization	O
of	O
an	O
axonemal	B-GENE
dynein	I-GENE
gene	I-GENE
.	O

The	O
granules	O
grew	O
as	O
the	O
melted	O
material	O
immersed	O
into	O
the	O
void	O
space	O
among	O
the	O
adhered	O
particles	O
.	O

We	O
conclude	O
that	O
administration	O
of	O
the	O
calcium	O
antagonist	O
Verapamil	O
is	O
of	O
no	O
additional	O
value	O
in	O
tocolytic	O
treatment	O
with	O
beta-mimetics	O
.	O

The	O
method	O
was	O
adapted	O
for	O
the	O
determination	O
of	O
nadolol	O
racemate	O
A	O
by	O
a	O
change	O
in	O
mobile	O
phase	O
composition	O
.	O

Examples	O
of	O
its	O
use	O
in	O
the	O
intensive	O
therapy	O
unit	O
are	O
described	O
.	O

At	O
physiological	O
doses	O
,	O
either	O
insulin-like	B-GENE
growth	I-GENE
factor	I-GENE
I	I-GENE
(	O
IGF-I	B-GENE
)	O
or	O
insulin	B-GENE
turned	O
out	O
to	O
be	O
as	O
potent	O
as	O
dibutyryl	O
cAMP	O
(	O
dbcAMP	O
)	O
in	O
increasing	O
UCP1	B-GENE
gene	I-GENE
transcription	O
rate	O
(	O
1	O
h	O
)	O
and	O
also	O
UCP1	B-GENE
mRNA	I-GENE
accumulation	O
(	O
3	O
h	O
)	O
,	O
their	O
maximal	O
effect	O
(	O
15-fold	O
increase	O
)	O
reached	O
upon	O
treatment	O
for	O
24	O
h	O
.	O

However	O
,	O
the	O
increase	O
in	O
biliary	O
excretion	O
did	O
not	O
compensate	O
for	O
the	O
reduced	O
elimination	O
of	O
bretylium	O
and	O
hexylsalicylic	O
acid	O
via	O
the	O
kidney	O
.	O

Therefore	O
,	O
the	O
positive	O
cAMP	O
control	O
of	O
the	O
hypoxic	O
SRP1	B-GENE
and	O
HEM13	B-GENE
genes	I-GENE
was	O
uncoupled	O
from	O
the	O
HOG	O
pathway	O
.	O

Auditory	O
threshold	O
shifts	O
,	O
as	O
measured	O
by	O
the	O
auditory	O
evoked	O
brainstem	O
response	O
,	O
were	O
measured	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
20	O
and	O
24	O
kHz	O
.	O

The	O
hybridizing	O
clone	O
of	O
V	O
.	O
vulnificus	O
chromosomal	O
DNA	O
complemented	O
a	O
V	B-GENE
.	I-GENE
cholerae	I-GENE
fur	I-GENE
mutant	I-GENE
.	O

Furthermore	O
,	O
RING1	B-GENE
overexpression	O
results	O
in	O
enhanced	O
expression	O
of	O
the	O
proto-oncogenes	O
c-jun	B-GENE
and	O
c-fos	B-GENE
.	O

TPTA	O
produced	O
brain	O
congestion	O
,	O
and	O
hepatic	O
and	O
pulmonary	O
petechial	O
and	O
generalized	O
hemorrhages	O
.	O

A	O
patient	O
with	O
an	O
infected	O
wound	O
or	O
one	O
on	O
a	O
primary	O
area	O
(	O
hands	O
,	O
feet	O
,	O
face	O
,	O
or	O
perineum	O
)	O
may	O
have	O
to	O
be	O
hospitalized	O
to	O
ensure	O
proper	O
care	O
.	O

STUDY	O
DESIGN	O
:	O
Fine	O
needle	O
aspiration	O
cytologic	O
smears	O
from	O
21	O
cases	O
of	O
invasive	O
lobular	O
carcinoma	O
(	O
ILC	O
)	O
of	O
breast	O
were	O
subjected	O
to	O
detailed	O
cytomorphologic	O
analysis	O
.	O

Detection	O
of	O
exercise-induced	O
asynergy	O
by	O
M-mode	O
echocardiography	O
.	O

Twenty-one	O
ELISA-positive	O
sera	O
were	O
tested	O
and	O
confirmed	O
positive	O
by	O
plaque	O
reduction	O
neutralization	O
testing	O
.	O

We	O
have	O
reviewed	O
the	O
experience	O
of	O
a	O
major	O
MMT	O
general	O
practice	O
with	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
from	O
1991	O
to	O
1995	O
.	O

An	O
intralobar	O
change	O
in	O
temperature	O
above	O
or	O
below	O
36	O
degrees	O
C	O
decreases	O
only	O
the	O
lobar	O
bronchial	O
blood	O
flow	O
and	O
does	O
not	O
influence	O
blood	O
flow	O
to	O
other	O
nearby	O
tissues	O
including	O
those	O
vascularized	O
by	O
the	O
bronchial	O
circulation	O
.	O

The	O
cloned	O
HindIII	B-GENE
fragment	I-GENE
,	O
which	O
was	O
shown	O
by	O
DNA	O
sequence	O
analysis	O
to	O
encode	O
the	O
N-terminal	O
half	O
of	O
the	O
B	B-GENE
.	I-GENE
subtilis	I-GENE
IF2	I-GENE
protein	I-GENE
and	O
0	O
.	O
2	O
kb	O
of	O
upstream	O
flanking	O
sequence	O
,	O
was	O
utilized	O
as	O
a	O
homologous	O
probe	O
to	O
clone	O
an	O
overlapping	O
2	B-GENE
.	I-GENE
76-kb	I-GENE
ClaI	I-GENE
chromosomal	I-GENE
fragment	I-GENE
containing	O
the	O
entire	B-GENE
IF2	I-GENE
structural	I-GENE
gene	I-GENE
.	O

The	O
5'flanking	O
region	O
is	O
highly	O
GC	O
rich	O
,	O
with	O
multiple	O
CpG	O
doublets	O
,	O
and	O
contains	O
multiple	O
binding	O
sites	O
for	O
Sp1	B-GENE
.	O

HTLV-1	O
decreases	O
Th2	O
type	O
of	O
immune	O
response	O
in	O
patients	O
with	O
strongyloidiasis	O
.	O

The	O
gene	O
product	O
of	O
cotS	B-GENE
was	O
confirmed	O
to	O
be	O
identical	O
to	O
Cot40-2	B-GENE
by	O
SDS-PAGE	O
and	O
immunoblotting	O
from	O
Escherichia	O
coli	O
transformed	O
with	O
a	O
plasmid	O
containing	O
the	O
cotS	B-GENE
region	I-GENE
.	O

All	O
four	O
of	O
the	O
genes	O
have	O
a	O
similar	O
structure	O
,	O
with	O
the	O
receptor	O
protein	O
encoded	O
in	O
a	O
single	O
exon	O
.	O

During	O
surgery	O
bone	O
cysts	O
were	O
excised	O
and	O
filled	O
by	O
bone	O
grafts	O
.	O

Presentation	O
of	O
a	O
horse	B-GENE
cytochrome	I-GENE
c	I-GENE
peptide	I-GENE
by	O
multiple	O
H-2b	B-GENE
class	I-GENE
I	I-GENE
major	I-GENE
histocompatibility	I-GENE
complex	I-GENE
(	O
MHC	B-GENE
)	O
molecules	O
to	O
C57BL	O
/	O
6-	O
and	O
bm1-derived	O
cytotoxic	O
T	O
lymphocytes	O
:	O
presence	O
of	O
a	O
single	O
MHC	B-GENE
anchor	I-GENE
residue	I-GENE
may	O
confer	O
efficient	O
peptide-specific	O
CTL	O
recognition	O
.	O

The	O
major	O
myosin-binding	B-GENE
domain	I-GENE
of	O
skeletal	B-GENE
muscle	I-GENE
MyBP-C	I-GENE
(	O
C	B-GENE
protein	I-GENE
)	O
resides	O
in	O
the	O
COOH-terminal	O
,	O
immunoglobulin	B-GENE
C2	B-GENE
motif	I-GENE
.	O

The	O
differences	O
in	O
the	O
CPIgG	B-GENE
,	O
CRP	B-GENE
,	O
and	O
fibrinogen	B-GENE
levels	O
in	O
patients	O
who	O
were	O
diagnosed	O
with	O
ACS	O
versus	O
those	O
who	O
were	O
not	O
(	O
non-ACS	O
)	O
were	O
evaluated	O
.	O

FTF	B-GENE
is	O
also	O
abundantly	O
expressed	O
in	O
the	O
pancreas	O
and	O
may	O
exert	O
differentiation	O
functions	O
in	O
endodermal	O
sublineages	O
,	O
similar	O
to	O
SF-1	B-GENE
in	O
steroidogenic	O
tissues	O
.	O

The	O
2	O
cDNAs	O
differed	O
in	O
the	O
length	O
of	O
their	O
respective	O
3'	O
untranslated	O
regions	O
,	O
of	O
577	O
bp	O
in	O
Cp	B-GENE
.	I-GENE
F6	I-GENE
and	O
72	O
bp	O
in	O
Cp	B-GENE
.	I-GENE
F10	I-GENE
,	O
in	O
both	O
of	O
which	O
a	O
putative	O
polyadenylation	O
signal	O
was	O
identified	O
.	O

Iron	O
and	O
folate	O
deficiency	O
in	O
pregnancy	O
.	O

In	O
the	O
first	O
part	O
of	O
our	O
study	O
,	O
the	O
highest	O
mutagenicity	O
was	O
revealed	O
by	O
TA98	O
strain	O
without	O
enzymatic	O
activation	O
,	O
suggesting	O
a	O
direct-acting	O
mutagenicity	O
prevalence	O
in	O
diesel	O
particulate	O
.	O

However	O
,	O
excretion	O
of	O
6-keto-prostaglandin	O
F1	O
alpha	O
was	O
further	O
reduced	O
in	O
the	O
smokers	O
who	O
used	O
oral	O
contraceptives	O
(	O
133	O
+	O
/	O
-	O
20	O
to	O
86	O
+	O
/	O
-	O
9	O
ng	O
/	O
gm	O
of	O
creatinine	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

R-wave	O
voltage	O
in	O
the	O
right	O
precordial	O
leads	O
in	O
anthracycline	O
cardiomyopathy	O
:	O
a	O
clinical	O
study	O
.	O

A	O
single	O
NMSC	O
was	O
present	O
in	O
69	O
.	O
4%	O
,	O
two	O
in	O
16%	O
,	O
three	O
in	O
6	O
.	O
4%	O
,	O
four	O
in	O
3	O
.	O
5%	O
,	O
five	O
to	O
nine	O
in	O
4	O
.	O
2%	O
,	O
and	O
0	O
.	O
5%	O
had	O
ten	O
or	O
more	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
overexpressed	O
Kex2p	B-GENE
using	O
the	O
baculovirus	O
/	O
insect	O
cell	O
expression	O
system	O
.	O

Basal	O
promoter	O
activity	O
is	O
enhanced	O
by	O
a	O
functional	O
M1	B-GENE
domain	I-GENE
in	O
LHR-expressing	O
mouse	O
Leydig	O
tumor	O
cells	O
(	O
MLTC	O
)	O
but	O
not	O
in	O
non-expressing	O
CHO	O
cells	O
.	O

In	O
contrast	O
,	O
no	O
change	O
was	O
detected	O
in	O
the	O
phenotype	O
of	O
'unstressed'	O
clones	O
,	O
with	O
respect	O
to	O
any	O
of	O
the	O
following	O
parameters	O
:	O
proliferation	O
rate	O
in	O
monolayer	O
,	O
serum-dependence	O
for	O
proliferation	O
or	O
survival	O
,	O
tumorigenicity	O
,	O
cellular	O
morphology	O
,	O
or	O
tissue-specific	O
differentiation	O
markers	O
.	O

In	O
vitro	O
penetration	O
tests	O
of	O
human	O
sperm	O
into	O
cervical	O
mucus	O
were	O
introduced	O
in	O
order	O
to	O
study	O
the	O
interaction	O
between	O
sperm	O
and	O
cervical	O
mucus	O
.	O

The	O
concentration	O
of	O
PGI2	O
on	O
the	O
newly-formed	O
luminal	O
surface	O
remained	O
low	O
.	O

The	O
most	O
important	O
risk	O
factors	O
are	O
:	O
1	O
)	O
genetic	O
;	O
2	O
)	O
Epstein-Barr	O
virus	O
(	O
infectious	O
mononucleosis	O
)	O
;	O
3	O
)	O
congenital	O
and	O
acquired	O
immunodeficiency	O
;	O
4	O
)	O
occupational	O
exposure	O
(	O
the	O
wood	O
industry	O
)	O
.	O

Urinary	O
urate	O
excretion	O
,	O
urate	O
clearance	O
,	O
and	O
fractional	O
excretion	O
of	O
urate	O
all	O
increased	O
significantly	O
during	O
water	O
immersion	O
,	O
and	O
decreased	O
in	O
the	O
hour	O
following	O
water	O
immersion	O
.	O

Statistically	O
significant	O
effects	O
were	O
noted	O
at	O
doses	O
which	O
did	O
not	O
appear	O
to	O
be	O
maternally	O
toxic	O
.	O

Recently	O
,	O
a	O
human	B-GENE
transcription	I-GENE
elongation	I-GENE
factor	I-GENE
P-TEFb	I-GENE
,	O
consisting	O
of	O
CDK9	B-GENE
kinase	I-GENE
,	O
cyclin	B-GENE
T	I-GENE
and	O
other	O
associated	O
factors	O
,	O
has	O
been	O
shown	O
to	O
interact	O
with	O
Tat	B-GENE
to	O
restore	O
Tat	B-GENE
activation	O
in	O
HeLa	O
nuclear	O
extract	O
depleted	O
of	O
P-TEFb	B-GENE
.	O

Following	O
the	O
injection	O
of	O
PGF2	B-GENE
alpha	I-GENE
,	O
heifers	O
were	O
observed	O
visually	O
for	O
signs	O
of	O
estrus	O
at	O
0730	O
and	O
1630	O
(	O
45	O
min	O
each	O
)	O
.	O

ECP	B-GENE
and	O
tryptase	B-GENE
levels	O
in	O
serum	O
were	O
measured	O
before	O
and	O
after	O
the	O
last	O
oral	O
challenge	O
.	O

The	O
combination	O
of	O
F1	O
and	O
F2	O
which	O
was	O
the	O
best	O
predictor	O
of	O
CHD	O
in	O
this	O
population	O
(	O
G1	O
)	O
might	O
be	O
interpreted	O
as	O
reflecting	O
trunk	O
adiposity	O
mainly	O
abdominal	O
.	O

Other	O
therapies	O
are	O
also	O
available	O
,	O
including	O
hypertonic	O
saline	O
solution	O
,	O
THAM	O
(	O
Tris-hydroxy-methyl-aminomethane	O
)	O
buffer	O
,	O
and	O
high-dose	O
barbiturates	O
.	O

Mean+	O
/	O
-SD	O
serum	B-GENE
VEGF	I-GENE
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
women	O
with	O
PCO	O
and	O
PCOS	O
(	O
3	O
.	O
4+	O
/	O
-0	O
.	O
7	O
and	O
3	O
.	O
2+	O
/	O
-0	O
.	O
66	O
ng	O
/	O
ml	O
respectively	O
)	O
compared	O
with	O
women	O
with	O
normal	O
ovaries	O
(	O
2	O
.	O
3+	O
/	O
-0	O
.	O
5	O
ng	O
/	O
ml	O
)	O
.	O

During	O
V-A	O
bypass	O
,	O
hemodynamics	O
were	O
stable	O
.	O

However	O
,	O
a	O
zinc-depleted	O
enzyme	O
was	O
obtained	O
after	O
prolonged	O
dialysis	O
against	O
the	O
specific	O
chelating	O
agent	O
1	O
,	O
10-phenanthroline	O
.	O

This	O
indicates	O
that	O
lipid	O
peroxidation	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
senile	O
cataract	O
and	O
,	O
as	O
a	O
direct	O
consequence	O
of	O
retinal	O
damage	O
,	O
also	O
in	O
the	O
pathogenesis	O
of	O
cataract	O
in	O
diabetes	O
and	O
in	O
severe	O
myopia	O
.	O

Major	O
clinical	O
symptoms	O
of	O
the	O
disease	O
were	O
defined	O
in	O
this	O
group	O
of	O
patients	O
.	O

The	O
effect	O
of	O
dietary	O
zinc	O
deficiency	O
on	O
the	O
mossy	O
fiber	O
zinc	O
content	O
of	O
the	O
rat	O
hippocampus	O
.	O

To	O
investigate	O
the	O
functions	O
of	O
GE	O
,	O
IG	O
,	O
and	O
GS	O
sequences	O
in	O
transcription	O
,	O
we	O
constructed	O
plasmids	O
containing	O
cDNAs	O
of	O
the	O
full-length	O
SV5	O
genome	O
in	O
which	O
the	O
gene	O
junction	O
sequences	O
(	O
GE	O
,	O
IG	O
,	O
and	O
GS	O
sequences	O
)	O
located	O
between	O
the	O
hemagglutinin-neuraminidase	B-GENE
(	O
HN	B-GENE
)	O
and	O
the	O
polymerase	B-GENE
(	I-GENE
L	I-GENE
)	I-GENE
genes	I-GENE
were	O
replaced	O
with	O
the	O
counterpart	O
sequences	O
from	O
other	O
gene	O
junctions	O
.	O

Effect	O
of	O
tracheal	O
insufflation	O
of	O
deferoxamine	O
on	O
acute	O
ozone	O
toxicity	O
in	O
rats	O
.	O

nos-1	B-GENE
and	O
nos-2	B-GENE
,	O
two	O
genes	O
related	O
to	O
Drosophila	B-GENE
nanos	I-GENE
,	O
regulate	O
primordial	O
germ	O
cell	O
development	O
and	O
survival	O
in	O
Caenorhabditis	O
elegans	O
.	O

The	O
addition	O
of	O
an	O
equimolar	O
complex	O
of	O
the	O
fourth	O
and	O
seventh	O
largest	O
subunits	O
,	O
purified	O
from	O
pol	B-GENE
II	I-GENE
holoenzyme	I-GENE
by	O
ion-exchange	O
chromatography	O
in	O
the	O
presence	O
of	O
urea	O
,	O
restored	O
promoter-directed	O
initiation	O
activity	O
to	O
pol	B-GENE
II	I-GENE
delta	I-GENE
4	I-GENE
/	I-GENE
7	I-GENE
.	O

We	O
propose	O
that	O
TFOs	O
represent	O
a	O
therapeutic	O
potential	O
to	O
specifically	O
diminish	O
the	O
expression	O
of	O
c-sis	B-GENE
/	I-GENE
PDGF-B	I-GENE
proto-oncogene	I-GENE
in	O
various	O
pathologic	O
settings	O
where	O
constitutive	O
expression	O
of	O
this	O
gene	O
has	O
been	O
observed	O
.	O

We	O
found	O
that	O
the	O
3'-end-adjacent	O
sequence	O
CA	O
(	O
N	O
)	O
3-10AGTNNAA	O
,	O
conserved	O
in	O
plant	O
Pol	B-GENE
II-specific	I-GENE
U	I-GENE
snRNA	I-GENE
genes	I-GENE
,	O
is	O
essential	O
for	O
the	O
3'-end	O
formation	O
of	O
U2	B-GENE
transcripts	I-GENE
and	O
,	O
similar	O
to	O
the	O
vertebrate	O
3'	O
box	O
,	O
is	O
highly	O
tolerant	O
to	O
mutation	O
.	O

The	O
effectiveness	O
of	O
the	O
haemodialysate	O
Solcoseryl	O
for	O
second-intention	O
wound	O
healing	O
in	O
horses	O
and	O
ponies	O
.	O

In	O
addition	O
,	O
the	O
gcd1-101	B-GENE
mutation	I-GENE
suppressed	O
the	O
low	O
translational	O
efficiency	O
of	O
GCN4-lacZ	B-GENE
mRNA	I-GENE
observed	O
in	O
gcn2-	B-GENE
and	O
gcn3-	B-GENE
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
two	O
early	O
class	B-GENE
II	I-GENE
flagellar	I-GENE
genes	I-GENE
contained	O
in	O
the	O
orfX-fliP	B-GENE
locus	I-GENE
.	O

The	O
effect	O
of	O
the	O
fatty	B-GENE
acid	I-GENE
cyclo-oxygenase	I-GENE
inhibitor	O
indomethacin	O
on	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
and	O
the	O
metabolic	O
rate	O
for	O
oxygen	O
(	O
CMRO2	O
)	O
was	O
studied	O
in	O
paralyzed	O
and	O
artificially	O
ventilated	O
rats	O
.	O

From	O
February	O
1991	O
to	O
August	O
1997	O
,	O
124	O
patients	O
with	O
endometrial	O
carcinoma	O
were	O
treated	O
postoperatively	O
with	O
high-dose-rate	O
vaginal	O
vault	O
brachytherapy	O
as	O
the	O
only	O
adjuvant	O
treatment	O
.	O

Contingency	O
contracting	O
between	O
clients	O
and	O
their	O
parents	O
/	O
caregivers	O
was	O
used	O
to	O
specify	O
consequences	O
for	O
daily	O
self-monitoring	O
,	O
reduced	O
caloric	O
intake	O
,	O
weight	O
loss	O
,	O
and	O
exercise	O
.	O

The	O
ParaSight-F	O
test	O
alone	O
was	O
used	O
to	O
monitor	O
serum	O
antigen	O
levels	O
after	O
treatment	O
in	O
24	O
patients	O
.	O

The	O
expressed	O
G1-G2	B-GENE
bound	O
to	O
both	O
hyaluronan	O
and	O
link	B-GENE
protein	I-GENE
indicating	O
that	O
the	O
immunoglobulin-fold	B-GENE
motif	I-GENE
and	O
proteoglycan	O
tandem	O
repeat	O
loops	O
of	O
the	O
G1	B-GENE
domain	I-GENE
were	O
correctly	O
folded	O
.	O

Among	O
genes	O
induced	O
by	O
added	O
pMesogenin1	B-GENE
is	O
Xwnt-8	B-GENE
,	O
a	O
signaling	O
factor	O
that	O
induces	O
a	O
similar	O
repertoire	O
of	O
marker	O
genes	O
and	O
a	O
similar	O
cellular	O
phenotype	O
.	O

A	O
phylogenetic	O
tree	O
of	O
members	O
of	O
the	O
T2	B-GENE
/	I-GENE
S-RNase	I-GENE
superfamily	I-GENE
in	O
plants	O
was	O
obtained	O
.	O

Characterization	O
of	O
the	O
promoter	O
for	O
the	O
human	B-GENE
85	I-GENE
kDa	I-GENE
cytosolic	I-GENE
phospholipase	I-GENE
A2	I-GENE
gene	I-GENE
.	O

Gtx	B-GENE
mRNA	I-GENE
accumulates	O
in	O
parallel	O
with	O
the	O
RNAs	O
encoding	O
the	O
major	O
structural	O
proteins	O
of	O
myelin	O
,	O
myelin	B-GENE
basic	I-GENE
protein	I-GENE
(	O
MBP	B-GENE
)	O
,	O
and	O
proteolipid	B-GENE
protein	I-GENE
(	O
PLP	B-GENE
)	O
during	O
postnatal	O
brain	O
development	O
;	O
Gtx	B-GENE
mRNA	I-GENE
decreases	O
in	O
parallel	O
with	O
MBP	B-GENE
and	O
PLP	B-GENE
mRNAs	I-GENE
in	O
the	O
brains	O
of	O
myelin-deficient	O
rats	O
,	O
which	O
have	O
a	O
point	O
mutation	O
in	O
the	O
PLP	B-GENE
gene	I-GENE
.	O

Two	O
separate	O
NF1-binding	B-GENE
loci	I-GENE
were	O
also	O
found	O
in	O
the	O
equivalent	O
IE68	B-GENE
gene	I-GENE
of	O
HCMV	O
(	O
Towne	O
)	O
DNA	O
,	O
but	O
in	O
this	O
case	O
the	O
DNA	O
sequence	O
and	O
competition	O
filter	O
binding	O
experiments	O
indicated	O
a	O
maximum	O
of	O
only	O
four	O
to	O
five	O
consensus	O
binding	O
sites	O
encompassing	O
the	O
promoter-enhancer	O
region	O
.	O

The	O
second	O
patient	O
had	O
received	O
pituitary-derived	B-GENE
growth	I-GENE
hormone	I-GENE
for	O
treatment	O
of	O
growth	B-GENE
hormone	I-GENE
deficiency	O
,	O
secondary	O
to	O
a	O
third	O
ventricle	O
teratoma	O
,	O
exised	O
13	O
yr	O
earlier	O
.	O

The	O
shift	O
in	O
the	O
earliest	O
activation	O
site	O
after	O
administration	O
of	O
esmolol	O
was	O
compared	O
with	O
the	O
shift	O
after	O
RFA	O
.	O
The	O
heart	O
rate	O
at	O
rest	O
and	O
in	O
drug-free	O
state	O
ranged	O
between	O
95	O
and	O
125	O
beats	O
/	O
min	O
(	O
mean	O
99	O
+	O
/	O
-	O
14	O
beats	O
/	O
min	O
)	O
.	O

The	O
hypertension	O
with	O
elevated	O
PRA	O
,	O
however	O
,	O
was	O
resistant	O
to	O
the	O
angiotensin	B-GENE
II	I-GENE
(	O
AII	B-GENE
)	O
analog	O
[	O
Sar1	O
,	O
Ile8	O
]	O
ALL	O
.	O

Eight	O
patients	O
with	O
ARC	O
and	O
renal	O
failure	O
were	O
recently	O
evaluated	O
.	O

The	O
Escherichia	B-GENE
coli	I-GENE
tet-repressor	I-GENE
(	O
TetR	B-GENE
)	O
operator	O
system	O
was	O
used	O
to	O
develop	O
a	O
variation	O
of	O
the	O
yeast	O
two-hybrid	O
assay	O
in	O
which	O
disruptions	O
of	O
protein-protein	O
interactions	O
can	O
be	O
identified	O
by	O
a	O
positive	O
selection	O
.	O

Western	O
blotting	O
(	O
immunoblotting	O
)	O
with	O
an	O
antiserum	O
to	O
a	O
partial	O
SOD	B-GENE
expressed	O
in	O
Escherichia	O
coli	O
revealed	O
two	O
proteins	O
with	O
estimated	O
molecular	O
masses	O
of	O
19	O
and	O
29	O
kDa	O
.	O

D	O
.	O

Determination	O
of	O
an	O
RNA	O
structure	O
involved	O
in	O
splicing	O
inhibition	O
of	O
a	O
muscle-specific	O
exon	O
.	O

The	O
authors	O
report	O
the	O
clinicopathologic	O
findings	O
in	O
four	O
cases	O
of	O
adult	O
women	O
with	O
rhabdomyosarcomas	O
that	O
originated	O
in	O
the	O
endometrium	O
or	O
cervix	O
,	O
or	O
both	O
.	O

A	O
total	O
of	O
112	O
patients	O
received	O
anistreplase	O
and	O
119	O
received	O
heparin	O
within	O
a	O
mean	O
period	O
of	O
188	O
+	O
/	O
-	O
62	O
min	O
following	O
the	O
onset	O
of	O
symptoms	O
.	O

Unlike	O
wild-type	B-GENE
p53	I-GENE
,	O
the	O
delta	B-GENE
proAE	I-GENE
mutant	I-GENE
cDNA	I-GENE
can	O
be	O
stably	O
expressed	O
in	O
tumor	O
derived	O
cell	O
lines	O
with	O
few	O
immediate	O
detrimental	O
effects	O
.	O

The	O
complete	O
exon-intron	O
structure	O
of	O
the	O
156-kb	B-GENE
human	I-GENE
gene	I-GENE
NFKB1	I-GENE
,	O
which	O
encodes	O
the	O
p105	B-GENE
and	O
p50	B-GENE
proteins	I-GENE
of	O
transcription	O
factors	O
NF-kappa	B-GENE
B	I-GENE
and	O
I	B-GENE
kappa	I-GENE
B-gamma	I-GENE
:	O
implications	O
for	O
NF-kappa	O
B-mediated	O
signal	O
transduction	O
.	O

The	O
platelet	O
adhesion	O
rate	O
on	O
these	O
layers	O
were	O
tested	O
concerning	O
the	O
valuation	O
of	O
the	O
haemocompatibility	O
of	O
the	O
basic-polymers	O
polyurethane	O
(	O
PUR	O
)	O
,	O
polyvinylchloride	O
(	O
PVC	O
)	O
,	O
and	O
polystyrene	O
(	O
PS	O
)	O
in	O
two	O
different	O
worked	O
test	O
chambers	O
.	O

Influence	O
of	O
compression	O
therapy	O
on	O
symptoms	O
following	O
soft	O
tissue	O
injury	O
from	O
maximal	O
eccentric	O
exercise	O
.	O

To	O
test	O
promotor	O
function	O
,	O
chimeric	O
genes	O
were	O
constructed	O
linking	O
fragments	O
of	O
chicken	O
IGF-I	B-GENE
5'-flanking	O
DNA	O
to	O
a	O
promoterless	O
reporter	O
plasmid	O
.	O

Here	O
,	O
we	O
identify	O
Rsc3	B-GENE
and	O
Rsc30	B-GENE
as	O
novel	O
components	O
of	O
the	O
essential	O
yeast	B-GENE
remodeler	I-GENE
RSC	I-GENE
complex	I-GENE
.	O

Urinary	O
LTE4	O
increased	O
after	O
both	O
challenges	O
the	O
rise	O
being	O
higher	O
following	O
oral	O
as	O
compared	O
to	O
inhalation	O
provocation	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

The	O
subepicardial	O
lymphatic	O
capillaries	O
were	O
ramified	O
and	O
anastomosed	O
with	O
each	O
other	O
to	O
form	O
a	O
relatively	O
dense	O
network	O
which	O
extended	O
over	O
the	O
entire	O
surface	O
of	O
both	O
ventricles	O
.	O

Recombination	O
and	O
transcription	O
of	O
the	O
endogenous	B-GENE
Ig	I-GENE
heavy	I-GENE
chain	I-GENE
locus	I-GENE
is	O
effected	O
by	O
the	O
Ig	B-GENE
heavy	I-GENE
chain	I-GENE
intronic	I-GENE
enhancer	I-GENE
core	I-GENE
region	I-GENE
in	O
the	O
absence	O
of	O
the	O
matrix	O
attachment	O
regions	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
locally-applied	O
TTC	O
in	O
combination	O
with	O
FDBA	O
enhances	O
new	O
bone	O
formation	O
in	O
experimental	O
alveolar	O
bone	O
defects	O
.	O

To	O
confirm	O
the	O
GapIII	B-GENE
protein	I-GENE
activity	O
,	O
constructs	O
containing	O
different	O
GapIII-GRD	B-GENE
domains	I-GENE
were	O
transformed	O
into	O
iral	O
mutant	O
yeast	O
to	O
determine	O
their	O
relative	O
ability	O
to	O
replace	O
IRA1	B-GENE
functionally	O
.	O

The	O
clinical	O
tolerance	O
and	O
pharmacokinetics	O
of	O
FCE	O
22101	O
(	O
sodium	O
(	O
5R	O
,	O
6S	O
)	O
-6-	O
[	O
(	O
1R	O
)	O
-hydroxyethyl	O
]	O
-2-carbamoyloxymethyl-2-penem-3-carboxylate	O
)	O
,	O
a	O
new	O
penem	O
antibiotic	O
,	O
have	O
been	O
studied	O
after	O
giving	O
a	O
single	O
i	O
.	O
v	O
.	O
dose	O
of	O
4	O
mg	O
.	O
kg-1	O
to	O
ten	O
healthy	O
male	O
volunteers	O
.	O

RESULTS	O
:	O
Acetabular	O
index	O
returned	O
to	O
normal	O
gradually	O
as	O
the	O
time	O
went	O
by	O
and	O
significantly	O
within	O
one	O
year	O
after	O
the	O
reduction	O
of	O
developmental	O
dislocation	O
of	O
the	O
hip	O
.	O

Growth	B-GENE
factor	I-GENE
stimulation	O
rapidly	O
induces	O
a	O
reversible	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
ternary	O
complex	O
,	O
accompanied	O
by	O
increased	O
phosphorylation	O
of	O
the	O
Elk-1	B-GENE
C-terminal	I-GENE
region	I-GENE
and	O
by	O
the	O
activation	O
of	O
a	O
42	B-GENE
kd	I-GENE
cellular	I-GENE
Elk-1	I-GENE
kinase	I-GENE
.	O

Inhibition	O
of	O
erythromycin	O
synthesis	O
by	O
disruption	O
of	O
malonyl-coenzyme	B-GENE
A	I-GENE
decarboxylase	I-GENE
gene	I-GENE
eryM	B-GENE
in	O
Saccharopolyspora	O
erythraea	O
.	O

This	O
experimental	O
design	O
was	O
used	O
to	O
determine	O
the	O
effect	O
of	O
displacement	O
of	O
the	O
alpha	B-GENE
4-2	I-GENE
binding	I-GENE
site	I-GENE
on	O
the	O
repression	O
of	O
alpha	B-GENE
4	I-GENE
gene	I-GENE
transcription	O
by	O
ICP4	B-GENE
.	O

We	O
analyzed	O
data	O
from	O
56	O
patients	O
with	O
Systemic	O
Lupus	O
Erythematosus	O
(	O
SLE	O
)	O
in	O
whom	O
renal	O
biopsies	O
were	O
done	O
systematically	O
.	O

We	O
have	O
screened	O
the	O
elastin	B-GENE
gene	I-GENE
for	O
mutations	O
responsible	O
for	O
supravalvular	O
aortic	O
stenosis	O
(	O
SVAS	O
)	O
in	O
two	O
large	O
,	O
independently	O
collected	O
families	O
with	O
isolated	O
(	O
nonsyndromic	O
)	O
SVAS	O
.	O

In	O
NASCIS	O
III	O
,	O
a	O
randomization	O
imbalance	O
occurred	O
that	O
allocated	O
a	O
disproportionate	O
number	O
of	O
patients	O
with	O
no	O
motor	O
deficit	O
(	O
and	O
therefore	O
no	O
chance	O
for	O
recovery	O
)	O
to	O
the	O
lower	O
dose	O
control	O
group	O
.	O

Southern	O
blotting	O
and	O
single	O
strand	O
conformation	O
polymorphism	O
analyses	O
did	O
not	O
show	O
tumor-specific	O
alterations	O
of	O
this	O
gene	O
in	O
gliomas	O
and	O
RT-PCR	O
studies	O
showed	O
expression	O
in	O
glioma	O
cell	O
lines	O
,	O
suggesting	O
that	O
ANOVA	B-GENE
is	O
not	O
the	O
chromosome	O
19q	O
glioma	O
tumor	O
suppressor	O
gene	O
.	O

The	O
backbone	O
dynamics	O
of	O
residues	O
located	O
in	O
the	O
folded	O
part	O
of	O
CRP2	B-GENE
(	I-GENE
LIM2	I-GENE
)	I-GENE
R122A	I-GENE
have	O
been	O
characterized	O
by	O
proton-detected	O
(	O
15	O
)	O
N	O
NMR	O
spectroscopy	O
.	O

In	O
protocol	O
2	O
,	O
eight	O
different	O
subjects	O
performed	O
Con	O
and	O
Ecc	O
arm	O
curls	O
to	O
fatigue	O
,	O
followed	O
by	O
postexercise	O
muscle	O
ischemia	O
,	O
by	O
using	O
the	O
same	O
resistance	O
as	O
in	O
protocol	O
1	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
cholesteryl	O
ester	O
transfer	O
(	O
CET	O
)	O
,	O
cholesteryl	B-GENE
ester	I-GENE
transfer	I-GENE
protein	I-GENE
(	O
CETP	B-GENE
)	O
activity	O
,	O
and	O
phospholipid	B-GENE
transfer	I-GENE
protein	I-GENE
(	O
PLTP	B-GENE
)	O
activity	O
in	O
the	O
increased	O
prevalence	O
of	O
coronary	O
artery	O
calcification	O
(	O
CAC	O
)	O
in	O
diabetic	O
subjects	O
compared	O
with	O
nondiabetic	O
subjects	O
and	O
in	O
the	O
loss	O
of	O
the	O
sex	O
difference	O
in	O
CAC	O
in	O
diabetes	O
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
the	O
differential	O
utilization	O
of	O
Staf	B-GENE
zinc	I-GENE
finger	I-GENE
1	I-GENE
represents	O
a	O
new	O
,	O
critical	O
determinant	O
of	O
the	O
transcriptional	O
activation	O
mechanism	O
for	O
the	O
Xenopus	B-GENE
tRNA	I-GENE
(	I-GENE
Sec	I-GENE
)	I-GENE
and	O
human	B-GENE
U6	I-GENE
snRNA	I-GENE
genes	I-GENE
.	O

The	O
corresponding	O
gene	O
was	O
identified	O
in	O
the	O
GenBankTM	O
data	O
base	O
by	O
sequence	O
alignment	O
and	O
termed	O
RPS30A	B-GENE
.	O

Southern	O
blot	O
analysis	O
of	O
endonuclease-digested	O
genomic	O
DNA	O
from	O
primary	O
chick	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
suggested	O
that	O
MEK2	B-GENE
is	O
a	O
single-copy	O
gene	O
in	O
this	O
vertebrate	O
species	O
.	O

The	O
members	O
of	O
the	O
Myb	B-GENE
family	I-GENE
of	I-GENE
transcription	I-GENE
factors	I-GENE
are	O
defined	O
by	O
homology	O
in	O
the	O
DNA-binding	O
domain	O
;	O
all	O
bind	O
the	O
Myb-binding	B-GENE
site	I-GENE
(	O
MBS	B-GENE
)	O
sequence	O
(	O
YG	B-GENE
(	I-GENE
A	I-GENE
/	I-GENE
G	I-GENE
)	I-GENE
C	I-GENE
(	I-GENE
A	I-GENE
/	I-GENE
C	I-GENE
/	I-GENE
G	I-GENE
)	I-GENE
GTT	I-GENE
(	I-GENE
G	I-GENE
/	I-GENE
A	I-GENE
)	I-GENE
)	I-GENE
.	O

The	O
predominant	O
binding	O
activity	O
was	O
not	O
Ets-1	B-GENE
but	O
rather	O
two	O
independent	O
DNA-protein	O
complexes	O
that	O
comigrated	O
in	O
mobility	O
shift	O
assays	O
.	O

(	O
i	O
)	O
Complete	O
Grb10	B-GENE
expression	O
from	O
cDNA	O
with	O
an	O
ecdysone-regulated	O
transient	O
expression	O
system	O
stimulated	O
PDGF-BB-	O
,	O
IGF-I	B-GENE
,	O
and	O
insulin-	O
but	O
not	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
(	O
EGF	B-GENE
)	O
-induced	O
DNA	O
synthesis	O
in	O
an	O
ecdysone	O
dose-responsive	O
fashion	O
.	O

Chronic	O
E-B	O
virus	O
infection	O
terminated	O
in	O
malignant	O
lymphoma	O
:	O
a	O
case	O
report	O
.	O

High	O
plasma	B-GENE
AVP	I-GENE
levels	O
observed	O
in	O
the	O
two	O
cases	O
suggest	O
that	O
SSRIs	O
stimulate	O
AVP	B-GENE
secretion	O
,	O
thereby	O
causing	O
SIADH	O
.	O

These	O
data	O
indicate	O
a	O
functional	O
role	O
for	O
U1	B-GENE
in	O
NRS-mediated	O
splicing	O
inhibition	O
.	O

Based	O
on	O
subcellular	O
fractionation	O
,	O
the	O
47-kDa	B-GENE
P-CIP2	I-GENE
protein	I-GENE
is	O
mostly	O
cytosolic	O
.	O

Role	O
of	O
c-myc	B-GENE
in	O
simian	O
virus	O
40	O
large	O
tumor	O
antigen-induced	O
DNA	O
synthesis	O
in	O
quiescent	O
3T3-L1	O
mouse	O
fibroblasts	O
.	O

Binding	O
of	O
cell	O
type-specific	O
nuclear	O
proteins	O
to	O
the	O
5'-flanking	O
region	O
of	O
maize	B-GENE
C4	I-GENE
phosphoenolpyruvate	I-GENE
carboxylase	I-GENE
gene	I-GENE
confers	O
its	O
differential	O
transcription	O
in	O
mesophyll	O
cells	O
.	O

With	O
histology	O
and	O
Evans	O
blue	O
injections	O
,	O
blood-brain	O
barrier	O
alterations	O
were	O
seen	O
as	O
early	O
as	O
4	O
days	O
after	O
a	O
dose	O
of	O
50	O
Gy	O
.	O

The	O
identity	O
between	O
hnRNPs	B-GENE
H	I-GENE
and	O
H'	B-GENE
is	O
96%	O
,	O
between	O
H	B-GENE
and	O
F	B-GENE
78%	O
,	O
and	O
between	O
H'	B-GENE
and	O
F	B-GENE
75%	O
,	O
respectively	O
.	O

Jkappa	B-GENE
DNA-binding	I-GENE
sites	I-GENE
were	O
not	O
required	O
for	O
this	O
activation	O
,	O
and	O
a	O
mutant	B-GENE
EBNA-3C	I-GENE
protein	I-GENE
unable	O
to	O
bind	O
Jkappa	B-GENE
activated	O
transcription	O
as	O
efficiently	O
as	O
wild-type	B-GENE
EBNA-3C	I-GENE
,	O
indicating	O
that	O
EBNA-3C	B-GENE
can	O
regulate	O
transcription	O
through	O
a	O
mechanism	O
that	O
is	O
independent	O
of	O
Jkappa	B-GENE
.	O

As	O
pH	O
and	O
Hb	B-GENE
can	O
also	O
affect	O
mixed	O
venous	O
CO2	O
content	O
,	O
the	O
effect	O
on	O
Q	O
was	O
also	O
assessed	O
.	O

Upon	O
UV	O
damage	O
,	O
Crb2	B-GENE
is	O
transiently	O
modified	O
,	O
probably	O
phosphorylated	O
,	O
with	O
a	O
similar	O
timing	O
of	O
phosphorylation	O
in	O
Chk1	B-GENE
kinase	I-GENE
,	O
which	O
is	O
reported	O
to	O
restrain	O
Cdc2	B-GENE
activation	O
.	O

CONCLUSION	O
:	O
This	O
retrospective	O
analysis	O
does	O
not	O
confirm	O
the	O
efficacy	O
of	O
one	O
course	O
of	O
simultaneous	O
Mitomycin-C	O
and	O
5-fluorouracil	O
,	O
at	O
least	O
in	O
association	O
with	O
full-dose	O
radiotherapy	O
incorporating	O
Iridium-192	O
boost	O
.	O

Furthermore	O
,	O
ICER	B-GENE
negatively	O
autoregulates	O
the	O
alternative	O
promoter	O
,	O
thus	O
generating	O
a	O
feedback	O
loop	O
.	O

Consistent	O
with	O
this	O
similarity	O
,	O
the	O
cdc28-P8	B-GENE
mutant	I-GENE
accumulates	O
unspliced	O
precursors	O
at	O
the	O
restrictive	O
temperature	O
.	O

Cotransfection	O
of	O
Ets-2	B-GENE
and	O
p44	B-GENE
mitogen-activated	B-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
expression	O
vectors	O
strongly	O
potentiated	O
HB-EGF	B-GENE
promoter	I-GENE
activation	O
in	O
response	O
to	O
deltaRaf-1	B-GENE
:	I-GENE
ER	I-GENE
.	O

A	O
reduction	O
in	O
blood	O
pressure	O
was	O
only	O
observed	O
at	O
the	O
end	O
of	O
the	O
study	O
,	O
from	O
142	O
+	O
/	O
-	O
17	O
/	O
86	O
.	O
6	O
+	O
/	O
-	O
9	O
.	O
1	O
to	O
139	O
+	O
/	O
-	O
13	O
/	O
82	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
9	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
DBP	O
)	O
.	O

With	O
chemical	O
shift	O
imaging	O
,	O
the	O
signal	O
intensity	O
decreased	O
on	O
the	O
out-of-phase	O
images	O
in	O
six	O
of	O
seven	O
(	O
86%	O
)	O
patients	O
with	O
APA	O
and	O
in	O
eight	O
of	O
nine	O
(	O
89%	O
)	O
patients	O
with	O
BAH	O
.	O

Creatine	B-GENE
kinase	I-GENE
release	O
after	O
hepatic	O
artery	O
embolization	O
in	O
patients	O
with	O
carcinoid	O
tumors	O
.	O

BACKGROUND	O
:	O
Ischemic	O
heart	O
disease	O
is	O
the	O
primary	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
diabetics	O
,	O
especially	O
those	O
who	O
became	O
ill	O
at	O
a	O
young	O
age	O
.	O

SRE	O
activity	O
is	O
dependent	O
upon	O
the	O
activation	O
by	O
phosphorylation	O
of	O
a	O
ternary	O
complex	O
factor	O
;	O
included	O
among	O
the	O
ternary	O
complex	O
factors	O
is	O
Elk-1	B-GENE
.	O

Significantly	O
,	O
two	O
proximal	O
GATA-1-binding	B-GENE
sites	I-GENE
(	O
-118	O
/	O
-113	O
and	O
-98	O
/	O
-93	O
)	O
and	O
a	O
region	O
located	O
within	O
-518	O
to	O
-315bp	O
of	O
the	O
mouse	B-GENE
ALAS2	I-GENE
promoter	I-GENE
were	O
essential	O
for	O
transcriptional	O
activation	O
during	O
chemically	O
induced	O
differentiation	O
of	O
MEL	O
cells	O
,	O
implying	O
their	O
importance	O
in	O
conferring	O
erythroid	O
specificity	O
to	O
the	O
ALAS2	B-GENE
transcriptional	O
activation	O
.	O

The	O
p73pct1	B-GENE
/	I-GENE
p85cdc10	I-GENE
complex	I-GENE
binds	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
to	O
MCB	B-GENE
but	O
not	O
SCB	B-GENE
or	O
E2F	B-GENE
sites	I-GENE
.	O

Transient	O
expression	O
of	O
VSF-1	B-GENE
in	O
protoplasts	O
stimulated	O
vs-1	B-GENE
dependent	O
activation	O
of	O
the	O
-76	B-GENE
/	I-GENE
grp1	I-GENE
.	I-GENE
8	I-GENE
minimal	I-GENE
promoter	I-GENE
.	O

To	O
analyze	O
the	O
VH	B-GENE
regions	I-GENE
of	O
polyreactive	O
antibodies	O
,	O
with	O
particular	O
attention	O
at	O
their	O
somatically	O
mutated	O
status	O
,	O
we	O
generated	O
five	O
IgG	B-GENE
(	O
three	O
IgG1	B-GENE
and	O
two	O
IgG3	B-GENE
)	O
mAb	O
(	O
using	O
B	O
cells	O
from	O
a	O
healthy	O
subject	O
,	O
a	O
patient	O
with	O
insulin-dependent	O
diabetes	O
mellitus	O
and	O
a	O
patient	O
with	O
SLE	O
)	O
,	O
which	O
bound	O
with	O
various	O
efficiencies	O
a	O
number	O
of	O
different	O
self	O
and	O
foreign	O
Ag	O
.	O

Non-complement-dependent	O
sperm-immobilizing	O
activity	O
was	O
also	O
detected	O
in	O
the	O
cervical	O
mucus	O
of	O
several	O
patients	O
.	O

The	O
c-myc	B-GENE
/	I-GENE
TGF-alpha	I-GENE
HCCs	O
were	O
also	O
characterized	O
by	O
a	O
particularly	O
strong	O
expression	O
of	O
TGF-alpha	B-GENE
and	O
very	O
low	O
apoptotic	O
index	O
in	O
contrast	O
to	O
high	O
levels	O
of	O
apoptosis	O
in	O
peritumorous	O
tissues	O
and	O
c-myc	B-GENE
HCCs	O
.	O

The	O
primary	O
structure	O
of	O
each	O
of	O
the	O
three	O
proteins	O
has	O
about	O
70%	O
homology	O
with	O
that	O
of	O
mouse	B-GENE
contrapsin	I-GENE
,	O
in	O
contrast	O
to	O
43-46%	O
homology	O
with	O
that	O
of	O
rat	B-GENE
alpha	I-GENE
1-protease	I-GENE
inhibitor	O
.	O

Linear	O
extrapolation	O
is	O
used	O
below	O
the	O
experimental	O
data	O
range	O
to	O
establish	O
an	O
upper	O
bound	O
on	O
carcinogenic	O
risk	O
at	O
low	O
doses	O
.	O

This	O
study	O
was	O
performed	O
to	O
assess	O
the	O
role	O
of	O
additional	O
diagnostic	O
laparoscopy	O
in	O
the	O
preoperative	O
staging	O
of	O
patients	O
with	O
adenocarcinoma	O
of	O
the	O
esophagus	O
,	O
gastric	O
cancer	O
and	O
pancreatic	O
cancer	O
prior	O
to	O
intended	O
curative	O
surgery	O
.	O

Treatment	O
of	O
N18TG-2	O
cells	O
with	O
a	O
demethylating	O
agent	O
,	O
5-aza-deoxycytidine	O
,	O
resulted	O
in	O
an	O
expression	O
of	O
mlt	B-GENE
1	I-GENE
,	O
indicating	O
that	O
the	O
repression	O
of	O
mlt	B-GENE
1	I-GENE
is	O
attributable	O
to	O
methylation	O
Thus	O
,	O
mlt	B-GENE
1	I-GENE
is	O
a	O
novel	O
target	O
gene	O
that	O
is	O
silenced	O
by	O
methylation	O
during	O
liver	O
tumorigenesis	O
initiated	O
by	O
SV40	B-GENE
T	I-GENE
antigen	I-GENE
.	O

Of	O
these	O
carriers	O
149	O
were	O
diagnosed	O
to	O
be	O
asymptomatic	O
clinically	O
,	O
biochemically	O
and	O
echographically	O
.	O

Animals	O
were	O
put	O
to	O
death	O
8	O
weeks	O
later	O
and	O
the	O
grafts	O
were	O
sterilely	O
explanted	O
and	O
analyzed	O
via	O
microbiologic	O
culture	O
and	O
standard	O
histologic	O
procedures	O
for	O
evidence	O
of	O
infection	O
.	O

A	O
13	O
base-pair	O
oligonucleotide	O
spanning	O
nucleotides	O
+80	O
to	O
+92	O
of	O
the	O
5	B-GENE
S	I-GENE
RNA	I-GENE
gene	I-GENE
retained	O
specific	O
and	O
high-affinity	O
binding	O
,	O
although	O
the	O
latter	O
was	O
reduced	O
sixfold	O
relative	O
to	O
longer	O
DNA	O
fragments	O
.	O

(	O
1986	O
)	O
method	O
of	O
separation	O
of	O
Cryptosporidium	O
spp	O
.	O
oocysts	O
from	O
feces	O
by	O
using	O
a	O
percoll	O
discontinuous	O
density	O
gradient	O
appeared	O
a	O
method	O
of	O
choice	O
for	O
obtaining	O
large	O
numbers	O
of	O
oocysts	O
of	O
C	O
.	O
parvum	O
free	O
of	O
fecal	O
contamination	O
.	O

The	O
deduced	O
protein	O
sequence	O
is	O
characterized	O
by	O
a	O
putative	O
16-residue	O
amino-terminal	O
signal	O
peptide	O
that	O
is	O
cleaved	O
,	O
resulting	O
in	O
a	O
239-residue	O
polypeptide	O
.	O

The	O
relationships	O
between	O
the	O
partial	O
pressures	O
of	O
O2	O
and	O
CO2	O
as	O
well	O
as	O
between	O
their	O
gradients	O
,	O
become	O
stronger	O
with	O
the	O
increase	O
of	O
the	O
ventilation-perfusion	O
ratio	O
.	O

Two	O
promoters	O
were	O
identified	O
by	O
S1	B-GENE
nuclease	I-GENE
mapping	O
:	O
P1	O
,	O
which	O
lies	O
about	O
72	O
bp	O
upstream	O
from	O
the	O
structural	O
gene	O
;	O
and	O
P2	O
,	O
which	O
lies	O
about	O
35	O
bp	O
upstream	O
.	O

Multiple	O
regression	O
analyses	O
revealed	O
that	O
WAIS-R	O
factor	O
scores	O
Verbal	O
Comprehension	O
and	O
Freedom	O
from	O
Distractibility	O
accounted	O
for	O
up	O
to	O
42%	O
of	O
the	O
variance	O
in	O
WMS-R	O
and	O
CVLT	O
indices	O
.	O

The	O
second	O
transcriptional	O
unit	O
,	O
designated	O
UL26	B-GENE
.	I-GENE
5	I-GENE
,	O
predicted	O
to	O
specify	O
a	O
protein	O
of	O
329	O
amino	O
acids	O
,	O
encodes	O
the	O
family	B-GENE
35	I-GENE
proteins	I-GENE
;	O
it	O
is	O
transcribed	O
by	O
an	O
mRNA	O
which	O
initiates	O
at	O
approximately	O
nucleotide	O
+1000	O
of	O
the	O
UL26	B-GENE
transcription	O
initiation	O
site	O
and	O
is	O
translated	O
from	O
the	O
methionine	O
initiation	O
codon	O
located	O
at	O
position	O
+1099	O
of	O
the	O
UL26	B-GENE
transcriptional	I-GENE
unit	I-GENE
.	O

The	O
MSY2	B-GENE
associated	O
kinase	B-GENE
is	O
not	O
casein	B-GENE
kinase	I-GENE
2	I-GENE
,	O
the	O
kinase	B-GENE
believed	O
to	O
phosphorylate	O
mRNP3+4	B-GENE
in	O
oocytes	O
,	O
but	O
a	O
yet	O
unidentified	O
kinase	B-GENE
.	O

(	O
1997	O
)	O
Nature	O
387	O
,	O
370-376	O
)	O
]	O
,	O
we	O
suggest	O
that	O
the	O
metal	O
fluoride	O
ions	O
replaced	O
phosphate	O
at	O
the	O
two	O
ATP-binding	O
sites	O
of	O
the	O
iron	O
protein	O
,	O
Kp2	B-GENE
.	O

Only	O
one	O
gene	O
,	O
fibronectin	B-GENE
(	O
FN	B-GENE
)	O
,	O
was	O
highly	O
overexpressed	O
(	O
>	O
60-fold	O
)	O
in	O
LNCaP-r	O
cells	O
,	O
consistent	O
with	O
previously	O
reported	O
overexpression	O
of	O
FN	B-GENE
in	O
prostate	O
cancer	O
.	O

The	O
former	O
procedure	O
is	O
economical	O
but	O
complicated	O
,	O
whereas	O
the	O
latter	O
is	O
simple	O
and	O
labour-saving	O
,	O
but	O
a	O
special	O
ultrafiltration	O
tube	O
is	O
required	O
.	O

Rat	B-GENE
kidney	I-GENE
carboxylesterase	I-GENE
.	O

This	O
suggests	O
roles	O
for	O
both	O
the	O
CE1	B-GENE
and	O
CE2	B-GENE
elements	O
in	O
regulating	O
Hoxb1	B-GENE
gene	I-GENE
expression	O
during	O
development	O
.	O

The	O
human	B-GENE
insulin-like	I-GENE
growth	I-GENE
factor	I-GENE
II	I-GENE
(	O
IGF-II	B-GENE
)	O
gene	O
contains	O
four	O
promoters	O
(	O
P1	O
,	O
P2	O
,	O
P3	O
and	O
P4	O
)	O
.	O

The	O
symptoms	O
and	O
objective	O
findings	O
were	O
caused	O
by	O
a	O
malignant	O
lymphoma	O
,	O
and	O
the	O
diagnosis	O
was	O
established	O
from	O
a	O
drill	O
biopsy	O
.	O

The	O
cis-acting	O
element	O
,	O
identified	O
as	O
CACGTGACCCG	B-GENE
,	O
is	O
located	O
34	O
bp	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
,	O
and	O
contains	O
the	O
core	O
sequence	O
of	O
the	O
upstream	O
promoter	O
sequence	O
of	O
Ad2MLP	O
.	O

Two	O
techniques	O
based	O
on	O
assay	O
coefficients	O
of	O
variation	O
were	O
employed	O
to	O
characterize	O
a	O
normal	O
circadian	O
pattern	O
of	O
cortisol	O
.	O

This	O
interaction	O
is	O
mediated	O
by	O
the	O
SH2	B-GENE
domain	I-GENE
of	O
Crk	B-GENE
and	O
can	O
be	O
inhibited	O
with	O
a	O
phosphopeptide	O
containing	O
the	O
Crk-SH2	B-GENE
binding	I-GENE
motif	I-GENE
.	O

The	O
differences	O
among	O
subgenera	O
of	O
the	O
genus	O
Dermacentor	O
are	O
more	O
significant	O
.	O

Luteinizing	B-GENE
hormone-releasing	I-GENE
hormone	I-GENE
analog	O
therapy	O
of	O
uterine	O
fibroid	O
:	O
analysis	O
of	O
results	O
obtained	O
with	O
buserelin	O
administered	O
intranasally	O
and	O
goserelin	O
administered	O
subcutaneously	O
as	O
a	O
monthly	O
depot	O
.	O

Proteins	O
known	O
to	O
bind	O
the	O
PEPCK	B-GENE
CRE	B-GENE
include	O
the	O
CRE-binding	B-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
and	O
members	O
of	O
the	O
CCAAT	B-GENE
/	I-GENE
enhancer-binding	I-GENE
protein	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
)	O
family	O
.	O

RESULTS	O
:	O
Statistically	O
significant	O
differences	O
were	O
obtained	O
between	O
group	O
I	O
and	O
II	O
concerning	O
the	O
number	O
of	O
patients	O
in	O
whom	O
induced	O
atrial	O
fibrillation	O
with	O
conduction	O
by	O
the	O
accessory	O
pathway	O
and	O
RR	O
<	O
or	O
=	O
250	O
msec	O
was	O
found	O
(	O
0	O
vs	O
6	O
,	O
p	O
=	O
0	O
.	O
0045	O
)	O
.	O

Other	O
hemostatic	O
values	O
evaluated	O
were	O
activated	O
partial	O
thromboplastin	B-GENE
times	O
,	O
prothrombin	B-GENE
times	O
,	O
thrombin	B-GENE
times	O
,	O
fibrinogen	B-GENE
,	O
platelet	O
counts	O
,	O
and	O
fibrin	B-GENE
/	I-GENE
fibrinogen	I-GENE
degradation	O
products	O
.	O

The	O
human	O
gene	O
fragment	O
ligated	O
to	O
the	O
minimal	O
rat	O
liver	O
glucokinase	B-GENE
promoter	O
was	O
shown	O
to	O
work	O
as	O
an	O
enhancer	O
in	O
the	O
hepatocyte	O
transfection	O
system	O
.	O

Esophageal	O
brush	O
cytological	O
screening	O
was	O
undertaken	O
and	O
blood	O
concentrations	O
of	O
micronutrients	O
(	O
vitamin	O
A	O
,	O
E	O
,	O
B12	O
,	O
folic	O
acid	O
and	O
methionine	O
)	O
determined	O
from	O
adults	O
at	O
risk	O
for	O
esophageal	O
carcinoma	O
(	O
EC	O
)	O
in	O
Transkei	O
and	O
Ciskei	O
,	O
Southern	O
Africa	O
.	O

The	O
large	O
fluxes	O
of	O
239+240Pu	O
might	O
be	O
attributed	O
to	O
episodic	O
lateral	O
transport	O
of	O
particles	O
that	O
flow	O
down	O
the	O
continental	O
slope	O
with	O
the	O
nepheloid	O
layer	O
which	O
was	O
considered	O
to	O
be	O
significant	O
for	O
239+240Pu	O
transport	O
on	O
the	O
continental	O
slope	O
in	O
the	O
East	O
China	O
Sea	O
.	O

In	O
only	O
two	O
patients	O
were	O
we	O
able	O
to	O
demonstrate	O
changes	O
suggestive	O
of	O
pulmonary	O
metastases	O
any	O
earlier	O
with	O
a	O
99mTc-EHDP	O
scan	O
than	O
with	O
chest	O
radiographs	O
and	O
one	O
of	O
these	O
resolved	O
spontaneously	O
.	O

A	O
chimeric	B-GENE
VP16-Tat	I-GENE
construct	I-GENE
containing	O
the	O
leucine	O
mutations	O
showed	O
no	O
increased	O
AP-1	B-GENE
responsiveness	O
in	O
comparison	O
with	O
that	O
of	O
the	O
VP16	B-GENE
activation	I-GENE
domain	I-GENE
alone	O
.	O

An	O
examination	O
of	O
the	O
role	O
of	O
the	O
carboxyl	O
terminus	O
in	O
regulating	O
NGFI-B	B-GENE
transcriptional	O
activity	O
revealed	O
that	O
,	O
in	O
accordance	O
with	O
other	O
nuclear	O
receptors	O
,	O
mutants	O
lacking	O
portions	O
of	O
the	O
carboxyl	O
terminus	O
had	O
greatly	O
decreased	O
activity	O
.	O

They	O
were	O
then	O
subjected	O
to	O
whole-body	O
heat	O
stress	O
(	O
water-perfused	O
suits	O
)	O
,	O
and	O
the	O
3	O
minutes	O
of	O
LBNP	O
was	O
repeated	O
.	O

Preservatives	O
are	O
an	O
important	O
component	O
of	O
ophthalmic	O
preparations	O
,	O
providing	O
antimicrobial	O
activity	O
in	O
the	O
bottle	O
and	O
preventing	O
decomposition	O
of	O
active	O
drug	O
.	O

Vaccinia	O
virus	O
(	O
VV	O
)	O
is	O
a	O
potent	O
immunogen	O
,	O
but	O
the	O
nature	O
of	O
VV	O
proteins	O
involved	O
in	O
the	O
activation	O
of	O
the	O
immune	O
response	O
of	O
the	O
host	O
is	O
not	O
yet	O
known	O
.	O

Beta	B-GENE
1	I-GENE
integrin-	I-GENE
and	O
proteoglycan-mediated	O
stimulation	O
of	O
T	O
lymphoma	O
cell	O
adhesion	O
and	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
signaling	O
by	O
thrombospondin-1	B-GENE
and	O
thrombospondin-1	B-GENE
peptides	I-GENE
.	O

In	O
addition	O
,	O
an	O
mck1	B-GENE
mds1	B-GENE
mrk1	B-GENE
triple	O
disruptant	O
was	O
viable	O
.	O

Evaluation	O
of	O
antiepileptic	O
drug	O
effect	O
on	O
membrane	O
fluidity	O
.	O

One	O
defective	O
RNA	O
with	O
a	O
large	O
deletion	O
in	O
the	O
p70	B-GENE
coding	I-GENE
region	I-GENE
was	O
able	O
to	O
replicate	O
efficiently	O
,	O
both	O
when	O
inoculated	O
with	O
the	O
helper	O
genome	O
and	O
when	O
inoculated	O
with	O
a	O
second	O
complementing	O
defective	O
RNA	O
that	O
supplied	O
a	O
wild-type	B-GENE
p70	I-GENE
.	O

In	O
contrast	O
,	O
H-NS	B-GENE
negative	O
regulation	O
operated	O
only	O
in	O
the	O
absence	O
of	O
Fur	B-GENE
.	O

Although	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
regulation	O
are	O
currently	O
being	O
elucidated	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
trans-acting	O
factors	O
that	O
allow	O
expression	O
of	O
the	O
nitrate	B-GENE
and	I-GENE
nitrite	I-GENE
reductase	I-GENE
genes	I-GENE
which	O
code	O
for	O
the	O
first	O
enzymes	O
in	O
the	O
pathway	O
.	O

The	O
sequence	O
up	O
to	O
-267	O
bp	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
was	O
sufficient	O
to	O
enhance	O
reporter	O
gene	O
expression	O
depending	O
on	O
the	O
mesodermal	O
differentiation	O
of	O
P19	O
cells	O
.	O

In	O
this	O
article	O
,	O
the	O
clinical	O
actions	O
of	O
the	O
principal	O
dopamine	B-GENE
receptor	I-GENE
stimulating	O
agents	O
(	O
apomorphine	O
and	O
its	O
derivatives	O
;	O
piribedil	O
,	O
rye-ergot	O
derivatives	O
)	O
are	O
discussed	O
on	O
the	O
basis	O
of	O
their	O
biochemical	O
and	O
pharmacological	O
properties	O
.	O

To	O
address	O
these	O
questions	O
,	O
a	O
recombinant	B-GENE
FRAP	I-GENE
/	I-GENE
mTOR	I-GENE
protein	I-GENE
and	O
a	O
FRAP	B-GENE
/	I-GENE
mTOR	I-GENE
immunoprecipitate	O
were	O
utilized	O
in	O
in	O
vitro	O
kinase	B-GENE
assays	O
to	O
phosphorylate	O
4E-BP1	B-GENE
.	O

Here	O
we	O
report	O
the	O
cloning	O
,	O
expression	O
,	O
and	O
biochemical	O
characterization	O
of	O
the	O
32-kDa	O
subunit	O
of	O
human	O
(	O
h	O
)	O
TFIID	B-GENE
,	O
termed	O
hTAFII32	B-GENE
.	O

The	O
Scm	B-GENE
and	O
ph	B-GENE
proteins	O
share	O
a	O
homology	O
domain	O
with	O
38%	O
identity	O
over	O
a	O
length	O
of	O
65	O
amino	O
acids	O
,	O
termed	O
the	O
SPM	B-GENE
domain	I-GENE
,	O
that	O
is	O
located	O
at	O
their	O
respective	O
C	O
termini	O
.	O

Clb	B-GENE
/	I-GENE
Cdc28	I-GENE
kinases	I-GENE
promote	O
nuclear	O
export	O
of	O
the	O
replication	B-GENE
initiator	I-GENE
proteins	I-GENE
Mcm2-7	I-GENE
.	O

This	O
repression	O
was	O
reversed	O
agonists	O
of	O
either	O
receptor	O
demonstrating	O
a	O
functional	O
interaction	O
between	O
NCoR	B-GENE
and	O
PPARalpha	B-GENE
.	I-GENE
RXRalpha	I-GENE
heterodimeric	I-GENE
complexes	I-GENE
in	O
mammalian	O
cells	O
.	O

When	O
the	O
degree	O
of	O
exercise	O
was	O
maximal	O
,	O
mPAP	O
was	O
maintained	O
,	O
SVI	O
decreased	O
,	O
HR	O
was	O
unchanged	O
,	O
and	O
CO	O
and	O
VO2	O
decreased	O
.	O

Thus	O
,	O
the	O
association	O
of	O
PS1	B-GENE
fragments	I-GENE
may	O
be	O
maintained	O
during	O
cycles	O
of	O
phosphorylation	O
/	O
dephosphorylation	O
of	O
the	O
PS1	B-GENE
CTF	I-GENE
.	O

Microcomputer	O
management	O
of	O
chronic	O
hepatitis	O
B	O
virus	O
asymptomatic	O
patients	O
.	O

Four	O
casein	B-GENE
kinase	I-GENE
I	I-GENE
isoforms	I-GENE
are	O
differentially	O
partitioned	O
between	O
nucleus	O
and	O
cytoplasm	O
.	O

Furthermore	O
,	O
the	O
validity	O
of	O
this	O
new	O
subset	O
of	O
questions	O
was	O
shown	O
to	O
be	O
significant	O
(	O
r	O
=	O
0	O
.	O
037	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
the	O
correlation	O
between	O
a	O
measure	O
of	O
the	O
severity	O
of	O
binocular	O
visual	O
field	O
loss	O
and	O
the	O
mean	O
score	O
of	O
the	O
variables	O
used	O
in	O
the	O
glaucoma	O
specific	O
subgroup	O
of	O
questions	O
.	O

FASEB	O
Federal	O
Funding	O
Consensus	O
Conference	O
FY	O
2000	O
.	O

Azithromycin	O
is	O
a	O
new	O
generation	O
macrolide	O
antibiotic	O
with	O
unusual	O
and	O
favorable	O
pharmacokinetics	O
,	O
and	O
seems	O
to	O
be	O
a	O
very	O
promising	O
agent	O
for	O
innovative	O
anti-H	O
.	O
pylori	O
regimens	O
.	O

Based	O
on	O
this	O
analysis	O
,	O
we	O
propose	O
that	O
the	O
interactions	O
of	O
Sos	B-GENE
with	O
the	O
switch	O
1	O
and	O
switch	O
2	O
regions	O
of	O
Ras	B-GENE
have	O
distinct	O
functional	O
consequences	O
:	O
the	O
interaction	O
with	O
switch	O
2	O
mediates	O
the	O
anchoring	O
of	O
Ras	B-GENE
to	O
Sos	B-GENE
,	O
whereas	O
the	O
interaction	O
with	O
switch	O
1	O
leads	O
to	O
disruption	O
of	O
the	O
nucleotide-binding	O
site	O
and	O
GDP	O
dissociation	O
.	O

Peroxisome	B-GENE
proliferator-activated	I-GENE
receptors	I-GENE
(	O
PPARs	B-GENE
)	O
and	O
retinoid	B-GENE
X	I-GENE
receptors	I-GENE
(	O
RXRs	B-GENE
)	O
are	O
nuclear	O
hormone	O
receptors	O
that	O
are	O
activated	O
by	O
fatty	O
acids	O
and	O
9-cis-retinoic	O
acid	O
,	O
respectively	O
.	O

Chenodeoxycholic	O
acid	O
(	O
cheno	O
)	O
and	O
ursodeoxycholic	O
acid	O
(	O
urso	O
)	O
dissolve	O
cholesterol	O
gallstones	O
in	O
man	O
.	O

The	O
second	O
part	O
of	O
this	O
paper	O
shows	O
some	O
medical	O
applications	O
of	O
these	O
two	O
aspects	O
of	O
NMR	O
,	O
with	O
help	O
of	O
some	O
examples	O
,	O
taken	O
from	O
the	O
literature	O
,	O
according	O
to	O
what	O
is	O
concerned	O
with	O
endocrinology	O
.	O

However	O
,	O
D8	B-GENE
binding	O
was	O
observed	O
by	O
nuclease	B-GENE
protection	O
with	O
lactotroph-	O
as	O
well	O
as	O
somatotroph-like	B-GENE
cell	I-GENE
nuclear	I-GENE
protein	I-GENE
.	O

These	O
findings	O
suggest	O
that	O
direct	O
cDNA	O
mapping	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
provides	O
an	O
accurate	O
and	O
rapid	O
approach	O
to	O
the	O
definition	O
of	O
a	O
transcribed	O
map	O
of	O
the	O
human	O
genome	O
.	O

The	O
significance	O
of	O
the	O
phenolphthalein	B-GENE
sulphatase	I-GENE
test	O
for	O
the	O
differentiation	O
and	O
identification	O
of	O
Nocardia	O
species	O
.	O

These	O
results	O
indicate	O
that	O
T	O
.	O
C	O
.	O
,	O
LDL-C	B-GENE
.	O
,	O
HDL-C	B-GENE
.	O
,	O
HDL2-C	B-GENE
.	O
,	O
apo	B-GENE
B	I-GENE
,	O
apo	B-GENE
A-I	I-GENE
/	I-GENE
B	I-GENE
ratio	O
and	O
apo	B-GENE
A-II	I-GENE
/	I-GENE
B	I-GENE
ratio	O
are	O
predictive	O
risk	O
factors	O
of	O
the	O
coronary	O
heart	O
disease	O
.	O

This	O
last	O
includes	O
tissue	O
O2	O
transfer	O
(	O
Ft'	O
)	O
and	O
mitochondrial	O
O2	O
utilization	O
(	O
Fm'	O
)	O
.	O

To	O
identify	O
cis-acting	O
elements	O
that	O
target	O
c-myc	B-GENE
mRNA	I-GENE
for	O
downregulation	O
during	O
myogenesis	O
,	O
we	O
stably	O
transfected	O
C2C12	O
cells	O
with	O
mutant	B-GENE
myc	I-GENE
genes	I-GENE
or	O
chimeric	O
genes	O
in	O
which	O
various	O
myc	B-GENE
sequences	I-GENE
were	O
fused	O
to	O
the	O
human	B-GENE
beta-globin	I-GENE
gene	I-GENE
or	O
to	O
the	O
bacterial	B-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
gene	O
.	O

We	O
report	O
here	O
that	O
in	O
cultured	O
Jurkat	O
T	O
cells	O
,	O
Cbl	B-GENE
is	O
coprecipitated	O
with	O
antibody	O
against	O
the	O
adapter	B-GENE
protein	I-GENE
Grb2	I-GENE
.	O

These	O
findings	O
and	O
the	O
differential	O
tissue	O
distribution	O
of	O
p54	B-GENE
suggest	O
that	O
this	O
novel	O
SR	B-GENE
protein	I-GENE
may	O
participate	O
in	O
regulation	O
of	O
alternative	O
splicing	O
in	O
a	O
tissue-	O
and	O
substrate-dependent	O
manner	O
.	O

Nine	O
cats	O
received	O
PMEA	O
at	O
a	O
dosage	O
of	O
10	O
mg	O
/	O
kg	O
body	O
weight	O
,	O
nine	O
cats	O
received	O
FPMPA	O
at	O
a	O
dosage	O
of	O
25	O
mg	O
/	O
kg	O
body	O
weight	O
.	O

Mutational	O
studies	O
revealed	O
that	O
it	O
was	O
the	O
homeodomain	B-GENE
binding	I-GENE
site	I-GENE
II	I-GENE
sequence	I-GENE
that	O
was	O
required	O
for	O
this	O
regulation	O
.	O

BACKGROUND	O
:	O
Left	O
ventricular	O
hypertrophy	O
is	O
a	O
heterogeneous	O
disorder	O
with	O
distinct	O
morphologies	O
.	O

Proliferative	O
vasculopathy	O
and	O
cutaneous	O
hemorrhages	O
in	O
porcine	O
neonates	O
infected	O
with	O
the	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
.	O

Additionally	O
,	O
MIP-2A	B-GENE
antagonizes	O
cell	O
growth	O
regulatory	O
role	O
of	O
MBP-1	B-GENE
.	O

We	O
also	O
reported	O
the	O
identification	O
of	O
three	O
corresponding	O
alternative	O
first	O
exons	O
and	O
an	O
intronic	O
promoter	O
in	O
the	O
human	B-GENE
PDE5A	I-GENE
gene	I-GENE
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Studies	O
were	O
undertaken	O
in	O
9	O
isolated	O
guinea	O
pig	O
hearts	O
,	O
which	O
demonstrated	O
reverse	O
use-dependent	O
prolongation	O
of	O
cardiac	O
repolarization	O
by	O
100	O
nmol	O
/	O
L	O
domperidone	O
.	O

In	O
the	O
point	O
mutant	O
we	O
observed	O
normal	O
repair	O
of	O
endonuclease	B-GENE
III	I-GENE
site	I-GENE
(	O
i	O
.	O
e	O
.	O
as	O
wild	O
type	O
)	O
,	O
but	O
no	O
removal	O
of	O
CPDs	O
at	O
the	O
MAT	B-GENE
alpha	I-GENE
and	O
HML	B-GENE
alpha	I-GENE
loci	I-GENE
.	O

The	O
amino-terminal	O
half	O
of	O
1a	B-GENE
is	O
a	O
distant	O
homolog	B-GENE
of	I-GENE
alphavirus	I-GENE
nonstructural	I-GENE
protein	I-GENE
nsP1	I-GENE
,	O
which	O
has	O
been	O
implicated	O
in	O
capping	O
viral	O
RNAs	O
.	O

Two	O
putative	O
Rev	B-GENE
proteins	I-GENE
with	O
apparent	O
molecular	O
masses	O
of	O
18	O
and	O
16	O
kDa	O
were	O
expressed	O
by	O
p2	O
/	O
2	O
and	O
p176	O
,	O
while	O
p20	O
expressed	O
only	O
a	O
16-kDa	O
species	O
.	O

These	O
analyses	O
re-open	O
the	O
question	O
whether	O
all	O
the	O
CesA	B-GENE
genes	I-GENE
encode	O
cellulose	B-GENE
synthases	I-GENE
or	O
whether	O
some	O
of	O
the	O
sub-class	O
members	O
may	O
encode	O
other	O
non-cellulosic	B-GENE
(	I-GENE
1--	I-GENE
>	I-GENE
4	I-GENE
)	I-GENE
beta-glycan	I-GENE
synthases	I-GENE
in	O
plants	O
.	O

E	O
50	O
,	O
843	O
(	O
1994	O
)	O
]	O
.	O

In	O
this	O
situation	O
the	O
convlusion	O
threshold	O
for	O
the	O
8	O
substances	O
is	O
as	O
follows	O
:	O
pethidine	O
20	O
mg	O
.	O
kg-1	O
I	O
.	O
V	O
.	O
,	O
piritramide	O
30	O
,	O
morphine	O
180	O
,	O
phenoperidine	O
4	O
,	O
R	O
39	O
209	O
5	O
,	O
fentanyl	O
4	O
,	O
sufentanil	O
4	O
and	O
R	O
34	O
995	O
10	O
mg	O
.	O
kg-1	O
I	O
.	O
V	O
.	O

Vibrio	O
fluvialis	O
(	O
group	O
F	O
vibrio	O
)	O
in	O
Maharashtra	O
.	O

To	O
assess	O
the	O
ability	O
of	O
the	O
atria	O
to	O
maintain	O
elevated	O
plasma	O
concentrations	O
of	O
atrial	B-GENE
natriuretic	I-GENE
peptide	I-GENE
(	O
ANP	B-GENE
)	O
,	O
the	O
temporal	O
changes	O
in	O
plasma	B-GENE
ANP	I-GENE
concentrations	O
were	O
studied	O
in	O
seven	O
chloralose-anaesthetized	O
dogs	O
during	O
4	O
h	O
of	O
sustained	O
rapid	O
cardiac	O
pacing	O
.	O

Our	O
results	O
show	O
that	O
the	O
temperature-sensitive	B-GENE
rad54-3	I-GENE
allele	I-GENE
blocks	O
mitotic	O
recombination	O
between	O
tandemly	O
repeated	O
DYZ3	B-GENE
satellite	I-GENE
sequences	I-GENE
and	O
significantly	O
stabilizes	O
a	O
human	B-GENE
DYZ5	I-GENE
satellite-containing	O
YAC	O
clone	O
.	O

Again	O
residue	O
Glu-381	O
of	O
beta	O
was	O
notably	O
reduced	O
and	O
no	O
missing	O
residue	O
from	O
the	O
epsilon	B-GENE
peptide	I-GENE
could	O
be	O
identified	O
,	O
but	O
the	O
peptide	O
sequence	O
limited	O
the	O
possible	O
choices	O
to	O
Ser-106	O
,	O
Ser-107	O
,	O
or	O
Ser-108	O
.	O

Differential	O
expression	O
and	O
regulation	O
by	O
20-hydroxyecdysone	O
of	O
mosquito	O
ultraspiracle	O
isoforms	O
.	O

Nucleotide	O
sequences	O
between	O
the	O
env	B-GENE
gene	I-GENE
and	O
the	O
LTR	O
of	O
SFV-1	O
were	O
determined	O
.	O

As	O
a	O
part	O
of	O
a	O
large	O
examination	O
,	O
total	O
and	O
free	O
serum	O
cholesterol	O
,	O
total	O
lipid	O
and	O
triglyceride	O
levels	O
were	O
determined	O
.	O

Only	O
two	O
patients	O
(	O
0	O
.	O
3%	O
)	O
had	O
a	O
CA	O
125	O
response	O
at	O
the	O
time	O
of	O
clinical	O
progression	O
.	O

The	O
alterations	O
in	O
differentiation	O
of	O
osteoprogenitor	O
cells	O
,	O
together	O
with	O
the	O
failure	O
of	O
mineralization	O
,	O
resulted	O
in	O
significantly	O
lower	O
rates	O
of	O
bone	O
formation	O
(	O
as	O
measured	O
by	O
fluorochrome	O
labeling	O
)	O
in	O
the	O
magnesium-deficient	O
rats	O
.	O

Radionuclide	O
study	O
and	O
endomyocardial	O
biopsy	O
revealed	O
remarkable	O
degeneration	O
of	O
myocardium	O
.	O

ICA	O
in	O
the	O
reference	O
solution	O
was	O
characterised	O
by	O
LC	O
and	O
time-of-flight	O
(	O
TOF	O
)	O
MS	O
and	O
quantified	O
by	O
LC	O
chemiluminescent	O
nitrogen	O
detection	O
(	O
LC-CLND	O
)	O
.	O

In	O
contrast	O
,	O
similar	O
rates	O
of	O
B	O
.	O
sphaericus	O
products	O
,	O
ABG-6184	O
technical	O
powder	O
and	O
BSP-2	O
flowable	O
concentrate	O
,	O
produced	O
no	O
significant	O
reduction	O
.	O

The	O
aspirate	O
from	O
a	O
parathyroid	O
cyst	O
was	O
watery	O
clear	O
and	O
contained	O
high	O
amount	O
of	O
parathyroid	B-GENE
hormone	I-GENE
.	O

The	O
number	O
of	O
fecal	O
pellets	O
ingested	O
peaked	O
at	O
5	O
to	O
6	O
weeks	O
old	O
(	O
13	O
pellets	O
/	O
day	O
)	O
and	O
gradually	O
decreased	O
,	O
thereafter	O
(	O
2	O
.	O
1	O
pellets	O
at	O
78	O
weeks	O
old	O
,	O
1	O
.	O
5	O
pellets	O
at	O
104	O
weeks	O
old	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
Shh	B-GENE
can	O
drive	O
continued	O
cycling	O
in	O
immature	O
,	O
proliferating	O
CGNPs	O
.	O

The	O
roxithromycin	O
doses	O
that	O
were	O
chosen	O
for	O
these	O
studies	O
were	O
less	O
than	O
achievable	O
blood	O
levels	O
.	O

Urease	B-GENE
activity	O
,	O
judged	O
as	O
the	O
amount	O
of	O
ammonia	O
production	O
from	O
urea	O
,	O
could	O
be	O
measured	O
at	O
25	O
ng	O
per	O
tube	O
(	O
S	O
/	O
N	O
=	O
1	O
.	O
5	O
)	O
with	O
Jack	B-GENE
bean	I-GENE
meal	I-GENE
urease	I-GENE
.	O

These	O
data	O
confirm	O
the	O
existence	O
of	O
hyperlipemic	O
abdominal	O
crisis	O
as	O
a	O
distinct	O
entity	O
and	O
testify	O
to	O
the	O
importance	O
of	O
recognizing	O
this	O
syndrome	O
in	O
order	O
to	O
avoid	O
the	O
occurrence	O
of	O
acute	O
pancreatitis	O
and	O
the	O
performance	O
of	O
unnecessary	O
and	O
potentially	O
harmful	O
surgery	O
.	O

Using	O
reference	O
probes	O
as	O
internal	O
standards	O
,	O
we	O
show	O
that	O
the	O
ost	B-GENE
transcription	I-GENE
unit	I-GENE
is	O
located	O
within	O
the	O
cytogenetic	O
band	O
interval	O
89A1	O
,	O
2	O
on	O
the	O
right	O
arm	O
of	O
the	O
third	O
chromosome	O
,	O
and	O
that	O
it	O
exerts	O
diagnostic	O
segmentation	O
gene	O
expression	O
patterns	O
in	O
the	O
embryo	O
.	O

The	O
proteasome	O
is	O
a	O
large	O
complex	O
consisting	O
of	O
two	O
multisubunit	O
structures	O
,	O
the	O
20S	B-GENE
and	O
19S	B-GENE
(	I-GENE
PA700	I-GENE
)	I-GENE
or	O
P28	B-GENE
complexes	I-GENE
,	O
that	O
combine	O
to	O
form	O
the	O
26S	B-GENE
particles	I-GENE
.	O

The	O
amino	O
acid	O
sequences	O
of	O
the	O
predicted	O
RfbA	B-GENE
and	O
RfbB	B-GENE
homologs	I-GENE
showed	O
identities	O
of	O
75	O
.	O
7%	O
(	O
87	O
.	O
9%	O
total	O
similarity	O
)	O
and	O
78	O
.	O
0%	O
(	O
86	O
.	O
5%	O
total	O
similarity	O
)	O
,	O
respectively	O
.	O

The	O
UBA	B-GENE
domains	I-GENE
of	O
RAD23	B-GENE
and	O
DDI1	B-GENE
are	O
required	O
for	O
these	O
interactions	O
.	O

Intracellular	O
recordings	O
were	O
performed	O
on	O
the	O
optic	O
tectum	O
of	O
the	O
carp	O
in	O
vitro	O
.	O

RESULTS	O
:	O
Nodular	O
opacities	O
,	O
mainly	O
centrilobular	O
in	O
distribution	O
,	O
were	O
the	O
most	O
common	O
finding	O
,	O
seen	O
in	O
21	O
(	O
72%	O
)	O
and	O
15	O
(	O
65%	O
)	O
of	O
patients	O
with	O
MTB	O
and	O
NTMB	O
,	O
respectively	O
.	O

The	O
results	O
strengthen	O
the	O
conclusion	O
that	O
predominantly	O
dynamic	O
activity	O
increases	O
the	O
G4	B-GENE
content	O
of	O
mature	O
innervated	O
fast	O
muscles	O
.	O

Green	O
pepper	O
significantly	O
inhibited	O
N-nitrosothiazolidine-carboxylic	O
acid	O
formation	O
relative	O
to	O
ascorbic	O
acid	O
alone	O
.	O

Serum	O
ferritin	B-GENE
concentration	O
and	O
bone	O
marrow	O
iron	O
stores	O
.	O

The	O
mechanism	O
of	O
ligand-activated	O
estrogen	B-GENE
receptor	I-GENE
alpha	I-GENE
(	O
ERalpha	B-GENE
)	O
-dependent	O
activation	O
of	O
gene	O
expression	O
through	O
the	O
SRE	B-GENE
was	O
determined	O
by	O
mutational	O
analysis	O
of	O
the	O
promoter	O
,	O
analysis	O
of	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAPK	B-GENE
)	O
pathway	O
activation	O
by	O
E2	B-GENE
,	O
and	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
alpha	I-GENE
(	O
TGF-alpha	B-GENE
)	O
as	O
a	O
positive	O
control	O
.	O

Risk	O
of	O
infection	O
in	O
the	O
treatment	O
of	O
fractures	O
.	O

The	O
large	O
subfamily	O
of	O
receptor	B-GENE
tyrosine	I-GENE
kinases	I-GENE
(	O
RTKs	B-GENE
)	O
for	O
which	O
EPH	B-GENE
is	O
the	O
prototype	O
have	O
likely	O
roles	O
in	O
intercellular	O
communication	O
during	O
normal	O
mammalian	O
development	O
,	O
but	O
the	O
biochemical	O
signalling	O
pathways	O
utilised	O
by	O
this	O
family	O
are	O
poorly	O
characterised	O
.	O

Analysis	O
of	O
RAR	B-GENE
alpha	I-GENE
mutants	I-GENE
in	O
transfection	O
studies	O
reveals	O
that	O
the	O
DNA	O
binding	O
domain	O
is	O
sufficient	O
for	O
inhibition	O
of	O
BZLF1	B-GENE
activity	O
.	O

At	O
both	O
companies	O
sites	O
Salmonella	O
enteritidis	O
and	O
Salmonella	O
typhimurium	O
Tr104	O
were	O
also	O
isolated	O
occasionally	O
from	O
various	O
locations	O
.	O

Comparison	O
of	O
the	O
proportion	O
of	O
nonsynonymous	O
(	O
pN	O
)	O
and	O
synonymous	O
(	O
pS	O
)	O
substitutions	O
occurring	O
per	O
site	O
within	O
tamarin	B-GENE
variable	I-GENE
region	I-GENE
genes	I-GENE
demonstrated	O
a	O
reduction	O
in	O
pN	O
in	O
the	O
framework	O
regions	O
compared	O
with	O
pN	O
in	O
the	O
presumed	O
MHC	B-GENE
contact	I-GENE
regions	I-GENE
(	O
CDR1	B-GENE
and	O
CDR2	B-GENE
)	O
.	O

Tracheal	O
transsection	O
combined	O
with	O
hilar	O
ligation	O
(	O
TL&PL	O
)	O
effected	O
a	O
reduction	O
of	O
19	O
.	O
9%	O
(	O
n	O
.	O
s	O
.	O
)	O
.	O

Papers	O
of	O
the	O
Society	O
for	O
Clinical	O
Vascular	O
Surgery	O
.	O

The	O
COOH-terminal	O
region	O
of	O
the	O
transcripts	O
contained	O
fifteen	O
triplet	O
repeats	O
(	O
GCT	O
;	O
alanine	O
)	O
at	O
nucleotide	O
465	O
to	O
509	O
,	O
which	O
is	O
significantly	O
expanded	O
compared	O
to	O
the	O
rat	B-GENE
RL14	I-GENE
.	O

Dual	O
radionuclide	O
subtraction	O
imaging	O
of	O
the	O
spleen	O
using	O
67Ga	O
citrate	O
and	O
99mTc	O
is	O
useful	O
in	O
further	O
delineating	O
lesions	O
that	O
are	O
identified	O
on	O
either	O
a	O
routine	O
radiogallium	O
survey	O
or	O
on	O
a	O
conventional	O
sulfur	O
colloid	O
liver-spleen	O
image	O
.	O

Gene	O
constructs	O
consisting	O
of	O
human	B-GENE
growth	I-GENE
hormone	I-GENE
(	O
hGH	B-GENE
)	O
gene	O
driven	O
by	O
promoter	O
/	O
regulatory	O
sequence	O
of	O
mouse	B-GENE
metallothionein	I-GENE
(	O
mMT	B-GENE
)	O
,	O
viral	B-GENE
thymidine	I-GENE
kinase	I-GENE
(	O
vTK	B-GENE
)	O
,	O
rat	B-GENE
cholecystokinin	I-GENE
(	O
rCCK	B-GENE
)	O
,	O
or	O
chicken	B-GENE
beta-actin	I-GENE
(	O
cBA	B-GENE
)	O
gene	O
were	O
injected	O
into	O
the	O
cytoplasm	O
of	O
fertilized	O
medaka	O
eggs	O
via	O
the	O
micropyle	O
.	O

DNase	B-GENE
I	I-GENE
footprinting	O
analysis	O
indicated	O
that	O
DREF	B-GENE
binds	O
to	O
the	O
24-bp	O
DRE	B-GENE
region	O
of	O
the	O
DNA	B-GENE
polymerase	I-GENE
alpha	I-GENE
gene	I-GENE
in	O
which	O
8-bp	O
palindromic	O
sequences	O
are	O
centered	O
.	O

This	O
study	O
was	O
carried	O
out	O
to	O
analyze	O
PRL	B-GENE
secretion	O
in	O
metastatic	O
prostate	O
cancer	O
patients	O
both	O
at	O
basal	O
conditions	O
and	O
in	O
response	O
to	O
L-Dopa	O
and	O
metoclopramide	O
,	O
which	O
represents	O
the	O
most	O
classical	O
inhibitory	O
and	O
stimulatory	O
tests	O
for	O
PRL	B-GENE
secretion	O
,	O
respectively	O
.	O

Expression	O
of	O
PTPRO	B-GENE
was	O
also	O
observed	O
in	O
human	B-GENE
CD34+	I-GENE
bone	O
marrow	O
cells	O
and	O
5-FU-treated	O
murine	O
primitive	O
stem	O
cells	O
.	O

A	O
3-yr	O
retrospective	O
review	O
is	O
effective	O
and	O
detects	O
94%	O
of	O
the	O
undercalls	O
.	O

The	O
partial	O
farm	O
budget	O
highlighted	O
the	O
importance	O
of	O
reducing	O
sub-clinical	O
lesions	O
in	O
a	O
feedlot	O
.	O

Additional	O
exonuclease	B-GENE
III	I-GENE
protection	O
was	O
observed	O
beyond	O
the	O
core	O
region	O
on	O
both	O
the	O
5'	O
and	O
3'	O
sides	O
,	O
suggesting	O
that	O
E1	B-GENE
interacted	O
with	O
more	O
distal	O
sequences	O
as	O
well	O
.	O

Serum	O
antibodies	O
were	O
detected	O
in	O
at	O
least	O
95%	O
of	O
the	O
infected	O
guinea	O
pigs	O
between	O
4-30	O
WPI	O
and	O
rats	O
between	O
3-16	O
WPI	O
.	O

Physiol	O
.	O

Two	O
experiments	O
were	O
conducted	O
to	O
study	O
the	O
vacuous	O
jaw	O
movements	O
induced	O
in	O
rats	O
by	O
acute	O
administration	O
of	O
the	O
monoamine-depleting	O
agent	O
reserpine	O
.	O

Impaction	O
of	O
gastrostomy	O
tube	O
in	O
the	O
abdominal	O
wall	O
.	O

However	O
,	O
during	O
our	O
work	O
with	O
a	O
replication-deficient	O
virus	O
expressing	O
the	O
ASF	B-GENE
/	I-GENE
SF2	I-GENE
splicing	I-GENE
factor	O
from	O
a	O
progesterone	O
antagonist-inducible	O
gene	O
cassette	O
,	O
we	O
discovered	O
that	O
ASF	B-GENE
/	I-GENE
SF2	I-GENE
was	O
expressed	O
at	O
a	O
significant	O
level	O
in	O
the	O
293	O
producer	O
cell	O
line	O
,	O
even	O
in	O
the	O
absence	O
of	O
inducer	O
.	O

Molecular	O
cloning	O
of	O
mouse	B-GENE
glycolate	I-GENE
oxidase	I-GENE
.	O

E2	O
treatments	O
elevated	O
hen	O
plasma	O
TG	O
7	O
.	O
2X	O
,	O
PL	O
5	O
.	O
1X	O
,	O
and	O
C	O
7	O
.	O
2X	O
;	O
and	O
pullet	O
plasma	O
TG	O
6	O
.	O
8X	O
,	O
PL	O
3	O
.	O
7X	O
,	O
and	O
C	O
2	O
.	O
5X	O
.	O

The	O
MVV-value	O
is	O
under	O
the	O
predicted	O
level	O
in	O
the	O
case	O
of	O
67-76	O
percent	O
.	O

Using	O
the	O
rap1t	B-GENE
alleles	I-GENE
to	O
generate	O
wild-type	O
cells	O
differing	O
only	O
in	O
telomere	O
tract	O
lengths	O
,	O
we	O
also	O
show	O
that	O
telomere	O
position	O
effects	O
are	O
highly	O
sensitive	O
to	O
changes	O
in	O
the	O
size	O
(	O
or	O
structure	O
)	O
of	O
the	O
telomeric	O
tract	O
.	O

Two	O
protease-resistant	O
fragments	O
spanning	O
the	O
N-	O
and	O
C-terminal	O
halves	O
of	O
the	O
nuclease	B-GENE
were	O
identified	O
using	O
different	O
proteases	B-GENE
which	O
cleave	O
the	O
protein	O
in	O
the	O
same	O
region	O
.	O

Dorsal	O
root	O
ganglia	O
neuron-specific	O
promoter	O
activity	O
of	O
the	O
rabbit	B-GENE
beta-galactoside	I-GENE
alpha1	I-GENE
,	I-GENE
2-fucosyltransferase	I-GENE
gene	I-GENE
.	O

Peroxisome	B-GENE
proliferator-activated	I-GENE
receptors	I-GENE
(	O
PPAR	B-GENE
)	O
modulate	O
transcription	O
by	O
binding	O
to	O
specific	O
peroxisome	B-GENE
proliferator-response	I-GENE
elements	I-GENE
(	O
PPRE	B-GENE
)	O
through	O
heterodimerization	O
with	O
the	O
9-cis	B-GENE
retinoic	I-GENE
acid	I-GENE
receptor	I-GENE
(	O
RXR	B-GENE
)	O
.	O

A	O
prospectively	O
gated	O
2D	O
axial	O
sequence	O
with	O
velocity	O
encoding	O
in	O
the	O
craniocaudal	O
direction	O
in	O
the	O
cervical	O
region	O
was	O
set	O
at	O
a	O
velocity	O
of	O
+	O
/	O
-	O
10	O
cm	O
/	O
s	O
.	O

Alterations	O
of	O
the	O
5q23-q31	O
interval	O
are	O
frequently	O
observed	O
in	O
myelodysplasia	O
and	O
myeloid	O
leukemia	O
.	O

Mechanistically	O
,	O
the	O
presence	O
of	O
the	O
GRR	O
appears	O
to	O
stop	O
further	O
degradation	O
of	O
p50	B-GENE
and	O
to	O
stabilize	O
the	O
molecule	O
.	O

Suppressive	O
therapy	O
for	O
thyroid	O
nodules	O
.	O

Therefore	O
,	O
in	O
order	O
to	O
search	O
for	O
the	O
latent	O
genes	O
,	O
we	O
used	O
allotype-specific	O
oligonucleotides	O
for	O
b5	B-GENE
,	O
b6	B-GENE
and	O
b9	B-GENE
to	O
probe	O
DNAs	O
from	O
both	O
normal	O
and	O
T	O
.	O
brucei-infected	O
rabbits	O
by	O
Southern	O
blotting	O
.	O

A	O
high-frequency	O
restriction	O
fragment	O
length	O
polymorphism	O
was	O
evident	O
in	O
the	O
DNA	O
from	O
29	O
unrelated	O
individuals	O
using	O
the	O
enzyme	O
BglII	B-GENE
.	O

RPA190	B-GENE
encodes	O
a	O
polypeptide	O
chain	O
of	O
186	O
,	O
270	O
daltons	O
in	O
a	O
large	O
uninterrupted	O
reading	O
frame	O
.	O

The	O
arginyl	O
peptide	O
bonds	O
that	O
are	O
cleaved	O
in	O
the	O
conversion	O
of	O
human	B-GENE
factor	I-GENE
IX	I-GENE
to	O
factor	B-GENE
IXa	I-GENE
by	O
factor	B-GENE
XIa	I-GENE
were	O
identified	O
as	O
Arg145-Ala146	O
and	O
Arg180-Val181	O
.	O

Synthetic	O
oligonucleotides	O
representing	O
the	O
19	O
bp	O
repeat	O
unit	O
strongly	O
reduced	O
the	O
activity	O
of	O
the	O
IE1	B-GENE
/	I-GENE
2	I-GENE
enhancer	I-GENE
/	I-GENE
promoter	I-GENE
in	O
cotransfection	O
assays	O
after	O
transient	O
expression	O
.	O

Toxicities	O
included	O
:	O
nausea	O
/	O
vomiting	O
(	O
69%	O
)	O
,	O
headache	O
(	O
25%	O
)	O
,	O
chills	O
(	O
69%	O
)	O
,	O
pain	O
at	O
tumor	O
sites	O
(	O
63%	O
)	O
,	O
hypotension	O
(	O
31%	O
)	O
,	O
and	O
hypertension	O
(	O
38%	O
)	O
.	O

Despite	O
the	O
existence	O
of	O
30	O
cysteine	O
residues	O
,	O
carboxymethylation	O
prevented	O
the	O
formation	O
of	O
most	O
if	O
not	O
all	O
disulfide	O
bonds	O
that	O
otherwise	O
occurred	O
when	O
the	O
cells	O
were	O
sonicated	O
.	O

A	O
control	O
group	O
of	O
nine	O
women	O
(	O
age	O
23-40	O
years	O
)	O
on	O
oral	O
contraceptives	O
(	O
Nordette-28	O
)	O
was	O
also	O
studied	O
four	O
times	O
during	O
a	O
pill	O
cycle	O
.	O

This	O
motif	O
has	O
been	O
shown	O
to	O
mediate	O
protein	O
interactions	O
in	O
the	O
case	O
of	O
ankyrin	B-GENE
as	O
well	O
as	O
several	O
other	O
repeat-bearing	O
proteins	O
.	O

The	O
coating	O
materials	O
were	O
poloxamine	O
904	O
,	O
poloxamine	O
908	O
,	O
poloxamine	O
1508	O
,	O
poloxamer	O
338	O
,	O
and	O
Brij	O
35	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
postdexamethasone	O
cortical	O
concentrations	O
with	O
age	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
;	O
r	O
=	O
0	O
.	O
31	O
)	O
.	O

Mycobacterium	O
avium-intracellulare	O
complex	O
infections	O
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

Recent	O
application	O
of	O
recombinant	O
canarypox	O
ALVAC	O
/	O
HIV-1	O
vectors	O
as	O
vaccine	O
immunogens	O
in	O
HIV-1	O
,	O
-noninfected	O
volunteers	O
has	O
produced	O
CTL	O
responses	O
in	O
a	O
significant	O
number	O
of	O
vaccinees	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
simplified	O
methods	O
for	O
estimation	O
of	O
Technetium	O
Tc	O
99m	O
(	O
99mTc	O
)	O
-pentetate	O
and	O
orthoiodohippurate	O
I	O
131	O
(	O
131I-OIH	O
)	O
plasma	O
clearance	O
in	O
dogs	O
and	O
cats	O
with	O
1	O
and	O
2	O
blood	O
samples	O
.	O

Hovenitin	O
I	O
and	O
(	O
+	O
)	O
-ampelopsin	O
,	O
both	O
of	O
which	O
were	O
principal	O
ingredients	O
of	O
the	O
active	O
fractions	O
from	O
this	O
natural	O
medicine	O
,	O
were	O
found	O
to	O
show	O
an	O
inhibitory	O
activity	O
on	O
the	O
ethanol-induced	O
muscle	O
relaxation	O
in	O
rats	O
.	O

This	O
paper	O
brings	O
together	O
data	O
,	O
obtained	O
from	O
a	O
variety	O
of	O
sources	O
,	O
on	O
the	O
extent	O
of	O
prescription	O
and	O
use	O
of	O
psychotropic	O
drugs	O
in	O
the	O
late	O
1960s	O
and	O
early	O
1970s	O
.	O

This	O
observation	O
suggests	O
that	O
the	O
methyl-directed	O
repair	O
system	O
utilizes	O
the	O
proximal	O
d	O
(	O
GATC	O
)	O
sequence	O
to	O
direct	O
correction	O
.	O

Elements	O
that	O
are	O
fundamental	O
to	O
the	O
safety	O
evaluation	O
of	O
flavor	O
ingredients	O
include	O
exposure	O
,	O
structural	O
analogy	O
,	O
metabolism	O
,	O
pharmacokinetics	O
and	O
toxicology	O
.	O

This	O
repression	O
does	O
not	O
require	O
the	O
PU	B-GENE
.	I-GENE
1	I-GENE
transactivation	O
or	O
PEST	B-GENE
domains	I-GENE
and	O
cannot	O
be	O
reversed	O
by	O
p300	B-GENE
expression	O
.	O

Possible	O
roles	O
of	O
RAD5	B-GENE
putative	O
ATPase	B-GENE
/	I-GENE
DNA	I-GENE
helicase	I-GENE
activity	O
in	O
DNA	O
repair	O
and	O
in	O
the	O
maintenance	O
of	O
wild-type	O
rates	O
of	O
instability	O
of	O
simple	O
repetitive	O
sequences	O
are	O
discussed	O
.	O

Factors	O
influencing	O
the	O
bond	O
strength	O
between	O
glass	O
polyalkenoate	O
(	O
ionomer	O
)	O
cements	O
and	O
dentine	O
.	O

CDC31	B-GENE
is	O
required	O
for	O
SPB	O
duplication	O
and	O
encodes	O
a	O
calmodulin-like	B-GENE
protein	I-GENE
that	O
is	O
most	O
closely	O
related	O
to	O
caltractin	O
/	O
centrin	O
,	O
a	O
protein	O
associated	O
with	O
the	O
Chlamydomonas	O
basal	O
body	O
.	O

The	O
occurrence	O
of	O
multiple	O
malignancy	O
was	O
studied	O
in	O
674	O
patients	O
with	O
hematologic	O
malignancies	O
who	O
were	O
admitted	O
to	O
this	O
department	O
during	O
the	O
past	O
10	O
years	O
.	O

RESULTS	O
:	O
Of	O
the	O
24	O
patients	O
,	O
6	O
had	O
Grade	O
1	O
pneumonitis	O
,	O
and	O
13	O
had	O
Grade	O
2	O
pneumonitis	O
.	O

The	O
effect	O
of	O
ethanol	O
on	O
human	O
sensorimotor	O
reactivity	O
was	O
assessed	O
by	O
examining	O
the	O
acoustic	O
startle	O
response	O
.	O

Corneal	O
scrapping	O
and	O
deep	O
stromal	O
biopsy	O
were	O
obtained	O
and	O
stained	O
for	O
microscopic	O
evaluation	O
with	O
periodic	O
acid-Schiff	O
,	O
Giemsa	O
,	O
and	O
Gomori's	O
methenamine	O
silver	O
stains	O
.	O

A	O
bovine	O
abomasum	O
lambda	O
gt11	O
cDNA	O
library	O
was	O
screened	O
with	O
a	O
monoclonal	O
antibody	O
raised	O
against	O
the	O
rabbit	B-GENE
H	I-GENE
,	I-GENE
K-ATPase	I-GENE
beta	I-GENE
subunit	I-GENE
.	O

All	O
pigs	O
had	O
significant	O
regional	O
LV	O
dysfunction	O
and	O
reduced	O
LV	O
ejection	O
fraction	O
(	O
41+	O
/	O
-11%	O
)	O
.	O

After	O
MOPP	O
therapy	O
,	O
complete	O
remission	O
of	O
Hodgkin's	O
disease	O
was	O
accompanied	O
by	O
normalization	O
of	O
the	O
glucocerebrosidase	B-GENE
level	O
and	O
disappearance	O
of	O
Gaucher's	O
cells	O
.	O

67	O
393	O
bp	O
of	O
contiguous	O
DNA	O
located	O
between	O
markers	O
cdc18	B-GENE
and	O
cdc14	B-GENE
on	O
the	O
right	O
arm	O
of	O
fission	O
yeast	O
chromosome	O
II	O
has	O
been	O
sequenced	O
as	O
part	O
of	O
the	O
European	O
Union	O
Schizosaccharomyces	O
pombe	O
genome	O
sequencing	O
project	O
.	O

Optical	O
CD	O
,	O
and	O
spectral	O
and	O
activity	O
analyses	O
were	O
used	O
to	O
examine	O
reactivity	O
of	O
HO	B-GENE
isozymes	I-GENE
with	O
NO	O
species	O
produced	O
by	O
NO	O
donors	O
.	O

Neither	O
gene	O
possesses	O
a	O
distinct	O
transcriptional	O
start	O
site	O
as	O
shown	O
by	O
nuclease	B-GENE
S1	I-GENE
analysis	O
.	O

Treatment	O
was	O
well-tolerated	O
.	O

Deletion	O
analyses	O
of	O
the	O
construct	O
revealed	O
that	O
the	O
transcription	O
of	O
BOXF1	B-GENE
gene	I-GENE
is	O
regulated	O
by	O
BOX	B-GENE
DNA	I-GENE
,	O
preferentially	O
in	O
undifferentiated	O
EC	O
cells	O
versus	O
differentiated	O
cells	O
.	O

Fluid	O
(	O
AVLF	O
)	O
31	O
.	O

Optimal	O
monitoring	O
of	O
ODA	O
remains	O
undefined	O
.	O

Ig-alpha	B-GENE
and	O
Ig-beta	B-GENE
contain	O
extended	O
cytoplasmic	O
structure	O
(	O
61	O
and	O
48	O
amino	O
acids	O
,	O
respectively	O
)	O
and	O
associate	O
with	O
cytoplasmic	O
effectors	O
indicating	O
that	O
they	O
are	O
directly	O
involved	O
in	O
signal	O
transduction	O
.	O

Topics	O
reviewed	O
here	O
include	O
:	O
data	O
supporting	O
the	O
association	O
of	O
myositis	O
with	O
cancer	O
and	O
the	O
appropriate	O
evaluations	O
for	O
malignancy	O
in	O
a	O
myositis	O
patient	O
;	O
an	O
approach	O
to	O
the	O
assessment	O
of	O
patients	O
with	O
dermatomyositis	O
sine	O
myositis	O
;	O
the	O
usefulness	O
of	O
the	O
clinicopathological	O
and	O
serological	O
classifications	O
;	O
a	O
discussion	O
of	O
whether	O
childhood	O
and	O
adult	O
myositis	O
are	O
the	O
same	O
or	O
different	O
entities	O
;	O
a	O
review	O
of	O
those	O
prognostic	O
factors	O
to	O
consider	O
in	O
the	O
clinical	O
management	O
of	O
myositis	O
patients	O
;	O
current	O
approaches	O
and	O
their	O
limitations	O
for	O
assessing	O
disease	O
activity	O
and	O
damage	O
.	O

Examination	O
of	O
the	O
sequence	O
of	O
the	O
Punta	B-GENE
Toro	I-GENE
M	I-GENE
gene	I-GENE
product	I-GENE
reveals	O
the	O
presence	O
of	O
multiple	O
hydrophobic	O
sequences	O
including	O
a	O
19-amino	B-GENE
acid	I-GENE
,	I-GENE
carboxy-proximal	I-GENE
,	I-GENE
hydrophobic	I-GENE
region	I-GENE
(	I-GENE
G2	I-GENE
)	I-GENE
.	O

In	O
angiodysplasia	O
,	O
ectatic	O
vessels	O
in	O
the	O
mucosa	O
appeared	O
to	O
contain	O
less	O
collagen	B-GENE
type	I-GENE
IV	I-GENE
than	O
similarly	O
sized	O
vessels	O
in	O
the	O
submucosa	O
,	O
and	O
perforating	O
vessels	O
appeared	O
in	O
many	O
cases	O
to	O
lose	O
staining	O
at	O
the	O
level	O
of	O
the	O
muscularis	O
mucosae	O
.	O

RESULTS	O
:	O
Total	O
IgE	B-GENE
levels	O
showed	O
a	O
tendency	O
to	O
diminish	O
.	O

In	O
ischemic	O
and	O
hypoxic	O
hypoxia	O
,	O
a	O
strong	O
correlation	O
was	O
found	O
between	O
cyt	O
a	O
,	O
a3	O
oxidation	O
level	O
and	O
VO2	O
in	O
both	O
ischemic	O
and	O
hypoxic	O
hypoxia	O
(	O
r2	O
=	O
.	O
90	O
and	O
.	O
87	O
,	O
respectively	O
)	O
.	O

The	O
sequence	O
of	O
the	O
putative	O
RBP1	B-GENE
protein	I-GENE
contains	O
two	O
copies	O
of	O
an	O
RNA	O
recognition	O
motif	O
,	O
two	O
glutamine	O
stretches	O
,	O
an	O
asparagine-rich	O
region	O
,	O
a	O
methionine-rich	O
region	O
,	O
and	O
two	O
long	O
potential	O
alpha-helixes	O
.	O

In	O
a	O
group	O
of	O
13	O
patients	O
with	O
obliterative	O
arteriopathies	O
of	O
the	O
lower	O
limbs	O
the	O
plasma	O
levels	O
of	O
thrombomodulin	B-GENE
(	O
TM	B-GENE
)	O
,	O
betathromboglobulin	B-GENE
(	O
beta-TG	B-GENE
)	O
,	O
D-dimer	B-GENE
(	O
DD	B-GENE
)	O
and	O
plasminogen	B-GENE
activator-inhibitor	I-GENE
(	O
pAI-1	B-GENE
)	O
were	O
measured	O
,	O
and	O
compared	O
to	O
the	O
values	O
obtained	O
from	O
10	O
healthy	O
volunteers	O
.	O

Research	O
was	O
carried	O
out	O
on	O
the	O
rheumatoid	B-GENE
factors	I-GENE
in	O
the	O
serum	O
of	O
917	O
patients	O
by	O
means	O
of	O
two	O
tests	O
(	O
one	O
using	O
polystyrene	O
and	O
one	O
with	O
erythrocytes	O
)	O
and	O
the	O
results	O
obtained	O
were	O
compared	O
using	O
a	O
method	O
of	O
reference	O
.	O

A	O
new	O
semi-automatic	O
method	O
for	O
quantifying	O
regional	O
cerebral	O
uptake	O
of	O
99m	O
technetium-hexamethylpropylene	O
amine	O
oxime	O
(	O
99mTc-HMPAO	O
)	O
was	O
used	O
to	O
assess	O
single	O
photon	O
emission	O
tomograms	O
from	O
5	O
normal	O
subjects	O
,	O
14	O
patients	O
with	O
Alzheimer's	O
disease	O
,	O
14	O
patients	O
with	O
dementia	O
of	O
frontal	O
lobe	O
type	O
and	O
4	O
patients	O
with	O
dementia	O
with	O
motor	O
neurone	O
disease	O
.	O

However	O
,	O
alterations	O
in	O
electrostatic	O
and	O
hydrophobic	O
interactions	O
created	O
by	O
the	O
three	O
amino	O
acid	O
substitutions	O
prevent	O
the	O
conformational	O
change	O
in	O
the	O
enzyme	O
usually	O
produced	O
by	O
calmodulin	B-GENE
binding	O
.	O

The	O
products	O
of	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
CIN1	I-GENE
,	O
CIN2	B-GENE
and	O
CIN4	B-GENE
genes	I-GENE
participate	O
in	O
a	O
nonessential	O
pathway	O
required	O
for	O
normal	O
microtubule	O
function	O
.	O

This	O
study	O
indicates	O
that	O
this	O
dose-intense	O
regimen	O
can	O
be	O
safely	O
administered	O
,	O
even	O
with	O
the	O
use	O
of	O
purged	O
marrow	O
,	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O

Transcription	O
initiation	O
sites	O
of	O
the	O
rat	B-GENE
II	I-GENE
beta-	I-GENE
,	I-GENE
III	I-GENE
beta	I-GENE
,	I-GENE
and	I-GENE
O	I-GENE
beta-globin	I-GENE
genes	I-GENE
were	O
determined	O
to	O
be	O
52	O
base	O
pairs	O
(	O
bp	O
)	O
5'-upstream	O
of	O
the	O
translation	O
initiation	O
codon	O
(	O
ATG	O
)	O
,	O
in	O
each	O
gene	O
by	O
primer	O
extension	O
analysis	O
.	O

Transabdominal	O
repair	O
of	O
type	O
IV	O
thoraco-abdominal	O
aortic	O
aneurysms	O
.	O

RESULTS	O
:	O
The	O
main	O
effect	O
of	O
muscle	O
pain	O
,	O
compared	O
to	O
non-painful	O
stimulation	O
,	O
was	O
a	O
significant	O
and	O
long-lasting	O
increase	O
of	O
delta	O
(	O
1-3	O
Hz	O
)	O
power	O
and	O
an	O
alpha-1	O
(	O
9-11	O
Hz	O
)	O
power	O
increase	O
over	O
the	O
contralateral	O
parietal	O
locus	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
the	O
distal	O
half	O
(	O
Stem	O
2	O
)	O
of	O
the	O
conserved	O
base-paired	O
stem	O
structure	O
found	O
in	O
all	O
hY	B-GENE
RNAs	I-GENE
also	O
plays	O
a	O
critical	O
role	O
in	O
the	O
export	O
process	O
.	O

While	O
the	O
examiner	O
observed	O
the	O
interior	O
of	O
the	O
eye	O
with	O
indirect	O
ophthalmoscopy	O
,	O
the	O
point	O
source	O
of	O
light	O
from	O
the	O
fiberoptic	O
light	O
pipe	O
was	O
moved	O
along	O
the	O
margins	O
of	O
the	O
episcleral	O
plaque	O
.	O

In	O
contrast	O
to	O
some	O
results	O
previously	O
published	O
for	O
a	O
very	O
close	O
sequence	O
variant	O
(	O
see	O
ref	O
.	O

S1	B-GENE
nuclease	I-GENE
analysis	O
of	O
RNA	O
from	O
chemically	O
induced	O
B95-8	O
cells	O
and	O
from	O
Vero	O
cells	O
cotransfected	O
with	O
NotI	B-GENE
repeat	I-GENE
promoter-CAT	I-GENE
and	O
Z	B-GENE
showed	O
that	O
Z	B-GENE
transactivation	O
increased	O
the	O
level	O
of	O
correctly	O
initiated	O
,	O
stable	O
RNA	O
transcripts	O
.	O

The	O
nifJ	B-GENE
and	O
nifH	B-GENE
promoters	I-GENE
of	I-GENE
Klebsiella	I-GENE
pneumoniae	I-GENE
are	O
divergently	O
transcribed	O
sigma	B-GENE
54-dependent	I-GENE
promoters	I-GENE
that	O
are	O
positively	O
activated	O
by	O
the	O
NifA	B-GENE
protein	I-GENE
.	O

Both	O
toxins	O
in	O
a	O
dose	O
10-fold	O
surpassimg	O
the	O
maximum	O
permissible	O
concentration	O
increased	O
activity	O
of	O
glutathione	B-GENE
peroxidase	I-GENE
in	O
brain	O
tissue	O
;	O
moreover	O
,	O
toluene	O
increased	O
chemiluminescence	O
intensity	O
,	O
which	O
attested	O
to	O
activation	O
of	O
free	O
radical	O
processes	O
.	O

To	O
this	O
end	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
status	O
of	O
a	O
universal	O
tyrosine	B-GENE
kinase	I-GENE
substrate	O
,	O
the	O
transforming	O
Shc	B-GENE
adapter	I-GENE
protein	I-GENE
,	O
in	O
fibroblasts	O
expressing	O
the	O
viral	O
oncogene	O
.	O

Partial	O
characterization	O
of	O
the	O
active	O
site	O
human	B-GENE
platelet	I-GENE
cAMP	I-GENE
phosphodiesterase	I-GENE
,	O
PDE3A	B-GENE
,	O
by	O
site-directed	O
mutagenesis	O
.	O

The	O
region	O
between	O
DXS52	B-GENE
and	O
Factor	B-GENE
VIII	I-GENE
gene	I-GENE
in	O
the	O
human	O
Xq28	O
chromosomal	O
band	O
contains	O
a	O
G+C-rich	O
isochore	O
to	O
which	O
many	O
genes	O
have	O
been	O
mapped	O
.	O

Biochemical	O
characterization	O
of	O
valosin-containing	B-GENE
protein	I-GENE
,	O
a	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
substrate	O
in	O
hematopoietic	O
cells	O
.	O

The	O
latency	O
time	O
for	O
the	O
lactate	O
concentration	O
to	O
reach	O
the	O
top	O
values	O
was	O
reduced	O
by	O
aerobic	O
training	O
(	O
T2	O
)	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
gar2	B-GENE
is	O
phosphorylated	O
in	O
vitro	O
by	O
a	O
p13	O
(	O
suc1	O
)	O
-Sepharose-bound	O
kinase	B-GENE
from	O
Schizosaccharomyces	O
pombe	O
extracts	O
that	O
displays	O
cell	O
cycle-regulated	O
activity	O
similar	O
to	O
that	O
of	O
the	O
p34	B-GENE
(	I-GENE
cdc2	I-GENE
(	I-GENE
kinase	I-GENE
.	O

Our	O
results	O
support	O
a	O
model	O
where	O
both	O
E2F-	O
and	O
CDE-mediated	O
repression	O
,	O
acting	O
at	O
different	O
stages	O
in	O
the	O
cell	O
cycle	O
,	O
are	O
dependent	O
on	O
promoter-specific	O
CHR	B-GENE
elements	I-GENE
.	O

Indeed	O
,	O
significant	O
level	O
of	O
CAT	B-GENE
activity	O
was	O
observed	O
in	O
human	O
lung	O
adenocarcinoma	O
(	O
A549-1	O
)	O
cells	O
which	O
had	O
been	O
incubated	O
with	O
a	O
complex	O
of	O
T7	B-GENE
RNA	I-GENE
polymerase	I-GENE
,	O
pT7-EMC-CAT	B-GENE
DNA	I-GENE
and	O
DC-chol	O
cationic	O
liposomes	O
.	O

CONCLUSIONS	O
.	O

Preceptorship	O
of	O
CNS	O
students	O
:	O
an	O
exploratory	O
study	O
.	O

The	O
difference	O
of	O
hardness	O
over	O
time	O
of	O
composite	O
specimens	O
was	O
measured	O
using	O
Knoop	O
hardness	O
measurements	O
taken	O
at	O
the	O
top	O
and	O
bottom	O
surfaces	O
of	O
resin	O
specimens	O
made	O
in	O
a	O
Teflon	O
mold	O
the	O
same	O
dimensions	O
as	O
the	O
cavity	O
prepared	O
in	O
dentin	B-GENE
.	O

An	O
alternatively	O
spliced	O
MAdCAM-1	B-GENE
variant	O
was	O
identified	O
that	O
lacks	O
exon	O
4	O
encoding	O
the	O
mucin	B-GENE
domain	O
,	O
and	O
may	O
mediate	O
leukocyte	O
adhesion	O
to	O
LPAM-1	B-GENE
without	O
adhesion	O
to	O
the	O
alternate	O
receptor	O
,	O
L-selectin	B-GENE
.	O

The	O
hypothesis	O
of	O
Geisler	O
(	O
Brain	O
Res	O
.	O

EM	O
analysis	O
demonstrated	O
that	O
only	O
one	O
Rep-DNA	B-GENE
complex	I-GENE
was	O
formed	O
on	O
ch-19	O
target	O
DNA	O
.	O

Epithelial	O
nerve	O
fiber	O
defects	O
included	O
absence	O
or	O
distorted	O
architecture	O
of	O
the	O
basal	O
epithelial	O
plexus	O
and	O
intra-epithelial	O
terminals	O
.	O

In	O
an	O
effort	O
to	O
contribute	O
to	O
the	O
transcript	O
map	O
of	O
human	O
chromosome	O
21	O
and	O
the	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
trisomy	O
21	O
,	O
we	O
have	O
used	O
exon	O
trapping	O
to	O
identify	O
fragments	O
of	O
chromosome	O
21	O
genes	O
.	O

We	O
previously	O
demonstrated	O
that	O
acute	O
expression	O
of	O
the	O
bovine	O
papillomavirus	O
type	O
1	O
(	O
BPV1	O
)	O
E2	B-GENE
protein	I-GENE
in	O
HeLa	O
and	O
HT-3	O
cervical	O
carcinoma	O
cell	O
lines	O
greatly	O
reduced	O
cellular	O
proliferation	O
by	O
imposing	O
a	O
specific	O
G1	O
/	O
S	O
phase	O
growth	O
arrest	O
.	O

The	O
mean	O
plasma	O
sodium	O
concentration	O
which	O
was	O
135	O
.	O
95	O
(	O
+	O
/	O
-	O
SD	O
4	O
.	O
14	O
)	O
mEq	O
/	O
kg	O
before	O
diuretic	O
treatment	O
was	O
significantly	O
decreased	O
during	O
treatment	O
to	O
129	O
.	O
19	O
(	O
+	O
/	O
-	O
SD	O
2	O
.	O
77	O
)	O
mEq	O
/	O
kg	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
.	O

In	O
insulin-responsive	O
cells	O
,	O
Akt	B-GENE
phosphorylates	O
and	O
inactivates	O
the	O
serine	B-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
glycogen	B-GENE
synthase	I-GENE
kinase-3	I-GENE
(	O
GSK-3	B-GENE
)	O
.	O

Cyclin	B-GENE
D1-associated	I-GENE
kinase	I-GENE
activity	O
and	O
protein	O
levels	O
were	O
increased	O
in	O
mammary	O
tumors	O
from	O
murine	B-GENE
mammary	I-GENE
tumor	I-GENE
virus-pp60	I-GENE
(	I-GENE
c-src527F	I-GENE
)	I-GENE
transgenic	O
mice	O
.	O

We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
controlled	O
trial	O
of	O
metoprolol	O
,	O
a	O
selective	O
beta-blocker	O
for	O
prevention	O
of	O
gastrointestinal	O
bleeding	O
from	O
portal	O
hypertension	O
in	O
29	O
non-selected	O
patients	O
with	O
liver	O
disease	O
and	O
previous	O
gastrointestinal	O
bleeding	O
.	O

[	O
Treatment	O
of	O
early	O
T1	O
small	O
T2N	O
breast	O
cancers	O
.	O

Mutation	O
analysis	O
demonstrates	O
that	O
the	O
motif	O
TCCCCT	B-GENE
is	O
critical	O
for	O
PyRo1	B-GENE
interaction	O
.	O

Cdc2	B-GENE
co-precipitates	O
with	O
Pch1	B-GENE
in	O
S	O
.	O
pombe	O
cell	O
lysates	O
,	O
although	O
Cdc2	B-GENE
may	O
not	O
be	O
the	O
major	O
catalytic	O
partner	O
of	O
a	O
Pch1	B-GENE
kinase	I-GENE
in	O
vivo	O
.	O

This	O
paper	O
presents	O
the	O
reasons	O
why	O
countries	O
to	O
which	O
Chagas	O
disease	O
is	O
endemic	O
should	O
carry	O
out	O
the	O
relevant	O
research	O
themselves	O
.	O

Copyright	O
2000	O
Academic	O
Press	O
.	O

Despite	O
significant	O
lethality	O
and	O
cardiovascular	O
dysfunction	O
,	O
in	O
the	O
septic	O
group	O
on	O
Days	O
1	O
and	O
2	O
,	O
septic	O
versus	O
control	O
animals	O
had	O
no	O
significant	O
differences	O
in	O
mean	O
metabolic	O
cart	O
measured	O
(	O
Vo2DIR	O
,	O
ml	O
/	O
kg	O
/	O
min	O
;	O
Day	O
1	O
:	O
11	O
.	O
9	O
versus	O
12	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
81	O
;	O
Day	O
2	O
:	O
14	O
.	O
2	O
versus	O
13	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
72	O
,	O
respectively	O
)	O
and	O
intravascular	O
catheter	O
calculated	O
(	O
Vo2INDIR	O
,	O
ml	O
/	O
kg	O
/	O
min	O
;	O
Day	O
1	O
:	O
11	O
.	O
2	O
versus	O
11	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
99	O
;	O
Day	O
2	O
:	O
12	O
.	O
8	O
versus	O
15	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
49	O
,	O
respectively	O
)	O
.	O

This	O
would	O
have	O
had	O
the	O
effect	O
of	O
positioning	O
the	O
genes	O
currently	O
on	O
the	O
long	O
arm	O
adjacent	O
to	O
the	O
centromeric	O
heterochromatin	O
,	O
perhaps	O
resulting	O
in	O
a	O
"position	O
effect"	O
on	O
transcription	O
of	O
these	O
genes	O
.	O

T1-weighted	O
MRI	O
on	O
the	O
49th	O
postoperative	O
day	O
demonstrated	O
bilateral	O
and	O
symmetrical	O
hyperintense	O
lesions	O
in	O
the	O
globus	O
pallidus	O
.	O

The	O
side-to-side	O
difference	O
was	O
statistically	O
significant	O
at	O
EXT	O
30	O
degrees	O
/	O
s	O
and	O
60	O
degrees	O
/	O
s	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Formalin	O
activated	O
both	O
SNO	O
NS	O
and	O
NnS	O
neurones	O
,	O
but	O
,	O
when	O
they	O
responded	O
,	O
NS	O
neurones	O
(	O
n	O
=	O
5	O
)	O
showed	O
only	O
the	O
first	O
phase	O
of	O
activity	O
while	O
NnS	O
neurones	O
showed	O
either	O
one	O
(	O
n	O
=	O
13	O
)	O
or	O
two	O
phases	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
IgG	B-GENE
subclass	O
profile	O
of	O
untreated	O
coeliac	O
disease	O
was	O
found	O
to	O
be	O
the	O
same	O
as	O
in	O
healthy	O
controls	O
(	O
IgG1	B-GENE
approximately	O
IgG2	B-GENE
>	O
IgG3	B-GENE
>	O
IgG4	B-GENE
)	O
,	O
with	O
only	O
the	O
magnitude	O
of	O
the	O
individual	O
subclass	O
responses	O
being	O
increased	O
in	O
coeliac	O
patients	O
.	O

1	O
.	O

An	O
8-h	O
exposure	O
to	O
10	O
mg	O
DMEA	O
/	O
m3	O
corresponds	O
to	O
a	O
postexposure	O
plasma	O
concentration	O
and	O
2-h	O
postexposure	O
urinary	O
excretion	O
of	O
4	O
.	O
9	O
mumol	O
/	O
l	O
and	O
75	O
mmol	O
/	O
mol	O
creatinine	O
,	O
respectively	O
.	O

Sequence	O
analysis	O
of	O
this	O
region	O
revealed	O
three	O
eight-bp	O
repetitive	O
elements	O
,	O
the	O
deletion	O
of	O
which	O
restored	O
wild-type	O
levels	O
of	O
luciferase	B-GENE
activity	O
to	O
the	O
-916-bp	O
reporter	O
plasmid	O
.	O

The	O
radiation	O
burden	O
associated	O
with	O
the	O
majority	O
of	O
examinations	O
in	O
nuclear	O
medicine	O
expressed	O
as	O
the	O
effective	O
dose	O
is	O
comparable	O
with	O
the	O
radiation	O
burden	O
of	O
radiodiagnostic	O
examinations	O
,	O
only	O
after	O
administration	O
of	O
preparations	O
with	O
131I	O
,	O
201Tl	O
,	O
67Ga	O
and	O
111In	O
it	O
is	O
markedly	O
higher	O
.	O

Here	O
,	O
we	O
describe	O
directional	O
chromosome	O
walking	O
studies	O
starting	O
from	O
D8S260	B-GENE
as	O
well	O
as	O
D8S285	B-GENE
.	O

RUSH-1	B-GENE
beta	I-GENE
is	O
a	O
95-kDa	O
truncated	O
version	O
of	O
RUSH-1	B-GENE
alpha	I-GENE
that	O
results	O
from	O
alternative	O
splicing	O
of	O
a	O
57-bp	O
exon	O
as	O
confirmed	O
by	O
genomic	O
cloning	O
.	O

Reduction	O
in	O
dosage	O
restored	O
normal	O
taste	O
sense	O
in	O
all	O
three	O
,	O
but	O
in	O
two	O
the	O
drug	O
had	O
to	O
be	O
discontinued	O
because	O
of	O
persisting	O
high	O
transaminase	B-GENE
levels	O
.	O

Thus	O
analysis	O
indicated	O
no	O
reliable	O
evidence	O
that	O
conscious	O
presleep	O
suggestions	O
become	O
incorporated	O
into	O
dream	O
content	O
.	O

Thus	O
,	O
our	O
studies	O
suggest	O
that	O
pV-mediated	O
activation	O
of	O
HIV-1	B-GENE
LTR	I-GENE
activity	O
is	O
controlled	O
by	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF-kappaB	B-GENE
transcription	I-GENE
factor	I-GENE
,	O
which	O
is	O
mediated	O
by	O
IkappaBalpha	B-GENE
serine	O
phosphorylation	O
and	O
degradation	O
,	O
but	O
also	O
by	O
a	O
still	O
undefined	O
NF-kappaB-independent	O
pathway	O
.	O

Acute	O
appearance	O
of	O
hemiparesis	O
or	O
hemiplegia	O
with	O
initial	O
marked	O
spasticity	O
was	O
observed	O
in	O
8	O
stroke	O
patients	O
.	O

Schlegel	O
,	O
J	O
.	O

Analysis	O
of	O
one	O
cDNA	O
revealed	O
an	O
unusual	O
splicing	O
event	O
involving	O
EZH1	B-GENE
and	O
a	O
tandemly	O
linked	O
gene	O
GPR2	B-GENE
and	O
suggests	O
a	O
potential	O
mechanism	O
for	O
modifying	O
the	O
EZH1	B-GENE
protein	I-GENE
in	O
the	O
conserved	O
C-terminal	O
domain	O
.	O

We	O
analysed	O
two	O
regions	O
involved	O
in	O
preS2	B-GENE
/	I-GENE
S	I-GENE
gene	I-GENE
transcription	O
of	O
the	O
HBV	O
adw	O
subtype	O
:	O
the	O
diverged	O
TATA	O
box	O
and	O
a	O
putative	O
initiator	O
element	O
.	O

Effect	O
of	O
chronic	O
undernutrition	O
on	O
susceptibility	O
to	O
cold	O
stress	O
in	O
young	O
adult	O
and	O
aged	O
rats	O
.	O

During	O
this	O
time	O
,	O
the	O
patients	O
all	O
had	O
the	O
characteristic	O
plasma	O
thyroid	O
hormone	O
changes	O
associated	O
with	O
amiodarone	O
therapy	O
,	O
i	O
.	O
e	O
.	O
increased	O
T4	O
,	O
free	O
T4	O
,	O
and	O
rT3	O
and	O
decreased	O
T3	O
,	O
while	O
remaining	O
clinically	O
euthyroid	O
.	O

Normal	O
rates	O
of	O
weight	O
gain	O
were	O
seen	O
once	O
absorbed	O
energy	O
intakes	O
reached	O
100-110%	O
of	O
requirements	O
.	O

The	O
C18	O
:	O
1	O
:	O
C10	O
value	O
is	O
a	O
convenient	O
measure	O
of	O
these	O
changes	O
and	O
can	O
be	O
determined	O
more	O
rapidly	O
than	O
determining	O
all	O
the	O
lower	O
fatty	O
acids	O
.	O

The	O
cytoprotective	O
and	O
antiulcer	O
activities	O
of	O
the	O
antacid	O
magaldrate	O
(	O
ES	O
Riopan	O
)	O
as	O
well	O
as	O
its	O
effects	O
on	O
gastric	O
mucosal	O
blood	O
flow	O
and	O
mucus	O
secretions	O
,	O
were	O
determined	O
in	O
the	O
rat	O
.	O

Retinal	O
changes	O
in	O
pigmentary	O
retinopathy	O
in	O
children	O
.	O

The	O
overall	O
prevalence	O
of	O
psoriasis	O
was	O
4	O
.	O
79%	O
in	O
men	O
and	O
4	O
.	O
85%	O
in	O
women	O
.	O

When	O
introduced	O
into	O
recJ+	B-GENE
strains	O
,	O
srjA	B-GENE
mutations	O
conferred	O
hyperrecombinational	O
and	O
hyper-UVr	O
phenotypes	O
.	O

Previous	O
studies	O
showed	O
that	O
mutations	O
in	O
the	O
6K	O
protein	O
led	O
to	O
the	O
slow	O
release	O
of	O
aberrant	O
,	O
multi-cored	O
infectious	O
virions	O
.	O

Performance	O
on	O
two	O
verbal	O
measures-the	O
National	O
Adult	O
Reading	O
Test-Revised	O
(	O
NART-R	O
)	O
and	O
the	O
Vocabulary	O
subtest	O
from	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale-Revised	O
(	O
WAIS-R	O
)	O
-showed	O
strong	O
correlations	O
with	O
level	O
of	O
education	O
.	O

The	O
influence	O
of	O
Epstein-Barr	O
virus	O
seropositivity	O
on	O
the	O
efficacy	O
of	O
intravenous	O
immune	B-GENE
globulin	I-GENE
in	O
children	O
with	O
immune	O
thrombocytopenic	O
purpura	O
.	O

Malaria	O
had	O
diminished	O
significantly	O
by	O
the	O
early	O
1940s	O
,	O
and	O
this	O
paper	O
queries	O
whether	O
that	O
reduction	O
was	O
due	O
to	O
the	O
control	O
projects	O
of	O
the	O
thirties	O
,	O
and	O
,	O
if	O
so	O
,	O
whether	O
such	O
projects	O
should	O
be	O
a	O
model	O
for	O
the	O
current	O
developing	O
world	O
,	O
where	O
malaria	O
is	O
a	O
growing	O
problem	O
today	O
.	O

Plasma	O
renin	B-GENE
activity	O
did	O
not	O
change	O
in	O
response	O
to	O
head-up	O
tilt	O
or	O
isoprenaline	O
infusion	O
in	O
the	O
patients	O
.	O

On	O
the	O
role	O
of	O
transferrin	B-GENE
in	O
the	O
uptake	O
of	O
gallium	O
by	O
tumor	O
cells	O
.	O

Spatial	O
accuracy	O
of	O
primary	O
and	O
secondary	O
memory-guided	O
saccades	O
in	O
schizophrenic	O
patients	O
.	O

A	O
16-year	O
follow-up	O
study	O
of	O
69	O
paraplegics	O
with	O
complete	O
lesions	O
from	O
T1-L3	O
is	O
presented	O
.	O

Combination	O
of	O
a	O
Shwachman	O
syndrome	O
and	O
a	O
complex	O
granulocyte	O
function	O
disorder	O
in	O
a	O
girl	O
.	O

This	O
shows	O
that	O
in	O
situations	O
of	O
separated	O
breaks	O
,	O
NHEJ	O
deficiency	O
leads	O
to	O
genomic	O
rearrangements	O
,	O
in	O
agreement	O
with	O
chromosomal	O
studies	O
.	O

Interestingly	O
,	O
the	O
IR5	B-GENE
ORF	I-GENE
of	O
EHV-1	O
possesses	O
a	O
sequence	O
of	O
13	O
amino	O
acids	O
(	O
CAYWCCLGHAFAC	B-GENE
)	O
that	O
is	O
a	O
perfect	O
match	O
to	O
the	O
consensus	O
zinc	O
finger	O
motif	O
(	O
C-X2-4-C-X2-15-C	B-GENE
/	I-GENE
H-X2-4-C	I-GENE
/	I-GENE
H	I-GENE
)	O
.	O

Mutating	O
a	O
potential	O
cleavage	O
site	O
located	O
N-terminal	O
to	O
the	O
protease	B-GENE
domain	I-GENE
,	I-GENE
Gln2526-Asp2527	I-GENE
,	O
diminished	O
processing	O
.	O

The	O
German	O
Society	O
of	O
Pediatric	O
Oncology	O
in	O
1981	O
initiated	O
the	O
Cooperative	O
Ewing's	O
Sarcoma	O
Study	O
(	O
CESS	O
81	O
)	O
using	O
a	O
four-drug	O
combination	O
of	O
chemotherapy	O
prior	O
to	O
definitive	O
local	O
control	O
with	O
surgery	O
and	O
/	O
or	O
radiation	O
.	O

An	O
RME1-independent	O
pathway	O
for	O
sporulation	O
control	O
in	O
Saccharomyces	O
cerevisiae	O
acts	O
through	O
IME1	B-GENE
transcript	I-GENE
accumulation	O
.	O

Reversal	O
of	O
the	O
increase	O
in	O
apomorphine-induced	O
stereotypy	O
and	O
aggression	O
in	O
REM	O
sleep	O
deprived	O
rats	O
by	O
dopamine	O
agonist	O
pretreatments	O
.	O

The	O
effect	O
of	O
osmotic	O
flow	O
on	O
the	O
distribution	O
of	O
horseradish	B-GENE
peroxidase	I-GENE
within	O
the	O
intercellular	O
spaces	O
of	O
toad	O
bladder	O
epithelium	O
.	O

There	O
was	O
no	O
evident	O
inciting	O
agent	O
of	O
the	O
disease	O
.	O

A	O
three-phased	O
analysis	O
of	O
treatment	O
plans	O
for	O
45	O
patients	O
was	O
undertaken	O
.	O

M	O
.	O
,	O
and	O
D	O
.	O

Here	O
we	O
show	O
that	O
a	O
novel	O
isoform	O
of	O
Rapl	B-GENE
GTPase-activating	I-GENE
protein	I-GENE
,	O
called	O
rap1GAPII	B-GENE
,	O
binds	O
specifically	O
to	O
the	O
alpha-subunits	O
of	O
the	O
G	B-GENE
(	I-GENE
i	I-GENE
)	I-GENE
family	I-GENE
of	O
heterotrimeric	B-GENE
G-proteins	I-GENE
.	O

The	O
kappa	O
coefficient	O
of	O
agreement	O
between	O
the	O
Patho	O
Dx	O
Kit	O
and	O
the	O
standard	O
method	O
was	O
0	O
.	O
958	O
.	O

Transient	O
transfection	O
assays	O
using	O
reporter	O
gene	O
constructs	O
containing	O
various	O
lengths	O
of	O
the	O
5'	B-GENE
mdr1b	I-GENE
sequences	I-GENE
revealed	O
that	O
the	O
sequence	O
located	O
between-247	O
to	O
-126	O
bp	O
was	O
important	O
for	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
in	O
many	O
different	O
cell	O
lines	O
.	O

It	O
is	O
concluded	O
that	O
opiate	B-GENE
receptors	I-GENE
bordering	O
the	O
fourth	O
cerebral	O
ventricle	O
mediate	O
the	O
cardiovascular	O
and	O
hypnotic	O
action	O
of	O
fentanyl	O
.	O

A	O
number	O
of	O
serological	O
tests	O
measuring	O
the	O
presence	O
of	O
Helicobacter	O
pylori-specific	O
serum	O
immunoglobulin	B-GENE
G	I-GENE
(	O
IgG	B-GENE
)	O
are	O
now	O
commercially	O
available	O
.	O

BACKGROUND	O
:	O
Delineation	O
of	O
the	O
morphologic	O
aspects	O
of	O
age-related	O
macular	O
degeneration	O
(	O
ARMD	O
)	O
is	O
helpful	O
in	O
correlation	O
with	O
the	O
clinical	O
features	O
and	O
may	O
contribute	O
to	O
understanding	O
the	O
pathogenesis	O
.	O

Twenty-three	O
sequence-tagged	O
sites	O
(	O
STSs	O
)	O
were	O
mapped	O
within	O
the	O
contig	O
,	O
a	O
density	O
of	O
approximately	O
1	O
per	O
200	O
kb	O
.	O

RT-PCR	O
and	O
in	O
situ	O
hybridization	O
analyses	O
of	O
a	O
time	O
course	O
of	O
juvenile	O
testis	O
development	O
indicate	O
that	O
Spo11	B-GENE
expression	O
begins	O
in	O
early	O
meiotic	O
Prophase	O
I	O
,	O
prior	O
to	O
the	O
pachytene	O
stage	O
,	O
with	O
increasing	O
accumulation	O
of	O
mRNA	O
through	O
the	O
pachytene	O
stage	O
.	O

However	O
,	O
the	O
beta5L	B-GENE
splice	I-GENE
variant	I-GENE
was	O
found	O
only	O
in	O
the	O
retina	O
.	O

The	O
P-wr	B-GENE
and	O
P-rr	B-GENE
cDNA	I-GENE
sequences	I-GENE
are	O
very	O
similar	O
in	O
their	O
5'	O
regions	O
.	O

By	O
site-specific	O
mutagenesis	O
,	O
we	O
also	O
show	O
that	O
individual	O
ICP27	B-GENE
C-terminal	I-GENE
amino	I-GENE
acid	I-GENE
residues	I-GENE
that	O
are	O
positionally	O
conserved	O
in	O
ICP27	B-GENE
homologs	I-GENE
in	O
other	O
herpesviruses	O
(	O
D-357	O
,	O
E-358	O
,	O
H-479	O
,	O
C-400	O
,	O
C-483	O
,	O
and	O
C-488	O
)	O
are	O
critical	O
for	O
trans-regulatory	O
activity	O
.	O

Electronic	O
structure	O
of	O
a	O
buried	O
NiSi2	O
or	O
CoSi2	O
layer	O
in	O
bulk	O
Si	O
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	B-GENE
element	I-GENE
linked	O
to	O
the	O
SV40	B-GENE
promoter	I-GENE
responded	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not	O
.	O

The	O
pWP-19	B-GENE
also	O
encodes	O
the	O
AAV	O
inverted	O
terminal	O
repeats	O
for	O
integration	O
and	O
replication	O
and	O
the	O
herpes	O
virus	O
thymidine	B-GENE
kinase	I-GENE
promoter-driven	O
gene	O
for	O
neomycin	O
resistance	O
(	O
neoR	B-GENE
)	O
.	O

Binding	O
site	O
selection	O
using	O
in	O
vitro-synthesized	O
proteins	O
reveals	O
that	O
the	O
ROR	B-GENE
alpha	I-GENE
1	I-GENE
and	O
ROR	B-GENE
alpha	I-GENE
2	I-GENE
isoforms	I-GENE
bind	O
DNA	O
as	O
monomers	O
to	O
hormone	B-GENE
response	I-GENE
elements	I-GENE
composed	O
of	O
a	O
6-bp	O
AT-rich	O
sequence	O
preceding	O
a	O
half-site	O
core	B-GENE
motif	I-GENE
PuGGTCA	I-GENE
(	O
RORE	B-GENE
)	O
.	O

Genotoxic	O
activity	O
of	O
a	O
tobacco-specific	O
nitrosamine	O
.	O

Our	O
findings	O
also	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
assays	O
to	O
screen	O
for	O
the	O
ligands	O
to	O
testis	B-GENE
receptor	I-GENE
2	I-GENE
and	O
hERR1	B-GENE
.	O

The	O
response	O
chain	O
in	O
each	O
component	O
was	O
maintained	O
by	O
food	O
presentation	O
under	O
a	O
fixed-ratio	O
schedule	O
.	O

Signaling	O
from	O
the	O
small	B-GENE
GTP-binding	I-GENE
proteins	I-GENE
Rac1	I-GENE
and	O
Cdc42	B-GENE
to	O
the	O
c-Jun	B-GENE
N-terminal	I-GENE
kinase	I-GENE
/	I-GENE
stress-activated	I-GENE
protein	I-GENE
kinase	I-GENE
pathway	O
.	O

METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
242	O
adult	O
cadaveric	O
renal	O
transplant	O
recipients	O
treated	O
between	O
11	O
/	O
91	O
and	O
5	O
/	O
97	O
.	O

UV	O
cross-linking	O
experiments	O
show	O
that	O
TEP	B-GENE
has	O
an	O
apparent	O
molecular	O
mass	O
of	O
approximately	O
65	O
kDa	O
.	O

Elevated	O
expression	O
of	O
a	O
previously	O
uncharacterized	O
gene	O
,	O
SPP381	B-GENE
,	O
efficiently	O
suppresses	O
the	O
growth	O
and	O
splicing	O
defects	O
of	O
a	O
temperature-sensitive	O
(	O
Ts	O
)	O
mutant	B-GENE
prp38-1	I-GENE
.	O

Based	O
on	O
a	O
type	O
I	O
error	O
of	O
0	O
.	O
05	O
,	O
our	O
study	O
had	O
a	O
power	O
greater	O
than	O
or	O
equal	O
to	O
75%	O
to	O
detect	O
group	O
differences	O
in	O
treatment	O
effect	O
of	O
greater	O
than	O
or	O
equal	O
to	O
15%	O
to	O
20%	O
.	O

Expression	O
of	O
activated	O
Cdc42	B-GENE
results	O
in	O
the	O
translocation	O
of	O
PKClambda	B-GENE
from	O
the	O
nucleus	O
into	O
the	O
cytosol	O
,	O
and	O
Cdc42	B-GENE
and	O
PKClambda	B-GENE
colocalize	O
at	O
the	O
plasma	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
.	O

NPT	B-GENE
II	I-GENE
synthesis	O
,	O
measured	O
by	O
agar	O
plate	O
assays	O
of	O
kanamycin	O
resistance	O
and	O
by	O
immunoprecipitation	O
of	O
the	O
NPT	B-GENE
II	I-GENE
protein	I-GENE
,	O
was	O
repressed	O
in	O
the	O
presence	O
of	O
cysteine	O
and	O
derepressed	O
in	O
its	O
absence	O
.	O

Also	O
like	O
the	O
thrombin	B-GENE
receptor	I-GENE
,	O
PAR2	B-GENE
can	O
be	O
activated	O
by	O
the	O
hexapeptide	O
corresponding	O
to	O
its	O
tethered	O
ligand	O
sequence	O
independent	O
of	O
receptor	O
cleavage	O
.	O

The	O
5'	O
region	O
of	O
ADH5	B-GENE
contains	O
consensus	O
binding	O
sites	O
for	O
the	O
transcriptional	O
regulatory	O
proteins	O
,	O
Sp1	B-GENE
,	O
AP2	B-GENE
,	O
LF-A1	B-GENE
,	O
NF-1	B-GENE
,	O
NF-A2	B-GENE
,	O
and	O
NF-E1	B-GENE
.	O

Tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
signaling	O
to	O
stress-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
SAPK	B-GENE
)	O
/	B-GENE
Jun	I-GENE
NH2-terminal	I-GENE
kinase	I-GENE
(	O
JNK	B-GENE
)	O
and	O
p38	B-GENE
.	O

The	O
class	B-GENE
II	I-GENE
Escherichia	I-GENE
coli	I-GENE
alanine	I-GENE
tRNA	I-GENE
synthetase	I-GENE
aminoacylates	I-GENE
RNA	I-GENE
miniduplexes	I-GENE
,	O
which	O
reconstruct	O
the	O
acceptor	O
end	O
of	O
alanine	B-GENE
tRNA	I-GENE
with	O
the	O
critical	O
G3	O
:	O
U70	O
base	O
pair	O
.	O

Breast-fed	O
newborn	O
infants	O
synthesize	O
n-6	O
long-chain	O
polyunsaturated	O
fatty	O
acids	O
already	O
during	O
the	O
first	O
week	O
of	O
life	O
,	O
but	O
the	O
contribution	O
of	O
endogenous	O
synthesis	O
to	O
the	O
total	O
plasma	O
long-chain	O
polyunsaturated	O
pool	O
is	O
small	O
.	O

Elevation	O
of	O
intracellular	O
Ca	O
(	O
2+	O
)	O
levels	O
are	O
also	O
involved	O
because	O
treatment	O
with	O
receptor-associated	O
protein	O
,	O
nifedipine	O
,	O
MK801	O
,	O
removal	O
of	O
Ca	O
(	O
2+	O
)	O
from	O
the	O
medium	O
and	O
dantrolene	O
all	O
served	O
to	O
inhibit	O
calcium	O
elevation	O
and	O
attenuate	O
the	O
activation	O
of	O
CREB	B-GENE
.	O

Ten	O
days	O
of	O
cefadroxil	O
therapy	O
was	O
used	O
to	O
treat	O
44	O
children	O
with	O
urinary	O
tract	O
infection	O
and	O
CRP	B-GENE
values	O
greater	O
than	O
or	O
equal	O
to	O
28	O
microgram	O
/	O
ml	O
(	O
CRP-positive	O
group	O
)	O
.	O

Studies	O
on	O
the	O
life	O
cycle	O
of	O
Haplorchis	O
pumilio	O
(	O
Looss	O
,	O
1896	O
)	O
Looss	O
,	O
1899	O
with	O
morphological	O
redescription	O
of	O
larval	O
and	O
adult	O
stages	O
.	O

R	O
.	O

The	O
amino	O
acid	O
sequence	O
alignment	O
of	O
TC	B-GENE
II	I-GENE
with	O
that	O
of	O
other	O
Cbl	B-GENE
binding	I-GENE
proteins	I-GENE
(	O
rat	B-GENE
intrinsic	I-GENE
factor	I-GENE
,	O
human	B-GENE
transcobalamin	I-GENE
I	I-GENE
and	O
porcine	B-GENE
haptocorrin	I-GENE
)	O
revealed	O
only	O
33%	O
overall	O
homology	O
.	O

Temperature	O
dependence	O
of	O
the	O
sublattice	O
spontaneous	O
magnetization	O
of	O
YBa2Cu3O6	O
.	O

A	O
reassessment	O
of	O
the	O
prevalence	O
data	O
was	O
carried	O
out	O
in	O
the	O
southern	O
province	O
of	O
Uusimaa	O
and	O
in	O
the	O
western	O
province	O
of	O
Vaasa	O
,	O
the	O
prevalence	O
day	O
being	O
January	O
1	O
,	O
1979	O
.	O

New	O
technologies	O
in	O
diagnosis	O
and	O
classification	O
of	O
malignancy	O
.	O

Me	O
(	O
2	O
)	O
SO-induced	O
neuronal	O
differentiation	O
of	O
N1E-115	O
neuroblastoma	O
cells	O
increased	O
both	O
the	O
expression	O
of	O
the	O
endogenous	B-GENE
Ntr-1	I-GENE
gene	I-GENE
and	O
reporter	O
genes	O
driven	O
by	O
NTR-1	B-GENE
promoter	I-GENE
sequences	I-GENE
by	O
3-4-fold	O
.	O

This	O
phenomenon	O
may	O
be	O
regarded	O
as	O
a	O
variant	O
of	O
selective	O
individual	O
cell	O
death	O
,	O
currently	O
referred	O
to	O
as	O
apoptosis	O
,	O
which	O
has	O
not	O
been	O
previously	O
reported	O
in	O
a	O
case	O
of	O
embryonal	O
rhabdomyosarcoma	O
.	O

The	O
E6	B-GENE
/	I-GENE
E7	I-GENE
promoter	I-GENE
of	O
all	O
genital	O
human	O
papillomaviruses	O
is	O
responsible	O
for	O
expression	O
of	O
the	O
viral	B-GENE
transforming	I-GENE
genes	I-GENE
.	O

The	O
effect	O
of	O
calcitonin	B-GENE
,	O
a	O
large	O
amount	O
of	O
calcium	O
given	O
orally	O
,	O
pentagastrin	O
and	O
glucagon	O
on	O
plasma	O
47Ca	O
radioactivity	O
curves	O
in	O
subjects	O
pretreated	O
with	O
47Ca	O
was	O
examined	O
.	O

CO2	O
assimilation	O
by	O
chloroplasts	O
illuminated	O
on	O
filter	O
paper	O
.	O

Comparative	O
analysis	O
of	O
various	O
techniques	O
of	O
prostatic	O
drainage	O
in	O
patients	O
with	O
chronic	O
obstructive	O
prostatitis	O
The	O
efficacy	O
of	O
prostatic	O
drainage	O
using	O
transurethral	O
vacuum	O
aspiration	O
(	O
Introl-4	O
unit	O
)	O
and	O
transrectal	O
pneumovibromassage	O
(	O
PVM-R-01	O
)	O
was	O
compared	O
in	O
1511	O
patients	O
with	O
chronic	O
obstructive	O
prostatitis	O
.	O

As	O
the	O
rate	O
of	O
protein	O
synthesis	O
decreases	O
during	O
late	O
embryogenesis	O
,	O
levels	O
of	O
SEC-1	B-GENE
and	O
its	O
cognate	O
mRNA	O
decline	O
precipitously	O
.	O

The	O
presence	O
of	O
type	O
I	O
hypersensitivity	O
in	O
a	O
subgroup	O
of	O
aspergillomas	O
suggests	O
an	O
immunoallergic	O
component	O
to	O
this	O
disease	O
which	O
could	O
contribute	O
to	O
a	O
chronic	O
inflammatory	O
response	O
to	O
Aspergillus	O
in	O
some	O
aspergillomas	O
.	O

No	O
TATA	O
or	O
Inr	B-GENE
sequence	I-GENE
was	O
found	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
roles	O
of	O
two	O
putative	O
cis-acting	O
elements	O
within	O
the	O
-73	O
to	O
+44	O
region	O
in	O
basal	O
exon	O
2	O
promoter	O
activity	O
were	O
evaluated	O
using	O
mutagenesis	O
and	O
nuclear	O
protein-DNA	O
binding	O
assays	O
.	O

Radionuclide	O
angiography	O
and	O
static	O
whole	O
body	O
imaging	O
performed	O
with	O
technetium-99m-labeled	O
particulates	O
can	O
clearly	O
demonstrate	O
differential	O
shunting	O
in	O
patients	O
with	O
patent	O
ductus	O
arteriosus	O
(	O
PDA	O
)	O
with	O
Eisenmenger	O
physiology	O
.	O

The	O
evolution	O
of	O
the	O
CCR5	B-GENE
cis-regulatory	I-GENE
region	I-GENE
versus	O
the	O
open	O
reading	O
frame	O
as	O
well	O
as	O
among	O
different	O
domains	O
of	O
the	O
open	O
reading	O
frame	O
differed	O
from	O
one	O
another	O
.	O

PURPOSE	O
:	O
A	O
two-generation	O
consanguineous	O
Pakistani	O
family	O
with	O
autosomal	O
recessive	O
Leber	O
congenital	O
amaurosis	O
(	O
LCA	O
,	O
MIM	O
204	O
,	O
000	O
)	O
and	O
keratoconus	O
was	O
identified	O
.	O

Gene	O
and	O
pseudogene	O
of	O
the	O
mouse	O
cation-dependent	O
mannose	B-GENE
6-phosphate	I-GENE
receptor	I-GENE
.	O

L-735	O
,	O
524	O
free	O
base	O
or	O
sulfate	O
salt	O
was	O
administered	O
orally	O
as	O
suspension	O
,	O
solution	O
or	O
in	O
solid	O
dosage	O
forms	O
to	O
fasted	O
or	O
fed	O
Beagle	O
dogs	O
.	O

The	O
results	O
strongly	O
support	O
the	O
notion	O
that	O
the	O
OBF1-binding	B-GENE
sites	I-GENE
and	O
the	O
OBF1	B-GENE
protein	I-GENE
are	O
important	O
for	O
normal	O
ARS	B-GENE
function	O
as	O
an	O
origin	O
of	O
replication	O
.	O

Moreover	O
,	O
in	O
one	O
patient	O
with	O
a	O
sarcoma	O
who	O
underwent	O
a	O
leg-sparing	O
procedure	O
,	O
no	O
sciatic	O
nerve	O
enlargement	O
was	O
seen	O
postoperatively	O
.	O

The	O
GHR	B-GENE
mRNA	I-GENE
:	O
GHBP	B-GENE
mRNA	I-GENE
ratio	O
was	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
12	O
and	O
remained	O
unchanged	O
during	O
differentiation	O
.	O

D	O
.	O

After	O
tilting	O
,	O
systolic	O
blood	O
pressure	O
fell	O
an	O
average	O
of	O
17%	O
in	O
patients	O
who	O
cramped	O
infrequently	O
(	O
p	O
=	O
0	O
.	O
0031	O
)	O
but	O
only	O
10%	O
in	O
frequently	O
cramping	O
patients	O
.	O

The	O
tissue	O
specificity	O
of	O
gene	O
expression	O
was	O
identical	O
to	O
that	O
described	O
previously	O
for	O
the	O
CaMV	B-GENE
35S	I-GENE
domain	I-GENE
B	I-GENE
enhancer	I-GENE
element	I-GENE
.	O

Substitution	O
of	O
the	O
Ser-Thr	O
sites	O
with	O
the	O
phosphomimetic	O
Asp	O
generated	O
a	O
constitutively	O
active	O
form	O
of	O
IRF-3	B-GENE
that	O
functioned	O
as	O
a	O
very	O
strong	O
activator	O
of	O
promoters	O
containing	O
PRDI-PRDIII	B-GENE
or	O
ISRE	B-GENE
regulatory	I-GENE
elements	I-GENE
.	O

Palindromic	O
rheumatism	O
.	O

Precipitation	O
using	O
GST	B-GENE
fusion	I-GENE
proteins	I-GENE
containing	O
Fyn	B-GENE
SH2	B-GENE
,	O
SH3	B-GENE
,	O
and	O
SH2	B-GENE
/	I-GENE
SH3	I-GENE
domains	I-GENE
revealed	O
that	O
PI	B-GENE
3-kinase	I-GENE
bound	O
principally	O
to	O
the	O
SH3	B-GENE
domain	I-GENE
of	O
Fyn	B-GENE
.	O

Five	O
of	O
the	O
Aeromonas	O
strains	O
and	O
one	O
of	O
V	O
cholerae	O
non-O1	O
were	O
positive	O
for	O
enterotoxin	B-GENE
activity	O
.	O

Northern	O
blot	O
analysis	O
of	O
total	O
cellular	O
RNA	O
indicated	O
that	O
xylP	B-GENE
encodes	O
a	O
1	O
.	O
3-kb	O
transcript	O
which	O
is	O
induced	O
by	O
xylan	O
.	O

Effects	O
of	O
spatial	O
and	O
temporal	O
smoothing	O
on	O
stimulated	O
brillouin	O
scattering	O
in	O
the	O
independent-hot-spot	O
model	O
limit	O
The	O
influence	O
of	O
laser	O
beam	O
smoothing	O
on	O
stimulated	O
Brillouin	O
backscattering	O
(	O
SBBS	O
)	O
is	O
studied	O
analytically	O
in	O
the	O
limit	O
of	O
the	O
independent	O
hot	O
spot	O
model	O
.	O

A	O
second	O
domain	O
,	O
located	O
in	O
the	O
C-terminal	O
437	O
amino	O
acids	O
of	O
IE1	B-GENE
,	O
is	O
required	O
for	O
inhibitory	O
and	O
DNA-binding	O
activities	O
.	O

Mean	O
(	O
+	O
/	O
-	O
SE	O
)	O
measurements	O
of	O
clearance	O
(	O
24	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
06	O
v	O
26	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
05	O
mL	O
/	O
min	O
/	O
m2	O
)	O
,	O
half-life	O
(	O
5	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
v	O
6	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
5	O
hours	O
)	O
,	O
and	O
volume	O
of	O
distribution	O
(	O
12	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
1	O
v	O
13	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
6	O
L	O
/	O
m2	O
)	O
were	O
not	O
significantly	O
different	O
in	O
patients	O
with	O
jaundice	O
when	O
compared	O
with	O
controls	O
.	O

Immunity	O
acquired	O
by	O
mice	O
during	O
I	O
.	O
scapularis	O
nymphal	O
activity	O
in	O
early	O
summer	O
may	O
exclude	O
a	O
large	O
proportion	O
of	O
the	O
mouse	O
population	O
from	O
maintaining	O
E	O
.	O
phagocytophila	O
during	O
the	O
period	O
of	O
larval	O
activity	O
later	O
in	O
the	O
season	O
.	O

To	O
evaluate	O
the	O
gas	O
chromatographic	O
electron	O
capture	O
detection	O
method	O
described	O
earlier	O
,	O
23	O
plasma	O
samples	O
have	O
been	O
analysed	O
by	O
both	O
techniques	O
.	O

Despite	O
abundant	O
expression	O
of	O
NtmybAS	B-GENE
transcripts	I-GENE
in	O
mature	O
pollen	O
,	O
gPAL1	B-GENE
transcripts	I-GENE
were	O
not	O
detectable	O
in	O
pollen	O
.	O

Moreover	O
,	O
Lck	B-GENE
was	O
reversibly	O
co-immunoprecipitated	O
with	O
p95Vav	B-GENE
,	O
and	O
the	O
stoichiometry	O
of	O
binding	O
increased	O
in	O
anti-CD3-treated	O
Jurkat	O
cells	O
.	O

The	O
muscles	O
from	O
the	O
ischemic	O
group	O
had	O
significantly	O
lower	O
(	O
P	O
less	O
than	O
.	O
05	O
)	O
values	O
for	O
capillary	O
density	O
and	O
capillary	O
to	O
fiber	O
ratio	O
and	O
significantly	O
higher	O
intercapillary	O
distance	O
than	O
those	O
from	O
the	O
normal	O
group	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
series	O
of	O
plasmid	O
constructs	O
encoding	O
different	O
forms	O
of	O
the	O
envelope	B-GENE
glycoprotein	I-GENE
E	I-GENE
of	I-GENE
the	I-GENE
flavivirus	I-GENE
tick-borne	I-GENE
encephalitis	I-GENE
virus	I-GENE
.	O

We	O
constructed	O
a	O
yeast	O
reporter	O
strain	O
containing	O
the	O
lacZ	B-GENE
gene	I-GENE
under	O
the	O
control	O
of	O
the	O
CYC1	B-GENE
promoter	I-GENE
associated	O
with	O
three	O
copies	O
of	O
TRE-1	B-GENE
.	O

Differences	O
in	O
profiles	O
of	O
viscosity	O
variables	O
between	O
subgroups	O
of	O
EAD	O
in	O
RA	O
patients	O
were	O
observed	O
.	O

Male	O
contraception	O
:	O
ideas	O
for	O
the	O
future	O
.	O

Fifteen	O
light	O
for	O
dates	O
infants	O
and	O
their	O
placentae	O
were	O
compared	O
to	O
15	O
well-grown	O
infants	O
and	O
their	O
placentae	O
.	O

Although	O
it	O
has	O
two	O
potential	O
binding	O
sites	O
,	O
the	O
purified	O
MerR	B-GENE
homodimer	I-GENE
binds	O
only	O
one	O
Hg	O
(	O
II	O
)	O
ion	O
,	O
employing	O
Cys82	O
from	O
one	O
monomer	O
and	O
Cys117	O
and	O
Cys126	O
from	O
the	O
other	O
.	O

The	O
envelope	B-GENE
glycoproteins	I-GENE
of	I-GENE
Rous	I-GENE
sarcoma	I-GENE
virus	I-GENE
(	I-GENE
RSV	I-GENE
)	I-GENE
,	O
gp85	B-GENE
and	O
gp37	B-GENE
,	O
are	O
anchored	O
in	O
the	O
membrane	O
by	O
a	O
27-amino	O
acid	O
,	O
hydrophobic	O
domain	O
that	O
lies	O
adjacent	O
to	O
a	O
22-amino	O
acid	O
,	O
cytoplasmic	O
domain	O
at	O
the	O
carboxy	O
terminus	O
of	O
gp37	B-GENE
.	O

HupI	B-GENE
showed	O
strong	O
identity	O
to	O
rubredoxin	B-GENE
and	O
rubredoxin-like	B-GENE
proteins	I-GENE
from	O
many	O
other	O
bacteria	O
.	O

The	O
already	O
elevated	O
prolactin	B-GENE
levels	O
in	O
nursing	O
women	O
were	O
not	O
influenced	O
by	O
chronic	O
oestradiol	O
administration	O
.	O

Osteocalcin	B-GENE
(	O
serum	B-GENE
bone-Gla	I-GENE
protein	I-GENE
,	O
sBGP	B-GENE
)	O
,	O
serum	B-GENE
alkaline	I-GENE
phosphatase	I-GENE
(	O
sAP	B-GENE
)	O
and	O
urinary	O
hydroxyproline	O
/	O
creatinine	O
ratio	O
(	O
uOH-Prol	O
/	O
creatinine	O
)	O
have	O
been	O
measured	O
in	O
21	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHPT	O
)	O
and	O
in	O
nine	O
patients	O
with	O
hypercalcaemia	O
of	O
malignancy	O
(	O
HM	O
)	O
.	O

During	O
the	O
conditioning	O
procedure	O
,	O
the	O
C-fiber	O
reflex	O
was	O
facilitated	O
(	O
wind-up	O
)	O
in	O
a	O
stimulus-dependent	O
fashion	O
in	O
intact	O
,	O
anesthetized	O
animals	O
during	O
the	O
application	O
of	O
the	O
first	O
seven	O
conditioning	O
stimuli	O
;	O
thereafter	O
,	O
the	O
magnitude	O
of	O
the	O
responses	O
reached	O
a	O
plateau	O
and	O
then	O
decreased	O
.	O

In	O
35	O
of	O
those	O
patients	O
DD	O
was	O
measured	O
also	O
with	O
microlatex	O
tests--Tinaquant	O
and	O
BC	O
d-dimer	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
discuss	O
the	O
factors	O
involved	O
in	O
the	O
selection	O
of	O
antibodies	O
,	O
radionuclides	O
and	O
labeling	O
methods	O
in	O
the	O
development	O
of	O
radioimmunotherapy	O
(	O
RIT	O
)	O
for	O
non-Hodgkin's	O
lymphoma	O
(	O
NHL	O
)	O
from	O
a	O
single	O
clinical	O
study	O
site	O
through	O
multicenter	O
trials	O
and	O
commercialization	O
.	O

For	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
disease	O
,	O
the	O
data	O
suggest	O
that	O
I-131	O
MIBG	O
scintigraphy	O
is	O
the	O
examination	O
of	O
choice	O
.	O

In	O
contrast	O
,	O
the	O
Anabaena	O
strain	O
7120	O
leuA	B-GENE
gene	O
did	O
not	O
complement	O
the	O
nifV	B-GENE
mutation	I-GENE
of	O
R229I	O
efficiently	O
.	O

Y15170	B-GENE
(	O
Surf-2	B-GENE
,	O
Surf-4	B-GENE
)	O
,	O
Y15171	B-GENE
(	O
Surf-3	B-GENE
,	O
Surf-1	B-GENE
,	O
Surf-6	B-GENE
)	O
,	O
and	O
Y15172	B-GENE
(	O
Surf-5	B-GENE
.	O
)	O
]	O

Yusuf	O
Dawood	O
Docrat	O
L	O
.	O
R	O
.	O
C	O
.	O
P	O
.	O

A	O
total	O
of	O
576	O
1-day-old	O
Ross	O
broiler	O
chicks	O
were	O
housed	O
in	O
six	O
treatment	O
groups	O
[	O
six	O
replicates	O
of	O
16	O
each	O
;	O
control	O
,	O
CLI	O
(	O
15	O
g	O
kg	O
(	O
-1	O
)	O
diet	O
)	O
,	O
50	O
parts	O
per	O
billion	O
(	O
ppb	O
)	O
AF	O
,	O
50	O
ppb	O
AF	O
plus	O
CLI	O
,	O
100	O
ppb	O
AF	O
,	O
100	O
ppb	O
AF	O
plus	O
CLI	O
]	O
for	O
42	O
days	O
.	O

Anti-HBc	B-GENE
production	O
of	O
PBMC	O
was	O
enhanced	O
remarkably	O
in	O
this	O
case	O
.	O

The	O
RNA-binding	O
and	O
RNA-DNA	B-GENE
helicase	I-GENE
activities	O
of	O
the	O
Escherichia	B-GENE
coli	I-GENE
transcription	I-GENE
termination	I-GENE
factor	I-GENE
rho	I-GENE
have	O
been	O
investigated	O
using	O
natural	O
RNA	O
molecules	O
that	O
are	O
255	O
and	O
391	O
nucleotide	O
residues	O
in	O
length	O
and	O
that	O
contain	O
the	O
trp	B-GENE
t'	I-GENE
rho-dependent	I-GENE
termination	I-GENE
sequence	I-GENE
of	O
E	O
.	O
coli	O
.	O

Effects	O
of	O
chronic	O
descending	O
tractotomy	O
on	O
the	O
response	O
patterns	O
of	O
neurons	O
in	O
the	O
trigeminal	O
nuclei	O
principalis	O
and	O
oralis	O
.	O

Short	O
therapy	O
with	O
omeprazole	O
20	O
mg	O
/	O
b	O
.	O
i	O
.	O
d	O
.	O
,	O
clarithromycin	O
500	O
mg	O
/	O
b	O
.	O
i	O
.	O
d	O
.	O
,	O
and	O
CBS	O
120	O
mg	O
/	O
q	O
.	O
i	O
.	O
d	O
.	O
is	O
a	O
safe	O
,	O
well	O
tolerated	O
combination	O
that	O
achieves	O
a	O
80	O
.	O
6%	O
eradication	O
rate	O
of	O
H	O
.	O
pylori	O
and	O
duodenal	O
ulcer	O
healing	O
rates	O
as	O
good	O
as	O
those	O
achieved	O
by	O
omeprazole	O
20	O
mg	O
/	O
d	O
when	O
given	O
for	O
4	O
wk	O
.	O

Using	O
adenoviral	O
transfer	O
of	O
IkappaBalpha	B-GENE
(	O
IkappaBalpha	B-GENE
overexpression	O
)	O
,	O
the	O
production	O
of	O
TNF-alpha	B-GENE
induced	O
by	O
whole	O
GBS	O
was	O
inhibited	O
by	O
only	O
20%	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
isolated	O
and	O
sequenced	O
several	O
p15E	B-GENE
cDNA	I-GENE
gene	I-GENE
fragments	I-GENE
amplified	O
by	O
means	O
of	O
polymerase	B-GENE
chain	O
reaction	O
(	O
PCR	O
)	O
from	O
parental	O
(	O
P815	O
)	O
and	O
xenogenized	O
(	O
P815	O
/	O
DTIC	O
)	O
tumour	O
cells	O
.	O

Documentation	O
of	O
a	O
successful	O
intrauterine	O
fertilization	O
with	O
delivery	O
of	O
a	O
term	O
baby	O
supports	O
the	O
theoretical	O
feasibility	O
of	O
the	O
EP	O
;	O
however	O
,	O
anovulation	O
incurred	O
by	O
our	O
procedure	O
appears	O
to	O
be	O
the	O
major	O
drawback	O
.	O

4	O
.	O
26	O
+	O
/	O
-	O
1	O
.	O
54	O
mmol	O
/	O
l	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
systolic	O
BP	O
responses	O
to	O
intravenous	O
norepinephrine	O
and	O
angiotensin	B-GENE
II	I-GENE
were	O
significantly	O
higher	O
on	O
glibenclamide	O
than	O
on	O
metformin	O
(	O
P	O
<	O
0	O
.	O
02	O
and	O
P	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O

Experimental	O
chlorpromazine	O
cataracts	O
.	O

Interactions	O
between	O
adrenergics	O
,	O
adrenolytics	O
and	O
monoamine	B-GENE
oxidase	I-GENE
inhibitors	O
.	O

Leukocyte	O
cultures	O
,	O
prepared	O
from	O
blood	O
drawn	O
from	O
these	O
18	O
children	O
at	O
6	O
months	O
of	O
age	O
,	O
produced	O
lower	O
yields	O
of	O
IFN	B-GENE
than	O
those	O
of	O
the	O
remaining	O
53	O
children	O
,	O
when	O
stimulated	O
with	O
adenovirus	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
coronavirus	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
or	O
rhinovirus	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

Using	O
the	O
yeast	O
two-hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B-GENE
,	O
we	O
isolated	O
the	O
B	O
subunit	O
of	O
the	O
CCAAT	B-GENE
binding	I-GENE
protein	I-GENE
NF-Y	B-GENE
from	O
a	O
HeLa	O
cDNA	O
library	O
.	O

Amisulpride	O
400	O
mg	O
had	O
several	O
adverse	O
effects	O
on	O
psychomotor	O
and	O
,	O
although	O
less	O
severe	O
,	O
on	O
cognitive	O
performance	O
on	O
the	O
fifth	O
day	O
only	O
.	O

The	O
pharmacokinetic	O
profiles	O
of	O
digoxin	O
and	O
warfarin	O
were	O
not	O
altered	O
by	O
the	O
simultaneous	O
and	O
continued	O
administration	O
of	O
sevelamer	O
.	O

Band-shift	O
assays	O
and	O
DNase	B-GENE
I	I-GENE
footprinting	O
experiments	O
using	O
purified	O
42	O
kDa	O
repressor	O
isoform	O
confirmed	O
that	O
CIRs	B-GENE
5	I-GENE
and	I-GENE
6	I-GENE
were	O
indeed	O
the	O
targets	O
for	O
binding	O
of	O
this	O
protein	O
.	O

Immediate-early	O
transcription	O
from	O
the	O
channel	O
catfish	O
virus	O
genome	O
:	O
characterization	O
of	O
two	O
immediate-early	B-GENE
transcripts	I-GENE
.	O

The	O
average	O
backscatter	O
coefficient	O
was	O
six	O
time	O
larger	O
in	O
regions	O
of	O
infarct	O
studied	O
8--10	O
weeks	O
after	O
occlusion	O
than	O
that	O
in	O
regions	O
of	O
infarct	O
studied	O
5--6	O
weeks	O
after	O
occlusion	O
.	O

INTERVENTIONS	O
:	O
Study	O
patients	O
were	O
randomly	O
divided	O
into	O
four	O
parallel	O
groups	O
to	O
receive	O
either	O
terbinafine	O
250	O
mg	O
a	O
day	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
T12	O
and	O
T16	O
)	O
or	O
itraconazole	O
400	O
mg	O
a	O
day	O
for	O
1	O
week	O
in	O
every	O
4	O
weeks	O
for	O
12	O
or	O
16	O
weeks	O
(	O
groups	O
I3	O
and	O
I4	O
)	O
.	O

However	O
,	O
limited	O
comparisons	O
reveal	O
domains	O
in	O
the	O
NH2	O
and	O
COOH	O
termini	O
that	O
have	O
a	O
high	O
degree	O
of	O
similarity	O
suggesting	O
functional	O
conservation	O
.	O

Interaction	O
of	O
HRI	B-GENE
with	O
Hsc70	B-GENE
was	O
required	O
for	O
the	O
transformation	O
of	O
HRI	B-GENE
,	O
as	O
the	O
Hsc70	B-GENE
antagonist	O
clofibric	O
acid	O
inhibited	O
the	O
folding	O
of	O
HRI	B-GENE
into	O
a	O
mature-competent	O
conformation	O
.	O

The	O
levels	O
of	O
transactivation	O
are	O
correlated	O
with	O
the	O
respective	O
binding	O
affinities	O
of	O
the	O
response	O
elements	O
(	O
IRper-1	B-GENE
>	O
DR-4	B-GENE
>	O
IRhsp-1	B-GENE
)	O
.	O

Long-term	O
results	O
with	O
MACOP-B	O
and	O
radiation	O
therapy	O
for	O
aggressive	O
lymphomas	O
BACKGROUND	O
:	O
Long-term	O
results	O
are	O
needed	O
to	O
evaluate	O
chemotherapy	O
regimens	O
and	O
prognostic	O
factors	O
in	O
non-Hodgkin's	O
lymphomas	O
(	O
NHL	O
)	O
.	O

In	O
analyses	O
with	O
control	O
for	O
multiple	O
variables	O
,	O
relative	O
risk	O
for	O
microalbuminuria	O
(	O
urinary	O
albumin	B-GENE
excretion	O
,	O
20-199	O
microg	O
/	O
min	O
)	O
in	O
men	O
and	O
women	O
was	O
2	O
.	O
51	O
and	O
1	O
.	O
62	O
,	O
respectively	O
,	O
with	O
18	O
mm	O
Hg	O
higher	O
(	O
1	O
SD	O
)	O
systolic	O
blood	O
pressure	O
;	O
2	O
.	O
25	O
and	O
2	O
.	O
10	O
,	O
respectively	O
,	O
with	O
1	O
.	O
0-mmol	O
/	O
L	O
(	O
40	O
mg	O
/	O
dL	O
)	O
higher	O
plasma	O
cholesterol	O
level	O
;	O
1	O
.	O
99	O
and	O
1	O
.	O
91	O
,	O
respectively	O
,	O
for	O
smokers	O
vs	O
nonsmokers	O
;	O
and	O
1	O
.	O
83	O
and	O
1	O
.	O
33	O
,	O
respectively	O
,	O
with	O
4	O
kg	O
/	O
m2	O
higher	O
body	O
mass	O
index	O
.	O

Solving	O
an	O
age	O
old	O
problem	O
.	O

DNA	O
sequencing	O
of	O
a	O
17-kb	O
segment	O
encompassing	O
a	O
gammaherpesvirus	O
divergent	O
locus	O
(	O
DL-B	O
)	O
between	O
ORF11	O
and	O
ORF17	O
revealed	O
the	O
presence	O
of	O
nine	O
viral	O
ORFs	O
with	O
predicted	O
gene	O
products	O
related	O
to	O
cellular	O
proteins	O
.	O

Here	O
we	O
describe	O
the	O
cloning	O
,	O
tissue-specific	O
expression	O
pattern	O
,	O
and	O
functional	O
characterization	O
of	O
two	O
novel	O
TEF-1	B-GENE
isoforms	I-GENE
,	O
TEF-1beta	B-GENE
and	O
TEF-1gamma	B-GENE
.	O

The	O
RFLP	O
patterns	O
of	O
the	O
isolates	O
from	O
six	O
of	O
these	O
patients	O
remained	O
essentially	O
unchanged	O
(	O
two	O
strains	O
showed	O
one	O
additional	O
band	O
)	O
despite	O
the	O
development	O
of	O
drug	O
resistance	O
.	O

Max	B-GENE
:	O
functional	O
domains	O
and	O
interaction	O
with	O
c-Myc	B-GENE
.	O

Conversely	O
,	O
treatment	O
of	O
human	B-GENE
protein-tyrosine	I-GENE
phosphatase	I-GENE
alpha-overexpressing	O
cells	O
with	O
phenylarsine	O
oxide	O
led	O
to	O
a	O
loss	O
of	O
the	O
constitutive	O
NF-kappa	B-GENE
B	I-GENE
activity	O
.	O

2	O
cases	O
of	O
toxic	O
lymphomononucleosis	O
.	O

Studies	O
on	O
the	O
pathogenicity	O
of	O
ECHO	O
9	O
(	O
HILL	O
)	O
virus	O
and	O
its	O
mutants	O
for	O
suckling	O
mice	O
.	O

1	O
,	O
among	O
which	O
nine	O
have	O
been	O
cloned	O
and	O
two	O
(	O
potentially	O
functional	O
)	O
sequenced	O
.	O

Using	O
immunogold	O
electron	O
microscopy	O
,	O
we	O
found	O
that	O
p58	B-GENE
/	I-GENE
p45	I-GENE
and	O
p54	B-GENE
are	O
localized	O
on	O
both	O
sides	O
of	O
the	O
nuclear	O
pore	O
complex	O
,	O
like	O
p62	B-GENE
.	O

HEF1	B-GENE
,	O
p130	B-GENE
(	I-GENE
Cas	I-GENE
)	I-GENE
,	O
and	O
Efs	B-GENE
/	I-GENE
Sin	I-GENE
constitute	O
a	O
family	O
of	O
multidomain	O
docking	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
coordinating	O
the	O
regulation	O
of	O
cell	O
adhesion	O
.	O

Role	O
of	O
biocenosis	O
in	O
the	O
manifestation	O
of	O
Shigella	O
virulence	O
.	O

Among	O
mammalian	B-GENE
HSFs	I-GENE
,	O
HSF1	B-GENE
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
regulation	O
of	O
the	O
heat-induced	B-GENE
stress	I-GENE
gene	I-GENE
expression	O
,	O
whereas	O
the	O
function	O
of	O
HSF2	B-GENE
in	O
stress	O
response	O
is	O
unclear	O
.	O

In	O
all	O
cells	O
,	O
the	O
accumulation	O
of	O
high	O
Dsg	B-GENE
protein	I-GENE
levels	O
required	O
calcium	O
and	O
was	O
not	O
observed	O
in	O
low	O
calcium	O
(	O
0	O
.	O
05-0	O
.	O
07	O
mM	O
)	O
media	O
.	O

Point	O
mutations	O
that	O
suppressed	O
the	O
in	O
vitro	O
binding	O
of	O
NF-Y	B-GENE
to	O
the	O
internal	O
palindromic	O
arm	O
reduced	O
the	O
activity	O
of	O
the	O
resident	O
P4	B-GENE
promoter	I-GENE
,	O
while	O
those	O
preventing	O
complex	O
formation	O
with	O
USF	B-GENE
did	O
not	O
,	O
as	O
determined	O
by	O
transient	O
expression	O
assays	O
using	O
the	O
luciferase	B-GENE
reporter	O
gene	O
.	O

Two	O
specific	O
DNA-protein	O
complexes	O
were	O
identified	O
in	O
gel	O
retardation	O
assays	O
using	O
HeLa	O
cell	O
nuclear	O
extracts	O
and	O
an	O
oligonucleotide	O
probe	O
spanning	O
the	O
footprinted	O
region	O
.	O

We	O
present	O
a	O
case	O
of	O
type	O
II	O
hyperbetalipoproteinemia	O
in	O
a	O
patient	O
whose	O
diagnosis	O
had	O
been	O
previously	O
unrecognized	O
,	O
and	O
who	O
had	O
previously	O
been	O
misdiagnosed	O
with	O
rheumatoid	O
arthritis	O
and	O
later	O
gout	O
.	O

We	O
found	O
that	O
the	O
SOCS	B-GENE
box	I-GENE
interacted	O
with	O
Cullin-2	B-GENE
and	O
promoted	O
ubiquitination	O
of	O
TEL-JAK2	B-GENE
.	O

TPA	O
and	O
TGF-beta	B-GENE
1	I-GENE
did	O
not	O
markedly	O
affect	O
the	O
activities	O
of	O
the	O
72-kDa	O
enzyme	O
.	O

The	O
remaining	O
six	O
patients	O
had	O
slightly	O
decreased	O
(	O
n	O
=	O
3	O
)	O
or	O
normal	O
(	O
n	O
=	O
3	O
)	O
seminal	O
parameters	O
.	O

AMY-1	B-GENE
was	O
localized	O
in	O
the	O
cytoplasm	O
in	O
cells	O
expressing	O
c-myc	B-GENE
at	O
low	O
levels	O
,	O
but	O
in	O
the	O
nucleus	O
in	O
the	O
cells	O
of	O
a	O
high	O
c-myc	B-GENE
expression	O
in	O
transiently	O
transfected	O
cells	O
.	O

Methysergide	O
is	O
a	O
serotonin	O
antagonist	O
and	O
has	O
been	O
demonstrated	O
to	O
reduce	O
wound	O
blood	O
flow	O
and	O
edema	O
formation	O
.	O

Imposed	O
angular	O
displacements	O
of	O
monkey's	O
wrist	O
produce	O
three	O
major	O
peaks	O
of	O
activity	O
(	O
terms	O
M1	O
,	O
M2	O
,	O
and	O
M3	O
peaks	O
)	O
in	O
the	O
averaged	O
gross	O
EMG	O
activity	O
ot	O
the	O
stretched	O
muscles	O
.	O

Because	O
the	O
adrenergic	O
nervous	O
system	O
influences	O
cardiac	O
arrhythmias	O
and	O
myocardial	O
infarction	O
can	O
directly	O
affect	O
sympathetic	O
innervation	O
in	O
the	O
heart	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
sympathetic	O
nervous	O
system	O
on	O
reentry	O
in	O
the	O
canine	O
heart	O
4	O
days	O
after	O
infarction	O
.	O

Though	O
the	O
BACTEC	O
9000	O
MB	O
system	O
is	O
recommended	O
for	O
respiratory	O
specimens	O
,	O
we	O
demonstrated	O
that	O
it	O
can	O
be	O
successfully	O
used	O
also	O
for	O
recovery	O
of	O
mycobacteria	O
from	O
clinical	O
specimens	O
from	O
various	O
extrapulmonary	O
sites	O
.	O

HL	O
02	O
type	O
oculomotor	O
stimulator	O
.	O

OBJECTIVE	O
:	O
This	O
meta-analysis	O
of	O
67	O
controlled	O
trials	O
was	O
performed	O
to	O
quantify	O
the	O
cholesterol-lowering	O
effect	O
of	O
major	O
dietary	O
fibers	O
.	O

Among	O
these	O
are	O
:	O
(	O
1	O
)	O
Is	O
there	O
sufficient	O
understanding	O
of	O
family	O
pathophysiology	O
,	O
of	O
the	O
sensitivity	O
and	O
specificity	O
of	O
diagnostic	O
techniques	O
and	O
of	O
the	O
safety	O
and	O
efficacy	O
of	O
therapeutic	O
modalities	O
to	O
make	O
true	O
family	O
health	O
care	O
possible	O
?	O
(	O
2	O
)	O
If	O
this	O
type	O
of	O
care	O
is	O
possible	O
,	O
how	O
are	O
the	O
needs	O
of	O
the	O
family	O
and	O
its	O
individual	O
members	O
met	O
,	O
or	O
value	O
judgements	O
made	O
about	O
their	O
relative	O
importance	O
?	O
and	O
(	O
3	O
)	O
What	O
are	O
the	O
consequences	O
for	O
the	O
health	O
care	O
delivery	O
system	O
of	O
this	O
type	O
of	O
care	O
?	O
An	O
extensive	O
literature	O
review	O
is	O
used	O
in	O
an	O
attempt	O
to	O
answer	O
these	O
queries	O
,	O
from	O
which	O
questions	O
for	O
further	O
study	O
are	O
posed	O
.	O

These	O
studies	O
suggest	O
an	O
additional	O
component	O
or	O
cellular	O
environment	O
is	O
required	O
for	O
SPRK	B-GENE
activation	O
by	O
Cdc42	B-GENE
.	O

The	O
response	O
of	O
serum	B-GENE
GH	I-GENE
to	O
arginine	O
infusion	O
was	O
normal	O
,	O
while	O
that	O
to	O
insulin-induced	O
hypoglycemia	O
was	O
poor	O
.	O

Convulsive	O
status	O
epilepticus	O
after	O
infusion	O
of	O
cisplatin	O
.	O

NDRF	B-GENE
/	I-GENE
NeuroD2	I-GENE
was	O
co-precipitated	O
with	O
PKN	B-GENE
from	O
the	O
lysate	O
of	O
COS-7	O
cells	O
transfected	O
with	O
both	O
expression	O
constructs	O
for	O
NDRF	B-GENE
/	I-GENE
NeuroD2	I-GENE
and	O
PKN	B-GENE
.	O

Effect	O
of	O
trauma	O
on	O
plasma	B-GENE
glucagon	I-GENE
and	O
insulin	B-GENE
concentrations	O
in	O
sheep	O
.	O

While	O
blood	O
pressure	O
and	O
noradrenergic	O
activity	O
,	O
assessed	O
as	O
changes	O
in	O
the	O
plasma	O
levels	O
and	O
urinary	O
excretion	O
of	O
norepinephrine	O
,	O
remained	O
unaffected	O
in	O
the	O
Pl	O
group	O
,	O
a	O
significant	O
drop	O
in	O
the	O
supine	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
,	O
as	O
well	O
as	O
in	O
the	O
resting	O
venous	O
norepinephrine	O
level	O
and	O
in	O
urinary	O
norepinephrine	O
excretion	O
was	O
found	O
after	O
the	O
first	O
month	O
of	O
dF	O
administration	O
.	O

In	O
vitro	O
protein	O
retention	O
experiments	O
in	O
which	O
Hsp90	B-GENE
heterocomplexes	I-GENE
were	O
precipitated	O
resulted	O
in	O
coprecipitation	O
of	O
Cns1	B-GENE
.	O

We	O
have	O
identified	O
two	O
functional	O
elements	O
,	O
both	O
located	O
downstream	O
from	O
the	O
TATA	O
motif	O
,	O
that	O
control	O
Id4	B-GENE
promoter	I-GENE
activity	O
.	O

Four	O
of	O
these	O
five	O
subjects	O
also	O
performed	O
mixed	O
sequences	O
under	O
conditional	O
control	O
of	O
the	O
words	O
(	O
e	O
.	O
g	O
.	O
,	O
A1----B2----A3----B4----A5	O
and	O
its	O
reversal	O
)	O
,	O
verifying	O
that	O
the	O
stimuli	O
which	O
occupied	O
the	O
same	O
position	O
in	O
each	O
sequence	O
were	O
members	O
of	O
the	O
same	O
class	O
.	O

This	O
inhibitory	O
domain	O
has	O
been	O
deleted	O
in	O
all	O
naturally	O
occurring	O
AHC	B-GENE
deletion	I-GENE
mutants	I-GENE
described	O
to	O
date	O
.	O

Zhu	O
,	O
V	O
.	O

The	O
xylose	B-GENE
isomerase-encoding	I-GENE
gene	I-GENE
(	O
xylA	B-GENE
)	O
of	O
Clostridium	O
thermosaccharolyticum	O
:	O
cloning	O
,	O
sequencing	O
and	O
phylogeny	O
of	O
XylA	B-GENE
enzymes	I-GENE
.	O

Two	O
disulphide	O
bridges	O
,	O
which	O
are	O
conserved	O
in	O
all	O
spermadhesin	O
molecules	O
and	O
many	O
CUB	B-GENE
domains	I-GENE
,	O
crosslink	O
loop	O
LA	O
and	O
strand	O
beta	O
4	O
and	O
loops	O
LE	O
and	O
LG	O
,	O
respectively	O
,	O
at	O
opposite	O
edges	O
of	O
the	O
same	O
face	O
of	O
the	O
domain	O
.	O

A	O
.	O

Etiopathogenetic	O
and	O
therapeutic	O
problems	O
in	O
acute	O
orbital	O
inflammation	O
.	O

Detection	O
of	O
anti-lymphocyte	O
antibodies	O
using	O
the	O
immunoperoxidase	B-GENE
antiglobulin	B-GENE
technic	O
.	O

Remarkably	O
,	O
both	O
TTD-A	O
and	O
XP-D	O
defects	O
are	O
associated	O
with	O
subunits	O
of	O
TFIIH	B-GENE
,	O
a	O
basal	O
transcription	O
factor	O
with	O
a	O
second	O
function	O
in	O
DNA	O
repair	O
.	O

Monotherapy	O
with	O
ceftazidime	O
was	O
clinically	O
and	O
bacteriologically	O
as	O
effective	O
as	O
a	O
combination	O
therapy	O
with	O
cefazolin	O
and	O
tobramycin	O
.	O

The	O
skp1+	B-GENE
gene	I-GENE
is	O
not	O
essential	O
.	O

Sequence	O
analysis	O
of	O
the	O
sMtCK	B-GENE
genomic	I-GENE
upstream	I-GENE
sequences	I-GENE
reveals	O
a	O
typical	O
TATAA	O
box	O
within	O
the	O
80	O
base	O
pairs	O
(	O
bp	O
)	O
that	O
,	O
by	O
transfection	O
experiments	O
,	O
are	O
sufficient	O
to	O
promote	O
expression	O
of	O
chimeric	O
plasmids	O
with	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	I-GENE
.	O

To	O
evaluate	O
the	O
effects	O
of	O
propranolol	O
on	O
myocardial	O
metabolism	O
after	O
coronary	O
reperfusion	O
,	O
serial	O
measurements	O
of	O
myocardial	B-GENE
creatine	I-GENE
kinase	I-GENE
(	O
CK	B-GENE
)	O
and	O
calcium	O
(	O
Ca	O
)	O
contents	O
and	O
CK	B-GENE
and	O
lactic	O
acid	O
(	O
LA	O
)	O
concentrations	O
in	O
coronary	O
sinus	O
blood	O
were	O
carried	O
out	O
in	O
33	O
open-chest	O
dogs	O
.	O

Titration	O
of	O
the	O
human	O
and	O
porcine	O
proteins	O
with	O
2-nitro-5-thiosulfabenzoate	O
indicates	O
that	O
membrane	B-GENE
dipeptidase	I-GENE
additionally	O
possesses	O
two	O
intrachain	O
disulfide	O
bonds	O
.	O

The	O
first	O
identification	O
of	O
the	O
active	B-GENE
37LRP	I-GENE
/	I-GENE
p40	I-GENE
gene	I-GENE
presented	O
in	O
this	O
study	O
is	O
a	O
critical	O
step	O
toward	O
the	O
isolation	O
of	O
the	O
corresponding	O
human	O
gene	O
and	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
up-regulation	O
of	O
its	O
expression	O
during	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Analyses	O
of	O
additional	O
tumors	O
induced	O
in	O
mice	O
from	O
two	O
reciprocal	O
crosses	O
,	O
A	O
/	O
J	O
x	O
C3H	O
/	O
HeJ	O
F1	O
(	O
hereafter	O
called	O
AC3F1	O
)	O
and	O
C3H	O
/	O
HeJ	O
x	O
A	O
/	O
J	O
F1	O
(	O
hereafter	O
called	O
C3AF1	O
)	O
,	O
provided	O
evidence	O
for	O
the	O
inactivation	O
of	O
one	O
allele	O
of	O
the	O
putative	O
chromosome	O
4	O
tumor	O
suppressor	O
gene	O
by	O
parental	O
imprinting	O
.	O

On	O
the	O
other	O
hand	O
,	O
if	O
the	O
measured	O
angle	O
ANB	O
is	O
smaller	O
than	O
the	O
calculated	O
angle	O
,	O
the	O
skeletal	O
relation	O
is	O
Class	O
III	O
.	O

Venkatesan	O
,	O
and	O
D	O
.	O

The	O
lack	O
of	O
the	O
C2	B-GENE
domain	I-GENE
of	O
the	O
Ca	B-GENE
(	I-GENE
2+	I-GENE
)	I-GENE
-dependent	I-GENE
PKCs	I-GENE
and	O
the	O
presence	O
of	O
a	O
unique	O
NH2-terminal	O
sequence	O
with	O
a	O
potential	O
signal	O
peptide	O
and	O
a	O
transmembrane	O
domain	O
suggest	O
that	O
PKC	B-GENE
mu	I-GENE
is	O
a	O
novel	O
member	O
of	O
the	O
subgroup	O
of	O
atypical	O
PKCs	B-GENE
.	O

However	O
,	O
whether	O
or	O
not	O
nonsense	O
codon	O
recognition	O
within	O
TPI	B-GENE
transcripts	I-GENE
takes	O
place	O
prior	O
to	O
or	O
after	O
splicing	O
remained	O
unresolved	O
.	O

18F	O
and	O
85Sr	O
scintimetry	O
in	O
the	O
study	O
of	O
primary	O
arthropathies	O
.	O

Separation	O
of	O
ninhydrin-positive	O
compounds	O
in	O
urine	O
by	O
the	O
combined	O
methods	O
of	O
medium-tension	O
intophoresis	O
and	O
partition	O
chromatography	O
.	O

Molecular	O
analysis	O
of	O
the	O
pRA2	O
partitioning	O
region	O
:	O
ParB	B-GENE
autoregulates	O
parAB	B-GENE
transcription	O
and	O
forms	O
a	O
nucleoprotein	O
complex	O
with	O
the	O
plasmid	O
partition	O
site	O
,	O
parS	B-GENE
.	O

The	O
5'	O
untranslated	O
and	O
coding	O
regions	O
are	O
contained	O
within	O
12	O
exons	O
,	O
with	O
the	O
translation	O
start	O
site	O
located	O
within	O
the	O
first	O
exon	O
.	O

A	O
mutation	O
in	O
the	O
C	O
domain	O
of	O
Rb	B-GENE
,	O
L901Q	O
,	O
has	O
been	O
identified	O
that	O
completely	O
abolishes	O
cdk4	B-GENE
/	I-GENE
D1	I-GENE
phosphorylation	O
of	O
the	O
isolated	O
C	O
domain	O
.	O

Specific	O
clotting	O
factor	O
assays	O
showed	O
an	O
isolated	O
deficiency	O
of	O
factor	B-GENE
X	I-GENE
ranging	O
from	O
7	O
to	O
12	O
per	O
cent	O
on	O
three	O
determinations	O
.	O

Thus	O
RV	O
O2	O
demand	O
fell	O
when	O
RC	O
O2	O
supply	O
was	O
reduced	O
,	O
although	O
a	O
flow	O
reserve	O
was	O
available	O
.	O

These	O
data	O
should	O
be	O
useful	O
in	O
developing	O
reagents	O
for	O
heterozygote	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
11	B-GENE
beta-hydroxylase	I-GENE
deficiency	O
,	O
the	O
second	O
most	O
frequent	O
cause	O
of	O
congenital	O
adrenal	O
hyperplasia	O
.	O

These	O
exons	O
,	O
further	O
identified	O
as	O
exons	O
9	O
,	O
10	O
,	O
and	O
11	O
,	O
together	O
encode	O
the	O
37	O
amino	O
acid	O
residues	O
present	O
in	O
alpha	B-GENE
s1-casein	I-GENE
variant	I-GENE
A	I-GENE
but	O
missing	O
in	O
variant	O
F	O
.	O

Since	O
1970	O
the	O
frequency	O
of	O
potassium-induced	O
ulceration	O
has	O
been	O
low--3	O
cases	O
per	O
100	O
000	O
patient-years	O
of	O
slow-release	O
tablet	O
use	O
.	O

Examination	O
of	O
neurohumoral	O
factors	O
revealed	O
a	O
hyperactive	O
sympathetic	O
nervous	O
system	O
and	O
an	O
increase	O
in	O
plasma	O
renin	B-GENE
activity	O
.	O

We	O
have	O
used	O
a	O
full-length	O
cDNA	O
clone	O
of	O
a	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
,	O
pMIDI-C	O
,	O
and	O
cassette	O
mutagenesis	O
to	O
study	O
the	O
mechanism	O
of	O
coronavirus	O
subgenomic	O
mRNA	O
synthesis	O
.	O

This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
whether	O
consuming	O
several	O
small	O
feedings	O
of	O
preexercise	O
carbohydrate	O
(	O
CHO	O
)	O
,	O
rather	O
than	O
a	O
single	O
bolus	O
,	O
would	O
affect	O
blood	O
glucose	O
and	O
insulin	B-GENE
responses	O
during	O
rest	O
and	O
exercise	O
.	O

A	O
triple	O
Ser--	O
>	O
Ala	O
mutant	O
form	O
of	O
yeast	O
eIF-2	B-GENE
alpha	I-GENE
was	O
found	O
to	O
be	O
no	O
longer	O
phosphorylated	O
by	O
either	O
of	O
the	O
yeast	O
(	O
or	O
mammalian	O
)	O
casein	B-GENE
kinase	I-GENE
activities	O
in	O
vitro	O
.	O

HexA71	B-GENE
negatively	O
affects	O
RpoS	B-GENE
,	O
as	O
the	O
levels	O
of	O
this	O
alternative	O
sigma	B-GENE
factor	I-GENE
are	O
higher	O
in	O
the	O
HexA-	B-GENE
mutant	I-GENE
than	O
in	O
the	O
HexA+	B-GENE
strain	O
.	O

Site-directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	B-GENE
proteins	I-GENE
BP1	I-GENE
and	O
BP2	B-GENE
in	O
the	O
upstream	O
portion	O
of	O
the	O
beta	B-GENE
globin	I-GENE
gene	I-GENE
flanking	I-GENE
region	I-GENE
led	O
to	O
a	O
4-6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

To	O
study	O
a	O
possible	O
functional	O
role	O
of	O
this	O
putative	O
chicken	O
ICS	B-GENE
,	O
an	O
oligonucleotide	O
spanning	O
the	O
upstream	O
sequences	O
of	O
the	O
BF-IV	B-GENE
gene	I-GENE
(	O
-174	O
/	O
-194	O
)	O
was	O
cloned	O
singly	O
or	O
in	O
multiple	O
copies	O
before	O
the	O
herpes	O
TK	B-GENE
promoter	I-GENE
controlling	O
the	O
chloramphenicol	B-GENE
acetyl	I-GENE
transferase	I-GENE
(	O
CAT	B-GENE
)	O
gene	O
(	O
pBLCAT2	O
)	O
.	O

The	O
results	O
suggested	O
that	O
,	O
depending	O
upon	O
the	O
cell	O
type	O
,	O
gene	O
cotransfer	O
using	O
aminoglycoside	O
resistance	O
as	O
a	O
selectable	O
marker	O
may	O
seriously	O
perturb	O
important	O
cellular	O
control	O
mechanisms	O
such	O
as	O
the	O
PKC	B-GENE
pathway	O
leading	O
to	O
activation	O
of	O
gene	O
expression	O
.	O

Pulmonary	O
embolectomy	O
and	O
lung	O
transplantation	O
are	O
the	O
main	O
indications	O
for	O
the	O
use	O
of	O
heart-lung-machine	O
.	O

With	O
the	O
increasing	O
use	O
of	O
ACE	B-GENE
inhibitors	O
,	O
the	O
incidence	O
of	O
rare	O
adverse	O
effects	O
such	O
as	O
potentially	O
lethal	O
pancreatitis	O
is	O
likely	O
to	O
increase	O
.	O

Staphylococcus	O
aureus	O
and	O
CNS	O
showed	O
high	O
or	O
moderate	O
resistance	O
rates	O
to	O
methicillin	O
(	O
DMPPC	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
relation	O
to	O
Type	O
A	O
behaviour	O
and	O
beta-adrenoceptor	B-GENE
blockade	O
.	O

The	O
genome	O
of	O
Thogoto	O
virus	O
comprises	O
six	O
segments	O
of	O
single-stranded	O
,	O
negative	O
sense	O
RNA	O
.	O

Overexpression	O
of	O
EFG1	B-GENE
in	O
C	O
.	O
albicans	O
leads	O
to	O
enhanced	O
filamentous	O
growth	O
in	O
the	O
form	O
of	O
extended	O
pseudohyphae	O
in	O
liquid	O
and	O
on	O
solid	O
media	O
.	O

The	O
26S	B-GENE
rRNA	I-GENE
binding	I-GENE
ribosomal	I-GENE
protein	I-GENE
equivalent	O
to	O
bacterial	B-GENE
protein	I-GENE
L11	I-GENE
is	O
encoded	O
by	O
unspliced	O
duplicated	O
genes	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

An	O
unexpected	O
finding	O
was	O
the	O
presence	O
at	O
position	O
-403	O
to	O
-385	O
of	O
a	O
putative	O
dioxin	B-GENE
responsive	I-GENE
element	I-GENE
,	O
a	O
sequence	O
found	O
to	O
be	O
responsible	O
for	O
the	O
induction	O
of	O
transcription	O
of	O
the	O
cytochrome	B-GENE
P450IA1	I-GENE
gene	I-GENE
(	O
CYPIA1	B-GENE
)	O
and	O
other	O
genes	O
involved	O
in	O
detoxification	O
/	O
activation	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
.	O

Hypertonic	O
glucose	O
administered	O
intrajejunally	O
in	O
Heidenhain	O
pouch	O
dogs	O
resulted	O
in	O
an	O
equal	O
inhibition	O
of	O
pentagastrin-induced	O
acid	O
secretion	O
from	O
the	O
pouch	O
and	O
the	O
main	O
stomach	O
,	O
whereas	O
hypertonic	O
saline	O
had	O
no	O
effect	O
.	O

APOE-epsilon4	B-GENE
count	O
predicts	O
age	O
when	O
prevalence	O
of	O
AD	O
increases	O
,	O
then	O
declines	O
:	O
the	O
Cache	O
County	O
Study	O
.	O

In	O
contrast	O
,	O
resensitization	O
of	O
a	O
sequestration-impaired	O
beta2AR	B-GENE
mutant	I-GENE
(	I-GENE
Y326A	I-GENE
)	I-GENE
was	O
reestablished	O
following	O
the	O
overexpression	O
of	O
either	O
GRK2	B-GENE
or	O
beta-arrestin	B-GENE
1	O
.	O

In	O
contrast	O
to	O
hemodynamic	O
and	O
histopathological	O
predictors	O
of	O
survival	O
,	O
vWF	O
:	O
Ag	O
does	O
not	O
require	O
invasive	O
techniques	O
to	O
be	O
determined	O
.	O

Despite	O
supraphysiologic	O
E2	O
concentrations	O
,	O
however	O
,	O
cervical	O
mucus	O
scores	O
were	O
significantly	O
reduced	O
in	O
the	O
CC-treated	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Oscillatory	O
exchange	O
of	O
atoms	O
between	O
traps	O
containing	O
Bose	O
condensates	O
.	O

Patients	O
with	O
a	O
secondary	O
cardiac	O
event	O
had	O
more	O
common	O
Type	O
A	O
behavior	O
patterns	O
and	O
higher	O
Bortner	O
scores	O
than	O
patients	O
without	O
a	O
secondary	O
cardiac	O
event	O
.	O

McCann	O
III	O
,	O
F	O
.	O

A	O
deproteinization	O
procedure	O
was	O
coupled	O
with	O
a	O
reversed-phase	O
HPLC	O
separation	O
using	O
a	O
250x4	O
.	O
6	O
mm	O
I	O
.	O
D	O
.	O

Recently	O
,	O
a	O
distantly	O
related	O
UmuC-homolog	B-GENE
,	O
DinB	B-GENE
,	O
has	O
also	O
been	O
identified	O
in	O
E	O
.	O
coli	O
.	O

Molecular	O
cloning	O
of	O
human	O
cDNA	O
encoding	O
a	O
novel	O
beta1	B-GENE
,	I-GENE
6-N-acetylglucosaminyltransferase	I-GENE
forming	O
core	O
2	O
and	O
core	O
4	O
.	O

On	O
the	O
constituents	O
of	O
Dryopteris	O
polylepis	O
.	O

The	O
basal	O
promoter	O
elements	O
of	O
murine	B-GENE
cytochrome	I-GENE
c	I-GENE
oxidase	I-GENE
subunit	I-GENE
IV	I-GENE
gene	I-GENE
consist	O
of	O
tandemly	O
duplicated	O
ets	B-GENE
motifs	I-GENE
that	O
bind	O
to	O
GABP-related	B-GENE
transcription	I-GENE
factors	I-GENE
.	O

The	O
alcoholic	O
patient	O
,	O
his	O
work	O
and	O
the	O
subjectivity	O
of	O
the	O
period	O
.	O

Expression	O
of	O
SREBP-1a	B-GENE
stimulated	O
StAR	B-GENE
promoter	I-GENE
activity	O
in	O
the	O
context	O
of	O
COS-1	O
cells	O
and	O
human	O
granulosa-lutein	O
cells	O
.	O

Serum	O
levels	O
of	O
albumin	B-GENE
,	O
globulin	B-GENE
,	O
and	O
coagulation	B-GENE
protein	I-GENE
activity	O
were	O
measured	O
preshock	O
,	O
postshock	O
,	O
and	O
daily	O
for	O
3	O
days	O
;	O
skin	O
lymph	O
levels	O
were	O
measured	O
on	O
Day	O
3	O
.	O

In	O
10	O
patients	O
with	O
subacute	O
cardiac	O
tamponade	O
,	O
pulmonary	O
wedge	O
pressure	O
(	O
PWP	O
)	O
,	O
RAP	O
,	O
and	O
IPP	O
were	O
measured	O
along	O
with	O
indexes	O
of	O
systolic	O
function	O
.	O

The	O
Drosophila	O
clathrin	B-GENE
heavy	I-GENE
chain	I-GENE
gene	O
:	O
clathrin	B-GENE
function	O
is	O
essential	O
in	O
a	O
multicellular	O
organism	O
.	O

Experimental	O
studies	O
on	O
virus	O
excretion	O
and	O
non-arthropod	O
transmission	O
.	O

Fregnac	O
,	O
M	O
.	O

However	O
,	O
after	O
repeated	O
infections	O
,	O
hypobiotic	O
larvae	O
were	O
numerous	O
.	O

After	O
28	O
days	O
of	O
haloperidol	O
treatment	O
,	O
similar	O
changes	O
were	O
observed	O
for	O
delta	O
,	O
together	O
with	O
an	O
increase	O
of	O
alpha	O
1	O
,	O
and	O
a	O
decrease	O
of	O
fast	O
beta	O
.	O

Incidences	O
of	O
nonfatal	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
und	O
left	O
ventricular	O
hypertrophy	O
could	O
also	O
be	O
lowered	O
.	O

Kidney	O
length	O
did	O
not	O
significantly	O
differ	O
between	O
right	O
and	O
left	O
,	O
however	O
,	O
kidney	O
width	O
,	O
cortical	O
thickness	O
and	O
size	O
did	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
late	O
MYO	O
/	O
M	O
is	O
more	O
useful	O
than	O
washout	O
rate	O
to	O
assess	O
the	O
effect	O
of	O
treatment	O
on	O
heart	O
failure	O
due	O
to	O
DCM	O
.	O

Rarely	O
,	O
patients	O
with	O
locally	O
advanced	O
,	O
uncontrollable	O
,	O
non-metastatic	O
prostatic	O
cancer	O
enjoy	O
prolonged	O
survival	O
.	O

Cells	O
differentiate	O
in	O
response	O
to	O
various	O
extracellular	O
stimuli	O
.	O

The	O
pathogenesis	O
of	O
Limited	O
Joint	O
Mobility	O
(	O
LJM	O
)	O
in	O
diabetes	O
is	O
unknown	O
,	O
but	O
the	O
abnormality	O
is	O
said	O
to	O
be	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
microangiopathy	O
.	O

Radiolabeled	O
biantennary	O
N-glycans	O
synthesized	O
by	O
Pro	B-GENE
(	I-GENE
-	I-GENE
)	I-GENE
5Lec20	I-GENE
were	O
proportionately	O
less	O
ricin-bound	O
than	O
similar	O
species	O
from	O
parental	O
CHO	O
cells	O
,	O
and	O
Lec20	O
cell	O
extracts	O
had	O
a	O
markedly	O
reduced	O
ability	O
to	O
transfer	O
Gal	O
to	O
GlcNAc-terminating	O
acceptors	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
the	O
cAMP-dependent	B-GENE
kinases	I-GENE
(	O
PKAs	B-GENE
)	O
promote	O
cytoplasmic	O
growth	O
and	O
modulate	O
the	O
growth-regulated	O
mechanism	O
triggering	O
the	O
begin	O
of	O
DNA	O
synthesis	O
.	O

In	O
marked	O
contrast	O
to	O
AgfA	B-GENE
,	O
none	O
of	O
the	O
chimeric	B-GENE
SefA	I-GENE
proteins	I-GENE
were	O
expressed	O
or	O
assembled	O
into	O
fimbriae	O
.	O

Kinetic	O
experiments	O
revealed	O
that	O
within	O
10	O
min	O
this	O
radiolabeled	O
precursor	O
protein	O
was	O
converted	O
in	O
HL-60	O
cells	O
into	O
an	O
Mr	O
approximately	O
150	O
,	O
000	O
chondroitin	O
sulfate	O
proteoglycan	O
intermediate	O
.	O

Heparin	O
had	O
no	O
effect	O
on	O
rAC-st	B-GENE
myosin	I-GENE
light	I-GENE
chain	I-GENE
phosphatase	I-GENE
activity	O
,	O
while	O
the	O
B	O
subunit-containing	O
forms	O
were	O
stimulated	O
2-3-fold	O
.	O

Randomly	O
selected	O
300	O
children	O
aged	O
3	O
months-3	O
yr	O
were	O
analysed	O
over	O
a	O
period	O
of	O
one	O
year	O
for	O
estimating	O
prevalence	O
of	O
nutritional	O
anaemia	O
.	O

Studies	O
using	O
the	O
yeast	O
two-hybrid	O
system	O
also	O
did	O
not	O
provide	O
evidence	O
for	O
the	O
formation	O
of	O
a	O
VDR-TR	B-GENE
protein-protein	O
interaction	O
.	O

The	O
frequency	O
of	O
lactase	B-GENE
phenotypes	I-GENE
in	O
Aymara	O
children	O
.	O

(	O
iii	O
)	O
In	O
these	O
cells	O
,	O
PKCbeta	B-GENE
plays	O
a	O
unique	O
Ras-independent	O
role	O
in	O
mediating	O
insulin	B-GENE
but	O
not	O
EGF	B-GENE
or	O
other	O
growth	B-GENE
factor	I-GENE
mitogenic	O
signals	O
.	O

Chem	O
.	O

Adenylosuccinate	B-GENE
synthetase	I-GENE
(	O
IMP	O
:	O
L-aspartate	B-GENE
ligase	I-GENE
(	O
GDP	O
)	O
,	O
EC	O
6	O
.	O
3	O
.	O
4	O
.	O
4	O
)	O
plays	O
an	O
important	O
role	O
in	O
purine	O
biosynthesis	O
catalyzing	O
the	O
GTP-dependent	O
conversion	O
of	O
IMP	O
to	O
AMP	O
.	O

Glucocorticoid	O
induced	O
hypertension	O
has	O
been	O
regarded	O
as	O
independent	O
of	O
sodium	O
(	O
Na	O
)	O
,	O
in	O
contrast	O
to	O
mineralocorticoid	O
induced	O
hypertension	O
,	O
which	O
is	O
Na+-dependent	O
.	O

These	O
experiments	O
delineate	O
a	O
186-bp	O
,	O
EBNA-2-responsive	O
cell	O
DNA	O
fragment	O
and	O
provide	O
firm	O
evidence	O
that	O
EBNA-2	B-GENE
transactivates	O
transcription	O
of	O
cell	O
genes	O
.	O

Northern	O
blot	O
analysis	O
demonstrated	O
that	O
the	O
STORP	B-GENE
gene	I-GENE
has	O
a	O
ubiquitous	O
pattern	O
of	O
expression	O
similar	O
to	O
that	O
of	O
the	O
PML	B-GENE
gene	I-GENE
.	O

These	O
data	O
provide	O
strong	O
evidence	O
that	O
E2F	B-GENE
or	O
an	O
E2F-related	B-GENE
transcription	I-GENE
factor	I-GENE
is	O
involved	O
in	O
the	O
regulation	O
of	O
nonmuscle	B-GENE
myosin	I-GENE
expression	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
entry	O
into	O
mitosis	O
requires	O
activation	O
of	O
the	O
cyclin-dependent	B-GENE
kinase	I-GENE
Cdc28	I-GENE
in	O
its	O
cyclin	B-GENE
B	I-GENE
(	O
Clb	B-GENE
)	O
-associated	O
form	O
.	O

Similar	O
data	O
were	O
also	O
obtained	O
when	O
either	O
dominant	B-GENE
negative	I-GENE
EGFR-CD533	I-GENE
or	O
dominant	B-GENE
negative	I-GENE
Ras	I-GENE
N17	I-GENE
were	O
used	O
to	O
block	O
MAPK	B-GENE
activation	O
.	O

HANYS	O
criticizes	O
laparoscopic	O
gall	O
bladder	O
guidelines	O
.	O

By	O
far-Western	O
analysis	O
and	O
coimmunoprecipitation	O
studies	O
,	O
we	O
demonstrate	O
that	O
ZNF74	B-GENE
interacts	O
,	O
via	O
its	O
zinc	O
finger	O
domain	O
,	O
with	O
the	O
hyperphosphorylated	O
largest	O
subunit	O
of	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
(	O
pol	B-GENE
IIo	I-GENE
)	O
but	O
not	O
with	O
the	O
hypophosphorylated	O
form	O
.	O

The	O
examination	O
must	O
include	O
T1	O
and	O
T2	O
sequences	O
and	O
scans	O
in	O
three	O
planes	O
.	O

Genetic	O
and	O
biochemical	O
evidence	O
suggests	O
that	O
v-Crk	B-GENE
can	O
induce	O
transformation	O
of	O
chicken	O
embryo	O
fibroblasts	O
by	O
influencing	O
the	O
activity	O
of	O
cellular	O
proteins	O
involved	O
in	O
growth	O
regulation	O
.	O

Heating	O
cells	O
to	O
43	O
degrees	O
C	O
decreased	O
the	O
amount	O
of	O
newly	O
synthesized	O
rRNA	B-GENE
to	O
less	O
than	O
5%	O
of	O
the	O
control	O
level	O
and	O
led	O
to	O
greater	O
than	O
95%	O
inhibition	O
of	O
transcription	O
termination	O
at	O
a	O
region	O
355	O
to	O
362	O
nucleotides	O
downstream	O
of	O
the	O
3'	O
end	O
of	O
28S	B-GENE
rRNA	I-GENE
,	O
with	O
readthrough	O
continuing	O
into	O
the	O
next	O
transcription	O
unit	O
.	O

Intravesical	O
chemotherapy	O
.	O

Antibodies	O
affinity-purified	O
using	O
the	O
bacterially	O
expressed	O
recombinant	O
protein	O
recognized	O
the	O
56K	B-GENE
autoantigen	I-GENE
in	O
a	O
HeLa	O
cell	O
extract	O
.	O
cDNA	O
sequencing	O
revealed	O
that	O
the	O
56K	B-GENE
cDNA	I-GENE
shares	O
a	O
high	O
degree	O
of	O
homology	O
in	O
both	O
nucleotide	O
(	O
87%	O
)	O
and	O
amino	O
acid	O
sequence	O
(	O
92	O
.	O
5%	O
)	O
with	O
bovine	B-GENE
annexin	I-GENE
XI	I-GENE
,	O
indicating	O
that	O
the	O
56K	B-GENE
cDNA	I-GENE
encodes	O
the	O
human	B-GENE
homologue	I-GENE
of	I-GENE
annexin	I-GENE
XI	I-GENE
,	O
a	O
member	O
of	O
the	O
Ca	B-GENE
(	I-GENE
2+	I-GENE
)	I-GENE
-dependent	I-GENE
phospholipid	I-GENE
binding	I-GENE
protein	I-GENE
family	I-GENE
.	O

Protein	B-GENE
cHMGI	I-GENE
binds	O
preferentially	O
to	O
AT-rich	O
DNA	O
with	O
a	O
half-saturation	O
value	O
of	O
1	O
.	O
1	O
nM	O
.	O

Total	O
VO2	O
was	O
decreased	O
in	O
both	O
groups	O
during	O
severe	O
hypoxia	O
but	O
limb	O
VO2	O
was	O
maintained	O
in	O
the	O
beta-block	O
group	O
.	O
beta-Block	O
prevented	O
the	O
fall	O
in	O
total	O
and	O
limb	O
peripheral	O
resistance	O
seen	O
in	O
severe	O
hypoxia	O
but	O
did	O
not	O
alter	O
the	O
consistently	O
more	O
efficient	O
utilization	O
of	O
total	O
O2	O
delivery	O
shown	O
by	O
the	O
limb	O
in	O
comparison	O
to	O
the	O
whole	O
body	O
by	O
higher	O
O2	O
extraction	O
ratios	O
and	O
lower	O
venous	O
O2	O
pressure	O
.	O
beta-Vasodilator	B-GENE
receptors	I-GENE
evidently	O
played	O
an	O
active	O
part	O
in	O
the	O
vasodilatation	O
seen	O
during	O
severe	O
hypoxia	O
.	O

SPECT	O
examination	O
of	O
the	O
TMJ	O
using	O
99m	O
Tc-MDP	O
was	O
performed	O
in	O
43	O
patients	O
with	O
arthrographically	O
proven	O
anterior	O
dislocation	O
of	O
the	O
disc	O
and	O
in	O
30	O
normals	O
.	O

J	O
.	O

The	O
size	O
of	O
the	O
group	O
allocated	O
to	O
the	O
good	O
compliance	O
category	O
by	O
the	O
use	O
of	O
the	O
digoxin	O
marker	O
was	O
equivalent	O
in	O
size	O
to	O
a	O
group	O
of	O
patients	O
who	O
had	O
returned	O
less	O
than	O
15%	O
of	O
their	O
prescribed	O
dose	O
or	O
reported	O
a	O
deviation	O
of	O
less	O
than	O
6%	O
from	O
their	O
prescription	O
.	O

In	O
the	O
mouse	O
,	O
CtBP1	B-GENE
is	O
expressed	O
from	O
embryo	O
to	O
adult	O
,	O
but	O
CtBP2	B-GENE
is	O
mainly	O
expressed	O
during	O
embryogenesis	O
.	O

Intracranial	O
arachnoid	O
cyst	O
of	O
the	O
middle	O
fossa	O
demonstrated	O
by	O
positive	O
99mTc	O
brainscintigraphy	O
.	O

Rat	B-GENE
liver	I-GENE
catalase	I-GENE
is	O
sorted	O
to	O
peroxisomes	O
by	O
its	O
C-terminal	O
tripeptide	O
Ala-Asn-Leu	B-GENE
,	O
not	O
by	O
the	O
internal	B-GENE
Ser-Lys-Leu	I-GENE
motif	I-GENE
.	O

Evidence	O
for	O
a	O
role	O
of	O
endogenous	B-GENE
corticotropin-releasing	I-GENE
factor	I-GENE
in	O
cold	O
,	O
ether	O
,	O
immobilization	O
,	O
and	O
traumatic	O
stress	O
.	O

The	O
encoded	O
amino	O
acid	O
sequences	O
in	O
the	O
full-length	O
bovine	O
and	O
porcine	O
cDNAs	O
were	O
identical	O
,	O
consisting	O
of	O
209	O
amino	O
acid	O
residues	O
,	O
and	O
were	O
nearly	O
the	O
same	O
as	O
the	O
published	O
sequence	O
determined	O
by	O
Edman	O
degradation	O
.	O

The	O
4	O
days	O
dexamethasone	O
suppression	O
test	O
showed	O
more	O
than	O
80%	O
suppression	O
of	O
dehydroepiandrosterone-sulphate	O
and	O
a	O
variable	O
(	O
40-60%	O
)	O
reduction	O
of	O
testosterone	O
and	O
androstenedione	O
levels	O
.	O

Dd	B-GENE
PK1	I-GENE
RNA	I-GENE
decreases	O
after	O
6	O
h	O
of	O
starvation	O
to	O
re-accumulate	O
once	O
the	O
cells	O
have	O
aggregated	O
.	O

She	O
also	O
had	O
slight	O
weakness	O
of	O
the	O
upper	O
extremities	O
.	O

Redistribution	O
of	O
mannosidase	B-GENE
I	I-GENE
was	O
also	O
observed	O
in	O
cells	O
incubated	O
at	O
15	O
degrees	O
C	O
.	O

In	O
some	O
cases	O
,	O
the	O
aberrant	O
methylation	O
of	O
CpGs	O
within	O
5'	O
regulatory	O
regions	O
has	O
led	O
to	O
suppression	O
of	O
gene	O
activity	O
.	O

The	O
second	O
transcript	O
,	O
rhis4l	B-GENE
,	O
is	O
bicistronic	O
.	O

Current	O
status	O
and	O
future	O
perspectives	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
we	O
demonstrate	O
that	O
MQ9b	B-GENE
binds	O
strongly	O
5	O
of	O
17	O
motif-positive	O
,	O
pathogen-derived	O
synthetic	O
peptides	O
.	O

Human	O
expressed	O
sequence	O
tag	O
clones	O
were	O
identified	O
by	O
sequence	O
similarity	O
to	O
mammalian	B-GENE
and	I-GENE
yeast	I-GENE
oligosaccharide-processing	I-GENE
mannosidases	I-GENE
,	O
and	O
the	O
full-length	O
coding	O
region	O
of	O
the	O
putative	O
mannosidase	B-GENE
homolog	I-GENE
was	O
isolated	O
by	O
a	O
combination	O
of	O
5'-rapid	O
amplification	O
of	O
cDNA	O
ends	O
and	O
direct	O
polymerase	B-GENE
chain	O
reaction	O
from	O
human	O
placental	O
cDNA	O
.	O

Irradiation	O
of	O
human	O
blood	O
platelets	O
with	O
UV-A	O
in	O
vitro	O
impairs	O
their	O
ability	O
to	O
aggregate	O
after	O
challenge	O
with	O
collagen	B-GENE
.	O

Exploration	O
on	O
the	O
effects	O
of	O
activating	O
blood	O
circulation	O
to	O
remove	O
blood	O
stasis	O
on	O
barrier	O
action	O
of	O
gastric	O
wall	O
in	O
chronic	O
atrophic	O
gastritis	O

Diagnosis	O
of	O
FHCS	O
has	O
been	O
weighed	O
upon	O
laparoscopic	O
findings	O
.	O

Because	O
all	O
PDGFbetaR	B-GENE
fusions	I-GENE
described	O
thus	O
far	O
result	O
in	O
splicing	O
to	O
a	O
common	O
exon	O
of	O
this	O
gene	O
,	O
we	O
performed	O
5'-rapid	O
amplification	O
of	O
cDNA	O
ends	O
PCR	O
on	O
patient	O
RNA	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
structural	O
requirements	O
and	O
consequences	O
of	O
regulatory	O
phosphorylation	O
for	O
the	O
interaction	O
between	O
c-Jun	B-GENE
and	O
JNK	B-GENE
in	O
vivo	O
.	O

To	O
determine	O
whether	O
mononuclear	O
cell	O
secretory	O
products	O
contribute	O
to	O
the	O
changes	O
in	O
bone	O
turnover	O
that	O
characterize	O
the	O
development	O
of	O
postmenopausal	O
osteoporosis	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
oophorectomy	O
and	O
subsequent	O
estrogen	O
replacement	O
on	O
the	O
spontaneous	O
secretion	O
of	O
interleukin	B-GENE
1	I-GENE
(	O
IL-1	B-GENE
)	O
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
alpha	I-GENE
(	O
TNF-alpha	B-GENE
)	O
and	O
on	O
the	O
phytohemagglutinin	O
A-induced	O
secretion	O
of	O
granulocyte-macrophage	B-GENE
colony-stimulating	I-GENE
factor	I-GENE
(	O
GM-CSF	B-GENE
)	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

METHODS	O
:	O
A	O
structured	O
interview	O
was	O
undertaken	O
at	O
the	O
time	O
of	O
initial	O
consultation	O
and	O
at	O
subsequent	O
1-year	O
intervals	O
regarding	O
type	O
of	O
BHS	O
,	O
frequency	O
of	O
spells	O
,	O
associated	O
phenomenon	O
,	O
sequelae	O
,	O
family	O
history	O
,	O
and	O
age	O
at	O
termination	O
of	O
spells	O
.	O

Selective	O
macrophage	O
inhibition	O
abolishes	O
warfarin-induced	O
reduction	O
of	O
metastasis	O
.	O

The	O
human	O
cDNA	O
was	O
used	O
to	O
demonstrate	O
that	O
tumor	B-GENE
necrosis	I-GENE
factor-alpha	I-GENE
could	O
rapidly	O
stimulate	O
MARCKS	B-GENE
gene	I-GENE
transcription	O
in	O
the	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
HL60	O
.	O

We	O
have	O
therefore	O
studied	O
the	O
molecular	O
mechanisms	O
of	O
TGF-beta1	B-GENE
action	O
on	O
thyroglobulin	B-GENE
(	O
TG	B-GENE
)	O
gene	O
expression	O
by	O
focusing	O
our	O
attention	O
on	O
TGF-beta1	B-GENE
regulation	O
of	O
thyroid-specific	O
transcription	O
factors	O
.	O

The	O
predicted	O
receptor	O
structure	O
includes	O
a	O
cysteine-rich	O
extracellular	O
domain	O
,	O
a	O
single	O
hydrophobic	O
transmembrane	O
domain	O
,	O
and	O
a	O
predicted	O
cytoplasmic	B-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
domain	I-GENE
.	O

DESIGN	O
:	O
A	O
retrospective	O
chart	O
review	O
of	O
9	O
,	O
322	O
patients	O
undergoing	O
surgical	O
procedures	O
in	O
the	O
period	O
January	O
1993	O
to	O
December	O
1998	O
.	O

Genetic	O
and	O
molecular	O
complexity	O
of	O
the	O
position	O
effect	O
variegation	O
modifier	O
mod	B-GENE
(	I-GENE
mdg4	I-GENE
)	I-GENE
in	O
Drosophila	O
.	O
mod	B-GENE
(	I-GENE
mdg4	I-GENE
)	I-GENE
,	O
also	O
known	O
as	O
E	B-GENE
(	I-GENE
var	I-GENE
)	I-GENE
3-93D	I-GENE
,	O
is	O
involved	O
in	O
a	O
variety	O
of	O
processes	O
,	O
such	O
as	O
gene	O
silencing	O
in	O
position	O
effect	O
variegation	O
(	O
PEV	O
)	O
,	O
the	O
control	O
of	O
gypsy	B-GENE
insulator	I-GENE
sequences	I-GENE
,	O
regulation	O
of	O
homeotic	B-GENE
gene	I-GENE
expression	O
,	O
and	O
programmed	O
cell	O
death	O
.	O

Studies	O
of	O
lipoproteins	O
should	O
,	O
however	O
,	O
be	O
made	O
in	O
children	O
from	O
families	O
known	O
to	O
have	O
FH	O
or	O
early	O
coronary	O
heart	O
disease	O
.	O

U4	B-GENE
/	I-GENE
U6	I-GENE
snRNP	I-GENE
is	O
one	O
of	O
four	O
essential	O
small	B-GENE
nuclear	I-GENE
ribonucleoprotein	I-GENE
(	I-GENE
snRNP	I-GENE
)	I-GENE
particles	I-GENE
(	I-GENE
U1	I-GENE
,	I-GENE
U2	I-GENE
,	I-GENE
U5	I-GENE
and	I-GENE
U4	I-GENE
/	I-GENE
U6	I-GENE
)	O
present	O
in	O
the	O
spliceosome	B-GENE
.	O

Eight	O
of	O
the	O
non-acceptable	O
inlays	O
/	O
onlays	O
and	O
five	O
of	O
the	O
direct	O
restorations	O
were	O
replaced	O
,	O
while	O
the	O
other	O
ones	O
were	O
repaired	O
with	O
resin	O
composite	O
.	O

Before	O
this	O
date	O
,	O
the	O
drug	O
directly	O
inhibits	O
fetal	O
weight	O
gain	O
,	O
whereas	O
the	O
sensitivity	O
of	O
the	O
placenta	O
is	O
only	O
transient	O
at	O
day	O
16	O
resulting	O
in	O
maximum	O
weight	O
decrease	O
of	O
this	O
organ	O
24	O
h	O
later	O
.	O

When	O
cotransfected	O
in	O
fibroblasts	O
with	O
a	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
expression	O
vector	O
,	O
reporter	O
gene	O
expression	O
increased	O
3-fold	O
only	O
in	O
the	O
wild-type	O
constructs	O
.	O

This	O
utilization	O
of	O
an	O
intronic	O
polyadenylation	O
site	O
without	O
alternative	O
exon	O
usage	O
is	O
comparable	O
to	O
the	O
mechanism	O
whereby	O
both	O
secreted	O
and	O
membrane-bound	O
forms	O
of	O
the	O
immunoglobulin	B-GENE
mu	I-GENE
heavy	I-GENE
chain	I-GENE
are	O
made	O
from	O
a	O
single	O
genetic	O
locus	O
.	O

The	O
characterized	O
Y'	B-GENE
repeated	I-GENE
sequence	I-GENE
families	I-GENE
provide	O
an	O
experimental	O
system	O
in	O
which	O
repeated	O
sequence	O
interactions	O
and	O
subsequent	O
evolution	O
can	O
be	O
studied	O
.	O

Also	O
discussed	O
is	O
the	O
possibility	O
of	O
a	O
combined	O
genetic	O
and	O
environmental	O
etiology	O
.	O

In	O
these	O
constructs	O
,	O
GUS	B-GENE
expression	O
was	O
driven	O
by	O
promoter	O
regions	O
derived	O
from	O
the	O
Arabidopsis	B-GENE
alcohol	I-GENE
dehydrogenase	I-GENE
(	O
Adh1	B-GENE
)	O
,	O
maize	B-GENE
ubiquitin	I-GENE
(	O
Ubi1	B-GENE
)	O
,	O
rice	B-GENE
actin	I-GENE
(	O
Act1	B-GENE
)	O
and	O
CaMV	B-GENE
35S	I-GENE
genes	I-GENE
.	O

The	O
films	O
were	O
analyzed	O
using	O
a	O
scanning	O
helium-neon	O
laser	O
densitometer	O
with	O
a	O
small	O
aperture	O
of	O
5-10	O
microns	O
.	O

While	O
no	O
obvious	O
transmembrane	O
regions	O
were	O
identified	O
,	O
several	O
short	O
hydrophobic	O
amino	O
acid	O
stretches	O
were	O
found	O
to	O
be	O
localized	O
in	O
and	O
around	O
the	O
Pro	B-GENE
II	I-GENE
region	I-GENE
,	O
and	O
these	O
may	O
be	O
responsible	O
for	O
attachment	O
of	O
precursors	O
to	O
membranes	O
.	O

In	O
addition	O
,	O
carp	B-GENE
JAK1	I-GENE
shows	O
higher	O
sequence	O
homology	O
to	O
mammalian	B-GENE
JAK1	I-GENE
in	O
both	O
the	O
kinase-like	B-GENE
(	O
JH2	B-GENE
)	O
and	O
kinase	B-GENE
(	O
JH1	B-GENE
)	O
domains	O
(	O
approximately	O
70%	O
identity	O
)	O
.	O

U73	B-GENE
contains	O
C	O
,	O
D	O
and	O
D'	O
boxes	O
and	O
a	O
12-nucleotide	O
antisense	O
complementarity	O
to	O
the	O
28S	B-GENE
ribosomal	I-GENE
RNA	I-GENE
.	O

This	O
paper	O
gives	O
an	O
overview	O
of	O
the	O
global	O
pattern	O
of	O
casualties	O
in	O
earthquakes	O
which	O
occurred	O
during	O
the	O
30-month	O
period	O
from	O
1	O
September	O
1993	O
to	O
29	O
February	O
1996	O
.	O

By	O
contrast	O
,	O
deletion	O
of	O
this	O
Ras-binding	B-GENE
site	I-GENE
did	O
not	O
diminish	O
activation	O
of	O
Raf-1	B-GENE
kinase	I-GENE
by	O
Src	B-GENE
,	O
implying	O
that	O
Src	B-GENE
and	O
Ras	B-GENE
can	O
activate	O
Raf-1	B-GENE
through	O
independent	O
mechanisms	O
.	O

The	O
clinical	O
picture	O
and	O
laboratory	O
parameters	O
were	O
consistent	O
with	O
a	O
serum	O
sickness	O
reaction	O
.	O

The	O
Stat5b	B-GENE
mRNA	I-GENE
has	O
a	O
size	O
of	O
5	O
.	O
6	O
kb	O
and	O
encodes	O
a	O
protein	O
of	O
786	O
amino	O
acids	O
.	O

Expression	O
of	O
the	O
wt1	B-GENE
gene	I-GENE
via	O
transient	O
transfection	O
in	O
COS-1	O
cells	O
revealed	O
a	O
52	O
kDa	O
protein	O
which	O
was	O
immunoprecipitated	O
by	O
both	O
the	O
N-terminal-	O
and	O
C-terminal-specific	O
antisera	O
.	O

Cotransfection	O
of	O
either	O
construct	O
with	O
plasmids	O
encoding	O
PKI	B-GENE
(	I-GENE
1-31	I-GENE
)	I-GENE
inhibits	O
cAMP-stimulated	O
but	O
not	O
basal-	O
or	O
phorbol	O
ester-stimulated	O
expression	O
.	O

Sequence	O
analysis	O
showed	O
that	O
the	O
5'-flanking	O
region	O
upstream	O
to	O
the	O
ATG	O
codon	O
did	O
not	O
contain	O
a	O
conventional	O
TATA	O
box	O
.	O

Tensile	O
bond	O
strengths	O
between	O
resin	O
composite	O
and	O
bovine	B-GENE
dentin	I-GENE
using	O
dentin	B-GENE
adhesive	O
systems	O
(	O
Clearfil	O
Liner	O
Bond	O
II	O
:	O
LB	O
II	O
;	O
Scotchbond	O
Multi-Purpose	O
:	O
MP	O
)	O
bonding	O
systems	O
showed	O
a	O
large	O
scatter	O
among	O
students	O
and	O
dentists	O
.	O

Regression	O
analyses	O
showed	O
that	O
SOREMP	O
dream	O
occurrences	O
were	O
significantly	O
related	O
to	O
the	O
amount	O
of	O
REM	O
sleep	O
,	O
while	O
NREMP	O
dream	O
occurrences	O
were	O
related	O
to	O
arousals	O
from	O
NREM	O
sleep	O
.	O

At	O
the	O
end	O
of	O
each	O
day	O
of	O
migration	O
the	O
pulmonary	O
hemolymph	O
PO2	O
decreased	O
by	O
1-2	O
.	O
5	O
kPa	O
,	O
but	O
the	O
hemocyanin	O
remained	O
saturated	O
with	O
O2	O
and	O
the	O
venous	O
reserve	O
was	O
largely	O
unchanged	O
(	O
O2	O
>	O
0	O
.	O
4	O
mmol	O
x	O
l	O
(	O
-1	O
)	O
)	O
.	O

Prominent	O
protein	B-GENE
kinase	I-GENE
cascades	I-GENE
are	O
those	O
that	O
activate	O
mitogen-activated	B-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinases	I-GENE
.	O

A	O
constitutive	O
mutant	O
form	O
with	O
a	O
single	O
substitution	O
(	O
V88A	O
)	O
in	O
the	O
amino-terminal	O
(	O
response	O
regulator	O
)	O
region	O
was	O
used	O
.	O

Substitution	O
of	O
a	O
threonine	O
residue	O
by	O
an	O
alanine	O
residue	O
at	O
position	O
-2	O
(	O
P2	O
)	O
of	O
this	O
cleavage	O
site	O
abolished	O
cleavage	O
,	O
whereas	O
substitution	O
of	O
a	O
tyrosine	O
residue	O
by	O
a	O
phenylalanine	O
residue	O
at	O
amino	O
acid	O
position	O
-1	O
(	O
P1	O
)	O
of	O
the	O
cleavage	O
site	O
did	O
not	O
influence	O
processing	O
.	O

In	O
previous	O
work	O
(	O
E	O
.	O

In	O
the	O
SPP2	O
screening	O
test	O
,	O
a	O
few	O
plates	O
were	O
not	O
seen	O
in	O
both	O
groups	O
.	O

Hydrocortisone	O
caused	O
lymphopenia	O
and	O
inhibited	O
the	O
blastogenic	O
response	O
of	O
peripheral	O
blood	O
lymphocytes	O
to	O
phytohemagglutinin	B-GENE
and	O
concanavalin	B-GENE
A	I-GENE
mitogens	O
.	O

A	O
deletion	O
series	O
of	O
the	O
5'	O
flanking	O
region	O
was	O
created	O
from	O
position	O
-1329	O
to	O
-74	O
relative	O
to	O
the	O
transcriptional	O
initiation	O
site	O
and	O
similarly	O
examined	O
in	O
transgenic	O
tobacco	O
.	O

A	O
subset	O
of	O
these	O
DMP1	B-GENE
recognition	I-GENE
sequences	I-GENE
containing	O
a	O
GGA	O
trinucleotide	O
core	O
can	O
also	O
function	O
as	O
Ets-responsive	B-GENE
elements	I-GENE
.	O

Ab-MLV	O
strains	O
expressing	O
P70	B-GENE
/	I-GENE
S2	I-GENE
failed	O
to	O
transform	O
NIH	O
3T3	O
cells	O
and	O
demonstrated	O
a	O
greatly	O
reduced	O
capacity	O
to	O
mediate	O
signaling	O
events	O
associated	O
with	O
the	O
Ras-dependent	B-GENE
mitogen-activated	I-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
pathway	O
.	O

The	O
promoter	O
activity	O
of	O
the	O
gene	B-GENE
encoding	I-GENE
Alzheimer	I-GENE
beta-amyloid	I-GENE
precursor	I-GENE
protein	I-GENE
(	O
APP	B-GENE
)	O
is	O
regulated	O
by	O
two	O
blocks	O
of	O
upstream	O
sequences	O
.	O

High-affinity	O
site-specific	O
DNA	O
binding	O
by	O
POU	B-GENE
domain	I-GENE
transcription	O
factors	O
requires	O
both	O
the	O
POU-specific	O
and	O
the	O
POU-homeodomain	B-GENE
.	O

These	O
utilisation	O
data	O
imply	O
annual	O
drug	O
costs	O
in	O
the	O
range	O
of	O
$US	O
480	O
,	O
000	O
to	O
$US	O
3	O
,	O
600	O
,	O
000	O
for	O
TNF	B-GENE
antagonists	O
for	O
RA	O
per	O
1	O
million	O
population	O
.	O

Prognosis	O
in	O
Bowen's	O
disease	O
localized	O
to	O
the	O
ano-genital	O
region	O
.	O

Nucleotide	O
sequence	O
analysis	O
revealed	O
that	O
TAR-binding	B-GENE
protein	I-GENE
is	O
very	O
similar	O
to	O
the	O
CREB2	B-GENE
protein	I-GENE
.	O

Hepatitis	O
B	O
vaccination	O
strategy	O
for	O
health-care	O
workers	O
in	O
a	O
country	O
of	O
intermediate	O
hepatitis	O
B	O
endemicity	O
.	O

So	O
far	O
no	O
problems	O
with	O
multiply	O
resistant	O
strains	O
have	O
developed	O
.	O

These	O
observed	O
drug	O
interactions	O
,	O
plus	O
the	O
known	O
effect	O
of	O
probenecid	O
to	O
block	O
secretion	O
of	O
PZA	O
,	O
have	O
to	O
be	O
considered	O
in	O
evaluating	O
the	O
effect	O
of	O
the	O
two	O
drugs	O
given	O
together	O
,	O
compared	O
to	O
the	O
effect	O
of	O
each	O
drug	O
given	O
separately	O
.	O

A	O
385	B-GENE
bp	I-GENE
Glucocorticoid	I-GENE
Response	I-GENE
Unit	I-GENE
(	O
GRU	B-GENE
)	O
was	O
identified	O
whose	O
glucocorticoid	O
induction	O
was	O
enhanced	O
by	O
dibutyryl-cAMP	O
and	O
reduced	O
by	O
phorbol	O
esters	O
.	O

The	O
Novacor	O
Left	O
Ventricular	O
Assist	O
System	O
(	O
LVAS	O
)	O
(	O
Novacor	O
Corp	O
,	O
Oakland	O
,	O
CA	O
)	O
was	O
initially	O
console-based	O
and	O
has	O
been	O
available	O
since	O
1993	O
in	O
a	O
wearable	O
configuration	O
.	O

In	O
the	O
absence	O
of	O
Mg2+	O
,	O
a	O
hydrophobic	O
exonuclease	B-GENE
site	I-GENE
dominates	O
over	O
the	O
polymerase	B-GENE
site	I-GENE
for	O
possession	O
of	O
the	O
primer	O
terminus	O
.	O

Both	O
carbachol	O
(	O
100	O
microM	O
)	O
and	O
EGF	B-GENE
(	O
10	O
nM	O
)	O
induced	O
Ras	B-GENE
activation	O
.	O

Statistics	O
for	O
nurse	O
managers--3	O
.	O

These	O
results	O
suggest	O
that	O
low	O
concentrations	O
of	O
IL-1	B-GENE
beta	I-GENE
may	O
be	O
useful	O
for	O
nonsurgical	O
treatment	O
of	O
human	O
vitreous	O
hemorrhage	O
.	O

Results	O
of	O
the	O
official	O
inspection	O
of	O
the	O
commercial	O
anti-inflammatory	O
enzyme	O
preparations	O
containing	O
chymotrypsin	B-GENE
and	O
trypsin	B-GENE
by	O
means	O
of	O
modified	O
NF	O
13	O
methods	O
.	O

T	O
cell	O
leukemia-associated	O
human	O
Notch	O
/	O
translocation-associated	O
Notch	B-GENE
homologue	I-GENE
has	O
I	O
kappa	O
B-like	O
activity	O
and	O
physically	O
interacts	O
with	O
nuclear	B-GENE
factor-kappa	I-GENE
B	I-GENE
proteins	I-GENE
in	O
T	O
cells	O
.	O

A	O
stratified	O
random	O
sample	O
of	O
20	O
active	O
employees	O
from	O
a	O
cohort	O
of	O
phenoxy	O
herbicide	O
workers	O
was	O
selected	O
in	O
1995	O
for	O
determining	O
PCDD	O
and	O
PCDF	O
congeners	O
in	O
blood	O
lipids	O
to	O
assess	O
the	O
extent	O
of	O
past	O
PCDD	O
and	O
PCDF	O
exposure	O
in	O
this	O
cohort	O
and	O
whether	O
that	O
exposure	O
might	O
explain	O
site-specific	O
cancer	O
findings	O
in	O
the	O
total	O
cohort	O
.	O

A	O
point	O
mutation	O
in	O
Galphao	B-GENE
and	O
Galphai1	B-GENE
blocks	O
interaction	O
with	O
regulator	O
of	O
G	B-GENE
protein	I-GENE
signaling	O
proteins	O
.	O

Linear	O
regression	O
analysis	O
was	O
performed	O
and	O
the	O
following	O
result	O
was	O
obtained	O
:	O
clearance	O
(	O
HMPAO	O
)	O
=	O
0	O
.	O
07	O
+	O
0	O
.	O
43	O
.	O
rCBF	O
with	O
a	O
high	O
significance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Copyright	O
2001	O
Academic	O
Press	O
.	O

Conformational	O
changes	O
of	O
the	O
ferric	O
uptake	O
regulation	O
protein	O
upon	O
metal	O
activation	O
and	O
DNA	O
binding	O
;	O
first	O
evidence	O
of	O
structural	O
homologies	O
with	O
the	O
diphtheria	B-GENE
toxin	I-GENE
repressor	I-GENE
.	O

The	O
genome	O
organization	O
of	O
the	O
mite-transmitted	O
wheat	O
streak	O
mosaic	O
virus	O
(	O
WSMV	O
)	O
appears	O
to	O
parallel	O
that	O
of	O
members	O
of	O
the	O
Potyviridae	O
with	O
monopartite	O
genomes	O
,	O
but	O
there	O
are	O
substantial	O
amino	O
acid	O
dissimilarities	O
with	O
other	O
potyviral	O
polyproteins	O
.	O

Acupuncture	O
effect	O
on	O
deep	O
receptors	O
was	O
not	O
limited	O
to	O
one	O
point	O
but	O
within	O
a	O
certain	O
area	O
,	O
namely	O
distant	O
effect	O
existed	O
.	O

Cbl	B-GENE
constitutively	O
interacts	O
with	O
the	O
SH3	B-GENE
domains	I-GENE
of	O
Grb2	B-GENE
,	O
with	O
a	O
preference	O
for	O
the	O
amino-terminal	O
domain	O
,	O
and	O
is	O
in	O
this	O
way	O
recruited	O
to	O
Shc	B-GENE
upon	O
BCR	B-GENE
stimulation	O
.	O

Colorectal	O
carcinoma	O
:	O
therapeutic	O
approach	O
in	O
patients	O
already	O
treated	O
with	O
metastasis	O
resection	O
.	O

The	O
frequency	O
of	O
previous	O
transfusion	O
in	O
chronic	O
hepatitis	O
,	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
of	O
type	O
NANB	O
was	O
42	O
.	O
8	O
,	O
37	O
.	O
1	O
and	O
15	O
.	O
1%	O
,	O
respectively	O
,	O
whereas	O
the	O
incidence	O
of	O
early	O
posttransfusion	O
hepatitis	O
was	O
8	O
.	O
5	O
,	O
8	O
.	O
6	O
and	O
7	O
.	O
5%	O
,	O
respectively	O
.	O
in	O
chronic	O
liver	O
diseases	O
with	O
a	O
history	O
of	O
jaundice	O
and	O
/	O
or	O
hepatitis	O
,	O
previous	O
transfusions	O
are	O
more	O
frequently	O
associated	O
with	O
type	O
NANB	O
than	O
with	O
type	O
B	O
disease	O
.	O

Distribution	O
and	O
changing	O
morphological	O
course	O
.	O

Bacteriol	O
.	O

By	O
creating	O
Pax-6-BSAP	B-GENE
fusion	I-GENE
proteins	I-GENE
,	O
we	O
were	O
able	O
to	O
identify	O
a	O
short	O
amino	O
acid	O
stretch	O
in	O
the	O
N-terminal	O
part	O
of	O
the	O
paired	O
domain	O
which	O
is	O
responsible	O
for	O
these	O
differences	O
in	O
DNA-binding	O
specificity	O
.	O

This	O
computerized	O
list	O
was	O
linked	O
to	O
the	O
central	O
files	O
of	O
the	O
Massachusetts	O
Cancer	O
Registry	O
and	O
cases	O
diagnosed	O
between	O
1982	O
and	O
1988	O
were	O
identified	O
.	O

Significance	O
of	O
delta-aminolevulinic	O
acid	O
analysis	O
in	O
clinical	O
tests	O
.	O

Following	O
iv	O
injection	O
of	O
0	O
.	O
5	O
g	O
galactose	O
per	O
kg	O
body	O
weight	O
,	O
together	O
with	O
2	O
mu	O
Ci	O
generally	O
14C-labelled	O
galactose	O
,	O
14CO2	O
is	O
collected	O
in	O
regular	O
intervals	O
during	O
one	O
hour	O
.	O

A	O
clinically	O
useful	O
diagnostic	O
method	O
has	O
been	O
developed	O
for	O
detecting	O
and	O
quantitating	O
periods	O
of	O
apnea	O
in	O
pediatric	O
patients	O
.	O

A	O
value	O
of	O
1	O
.	O
1	O
l	O
/	O
kg	O
was	O
used	O
for	O
V	O
in	O
calculating	O
all	O
single	O
sample	O
estimates	O
of	O
clearance	O
(	O
CL	O
)	O
,	O
and	O
a	O
value	O
of	O
4	O
.	O
3	O
l	O
/	O
kg	O
was	O
used	O
to	O
calculate	O
single	O
sample	O
estimates	O
of	O
clearance	O
of	O
plasma	O
unbound	O
drug	O
(	O
CLunb	O
)	O
.	O

The	O
catenins	B-GENE
bind	O
to	O
APC	B-GENE
and	O
E-cadherin	B-GENE
in	O
a	O
similar	O
fashion	O
,	O
but	O
APC	B-GENE
and	O
E-cadherin	B-GENE
do	O
not	O
associate	O
with	O
each	O
other	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
catenins	B-GENE
.	O

The	O
rhaB	B-GENE
transcription	I-GENE
start	I-GENE
site	I-GENE
was	O
mapped	O
to	O
-24	O
relative	O
to	O
the	O
start	O
of	O
translation	O
.	O

Despite	O
the	O
activation	O
of	O
these	O
intracellular	O
signaling	O
molecules	O
,	O
PDGF	B-GENE
beta	I-GENE
receptor	I-GENE
activation	O
elicited	O
no	O
detectable	O
effect	O
on	O
cell	O
proliferation	O
or	O
differentiation	O
.	O

A	O
fusion	O
protein	O
composed	O
of	O
beta-galactosidase	B-GENE
and	O
full-length	B-GENE
Ahr	I-GENE
translocates	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
in	O
a	O
ligand-dependent	O
manner	O
.	O

In	O
strains	O
lacking	O
tup11	B-GENE
and	O
tup12	B-GENE
,	O
the	O
atf1-pcr1	B-GENE
transcriptional	I-GENE
activator	I-GENE
continues	O
to	O
play	O
a	O
central	O
role	O
in	O
fbp1-lacZ	B-GENE
expression	O
;	O
however	O
,	O
spc1	B-GENE
MAPK	I-GENE
phosphorylation	O
of	O
atf1	B-GENE
is	O
no	O
longer	O
essential	O
for	O
its	O
activation	O
.	O

In	O
contrast	O
to	O
full-length	B-GENE
E2F-3	I-GENE
,	O
which	O
is	O
expressed	O
only	O
at	O
the	O
G1	O
/	O
S	O
boundary	O
,	O
E2F-3B	B-GENE
is	O
detected	O
throughout	O
the	O
cell	O
cycle	O
with	O
peak	O
levels	O
in	O
GO	O
where	O
it	O
is	O
associated	O
with	O
Rb	O
.	O

A	O
5	B-GENE
.	I-GENE
8S-like	I-GENE
structure	I-GENE
is	O
present	O
within	O
the	O
5'-terminal	O
region	O
of	O
all	O
three	O
fungal	B-GENE
mitochondrial	I-GENE
LSU	I-GENE
rRNAs	I-GENE
;	O
in	O
contrast	O
,	O
no	O
4	B-GENE
.	I-GENE
5S-like	I-GENE
structure	I-GENE
is	O
evident	O
at	O
the	O
3'	O
end	O
of	O
these	O
molecules	O
.	O

Phenotypic	O
changes	O
induced	O
by	O
wild	B-GENE
type	I-GENE
and	I-GENE
variant	I-GENE
c-src	I-GENE
genes	I-GENE
carrying	O
C-terminal	O
sequence	O
alterations	O
.	O

These	O
results	O
suggest	O
that	O
members	O
of	O
the	O
ATF	B-GENE
family	I-GENE
are	O
involved	O
in	O
mediating	O
the	O
transcriptional	O
regulation	O
of	O
the	O
KGF	B-GENE
gene	I-GENE
in	O
response	O
to	O
extracellular	O
stimuli	O
via	O
a	O
novel	O
CRE	B-GENE
regulatory	I-GENE
element	I-GENE
.	O

Unusual	O
two-domain	B-GENE
arginine	I-GENE
kinases	I-GENE
(	O
AKs	B-GENE
)	O
arose	O
independently	O
at	O
least	O
two	O
times	O
during	O
molecular	O
evolution	O
of	O
phosphagen	B-GENE
kinases	I-GENE
:	O
AKs	B-GENE
from	O
the	O
primitive	O
sea	O
anemone	O
Anthopleurura	O
japonicus	O
and	O
from	O
the	O
clam	O
Pseudocardium	O
sachalinensis	O
.	O

Stable	O
expression	O
of	O
the	O
chimeric	O
alpha	O
i	O
(	O
54	O
)	O
/	O
s	O
polypeptide	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
constitutively	O
increased	O
both	O
cAMP	O
synthesis	O
and	O
cAMP-dependent	B-GENE
protein	I-GENE
kinase	I-GENE
activity	O
.	O

Ca2+	O
decreased	O
Zn2+	O
binding	O
in	O
S100	B-GENE
beta	I-GENE
but	O
it	O
did	O
not	O
influence	O
binding	O
to	O
MRP14	B-GENE
,	O
suggesting	O
that	O
the	O
Zn2+	O
binding	O
site	O
was	O
distinct	O
from	O
and	O
independent	O
of	O
the	O
two	O
Ca2+	O
binding	O
domains	O
.	O

However	O
,	O
rapamycin	O
inhibited	O
proliferation	O
of	O
Ba	O
/	O
F3-EpoRgp55	O
but	O
not	O
of	O
MEL	O
cells	O
despite	O
inhibition	O
of	O
p70	B-GENE
S6	I-GENE
kinase	I-GENE
activity	O
in	O
both	O
cells	O
.	O

Further	O
,	O
the	O
PIP2	O
content	O
of	O
the	O
85-90	O
kDa	O
protein	O
appeared	O
to	O
decrease	O
with	O
CSF-1	B-GENE
treatment	O
.	O

Experimental	O
ischemic	O
heart	O
disease	O
induced	O
by	O
thromboxane	B-GENE
A2	I-GENE
in	O
rabbits	O
.	O

This	O
spindle	O
defect	O
of	O
pds1	B-GENE
mutants	I-GENE
results	O
from	O
a	O
temperature-sensitive	O
step	O
that	O
occurs	O
around	O
the	O
G1	O
/	O
S	O
boundary	O
about	O
the	O
time	O
of	O
spindle	O
assembly	O
.	O

The	O
discordant	O
behaviour	O
in	O
weakly	O
infected	O
mice	O
was	O
due	O
to	O
the	O
occurrence	O
in	O
some	O
animals	O
of	O
a	O
second	O
phase	O
of	O
more	O
rapid	O
increase	O
of	O
the	O
parasitemia	O
.	O

Behcet's	O
syndrome	O
.	O

Serum	O
lipids	O
and	O
lipoproteins	O
of	O
29	O
insulin	B-GENE
dependent	O
diabetic	O
children	O
have	O
been	O
determined	O
and	O
related	O
to	O
the	O
metabolic	O
status	O
of	O
the	O
patients	O
.	O

Since	O
general	B-GENE
regulatory	I-GENE
factor	I-GENE
I	I-GENE
(	O
GRFI	B-GENE
)	O
/	B-GENE
repressor	I-GENE
/	I-GENE
activator	I-GENE
site	I-GENE
binding	I-GENE
protein	I-GENE
1	I-GENE
(	O
RAP1	B-GENE
)	O
/	B-GENE
translation	I-GENE
upstream	I-GENE
factor	I-GENE
(	O
TUF	B-GENE
)	O
is	O
believed	O
to	O
be	O
an	O
activator	O
of	O
MAT	B-GENE
alpha	I-GENE
expression	O
,	O
we	O
examined	O
whether	O
PYK1	B-GENE
,	O
which	O
is	O
known	O
to	O
be	O
regulated	O
by	O
GRFI	B-GENE
/	I-GENE
RAP1	I-GENE
/	I-GENE
TUF	I-GENE
,	O
is	O
also	O
affected	O
by	O
the	O
gal11	B-GENE
mutation	I-GENE
.	O

In	O
both	O
groups	O
there	O
were	O
5	O
management	O
failure	O
of	O
therapy	O
,	O
so	O
that	O
alternative	O
medication	O
or	O
a	O
cesarean	O
section	O
lead	O
to	O
delivery	O
.	O

LHbeta	B-GENE
is	O
expressed	O
in	O
pituitary	O
gonadotrope	O
cells	O
and	O
CGbeta	B-GENE
is	O
expressed	O
in	O
placental	O
trophoblast	O
cells	O
.	O

Williams	O
,	O
2	O
August	O
1977	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
this	O
experimental	O
model	O
,	O
ACE	B-GENE
inhibitors	O
limit	O
the	O
arrhythmias	O
following	O
ischemia-reperfusion	O
and	O
free	O
radical	O
scavenging	O
action	O
of	O
these	O
drugs	O
does	O
not	O
have	O
a	O
major	O
contributory	O
role	O
in	O
their	O
protective	O
effect	O
.	O

Skin	O
cancers	O
,	O
followed	O
by	O
gastrointestinal	O
tract	O
and	O
male	O
genital	O
system	O
affected	O
mostly	O
older	O
age	O
patients	O
.	O

ICAM-1	B-GENE
has	O
been	O
suggested	O
a	O
predictor	O
of	O
the	O
onset	O
of	O
GO	O
.	O

CONCLUSIONS	O
:	O
EBCT	O
technology	O
allows	O
minimally	O
invasive	O
evaluation	O
of	O
intramyocardial	O
microcirculatory	O
function	O
and	O
permits	O
assessment	O
of	O
microvascular	O
BV	O
distribution	O
in	O
different	O
functional	O
components	O
.	O

(	O
2	O
)	O
The	O
inappropriateness	O
of	O
adaptive	O
segmentation	O
for	O
the	O
isolation	O
of	O
spikes	O
and	O
sharp	O
waves	O
,	O
which	O
had	O
been	O
anticipated	O
in	O
view	O
of	O
the	O
short	O
duration	O
of	O
such	O
transients	O
in	O
relation	O
to	O
the	O
length	O
of	O
the	O
window	O
(	O
1	O
.	O
2	O
sec	O
)	O
used	O
for	O
the	O
autocorrelation	O
functions	O
employed	O
in	O
the	O
segmentation	O
algorithm	O
,	O
was	O
confirmed	O
.	O

The	O
acids	O
were	O
obtained	O
by	O
hydrolysis	O
of	O
the	O
corresponding	O
esters	O
,	O
and	O
their	O
anti-inflammatory	O
activity	O
was	O
tested	O
.	O

All	O
six	O
genes	O
were	O
cloned	O
and	O
characterised	O
.	O

Autotransplantation	O
of	O
a	O
vein	O
segment	O
with	O
valve	O
in	O
the	O
treatment	O
of	O
deep	O
vein	O
valvular	O
insufficiency	O
of	O
the	O
lower	O
extremity	O
.	O

The	O
mean	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
31	O
.	O
8	O
+	O
/	O
-	O
6	O
.	O
3	O
kg	O
/	O
m2	O
and	O
28	O
.	O
5	O
+	O
/	O
-	O
6	O
.	O
3	O
kg	O
/	O
m2	O
in	O
women	O
and	O
men	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
In	O
women	O
who	O
want	O
or	O
require	O
conservative	O
management	O
of	O
grade	O
4	O
prolapse	O
and	O
are	O
unable	O
to	O
retain	O
a	O
single	O
pessary	O
,	O
the	O
placement	O
of	O
two	O
pessaries	O
often	O
will	O
be	O
successful	O
.	O

JCAHO	O
asks	O
for	O
hospitals'	O
patience	O
.	O

This	O
interaction	O
is	O
reciprocal	O
,	O
since	O
C	B-GENE
/	I-GENE
EBP	I-GENE
dimer	I-GENE
binding	O
to	O
a	O
strong	O
C	B-GENE
/	I-GENE
EBP	I-GENE
site	I-GENE
leads	O
to	O
enhanced	O
CREB-1	B-GENE
recruitment	O
to	O
ATF	B-GENE
/	I-GENE
CREB	I-GENE
sites	I-GENE
that	O
are	O
weakly	O
bound	O
by	O
CREB	B-GENE
.	O

Possible	O
relationship	O
between	O
hyperinsulinemia	O
and	O
glomerular	O
hypertrophy	O
in	O
nephrosclerosis	O
.	O

Mutations	O
in	O
the	O
alpha-amanitin	B-GENE
conserved	O
domain	O
of	O
the	O
largest	O
subunit	O
of	O
yeast	B-GENE
RNA	I-GENE
polymerase	I-GENE
III	I-GENE
affect	O
pausing	O
,	O
RNA	O
cleavage	O
and	O
transcriptional	O
transitions	O
.	O

Since	O
very	O
recent	O
scanning-deletion	O
analysis	O
indicates	O
that	O
there	O
is	O
a	O
critical	O
region	O
for	O
activity	O
near	O
Cys-118	O
and	O
that	O
Cys-118	O
is	O
necessary	O
for	O
maximal	O
activity	O
,	O
we	O
conclude	O
that	O
the	O
Cys-118	O
residue	O
is	O
necessary	O
for	O
proper	O
glycosylation	O
and	O
maximal	O
biologic	O
activity	O
of	O
GM-CSF	B-GENE
.	O

1972	O
.	O

The	O
findings	O
suggest	O
that	O
,	O
although	O
iodine	O
deficiency	O
is	O
the	O
most	O
probable	O
cause	O
of	O
goiter	O
among	O
immigrants	O
of	O
the	O
1928	O
cohort	O
,	O
where	O
the	O
native	O
population	O
is	O
concerned	O
(	O
both	O
men	O
and	O
women	O
)	O
,	O
some	O
other	O
goitrogenic	O
factor	O
(	O
s	O
)	O
must	O
be	O
involved	O
.	O

"Let	O
the	O
hundred	O
flowers	O
bloom"	O
.	O

Fragments	O
and	O
analogs	O
of	O
the	O
hormone	O
ACTH	B-GENE
were	O
previously	O
shown	O
to	O
have	O
beneficial	O
effect	O
on	O
the	O
outcome	O
of	O
head	O
injury	O
,	O
while	O
elevated	O
levels	O
of	O
corticosterone	O
(	O
CS	O
)	O
exacerbate	O
it	O
.	O

Cardiac	O
taurine	O
levels	O
and	O
sarcolemmal	O
calcium	O
binding	O
activity	O
in	O
furazolidone-induced	O
cardiomyopathy	O
.	O

This	O
is	O
concluded	O
from	O
the	O
isolation	O
of	O
cDNAs	O
from	O
spinach	O
(	O
Spinacia	O
oleracea	O
)	O
and	O
barley	O
(	O
Hordeum	O
vulgare	O
cv	O
.	O

Over-expression	O
of	O
Azf1p	B-GENE
in	O
the	O
yeast	O
cell	O
does	O
not	O
influence	O
the	O
expression	O
level	O
of	O
the	O
mitochondrial	B-GENE
transcription	I-GENE
factor	I-GENE
Mtf1p	I-GENE
,	O
indicating	O
that	O
the	O
influence	O
of	O
Azf1p	B-GENE
on	O
the	O
suppression	O
of	O
the	O
special	O
mitochondrial	B-GENE
RNA	I-GENE
polymerase	I-GENE
mutant	I-GENE
is	O
an	O
indirect	O
one	O
.	O

Treatment	O
with	O
MK-801	O
induced	O
a	O
burst	O
suppression	O
in	O
the	O
EEG	O
and	O
a	O
transient	O
drop	O
(	O
11	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
5	O
mm	O
Hg	O
)	O
in	O
the	O
mean	O
arterial	O
pressure	O
.	O

We	O
have	O
also	O
found	O
that	O
the	O
in	O
vitro	O
interaction	O
between	O
the	O
SV40	O
octamer	O
motif	O
and	O
the	O
lymphoid	B-GENE
cell-specific	I-GENE
protein	I-GENE
oct-B2	I-GENE
was	O
negatively	O
modulated	O
by	O
a	O
component	O
present	O
in	O
the	O
nuclear	O
extracts	O
from	O
several	O
lymphoid	O
cell	O
lines	O
.	O

The	O
appearance	O
of	O
dyskinetic	O
movement	O
disorders	O
in	O
humans	O
following	O
the	O
chronic	O
use	O
of	O
levodopa	O
or	O
amphetamine	O
may	O
be	O
a	O
manifestation	O
of	O
similarly	O
increased	O
dopamine	B-GENE
receptor	I-GENE
site	I-GENE
sensitivity	O
within	O
the	O
striatum	O
.	O

The	O
obtained	O
results	O
were	O
compared	O
with	O
control	O
group	O
(	O
10	O
female	O
volunteers	O
)	O
.	O

DNA-STAT	B-GENE
complexes	I-GENE
were	O
detected	O
in	O
all	O
Bcr	O
/	O
Abl-transformed	O
cell	O
lines	O
and	O
they	O
were	O
supershifted	O
by	O
antibodies	O
against	O
STAT1	B-GENE
and	O
STAT5	B-GENE
.	O

But	O
the	O
application	O
solutions	O
of	O
instrument	O
disinfectants	O
should	O
not	O
be	O
used	O
longer	O
than	O
one	O
day	O
.	O

Four	O
CsA-treated	O
patients	O
developed	O
persistently	O
elevated	O
UAER	O
>	O
30	O
mg	O
/	O
24	O
h	O
(	O
n	O
=	O
3	O
with	O
microalbuminuria	O
)	O
,	O
whereas	O
all	O
the	O
17	O
placebo-treated	O
patients	O
had	O
normal	O
UAER	O
(	O
<	O
30	O
mg	O
/	O
24	O
h	O
)	O
after	O
7	O
years	O
of	O
follow-up	O
.	O

This	O
brief	O
review	O
analyses	O
these	O
interactions	O
and	O
defines	O
clinical	O
settings	O
where	O
antibiotic-induced	O
endotoxin	B-GENE
release	O
may	O
prove	O
to	O
be	O
clinically	O
relevant	O
.	O

These	O
studies	O
serve	O
as	O
the	O
basis	O
for	O
the	O
further	O
characterization	O
of	O
the	O
regulatory	O
mechanism	O
of	O
aromatase	B-GENE
expression	O
in	O
human	O
breast	O
cancer	O
and	O
ASCs	O
.	O

However	O
,	O
a	O
similar	O
mutation	O
of	O
a	O
leucine	O
residue	O
to	O
arginine	O
at	O
position	O
422	O
showed	O
no	O
alteration	O
of	O
heterodimerization	O
,	O
DNA	O
binding	O
,	O
or	O
transcriptional	O
activation	O
.	O

Studies	O
carried	O
out	O
with	O
the	O
Glossina	O
morsitans	O
colony	O
of	O
Lisbon	O
.	O

Steal	O
is	O
a	O
pathophysiological	O
process	O
in	O
which	O
increased	O
blood	O
flow	O
through	O
a	O
low-resistance	O
vascular	O
bed	O
is	O
sufficient	O
to	O
divert	O
flow	O
away	O
from	O
a	O
region	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Cross-reaction	O
between	O
a	O
monoclonal	O
antibody	O
and	O
two	O
alpha	B-GENE
beta	I-GENE
T	I-GENE
cell	I-GENE
receptors	I-GENE
.	O

The	O
coordinate	O
increase	O
in	O
cyclin	B-GENE
D1	I-GENE
and	O
p21	B-GENE
had	O
the	O
effect	O
of	O
decreasing	O
the	O
specific	O
but	O
not	O
absolute	O
activity	O
of	O
cyclin	B-GENE
D1	I-GENE
/	I-GENE
cdk4	I-GENE
.	O
p53	B-GENE
was	O
not	O
involved	O
since	O
CSF-1	B-GENE
induction	O
of	O
p21	B-GENE
was	O
unaffected	O
by	O
dominant-negative	B-GENE
p53	I-GENE
expression	O
.	O

We	O
show	O
that	O
stabilization	O
of	O
the	O
hairpin	O
reduced	O
the	O
amount	O
of	O
tRNA	O
primer	O
that	O
is	O
annealed	O
to	O
the	O
PBS	O
.	O

Our	O
findings	O
support	O
the	O
view	O
of	O
a	O
multifactorial	O
genesis	O
of	O
the	O
cardiac	O
involvement	O
in	O
uremic	O
patients	O
.	O

Myocardial	O
antioxidant	O
enzymes	O
,	O
catalase	B-GENE
,	O
glutathione	B-GENE
peroxidase	I-GENE
and	O
superoxide	B-GENE
dismutase	I-GENE
,	O
in	O
the	O
MCT-treated	O
rats	O
were	O
not	O
different	O
compared	O
to	O
control	O
rats	O
.	O

Dietetics	O
of	O
childhood-	O
and	O
juvenile	O
diabetes	O
.	O

AP	O
was	O
induced	O
by	O
intraductal	O
infusion	O
of	O
two	O
different	O
concentrations	O
of	O
glycodeoxycholic	O
acid	O
(	O
GDOC	O
17	O
mmol	O
and	O
34	O
mmol	O
)	O
.	O

Penicillinase	B-GENE
production	O
in	O
Staphylococcus	O
aureus	O
strains	O
of	O
clinical	O
importance	O
.	O

The	O
PC-based	O
RTPS	O
is	O
designed	O
to	O
run	O
in	O
the	O
Microsoft	O
Windows	O
3	O
.	O
11	O
environment	O
(	O
and	O
later	O
versions	O
)	O
,	O
for	O
computers	O
equipped	O
with	O
486	O
or	O
Pentium	O
processors	O
.	O

Our	O
data	O
show	O
also	O
that	O
phagocytic	O
killing	O
of	O
meningococci	O
is	O
probably	O
a	O
more	O
consistent	O
assay	O
than	O
antibody	O
titer	O
levels	O
for	O
antimeningococcal	O
immunity	O
,	O
especially	O
in	O
LCC-deficient	O
patients	O
.	O

Human	O
synovial	O
fluid	O
:	O
detection	O
of	O
a	O
new	O
component	O
.	O

Desmethylferrochloroquine	O
1a	O
and	O
didesmethylferrochloroquine	O
2	O
would	O
be	O
more	O
potent	O
against	O
schizontocides	O
than	O
CQ	O
in	O
vitro	O
against	O
two	O
strains	O
(	O
HB3	O
and	O
Dd2	O
)	O
of	O
Plasmodium	O
falciparum	O
.	O

Furthermore	O
,	O
this	O
study	O
looks	O
at	O
the	O
impact	O
of	O
synthesis	O
conditions	O
on	O
block	O
length	O
and	O
crystallinity	O
,	O
and	O
the	O
impact	O
of	O
the	O
blocking	O
on	O
both	O
,	O
crystallinity	O
and	O
solubility	O
of	O
the	O
polymers	O
.	O

The	O
carboxy	O
terminus	O
of	O
Mbp1	B-GENE
is	O
sufficient	O
for	O
interaction	O
with	O
Swi6	B-GENE
,	O
and	O
the	O
carboxy	O
terminus	O
of	O
Swi6	B-GENE
is	O
required	O
for	O
interaction	O
with	O
Mbp1	B-GENE
.	O

10	O
long-term	O
hemodialysis	O
patients	O
had	O
immediate	O
and	O
redistribution	O
thallium-201	O
myocardial	O
imaging	O
performed	O
after	O
a	O
course	O
of	O
hemodialysis	O
.	O

However	O
,	O
L-plastin	B-GENE
has	O
been	O
found	O
in	O
many	O
types	O
of	O
malignant	O
human	O
cells	O
of	O
non-hemopoietic	O
origin	O
suggesting	O
that	O
its	O
expression	O
is	O
induced	O
accompanying	O
tumorigenesis	O
in	O
solid	O
tissues	O
.	O

Neither	O
is	O
it	O
a	O
major	O
cause	O
of	O
rehydration-induced	O
renal	O
Na	O
retention	O
.	O

Gel	O
mobility	O
shift	O
and	O
super-shift	O
assays	O
using	O
liver	O
nuclear	O
extracts	O
from	O
either	O
rat	O
liver	O
or	O
DDT1MF-2	O
cells	O
demonstrated	O
that	O
the	O
CRE	B-GENE
in	O
the	O
alpha	B-GENE
1B-AR	I-GENE
gene	I-GENE
bound	O
CRE	B-GENE
binding	I-GENE
protein	I-GENE
.	O

Therefore	O
,	O
analogs	O
of	O
vitamin	O
D3	O
have	O
been	O
investigated	O
in	O
a	O
number	O
of	O
trials	O
showing	O
improvement	O
of	O
psoriasis	O
.	O

A	O
larger	O
region	O
upstream	O
of	O
human	B-GENE
CMV	I-GENE
dbp	I-GENE
also	O
mediated	O
replication	O
in	O
transient	O
assays	O
.	O

There	O
is	O
no	O
TATA	O
box	O
appropriately	O
spaced	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O

Using	O
this	O
method	O
,	O
we	O
were	O
able	O
to	O
select	O
strong	O
enhancer-type	O
activation	O
domains	O
from	O
the	O
immediate	B-GENE
early	I-GENE
regions	I-GENE
of	O
two	O
herpesviruses	O
,	O
namely	O
pseudorabies	O
virus	O
and	O
bovine	O
herpesvirus	O
1	O
.	O

An	O
association	O
was	O
demonstrated	O
between	O
the	O
expression	O
of	O
aberrantly	O
and	O
/	O
or	O
alternatively	O
spliced	O
mdm2	B-GENE
mRNAs	I-GENE
and	O
a	O
lack	O
of	O
progesterone	B-GENE
receptor	I-GENE
.	O

The	O
differentiation	O
and	O
maintenance	O
of	O
a	O
neurotransmitter	O
phenotype	O
is	O
guided	O
by	O
the	O
interaction	O
of	O
exogenous	O
cues	O
with	O
intrinsic	O
genetic	O
machinery	O
.	O

Data	O
supported	O
the	O
brevity	O
of	O
the	O
WISC-III	O
short	O
form	O
and	O
the	O
criterion-related	O
validity	O
of	O
both	O
the	O
K-FAST	O
and	O
and	O
Kaufman	O
Short	O
Neuropsychological	O
Assessment	O
Procedure	O
(	O
K-SNAP	O
)	O
.	O

In	O
contrast	O
,	O
rats	O
receiving	O
U74500A	O
(	O
2	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
infusion	O
commencing	O
30	O
min	O
prior	O
to	O
revascularisation	O
)	O
exhibited	O
enhanced	O
GMBF	O
throughout	O
reperfusion	O
[	O
PI	O
10	O
min	O
:	O
3	O
.	O
26	O
(	O
2	O
.	O
56-3	O
.	O
63	O
)	O
;	O
120	O
min	O
:	O
2	O
.	O
03	O
(	O
1	O
.	O
73-2	O
.	O
25	O
)	O
;	O
240	O
min	O
:	O
2	O
.	O
13	O
(	O
1	O
.	O
75-2	O
.	O
44	O
)	O
,	O
p	O
<	O
0	O
.	O
01	O
vs	O
.	O
controls	O
and	O
normals	O
]	O
with	O
complete	O
muscle	O
salvage	O
[	O
GMV	O
100%	O
in	O
all	O
reperfused	O
muscles	O
,	O
p	O
<	O
0	O
.	O
01	O
vs	O
.	O
controls	O
,	O
not	O
significant	O
(	O
NS	O
)	O
vs	O
.	O
normals	O
and	O
6	O
h	O
ischaemia	O
]	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Phosphotyrosyl	B-GENE
peptides	I-GENE
block	O
Stat3-mediated	O
DNA-binding	O
activity	O
,	O
gene	O
regulation	O
and	O
cell	O
transformation	O
.	O

The	O
therapy	O
time	O
to	O
deliver	O
the	O
NCS	O
therapeutic	O
dose	O
of	O
10000	O
RBE-cGy	O
,	O
is	O
27	O
times	O
longer	O
when	O
157Gd	O
is	O
used	O
instead	O
of	O
10B	O
.	O

G-CSF	B-GENE
(	O
480	O
micrograms	O
subcutaneously	O
(	O
s	O
.	O
c	O
.	O
)	O
)	O
were	O
used	O
in	O
55	O
and	O
GM-CSF	B-GENE
(	O
400	O
micrograms	O
s	O
.	O
c	O
.	O
)	O
in	O
28	O
chemotherapeutic	O
cycles	O
.	O

A	O
significant	O
relationship	O
existed	O
during	O
the	O
evolution	O
of	O
the	O
disease	O
between	O
CRS	O
/	O
BW	O
and	O
gas	O
exchange	O
parameters	O
(	O
FIO2	O
and	O
a	O
/	O
AO2	O
ratio	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
but	O
gas	O
exchange	O
improved	O
earlier	O
than	O
lung	O
mechanics	O
.	O

Specific	O
IgE	B-GENE
levels	O
decreased	O
slightly	O
,	O
but	O
always	O
remained	O
within	O
the	O
pathological	O
range	O
.	O

Mutating	O
the	O
E-box	O
in	O
the	O
context	O
of	O
the	O
3'-flanking	O
region	O
confirmed	O
that	O
it	O
contributes	O
to	O
the	O
enhancement	O
of	O
transcriptional	O
activity	O
of	O
the	O
alpha1	B-GENE
(	I-GENE
I	I-GENE
)	I-GENE
collagen	I-GENE
gene	I-GENE
promoter	I-GENE
.	O

The	O
study	O
was	O
repeated	O
after	O
administration	O
of	O
oral	O
amiodarone	O
,	O
50	O
mg	O
/	O
kg	O
/	O
day	O
for	O
2	O
days	O
in	O
8	O
divided	O
doses	O
(	O
mean	O
dose	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
4	O
g	O
)	O
.	O

VII	O
.	O

Ischemic	O
heart	O
disease	O
,	O
age	O
of	O
more	O
than	O
75	O
years	O
,	O
and	O
the	O
fact	O
that	O
the	O
patient	O
was	O
a	O
woman	O
were	O
independent	O
predictors	O
of	O
poor	O
cardiac	O
function	O
.	O

To	O
determine	O
if	O
the	O
NF	B-GENE
(	I-GENE
H	I-GENE
)	I-GENE
promoter	I-GENE
can	O
be	O
activated	O
in	O
a	O
tissue	O
specific	O
manner	O
during	O
development	O
transgenic	O
mice	O
containing	O
the	O
promoter	O
region	O
linked	O
to	O
a	O
beta-galactosidase	B-GENE
reporter	I-GENE
gene	I-GENE
were	O
generated	O
.	O

Serum	B-GENE
IgE	I-GENE
levels	O
in	O
Tauranga	O
children	O
.	O

Renal	O
excretion	O
of	O
sulphadimidine	O
in	O
normal	O
and	O
uraemic	O
subjects	O
.	O

It	O
is	O
considered	O
that	O
the	O
recurrent	O
annular	O
erythema	O
is	O
a	O
specific	O
skin	O
manifestation	O
of	O
SjS	O
with	O
anti	B-GENE
SS-A	I-GENE
/	I-GENE
SS-B	I-GENE
antibodies	I-GENE
.	O

Changes	O
of	O
thirtynine	O
serum	O
protein	O
components	O
following	O
surgical	O
stress	O
.	O

The	O
TAF	O
factor	O
appears	O
to	O
be	O
particularly	O
significant	O
in	O
OCD	O
.	O

A	O
developmentally	O
regulated	O
4	O
.	O
6	O
kb	O
mRNA	O
is	O
recognized	O
on	O
Northern	O
blots	O
of	O
oocyte	O
RNA	O
using	O
the	O
X	O
.	O
laevis	O
cDNA	O
.	O

Cell	O
.	O

Reperfusion	O
caused	O
a	O
transient	O
reduction	O
in	O
lactate	O
production	O
and	O
a	O
significant	O
increase	O
in	O
LDH	B-GENE
release	O
.	O

Secondary	O
pancreatic	O
involvement	O
of	O
mycosis	O
fungoides	O
detected	O
by	O
a	O
clinically	O
palpable	O
mass	O
.	O

The	O
relationship	O
between	O
primary	O
malignant	O
lymphoma	O
of	O
the	O
thyroid	O
and	O
chronic	O
thyroiditis	O
is	O
discussed	O
.	O

Finally	O
,	O
antibody	O
binding	O
to	O
site	O
IIIa	O
on	O
the	O
hCG-ectodomain	B-GENE
complex	I-GENE
was	O
also	O
hindered	O
by	O
an	O
anti-peptide	B-GENE
mAb	I-GENE
directed	O
against	O
a	O
peptide	O
encoded	O
by	O
the	O
eighth	O
exon	O
(	O
pE	O
x	O
8	O
)	O
of	O
the	O
LHR	B-GENE
.	O

Identical	O
c-erbB3	B-GENE
transcripts	I-GENE
are	O
expressed	O
in	O
normal	O
human	O
placental	O
tissues	O
.	O

T-cell	O
hybridomas	O
,	O
thymocytes	O
,	O
and	O
T	O
cells	O
can	O
be	O
induced	O
to	O
undergo	O
apoptotic	O
cell	O
death	O
by	O
activation	O
through	O
the	O
T-cell	B-GENE
receptor	I-GENE
.	O

These	O
data	O
demonstrate	O
the	O
presence	O
of	O
a	O
single	O
binding	O
site	O
for	O
vinculin	B-GENE
,	O
and	O
at	O
least	O
two	O
binding	O
sites	O
for	O
FAK	B-GENE
that	O
are	O
separated	O
by	O
an	O
intervening	O
stretch	O
of	O
100	O
amino	O
acids	O
.	O

As	O
stands	O
shifted	O
in	O
dominance	O
from	O
pine	O
to	O
fir	O
with	O
age	O
,	O
subalpine	O
fir	O
appeared	O
to	O
maintain	O
gradually	O
increasing	O
rates	O
of	O
whole-forest	O
productivity	O
until	O
stands	O
were	O
approximately	O
400	O
years	O
old	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
the	O
structure	O
of	O
the	O
Spec1	B-GENE
gene	I-GENE
in	O
the	O
sea	O
urchin	O
Strongylocentrotus	O
purpuratus	O
.	O

The	O
cDNA	O
contained	O
an	O
open	O
reading	O
frame	O
of	O
1392	O
bp	O
that	O
predicted	O
a	O
protein	O
of	O
464	O
amino	O
acids	O
and	O
a	O
molecular	O
mass	O
of	O
52	O
kDa	O
;	O
this	O
protein	O
has	O
97%	O
identity	O
to	O
rat	B-GENE
liver	I-GENE
glucokinase	I-GENE
.	O

The	O
real	O
challenge	O
for	O
the	O
future	O
will	O
be	O
the	O
management	O
of	O
patients	O
who	O
do	O
not	O
respond	O
to	O
first-line	O
treatment	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
and	O
compare	O
the	O
ability	O
of	O
three	O
different	O
forms	O
of	O
DSG	O
to	O
block	O
EIB	O
.	O

In	O
the	O
whole	O
group	O
of	O
infected	O
children	O
,	O
an	O
age-specific	O
z	O
score	O
<	O
-2	O
for	O
weight	O
and	O
for	O
FFM	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
[	O
relative	O
risk	O
(	O
95%	O
CI	O
)	O
=	O
11	O
.	O
4	O
(	O
3	O
.	O
1	O
,	O
41	O
.	O
0	O
)	O
and	O
5	O
.	O
1	O
(	O
1	O
.	O
5	O
,	O
18	O
.	O
2	O
)	O
,	O
respectively	O
]	O
;	O
when	O
only	O
children	O
with	O
more	O
severe	O
disease	O
were	O
considered	O
,	O
only	O
z	O
score	O
for	O
weight	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
[	O
4	O
.	O
6	O
(	O
1	O
.	O
4	O
,	O
14	O
.	O
9	O
)	O
]	O
.	O

His	O
carnitine	B-GENE
palmitoyltransferase	I-GENE
(	I-GENE
CPT	I-GENE
)	I-GENE
I	I-GENE
and	I-GENE
II	I-GENE
activities	O
were	O
0	O
.	O
06	O
and	O
0	O
.	O
12	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
as	O
compared	O
with	O
a	O
mean	O
value	O
of	O
0	O
.	O
22	O
+	O
/	O
-	O
0	O
.	O
14	O
and	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
07	O
nmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
,	O
in	O
control	O
subjects	O
.	O

However	O
,	O
neu	B-GENE
differentiation	O
factor-induced	O
heterodimers	O
of	O
ErbB2	B-GENE
and	O
ErbB4	B-GENE
activated	O
Stat5	B-GENE
.	O

Coexpression	O
of	O
the	O
p120	B-GENE
(	I-GENE
ctn	I-GENE
)	I-GENE
protein	I-GENE
with	O
an	O
N-terminal	O
deletion	O
,	O
which	O
eliminates	O
some	O
potential	O
tyrosine	O
phosphorylation	O
sites	O
,	O
or	O
the	O
protein	O
with	O
a	O
single	O
amino	O
acid	O
substitution	O
(	O
tyrosine	O
at	O
217	O
to	O
phenylalanine	O
)	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
aggregation	O
of	O
v-Src-transformed	O
EL	O
and	O
EalphaCL	O
cells	O
.	O

In	O
a	O
control	O
group	O
both	O
common	O
carotid	O
arteries	O
(	O
CCA	O
)	O
were	O
ligated	O
.	O

Thus	O
,	O
it	O
was	O
confirmed	O
that	O
the	O
sodium	O
lauryl	O
sulfate	O
method	O
of	O
estimating	O
hemoglobin	B-GENE
concentration	O
is	O
an	O
appropriate	O
alternative	O
to	O
the	O
cyanmethemoglobin	O
method	O
and	O
avoids	O
the	O
generation	O
of	O
toxic	O
wastes	O
.	O

CTF1alpha	B-GENE
,	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
showed	O
specific	O
binding	O
to	O
the	O
palindrome	O
2	O
DNA	O
fragment	O
but	O
not	O
to	O
palindrome	O
1	O
or	O
mutant	O
palindrome	O
2	O
DNA	O
fragments	O
,	O
suggesting	O
specific	O
binding	O
of	O
CTF1alpha	B-GENE
to	O
palindrome	O
2	O
.	O

BACKGROUND	O
:	O
The	O
effectiveness	O
of	O
monoamine	B-GENE
oxidase	I-GENE
inhibitors	O
(	O
MAOIs	O
)	O
in	O
tricyclic	O
resistant	O
depression	O
has	O
received	O
surprisingly	O
little	O
systematic	O
study	O
.	O

Monospecific	O
antibodies	O
,	O
eluted	O
from	O
the	O
beta-galactosidase	B-GENE
fusion	O
protein	O
of	O
either	O
clone	O
reacted	O
with	O
the	O
U1	B-GENE
snRNP-specific	I-GENE
A	I-GENE
antigen	I-GENE
.	O

However	O
,	O
at	O
18	O
months	O
of	O
age	O
,	O
significantly	O
higher	O
levels	O
of	O
IgG1	B-GENE
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
of	O
IgG4	B-GENE
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
were	O
found	O
in	O
infants	O
with	O
an	O
elevated	O
IgE	B-GENE
(	O
greater	O
than	O
or	O
equal	O
to	O
8	O
.	O
0	O
kU	O
/	O
l	O
)	O
than	O
in	O
those	O
with	O
a	O
lower	O
level	O
.	O

RNA	O
gel	O
retardation	O
and	O
competition	O
analyses	O
indicate	O
that	O
TRP-185	B-GENE
binding	O
is	O
strongly	O
dependent	O
on	O
the	O
TAR	B-GENE
RNA	I-GENE
loop	I-GENE
sequences	I-GENE
.	O

Transcript	O
analysis	O
reveals	O
that	O
lethal	O
B	B-GENE
block	I-GENE
substitutions	O
reduce	O
U6	B-GENE
RNA	I-GENE
synthesis	O
at	O
least	O
10-fold	O
in	O
vivo	O
and	O
20-fold	O
in	O
vitro	O
.	O

KEY	O
WORDS	O
:	O
Melaleuca	O
;	O
Lake	O
Okeechobee	O
;	O
Littoral	O
zone	O
;	O
Water	O
level	O
;	O
Regulation	O
schedule	O

The	O
primers	O
were	O
degenerate	O
sets	O
of	O
oligonucleotides	O
derived	O
from	O
known	O
amino	O
acid	O
sequences	O
of	O
the	O
PBAN	B-GENE
precursor	I-GENE
.	O

Therefore	O
,	O
the	O
results	O
indicate	O
that	O
repeated	O
exposure	O
to	O
amphetamine	O
or	O
apomorphine	O
overcomes	O
the	O
context-dependent	O
component	O
of	O
sensitization	O
of	O
amphetamine-	O
or	O
apomorphine-induced	O
stereotyped	O
behavior	O
.	O

An	O
end-to-end	O
pancreaticojejunostomy	O
using	O
a	O
mechanical	O
purse-string	O
device	O
.	O

Because	O
the	O
CAP	O
measures	O
variables	O
predictive	O
of	O
abusive	O
behavior	O
,	O
a	O
substantial	O
relationship	O
was	O
expected	O
between	O
the	O
CAP	O
and	O
the	O
MHI	O
Loss	O
of	O
Behavioral	O
/	O
Emotional	O
Control	O
scale	O
.	O

Soft-x-ray	O
lasing	O
at	O
32	O
.	O
6	O
nm	O
in	O
Ne-like	O
Ti	O
ions	O
driven	O
by	O
40	O
J	O
of	O
energy	O
from	O
two	O
650-ps	O
laser	O
pulses	O
.	O

After	O
measuring	O
baseline	O
Vmca	O
at	O
a	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
in	O
arterial	O
blood	O
(	O
PaCO2	O
)	O
of	O
37	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
5	O
mmHg	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
,	O
measurements	O
were	O
repeated	O
at	O
a	O
PaCO	O
of	O
44	O
.	O
2	O
+	O
/	O
-	O
3	O
.	O
8	O
mmHg	O
,	O
and	O
the	O
carbon	O
dioxide	O
reactivity	O
(	O
absolute	O
value	O
:	O
cm	O
x	O
s	O
(	O
-1	O
)	O
x	O
mmHg	O
(	O
-1	O
)	O
;	O
relative	O
value	O
:	O
percentage	O
of	O
baseline	O
Vmca	O
/	O
mmHg	O
)	O
was	O
calculated	O
.	O

Isoelectric	O
focusing	O
of	O
tryptic	O
peptides	O
generated	O
from	O
MHC-B	B-GENE
phosphorylated	O
with	O
cdc2	B-GENE
kinase	I-GENE
revealed	O
one	O
major	O
phosphopeptide	O
that	O
was	O
purified	O
by	O
reverse-phase	O
high	O
performance	O
liquid	O
chromatography	O
and	O
sequenced	O
.	O

Such	O
an	O
interaction	O
could	O
be	O
detected	O
using	O
a	O
GST-POU	B-GENE
fusion	I-GENE
protein	I-GENE
bound	O
to	O
glutathione-agarose	O
beads	O
.	O

Molecular	O
cloning	O
of	O
mouse	B-GENE
thioredoxin	I-GENE
reductases	I-GENE
.	O

Factors	O
that	O
showed	O
significant	O
correlation	O
to	O
elevated	O
CIC's	O
in	O
the	O
highly	O
elevated	O
portion	O
of	O
our	O
CIC	O
population	O
were	O
poor	O
NIH	O
score	O
,	O
increased	O
patient	O
age	O
,	O
low	O
peak	O
expiratory	O
flow	O
rate	O
,	O
and	O
elevated	O
total	O
serum	B-GENE
IgG	I-GENE
.	O

There	O
are	O
many	O
different	O
proposals	O
for	O
the	O
statistical	O
analysis	O
of	O
data	O
to	O
determine	O
early	O
onset	O
of	O
action	O
.	O

A	O
chaotropic	O
detergent	O
,	O
0	O
.	O
1%	O
Nonidet	O
P-40	O
,	O
also	O
abolished	O
the	O
interaction	O
,	O
further	O
supporting	O
the	O
hydrophobic	O
nature	O
of	O
the	O
interaction	O
.	O

Thus	O
,	O
the	O
inhibition	O
of	O
pepsin	B-GENE
in	O
human	O
gastric	O
juice	O
does	O
not	O
appear	O
to	O
have	O
a	O
major	O
influence	O
on	O
the	O
healing	O
of	O
duodenal	O
ulcer	O
.	O

Restarting	O
time	O
was	O
not	O
affected	O
by	O
magnesium	O
cardioplegia	O
.	O

These	O
cell	O
lines	O
displayed	O
methylation	O
of	O
the	O
CpG	O
island	O
surrounding	O
the	O
first	O
exon	O
of	O
p16INK4A	B-GENE
and	O
expressed	O
abundant	O
levels	O
of	O
a	O
nontranslated	O
mRNA	O
containing	O
an	O
alternative	O
first	O
exon	O
(	O
E1	B-GENE
beta	I-GENE
)	O
,	O
as	O
did	O
all	O
other	O
cell	O
lines	O
in	O
which	O
the	O
p16INK4A	B-GENE
locus	I-GENE
was	O
not	O
deleted	O
.	O

In	O
reconstitution	O
experiments	O
,	O
we	O
first	O
showed	O
that	O
expression	O
in	O
the	O
RAW	O
264	O
.	O
7	O
cell	O
line	O
of	O
C-terminal	B-GENE
Src	I-GENE
kinase	I-GENE
(	O
Csk	B-GENE
)	O
inhibited	O
and	O
that	O
of	O
a	O
membrane-anchored	O
,	O
gain-of-function	O
Csk	B-GENE
abolished	O
the	O
Fc	O
gamma	O
R-mediated	O
signaling	O
that	O
leads	O
to	O
phagocytosis	O
in	O
a	O
kinase-dependent	O
manner	O
.	O

These	O
mutants	O
were	O
tested	O
for	O
ability	O
to	O
bind	O
each	O
of	O
the	O
Site	B-GENE
II	I-GENE
cognate	I-GENE
proteins	I-GENE
,	O
and	O
subsequently	O
evaluated	O
for	O
ability	O
to	O
confer	O
H4	B-GENE
transcriptional	O
activity	O
using	O
chimeric	O
H4	B-GENE
promoter	I-GENE
/	I-GENE
CAT	I-GENE
fusion	I-GENE
constructs	O
in	O
different	O
cell	O
types	O
.	O

The	O
determination	O
of	O
the	O
double	O
bounds	O
in	O
blood	O
serum	O
lipids	O
by	O
titration	O
with	O
ozone	O
:	O
the	O
pathophysiology	O
and	O
diagnostic	O
significance	O
In	O
this	O
article	O
the	O
method	O
of	O
definition	O
of	O
double	O
binders	O
in	O
lipids	O
of	O
blood	O
serum	O
in	O
patients	O
with	O
different	O
diseases	O
basically	O
atherosclerosis	O
and	O
ischemic	O
heart	O
disease	O
,	O
with	O
use	O
titration	O
by	O
ozone	O
is	O
given	O
.	O

On	O
the	O
other	O
hand	O
,	O
neither	O
phosphate	O
buffered	O
saline	O
injection	O
into	O
the	O
ES	O
nor	O
primary	O
KLH	B-GENE
challenges	O
of	O
the	O
ES	O
were	O
capable	O
of	O
elevating	O
the	O
threshold	O
level	O
and	O
changing	O
the	O
latency	O
.	O

Viral	O
and	O
atypical	O
pathogens	O
as	O
causes	O
of	O
type	O
1	O
acute	O
exacerbations	O
of	O
chronic	O
bronchitis	O
.	O

Thus	O
,	O
depending	O
on	O
their	O
location	O
,	O
psoralen	B-GENE
cross-links	O
affected	O
different	O
steps	O
in	O
the	O
initiation	O
process	O
.	O

The	O
5'	O
end	O
of	O
the	O
genomic	O
RNA	O
of	O
rubella	O
virus	O
(	O
RUB	O
)	O
contains	O
a	O
14-nucleotide	O
(	O
nt	O
)	O
single-stranded	O
leader	O
(	O
ss-leader	O
)	O
followed	O
by	O
a	O
stem-and-loop	O
structure	O
[	O
5'	O
(	O
+	O
)	O
SL	O
]	O
(	O
nt	O
15	O
to	O
65	O
)	O
,	O
the	O
complement	O
of	O
which	O
at	O
the	O
3'	O
end	O
of	O
the	O
minus-strand	O
RNA	O
[	O
3'	O
(	O
-	O
)	O
SL	O
]	O
has	O
been	O
proposed	O
to	O
function	O
as	O
a	O
promoter	O
for	O
synthesis	O
of	O
genomic	O
plus	O
strands	O
.	O

We	O
examined	O
behavioral	O
alterations	O
in	O
the	O
brown	O
cockroach	O
,	O
Periplaneta	O
brunnea	O
,	O
infected	O
with	O
the	O
acanthocephalan	O
,	O
Moniliformis	O
moniliformis	O
.	O

The	O
prominent	O
lesions	O
were	O
confined	O
to	O
the	O
cerebral	O
surface	O
layer	O
and	O
leptomeningeal	O
tissue	O
including	O
the	O
arachnoid	O
vessels	O
,	O
which	O
were	O
all	O
bathed	O
in	O
the	O
cerebrospinal	O
fluid	O
,	O
suggesting	O
that	O
some	O
necrotizing	O
toxins	O
had	O
been	O
secreted	O
into	O
the	O
fluid	O
by	O
the	O
B	O
.	O
cereus	O
.	O

A	O
decrease	O
in	O
insulin-induced	O
receptor	B-GENE
kinase	I-GENE
activity	O
was	O
observed	O
for	O
solubilized	O
chimeric	O
receptors	O
.	O

BYV	O
,	O
citrus	O
tristeza	O
virus	O
(	O
CTV	O
)	O
,	O
beet	O
yellow	O
stunt	O
virus	O
(	O
BYSV	O
)	O
and	O
carnation	O
necrotic	O
fleck	O
virus	O
templates	O
produced	O
1	O
kb	O
amplification	O
products	O
,	O
which	O
were	O
shown	O
by	O
sequencing	O
to	O
represent	O
fragments	O
of	O
the	O
respective	O
HSP70	B-GENE
genes	I-GENE
.	O

At	O
the	O
same	O
time	O
,	O
the	O
results	O
indicate	O
that	O
p53	B-GENE
plays	O
a	O
defensive	O
role	O
against	O
HBV	O
by	O
transcriptionally	O
repressing	O
the	O
HBV	B-GENE
core	I-GENE
promoter	I-GENE
through	O
liver-specific	B-GENE
enhancer	I-GENE
II	I-GENE
and	O
HBx	B-GENE
is	O
required	O
to	O
counteract	O
this	O
inhibitory	O
function	O
of	O
p53	B-GENE
.	O

The	O
vaccine	O
used	O
was	O
known	O
to	O
be	O
immunogenic	O
for	O
older	O
children	O
and	O
adults	O
.	O

The	O
first	O
group	O
of	O
sequential	O
BMB	O
showed	O
a	O
significant	O
progress	O
to	O
myelofibrosis	O
in	O
so-called	O
"Chronic	O
Megakaryocytic-Granulocytic	O
Myelosis"--CMGM-	O
,	O
which	O
corresponds	O
to	O
Agnogenic	O
Myeloid	O
Metaplasia-AMM-in	O
72	O
.	O
4%	O
(	O
21	O
/	O
29	O
patients	O
)	O
,	O
as	O
well	O
as	O
in	O
CML	O
with	O
megakaryocytic	O
increase-CML	O
.	O
MI-in	O
39	O
.	O
2%	O
(	O
20	O
/	O
51	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
V3	B-GENE
peptides	O
from	O
all	O
major	O
clades	O
of	O
HIV-1	O
carried	O
by	O
HIV-2	B-GENE
gag	I-GENE
can	O
be	O
used	O
as	O
a	O
potential	O
HIV	O
/	O
AIDS	O
vaccine	O
.	O

The	O
stereoselectivity	O
of	O
drug	O
action	O
.	O

Thrombophlebitis	O
and	O
pulmonary	O
embolism	O
in	O
congenital	O
factor	B-GENE
XII	I-GENE
deficiency	O
.	O

Guidelines	O
for	O
performing	O
a	O
routine	O
spiral	O
assay	O
are	O
presented	O
,	O
and	O
alternative	O
test	O
methods	O
intended	O
to	O
overcome	O
a	O
variety	O
of	O
technical	O
difficulties	O
(	O
such	O
as	O
restricted	O
sample	O
availability	O
,	O
sample	O
viscosity	O
or	O
volatility	O
,	O
etc	O
.	O
)	O
are	O
recommended	O
.	O

A	O
further	O
subdivision	O
of	O
Category	O
pN1	O
into	O
pN1a	O
(	O
metastasis	O
in	O
single	O
node	O
)	O
and	O
pN1b	O
(	O
two	O
or	O
more	O
nodes	O
)	O
is	O
recommended	O
.	O

In	O
contrast	O
,	O
the	O
CRE	B-GENE
of	O
the	O
human	B-GENE
c-fos	I-GENE
promoter	I-GENE
located	O
at	O
-60	O
was	O
weakly	O
induced	O
by	O
cAMP	O
and	O
E1a	B-GENE
in	O
both	O
HeLa	O
and	O
PC12	O
cells	O
.	O

The	O
RAD6	B-GENE
/	I-GENE
UBC2	I-GENE
gene	I-GENE
from	O
Saccharomyces	O
cerevisiae	O
encodes	O
a	O
ubiquitin-conjugating	B-GENE
enzyme	I-GENE
involved	O
in	O
DNA	O
repair	O
,	O
induced	O
mutagenesis	O
,	O
and	O
sporulation	O
.	O

Deletion	O
of	O
a	O
53-bp	O
early	O
promoter	O
region	O
containing	O
the	O
transcription	O
start	O
site	O
and	O
a	O
putative	O
TATA	O
box	O
completely	O
abolishes	O
the	O
ability	O
of	O
upstream	O
elements	O
to	O
drive	O
transcription	O
of	O
the	O
luciferase	B-GENE
cDNA	I-GENE
.	O

However	O
,	O
the	O
few	O
studies	O
that	O
address	O
antimicrobial	O
prophylaxis	O
in	O
bone	O
marrow	O
transplantation	O
have	O
not	O
always	O
shown	O
a	O
survival	O
benefit	O
.	O

Transcriptional	O
control	O
of	O
a	O
nuclear	O
gene	O
encoding	O
a	O
mitochondrial	O
fatty	O
acid	O
oxidation	O
enzyme	O
in	O
transgenic	O
mice	O
:	O
role	O
for	O
nuclear	O
receptors	O
in	O
cardiac	O
and	O
brown	O
adipose	O
expression	O
.	O

Insulin	B-GENE
stimulation	O
promoted	O
the	O
association	O
of	O
mIRS3	B-GENE
with	O
p85	B-GENE
,	O
SHP2	B-GENE
,	O
Nck	B-GENE
,	O
and	O
Shc	B-GENE
.	O

Experience	O
with	O
the	O
tensor	O
fasciae	O
latae	O
free	O
flap	O
.	O

In	O
particular	O
,	O
71	O
and	O
69%	O
amino	O
acid	O
sequence	O
similarities	O
were	O
identified	O
with	O
hsp70	B-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
and	I-GENE
Bacillus	I-GENE
megaterium	I-GENE
,	O
respectively	O
.	O

Thirty	O
cadaver	O
brains	O
were	O
examined	O
under	O
X	O
6	O
to	O
16	O
magnification	O
in	O
order	O
to	O
define	O
the	O
microsurgical	O
anatomy	O
of	O
the	O
pineal	O
region	O
,	O
particularly	O
the	O
relationship	O
of	O
the	O
pineal	O
body	O
,	O
posterior	O
cerebral	O
artery	O
,	O
superior	O
cerebellar	O
artery	O
,	O
vein	O
of	O
Galen	O
,	O
basal	O
vein	O
of	O
Rosenthal	O
,	O
internal	O
cerebral	O
vein	O
,	O
straight	O
sinus	O
,	O
bridging	O
vein	O
,	O
the	O
size	O
of	O
the	O
tentorial	O
notch	O
,	O
and	O
the	O
third	O
and	O
the	O
fourth	O
cranial	O
nerves	O
.	O

Increased	O
erythropoietin	B-GENE
synthesis	O
in	O
patients	O
with	O
COLD	O
or	O
left	O
heart	O
failure	O
is	O
related	O
to	O
alterations	O
in	O
renal	O
haemodynamics	O
.	O

Unlike	O
ARF	B-GENE
,	O
the	O
ARP	B-GENE
immunoreactivity	O
was	O
detected	O
in	O
plasma	O
membranes	O
but	O
not	O
in	O
cytosol	O
of	O
fractionated	O
3T3-L1	O
cells	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
destrin	B-GENE
is	O
165	O
residues	O
long	O
and	O
is	O
very	O
similar	O
(	O
71%	O
identical	O
)	O
to	O
that	O
of	O
cofilin	B-GENE
,	O
a	O
widely	O
distributed	O
,	O
pH-sensitive	O
actin-modulating	O
protein	O
.	O

Effects	O
of	O
chronic	O
metaraminol	O
treatment	O
on	O
the	O
sympathetic	O
activity	O
of	O
intact	O
and	O
adrenal	O
demedullated	O
rats	O
kept	O
in	O
warm	O
or	O
cold	O
environments	O
.	O

Bepridil	O
,	O
a	O
calcium	O
antagonist	O
with	O
a	O
half-life	O
of	O
approximately	O
42	O
hours	O
,	O
was	O
compared	O
with	O
placebo	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
crossover	O
trial	O
.	O

Involvement	O
of	O
AP1	B-GENE
and	O
PEA3	B-GENE
binding	I-GENE
sites	I-GENE
in	O
the	O
regulation	O
of	O
murine	B-GENE
tissue	I-GENE
inhibitor	I-GENE
of	I-GENE
metalloproteinases-1	I-GENE
(	O
TIMP-1	B-GENE
)	O
transcription	O
.	O

Alternative	O
processing	O
of	O
the	O
tryptophanyl-tRNA	B-GENE
synthetase	I-GENE
mRNA	I-GENE
from	O
interferon-treated	O
human	O
cells	O
.	O

Oligonucleotide	O
competitors	O
were	O
used	O
to	O
evaluate	O
the	O
accessibility	O
of	O
the	O
TATA-binding	O
site	O
in	O
TIF-IB	B-GENE
,	O
TFIID	B-GENE
,	O
and	O
TFIIIB	B-GENE
.	O

The	O
East	O
African	O
dik-dik	O
antelope	O
represents	O
a	O
miniature	O
model	O
ruminant	O
for	O
comparative	O
studies	O
.	O

Three	O
patients	O
had	O
well-	O
,	O
6	O
patients	O
had	O
moderately-	O
,	O
and	O
5	O
patients	O
had	O
poorly-differentiated	O
adenocarcinoma	O
of	O
the	O
prostate	O
.	O

The	O
"28	O
percent"	O
Venturi	O
mask	O
in	O
obstructive	O
airway	O
disease	O
.	O

Human	B-GENE
LAF-4	I-GENE
readily	O
hybridized	O
with	O
genes	O
in	O
mouse	O
and	O
chicken	O
,	O
thus	O
showing	O
that	O
this	O
gene	O
family	O
has	O
been	O
highly	O
conserved	O
during	O
vertebrate	O
evolution	O
.	O

Northern	O
analysis	O
,	O
to	O
search	O
for	O
a	O
pcbAB	B-GENE
transcript	I-GENE
,	O
showed	O
no	O
distinct	O
transcript	O
and	O
indicated	O
severely	O
degraded	O
mRNA	O
.	O

RESULTS	O
:	O
In	O
an	O
18	O
moth	O
period	O
and	O
out	O
of	O
a	O
total	O
of	O
284	O
positive	O
blood	O
cultures	O
(	O
154	O
significant	O
isolations	O
)	O
14	O
episodes	O
of	O
bacteremia	O
by	O
M	O
.	O
tuberculosis	O
were	O
studied	O
in	O
12	O
prison	O
patients	O
coinfected	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
with	O
associated	O
severe	O
immunosuppression	O
(	O
mean	O
of	O
CD4	B-GENE
=	O
0	O
.	O
068	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
)	O
.	O

Morphologic	O
variables	O
included	O
cancer	O
volume	O
,	O
histologic	O
grade	O
,	O
capsular	O
penetration	O
,	O
seminal	O
vesicle	O
invasion	O
,	O
and	O
lymph	O
node	O
metastasis	O
.	O

The	O
genes	O
encoding	O
the	O
transcription	B-GENE
factor	I-GENE
yTAFII60	I-GENE
,	O
the	O
G4p1	B-GENE
protein	I-GENE
and	O
a	O
putative	O
glucose	B-GENE
transporter	I-GENE
are	O
contained	O
in	O
a	O
12	O
.	O
3	O
kb	O
DNA	O
fragment	O
on	O
the	O
left	O
arm	O
of	O
Saccharomyces	O
cerevisiae	O
chromosome	O
VII	O
.	O

Evaluation	O
of	O
the	O
new	O
Gravigard	O
IUCD	O
inserter	O
.	O

In	O
the	O
presence	O
of	O
the	O
in	O
vivo	O
reducing	O
system	O
(	O
thioredoxin	B-GENE
,	O
thioredoxin	B-GENE
reductase	I-GENE
,	O
and	O
NADPH	O
)	O
,	O
however	O
,	O
each	O
of	O
these	O
mutants	O
catalyzed	O
the	O
formation	O
of	O
only	O
0	O
.	O
6-0	O
.	O
8	O
dCTPs	O
per	O
mole	O
of	O
enzyme	O
.	O

Not	O
Available	O

Functional	O
and	O
regulatory	O
analysis	O
of	O
the	O
two	O
copies	O
of	O
the	O
fixNOQP	B-GENE
operon	I-GENE
of	O
Rhizobium	O
leguminosarum	O
strain	O
VF39	O
.	O

The	O
9	O
;	O
22	O
chromosomal	O
translocation	O
characteristic	O
of	O
CML	O
results	O
in	O
a	O
fused	B-GENE
bcr	I-GENE
/	I-GENE
abl	I-GENE
gene	I-GENE
and	O
an	O
abnormal	O
fusion	O
protein	O
,	O
p210bcr	B-GENE
/	I-GENE
abl	I-GENE
.	O

We	O
have	O
measured	O
the	O
MBF	O
on	O
incisors	O
and	O
its	O
direction	O
in	O
three	O
dimensions	O
for	O
different	O
jaw	O
openings	O
in	O
ten	O
subjects	O
.	O

RNAs	O
are	O
not	O
only	O
essential	O
components	O
of	O
both	O
ribosomal	O
subunits	O
but	O
also	O
transiently	O
interacting	O
factors	O
during	O
particle	O
formation	O
.	O

Subcellular	O
localizations	O
of	O
the	O
wild-type	B-GENE
CBFbeta	I-GENE
and	O
the	O
CBFbeta-SMMHC	B-GENE
fusion	I-GENE
protein	I-GENE
were	O
determined	O
by	O
immunofluorescence	O
of	O
NIH	O
3T3	O
cells	O
that	O
overexpress	O
wild-type	O
or	O
fusion	O
protein	O
.	O

In	O
conclusion	O
,	O
IgM	B-GENE
class	O
CIC	O
is	O
the	O
predominant	O
CIC	O
in	O
acute	O
hepatitis	O
A	O
and	O
correlated	O
with	O
disease	O
activity	O
.	O

Echinostomiasis	O
is	O
aggravated	O
by	O
socioeconomic	O
factors	O
such	O
as	O
poverty	O
,	O
malnutrition	O
,	O
an	O
explosively	O
growing	O
free-food	O
market	O
,	O
a	O
lack	O
of	O
supervised	O
food	O
inspection	O
,	O
poor	O
or	O
insufficient	O
sanitation	O
,	O
other	O
helminthiases	O
,	O
and	O
declining	O
economic	O
conditions	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
Stress-Activated-Protein-Kinase	B-GENE
(	O
SAPK	B-GENE
)	O
target	O
sites	O
of	O
ATF2	B-GENE
,	O
Thr69	O
and	O
Thr71	O
are	O
not	O
required	O
for	O
the	O
formation	O
of	O
the	O
p300	B-GENE
/	I-GENE
CBP-ATF2	I-GENE
multiprotein	O
complex	O
.	O

Patch	O
test	O
results	O
obtained	O
with	O
corticosteroid	O
allergic	O
patients	O
tested	O
with	O
a	O
large	O
corticosteroid	O
series	O
validated	O
the	O
earlier	O
classification	O
of	O
corticosteroid	O
molecules	O
in	O
four	O
groups	O
of	O
cross-reacting	O
molecules	O
:	O
i	O
.	O
e	O
.	O
,	O
group	O
A	O
(	O
hydrocortisone	O
type	O
)	O
,	O
group	O
B	O
(	O
acetonides	O
)	O
,	O
group	O
C	O
(	O
betamethasone	O
type-non	O
esterified	O
)	O
and	O
group	O
D	O
(	O
esters	O
)	O
.	O

Mae	O
West	O
and	O
the	O
doctor	O
shortage	O
.	O

Oncogenic	O
capacity	O
of	O
the	O
E2F1	B-GENE
gene	I-GENE
.	O

Thus	O
,	O
Sir	B-GENE
proteins	I-GENE
from	O
K	O
.	O
lactis	O
have	O
roles	O
in	O
both	O
silencing	O
and	O
telomere	O
length	O
maintenance	O
,	O
reflecting	O
conserved	O
functional	O
themes	O
.	O

The	O
p55	B-GENE
mRNA	I-GENE
is	O
undetectable	O
in	O
non-EBV-infected	O
B-	O
and	O
T-cell	O
lines	O
or	O
in	O
a	O
myelomonocytic	O
cell	O
line	O
(	O
U937	O
)	O
.	O

Histone	O
acetylation	O
levels	O
in	O
cells	O
result	O
from	O
a	O
dynamic	O
equilibrium	O
between	O
competing	O
histone	B-GENE
acetylases	I-GENE
and	O
deacetylases	B-GENE
.	O

In	O
Experiments	O
1	O
and	O
2	O
,	O
infants	O
,	O
like	O
adults	O
,	O
initially	O
categorized	O
novel	O
objects	O
on	O
the	O
basis	O
of	O
physical	O
appearance	O
,	O
but	O
only	O
if	O
trained	O
with	O
multiple	O
exemplars	O
,	O
after	O
delays	O
of	O
1	O
and	O
7	O
days	O
.	O

Successful	O
use	O
of	O
transureteroureterostomy	O
to	O
salvage	O
ureterosigmoidostomy	O
after	O
anastomotic	O
failure	O
.	O

SRF-deficient	O
embryos	O
(	O
Srf	B-GENE
-	O
/	O
-	O
)	O
have	O
a	O
severe	O
gastrulation	O
defect	O
and	O
do	O
not	O
develop	O
to	O
term	O
.	O

Four	O
full-thickness	O
skin	O
incisions	O
were	O
made	O
in	O
the	O
back	O
of	O
10	O
female	O
pigs	O
that	O
treated	O
twice	O
a	O
day	O
for	O
14	O
days	O
with	O
2	O
ml	O
of	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
(	O
300	O
ng	O
/	O
ml	O
)	O
or	O
2	O
ml	O
of	O
Ringer's	O
lactate	O
solution	O
in	O
a	O
single-blind	O
,	O
randomized	O
fashion	O
.	O

Various	O
companies	O
produce	O
this	O
type	O
of	O
lens	O
.	O

In	O
mammalian	O
tissue	O
culture	O
cells	O
,	O
overexpression	O
of	O
any	O
of	O
the	O
four	O
mouse	O
deltex	O
homologs	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
E47	B-GENE
,	O
a	O
basic	B-GENE
helix-loop-helix	I-GENE
(	I-GENE
bHLH	I-GENE
)	I-GENE
protein	I-GENE
,	O
in	O
a	O
manner	O
similar	O
to	O
suppression	O
by	O
an	O
activated	O
form	O
of	O
human	B-GENE
Notch1	I-GENE
or	O
human	B-GENE
DTX1	I-GENE
.	O

However	O
,	O
kidneys	O
perfused	O
for	O
72	O
hr	O
demonstrated	O
more	O
similar	O
renal	O
functions	O
when	O
tested	O
by	O
either	O
IMPK	O
or	O
IBPK	O
.	O

Patients	O
with	O
antibody	O
peaks	O
,	O
defined	O
as	O
fivefold	O
or	O
higher	O
increase	O
in	O
antibody	O
titer	O
compared	O
to	O
the	O
lowest	O
antibody	O
titer	O
over	O
the	O
course	O
of	O
GBS	O
,	O
had	O
higher	O
disability	O
scores	O
during	O
the	O
first	O
two	O
weeks	O
of	O
GBS	O
and	O
a	O
worse	O
clinical	O
outcome	O
(	O
anti-GM1	B-GENE
IgG	I-GENE
and	O
anti-GD1a	B-GENE
IgM	I-GENE
antibody	I-GENE
peaks	O
)	O
and	O
axonal	O
damage	O
(	O
anti-GD1a	B-GENE
IgM	I-GENE
antibody	I-GENE
peaks	O
)	O
,	O
compared	O
to	O
patients	O
without	O
peak	O
antibody	O
titers	O
.	O

This	O
core	O
sequence	O
,	O
along	O
with	O
additional	O
nonspecific	O
downstream	O
nucleotides	O
,	O
is	O
sufficient	O
for	O
partial	O
suppression	O
of	O
spliceosome	O
assembly	O
and	O
splicing	O
of	O
BPV-1	O
pre-mRNAs	O
.	O

CONCLUSIONS	O
:	O
Turbutest	O
is	O
a	O
valuable	O
tool	O
in	O
asthmatic	O
patients'	O
training	O
,	O
allowing	O
identification	O
and	O
improvement	O
of	O
an	O
inadequate	O
inhalation	O
technique	O
with	O
Turbuhaler	O
.	O

Inhibition	O
of	O
the	O
Raf-1	B-GENE
target	I-GENE
ERK	B-GENE
kinase	I-GENE
(	O
MEK	B-GENE
)	O
either	O
attenuated	O
or	O
abolished	O
Rp-cAMPS-	O
and	O
PKI-induced	O
ERK	B-GENE
activation	O
,	O
caldesmon	B-GENE
phosphorylation	O
,	O
and	O
stress	O
fiber	O
formation	O
.	O

METHODS	O
:	O
T2*-weighted	O
,	O
three-dimensional	O
gradient-echo	O
images	O
were	O
acquired	O
by	O
exploiting	O
the	O
magnetic	O
susceptibility	O
difference	O
between	O
oxygenated	O
and	O
deoxygenated	O
hemoglobin	B-GENE
in	O
the	O
vasculature	O
and	O
microvasculature	O
.	O

In	O
a	O
second	O
experiment	O
involving	O
an	O
18-h	O
lung	O
clearance	O
assay	O
,	O
we	O
used	O
the	O
mAb	O
3	O
.	O
2	O
.	O
3	O
to	O
deplete	O
rats	O
of	O
LGL	O
/	O
NK	O
cells	O
with	O
the	O
following	O
rationale	O
:	O
if	O
LGL	O
/	O
NK	O
cells	O
are	O
necessary	O
to	O
mediate	O
an	O
event	O
,	O
then	O
in	O
their	O
absence	O
,	O
that	O
event	O
should	O
not	O
occur	O
.	O

The	O
rci	B-GENE
gene	I-GENE
was	O
fused	O
with	O
lacZ	B-GENE
and	O
its	O
gene	O
product	O
was	O
identified	O
by	O
Western	O
blot	O
analysis	O
.	O

Thus	O
,	O
multiple	O
myogenic	O
factors	O
that	O
vary	O
qualitatively	O
and	O
quantitatively	O
may	O
be	O
responsible	O
for	O
the	O
different	O
and	O
complex	O
modulatory	O
programs	O
of	O
actin	B-GENE
gene	I-GENE
expression	O
observed	O
during	O
in	O
vivo	O
muscle	O
differentiation	O
.	O

Variety	O
of	O
cows	O
and	O
sires	O
according	O
to	O
types	O
of	O
dermatoglyphics	O
(	O
patterns	O
)	O
of	O
the	O
nose-labial	O
mirror	O
of	O
cattle	O
.	O

Many	O
cells	O
were	O
negative	O
for	O
endothelial-cell	O
markers	O
,	O
and	O
they	O
reacted	O
with	O
a	O
monoclonal	O
antibody	O
against	O
muscle	O
actin	B-GENE
.	O

We	O
studied	O
the	O
role	O
of	O
prostaglandins	O
in	O
acid-induced	O
esophagitis	O
and	O
the	O
associated	O
LES	O
hypotension	O
by	O
simultaneous	O
treatment	O
of	O
some	O
animals	O
with	O
indomethacin	O
(	O
150	O
micrograms	O
/	O
kg	O
intravenous	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
prostaglandin	O
synthesis	O
,	O
either	O
during	O
production	O
of	O
esophagitis	O
or	O
during	O
recovery	O
.	O

Of	O
these	O
sites	O
,	O
PEA3	B-GENE
and	O
STAT	B-GENE
contributed	O
specifically	O
to	O
induction	O
by	O
v-src	B-GENE
,	O
whereas	O
the	O
remaining	O
elements	O
were	O
also	O
involved	O
in	O
induction	O
by	O
the	O
phorbol	O
ester	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

There	O
were	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
between	O
the	O
fracture	O
and	O
nonfracture	O
groups	O
in	O
the	O
total	O
femur	O
BMD	O
(	O
13%	O
)	O
,	O
trabecular	O
BMD	O
in	O
the	O
distal	O
radius	O
(	O
4%	O
)	O
,	O
and	O
the	O
fractal	O
dimension	O
in	O
the	O
radiographs	O
(	O
FD2	O
)	O
(	O
3%	O
)	O
.	O

An	O
ASSEMBLER	O
routine	O
for	O
on-line	O
graphic	O
display	O
and	O
averaging	O
of	O
data	O
acquired	O
on	O
a	O
personal	O
microcomputer	O
.	O

The	O
exodomain	O
alone	O
has	O
the	O
high	O
affinity	O
hormone	O
binding	O
site	O
but	O
is	O
not	O
capable	O
of	O
generating	O
hormonal	O
signal	O
.	O

We	O
therefore	O
applied	O
a	O
radiolabelled	O
serumalbumin	O
method	O
to	O
determine	O
blood	O
volume	O
after	O
haemodilution	O
with	O
crosslinked	O
or	O
conjugated	O
haemoglobin	B-GENE
,	O
in	O
comparison	O
with	O
a	O
reference	O
solution	O
of	O
hydroxyethyl	O
starch	O
(	O
HES	O
)	O
.	O

The	O
average	O
birth	O
mass	O
of	O
these	O
newborns	O
was	O
3491	O
.	O
9	O
+	O
/	O
-	O
2	O
SD	O
780	O
.	O
5	O
g	O
and	O
that	O
in	O
the	O
control	O
group	O
3	O
,	O
767	O
.	O
5	O
+	O
/	O
-	O
2	O
SD	O
824	O
.	O
2	O
g	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
effect	O
of	O
iron	O
intake	O
on	O
59Fe	O
absorption	O
throughout	O
pregnancy	O
,	O
and	O
on	O
maternal	O
and	O
fetal	O
Fe	O
status	O
towards	O
the	O
end	O
of	O
pregnancy	O
,	O
was	O
investigated	O
in	O
rats	O
.	O

This	O
exon	O
,	O
here	O
named	O
exon	O
0	O
,	O
contained	O
the	O
entire	O
5'	O
untranslated	O
region	O
and	O
the	O
N-terminal	O
signal	O
sequence	O
of	O
the	O
polypeptide	O
.	O

Expression	O
of	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
beta	I-GENE
and	I-GENE
gamma	I-GENE
genes	I-GENE
integrated	O
in	O
mammalian	O
cells	O
and	O
their	O
induction	O
by	O
an	O
alpha	B-GENE
gene	I-GENE
product	I-GENE
.	O

A	O
.	O
,	O
Slatkin	O
,	O
D	O
.	O

Analysis	O
of	O
the	O
rate	O
constants	O
indicated	O
that	O
the	O
isomerization	O
rate	O
k12	O
was	O
approximately	O
equal	O
to	O
the	O
apparent	O
degradation	O
rate	O
of	O
the	O
delta	O
3	O
ester	O
kdeg	O
,	O
and	O
slower	O
than	O
the	O
hydrolysis	O
rate	O
of	O
the	O
delta	O
2	O
ester	O
k24	O
.	O

The	O
human	B-GENE
ABCG1	I-GENE
gene	I-GENE
encodes	O
a	O
member	O
of	O
the	O
ATP-binding	B-GENE
cassette	I-GENE
(	O
ABC	B-GENE
)	O
superfamily	O
of	O
transporter	B-GENE
proteins	I-GENE
and	O
is	O
highly	O
induced	O
when	O
macrophages	O
are	O
incubated	O
with	O
oxysterols	O
.	O

Yap1p	B-GENE
is	O
constitutively	O
nuclear	O
in	O
a	O
crm1	B-GENE
mutant	I-GENE
,	O
and	O
Crm1p	B-GENE
binds	O
to	O
a	O
nuclear	O
export	O
sequence	O
(	O
NES	O
)	O
-like	O
sequence	O
in	O
Yap1p	B-GENE
in	O
the	O
presence	O
of	O
RanGTP	B-GENE
.	O

Clinical	O
chemistry	O
.	O

Hematopoietic	O
system	O
in	O
streptococcal	O
allergy	O
.	O

However	O
,	O
using	O
ATL-16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA-4	B-GENE
is	O
the	O
only	O
GATA-binding	B-GENE
protein	I-GENE
that	O
forms	O
specific	O
DNA-protein	O
complex	O
with	O
the	O
-70	B-GENE
GATA	I-GENE
site	I-GENE
.	O

We	O
suppose	O
that	O
this	O
injection	O
speed	O
(	O
0	O
.	O
1-0	O
.	O
2	O
ml	O
.	O
s-1	O
)	O
is	O
suitable	O
for	O
spinal	O
anesthesia	O
.	O

Toluene	O
is	O
the	O
chemical	O
most	O
frequently	O
present	O
in	O
cases	O
involving	O
volatile	O
solvents	O
.	O

Thus	O
,	O
we	O
have	O
produced	O
lipoyl	O
domain	O
constructs	O
that	O
can	O
be	O
employed	O
in	O
sorting	O
the	O
specific	O
roles	O
of	O
E2L1	B-GENE
and	O
E2L2	B-GENE
in	O
facilitating	O
catalytic	O
and	O
regulatory	O
processes	O
.	O

Transfecting	O
the	O
cloned	B-GENE
bovine	I-GENE
PBR	I-GENE
/	I-GENE
IBP	I-GENE
cDNA	I-GENE
into	O
COS-7	O
cells	O
resulted	O
in	O
an	O
11-fold	O
increase	O
in	O
the	O
density	O
of	O
high	O
affinity	O
[	O
3H	O
]	O
PK	O
11195	O
binding	O
sites	O
which	O
had	O
only	O
low	O
affinity	O
for	O
Ro5-4864	O
.	O

Digestion	O
of	O
NF-IL6	B-GENE
with	O
endoprotease	B-GENE
Asp-N	I-GENE
produced	O
a	O
domain	O
smaller	O
than	O
the	O
TCD	B-GENE
(	O
NF-IL6	B-GENE
bZIP	I-GENE
domains	I-GENE
(	O
NFBD	B-GENE
)	O
(	O
272-345	O
)	O
)	O
,	O
a	O
domain	O
identified	O
either	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
DNA	O
.	O

A	O
combination	O
of	O
comparative	O
sequence	O
analysis	O
and	O
thermodynamic	O
methods	O
reveals	O
the	O
conservation	O
of	O
tertiary	O
structure	O
elements	O
in	O
the	O
5'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
human	O
enteroviruses	O
and	O
rhinoviruses	O
.	O

Hypothalamic	O
control	O
of	O
coronary	O
circulation	O
in	O
the	O
dog	O
.	O

Intensification	O
of	O
human	O
myocardial	O
contractile	O
activity	O
as	O
affected	O
by	O
blood	O
serum	O
.	O

These	O
results	O
demonstrate	O
that	O
although	O
PI2	O
and	O
PI3	O
viruses	O
belong	O
to	O
the	O
same	O
parainfluenza	O
virus	O
genus	O
,	O
these	O
viruses	O
show	O
marked	O
differences	O
with	O
respect	O
to	O
functional	O
requirements	O
for	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
F	B-GENE
glycoprotein	I-GENE
.	O

The	O
human	B-GENE
cytomegalovirus	I-GENE
(	I-GENE
HCMV	I-GENE
)	I-GENE
major	I-GENE
immediate-early	I-GENE
protein	I-GENE
IE2	I-GENE
is	O
a	O
nuclear	B-GENE
phosphoprotein	I-GENE
that	O
is	O
believed	O
to	O
be	O
a	O
key	O
regulator	O
in	O
both	O
lytic	O
and	O
latent	O
infections	O
.	O

The	O
highest	O
prevalence	O
of	O
reported	O
pet	O
allergy	O
,	O
chronic	O
cough	O
,	O
wheeze	O
,	O
attacks	O
of	O
shortness	O
of	O
breath	O
with	O
wheezing	O
,	O
and	O
doctor-diagnosed	O
asthma	O
was	O
found	O
in	O
children	O
who	O
had	O
pets	O
in	O
the	O
past	O
but	O
not	O
anymore	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Lung	O
elastance	O
(	O
EL	O
)	O
and	O
resistance	O
(	O
RL	O
)	O
were	O
calculated	O
from	O
measurements	O
of	O
airway	O
pressure	O
,	O
esophageal	O
pressure	O
,	O
and	O
airway	O
flow	O
in	O
five	O
anesthetized	O
,	O
paralyzed	O
dogs	O
during	O
sinusoidal	O
forcing	O
at	O
a	O
constant	O
mean	O
airway	O
pressure	O
of	O
10	O
cmH2O	O
in	O
a	O
wide	O
range	O
of	O
breathing	O
frequencies	O
(	O
0	O
.	O
2	O
to	O
1	O
.	O
0	O
Hz	O
in	O
intervals	O
of	O
0	O
.	O
2	O
)	O
and	O
tidal	O
volumes	O
(	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
to	O
300	O
mL	O
)	O
.	O

The	O
mean	O
power	O
(	O
in	O
mu	O
W	O
)	O
required	O
to	O
produce	O
the	O
observed	O
flow	O
rate	O
was	O
estimated	O
at	O
each	O
outflow	O
pressure	O
as	O
the	O
product	O
of	O
the	O
flow	O
rate	O
and	O
the	O
pressure	O
across	O
the	O
lymphatic	O
vessel	O
.	O

A	O
mutational	O
analysis	O
has	O
resolved	O
a	O
region	O
of	O
seven	O
amino	O
acids	O
(	O
amino	O
acids	O
26-32	O
)	O
in	O
the	O
N-terminus	O
of	O
Bob1	B-GENE
that	O
are	O
important	O
for	O
contacting	O
the	O
DNA	O
binding	O
POU	B-GENE
domain	I-GENE
of	O
Oct-1	B-GENE
or	O
Oct-2	B-GENE
.	O

Ethylene	O
glycol	O
and	O
diethylene	O
glycol	O
were	O
each	O
administered	O
once	O
weekly	O
subcutaneously	O
to	O
groups	O
of	O
100	O
female	O
NMRI	O
mice	O
at	O
3	O
dosages	O
(	O
30	O
;	O
10	O
und	O
3	O
mg	O
single	O
dose	O
per	O
mouse	O
)	O
.	O

These	O
findings	O
show	O
that	O
EBP50	B-GENE
is	O
a	O
physiologically	O
relevant	O
ezrin	B-GENE
binding	I-GENE
protein	I-GENE
.	O

METHODS	O
:	O
Sixteen	O
pigs	O
were	O
assigned	O
randomly	O
to	O
control	O
and	O
shock	O
groups	O
.	O

Because	O
endogenous	O
HSF	B-GENE
DNA-binding	O
activity	O
is	O
low	O
and	O
anti-hHSF1	B-GENE
antibody	I-GENE
does	O
not	O
recognize	O
Xenopus	B-GENE
HSF	I-GENE
,	O
we	O
employed	O
this	O
system	O
for	O
mapping	O
regions	O
in	O
hHSF1	B-GENE
that	O
are	O
required	O
for	O
the	O
maintenance	O
of	O
the	O
monomeric	O
state	O
.	O

On	O
the	O
comparison	O
of	O
correlated	O
proportions	O
for	O
clustered	O
data	O
.	O

No	O
significant	O
correlations	O
of	O
peak	O
VO2	O
were	O
observed	O
between	O
the	O
3	O
tests	O
.	O

We	O
discuss	O
these	O
results	O
with	O
respect	O
to	O
the	O
transcriptional	O
induction	O
of	O
the	O
HNF-3	B-GENE
alpha	I-GENE
gene	I-GENE
in	O
respiratory	O
epithelium	O
during	O
embryogenesis	O
.	O

We	O
were	O
interested	O
in	O
studying	O
the	O
relationship	O
between	O
the	O
circadian	O
rhythm	O
in	O
body	O
temperature	O
and	O
24-h	O
variations	O
in	O
plasma	O
concentrations	O
of	O
iron	O
,	O
zinc	O
,	O
circulating	O
leukocyte	O
counts	O
,	O
and	O
plasma	O
interleukin	B-GENE
1	I-GENE
(	O
IL-1	B-GENE
)	O
activity	O
.	O

Activation	O
was	O
biphasic	O
;	O
peaking	O
at	O
5-10	O
min	O
and	O
24	O
h	O
after	O
treatment	O
.	O

Three	O
cysteine	O
and	O
four	O
tryptophan	O
residues	O
,	O
previously	O
identified	O
as	O
conserved	O
amongst	O
nitrous-oxide	B-GENE
reductases	I-GENE
,	O
are	O
found	O
in	O
the	O
Paracoccus	O
enzyme	O
.	O

Animal	O
age	O
and	O
sex	O
had	O
no	O
significant	O
effects	O
on	O
CSF	O
composition	O
,	O
but	O
serum	O
IgG	B-GENE
concentration	O
increased	O
with	O
age	O
.	O

These	O
studies	O
point	O
to	O
the	O
involvement	O
of	O
the	O
MAP	B-GENE
kinase	I-GENE
pathway	O
in	O
the	O
activation	O
of	O
monocytic	O
cells	O
during	O
transmigration	O
to	O
inflammatory	O
sites	O
.	O

This	O
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
regions	O
of	O
homology	O
to	O
several	O
other	O
proteins	O
including	O
the	O
zinc	O
fingers	O
and	O
other	O
domains	O
of	O
the	O
Drosophila	B-GENE
trithorax	I-GENE
gene	I-GENE
product	I-GENE
,	O
and	O
the	O
"AT-hook"	B-GENE
DNA-binding	I-GENE
motif	I-GENE
of	O
high	B-GENE
mobility	I-GENE
group	I-GENE
proteins	I-GENE
.	O

High	O
trough	O
serum	O
TOB	O
concentrations	O
were	O
associated	O
with	O
death	O
and	O
very	O
low	O
levels	O
with	O
recovery	O
.	O

Baseline	O
MBF	O
in	O
females	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
higher	O
than	O
in	O
males	O
.	O

Delayed	O
or	O
paradoxically	O
emptying	O
regions	O
of	O
the	O
left	O
ventricle	O
were	O
detected	O
by	O
a	O
relatively	O
new	O
nuclear	O
technique--phase	O
imaging	O
.	O

To	O
clarify	O
whether	O
seizure-offset	O
patterns	O
are	O
reliable	O
in	O
predicting	O
seizure	O
outcome	O
,	O
we	O
studied	O
SEEG	O
/	O
ECoG	O
in	O
a	O
similar	O
group	O
of	O
patients	O
with	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
.	O

The	O
11	O
;	O
22	O
chromosomal	O
translocation	O
specifically	O
linked	O
to	O
Ewing	O
sarcoma	O
and	O
primitive	O
neuroectodermal	O
tumor	O
results	O
in	O
a	O
chimeric	O
molecule	O
fusing	O
the	O
amino-terminal-encoding	O
portion	O
of	O
the	O
EWS	B-GENE
gene	I-GENE
to	O
the	O
carboxyl-terminal	O
DNA-binding	O
domain	O
encoded	O
by	O
the	O
FLI1	B-GENE
gene	I-GENE
.	O

Immediately	O
after	O
surgery	O
,	O
dialysate	O
PGE2	O
and	O
adenosine	O
concentrations	O
were	O
3	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
and	O
296	O
+	O
/	O
-	O
127	O
nM	O
,	O
respectively	O
.	O

We	O
randomly	O
assigned	O
1	O
,	O
219	O
subjects	O
to	O
receive	O
either	O
the	O
standard	O
three-times-weekly	O
(	O
TIW	O
)	O
interferon	B-GENE
alfa-2b	I-GENE
dose	O
(	O
3	O
MIU	O
)	O
or	O
the	O
once-weekly	O
(	O
QW	O
)	O
peginterferon	O
alfa-2b	O
(	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
or	O
1	O
.	O
5	O
microg	O
/	O
kg	O
)	O
.	O

We	O
show	O
that	O
CBF-A	B-GENE
and	O
CBF-C	B-GENE
interact	O
with	O
each	O
other	O
to	O
form	O
a	O
CBF-A-CBF-C	B-GENE
complex	I-GENE
and	O
that	O
CBF-B	B-GENE
does	O
not	O
interact	O
with	O
CBF-A	B-GENE
or	O
CBF-C	B-GENE
individually	O
but	O
that	O
it	O
associates	O
with	O
the	O
CBF-A-CBF-C	B-GENE
complex	I-GENE
.	O

Protein	B-GENE
S	I-GENE
levels	O
were	O
virtually	O
undetectable	O
at	O
the	O
time	O
of	O
admission	O
and	O
failed	O
to	O
respond	O
to	O
infusions	O
of	O
fresh	O
frozen	O
plasma	O
,	O
despite	O
correction	O
of	O
other	O
procoagulant	O
and	O
anticoagulant	O
factors	O
.	O

Low-grade	O
glioma	O
.	O

While	O
Pt	B-GENE
;	I-GENE
cycH	I-GENE
;	I-GENE
1	I-GENE
and	O
Os	B-GENE
;	I-GENE
cycH	I-GENE
;	I-GENE
1	I-GENE
were	O
expressed	O
in	O
all	O
tissues	O
examined	O
,	O
the	O
transcripts	O
accumulated	O
abundantly	O
in	O
dividing	O
cells	O
.	O

In	O
patients	O
in	O
group	O
A	O
(	O
"normal"	O
CI	O
)	O
,	O
the	O
CI	O
,	O
heart	O
rate	O
and	O
the	O
mean	O
circumferential	O
fiber	O
shortening	O
velocity	O
(	O
mVCF	O
)	O
were	O
normal	O
,	O
but	O
the	O
TPR	O
was	O
increased	O
significantly	O
.	O

The	O
other	O
patients	O
continued	O
the	O
trial	O
with	O
single	O
daily	O
doses	O
of	O
monotherapy	O
.	O

Our	O
results	O
suggest	O
that	O
proteasome	O
inhibition	O
leads	O
to	O
upregulation	O
of	O
specific	O
members	O
of	O
transcription	O
factor	O
families	O
controlling	O
cellular	O
stress	O
response	O
and	O
proliferation	O
.	O

Potency	O
of	O
enflurane	O
in	O
dogs	O
:	O
comparison	O
with	O
halothane	O
and	O
isoflurane	O
.	O

Oxfendazole	O
,	O
which	O
was	O
active	O
for	O
the	O
shortest	O
time	O
(	O
about	O
65	O
days	O
)	O
from	O
the	O
start	O
of	O
grazing	O
(	O
May	O
1	O
)	O
,	O
produced	O
a	O
78	O
.	O
1	O
per	O
cent	O
reduction	O
in	O
Ostertagia	O
species	O
and	O
an	O
84	O
.	O
4	O
per	O
cent	O
reduction	O
in	O
D	O
viviparus	O
.	O

METHODS	O
:	O
93	O
female	O
and	O
43	O
male	O
patients	O
undergoing	O
thyroid	O
surgery	O
were	O
stratified	O
according	O
to	O
gender	O
and	O
then	O
randomised	O
to	O
receive	O
double-blind	O
one	O
of	O
four	O
antiemetic	O
regimes	O
:	O
50	O
mg	O
dolasetron	O
given	O
orally	O
45	O
minutes	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
(	O
group	O
I	O
)	O
,	O
12	O
.	O
5	O
mg	O
dolasetron	O
given	O
intravenously	O
during	O
induction	O
of	O
anaesthesia	O
(	O
group	O
II	O
)	O
,	O
1	O
.	O
25	O
mg	O
DHB	B-GENE
given	O
intravenously	O
during	O
induction	O
of	O
anaesthesia	O
(	O
group	O
III	O
)	O
or	O
placebo	O
(	O
group	O
IV	O
)	O
.	O

The	O
specific	O
interaction	O
between	O
a	O
defined	O
structural	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
mRNA	O
(	O
RRE	B-GENE
,	O
the	O
Rev	B-GENE
response	I-GENE
element	I-GENE
)	O
and	O
the	O
virus-encoded	B-GENE
protein	I-GENE
Rev	I-GENE
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
the	O
export	O
of	O
unspliced	O
or	O
singly	O
spliced	O
mRNA	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

These	O
cells	O
were	O
able	O
to	O
present	O
influenza	O
virus	O
particles	O
to	O
HLA-DR1-restricted	O
T	O
cell	O
clones	O
.	O

The	O
4	O
degrees	O
stimuli	O
were	O
found	O
to	O
elicit	O
scalp	O
distributions	O
for	O
the	O
pattern	O
reversal	O
P100	O
and	O
the	O
pattern	O
onset	O
C1	O
consistent	O
with	O
striate	O
and	O
extrastriate	O
visual	O
cortical	O
origins	O
respectively	O
.	O

In	O
conclusion	O
,	O
these	O
observations	O
demonstrated	O
that	O
stratification	O
of	O
acute	O
MI	O
patients	O
by	O
plasma	O
ANF	B-GENE
level	O
is	O
a	O
useful	O
non-invasive	O
method	O
for	O
predicting	O
prognosis	O
and	O
for	O
identifying	O
individuals	O
at	O
high	O
risk	O
of	O
cardiac	O
death	O
.	O

Heat-inducible	O
CAT	B-GENE
activity	O
was	O
detectable	O
when	O
additional	O
sequences	O
from	O
the	O
native	O
promoter	O
containing	O
three	O
CCAAT	O
boxes	O
and	O
a	O
single	O
HSE	B-GENE
were	O
present	O
in	O
the	O
constructions	O
.	O

Characterization	O
of	O
a	O
Xenopus	B-GENE
laevis	I-GENE
CXC	I-GENE
chemokine	I-GENE
receptor	I-GENE
4	I-GENE
:	O
implications	O
for	O
hematopoietic	O
cell	O
development	O
in	O
the	O
vertebrate	O
embryo	O
.	O

The	O
effect	O
of	O
crude	O
oil	O
spillage	O
on	O
growth	O
,	O
productivity	O
and	O
nutrient	O
uptake	O
of	O
maize	O
(	O
Zea	O
mays	O
L	O
.	O
)	O
was	O
assessed	O
in	O
a	O
pot	O
experiment	O
using	O
an	O
Evwreni	O
manifold	O
sample	O
of	O
a	O
petroleum	O
development	O
company	O
,	O
which	O
had	O
a	O
specific	O
gravity	O
of	O
0	O
.	O
8778	O
.	O

Moreover	O
,	O
the	O
hypoxia-induced	O
expression	O
of	O
the	O
endogenous	O
Epo	B-GENE
gene	I-GENE
was	O
significantly	O
inhibited	O
in	O
Hep3B	O
cells	O
stably	O
transfected	O
with	O
HNF-4	B-GENE
delta	I-GENE
C	I-GENE
.	O

The	O
subjects	O
were	O
shown	O
to	O
be	O
capable	O
of	O
assessing	O
integrally	O
the	O
value	O
of	O
accelerations	O
and	O
estimating	O
it	O
with	O
an	O
error	O
of	O
0	O
.	O
1-0	O
.	O
12	O
g	O
.	O

Two	O
XPG	B-GENE
regions	I-GENE
with	O
putative	O
NLS	O
[	O
amino	O
acid	O
(	O
AA	O
)	O
coordinates	O
:	O
NLS-B	O
(	O
AA	O
1057-1074	O
)	O
and	O
NLS-C	O
(	O
AA	O
1171-1185	O
)	O
]	O
were	O
each	O
shown	O
to	O
independently	O
localize	O
the	O
beta-gal	B-GENE
extensively	O
(	O
>	O
80%	O
)	O
to	O
the	O
nucleus	O
of	O
HeLa	O
cells	O
.	O

Although	O
metabolized	O
by	O
the	O
cytochrome	B-GENE
P-450	I-GENE
(	O
CYP	B-GENE
)	O
system	O
,	O
venlafaxine	O
inhibits	O
CYP	B-GENE
2D6	I-GENE
and	I-GENE
3A4	I-GENE
to	O
a	O
far	O
lesser	O
extent	O
than	O
do	O
the	O
SSRIs	O
.	O

Signaling	O
by	O
tyrosine	B-GENE
kinases	I-GENE
involves	O
direct	O
associations	O
between	O
proteins	O
with	O
Src	B-GENE
homology	I-GENE
2	I-GENE
(	O
SH2	B-GENE
)	O
domains	O
and	O
sites	O
of	O
tyrosine	O
phosphorylation	O
.	O

In	O
addition	O
,	O
and	O
in	O
support	O
of	O
a	O
mediating	O
role	O
of	O
STATs	B-GENE
in	O
the	O
activation	O
of	O
the	O
p21	B-GENE
promoter	I-GENE
,	O
overexpression	O
of	O
Stat3	B-GENE
potentiated	O
the	O
cytokine	O
effect	O
on	O
the	O
p21	B-GENE
promoter	I-GENE
;	O
whereas	O
a	O
dominant	B-GENE
negative	I-GENE
Stat3	I-GENE
,	O
or	O
a	O
mutation	O
of	O
the	O
STAT	B-GENE
response	I-GENE
element	I-GENE
on	O
the	O
promoter	O
,	O
significantly	O
reduced	O
the	O
cytokine	O
effect	O
.	O

Extramedullary	O
relapse	O
in	O
childhood	O
leukemia	O
.	O

Testing	O
for	O
serum	B-GENE
IgM	I-GENE
binding	O
to	O
GM1	O
ganglioside	O
in	O
clinical	O
practice	O
.	O

Using	O
GST-PKR	B-GENE
fusion	I-GENE
chromatography	O
,	O
direct	O
physical	O
interaction	O
between	O
the	O
mouse	O
and	O
human	B-GENE
PKR	I-GENE
homologs	I-GENE
was	O
established	O
.	O

In	O
contrast	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
a	O
second	O
family	O
(	O
ART5	B-GENE
)	O
of	O
transferases	B-GENE
,	O
cloned	O
from	O
murine	O
lymphoma	O
cells	O
and	O
expressed	O
in	O
high	O
abundance	O
in	O
testis	O
,	O
displays	O
a	O
hydrophobic	O
amino	O
terminus	O
,	O
consistent	O
with	O
a	O
signal	O
sequence	O
,	O
but	O
lacks	O
a	O
hydrophobic	O
signal	O
sequence	O
at	O
its	O
carboxyl	O
terminus	O
,	O
suggesting	O
that	O
the	O
protein	O
is	O
destined	O
for	O
export	O
.	O

Sp1's	O
role	O
in	O
transactivation	O
of	O
the	O
pgp2	B-GENE
/	I-GENE
mdr1b	I-GENE
promoter	I-GENE
was	O
tested	O
in	O
Drosophila	O
Schneider	O
cells	O
.	O

Prostaglandins	O
and	O
gallstones	O
.	O

Studies	O
were	O
performed	O
on	O
several	O
superficial	O
veins	O
from	O
the	O
rabbit	O
face	O
to	O
examine	O
the	O
relationship	O
between	O
beta	B-GENE
adrenoceptor	I-GENE
subtype	I-GENE
distribution	O
,	O
intrinsic	O
myogenic	O
tone	O
and	O
sympathetic	O
nerve	O
innervation	O
.	O

Several	O
lines	O
of	O
evidence	O
demonstrate	O
that	O
this	O
growth	O
inhibition	O
requires	O
active	O
PKA	B-GENE
subunits	I-GENE
and	O
cAMP	O
:	O
(	O
i	O
)	O
this	O
phenotype	O
is	O
dependent	O
on	O
cAMP	O
since	O
it	O
is	O
not	O
seen	O
in	O
a	O
strain	O
lacking	O
adenylyl	B-GENE
cyclase	I-GENE
activity	O
,	O
but	O
the	O
growth	O
rate	O
of	O
these	O
transformants	O
is	O
slower	O
when	O
exogenous	O
cAMP	O
is	O
added	O
;	O
(	O
ii	O
)	O
normal	O
growth	O
occurs	O
when	O
wild-type	O
RI	B-GENE
cDNA	O
is	O
replaced	O
by	O
a	O
mutant	B-GENE
RI	I-GENE
cDNA	I-GENE
encoding	O
a	O
RI	B-GENE
protein	I-GENE
with	O
reduced	O
cAMP	O
binding	O
;	O
and	O
(	O
iii	O
)	O
the	O
growth-inhibited	O
phenotype	O
of	O
the	O
transformed	O
BL21	O
(	O
DE3	O
)	O
cells	O
requires	O
soluble	O
,	O
active	O
C	B-GENE
alpha	I-GENE
protein	I-GENE
.	O

In	O
this	O
paper	O
,	O
we	O
have	O
analyzed	O
the	O
structure	O
of	O
human	O
gene	O
for	O
Gx	B-GENE
alpha	I-GENE
,	O
which	O
spans	O
more	O
than	O
60	O
kilobases	O
.	O

The	O
author	O
analyzes	O
extensive	O
own	O
data	O
based	O
on	O
study	O
into	O
particular	O
features	O
of	O
cardiovascular	O
disorders	O
in	O
chronic	O
renal	O
impairement	O
with	O
making	O
use	O
of	O
modern	O
diagnostic	O
tools	O
.	O

Nuclear	B-GENE
protein	I-GENE
phosphatase	I-GENE
2A	I-GENE
dephosphorylates	O
protein	B-GENE
kinase	I-GENE
A-phosphorylated	O
CREB	B-GENE
and	O
regulates	O
CREB	B-GENE
transcriptional	O
stimulation	O
.	O

Antileukoproteinase	B-GENE
(	O
ALP	B-GENE
)	O
is	O
a	O
low	O
mol	O
wt	O
mucosal	O
secretory	O
protein	O
which	O
,	O
in	O
human	O
tissues	O
,	O
inhibits	O
the	O
activities	O
of	O
the	O
neutral	O
serine	B-GENE
lysosomal	I-GENE
proteinases	I-GENE
elastase	B-GENE
and	O
cathepsin-G	B-GENE
.	O

No	O
dominant	O
clinical	O
factor	O
of	O
risk	O
was	O
found	O
,	O
but	O
multiple	O
regression	O
analysis	O
identified	O
age	O
,	O
body	O
surface	O
area	O
,	O
valve	O
size	O
,	O
shop	O
order	O
fracture	O
rate	O
,	O
and	O
manufacturing	O
period	O
as	O
risk	O
factors	O
for	O
OSF	O
.	O

It	O
is	O
useful	O
as	O
an	O
adjunct	O
to	O
mammography	O
in	O
those	O
patients	O
with	O
radiographically	O
dense	O
breasts	O
for	O
the	O
characterization	O
of	O
palpable	O
masses	O
.	O

There	O
was	O
however	O
,	O
no	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
chronic	O
respiratory	O
symptoms	O
between	O
animal	O
food	O
workers	O
with	O
positive	O
and	O
negative	O
skin	O
tests	O
to	O
house	O
dust	O
or	O
to	O
fish	O
flour	O
or	O
among	O
those	O
with	O
increased	O
or	O
normal	O
IgE	B-GENE
(	O
except	O
for	O
dyspnea	O
)	O
.	O

This	O
protein	O
with	O
a	O
hydrophobic	O
amino	O
terminus	O
appears	O
to	O
be	O
a	O
secreted	O
protein	O
.	O

Initial	O
estimates	O
indicate	O
that	O
27	O
,	O
193	O
people	O
are	O
either	O
in	O
receipt	O
of	O
or	O
in	O
need	O
of	O
mental	O
handicap	O
services	O
.	O

Significance	O
of	O
the	O
biopsy	O
site	O
of	O
the	O
latissimus	O
dorsi	O
muscle	O
for	O
fiber	O
typing	O
.	O

Our	O
mapping	O
results	O
did	O
not	O
suggest	O
involvement	O
of	O
this	O
gene	O
in	O
previously	O
mapped	O
genetic	O
disorders	O
or	O
in	O
known	O
neoplasia-associated	O
translocation	O
breakpoints	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
common	O
cause	O
of	O
asthenopia	O
,	O
mixed	O
astigmatism	O
.	O

The	O
5-year	O
OS	O
for	O
stage	O
IIIB	O
was	O
30	O
.	O
9%	O
,	O
compared	O
to	O
7	O
.	O
8%	O
for	O
stage	O
IV	O
.	O

The	O
simultaneous	O
recording	O
of	O
electrical	O
activity	O
from	O
the	O
surface	O
electrocardiogram	O
,	O
right	O
ventricular	O
apex	O
,	O
His	O
bundle	O
,	O
high	O
right	O
atrium	O
,	O
coronary	O
sinus	O
,	O
with	O
or	O
without	O
a	O
roving	O
mapping	O
catheter	O
,	O
enables	O
us	O
to	O
precisely	O
map	O
the	O
electrical	O
activation	O
sequence	O
in	O
the	O
heart	O
.	O

As	O
with	O
the	O
murine	B-GENE
and	I-GENE
human	I-GENE
mb-1	I-GENE
genes	I-GENE
,	O
the	O
5'	O
region	O
of	O
the	O
bovine	B-GENE
mb-1	I-GENE
gene	I-GENE
lacked	O
a	O
TATA	O
box	O
.	O

Sequence	O
analyses	O
of	O
sos2	B-GENE
mutant	I-GENE
alleles	I-GENE
reveal	O
that	O
both	O
the	O
N-terminal	O
catalytic	O
domain	O
and	O
the	O
C-terminal	O
regulatory	O
domain	O
of	O
SOS2	B-GENE
are	O
functionally	O
essential	O
.	O

Furthermore	O
,	O
analysis	O
of	O
the	O
E2	B-GENE
proteins	I-GENE
present	O
in	O
various	O
cell	O
lines	O
harboring	O
specific	O
BPV-1	O
mutants	O
,	O
including	O
the	O
2558	B-GENE
acceptor	I-GENE
mutant	I-GENE
,	O
proves	O
that	O
alternate	O
modes	O
of	O
E2	B-GENE
expression	O
exist	O
.	O

When	O
statistically	O
analyzed	O
in	O
various	O
subgroupings	O
,	O
the	O
obtained	O
average	O
sedimentation	O
coefficients	O
and	O
polydispersity	O
profiles	O
supported	O
the	O
following	O
conclusions	O
:	O
(	O
a	O
)	O
loss	O
of	O
proteoglycan	O
aggregation	O
and	O
sedimentability	O
is	O
confirmed	O
to	O
be	O
a	O
primary	O
sign	O
of	O
cartilage	O
matrix	O
degradation	O
;	O
(	O
b	O
)	O
higher	O
S	O
values	O
for	O
proteoglycans	O
of	O
the	O
high	O
weight	O
(	O
HW	O
)	O
-bearing	O
areas	O
and	O
lower	O
values	O
for	O
those	O
of	O
the	O
low	O
weight	O
(	O
LW	O
)	O
-bearing	O
areas	O
were	O
a	O
typical	O
finding	O
in	O
normal	O
cartilage	O
samples	O
;	O
(	O
c	O
)	O
inversion	O
of	O
this	O
pattern	O
was	O
indicative	O
of	O
matrix	O
degradation	O
,	O
suggesting	O
that	O
the	O
HW	O
regions	O
are	O
more	O
affected	O
than	O
the	O
LW-bearing	O
areas	O
;	O
(	O
d	O
)	O
the	O
average	O
S	O
value	O
distribution	O
across	O
cartilage	O
thickness	O
tended	O
to	O
resemble	O
the	O
corresponding	O
proteoglycan	O
content	O
versus	O
distance	O
from	O
articular	O
surface	O
;	O
and	O
(	O
e	O
)	O
the	O
deepest	O
cartilage	O
layer	O
had	O
,	O
in	O
most	O
cases	O
,	O
the	O
smallest	O
amount	O
of	O
aggregates	O
while	O
the	O
highest	O
average	O
sedimentability	O
was	O
observed	O
at	O
the	O
middle	O
zone	O
of	O
the	O
normal	O
samples	O
.	O

Cyclins	B-GENE
are	O
one	O
of	O
the	O
pivotal	O
determinants	O
regulating	O
cell	O
cycle	O
progression	O
.	O

A	O
centromere	O
in	O
S	O
.	O
cerevisiae	O
consists	O
of	O
a	O
region	O
of	O
DNA	O
,	O
approximately	O
150	O
bp	O
in	O
length	O
,	O
containing	O
three	O
important	O
sequence	O
elements	O
,	O
which	O
are	O
folded	O
with	O
proteins	O
into	O
a	O
specific	O
conformation	O
in	O
the	O
chromatin	O
(	O
the	O
yeast	O
kinetochore	O
)	O
.	O

The	O
first	O
146	O
consecutive	O
patients	O
treated	O
with	O
EVL	O
during	O
the	O
period	O
from	O
August	O
,	O
1986	O
to	O
July	O
,	O
1989	O
are	O
reported	O
.	O

Two	O
scintigraphic	O
methods	O
,	O
resting	O
dipyridamole	O
and	O
exercise	O
thallium-201	O
myocardial	O
perfusion	O
imaging	O
,	O
to	O
detect	O
and	O
localize	O
coronary	O
artery	O
stenosis	O
were	O
compared	O
in	O
32	O
patients	O
suffering	O
from	O
coronary	O
artery	O
disease	O
.	O

In	O
all	O
sessions	O
under	O
IFN	B-GENE
,	O
the	O
latency	O
of	O
the	O
P100	O
component	O
of	O
the	O
VEP	O
was	O
shortened	O
as	O
compared	O
to	O
baseline	O
conditions	O
.	O

CONCLUSIONS	O
:	O
Our	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
of	O
HRT	O
noted	O
a	O
statistically	O
significant	O
reduction	O
in	O
nonvertebral	O
fractures	O
.	O

Prevention	O
of	O
transfusion	O
reactions	O
by	O
the	O
use	O
of	O
saline	O
washed	O
red	O
blood	O
cells	O
.	O

In	O
human	O
proliferative	O
cells	O
,	O
the	O
NADP-dependent	O
ME	B-GENE
activity	O
is	O
poorly	O
expressed	O
and	O
barely	O
inducible	O
by	O
thyroid	O
hormones	O
.	O

The	O
delta	B-GENE
srb10	I-GENE
mutation	I-GENE
also	O
influenced	O
on	O
the	O
transcript	O
levels	O
of	O
meiosis-inducing	O
genes	O
called	O
IME1	B-GENE
and	O
IME2	B-GENE
:	O
the	O
mutation	O
elevated	O
the	O
transcript	O
level	O
of	O
IME1	B-GENE
but	O
reduced	O
that	O
of	O
IME2	B-GENE
,	O
resulting	O
in	O
partial	O
defects	O
in	O
premeiotic	O
DNA	O
synthesis	O
and	O
meiosis	O
.	O

After	O
screening	O
the	O
Berkeley	O
Drosophila	O
Genome	O
Project	O
database	O
with	O
sequences	O
from	O
a	O
recently	O
characterized	O
Leu-rich	B-GENE
repeats-containing	I-GENE
G	I-GENE
protein-coupled	I-GENE
receptor	I-GENE
(	O
LGR	B-GENE
)	O
from	O
Drosophila	O
(	O
DLGR-1	B-GENE
)	O
,	O
we	O
identified	O
a	O
second	O
gene	O
for	O
a	O
different	O
LGR	B-GENE
(	O
DLGR-2	B-GENE
)	O
and	O
cloned	O
its	O
cDNA	O
.	O

Takahashi	O
,	O
H	O
.	O

The	O
telomerase	B-GENE
RNA-protein	I-GENE
complex	I-GENE
responsible	O
for	O
maintenance	O
of	O
telomeric	O
DNA	O
at	O
chromosome	O
ends	O
,	O
is	O
usually	O
inactive	O
in	O
most	O
primary	O
somatic	O
human	O
cells	O
,	O
but	O
is	O
specifically	O
activated	O
with	O
in	O
vitro	O
immortalization	O
and	O
during	O
tumorigenesis	O
.	O

Sequence	O
analysis	O
of	O
these	O
genes	O
and	O
their	O
surrounding	O
sequences	O
are	O
presented	O
and	O
compared	O
with	O
other	O
known	O
tRNA	O
genes	O
from	O
plant	O
mitochondria	O
.	O

Interferon	B-GENE
type	I-GENE
I	I-GENE
in	O
protective	O
body	O
reactions	O
in	O
an	O
experimental	O
Klebsiella	O
infection	O
.	O

In	O
addition	O
,	O
the	O
consensus	O
amino	O
acid	O
motif	O
for	O
serine	B-GENE
threonine	I-GENE
receptor	I-GENE
kinases	I-GENE
was	O
also	O
present	O
.	O

However	O
,	O
despite	O
its	O
relationship	O
to	O
the	O
TR	B-GENE
,	O
Rev-Erb	B-GENE
bound	O
poorly	O
to	O
TR	B-GENE
binding	I-GENE
sites	I-GENE
.	O

These	O
data	O
suggest	O
that	O
the	O
G-protein	B-GENE
gene	I-GENE
family	I-GENE
may	O
be	O
distributed	O
over	O
at	O
least	O
two	O
human	O
chromosomes	O
.	O

Radioimmunoassay	O
of	O
serum	O
creatine	B-GENE
kinase	I-GENE
B	I-GENE
isoenzyme	I-GENE
in	O
the	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
.	O

Two	O
potential	O
regulatory	O
sequences	O
for	O
DNA	O
binding	O
proteins	O
were	O
found	O
in	O
the	O
non-coding	O
5'	O
region	O
:	O
a	O
HAP2	B-GENE
/	I-GENE
HAP3	I-GENE
consensus	I-GENE
recognition	I-GENE
sequence	I-GENE
at	O
nucleotide-154	O
and	O
a	O
BAF1	B-GENE
consensus	I-GENE
recognition	I-GENE
sequence	I-GENE
at	O
nucleotide-136	O
.	O

Transfection	O
experiments	O
using	O
preformed	O
triplexes	O
with	O
a	O
reporter	O
plasmid	O
containing	O
the	O
collagen	B-GENE
promoter	I-GENE
sequence	I-GENE
showed	O
significant	O
inhibition	O
of	O
transcription	O
when	O
compared	O
with	O
a	O
control	O
phosphorothioate	O
ODN	O
.	O

The	O
nucleotide	O
sequences	O
at	O
the	O
5'	O
and	O
3'	O
ends	O
of	O
these	O
introns	O
are	O
characteristic	O
of	O
spliced	O
transcripts	O
from	O
eukaryotic	O
protein-encoding	O
genes	O
,	O
with	O
one	O
significant	O
difference	O
;	O
i	O
.	O
e	O
.	O
,	O
the	O
5'	O
end	O
of	O
the	O
LAT	B-GENE
intron	I-GENE
is	O
GC	O
instead	O
of	O
the	O
consensus	O
sequence	O
GT	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-GENE
activation	O
of	O
NF-kappa	B-GENE
B	I-GENE
/	I-GENE
Rel	I-GENE
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
and	O
RelA	B-GENE
(	O
p65	B-GENE
)	O
-mediated	O
induction	O
of	O
the	O
c-rel	B-GENE
gene	I-GENE
.	O

Before	O
birth	O
,	O
there	O
were	O
a	O
few	O
perivascular	O
adrenergic	O
nerves	O
and	O
correspondingly	O
low	O
ovarian	O
NE	O
levels	O
.	O

Habituation	O
of	O
completely	O
isolated	O
neurons	O
of	O
the	O
edible	O
snail	O
to	O
electrical	O
stimulation	O
.	O

A	O
synergistic	O
effect	O
on	O
HCK	B-GENE
promoter	I-GENE
activity	O
was	O
observed	O
at	O
high	O
concentrations	O
of	O
Sp1	B-GENE
.	O

Further	O
characterization	O
of	O
these	O
putative	O
Hoxa-1	B-GENE
target	I-GENE
genes	I-GENE
will	O
aid	O
in	O
delineating	O
the	O
functions	O
of	O
the	O
Hoxa-1	B-GENE
protein	I-GENE
in	O
the	O
differentiation	O
processes	O
which	O
occur	O
during	O
embryogenesis	O
.	O

The	O
ANB1	B-GENE
locus	I-GENE
of	O
Saccharomyces	O
cerevisiae	O
encodes	O
the	O
protein	B-GENE
synthesis	I-GENE
initiation	I-GENE
factor	I-GENE
eIF-4D	I-GENE
.	O

No	O
serious	O
side	O
effects	O
were	O
observed	O
.	O

Although	O
the	O
risk	O
of	O
malformation	O
in	O
children	O
born	O
after	O
ICSI	O
is	O
not	O
increased	O
there	O
is	O
an	O
increased	O
risk	O
to	O
transmit	O
genetic	O
abnormalities	O
in	O
case	O
of	O
NOA	O
(	O
such	O
as	O
the	O
rate	O
of	O
sex	O
chromosome	O
,	O
or	O
microdeletions	O
of	O
the	O
Y	O
chromosome	O
)	O
and	O
in	O
case	O
of	O
congenital	O
OA	O
(	O
mutations	O
of	O
the	O
cystic	B-GENE
fibrosis	I-GENE
gene	I-GENE
)	O
.	O

Mg2+	O
and	O
Mn2+	O
compete	O
for	O
binding	O
sites	O
,	O
with	O
the	O
former	O
having	O
lower	O
affinity	O
.	O

Promoter	O
activities	O
were	O
estimated	O
using	O
beta-glucuronidase	B-GENE
and	O
neomycin	B-GENE
phosphotransferase	I-GENE
II	I-GENE
reporter	I-GENE
gene	I-GENE
systems	I-GENE
.	O

Timing	O
of	O
symptoms	O
and	O
oocyst	O
excretion	O
in	O
human	O
cryptosporidiosis	O
.	O

In	O
vivo	O
association	O
between	O
Shb-SH3	B-GENE
domain	I-GENE
proteins	O
v-Src	B-GENE
and	O
Eps8	B-GENE
was	O
detected	O
by	O
coimmunoprecipitation	O
.	O

The	O
first	O
gene	O
codes	O
for	O
a	O
protein	O
containing	O
11	O
cystein	O
residues	O
in	O
an	O
arrangement	O
typical	O
for	O
Fe	B-GENE
/	I-GENE
S	I-GENE
proteins	I-GENE
.	O

In	O
7	O
of	O
9	O
cases	O
,	O
the	O
enhancer	O
is	O
fused	O
to	O
the	O
c-myc	B-GENE
bearing	I-GENE
sequences	I-GENE
of	O
chromosome	O
8	O
.	O

The	O
critical	O
mutations	O
were	O
likely	O
to	O
have	O
been	O
multiple	O
and	O
dispersed	O
,	O
including	O
elongation	O
of	O
the	O
TM	B-GENE
and	O
Nef	B-GENE
coding	I-GENE
sequences	I-GENE
;	O
changes	O
in	O
RNA	O
splice	O
donor	O
and	O
acceptor	O
sites	O
,	O
TATA	O
box	O
sites	O
,	O
and	O
Sp1	B-GENE
sites	I-GENE
;	O
multiple	O
changes	O
in	O
the	O
V2	B-GENE
region	I-GENE
of	O
SU	B-GENE
,	O
including	O
a	O
consensus	O
neutralization	O
epitope	O
;	O
and	O
five	O
new	O
N-linked	O
glycosylation	O
sites	O
in	O
SU	B-GENE
.	O

These	O
patients	O
failed	O
to	O
respond	O
to	O
intravenous	O
cyclophosphamide	O
and	O
steroids	O
and	O
were	O
then	O
changed	O
to	O
receive	O
oral	O
cyclosporine	O
A	O
,	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

The	O
yeast	O
enzyme	O
was	O
6-fold	O
slower	O
than	O
the	O
mammalian	O
enzymes	O
,	O
which	O
made	O
it	O
amenable	O
to	O
pre-steady-state	O
stopped-flow	O
spectroscopic	O
kinetic	O
analysis	O
at	O
30	O
degrees	O
C	O
and	O
pH	O
6	O
.	O
0	O
.	O

Each	O
immunoprecipitate	O
contained	O
a	O
complex	O
of	O
N1	B-GENE
(	I-GENE
deltaEC	I-GENE
)	I-GENE
and	O
CBF1	B-GENE
.	O

In	O
vitro	O
evaluation	O
of	O
the	O
mucolytic	O
action	O
of	O
urea	O
.	O

The	O
hBRAG	B-GENE
gene	I-GENE
was	O
localized	O
to	O
the	O
long	O
arm	O
of	O
chromosome	O
10	O
(	O
10q26	O
)	O
.	O

Dopamine	B-GENE
receptor	I-GENE
blockade	O
and	O
the	O
neuroleptics	O
,	O
a	O
crystallographic	O
study	O
.	O

Expression	O
was	O
cell	O
cycle	O
controlled	O
,	O
with	O
steady-state	O
RNA	O
levels	O
significantly	O
higher	O
in	O
growth-arrested	O
than	O
in	O
growth-stimulated	O
cells	O
.	O

Pharmacologic	O
aspects	O
of	O
neonatal	O
hyperbilirubinemia	O
.	O

Of	O
the	O
21	O
quadrants	O
positive	O
in	O
the	O
controls	O
,	O
17	O
were	O
correlated	O
with	O
previously	O
detected	O
jaw	O
pathoses	O
.	O

In	O
15	O
ventilator-dependent	O
,	O
SB	O
,	O
and	O
actively	O
expiring	O
patients	O
,	O
we	O
found	O
that	O
the	O
difference	O
PEEP	O
(	O
i	O
)	O
,	O
dyn	O
-	O
Pga	O
,	O
total	O
decay	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
5	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
was	O
quite	O
similar	O
to	O
PEEP	O
(	O
i	O
)	O
,	O
dyn	O
ref	O
(	O
5	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
.	O

Perfusion	O
technique	O
for	O
perfusion-assisted	O
direct	O
coronary	O
artery	O
bypass	O
(	O
PADCAB	O
)	O
.	O

By	O
contrast	O
,	O
kidneys	O
from	O
rats	O
with	O
chronic	O
metabolic	O
acidosis	O
produced	O
significantly	O
more	O
NH3	O
than	O
both	O
these	O
groups	O
(	O
2	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
29	O
mumol	O
X	O
min-1	O
X	O
g-1	O
)	O
.	O

This	O
phosphorylation	O
can	O
be	O
catalyzed	O
by	O
a	O
break-ended	O
double-stranded	O
DNA-activated	O
protein	B-GENE
kinase	I-GENE
activity	O
from	O
the	O
sea	O
urchin	O
nucleus	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
we	O
also	O
show	O
that	O
cdk7	B-GENE
may	O
phosphorylate	O
the	O
carboxy-terminal	O
domain	O
(	O
CTD	O
)	O
of	O
RNA	B-GENE
pol	I-GENE
II	I-GENE
in	O
the	O
absence	O
of	O
promoter	O
opening	O
.	O

Delayed	O
gallbladder	O
visualization	O
and	O
reduction	O
in	O
ejection	O
fraction	O
were	O
sensitive	O
but	O
nonspecific	O
indicators	O
of	O
biliary	O
disease	O
.	O

Managing	O
vertigo	O
and	O
vertigo	O
syndromes	O
in	O
the	O
elderly	O

After	O
base-line	O
CBF	O
was	O
established	O
,	O
hexamethonium	O
bromide	O
(	O
2	O
mg	O
/	O
kg	O
iv	O
)	O
,	O
ipratropium	O
bromide	O
(	O
0	O
.	O
5	O
microgram	O
/	O
kg	O
iv	O
)	O
,	O
indomethacin	O
(	O
2	O
mg	O
/	O
kg	O
iv	O
)	O
,	O
or	O
intravenous	O
0	O
.	O
9%	O
saline	O
was	O
administered	O
.	O

Mean	O
intake	O
of	O
vitamin	O
A	O
amounted	O
to	O
1	O
.	O
1	O
and	O
0	O
.	O
9	O
mg	O
RE	O
/	O
day	O
for	O
men	O
and	O
women	O
,	O
respectively	O
;	O
the	O
contributions	O
of	O
meat	O
,	O
fats	O
and	O
oils	O
,	O
vegetables	O
and	O
dairy	O
products	O
to	O
total	O
intake	O
were	O
35%	O
,	O
24%	O
,	O
16%	O
,	O
and	O
16%	O
,	O
respectively	O
.	O

The	O
risk	O
for	O
these	O
complications	O
is	O
increased	O
by	O
the	O
following	O
factors	O
:	O
multiple	O
gestation	O
,	O
the	O
combination	O
of	O
magnesium	O
sulfate	O
and	O
beta-adrenergic	O
agonist	O
,	O
and	O
the	O
use	O
of	O
adrenocortico-steroids	O
to	O
hasten	O
fetal	O
pulmonary	O
maturity	O
.	O

Human	B-GENE
rIL-3	I-GENE
expressed	O
in	O
COS7	O
cells	O
has	O
multipotential	O
CSF	B-GENE
activity	O
in	O
semisolid	O
cultures	O
of	O
bone	O
marrow	O
cells	O
,	O
and	O
selectively	O
induced	O
the	O
proliferation	O
of	O
My-10+	O
marrow	O
or	O
cord	O
blood	O
cells	O
in	O
liquid	O
cultures	O
.	O

EBER1	B-GENE
mRNA	I-GENE
,	O
a	O
consistent	O
marker	O
of	O
viral	O
latency	O
,	O
was	O
positive	O
in	O
all	O
PEL	O
cases	O
,	O
although	O
at	O
lower	O
levels	O
than	O
in	O
the	O
non-PEL	O
controls	O
due	O
to	O
EBER1	B-GENE
expression	O
by	O
only	O
a	O
variable	O
subset	O
of	O
lymphoma	O
cells	O
.	O

We	O
used	O
two	O
approaches	O
to	O
ascertain	O
whether	O
CDP	B-GENE
/	I-GENE
cut	I-GENE
serves	O
as	O
a	O
repressor	O
of	O
gp91-phox	B-GENE
gene	I-GENE
expression	O
.	O

Interestingly	O
,	O
one	O
IRF	B-GENE
binding	I-GENE
site	I-GENE
was	O
found	O
within	O
the	O
IRF-2	B-GENE
promoter	I-GENE
,	O
and	O
expression	O
of	O
the	O
IRF-2	B-GENE
gene	I-GENE
was	O
affected	O
by	O
both	O
transient	O
and	O
stable	O
IRF-1	B-GENE
expression	O
.	O

The	O
domains	O
involved	O
in	O
superactivation	O
appear	O
to	O
be	O
a	O
subset	O
of	O
those	O
necessary	O
to	O
achieve	O
synergistic	O
activation	O
.	O

Effects	O
of	O
posteroventral	O
pallidotomy	O
on	O
Parkinson's	O
disease	O
.	O

We	O
also	O
demonstrate	O
that	O
preformed	O
triplexes	O
are	O
quite	O
stable	O
when	O
precipitated	O
with	O
ethanol	O
and	O
resuspended	O
in	O
water	O
.	O

Furthermore	O
,	O
both	O
rhHR23	B-GENE
proteins	I-GENE
function	O
in	O
a	O
defined	O
NER	O
system	O
reconstituted	O
with	O
purified	O
proteins	O
,	O
indicating	O
direct	O
involvement	O
of	O
hHR23	B-GENE
proteins	I-GENE
in	O
the	O
DNA	O
repair	O
reaction	O
via	O
interaction	O
with	O
XPC	B-GENE
.	O

2	O
.	O

All	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
and	O
9	O
for	O
response	O
.	O

It	O
was	O
found	O
that	O
increase	O
in	O
the	O
RH	O
level	O
boosts	O
the	O
current	O
values	O
by	O
2-3	O
orders	O
of	O
magnitude	O
;	O
contrariwise	O
,	O
the	O
voltage	O
values	O
rise	O
by	O
about	O
three	O
times	O
with	O
drop	O
in	O
the	O
RH	O
.	O

Both	O
verapamil	O
and	O
propranolol	O
can	O
exhibit	O
additive	O
effects	O
with	O
adenosine	O
in	O
prolonging	O
AV	O
nodal	O
conduction	O
time	O
;	O
however	O
,	O
only	O
verapamil	O
can	O
reduce	O
the	O
dose	O
of	O
adenosine	O
required	O
to	O
produce	O
AV	O
nodal	O
block	O
.	O

The	O
extents	O
of	O
phosphorylation	O
of	O
Ser44	O
and	O
Ser64	O
were	O
1	O
:	O
1	O
,	O
whereas	O
those	O
of	O
the	O
four	O
minor	O
sites	O
all	O
together	O
were	O
<	O
30%	O
of	O
the	O
major	O
one	O
.	O

DNA	O
blot	O
hybridization	O
suggests	O
that	O
the	O
rat	O
genome	O
may	O
contain	O
more	O
than	O
one	O
gene	O
encoding	O
PtdIns	B-GENE
transfer	I-GENE
protein	I-GENE
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
88%	O
homologous	O
to	O
that	O
of	O
hNUC	B-GENE
I	I-GENE
,	O
isolated	O
from	O
human	O
osteosarcoma	O
cells	O
.	O

The	O
experimental	O
end	O
points	O
were	O
the	O
time	O
required	O
for	O
treated	O
tumors	O
to	O
reach	O
3	O
times	O
their	O
treatment	O
size	O
,	O
the	O
survival	O
of	O
stem	O
cells	O
in	O
the	O
duodenal	O
crypts	O
,	O
and	O
the	O
breathing	O
rate	O
measured	O
early	O
(	O
19-23	O
weeks	O
)	O
and	O
late	O
(	O
41-46	O
weeks	O
)	O
after	O
treatment	O
.	O

Recruitment	O
of	O
an	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
complex	I-GENE
is	O
mediated	O
by	O
the	O
constitutive	O
activation	O
domain	O
in	O
CREB	B-GENE
,	O
independently	O
of	O
CREB	B-GENE
phosphorylation	O
.	O

The	O
potential	O
for	O
highly	O
reactive	O
nanoparticles	O
(	O
RNP	O
)	O
to	O
absorb	O
destructively	O
,	O
i	O
.	O
e	O
.	O
to	O
neutralize	O
highly	O
toxic	O
substances	O
such	O
as	O
the	O
warfare	O
agents	O
GA	O
,	O
GB	O
,	O
HD	O
and	O
VX	O
,	O
has	O
been	O
demonstrated	O
in	O
the	O
laboratory	O
.	O

The	O
procedure	O
is	O
less	O
aggressive	O
and	O
painful	O
than	O
sternotomy	O
.	O

Treatment	O
of	O
keratinocytes	O
expressing	O
a	O
normal	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
EGFR	B-GENE
)	O
with	O
TGFalpha	B-GENE
or	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
for	O
5	O
min	O
induced	O
PKCdelta	B-GENE
tyrosine	O
phosphorylation	O
.	O

SV	O
increased	O
less	O
in	O
SHR	O
,	O
mainly	O
reflecting	O
the	O
reduced	O
diastolic	O
compliance	O
of	O
the	O
hypertrophied	O
SHR	O
left	O
ventricle	O
and	O
the	O
consequent	O
rightward	O
shift	O
of	O
its	O
Frank-Starling	O
curve	O
.	O

The	O
first	O
transfusion	O
resulted	O
in	O
a	O
platelet	O
increment	O
to	O
32	O
Gpt	O
/	O
l	O
(	O
CCI	O
11	O
)	O
.	O

We	O
also	O
mapped	O
a	O
3'-polyadenylation	O
site	O
504bp	O
downstream	O
of	O
the	O
TGA	O
stop	O
codon	O
,	O
consistent	O
with	O
the	O
2	O
.	O
5kb	O
transcript	O
size	O
.	O

265	O
,	O
1102-1110	O
)	O
.	O

As	O
an	O
oral	O
,	O
nontoxic	O
compound	O
with	O
a	O
mechanism	O
of	O
action	O
distinct	O
from	O
that	O
of	O
ABL	B-GENE
tyrosine	I-GENE
kinase	I-GENE
inhibition	O
,	O
FTI	O
SCH66336	O
shows	O
promise	O
for	O
the	O
treatment	O
of	O
BCR	O
/	O
ABL-induced	O
leukemia	O
.	O

REM	O
sleep	O
deprivation	O
was	O
performed	O
using	O
the	O
platform	O
technique	O
.	O

Genomic	O
locus	O
of	O
chCTCF	B-GENE
contains	O
a	O
GC-rich	O
untranslated	O
exon	O
separated	O
from	O
seven	O
coding	O
exons	O
by	O
a	O
long	O
intron	O
.	O

Primary	O
and	O
secondary	O
structural	O
elements	O
required	O
for	O
synthesis	O
of	O
barley	O
yellow	O
dwarf	O
virus	O
subgenomic	O
RNA1	O
.	O

Heparin	O
(	O
100	O
Ucenter	O
dotkg	O
(	O
minus	O
sign1	O
)	O
center	O
dotday	O
(	O
minus	O
sign1	O
)	O
)	O
was	O
injected	O
subcutaneously	O
to	O
the	O
rats	O
in	O
H	O
group	O
while	O
normal	O
saline	O
to	O
those	O
in	O
N	O
group	O
once	O
a	O
day	O
.	O

Deletion	O
and	O
site-directed	O
mutagenesis	O
localized	O
a	O
novel	O
SF-1	B-GENE
regulatory	I-GENE
element	I-GENE
(	O
TCA	B-GENE
GGGCCA	I-GENE
;	O
-137	O
to	O
-129	O
)	O
adjacent	O
to	O
a	O
variant	O
cAMP-response	B-GENE
element	I-GENE
(	O
CRE	B-GENE
;	O
-120	O
to	O
-114	O
)	O
.	O

If	O
we	O
apply	O
the	O
finding	O
of	O
non-visualization	O
of	O
the	O
GB	O
at	O
4	O
h	O
post	O
injection	O
as	O
the	O
criterion	O
for	O
the	O
diagnosis	O
of	O
AC	O
,	O
the	O
diagnostic	O
accuracy	O
was	O
only	O
40	O
.	O
7%	O
(	O
11	O
/	O
27	O
)	O
.	O

Regional	O
insertional	O
mutagenesis	O
of	O
specific	O
genes	O
on	O
the	O
CIC5F11	B-GENE
/	I-GENE
CIC2B9	I-GENE
locus	I-GENE
of	O
Arabidopsis	O
thaliana	O
chromosome	O
5	O
using	O
the	O
Ac	B-GENE
/	I-GENE
Ds	I-GENE
transposon	I-GENE
in	O
combination	O
with	O
the	O
cDNA	O
scanning	O
method	O
.	O

Two	O
remotely	O
situated	O
exons	O
within	O
the	O
complement	B-GENE
C3	I-GENE
gene	O
locus	O
encode	O
an	O
alternate	O
5'	O
end	O
and	O
proximal	O
ORF	O
under	O
the	O
control	O
of	O
a	O
bidirectional	O
promoter	O
.	O

Three	O
of	O
the	O
short	O
ORFs	O
in	O
the	O
central	O
region	O
of	O
BIV	O
have	O
been	O
identified	O
by	O
location	O
and	O
structural	O
similarity	O
to	O
the	O
nonstructural	O
/	O
regulatory	O
genes	O
(	O
vif	B-GENE
,	O
tat	B-GENE
,	O
and	O
rev	B-GENE
)	O
of	O
other	O
lentiviruses	O
;	O
we	O
also	O
discovered	O
two	O
unique	O
ORFs	O
,	O
termed	O
W	B-GENE
and	O
Y	B-GENE
,	O
which	O
may	O
serve	O
as	O
exons	O
for	O
novel	O
genes	O
.	O

This	O
dependence	O
,	O
however	O
,	O
can	O
be	O
overcome	O
to	O
a	O
large	O
extent	O
by	O
dividing	O
min	O
LVdP	O
/	O
dt	O
by	O
mean	O
aortic	O
pressure	O
.	O

A	O
randomized	O
clinical	O
trial	O
in	O
sixty-two	O
adult	O
patients	O
suffering	O
from	O
typhoid	O
fever	O
,	O
proved	O
by	O
blood	O
and	O
marrow	O
culture	O
,	O
showed	O
that	O
amoxycillin	O
in	O
a	O
dosage	O
schedule	O
of	O
1	O
g	O
8-hourly	O
orally	O
for	O
fourteen	O
days	O
was	O
better	O
than	O
chloramphenicol	O
with	O
regard	O
to	O
clinical	O
and	O
temperature	O
response	O
and	O
in	O
respect	O
of	O
carriers	O
and	O
relapse	O
rates	O
.	O

The	O
systolic	O
pressure	O
gradient	O
(	O
SPG	O
)	O
between	O
the	O
left	O
ventricle	O
(	O
LV	O
)	O
and	O
left	O
atrium	O
(	O
LA	O
)	O
was	O
obtained	O
from	O
high-fidelity	O
pressure	O
transducers	O
.	O

Serum	B-GENE
PTH	I-GENE
tended	O
to	O
increase	O
in	O
the	O
WL	O
group	O
but	O
not	O
in	O
the	O
WM	O
group	O
(	O
P	O
<	O
0	O
.	O
06	O
)	O
.	O

When	O
multiple	O
copies	O
of	O
the	O
IL-1	B-GENE
beta	I-GENE
NF-kappa	B-GENE
B	I-GENE
site	I-GENE
were	O
linked	O
to	O
an	O
enhancerless	O
simian	O
virus	O
40	O
promoter	O
,	O
this	O
element	O
was	O
able	O
to	O
mediate	O
phorbol	O
ester-	O
or	O
lipopolysaccharide-inducible	O
gene	O
expression	O
.	O

The	O
ability	O
of	O
BCL-6	B-GENE
to	O
function	O
as	O
a	O
transcriptional	O
repressor	O
may	O
contribute	O
to	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
in	O
diffuse	O
large	O
cell	O
lymphoma	O
.	O

Recipients	O
with	O
acute	O
leukaemia	O
in	O
first	O
remission	O
or	O
chronic	O
myeloid	O
leukaemia	O
in	O
first	O
chronic	O
phase	O
were	O
analysed	O
as	O
good	O
risk	O
,	O
and	O
those	O
beyond	O
these	O
stages	O
,	O
as	O
poor	O
risk	O
patients	O
.	O

It	O
can	O
also	O
be	O
used	O
to	O
examine	O
various	O
laryngeal	O
parameters	O
obtained	O
from	O
videotaped	O
endoscopic	O
and	O
stroboscopic	O
examinations	O
.	O

Chemotherapy	O
of	O
metastasizing	O
breast	O
cancer	O
.	O

Diagnostic	O
value	O
of	O
serum	B-GENE
myoglobin	I-GENE
in	O
cases	O
of	O
neuromuscular	O
disease	O
.	O

We	O
found	O
the	O
following	O
:	O
Specific	O
mutations	O
affected	O
the	O
precise	O
carbohydrate	O
structure	O
and	O
folding	O
of	O
the	O
HA	B-GENE
trimer	I-GENE
.	O

The	O
patients	O
undergoing	O
VTLB	O
had	O
significantly	O
shorter	O
operative	O
times	O
(	O
VTLB	O
,	O
100	O
.	O
2	O
+	O
/	O
-	O
27	O
.	O
2	O
min	O
.	O
vs	O
OLB	O
,	O
119	O
.	O
8	O
+	O
/	O
-	O
42	O
.	O
6	O
min	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
less	O
blood	O
loss	O
(	O
VTLB	O
,	O
4	O
.	O
7	O
+	O
/	O
-	O
14	O
.	O
6	O
ml	O
vs	O
OLB	O
,	O
65	O
.	O
7	O
+	O
/	O
-	O
77	O
.	O
0	O
ml	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
'Newcastle'	O
model	O
,	O
which	O
is	O
based	O
on	O
Hotelling's	O
T2	O
statistic	O
,	O
proved	O
to	O
be	O
more	O
sensitive	O
and	O
diagnosed	O
a	O
systematic	O
displacement	O
for	O
three	O
prostate	O
patients	O
.	O

Validation	O
of	O
automated	O
systems--system	O
definition	O
.	O

Radioligand	O
binding	O
was	O
indistinguishable	O
for	O
both	O
transiently	O
expressed	O
constructs	O
.	O

A	O
22K	O
polypeptide	O
was	O
detected	O
as	O
a	O
translation	O
product	O
of	O
late	O
RNA	O
that	O
hybridized	O
to	O
this	O
DNA	O
fragment	O
.	O

Gastrointestinal	O
manifestations	O
of	O
systemic	O
sclerosis	O
.	O

Transient	O
transfection	O
experiments	O
revealed	O
that	O
Pax-8	B-GENE
isoforms	I-GENE
a	I-GENE
and	I-GENE
b	I-GENE
,	O
but	O
not	O
c	O
and	O
d	O
,	O
strongly	O
stimulate	O
transcription	O
from	O
a	O
promoter	O
containing	O
six	O
copies	O
of	O
a	O
paired-domain	B-GENE
recognition	I-GENE
sequence	I-GENE
.	O

Low-selenium	O
diet	O
has	O
a	O
human	O
unfavourable	O
impact	O
.	O

In	O
DNase	B-GENE
I	I-GENE
footprinting	O
protection	O
analysis	O
,	O
both	O
SFRE	B-GENE
and	O
ERE	B-GENE
regions	I-GENE
were	O
protected	O
by	O
glutathione	B-GENE
S-transferase-ERRalpha1	I-GENE
fusion	I-GENE
protein	I-GENE
.	O

In	O
the	O
BF	O
ECT	O
group	O
the-age	O
based	O
dose	O
would	O
have	O
been	O
similarly	O
dependent	O
on	O
the	O
initial	O
seizure	O
threshold	O
level	O
.	O

CONCLUSIONS	O
:	O
The	O
mechanism	O
of	O
MIRI	O
is	O
Qi	O
deficiency	O
and	O
blood	O
stasis	O
in	O
TCM	O
,	O
its	O
treating	O
principles	O
should	O
be	O
promoting	O
Qi	O
and	O
removing	O
the	O
blood	O
stasis	O
.	O

Instead	O
,	O
mRNA	O
of	O
2	O
.	O
0	O
and	O
2	O
.	O
8	O
kb	O
are	O
detected	O
in	O
varying	O
abundance	O
.	O

Transcription	O
from	O
adenovirus	B-GENE
E2-early	I-GENE
promoter	I-GENE
is	O
controlled	O
by	O
a	O
unique	O
array	O
of	O
four	O
cis-acting	O
elements	O
which	O
include	O
an	O
atypical	O
TBP	B-GENE
site	I-GENE
,	O
two	O
E2F	B-GENE
sites	I-GENE
present	O
in	O
an	O
inverted	O
orientation	O
relative	O
to	O
each	O
other	O
,	O
and	O
an	O
ATF	B-GENE
site	I-GENE
.	O

Three	O
women	O
have	O
had	O
abnormal	O
endocervical	O
follow	O
up	O
cytology	O
suggestive	O
of	O
residual	O
disease	O
.	O

Clone	O
pSRc200	O
hybrid	O
selected	O
an	O
mRNA	O
that	O
on	O
cell-free	O
translation	O
produced	O
a	O
38-kDa	O
polypeptide	O
.	O

More	O
generally	O
,	O
Ets1	B-GENE
and	O
Ets2	B-GENE
could	O
regulate	O
transcription	O
of	O
cellular	O
genes	O
.	O

The	O
cdr1	B-GENE
sequence	I-GENE
includes	O
an	O
additional	O
237	O
amino	O
acids	O
of	O
the	O
contiguous	O
fragment	O
and	O
encodes	O
a	O
product	O
of	O
predicted	O
Mr	O
67	O
,	O
000	O
.	O

In	O
14	O
cases	O
,	O
isolates	O
were	O
biotyped	O
yielding	O
eight	O
with	O
biotype	O
II	O
,	O
four	O
with	O
biotype	O
III	O
,	O
and	O
one	O
each	O
with	O
biotypes	O
IV	O
and	O
V	O
.	O

In	O
one	O
,	O
exploratory	O
behavior	O
(	O
assessed	O
by	O
hole	O
pokes	O
)	O
and	O
locomotion	O
were	O
assessed	O
during	O
a	O
10-min	O
test	O
session	O
.	O

Sequence	O
analysis	O
of	O
these	O
regions	O
showed	O
a	O
CAAT	O
box	O
upstream	O
of	O
exon	O
1a	O
and	O
high	O
G-C	O
content	O
regions	O
within	O
both	O
P1	B-GENE
and	O
P2	B-GENE
.	O

Both	O
reduced	O
spontaneous	O
locomotor	O
activity	O
in	O
mice	O
,	O
protected	O
them	O
from	O
death	O
from	O
amphetamine	O
induced	O
toxicity	O
,	O
prolonged	O
hexobarbitone	O
sleeping	O
time	O
and	O
caused	O
a	O
depletion	O
of	O
catecholamines	O
from	O
various	O
organs	O
of	O
the	O
rat	O
.	O

This	O
construct	O
,	O
termed	O
pDeltaCREC	B-GENE
/	I-GENE
EBP	I-GENE
,	O
binds	O
C	B-GENE
/	I-GENE
EBPalpha	I-GENE
and	I-GENE
beta	I-GENE
but	O
not	O
CREB	B-GENE
,	O
yet	O
it	O
confers	O
a	O
nearly	O
complete	O
glucocorticoid	O
response	O
when	O
transiently	O
transfected	O
into	O
H4IIE	O
rat	O
hepatoma	O
cells	O
.	O

The	O
region	O
containing	O
both	O
serines	O
is	O
homologous	O
to	O
the	O
N-terminal	O
destruction	O
box	O
of	O
IkappaBalpha	B-GENE
,	I-GENE
-beta	I-GENE
,	I-GENE
and	I-GENE
-epsilon	I-GENE
.	O

Echinococcus	O
granulosus	O
was	O
diagnosed	O
by	O
fine-needle	O
aspiration	O
cytology	O
of	O
a	O
lung	O
cyst	O
in	O
a	O
6-yr-old	O
white	O
female	O
in	O
central	O
Missouri	O
.	O

Herein	O
,	O
we	O
show	O
that	O
Smad3	B-GENE
physically	O
interacts	O
with	O
the	O
HMG	B-GENE
box	I-GENE
domain	I-GENE
of	O
LEF1	B-GENE
and	O
that	O
TGFbeta	B-GENE
and	O
Wnt	B-GENE
pathways	I-GENE
synergize	O
to	O
activate	O
transcription	O
of	O
the	O
Xenopus	B-GENE
homeobox	I-GENE
gene	I-GENE
twin	B-GENE
(	O
Xtwn	B-GENE
)	O
.	O

The	O
association	O
of	O
clopamide	O
and	O
hydergine	O
(	O
Brinedine	O
)	O
in	O
the	O
treatment	O
of	O
the	O
vasculo-renal	O
syndromes	O
of	O
pregnancy	O
.	O

Thromboelastography	O
is	O
a	O
test	O
that	O
could	O
potentially	O
correlate	O
with	O
the	O
degree	O
of	O
anticoagulation	O
produced	O
by	O
low	O
molecular	O
weight	O
heparin	O
.	O

Using	O
the	O
postural	O
and	O
force	O
data	O
as	O
input	O
to	O
a	O
3-D	O
biomechanical	O
model	O
,	O
the	O
lumbosacral	O
spinal	O
compression	O
was	O
calculated	O
.	O

Within	O
12	O
hours	O
after	O
MR	O
tomography	O
the	O
patients	O
were	O
surgically	O
explored	O
,	O
biopsied	O
and	O
if	O
necessary	O
orchiectomised	O
.	O

The	O
human	O
protein	O
sequence	O
exhibits	O
a	O
putative	O
DNA-binding	O
domain	O
similar	O
to	O
that	O
seen	O
in	O
rat	B-GENE
HBP1	I-GENE
and	O
shows	O
homology	O
with	O
the	O
activation	O
and	O
repressor	O
domains	O
previously	O
demonstrated	O
in	O
the	O
rat	O
protein	O
.	O

These	O
results	O
demonstrate	O
that	O
EKLF	B-GENE
provides	O
a	O
crucial	O
transactivation	O
function	O
for	O
globin	B-GENE
expression	O
and	O
further	O
reinforce	O
the	O
idea	O
that	O
EKLF	B-GENE
is	O
an	O
important	O
regulator	O
of	O
CACCC	O
element-directed	O
transcription	O
in	O
erythroid	O
cells	O
.	O

Although	O
the	O
DSK2-1	B-GENE
mutation	I-GENE
alters	O
a	O
conserved	O
residue	O
in	O
the	O
Dsk2p	B-GENE
ubiquitin-like	B-GENE
domain	I-GENE
,	O
we	O
detect	O
no	O
differences	O
in	O
Dsk2p	B-GENE
or	O
Cdc31p	B-GENE
stability	O
.	O

Characteristics	O
of	O
lipase	B-GENE
activity	O
.	O

The	O
complete	O
cDNA	O
sequence	O
of	O
human	B-GENE
betaV	I-GENE
spectrin	I-GENE
is	O
available	O
from	O
GenBank	O
(	O
TM	O
)	O
as	O
accession	O
number	O
.	O

Although	O
the	O
effects	O
of	O
the	O
calcium	O
supplement	O
or	O
calcium	O
antagonist	O
alone	O
were	O
significant	O
,	O
such	O
hypotensive	O
responses	O
were	O
not	O
optimal	O
or	O
predictable	O
or	O
clearly	O
dose-dependent	O
.	O

At	O
a	O
PaCO2	O
of	O
40	O
mmHg	O
,	O
baseline	O
brain	O
pHi	O
measured	O
7	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
while	O
regional	O
cortical	O
blood	O
flow	O
was	O
47	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
3	O
ml	O
.	O
100	O
g-1	O
.	O
min-1	O
.	O

In	O
contrast	O
,	O
the	O
neu	B-GENE
proto-oncogene	I-GENE
did	O
not	O
show	O
kinase	O
activity	O
or	O
transforming	O
properties	O
when	O
expressed	O
at	O
similar	O
levels	O
in	O
NIH	O
3T3	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
CVA16	B-GENE
.	I-GENE
4	I-GENE
proteolipid	I-GENE
transcript	I-GENE
is	O
the	O
most	O
prevalent	O
of	O
the	O
two	O
proteolipid	O
messages	O
in	O
expanding	O
ovules	O
harvested	O
10	O
d	O
post-anthesis	O
.	O

Furthermore	O
,	O
interactions	O
were	O
identified	O
between	O
endogenous	B-GENE
E-cadherin	I-GENE
and	O
the	O
chimera	O
containing	O
the	O
E-cadherin	B-GENE
extracellular	I-GENE
domain	I-GENE
and	O
the	O
desmoglein	B-GENE
1	I-GENE
intracellular	I-GENE
domain	I-GENE
providing	O
in	O
vivo	O
evidence	O
for	O
previously	O
predicted	O
lateral	O
interactions	O
of	O
E-cadherin	B-GENE
extracellular	I-GENE
domains	I-GENE
.	O

No	O
UOxase	B-GENE
mRNA	I-GENE
was	O
detected	O
in	O
11	O
nonhepatic	O
tissues	O
of	O
rat	O
,	O
suggesting	O
tissue	O
specificity	O
of	O
expression	O
of	O
this	O
UOxase	B-GENE
gene	I-GENE
.	O

CONCLUSION	O
:	O
We	O
were	O
unable	O
to	O
identify	O
features	O
of	O
disease	O
likely	O
to	O
be	O
associated	O
with	O
a	O
clinically	O
useful	O
response	O
to	O
inhaled	O
NO	O
therapy	O
using	O
the	O
parameters	O
studied	O
.	O

High	O
levels	O
of	O
IC	O
coincided	O
with	O
relative	O
hypocomplementemia	O
.	O

The	O
CAPLC1	B-GENE
protein	I-GENE
also	O
exhibited	O
several	O
unique	O
features	O
,	O
including	O
a	O
novel	O
stretch	O
of	O
18-19	O
amino	O
acid	O
residues	O
within	O
the	O
X	B-GENE
domain	I-GENE
and	O
an	O
unusually	O
long	O
N-terminus	O
which	O
did	O
not	O
contain	O
a	O
recognizable	O
EF-hand	B-GENE
Ca	I-GENE
(	I-GENE
2+	I-GENE
)	I-GENE
-binding	I-GENE
domain	I-GENE
.	O

Besides	O
the	O
characterization	O
and	O
discussion	O
of	O
the	O
experimental	O
setup	O
used	O
,	O
the	O
rate	O
constants	O
obtained	O
are	O
discussed	O
and	O
compared	O
with	O
estimated	O
values	O
.	O

We	O
consider	O
that	O
DIL-CP	O
is	O
a	O
safe	O
and	O
excellent	O
CP	O
in	O
CABG	O
surgery	O
and	O
we	O
are	O
now	O
utilizing	O
this	O
CP	O
in	O
all	O
patients	O
requiring	O
CABG	O
surgery	O
.	O

Isolation	O
of	O
a	O
temperature-sensitive	O
mutant	O
with	O
an	O
altered	O
tRNA	B-GENE
nucleotidyltransferase	I-GENE
and	O
cloning	O
of	O
the	O
gene	B-GENE
encoding	I-GENE
tRNA	I-GENE
nucleotidyltransferase	I-GENE
in	I-GENE
the	I-GENE
yeast	I-GENE
Saccharomyces	I-GENE
cerevisiae	I-GENE
.	O

Measurement	O
of	O
open-loop	O
responses	O
to	O
electrical	O
stimulation	O
in	O
olfactory	O
bulb	O
of	O
cat	O
.	O

Finally	O
,	O
we	O
present	O
evidence	O
that	O
fimbrin	B-GENE
is	O
a	O
third	O
distinct	O
plastin	B-GENE
isoform	I-GENE
which	O
is	O
specifically	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
small	O
intestine	O
.	O

The	O
UV	O
absorption	O
spectrum	O
revealed	O
a	O
shoulder	O
at	O
250	O
nm	O
,	O
characteristic	O
of	O
CysS-Cd	O
(	O
II	O
)	O
ligand-to-metal	O
charge-transfer	O
transitions	O
,	O
and	O
the	O
difference	O
absorption	O
coefficient	O
after	O
acidification	O
(	O
delta	O
epsilon	O
248	O
,	O
24	O
mM-1	O
cm-1	O
)	O
indicated	O
the	O
presence	O
of	O
a	O
Cd	O
(	O
Cys-S	O
)	O
4	O
center	O
.	O

Growth	B-GENE
hormone	I-GENE
and	O
insulin-like	B-GENE
growth	I-GENE
factor	I-GENE
I	I-GENE
receptors	I-GENE
in	O
the	O
temporomandibular	O
joint	O
of	O
the	O
rat	O
.	O

Adverse	O
foetal	O
outcome	O
in	O
specific	O
IgM	B-GENE
positive	O
Chlamydia	O
trachomatis	O
infection	O
in	O
pregnancy	O
.	O

On	O
the	O
basis	O
of	O
size	O
,	O
the	O
CRS	B-GENE
sequence	I-GENE
to	O
which	O
it	O
binds	O
,	O
and	O
its	O
tentative	O
identification	O
as	O
a	O
zinc	B-GENE
finger	I-GENE
protein	I-GENE
,	O
Adx	B-GENE
factor	I-GENE
has	O
been	O
identified	O
as	O
a	O
Kruppel-like	B-GENE
zinc	I-GENE
finger	I-GENE
protein	I-GENE
(	O
a	O
mouse	B-GENE
ZBP-89	I-GENE
homologue	I-GENE
)	O
.	O

STP1	B-GENE
is	O
an	O
unessential	O
yeast	O
gene	O
involved	O
in	O
the	O
removal	O
of	O
intervening	O
sequences	O
from	O
some	O
,	O
but	O
not	O
all	O
,	O
families	O
of	O
intervening	O
sequence-containing	O
pre-tRNAs	O
.	O

The	O
downstream	O
,	O
TATA-less	O
promoter	O
has	O
high	O
G+C	O
content	O
,	O
and	O
exon	O
1b	O
predominates	O
among	O
abundantly	O
expressed	O
mRNA	O
species	O
.	O

Both	O
P5CDh	B-GENE
cDNA	I-GENE
clones	O
detect	O
a	O
single	O
3	O
.	O
2-kb	O
transcript	O
on	O
Northern	O
blots	O
of	O
multiple	O
human	O
tissues	O
,	O
indicating	O
the	O
long	O
cDNA	O
containing	O
the	O
3'-untranslated	O
intron	O
represents	O
the	O
predominant	O
transcript	O
.	O

Although	O
there	O
are	O
no	O
octamer	O
elements	O
in	O
the	O
adenovirus	O
genome	O
that	O
are	O
known	O
to	O
be	O
important	O
for	O
transcription	O
,	O
there	O
are	O
octamer	O
elements	O
in	O
the	O
viral	O
terminal	O
repeat	O
sequences	O
.	O

Carcinoembryonic	B-GENE
antigen	I-GENE
(	O
CEA	B-GENE
)	O
procedures	O
and	O
clinical	O
evaluation	O
.	O
pp	O
.	O

Functional	O
recognition	O
of	O
5'	O
splice	O
site	O
by	O
U4	B-GENE
/	I-GENE
U6	I-GENE
.	I-GENE
U5	I-GENE
tri-snRNP	I-GENE
defines	O
a	O
novel	O
ATP-dependent	O
step	O
in	O
early	O
spliceosome	O
assembly	O
.	O

Acylation	O
with	O
the	O
palmitate	O
analog	O
was	O
prevented	O
when	O
Gly-2	O
was	O
mutated	O
to	O
alanine	O
,	O
implying	O
that	O
N-myristylation	O
is	O
required	O
for	O
palmitylation	O
,	O
and	O
when	O
either	O
Cys-3	O
or	O
Cys-6	O
was	O
mutated	O
to	O
serine	O
.	O

Follow-up	O
controls	O
of	O
luteinizing	B-GENE
hormone	I-GENE
(	O
LH	B-GENE
)	O
,	O
follicle	B-GENE
stimulating	I-GENE
hormone	I-GENE
(	O
FSH	B-GENE
)	O
,	O
prolactin	B-GENE
(	O
HPRL	B-GENE
)	O
,	O
oestradiol	O
(	O
E2	O
)	O
,	O
progesterone	O
(	O
P	O
)	O
and	O
testosterone	O
(	O
T	O
)	O
in	O
the	O
catabolic	O
and	O
healing	O
phase	O
of	O
burn	O
disease	O
.	O

Confirming	O
measures	O
made	O
by	O
nurses	O
and	O
additionally	O
,	O
ABPM	O
for	O
women	O
,	O
seem	O
to	O
lessen	O
this	O
effect	O
.	O

The	O
gene	B-GENE
cat-86	I-GENE
,	O
specifying	O
chloramphenicol-inducible	B-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
,	O
is	O
located	O
on	O
the	O
1	O
.	O
1-kilobase	O
cloned	O
DNA	O
.	O

Effects	O
of	O
perceptual	O
salience	O
on	O
the	O
matrix	O
task	O
performance	O
of	O
four-	O
and	O
six-year-old	O
children	O
.	O

UDP-GlcNAc	B-GENE
:	O
alpha-6-D-mannoside	B-GENE
beta-1	I-GENE
,	I-GENE
2-N-acetylglucosaminyltransferase	I-GENE
II	I-GENE
(	O
GnT	B-GENE
II	I-GENE
;	O
EC	B-GENE
2	I-GENE
.	I-GENE
4	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
143	I-GENE
)	O
is	O
essential	O
for	O
the	O
normal	O
assembly	O
of	O
complex	O
Asn-linked	O
glycans	O
.	O

The	O
MET4	B-GENE
gene	O
was	O
cloned	O
,	O
and	O
its	O
sequence	O
reveals	O
that	O
it	O
encodes	O
a	O
protein	O
related	O
to	O
the	O
family	O
of	O
the	O
bZIP	B-GENE
transcriptional	I-GENE
activators	I-GENE
.	O

This	O
region	O
of	O
hsp90	B-GENE
mediates	O
ATP-independent	O
chaperone	B-GENE
activity	O
,	O
overlaps	O
the	O
hsp90	B-GENE
dimerization	I-GENE
domain	I-GENE
,	O
and	O
includes	O
structural	O
elements	O
important	O
for	O
steroid	B-GENE
receptor	I-GENE
interaction	O
.	O

The	O
novel	O
Notch	B-GENE
homologue	I-GENE
mouse	B-GENE
Notch	I-GENE
3	I-GENE
lacks	O
specific	O
epidermal	B-GENE
growth	I-GENE
factor-repeats	I-GENE
and	O
is	O
expressed	O
in	O
proliferating	O
neuroepithelium	O
.	O

GGS1	B-GENE
is	O
the	O
same	O
gene	O
as	O
TPS1	B-GENE
which	O
was	O
identified	O
as	O
encoding	O
a	O
subunit	O
of	O
the	O
trehalose-6-phosphate	B-GENE
synthase	I-GENE
/	I-GENE
phosphatase	I-GENE
complex	I-GENE
and	O
it	O
is	O
allelic	O
to	O
the	O
fdp1	B-GENE
,	O
byp1	B-GENE
,	O
glc6	B-GENE
and	O
cif1	O
mutations	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
alternative	O
sigma	O
factor	O
,	O
RpoN	B-GENE
,	O
in	O
Rhodobacter	O
capsulatus	O
;	O
physiological	O
relevance	O
of	O
an	O
autoactivated	O
nifU2-rpoN	B-GENE
superoperon	O
.	O

Pneumonia	O
in	O
children	O
.	O

Statement	O
on	O
the	O
development	O
of	O
guidelines	O
for	O
the	O
prevention	O
of	O
AIDS	O
transmission	O
in	O
the	O
workplace	O
.	O

M-Ras	B-GENE
interacted	O
poorly	O
in	O
a	O
yeast	O
two-hybrid	O
assay	O
with	O
multiple	O
Ras	B-GENE
effectors	O
,	O
including	O
c-Raf-1	B-GENE
,	O
A-Raf	B-GENE
,	O
B-Raf	B-GENE
,	O
phosphoinositol-3	B-GENE
kinase	I-GENE
delta	I-GENE
,	O
RalGDS	B-GENE
,	O
and	O
Rin1	B-GENE
.	O

Isolation	O
and	O
characterization	O
of	O
SRF	B-GENE
accessory	I-GENE
proteins	I-GENE
.	O

The	O
3	O
.	O
3-fold	O
higher	O
expression	O
in	O
the	O
fetal	O
heart	O
than	O
in	O
the	O
adult	O
heart	O
suggests	O
that	O
HFHZ	B-GENE
mRNA	I-GENE
is	O
downregulated	O
in	O
the	O
process	O
of	O
development	O
.	O

On	O
an	O
antithrombin	O
unit	O
basis	O
,	O
CY	O
216	O
and	O
CY	O
222	O
were	O
equivalent	O
and	O
more	O
potent	O
than	O
UH	O
.	O

Marked	O
racial	O
variation	O
in	O
birthweight	O
percentiles	O
by	O
gestational	O
age	O
was	O
evident	O
.	O

2	O
-	O
Chemical	O
occlusion	O
of	O
vas	O
is	O
quite	O
effective	O
in	O
producing	O
a	O
block	O
in	O
the	O
vas	O
deferens	O
of	O
dogs	O
.	O

SPA	O
from	O
PAG	O
sites	O
was	O
associated	O
with	O
aversion	O
.	O

The	O
observation	O
of	O
late	O
effects	O
after	O
irradiations	O
or	O
after	O
space	O
flights	O
show	O
the	O
difficulties	O
encountered	O
in	O
assessing	O
radiative	O
risks	O
during	O
long	O
duration	O
space	O
flights	O
.	O

TEMTU	O
and	O
DPTU	O
were	O
the	O
most	O
potent	O
teratogens	O
.	O

An	O
intravenous	O
drip	O
infusion	O
of	O
AMK	O
in	O
adequate	O
dosage	O
would	O
be	O
beneficial	O
to	O
use	O
against	O
some	O
infectious	O
diseases	O
of	O
otorhinolaryngologic	O
field	O
.	O

Antithrombin	B-GENE
III	I-GENE
deficiency	O
:	O
when	O
substitute	O
,	O
when	O
heparin	O
?	O
Thrombosis	O
ABC	O
,	O
3	O
:	O
The	O
role	O
of	O
antithrombin	B-GENE
III	I-GENE
.	O

Identification	O
of	O
Ets-	B-GENE
and	I-GENE
notch-related	I-GENE
subunits	I-GENE
in	O
GA	B-GENE
binding	I-GENE
protein	I-GENE
.	O

40	O
patients	O
with	O
chronic	O
osteomyelitis	O
were	O
treated	O
per	O
os	O
with	O
the	O
bactericidal	O
beta-lactam-antibiotic	O
cephalexin	O
during	O
3	O
to	O
60	O
weeks	O
.	O

It	O
was	O
concluded	O
that	O
both	O
of	O
these	O
surgical	O
procedures	O
were	O
as	O
effective	O
as	O
pinealectomy	O
in	O
reversing	O
the	O
pineal-induced	O
alterations	O
in	O
the	O
reproductive	O
physiology	O
of	O
the	O
blind-anosmic	O
female	O
rat	O
.	O

Is	O
nisoldipine	O
capable	O
of	O
reducing	O
left	O
ventricular	O
preload	O
?	O
In	O
ten	O
anesthetized	O
pigs	O
,	O
nisoldipine	O
(	O
2-4	O
micrograms	O
X	O
kg-1	O
X	O
min-1	O
)	O
,	O
a	O
calcium	O
channel	O
blocker	O
structurally	O
related	O
to	O
nifedipine	O
,	O
reduced	O
left	O
ventricular	O
systolic	O
pressure	O
(	O
40%	O
)	O
and	O
systemic	O
vascular	O
resistance	O
(	O
35%	O
)	O
,	O
whereas	O
maxLVdP	O
/	O
dt	O
decreased	O
by	O
20%	O
and	O
cardiac	O
output	O
was	O
unchanged	O
.	O

In	O
a	O
reconstituted	O
human	O
DNA	O
repair	O
system	O
containing	O
DNA	B-GENE
polymerase	I-GENE
beta	I-GENE
and	O
DNA	B-GENE
ligase	I-GENE
III-XRCC1	I-GENE
,	O
accurate	O
rejoining	O
of	O
a	O
3'	O
mismatched	O
base	O
residue	O
at	O
a	O
single-strand	O
break	O
is	O
dependent	O
on	O
addition	O
of	O
the	O
exonuclease	B-GENE
.	O

Soluble	O
FasR	B-GENE
ligand-binding	O
domain	O
:	O
high-yield	O
production	O
of	O
active	O
fusion	O
and	O
non-fusion	O
recombinant	O
proteins	O
using	O
the	O
baculovirus	O
/	O
insect	O
cell	O
system	O
.	O

Furthermore	O
,	O
co-expression	O
of	O
both	O
p46	B-GENE
and	O
p54	B-GENE
subunits	I-GENE
markedly	O
altered	O
the	O
subcellular	O
distribution	O
of	O
p46	B-GENE
;	O
co-expressed	O
p46	B-GENE
was	O
transported	O
into	O
the	O
nucleus	O
as	O
efficiently	O
as	O
p54	B-GENE
.	O

Evaluation	O
of	O
myocardial	O
perfusion	O
by	O
99mTc-tetrofosmin	O
SPECT	O
before	O
and	O
after	O
emergent	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
for	O
acute	O
myocardial	O
infarction	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
p53	B-GENE
protein	I-GENE
contributes	O
to	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
through	O
recombinational	O
repair	O
.	O

Posttranslational	O
regulation	O
of	O
Ty1	B-GENE
retrotransposition	O
by	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
Fus3	I-GENE
.	O

Finally	O
,	O
we	O
determined	O
the	O
genomic	O
organization	O
of	O
the	O
human	B-GENE
TrxR2	I-GENE
gene	I-GENE
,	O
which	O
consists	O
of	O
18	O
exons	O
spanning	O
about	O
67	O
kb	O
,	O
and	O
its	O
chromosomal	O
localization	O
at	O
position	O
22q11	O
.	O
2	O
.	O

The	O
5'	O
flanking	O
region	O
contains	O
potential	O
binding	O
sites	O
for	O
TATA-binding	B-GENE
protein	I-GENE
,	O
Sp1	B-GENE
,	O
nuclear	B-GENE
factor	I-GENE
1	I-GENE
(	O
NF1	B-GENE
)	O
,	O
CAAT-box	B-GENE
binding	I-GENE
protein	I-GENE
(	O
C	B-GENE
/	I-GENE
EBP	I-GENE
)	O
,	O
hepatocyte	B-GENE
nuclear	I-GENE
factors	I-GENE
1	I-GENE
and	I-GENE
5	I-GENE
(	O
HNF1	B-GENE
,	O
HNF5	B-GENE
)	O
and	O
activator	B-GENE
proteins	I-GENE
1	I-GENE
and	I-GENE
2	I-GENE
(	O
AP1	B-GENE
,	O
AP2	B-GENE
)	O
.	O

The	O
most	O
likely	O
explanation	O
for	O
this	O
is	O
that	O
gold	O
principally	O
accumulates	O
in	O
the	O
Kupffer	O
cells	O
and	O
renal	O
cortex	O
and	O
these	O
cells	O
do	O
not	O
express	O
Type	B-GENE
I	I-GENE
deiodinase	I-GENE
.	O

The	O
importance	O
of	O
this	O
new	O
epidemiological	O
profile	O
of	O
schistosomiasis	O
in	O
the	O
State	O
of	O
Pernambuco	O
relies	O
on	O
the	O
fact	O
that	O
it	O
can	O
be	O
related	O
with	O
the	O
drastic	O
human	O
interference	O
on	O
the	O
environment	O
.	O

All	O
nuclear	O
receptors	O
have	O
several	O
well-characterized	O
structural	O
domains	O
,	O
including	O
a	O
conserved	O
DNA-binding	O
domain	O
,	O
and	O
a	O
ligand	O
binding	O
domain	O
at	O
the	O
carboxyl	O
terminus	O
of	O
the	O
receptor	O
.	O

New	O
alkaloids	O
from	O
bark	O
of	O
Erythrophleum	O
ivorense	O
.	O

In	O
order	O
to	O
investigate	O
to	O
what	O
extent	O
this	O
interaction	O
might	O
contribute	O
to	O
tumor	O
induction	O
by	O
the	O
virus	O
,	O
we	O
have	O
introduced	O
two	O
different	O
point	O
mutations	O
within	O
the	O
putative	O
pRb-binding	B-GENE
sequence	I-GENE
of	O
large	B-GENE
T	I-GENE
antigen	I-GENE
,	O
and	O
as	O
a	O
preliminary	O
to	O
in	O
vivo	O
experiments	O
we	O
have	O
studied	O
their	O
effects	O
in	O
vitro	O
on	O
some	O
biological	O
activities	O
relevant	O
to	O
tumor	O
induction	O
.	O

However	O
,	O
calphostin	O
C	O
,	O
a	O
specific	O
inhibitor	O
of	O
PKC	B-GENE
,	O
abolished	O
the	O
TPA-induced	O
increase	O
in	O
CFI	B-GENE
mRNA	I-GENE
levels	O
.	O

An	O
intravenous	O
preparation	O
of	O
doxycycline	O
(	O
DOTC	O
,	O
Vibramycin	O
'Pfizer'	O
)	O
,	O
a	O
long-lasting	O
tetracycline	O
,	O
was	O
administered	O
mainly	O
by	O
drip	O
infusion	O
for	O
a	O
series	O
of	O
study	O
in	O
the	O
pediatrics	O
field	O
,	O
and	O
the	O
results	O
were	O
as	O
follows	O
:	O
1	O
)	O
DOTC	O
(	O
100	O
mg	O
)	O
was	O
dissolved	O
in	O
a	O
100	O
ml	O
of	O
glucose	O
solution	O
and	O
2--3	O
mg	O
/	O
kg	O
was	O
administered	O
intravenously	O
.	O

Cytomegalovirus	O
,	O
Chlamydia	O
pneumoniae	O
,	O
and	O
Helicobacter	O
pylori	O
IgG	B-GENE
antibodies	I-GENE
and	O
restenosis	O
after	O
stent	O
implantation	O
:	O
an	O
angiographic	O
and	O
intravascular	O
ultrasound	O
study	O
.	O

The	O
mechanism	O
by	O
which	O
E2-C	B-GENE
represses	O
E2-dependent	B-GENE
enhancer	I-GENE
activity	O
most	O
likely	O
involves	O
competition	O
with	O
E2	B-GENE
for	O
binding	O
to	O
a	O
common	O
transcriptional	O
regulatory	O
site	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Upon	O
serum	O
withdrawal	O
at	O
the	O
permissive	O
temperature	O
,	O
p53-mediated	O
apoptosis	O
was	O
induced	O
in	O
50	O
to	O
60%	O
of	O
the	O
cells	O
.	O

A	O
needs	O
assessment	O
of	O
these	O
families	O
was	O
also	O
done	O
.	O

Recording	O
of	O
the	O
digital	O
sphygmic	O
activity	O
in	O
the	O
lower	O
extremities	O
with	O
the	O
photoplethysmographic	O
and	O
strain-gauge	O
methods	O
.	O

No	O
positive	O
family	O
history	O
was	O
obtained	O
.	O

In	O
this	O
paper	O
we	O
describe	O
properties	O
of	O
the	O
cdc10-C4	B-GENE
mutant	I-GENE
of	I-GENE
the	I-GENE
fission	I-GENE
yeast	I-GENE
Schizosaccharomyces	I-GENE
pombe	I-GENE
.	O

Consistent	O
with	O
ErbB-2	B-GENE
being	O
a	O
shared	O
receptor	O
subunit	O
,	O
its	O
tyrosine	O
phosphorylation	O
was	O
increased	O
by	O
both	O
heterologous	O
ligands	O
and	O
it	O
mediated	O
a	O
trans-inhibitory	O
effect	O
of	O
NDF	B-GENE
on	O
EGF	B-GENE
binding	O
.	O

This	O
conformer	O
features	O
a	O
Type	O
I	O
beta-turn	O
and	O
has	O
extensive	O
hydrophobic	O
contacts	O
with	O
the	O
FKBP12	B-GENE
binding	O
surface	O
.	O

Endocytosis	O
and	O
vacuolar	O
degradation	O
of	O
the	O
plasma	O
membrane-localized	O
Pdr5	B-GENE
ATP-binding	I-GENE
cassette	I-GENE
multidrug	I-GENE
transporter	I-GENE
in	O
Saccharomyces	O
cerevisiae	O
.	O

Of	O
7	O
patients	O
treated	O
with	O
cyclophosphamide	O
,	O
hexamethylmelamine	O
,	O
adriamycin	O
and	O
cisplatin	O
(	O
CHAP-5	O
)	O
,	O
6	O
had	O
measurable	O
disease	O
,	O
of	O
whom	O
5	O
yielded	O
a	O
response	O
(	O
2	O
complete	O
responses	O
for	O
19+	O
and	O
40	O
months	O
and	O
3	O
partial	O
responses	O
for	O
4	O
,	O
7	O
and	O
8	O
months	O
)	O
.	O

Morphometrical	O
quantification	O
of	O
brain	O
edema	O
related	O
to	O
experimental	O
multiple	O
micro-infarcts	O
in	O
mice	O
:	O
assessment	O
of	O
neurotropin	O
effect	O
.	O

The	O
degree	O
of	O
lung	O
destruction	O
,	O
reflected	O
by	O
interstitial	O
hemorrhage	O
was	O
assessed	O
by	O
measuring	O
hemoglobin	B-GENE
content	O
in	O
the	O
fluid	O
of	O
the	O
lavaged	O
lungs	O
.	O

To	O
elucidate	O
the	O
functional	O
significance	O
of	O
Fyn	B-GENE
in	O
the	O
expression	O
of	O
viral	O
promoters	O
,	O
we	O
transfected	O
a	O
Fyn-expression	O
vector	O
together	O
with	O
a	O
reporter	O
plasmid	O
containing	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
gene	I-GENE
driven	O
by	O
HIV	B-GENE
LTR	I-GENE
into	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O

They	O
consist	O
of	O
at	O
least	O
two	O
separable	O
components	O
,	O
one	O
heat	O
stable	O
and	O
the	O
other	O
heat	O
labile	O
.	O

Polymyxin	O
B	O
was	O
given	O
intravenously	O
for	O
1	O
week	O
postburn	O
in	O
doses	O
designed	O
to	O
neutralize	O
circulating	O
endotoxemia	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
the	O
neuron-specific	B-GENE
SCG10	I-GENE
gene	I-GENE
evolved	O
by	O
duplication	O
and	O
modification	O
of	O
the	O
more	O
broadly	O
expressed	O
stathmin	B-GENE
/	I-GENE
Lap18	I-GENE
gene	I-GENE
.	O

We	O
studied	O
GSH-Px	B-GENE
enzyme	I-GENE
activity	O
in	O
serum	O
after	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
and	O
unstable	O
angina	O
pectoris	O
(	O
UAP	O
)	O
.	O

The	O
N-terminal	O
115	O
amino	O
acids	O
correspond	O
to	O
a	O
putative	O
DNA-binding	O
domain	O
and	O
show	O
significant	O
sequence	O
similarity	O
with	O
other	O
cloned	O
IFN	B-GENE
response	I-GENE
factors	I-GENE
(	O
IRF-1	B-GENE
and	O
IRF-2	B-GENE
)	O
.	O

OBJECTIVE	O
:	O
The	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
frequency	O
of	O
alterations	O
in	O
serum	O
creatinine	O
in	O
patients	O
with	O
psoriasis	O
receiving	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
cyclosporine	O
.	O

Thirty	O
isolates	O
of	O
Haemophilus	O
influenzae	O
type	O
b	O
were	O
obtained	O
during	O
an	O
outbreak	O
of	O
invasive	O
H	O
.	O
influenzae	O
type	O
b	O
disease	O
and	O
were	O
classified	O
by	O
the	O
electrophoretic	O
profile	O
of	O
their	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

A	O
combination	O
of	O
cisplatin	O
and	O
5-fluorouracil	O
,	O
both	O
administered	O
4	O
days	O
continuously	O
as	O
infusion	O
,	O
was	O
assessed	O
in	O
advanced	O
head	O
and	O
neck	O
cancer	O
.	O

NE	B-GENE
and	O
PR3	B-GENE
assist	O
in	O
the	O
destruction	O
of	O
phagocytosed	O
microorganisms	O
,	O
cleave	O
the	O
important	O
connective-tissue	B-GENE
protein	I-GENE
elastin	I-GENE
,	O
and	O
generate	O
chemotactic	O
activities	O
by	O
forming	O
alpha	B-GENE
1-proteinase	I-GENE
inhibitor	I-GENE
complexes	I-GENE
and	O
elastin	B-GENE
peptides	I-GENE
.	O

They	O
suggest	O
that	O
decreased	O
steady-state	O
levels	O
of	O
IME1	B-GENE
and	O
IME2	B-GENE
mRNA	I-GENE
were	O
not	O
merely	O
the	O
result	O
of	O
non-specific	O
adverse	O
affects	O
on	O
nucleic	O
acid	O
metabolism	O
caused	O
by	O
the	O
yvh1	B-GENE
disruption	O
.	O

Blood	O
levels	O
of	O
melatonin	O
,	O
serotonin	O
,	O
cortisol	O
,	O
and	O
prolactin	B-GENE
in	O
relation	O
to	O
the	O
circadian	O
rhythm	O
of	O
platelet	O
serotonin	O
uptake	O
.	O

Induction	O
of	O
correctly	O
spliced	O
germline	O
transcripts	O
is	O
necessary	O
to	O
target	O
a	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

A	O
narrow	O
zone	O
of	O
myelin-axonal	O
dissociation	O
was	O
also	O
observed	O
.	O

Tranilast	O
in	O
the	O
Therapy	O
of	O
Coronary	O
Artery	O
Disease	O
.	O

Analysis	O
of	O
this	O
sequence	O
combined	O
with	O
that	O
previously	O
reported	O
for	O
the	O
5'-flanking	O
region	O
directly	O
proximal	O
to	O
the	O
start	O
of	O
transcription	O
revealed	O
several	O
putative	O
regulatory	O
sequences	O
.	O

Polyadenylation	O
of	O
B4	B-GENE
RNA	I-GENE
,	O
which	O
occurs	O
very	O
early	O
during	O
maturation	O
,	O
is	O
limited	O
to	O
150	O
residues	O
,	O
and	O
it	O
is	O
this	O
number	O
that	O
is	O
required	O
for	O
polysomal	O
recruitment	O
.	O

In	O
comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
four	O
RNA	O
editing	O
events	O
were	O
found	O
in	O
both	O
atp9	B-GENE
genes	I-GENE
.	O

We	O
show	O
that	O
these	O
three	O
gain-of-function	O
mutants	O
differ	O
considerably	O
in	O
their	O
ability	O
to	O
bypass	O
the	O
sex	O
determination	O
signal	O
,	O
with	O
SxlM4	B-GENE
being	O
the	O
strongest	O
and	O
SxlM1	B-GENE
the	O
weakest	O
.	O

Overlapping	O
cDNA	O
clones	O
were	O
isolated	O
and	O
sequenced	O
.	O

Of	O
270	O
patients	O
with	O
well-defined	O
drug	O
reactions	O
,	O
190	O
(	O
70	O
per	O
cent	O
)	O
gave	O
a	O
positive	O
response	O
to	O
the	O
mast	O
cell	O
test	O
.	O

(	O
2	O
)	O
Diffusion	O
limitation	O
in	O
the	O
heterogeneous	O
model	O
sets	O
in	O
at	O
a	O
lower	O
O2	O
requirement	O
value	O
,	O
and	O
increases	O
more	O
gradually	O
with	O
increasing	O
O2	O
requirement	O
,	O
than	O
in	O
the	O
corresponding	O
homogeneous	O
models	O
with	O
the	O
same	O
average	O
cylinder	O
diameter	O
.	O

BACKGROUND	O
:	O
There	O
is	O
increasing	O
interest	O
on	O
the	O
part	O
of	O
investigators	O
and	O
the	O
public	O
at	O
large	O
in	O
finding	O
ways	O
to	O
study	O
and	O
improve	O
treatments	O
for	O
the	O
seriously	O
mentally	O
ill	O
without	O
exposing	O
such	O
individuals	O
to	O
unnecessary	O
risks	O
.	O

In	O
mammals	O
,	O
the	O
Rb	B-GENE
protein	I-GENE
interacts	O
specifically	O
with	O
D-type	B-GENE
cyclins	I-GENE
and	O
regulates	O
cell	O
proliferation	O
by	O
binding	O
and	O
inhibiting	O
E2F	B-GENE
transcription	I-GENE
factors	I-GENE
.	O

The	O
data	O
imply	O
that	O
JAK	B-GENE
/	I-GENE
STAT	I-GENE
signaling	O
has	O
a	O
role	O
in	O
EBV-associated	O
malignancies	O
.	O

Against	O
200	O
strains	O
of	O
methicillin-resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
isolated	O
from	O
1990	O
to	O
1991	O
,	O
minimum	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
of	O
a	O
total	O
of	O
15	O
antibacterial	O
agents	O
including	O
arbekacin	O
(	O
ABK	O
)	O
were	O
determined	O
.	O

The	O
perioperative	O
mortality	O
of	O
all	O
patients	O
was	O
1	O
.	O
9%	O
,	O
the	O
mortality	O
of	O
patients	O
older	O
than	O
70	O
years	O
was	O
4	O
.	O
3%	O
.	O

We	O
determined	O
whether	O
a	O
single	O
injection	O
of	O
slow-release	O
estradiol-17beta	O
(	O
SRE2	O
)	O
would	O
induce	O
pseudopregnancy	O
in	O
gilts	O
and	O
whether	O
PGF2alpha	O
would	O
regress	O
the	O
corpora	O
lutea	O
(	O
CL	O
)	O
of	O
pseudopregnancy	O
.	O

Fecal	O
samples	O
were	O
collected	O
at	O
the	O
beginning	O
and	O
end	O
of	O
each	O
trial	O
period	O
and	O
were	O
analyzed	O
for	O
gastrointestinal	O
nematode	O
eggs	O
and	O
Giardia	O
cyst	O
.	O

Analysis	O
for	O
DNA-protein	O
interactions	O
by	O
in	O
vitro	O
DNase-I	B-GENE
footprinting	O
identified	O
a	O
broad	O
region	O
of	O
protection	O
extending	O
from	O
nt	O
-12	O
to	O
+38	O
.	O

Using	O
himA	B-GENE
mutants	I-GENE
,	O
we	O
confirmed	O
that	O
IHF	B-GENE
plays	O
a	O
role	O
in	O
the	O
molybdate-dependent	O
regulation	O
of	O
dmsA-lacZ	B-GENE
expression	O
in	O
vivo	O
.	O

A	O
heterologous	O
promoter	O
construct	O
containing	O
three	O
repeats	O
of	O
a	O
consensus	O
Sp1	B-GENE
site	I-GENE
,	O
cloned	O
upstream	O
of	O
a	O
single	O
copy	O
of	O
the	O
ZII	B-GENE
(	O
CREB	B-GENE
/	I-GENE
AP1	I-GENE
)	O
element	O
from	O
the	O
BZLF1	B-GENE
promoter	I-GENE
linked	O
to	O
the	O
beta-globin	B-GENE
TATA	O
box	O
,	O
exhibited	O
phorbol	O
ester	O
inducibility	O
.	O

Early-onset	O
scleral	O
necrosis	O
after	O
iodine	O
I	O
125	O
plaque	O
radiotherapy	O
for	O
ciliochoroidal	O
melanoma	O
.	O

Treatment	O
and	O
care	O
of	O
adult	O
diabetes	O
mellitus	O
without	O
coma	O
.	O

Identification	O
and	O
structure	O
of	O
the	O
Marek's	B-GENE
disease	I-GENE
virus	I-GENE
serotype	I-GENE
2	I-GENE
glycoprotein	I-GENE
M	I-GENE
gene	I-GENE
:	O
comparison	O
with	O
glycoprotein	B-GENE
M	I-GENE
genes	I-GENE
of	O
Herpesviridae	O
family	O
.	O

Dimerization	O
of	O
Myf-5	B-GENE
with	O
the	O
ubiquitously	O
expressed	O
bHLH	B-GENE
protein	I-GENE
E12	B-GENE
not	O
only	O
increases	O
the	O
affinity	O
for	O
DNA	O
but	O
also	O
stimulates	O
transactivation	O
independently	O
of	O
DNA	O
binding	O
.	O

Myocardial	O
perfusion	O
was	O
evaluated	O
using	O
the	O
enhanced	O
gray	O
level	O
after	O
contrast	O
injection	O
,	O
and	O
the	O
level	O
was	O
compared	O
with	O
the	O
morphology	O
and	O
degree	O
of	O
collateral	O
development	O
.	O

Changes	O
in	O
body	O
weight	O
and	O
agonistic	O
behavior	O
were	O
also	O
recorded	O
.	O

The	O
mechanisms	O
that	O
govern	O
the	O
activation	O
or	O
suppression	O
of	O
the	O
CD8	B-GENE
gene	I-GENE
are	O
likely	O
to	O
be	O
central	O
to	O
the	O
T	O
cell	O
development	O
program	O
.	O

A	O
segmental	O
analysis	O
of	O
the	O
key	O
regions	O
of	O
HLA-DR1	B-GENE
that	O
control	O
T	O
cell	O
allorecognition	O
was	O
performed	O
by	O
using	O
a	O
series	O
of	O
transfected	O
cell	O
lines	O
expressing	O
the	O
products	O
of	O
recombinant	B-GENE
DRB	I-GENE
/	I-GENE
H-2Eb	I-GENE
genes	I-GENE
,	O
paired	O
with	O
either	O
DR	B-GENE
alpha	I-GENE
or	O
H-2E	B-GENE
alpha	I-GENE
.	O

Effects	O
of	O
methylene	O
chloride	O
,	O
trichloroethane	O
,	O
trichloroethylene	O
,	O
tetrachloroethylene	O
and	O
toluene	O
on	O
the	O
development	O
of	O
chick	O
embryos	O
.	O

To	O
assess	O
more	O
specific	O
PKA-dependent	O
mediation	O
of	O
LH's	B-GENE
contribution	O
to	O
combined	O
hormonal	O
drive	O
,	O
the	O
LDL	B-GENE
receptor	I-GENE
(	I-GENE
-1076	I-GENE
to	I-GENE
+11	I-GENE
bp	I-GENE
)	I-GENE
reporter	I-GENE
plasmid	O
was	O
cotransfected	O
with	O
a	O
full-sequence	B-GENE
rabbit	I-GENE
muscle	I-GENE
protein	I-GENE
kinase	I-GENE
inhibitor	I-GENE
(	O
PKI	B-GENE
)	O
minigene	O
driven	O
constitutively	O
by	O
a	O
Rous	O
sarcoma	O
virus	O
promoter	O
.	O

A	O
full-length	B-GENE
human	I-GENE
pim-1	I-GENE
cDNA	I-GENE
was	O
subcloned	O
into	O
the	O
bacterial	O
vector	O
pGEX-2T	O
and	O
the	O
Pim-1	B-GENE
protein	I-GENE
expressed	O
as	O
a	O
fusion	O
product	O
with	O
bacterial	B-GENE
glutathione	I-GENE
S-transferase	I-GENE
(	O
GST	B-GENE
)	O
.	O

Although	O
L-threo-dihydroxyphenylserine	O
(	O
DOPS	O
)	O
,	O
an	O
artificial	O
norepinephrine	O
(	O
NE	O
)	O
precursor	O
,	O
did	O
not	O
change	O
immobility	O
in	O
intact	O
mice	O
,	O
DOPS	O
significantly	O
reduced	O
immobility	O
in	O
mice	O
pretreated	O
with	O
the	O
selective	O
NE	O
neurotoxin	O
DSP4	O
.	O

Circulating	O
thrombomodulin	B-GENE
:	O
current	O
knowledge	O
and	O
future	O
prospects	O
.	O

Six	O
hours	O
after	O
the	O
last	O
administration	O
,	O
uterus	O
of	O
Gf	O
and	O
Cv	O
mice	O
were	O
weight	O
337	O
.	O
6	O
mg%	O
and	O
423	O
.	O
5	O
mg%	O
respectively	O
,	O
the	O
difference	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

In	O
contrast	O
to	O
the	O
situation	O
in	O
mammalian	O
cells	O
,	O
prolonged	O
exposure	O
of	O
the	O
agonist	O
(	O
24	O
h	O
)	O
does	O
not	O
result	O
in	O
down	O
regulation	O
of	O
the	O
remaining	O
70%	O
of	O
the	O
receptors	O
.	O

The	O
mitochondrial	B-GENE
regulatory	I-GENE
region	I-GENE
(	O
mrr	B-GENE
)	O
located	O
between	O
the	O
tRNAPhe	B-GENE
and	O
tRNAPro	B-GENE
genes	I-GENE
of	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
is	O
essential	O
for	O
regulation	O
of	O
replication	O
and	O
transcription	O
of	O
the	O
mitochondrial	O
genome	O
.	O

In	O
order	O
to	O
examine	O
the	O
potential	O
role	O
of	O
transcriptional	O
silencing	O
during	O
productive	O
HSV-1	O
infection	O
,	O
recombinant	O
viruses	O
were	O
generated	O
in	O
which	O
wild-type	B-GENE
or	I-GENE
mutant	I-GENE
ICP34	I-GENE
.	I-GENE
5	I-GENE
promoters	I-GENE
controlling	O
the	O
expression	O
of	O
a	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	I-GENE
gene	I-GENE
were	O
inserted	O
into	O
the	O
thymidine	B-GENE
kinase	I-GENE
gene	I-GENE
of	O
the	O
viral	O
genome	O
.	O

The	O
gene	O
structure	O
of	O
Elk1	B-GENE
spans	O
15	O
.	O
2	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
and	O
six	O
introns	O
.	O

The	O
structure	O
of	O
digiprogenin	O
.	O

We	O
have	O
isolated	O
and	O
characterised	O
a	O
differentially-regulated	O
gene	O
family	O
in	O
the	O
protozoan	O
parasite	O
Leishmania	O
major	O
.	O

The	O
quantitative	O
determination	O
of	O
HBSAG--a	O
valuable	O
aid	O
in	O
evaluating	O
the	O
infectiousness	O
of	O
hepatitis	O
B	O
virus	O
carriers	O
.	O

We	O
could	O
demonstrate	O
the	O
involvement	O
of	O
cAMP-dependent	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
PKA	B-GENE
)	O
in	O
the	O
phosphorylation	O
of	O
CDC25Mm	B-GENE
in	O
fibroblasts	O
overexpressing	O
this	O
RasGEF	B-GENE
as	O
well	O
as	O
in	O
mouse	O
brain	O
synaptosomal	O
membranes	O
.	O

Saccharomyces	O
cerevisiae	O
activates	O
a	O
regulatory	O
network	O
called	O
"general	O
control"	O
that	O
provides	O
the	O
cell	O
with	O
sufficient	O
amounts	O
of	O
protein	O
precursors	O
during	O
amino	O
acid	O
starvation	O
.	O

The	O
cardiac	B-GENE
myosin	I-GENE
light	I-GENE
chain-2	I-GENE
(	O
MLC-2	B-GENE
)	O
gene	O
promoter	O
contains	O
several	O
positive	O
and	O
negative	O
cis-acting	O
sequences	O
that	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
its	O
expression	O
.	O

No	O
apparent	O
clinical	O
signs	O
indicative	O
of	O
systemic	O
toxicity	O
were	O
observed	O
in	O
the	O
F0	O
and	O
F1	O
animals	O
of	O
either	O
sex	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
endometriosis	O
increases	O
soluble	O
CD23	B-GENE
levels	O
,	O
which	O
can	O
be	O
suppressed	O
with	O
either	O
danazol	O
or	O
leuprolide	O
acetate	O
injection	O
.	O

Diagnosis	O
of	O
unilateral	O
renal	O
artery	O
lesions	O
after	O
captopril	O
administration	O
.	O

Insulin-regulated	O
events	O
,	O
however	O
,	O
occur	O
in	O
all	O
cells	O
.	O

The	O
major	O
urinary	O
metabolites	O
were	O
3-	O
(	O
3-carboxyphenyl	O
)	O
-5-hydroxymethyl-2-oxazolidinone	O
and	O
a	O
glucuronide	O
of	O
toloxatone	O
.	O

This	O
suggested	O
that	O
baboon	B-GENE
liver	I-GENE
class	I-GENE
I	I-GENE
ADH	I-GENE
is	O
of	O
the	O
same	O
ancestral	O
lineage	O
as	O
the	O
human	B-GENE
ADH-beta	I-GENE
.	O

Nine	O
DNA	O
fragments	O
that	O
were	O
specifically	O
recognized	O
and	O
bound	O
by	O
histidine-tagged	O
AdpA	B-GENE
were	O
isolated	O
by	O
cycles	O
of	O
a	O
gel	O
mobility	O
shift-PCR	O
method	O
.	O

We	O
conclude	O
that	O
pancreatic	B-GENE
polypeptide	I-GENE
and	O
motilin	B-GENE
responses	O
to	O
a	O
meal	O
are	O
different	O
in	O
encopretic	O
children	O
than	O
in	O
children	O
in	O
the	O
control	O
group	O
.	O

The	O
zta	B-GENE
transactivator	I-GENE
involved	O
in	O
induction	O
of	O
lytic	O
cycle	O
gene	O
expression	O
in	O
Epstein-Barr	O
virus-infected	O
lymphocytes	O
binds	O
to	O
both	O
AP-1	B-GENE
and	O
ZRE	B-GENE
sites	I-GENE
in	O
target	O
promoter	O
and	O
enhancer	O
regions	O
.	O

The	O
pen	O
can	O
heal	O
.	O

The	O
nuclear	O
proteins	O
encoded	O
by	O
the	O
c-fos	B-GENE
and	O
c-jun	B-GENE
protooncogenes	I-GENE
are	O
expressed	O
during	O
the	O
proliferation	O
period	O
of	O
osteoblast	O
phenotype	O
development	O
.	O

The	O
effect	O
of	O
the	O
thromboxane	B-GENE
A2	I-GENE
(	I-GENE
TXA2	I-GENE
)	I-GENE
/	I-GENE
prostaglandin	I-GENE
endoperoxide	I-GENE
receptor	I-GENE
antagonist	O
,	O
SQ	O
29	O
,	O
548	O
on	O
pacing-induced	O
ischemia	O
was	O
determined	O
in	O
anesthetized	O
open-chest	O
dogs	O
.	O

Strontium	O
nitrate	O
mixed	O
with	O
glycolic	O
acid	O
,	O
in	O
comparison	O
with	O
glycolic	O
acid	O
alone	O
,	O
markedly	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
shortened	O
the	O
duration	O
of	O
the	O
irritation	O
sensation	O
from	O
24	O
.	O
4+	O
/	O
-4	O
.	O
1	O
(	O
mean+	O
/	O
-SEM	O
)	O
min	O
to	O
8	O
.	O
9+	O
/	O
-3	O
.	O
7	O
(	O
mean+	O
/	O
-SEM	O
)	O
min	O
,	O
and	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
reduced	O
the	O
mean	O
magnitude	O
of	O
the	O
irritation	O
sensation	O
at	O
all	O
time	O
points	O
(	O
overall	O
)	O
.	O

Two	O
differentially	O
expressed	O
LNX	B-GENE
messages	I-GENE
encode	O
overlapping	O
proteins	O
with	O
predicted	O
molecular	O
masses	O
of	O
80	B-GENE
kDa	I-GENE
(	I-GENE
LNX	I-GENE
)	I-GENE
and	O
70	B-GENE
kDa	I-GENE
(	I-GENE
LNX-b	I-GENE
)	I-GENE
.	O

Recessive	O
lethal	O
mutations	O
were	O
isolated	O
based	O
upon	O
failure	O
to	O
complement	O
the	O
recessive	O
lethality	O
of	O
Df	O
(	O
3L	O
)	O
RR2	O
,	O
a	O
deletion	O
of	O
the	O
DRE	B-GENE
region	I-GENE
that	O
removes	O
16-18	O
polytene	O
chromosome	O
bands	O
.	O

Therefore	O
,	O
the	O
molecular	O
mechanisms	O
of	O
the	O
estrogen	O
action	O
that	O
govern	O
the	O
lactoferrin	B-GENE
gene	I-GENE
expression	O
differ	O
between	O
mouse	O
and	O
human	O
.	O

The	O
program	O
has	O
been	O
written	O
in	O
a	O
generic	O
BASIC	O
in	O
order	O
to	O
make	O
the	O
procedure	O
user-friendly	O
.	O

SPECT	O
is	O
an	O
important	O
aid	O
in	O
the	O
diagnosis	O
of	O
AIDS	O
dementia	O
complex	O
and	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
pathophysiological	O
mechanisms	O
of	O
this	O
disorder	O
.	O

Small	B-GENE
Maf	I-GENE
proteins	I-GENE
heterodimerize	O
with	O
Fos	B-GENE
and	O
may	O
act	O
as	O
competitive	O
repressors	O
of	O
the	O
NF-E2	B-GENE
transcription	I-GENE
factor	I-GENE
.	O

These	O
and	O
other	O
data	O
presented	O
suggest	O
that	O
TAg	B-GENE
're-models'	O
host	O
cell	O
transcription	O
factors	O
that	O
are	O
used	O
early	O
in	O
viral	O
infection	O
,	O
and	O
thereby	O
mimics	O
an	O
event	O
that	O
naturally	O
occurs	O
during	O
transformation	O
.	O

One	O
P1	O
genomic	O
clone	O
and	O
six	O
subsequent	O
plasmid	O
subclones	O
were	O
isolated	O
and	O
analyzed	O
for	O
the	O
exon-intron	O
organization	O
of	O
the	O
Ctpct	B-GENE
gene	I-GENE
.	O

A	O
second	O
study	O
group	O
,	O
with	O
intact	O
cardiac	O
innervation	O
,	O
consisted	O
of	O
19	O
patients	O
with	O
stable	O
angina	O
pectoris	O
class	O
I	O
to	O
III	O
.	O

Mature	O
mRNA	O
for	O
cytosolic	B-GENE
phosphoenolpyruvate	I-GENE
carboxykinase	I-GENE
of	I-GENE
the	I-GENE
chicken	I-GENE
is	O
2	O
.	O
8	O
kilobases	O
in	O
length	O
,	O
similar	O
to	O
that	O
previously	O
noted	O
for	O
mRNA	O
coding	O
for	O
the	O
same	O
enzyme	O
in	O
the	O
rat	O
.	O

No	O
significant	O
differences	O
could	O
be	O
seen	O
in	O
response	O
rates	O
according	O
to	O
the	O
concentration	O
of	O
estrogen	B-GENE
receptors	I-GENE
or	O
presence	O
of	O
progesteron	B-GENE
receptors	I-GENE
in	O
this	O
group	O
of	O
patients	O
.	O

Surface-coil	O
experiments	O
on	O
phantoms	O
and	O
on	O
human	O
calf	O
muscles	O
in	O
vivo	O
are	O
presented	O
.	O

Six	O
patients	O
with	O
glomerulonephritis	O
in	O
association	O
with	O
a	O
ventriculovascular	O
shunt	O
were	O
treated	O
with	O
three	O
basic	O
modes	O
of	O
therapy	O
.	O

The	O
results	O
obtained	O
tend	O
to	O
prove	O
that	O
the	O
reticuloendothelial	O
system	O
mainly	O
participated	O
in	O
beryllium	O
retention	O
.	O

Molecular	O
characterization	O
of	O
the	O
50-	O
and	O
57-kDa	O
subunits	O
of	O
the	O
bovine	B-GENE
vacuolar	I-GENE
proton	I-GENE
pump	I-GENE
.	O

One	O
hundred	O
twenty	O
units	O
of	O
deglycerolized	O
red	O
blood	O
cells	O
,	O
some	O
with	O
glycerol	O
added	O
so	O
as	O
to	O
exceed	O
an	O
acceptable	O
1%	O
glycerol	O
content	O
,	O
had	O
measurements	O
made	O
of	O
the	O
post-wash	O
supernatant	O
fluid	O
by	O
refractive	O
index	O
and	O
osmometry	O
.	O

The	O
E-box	O
sequence	O
in	O
the	O
SE2	B-GENE
fragment	I-GENE
of	O
the	O
transferrin	B-GENE
promoter	I-GENE
was	O
CATCTG	O
and	O
was	O
similar	O
in	O
gel	O
shifts	O
to	O
the	O
consensus	O
E-box	O
elements	O
(	O
CANNTG	O
)	O
previously	O
characterized	O
.	O

Although	O
human	O
infections	O
with	O
bacteraemia	O
due	O
to	O
Pasteurella	O
multocida	O
are	O
not	O
uncommon	O
,	O
endocarditis	O
associated	O
with	O
P	O
.	O
haemolytica	O
is	O
rare	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
association	O
of	O
depressive	O
symptoms	O
with	O
HIV-related	O
mortality	O
and	O
decline	O
in	O
CD4	B-GENE
lymphocyte	O
counts	O
among	O
women	O
with	O
HIV	O
.	O

Complex	O
repetitive	O
discharges	O
were	O
observed	O
in	O
muscles	O
of	O
mdx	O
mice	O
but	O
no	O
complex	O
repetitive	O
discharges	O
or	O
other	O
abnormalities	O
were	O
observed	O
in	O
muscles	O
of	O
normal	O
control	O
mice	O
.	O

Positive	O
CRP	B-GENE
test	O
were	O
seen	O
.	O

RA-treatment	O
of	O
these	O
transfectants	O
induced	O
morphologic	O
and	O
immunophenotypic	O
maturation	O
,	O
changes	O
in	O
RA-regulated	O
genes	O
,	O
and	O
a	O
G1	O
cell	O
cycle	O
arrest	O
in	O
a	O
manner	O
similar	O
to	O
parental	O
NT2	O
/	O
D1	O
cells	O
.	O

Surprisingly	O
,	O
TFIIIC	B-GENE
alpha	I-GENE
has	O
no	O
homology	O
to	O
any	O
of	O
the	O
yeast	B-GENE
TFIIIC	I-GENE
subunits	I-GENE
already	O
cloned	O
,	O
suggesting	O
a	O
significant	O
degree	O
of	O
evolutionary	O
divergence	O
for	O
RNA	B-GENE
polymerase	I-GENE
III	I-GENE
factors	I-GENE
.	O

When	O
used	O
subcutaneously	O
or	O
intravenously	O
in	O
maximum	O
tolerated	O
doses	O
the	O
antibiotic	O
inhibited	O
the	O
development	O
of	O
lymphadenosis	O
NK	O
/	O
Li	O
by	O
90	O
and	O
70	O
per	O
cent	O
respectively	O
.	O

The	O
sequence-specific	O
interaction	O
of	O
nuclear	B-GENE
factor	I-GENE
HiNF-D	I-GENE
with	O
this	O
key	O
proximal	O
promoter	O
element	O
of	O
the	O
H4-FO108	B-GENE
gene	I-GENE
is	O
cell	O
cycle	O
regulated	O
in	O
normal	O
diploid	O
cells	O
(	O
J	O
.	O

Only	O
after	O
a	O
pretreatment	O
aimed	O
at	O
increasing	O
its	O
oxide	O
surface	O
layer	O
was	O
titanium	O
powder	O
found	O
to	O
accelerate	O
the	O
precipitation	O
from	O
solutions	O
containing	O
2	O
mmol	O
/	O
L	O
CaCl2	O
,	O
2	O
mmol	O
/	O
L	O
KH2PO4	O
,	O
50	O
mmol	O
/	O
L	O
Hepes	O
,	O
pH	O
7	O
.	O
2	O
,	O
and	O
to	O
induce	O
precipitation	O
from	O
metastable	O
solutions	O
containing	O
1	O
.	O
2	O
mmol	O
/	O
L	O
CaCl2	O
,	O
1	O
.	O
2	O
mmol	O
/	O
L	O
KH2PO4	O
,	O
50	O
mmol	O
/	O
L	O
Hepes	O
,	O
pH	O
7	O
.	O
2	O
,	O
at	O
37	O
degrees	O
C	O
.	O

The	O
approach	O
derives	O
from	O
a	O
recently	O
described	O
strategy	O
for	O
making	O
recombinants	O
from	O
five	O
overlapping	O
EBV	O
cosmid-cloned	O
DNAs	O
(	O
B	O
.	O

Using	O
homology	O
cloning	O
techniques	O
,	O
we	O
identified	O
a	O
mouse	O
homologue	O
of	O
E	B-GENE
(	I-GENE
Pc	I-GENE
)	I-GENE
,	O
termed	O
Epc1	B-GENE
,	O
a	O
yeast	O
protein	O
that	O
we	O
name	O
EPL1	B-GENE
,	O
and	O
as	O
well	O
as	O
additional	O
ESTs	O
from	O
Caenorhabditis	O
elegans	O
,	O
mice	O
and	O
humans	O
.	O

The	O
promoter	O
of	O
the	O
rat	B-GENE
pgp2	I-GENE
/	I-GENE
mdr1b	I-GENE
gene	I-GENE
has	O
a	O
GC-rich	O
region	O
(	O
pgp2GC	B-GENE
)	O
that	O
is	O
highly	O
conserved	O
in	O
mdr	B-GENE
genes	I-GENE
and	O
contains	O
an	O
consensus	O
Sp1	B-GENE
site	I-GENE
.	O

Natural	O
and	O
induced	O
malarias	O
in	O
western	O
hemisphere	O
monkeys	O
.	O

Detection	O
of	O
congenital	O
hypothyroidism	O
in	O
26	O
,	O
282	O
newborn	O
infants	O
.	O

A	O
polymorphic	O
bipartite	O
motif	O
signals	O
nuclear	O
targeting	O
of	O
early	O
auxin-inducible	O
proteins	O
related	O
to	O
PS-IAA4	B-GENE
from	I-GENE
pea	I-GENE
(	I-GENE
Pisum	I-GENE
sativum	I-GENE
)	I-GENE
.	O

A	O
two	O
phase	O
slug	O
flow	O
tubular	O
heat	O
exchanger	O
was	O
used	O
for	O
the	O
thermal	O
inactivation	O
of	O
Listeria	O
monocytogenes	O
in	O
natural	O
infected	O
milk	O
from	O
seven	O
cows	O
.	O

Granisetron	O
,	O
but	O
not	O
saline	O
,	O
abolished	O
vomiting	O
and	O
nausea	O
when	O
given	O
as	O
intervention	O
after	O
this	O
combined	O
emetic	O
regimen	O
.	O

Specific	O
and	O
heritable	O
genetic	O
interference	O
by	O
double-stranded	O
RNA	O
in	O
Arabidopsis	O
thaliana	O
.	O

Upstream	O
of	O
-37	O
,	O
the	O
5'	O
untranslated	O
sequences	O
of	O
the	O
isolates	O
differ	O
in	O
both	O
length	O
and	O
sequence	O
.	O

Lysine-ketoglutarate	B-GENE
reductase	I-GENE
and	O
saccharopine	B-GENE
dehydrogenase	I-GENE
from	O
Arabidopsis	O
thaliana	O
:	O
nucleotide	O
sequence	O
and	O
characterization	O
.	O

To	O
test	O
the	O
feasibility	O
of	O
using	O
liposomes	O
to	O
deliver	O
therapeutic	O
agents	O
to	O
the	O
lungs	O
,	O
the	O
effect	O
of	O
liposome-encapsulated	O
superoxide	B-GENE
dismutase	I-GENE
(	O
SOD	B-GENE
)	O
or	O
catalase	B-GENE
on	O
pulmonary	O
oxygen	O
toxicity	O
was	O
studied	O
in	O
rats	O
.	O

3	O
activities	O
of	O
the	O
factor	B-GENE
II	I-GENE
molecule	O
in	O
the	O
newborn	O
infant	O
at	O
term	O
.	O

There	O
was	O
no	O
evidence	O
of	O
linkage	O
disequilibrium	O
between	O
the	O
polymorphic	O
site	O
in	O
the	O
B	O
cell	O
specific	O
promoter	O
and	O
those	O
in	O
the	O
3'	O
UTR	O
.	O

Patients	O
with	O
lesions	O
affecting	O
the	O
PRC	O
but	O
sparing	O
the	O
PHC	O
,	O
and	O
patients	O
with	O
lesions	O
affecting	O
both	O
PRC	O
and	O
PHC	O
,	O
performed	O
an	O
oculomotor	O
delayed	O
response	O
task	O
with	O
unpredictably	O
varied	O
memory	O
delays	O
of	O
up	O
to	O
30	O
s	O
.	O

Relaxation	O
of	O
catch	O
in	O
a	O
molluscan	O
smooth	O
muscle	O
.	O

Chinese	O
Spring	O
(	O
CS	O
)	O
carrying	O
the	O
Q	B-GENE
gene	I-GENE
to	O
those	O
of	O
a	O
chromosome	O
deletion	O
line	O
of	O
CS	O
,	O
namely	O
,	O
q5	O
,	O
which	O
lacks	O
15%	O
of	O
5AL	O
including	O
the	O
Q	B-GENE
gene	I-GENE
.	O

The	O
resulting	O
R	B-GENE
protein	I-GENE
terminates	O
five	O
codons	O
downstream	O
of	O
the	O
frameshift	O
site	O
at	O
the	O
V	B-GENE
protein	I-GENE
stop	O
codon	O
.	O

Here	O
we	O
report	O
that	O
expression	O
of	O
the	O
I-POU	B-GENE
/	I-GENE
tI-POU	I-GENE
message	I-GENE
is	O
maximal	O
late	O
in	O
the	O
embryonic	O
phase	O
of	O
Drosophila	O
development	O
,	O
and	O
I-POU	B-GENE
is	O
the	O
preferred	O
splice	O
variant	O
.	O

Perilunar	O
luxation--an	O
unusual	O
injury	O
demanding	O
immediate	O
and	O
correct	O
treatment	O
.	O

Insulin-like	B-GENE
growth	I-GENE
factor-binding	I-GENE
protein-2	I-GENE
(	O
IGF-BP-2	B-GENE
)	O
transcription	O
in	O
rat	O
liver	O
varies	O
with	O
developmental	O
age	O
and	O
fasting	O
.	O

In	O
recent	O
years	O
,	O
successful	O
physiological	O
models	O
have	O
been	O
developed	O
for	O
a	O
variety	O
of	O
volatile	O
and	O
nonvolatile	O
chemicals	O
,	O
and	O
their	O
ability	O
to	O
perform	O
the	O
extrapolations	O
needed	O
in	O
risk	O
assessment	O
has	O
been	O
demonstrated	O
.	O

These	O
data	O
indicate	O
that	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
rat	B-GENE
GnRH-R	I-GENE
is	O
involved	O
in	O
receptor	B-GENE
G	I-GENE
(	I-GENE
q	I-GENE
/	I-GENE
11	I-GENE
)	I-GENE
protein	I-GENE
coupling	O
and	O
/	O
or	O
selectivity	O
,	O
and	O
in	O
the	O
GGH	O
(	O
3	O
)	O
1'	O
cell	O
line	O
,	O
this	O
loop	O
is	O
also	O
involved	O
in	O
signal	O
transduction	O
mediated	O
through	O
the	O
Gs	B-GENE
protein	I-GENE
pathway	I-GENE
.	O

Administration	O
of	O
growth	B-GENE
hormone	I-GENE
leads	O
to	O
faster	O
growth	O
,	O
but	O
also	O
faster	O
bone	O
maturation	O
.	O

Evidence	O
from	O
the	O
structure	O
of	O
a	O
number	O
of	O
cDNA	O
clones	O
,	O
as	O
well	O
as	O
S1	B-GENE
nuclease	I-GENE
and	O
primer	O
extension	O
studies	O
supports	O
the	O
hypothesis	O
that	O
the	O
PTHrP	B-GENE
gene	I-GENE
contains	O
at	O
least	O
two	O
mRNA	O
transcription	O
start	O
points	O
that	O
define	O
two	O
putative	O
regulatory	O
domains	O
.	O

Since	O
proteins	O
containing	O
TPR	B-GENE
elements	I-GENE
are	O
typically	O
involved	O
in	O
multiple	O
protein-protein	O
interactions	O
,	O
we	O
suggest	O
that	O
the	O
102kD	O
protein	O
interacts	O
within	O
the	O
tri-snRNP	B-GENE
with	O
both	O
the	O
U5	B-GENE
and	I-GENE
U4	I-GENE
/	I-GENE
U6	I-GENE
snRNPs	I-GENE
,	O
thus	O
bridging	O
the	O
two	O
particles	O
.	O

The	O
comparison	O
of	O
the	O
expression	O
patterns	O
of	O
the	O
known	O
Kv4	B-GENE
family	I-GENE
members	I-GENE
shows	O
subtype	O
specificity	O
with	O
significant	O
overlaps	O
.	O

Some	O
strains	O
of	O
A	O
.	O
parasiticus	O
produced	O
all	O
four	O
aflatoxins	B-GENE
B1	I-GENE
B2	I-GENE
G1	I-GENE
G2	I-GENE
,	O
while	O
the	O
other	O
ones	O
produced	O
AF	B-GENE
B1	I-GENE
+	O
G1	B-GENE
only	O
,	O
with	O
concentrations	O
of	O
aflatoxins	B-GENE
from	O
0	O
.	O
1	O
to	O
450	O
mg	O
/	O
kg	O
.	O

We	O
have	O
tested	O
this	O
possibility	O
by	O
constructing	O
a	O
consecutive	O
series	O
of	O
cysteine	O
substitutions	O
in	O
the	O
Neu	B-GENE
juxtamembrane	I-GENE
domain	I-GENE
in	O
order	O
to	O
force	O
dimerization	O
along	O
a	O
series	O
of	O
interreceptor	O
faces	O
.	O

4	O
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
various	O
NF-kappa	B-GENE
B	I-GENE
subunits	I-GENE
to	O
bind	O
to	O
,	O
and	O
activate	O
transcription	O
from	O
,	O
the	O
IL-8	B-GENE
promoter	I-GENE
.	O

In	O
another	O
study	O
,	O
intravenous	O
administration	O
of	O
devazepide	O
,	O
a	O
specific	O
cholecystokinin-A	B-GENE
receptor	I-GENE
antagonist	O
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
hr	O
was	O
begun	O
15	O
min	O
before	O
postprandial	O
saline	O
intake	O
and	O
continued	O
for	O
1	O
hr	O
.	O

In	O
the	O
icosahaedral	O
MVMi	O
capsid	O
,	O
this	O
sequence	O
forms	O
the	O
carboxy	O
end	O
of	O
the	O
amphipathic	O
beta-strand	B-GENE
I	I-GENE
(	O
betaI	B-GENE
)	O
,	O
and	O
all	O
its	O
basic	O
residues	O
are	O
contiguously	O
positioned	O
at	O
the	O
face	O
that	O
in	O
the	O
unassembled	O
subunit	O
would	O
be	O
exposed	O
to	O
solvent	O
.	O

UAS1	B-GENE
is	O
the	O
binding	O
site	O
for	O
the	O
transcriptional	O
regulator	O
Adr1p	B-GENE
.	O

Both	O
receptors	O
utilize	O
protein	B-GENE
tyrosine	I-GENE
kinases	I-GENE
(	O
PTKs	B-GENE
)	O
for	O
the	O
phosphorylation	O
of	O
various	O
signaling	O
molecules	O
,	O
a	O
process	O
that	O
is	O
critical	O
for	O
the	O
function	O
of	O
both	O
receptors	O
.	O

Because	O
the	O
Pit-1	B-GENE
sites	I-GENE
in	O
the	O
hGH-N	B-GENE
gene	I-GENE
promoter	I-GENE
are	O
insufficient	O
for	O
such	O
gene	O
activation	O
in	O
vivo	O
,	O
these	O
data	O
suggested	O
a	O
unique	O
chromatin-mediated	O
developmental	O
role	O
for	O
Pit-1	B-GENE
in	O
the	O
hGH	B-GENE
LCR	I-GENE
.	O

Optical-absorption	O
spectra	O
,	O
crystal-field	O
energy	O
levels	O
,	O
and	O
transition	O
line	O
strengths	O
of	O
holmium	O
in	O
trigonal	O
Na3	O
[	O
Ho	O
(	O
C4H4O5	O
)	O
3	O
]	O
[	O
sdot	O
]	O
2NaClO4	O
[	O
sdot	O
]	O
6H2O	O
.	O

During	O
organogenesis	O
,	O
HFH-8	B-GENE
expression	O
is	O
found	O
in	O
the	O
splanchnic	O
mesoderm	O
in	O
close	O
apposition	O
of	O
the	O
gut	O
endoderm	O
,	O
suggesting	O
a	O
role	O
in	O
mesenchymal-epithelial	O
induction	O
of	O
lung	O
and	O
gut	O
morphogenesis	O
.	O

Atrial	O
fibrillation	O
and	O
the	O
autonomic	O
nervous	O
system	O
.	O

The	O
IgA	B-GENE
deficiency	O
is	O
combined	O
with	O
the	O
IgE	B-GENE
one	O
.	O

Our	O
results	O
suggest	O
that	O
Anu2p	B-GENE
is	O
the	O
yeast	B-GENE
homologue	I-GENE
of	I-GENE
mammalian	I-GENE
epsilon-COP	I-GENE
and	O
the	O
abrupt	O
accumulation	O
of	O
the	O
ER	O
membrane	O
caused	O
by	O
a	O
blockage	O
of	O
the	O
early	O
protein	O
transport	O
pathway	O
leads	O
to	O
alteration	O
of	O
nuclear	O
morphology	O
of	O
the	O
budding	O
yeast	O
cells	O
.	O

The	O
penicillin	B-GENE
binding	I-GENE
proteins	I-GENE
(	O
PBPs	B-GENE
)	O
synthesize	O
and	O
remodel	O
peptidoglycan	O
,	O
the	O
structural	O
component	O
of	O
the	O
bacterial	O
cell	O
wall	O
.	O

Effect	O
of	O
hyperglycemia	O
on	O
pain	O
threshold	O
in	O
alloxan-diabetic	O
rats	O
.	O

The	O
juxtamembrane	O
region	O
of	O
the	O
insulin	B-GENE
receptor	I-GENE
(	I-GENE
IR	I-GENE
)	I-GENE
beta-subunit	I-GENE
contains	O
an	O
unphosphorylated	O
tyrosyl	O
residue	O
(	O
Tyr960	O
)	O
that	O
is	O
essential	O
for	O
insulin-stimulated	O
tyrosyl	O
phosphorylation	O
of	O
some	O
endogenous	O
substrates	O
and	O
certain	O
biological	O
responses	O
(	O
White	O
,	O
M	O
.	O
F	O
.	O
,	O
Livingston	O
,	O
J	O
.	O
N	O
.	O
,	O
Backer	O
,	O
J	O
.	O
M	O
.	O
,	O
Lauris	O
,	O
V	O
.	O
,	O
Dull	O
,	O
T	O
.	O
J	O
.	O
,	O
Ullrich	O
,	O
A	O
.	O
,	O
and	O
Kahn	O
,	O
C	O
.	O
R	O
.	O

Using	O
an	O
ELISA	O
,	O
we	O
found	O
that	O
surfactant	B-GENE
protein	I-GENE
A	I-GENE
(	O
SP-A	B-GENE
)	O
was	O
markedly	O
elevated	O
in	O
the	O
pneumonia	O
patients	O
.	O

Resistance	O
ratios	O
for	O
the	O
other	O
field	O
strains	O
obtained	O
by	O
comparison	O
with	O
the	O
R5	O
strain	O
ranged	O
from	O
24	O
.	O
5	O
to	O
239	O
for	O
topical	O
application	O
and	O
from	O
1	O
.	O
2	O
to	O
9	O
.	O
8	O
for	O
the	O
glass	O
jar	O
method	O
.	O

Among	O
the	O
v-myc	B-GENE
codons	O
,	O
the	O
first	O
5	O
are	O
derived	O
from	O
the	O
noncoding	O
5'	O
terminus	O
of	O
the	O
second	O
c-myc	B-GENE
exon	O
,	O
and	O
412	O
codons	O
correspond	O
to	O
the	O
c-myc	B-GENE
coding	O
region	O
.	O

A	O
cDNA	O
for	O
a	O
newly	O
discovered	O
pseudogene	O
,	O
closely	O
related	O
to	O
the	O
mouse	B-GENE
mast	I-GENE
cell	I-GENE
chymases	I-GENE
was	O
isolated	O
by	O
polymerase	B-GENE
chain	O
reaction	O
amplification	O
from	O
a	O
mouse	O
connective	O
tissue-like	O
mast	O
cell	O
line	O
.	O

Their	O
circadian	O
responses	O
to	O
both	O
photic	O
and	O
non-photic	O
cues	O
were	O
then	O
tested	O
.	O

Expression	O
of	O
the	O
mouse	B-GENE
TSH	I-GENE
beta	I-GENE
gene	I-GENE
,	O
therefore	O
,	O
gives	O
rise	O
to	O
multiple	O
mRNAs	O
,	O
each	O
with	O
a	O
unique	O
5'-untranslated	O
region	O
.	O

The	O
nucleotide	O
sequences	O
of	O
these	O
genes	O
differ	O
at	O
only	O
nine	O
positions	O
,	O
resulting	O
in	O
three	O
amino	O
acid	O
differences	O
.	O

Thromboplastic	O
and	O
fibrynolytic	O
activity	O
of	O
the	O
blood	O
after	O
administration	O
of	O
intralipid	O
in	O
men	O
with	O
history	O
of	O
myocardial	O
infarction	O
up	O
to	O
45	O
year	O
of	O
life	O
.	O

Many	O
factors	O
do	O
influence	O
the	O
educational	O
outcome	O
in	O
students	O
and	O
large	O
statistical	O
power	O
(	O
such	O
as	O
meta	O
analysis	O
)	O
should	O
be	O
helpful	O
to	O
eliminate	O
many	O
souces	O
of	O
error	O
.	O

Most	O
of	O
the	O
expressed	O
human	B-GENE
E3	I-GENE
polypeptides	I-GENE
(	O
five	O
bands	O
)	O
were	O
found	O
in	O
the	O
insoluble	O
pellet	O
while	O
primarily	O
full-length	B-GENE
mature	I-GENE
E3	I-GENE
was	O
found	O
in	O
the	O
soluble	O
fraction	O
.	O

We	O
show	O
that	O
a	O
protein	O
,	O
UBC9	B-GENE
,	O
interacts	O
specifically	O
with	O
TEL	B-GENE
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
reading	O
frame	O
was	O
concluded	O
to	O
encode	O
the	O
precursor	O
of	O
mitochondrial	B-GENE
fumarase	I-GENE
.	O

By	O
contrast	O
,	O
all	O
proteins	O
initiated	O
with	O
a	O
methionine	O
placed	O
one	O
residue	O
upstream	O
of	O
the	O
natural	O
N	O
terminus	O
of	O
PR	B-GENE
failed	O
to	O
show	O
specific	O
proteolysis	O
.	O

In	O
this	O
paper	O
,	O
characterization	O
is	O
given	O
of	O
clinical	O
and	O
biochemical	O
features	O
of	O
VH	O
B	O
course	O
against	O
the	O
background	O
of	O
narcomania	O
.	O

The	O
statistical	O
significance	O
of	O
the	O
prognosis	O
factors	O
was	O
studied	O
by	O
uni-	O
and	O
multivariative	O
methods	O
,	O
according	O
to	O
the	O
model	O
of	O
Cox	O
,	O
with	O
the	O
help	O
of	O
an	O
IMB	O
computer	O
.	O

Current	O
evidence	O
for	O
this	O
type	O
of	O
DNA	O
supercoiling-dependent	O
transcriptional	O
coupling	O
,	O
based	O
largely	O
on	O
the	O
in	O
vivo	O
activities	O
of	O
promoters	O
contained	O
in	O
engineered	O
DNA	O
constructs	O
,	O
suggests	O
that	O
the	O
transcription	O
complex	O
must	O
be	O
physically	O
hindered	O
to	O
generate	O
DNA	O
supercoils	O
and	O
to	O
prevent	O
their	O
diffusion	O
throughout	O
the	O
DNA	O
duplex	O
.	O

With	O
the	O
help	O
of	O
a	O
nomogram	O
one	O
can	O
read	O
off	O
the	O
refraction	O
,	O
when	O
axis	O
length	O
and	O
corneal	O
curvature	O
are	O
known	O
.	O

A	O
subset	O
of	O
patients	O
(	O
n	O
=	O
30	O
)	O
underwent	O
multichannel	O
pressure	O
flow	O
studies	O
,	O
which	O
demonstrated	O
that	O
transrectal	O
HIFU	O
reduces	O
bladder	O
outflow	O
obstruction	O
.	O

Two	O
of	O
seven	O
initiation	O
sites	O
were	O
flanked	O
by	O
a	O
sequence	O
homologous	O
to	O
the	O
consensus	O
promoter	O
motif	O
that	O
includes	O
the	O
CRTA	O
motif	O
(	O
where	O
R	O
is	O
A	O
or	O
G	O
)	O
of	O
the	O
rice	O
mitochondrion	O
.	O

Recent	O
molecular	O
analysis	O
has	O
revealed	O
that	O
the	O
S	B-GENE
locus	I-GENE
is	O
highly	O
polymorphic	O
and	O
contains	O
several	O
genes	O
,	O
i	O
.	O
e	O
.	O
,	O
SLG	B-GENE
,	O
SRK	B-GENE
,	O
the	O
as-yet-unidentified	O
pollen	B-GENE
S	I-GENE
gene	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
,	O
and	O
other	O
linked	O
genes	O
.	O

The	O
major	O
type	O
involves	O
activator	O
proteins	O
that	O
bind	O
to	O
DNA	O
adjacent	O
to	O
where	O
the	O
RNA	B-GENE
polymerase	I-GENE
(	O
RNAP	B-GENE
)	O
holoenzyme	O
binds	O
,	O
usually	O
assisting	O
in	O
recruitment	O
of	O
the	O
RNAP	B-GENE
to	O
the	O
promoter	O
.	O

The	O
sub-acute	O
inhalation	O
toxicity	O
of	O
furfural	O
was	O
studied	O
in	O
Syrian	O
golden	O
hamsters	O
.	O

Gel	O
retardation	O
assays	O
combined	O
with	O
DNase	B-GENE
I	I-GENE
footprinting	O
and	O
diethyl	O
pyrocarbonate	O
interference	O
showed	O
that	O
a	O
nuclear	O
factor	O
from	O
differentiated	O
C2	O
myotubes	O
and	O
BC3H1	O
myocytes	O
recognized	O
a	O
conserved	O
A	O
+	O
T-rich	O
sequence	O
within	O
the	O
peripheral	O
activating	O
region	O
.	O

The	O
application	O
of	O
these	O
instruments	O
allows	O
occlusion	O
of	O
the	O
ascending	O
aorta	O
traversed	O
by	O
the	O
perfusion	O
cannula	O
inserted	O
directly	O
or	O
through	O
the	O
apex	O
of	O
the	O
heart	O
as	O
well	O
as	O
simultaneous	O
left	O
ventricular	O
venting	O
.	O

Chronic	O
renal	O
failure	O
patients	O
essentially	O
die	O
from	O
cardiovascular	O
causes	O
,	O
and	O
the	O
frequency	O
of	O
malignant	O
disease	O
responsible	O
for	O
death	O
is	O
estimated	O
to	O
be	O
10%	O
.	O

In	O
the	O
formalin	O
test	O
,	O
however	O
,	O
naloxone	O
attenuated	O
morphine	O
analgesia	O
at	O
the	O
lower	O
doses	O
(	O
0	O
.	O
1	O
and	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
and	O
potentiated	O
morphine	O
analgesia	O
at	O
the	O
highest	O
dose	O
(	O
10	O
mg	O
/	O
kg	O
)	O
.	O

5	O
(	O
Sunset	O
Yellow	O
FCF	O
)	O
were	O
determined	O
using	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
)	O
with	O
electrospray	O
ionization	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
rats	O
with	O
relatively	O
small	O
remnants	O
of	O
one	O
olfactory	O
bulb	O
can	O
perform	O
a	O
variety	O
of	O
odor	O
detection	O
and	O
discrimination	O
tasks	O
as	O
well	O
or	O
nearly	O
as	O
well	O
as	O
controls	O
.	O

Most	O
patients	O
preferred	O
tablets	O
to	O
injection	O
both	O
on	O
day	O
1	O
(	O
313	O
v	O
200	O
)	O
and	O
at	O
follow	O
up	O
(	O
373	O
v	O
104	O
)	O
.	O

Two	O
of	O
these	O
six	O
cases	O
showed	O
mucosal	O
spread	O
without	O
stromal	O
invasion	O
(	O
type	O
A	O
)	O
;	O
the	O
remaining	O
four	O
cases	O
presented	O
a	O
direct	O
extension	O
(	O
type	O
B	O
)	O
from	O
muscle-invasive	O
carcinomas	O
of	O
the	O
bladder	O
.	O

IV	O
.	O

Competitive	O
mobility	O
shift	O
assays	O
using	O
either	O
alphaT3-1	O
nuclear	O
extract	O
or	O
recombinant	B-GENE
SF-1	I-GENE
protein	I-GENE
clearly	O
indicated	O
that	O
SF-1	B-GENE
is	O
able	O
to	O
interact	O
specifically	O
with	O
this	O
GSE	B-GENE
element	I-GENE
positioned	O
at	O
-134	O
.	O

A	O
liquid	O
chromatographic	O
method	O
is	O
described	O
for	O
analysis	O
of	O
beta-carotene	O
in	O
medical	O
food	O
.	O

Animals	O
that	O
received	O
DSP-4	O
were	O
significantly	O
retarded	O
in	O
motor	O
recovery	O
compared	O
with	O
the	O
saline	O
group	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
R2	B-GENE
protein	I-GENE
was	O
used	O
to	O
provide	O
evidence	O
that	O
this	O
motif	O
is	O
also	O
part	O
of	O
the	O
active	O
site	O
of	O
the	O
endonuclease	B-GENE
encoded	O
by	O
this	O
element	O
.	O

We	O
determined	O
whether	O
the	O
human	B-GENE
StAR	I-GENE
promoter	I-GENE
is	O
responsive	O
to	O
sterol	B-GENE
regulatory	I-GENE
element-binding	I-GENE
proteins	I-GENE
(	O
SREBPs	B-GENE
)	O
.	O

We	O
show	O
that	O
other	O
cdc33	B-GENE
mutants	I-GENE
also	O
arrest	O
in	O
G1	O
.	O

The	O
network	O
evolution	O
was	O
interpreted	O
by	O
an	O
approach	O
based	O
on	O
the	O
Flory	O
model	O
.	O

In	O
addition	O
,	O
the	O
ketamine-treated	O
rats	O
had	O
more	O
neurons	O
and	O
glial	O
cells	O
surrounding	O
the	O
ventricles	O
.	O

RESULTS	O
:	O
In	O
this	O
group	O
of	O
patients	O
,	O
male	O
gender	O
(	O
P	O
=	O
0	O
.	O

The	O
results	O
presented	O
suggest	O
that	O
TIQ	O
reduces	O
the	O
turnover	O
rate	O
of	O
the	O
nigrostriatal	O
dopamine	O
neurons	O
after	O
repeated	O
administration	O
for	O
a	O
long	O
period	O
in	O
mice	O
.	O

And	O
the	O
natural	O
barriers	O
?	O

In	O
experiments	O
with	O
the	O
D1	B-GENE
antagonist	O
SCH	O
23390	O
,	O
buprenorphine-induced	O
depression	O
was	O
consistently	O
blocked	O
,	O
but	O
facilitation	O
was	O
unaffected	O
.	O

Each	O
individual	O
shot	O
25	O
bullets	O
in	O
about	O
5	O
minutes	O
,	O
at	O
an	O
intensity	O
level	O
calculated	O
at	O
163	O
dB	O
.	O

Positioning	O
this	O
uORF	O
,	O
together	O
with	O
its	O
accompanying	O
Kozak	O
sequences	O
,	O
between	O
a	O
heterologous	O
promoter	O
from	O
SV40	O
and	O
a	O
CAT	B-GENE
reporter	I-GENE
gene	I-GENE
resulted	O
in	O
marked	O
inhibition	O
of	O
CAT	B-GENE
protein	I-GENE
production	O
without	O
a	O
decrease	O
in	O
CAT	B-GENE
mRNA	I-GENE
.	O

Morphine	O
injected	O
into	O
the	O
lateral	O
ventricle	O
of	O
the	O
rat	O
produced	O
unilateral	O
analgesia	O
in	O
the	O
formalin	O
test	O
,	O
which	O
involves	O
continuous	O
,	O
moderate	O
pain	O
.	O

The	O
subjects	O
from	O
the	O
two	O
regions	O
with	O
a	O
higher	O
pollution	O
level	O
had	O
lower	O
FVC	O
and	O
FEV1	O
values	O
than	O
those	O
from	O
the	O
Viskovo	O
region	O
.	O

Specific	O
hyperimmune	B-GENE
globulins	I-GENE
to	O
pathogens	O
such	O
as	O
Haemophilus	O
influenzae	O
and	O
Streptococcus	O
pneumoniae	O
have	O
also	O
been	O
studied	O
.	O

From	O
day	O
30	O
after	O
turnout	O
,	O
the	O
PFB-group	O
had	O
significantly	O
lower	O
serum	B-GENE
pepsinogen	I-GENE
levels	O
,	O
which	O
reflects	O
the	O
low	O
degree	O
of	O
abomasal	O
damage	O
in	O
these	O
animals	O
.	O

This	O
technique	O
has	O
a	O
sensitivity	O
and	O
a	O
specificity	O
of	O
almost	O
100%	O
,	O
and	O
is	O
currently	O
the	O
best	O
way	O
to	O
diagnose	O
nodal	O
involvement	O
,	O
apart	O
from	O
laparotomy	O
.	O

At	O
the	O
C-terminus	O
of	O
the	O
protein	O
is	O
a	O
domain	O
that	O
contains	O
sequences	O
very	O
similar	O
to	O
those	O
found	O
in	O
the	O
breakpoint	O
cluster	O
region	O
gene	O
product	O
,	O
n-chimerin	B-GENE
,	O
and	O
rho	B-GENE
GAP	I-GENE
,	O
all	O
of	O
which	O
have	O
been	O
shown	O
to	O
possess	O
intrinsic	O
GAP	B-GENE
activity	O
on	O
small	B-GENE
GTPases	I-GENE
.	O

Skin	O
and	O
bowel	O
TPO2	O
varied	O
with	O
DO2	O
and	O
each	O
other	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
order	O
to	O
identify	O
and	O
classify	O
the	O
basic	O
CT	O
appearances	O
of	O
interstitial	O
pneumonia	O
,	O
radiologic	O
-pathologic	O
correlative	O
study	O
was	O
performed	O
using	O
inflated	O
and	O
fixed	O
lungs	O
from	O
autopsy	O
and	O
surgery	O
.	O

Thrombotic	O
thrombocytopenic	O
purpura	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

The	O
expression	O
analysis	O
of	O
the	O
KlHIS4	B-GENE
gene	I-GENE
under	O
phosphate	O
starvation	O
or	O
high	O
adenine	O
supply	O
shows	O
that	O
factors	O
,	O
such	O
as	O
Bas1	B-GENE
or	O
Bas2	B-GENE
,	O
involved	O
in	O
the	O
basal	O
control	O
may	O
also	O
operate	O
in	O
a	O
different	O
way	O
in	O
K	O
.	O
lactis	O
.	O

Local	O
graft	O
irradiation	O
as	O
an	O
adjunct	O
to	O
pharmacologic	O
immunosuppression	O
.	O

The	O
US	O
National	O
Institute	O
on	O
Alcohol	O
Abuse	O
and	O
Alcoholism	O
(	O
NIAAA	O
)	O
recognizes	O
two	O
forms	O
of	O
problematic	O
drinking	O
:	O
'willful	O
alcohol	O
abuse'	O
,	O
a	O
behavioural	O
problem	O
,	O
and	O
'alcohol	O
dependence'	O
,	O
a	O
true	O
medical	O
disorder	O
,	O
which	O
includes	O
a	O
genetic	O
component	O
,	O
that	O
can	O
be	O
scientifically	O
understood	O
and	O
medically	O
treated	O
.	O

Oleate	O
induced	O
steady-state	O
levels	O
of	O
M-CPT	B-GENE
I	I-GENE
mRNA	I-GENE
4	O
.	O
5-fold	O
.	O

A	O
MEK-specific	O
inhibitor	O
(	O
PD098059	O
)	O
(	O
Dudley	O
,	O
D	O
.	O

Homozygous	O
null	O
embryos	O
also	O
displayed	O
abnormalities	O
in	O
heart	O
development	O
,	O
consistent	O
with	O
the	O
conclusion	O
that	O
Tek	B-GENE
is	O
necessary	O
for	O
endocardial	O
/	O
myocardial	O
interactions	O
during	O
development	O
.	O

Of	O
major	O
concern	O
to	O
food	O
processors	O
is	O
the	O
inadvertent	O
cross-contact	O
of	O
food	O
products	O
with	O
allergenic	O
residues	O
,	O
which	O
could	O
result	O
in	O
potentially	O
life-threatening	O
reactions	O
in	O
those	O
with	O
a	O
food	O
allergy	O
.	O

No	O
homologs	O
of	O
other	O
members	O
of	O
the	O
Surfeit	B-GENE
gene	I-GENE
cluster	I-GENE
were	O
detected	O
in	O
close	O
proximity	O
to	O
the	O
D	B-GENE
.	I-GENE
melanogaster	I-GENE
Surf-3	I-GENE
/	I-GENE
rpL7a	I-GENE
gene	I-GENE
.	I-GENE
(	I-GENE
ABSTRACT	I-GENE
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Dopamine	O
caused	O
a	O
prominent	O
potassium	O
efflux	O
measured	O
as	O
86Rb+	O
efflux	O
from	O
control	O
glands	O
,	O
but	O
was	O
without	O
effect	O
in	O
denervated	O
glands	O
.	O

DATA	O
SYNTHESIS	O
:	O
Intracoronary	O
ultrasound	O
has	O
been	O
shown	O
to	O
improve	O
upon	O
demonstrated	O
weaknesses	O
of	O
coronary	O
angiography	O
.	O

These	O
mutants	O
grow	O
normally	O
in	O
3T6	O
mouse	O
fibroblast	O
cells	O
,	O
and	O
they	O
do	O
not	O
complement	O
the	O
wild-type	O
virus	O
in	O
coinfection	O
experiments	O
of	O
C2	O
myoblasts	O
.	O

Serial	O
levels	O
of	O
troponin	B-GENE
T	I-GENE
and	O
the	O
activity	O
of	O
CK-MB	B-GENE
were	O
measured	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
h	O
after	O
aortic	O
unclamping	O
.	O

We	O
also	O
show	O
that	O
activation	O
of	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
)	O
signaling	O
is	O
sufficient	O
to	O
down-regulate	O
caveolin-1	B-GENE
protein	I-GENE
expression	O
and	O
promoter	O
activity	O
.	O

As	O
expected	O
,	O
glycosylation	O
of	O
Env	B-GENE
produced	O
from	O
mutants	O
was	O
affected	O
but	O
,	O
irrespective	O
of	O
the	O
glycosylation	O
phenotype	O
,	O
(	O
i	O
)	O
similar	O
quantities	O
of	O
Env	B-GENE
were	O
synthesized	O
,	O
(	O
ii	O
)	O
the	O
immunoreactivity	O
of	O
V3	O
was	O
similar	O
,	O
(	O
iii	O
)	O
gp160	B-GENE
was	O
efficiently	O
cleaved	O
into	O
gp120	B-GENE
and	O
gp41	B-GENE
,	O
(	O
vi	O
)	O
Env	B-GENE
was	O
exposed	O
at	O
the	O
cell	O
membrane	O
,	O
(	O
v	O
)	O
secreted	O
gp120	B-GENE
bound	O
CD4	B-GENE
,	O
and	O
(	O
vi	O
)	O
membrane	O
gp41	B-GENE
was	O
able	O
to	O
induce	O
membrane	O
fusion	O
with	O
CD4+	B-GENE
cells	O
.	O

Significantly	O
,	O
the	O
polymerase	O
chain	O
reaction	O
results	O
demonstrated	O
that	O
gene	B-GENE
IV	I-GENE
transcripts	I-GENE
were	O
associated	O
with	O
hepatic	O
polysome	O
fractions	O
,	O
indicating	O
their	O
active	O
utilization	O
in	O
this	O
tissue	O
.	O

Stability	O
of	O
pyrimethamine	O
in	O
a	O
liquid	O
dosage	O
formulation	O
stored	O
for	O
three	O
months	O
.	O

On	O
transition	O
from	O
high	O
to	O
low	O
voltage	O
there	O
was	O
a	O
significant	O
fall	O
in	O
arterial	O
pressure	O
(	O
7%	O
)	O
and	O
an	O
increase	O
in	O
flow	O
(	O
19-38%	O
)	O
to	O
areas	O
of	O
the	O
brain	O
corresponding	O
to	O
the	O
arborization	O
of	O
the	O
reticular	O
formation	O
,	O
i	O
.	O
e	O
.	O
excluding	O
the	O
cerebrum	O
and	O
cerebellum	O
.	O

The	O
results	O
indicate	O
that	O
the	O
pooling	O
requirements	O
are	O
task	O
dependent	O
.	O

Also	O
,	O
the	O
anti-inflammatory	O
activities	O
of	O
an	O
aqueous	O
extract	O
of	O
Buddleia	O
cordata	O
and	O
its	O
principal	O
glycoside	O
linarin	O
were	O
evaluated	O
.	O

The	O
possible	O
mechanisms	O
underlying	O
differences	O
in	O
post-tetanic	O
effects	O
from	O
muscle	O
and	O
cutaneous	O
afferents	O
in	O
adults	O
and	O
neonates	O
are	O
discussed	O
.	O

For	O
immunological	O
methods	O
,	O
identification	O
of	O
such	O
antigens	O
with	O
intermolecular	O
variability	O
,	O
e	O
.	O
g	O
.	O
,	O
the	O
structural	O
aescin	O
analogs	O
,	O
is	O
of	O
unknown	O
validity	O
.	O

This	O
report	O
provides	O
further	O
evidence	O
for	O
the	O
riMLF	O
in	O
the	O
control	O
of	O
downgaze	O
,	O
and	O
a	O
synkinesis	O
is	O
postulated	O
for	O
the	O
development	O
of	O
the	O
convergence	O
retraction	O
nystagmus	O
.	O

Abnormal	O
calcium	O
metabolism	O
in	O
normocalcaemic	O
sarcoidosis	O
[	O
letter	O
]	O
.	O

All	O
patients	O
diagnosed	O
of	O
H	O
.	O
influenza	O
type	O
b	O
meningitis	O
were	O
less	O
than	O
3	O
years	O
old	O
.	O

This	O
lack	O
of	O
correlation	O
may	O
be	O
due	O
to	O
variations	O
in	O
the	O
metabolic	O
activity	O
of	O
the	O
endometriotic	O
implants	O
present	O
at	O
different	O
stages	O
of	O
the	O
disease	O
.	O

Patients	O
with	O
acute	O
myocardial	O
infarction	O
had	O
higher	O
plasma	O
concentrations	O
of	O
neutrophil	B-GENE
elastase	I-GENE
and	O
the	O
non-peroxide	O
diene	O
conjugated	O
isomer	O
of	O
linoleic	O
acid	O
than	O
normal	O
volunteers	O
or	O
patients	O
with	O
stable	O
ischaemic	O
heart	O
disease	O
.	O

A	O
probe	O
evoked	O
potentials	O
procedure	O
was	O
used	O
to	O
assess	O
the	O
relative	O
engagement	O
of	O
both	O
cerebral	O
hemispheres	O
during	O
a	O
language	O
task	O
in	O
the	O
following	O
four	O
groups	O
of	O
dextral	O
adults	O
:	O
left	O
hemisphere	O
(	O
LH	O
)	O
-damaged	O
aphasics	O
recovering	O
from	O
stroke	O
,	O
dysarthrics	O
,	O
right	O
hemisphere	O
(	O
RH	O
)	O
-damaged	O
nonaphasic	O
patients	O
,	O
and	O
normal	O
control	O
subjects	O
.	O

On	O
Day	O
8	O
,	O
the	O
CIDR-B	O
was	O
removed	O
and	O
500	O
micrograms	O
cloprostenol	O
injected	O
,	O
IM	O
.	O

Plasma	O
glucose	O
,	O
immunoreactive	B-GENE
insulin	I-GENE
(	O
IRI	B-GENE
)	O
,	O
C-peptide	B-GENE
,	O
glucagon	B-GENE
,	O
and	O
GLP-1	B-GENE
levels	O
at	O
each	O
time	O
point	O
during	O
OGTT	O
were	O
measured	O
.	O

The	O
Drosophila	B-GENE
insulin	I-GENE
receptor	I-GENE
homolog	I-GENE
:	O
a	O
gene	O
essential	O
for	O
embryonic	O
development	O
encodes	O
two	O
receptor	O
isoforms	O
with	O
different	O
signaling	O
potential	O
.	O

Internal	O
modes	O
of	O
a	O
soliton	O
.	O

Vitrectomy	O
was	O
still	O
a	O
significant	O
risk	O
factor	O
when	O
macular	O
holes	O
were	O
excluded	O
.	O

The	O
absolute	O
concentrations	O
of	O
alpha	B-GENE
2-plasmin	I-GENE
inhibitor	O
,	O
alpha	B-GENE
2-macroglobulin	I-GENE
,	O
and	O
antithrombin	B-GENE
III	I-GENE
increased	O
with	O
exercise	O
(	O
all	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
but	O
when	O
concentrations	O
were	O
corrected	O
for	O
acute	O
shifts	O
of	O
plasma	O
water	O
during	O
exercise	O
,	O
the	O
quantity	O
of	O
these	O
inhibitors	O
actually	O
decreased	O
(	O
all	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

In	O
Rat	O
1a	O
cells	O
,	O
m1R	B-GENE
stimulation	O
of	O
phospholipase	B-GENE
C	I-GENE
beta	I-GENE
and	O
the	O
marked	O
rise	O
in	O
intracellular	O
calcium	O
stimulated	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
synthesis	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
protein	B-GENE
kinase	I-GENE
A	O
.	O

Electron	O
microscopic	O
and	O
enzymatic	O
analyses	O
revealed	O
that	O
the	O
A118	O
genome	O
is	O
a	O
linear	O
,	O
circularly	O
permuted	O
,	O
terminally	O
redundant	O
collection	O
of	O
double-stranded	O
DNA	O
molecules	O
.	O

Vbeta	B-GENE
segments	I-GENE
are	O
appended	O
to	O
DJbeta	B-GENE
rearrangements	I-GENE
,	O
with	O
little	O
or	O
no	O
direct	O
Vbeta	B-GENE
to	O
Jbeta	B-GENE
joining	O
,	O
despite	O
12	O
/	O
23	O
compatibility	O
of	O
Vbeta	B-GENE
23-RSSs	I-GENE
and	O
Jbeta12-RSSs	B-GENE
.	O

Immunophenotyping	O
in	O
four	O
cases	O
,	O
demonstrated	O
non-B	O
,	O
non-T	O
cell	O
origin	O
in	O
three	O
and	O
pre-B	O
cell	O
origin	O
in	O
one	O
.	O

Of	O
254	O
children	O
with	O
neuroblastoma	O
treated	O
at	O
St	O
.	O

SAMPLE	O
POPULATION	O
:	O
MCB	O
from	O
7	O
racing	O
Greyhounds	O
euthanatized	O
for	O
reasons	O
unrelated	O
to	O
MCB	O
abnormalities	O
.	O

Wild-type	O
protein	O
bound	O
azido-ATP	O
well	O
,	O
but	O
mutants	O
with	O
substitutions	O
in	O
the	O
consensus	O
amino	O
acids	O
were	O
unable	O
to	O
bind	O
azido-ATP	O
.	O

The	O
UAS	B-GENE
of	O
the	O
AAC2	B-GENE
gene	I-GENE
contains	O
at	O
least	O
two	O
distinct	O
motifs	O
for	O
DNA-binding	B-GENE
transcriptional	I-GENE
activators	I-GENE
,	O
including	O
one	O
which	O
is	O
identical	O
with	O
the	O
core	O
HAP2	B-GENE
/	I-GENE
3	I-GENE
/	I-GENE
4	I-GENE
binding	I-GENE
motif	I-GENE
,	O
and	O
a	O
second	O
one	O
with	O
the	O
ABF1	B-GENE
consensus	I-GENE
binding	I-GENE
sequence	I-GENE
.	O

At	O
temperatures	O
permissive	O
for	O
transformation	O
,	O
6m2	O
cells	O
contain	O
P58gag	B-GENE
produced	O
from	O
the	O
4	O
.	O
0-kilobase	O
(	O
kb	O
)	O
viral	O
RNA	O
genome	O
and	O
P85gag-mos	B-GENE
translated	O
from	O
a	O
3	O
.	O
5-kb	O
spliced	O
mRNA	O
.	O

The	O
reconstituted	O
RNA	B-GENE
polymerases	I-GENE
containing	O
the	O
mutant	O
alpha	O
subunits	O
were	O
examined	O
for	O
their	O
response	O
to	O
transcription	O
activation	O
by	O
cAMP-CRP	B-GENE
and	O
the	O
rrnBP1	B-GENE
UP	I-GENE
element	I-GENE
.	O

2001	O
.	O

In	O
short-term	O
cotransfections	O
,	O
a	O
pFRTK-CAT	B-GENE
target	O
containing	O
EBNA-1-binding	B-GENE
sites	I-GENE
from	O
the	O
EBV	O
origin	O
of	O
plasmid	O
replication	O
,	O
ori-P	B-GENE
,	O
was	O
transactivated	O
by	O
a	O
carboxy-terminal	B-GENE
EBNA-1	I-GENE
construction	I-GENE
(	O
amino	O
acids	O
450	O
to	O
641	O
)	O
that	O
also	O
carried	O
a	O
c-myc	B-GENE
nuclear	I-GENE
localization	I-GENE
signal	I-GENE
.	O

The	O
atp	B-GENE
1	I-GENE
and	O
atp	B-GENE
2	I-GENE
types	O
of	O
cDNA	O
sequences	O
were	O
the	O
most	O
redundant	O
among	O
the	O
28	O
different	O
isoperoxidases	B-GENE
identified	O
among	O
about	O
200	O
peroxidase	B-GENE
encoding	I-GENE
ESTs	I-GENE
.	O

REV	O
I	O
:	O
All	O
vessels	O
up	O
to	O
50%	O
stenosed	O
have	O
a	O
patent	O
graft	O
.	O

One	O
is	O
to	O
act	O
within	O
the	O
visceral	O
endoderm	O
to	O
promote	O
proper	O
streak	O
morphogenesis	O
.	O

Interestingly	O
,	O
the	O
activated	O
PDGF	B-GENE
beta-receptor	I-GENE
was	O
found	O
not	O
to	O
bind	O
Crk	B-GENE
proteins	I-GENE
.	O

The	O
transverse	O
magnetization	O
decays	O
mentioned	O
above	O
exhibited	O
two	O
components	O
,	O
a	O
T2	O
fast	O
(	O
T2f	O
)	O
and	O
a	O
T2	O
slow	O
(	O
T2s	O
)	O
component	O
.	O

The	O
deduced	O
96-residue	O
amino	O
acid	O
coding	O
sequence	O
of	O
the	O
murine	O
HMG-I	B-GENE
(	I-GENE
Y	I-GENE
)	I-GENE
cDNA	O
is	O
very	O
similar	O
to	O
the	O
reported	O
amino	O
acid	O
sequence	O
of	O
human	O
HMG-I	B-GENE
,	O
except	O
that	O
it	O
lacks	O
11	O
internal	O
amino	O
acids	O
reported	O
in	O
the	O
human	O
protein	O
.	O

Furthermore	O
,	O
SB203580	O
inhibited	O
LPS-induced	O
activation	O
of	O
Sp1	B-GENE
,	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
in	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
Sp1	B-GENE
consensus	O
sequence	O
.	O

It	O
is	O
now	O
recognized	O
that	O
essentially	O
all	O
eukaryotic	O
and	O
prokaryotic	O
genes	O
whose	O
5'-flanking	O
regions	O
are	O
known	O
and	O
that	O
encode	O
barbiturate-inducible	O
proteins	O
contain	O
the	O
Barbie	B-GENE
box	I-GENE
element	I-GENE
.	O

The	O
effects	O
of	O
mean	O
luminance	O
were	O
also	O
measured	O
and	O
a	O
general	O
expression	O
that	O
would	O
take	O
them	O
into	O
account	O
was	O
derived	O
.	O

The	O
structural	O
study	O
of	O
peptides	O
belonging	O
to	O
the	O
terminal	O
domains	O
of	O
histone	B-GENE
H1	I-GENE
can	O
be	O
considered	O
as	O
a	O
step	O
toward	O
the	O
understanding	O
of	O
the	O
function	O
of	O
H1	B-GENE
in	O
chromatin	O
.	O

3	O
.	O

Clear	O
and	O
evidenced-based	O
information	O
should	O
be	O
provided	O
to	O
patients	O
as	O
to	O
the	O
means	O
of	O
prevention	O
with	O
special	O
attention	O
to	O
individual	O
risk	O
groups	O
such	O
as	O
IV	O
drug	O
abusers	O
.	O

The	O
eating	O
and	O
drinking	O
patterns	O
of	O
pygmy	O
goats	O
fed	O
ad	O
lib	O
and	O
kept	O
on	O
a	O
12	O
h	O
light	O
/	O
12	O
h	O
dark	O
cycle	O
were	O
recorded	O
and	O
analyzed	O
.	O

Chaotic	O
electron	O
dynamics	O
around	O
a	O
single	O
elliptically	O
shaped	O
antidot	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrated	O
a	O
unique	O
mechanism	O
of	O
action	O
of	O
8-Cl-cAMP	O
in	O
the	O
regulation	O
of	O
these	O
kinase	B-GENE
isozymes	I-GENE
in	O
HL-60	O
human	O
promyelocytic	O
leukemia	O
cells	O
.	O

The	O
comparisons	O
revealed	O
that	O
female	O
homicide-suicide	O
perpetrators	O
were	O
more	O
likely	O
than	O
female	O
homicide-suicide	O
victims	O
to	O
live	O
in	O
mobile	O
homes	O
,	O
kill	O
their	O
lover	O
or	O
ex-lover	O
,	O
have	O
their	O
crime	O
accidentally	O
discovered	O
,	O
leave	O
a	O
suicide	O
note	O
,	O
kill	O
on	O
a	O
weekend	O
,	O
and	O
be	O
depressed	O
,	O
but	O
are	O
less	O
likely	O
than	O
female	O
homicide-suicide	O
victims	O
to	O
live	O
with	O
a	O
spouse	O
.	O

Efficacy	O
and	O
safety	O
of	O
aspirin	O
in	O
the	O
long-term	O
management	O
of	O
atherothrombosis	O
.	O

Northern	O
(	O
RNA	O
)	O
blot	O
analyses	O
indicated	O
that	O
the	O
cdh	B-GENE
genes	I-GENE
encoding	O
the	O
five	O
subunits	O
and	O
an	O
open	O
reading	O
frame	O
(	O
ORF1	O
)	O
with	O
unknown	O
function	O
are	O
cotranscribed	O
during	O
growth	O
on	O
acetate	O
.	O

Prospects	O
for	O
controlled-delivery	O
systems	O
.	O

Mycoplasma	O
hominis	O
infections	O
are	O
easily	O
missed	O
because	O
conventional	O
methods	O
for	O
bacterial	O
detection	O
may	O
fail	O
.	O

Finally	O
,	O
in	O
situ	O
RNA	O
hybridization	O
studies	O
revealed	O
a	O
very	O
specific	O
pattern	O
of	O
EphA8	B-GENE
gene	I-GENE
expression	O
restricted	O
to	O
the	O
rostral	O
region	O
of	O
midbrain	O
tectum	O
during	O
embryonic	O
development	O
.	O

The	O
1	O
.	O
7	O
kb	O
cloned	O
fragment	O
was	O
sequenced	O
and	O
shown	O
to	O
contain	O
the	O
entire	O
fliA	B-GENE
gene	I-GENE
.	O

The	O
results	O
indicate	O
that	O
the	O
carbon-perfused	O
areas	O
and	O
MBF	O
in	O
the	O
liver	O
,	O
renal	O
cortex	O
,	O
spleen	O
,	O
and	O
small	O
intestinal	O
serosa	O
(	O
only	O
MBF	O
)	O
increased	O
significantly	O
5	O
h	O
after	O
CLP	O
.	O

Since	O
RCC1p	B-GENE
acts	O
as	O
GNRP	B-GENE
for	O
Ran	B-GENE
,	O
a	O
small	B-GENE
nuclear	I-GENE
GTPase	I-GENE
of	O
the	O
ras	B-GENE
superfamily	I-GENE
,	O
we	O
have	O
identified	O
two	O
homologs	O
of	O
Ran	B-GENE
in	O
S	O
.	O
cerevisiae	O
(	O
CNR1	B-GENE
and	O
CNR2	B-GENE
)	O
.	O

These	O
mutant	O
proteins	O
retained	O
the	O
ability	O
to	O
competitively	O
inhibit	O
kappa	O
B-mediated	O
transcriptional	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
but	O
failed	O
to	O
efficiently	O
transform	O
chicken	O
lymphoid	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

A	O
patient	O
of	O
Group	O
B	O
had	O
severe	O
athetoid	O
CP	O
with	O
spasticity	O
,	O
being	O
unable	O
to	O
right	O
his	O
trunk	O
and	O
neck	O
.	O

Mapping	O
of	O
the	O
human	B-GENE
Voltage-Dependent	I-GENE
Anion	I-GENE
Channel	I-GENE
isoforms	I-GENE
1	I-GENE
and	I-GENE
2	I-GENE
reconsidered	O
.	O

The	O
Functional	O
Independence	O
Measure	O
:	O
a	O
comparative	O
study	O
of	O
clinician	O
and	O
self	O
ratings	O
.	O

The	O
combination	O
of	O
MISO	O
and	O
WR-2721	O
gave	O
an	O
intermediate	O
response	O
compared	O
with	O
either	O
drug	O
used	O
alone	O
,	O
resulting	O
in	O
some	O
sensitization	O
with	O
single	O
doses	O
and	O
an	O
overall	O
protection	O
with	O
repeated	O
small	O
doses	O
.	O

To	O
determine	O
whether	O
P35	B-GENE
could	O
activate	O
the	O
39k	O
promoter	O
in	O
the	O
absence	O
of	O
IE1	B-GENE
,	O
the	O
p35	B-GENE
open	O
reading	O
frame	O
was	O
cloned	O
under	O
the	O
control	O
of	O
the	O
ie1	B-GENE
promoter	I-GENE
.	O

A	O
previous	O
report	O
described	O
that	O
a	O
548-bp	B-GENE
BglII-SmaI	I-GENE
fragment	I-GENE
has	O
an	O
SSO	O
activity	O
(	O
ori2	O
;	O
Kataoka	O
et	O
al	O
.	O
,	O
Mol	O
.	O

In	O
summary	O
,	O
the	O
segments	O
of	O
C3	B-GENE
represented	O
by	O
amino	O
acid	O
residues	O
1082-1118	O
,	O
1117-1155	O
,	O
1234-1294	O
and	O
1312-1404	O
accommodate	O
C3	B-GENE
(	I-GENE
D	I-GENE
)	I-GENE
epitopes	I-GENE
that	O
are	O
expressed	O
by	O
erythrocyte-bound	O
C3	B-GENE
fragments	I-GENE
,	O
but	O
not	O
by	O
the	O
corresponding	O
fluid-phase	O
fragment	O
,	O
whereas	O
the	O
segments	O
spanning	O
residues	O
973-1026	O
and	O
1477-1510	O
contain	O
C3	B-GENE
(	I-GENE
D	I-GENE
)	I-GENE
epitopes	I-GENE
that	O
are	O
exposed	O
exclusively	O
in	O
denatured	O
C3	B-GENE
and	O
therefore	O
hidden	O
in	O
physiological	O
fragments	O
of	O
the	O
protein	O
.	O

Thus	O
,	O
TRAF2	B-GENE
initiates	O
SAPK	B-GENE
and	O
p38	B-GENE
activation	O
by	O
binding	O
two	O
proximal	O
protein	B-GENE
kinases	I-GENE
:	O
GCK	B-GENE
and	O
RIP	B-GENE
.	O

Of	O
the	O
43	O
infants	O
with	O
a	O
(	O
probable	O
)	O
loss	O
18	O
were	O
examined	O
again	O
at	O
3	O
months	O
corrected	O
age	O
.	O

3	O
cases	O
.	O

The	O
52-protein	O
subunit	O
of	O
T4	B-GENE
DNA	I-GENE
topoisomerase	I-GENE
is	O
homologous	O
to	O
the	O
gyrA-protein	B-GENE
of	O
gyrase	B-GENE
.	O

Intensive	O
synthesis	O
of	O
PNA	B-GENE
in	O
the	O
cells	O
of	O
microvascular	O
wall	O
evidenced	O
of	O
their	O
high	O
functional	O
activity	O
,	O
and	O
the	O
synthesis	O
of	O
DNA	O
in	O
them	O
showed	O
their	O
ability	O
for	O
proliferation	O
,	O
i	O
.	O
g	O
.	O
--for	O
growth	O
.	O

In	O
a	O
randomized	O
study	O
on	O
150	O
patients	O
(	O
ASA	O
1	O
)	O
undergoing	O
induction	O
of	O
anaesthesia	O
,	O
the	O
effects	O
of	O
Fentanyl	O
(	O
0	O
.	O
1	O
mg	O
)	O
,	O
the	O
combination	O
of	O
Fentanyl	O
(	O
0	O
.	O
1	O
mg	O
)	O
and	O
Droperidol	O
(	O
5	O
mg	O
)	O
(	O
Innovar	O
,	O
Thalamonal	O
)	O
and	O
Atropine	O
(	O
0	O
.	O
01	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
)	O
alone	O
on	O
cardiocirculatory	O
parameters	O
were	O
studied	O
.	O

Since	O
the	O
ETS	B-GENE
domain	I-GENE
,	O
which	O
is	O
localized	O
in	O
the	O
carboxy	O
terminal	O
region	O
of	O
the	O
encoded	O
protein	O
,	O
is	O
95%	O
and	O
96%	O
identical	O
to	O
that	O
of	O
PEA3	B-GENE
and	O
ER81	B-GENE
,	O
respectively	O
,	O
we	O
named	O
this	O
new	O
member	O
'Ets	B-GENE
Related	I-GENE
Molecule	I-GENE
PEA3-like'	I-GENE
(	O
ERM	B-GENE
)	O
.	O

Relative	O
to	O
coherent	O
control	O
words	O
(	O
e	O
.	O
g	O
.	O
,	O
quick	O
)	O
,	O
these	O
discourse-dependent	O
semantic	O
anomalies	O
elicited	O
a	O
large	O
N400	O
effect	O
that	O
began	O
at	O
about	O
200	O
to	O
250	O
msec	O
after	O
word	O
onset	O
.	O

The	O
second	O
primary	O
mutant	O
contained	O
a	O
proline-to-leucine	O
change	O
at	O
position	O
243	O
(	O
P243L	O
)	O
.	O

The	O
fast	O
real-time	O
digital	O
processing	O
of	O
the	O
N2	O
and	O
flow	O
signals	O
incorporated	O
filtering	O
,	O
delay	O
compensation	O
,	O
and	O
corrections	O
for	O
the	O
effects	O
of	O
changes	O
in	O
gas	O
composition	O
and	O
temperature	O
.	O

In	O
patients	O
with	O
myalgia	O
,	O
Raynaud's	O
syndrome	O
,	O
skin	O
vasculitis	O
and	O
vascular	O
diseases	O
WFAg	B-GENE
concentrations	O
were	O
higher	O
than	O
in	O
patients	O
without	O
them	O
.	O

The	O
Y	O
.	O
lipolytica	O
genomic	O
POT1	B-GENE
gene	O
was	O
disrupted	O
by	O
replacing	O
120	O
bp	O
of	O
its	O
coding	O
sequence	O
with	O
2	O
.	O
7	O
kbp	O
of	O
DNA	O
including	O
the	O
Y	O
.	O
lipolytica	O
LEU2	B-GENE
gene	I-GENE
.	O

Activated	O
PKR	B-GENE
may	O
exist	O
as	O
a	O
dimer	O
and	O
phosphorylates	O
the	O
eukaryotic	B-GENE
translation	I-GENE
initiation	I-GENE
factor	I-GENE
2	I-GENE
alpha	I-GENE
subunit	I-GENE
(	O
cIF-2	B-GENE
alpha	I-GENE
)	O
to	O
inhibit	O
polypeptide	O
chain	O
initiation	O
.	O

After	O
24	O
hour	O
incubation	O
,	O
total	O
cell-associated	O
IL-1Ra	B-GENE
and	O
IL-1	B-GENE
beta	I-GENE
were	O
measured	O
by	O
specific	O
radioimmunoassay	O
.	O

SGPT	B-GENE
,	O
SGOT	B-GENE
,	O
and	O
alkaline	B-GENE
phosphatase	I-GENE
concentrations	O
were	O
essentially	O
normal	O
in	O
all	O
subjects	O
.	O

Weak	O
allergenicity	O
of	O
recombinant	B-GENE
hirudin	I-GENE
CGP	I-GENE
39393	I-GENE
(	O
REVASC	O
)	O
in	O
immunocompetent	O
volunteers	O
.	O

The	O
DNA	O
sequencing	O
of	O
the	O
recombinant	O
clones	O
revealed	O
the	O
expression	O
of	O
RXR	B-GENE
alpha	I-GENE
and	O
RXR	B-GENE
beta	I-GENE
.	O

TBARS	O
levels	O
,	O
oxygen-radical	O
absorbing	O
capacity	O
assay	O
and	O
AFR	O
release	O
assessed	O
by	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
were	O
used	O
to	O
explore	O
the	O
existence	O
of	O
oxidative	O
stress	O
in	O
diabetes	O
.	O

METHODS	O
:	O
A	O
population	O
survey	O
was	O
undertaken	O
in	O
10	O
,	O
148	O
individuals	O
to	O
measure	O
the	O
prevalence	O
and	O
identify	O
the	O
causes	O
of	O
blindness	O
in	O
Lebanon	O
.	O

A	O
73	B-GENE
bp	I-GENE
fragment	I-GENE
(	I-GENE
X1	I-GENE
region	I-GENE
)	I-GENE
of	O
the	O
PRB-1b	B-GENE
promoter	I-GENE
,	O
located	O
between	O
positions	O
-213	O
and	O
-141	O
,	O
was	O
sufficient	O
to	O
confer	O
ethylene	O
responsiveness	O
to	O
the	O
reporter	O
gene	O
.	O

More	O
recently	O
,	O
however	O
,	O
a	O
number	O
of	O
developments	O
such	O
as	O
the	O
successful	O
use	O
of	O
the	O
inhaled	O
steroid	O
budesonide	O
and	O
oral	O
dexamethasone	O
have	O
reinforced	O
the	O
argument	O
for	O
using	O
steroids	O
.	O

Comparison	O
with	O
a	O
recently	O
described	O
c-sis	B-GENE
cDNA	I-GENE
clone	I-GENE
(	O
Collins	O
et	O
al	O
.	O
,	O
Nature	O
316	O
,	O
748-750	O
(	O
1985	O
)	O
)	O
revealed	O
that	O
the	O
1	O
.	O
9	O
kbp	O
DNA	O
region	O
contained	O
a	O
large	O
5'	B-GENE
c-sis	I-GENE
exon	I-GENE
of	O
at	O
least	O
1050	O
bp	O
.	O

This	O
cluster	O
consisted	O
of	O
four	O
apparently	O
unrelated	O
ESTs	O
and	O
two	O
genes	O
,	O
pregnancy-associated	B-GENE
plasma	I-GENE
protein-A	I-GENE
(	O
PAPP-A	B-GENE
)	O
and	O
a	O
novel	O
gene	O
(	O
tentatively	O
named	O
EST-YD1	B-GENE
)	O
.	O

The	O
revertant	O
TATA	O
boxes	O
accelerated	O
the	O
kinetics	O
of	O
HIV	O
replication	O
when	O
present	O
in	O
the	O
context	O
of	O
an	O
LTR	O
containing	O
a	O
Sp1	B-GENE
mutation	O
(	O
deletion	O
or	O
site	O
specific	O
)	O
;	O
no	O
effect	O
was	O
observed	O
on	O
the	O
infectivity	O
of	O
wild-type	O
HIV	O
.	O

Higher	O
CYP3A23	B-GENE
basal	O
activity	O
appears	O
to	O
be	O
due	O
to	O
an	O
E-box	O
in	O
3A23SiteA	B-GENE
that	O
interacts	O
with	O
USF1	B-GENE
,	O
a	O
ubiquitous	O
bHLH	B-GENE
/	I-GENE
leucine	I-GENE
zipper	I-GENE
transcription	I-GENE
factor	I-GENE
.	O

Transcription	O
factor	O
binding	O
sites	O
downstream	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
start	O
site	O
are	O
important	O
for	O
virus	O
infectivity	O
.	O

Results	O
from	O
our	O
and	O
other	O
laboratories	O
have	O
suggested	O
that	O
UCN-01	O
induces	O
preferential	O
G1-phase	O
accumulation	O
in	O
several	O
human	O
tumor	O
cell	O
lines	O
tested	O
.	O

To	O
understand	O
the	O
basis	O
for	O
the	O
increased	O
cell	O
surface	O
stability	O
compared	O
with	O
wild-type	O
peptide	O
and	O
to	O
understand	O
the	O
differences	O
in	O
T	O
cell	O
recognition	O
between	O
I1Y	B-GENE
and	O
I1F	B-GENE
,	O
we	O
determined	O
the	O
x-ray	O
crystal	O
structures	O
of	O
the	O
two	O
class	B-GENE
I	I-GENE
MHC-peptide	I-GENE
complexes	I-GENE
.	O

AgMNPV	O
and	O
Orgyia	O
pseudotsugata	O
MNPV	O
(	O
OpMNPV	O
)	O
are	O
similar	O
in	O
terms	O
of	O
promoter	O
structure	O
and	O
polyhedrin	B-GENE
primary	I-GENE
sequence	I-GENE
,	O
and	O
the	O
polyhedrin	B-GENE
gene	I-GENE
of	O
both	O
viruses	O
is	O
transcribed	O
in	O
the	O
anti-clockwise	O
direction	O
in	O
relation	O
to	O
their	O
physical	O
maps	O
.	O

Stress	O
effects	O
on	O
affiliation	O
preferences	O
among	O
subjects	O
possessing	O
the	O
type	O
A	O
coronary-prone	O
behavior	O
pattern	O
.	O

The	O
performance	O
of	O
pH-sensitive	O
particles	O
is	O
attributed	O
to	O
their	O
ability	O
to	O
release	O
the	O
drug	O
selectively	O
in	O
the	O
upper	O
part	O
of	O
the	O
intestine	O
in	O
a	O
molecular	O
or	O
amorphous	O
form	O
.	O

Chlamydia	O
and	O
cervical	O
cancer	O
:	O
a	O
real	O
association	O
?	O

From	O
250	O
g	O
of	O
cells	O
,	O
we	O
isolated	O
1	O
mg	O
of	O
PDH	B-GENE
complex	I-GENE
with	O
a	O
specific	O
activity	O
of	O
12	O
.	O
6	O
U	O
/	O
mg	O
of	O
protein	O
.	O

Progression	O
after	O
first-line	O
chemotherapy	O
was	O
associated	O
with	O
significantly	O
worse	O
survival	O
for	O
patients	O
with	O
metastasis	O
.	O

The	O
histopathology	O
and	O
neovascularization	O
did	O
not	O
appreciably	O
differ	O
between	O
xenograft	O
tumors	O
derived	O
from	O
FGF4	B-GENE
over-expressing	O
versus	O
control	O
transfectants	O
.	O

ORF	O
2	O
potentially	O
encoded	O
a	O
hydrophobic	O
protein	O
of	O
29	O
,	O
705	O
Da	O
with	O
six	O
potential	O
membrane-spanning	O
regions	O
.	O

Genomic	O
structure	O
and	O
chromosomal	O
location	O
of	O
the	O
mouse	B-GENE
pre-T-cell	I-GENE
receptor	I-GENE
alpha	I-GENE
gene	I-GENE
.	O

When	O
the	O
entire	O
diet	O
consisted	O
of	O
SBF	O
,	O
voluntary	O
feed	O
intake	O
was	O
reduced	O
,	O
indicating	O
that	O
SBF	O
should	O
not	O
be	O
fed	O
to	O
ponies	O
as	O
the	O
sole	O
dietary	O
ingredient	O
.	O

The	O
authors	O
made	O
an	O
analysis	O
of	O
social-economical	O
conditions	O
limiting	O
the	O
possibilities	O
of	O
rendering	O
cardiosurgical	O
care	O
to	O
children	O
.	O

Therefore	O
,	O
it	O
is	O
hoped	O
that	O
by	O
defining	O
the	O
transcriptional	O
control	O
of	O
the	O
L7	B-GENE
gene	I-GENE
insights	O
into	O
the	O
mechanisms	O
that	O
control	O
functional	O
fate	O
and	O
organization	O
in	O
the	O
nervous	O
system	O
can	O
be	O
gained	O
.	O

We	O
showed	O
previously	O
that	O
a	O
fusion	O
protein	O
(	O
GAL4-p40	B-GENE
)	O
containing	O
the	O
DNA-binding	O
domain	O
of	O
GAL4	B-GENE
and	O
sequences	O
of	O
chicken	B-GENE
l	I-GENE
kappa	I-GENE
B-alpha	I-GENE
(	O
p40	B-GENE
)	O
inhibits	O
growth	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Activation	O
of	O
the	O
SH2-containing	B-GENE
protein	I-GENE
tyrosine	I-GENE
phosphatase	I-GENE
,	O
SH-PTP2	B-GENE
,	O
by	O
phosphotyrosine-containing	O
peptides	O
derived	O
from	O
insulin	B-GENE
receptor	I-GENE
substrate-1	I-GENE
.	O

We	O
thus	O
conclude	O
that	O
the	O
NFAT	B-GENE
RIR	I-GENE
plays	O
an	O
essential	O
dual	O
role	O
in	O
DNA	O
recognition	O
and	O
cooperative	O
binding	O
to	O
AP-1	B-GENE
family	I-GENE
transcription	I-GENE
factors	I-GENE
.	O

Atheroma	O
appears	O
as	O
a	O
very	O
low	O
signal	O
intensity	O
area	O
on	O
2-dimensional	O
time-of-flight	O
(	O
TOF	O
)	O
magnetic	O
resonance	O
(	O
MR	O
)	O
images	O
,	O
and	O
its	O
components	O
have	O
various	O
signal	O
intensities	O
on	O
spin-echo	O
(	O
SE	O
)	O
images	O
.	O

After	O
that	O
report	O
,	O
carboxypeptidase	B-GENE
D	I-GENE
(	O
CPD	B-GENE
)	O
was	O
subsequently	O
purified	O
from	O
bovine	O
pituitary	O
and	O
characterized	O
as	O
a	O
novel	O
carboxypeptidase	B-GENE
E	I-GENE
(	O
CPE	B-GENE
)	O
-like	O
enzyme	O
,	O
with	O
many	O
characteristics	O
in	O
common	O
with	O
duck	O
gp180	B-GENE
(	O
Song	O
,	O
L	O
.	O
,	O
Fricker	O
,	O
L	O
.	O
D	O
.	O
,	O
1995	O
.	O

Proteinuria--selected	O
physiopathological	O
and	O
clinical	O
problems	O
.	O

Although	O
popular	O
this	O
hypothesis	O
is	O
far	O
from	O
explaining	O
all	O
the	O
clinical	O
facts	O
,	O
namely	O
that	O
rigidity	O
is	O
equal	O
in	O
extensor	O
and	O
flexor	O
,	O
proximal	O
and	O
distal	O
muscles	O
.	O

In	O
patients	O
with	O
osteomyelitis	O
and	O
joint	O
empyema	O
(	O
n	O
=	O
48	O
)	O
PMN	B-GENE
elastase	I-GENE
had	O
a	O
sensitivity	O
of	O
77%	O
,	O
which	O
was	O
only	O
exceeded	O
by	O
that	O
of	O
the	O
unspecific	O
erythrocyte	O
sedimentation	O
rate	O
(	O
sensitivity	O
89%	O
)	O
.	O

Cytoplasmic	B-GENE
dynein	I-GENE
is	O
a	O
multisubunit	O
,	O
microtubule-dependent	O
mechanochemical	O
enzyme	O
that	O
has	O
been	O
proposed	O
to	O
function	O
in	O
a	O
variety	O
of	O
intracellular	O
movements	O
,	O
including	O
minus-end-directed	O
transport	O
of	O
organelles	O
.	O

The	O
authors	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
pathology	O
with	O
quantification	O
of	O
the	O
percentage	O
of	O
papillary	O
serous	O
component	O
(	O
%	O
PSC	O
)	O
and	O
p53	B-GENE
expression	O
.	O

The	O
maximum	O
induction	O
of	O
ACC-oxidase	B-GENE
transcripts	I-GENE
occurred	O
at	O
about	O
6	O
h	O
after	O
excision	O
,	O
while	O
the	O
maximum	O
enzyme	O
activity	O
was	O
observed	O
at	O
24	O
h	O
.	O

TPO	B-GENE
by	O
itself	O
did	O
not	O
activate	O
ERK1	B-GENE
,	O
ERK2	B-GENE
and	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
(	O
PKC	B-GENE
)	O
,	O
whereas	O
TPO	B-GENE
directly	O
enhanced	O
the	O
PKC-dependent	O
activation	O
of	O
ERKs	B-GENE
induced	O
by	O
other	O
agonists	O
including	O
thrombin	B-GENE
and	O
phorbol	O
esters	O
,	O
without	O
affecting	O
the	O
PKC	B-GENE
activation	O
by	O
those	O
agonists	O
.	O

Except	O
for	O
nonperfusion	O
of	O
neurosensory	O
retinal	O
vessels	O
at	O
a	O
light	O
dose	O
of	O
150	O
J	O
/	O
cm2	O
,	O
no	O
other	O
adverse	O
events	O
were	O
of	O
concern	O
.	O

The	O
complement	B-GENE
C3a	I-GENE
anaphylatoxin	I-GENE
receptor	I-GENE
(	O
C3aR	B-GENE
)	O
is	O
a	O
seven-transmembrane	B-GENE
G-protein	I-GENE
coupled	I-GENE
chemoattractant	I-GENE
receptor	I-GENE
that	O
on	O
binding	O
the	O
C3a	B-GENE
peptide	I-GENE
ligand	I-GENE
mediates	O
numerous	O
cellular	O
responses	O
,	O
including	O
histamine	O
release	O
from	O
mast	O
cells	O
.	O
smooth	O
muscle	O
contraction	O
,	O
and	O
the	O
directed	O
migration	O
of	O
eosinophils	O
.	O

With	O
constructs	O
containing	O
the	O
binding	O
site	O
of	O
one	O
gene	O
fused	O
to	O
the	O
promoter	O
of	O
the	O
other	O
,	O
we	O
demonstrated	O
that	O
the	O
positional	O
requirements	O
are	O
a	O
function	O
of	O
the	O
specific	O
binding	O
site	O
,	O
not	O
the	O
promoter	O
.	O

These	O
results	O
indicate	O
that	O
CSFHU	B-GENE
can	O
increase	O
neutrophil	O
counts	O
by	O
increasing	O
the	O
number	O
and	O
maturity	O
of	O
the	O
marrow	O
neutrophil	O
precursors	O
in	O
some	O
types	O
of	O
childhood	O
chronic	O
neutropenia	O
.	O

Initial	O
experience	O
with	O
a	O
serotonin	O
agonist	O
.	O

(	O
1998	O
)	O
FASEB	O
J	O
.	O

Lung	O
prostacyclin	O
production	O
may	O
be	O
related	O
to	O
flow	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
R	B-GENE
has	O
revealed	O
similarities	O
to	O
the	O
R1	O
plasmid	O
found	O
in	O
some	O
South	O
American	O
maize	O
races	O
with	O
RU	O
cytoplasm	O
,	O
to	O
the	O
M1	O
plasmid	O
found	O
in	O
one	O
source	O
of	O
Zea	O
luxurians	O
teosinte	O
,	O
to	O
the	O
atp9	B-GENE
mitochondrial	I-GENE
gene	I-GENE
and	O
its	O
3'	O
flanking	O
sequence	O
,	O
and	O
also	O
to	O
a	O
region	O
3'	O
to	O
the	O
orf221	B-GENE
gene	I-GENE
.	O

The	O
P13	O
and	O
N22	O
of	O
ppSEPs	O
had	O
phase	O
reversal	O
relationship	O
with	O
the	O
P2	O
and	O
N2	O
recorded	O
from	O
the	O
PES	O
,	O
respectively	O
.	O

Three	O
classes	O
of	O
test	O
objects	O
were	O
considered	O
:	O
(	O
1	O
)	O
a	O
multicompartment	O
test	O
object	O
for	O
31P	O
MRS	O
measurements	O
performed	O
with	O
slice-selective	O
sequences	O
;	O
(	O
2	O
)	O
a	O
two-compartment	O
test	O
object	O
for	O
volume-selection	O
1H	O
MRS	O
;	O
and	O
(	O
3	O
)	O
two-compartment	O
test	O
objects	O
for	O
assessing	O
the	O
performance	O
of	O
experimental	O
systems	O
using	O
ISIS	O
as	O
volume	O
localization	O
sequence	O
in	O
31P	O
MRS	O
.	O

Purified	O
spleen	O
GAP	B-GENE
accelerated	O
hydrolysis	O
of	O
GTP	O
bound	O
to	O
recombinant	B-GENE
ARF1	I-GENE
,	O
ARF3	B-GENE
,	O
ARF5	B-GENE
,	O
and	O
ARF6	B-GENE
;	O
no	O
effect	O
of	O
NH2-terminal	O
myristoylation	O
was	O
observed	O
.	O

Specifically	O
,	O
recombination	O
at	O
HMR	B-GENE
was	O
used	O
to	O
produce	O
rings	O
that	O
lacked	O
the	O
E	B-GENE
and	I-GENE
I	I-GENE
silencers	I-GENE
.	O

Twenty	O
patients	O
aged	O
45	O
or	O
older	O
with	O
the	O
diagnosis	O
of	O
endogenous	O
depression	O
were	O
evaluated	O
in	O
terms	O
of	O
safety	O
and	O
efficacy	O
in	O
their	O
response	O
to	O
multiple	O
monitored	O
electroconvulsive	O
therapy	O
(	O
MMECT	O
)	O
versus	O
single	O
electroconvulsive	O
therapy	O
(	O
SECT	O
)	O
.	O

Despite	O
the	O
reported	O
detrimental	O
effects	O
on	O
CNS	O
development	O
,	O
a	O
number	O
of	O
animal	O
studies	O
have	O
shown	O
that	O
pretreatment	O
with	O
corticosteroids	O
nevertheless	O
protect	O
the	O
brain	O
from	O
hypoxia-ischemic	O
injury	O
;	O
however	O
,	O
clinically	O
such	O
treatment	O
is	O
no	O
longer	O
favored	O
.	O

V	O
.	O

No	O
previous	O
studies	O
have	O
determined	O
the	O
pharmaco-dynamics	O
of	O
intravenous	O
procainamide	O
when	O
administered	O
in	O
a	O
dose	O
of	O
15	O
mg	O
/	O
kg	O
and	O
at	O
a	O
rate	O
of	O
50	O
mg	O
/	O
min	O
,	O
as	O
is	O
common	O
practice	O
during	O
electropharmacologic	O
testing	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
HHCA	O
and	O
other	O
serological	O
factors	O
upon	O
the	O
development	O
of	O
VGS	O
.	O

Separate	O
experiments	O
measured	O
AIB	O
and	O
86RbCl	O
uptake	O
in	O
36B-10	O
cells	O
in	O
vitro	O
1	O
and	O
2	O
days	O
following	O
20	O
Gy	O
irradiation	O
to	O
assess	O
whether	O
this	O
radiation	O
dose	O
reduced	O
the	O
capacity	O
of	O
tumor	O
cells	O
to	O
trap	O
AIB	O
or	O
Rb+	O
.	O

Hydropathy	O
analysis	O
of	O
KCC1	B-GENE
indicates	O
structural	O
homology	O
to	O
NKCC	B-GENE
,	O
including	O
12	O
transmembrane	O
domains	O
,	O
a	O
large	O
extracellular	O
loop	O
with	O
potential	O
N-linked	O
glycosylation	O
sites	O
,	O
and	O
cytoplasmic	O
N-	O
and	O
C-terminal	O
regions	O
.	O

Liver	O
injuries	O
.	O

Furthermore	O
,	O
experiments	O
with	O
32D	O
temperature-sensitive	O
p53	B-GENE
cells	O
indicate	O
that	O
aberrant	O
tal-1	B-GENE
expression	O
at	O
the	O
permissive	O
temperature	O
does	O
not	O
exert	O
a	O
proliferative	O
effect	O
but	O
causes	O
p53-mediated	O
apoptosis	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
tal-1	B-GENE
proliferative	O
effect	O
depends	O
on	O
the	O
integrity	O
of	O
the	O
cell	O
cycle	O
checkpoints	O
of	O
the	O
host	O
cell	O
,	O
as	O
observed	O
for	O
c-myc	B-GENE
and	O
other	O
oncogenes	O
.	O
tal-1	B-GENE
mutant	I-GENE
experiments	O
indicate	O
that	O
ectopic	O
tal-1	B-GENE
effects	O
are	O
mediated	O
by	O
both	O
the	O
DNA-binding	O
and	O
the	O
heterodimerization	O
domains	O
,	O
while	O
the	O
N-terminally	B-GENE
truncated	I-GENE
tal-1	I-GENE
variant	I-GENE
(	O
M3	B-GENE
)	O
expressed	O
in	O
T-ALL	O
malignant	O
cells	O
mimics	O
the	O
effects	O
of	O
the	O
wild-type	O
protein	O
.	O

However	O
,	O
each	O
promoter	O
activated	O
by	O
IEP86	B-GENE
was	O
synergistically	O
affected	O
by	O
the	O
addition	O
of	O
IEP72	B-GENE
.	O

Computer	O
software	O
assisted	O
ordering	O
(	O
CSAO	O
)	O
was	O
developed	O
to	O
integrate	O
PN	O
Ca	O
:	O
P	O
solubility	O
with	O
clinical	O
data	O
to	O
improve	O
parenteral	O
Ca	O
and	O
P	O
administration	O
.	O

In	O
adulthood	O
these	O
rats	O
were	O
hyperactive	O
and	O
learned	O
the	O
active	O
avoidance	O
response	O
later	O
than	O
the	O
controls	O
.	O

Activation	O
of	O
PKA	B-GENE
by	O
8-bromo-cyclic	O
AMP	O
or	O
forskolin	O
,	O
and	O
inhibition	O
of	O
PKC	B-GENE
by	O
calphostin	O
C	O
,	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
3TP	B-GENE
activity	O
as	O
well	O
as	O
in	O
vitro	O
ERK	B-GENE
kinase	I-GENE
activity	O
in	O
CRAC	O
.	O

When	O
tested	O
with	O
wild-type	O
(	O
DBA	O
/	O
2	O
)	O
p16	B-GENE
,	O
both	O
A134C	O
and	O
G232A	O
BALB	O
/	O
c-specific	O
variants	O
of	O
p16	B-GENE
were	O
inefficient	O
in	O
their	O
ability	O
to	O
inhibit	O
the	O
activity	O
of	O
cyclin	B-GENE
D2	I-GENE
/	I-GENE
CDK4	I-GENE
in	O
kinase	O
assays	O
with	O
retinoblastoma	B-GENE
protein	I-GENE
,	O
suggesting	O
this	O
defective	O
,	O
inherited	O
allele	O
plays	O
an	O
important	O
role	O
in	O
the	O
genetic	O
susceptibility	O
of	O
BALB	O
/	O
c	O
mice	O
for	O
plasmacytoma	O
induction	O
and	O
that	O
p16	B-GENE
(	I-GENE
INK4a	I-GENE
)	I-GENE
is	O
a	O
strong	O
candidate	O
for	O
the	O
Pctr1	B-GENE
locus	I-GENE
.	O

We	O
previously	O
delineated	O
a	O
region	O
in	O
the	O
fatty-acid	B-GENE
synthase	I-GENE
promoter	I-GENE
,	O
which	O
was	O
responsible	O
for	O
obesity-related	O
overexpression	O
of	O
the	O
fatty-acid	B-GENE
synthase	I-GENE
(	O
FAS	B-GENE
)	O
gene	O
,	O
by	O
negatively	O
regulating	O
the	O
activity	O
of	O
the	O
downstream	O
promoter	O
in	O
lean	O
but	O
not	O
obese	O
rat	O
fat	O
cells	O
.	O

DESIGN	O
:	O
A	O
cross-sectional	O
study	O
.	O

Therefore	O
,	O
in	O
a	O
large	O
animal	O
model	O
of	O
permanent	O
focal	O
ischemia	O
in	O
which	O
transfusion	O
starts	O
30	O
min	O
after	O
ischemia	O
,	O
tetrameric	O
cross-linked	O
hemoglobin	B-GENE
transfusion	O
can	O
augment	O
oxygen	O
transport	O
to	O
the	O
ischemic	O
cortex	O
,	O
but	O
the	O
increase	O
can	O
be	O
delayed	O
and	O
not	O
necessarily	O
provide	O
protection	O
.	O

One	O
such	O
element	O
,	O
1P	B-GENE
,	O
was	O
employed	O
to	O
clone	O
from	O
a	O
rat	O
pituitary	O
cDNA	O
expression	O
library	O
a	O
novel	O
417-amino	B-GENE
acid	I-GENE
WD	I-GENE
protein	I-GENE
,	O
designated	O
PREB	B-GENE
(	I-GENE
PRL	I-GENE
regulatory	I-GENE
element	I-GENE
binding	I-GENE
)	I-GENE
protein	I-GENE
.	O

Thus	O
,	O
a	O
critical	O
question	O
is	O
how	O
HOX	B-GENE
proteins	I-GENE
select	O
the	O
correct	O
sets	O
of	O
target	O
genes	O
in	O
vivo	O
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	B-GENE
gene	I-GENE
have	O
now	O
been	O
isolated	O
.	O

Thus	O
,	O
the	O
human	B-GENE
D1A	I-GENE
gene	I-GENE
belongs	O
to	O
the	O
category	O
of	O
tissue-specific	O
,	O
regulated	O
genes	O
that	O
have	O
housekeeping-type	O
promoters	O
.	O

As	O
PP2A	B-GENE
exerts	O
a	O
range	O
of	O
cellular	O
functions	O
including	O
cell	O
cycle	O
regulation	O
and	O
cell	O
fate	O
determination	O
,	O
we	O
were	O
surprised	O
to	O
find	O
that	O
these	O
embryos	O
develop	O
normally	O
until	O
postimplantation	O
,	O
around	O
embryonic	O
day	O
5	O
.	O
5	O
/	O
6	O
.	O
0	O
.	O

The	O
femoral	O
artery	O
/	O
vein	O
and	O
the	O
soleus	O
and	O
gastrocnemius	O
muscles	O
were	O
examined	O
in	O
healthy	O
human	O
male	O
volunteers	O
.	O

We	O
also	O
show	O
that	O
zygotically	O
activated	O
Xretpos	O
transcripts	O
are	O
restricted	O
to	O
ventro-posterior	O
specific	O
regions	O
and	O
induced	O
by	O
UV-irradiation	O
and	O
BMP-4	B-GENE
overexpression	O
in	O
cycloheximide-dependent	O
way	O
.	O
genesis	O
26	O
:	O
198-207	O
,	O
2000	O
.	O

All	O
runners	O
drank	O
a	O
total	O
of	O
1	O
.	O
4	O
L	O
of	O
water	O
during	O
the	O
race	O
.	O

An	O
abundant	O
1	O
.	O
1-kb	O
virion-sense	O
polyadenylated	O
RNA	O
and	O
four	O
complementary-sense	O
polyadenylated	O
RNAs	O
of	O
1	O
.	O
7	O
,	O
1	O
.	O
5	O
,	O
1	O
.	O
3	O
,	O
and	O
0	O
.	O
7	O
kb	O
have	O
been	O
identified	O
by	O
northern	O
blot	O
hybridization	O
,	O
confirming	O
the	O
bidirectional	O
transcription	O
strategy	O
implied	O
by	O
the	O
arrangement	O
of	O
ORFs	O
.	O

A	O
case	O
of	O
manifest	O
latent	O
nystagmus	O
of	O
late	O
onset	O
in	O
a	O
13-year-old	O
girl	O
is	O
reported	O
.	O

Tightly	O
ordered	O
proteasomal	O
degradation	O
of	O
proteins	O
critical	O
for	O
cell	O
cycle	O
control	O
implies	O
a	O
role	O
of	O
the	O
proteasome	O
in	O
maintaining	O
cell	O
proliferation	O
and	O
cell	O
survival	O
.	O

We	O
found	O
in	O
the	O
control	O
subjects	O
rCBF	O
increases	O
in	O
regions	O
associated	O
with	O
the	O
meso-striatal	O
and	O
meso-corticolimbic	O
circuits	O
in	O
response	O
to	O
both	O
monetary	O
reward	O
and	O
nonmonetary	O
reinforcement	O
.	O

The	O
TA	O
muscle	O
was	O
fatigued	O
by	O
four	O
forms	O
of	O
repeated	O
isometric	O
contractions	O
:	O
(	O
1	O
)	O
maximal	O
voluntary	O
contractions	O
(	O
MVC	O
)	O
,	O
(	O
2	O
)	O
MVC	O
with	O
circulation	O
occluded	O
,	O
(	O
3	O
)	O
electrically	O
evoked	O
contractions	O
with	O
20	O
Hz	O
supramaximal	O
voltage	O
stimulation	O
and	O
(	O
4	O
)	O
electrically	O
evoked	O
contractions	O
with	O
circulation	O
occluded	O
.	O

Growth	O
of	O
tracheal	O
anastomoses	O
in	O
growing	O
animals	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
preferentially	O
infects	O
CD4+	B-GENE
T	O
lymphocytes	O
and	O
may	O
exist	O
as	O
a	O
latent	O
provirus	O
within	O
these	O
cells	O
for	O
extended	O
periods	O
.	O

However	O
,	O
it	O
is	O
only	O
one-half	O
and	O
one-third	O
the	O
size	O
of	O
the	O
proteolipids	O
from	O
M	O
.	O
thermoautotrophicum	O
and	O
M	O
.	O
jannaschii	O
,	O
respectively	O
.	O
ahaK	B-GENE
is	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
and	O
it	O
is	O
incorporated	O
into	O
the	O
cytoplasmic	O
membrane	O
despite	O
the	O
different	O
chemical	O
natures	O
of	O
lipids	O
from	O
archaea	O
and	O
bacteria	O
.	O

Calves	O
fed	O
MCT-milk	O
had	O
significantly	O
lower	O
blood	O
cholesterol	O
than	O
calves	O
fed	O
T-	O
or	O
SBO-milk	O
.	O

It	O
is	O
mainly	O
transcribed	O
in	O
neural	O
structures	O
and	O
in	O
developing	O
organs	O
characterized	O
by	O
epithelial-mesenchymal	O
interactions	O
.	O

Although	O
the	O
extracellular	O
domain	O
of	O
the	O
TSH-R	B-GENE
is	O
sufficient	O
for	O
high	O
affinity	O
binding	O
of	O
TSH	B-GENE
,	O
we	O
conclude	O
that	O
the	O
hyt	O
mutation	O
in	O
the	O
fourth	O
transmembrane	O
domain	O
eliminates	O
TSH	B-GENE
binding	O
.	O

Pseudomonas	O
aeruginosa	O
strains	O
infecting	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
acquire	O
a	O
mucoid	O
phenotype	O
due	O
to	O
overproduction	O
of	O
alginate	O
.	O

All	O
the	O
women	O
received	O
13	O
.	O
5	O
mg	O
plain	O
bupivacaine	O
via	O
subarachnoid	O
injection	O
at	O
the	O
L2-3	O
interspace	O
.	O

The	O
level	O
of	O
subclinical	O
infection	O
was	O
75%	O
among	O
seropositive	O
dogs	O
.	O

The	O
susceptibility	O
of	O
the	O
PPNG	O
strains	O
to	O
clinically	O
relevant	O
antibiotics	O
varied	O
with	O
the	O
plasmid	O
pattern	O
;	O
this	O
stresses	O
the	O
necessity	O
of	O
permanent	O
surveillance	O
of	O
gonococcal	O
infections	O
and	O
of	O
regular	O
evaluation	O
of	O
the	O
recommendations	O
for	O
antimicrobial	O
treatment	O
.	O

Benztropine	O
for	O
venlafaxine-induced	O
night	O
sweats	O
.	O

(	O
1992	O
)	O
Genomics	O
12	O
,	O
58-62	O
)	O
.	O

The	O
future	O
of	O
research	O
with	O
interferon	B-GENE
may	O
be	O
divided	O
into	O
three	O
areas	O
:	O
Efforts	O
must	O
be	O
made	O
to	O
determine	O
how	O
best	O
to	O
translate	O
the	O
in	O
vitro	O
synergy	O
into	O
clinically	O
meaningful	O
terms	O
;	O
in	O
order	O
to	O
exploit	O
the	O
fullest	O
potential	O
of	O
IFN	B-GENE
,	O
research	O
is	O
moving	O
toward	O
using	O
this	O
agent	O
earlier	O
in	O
disease	O
either	O
as	O
an	O
adjuvant	O
after	O
tumor	O
debulking	O
or	O
after	O
initial	O
diagnosis	O
;	O
the	O
medical	O
community	O
must	O
rethink	O
the	O
natural	O
history	O
of	O
some	O
diseases	O
,	O
because	O
the	O
fullest	O
potential	O
of	O
the	O
biologic	O
agents	O
will	O
most	O
likely	O
manifest	O
itself	O
when	O
these	O
agents	O
are	O
used	O
together	O
.	O

Proteasomes	B-GENE
are	O
the	O
multisubunit	O
protease	B-GENE
involved	O
in	O
the	O
generation	O
of	O
peptides	O
presented	O
by	O
MHC	B-GENE
class	I-GENE
I	I-GENE
molecules	I-GENE
.	O

Degenerate	O
primers	O
homologous	O
to	O
highly	O
conserved	O
regions	O
of	O
known	O
CYP3A	B-GENE
sequences	I-GENE
were	O
used	O
for	O
initial	O
RT-PCRs	O
.	O

IFN-gamma	B-GENE
was	O
elevated	O
during	O
active	O
TB	O
when	O
compared	O
with	O
healthy	O
controls	O
,	O
declining	O
during	O
and	O
after	O
treatment	O
.	O

Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B-GENE
I	I-GENE
footprints	I-GENE
,	O
NFAT-1	B-GENE
and	O
NFIL-2B	B-GENE
,	O
respectively	O
.	O

Analysis	O
of	O
SRE	O
oligonucleotide	O
gel	O
mobility	O
shift	O
assays	O
with	O
nuclear	O
extracts	O
from	O
Sertoli	O
cells	O
demonstrated	O
the	O
presence	O
of	O
both	O
the	O
SRF	B-GENE
and	O
the	O
ubiquitously	O
expressed	O
bHLH	B-GENE
protein	I-GENE
E12	B-GENE
/	I-GENE
E47	I-GENE
.	O

These	O
results	O
lead	O
us	O
to	O
hypothesize	O
that	O
a	O
single	O
multisubunit	B-GENE
TFIID	I-GENE
protein	I-GENE
supports	O
transcriptional	O
stimulation	O
by	O
diverse	O
activation	O
domains	O
and	O
from	O
a	O
TATA-less	O
promoter	O
.	O

Tumor	O
stages	O
were	O
IIB	O
(	O
T3	O
N0	O
)	O
in	O
52%	O
,	O
IIIA	O
in	O
15%	O
,	O
and	O
IIIB	O
in	O
27%	O
of	O
patients	O
.	O

The	O
ZnF20	B-GENE
cDNA	I-GENE
hybridized	O
to	O
multiple	O
transcripts	O
in	O
a	O
thyroid	O
cancer	O
cell	O
line	O
(	O
8	O
.	O
0	O
,	O
4	O
.	O
5	O
and	O
2	O
kb	O
)	O
that	O
increased	O
after	O
cycloheximide	O
treatment	O
and	O
decayed	O
<	O
2	O
h	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

This	O
fragment	O
contained	O
the	O
C-terminal	O
47	O
nucleotides	O
of	O
leuB	B-GENE
,	O
encoding	O
3-isopropylmalate	B-GENE
dehydrogenase	I-GENE
;	O
asd	B-GENE
,	O
encoding	O
aspartate-beta-semialdehyde	B-GENE
dehydrogenase	I-GENE
(	O
Asd	B-GENE
)	O
;	O
and	O
orfA	O
,	O
whose	O
product	O
showed	O
similarity	O
to	O
the	O
Asd	B-GENE
proteins	I-GENE
from	I-GENE
Vibrio	I-GENE
spp	I-GENE
.	O

Sp1	B-GENE
can	O
activate	O
transcription	O
through	O
immunoglobulin	B-GENE
kappa-chain	I-GENE
enhancer	I-GENE
or	O
P-selectin	B-GENE
promoter	I-GENE
NF-kappaB	B-GENE
sites	I-GENE
.	O
p50	B-GENE
homodimers	I-GENE
replace	O
Sp1	B-GENE
from	O
the	O
P-selectin	B-GENE
promoter	I-GENE
by	O
binding	O
site	O
competition	O
and	O
thereby	O
either	O
inhibit	O
basal	O
Sp1-driven	O
expression	O
or	O
,	O
in	O
concert	O
with	O
Bcl-3	B-GENE
,	O
stimulate	O
expression	O
.	O

Results	O
of	O
two-hybrid	O
assays	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
all	O
HD-Zip	B-GENE
proteins	I-GENE
of	O
families	O
I	O
and	O
II	O
can	O
form	O
homodimers	O
and	O
also	O
heterodimers	O
with	O
all	O
HD-Zip	B-GENE
proteins	I-GENE
of	O
the	O
same	O
family	O
.	O

Nine	O
new	O
naphthalene	O
related	O
compounds	O
(	O
I	O
,	O
IV	O
,	O
V	O
,	O
VII-XII	O
)	O
together	O
with	O
four	O
known	O
compounds	O
(	O
II	O
,	O
III	O
,	O
VI	O
,	O
XIII	O
)	O
were	O
isolated	O
from	O
the	O
root	O
bark	O
of	O
Oroxylum	O
indicum	O
Vent	O
.	O

Simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
is	O
a	O
lentivirus	O
with	O
morphological	O
and	O
antigenic	O
similarities	O
to	O
human	O
immunodeficiency	O
virus	O
,	O
the	O
causative	O
agent	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
of	O
humans	O
.	O

This	O
sequence	O
possessed	O
homology	O
with	O
a	O
methylation-sensitive	O
promoter	O
element	O
,	O
Enh2	B-GENE
,	O
present	O
in	O
the	O
LTR	O
of	O
mouse	O
intractisternal	O
A-particles	O
.	O

The	O
p36	B-GENE
gene	I-GENE
is	O
at	O
least	O
22	O
kb	O
in	O
length	O
and	O
has	O
a	O
coding	O
sequence	O
of	O
approximately	O
1	O
kb	O
,	O
representing	O
only	O
4	O
.	O
5%	O
of	O
the	O
gene	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Members	O
of	O
the	O
mitogen	B-GENE
activated	I-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
family	I-GENE
,	O
extracellular	B-GENE
signal-regulated	I-GENE
kinase	I-GENE
,	O
stress-activated	B-GENE
protein	I-GENE
kinase-1	I-GENE
/	I-GENE
c-Jun	I-GENE
NH2-terminal	I-GENE
kinase	I-GENE
,	O
and	O
p38	B-GENE
,	O
are	O
central	O
elements	O
that	O
transduce	O
the	O
signal	O
generated	O
by	O
growth	B-GENE
factors	I-GENE
,	O
cytokines	O
,	O
and	O
stressing	O
agents	O
.	O

To	O
assess	O
the	O
function	O
(	O
s	O
)	O
of	O
E74	B-GENE
during	O
metamorphosis	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
recessive	O
loss-of-function	O
mutations	O
specific	O
to	O
each	O
transcription	O
unit	O
.	O

Fifty-four	O
patients	O
were	O
divided	O
into	O
groups	O
according	O
to	O
their	O
clinical	O
presentation	O
;	O
seven	O
asymptomatic	O
volunteers	O
,	O
20	O
patients	O
with	O
duodenal-gastric	O
reflux	O
gastropathy	O
(	O
DRG	O
)	O
,	O
16	O
patients	O
with	O
recurrent	O
ulcers	O
of	O
the	O
duodenal	O
bulb	O
(	O
RUD	O
)	O
,	O
and	O
11	O
patients	O
with	O
Moynihan's	O
disease	O
.	O

If	O
this	O
is	O
unavailable	O
,	O
then	O
Supramid	O
has	O
a	O
proven	O
record	O
for	O
good	O
tissue	O
compatibility	O
and	O
resistance	O
to	O
infection	O
.	O

Recently	O
,	O
our	O
laboratory	O
developed	O
a	O
screen	O
that	O
identified	O
five	O
multicopy	O
suppressors	O
that	O
can	O
rescue	O
lethal	O
strains	O
of	O
clathrin	B-GENE
heavy	O
chain-deficient	O
yeast	O
(	O
Chc	B-GENE
-	I-GENE
scd1-i	I-GENE
)	O
to	O
viability	O
.	O

In	O
19	O
patients	O
vagotomy	O
not	O
only	O
curbed	O
the	O
bleeding	O
but	O
provided	O
definitive	O
therapy	O
(	O
Visick	O
I-II	O
)	O
;	O
4	O
patients	O
died	O
(	O
mortality	O
rate	O
16%	O
)	O
.	O

Saunders	O
Company	O
.	O

Cytokine-induced	O
NF-kappa	B-GENE
B	I-GENE
DNA	O
binding	O
activity	O
,	O
RelA	B-GENE
nuclear	O
translocation	O
,	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
degradation	O
,	O
I	B-GENE
kappa	I-GENE
B	I-GENE
serine	O
32	O
phosphorylation	O
,	O
and	O
I	B-GENE
kappa	I-GENE
B	I-GENE
kinase	I-GENE
(	O
IKK	B-GENE
)	O
activity	O
were	O
blocked	O
by	O
curcumin	O
treatment	O
.	O

HPLC	O
phosphopeptide	O
mapping	O
,	O
amino	O
acid	O
sequencing	O
,	O
and	O
site-directed	O
mutagenesis	O
determined	O
that	O
NCLK	B-GENE
phosphorylates	O
Ser	O
(	O
67	O
)	O
of	O
I-1	B-GENE
.	O

Identification	O
of	O
a	O
consensus	O
cyclin-dependent	B-GENE
kinase	I-GENE
phosphorylation	I-GENE
site	I-GENE
unique	O
to	O
the	O
nuclear	O
form	O
of	O
human	B-GENE
deoxyuridine	I-GENE
triphosphate	I-GENE
nucleotidohydrolase	I-GENE
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
ability	O
of	O
pretreatment	O
and	O
post-treatment	O
prostate-specific	B-GENE
antigen	I-GENE
(	O
PSA	B-GENE
)	O
measurements	O
,	O
clinical	O
tumor	O
stage	O
,	O
tumor	O
grade	O
,	O
Gleason	O
sum	O
,	O
race	O
,	O
age	O
,	O
and	O
radiation	O
dose	O
to	O
predict	O
the	O
recurrence	O
of	O
prostate	O
cancer	O
following	O
external	O
beam	O
radiation	O
therapy	O
(	O
XRT	O
)	O
since	O
the	O
introduction	O
of	O
PSA	B-GENE
as	O
a	O
tumor	O
marker	O
at	O
one	O
tertiary	O
care	O
center	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
multiple	O
survival	O
pathways	O
are	O
triggered	O
via	O
this	O
receptor	O
,	O
whereas	O
NF-kappaB	B-GENE
/	I-GENE
Rel	I-GENE
and	O
PI-3K	B-GENE
are	O
crucial	O
for	O
CD40-induced	O
proliferation	O
.	O

The	O
activity	O
of	O
Rac1	B-GENE
leads	O
to	O
STAT3	B-GENE
translocation	O
to	O
the	O
nucleus	O
coincident	O
with	O
STAT3-dependent	O
gene	O
expression	O
.	O

In	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
of	O
the	O
cyclin	B-GENE
E	I-GENE
promoter	I-GENE
revealed	O
several	O
regions	O
of	O
protection	O
and	O
hypersensitivity	O
that	O
were	O
unique	O
to	O
infected	O
cells	O
.	O

Prognostic	O
value	O
of	O
a	O
treadmill	O
exercise	O
score	O
in	O
symptomatic	O
patients	O
with	O
nonspecific	O
ST-T	O
abnormalities	O
on	O
resting	O
ECG	O
.	O

Nonvascular	O
ophthalmic	O
and	O
neurologic	O
disorders	O
that	O
can	O
be	O
confused	O
with	O
amaurosis	O
fugax	O
are	O
listed	O
,	O
and	O
an	O
algorithm	O
for	O
evaluation	O
(	O
which	O
includes	O
ophthalmic	O
examination	O
,	O
laboratory	O
studies	O
,	O
and	O
noninvasive	O
carotid	O
artery	O
studies	O
)	O
is	O
given	O
.	O

OND	O
8	O
mg	O
tid	O
days	O
2-3	O
,	O
and	O
8	O
mg	O
tid	O
prn	O
days	O
4-5	O
and	O
prednisolone	O
75-100	O
mg	O
qds	O
days	O
2-5	O
and	O
2	O
)	O
MCP	O
30	O
mg	O
/	O
metylprednisolone	O
80	O
mg	O
i	O
.	O
v	O
.	O
before	O
CT	O
and	O
MCP	O
20	O
mg	O
p	O
.	O
r	O
.	O
after	O
4	O
and	O
8	O
h	O
respectively	O
.	O

Aspirin	O
intolerance	O
:	O
unaltered	O
susceptibility	O
of	O
platelet	B-GENE
cyclo-oxygenase	I-GENE
to	O
inhibition	O
by	O
aspirin	O
in	O
vitro	O
.	O

The	O
second	O
group	O
of	O
homologous	O
elements	O
is	O
present	O
in	O
the	O
upstream	O
region	O
of	O
both	O
genes	O
.	O

In	O
SN-48	O
neuronal	O
cells	O
that	O
express	O
MR	B-GENE
,	O
GR	B-GENE
,	O
and	O
5-HT1A	B-GENE
receptors	I-GENE
,	O
deletion	O
or	O
inactivation	O
of	O
the	O
nGRE	B-GENE
(	O
negative	B-GENE
GRE	I-GENE
)	O
eliminated	O
negative	O
regulation	O
of	O
the	O
rat	B-GENE
5-HT1A	I-GENE
or	O
heterologous	O
promoters	O
by	O
corticosteroids	O
,	O
whereas	O
its	O
inclusion	O
conferred	O
corticosteroid-induced	O
inhibition	O
to	O
a	O
heterologous	O
promoter	O
.	O

To	O
evaluate	O
the	O
cost	O
and	O
benefits	O
of	O
screening	O
tests	O
for	O
Chlamydia	O
trachomatis	O
in	O
adolescent	O
males	O
,	O
we	O
developed	O
a	O
decision	O
analysis	O
model	O
and	O
compared	O
the	O
leukocyte	B-GENE
esterase	I-GENE
urine	O
dipstick	O
test	O
with	O
culture	O
,	O
with	O
direct-smear	O
fluorescent	O
antibody	O
(	O
DFA	O
)	O
,	O
and	O
with	O
the	O
option	O
of	O
no	O
screening	O
(	O
no	O
treatment	O
)	O
.	O

No	O
hypotension	O
was	O
noted	O
in	O
patients	O
with	O
toxemia	O
and	O
only	O
2	O
ran	O
a	O
fever	O
above	O
37	O
.	O
5	O
degrees	O
C	O
.	O

Initial	O
screening	O
of	O
a	O
rat	O
liver	O
cDNA	O
library	O
with	O
an	O
oligonucleotide	O
probe	O
derived	O
from	O
the	O
rat	O
SCP2	B-GENE
protein	O
sequence	O
revealed	O
an	O
825-base	O
pair	O
cDNA	O
clone	O
coding	O
for	O
the	O
complete	O
SCP2	B-GENE
protein	O
sequence	O
.	O

It	O
seems	O
that	O
the	O
way	O
in	O
which	O
drugs	O
modify	O
a	O
patient's	O
serum	O
chemistry	O
may	O
be	O
used	O
to	O
assess	O
the	O
efficacy	O
with	O
which	O
they	O
control	O
the	O
inflammatory	O
process	O
.	O

Two	O
experiments	O
(	O
N	O
=	O
20	O
each	O
)	O
were	O
carried	O
out	O
to	O
explore	O
the	O
nature	O
of	O
ERP	O
negativities	O
in	O
a	O
visuospatial	O
memory	O
task	O
and	O
in	O
an	O
auditory	O
spatial	O
memory	O
task	O
,	O
respectively	O
.	O

A	O
coiled-coil	O
related	O
protein	O
specific	O
for	O
synapsed	O
regions	O
of	O
meiotic	O
prophase	O
chromosomes	O
.	O

The	O
COOH-terminus	O
of	O
this	O
new	O
isoform	O
,	O
which	O
we	O
designate	O
beta	B-GENE
4	I-GENE
,	O
lacks	O
a	O
22	O
amino	O
acid	O
lysine-rich	O
sequence	O
common	O
to	O
both	O
the	O
human	B-GENE
red	I-GENE
cell	I-GENE
alpha-	I-GENE
and	I-GENE
beta-adducin	I-GENE
subunits	I-GENE
and	O
homologous	O
to	O
a	O
highly	O
conserved	O
region	O
in	O
MARCKS	B-GENE
,	O
a	O
filamentous	O
actin-cross	O
linking	O
protein	O
regulated	O
by	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
and	O
calcium	O
/	O
calmodulin	O
.	O
beta	B-GENE
4-adducin	I-GENE
preserves	O
a	O
previously	O
identified	O
calmodulin	B-GENE
binding	I-GENE
domain	I-GENE
.	O

Lack	O
of	O
sufficient	O
data	O
on	O
vibration	O
measurements	O
and	O
employment	O
durations	O
add	O
to	O
the	O
uncertainty	O
,	O
as	O
do	O
variations	O
in	O
tool	O
conditions	O
(	O
grinder	O
wheels	O
,	O
etc	O
)	O
and	O
inherent	O
difficulties	O
in	O
measurement	O
.	O

These	O
results	O
suggest	O
that	O
Thr115	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
MyoD	B-GENE
function	O
under	O
conditions	O
of	O
high	O
mitogenesis	O
.	O

To	O
determine	O
whether	O
vanadate	O
could	O
inhibit	O
PEPCK	B-GENE
gene	I-GENE
transcription	O
,	O
a	O
series	O
of	O
chimeric	O
genes	O
containing	O
several	O
deletions	O
in	O
the	O
P-enolypyruvate	B-GENE
carboxykinase	I-GENE
promoter	I-GENE
between	O
-550	O
and	O
-68	O
was	O
linked	O
to	O
the	O
structural	O
genes	O
for	O
either	O
amino-3-glycosyl	B-GENE
phosphotransferase	I-GENE
(	O
neo	B-GENE
)	O
or	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
and	O
introduced	O
into	O
hepatoma	O
cells	O
using	O
three	O
methods	O
:	O
(	O
a	O
)	O
infection	O
with	O
a	O
Moloney	O
murine	O
leukemia	O
virus-based	O
retrovirus	O
,	O
(	O
b	O
)	O
transfection	O
and	O
stable	O
selection	O
for	O
neo	O
expression	O
,	O
or	O
(	O
c	O
)	O
transient	O
expression	O
of	O
chloroamphenicol	B-GENE
acetyltransferase	I-GENE
.	O

Peptide	O
sequences	O
of	O
the	O
zinc	B-GENE
finger	I-GENE
protein	I-GENE
Ttk	I-GENE
and	O
the	O
transcription	B-GENE
factor	I-GENE
Adf-1	I-GENE
were	O
obtained	O
.	O

Endoscopic	O
examinations	O
,	O
peripheral	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
counts	O
,	O
and	O
assays	O
of	O
myeloperoxidase	B-GENE
activity	O
(	O
MPO	B-GENE
)	O
in	O
homogenates	O
of	O
colon	O
mucosa	O
were	O
performed	O
after	O
one	O
week	O
(	O
4%	O
DSS	O
model	O
)	O
and	O
eight	O
weeks	O
(	O
1%	O
DSS	O
model	O
)	O
.	O

Both	O
resting	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
maximal	O
blood	O
flow	O
(	O
NBF	O
)	O
were	O
studied	O
by	O
Xenon	O
133	O
clearance	O
.	O

INO2	B-GENE
,	O
a	O
regulatory	O
gene	O
in	O
yeast	O
phospholipid	O
biosynthesis	O
,	O
affects	O
nuclear	O
segregation	O
and	O
bud	O
pattern	O
formation	O
.	O

We	O
established	O
that	O
the	O
2	B-GENE
.	I-GENE
6	I-GENE
kb	I-GENE
mRNA	I-GENE
V-1	I-GENE
and	O
the	O
2	B-GENE
.	I-GENE
3	I-GENE
kb	I-GENE
GGT	I-GENE
mRNA	I-GENE
V-2	I-GENE
derive	O
,	O
by	O
alternate	O
splicing	O
,	O
from	O
a	O
primary	O
transcript	O
initiated	O
on	O
a	O
distal	O
promoter	O
on	O
the	O
rat	B-GENE
GGT	I-GENE
gene	I-GENE
.	O

Pulmonary	O
hypertension	O
,	O
with	O
or	O
without	O
coronary	O
arterial	O
narrowing	O
,	O
is	O
the	O
major	O
condition	O
leading	O
to	O
isolated	O
atrial	O
infarction	O
.	O

Citrate	B-GENE
synthase	I-GENE
activity	O
was	O
increased	O
in	O
the	O
medial	O
head	O
(	O
81%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
the	O
red	O
long	O
head	O
(	O
88%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
of	O
the	O
triceps	O
brachii	O
muscle	O
in	O
R	O
rats	O
but	O
not	O
in	O
the	O
white	O
long	O
head	O
(	O
25%	O
,	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

These	O
results	O
suggest	O
that	O
mitochondrial	O
presequences	O
interact	O
with	O
the	O
mt-hsp70	B-GENE
during	O
or	O
after	O
mitochondrial	O
protein	O
import	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
25	O
open-chest	O
,	O
anesthetized	O
dogs	O
,	O
progressive	O
circumflex	O
artery	O
stenosis	O
led	O
to	O
a	O
concordant	O
decrease	O
of	O
circumflex	O
artery	O
resting	O
and	O
hyperemic	O
flow	O
,	O
coronary	O
flow	O
reserve	O
,	O
and	O
inverse	O
angiographic	O
mean	O
transit	O
time	O
Tmicro-1	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

Conversely	O
,	O
the	O
central	O
regions	O
are	O
highly	O
variable	O
.	O

In	O
an	O
attempt	O
to	O
understand	O
Wee1	B-GENE
regulation	O
during	O
cell	O
cycle	O
,	O
yeast	O
two-hybrid	O
screening	O
was	O
used	O
to	O
identify	O
Wee1-binding	B-GENE
protein	I-GENE
(	I-GENE
s	I-GENE
)	I-GENE
.	O

Alternatively	O
,	O
the	O
similarity	O
in	O
apparent	O
regulatory	O
action	O
of	O
the	O
genes	O
may	O
indicate	O
allelic	O
differences	O
wherein	O
the	O
IS1112C	B-GENE
Rf3	B-GENE
allele	I-GENE
may	O
differ	O
from	O
alleles	O
of	O
maintainer	O
lines	O
by	O
the	O
capability	O
to	O
regulate	O
both	O
orf107	B-GENE
and	O
urf209	B-GENE
processing	O
activities	O
.	O

This	O
philosophy	O
was	O
instituted	O
for	O
the	O
compound	O
RP	O
73401	O
,	O
a	O
specific	O
phosphodiesterase	B-GENE
IV	I-GENE
inhibitor	O
,	O
that	O
was	O
being	O
developed	O
simultaneously	O
for	O
delivery	O
by	O
both	O
oral	O
and	O
pulmonary	O
routes	O
of	O
administration	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
expression	O
of	O
the	O
gene	O
for	O
the	O
reproductive	O
neuropeptide	O
,	O
GnRH	B-GENE
,	O
is	O
repressed	O
by	O
the	O
glutamate	O
/	O
NO	O
/	O
cyclic	O
GMP	O
(	O
cGMP	O
)	O
signal	O
transduction	O
pathway	O
through	O
cGMP-dependent	B-GENE
protein	I-GENE
kinase	I-GENE
in	O
the	O
hypothalamic	O
GnRH-secreting	O
neuronal	O
cell	O
line	O
GT1-7	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
HRT	O
on	O
those	O
factors	O
in	O
end-stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
patients	O
,	O
we	O
evaluated	O
the	O
changes	O
of	O
lipid	O
profile	O
,	O
coagulation	O
and	O
fibrinolysis	O
markers	O
,	O
and	O
plasma	O
homocysteine	O
levels	O
after	O
treatment	O
.	O

Decreased	O
serum	B-GENE
ceruloplasmin	I-GENE
and	O
copper	O
levels	O
in	O
cervical	O
dystonia	O
.	O

Symptoms	O
due	O
to	O
the	O
action	O
of	O
mastocyte	O
mediators	O
were	O
observed	O
.	O

The	O
encoded	O
sequence	O
revealed	O
a	O
typical	O
signal	O
peptide	O
,	O
a	O
predominantly	O
hydrophilic	O
707	O
amino	O
acid	O
residue	O
domain	O
with	O
8	O
N-glycosylation	O
sites	O
,	O
a	O
transmembrane	O
domain	O
,	O
and	O
a	O
C-terminal	O
domain	O
of	O
52	O
amino	O
acids	O
.	O

Oncogenic	O
signalling	O
by	O
E2F1	B-GENE
has	O
recently	O
been	O
linked	O
to	O
stabilization	O
and	O
activation	O
of	O
the	O
tumour	O
suppressor	O
p53	B-GENE
(	O
refs	O
1	O
,	O
3	O
,	O
4	O
)	O
.	O

PPD-specific	B-GENE
IgG	I-GENE
subclass	O
responses	O
were	O
evident	O
to	O
all	O
four	O
IgG	B-GENE
subclasses	O
.	O

Biohydrogenation	O
of	O
linoleic	O
acid	O
into	O
octadecenoic	O
acid	O
was	O
observed	O
.	O

Similarly	O
,	O
we	O
observed	O
synthetic	O
phenotypes	O
between	O
mutations	O
in	O
MIF2	B-GENE
and	O
trans-acting	O
mutations	O
in	O
three	O
known	O
yeast	B-GENE
centromere	I-GENE
protein	I-GENE
genes-CEP1	I-GENE
/	I-GENE
CBF1	I-GENE
/	I-GENE
CPF1	I-GENE
,	O
NDC10	B-GENE
/	I-GENE
CBF2	I-GENE
,	O
and	O
CEP3	B-GENE
/	I-GENE
CBF3B	I-GENE
.	O

(	O
total	O
soluble	O
solids	O
)	O
and	O
organoleptic	O
characteristics	O
under	O
the	O
influence	O
of	O
different	O
treatments	O
.	O

Furthermore	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
protein-protein	O
interaction	O
experiments	O
have	O
shown	O
that	O
SR33	B-GENE
protein	I-GENE
interacts	O
with	O
itself	O
and	O
with	O
SR45	B-GENE
protein	I-GENE
but	O
not	O
with	O
two	O
other	O
members	O
(	O
SRZ21	B-GENE
and	O
SRZ22	B-GENE
)	O
of	O
the	O
SR	B-GENE
family	I-GENE
that	O
are	O
known	O
to	O
interact	O
with	O
the	O
Arabidopsis	O
full-length	O
U-70K	B-GENE
only	O
.	O

The	O
prophylactic	O
use	O
of	O
new	O
medication	O
for	O
patients	O
between	O
the	O
first	O
and	O
second	O
cycle	O
of	O
chemotherapy	O
,	O
in	O
agreement	O
with	O
the	O
estimates	O
calculated	O
,	O
does	O
not	O
save	O
health	O
care	O
costs	O
but	O
may	O
improve	O
the	O
quality	O
of	O
life	O
in	O
these	O
patients	O
and	O
permit	O
the	O
continuation	O
of	O
a	O
therapeutic	O
schedule	O
without	O
interruption	O
which	O
may	O
improve	O
the	O
life	O
expectancy	O
of	O
the	O
patient	O
.	O

Alveolar	O
lymphocytes	O
were	O
surprisingly	O
increased	O
in	O
most	O
patients	O
with	O
AIDS	O
(	O
mean	O
26	O
.	O
1	O
+	O
/	O
-	O
21	O
.	O
9%	O
;	O
range	O
1-76%	O
)	O
and	O
CGL	O
(	O
mean	O
26	O
.	O
6	O
+	O
/	O
-	O
22	O
.	O
6%	O
;	O
range	O
3-76%	O
)	O
with	O
criteria	O
of	O
activation	O
contrasting	O
with	O
the	O
blood	O
lymphopenia	O
.	O

Control	O
Tmuscle	O
was	O
35	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
7	O
degrees	O
C	O
,	O
with	O
control	O
Wi	O
,	O
max	O
being	O
51	O
.	O
6	O
(	O
SD	O
8	O
.	O
7	O
)	O
W	O
.	O
kg-1	O
.	O

Overexpression	O
of	O
SCS1	B-GENE
could	O
not	O
complement	O
an	O
HSP60-null	B-GENE
allele	I-GENE
,	O
indicating	O
that	O
suppression	O
was	O
not	O
due	O
to	O
the	O
bypassing	O
of	O
Hsp60	B-GENE
activity	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
trial	O
E3186	O
was	O
initiated	O
to	O
explore	O
this	O
question	O
.	O

Through	O
Southern	O
blot	O
analyses	O
of	O
DNA	O
from	O
backcross	O
and	O
cogenic	O
mice	O
,	O
recombinant	O
inbred	O
strains	O
,	O
and	O
somatic	O
cell	O
hybrids	O
,	O
the	O
genetic	O
loci	O
that	O
produce	O
the	O
cyclin	B-GENE
B1-related	I-GENE
sequences	I-GENE
(	O
designated	O
loci	B-GENE
Cycb1-rs1	I-GENE
to	O
Cycb1-rs9	B-GENE
)	O
were	O
mapped	O
on	O
mouse	O
chromosomes	O
5	O
,	O
1	O
,	O
17	O
,	O
4	O
,	O
14	O
,	O
13	O
,	O
7	O
,	O
X	O
,	O
and	O
8	O
,	O
respectively	O
.	O

The	O
diet	O
of	O
migrants	O
showed	O
both	O
positive	O
(	O
macronutrients	O
)	O
and	O
negative	O
(	O
micronutrients	O
)	O
differences	O
with	O
the	O
general	O
Dutch	O
diet	O
.	O

METHODS	O
:	O
9	O
cases	O
of	O
conventional	O
intermittent	O
tissue	O
expansion	O
(	O
CITE	O
)	O
and	O
9	O
cases	O
of	O
continuous	O
pressure-controlled	O
tissue	O
expansion	O
(	O
CPTE	O
)	O
were	O
chosen	O
for	O
the	O
study	O
.	O

Greater	O
rupture	O
force	O
was	O
required	O
in	O
the	O
adult	O
pigs	O
than	O
in	O
the	O
young	O
pigs	O
.	O

Identical	O
effects	O
were	O
obtained	O
when	O
inhibitors	O
and	O
dominant	O
negative	O
mutants	O
were	O
tested	O
on	O
the	O
-29	O
to	O
+139	O
bp	O
region	O
of	O
the	O
cyclin	B-GENE
D1	I-GENE
promoter	I-GENE
.	O

Recent	O
literature	O
has	O
suggested	O
that	O
beta-2	B-GENE
transferrin	I-GENE
can	O
also	O
be	O
used	O
as	O
a	O
clinical	O
marker	O
for	O
perilymph	O
.	O

Expression	O
of	O
the	O
human	B-GENE
heat	I-GENE
shock	I-GENE
protein	I-GENE
70	I-GENE
gene	I-GENE
(	O
hsp70	B-GENE
)	O
is	O
induced	O
by	O
various	O
kinds	O
of	O
stress	O
and	O
by	O
oncogenes	O
.	O

Cultivation	O
technics	O
for	O
Codonopsis	O
pilosula	O
.	O

We	O
have	O
investigated	O
the	O
requirements	O
of	O
the	O
CH	B-GENE
gene	I-GENE
switch	O
by	O
characterizing	O
two	O
rearranged	B-GENE
gamma	I-GENE
2b	I-GENE
genes	I-GENE
from	O
a	O
gamma	B-GENE
2b	I-GENE
producing	O
mouse	O
myeloma	O
(	O
MPC-11	O
)	O
.	O

Exchanging	O
the	O
human	O
propeptide	O
in	O
this	O
chimera	O
with	O
either	O
the	O
murine	B-GENE
MIC-1	I-GENE
or	O
TGF-beta1	B-GENE
propeptide	I-GENE
resulted	O
in	O
secretion	O
of	O
the	O
unprocessed	O
,	O
monomeric	O
chimera	O
,	O
suggesting	O
a	O
specific	O
interaction	O
between	O
the	O
human	B-GENE
MIC-1	I-GENE
propeptide	I-GENE
and	O
mature	O
peptide	O
.	O

CONCLUSION	O
:	O
Although	O
quantitative	O
and	O
qualitative	O
criteria	O
for	O
diagnosing	O
fatty	O
liver	O
on	O
helical	O
CT	O
can	O
be	O
determined	O
,	O
they	O
are	O
protocol-specific	O
.	O

Syndecan-4	B-GENE
is	O
a	O
focal	O
adhesion	O
component	O
,	O
and	O
this	O
interaction	O
may	O
both	O
localize	O
PKC	B-GENE
and	O
amplify	O
its	O
activity	O
at	O
sites	O
of	O
forming	O
adhesions	O
.	O

Who	O
says	O
'National	O
Health	O
Dis-service'	O
.	O

A-69-year-old	O
patient	O
with	O
postoperative	O
small-bowel	O
obstruction	O
underwent	O
laparotomy	O
three	O
times	O
.	O

The	O
VirR	B-GENE
response	I-GENE
regulator	I-GENE
from	O
Clostridium	O
perfringens	O
binds	O
independently	O
to	O
two	O
imperfect	O
direct	O
repeats	O
located	O
upstream	O
of	O
the	O
pfoA	B-GENE
promoter	I-GENE
.	O

Ion	O
injection	O
.	O

These	O
data	O
suggest	O
that	O
AP-A	B-GENE
may	O
be	O
potentially	O
useful	O
in	O
the	O
management	O
of	O
heart	O
failure	O
.	O

Significance	O
of	O
thin	O
glomerular	O
basement	O
membranes	O
in	O
hematuric	O
children	O
.	O

The	O
effect	O
of	O
low-profile	O
serine	O
substitutions	O
in	O
the	O
V3	O
loop	O
of	O
HIV-1	B-GENE
gp120	I-GENE
IIIB	I-GENE
/	I-GENE
LAI	I-GENE
on	O
the	O
immunogenicity	O
of	O
the	O
envelope	O
protein	O
.	O

Laboratory	O
pyrolyses	O
have	O
indeed	O
shown	O
that	O
PCBs	O
give	O
significant	O
yields	O
of	O
PCDFs	O
,	O
and	O
chlorobenzenes	O
give	O
both	O
PCDFs	O
and	O
PCDDs	O
.	O

A	O
marked	O
decrease	O
in	O
the	O
type	B-GENE
1	I-GENE
insulin-like	I-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
IGF	I-GENE
)	I-GENE
receptor	I-GENE
(	O
IGF-IR	B-GENE
)	O
occurs	O
in	O
prostate	O
epithelial	O
cells	O
during	O
transformation	O
from	O
the	O
benign	O
to	O
the	O
metastatic	O
state	O
.	O

Pokeweed	B-GENE
antiviral	I-GENE
protein	I-GENE
(	O
PAP	B-GENE
)	O
from	O
Phytolacca	O
americana	O
is	O
a	O
highly	O
specific	O
N-glycosidase	B-GENE
removing	O
adenine	O
residues	O
(	O
A4324	O
in	O
28S	B-GENE
rRNA	I-GENE
and	O
A2660	O
in	O
23S	B-GENE
rRNA	I-GENE
)	O
from	O
intact	O
ribosomes	O
of	O
both	O
eukaryotes	O
and	O
prokaryotes	O
.	O

We	O
also	O
identified	O
Sp1	B-GENE
,	O
Sp3	B-GENE
,	O
and	O
NGFI-A	B-GENE
/	I-GENE
Egr-1	I-GENE
as	O
the	O
primary	O
nuclear	O
transcription	O
factors	O
binding	O
to	O
TRE1	B-GENE
which	O
mediate	O
Tax	B-GENE
responsiveness	O
.	O

This	O
study	O
indicated	O
that	O
the	O
Japanese	O
quail	O
was	O
less	O
sensitive	O
to	O
particulate	O
Mn3O4	O
exposure	O
than	O
rodents	O
treated	O
comparably	O
.	O

The	O
significance	O
of	O
these	O
palindromic	O
domains	O
in	O
this	O
ORF	O
is	O
unclear	O
but	O
the	O
coincidence	O
of	O
the	O
end	O
of	O
one	O
larger	O
palindrome	O
with	O
the	O
end	O
of	O
the	O
translated	O
protein	O
sequence	O
that	O
has	O
homology	O
with	O
the	O
B	B-GENE
chain	I-GENE
of	O
insulin	B-GENE
suggests	O
that	O
the	O
palindromes	O
may	O
divide	O
the	O
T2	B-GENE
protein	I-GENE
into	O
several	O
functional	O
units	O
.	O

In	O
contrast	O
,	O
when	O
the	O
isoform	O
containing	O
the	O
C	B-GENE
epsilon4	I-GENE
domain	I-GENE
joined	O
directly	O
to	O
the	O
M2	B-GENE
exon	I-GENE
(	O
IgE	B-GENE
grande	I-GENE
)	O
is	O
expressed	O
in	O
the	O
J558L	O
cell	O
line	O
,	O
it	O
is	O
degraded	O
intracellularly	O
,	O
suggesting	O
a	O
cell	O
line-dependent	O
regulation	O
of	O
secretion	O
.	O

Positive	O
correlations	O
were	O
seen	O
between	O
the	O
measurements	O
for	O
protein	O
intake	O
(	O
r	O
=	O
.	O
58	O
,	O
P	O
=	O
.	O
0026	O
)	O
energy	O
intake	O
(	O
r	O
=	O
.	O
78	O
,	O
P	O
<	O
.	O
00001	O
)	O
,	O
with	O
mean	O
differences	O
of	O
.	O
066	O
g	O
/	O
kg	O
/	O
d	O
(	O
SD	O
.	O
38	O
)	O
2	O
.	O
04	O
kcal	O
/	O
kg	O
/	O
day	O
(	O
SD	O
6	O
.	O
67	O
)	O
,	O
respectively	O
.	O

Grimelius	O
stain	O
was	O
positive	O
,	O
Masson	O
Fontana	O
stain	O
negative	O
.	O

SPP41	B-GENE
was	O
cloned	O
and	O
sequenced	O
and	O
found	O
to	O
be	O
essential	O
.	O
spp43	B-GENE
is	O
allelic	O
to	O
the	O
previously	O
identified	O
suppressor	B-GENE
srn1	I-GENE
,	O
which	O
encodes	O
a	O
negative	O
regulator	O
of	O
gene	O
expression	O
.	O

Thus	O
,	O
phosphodiesterase	B-GENE
inhibitors	O
that	O
produce	O
an	O
opiate	O
quasi-withdrawal	O
syndrome	O
potentiate	O
interoceptive	O
stimuli	O
and	O
weight	O
loss	O
associated	O
with	O
the	O
withdrawal	O
syndrome	O
precipitated	O
by	O
naltrexone	O
in	O
morphine-dependent	O
rats	O
.	O

No	O
differences	O
in	O
fixation	O
quality	O
were	O
observed	O
between	O
cochleas	O
fixed	O
by	O
intravascular	O
perfusion	O
and	O
cochleas	O
fixed	O
by	O
intralabyrinthine	O
perfusion	O
.	O

Effects	O
of	O
diltiazem	O
on	O
netilmicin-induced	O
nephrotoxicity	O
in	O
rabbits	O
.	O

Substitution	O
of	O
serine	O
residues	O
at	O
the	O
C-terminus	O
indicated	O
that	O
loss	O
of	O
phosphorylation	O
sites	O
did	O
not	O
appear	O
to	O
have	O
any	O
effect	O
on	O
transcription	O
and	O
replication	O
.	O

The	O
results	O
show	O
that	O
cognitive	O
stimulation	O
enhanced	O
performance	O
on	O
the	O
Boston	O
Naming	O
Test	O
and	O
a	O
Word	O
List	O
Recognition	O
Task	O
;	O
physical	O
intervention	O
,	O
however	O
,	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

A	O
DNA	O
fragment	O
encoding	O
the	O
DNA-binding	O
domain	O
(	O
amino	O
acids	O
1-60	O
)	O
of	O
the	O
Escherichia	B-GENE
coli	I-GENE
fru	I-GENE
transcriptional	I-GENE
regulator	I-GENE
was	O
cloned	O
into	O
the	O
pGEX-KT	O
vector	O
and	O
expressed	O
in	O
frame	O
with	O
the	O
fused	O
gene	O
encoding	O
glutathione	B-GENE
S-transferase	I-GENE
.	O

It	O
is	O
believed	O
that	O
these	O
domains	O
are	O
important	O
for	O
directing	O
specific	O
protein-protein	O
interactions	O
necessary	O
for	O
the	O
proper	O
functioning	O
of	O
Src	B-GENE
.	O

Obesity	O
was	O
strongly	O
associated	O
with	O
the	O
proportions	O
of	O
nonprotein-bound	O
and	O
albumin-bound	O
estradiol	O
,	O
and	O
inversely	O
associated	O
with	O
sex	B-GENE
hormone	I-GENE
binding	I-GENE
globulin	I-GENE
(	O
SHBG	B-GENE
)	O
levels	O
and	O
the	O
proportion	O
of	O
SHBG-bound	O
estradiol	O
.	O

Although	O
a	O
carboxyl-terminal	O
HSF	B-GENE
transcriptional	O
activation	O
domain	O
is	O
critical	O
for	O
the	O
activation	O
of	O
CUP1	B-GENE
transcription	O
in	O
response	O
to	O
both	O
heat	O
shock	O
stress	O
and	O
glucose	O
starvation	O
,	O
this	O
region	O
is	O
dispensable	O
for	O
transient	O
heat	O
shock	O
activation	O
of	O
at	O
least	O
two	O
genes	O
encoding	O
members	O
of	O
the	O
S	O
.	O
cerevisiae	O
hsp70	B-GENE
family	I-GENE
.	O

METHODS	O
:	O
We	O
obtained	O
maximal	O
inspiratory	O
and	O
expiratory	O
flow-volume	O
curves	O
in	O
41	O
unselected	O
patients	O
with	O
essential	O
tremor	O
(	O
14	O
males	O
,	O
27	O
females	O
,	O
age	O
61	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
14	O
years	O
)	O
.	O

This	O
correlated	O
with	O
reduced	O
levels	O
of	O
secreted	O
hepatitis	B-GENE
B	I-GENE
e	I-GENE
antigen	I-GENE
and	O
increased	O
intracellular	O
levels	O
of	O
core	B-GENE
and	O
Pol	B-GENE
proteins	I-GENE
and	O
replicative	O
HBV	O
DNA	O
intermediates	O
.	O

Relapse	O
of	O
leukemia	O
after	O
prolonged	O
remission	O
.	O

A	O
new	O
physiopathological	O
treatment	O
of	O
HBV-related	O
polyarteritis	O
inspired	O
by	O
advances	O
in	O
the	O
treatment	O
of	O
chronic	O
active	O
hepatitis	O
B	O
was	O
tested	O
in	O
7	O
patients	O
.	O

The	O
ipsilateral	O
breast	O
tumor	O
relapse	O
rate	O
was	O
similar	O
between	O
the	O
PALP	O
and	O
MGDET	O
groups	O
.	O

Possibilities	O
of	O
needleless	O
administration	O
of	O
various	O
substances	O
to	O
animals	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
LVM	O
or	O
wall	O
thickness	O
and	O
body	O
surface	O
area	O
,	O
age	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
total	O
peripheral	O
resistance	O
and	O
left	O
ventricular	O
systolic	O
wall	O
stress	O
,	O
whereas	O
CD25	O
was	O
correlated	O
with	O
urinary	O
catecholamines	O
only	O
in	O
hypertensive	O
patients	O
(	O
r	O
=	O
0	O
.	O
606	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Uses	O
of	O
orthoclone	O
OKT3	O
for	O
prophylaxis	O
of	O
rejection	O
and	O
induction	O
in	O
initial	O
nonfunction	O
in	O
kidney	O
transplantation	O
.	O

(	O
iv	O
)	O
Although	O
UCRBP	B-GENE
has	O
been	O
previously	O
shown	O
to	O
act	O
as	O
a	O
transcriptional	O
repressor	O
,	O
we	O
show	O
here	O
that	O
UCRBP	B-GENE
can	O
also	O
act	O
as	O
a	O
positive	O
transactivator	O
of	O
a	O
reporter	O
driven	O
by	O
UCR	B-GENE
elements	I-GENE
when	O
used	O
in	O
co-transfection	O
assays	O
.	O

RNase	B-GENE
protection	O
assays	O
reveal	O
that	O
this	O
gene	O
,	O
unr	B-GENE
,	O
is	O
transcribed	O
in	O
the	O
same	O
direction	O
as	O
N-ras	B-GENE
and	O
that	O
its	O
3'	O
end	O
is	O
located	O
just	O
130	O
base	O
pairs	O
away	O
from	O
the	O
point	O
at	O
which	O
N-ras	B-GENE
transcription	O
begins	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
HIP	B-GENE
is	O
a	O
membrane-associated	O
HP-binding	O
protein	O
expressed	O
on	O
the	O
surface	O
of	O
normal	O
human	O
uterine	O
epithelia	O
and	O
uterine	O
epithelial	O
cell	O
lines	O
.	O

The	O
second	O
mutation	O
present	O
in	O
the	O
original	O
mutant	O
proved	O
to	O
be	O
an	O
allele	O
of	O
a	O
known	O
gene	O
,	O
PBS2	B-GENE
,	O
which	O
encodes	O
a	O
putative	O
protein	B-GENE
kinase	I-GENE
that	O
functions	O
in	O
the	O
high	O
osmolarity	O
stress	O
pathway	O
.	O

Clinical	O
implication	O
of	O
protein	O
levels	O
of	O
IL-5	B-GENE
in	O
induced	O
sputum	O
in	O
asthmatic	O
patients	O
.	O

The	O
enzyme	O
displays	O
optimal	O
activity	O
at	O
about	O
0	O
.	O
5	O
mM	O
pantoate	O
(	O
k	O
(	O
cat	O
)	O
0	O
.	O
63	O
s	O
(	O
-1	O
)	O
)	O
and	O
at	O
pH	O
7	O
.	O
8	O
.	O

Biol	O
.	O

These	O
properties	O
indicate	O
that	O
Gle1	B-GENE
is	O
an	O
RNA-export	O
factor	O
and	O
that	O
Rev	B-GENE
may	O
mediate	O
viral	O
RNA	O
export	O
by	O
mimicking	O
the	O
function	O
of	O
Gle1	B-GENE
.	O

Dynamic	O
imaging	O
of	O
nuclear	O
wave	O
functions	O
with	O
ultrashort	O
UV	O
laser	O
pulses	O
.	O

Co-administration	O
of	O
5FU	O
,	O
angiotensin	B-GENE
II	I-GENE
and	O
microspheres	O
via	O
the	O
hepatic	O
artery	O
may	O
reduce	O
drug	O
exposure	O
in	O
the	O
systemic	O
compartment	O
and	O
therefore	O
may	O
increase	O
the	O
therapeutic	O
ratio	O
of	O
5FU	O
administration	O
via	O
the	O
hepatic	O
artery	O
.	O

Specific	O
binding	O
of	O
the	O
protein	O
factors	O
to	O
the	O
sites	O
,	O
possibly	O
to	O
the	O
three	O
Mt	B-GENE
sequences	I-GENE
,	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
regulation	O
of	O
the	O
transcription	O
of	O
nuclear	O
genes	O
encoding	O
subunits	O
responsible	O
for	O
mitochondrial	O
oxidative	O
phosphorylation	O
.	O

The	O
pattern	O
for	O
catalytic	O
zinc	O
sites	O
included	O
two	O
ligands	O
close	O
in	O
sequence	O
,	O
a	O
sequence-distant	O
ligand	O
,	O
and	O
a	O
main-chain	O
hydrogen	O
bond	O
joining	O
two	O
ligands	O
.	O

Neutrophil	O
:	O
lymphocyte	O
ratio	O
,	O
plasma	O
haptoglobin	B-GENE
,	O
and	O
CBG	B-GENE
levels	O
were	O
greater	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
during	O
the	O
INITIAL	O
period	O
than	O
during	O
the	O
PRE	O
or	O
POST	O
periods	O
but	O
did	O
not	O
differ	O
between	O
treatments	O
.	O

In	O
a	O
prospective	O
randomized	O
study	O
,	O
287	O
patients	O
with	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
stage	O
IIIb	O
or	O
IV	O
with	O
ECOG	O
performance	O
status	O
(	O
PS	O
)	O
0-1	O
or	O
2	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
best	O
supportive	O
care	O
(	O
BSC	O
)	O
or	O
supportive	O
care	O
plus	O
combination	O
chemotherapy	O
(	O
IEP	O
regimen	O
:	O
ifosfamide	O
3	O
gm	O
/	O
m2	O
IV	O
with	O
mesna	O
uroprotection	O
,	O
epirubicin	O
60	O
mg	O
/	O
m2	O
IV	O
on	O
day	O
1	O
and	O
cisplatin	O
60	O
mg	O
/	O
m2	O
IV	O
on	O
day	O
2	O
;	O
or	O
MVP	O
regimen	O
:	O
mitomycin-C	O
8	O
mg	O
/	O
m2	O
,	O
cisplatin	O
100	O
mg	O
/	O
m2	O
IV	O
on	O
day	O
1	O
,	O
vinblastine	O
4	O
mg	O
/	O
m2	O
IV	O
on	O
days	O
1	O
and	O
15	O
)	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
low	O
binding	O
activity	O
of	O
CBF	B-GENE
to	O
the	O
wild-type	B-GENE
AtpC	I-GENE
promoter	I-GENE
sequence	I-GENE
was	O
observed	O
with	O
nuclear	O
extracts	O
from	O
tissue	O
with	O
low	O
AtpC	B-GENE
expression	O
levels	O
,	O
i	O
.	O
e	O
.	O
extracts	O
from	O
etiolated	O
and	O
photobleached	O
seedlings	O
,	O
whereas	O
high	O
binding	O
activity	O
was	O
detectable	O
with	O
extracts	O
from	O
tissues	O
with	O
high	O
AtpC	B-GENE
expression	O
levels	O
,	O
i	O
.	O
e	O
.	O
extracts	O
from	O
light-grown	O
seedlings	O
and	O
etiolated	O
seedlings	O
treated	O
with	O
cytokinin	B-GENE
.	O

The	O
data	O
indicate	O
that	O
calcitonin	B-GENE
induced	O
a	O
beta-endorphin	B-GENE
increase	O
independent	O
of	O
enhanced	O
corticotrophin-cortisol	O
release	O
.	O

Electrocardiographic	O
right	O
ventricular	O
hypertrophy	O
was	O
seen	O
in	O
4	O
,	O
and	O
biventricular	O
hypertrophy	O
in	O
5	O
patients	O
.	O

The	O
plasmin-derived	B-GENE
D	I-GENE
(	I-GENE
approximately	I-GENE
105-kDa	I-GENE
)	I-GENE
product	I-GENE
,	O
however	O
,	O
could	O
be	O
cross-linked	O
into	O
DD	B-GENE
dimers	I-GENE
.	O

Furthermore	O
,	O
the	O
deletion	O
of	O
bcp	B-GENE
from	O
the	O
chromosome	O
had	O
no	O
effect	O
on	O
gcv-lacZ	B-GENE
expression	O
.	O

The	O
amino-terminal	O
region	O
of	O
E1A	B-GENE
binds	O
several	O
high	O
molecular	O
weight	O
proteins	O
and	O
inhibits	O
the	O
transcriptional	O
coactivator	O
function	O
of	O
p300	B-GENE
and	O
the	O
homologous	O
cAMP	B-GENE
response	I-GENE
element	I-GENE
(	I-GENE
CRE	I-GENE
)	I-GENE
-binding	I-GENE
protein	I-GENE
.	O

To	O
investigate	O
the	O
effects	O
of	O
exogenous	O
hyaluronic	O
acid	O
,	O
the	O
development	O
of	O
port-site	O
metastasis	O
was	O
examined	O
using	O
mouse	O
adenocarcinoma	O
cell-line	O
colon	O
26	O
cells	O
.	O

Some	O
users	O
will	O
willingly	O
comply	O
with	O
management	O
measures	O
,	O
other	O
users	O
will	O
comply	O
in	O
response	O
to	O
education	O
,	O
but	O
there	O
will	O
be	O
another	O
group	O
who	O
will	O
only	O
respond	O
to	O
enforcement	O
activities	O
.	O

The	O
extraction	O
was	O
subsequently	O
rated	O
as	O
'easy'	O
or	O
'difficult'	O
.	O
Taking	O
Pell-Gregory	O
class	O
C	O
as	O
a	O
predictor	O
of	O
a	O
'difficult'	O
extraction	O
,	O
specificity	O
was	O
88%	O
but	O
sensitivity	O
was	O
low	O
at	O
15%	O
.	O

Chrispeels	O
[	O
1993	O
]	O
EMBO	O
J	O
12	O
:	O
2241-2247	O
)	O
.	O

Therefore	O
,	O
vitamin	O
D3	O
analogues	O
have	O
a	O
substantial	O
antipsoriatic	O
effect	O
.	O

A	O
mutant	B-GENE
areA	I-GENE
product	I-GENE
truncated	O
immediately	O
after	O
the	O
last	O
residue	O
of	O
the	O
highly	O
conserved	O
GATA	B-GENE
(	O
DNA-binding	O
)	O
domain	O
retains	O
partial	O
function	O
.	O

Thus	O
,	O
the	O
CCAAT	O
box	O
also	O
has	O
tissue-specific	O
characteristics	O
that	O
assist	O
in	O
targeting	O
expression	O
of	O
the	O
alpha-subunit	B-GENE
gene	I-GENE
to	O
trophoblasts	O
.	O

The	O
identification	O
of	O
the	O
hepatitis	O
C	O
virus	O
as	O
the	O
major	O
cause	O
of	O
liver	O
disease	O
both	O
in	O
dialysis	O
patients	O
and	O
in	O
transplant	O
patients	O
has	O
focused	O
attention	O
on	O
the	O
epidemiology	O
and	O
the	O
impact	O
of	O
continuing	O
infection	O
in	O
these	O
patient	O
groups	O
.	O

IL-1	B-GENE
and	O
TNF	B-GENE
increase	O
AND-34	B-GENE
transcript	I-GENE
levels	O
in	O
thymic	O
cortical	O
reticular	O
,	O
thymic	O
nurse	O
,	O
and	O
fibroblast	O
cell	O
lines	O
.	O

Sequence	O
divergence	O
is	O
observed	O
in	O
untranslated	O
regions	O
which	O
allows	O
the	O
definition	O
of	O
gene-specific	O
probes	O
.	O

This	O
site	O
is	O
upstream	O
from	O
the	O
TATA	O
box	O
used	O
in	O
somatic	O
cells	O
.	O

It	O
also	O
suggests	O
that	O
there	O
is	O
another	O
pathway	O
which	O
can	O
activate	O
SWI4	B-GENE
transcription	O
in	O
the	O
absence	O
of	O
SWI6	B-GENE
.	O

Furthermore	O
,	O
45Ca-binding	O
assays	O
revealed	O
that	O
CCaMK	B-GENE
directly	O
binds	O
Ca2+	O
.	O

To	O
analyze	O
the	O
regulatory	O
activity	O
of	O
Gtx	B-GENE
,	O
we	O
first	O
identified	O
the	O
optimal	O
Gtx-binding	B-GENE
sequence	I-GENE
using	O
an	O
in	O
vitro	O
DNA-binding	O
assay	O
.	O

Generally	O
the	O
differences	O
between	O
short	O
gut	O
and	O
sham	O
operation	O
animals	O
disappeared	O
when	O
the	O
data	O
were	O
normalised	O
for	O
mucosal	O
weight	O
.	O

Dopaminergic	O
modulation	O
of	O
transcallosal	O
activity	O
of	O
cat	O
motor	O
cortical	O
neurons	O
.	O

In	O
children	O
unable	O
to	O
perform	O
forced	O
expiratory	O
maneuvers	O
(	O
n	O
=	O
25	O
)	O
,	O
FOT	O
,	O
contrary	O
to	O
the	O
interrupter	O
technique	O
,	O
clearly	O
identified	O
a	O
subgroup	O
of	O
young	O
children	O
with	O
high	O
resistance	O
values	O
at	O
baseline	O
,	O
which	O
returned	O
to	O
normal	O
after	O
bronchodilation	O
.	O

An	O
increase	O
in	O
bone	O
mineral	O
density	O
at	O
the	O
spine	O
,	O
total	O
hip	O
,	O
and	O
total	O
body	O
has	O
been	O
reported	O
with	O
raloxifene	O
but	O
seems	O
to	O
be	O
less	O
than	O
that	O
seen	O
with	O
estrogen	O
or	O
alendronate	O
therapy	O
.	O

The	O
retinoid	B-GENE
Z	I-GENE
receptor	I-GENE
beta	I-GENE
(	O
RZR	B-GENE
beta	I-GENE
)	O
,	O
an	O
orphan	B-GENE
receptor	I-GENE
,	O
is	O
a	O
member	O
of	O
the	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
(	O
RAR	B-GENE
)	B-GENE
/	I-GENE
thyroid	I-GENE
hormone	I-GENE
receptor	I-GENE
(	O
TR	B-GENE
)	O
subfamily	O
of	O
nuclear	O
receptors	O
.	O

We	O
conclude	O
that	O
grade	O
III	O
BGCT	O
can	O
be	O
treated	O
by	O
modified	O
intralesional	O
excision	O
provided	O
the	O
articular	O
surfaces	O
and	O
part	O
of	O
the	O
metaphysis	O
are	O
intact	O
.	O

A	O
reversed-phase	O
high-performance	O
liquid	O
chromatographic	O
(	O
HPLC	O
)	O
method	O
for	O
the	O
determination	O
of	O
cocaine	O
metabolites	O
produced	O
in	O
vitro	O
by	O
serum	B-GENE
and	I-GENE
liver	I-GENE
esterases	I-GENE
is	O
described	O
.	O

The	O
functions	O
of	O
isolated	O
portions	O
of	O
the	O
insulin	B-GENE
,	O
IAPP	B-GENE
,	O
and	O
beta	B-GENE
GK	I-GENE
promoters	I-GENE
were	O
studied	O
by	O
using	O
transient	O
expression	O
and	O
DNA	O
binding	O
assays	O
.	O

Caries	O
prevention	O
in	O
the	O
dental	O
office	O
.	O

Use	O
of	O
the	O
vena	O
cava	O
to	O
extend	O
the	O
right	O
renal	O
vein	O
for	O
cadaver	O
transplantation	O
is	O
controversial	O
.	O

During	O
the	O
observation	O
period	O
of	O
0	O
.	O
4-30	O
weeks	O
,	O
cardiac	O
white	O
spots	O
on	O
the	O
right	O
ventricle	O
of	O
BALB	O
/	O
c	O
mice	O
were	O
first	O
detected	O
at	O
three	O
weeks	O
(	O
6	O
of	O
20	O
mice	O
;	O
30%	O
)	O
,	O
and	O
the	O
maximal	O
incidence	O
of	O
cardiac	O
white	O
spots	O
was	O
obtained	O
at	O
nine	O
weeks	O
(	O
39	O
of	O
44	O
mice	O
;	O
88%	O
)	O
.	O

We	O
have	O
used	O
the	O
hydrophobic	O
repeats	O
of	O
the	O
HSF1	B-GENE
trimerization	I-GENE
domain	I-GENE
in	O
the	O
yeast	O
two-hybrid	O
protein	O
interaction	O
assay	O
to	O
identify	O
heat	B-GENE
shock	I-GENE
factor	I-GENE
binding	I-GENE
protein	I-GENE
1	I-GENE
(	O
HSBP1	B-GENE
)	O
,	O
a	O
novel	O
,	O
conserved	O
,	O
76-amino-acid	O
protein	O
that	O
contains	O
two	O
extended	O
arrays	O
of	O
hydrophobic	O
repeats	O
that	O
interact	O
with	O
the	O
HSF1	B-GENE
heptad	I-GENE
repeats	I-GENE
.	O

The	O
CNXA	B-GENE
domain	I-GENE
is	O
similar	O
at	O
the	O
amino	O
acid	O
level	O
to	O
the	O
Escherichia	B-GENE
coli	I-GENE
moaA	I-GENE
gene	I-GENE
product	I-GENE
,	O
while	O
CNXC	B-GENE
is	O
similar	O
to	O
the	O
E	B-GENE
.	I-GENE
coli	I-GENE
moaC	I-GENE
product	I-GENE
,	O
with	O
both	O
E	O
.	O
coli	O
products	O
encoded	O
by	O
different	O
cistrons	O
.	O

One	O
of	O
its	O
unique	O
features	O
appears	O
to	O
be	O
the	O
unusually	O
short	O
5'-untranslated	O
regions	O
(	O
UTR	O
)	O
(	O
1-6	O
nucleotides	O
(	O
nts	O
)	O
)	O
and	O
the	O
apparent	O
absence	O
of	O
5'-cap	O
structures	O
from	O
its	O
mRNAs	O
.	O

The	O
COP-PAWP	O
gradient	O
was	O
markedly	O
decreased	O
in	O
both	O
shock	O
and	O
non-shock	O
patients	O
with	O
pulmonary	O
edema	O
.	O

Chick	B-GENE
brain	I-GENE
actin	I-GENE
depolymerizing	I-GENE
factor	I-GENE
(	O
ADF	B-GENE
)	O
is	O
a	O
19-kDa	O
protein	O
that	O
severs	O
actin	B-GENE
filaments	I-GENE
and	O
binds	O
actin	B-GENE
monomers	I-GENE
.	O

CodY	B-GENE
does	O
not	O
have	O
any	O
homologues	O
in	O
the	O
data-bases	O
.	O

A	O
15	O
.	O
1	O
kb	O
fragment	O
of	O
the	O
yeast	O
genome	O
was	O
allocated	O
to	O
the	O
centromeric	O
region	O
of	O
chromosome	O
XIV	O
by	O
genetic	O
mapping	O
.	O

The	O
test	O
for	O
alpha-naphthyl	B-GENE
esterase	I-GENE
and	O
quantitation	O
of	O
macrophages	O
(	O
absolute	O
number	O
)	O
per	O
infiltration	O
area	O
unit	O
adjacent	O
to	O
the	O
abscess	O
suggest	O
a	O
direct	O
correlation	O
between	O
the	O
absolute	O
number	O
of	O
macrophages	O
and	O
the	O
width	O
of	O
the	O
capsule	O
.	O

Here	O
,	O
we	O
have	O
more	O
closely	O
investigated	O
transactivation	O
of	O
the	O
human	B-GENE
HSP70	I-GENE
promoter	I-GENE
by	O
Myb	B-GENE
proteins	I-GENE
.	O

Varieties	O
of	O
envious	O
experience	O
.	O

In	O
the	O
absence	O
of	O
histological	O
criteria	O
,	O
which	O
it	O
is	O
difficult	O
to	O
demand	O
in	O
view	O
of	O
the	O
variability	O
of	O
results	O
and	O
potential	O
dangers	O
of	O
endomyocardial	O
biopsy	O
involving	O
such	O
thin	O
and	O
fragile	O
ventricular	O
walls	O
,	O
the	O
diagnosis	O
of	O
ACRV	O
is	O
based	O
upon	O
the	O
concomitant	O
existence	O
of	O
:	O
(	O
1	O
)	O
electrophysiological	O
criteria	O
:	O
ventricular	O
arrhythmias	O
,	O
in	O
particular	O
sustained	O
monomorphous	O
VT	O
,	O
with	O
the	O
particular	O
feature	O
of	O
a	O
very	O
high	O
degree	O
of	O
sensitivity	O
to	O
adrenergic	O
stimulation	O
(	O
exercise	O
)	O
,	O
the	O
existence	O
of	O
late	O
potentials	O
on	O
the	O
high	O
amplification	O
ECG	O
,	O
a	O
highly	O
specific	O
sign	O
,	O
though	O
unfortunately	O
of	O
poor	O
sensitivity	O
in	O
localized	O
froms	O
,	O
those	O
which	O
are	O
most	O
difficult	O
to	O
identify	O
(	O
2	O
)	O
;	O
segmentary	O
morphological	O
and	O
kinetic	O
RV	O
abnormalities	O
,	O
most	O
often	O
resulting	O
in	O
localized	O
akinetic	O
or	O
dyskinetic	O
parietal	O
vaulting	O
,	O
with	O
stasis	O
"in	O
situ"	O
.	O

We	O
show	O
here	O
that	O
v-Rel	B-GENE
specifically	O
increased	O
expression	O
from	O
a	O
reporter	O
plasmid	O
containing	O
multiple	O
Sp1	B-GENE
binding	I-GENE
sites	I-GENE
approximately	O
sixfold	O
in	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEFs	O
)	O
,	O
even	O
though	O
v-Rel	B-GENE
did	O
not	O
bind	O
directly	O
to	O
these	O
sites	O
.	O
v-Rel	B-GENE
also	O
increased	O
expression	O
from	O
a	O
reporter	O
plasmid	O
containing	O
a	O
human	B-GENE
immunodeficiency	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
(	I-GENE
HIV-1	I-GENE
)	I-GENE
long	I-GENE
terminal	I-GENE
repeat	I-GENE
(	O
LTR	B-GENE
)	O
in	O
which	O
the	O
kappa	B-GENE
B	I-GENE
binding	I-GENE
sites	I-GENE
were	O
mutated	O
but	O
which	O
still	O
contained	O
intact	O
Sp1	B-GENE
binding	I-GENE
sites	I-GENE
.	O

Use	O
of	O
Medi-Jector	O
EZ	O
dermojet	O
for	O
anesthesia	O
in	O
minor	O
surgery	O
.	O

Each	O
half	O
molecule	O
contains	O
four	O
disulfide	O
linkages	O
and	O
four	O
cis	O
peptides	O
.	O

The	O
alpha-subunit	O
by	O
itself	O
binds	O
to	O
telomeric	O
DNA	O
.	O

The	O
positive-acting	O
global	O
sulfur	O
regulatory	O
protein	O
,	O
CYS3	B-GENE
,	O
of	O
Neurospora	O
crassa	O
turns	O
on	O
the	O
expression	O
of	O
a	O
family	O
of	O
unlinked	O
structural	O
genes	O
that	O
encode	O
enzymes	O
of	O
sulfur	O
catabolism	O
.	O

Mechanism	O
of	O
immunogenesis	O
in	O
vaccination	O
with	O
streptomycin-dependent	O
mutants	O
of	O
salmonellae	O
and	O
shigellae	O
.	O

Cortisol	O
excretion	O
,	O
appeared	O
to	O
be	O
markedly	O
affected	O
by	O
the	O
season	O
although	O
other	O
factors	O
such	O
as	O
social	O
and	O
environmental	O
stress	O
cannot	O
be	O
discounted	O
.	O

The	O
minimal	O
promoter	O
of	O
the	O
RII	B-GENE
beta	I-GENE
gene	I-GENE
was	O
composed	O
of	O
two	O
adjacent	O
functional	O
elements	O
.	O

Our	O
results	O
,	O
however	O
,	O
were	O
obtained	O
for	O
Z	O
itself	O
and	O
not	O
for	O
[	O
Z	O
]	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
mouse	B-GENE
growth	I-GENE
hormone	I-GENE
receptor	I-GENE
/	I-GENE
growth	I-GENE
hormone	I-GENE
binding	I-GENE
protein	I-GENE
gene	I-GENE
.	O

Among	O
individuals	O
,	O
however	O
,	O
changes	O
were	O
strongly	O
correlated	O
with	O
ACR	O
levels	O
at	O
baseline	O
.	O

Investigations	O
using	O
hippocampal	O
slices	O
maintained	O
in	O
vitro	O
have	O
demonstrated	O
that	O
bursts	O
of	O
oscillatory	O
field	O
potentials	O
in	O
the	O
gamma	O
frequency	O
range	O
(	O
30-80	O
Hz	O
)	O
are	O
followed	O
by	O
a	O
slower	O
oscillation	O
in	O
the	O
beta	O
1	O
range	O
(	O
12-20	O
Hz	O
)	O
.	O

We	O
suggest	O
that	O
CT	O
scan	O
be	O
preferable	O
in	O
diagnosis	O
of	O
tumors	O
in	O
that	O
area	O
.	O

Several	O
features	O
of	O
10	O
.	O
24	O
.	O
6	O
cells	O
suggest	O
that	O
the	O
mutation	O
disrupts	O
normal	O
intracellular	O
formation	O
of	O
peptide	B-GENE
/	I-GENE
DR	I-GENE
complexes	I-GENE
.	O

Human	O
antitetanus	O
serum	O
:	O
an	O
unused	O
wealth	O
.	O

Depending	O
on	O
treatment	O
exposures	O
,	O
this	O
at-risk	O
population	O
may	O
experience	O
life-threatening	O
late	O
effects	O
,	O
such	O
as	O
cirrhosis	O
secondary	O
to	O
hepatitis	O
C	O
or	O
late-onset	O
anthracycline-induced	O
cardiomyopathy	O
,	O
or	O
life-changing	O
late	O
effects	O
,	O
such	O
as	O
cognitive	O
dysfunction	O
.	O

Their	O
effect	O
on	O
the	O
guinea	O
pig	O
vas	O
deferens	O
.	O

This	O
enabled	O
the	O
formation	O
of	O
stem-loop	O
templates	O
with	O
the	O
fusion	O
point	O
of	O
the	O
chimeric	O
transcript	O
in	O
the	O
loop	O
and	O
the	O
use	O
of	O
MLL	B-GENE
primers	O
in	O
two-sided	O
PCR	O
.	O

We	O
recently	O
reported	O
a	O
placenta-specific	O
enhancer	O
in	O
the	O
human	B-GENE
leukemia	I-GENE
inhibitory	I-GENE
factor	I-GENE
receptor	I-GENE
(	O
LIFR	B-GENE
)	O
gene	O
and	O
now	O
show	O
detailed	O
characterization	O
of	O
the	O
226-base	O
pair	O
enhancer	O
(	O
-4625	O
/	O
-4400	O
nucleotides	O
)	O
.	O

Factors	O
influencing	O
semen	O
characteristics	O
in	O
young	O
boars	O
reared	O
in	O
a	O
subtropical	O
environment	O
were	O
studied	O
.	O

These	O
equilibrium	O
solutions	O
are	O
then	O
shown	O
to	O
arise	O
from	O
the	O
vertices	O
of	O
a	O
particular	O
convex	O
polyhedron	O
.	O

The	O
studied	O
protein	O
fragments	O
consist	O
of	O
residues	O
Arg183-His267	O
of	O
the	O
human	B-GENE
ER	I-GENE
and	O
residues	O
Lys438-Gln520	O
of	O
the	O
rat	B-GENE
GR	O
.	O

Micro	O
high-performance	O
liquid	O
chromatographic	O
system	O
with	O
micro	O
precolumn	O
and	O
dual	O
electrochemical	O
detector	O
for	O
direct	O
injection	O
analysis	O
of	O
catecholamines	O
in	O
body	O
fluids	O
.	O

Human	B-GENE
cytomegalovirus	I-GENE
immediate-early	I-GENE
protein	I-GENE
IE2	I-GENE
tethers	O
a	O
transcriptional	O
repression	O
domain	O
to	O
p53	B-GENE
.	O

Neither	O
verapamil	O
nor	O
nifedipine	O
changed	O
collateral	O
myocardial	O
blood	O
flow	O
from	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
02	O
in	O
the	O
subendocardium	O
and	O
0	O
.	O
17	O
+	O
/	O
-	O
0	O
.	O
03	O
ml	O
/	O
min	O
/	O
g	O
in	O
the	O
subepicardium	O
.	O

Sequence	O
comparison	O
of	O
the	O
0	O
.	O
38	O
kb	O
promoter	O
sequence	O
with	O
the	O
promoters	O
of	O
the	O
Sm-E	B-GENE
gene	O
and	O
U1	B-GENE
snRNA	I-GENE
genes	I-GENE
revealed	O
several	O
homologous	O
motifs	O
,	O
suggesting	O
that	O
genes	O
encoding	O
the	O
snRNP	B-GENE
components	O
may	O
be	O
coordinately	O
regulated	O
.	O

The	O
most	O
common	O
cause	O
of	O
renal	O
deterioration	O
in	O
the	O
spinal	O
cord	O
injured	O
patient	O
is	O
irreversible	O
vesicoureteral	O
reflux	O
.	O

Identification	O
of	O
eotaxin-3	B-GENE
will	O
further	O
promote	O
our	O
understanding	O
of	O
the	O
control	O
of	O
eosinophil	O
trafficking	O
and	O
other	O
CCR3-mediated	O
biological	O
phenomena	O
.	O

The	O
efficacy	O
of	O
a	O
Propionibacterium	O
acnes	O
product	O
for	O
treatment	O
of	O
coliform	O
mastitis	O
was	O
evaluated	O
following	O
intramammary	O
infusion	O
of	O
Escherichia	O
coli	O
.	O

Patients	O
had	O
to	O
have	O
adequate	O
liver	O
,	O
renal	O
,	O
and	O
marrow	O
functions	O
.	O

Comparison	O
with	O
the	O
bovine	O
gene	O
showed	O
that	O
the	O
5'-flanking	O
region	O
of	O
the	O
hATP1	B-GENE
gene	I-GENE
has	O
an	O
unconserved	O
guanine-cytosine	O
(	O
GC	O
)	O
rich	O
region	O
,	O
including	O
several	O
binding	O
motifs	O
of	O
transcriptional	O
factors	O
,	O
such	O
as	O
Sp1	B-GENE
,	O
AP-2	B-GENE
,	O
and	O
GCF	B-GENE
.	O

Reconstitution	O
of	O
Raf-1	B-GENE
activity	O
was	O
observed	O
only	O
with	O
kinase	B-GENE
active	O
Jak1	B-GENE
in	O
both	O
cell	O
lines	O
.	O

Binding	O
of	O
meAda	B-GENE
is	O
necessary	O
to	O
activate	O
transcription	O
of	O
the	O
adaptive	O
response	O
genes	O
;	O
accordingly	O
,	O
in	O
vitro	O
transcription	O
of	O
aidB	B-GENE
is	O
dependent	O
on	O
the	O
presence	O
of	O
meAda	B-GENE
.	O

Spatiotemporal	O
expression	O
of	O
the	O
PAX3	B-GENE
gene	I-GENE
is	O
tightly	O
regulated	O
during	O
development	O
.	O

Neural	O
blockade	O
in	O
chronic	O
and	O
cancer	O
pain	O
.	O

OBJECTIVES	O
:	O
1	O
)	O
to	O
determine	O
serum	B-GENE
ACE	I-GENE
activity	O
in	O
patients	O
with	O
COPD	O
treated	O
with	O
and	O
without	O
continuous	O
ambulatory	O
oxygen	O
therapy	O
(	O
CAOT	O
)	O
;	O
2	O
)	O
to	O
verify	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
ACE	B-GENE
and	O
any	O
hematological	O
,	O
spirometric	O
or	O
gasometric	O
parameter	O
.	O

Lymphoproliferative	O
disorders	O
arising	O
under	O
immunosuppression	O
with	O
FK	O
506	O
:	O
initial	O
observations	O
in	O
a	O
large	O
transplant	O
population	O
.	O

Furthermore	O
,	O
plasma	O
fibrinogen	B-GENE
levels	O
increased	O
by	O
a	O
mean	O
of	O
17	O
.	O
6%	O
,	O
a	O
potentially	O
adverse	O
effect	O
of	O
gemfibrozil	O
that	O
has	O
not	O
been	O
previously	O
reported	O
.	O

This	O
5'	O
splice	O
site	O
sequence	O
was	O
required	O
for	O
enhanced	O
polyadenylation	O
and	O
was	O
recognized	O
by	O
both	O
U1	B-GENE
small	I-GENE
nuclear	I-GENE
ribonucleoproteins	I-GENE
(	O
snRNPs	B-GENE
)	O
and	O
alternative	B-GENE
splicing	I-GENE
factor	I-GENE
/	I-GENE
splicing	I-GENE
factor	I-GENE
2	I-GENE
(	O
ASF	B-GENE
/	I-GENE
SF2	I-GENE
)	O
.	O

One	O
R-EST	O
and	O
one	O
Pto-like	B-GENE
sequence	I-GENE
each	O
mapped	O
to	O
two	O
locations	O
.	O

Expression	O
of	O
a	O
dominant	B-GENE
negative	I-GENE
Smad2	I-GENE
significantly	O
reduces	O
the	O
level	O
of	O
luciferase	B-GENE
reporter	I-GENE
activity	O
induced	O
by	O
nodal	O
treatment	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
and	O
possibly	O
randomised	O
trials	O
using	O
acupuncture	O
to	O
treat	O
asthma	O
and	O
asthma-like	O
symptoms	O
.	O

The	O
size	O
of	O
the	O
mutant	O
molecule	O
corresponds	O
to	O
the	O
unprocessed	O
cytoplasmic	O
precursor	O
(	O
pre-super-pro-PrB	B-GENE
)	O
,	O
as	O
detected	O
in	O
sec61	B-GENE
mutants	I-GENE
,	O
when	O
translocation	O
into	O
the	O
endoplasmic	O
reticulum	O
is	O
blocked	O
.	O

Malonate	O
decarboxylation	O
in	O
Malonomonas	O
rubra	O
involves	O
the	O
formation	O
of	O
malonyl-S-	B-GENE
[	I-GENE
acyl-carrier	I-GENE
protein	I-GENE
]	I-GENE
from	O
acetyl-S-	B-GENE
[	I-GENE
acyl-carrier	I-GENE
protein	I-GENE
]	I-GENE
and	O
malonate	O
,	O
carboxyltransfer	O
to	O
a	O
biotin	B-GENE
protein	I-GENE
and	O
its	O
decarboxylation	O
that	O
is	O
coupled	O
to	O
delta	O
mu	O
Na+	O
generation	O
.	O

Production	O
of	O
C	B-GENE
mu	I-GENE
RNAs	I-GENE
,	O
unlike	O
mu	B-GENE
mRNAs	I-GENE
,	O
does	O
not	O
require	O
recombination	O
with	O
the	O
joining	B-GENE
region	I-GENE
(	I-GENE
JH	I-GENE
)	I-GENE
locus	I-GENE
.	O

Finally	O
,	O
a	O
role	O
for	O
NF-kappaB	B-GENE
in	O
preventing	O
apoptosis	O
induced	O
by	O
ER	O
calcium	O
release	O
was	O
demonstrated	O
by	O
data	O
showing	O
that	O
sAPPalpha	B-GENE
prevents	O
thapsigargin-induced	O
apoptosis	O
,	O
an	O
effect	O
blocked	O
by	O
kappaB	B-GENE
decoy	O
DNA	O
.	O

Neurons	O
were	O
held	O
at	O
-67	O
mV	O
to	O
equate	O
voltage-dependent	O
effects	O
.	O

Prenatal	O
diagnosis	O
of	O
galactosaemia	O
[	O
letter	O
]	O
.	O

All	O
tumors	O
proved	O
histologically	O
to	O
be	O
neuroendocrine	O
in	O
origin	O
.	O

Mechanisms	O
of	O
tachyphylaxis	O
in	O
regional	O
anesthesia	O
of	O
long	O
duration	O
.	O

Patients	O
with	O
more	O
than	O
250	O
PVC	O
/	O
24	O
hours	O
were	O
selected	O
for	O
distribution	O
of	O
PVC	O
and	O
CI	O
evaluation	O
.	O

This	O
dynamic	O
response	O
strongly	O
suggests	O
that	O
the	O
p53	B-GENE
and	O
Rb	B-GENE
tumor	O
suppressor	O
pathways	O
are	O
intact	O
in	O
HeLa	O
cells	O
and	O
that	O
repression	O
of	O
HPV	B-GENE
E6	I-GENE
and	O
E7	B-GENE
mobilizes	O
these	O
pathways	O
in	O
an	O
orderly	O
fashion	O
to	O
deliver	O
growth	O
inhibitory	O
signals	O
to	O
the	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
prostate	O
carcinomas	O
with	O
the	O
Ras	B-GENE
/	I-GENE
MAPK	I-GENE
pathway	O
activation	O
might	O
have	O
a	O
selective	O
growth	O
advantage	O
by	O
autocrine	O
TGF-beta1	B-GENE
production	O
.	O

Optima	O
)	O
genomic	O
library	O
by	O
hybridizing	O
with	O
elicitor-induced	O
stilbene	B-GENE
synthase	I-GENE
cDNA	I-GENE
as	O
a	O
probe	O
.	O

The	O
GTPase	B-GENE
activity	O
of	O
CDC42Ce	B-GENE
is	O
moderately	O
stimulated	O
by	O
human	B-GENE
n-chimaerin	I-GENE
,	O
a	O
GTPase-activating	B-GENE
protein	I-GENE
for	O
the	O
related	O
p21	B-GENE
rac1	I-GENE
.	O

Renin	O
studies	O
performed	O
in	O
34	O
hypertensive	O
patients	O
and	O
in	O
a	O
control	O
group	O
of	O
11	O
recipients	O
showed	O
that	O
elevation	O
of	O
plasma	B-GENE
renin	I-GENE
activity	O
and	O
of	O
plasma	O
aldosterone	O
level	O
is	O
frequent	O
but	O
difficult	O
to	O
interpret	O
,	O
particularly	O
when	O
a	O
renal	O
artery	O
stenosis	O
is	O
observed	O
.	O

The	O
CCAAT	B-GENE
core	I-GENE
sequence	I-GENE
mutants	I-GENE
in	O
which	O
both	O
CIII	B-GENE
and	O
CI	B-GENE
/	I-GENE
CII	I-GENE
were	O
abolished	O
,	O
also	O
increased	O
the	O
promoter	O
activity	O
.	O

In	O
the	O
present	O
study	O
,	O
beta-funaltrexamine	O
(	O
beta-FNA	O
)	O
and	O
naltrindole	O
(	O
NTI	O
)	O
(	O
nonequilibrium	O
mu-	O
and	O
delta-antagonist	O
,	O
respectively	O
)	O
were	O
used	O
to	O
precipitate	O
withdrawal	O
in	O
butorphanol-dependent	O
rats	O
.	O

The	O
frequency	O
of	O
SPs	O
for	O
both	O
the	O
moderate	O
and	O
severe	O
groups	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
a	O
normal	O
MMFCV	O
(	O
p	O
<	O
.	O
01	O
)	O
;	O
of	O
154	O
arms	O
with	O
a	O
normal	O
MMFCV	O
,	O
only	O
9	O
(	O
6%	O
)	O
had	O
an	O
SP	O
.	O

The	O
pattern	O
and	O
timing	O
of	O
CARP	B-GENE
mRNA	I-GENE
expression	O
,	O
including	O
transient	O
expression	O
in	O
the	O
tongue	O
at	O
14	O
.	O
5	O
days	O
p	O
.	O
c	O
.	O
,	O
coincides	O
with	O
that	O
of	O
Nkx2	B-GENE
.	I-GENE
5	I-GENE
/	I-GENE
Csx	I-GENE
(	O
a	O
putative	O
homolog	O
of	O
tinman	B-GENE
,	O
the	O
Drosophila	O
melanogaster	O
gene	O
responsible	O
for	O
cardiac	O
development	O
)	O
.	O

188	O
patients	O
received	O
cimetidine	O
400	O
mg	O
q	O
.	O
i	O
.	O
d	O
.	O
intravenously	O
and	O
1	O
,	O
000	O
mg	O
daily	O
orally	O
in	O
divided	O
doses	O
.	O

Mechanism	O
of	O
activation	O
of	O
the	O
vav	B-GENE
protooncogene	I-GENE
.	O
vav	B-GENE
is	O
a	O
human	O
locus	O
that	O
appears	O
to	O
be	O
specifically	O
expressed	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
regardless	O
of	O
their	O
differentiation	O
lineage	O
.	O

Not	O
even	O
extensive	O
pancreatic	O
resection	O
could	O
prevent	O
pancreatic	O
remnant	O
infection	O
.	O

This	O
concept	O
is	O
supported	O
by	O
the	O
identification	O
of	O
RH-like	B-GENE
genes	I-GENE
in	O
non	O
human	O
primates	O
.	O

The	O
ultrastructural	O
findings	O
,	O
as	O
well	O
as	O
the	O
urinary	O
C-peptide	B-GENE
excretion	O
,	O
confirmed	O
that	O
the	O
glycemic	O
effects	O
should	O
not	O
be	O
thought	O
to	O
be	O
due	O
to	O
a	O
direct	O
action	O
of	O
the	O
drugs	O
used	O
on	O
the	O
endocrine	O
pancreas	O
.	O

HIV-1	O
infection	O
in	O
rural	O
Africa	O
:	O
is	O
there	O
a	O
difference	O
in	O
median	O
time	O
to	O
AIDS	O
and	O
survival	O
compared	O
with	O
that	O
in	O
industrialized	O
countries	O
?	O
OBJECTIVES	O
:	O
To	O
describe	O
the	O
progression	O
times	O
of	O
HIV-1	O
infection	O
from	O
seroconversion	O
to	O
AIDS	O
and	O
to	O
death	O
,	O
and	O
time	O
from	O
first	O
developing	O
AIDS	O
to	O
death	O
in	O
rural	O
Uganda	O
.	O

Both	O
functional	O
analyses	O
in	O
undifferentiated	O
and	O
differentiated	O
F9	O
cells	O
and	O
characterization	O
of	O
DNA-protein	O
complexes	O
in	O
vitro	O
have	O
identified	O
the	O
sequence	B-GENE
motifs	I-GENE
GTGACT	I-GENE
(	I-GENE
C	I-GENE
)	I-GENE
,	O
ATTGT	B-GENE
,	O
and	O
GATA	B-GENE
as	O
the	O
key	O
transcription	O
factor	O
binding	O
sites	O
.	O

Estrogen	O
replacement	O
therapy	O
and	O
risk	O
of	O
breast	O
cancer	O
:	O
results	O
of	O
two	O
meta-analyses	O
.	O

The	O
first	O
gene	O
,	O
NSR1	B-GENE
,	O
a	O
previously	O
identified	O
gene	O
,	O
encodes	O
a	O
protein	O
involved	O
in	O
ribosomal	O
RNA	O
maturation	O
and	O
possibly	O
in	O
transport	O
of	O
proteins	O
into	O
the	O
nucleus	O
.	O

Northern-blot	O
analysis	O
of	O
mRNA	O
from	O
Avicel-grown	O
N	O
.	O
patriciarum	O
showed	O
that	O
xynB	B-GENE
hybridized	O
to	O
a	O
3	O
.	O
4	O
kb	O
mRNA	O
species	O
.	O

There	O
were	O
9	O
patients	O
in	O
NYHA	O
class	O
III	O
and	O
8	O
in	O
class	O
IV	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

To	O
assess	O
the	O
relationship	O
between	O
G	O
(	O
q	O
)	O
/	O
G	O
(	O
11	O
)	O
function	O
with	O
the	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
dependent	O
pathway	O
,	O
expression	O
of	O
a	O
dominant-interfering	O
p85	B-GENE
regulatory	I-GENE
subunit	I-GENE
,	O
as	O
well	O
as	O
wortmannin	O
treatment	O
inhibited	O
insulin-stimulated	O
but	O
not	O
G	O
(	O
q	O
)	O
/	O
Q209L-stimulated	O
GLUT4-EGFP	B-GENE
translocation	O
.	O

Changes	O
of	O
the	O
DB	B-GENE
sequence	I-GENE
without	O
affecting	O
the	O
postulated	O
stem	O
structure	O
led	O
to	O
drastic	O
losses	O
of	O
translation	O
efficiency	O
.	O

Northern	O
blot	O
analysis	O
of	O
LeMT	B-GENE
(	I-GENE
A	I-GENE
)	I-GENE
and	O
LeMT	B-GENE
(	I-GENE
B	I-GENE
)	I-GENE
showed	O
that	O
transcripts	O
of	O
both	O
MT-like	B-GENE
genes	I-GENE
were	O
more	O
abundant	O
in	O
leaves	O
than	O
roots	O
in	O
tomato	O
plants	O
grown	O
without	O
addition	O
of	O
extra	O
metal	O
ions	O
,	O
a	O
characteristic	O
of	O
type	B-GENE
II	I-GENE
MTs	I-GENE
.	O

Blood	O
variables	O
measured	O
at	O
eight	O
intervals	O
before	O
,	O
during	O
,	O
and	O
after	O
operation	O
were	O
as	O
follows	O
:	O
seven	O
plasma	O
proteins	O
,	O
free	O
hemoglobin	B-GENE
,	O
formed	O
elements	O
,	O
and	O
clotting	O
functions	O
.	O

Results	O
of	O
electron	O
therapy	O
of	O
tumors	O
in	O
different	O
sites	O
.	O

Echo	O
modulation	O
in	O
Pr3+	O
:	O
YAlO3	O
.	O

The	O
various	O
forms	O
of	O
sickle	O
cell	O
disease	O
share	O
the	O
common	O
feature	O
of	O
an	O
abnormal	O
globin	B-GENE
chain	I-GENE
that	O
,	O
under	O
certain	O
conditions	O
such	O
as	O
hypoxia	O
,	O
results	O
in	O
the	O
sickling	O
of	O
red	O
blood	O
cells	O
and	O
obstruction	O
of	O
blood	O
vessels	O
.	O

No	O
TATA	O
box	O
was	O
found	O
in	O
the	O
putative	O
promoter	O
region	O
,	O
but	O
multiple	O
GC	O
boxes	O
were	O
found	O
around	O
the	O
cap	O
sites	O
,	O
supporting	O
the	O
previously	O
inferred	O
housekeeping	O
nature	O
of	O
CYP51	B-GENE
gene	I-GENE
and	O
the	O
existence	O
of	O
the	O
multiple	O
transcription	O
initiation	O
sites	O
.	O

Sequencing	O
the	O
gene	O
for	O
an	O
imipenem-cefoxitin-hydrolyzing	O
enzyme	O
(	O
CfiA	B-GENE
)	O
from	O
Bacteroides	O
fragilis	O
TAL2480	O
reveals	O
strong	O
similarity	O
between	O
CfiA	B-GENE
and	O
Bacillus	B-GENE
cereus	I-GENE
beta-lactamase	I-GENE
II	O
.	O

The	O
ED30	O
values	O
were	O
2	O
.	O
4	O
and	O
2	O
.	O
2	O
mg	O
/	O
kg	O
and	O
similar	O
to	O
the	O
respective	O
values	O
of	O
nifedipine	O
(	O
ED	O
30	O
:	O
2	O
.	O
4	O
,	O
2	O
.	O
1	O
mg	O
/	O
kg	O
)	O
.	O

The	O
SH2	B-GENE
domain-containing	I-GENE
inositol	I-GENE
5'-phosphatase	I-GENE
(	O
SHIP	B-GENE
)	O
recruits	O
the	O
p85	B-GENE
subunit	I-GENE
of	O
phosphoinositide	B-GENE
3-kinase	I-GENE
during	O
FcgammaRIIb1-mediated	O
inhibition	O
of	O
B	B-GENE
cell	I-GENE
receptor	I-GENE
signaling	O
.	O

In	O
the	O
face	O
of	O
the	O
outbreak	O
,	O
there	O
was	O
a	O
delay	O
before	O
vaccination	O
was	O
able	O
to	O
stop	O
deaths	O
.	O

Hydrocortisone	O
seems	O
to	O
be	O
unable	O
to	O
hinder	O
the	O
postdenervation	O
changes	O
in	O
the	O
muscle	O
membrane	O
whereas	O
high	O
doses	O
of	O
the	O
hormone	O
are	O
able	O
to	O
induce	O
changes	O
in	O
the	O
muscle	O
membrane	O
.	O

The	O
recovered	O
calves	O
were	O
tested	O
for	O
immunity	O
to	O
homologous	O
severe	O
challenge	O
,	O
50	O
or	O
73	O
days	O
after	O
the	O
first	O
infection	O
.	O

The	O
transport	O
of	O
a	O
genetically	O
engineered	O
chimeric	O
transmembrane	O
protein	O
connected	O
to	O
this	O
ER	O
leader	O
sequence	O
was	O
as	O
efficient	O
as	O
that	O
of	O
the	O
original	O
protein	O
from	O
which	O
the	O
ER	O
sequence	O
has	O
been	O
derived	O
.	O

J	O
.	O

Results	O
from	O
in	O
vitro	O
transcription-translation	O
analysis	O
and	O
maxicell	O
experiments	O
suggested	O
that	O
the	O
447-bp	O
ORF	O
was	O
the	O
one	O
being	O
actively	O
expressed	O
.	O

Extensive	O
DNA	O
rearrangement	O
occurs	O
during	O
the	O
development	O
of	O
the	O
somatic	O
macronucleus	O
from	O
the	O
germ	O
line	O
micronucleus	O
in	O
ciliated	O
protozoans	O
.	O

Thus	O
,	O
dpp	B-GENE
and	O
omb	B-GENE
promote	O
both	O
dorsal	O
leg	O
cell	O
fate	O
as	O
well	O
as	O
transdetermination-competent	O
leg	O
disc	O
cells	O
.	O

Germ-free	O
rabbits	O
given	O
mouse	O
CRF-flora	O
showed	O
values	O
quite	O
different	O
from	O
control	O
animals	O
for	O
most	O
parameters	O
,	O
indicating	O
unsuitability	O
of	O
mouse	O
CRF	O
flora	O
to	O
'normalize'	O
rabbits	O
.	O

Based	O
on	O
mutational	O
data	O
and	O
possible	O
mRNA	O
structure	O
,	O
we	O
hypothesized	O
about	O
the	O
effect	O
of	O
mRNA	O
structure	O
on	O
translation	O
of	O
the	O
two	O
major	O
C	B-GENE
/	I-GENE
EBPepsilon	I-GENE
isoforms	I-GENE
:	O
p32	B-GENE
and	O
p30	B-GENE
.	O

Moreover	O
,	O
unlike	O
control	O
rats	O
operated	O
animals	O
did	O
not	O
show	O
aversion	O
to	O
the	O
highest	O
concentrations	O
of	O
saccharin	O
solutions	O
.	O

We	O
recently	O
found	O
that	O
17	O
beta-estradiol	O
(	O
E2	O
)	O
not	O
only	O
suppresses	O
bone	O
resorption	O
but	O
also	O
stimulates	O
bone	O
formation	O
in	O
the	O
cancellous	O
bone	O
of	O
female	O
rats	O
.	O

Although	O
the	O
E-box	O
consensus	O
is	O
minimally	O
defined	O
as	O
CANNTG	B-GENE
,	O
the	O
adjacent	O
nucleotides	O
of	O
functional	O
E-boxes	O
are	O
variable	O
for	O
genes	O
regulated	O
by	O
the	O
bHLH	B-GENE
proteins	I-GENE
.	O

Forty	O
patients	O
,	O
divided	O
according	O
to	O
their	O
initial	O
total	O
gastrointestinal	O
transit	O
times	O
and	O
presenting	O
symptoms	O
,	O
were	O
treated	O
with	O
cimetropium	O
bromide	O
50	O
mg	O
t	O
.	O
d	O
.	O
s	O
.	O
or	O
placebo	O
for	O
1	O
month	O
according	O
to	O
a	O
double-blind	O
,	O
parallel	O
group	O
design	O
.	O

Far	O
Western	O
blot	O
analysis	O
suggested	O
that	O
the	O
tandem	O
SH2	B-GENE
domains	I-GENE
of	O
SHP2	B-GENE
bind	O
to	O
Gab1	B-GENE
in	O
a	O
specific	O
orientation	O
,	O
in	O
which	O
the	O
N-SH2	B-GENE
domain	I-GENE
binds	O
to	O
phosphotyrosine	O
(	O
Tyr	O
(	O
P	O
)	O
)	O
-627	O
and	O
the	O
C-SH2	B-GENE
domain	I-GENE
binds	O
to	O
Tyr	O
(	O
P	O
)	O
-659	O
.	O

These	O
results	O
suggest	O
that	O
G	O
beta	O
gamma-stimulated	O
Shc	B-GENE
phosphorylation	O
represents	O
an	O
early	O
step	O
in	O
the	O
pathway	O
leading	O
to	O
p21ras	B-GENE
activation	O
,	O
similar	O
to	O
the	O
mechanism	O
utilized	O
by	O
growth	B-GENE
factor	I-GENE
tyrosine	I-GENE
kinase	I-GENE
receptors	I-GENE
.	O

The	O
Oct-2	B-GENE
glutamine-rich	O
and	O
proline-rich	O
activation	O
domains	O
can	O
synergize	O
with	O
each	O
other	O
or	O
duplicates	O
of	O
themselves	O
to	O
activate	O
transcription	O
.	O

This	O
sequence	O
also	O
confers	O
VDR	B-GENE
and	O
vitamin	O
D	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O

A	O
follow-up	O
study	O
of	O
22	O
patients	O
with	O
Ebstein's	O
anomaly	O
has	O
been	O
performed	O
.	O

Processivity	O
of	O
DNA	O
synthesis	O
by	O
the	O
mutant	O
holoenzyme	O
containing	O
pcna-79	B-GENE
was	O
unaffected	O
on	O
poly	O
(	O
dA	O
)	O
x	O
oligo	O
(	O
dT	O
)	O
but	O
was	O
dramatically	O
reduced	O
on	O
a	O
natural	O
template	O
with	O
secondary	O
structure	O
.	O

The	O
present	O
treatment	O
strategy	O
in	O
progressive	O
disorders	O
is	O
mainly	O
based	O
on	O
the	O
complementary	O
effect	O
of	O
intensive	O
radiochemotherapy	O
,	O
autologous	O
stem-cell	O
transplantation	O
and	O
the	O
rational	O
use	O
of	O
cytokines	O
,	O
mostly	O
colony-stimulating	B-GENE
factors	I-GENE
.	O

Competition	O
electrophoretic	O
mobility	O
shift	O
and	O
immunoshift	O
assays	O
confirmed	O
that	O
NF1	B-GENE
factors	I-GENE
present	O
in	O
nuclear	O
extracts	O
of	O
HeLa	O
and	O
CV-1	O
cells	O
bind	O
to	O
the	O
BKV-MLP	B-GENE
.	O

CKbeta4GT-II	B-GENE
is	O
predicted	O
to	O
encode	O
a	O
type	B-GENE
II	I-GENE
transmembrane	I-GENE
glycoprotein	I-GENE
of	O
43	O
kDa	O
with	O
five	O
potential	O
N-linked	O
glycosylation	O
sites	O
.	O

Analysis	O
of	O
the	O
binding	O
of	O
Lrp	B-GENE
to	O
a	O
set	O
of	O
circularly	O
permuted	O
DNA	O
fragments	O
from	O
this	O
region	O
indicates	O
that	O
Lrp	B-GENE
induces	O
DNA	O
bending	O
.	O

Plasmids	O
were	O
constructed	O
with	O
the	O
mouse	O
promoter	O
region	O
linked	O
to	O
the	O
reporter	B-GENE
gene	I-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
,	O
and	O
transiently	O
and	O
stably	O
transfected	O
in	O
the	O
INS-1	O
cells	O
.	O

A	O
set	O
of	O
peptides	O
corresponding	O
to	O
the	O
individual	O
elements	O
of	O
secondary	O
structure	O
derived	O
from	O
the	O
N-terminal	O
domain	O
of	O
the	O
ribosomal	B-GENE
protein	I-GENE
L9	I-GENE
have	O
been	O
synthesized	O
.	O

Both	O
can	O
be	O
elevated	O
on	O
a	O
single	O
vascular	O
pedicle	O
based	O
on	O
the	O
superficial	O
temporal	O
artery	O
,	O
the	O
double-layered	O
temporal	O
fascia	O
flap	O
.	O

The	O
two-wave	O
,	O
1995-1996	O
National	O
Longitudinal	O
Study	O
of	O
Adolescent	O
Health	O
uses	O
a	O
measure	O
of	O
depressive	O
symptomatology	O
across	O
a	O
12-month	O
interval	O
.	O

Although	O
the	O
consumption	O
of	O
myoglobin-bound	O
O2	O
(	O
MbO2	O
)	O
stores	O
in	O
seal	O
muscles	O
has	O
been	O
demonstrated	O
in	O
seal	O
muscles	O
during	O
laboratory	O
simulations	O
of	O
diving	O
,	O
this	O
may	O
not	O
be	O
a	O
feature	O
of	O
normal	O
field	O
diving	O
in	O
which	O
measurements	O
of	O
heart	O
rate	O
and	O
lactate	O
production	O
show	O
marked	O
differences	O
from	O
the	O
profound	O
diving	O
response	O
induced	O
by	O
forced	O
immersion	O
.	O

Postprandial	O
plasma	B-GENE
enteroglucagon	I-GENE
concentration	O
after	O
90	O
minutes	O
in	O
untreated	O
patients	O
correlated	O
positively	O
to	O
the	O
faecal	O
fat	O
excretion	O
(	O
r	O
=	O
0	O
.	O
58	O
,	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

In	O
addition	O
,	O
the	O
megabase	O
region	O
surrounding	O
the	O
dagA	B-GENE
locus	I-GENE
was	O
mapped	O
.	O

In	O
an	O
attempt	O
to	O
investigate	O
whether	O
the	O
intergenic	O
region	O
between	O
the	O
oleosin	B-GENE
and	O
a	O
second	O
open	O
reading	O
frame	O
(	O
ORFII	O
)	O
in	O
Brassica	O
napus	O
(	O
L	O
.	O
)	O
is	O
a	O
divergent	O
promoter	O
,	O
and	O
also	O
to	O
characterize	O
the	O
ORFII	B-GENE
,	O
cDNA	B-GENE
clones	I-GENE
homologous	I-GENE
to	I-GENE
ORFII	I-GENE
were	O
isolated	O
from	O
a	O
leaf	O
cDNA	O
library	O
.	O

The	O
protein	O
is	O
composed	O
of	O
a	O
central	O
alpha-helical	O
portion	O
with	O
globular	O
domains	O
at	O
both	O
NH2	O
and	O
COOH	O
termini	O
,	O
and	O
the	O
epitope	O
to	O
the	O
monoclonal	O
antibody	O
resides	O
in	O
the	O
central	O
alpha-helical	O
stalk	O
.	O

Furthermore	O
,	O
using	O
transgenic	O
mouse	O
technology	O
we	O
localized	O
independent	O
cis-regulatory	O
elements	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
Pax6	B-GENE
.	O

Indirect	O
plasma	O
parameters	O
such	O
as	O
vitamin	O
E	O
,	O
thiol	O
and	O
uric	O
acid	O
levels	O
were	O
also	O
quantified	O
.	O

In	O
addition	O
,	O
we	O
did	O
not	O
detect	O
significant	O
differences	O
in	O
CDR3	B-GENE
sequences	I-GENE
of	O
endogenous	B-GENE
Ig	I-GENE
lambdaL	I-GENE
and	O
kappaL	B-GENE
chain	I-GENE
gene	I-GENE
loci	I-GENE
cloned	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
an	O
NBS	O
patient	O
and	O
of	O
healthy	O
individuals	O
.	O

To	O
investigate	O
the	O
convergent	O
role	O
of	O
the	O
insulin	B-GENE
/	I-GENE
IGF-I	I-GENE
effector	O
pathway	O
mediating	O
bihormonal	O
stimulation	O
of	O
LDL	B-GENE
receptor	I-GENE
promoter	I-GENE
expression	O
,	O
transfected	O
granulosa-luteal	O
cells	O
were	O
pretreated	O
for	O
30	O
min	O
with	O
two	O
specific	O
inhibitors	O
of	O
phophatidylinositol	B-GENE
3-kinase	I-GENE
,	O
wortmannin	O
(	O
100	O
nM	O
)	O
and	O
LY	O
294002	O
(	O
10	O
microM	O
)	O
,	O
or	O
of	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
kinase	I-GENE
,	O
PD	O
98059	O
(	O
50	O
microM	O
)	O
,	O
U0126	O
(	O
10	O
microM	O
)	O
,	O
or	O
the	O
latter's	O
inactive	O
derivative	O
,	O
U0124	O
(	O
10	O
microM	O
)	O
.	O

Thus	O
,	O
the	O
consensus	O
sequences	O
for	O
phosphatase	B-GENE
regulation	O
are	O
5'-GCACGTGGG-3'	B-GENE
and	O
5'-GCACGTTTT-3'	B-GENE
which	O
differ	O
from	O
the	O
binding	O
sequences	O
for	O
the	O
Cpflp	B-GENE
protein	O
required	O
for	O
transcription	O
of	O
the	O
genes	O
in	O
methionine	O
biosynthesis	O
and	O
for	O
centromere	O
function	O
.	O

We	O
conclude	O
from	O
this	O
study	O
that	O
Arix	B-GENE
and	O
NBPhox	B-GENE
exhibit	O
indistinguishable	O
and	O
independent	O
transcriptional	O
regulatory	O
properties	O
on	O
the	O
DBH	B-GENE
promoter	I-GENE
.	O

The	O
human	B-GENE
T	I-GENE
cell	I-GENE
leukemia	I-GENE
/	I-GENE
lymphotropic	I-GENE
virus	I-GENE
type	I-GENE
1	I-GENE
Tax	I-GENE
protein	I-GENE
represses	O
MyoD-dependent	O
transcription	O
by	O
inhibiting	O
MyoD-binding	O
to	O
the	O
KIX	B-GENE
domain	I-GENE
of	O
p300	B-GENE
.	O

With	O
current	O
methodology	O
beta-2	B-GENE
transferrin	I-GENE
does	O
not	O
appear	O
to	O
be	O
a	O
reliable	O
clinical	O
marker	O
for	O
perilymph	O
in	O
the	O
operative	O
setting	O
.	O

This	O
sequence	O
is	O
almost	O
identical	O
with	O
that	O
of	O
human	B-GENE
luteinizing	I-GENE
hormone	I-GENE
(	O
Sairam	O
,	O
M	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
the	O
genomic	O
organization	O
and	O
developmental	O
expression	O
of	O
the	O
caveolin	B-GENE
gene	I-GENE
family	I-GENE
.	O

Avian	O
reproductive	O
system	O
:	O
daily	O
variations	O
in	O
responses	O
to	O
hormones	O
.	O
pp	O
.	O

The	O
number	O
of	O
polymerases	B-GENE
active	O
in	O
vitro	O
at	O
the	O
E	B-GENE
strand	I-GENE
promoter	I-GENE
was	O
similar	O
to	O
the	O
number	O
of	O
polymerases	B-GENE
at	O
the	O
L	B-GENE
strand	I-GENE
promoter	I-GENE
.	O

Our	O
data	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
individualize	O
hCG	B-GENE
administration	O
at	O
midcycle	O
by	O
determining	O
the	O
number	O
of	O
follicles	O
greater	O
than	O
1	O
cm	O
by	O
ultrasound	O
on	O
cycle	O
day	O
12	O
or	O
13	O
and	O
giving	O
hCG	B-GENE
when	O
serum	O
E2	O
levels	O
reach	O
1100	O
to	O
1200	O
pmol	O
/	O
l	O
per	O
follicle	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
was	O
performed	O
to	O
characterize	O
the	O
binding	O
property	O
of	O
TR2	B-GENE
and	O
its	O
truncated	O
isoform	O
.	O

Adrenergic	O
nerve	O
function	O
,	O
noradrenaline	O
level	O
and	O
noradrenaline	O
uptake	O
in	O
cat	O
nictitating	O
membrane	O
after	O
reserpine	O
treatment	O
.	O

STAT5A	B-GENE
mutations	O
in	O
the	O
Src	B-GENE
homology	I-GENE
2	I-GENE
(	O
SH2	B-GENE
)	O
and	O
SH3	B-GENE
domains	I-GENE
did	O
not	O
alter	O
the	O
BTK-mediated	O
tyrosine	O
phosphorylation	O
.	O

After	O
determining	O
isoflurane	O
MAC	O
in	O
triplicate	O
,	O
birds	O
were	O
given	O
a	O
mu-opioid	O
agonist	O
(	O
morphine	O
,	O
n	O
=	O
9	O
)	O
or	O
a	O
kappa-opioid	O
agonist	O
(	O
U50488H	O
,	O
n	O
=	O
9	O
)	O
.	O

Functional	O
disorders	O
of	O
the	O
ureter	O
following	O
gynecologic	O
surgery	O
.	O

Based	O
on	O
the	O
comparison	O
of	O
the	O
predicted	O
amino	O
acid	O
sequences	O
of	O
1-sst	B-GENE
and	O
1-fft	B-GENE
with	O
those	O
of	O
other	O
plant	O
fructosyl	B-GENE
transferase	I-GENE
genes	I-GENE
,	O
we	O
postulate	O
that	O
both	O
plant	O
fructan	B-GENE
genes	I-GENE
have	O
evolved	O
from	O
plant	O
invertase	B-GENE
genes	O
.	O

Further	O
investigations	O
are	O
necessary	O
to	O
elucidate	O
the	O
biochemical	O
and	O
physiological	O
properties	O
of	O
DLIS	O
.	O

Animals	O
may	O
be	O
immunized	O
by	O
oral	O
vaccination	O
,	O
but	O
natural	O
mechanisms	O
that	O
also	O
can	O
terminate	O
outbreaks	O
are	O
discussed	O
.	O

Together	O
with	O
a	O
considerably	O
shortened	O
and	O
interrupted	O
aromatic	O
aa	O
stretch	O
in	O
this	O
region	O
,	O
these	O
differences	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
peculiar	O
affinity	O
of	O
cyanobacterial	B-GENE
cytochrome	I-GENE
oxidases	I-GENE
for	O
acidic	O
c-type	B-GENE
cytochromes	I-GENE
.	O

Comparison	O
of	O
sequences	O
from	O
-215	O
to	O
+1	O
bp	O
identified	O
consensus	O
binding	O
sites	O
for	O
the	O
homeodomain	B-GENE
transcription	I-GENE
factor	I-GENE
thyroid	B-GENE
transcription	I-GENE
factor-1	I-GENE
(	O
TTF-1	B-GENE
)	O
.	O

An	O
approach	O
to	O
a	O
biomathematical	O
model	O
of	O
lymphocytopoiesis	O
.	O

A	O
five-phase	O
experiment	O
was	O
designed	O
to	O
investigate	O
(	O
a	O
)	O
whether	O
contingent	O
music-listening	O
would	O
act	O
as	O
a	O
reinforcer	O
to	O
increase	O
arithmetic	O
performance	O
of	O
EMR	O
children	O
and	O
(	O
b	O
)	O
whether	O
this	O
contingent	O
reinforcement	O
would	O
affect	O
preference	O
for	O
that	O
reinforcer	O
.	O

Purified	O
PLB	B-GENE
showed	O
optimal	O
lyase	B-GENE
activity	O
at	O
pH	O
10	O
.	O
0	O
.	O

We	O
now	O
show	O
that	O
RNU2	B-GENE
fragility	O
can	O
be	O
induced	O
by	O
transfection	O
with	O
an	O
expression	O
vector	O
encoding	O
Ad12	B-GENE
E1B	I-GENE
55	O
kDa	O
alone	O
but	O
not	O
by	O
an	O
E1	B-GENE
vector	O
encoding	O
all	O
E1	B-GENE
products	I-GENE
(	O
3	O
E1A	B-GENE
proteins	I-GENE
,	O
as	O
well	O
as	O
the	O
E1B	B-GENE
19	O
kDa	O
and	O
55	O
kDa	O
proteins	O
)	O
.	O

A	O
case	O
report	O
with	O
angiographic	O
follow-up	O
study	O
.	O

The	O
PAI-2	B-GENE
gene	I-GENE
is	O
one	O
of	O
the	O
most	O
TNF-responsive	B-GENE
genes	I-GENE
known	O
and	O
is	O
also	O
highly	O
induced	O
by	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
the	O
phosphatase	B-GENE
inhibitor	O
,	O
okadaic	O
acid	O
,	O
in	O
both	O
HT-1080	O
fibrosarcoma	O
and	O
U-937	O
histiocytic	O
cells	O
.	O

Mutational	O
analyses	O
showed	O
that	O
in-frame	O
stop	O
codons	O
introduced	O
into	O
five	O
of	O
seven	O
RNA	B-GENE
2	I-GENE
ORFs	I-GENE
did	O
not	O
affect	O
accumulation	O
of	O
progeny	O
LIYV	B-GENE
RNA	I-GENE
1	I-GENE
or	O
RNA	B-GENE
2	I-GENE
,	O
confirming	O
that	O
RNA	B-GENE
2	I-GENE
does	O
not	O
encode	O
proteins	O
necessary	O
for	O
LIYV	B-GENE
RNA	I-GENE
replication	O
.	O

CPT-11	O
was	O
administered	O
as	O
a	O
30-minute	O
i	O
.	O
v	O
.	O
infusion	O
at	O
a	O
dose	O
of	O
350	O
mg	O
/	O
m2	O
diluted	O
in	O
250	O
ml	O
normal	O
saline	O
every	O
3	O
weeks	O
.	O

Responses	O
of	O
TLD	O
Mg2SiO4	O
:	O
Tb	O
and	O
radiophotoluminescent	O
glass	O
to	O
heavy	O
charged	O
particles	O
and	O
space	O
radiation	O
.	O

Because	O
of	O
the	O
increased	O
CPK	B-GENE
activity	O
found	O
in	O
normal	O
newborns	O
,	O
screening	O
for	O
Duchenne-type	O
muscular	O
dystrophy	O
should	O
be	O
postponed	O
for	O
a	O
few	O
weeks	O
after	O
delivery	O
.	O

CYC2	B-GENE
encodes	O
a	O
24-kDa	O
protein	O
that	O
has	O
sequence	O
identity	O
to	O
the	O
Neurospora	B-GENE
crassa	I-GENE
PREG1	I-GENE
and	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
PHO80	I-GENE
cyclin	I-GENE
.	O

Similarly	O
,	O
overexpression	O
of	O
increasing	O
concentration	O
of	O
COUP-TFI	B-GENE
,	O
but	O
not	O
COUP-TFI	B-GENE
delta35	I-GENE
,	O
can	O
squelch	O
the	O
silencing	O
activity	O
of	O
the	O
unliganded	O
TRbeta	B-GENE
.	O

It	O
was	O
concluded	O
,	O
that	O
on	O
a	O
given	O
section	O
,	O
75	O
,	O
7	O
per	O
cent	O
of	O
the	O
trabeculae	O
were	O
in	O
contact	O
with	O
vascular	O
cavities	O
.	O

The	O
immuno-purified	O
mRNA	O
in	O
the	O
polysome	O
complex	O
was	O
used	O
to	O
prepare	O
cDNA	O
with	O
which	O
to	O
probe	O
a	O
D	O
.	O
melanogaster	O
genomic	O
library	O
.	O

Retrogradely	O
labelled	O
neurons	O
significantly	O
prevailed	O
in	O
the	O
ipsilateral	O
substantia	O
nigra	O
pars	O
compacta	O
.	O

Mechanism	O
of	O
the	O
t	O
(	O
14	O
;	O
18	O
)	O
chromosomal	O
translocation	O
:	O
structural	O
analysis	O
of	O
both	O
derivative	O
14	O
and	O
18	O
reciprocal	O
partners	O
.	O

In	O
the	O
free-swimming	O
rotatory	O
test	O
mice	O
spend	O
most	O
of	O
the	O
time	O
swimming	O
close	O
to	O
the	O
wall	O
of	O
the	O
container	O
attempting	O
to	O
escape	O
from	O
an	O
aversive	O
test	O
situation	O
.	O

We	O
have	O
examined	O
by	O
in	O
vitro	O
footprinting	O
a	O
region	O
located	O
downstream	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
,	O
type	O
1	O
(	O
HIV-1	O
)	O
promoter	O
found	O
to	O
be	O
hypersensitive	O
to	O
DNase	B-GENE
I	I-GENE
digestion	O
in	O
vivo	O
.	O

Sequencing	O
of	O
the	O
three	O
pag-3	B-GENE
alleles	I-GENE
showed	O
that	O
two	O
apparent	O
null	O
alleles	O
encode	O
a	O
nonsense	O
mutation	O
before	O
the	O
zinc	O
fingers	O
and	O
a	O
missense	O
mutation	O
in	O
the	O
fourth	O
zinc	O
finger	O
that	O
changes	O
a	O
coordinating	O
histidine	O
to	O
a	O
tyrosine	O
.	O

Codon	O
usage	O
in	O
C	O
.	O
reinhardtii	O
mitochondria	O
is	O
highly	O
biased	O
,	O
with	O
eight	O
codons	O
entirely	O
absent	O
from	O
all	O
protein-coding	O
genes	O
;	O
however	O
,	O
even	O
though	O
codon	O
usage	O
is	O
restricted	O
,	O
it	O
appears	O
that	O
C	O
.	O
reinhardtii	O
mtDNA	O
cannot	O
encode	O
the	O
minimum	O
number	O
of	O
tRNAs	O
needed	O
to	O
support	O
mitochondrial	O
protein	O
synthesis	O
.	O

Dialyzable	O
transfer	B-GENE
factor	I-GENE
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
IL-1	B-GENE
beta	I-GENE
induces	O
VEGF	B-GENE
gene	I-GENE
expression	O
at	O
both	O
transcriptional	O
and	O
post-transcriptional	O
levels	O
,	O
and	O
IL-1	B-GENE
beta	I-GENE
evokes	O
p38	B-GENE
MAPK	I-GENE
and	O
JNK	B-GENE
signalings	O
,	O
which	O
in	O
turn	O
stimulate	O
the	O
transcription	O
of	O
the	O
VEGF	B-GENE
gene	I-GENE
through	O
Sp1-binding	B-GENE
sites	I-GENE
.	O

We	O
measured	O
basal	O
plasma	O
prolactin	B-GENE
concentrations	O
(	O
in	O
samples	O
obtained	O
during	O
the	O
early	O
follicular	O
phase	O
)	O
in	O
25	O
normal	O
(	O
control	O
)	O
women	O
and	O
in	O
a	O
similar	O
group	O
of	O
40	O
patients	O
with	O
a	O
long-standing	O
history	O
of	O
infertility	O
.	O

We	O
report	O
here	O
the	O
discovery	O
of	O
a	O
new	O
actin-related	B-GENE
gene	I-GENE
in	O
this	O
organism	O
,	O
which	O
we	O
have	O
named	O
ACT4	B-GENE
.	O

In	O
this	O
method	O
,	O
PLP	O
in	O
plasma	O
can	O
be	O
determined	O
with	O
high	O
sensitivity	O
using	O
derivatization	O
with	O
sodium	O
bisulfite	O
in	O
the	O
mobile	O
phase	O
.	O

Polypeptide	B-GENE
growth	I-GENE
factors	I-GENE
and	O
cytokines	O
mediate	O
their	O
biochemical	O
functions	O
through	O
their	O
responsive	O
receptors	O
.	O

Auditory	O
clicks	O
were	O
given	O
at	O
a	O
rate	O
of	O
20	O
s	O
(	O
-1	O
)	O
.	O

PPAR	B-GENE
gamma	I-GENE
mRNA	I-GENE
levels	O
were	O
reduced	O
by	O
95%	O
with	O
3	O
nM	O
TNF	B-GENE
alpha	I-GENE
treatment	O
for	O
24	O
h	O
.	O

We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	O
embryonic	O
zeta	B-GENE
2	I-GENE
globin	I-GENE
promoter	O
and	O
the	O
alpha	B-GENE
globin	I-GENE
regulatory	I-GENE
element	I-GENE
(	O
HS-40	B-GENE
)	O
located	O
40	O
kb	O
upstream	O
of	O
the	O
zeta	B-GENE
2	I-GENE
globin	I-GENE
gene	I-GENE
.	O

The	O
HiNF-D	B-GENE
(	I-GENE
CDP	I-GENE
/	I-GENE
cut	I-GENE
)	I-GENE
complex	I-GENE
with	O
the	O
H4	B-GENE
promoter	I-GENE
is	O
immunoreactive	O
with	O
antibodies	O
against	O
CDP	B-GENE
/	I-GENE
cut	I-GENE
and	O
pRB	B-GENE
but	O
not	O
p107	B-GENE
,	O
whereas	O
the	O
CDP	B-GENE
/	I-GENE
cut	I-GENE
complex	I-GENE
with	O
a	O
nonhistone	B-GENE
promoter	I-GENE
(	O
gp91-phox	B-GENE
)	O
reacts	O
only	O
with	O
CDP	B-GENE
and	O
p107	B-GENE
antibodies	O
.	O

The	O
genome	O
of	O
all	O
retroviruses	O
consists	O
of	O
two	O
identical	O
RNAs	O
noncovalently	O
linked	O
near	O
their	O
5'	O
end	O
.	O

Adding	O
phytase	B-GENE
and	O
nP	O
improved	O
the	O
orderliness	O
of	O
development	O
,	O
mineralization	O
and	O
arrangement	O
of	O
cartilage	O
and	O
bone	O
cells	O
,	O
and	O
alleviated	O
the	O
effects	O
of	O
P	O
deficiency	O
on	O
the	O
histological	O
and	O
gross	O
structure	O
of	O
the	O
tibias	O
.	O

Characterization	O
of	O
the	O
microtubule	B-GENE
binding	I-GENE
domain	I-GENE
of	O
microtubule	B-GENE
actin	I-GENE
crosslinking	I-GENE
factor	I-GENE
(	O
MACF	B-GENE
)	O
:	O
identification	O
of	O
a	O
novel	O
group	O
of	O
microtubule	B-GENE
associated	I-GENE
proteins	I-GENE
.	O

Somatostatin	B-GENE
gene	I-GENE
expression	O
in	O
pancreatic	O
islet	O
cells	O
is	O
directed	O
by	O
cell-specific	O
DNA	O
control	O
elements	O
and	O
DNA-binding	O
proteins	O
.	O

In	O
about	O
one	O
third	O
of	O
the	O
cases	O
this	O
operation	O
results	O
in	O
tonal	O
and	O
vocal	O
improvement	O
for	O
patients	O
suffering	O
from	O
progressive	O
perceptive	O
deafness	O
.	O

Apart	O
from	O
iron	O
regulation	O
,	O
sodA	B-GENE
expression	O
was	O
affected	O
by	O
changes	O
in	O
DNA	O
topology	O
induced	O
by	O
coumermycin	O
A	O
but	O
not	O
by	O
the	O
global	O
virulence	O
regulatory	O
Bvg	B-GENE
system	I-GENE
.	O

Influence	O
of	O
neural	O
regulation	O
on	O
anti-arrhythmic	O
effects	O
of	O
GABA	O
in	O
rats	O
.	O

The	O
wild-type	O
and	O
altered	O
forms	O
of	O
the	O
F	B-GENE
protein	I-GENE
were	O
expressed	O
in	O
BHK-21	O
and	O
HeLa	O
T4	O
cells	O
by	O
use	O
of	O
the	O
recombinant	B-GENE
vaccinia	I-GENE
virus-encoding	I-GENE
T7	I-GENE
polymerase	I-GENE
system	O
.	O

Nuclear	O
localization	O
and	O
protein	O
sequence	O
similarities	O
suggested	O
that	O
the	O
SPT2	B-GENE
/	I-GENE
SIN1	I-GENE
protein	I-GENE
may	O
be	O
related	O
to	O
the	O
nonhistone	B-GENE
chromosomal	I-GENE
protein	I-GENE
HMG1	I-GENE
.	O

In	O
contrast	O
with	O
previous	O
two-pool	O
models	O
,	O
provisions	O
were	O
made	O
for	O
folate	O
turnover	O
by	O
urinary	O
folate	O
excretion	O
(	O
as	O
measured	O
here	O
)	O
and	O
by	O
fecal	O
excretion	O
and	O
catabolic	O
processes	O
.	O

These	O
results	O
suggest	O
that	O
,	O
for	O
the	O
HML	B-GENE
ARS	B-GENE
cluster	I-GENE
(	O
ARS303	B-GENE
,	O
ARS320	B-GENE
,	O
and	O
ARS302	B-GENE
)	O
,	O
inactivity	O
of	O
origins	O
is	O
independent	O
of	O
local	O
transcriptional	O
silencing	O
,	O
even	O
though	O
origins	O
and	O
silencers	O
share	O
key	O
cis-	O
and	O
trans-acting	O
components	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C	B-GENE
/	I-GENE
EBP	I-GENE
alpha	I-GENE
can	O
also	O
active	O
the	O
GM-CSF	B-GENE
receptor	I-GENE
alpha	I-GENE
promoter	O
in	O
nonmyeloid	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Resources	O
for	O
helping	O
patients	O
to	O
quit	O
smoking	O
.	O

Antibiotic	O
effect	O
of	O
the	O
mud	O
from	O
heviz	O
.	O

A	O
case	O
observed	O
in	O
Saigon	O
.	O

Sequences	O
required	O
for	O
interaction	O
of	O
mu2	B-GENE
and	O
CTLA-4	B-GENE
were	O
localized	O
to	O
residues	O
,	O
161TTGVY	B-GENE
in	O
CTLA-4	B-GENE
;	O
this	O
sequence	O
is	O
N-terminal	O
to	O
,	O
but	O
overlaps	O
with	O
,	O
a	O
previously	O
identified	O
SH2	B-GENE
binding	I-GENE
motif	I-GENE
,	O
165YVKM	B-GENE
,	O
involved	O
in	O
CTLA-4	B-GENE
signaling	O
.	O

The	O
accuracies	O
of	O
presence	O
or	O
absence	O
of	O
neuroblastoma	O
were	O
compared	O
between	O
131I-MIBG	O
imaging	O
and	O
several	O
tumor	O
markers	O
.	O

Cytosolic	O
extracts	O
from	O
a	O
variety	O
of	O
mammalian	O
cell	O
lines	O
(	O
monkey	O
Cos7	O
,	O
several	O
mouse	O
fibrosarcomas	O
and	O
human	O
HeLa	O
S3	O
)	O
demonstrated	O
similar	O
TGF-beta	B-GENE
1	I-GENE
dependent	O
RNA-protein	O
band	O
shifts	O
as	O
cell	O
extract	O
from	O
BALB	O
/	O
c	O
3T3	O
mouse	O
fibroblasts	O
.	O

We	O
determined	O
whether	O
regional	O
myocardial	O
work	O
efficiency	O
(	O
segment	O
work	O
/	O
regional	O
O2	O
consumption	O
)	O
would	O
be	O
elevated	O
by	O
surgically-augmented	O
inflow	O
.	O

Phylogenetic	O
analysis	O
showed	O
that	O
the	O
ToLCV	O
isolates	O
from	O
Bangalore	O
constitute	O
a	O
group	O
of	O
viruses	O
separated	O
from	O
those	O
of	O
Northern	O
India	O
.	O

Recombinant	B-GENE
HRMT1L2	I-GENE
protein	I-GENE
encoded	O
by	O
the	O
most	O
common	O
5'-variant	O
exhibited	O
methyltransferase	B-GENE
activity	O
in	O
vitro	O
.	O

These	O
results	O
indicate	O
that	O
the	O
effect	O
of	O
the	O
isomers	O
of	O
pentobarbital	O
and	O
secobarbital	O
on	O
mult	O
FR30	O
FI600	O
responding	O
and	O
on	O
suppressed	O
responding	O
are	O
qualitatively	O
similar	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
infection	O
rate	O
was	O
five	O
times	O
greater	O
in	O
patients	O
with	O
Hickman	O
catheters	O
than	O
in	O
those	O
with	O
Broviac	O
catheters	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

SKP1-SnRK	B-GENE
protein	I-GENE
kinase	I-GENE
interactions	O
mediate	O
proteasomal	O
binding	O
of	O
a	O
plant	O
SCF	B-GENE
ubiquitin	I-GENE
ligase	I-GENE
.	O

IdB	O
1031	O
was	O
first	O
extracted	O
by	O
liquid-solid	O
partition	O
and	O
the	O
extracts	O
were	O
evaporated	O
and	O
analysed	O
on	O
a	O
reversed-phase	O
column	O
under	O
isocratic	O
conditions	O
,	O
using	O
either	O
an	O
electrochemical	O
or	O
a	O
UV	O
detector	O
.	O

This	O
study	O
represents	O
the	O
first	O
published	O
long-term	O
follow-up	O
regarding	O
this	O
mode	O
of	O
treatment	O
in	O
patients	O
with	O
alveolar	O
hypoventilation	O
.	O

Moreover	O
,	O
the	O
same	O
mutations	O
alter	O
the	O
structure	O
of	O
junB	B-GENE
5'	O
flanking	O
DNA	O
within	O
chromatin	O
.	O

These	O
articles	O
both	O
report	O
the	O
results	O
of	O
multi-institutional	O
,	O
randomized	O
,	O
phase	O
3	O
trials	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
localized	O
(	O
T1-3	O
N0-1	O
M0	O
)	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
or	O
esophageal	O
adenocarcinoma	O
.	O

Basal	O
FSH	B-GENE
and	O
LH	B-GENE
levels	O
were	O
significantly	O
lower	O
in	O
addicts	O
;	O
after	O
GnRH	B-GENE
stimulation	O
the	O
addicts'	O
FSH	B-GENE
and	O
LH	B-GENE
values	O
increased	O
but	O
not	O
significantly	O
compared	O
to	O
controls	O
.	O

Secretory	O
function	O
of	O
the	O
prostate	O
gland	O
.	O

Mitogen-activated	B-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
phosphatase-3	I-GENE
(	O
MKP-3	B-GENE
)	O
is	O
a	O
dual	O
specificity	O
phosphatase	B-GENE
that	O
inactivates	O
extracellular	B-GENE
signal-regulated	I-GENE
kinase	I-GENE
(	O
ERK	B-GENE
)	O
MAP	B-GENE
kinases	I-GENE
.	O

It	O
is	O
clear	O
that	O
subclinical	O
and	O
silent	O
CD	O
exist	O
in	O
a	O
large	O
subgroup	O
of	O
the	O
celiac	O
population	O
.	O

Furthermore	O
,	O
MOM-4	B-GENE
and	O
TAK1	B-GENE
bind	O
related	O
proteins	O
that	O
promote	O
their	O
kinase	B-GENE
activities	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Palmaz-Schatz	O
stents	O
were	O
dip-coated	O
with	O
paclitaxel	O
(	O
0	O
,	O
0	O
.	O
2	O
,	O
15	O
,	O
or	O
187	O
microgram	O
/	O
stent	O
)	O
by	O
immersion	O
in	O
ethanolic	O
paclitaxel	O
and	O
evaporation	O
of	O
the	O
solvent	O
.	O

Furthermore	O
,	O
unlike	O
the	O
case	O
for	O
HIS3	B-GENE
where	O
only	O
a	O
limited	O
subset	O
of	O
TATA-like	B-GENE
sequences	I-GENE
can	O
activate	O
transcription	O
in	O
conjunction	O
with	O
GCN4p	B-GENE
,	O
many	O
divergent	O
TATA-like	B-GENE
sequences	I-GENE
allowed	O
GCN4p	B-GENE
activation	O
of	O
TRP3	B-GENE
.	O

The	O
peptide	O
sequences	O
reveal	O
that	O
the	O
factor	O
consists	O
of	O
GABP	B-GENE
alpha	I-GENE
and	O
GABP	B-GENE
beta	I-GENE
1	I-GENE
with	O
Ets	B-GENE
and	O
Notch	B-GENE
motifs	I-GENE
,	O
respectively	O
.	O

The	O
ubiquitous	O
transcription	O
factor	O
Oct-1	B-GENE
forms	O
complexes	O
with	O
an	O
octamer	O
motif	O
present	O
within	O
FPIV	O
by	O
gel	O
shift	O
analysis	O
with	O
liver	O
and	O
kidney	O
extracts	O
,	O
making	O
Oct-1	B-GENE
an	O
intriguing	O
candidate	O
for	O
partnership	O
in	O
androgen	O
regulation	O
.	O

The	O
effect	O
of	O
acute	O
,	O
mid-cervical	O
spinal	O
cord	O
lesions	O
on	O
neuronal	O
and	O
reflex	O
activity	O
evoked	O
by	O
the	O
noxious	O
visceral	O
stimulus	O
,	O
colorectal	O
distension	O
(	O
CRD	O
;	O
80	O
mmHg	O
,	O
20	O
s	O
)	O
,	O
was	O
determined	O
in	O
halothane-anesthetized	O
rats	O
.	O

These	O
two	O
mRNA	O
species	O
are	O
produced	O
by	O
differential	O
polyadenylation	O
site	O
usage	O
.	O

When	O
mixed	O
with	O
aqueous	O
solutions	O
of	O
TMT-55	O
,	O
aqueous	O
solutions	O
of	O
either	O
reagent-grade	O
zinc	O
,	O
cadmium	O
,	O
or	O
lead	O
salts	O
precipitate	O
crystalline	O
"Zn-TMT"	O
,	O
amorphous	O
or	O
crystalline	O
"Cd-TMT"	O
or	O
amorphous	O
"Pb-TMT"	O
(	O
M3	O
[	O
S3C3N3	O
]	O
2	O
.	O
nH2O	O
,	O
where	O
M	O
=	O
Cd2+	O
,	O
Pb2+	O
,	O
and	O
Zn2+	O
and	O
n	O
>	O
or	O
=	O
0	O
)	O
that	O
may	O
eventually	O
crystallize	O
if	O
stored	O
in	O
air	O
.	O

We	O
report	O
the	O
isolation	O
of	O
genomic	O
and	O
cDNA	O
clones	O
of	O
the	O
light-independent	O
Sn	B-GENE
:	I-GENE
bol3	I-GENE
allele	I-GENE
.	O

Pharmacokinetics	O
of	O
FK	O
506	O
in	O
transplant	O
patients	O
.	O

A	O
receptor-like	B-GENE
protein	I-GENE
kinase	I-GENE
,	O
OsPK10	B-GENE
,	O
has	O
been	O
cloned	O
from	O
rice	O
(	O
Oryza	O
sativa	O
)	O
.	O

Therefore	O
,	O
the	O
strD	B-GENE
and	O
strE	B-GENE
genes	I-GENE
could	O
serve	O
as	O
universal	O
probes	O
indicative	O
of	O
the	O
presence	O
of	O
biosynthetic	O
capacity	O
for	O
6-deoxyhexose	O
moieties	O
.	O

The	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
year	O
survival	O
rates	O
were	O
94%	O
,	O
84%	O
,	O
76%	O
and	O
63%	O
,	O
respectively	O
.	O

For	O
the	O
study	O
of	O
the	O
transition	O
of	O
long	O
to	O
short	O
waves	O
(	O
deep-water	O
waves	O
)	O
a	O
closed-form	O
solution	O
is	O
advantageous	O
;	O
this	O
can	O
,	O
however	O
,	O
only	O
be	O
obtained	O
at	O
the	O
cost	O
of	O
further	O
simplification	O
.	O

TcPO2	O
measurement	O
appears	O
to	O
be	O
a	O
reliable	O
technique	O
that	O
can	O
influence	O
ischaemic	O
ulcer	O
management	O
.	O

Production	O
costs	O
included	O
feed	O
,	O
non-feed	O
operating	O
,	O
fixed	O
,	O
and	O
replacement	O
stock	O
costs	O
.	O

Molecular	O
modelling	O
suggested	O
that	O
the	O
tetramerization	O
domain	O
was	O
a	O
four-helix	O
bundle	O
,	O
stabilized	O
by	O
interactions	O
of	O
seven	O
conserved	O
aromatic	O
amino	O
acids	O
.	O

It	O
is	O
concluded	O
that	O
suppression	O
of	O
elevated	O
prolactin	B-GENE
levels	O
in	O
progressive	O
metastatic	O
breast	O
cancer	O
patients	O
is	O
not	O
effective	O
in	O
restoring	O
tumor	O
sensitivity	O
to	O
chemotherapy	O
.	O

Apart	O
from	O
two	O
proline-rich	O
regions	O
(	O
amino	O
acids	O
1-117	O
and	O
239-270	O
)	O
,	O
p230	B-GENE
contains	O
a	O
very	O
high	O
frequency	O
of	O
heptad	O
repeats	O
,	O
characteristic	O
of	O
alpha-helices	O
that	O
form	O
dimeric	O
coiled-coil	O
structures	O
.	O
p230	B-GENE
also	O
includes	O
the	O
sequence	B-GENE
ESLALEELEL	I-GENE
(	I-GENE
amino	I-GENE
acids	I-GENE
538-546	I-GENE
)	I-GENE
,	O
a	O
motif	O
found	O
in	O
the	O
granin	B-GENE
family	I-GENE
of	O
acidic	O
proteins	O
present	O
in	O
secretory	O
granules	O
of	O
neuroendocrine	O
cells	O
.	O

Constantly	O
rectilinear	O
pressure	O
curves	O
without	O
uterine	O
activities	O
are	O
interpreted	O
as	O
characteristic	O
tocographic	O
criteria	O
of	O
an	O
advanced	O
ectopic	O
gravidity	O
.	O

Ask	O
AONE's	O
experts	O
.	O
.	O
.	O
about	O
productivity	O
indicators	O
.	O

Use	O
of	O
a	O
dual-pulse	O
lithotripter	O
to	O
generate	O
a	O
localized	O
and	O
intensified	O
cavitation	O
field	O
.	O

Critical	O
study	O
.	O

No	O
post-operative	O
haemorrhages	O
from	O
the	O
prostheses	O
were	O
observed	O
.	O

CONCLUSIONS	O
:	O
Adding	O
MMF	O
,	O
a	O
potent	O
topical	O
corticosteroid	O
,	O
to	O
an	O
emollient	O
cream	O
is	O
statistically	O
significantly	O
more	O
effective	O
than	O
emollient	O
cream	O
alone	O
in	O
reducing	O
acute	O
radiation	O
dermatitis	O
.	O

TbRAB31	B-GENE
behaviour	O
was	O
also	O
studied	O
during	O
the	O
cell	O
cycle	O
;	O
TbRAB31	B-GENE
always	O
localised	O
to	O
a	O
discrete	O
structure	O
that	O
duplicated	O
very	O
early	O
in	O
mitosis	O
and	O
relocated	O
to	O
daughter	O
cells	O
in	O
a	O
coordinate	O
manner	O
with	O
the	O
basal	O
body	O
and	O
kinetoplast	O
,	O
suggesting	O
the	O
involvement	O
of	O
microtubules	O
.	O

Yeast	B-GENE
Gal11	I-GENE
protein	I-GENE
mediates	O
the	O
transcriptional	O
activation	O
signal	O
of	O
two	O
different	O
transacting	O
factors	O
,	O
Gal4	B-GENE
and	O
general	B-GENE
regulatory	I-GENE
factor	I-GENE
I	I-GENE
/	I-GENE
repressor	I-GENE
/	I-GENE
activator	I-GENE
site	I-GENE
binding	I-GENE
protein	I-GENE
1	I-GENE
/	I-GENE
translation	I-GENE
upstream	I-GENE
factor	I-GENE
.	O

It	O
was	O
concluded	O
that	O
Scotchbond	O
2	O
and	O
Prisma	O
Universal	O
Bond	O
2	O
are	O
effective	O
and	O
are	O
the	O
dentine	O
bonding	O
agents	O
of	O
choice	O
.	O

The	O
activity	O
of	O
serum	B-GENE
lipase	I-GENE
and	O
amylase	B-GENE
distinctly	O
increased	O
at	O
3	O
h	O
and	O
went	O
up	O
to	O
the	O
maximum	O
at	O
12	O
h	O
after	O
injection	O
of	O
Na-Tc	O
.	O

Characterization	O
of	O
polymorphic	O
TNRs	B-GENE
in	O
novel	O
and	O
even	O
known	O
genes	O
expressed	O
in	O
human	O
spinal	O
cord	O
is	O
likely	O
to	O
help	O
in	O
the	O
identification	O
of	O
new	O
candidates	O
for	O
genes	O
involved	O
in	O
neurodegenerative	O
disorders	O
.	O

This	O
slow	O
progression	O
through	O
the	O
early	O
G1-phase	O
resulted	O
in	O
decreased	O
phosphorylation	O
of	O
the	O
RB	B-GENE
protein	I-GENE
and	O
subsequent	O
delay	O
into	O
the	O
S	O
phase	O
transition	O
.	O

The	O
RAD18	B-GENE
gene	I-GENE
open	I-GENE
reading	I-GENE
frame	I-GENE
encodes	O
a	O
protein	O
of	O
487	O
amino	O
acids	O
,	O
with	O
a	O
calculated	O
molecular	O
weight	O
of	O
55	O
,	O
512	O
.	O

In	O
the	O
10	O
patients	O
with	O
a	O
more	O
severe	O
degree	O
of	O
steatorrhea	O
the	O
decrease	O
in	O
fat	O
loss	O
approached	O
20%	O
and	O
a	O
close	O
relationship	O
was	O
found	O
(	O
r	O
=	O
0	O
.	O
84	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
between	O
the	O
extent	O
of	O
the	O
fatty	O
acid	O
loss	O
on	O
placebo	O
and	O
the	O
decrease	O
of	O
this	O
loss	O
on	O
taurine	O
.	O

Laryngographic	O
changes	O
following	O
endotracheal	O
intubation	O
in	O
adults	O
.	O

The	O
partial	O
sequence	O
of	O
the	O
62-kDa	B-GENE
nuclear	I-GENE
pore	I-GENE
glycoprotein	I-GENE
shows	O
little	O
similarity	O
to	O
other	O
characterized	O
proteins	O
and	O
elucidates	O
structural	O
features	O
of	O
a	O
member	O
of	O
the	O
family	O
of	O
nuclear	B-GENE
pore	I-GENE
glycoproteins	I-GENE
.	O

Data	O
collection	O
was	O
made	O
with	O
a	O
query	O
language	O
,	O
and	O
data	O
analysis	O
performed	O
with	O
an	O
interactive	O
knowledge-based	O
statistical	O
tool	O
,	O
MAXITAB	O
,	O
employing	O
a	O
multivariate	O
tabular	O
analysis	O
technique	O
.	O

In	O
order	O
to	O
investigate	O
how	O
these	O
expression	O
patterns	O
are	O
established	O
,	O
we	O
fused	O
promoter	O
regions	O
of	O
an	O
acidic	O
and	O
a	O
basic	O
glucanase	B-GENE
gene	I-GENE
to	O
the	O
beta-glucuronidase	B-GENE
(	O
GUS	B-GENE
)	O
reporter	O
gene	O
and	O
examined	O
expression	O
of	O
these	O
constructs	O
in	O
transgenic	O
tobacco	O
plants	O
.	O

Sixty-five	O
patients	O
(	O
aged	O
between	O
3	O
years	O
5	O
months	O
and	O
60	O
years	O
)	O
suffering	O
from	O
medically	O
resistant	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
were	O
operated	O
on	O
over	O
a	O
period	O
of	O
33	O
months	O
in	O
Bethel	O
Epilepsy	O
Center	O
.	O

The	O
results	O
showed	O
that	O
IFN-gamma	B-GENE
stimulated	O
the	O
rapid	O
accumulation	O
of	O
interferon	B-GENE
regulated	I-GENE
factor	I-GENE
(	I-GENE
IRF	I-GENE
)	I-GENE
-1	I-GENE
mRNA	I-GENE
,	O
followed	O
by	O
a	O
delayed	O
and	O
dose-dependent	O
inhibition	O
of	O
alpha1	B-GENE
(	I-GENE
I	I-GENE
)	I-GENE
procollagen	I-GENE
mRNA	I-GENE
expression	O
in	O
skin	O
fibroblasts	O
from	O
several	O
different	O
donors	O
.	O

A	O
split	O
motor	O
domain	O
in	O
a	O
cytoplasmic	B-GENE
dynein	I-GENE
.	O

Effect	O
of	O
heparin	O
on	O
the	O
inactivation	O
of	O
serum	B-GENE
lipoprotein	I-GENE
lipase	I-GENE
by	O
the	O
liver	O
in	O
unanesthetized	O
dogs	O
.	O

CONCLUSIONS	O
:	O
The	O
largest	O
value	O
of	O
the	O
joint	O
space	O
may	O
be	O
used	O
when	O
evaluating	O
rheumatoid	O
AC	O
joint	O
space	O
.	O

We	O
then	O
demonstrated	O
that	O
1	O
)	O
GAL4-REV-erbA	B-GENE
alpha	I-GENE
chimeras	I-GENE
that	O
contain	O
the	O
'AB'	B-GENE
region	I-GENE
and	O
lack	O
the	O
'E'	B-GENE
region	I-GENE
activated	O
transcription	O
of	O
GAL4	B-GENE
response	I-GENE
elements	I-GENE
in	O
the	O
presence	O
of	O
8-Br-cAMP	O
and	O
2	O
)	O
the	O
ligand-binding	O
domain	O
(	O
LBD	O
)	O
contains	O
an	O
active	O
transcriptional	O
silencer	O
.	O

When	O
transfected	O
into	O
Drosophila	O
SL-2	O
cells	O
,	O
pCAT	O
plasmid	O
containing	O
2	O
,	O
090	O
bp	O
of	O
5'-flanking	O
region	O
shows	O
a	O
3	O
.	O
0-	O
to	O
3	O
.	O
5-fold	O
increase	O
in	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
activity	O
after	O
induction	O
with	O
retinoic	O
acid	O
and	O
/	O
or	O
8-bromo-cAMP	O
.	O

In	O
the	O
course	O
of	O
screening	O
for	O
transcription	O
factors	O
which	O
interact	O
with	O
the	O
human	B-GENE
myeloperoxidase	I-GENE
(	O
MPO	B-GENE
)	O
promoter	O
we	O
,	O
for	O
the	O
first	O
time	O
,	O
identified	O
and	O
cloned	O
the	O
cDNA	O
and	O
genomic	O
DNA	O
for	O
human	B-GENE
HBP1	I-GENE
(	O
HMG-Box	B-GENE
containing	I-GENE
protein	I-GENE
1	I-GENE
)	O
,	O
a	O
member	O
of	O
the	O
high	B-GENE
mobility	I-GENE
group	I-GENE
of	I-GENE
non-histone	I-GENE
chromosomal	I-GENE
proteins	I-GENE
.	O

This	O
analysis	O
revealed	O
that	O
SAP	B-GENE
145	I-GENE
,	O
together	O
with	O
four	O
other	O
SF3a	B-GENE
/	I-GENE
SF3b	I-GENE
subunits	I-GENE
,	O
UV	O
cross-links	O
to	O
pre-mRNA	O
in	O
a	O
20-nucleotide	O
region	O
upstream	O
of	O
the	O
BPS	B-GENE
.	O

The	O
first	O
contains	O
ATF	B-GENE
/	I-GENE
CRE	I-GENE
and	O
TBP	B-GENE
/	I-GENE
TATA	I-GENE
sequence	I-GENE
motifs	I-GENE
within	O
an	O
87-bp	O
region	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
accuracy	O
of	O
working	O
casts	O
for	O
crown	O
and	O
bridge	O
restorations	O
made	O
from	O
twin	O
mix	O
putty	O
/	O
wash	O
silicone	O
elastomeric	O
impression	O
materials	O
using	O
different	O
types	O
of	O
stock	O
tray	O
.	O

The	O
final	O
predicted	O
structure	O
has	O
an	O
overall	O
backbone	O
deviation	O
of	O
0	O
.	O
7	O
A	O
from	O
that	O
of	O
ras-p21	B-GENE
.	O

As	O
a	O
consequence	O
of	O
dark	O
rearing	O
,	O
the	O
numerical	O
density	O
of	O
cortical	O
neurons	O
in	O
area	O
17	O
amounted	O
to	O
about	O
double	O
of	O
the	O
value	O
observed	O
in	O
normally	O
reared	O
kittens	O
and	O
was	O
also	O
significantly	O
higher	O
in	O
area	O
18	O
.	O

The	O
role	O
of	O
ascorbic	O
acid	O
in	O
the	O
prevention	O
of	O
bladder	O
tumor	O
formation	O
.	O

Ten	O
out	O
of	O
10	O
patients	O
with	O
progressive	O
disease	O
had	O
mast	O
cells	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
5%	O
,	O
hyaluronan	O
greater	O
than	O
or	O
equal	O
to	O
50	O
micrograms	O
.	O
l-1	O
and	O
fibronectin	B-GENE
greater	O
than	O
or	O
equal	O
to	O
350	O
micrograms	O
.	O
l-1	O
compared	O
to	O
eight	O
out	O
of	O
41	O
patients	O
with	O
stable	O
or	O
regressive	O
disease	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Since	O
1990	O
the	O
University	O
Hospital	O
of	O
Tromso	O
has	O
provided	O
local	O
hospitals	O
in	O
northern	O
Norway	O
with	O
a	O
remote	O
frozen	O
section	O
service	O
and	O
with	O
access	O
to	O
video	O
conferences	O
for	O
the	O
review	O
of	O
microscopic	O
findings	O
and	O
for	O
the	O
discussion	O
of	O
major	O
diagnostic	O
issues	O
.	O

NSCL-1	B-GENE
is	O
expressed	O
in	O
a	O
larger	O
number	O
of	O
these	O
cell	O
lines	O
.	O

Both	O
of	O
these	O
dogs	O
had	O
low	O
serum	O
IgG	B-GENE
(	O
3	O
.	O
5	O
to	O
7	O
.	O
2	O
mg	O
/	O
ml	O
)	O
and	O
the	O
second	O
littermate	O
also	O
had	O
reduced	O
serum	O
IgA	B-GENE
(	O
<	O
0	O
.	O
1	O
to	O
0	O
.	O
15	O
mg	O
/	O
ml	O
)	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
a	O
correlation	O
between	O
serum	O
and	O
seminal	B-GENE
plasma	I-GENE
PSA	I-GENE
levels	O
.	O

A	O
.	O

Direct	O
proof	O
that	O
the	O
heightened	O
renal	O
cellular	O
apoptosis	O
in	O
PKD	O
is	O
not	O
occurring	O
through	O
p53	B-GENE
was	O
obtained	O
by	O
successive	O
matings	O
between	O
SBM	O
and	O
p53	B-GENE
(	I-GENE
-	I-GENE
/	I-GENE
-	I-GENE
)	I-GENE
mice	O
.	O

Evoked	O
electromyographic	O
response	O
to	O
indirect	O
supramaximal	O
stimulation	O
at	O
1	O
Hz	O
was	O
monitored	O
in	O
ten	O
adult	O
goats	O
under	O
thiopentone-halothane	O
anaesthesia	O
.	O

It	O
has	O
been	O
demonstrated	O
previously	O
that	O
Pax-6	B-GENE
,	O
a	O
paired	B-GENE
domain	I-GENE
(	I-GENE
PD	I-GENE
)	I-GENE
/	I-GENE
homeodomain	I-GENE
(	I-GENE
HD	I-GENE
)	I-GENE
transcription	I-GENE
factor	I-GENE
critical	O
for	O
eye	O
development	O
,	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
alphaB-	B-GENE
,	O
alphaA-	B-GENE
,	O
delta1-	B-GENE
,	O
and	O
zeta-crystallin	B-GENE
genes	I-GENE
in	O
the	O
lens	O
.	O

TCR	B-GENE
alpha	I-GENE
and	I-GENE
beta	I-GENE
gene	I-GENE
expression	O
may	O
be	O
regulated	O
by	O
a	O
common	O
set	O
of	O
T-cell	B-GENE
nuclear	I-GENE
proteins	I-GENE
in	O
that	O
the	O
T	B-GENE
beta	I-GENE
2	I-GENE
element	I-GENE
binding	O
a	O
set	O
of	O
cyclic	B-GENE
AMP	I-GENE
response	I-GENE
element-binding	I-GENE
proteins	I-GENE
that	O
are	O
also	O
bound	O
by	O
the	O
T	B-GENE
alpha	I-GENE
1	I-GENE
element	I-GENE
of	O
the	O
human	O
TCR	B-GENE
alpha	I-GENE
enhancer	O
and	O
the	O
decamer	O
element	O
present	O
in	O
a	O
large	O
number	O
of	O
human	O
and	O
murine	O
TCR	B-GENE
beta	I-GENE
promoters	O
.	O

The	O
transverse	O
relaxation	O
time	O
(	O
T2	O
)	O
and	O
apparent	O
diffusion	O
coefficient	O
of	O
water	O
were	O
determined	O
.	O

Female	O
mice	O
were	O
significantly	O
more	O
resistant	O
to	O
infection	O
than	O
males	O
.	O

Three	O
ORFs	O
(	O
9765orfR002	B-GENE
,	O
9765orfR011	B-GENE
and	O
9765orfR013	B-GENE
)	O
were	O
found	O
to	O
be	O
homologous	O
with	O
Schizosaccharomyces	O
pombe	O
polyadenylate	B-GENE
binding	I-GENE
protein	I-GENE
,	O
Escherichia	O
coli	O
hypothetical	O
38	O
.	O
1-kDa	O
protein	O
in	O
the	O
BCR	B-GENE
5'	O
region	O
,	O
and	O
transcription	O
regulatory	O
protein	O
Swi3	B-GENE
,	O
respectively	O
.	O

EBNA-2	B-GENE
and	O
the	O
cis-acting	O
CD23	B-GENE
element	I-GENE
increased	O
TK-promoted	O
mRNA	O
and	O
did	O
not	O
alter	O
the	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
TK	I-GENE
promoter	I-GENE
transcription	I-GENE
start	I-GENE
site	I-GENE
.	O

Analysis	O
of	O
ace2Delta	O
cells	O
reveals	O
that	O
Ace2p	B-GENE
is	O
required	O
for	O
cell	O
separation	O
but	O
not	O
for	O
polarized	O
growth	O
.	O

The	O
case	O
described	O
is	O
that	O
of	O
a	O
72-year-old	O
man	O
with	O
ochronosis	O
who	O
suffered	O
a	O
hyperextension	O
injury	O
to	O
his	O
spine	O
in	O
a	O
fall	O
,	O
resulting	O
in	O
a	O
fracture	O
through	O
an	O
ankylosed	O
L2-L3	O
disk	O
space	O
.	O

Although	O
stone-formers	O
were	O
not	O
found	O
to	O
display	O
any	O
features	O
of	O
magnesium	O
metabolism	O
that	O
were	O
different	O
from	O
those	O
in	O
the	O
control	O
group	O
,	O
their	O
lower	O
urinary	O
excretion	O
of	O
magnesium	O
in	O
relation	O
to	O
calcium	O
may	O
be	O
a	O
factor	O
in	O
their	O
increased	O
stone-forming	O
propensity	O
.	O

Phosphoamino	O
acid	O
analysis	O
of	O
radiolabeled	O
ASGPR	B-GENE
subunits	I-GENE
identified	O
Ser	O
(	O
P	O
)	O
as	O
the	O
predominant	O
(	O
approximately	O
95%	O
)	O
and	O
Thr	O
(	O
P	O
)	O
as	O
a	O
minor	O
(	O
approximately	O
5%	O
)	O
phosphoamino	O
acid	O
in	O
each	O
polypeptide	O
and	O
confirmed	O
the	O
presence	O
of	O
Tyr	O
(	O
P	O
)	O
(	O
approximately	O
1%	O
)	O
in	O
RHL1	B-GENE
.	O

Cheung	O
and	O
S	O
.	O

Pentobarbital	O
(	O
1	O
,	O
3	O
,	O
10	O
,	O
and	O
17	O
.	O
5	O
mg	O
/	O
kg	O
)	O
was	O
also	O
tested	O
in	O
combination	O
with	O
rate-decreasing	O
doses	O
of	O
normeperidine	O
(	O
17	O
.	O
5	O
mg	O
/	O
kg	O
)	O
,	O
anileridine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
alphaprodine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
and	O
fentanyl	O
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
.	O

Dentalplaque	O
was	O
controlled	O
by	O
the	O
oral	O
higienic	O
index	O
of	O
the	O
whole	O
dentition	O
daily	O
,	O
after	O
staining	O
with	O
1	O
per	O
cent	O
alkaline	O
fuxin	O
.	O

The	O
antinociceptive	O
properties	O
,	O
as	O
measured	O
by	O
the	O
tail-flick	O
and	O
hot-plate	O
tests	O
,	O
and	O
the	O
motor	O
effects	O
of	O
an	O
intrathecally-administered	O
benzodiazepine	O
agonist	O
midazolam	O
,	O
alone	O
,	O
and	O
in	O
combination	O
with	O
morphine	O
,	O
was	O
examined	O
in	O
rats	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
successful	O
resection	O
of	O
a	O
MFH	O
originating	O
in	O
the	O
renal	O
capsular	O
tissue	O
and	O
extending	O
into	O
the	O
inferior	O
vena	O
cava	O
.	O

In	O
connective	O
tissue	O
,	O
cell	O
structure	O
contributes	O
to	O
type	B-GENE
I	I-GENE
collagen	I-GENE
expression	O
.	O

Pathways	O
linking	O
the	O
olfactory	O
bulbs	O
with	O
the	O
medial	O
preoptic	O
anterior	O
hypothalamus	O
are	O
important	O
for	O
intermale	O
aggression	O
in	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
cloned	O
the	O
human	B-GENE
DSG3	I-GENE
gene	I-GENE
and	O
examined	O
the	O
transcriptional	O
regulation	O
of	O
its	O
expression	O
.	O

In	O
simpler	O
organisms	O
,	O
the	O
ATP	B-GENE
sulfurylase	I-GENE
and	O
APS	B-GENE
kinase	I-GENE
reactions	O
are	O
catalyzed	O
by	O
separate	O
enzymes	O
encoded	O
by	O
two	O
or	O
three	O
genes	O
,	O
suggesting	O
that	O
a	O
fusion	O
of	O
separate	O
genes	O
during	O
the	O
course	O
of	O
evolution	O
generated	O
the	O
bifunctional	O
enzyme	O
.	O

The	O
protein	O
predicted	O
by	O
the	O
sequence	O
of	O
the	O
human	B-GENE
pim-1	I-GENE
proto-oncogene	I-GENE
shares	O
extensive	O
homology	O
with	O
known	O
serine	B-GENE
/	I-GENE
threonine	I-GENE
protein	I-GENE
kinases	I-GENE
,	O
and	O
yet	O
the	O
human	B-GENE
Pim-1	I-GENE
enzyme	I-GENE
has	O
previously	O
been	O
reported	O
to	O
exhibit	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Compared	O
to	O
its	O
counterpart	O
in	O
the	O
GPB	B-GENE
gene	I-GENE
,	O
exon	O
3	O
of	O
the	O
GPE	B-GENE
gene	I-GENE
contains	O
several	O
point	O
mutations	O
,	O
an	O
insertion	O
of	O
24	O
bp	O
,	O
and	O
a	O
stop	O
codon	O
which	O
shortens	O
the	O
reading	O
frame	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
Mif2	B-GENE
protein	I-GENE
interacts	O
with	O
Cep1p	B-GENE
at	O
the	O
centromere	O
and	O
that	O
the	O
yeast	O
centromere	O
indeed	O
exists	O
as	O
a	O
higher	O
order	O
protein-DNA	O
complex	O
.	O

These	O
findings	O
demonstrate	O
that	O
signature-tagged	O
mutagenesis	O
is	O
a	O
viable	O
approach	O
to	O
identify	O
bacterial	O
genes	O
associated	O
with	O
the	O
ability	O
to	O
infect	O
the	O
urinary	O
tract	O
.	O

CONCLUSION	O
:	O
Monitoring	O
SpO2	O
at	O
the	O
nasal	O
septum	O
site	O
is	O
more	O
reliable	O
than	O
monitoring	O
it	O
at	O
the	O
finger	O
site	O
in	O
hypothermic	O
patients	O
.	O

Hemorrhagic	O
shock	O
and	O
bacterial	O
translocation	O
in	O
a	O
swine	O
model	O
.	O

Induction	O
of	O
the	O
CINC	B-GENE
promoter	I-GENE
by	O
IL-17	B-GENE
in	O
IEC-6	O
cells	O
was	O
TNF	B-GENE
receptor-associated	I-GENE
factor-6	I-GENE
(	O
TRAF6	B-GENE
)	O
,	O
but	O
not	O
TRAF2	B-GENE
,	O
dependent	O
.	O

This	O
study	O
reports	O
the	O
isolation	O
of	O
a	O
P	O
.	O
hybrida	O
gene	O
,	O
jaf13	B-GENE
,	O
encoding	O
a	O
basic	B-GENE
helix-loop-helix	I-GENE
protein	I-GENE
that	O
,	O
on	O
the	O
basis	O
of	O
sequence	O
homology	O
and	O
intron	O
/	O
exon	O
structure	O
,	O
represents	O
the	O
P	O
.	O
hybrida	O
orthologue	O
of	O
the	O
Z	B-GENE
.	I-GENE
mays	I-GENE
r	I-GENE
genes	I-GENE
.	O

However	O
,	O
while	O
IL-1beta	B-GENE
and	O
TNF-alpha	B-GENE
both	O
induced	O
nuclear	O
binding	O
of	O
the	O
Rel	B-GENE
proteins	I-GENE
p50	B-GENE
and	O
p65	B-GENE
to	O
an	O
NF-kappaB	B-GENE
consensus	I-GENE
oligonucleotide	I-GENE
in	O
gel	O
shift	O
assays	O
and	O
caused	O
transient	O
degradation	O
of	O
inhibitor	B-GENE
of	I-GENE
NF-kappaB-alpha	I-GENE
(	O
IkappaB-alpha	B-GENE
)	O
in	O
the	O
cytoplasm	O
of	O
myofibroblasts	O
,	O
only	O
IL-1beta	B-GENE
upregulated	O
PDGF-Ralpha	B-GENE
.	O

Oculus-500	O
is	O
a	O
group	O
of	O
high	O
resolution	O
imaging	O
boards	O
for	O
use	O
with	O
IBM-AT	O
and	O
compatible	O
computers	O
.	O

The	O
mRNA	O
from	O
this	O
gene	O
,	O
termed	O
HES1	B-GENE
,	O
is	O
ubiquitously	O
expressed	O
,	O
but	O
strongly	O
so	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

When	O
ligated	O
to	O
the	O
proIL-1	B-GENE
beta	I-GENE
cap	I-GENE
site-proximal	I-GENE
region	I-GENE
(	O
located	O
between	O
-131	O
to	O
+12	O
)	O
,	O
both	O
the	O
proIL-1	B-GENE
beta	I-GENE
and	O
the	O
simian	B-GENE
virus	I-GENE
40	I-GENE
enhancer	I-GENE
elements	I-GENE
functioned	O
more	O
efficiently	O
in	O
monocytes	O
than	O
in	O
HeLa	O
cells	O
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL-1	B-GENE
beta	I-GENE
expression	O
.	O

Minor	O
differences	O
were	O
noted	O
with	O
latamoxef	O
producing	O
mild	O
persistant	O
elevation	O
of	O
prothrombin	B-GENE
time	O
(	O
0	O
.	O
7	O
second	O
)	O
associated	O
with	O
depression	O
of	O
factor	B-GENE
II	I-GENE
and	O
factor	B-GENE
VII	I-GENE
.	O

We	O
report	O
two	O
patients	O
receiving	O
maintenance	O
valproate	O
,	O
one	O
with	O
resolving	O
acute	O
hepatitis	O
C	O
and	O
the	O
other	O
with	O
chronic	O
persistent	O
hepatitis	O
C	O
,	O
with	O
incidental	O
microvesicular	O
steatosis	O
demonstrated	O
on	O
oil-red	O
O	O
stains	O
.	O

One	O
of	O
these	O
,	O
the	O
origin	O
core	O
,	O
is	O
required	O
only	O
for	O
DNA	O
replication	O
.	O

Levels	O
of	O
serum	O
IgE	B-GENE
were	O
measured	O
monthly	O
,	O
and	O
nasal	O
IgE	B-GENE
was	O
measured	O
at	O
the	O
height	O
and	O
end	O
of	O
the	O
season	O
.	O

PDGF	B-GENE
A-chain	I-GENE
levels	O
increase	O
in	O
cultured	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
exposed	O
to	O
ATII	B-GENE
.	O

Standardized	O
gastric	O
wall	O
specimens	O
from	O
the	O
area	O
of	O
grossly	O
healed	O
ulcers	O
were	O
obtained	O
,	O
processed	O
,	O
and	O
evaluated	O
by	O
light	O
microscopy	O
and	O
by	O
transmission	O
electron	O
microscopy	O
.	O

Likewise	O
,	O
at	O
150	O
degrees	O
C	O
with	O
2%	O
APS	O
the	O
surface	O
density	O
of	O
NH2	O
groups	O
reached	O
a	O
maximum	O
at	O
24	O
hr	O
and	O
remained	O
relatively	O
constant	O
up	O
to	O
96	O
hr	O
.	O

HeLa	O
and	O
Jurkat	O
cell	O
lines	O
carrying	O
the	O
nef	B-GENE
gene	I-GENE
linked	O
to	O
the	O
CMV	O
promoter	O
or	O
the	O
HIV-1	O
LTR	O
were	O
isolated	O
by	O
coselection	O
for	O
neomycin	O
resistance	O
.	O

We	O
have	O
isolated	O
and	O
characterized	O
the	O
GCD6	B-GENE
and	O
GCD7	B-GENE
genes	I-GENE
and	O
shown	O
that	O
their	O
products	O
are	O
required	O
to	O
repress	O
GCN4	B-GENE
translation	O
under	O
nonstarvation	O
conditions	O
.	O

We	O
have	O
visualized	O
DNA-protein	O
complexes	O
by	O
electron	O
microscopy	O
and	O
a	O
high-affinity	O
binding	O
site	O
of	O
WDV	B-GENE
Rep	I-GENE
protein	I-GENE
within	O
the	O
core	O
element	O
has	O
been	O
mapped	O
to	O
approximately	O
144	O
+	O
/	O
-	O
18	O
bp	O
upstream	O
from	O
the	O
initiation	O
site	O
,	O
between	O
the	O
start	O
site	O
for	O
complementary-sense	O
transcription	O
and	O
the	O
TATA	O
box	O
.	O

Both	O
in	O
vitro-synthesized	O
S2	B-GENE
protein	I-GENE
and	O
synthetic	O
peptides	O
corresponding	O
to	O
S2	B-GENE
are	O
shown	O
to	O
react	O
positively	O
with	O
sera	O
obtained	O
from	O
EIAV-infected	O
horses	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
of	O
expression	O
of	O
this	O
protein	O
in	O
infected	O
animals	O
.	O

For	O
these	O
patients	O
the	O
introduction	O
of	O
a	O
separate	O
category	O
"extended	O
oligoarthritis	O
at	O
onset"	O
should	O
be	O
considered	O
to	O
establish	O
comparable	O
patient	O
groups	O
.	O

The	O
number	O
of	O
bacteria	O
in	O
the	O
lung	O
,	O
peripheral	O
white	O
blood	O
cell	O
and	O
BAL	O
fluid	O
cell	O
also	O
decreased	O
by	O
the	O
administration	O
of	O
FN	B-GENE
.	O

A	O
major	O
mechanism	O
by	O
which	O
estrogens	O
prevent	O
osteoporosis	O
seems	O
to	O
be	O
repression	O
of	O
transcription	O
of	O
NF-kappa	B-GENE
B	I-GENE
target	I-GENE
genes	I-GENE
,	O
such	O
as	O
the	O
osteoclast-activating	O
cytokines	O
interleukin-6	B-GENE
and	O
interleukin-1	B-GENE
.	O

Suppressors	O
of	O
defective	O
silencing	O
in	O
yeast	O
:	O
effects	O
on	O
transcriptional	O
repression	O
at	O
the	O
HMR	B-GENE
locus	I-GENE
,	O
cell	O
growth	O
and	O
telomere	O
structure	O
.	O

Following	O
extended	O
recovery	O
hippocampal	O
EEG	O
was	O
normal	O
despite	O
extensive	O
cellular	O
loss	O
in	O
areas	O
CA3	O
and	O
CA4	O
.	O

Patients	O
received	O
either	O
diltiazem	O
CD	O
180	O
mg	O
or	O
placebo	O
once	O
/	O
day	O
in	O
combination	O
with	O
existing	O
antianginal	O
therapy	O
.	O

A	O
haemolytic	O
enterotoxigenic	O
strain	O
of	O
E	O
.	O
coli	O
(	O
O149	O
:	O
K88	O
:	O
H10	O
)	O
was	O
regularly	O
recovered	O
from	O
piglets	O
with	O
PWD	O
while	O
rotavirus	O
was	O
demonstrated	O
on	O
a	O
number	O
of	O
occasions	O
.	O

These	O
findings	O
indicate	O
that	O
hypergastrinemia	O
induced	O
by	O
surgical	O
removal	O
of	O
acid-producing	O
mucosa	O
in	O
the	O
rat	O
has	O
the	O
same	O
effects	O
on	O
oxyntical	O
mucosal	B-GENE
HDC	I-GENE
activity	O
,	O
histamine	O
concentration	O
and	O
ECL	O
cell	O
density	O
as	O
hypergastrinemia	O
induced	O
by	O
continuous	O
gastrin	B-GENE
infusion	O
or	O
by	O
long-term	O
treatment	O
with	O
effective	O
antisecretagogues	O
.	O

We	O
have	O
isolated	O
and	O
analyzed	O
human	B-GENE
CTCF	I-GENE
cDNA	I-GENE
clones	O
and	O
show	O
here	O
that	O
the	O
ubiquitously	O
expressed	O
11-zinc-finger	B-GENE
factor	I-GENE
CTCF	I-GENE
is	O
an	O
exceptionally	O
highly	O
conserved	O
protein	O
displaying	O
93%	O
identity	O
between	O
avian	O
and	O
human	O
amino	O
acid	O
sequences	O
.	O

The	O
influence	O
of	O
patient-related	O
factors	O
on	O
inter-observer	O
variability	O
in	O
the	O
evaluation	O
of	O
neurological	O
signs	O
was	O
investigated	O
.	O

The	O
glucose	O
areas	O
following	O
the	O
ingestion	O
of	O
the	O
foods	O
were	O
:	O
Study	O
1	O
:	O
glucose	O
11	O
.	O
7	O
,	O
orange	O
juice	O
7	O
.	O
3	O
,	O
sucrose	O
5	O
.	O
2	O
,	O
glucose	O
+	O
fructose	O
6	O
.	O
3	O
,	O
and	O
fructose	O
0	O
.	O
7	O
mmol	O
X	O
h	O
/	O
l	O
;	O
Study	O
2	O
:	O
glucose	O
14	O
.	O
6	O
,	O
orange	O
juice	O
7	O
.	O
3	O
,	O
apples	O
5	O
.	O
5	O
,	O
and	O
apple	O
juice	O
4	O
.	O
7	O
mmol	O
X	O
h	O
/	O
l	O
;	O
Study	O
3	O
:	O
glucose	O
12	O
.	O
6	O
,	O
ice	O
cream	O
8	O
.	O
1	O
,	O
milk	O
3	O
.	O
7	O
,	O
and	O
lactose	O
4	O
.	O
1	O
mmol	O
X	O
h	O
/	O
l	O
.	O

Nevertheless	O
,	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
stimulation	O
induces	O
CREMalpha	B-GENE
to	O
activate	O
the	O
complex	O
native	O
promoter	O
in	O
the	O
phosphoenolpyruvate	B-GENE
carboxykinase	I-GENE
(	O
PEPCK	B-GENE
)	O
gene	O
.	O

The	O
calcitonin-induced	O
tyrosine	O
phosphorylation	O
of	O
HEF1	B-GENE
increased	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O

These	O
data	O
locate	O
the	O
aniridia	B-GENE
gene	I-GENE
(	O
AN2	B-GENE
)	O
and	O
a	O
recurrent	O
T-cell	B-GENE
leukemia	I-GENE
breakpoint	I-GENE
(	O
TCL2	B-GENE
)	O
in	O
the	O
marker	O
sequence	O
,	O
on	O
opposite	O
sides	O
of	O
MIC1	B-GENE
.	O

The	O
p130	B-GENE
and	O
p62	B-GENE
tyrosine-phosphorylated	O
proteins	O
that	O
complexed	O
v-Src	B-GENE
SH2	B-GENE
in	O
vitro	O
also	O
associated	O
with	O
v-Src	B-GENE
in	O
v-src-transformed	O
Rat-2	O
cells	O
;	O
this	O
in	O
vivo	O
binding	O
was	O
dependent	O
on	O
the	O
v-Src	B-GENE
SH2	B-GENE
domain	O
.	O

A	O
study	O
was	O
conducted	O
of	O
a	O
human	O
male	O
who	O
had	O
inhaled	O
a	O
mixture	O
of	O
241Am	O
and	O
Pu	O
.	O

In	O
slightly	O
older	O
embryos	O
,	O
the	O
expression	O
was	O
skewed	O
to	O
one	O
side	O
of	O
the	O
embryo	O
and	O
by	O
E6	O
.	O
5	O
,	O
at	O
the	O
onset	O
of	O
gastrulation	O
,	O
expression	O
was	O
seen	O
in	O
the	O
epiblast	O
,	O
visceral	O
endoderm	O
,	O
nascent	O
mesoderm	O
,	O
and	O
the	O
primitive	O
streak	O
.	O

As	O
for	O
31	O
stage	O
I-II	O
lung	O
cancer	O
patients	O
,	O
CR	O
has	O
been	O
observed	O
in	O
82	O
.	O
8%	O
of	O
them	O
and	O
PR	O
in	O
13	O
.	O
8%	O
;	O
the	O
response	O
was	O
always	O
assessed	O
with	O
chest	O
radiography	O
,	O
CT	O
,	O
FBS	O
,	O
cytology	O
and	O
/	O
or	O
histology	O
.	O

The	O
technique	O
of	O
the	O
TEE	O
visualization	O
of	O
the	O
proximal	O
coronary	O
arteries	O
is	O
described	O
.	O

This	O
negative	O
regulatory	O
pathway	O
may	O
be	O
important	O
for	O
determining	O
cell	O
fate	O
or	O
maintaining	O
an	O
inducible	O
state	O
in	O
the	O
ventroposterior	O
region	O
of	O
the	O
embryo	O
.	O

Myogenic	O
differentiation	O
can	O
be	O
inhibited	O
by	O
the	O
adenovirus	O
E1a	B-GENE
protein	I-GENE
in	O
the	O
rat	O
L6	O
muscle	O
cell	O
line	O
.	O

Two	O
points	O
are	O
indicated	O
:	O
first	O
,	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
interrelated	O
to	O
not	O
only	O
1O2	O
,	O
but	O
also	O
free	O
radicals	O
(	O
O2-	O
.	O
.	O
OH	O
and	O
YHPD-	O
.	O
)	O
;	O
second	O
,	O
although	O
the	O
photosensitized	O
damage	O
of	O
YHPD	O
is	O
stronger	O
than	O
that	O
of	O
BHPD	O
,	O
yet	O
the	O
photosensitized	O
damage	O
is	O
negatively	O
correlated	O
to	O
the	O
yield	O
of	O
1O2	O
but	O
positively	O
correlated	O
to	O
those	O
of	O
O2-	O
.	O
and	O
OH	O
.	O

Selection	O
using	O
SC	O
EPD	O
was	O
more	O
effective	O
than	O
phenotypic	O
selection	O
in	O
reducing	O
age	O
at	O
puberty	O
in	O
daughters	O
.	O

The	O
results	O
indicate	O
that	O
increased	O
pulmonary	O
blood	O
flow	O
and	O
decreased	O
pulmonary	O
vascular	O
resistance	O
with	O
advancing	O
gestation	O
are	O
due	O
to	O
an	O
increase	O
in	O
the	O
total	O
number	O
of	O
vessels	O
and	O
increased	O
vasomotor	O
reactivity	O
is	O
related	O
to	O
an	O
increase	O
in	O
the	O
total	O
amount	O
of	O
smooth	O
muscle	O
while	O
the	O
thickness	O
of	O
muscle	O
in	O
individual	O
vessels	O
remains	O
constant	O
.	O

Immunofixation	O
experiments	O
of	O
C4A	B-GENE
and	O
C4B	B-GENE
demonstrate	O
>	O
41	O
allotypes	O
in	O
the	O
two	O
classes	O
of	O
proteins	O
.	O

Thirty	O
of	O
the	O
clones	O
contained	O
a	O
complete	O
340	O
base-pair	O
dimer	O
unit	O
of	O
the	O
repeat	O
.	O

Primer	O
extension	O
and	O
cDNA	O
cloning	O
were	O
used	O
to	O
isolate	O
the	O
complete	O
5'	O
end	O
of	O
the	O
Nramp1	B-GENE
mRNA	I-GENE
.	O

A	O
736-bp	O
sequence	O
of	O
the	O
5'	O
flanking	O
region	O
adjacent	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	B-GENE
AFP	I-GENE
gene	I-GENE
shows	O
a	O
61%	O
similarity	O
with	O
the	O
corresponding	O
region	O
of	O
the	O
mouse	B-GENE
AFP	I-GENE
gene	I-GENE
.	O

A	O
new	O
species	O
of	O
Euspondylus	O
is	O
described	O
based	O
on	O
a	O
female	O
(	O
taken	O
within	O
a	O
bromeliad	O
)	O
from	O
Cerro	O
El	O
Humo	O
,	O
Sucre	O
,	O
northeastern	O
Venezuela	O
.	O

The	O
effect	O
of	O
site-specific	O
mutations	O
in	O
the	O
mouse	B-GENE
platelet-derived	I-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
PDGF	I-GENE
)	I-GENE
beta-receptor	I-GENE
on	O
activation	O
of	O
the	O
Na+	B-GENE
/	I-GENE
H+	I-GENE
exchanger	I-GENE
was	O
examined	O
in	O
normal	O
murine	O
mammary	O
gland	O
epithelial	O
(	O
NMuMG	O
)	O
and	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O

The	O
Og4C3	B-GENE
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
to	O
detect	O
circulating	O
Wuchereria	B-GENE
bancrofti	I-GENE
antigen	I-GENE
uses	O
50	O
microL	O
of	O
serum	O
.	O

Pharmacological	O
desympathization	O
leads	O
to	O
the	O
development	O
of	O
hyper-reactivity	O
of	O
the	O
true	O
pacemakers	O
to	O
noradrenaline	O
and	O
dopamine	O
and	O
triggers	O
off	O
changes	O
in	O
the	O
regulation	O
of	O
the	O
electric	O
activity	O
of	O
these	O
cells	O
by	O
catecholamines	O
.	O

The	O
inhibition	O
of	O
focus	O
formation	O
observed	O
in	O
the	O
presence	O
of	O
C3G	B-GENE
was	O
not	O
due	O
to	O
toxic	O
effects	O
on	O
cell	O
viability	O
,	O
since	O
transfected	O
C3G	B-GENE
cells	O
exhibited	O
the	O
same	O
survival	O
and	O
growth	O
rates	O
as	O
untransfected	O
NIH3T3	O
cells	O
or	O
cells	O
transfected	O
with	O
plasmid	O
vector	O
alone	O
.	O

In	O
rubella	O
patients	O
with	O
serologic	O
confirmation	O
by	O
HI	O
,	O
the	O
IF	O
test	O
detected	O
significant	O
rises	O
in	O
219	O
(	O
99	O
.	O
1%	O
)	O
of	O
221	O
patients	O
and	O
the	O
PHA	B-GENE
test	O
detected	O
antibody	O
conversion	O
in	O
68	O
(	O
93%	O
)	O
of	O
73	O
patients	O
.	O

Exposure	O
of	O
peripheral	O
blood	O
T	O
cells	O
from	O
young	O
subjects	O
to	O
PHA	O
or	O
cross-linked	O
anti-CD3	B-GENE
monoclonal	I-GENE
antibodies	I-GENE
stimulated	O
rapid	O
increases	O
in	O
MAPK	B-GENE
and	O
MEK	B-GENE
enzymatic	O
activity	O
.	O

Southern	O
blotting	O
analysis	O
implied	O
the	O
occurrence	O
of	O
multiple	O
COXVb	B-GENE
genes	I-GENE
in	O
the	O
rat	O
genome	O
.	O

Cryopreservation	O
straws	O
filled	O
with	O
media	O
plus	O
additive	O
are	O
emersed	O
below	O
the	O
surface	O
of	O
an	O
unprocessed	O
donor	O
ejaculate	O
.	O

Clinical	O
course	O
and	O
nursing	O
care	O
of	O
patients	O
with	O
decubitus	O
ulcer--use	O
of	O
pillows	O
stuffed	O
with	O
buckwheat	O
chaff	O
.	O

An	O
examination	O
was	O
performed	O
in	O
15	O
patients	O
who	O
had	O
developed	O
pronounced	O
osteomalacia	O
following	O
gastric	O
resection	O
.	O

Adjacent	O
to	O
those	O
lesions	O
,	O
and	O
in	O
homologous	O
contralateral	O
structures	O
,	O
FMZ	O
binding	O
was	O
analysed	O
in	O
four	O
pairs	O
of	O
cortical	O
9	O
x	O
9-mm	O
regions	O
of	O
interest	O
(	O
ROIs	O
)	O
placed	O
on	O
transaxial	O
and	O
coronal	O
slices	O
,	O
respectively	O
,	O
as	O
well	O
as	O
in	O
the	O
lesion	O
volume	O
and	O
its	O
mirror	O
region	O
.	O

Doppler	O
ultrasound	O
studies	O
of	O
long-term	O
follow-up	O
of	O
children	O
with	O
hemolytic-uremic	O
syndrome	O
.	O

The	O
contrasting	O
effects	O
of	O
dopaminergic	O
stimulation	O
on	O
the	O
motor	O
performance	O
and	O
on	O
some	O
aspects	O
of	O
cognitive	O
processing	O
suggest	O
the	O
existence	O
of	O
complex	O
interactions	O
within	O
pre-	O
and	O
postsynaptic	O
brain	B-GENE
dopamine	I-GENE
receptors	I-GENE
,	O
and	O
an	O
intervention	O
of	O
segregated	O
basal	O
ganglia-prefrontal	O
cortex	O
loops	O
in	O
motor	O
and	O
cognitive	O
behaviour	O
.	O

As	O
in	O
Tb	O
,	O
U6	B-GENE
is	O
a	O
single-copy	O
gene	O
and	O
two	O
tRNA	B-GENE
genes	I-GENE
,	O
tRNAGln	B-GENE
and	O
tRNAIle	B-GENE
,	O
are	O
found	O
upstream	O
to	O
the	O
gene	O
.	O

Experimental	O
adhesion	O
prophylaxis	O
with	O
recombinant	B-GENE
tissue	I-GENE
plasminogen	I-GENE
activator	I-GENE
.	O

Thigh	O
girth	O
correlated	O
positively	O
with	O
HDL	B-GENE
and	O
HDL2-C	B-GENE
and	O
mass	O
,	O
and	O
with	O
LDL	B-GENE
particle	O
size	O
among	O
women	O
.	O

Cotransfection	O
analyses	O
of	O
the	O
T	B-GENE
/	I-GENE
EBP	I-GENE
promoter-reporter	I-GENE
constructs	I-GENE
with	O
a	O
T	B-GENE
/	I-GENE
EBP	I-GENE
expression	O
vector	O
into	O
human	O
HepG2	O
cells	O
,	O
which	O
do	O
not	O
express	O
T	B-GENE
/	I-GENE
EBP	I-GENE
,	O
suggested	O
that	O
autoregulation	O
may	O
be	O
involved	O
in	O
controlling	O
both	O
rat	O
and	O
human	B-GENE
T	I-GENE
/	I-GENE
EBP	I-GENE
gene	I-GENE
expression	O
.	O

A	O
newly	O
developed	O
broad-spectrum	O
fluoroquinolone	O
,	O
levofloxacin	O
(	O
LVFX	O
,	O
DR-3355	O
)	O
,	O
was	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
comparison	O
with	O
ciprofloxacin	O
(	O
CPFX	O
)	O
,	O
ofloxacin	O
(	O
OFLX	O
)	O
and	O
norfloxacin	O
(	O
NFLX	O
)	O
.	O

Previous	O
studies	O
indicated	O
that	O
the	O
20S	B-GENE
proteasome	I-GENE
is	O
a	O
catalytic	O
core	O
of	O
the	O
26S	B-GENE
proteolytic	I-GENE
complex	I-GENE
that	O
possesses	O
a	O
latent	O
multicatalytic	O
proteinase	B-GENE
activity	O
and	O
catalyzes	O
an	O
ATP-dependent	O
,	O
selective	O
breakdown	O
of	O
proteins	O
ligated	O
to	O
ubiquitin	B-GENE
.	O

The	O
fission	B-GENE
yeast	I-GENE
dsk1+	I-GENE
gene	I-GENE
,	O
a	O
multicopy	O
suppressor	O
for	O
cold-sensitive	O
dis1	B-GENE
mutants	I-GENE
,	O
encodes	O
a	O
novel	O
61-kd	B-GENE
protein	I-GENE
kinase	I-GENE
.	O

The	O
results	O
were	O
as	O
follows	O
:	O
1	O
)	O
Total	O
integrated	O
EMG	O
activity	O
of	O
FB	O
group	O
was	O
approximately	O
equal	O
in	O
any	O
occluded	O
position	O
,	O
whereas	O
that	O
of	O
CG	O
and	O
GF	O
group	O
varied	O
from	O
position	O
to	O
position	O
.	O

The	O
requirement	O
of	O
different	O
essential	O
fatty	O
acids	O
in	O
patients	O
with	O
total	O
parenteral	O
nutrition	O
after	O
heavy	O
injury	O
is	O
of	O
special	O
interest	O
with	O
respect	O
to	O
the	O
development	O
and	O
prognosis	O
of	O
shock	O
,	O
sepsis	O
or	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

These	O
consisted	O
of	O
beading	O
and	O
strictures	O
mainly	O
of	O
the	O
intrahepatic	O
biliary	O
tree	O
(	O
IHB	O
)	O
.	O

Comparison	O
of	O
the	O
genomes	O
of	O
PMTV	O
,	O
BNYVV	O
,	O
and	O
SBWMV	O
shows	O
that	O
furoviruses	O
exhibit	O
considerable	O
heterogeneity	O
in	O
genome	O
organization	O
.	O

Hybrid-selection	O
experiments	O
against	O
total	O
PB-inducible	O
RNA	O
were	O
performed	O
with	O
plasmid	O
DNA	O
derived	O
from	O
clones	O
enriched	O
in	O
PB-inducible	O
information	O
.	O

Sterol	O
analysis	O
of	O
the	O
disrupted	O
mutant	O
demonstrated	O
the	O
accumulation	O
of	O
ignosterol	O
,	O
indicating	O
a	O
loss	O
of	O
Erg24p	B-GENE
activity	O
.	O

However	O
,	O
tyrA	B-GENE
can	O
be	O
expressed	O
efficiently	O
from	O
an	O
internal	O
promoter	O
which	O
appears	O
to	O
lie	O
within	O
the	O
3'	O
portion	O
of	O
aroF	B-GENE
.	O

The	O
interaction	O
between	O
U	O
(	O
L	O
)	O
3	O
.	O

The	O
percutaneous	O
absorption	O
of	O
clindamycin	O
was	O
studied	O
in	O
healthy	O
male	O
volunteers	O
,	O
comparing	O
two	O
investigative	O
clindamycin	O
(	O
%	O
w	O
/	O
v	O
)	O
/	O
tretinoin	O
(	O
0	O
.	O
025%	O
w	O
/	O
v	O
)	O
gels	O
,	O
containing	O
clindamycin	O
phosphate	O
ester	O
and	O
clindamycin	O
HCl	O
,	O
respectively	O
,	O
relative	O
to	O
a	O
clindamycin	O
phosphate	O
lotion	O
(	O
1%	O
clindamycin	O
;	O
Dalacin	O
T	O
)	O
.	O

Urinary	B-GENE
N-acetylglucosaminidase	I-GENE
activity	O
per	O
mg	O
creatinine	O
did	O
not	O
differ	O
significantly	O
between	O
groups	O
.	O

To	O
those	O
of	O
us	O
who	O
are	O
not	O
satisfied	O
with	O
the	O
present	O
outlook	O
there	O
is	O
much	O
to	O
be	O
investigated	O
and	O
much	O
to	O
be	O
contributed	O
.	O

Ritanserin	O
is	O
a	O
new	O
substance	O
with	O
highly	O
selective	O
blocking	O
activity	O
on	O
S2	B-GENE
receptors	I-GENE
for	O
5-HT	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Mortality	O
on	O
the	O
last	O
ranch	O
was	O
particularly	O
severe	O
among	O
certain	O
segregated	O
groups	O
of	O
turkeys	O
that	O
included	O
toms	O
,	O
heavier	O
birds	O
,	O
and	O
birds	O
undergoing	O
a	O
stressful	O
event	O
such	O
as	O
artificial	O
insemination	O
.	O

NERVTRACK	O
contains	O
4000	O
anatomical	O
data	O
items	O
arranged	O
in	O
a	O
tree-like	O
manner	O
reflecting	O
structural	O
and	O
functional	O
relationships	O
.	O

Myocardial	O
infarction	O
in	O
patients	O
with	O
previous	O
bypass	O
surgery	O
.	O

Lung	O
density	O
increased	O
in	O
quartz-exposed	O
,	O
but	O
not	O
in	O
volcanic-ash-exposed	O
animals	O
.	O

Management	O
of	O
hypertension	O
in	O
the	O
elderly	O
.	O

By	O
using	O
the	O
full-length	O
cytoplasmic	O
domain	O
and	O
mutants	O
with	O
progressive	O
carboxy-terminal	O
deletions	O
,	O
internal	O
deletions	O
,	O
or	O
point	O
mutations	O
,	O
we	O
identified	O
the	O
first	O
150	O
amino	O
acid	O
residues	O
of	O
LIFR	B-GENE
as	O
the	O
minimal	O
region	O
necessary	O
for	O
signaling	O
.	O

In	O
the	O
predicted	O
transmembrane	O
domain	O
,	O
Casr-rs2	B-GENE
and	O
Casr-rs3	B-GENE
are	O
95%	O
identical	O
to	O
Casr-rs1	B-GENE
.	O

Serum	O
magnesium	O
in	O
79	O
patients	O
of	O
gynecologic	O
neoplasms	O
treated	O
with	O
cisplatin	O
and	O
their	O
controls	O
was	O
measured	O
.	O

A	O
new	O
intron	O
of	O
476	O
base	O
pairs	O
was	O
found	O
in	O
the	O
middle	O
of	O
the	O
5'-untranslated	O
leader	O
sequence	O
and	O
was	O
shown	O
to	O
robustly	O
enhance	O
the	O
promoter	O
activity	O
.	O

In	O
order	O
to	O
overcome	O
the	O
false	O
positive	O
readings	O
that	O
are	O
possible	O
in	O
sphincter	O
manometry	O
,	O
we	O
proposed	O
to	O
use	O
secretin	B-GENE
stimulated	O
endoscopic	O
ultrasound	O
(	O
SSEUS	O
)	O
to	O
measure	O
pancreatic	O
ductal	O
response	O
as	O
an	O
adjunctive	O
method	O
to	O
aid	O
and	O
supplement	O
the	O
diagnosis	O
.	O

CES4	B-GENE
on	O
a	O
multicopy	O
plasmid	O
was	O
unable	O
to	O
suppress	O
tif1-A79V	B-GENE
.	O

A	O
prospective	O
trial	O
was	O
undertaken	O
to	O
determine	O
(	O
1	O
)	O
clinical	O
characteristics	O
of	O
patients	O
with	O
chest	O
pain	O
;	O
(	O
2	O
)	O
value	O
of	O
cardiac	O
markers	O
troponin	B-GENE
T	I-GENE
,	O
myoglobin	B-GENE
and	O
CK-MB	B-GENE
mass	O
in	O
differentiating	O
cardiac	O
and	O
noncardiac	O
chest	O
pain	O
;	O
(	O
3	O
)	O
the	O
proportion	O
of	O
patients	O
with	O
ACS	O
in	O
whom	O
these	O
markers	O
provided	O
helpful	O
additional	O
information	O
on	O
admission	O
and	O
afterwards	O
.	O

Mutational	O
analysis	O
of	O
the	O
major	O
homology	O
region	O
of	O
Mason-Pfizer	O
monkey	O
virus	O
by	O
use	O
of	O
saturation	O
mutagenesis	O
.	O

We	O
report	O
here	O
the	O
isolation	O
of	O
a	O
full-length	O
cDNA	O
clone	O
coding	O
for	O
a	O
hitherto	O
undiscovered	O
isoform	O
of	O
the	O
bovine	B-GENE
C-subunit	I-GENE
.	O

STUDY	O
OBJECTIVE	O
:	O
This	O
study	O
assessed	O
several	O
methodological	O
aspects	O
related	O
to	O
the	O
quality	O
of	O
published	O
controlled	O
clinical	O
trials	O
(	O
CCTs	O
)	O
in	O
relation	O
to	O
the	O
participation	O
of	O
an	O
epidemiologist	O
/	O
biostatistician	O
(	O
E	O
/	O
B	O
)	O
.	O

Neuronal	O
signaling	O
properties	O
are	O
largely	O
determined	O
by	O
the	O
quantity	O
and	O
combination	O
of	O
ion	O
channels	O
expressed	O
.	O

Triumph	O
of	O
Leninist	O
national	O
policy	O
.	O

If	O
no	O
reply	O
was	O
received	O
,	O
telephone	O
contact	O
or	O
home	O
visits	O
were	O
made	O
.	O

The	O
effect	O
of	O
sodium	O
saccharin	O
in	O
the	O
diet	O
on	O
caecal	O
microflora	O
.	O

A	O
cDNA	O
encoding	O
the	O
amino-terminal	O
17%	O
of	O
apoB	B-GENE
(	O
apoB17	B-GENE
)	O
was	O
fused	O
to	O
a	O
cDNA	O
coding	O
for	O
the	O
last	O
37	O
amino	O
acids	O
of	O
decay-accelerating	B-GENE
factor	I-GENE
(	O
DAF	B-GENE
)	O
,	O
which	O
contains	O
the	O
signal	O
for	O
glycosylphosphatidylinositol	O
anchor	O
attachment	O
.	O

It	O
then	O
merged	O
with	O
right	O
ventricular	O
wavefronts	O
ending	O
along	O
the	O
right	O
ventricular	O
anterior	O
atrioventricular	O
groove	O
and	O
outflow	O
tract	O
.	O

Selective	O
visual	O
attention	O
involves	O
dynamic	O
interplay	O
between	O
attentional	O
control	O
systems	O
and	O
sensory	O
brain	O
structures	O
.	O

A	O
variety	O
of	O
receptor-mediated	O
signaling	O
pathways	O
are	O
controlled	O
by	O
both	O
positive	O
and	O
negative	O
extracellular	O
regulators	O
.	O

Comparison	O
with	O
the	O
sequence	O
databanks	O
show	O
that	O
Tactile	B-GENE
is	O
a	O
member	O
of	O
the	O
immunoglobulin	B-GENE
gene	I-GENE
superfamily	I-GENE
,	O
with	O
similarity	O
to	O
Drosophila	B-GENE
amalgam	I-GENE
,	O
the	O
melanoma	B-GENE
Ag	I-GENE
MUC-18	I-GENE
,	O
members	O
of	O
the	O
carcinoembryonic	B-GENE
Ag	I-GENE
family	I-GENE
,	O
the	O
poliovirus	B-GENE
receptor	I-GENE
,	O
and	O
the	O
neural	B-GENE
cell	I-GENE
adhesion	I-GENE
molecule	I-GENE
.	O

Statistical	O
Analysis	O
included	O
ANOVA	O
,	O
the	O
Pearson	O
Product	O
Moment	O
Correlation	O
Coefficient	O
,	O
Principal	O
Components	O
Analysis	O
and	O
Discriminant	O
Function	O
Analysis	O
and	O
the	O
calculation	O
of	O
Cronbach's	O
alpha	O
(	O
alpha	O
)	O
RESULTS	O
:	O
Both	O
Sensitivity	O
and	O
specificity	O
exceed	O
90	O
.	O
00	O
at	O
23	O
/	O
24	O
,	O
Chronbach's	O
alpha	O
for	O
the	O
total	O
scale	O
was	O
equal	O
to	O
0	O
.	O
95	O
.	O

Mnt	B-GENE
:	I-GENE
Max	I-GENE
complexes	I-GENE
also	O
efficiently	O
suppress	O
Myc-dependent	O
activation	O
from	O
the	O
same	O
promoter	O
.	O

An	O
epidemiological	O
survey	O
of	O
rheumatic	O
valve	O
disease	O
and	O
rheumatic	O
fever	O
in	O
primary	O
and	O
secondary	O
school	O
students	O
in	O
Jiangxi	O
Province	O
.	O

Haplotype	O
mapping	O
and	O
sequence	O
analysis	O
of	O
the	O
mouse	O
Nramp	B-GENE
gene	I-GENE
predict	O
susceptibility	O
to	O
infection	O
with	O
intracellular	O
parasites	O
.	O

Because	O
RNase	B-GENE
III	I-GENE
host	I-GENE
mutants	I-GENE
are	O
defective	O
in	O
sib	B-GENE
regulation	O
,	O
processing	O
of	O
the	O
PL	B-GENE
mRNA	I-GENE
at	O
sib	B-GENE
by	O
this	O
endoribonuclease	B-GENE
may	O
cause	O
int	B-GENE
mRNA	I-GENE
decay	O
and	O
decrease	O
int	B-GENE
synthesis	O
.	O

Transient	O
cotransfection	O
of	O
tat	B-GENE
cDNA	I-GENE
in	O
sense	O
orientation	O
(	O
tat	B-GENE
/	I-GENE
S	I-GENE
)	O
,	O
together	O
with	O
a	O
plasmid	O
containing	O
the	O
c-fos	B-GENE
promoter	I-GENE
(	O
FC3	B-GENE
,	O
from	O
-711	O
to	O
+42	O
)	O
in	O
front	O
of	O
the	O
bacterial	B-GENE
chloramphenicol	I-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
gene	O
significantly	O
enhanced	O
CAT	B-GENE
activity	O
in	O
Jurkat	O
cells	O
activated	O
by	O
the	O
addition	O
of	O
15%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
or	O
5	O
micrograms	O
/	O
mL	O
phytohemagglutinin	B-GENE
plus	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
U937	O
cells	O
activated	O
by	O
15%	O
FCS	O
or	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
PMA	O
.	O

The	O
most	O
important	O
one	O
among	O
them	O
is	O
Cyclosporin	O
A	O
,	O
which	O
is	O
a	O
selective	O
immunosuppressive	O
drug	O
.	O

A	O
genetic	O
complementation	O
system	O
was	O
developed	O
in	O
which	O
tobacco	B-GENE
etch	I-GENE
virus	I-GENE
(	I-GENE
TEV	I-GENE
)	I-GENE
polymerase	I-GENE
(	O
NIb	B-GENE
)	O
-expressing	O
transgenic	O
plants	O
or	O
protoplasts	O
were	O
inoculated	O
with	O
NIb-defective	O
TEV	B-GENE
mutants	I-GENE
.	O

Furthermore	O
,	O
as	O
in	O
the	O
human	O
gene	O
,	O
the	O
3'	O
end	O
of	O
the	O
Cacna1f	B-GENE
gene	I-GENE
maps	O
within	O
5	O
kb	O
of	O
the	O
5'	O
end	O
of	O
the	O
mouse	B-GENE
synaptophysin	I-GENE
gene	I-GENE
in	O
a	O
region	O
orthologous	O
to	O
Xp11	O
.	O
23	O
.	O

The	O
following	O
evidence	O
indicates	O
that	O
the	O
69-kD	O
protein	O
is	O
a	O
common	O
,	O
rather	O
than	O
a	O
U1-specific	O
,	O
protein	O
,	O
possibly	O
associating	O
with	O
the	O
snRNP	B-GENE
core	I-GENE
particles	I-GENE
by	O
protein-protein	O
interaction	O
.	O

The	O
logistic	O
regression	O
analysis	O
of	O
the	O
manual	O
method	O
(	O
percentage	O
normal	O
morphology	O
)	O
and	O
IVOS	O
indicated	O
that	O
both	O
were	O
predictors	O
of	O
fertilization	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
BOX	B-GENE
DNA	I-GENE
enhances	O
transcription	O
from	O
the	O
thymidine	B-GENE
kinase	I-GENE
(	O
TK	B-GENE
)	O
promoter	O
in	O
various	O
EC	O
cells	O
.	O

The	O
clinical	O
efficacy	O
rates	O
evaluated	O
in	O
151	O
cases	O
(	O
KS-R1	O
group	O
in	O
77	O
cases	O
,	O
oral	O
group	O
in	O
74	O
cases	O
)	O
on	O
standard	O
criteria	O
of	O
committee	O
members	O
were	O
88	O
.	O
3%	O
for	O
the	O
KS-R1	O
group	O
and	O
86	O
.	O
5%	O
for	O
the	O
oral	O
group	O
,	O
respectively	O
.	O

We	O
show	O
here	O
that	O
the	O
third	O
SH3	B-GENE
domain	I-GENE
binds	O
to	O
Sos	B-GENE
,	O
a	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
for	O
Ras	B-GENE
and	O
Rac	B-GENE
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Its	O
predicted	O
amino	O
acid	O
sequence	O
shows	O
extensive	O
homology	O
to	O
those	O
of	O
Drosophila	B-GENE
hsp70	I-GENE
,	O
trout	B-GENE
hsp70	I-GENE
,	O
Xenopus	B-GENE
hsp70	I-GENE
,	O
yeast	B-GENE
hsp70	I-GENE
,	O
and	O
some	O
homology	O
to	O
the	O
heat-inducible	B-GENE
dnaK	I-GENE
gene	I-GENE
product	I-GENE
of	O
Escherichia	O
coli	O
.	O

A	O
dose	O
of	O
3	O
and	O
6	O
micrograms	O
/	O
kg	O
/	O
day	O
GM-CSF	O
reduces	O
the	O
severity	O
of	O
neutropenia	O
and	O
thrombocytopenia	O
after	O
carboplatin-cyclophosphamide	O
chemotherapy	O
,	O
which	O
may	O
lead	O
to	O
more	O
effective	O
chemotherapy	O
for	O
ovarian	O
cancer	O
in	O
the	O
future	O
.	O

SH2D1A	B-GENE
protein	I-GENE
levels	O
are	O
up-regulated	O
by	O
CD40	B-GENE
cross-linking	O
and	O
down-regulated	O
by	O
B	B-GENE
cell	I-GENE
receptor	I-GENE
ligation	O
.	O

[	O
82Br	O
]	O
MISO	O
was	O
prepared	O
by	O
irradiating	O
samples	O
of	O
Br-MISO	O
in	O
a	O
SLOWPOKE	O
reactor	O
for	O
2	O
h	O
at	O
a	O
thermal	O
neutron	O
flux	O
of	O
10	O
(	O
12	O
)	O
n	O
cm-2	O
s-1	O
.	O

A	O
partial	O
cDNA	O
sequence	O
indicated	O
that	O
the	O
T	B-GENE
lymphocyte	I-GENE
early-activation	I-GENE
gene	I-GENE
(	O
Tea	B-GENE
)	O
encodes	O
a	O
protein	O
related	O
to	O
the	O
dual-function	O
ecotropic	B-GENE
retrovirus	I-GENE
receptor	I-GENE
/	I-GENE
cationic	I-GENE
amino	I-GENE
acid	I-GENE
transporter	I-GENE
(	O
ecoR	B-GENE
/	I-GENE
CAT1	I-GENE
)	O
,	O
and	O
RNA	O
blots	O
suggested	O
highest	O
Tea	B-GENE
expression	O
in	O
T	O
lymphocytes	O
and	O
liver	O
(	O
MacLeod	O
,	O
C	O
.	O
L	O
.	O
,	O
Finley	O
,	O
K	O
.	O
,	O
Kakuda	O
,	O
D	O
.	O

Vitrectomy	O
with	O
an	O
alternative	O
instrument	O
system	O
.	O
pp	O
.	O

Precipitating	O
antibodies	O
for	O
Thermophilic	O
actinomycetes	O
and	O
M	O
.	O
f	O
.	O
were	O
negative	O
.	O

UbiA	B-GENE
is	O
also	O
unique	O
among	O
known	O
polyubiquitin	B-GENE
genes	I-GENE
in	O
containing	O
four	O
cis-spliced	O
introns	O
within	O
its	O
coding	O
sequence	O
.	O

Stress-inducible	B-GENE
protein	I-GENE
kinases	I-GENE
capable	O
of	O
activating	O
c-jun	B-GENE
expression	O
include	O
stress-activated	B-GENE
protein	I-GENE
kinase	I-GENE
/	I-GENE
c-Jun	I-GENE
N-terminal	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
SAPK	B-GENE
/	I-GENE
JNK	I-GENE
)	O
and	O
p38	B-GENE
members	O
of	O
the	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
(	O
MAPK	B-GENE
)	O
superfamily	O
of	O
signaling	O
molecules	O
.	O

The	O
variable	O
regions	O
of	O
vertebrate	O
striated	O
TnT	B-GENE
isoforms	I-GENE
reflect	O
the	O
subsequent	O
addition	O
and	O
modification	O
of	O
genomic	O
sequences	O
to	O
give	O
rise	O
to	O
members	O
of	O
the	O
TnT	B-GENE
multigene	I-GENE
family	I-GENE
.	O

RESULTS	O
:	O
Factors	O
associated	O
with	O
significantly	O
(	O
P	O
<	O
.	O
05	O
)	O
increased	O
risk	O
of	O
treatment	O
failure	O
in	O
a	O
Cox	O
multivariate	O
analysis	O
included	O
age	O
older	O
than	O
45	O
years	O
(	O
relative	O
hazard	O
,	O
1	O
.	O
17	O
;	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
02-1	O
.	O
33	O
)	O
,	O
Karnofsky	O
performance	O
score	O
less	O
than	O
90%	O
(	O
1	O
.	O
27	O
;	O
95%	O
CI	O
,	O
1	O
.	O
07-1	O
.	O
51	O
)	O
,	O
absence	O
of	O
hormone	O
receptors	O
(	O
1	O
.	O
31	O
;	O
95%	O
CI	O
,	O
1	O
.	O
15-1	O
.	O
51	O
)	O
,	O
prior	O
use	O
of	O
adjuvant	O
chemotherapy	O
(	O
1	O
.	O
31	O
;	O
95%	O
CI	O
,	O
1	O
.	O
10-1	O
.	O
56	O
)	O
,	O
initial	O
disease-free	O
survival	O
interval	O
after	O
adjuvant	O
treatment	O
of	O
no	O
more	O
than	O
18	O
months	O
(	O
1	O
.	O
99	O
;	O
95%	O
CI	O
,	O
1	O
.	O
62-2	O
.	O
43	O
)	O
,	O
metastases	O
in	O
the	O
liver	O
(	O
1	O
.	O
47	O
;	O
95%	O
CI	O
,	O
1	O
.	O
20-1	O
.	O
80	O
)	O
or	O
central	O
nervous	O
system	O
(	O
1	O
.	O
56	O
;	O
95%	O
CI	O
,	O
0	O
.	O
99-2	O
.	O
46	O
[	O
approaches	O
significance	O
]	O
)	O
vs	O
soft	O
tissue	O
,	O
bone	O
,	O
or	O
lung	O
,	O
3	O
or	O
more	O
sites	O
of	O
metastatic	O
disease	O
(	O
1	O
.	O
32	O
;	O
95%	O
CI	O
,	O
1	O
.	O
13-1	O
.	O
54	O
)	O
,	O
and	O
incomplete	O
response	O
vs	O
complete	O
response	O
to	O
standard-dose	O
chemotherapy	O
(	O
1	O
.	O
65	O
;	O
95%	O
CI	O
,	O
1	O
.	O
36-1	O
.	O
99	O
)	O
.	O

Alternative	O
splicing	O
of	O
the	O
cytoplasmic	O
tail	O
appears	O
to	O
generate	O
multiple	O
PECAM-1	B-GENE
isoforms	I-GENE
that	O
may	O
regulate	O
phosphorylation	O
,	O
cytoskeletal	O
association	O
,	O
and	O
affinity	O
modulation	O
of	O
the	O
mature	O
protein	O
.	O

In	O
26	O
patients	O
with	O
angina	O
pectoris	O
,	O
the	O
changes	O
of	O
LVEF	O
,	O
LVESV	O
and	O
PSP	O
/	O
LVESV	O
were	O
more	O
sensitive	O
for	O
the	O
detection	O
of	O
exercise-induced	O
ischemia	O
than	O
the	O
appearance	O
of	O
chest	O
pain	O
and	O
the	O
changes	O
of	O
ECG	O
.	O

Here	O
,	O
we	O
have	O
used	O
specific	O
antibody	O
to	O
identify	O
and	O
characterize	O
the	O
SSN6	B-GENE
protein	I-GENE
.	O

Many	O
mammary	O
tumors	O
induced	O
by	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
contain	O
a	O
provirus	O
in	O
the	O
same	O
region	O
of	O
the	O
host-cell	O
genome	O
,	O
leading	O
to	O
expression	O
of	O
a	O
putative	O
cellular	O
oncogene	O
called	O
int-1	B-GENE
.	O

Bifunctionality	O
of	O
the	O
AcMNPV	B-GENE
homologous	I-GENE
region	I-GENE
sequence	I-GENE
(	O
hr1	B-GENE
)	O
:	O
enhancer	O
and	O
ori	O
functions	O
have	O
different	O
sequence	O
requirements	O
.	O

Grossly	O
,	O
the	O
incidence	O
of	O
a	O
type	O
IIc	O
carcinoma	O
was	O
46	O
.	O
5%	O
and	O
that	O
of	O
a	O
IIc	O
+	O
III	O
type	O
was	O
20	O
.	O
5%	O
,	O
respectively	O
.	O

In	O
XO	O
males	O
,	O
two	O
her-1	B-GENE
mRNAs	I-GENE
,	O
her-1a	B-GENE
and	O
her-1b	B-GENE
,	O
are	O
transcribed	O
from	O
two	O
separate	O
promoters	O
:	O
P1	O
,	O
located	O
in	O
the	O
5'-flanking	O
region	O
,	O
and	O
P2	O
,	O
located	O
in	O
the	O
large	O
second	O
intron	O
.	O

One	O
hundred	O
fifty	O
patients	O
were	O
reviewed	O
at	O
1	O
year	O
after	O
arthroplasty	O
.	O

The	O
human	B-GENE
CD38	I-GENE
gene	I-GENE
consists	O
of	O
8	O
exons	O
that	O
extend	O
more	O
than	O
77	O
kb	O
on	O
the	O
human	O
genome	O
.	O

MED1	B-GENE
has	O
a	O
weak	O
glycosylase	B-GENE
activity	O
on	O
the	O
mutagenic	O
adduct	O
3	O
,	O
N	O
(	O
4	O
)	O
-ethenocytosine	O
,	O
a	O
metabolite	O
of	O
vinyl	O
chloride	O
and	O
ethyl	O
carbamate	O
.	O

Screening	O
of	O
asthma	O
patients	O
by	O
determination	O
of	O
IgE	B-GENE
and	O
by	O
comprehension	O
of	O
spectrum	O
of	O
allergospecific	B-GENE
IgE	I-GENE
antibodies	I-GENE
.	O

To	O
evaluate	O
the	O
relative	O
accuracy	O
of	O
continuous	O
wave	O
(	O
CW	O
)	O
and	O
high	O
pulse	O
repetition	O
frequency	O
(	O
HPRF	O
)	O
Doppler	O
for	O
estimating	O
aortic	O
transvalvular	O
pressure	O
gradients	O
,	O
Doppler	O
examinations	O
with	O
both	O
devices	O
were	O
obtained	O
in	O
87	O
consecutive	O
patients	O
with	O
aortic	O
valve	O
disease	O
.	O

PABP	B-GENE
is	O
a	O
modular	O
protein	O
,	O
with	O
four	O
N-terminal	O
RNA-binding	O
domains	O
and	O
an	O
extensive	O
C	O
terminus	O
.	O

Pit-1	B-GENE
is	O
a	O
tissue-specific	O
POU	B-GENE
domain	I-GENE
factor	I-GENE
obligatory	O
for	O
the	O
appearance	O
of	O
three	O
cell	O
phenotypes	O
in	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Deletion	O
of	O
an	O
intergenic	O
DNA-binding	O
site	O
for	O
this	O
complex	O
from	O
a	O
human	B-GENE
beta-globin	I-GENE
locus	I-GENE
construct	I-GENE
results	O
in	O
delayed	O
human	B-GENE
gamma-	I-GENE
to	O
beta-globin	B-GENE
switching	O
in	O
transgenic	O
mice	O
,	O
suggesting	O
that	O
the	O
PYR	B-GENE
complex	I-GENE
acts	O
to	O
facilitate	O
the	O
switch	O
.	O

Proteins	O
immunoprecipitated	O
from	O
lysates	O
of	O
control-	O
and	O
VEGF-stimulated	O
BAEC	O
with	O
antisera	O
to	O
phospholipase	B-GENE
C-gamma	I-GENE
(	O
PLC-gamma	B-GENE
)	O
were	O
fractionated	O
by	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
and	O
transferred	O
to	O
Immobilon-P	O
.	O

Dissociation	O
and	O
complexation	O
of	O
the	O
fluoroquinolone	O
antimicrobials--an	O
update	O
.	O

These	O
data	O
suggest	O
that	O
other	O
Ras	B-GENE
effectors	I-GENE
can	O
collaborate	O
with	O
PI	B-GENE
3-kinase	I-GENE
and	O
with	O
each	O
other	O
to	O
activate	O
Pak	B-GENE
.	O

Blood	O
flow	O
and	O
velocity	O
(	O
measured	O
using	O
Doppler	O
ultrasound	O
)	O
gradually	O
decreased	O
during	O
diastole	O
and	O
ultimately	O
reversed	O
in	O
direction	O
as	O
cotyledon	O
resistance	O
was	O
increased	O
up	O
to	O
14	O
fold	O
.	O

The	O
ORF1	O
product	O
was	O
required	O
for	O
competence	O
,	O
while	O
ORF2	O
,	O
which	O
was	O
cotranscribed	O
with	O
ORF1	O
and	O
encoded	O
a	O
predicted	O
protein	O
of	O
126	O
amino	O
acids	O
,	O
was	O
not	O
.	O

Harel	O
,	O
E	O
.	O
M	O
.	O

Daily	O
and	O
seasonal	O
rhythmicity	O
in	O
the	O
methylation	O
of	O
pineal	O
indolic	O
compounds	O
in	O
adult	O
male	O
golden	O
hamsters	O
,	O
kept	O
under	O
natural	O
conditions	O
.	O

Seventy-one	O
percent	O
of	O
patients	O
treated	O
with	O
ticarcillin	O
alone	O
responded	O
favorably	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
TATA-less	O
promoter	O
for	O
the	O
human	B-GENE
beta	I-GENE
3	I-GENE
integrin	I-GENE
gene	I-GENE
.	O

OBJECTIVE	O
:	O
To	O
demonstrate	O
a	O
lack	O
of	O
effect	O
of	O
steady-state	O
concentrations	O
of	O
cilomilast	O
,	O
a	O
new	O
oral	O
phosphodiesterase	B-GENE
4	I-GENE
inhibitor	O
for	O
the	O
treatment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
on	O
warfarin-induced	O
anticoagulation	O
.	O

Histopathologic	O
response	O
of	O
gingival	O
tissues	O
to	O
hemodent	O
and	O
aluminum	O
chloride	O
solutions	O
as	O
tissue	O
displacement	O
materials	O
.	O

Deglutition	O
is	O
considered	O
to	O
be	O
immature	O
in	O
infants	O
and	O
to	O
mature	O
postnatally	O
.	O

Antidepressant-like	O
properties	O
of	O
some	O
serotonin	B-GENE
receptor	I-GENE
ligands	O
and	O
calcium	O
channel	O
antagonists	O
measured	O
with	O
the	O
forced	O
swimming	O
test	O
in	O
mice	O
.	O

Regulation	O
of	O
avian	B-GENE
fibroblast	I-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
1	I-GENE
(	O
FGFR-1	B-GENE
)	O
gene	O
expression	O
during	O
skeletal	O
muscle	O
differentiation	O
.	O

Data	O
on	O
the	O
line	O
spread	O
function	O
(	O
LSF	O
)	O
were	O
obtained	O
from	O
the	O
image	O
of	O
a	O
0	O
.	O
2	O
mm	O
wide	O
slit	O
between	O
tungsten	O
blocks	O
that	O
were	O
positioned	O
at	O
the	O
isocentre	O
in	O
front	O
of	O
a	O
polystyrene	O
phantom	O
.	O

To	O
confirm	O
the	O
binding	O
of	O
protein	O
to	O
these	O
sites	O
in	O
cells	O
,	O
we	O
carried	O
out	O
an	O
in	O
vivo	O
genomic	O
footprinting	O
analysis	O
of	O
this	O
portion	O
of	O
the	O
TGF	B-GENE
alpha	I-GENE
promoter	I-GENE
in	O
normal	O
and	O
transformed	O
rat	O
liver	O
epithelial	O
cell	O
lines	O
that	O
express	O
the	O
endogenous	O
gene	O
at	O
varying	O
levels	O
.	O

Grade	O
3-4	O
mucositis	O
was	O
present	O
in	O
13%	O
of	O
the	O
cycles	O
.	O

Subdural	O
electrodes	O
may	O
yield	O
larger	O
VEP	O
amplitudes	O
than	O
skull	O
or	O
scalp	O
electrodes	O
.	O

The	O
desirability	O
function	O
is	O
based	O
on	O
the	O
search	O
for	O
a	O
global	O
optimum	O
[	O
D	O
=	O
f	O
(	O
Y1	O
,	O
Y2	O
,	O
.	O
.	O
.	O
,	O
Yn	O
)	O
]	O
by	O
the	O
transformation	O
of	O
the	O
measured	O
property	O
to	O
a	O
dimensionless	O
scale	O
for	O
each	O
criterion	O
.	O

Three	O
groups	O
of	O
patients	O
who	O
had	O
undergone	O
subtotal	O
thyroidectomy	O
for	O
Graves's	O
disease	O
,	O
toxic	O
multinodular	O
goitre	O
,	O
or	O
euthyroid	O
multinodular	O
goitre	O
12	O
to	O
15	O
years	O
before	O
and	O
in	O
whom	O
a	O
normal	O
serum	O
thyroxine	O
(	O
T-4	O
)	O
level	O
was	O
found	O
were	O
each	O
divided	O
into	O
two	O
subgroups	O
on	O
the	O
basis	O
of	O
a	O
normal	O
or	O
a	O
raised	O
serum	O
thyrotrophin	O
concentration	O
.	O

(	O
ii	O
)	O
opening	O
of	O
KATP	O
attenuates	O
,	O
inhibition	O
of	O
the	O
channel	O
exacerbates	O
functional	O
consequences	O
of	O
coronary	O
occlusion	O
,	O
and	O
(	O
iii	O
)	O
KATP	O
opening	O
attenuates	O
reperfusion-induced	O
VF	O
,	O
but	O
it	O
triggers	O
ischemia-induced	O
VF	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Increased	O
cortical	O
thickness	O
and	O
geometric	O
properties	O
of	O
left	O
MCB-IV	O
and	O
-V	O
of	O
Greyhounds	O
,	O
together	O
with	O
altered	O
turnover	O
and	O
orientation	O
of	O
osteons	O
in	O
the	O
dorsal	O
quadrants	O
of	O
left	O
MCB	O
,	O
are	O
site-specific	O
adaptive	O
responses	O
associated	O
with	O
asymmetric	O
cyclic	O
loading	O
as	O
a	O
result	O
of	O
racing	O
on	O
circular	O
tracks	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
SRm160	B-GENE
/	I-GENE
300	I-GENE
is	O
required	O
for	O
a	O
purine-rich	O
ESE	B-GENE
to	O
promote	O
the	O
splicing	O
of	O
a	O
pre-mRNA	O
derived	O
from	O
the	O
Drosophila	B-GENE
doublesex	I-GENE
gene	I-GENE
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
genomic	O
fragment	O
containing	O
the	O
most	O
distal	O
5'	O
sequences	O
of	O
the	O
major	O
GGT	B-GENE
mRNA	I-GENE
in	O
HepG2	O
cells	O
.	O

The	O
seventh	O
cysteine	O
residue	O
of	O
CTSE	B-GENE
is	O
located	O
within	O
the	O
activation	O
peptide	O
region	O
of	O
the	O
proenzyme	O
.	O

(	O
5	O
)	O
No	O
changes	O
were	O
observed	O
in	O
the	O
gastric	O
venous	O
blood	O
flow	O
by	O
continuous	O
intravenous	O
injection	O
of	O
cimetidine	O
,	O
but	O
by	O
rapid	O
injection	O
both	O
the	O
flow	O
was	O
augmented	O
and	O
the	O
systemic	O
blood	O
pressure	O
decreased	O
transiently	O
.	O

To	O
determine	O
the	O
signal	B-GENE
recognition	I-GENE
particle	I-GENE
(	I-GENE
SRP	I-GENE
)	I-GENE
-SRP	I-GENE
receptor	I-GENE
(	I-GENE
Srb	I-GENE
)	I-GENE
system	I-GENE
in	I-GENE
Bacillus	I-GENE
subtilis	I-GENE
(	I-GENE
Bs	I-GENE
)	I-GENE
,	O
we	O
cloned	O
the	O
Bs	B-GENE
srb	I-GENE
gene	I-GENE
,	O
which	O
encodes	O
a	O
homologue	O
of	O
the	O
mammalian	B-GENE
SRP	I-GENE
receptor	I-GENE
alpha-subunit	I-GENE
[	O
Oguro	O
et	O
al	O
.	O
,	O
DNA	O
Res	O
.	O

TREB7	B-GENE
and	O
TREB36	B-GENE
protected	O
all	O
three	O
repeats	O
of	O
the	O
21	O
bp	O
,	O
but	O
TREB5	B-GENE
protected	O
only	O
the	O
second	O
repeat	O
.	O

Biol	O
.	O

Preheparin	O
LPL	O
mass	O
level	O
did	O
not	O
significantly	O
differ	O
in	O
individuals	O
from	O
19	O
to	O
70	O
years	O
old	O
,	O
for	O
both	O
men	O
and	O
women	O
.	O

OODG	O
is	O
a	O
diagnostic	O
method	O
permitting	O
assessment	O
of	O
ocular	O
pulse	O
curves	O
and	O
objective	O
determination	O
of	O
blood	O
pressures	O
in	O
the	O
ophthalmic	O
circulatory	O
system	O
(	O
retinal	O
and	O
ciliary	O
arterial	O
blood	O
pressures	O
)	O
simultaneously	O
for	O
both	O
eyes	O
,	O
without	O
dilatation	O
of	O
the	O
pupils	O
.	O

The	O
carboxyl-terminal	B-GENE
CCCC	I-GENE
module	I-GENE
is	O
structurally	O
related	O
to	O
the	O
DNA-binding	O
domain	O
of	O
the	O
erythroid	B-GENE
transcription	I-GENE
factor	I-GENE
GATA-1	I-GENE
.	O

The	O
median	O
levels	O
of	O
particles	O
with	O
50%	O
cut-off	O
aerodynamic	O
diameters	O
of	O
10	O
(	O
PM10	O
)	O
and	O
2	O
.	O
5	O
microm	O
(	O
PM2	O
.	O
5	O
)	O
were	O
170	O
(	O
range	O
103-613	O
)	O
and	O
95	O
(	O
range	O
61-218	O
)	O
micro	O
x	O
m-3	O
,	O
respectively	O
.	O

The	O
novel	O
approach	O
to	O
insulin	B-GENE
administration	O
known	O
as	O
chronic	O
intermittent	O
intravenous	O
insulin	B-GENE
therapy	O
(	O
CIIIT	O
)	O
delivers	O
insulin	B-GENE
in	O
a	O
pulsatile	O
fashion	O
and	O
achieves	O
physiological	O
insulin	B-GENE
concentration	O
in	O
the	O
portal	O
vein	O
.	O

The	O
kallistatin	B-GENE
gene	I-GENE
was	O
localized	O
by	O
in	O
situ	O
hybridization	O
to	O
human	O
chromosome	O
14q31-q32	O
.	O
1	O
,	O
close	O
to	O
the	O
serpin	B-GENE
genes	I-GENE
encoding	O
alpha	B-GENE
1-antichymotrypsin	I-GENE
,	O
protein	B-GENE
C	I-GENE
inhibitor	I-GENE
,	O
alpha	B-GENE
1-antitrypsin	I-GENE
,	O
and	O
corticosteroid-binding	B-GENE
globulin	I-GENE
.	O

The	O
shift	O
to	O
the	O
nonpermissive	O
temperature	O
is	O
accompanied	O
by	O
the	O
loss	O
of	O
guanyl	O
nucleotide-dependent	O
activity	O
of	O
adenylylcyclase	B-GENE
in	O
vitro	O
.	O

In	O
vitro	O
translation	O
of	O
the	O
mTRF1	B-GENE
cDNA	I-GENE
resulted	O
in	O
a	O
56	O
kDa	O
protein	O
that	O
binds	O
to	O
TTAGGG	B-GENE
repeat	I-GENE
arrays	O
.	O
mTRF1	B-GENE
displayed	O
the	O
same	O
sequence	O
specificity	O
as	O
hTRF1	B-GENE
,	O
preferring	O
arrays	O
of	O
TTAGGG	B-GENE
repeats	I-GENE
as	O
a	O
binding	O
substrate	O
over	O
TTAGGC	B-GENE
and	O
TTGGGG	B-GENE
repeats	I-GENE
.	O

4	O
.	O

Our	O
study	O
differs	O
from	O
previous	O
studies	O
in	O
that	O
it	O
is	O
limited	O
to	O
one	O
diagnostic	O
entity	O
,	O
yet	O
at	O
the	O
same	O
time	O
evaluates	O
a	O
broad	O
range	O
of	O
social	O
and	O
work-related	O
factors	O
in	O
disability	O
.	O

From	O
these	O
results	O
,	O
we	O
concluded	O
that	O
this	O
ORF	O
is	O
the	O
FRDS	B-GENE
gene	I-GENE
.	O

Oral	O
candidiasis	O
.	O

Intron-exon	O
structure	O
of	O
the	O
porcine	B-GENE
I	I-GENE
kappa	I-GENE
B	I-GENE
alpha-encoding	I-GENE
gene	I-GENE
.	O

Interleukin-6	B-GENE
(	O
IL-6	B-GENE
)	O
is	O
a	O
pleiotropic	O
cytokine	O
,	O
which	O
is	O
involved	O
in	O
inflammatory	O
and	O
immune	O
responses	O
,	O
acute	O
phase	O
reactions	O
,	O
and	O
hematopoiesis	O
.	O

Bacterial	O
metabolism	O
of	O
4-chlorophenoxyacetate	O
.	O

Serotonin	O
levels	O
in	O
infant	O
hypothyroidism	O
.	O

The	O
character	O
of	O
specific	O
immune	O
response	O
in	O
101	O
immunized	O
children	O
and	O
in	O
12	O
adults	O
belonging	O
to	O
a	O
high	O
risk	O
group	O
with	O
respect	O
to	O
VHB	O
.	O

A	O
short	O
history	O
of	O
dermatology	O
in	O
Lagos	O
,	O
Nigeria	O
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
myr	B-GENE
4	I-GENE
(	O
myosin	B-GENE
from	I-GENE
rat	I-GENE
)	O
,	O
the	O
first	O
mammalian	B-GENE
myosin	I-GENE
I	I-GENE
that	O
is	O
not	O
closely	O
related	O
to	O
brush	O
border	O
myosin	B-GENE
I	I-GENE
.	O

Only	O
nine	O
patients	O
were	O
offered	O
surgery	O
(	O
six	O
were	O
resected	O
and	O
three	O
were	O
found	O
inoperable	O
)	O
.	O

The	O
time	O
course	O
of	O
RNA1	B-GENE
replication	O
and	O
RNA3	B-GENE
synthesis	O
in	O
induced	O
yeast	O
paralleled	O
that	O
in	O
yeast	O
transfected	O
with	O
natural	O
FHV	O
virion	O
RNA	O
.	O

The	O
relevance	O
of	O
these	O
elements	O
in	O
conferring	O
anaerobic	O
induction	O
of	O
gpc4	B-GENE
gene	I-GENE
expression	O
is	O
discussed	O
.	O

The	O
genomic	O
structure	O
and	O
chromosomal	O
location	O
of	O
the	O
human	B-GENE
TR2	I-GENE
orphan	I-GENE
receptor	I-GENE
,	O
a	O
member	O
of	O
the	O
steroid	B-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

We	O
identify	O
considerable	O
spatio-temporal	O
similarities	O
between	O
reported	O
expression	O
patterns	O
of	O
Ypr10	B-GENE
genes	I-GENE
and	O
ribonuclease	B-GENE
genes	I-GENE
,	O
which	O
,	O
together	O
with	O
the	O
significant	O
sequence	O
similarity	O
to	O
the	O
ginseng	B-GENE
ribonuclease	I-GENE
,	O
support	O
the	O
hypothesis	O
of	O
a	O
ribonuclease	B-GENE
function	O
for	O
PR-10	B-GENE
proteins	I-GENE
and	O
allow	O
the	O
prediction	O
of	O
possible	O
biological	O
roles	O
.	O

The	O
p20-CGGBP	B-GENE
gene	I-GENE
is	O
conserved	O
among	O
mammals	O
but	O
shows	O
no	O
homology	O
to	O
non-vertebrate	O
species	O
.	O

Estimated	O
nucleic	O
acid	O
N	O
absorption	O
is	O
7-8%	O
of	O
N	O
intake	O
.	O

The	O
diagnostic	O
significance	O
of	O
creatine	B-GENE
phosphokinase	I-GENE
antibodies	O
in	O
the	O
cardiac	O
muscle	O
in	O
non-coronarogenic	O
myocardial	O
diseases	O
.	O

Note	O
on	O
Slot's	O
method	O
for	O
the	O
specific	O
determination	O
of	O
creatinine	O
.	O

When	O
the	O
blood	O
clot	O
is	O
formed	O
in	O
the	O
vitreous	O
cavity	O
,	O
intravitreal	O
injection	O
of	O
t-PA	B-GENE
can	O
convert	O
plasminogen	B-GENE
to	O
plasmin	O
and	O
remove	O
the	O
clot	O
.	O

We	O
report	O
herein	O
the	O
case	O
of	O
a	O
30-year-old	O
man	O
in	O
whom	O
ectopic	O
mediastinal	O
parathyroid	O
adenoma	O
was	O
detected	O
by	O
99mTc-methoxyisobutylisonitrile	O
scintigraphy	O
(	O
99mTc-MIBI	O
)	O
.	O

1	O
(	O
"long	O
method"	O
)	O
and	O
the	O
HML	O
method	O
.	O

The	O
distinguishing	O
features	O
involved	O
eight	O
amino	O
acid	O
changes	O
,	O
including	O
a	O
single	O
lysine	O
deletion	O
relative	O
to	O
a	O
primate	O
consensus	O
sequence	O
in	O
the	O
first	O
complementary-determing	O
region	O
of	O
V1J1	B-GENE
.	O

We	O
cloned	O
a	O
complete	O
cDNA	O
(	O
2	O
.	O
9	O
kb	O
)	O
for	O
HET	B-GENE
from	O
an	O
MCF-7	O
cDNA	O
library	O
.	O

NF-kappaB	B-GENE
is	O
a	O
redox-sensitive	O
transcription	O
factor	O
known	O
to	O
be	O
activated	O
by	O
oxidative	O
stress	O
as	O
well	O
as	O
chemical	O
and	O
biological	O
reductants	O
.	O

Many	O
of	O
the	O
important	O
genes	O
associated	O
with	O
G1	O
regulation	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
proliferation	O
,	O
differentiation	O
and	O
oncogenic	O
transformation	O
and	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

On	O
a	O
separate	O
occasion	O
the	O
T1	O
weighted	O
and	O
T2	O
weighted	O
sagittal	O
and	O
T2	O
weighted	O
axial	O
sequences	O
were	O
reported	O
blind	O
in	O
relation	O
to	O
the	O
initial	O
assessment	O
.	O

Enoxacin	O
appears	O
to	O
be	O
well	O
suited	O
for	O
the	O
treatment	O
of	O
complicated	O
UTI	O
.	O

The	O
primary	O
pancreatic	O
insult	O
seemed	O
to	O
be	O
unaffected	O
by	O
the	O
treatment	O
,	O
because	O
neither	O
the	O
rise	O
in	O
plasma	B-GENE
lipase	I-GENE
nor	O
the	O
development	O
of	O
ascites	O
or	O
the	O
extension	O
of	O
the	O
pancreatic	O
necrosis	O
were	O
diminished	O
.	O

Detailed	O
analysis	O
of	O
alpha1	B-GENE
,	I-GENE
3GT	I-GENE
transcripts	I-GENE
revealed	O
two	O
major	O
alternative	O
splicing	O
patterns	O
in	O
the	O
5'-untranslated	O
region	O
(	O
5'-UTR	O
)	O
and	O
evidence	O
for	O
minor	O
splicing	O
activity	O
that	O
occurs	O
in	O
a	O
tissue-specific	O
manner	O
.	O

The	O
segmental	O
and	O
regional	O
projections	O
of	O
the	O
sciatic	O
,	O
tibial	O
and	O
common	O
peroneal	O
nerves	O
to	O
the	O
substantia	O
gelatinosa	O
of	O
the	O
spinal	O
cord	O
in	O
rats--an	O
experimental	O
study	O
by	O
means	O
of	O
an	O
acid	B-GENE
phosphatase	I-GENE
(	O
ACP	B-GENE
)	O
method	O
.	O

Angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
inhibitors	O
enhance	O
the	O
antihypertensive	O
efficacy	O
of	O
diuretics	O
and	O
blunt	O
or	O
prevent	O
adverse	O
metabolic	O
effects	O
.	O

Two	O
closely	O
related	O
variants	O
of	O
Stat5	B-GENE
,	O
Stat5a	B-GENE
and	O
Stat5b	B-GENE
,	O
are	O
encoded	O
by	O
distinct	O
genes	O
.	O

Also	O
,	O
small	O
,	O
sense	O
and	O
antisense	O
approximately	O
22	O
nt	O
RNAs	O
,	O
derived	O
from	O
the	O
satRNA	B-GENE
,	O
were	O
associated	O
with	O
the	O
replicating	O
satellite	O
.	O

Induction	O
of	O
both	O
potential	O
transcripts	O
follows	O
heat	O
shock	O
in	O
vivo	O
.	O

Limb	O
allografts	O
in	O
rats	O
immunosuppressed	O
with	O
cyclosporin	O
A	O
.	O

Pseudomembranous	O
conjunctivitis	O
following	O
bone	O
marrow	O
transplantation	O
:	O
immunopathological	O
and	O
ultrastructural	O
study	O
of	O
one	O
case	O
.	O

Regulation	O
of	O
myosin	B-GENE
phosphatase	I-GENE
activity	O
involves	O
changes	O
in	O
subunit	O
interactions	O
,	O
although	O
molecular	O
mechanisms	O
are	O
not	O
defined	O
.	O

However	O
,	O
the	O
history	O
of	O
acute	O
severe	O
complications	O
from	O
otitis	O
media	O
revealed	O
a	O
higher	O
frequency	O
in	O
those	O
individuals	O
with	O
alpha	B-GENE
1-antitrypsin	I-GENE
deficiency	O
as	O
compared	O
to	O
normals	O
.	O

Unlike	O
P135gag-myb-ets	B-GENE
and	O
the	O
Mr	O
75	O
,	O
000	O
translation	O
product	O
of	O
c-myb	B-GENE
(	O
P75c-myb	B-GENE
)	O
,	O
which	O
are	O
nuclear	O
proteins	O
,	O
P54c-ets	B-GENE
was	O
found	O
to	O
be	O
predominantly	O
cytoplasmic	O
.	O

Although	O
differences	O
were	O
not	O
significant	O
,	O
infants	O
in	O
the	O
experimental	O
group	O
had	O
more	O
changes	O
in	O
the	O
intermittent	O
mandatory	O
ventilation	O
(	O
IMV	O
)	O
settings	O
during	O
transport	O
,	O
and	O
more	O
such	O
infants	O
arrived	O
at	O
the	O
receiving	O
hospital	O
with	O
acceptable	O
pH	O
and	O
PCO2	O
values	O
.	O

We	O
now	O
describe	O
a	O
second	O
RIM	B-GENE
protein	I-GENE
,	O
called	O
RIM2	B-GENE
,	O
that	O
is	O
highly	O
homologous	O
to	O
RIM1	B-GENE
and	O
also	O
expressed	O
primarily	O
in	O
brain	O
.	O

The	O
priming	O
activity	O
of	O
DNA	O
incised	O
by	O
either	O
of	O
the	O
Drosophila	O
enzymes	O
can	O
be	O
enhanced	O
,	O
however	O
,	O
by	O
an	O
additional	O
incubation	O
with	O
E	B-GENE
.	I-GENE
coli	I-GENE
endonuclease	I-GENE
IV	I-GENE
,	O
which	O
is	O
known	O
to	O
cleave	O
depurinated	O
DNA	O
on	O
the	O
5'-side	O
of	O
an	O
apurinic	O
site	O
.	O

Subsequently	O
,	O
these	O
coordinates	O
must	O
be	O
interpreted	O
to	O
define	O
particular	O
tissues	O
and	O
organs	O
.	O

To	O
assess	O
the	O
functional	O
importance	O
of	O
these	O
NBS	O
in	O
the	O
overall	O
drug	O
resistance	O
phenotype	O
conferred	O
by	O
mdr1	B-GENE
,	O
we	O
introduced	O
amino	O
acid	O
substitutions	O
in	O
the	O
core	O
consensus	O
sequence	O
for	O
nucleotide	O
binding	O
,	O
GXGKST	B-GENE
.	O

Excision	O
repair	O
at	O
the	O
level	O
of	O
the	O
nucleotide	O
in	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
MFA2	I-GENE
gene	I-GENE
:	O
mapping	O
of	O
where	O
enhanced	O
repair	O
in	O
the	O
transcribed	O
strand	O
begins	O
or	O
ends	O
and	O
identification	O
of	O
only	O
a	O
partial	O
rad16	B-GENE
requisite	O
for	O
repairing	O
upstream	O
control	O
sequences	O
.	O

After	O
4	O
h	O
,	O
lesions	O
in	O
the	O
secretory	O
part	O
of	O
the	O
stomach	O
were	O
scored	O
and	O
mucosal	O
prostaglandin	O
E2	O
synthesis	O
was	O
determined	O
by	O
the	O
ex	O
vivo	O
prostaglandin	O
generation	O
technique	O
.	O

Behavior	O
of	O
aspartate	B-GENE
aminotransferase	I-GENE
(	O
EC	B-GENE
2	I-GENE
.	I-GENE
6	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
1	I-GENE
)	O
and	O
alanine	B-GENE
aminotransferase	I-GENE
(	O
EC	B-GENE
2	I-GENE
.	I-GENE
6	I-GENE
.	I-GENE
1	I-GENE
.	I-GENE
2	I-GENE
)	O
in	O
rat	O
serum	O
during	O
the	O
course	O
of	O
acute	O
radiation	O
syndrome	O
following	O
whole	O
body	O
X-irradiation	O
.	O

NUP145	B-GENE
was	O
previously	O
identified	O
by	O
using	O
a	O
genetic	O
synthetic	O
lethal	O
screen	O
(	O
E	O
.	O

However	O
,	O
there	O
is	O
still	O
a	O
subset	O
of	O
tumors	O
that	O
displayed	O
no	O
changes	O
in	O
these	O
genes	O
.	O

Results	O
confirmed	O
that	O
stress	O
produced	O
CA3	O
dendritic	O
atrophy	O
and	O
tianeptine	O
prevented	O
it	O
.	O

TPBF	B-GENE
has	O
two	O
potential	O
coiled-coil	O
regions	O
,	O
a	O
basic	O
region	O
,	O
a	O
proline-rich	O
region	O
,	O
a	O
histidine-rich	O
N	O
terminus	O
,	O
and	O
a	O
nuclear	O
targeting	O
sequence	O
.	O

This	O
led	O
to	O
the	O
conclusion	O
that	O
the	O
metatarsal	O
artery	O
should	O
be	O
used	O
for	O
toe	O
MP	O
joint	O
grafts	O
,	O
while	O
the	O
unilateral	O
proper	O
digital	O
artery	O
is	O
suitable	O
for	O
toe	O
PIP	O
joint	O
grafts	O
,	O
together	O
with	O
concomitant	O
or	O
dorsal	O
cutaneous	O
vein	O
.	O

Clinical	O
trials	O
with	O
1	O
,	O
3-bis	O
(	O
2-chloroethyl	O
)	O
-1-nitrosourea	O
,	O
NSC-409962	O
.	O

Identity	O
elements	O
in	O
tRNA	B-GENE
for	O
mono-	O
and	O
dimethylation	O
reactions	O
by	O
the	O
recombinant	B-GENE
pfTrm1p	I-GENE
were	O
identified	O
using	O
in	O
vitro	O
T7	O
transcripts	O
of	O
33	O
variants	O
of	O
tRNA	B-GENE
(	I-GENE
Asp	I-GENE
)	I-GENE
and	I-GENE
tRNA	I-GENE
(	I-GENE
Phe	I-GENE
)	I-GENE
from	I-GENE
yeast	I-GENE
.	O

Results	O
indicate	O
that	O
KNM-LU	O
335	O
differs	O
from	O
both	O
human	O
and	O
chimpanzee	O
M1s	O
in	O
relative	O
distances	O
(	O
measured	O
in	O
three	O
dimensions	O
)	O
between	O
crown	O
fissure	O
termini	O
.	O

This	O
E	B-GENE
box	I-GENE
sequence	I-GENE
(	I-GENE
CACGTG	I-GENE
)	I-GENE
is	O
identical	O
to	O
the	O
binding	O
element	O
for	O
USF	B-GENE
(	O
upstream	B-GENE
stimulatory	I-GENE
factor	I-GENE
)	O
,	O
a	O
member	O
of	O
the	O
helix-loop-helix	B-GENE
family	I-GENE
of	I-GENE
transcription	I-GENE
factors	I-GENE
.	O

We	O
have	O
demonstrated	O
previously	O
that	O
two	O
binding	O
sites	O
in	O
the	O
-184	B-GENE
HNF-3	I-GENE
beta	I-GENE
promoter	I-GENE
are	O
recognized	O
by	O
widely	O
distributed	O
factors	O
and	O
that	O
there	O
is	O
also	O
a	O
critical	O
autoregulatory	O
site	O
,	O
we	O
identified	O
a	O
binding	O
site	O
for	O
a	O
cell-specific	O
factor	O
,	O
LF-H3	B-GENE
beta	I-GENE
,	O
that	O
may	O
function	O
in	O
restricting	O
HNF-3	B-GENE
beta	I-GENE
gene	I-GENE
expression	O
to	O
hepatocytes	O
.	O

Overlapping	O
clones	O
representing	O
full-length	O
cDNAs	O
for	O
MMI	B-GENE
alpha	I-GENE
were	O
obtained	O
from	O
mouse	O
brain	O
.	O

Since	O
GAGs	O
are	O
the	O
components	O
of	O
cartilage	O
matrix	O
,	O
the	O
depletion	O
of	O
which	O
is	O
associated	O
with	O
osteoarthrosis	O
,	O
a	O
method	O
for	O
measuring	O
sulphated	O
GAG	O
synthesis	O
in	O
culture	O
has	O
been	O
investigated	O
.	O

Chagas'	O
disease	O
,	O
visceral	O
leishmaniasis	O
,	O
anti-nuclear	B-GENE
factor	I-GENE
,	O
schistosomiasis	O
,	O
rheumatoid	B-GENE
factor	I-GENE
and	O
normal	O
controls	O
.	O

MZF-1	B-GENE
represses	O
CAT	B-GENE
reporter	I-GENE
gene	I-GENE
expression	O
via	O
GAL4	B-GENE
binding	I-GENE
sites	I-GENE
in	O
the	O
nonhematopoietic	O
cell	O
lines	O
NIH	O
3T3	O
and	O
293	O
.	O

The	O
bcl-2	B-GENE
gene	I-GENE
can	O
potentially	O
encode	O
26-	O
and	O
22-kDa	O
proteins	O
that	O
differ	O
only	O
in	O
their	O
carboxyl	O
tails	O
because	O
of	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

We	O
have	O
identified	O
a	O
strong	O
Tas-responsive	B-GENE
element	I-GENE
,	O
designated	O
TRE	B-GENE
(	O
GP	B-GENE
)	O
,	O
near	O
the	O
3'	O
end	O
of	O
the	O
gag	B-GENE
gene	I-GENE
and	O
preceding	O
the	O
pol	B-GENE
gene	I-GENE
of	O
SFV-1	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
factors	O
present	O
in	O
nuclear	O
extracts	O
derived	O
from	O
differentiated	O
osteoblast	O
bound	O
to	O
oligonucleotide	O
probes	O
containing	O
the	O
E-box	B-GENE
1	I-GENE
and	O
E-box	B-GENE
2	I-GENE
elements	I-GENE
.	O

Induction	O
of	O
proto-oncogene	B-GENE
fos	I-GENE
transcription	O
through	O
the	O
adenylate	B-GENE
cyclase	I-GENE
pathway	I-GENE
:	O
characterization	O
of	O
a	O
cAMP-responsive	B-GENE
element	I-GENE
.	O

Role	O
of	O
g2	O
in	O
relating	O
the	O
Schwinger	O
and	O
Gerasimov-Drell-Hearn	O
sum	O
rules	O
.	O

We	O
conclude	O
that	O
common	O
upstream	O
signals	O
cause	O
activation	O
of	O
Ras	B-GENE
and	O
TC21	B-GENE
,	O
but	O
activated	O
TC21	B-GENE
controls	O
cell	O
growth	O
via	O
distinct	O
Raf-independent	O
downstream	O
signaling	O
pathways	O
.	O

Our	O
experiments	O
suggest	O
that	O
the	O
SCL	B-GENE
gene	I-GENE
can	O
be	O
a	O
target	O
for	O
the	O
erythroid	B-GENE
transcription	I-GENE
factor	I-GENE
GATA-1	I-GENE
and	O
that	O
the	O
SCL	B-GENE
gene	I-GENE
product	I-GENE
serves	O
as	O
a	O
positive	O
regulator	O
of	O
erythroid	O
differentiation	O
.	O

Because	O
GH-induced	O
Akt	B-GENE
activation	O
was	O
completely	O
inhibited	O
in	O
both	O
cells	O
by	O
the	O
same	O
concentration	O
of	O
LY294002	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
wortmannin	O
sensitivity	O
of	O
both	O
the	O
IRS-1-independent	O
and	O
-dependent	O
GH-induced	O
MAP	B-GENE
kinase	I-GENE
activation	O
may	O
reflect	O
the	O
activity	O
of	O
another	O
wortmannin-sensitive	O
target	O
(	O
s	O
)	O
in	O
addition	O
to	O
PI3K	B-GENE
in	O
mediation	O
of	O
GH-induced	O
MAP	B-GENE
kinase	I-GENE
activation	O
in	O
these	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
Rb	B-GENE
protein	I-GENE
is	O
interacting	O
with	O
some	O
component	O
(	O
s	O
)	O
of	O
the	O
cell	O
cycle-regulatory	O
machinery	O
during	O
G2	O
phase	O
.	O

A	O
small	O
amount	O
of	O
HSP81-1	B-GENE
mRNA	I-GENE
was	O
detected	O
only	O
in	O
roots	O
.	O

The	O
RS447	B-GENE
human	B-GENE
megasatellite	I-GENE
tandem	I-GENE
repetitive	I-GENE
sequence	I-GENE
encodes	O
a	O
novel	O
deubiquitinating	O
enzyme	O
with	O
a	O
functional	O
promoter	O
.	O

There	O
was	O
no	O
correlation	O
between	O
secretor	O
status	O
and	O
clinical	O
status	O
,	O
spirometry	O
measurements	O
,	O
salivary	O
and	O
serum	B-GENE
lysozyme	I-GENE
levels	O
or	O
rates	O
of	O
respiratory	O
tract	O
colonization	O
with	O
P	O
.	O
aeruginosa	O
and	O
S	O
.	O
aureus	O
.	O

Urine	O
specimens	O
containing	O
either	O
phencyclidine	O
(	O
PCP	O
)	O
or	O
11-nor-delta	O
9-tetrahydrocannabinol-9-carboxylic	O
acid	O
(	O
9-THC-COOH	O
)	O
were	O
adulterated	O
with	O
sodium	O
chloride	O
,	O
bleach	O
,	O
vinegar	O
,	O
potassium	O
hydroxide	O
,	O
liquid	O
soap	O
,	O
2-propanol	O
,	O
and	O
ammonia	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
such	O
differences	O
in	O
polyadenylation	O
affect	O
the	O
steady-state	O
levels	O
of	O
DHFR	B-GENE
and	O
mRNAs	O
expressed	O
from	O
either	O
allele	O
and	O
,	O
in	O
a	O
more	O
general	O
sense	O
,	O
to	O
ask	O
whether	O
differences	O
in	O
3'	O
end	O
RNA	O
processing	O
in	O
a	O
gene	O
containing	O
multiple	O
poly	O
(	O
A	O
)	O
sites	O
affects	O
the	O
final	O
level	O
of	O
gene	O
expression	O
.	O

Schizosaccharomyces	O
pombe	O
cells	O
respond	O
to	O
nutrient	O
deprivation	O
by	O
altering	O
G2	O
/	O
M	O
cell	O
size	O
control	O
.	O

ACTH	B-GENE
release	O
is	O
transiently	O
suppressed	O
in	O
some	O
children	O
after	O
exogenous	O
ACTH	B-GENE
treatment	O
.	O

In	O
the	O
cell-free	O
import	O
assay	O
,	O
beta-catenin	B-GENE
rapidly	O
migrates	O
into	O
the	O
nucleus	O
without	O
the	O
exogenous	O
addition	O
of	O
cytosol	O
,	O
Ran	B-GENE
,	O
or	O
ATP	O
/	O
GTP	O
.	O

The	O
protein	O
sequence	O
contains	O
seven	O
potential	O
N-linked	O
glycosylation	O
sites	O
and	O
a	O
threonine	O
/	O
serine-rich	O
region	O
which	O
is	O
a	O
potential	O
site	O
for	O
attachment	O
of	O
O-linked	O
carbohydrate	O
.	O

Inverse	O
relation	O
between	O
serum	O
IgG	B-GENE
concentration	O
and	O
glucose	O
and	O
xylose	O
absorption	O
in	O
Zambian	O
African	O
adults	O
.	O

Moreover	O
,	O
glucan	B-GENE
synthase	I-GENE
activity	O
,	O
which	O
is	O
activated	O
by	O
Rho1p	B-GENE
,	O
was	O
significantly	O
reduced	O
in	O
the	O
deltabem4	B-GENE
mutant	I-GENE
.	O

The	O
authors	O
report	O
the	O
results	O
of	O
a	O
series	O
of	O
toxicological	O
tests	O
conducted	O
on	O
plastic	O
materials	O
(	O
polyethylene	O
)	O
activated	O
with	O
tetraphenylbutadiene	O
(	O
TPB	O
)	O
an	O
additive	O
recently	O
proposed	O
as	O
a	O
sensitizer	O
capable	O
of	O
photodegrading	O
plastic	O
materials	O
.	O

The	O
human	B-GENE
T	I-GENE
cell	I-GENE
lymphotropic	I-GENE
retrovirus	I-GENE
type	I-GENE
I	I-GENE
(	I-GENE
HTLV-I	I-GENE
)	I-GENE
trans-activator	I-GENE
,	O
Tax	B-GENE
,	O
interacts	O
specifically	O
with	O
the	O
basic-domain	B-GENE
/	I-GENE
leucine-zipper	I-GENE
(	I-GENE
bZip	I-GENE
)	I-GENE
protein	I-GENE
,	O
cAMP	B-GENE
response	I-GENE
element	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREB	B-GENE
)	O
,	O
bound	O
to	O
the	O
viral	B-GENE
Tax-responsive	I-GENE
element	I-GENE
consisting	O
of	O
three	O
imperfect	O
21-base	O
pair	O
repeats	O
,	O
each	O
with	O
a	O
cAMP	B-GENE
response	I-GENE
element	I-GENE
core	I-GENE
flanked	O
by	O
G	O
/	O
C-rich	O
sequences	O
.	O

METHODS	O
:	O
Von	B-GENE
Willebrand	I-GENE
factor	I-GENE
(	O
vWF	B-GENE
)	O
and	O
the	O
fibrinolytic	O
factors	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
tPA	B-GENE
)	O
,	O
measured	O
as	O
tPA	B-GENE
capacity	O
,	O
and	O
plasminogen	B-GENE
activator	I-GENE
inhibitor	I-GENE
1	I-GENE
(	O
PAI-1	B-GENE
)	O
,	O
platelets	O
,	O
fibrinogen	B-GENE
,	O
and	O
inflammatory	O
markers	O
were	O
measured	O
in	O
74	O
patients	O
with	O
active	O
seropositive	O
RA	O
.	O

Regressing	O
microaneurysms	O
in	O
5	O
cases	O
of	O
hepatitis	O
B	O
virus	O
related	O
polyarteritis	O
nodosa	O
.	O

Prevention	O
by	O
a	O
heparin-antithrombin	B-GENE
III	I-GENE
combination	O
.	O

Positron	O
emission	O
tomography	O
radioligands	O
for	O
dopamine	B-GENE
transporters	I-GENE
and	O
studies	O
in	O
human	O
and	O
nonhuman	O
primates	O
.	O

Several	O
cDNAs	O
corresponding	O
to	O
the	O
human	B-GENE
PWP2	I-GENE
gene	I-GENE
were	O
identified	O
and	O
partially	O
sequenced	O
.	O

The	O
primary	O
structure	O
and	O
cotranscription	O
of	O
the	O
petCA	B-GENE
genes	I-GENE
encoding	O
the	O
Rieske-FeS	B-GENE
(	O
nuclear	B-GENE
encoded	I-GENE
in	I-GENE
plants	I-GENE
)	O
and	O
apocytochrome	B-GENE
f	I-GENE
proteins	I-GENE
has	O
been	O
described	O
previously	O
(	O
Kallas	O
,	O
T	O
.	O
,	O
Spiller	O
,	O
S	O
.	O
,	O
and	O
Malkin	O
,	O
R	O
.	O

Nonteratogenicity	O
in	O
rats	O
of	O
blighted	O
potatoes	O
and	O
compounds	O
contained	O
in	O
them	O
.	O

Pregnant	O
women	O
at	O
term	O
had	O
the	O
lowest	O
levels	O
of	O
antithrombin	B-GENE
III	I-GENE
.	O

Herpes	O
virus	O
infection	O
was	O
characterized	O
by	O
inversion	O
of	O
the	O
T4	O
/	O
T8	O
ratio	O
below	O
1	O
.	O
0	O
(	O
sensitivity	O
90%	O
,	O
specificity	O
88%	O
)	O
,	O
caused	O
by	O
proliferation	O
of	O
the	O
T8	O
subpopulation	O
,	O
which--compared	O
with	O
the	O
findings	O
in	O
patients	O
with	O
rejection	O
crises--was	O
significantly	O
raised	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
significant	O
differences	O
between	O
the	O
5'	O
region	O
of	O
the	O
beta	B-GENE
subunit	I-GENE
gene	I-GENE
and	O
the	O
corresponding	O
regions	O
of	O
the	O
homologous	B-GENE
GlyR	I-GENE
alpha	I-GENE
subunit	I-GENE
genes	I-GENE
;	O
it	O
also	O
identified	O
a	O
novel	O
exon	O
(	O
exon	O
0	O
)	O
that	O
encodes	O
most	O
of	O
the	O
5'-untranslated	O
portion	O
of	O
the	O
GlyR	B-GENE
beta	I-GENE
mRNA	I-GENE
.	O

A	O
study	O
in	O
vivo	O
of	O
adrenergic	B-GENE
receptors	I-GENE
in	O
the	O
rectum	O
and	O
in	O
the	O
internal	O
and	O
sphincter	O
of	O
the	O
cat	O
.	O

The	O
unfolded	O
protein	O
response	O
regulates	O
multiple	O
aspects	O
of	O
secretory	O
and	O
membrane	O
protein	O
biogenesis	O
and	O
endoplasmic	O
reticulum	O
quality	O
control	O
.	O

The	O
resulting	O
mutants	O
were	O
coexpressed	O
with	O
gE	B-GENE
in	O
the	O
vaccinia	O
virus-based	O
vTF7-3	O
system	O
,	O
and	O
the	O
formation	O
and	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-to-Golgi	O
transport	O
of	O
the	O
hetero-oligomeric	O
complex	O
were	O
monitored	O
.	O

Molecular	O
dissection	O
of	O
the	O
multimeric	B-GENE
CD3-TCR	I-GENE
complex	I-GENE
revealed	O
that	O
at	O
least	O
two	O
associated	O
polypeptides	O
,	O
CD3	B-GENE
zeta	I-GENE
and	O
CD3	B-GENE
epsilon	I-GENE
,	O
autonomously	O
couple	O
antigenic	O
recognition	O
event	O
to	O
early	O
and	O
late	O
events	O
of	O
the	O
intracytoplasmic	O
activation	O
cascade	O
.	O

Comparison	O
with	O
alkaline	B-GENE
phosphatases	I-GENE
and	O
5-nucleotidase	B-GENE
.	O

The	O
GAC1	B-GENE
gene	I-GENE
encodes	O
the	O
regulatory	O
subunit	O
for	O
a	O
type	B-GENE
1	I-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
phosphoprotein	I-GENE
phosphatase	I-GENE
,	O
Glc7	B-GENE
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
roles	O
that	O
CCK	B-GENE
and	O
trypsin	B-GENE
inhibitors	O
are	O
believed	O
to	O
play	O
in	O
the	O
negative	O
feedback	O
control	O
of	O
pancreatic	O
exocrine	O
function	O
.	O

Leukocyte	O
enzyme	O
activity	O
and	O
blood	O
lymphocyte	O
blast	O
transformation	O
in	O
chronic	O
bronchitis	O
.	O

The	O
numerous	O
tests	O
demonstrate	O
that	O
the	O
HDL-2M	O
can	O
be	O
extensively	O
and	O
successfully	O
used	O
for	O
therapy	O
of	O
insulin-dependent	O
diabetes	O
mellitus	O
in	O
clinical	O
practice	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16	O
.	O
3	O
;	O
q32	O
)	O
represents	O
a	O
novel	O
,	O
recurrent	O
chromosomal	O
translocation	O
in	O
MM	O
,	O
and	O
suggest	O
that	O
the	O
FGFR3	B-GENE
gene	I-GENE
may	O
be	O
the	O
target	O
of	O
this	O
abnormality	O
and	O
thus	O
contribute	O
to	O
tumorigenesis	O
in	O
MM	O
.	O

All	O
injections	O
of	O
CSF	B-GENE
were	O
given	O
after	O
the	O
initiation	O
of	O
neutropenia	O
and	O
continued	O
until	O
the	O
occurrence	O
of	O
an	O
absolute	O
neutrophil	O
recovery	O
.	O
rHu	B-GENE
GM-CSF	I-GENE
and	O
rHu	B-GENE
G-CSF	I-GENE
,	O
administered	O
once	O
daily	O
at	O
the	O
250	O
microg	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
and	O
5	O
microg	O
kg	O
(	O
-1	O
)	O
day	O
(	O
-1	O
)	O
level	O
,	O
were	O
effective	O
in	O
increasing	O
the	O
absolute	O
neutrophil	O
count	O
and	O
neutrophil	O
function	O
,	O
as	O
measured	O
by	O
an	O
automated	O
chemiluminescence	O
system	O
.	O

Stringent	O
hybridization	O
of	O
EHS-1	B-GENE
back	O
to	O
primate	O
genomic	O
DNA	O
indicates	O
two	O
distinct	O
EHS-1	B-GENE
loci	I-GENE
in	O
normal	O
human	O
DNA	O
,	O
an	O
identical	O
band	O
pattern	O
in	O
chimpanzee	O
DNA	O
,	O
and	O
a	O
single	O
locus	O
in	O
rhesus	O
monkey	O
DNA	O
.	O

All	O
subsequent	O
patients	O
were	O
treated	O
at	O
the	O
maximal	O
tolerated	O
dose	O
of	O
EDXR	O
(	O
35	O
mg	O
/	O
m2	O
/	O
day	O
)	O
.	O

The	O
results	O
suggest	O
that	O
the	O
calcium	O
antagonist	O
,	O
diltiazem	O
,	O
may	O
modify	O
the	O
effects	O
of	O
isoflurane	O
on	O
myocardial	O
function	O
.	O

Twenty	O
eligible	O
patients	O
with	O
cirrhosis	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
10	O
patients	O
treated	O
with	O
6	O
million	O
units	O
of	O
natural	O
IFN-beta	B-GENE
twice	O
a	O
week	O
for	O
36	O
months	O
and	O
10	O
patients	O
without	O
IFN	B-GENE
therapy	O
.	O

The	O
multidomain	O
structure	O
includes	O
a	O
cysteine-rich	O
motif	O
resembling	O
those	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
and	O
n-chimaerin	B-GENE
and	O
a	O
putative	O
pleckstrin	B-GENE
homology	I-GENE
domain	I-GENE
.	O

For	O
the	O
sample	O
of	O
systematic	O
reviews	O
drawn	O
from	O
ACP	O
Journal	O
Club	O
(	O
n	O
=	O
103	O
)	O
,	O
the	O
PubMed	O
strategy	O
achieved	O
a	O
sensitivity	O
of	O
97%	O
(	O
CI	O
,	O
91%	O
to	O
99%	O
)	O
.	O

Method	O
of	O
synthesis	O
of	O
the	O
rheumatoid	B-GENE
factor	I-GENE
in	O
clinico-immunological	O
studies	O
.	O

Trypanosoma	O
cruzi	O
.	O

Dangers	O
in	O
use	O
of	O
live-virus	O
vaccines	O
[	O
letter	O
]	O
.	O

Expression	O
plasmids	O
harboring	O
full-length	O
or	O
kinase	O
domain	O
of	O
PKC	B-GENE
alpha	I-GENE
and	O
PKC	B-GENE
delta	I-GENE
(	O
PKC	B-GENE
alpha	I-GENE
K	I-GENE
and	O
PKC	B-GENE
delta	I-GENE
K	I-GENE
)	O
were	O
constructed	O
.	O

The	O
major	O
transcription	O
factors	O
controlling	O
arginine	O
metabolism	O
in	O
Escherichia	O
coli	O
and	O
Bacillus	O
subtilis	O
,	O
ArgR	B-GENE
and	O
AhrC	B-GENE
,	O
respectively	O
,	O
are	O
homologous	O
multimeric	O
proteins	O
that	O
form	O
l	O
-arginine-dependent	O
DNA-binding	O
complexes	O
capable	O
of	O
repressing	O
transcription	O
of	O
the	O
biosynthetic	O
genes	O
(	O
both	O
)	O
,	O
activating	O
transcription	O
of	O
catabolic	O
genes	O
(	O
AhrC	B-GENE
only	O
)	O
or	O
facilitating	O
plasmid	O
dimer	O
resolution	O
(	O
both	O
)	O
.	O

The	O
asymmetric	O
methylation	O
was	O
associated	O
with	O
tissue-specific	O
disruption	O
of	O
H19	B-GENE
genomic	O
imprinting	O
in	O
fetal	O
brain	O
.	O

On	O
Cox	O
proportional	O
hazards	O
regression	O
adenocarcinoma	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
the	O
development	O
of	O
BPF	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
older	O
age	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
higher	O
pathological	O
stage	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
were	O
independent	O
adverse	O
predictors	O
of	O
survival	O
.	O

Interestingly	O
,	O
however	O
,	O
it	O
is	O
homologous	O
to	O
several	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
of	O
unknown	O
function	O
from	O
Caenorhabditis	O
elegans	O
,	O
Oryza	O
sativa	O
and	O
Homo	O
sapiens	O
.	O

A	O
poor	O
correlation	O
was	O
also	O
observed	O
between	O
PbB	O
and	O
ALAD	B-GENE
activity	O
of	O
the	O
stearate	O
workers	O
.	O

Analysis	O
of	O
several	O
Tat	B-GENE
mutants	I-GENE
indicated	O
that	O
both	O
the	O
cysteine-rich	O
and	O
the	O
core	O
domains	O
of	O
this	O
transactivator	O
are	O
necessary	O
and	O
sufficient	O
to	O
activate	O
transcription	O
when	O
TBP	B-GENE
is	O
overexpressed	O
.	O

Rice	B-GENE
dwarf	I-GENE
phytoreovirus	I-GENE
segment	I-GENE
S12	I-GENE
transcript	I-GENE
is	O
tricistronic	O
in	O
vitro	O
.	O

These	O
results	O
indicate	O
that	O
both	O
N-	O
and	O
C-terminal	O
mutations	O
are	O
required	O
to	O
inhibit	O
transrepression	O
by	O
FBR	B-GENE
protein	I-GENE
and	O
that	O
multiple	O
structural	O
mutations	O
accompanied	O
by	O
posttranslational	O
protein	O
modification	O
alter	O
gene	O
regulation	O
by	O
FBR	B-GENE
protein	I-GENE
.	O

Alveolar	O
growth	O
,	O
contemporary	O
with	O
dental	O
eruption	O
,	O
is	O
sufficient	O
to	O
compensate	O
possible	O
hypotrophy	O
of	O
maxillary	O
bone	O
bases	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
NF-kappaB	B-GENE
activity	O
may	O
be	O
regulated	O
by	O
its	O
interaction	O
with	O
the	O
cell	O
cycle	O
regulatory	O
protein	O
,	O
E2F-1	B-GENE
.	O

In	O
accordance	O
with	O
clinical	O
improvement	O
we	O
found	O
a	O
decrease	O
of	O
laboratory	O
indicators	O
of	O
inflammation	O
(	O
C-reactive	B-GENE
protein	I-GENE
,	O
alpha	B-GENE
2-globuline	I-GENE
,	O
prostaglandin	O
E2	O
)	O
.	O

Dominant	O
negative	O
Sos	B-GENE
did	O
not	O
affect	O
carbachol	O
stimulation	O
of	O
HA-ERK2	B-GENE
but	O
inhibited	O
the	O
stimulatory	O
effect	O
of	O
EGF	B-GENE
by	O
60%	O
.	O

The	O
PRB-1b	B-GENE
gene	I-GENE
encodes	O
for	O
a	O
basic-type	O
component	O
of	O
the	O
pathogenesis-related	O
PR-1	B-GENE
protein	I-GENE
family	I-GENE
.	O

Two-dimensional	O
phosphotryptic	O
analyses	O
indicate	O
that	O
phosphorylation	O
on	O
Ser-12	O
and	O
Ser-48	O
in	O
unstimulated	O
cells	O
is	O
associated	O
with	O
the	O
ability	O
of	O
overexpressed	O
pp60c-src	B-GENE
to	O
potentiate	O
beta-adrenergic	O
signalling	O
.	O

Methods	O
included	O
24-hour	O
dietary	O
recall	O
,	O
menu	O
weights	O
,	O
and	O
recipe	O
analysis	O
.	O

A	O
2	O
.	O
3-kb	O
full-length	O
cDNA	O
clone	O
of	O
an	O
Atlantic	B-GENE
halibut	I-GENE
Mx	I-GENE
gene	I-GENE
was	O
isolated	O
from	O
a	O
liver	O
cDNA	O
library	O
.	O

A	O
20-base	O
pair	O
oligonucleotide	O
containing	O
this	O
nonamer	O
confers	O
up-regulation	O
by	O
hypoxia	O
and	O
inhibition	O
by	O
unsaturated	O
fatty	O
acids	O
when	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
in	O
a	O
lacZ	B-GENE
reporter	I-GENE
construct	I-GENE
.	O

Mapping	O
the	O
cAMP	B-GENE
receptor	I-GENE
protein	I-GENE
contact	I-GENE
site	I-GENE
on	O
the	O
alpha	O
subunit	O
of	O
Escherichia	B-GENE
coli	I-GENE
RNA	I-GENE
polymerase	I-GENE
.	O

Transforming	B-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
TGF	I-GENE
)	I-GENE
-beta1	I-GENE
induces	O
extracellular	O
matrix	O
deposition	O
and	O
proliferation	O
of	O
mesenchymal	O
cells	O
.	O

Results	O
were	O
supported	O
by	O
the	O
agar	O
diffusion	O
method	O
for	O
Y	O
.	O
enterocolitica	O
,	O
whereas	O
inhibition	O
activity	O
was	O
not	O
found	O
for	O
A	O
.	O
hydrophila	O
.	O

JCAHO	O
revised	O
interpretation	O
.	O

Cattaneo	O
,	O
and	O
J	O
.	O

These	O
data	O
suggest	O
that	O
mammalian	O
erythroid	O
alpha-spectrin	B-GENE
evolved	O
by	O
duplication	O
and	O
rapid	O
divergence	O
from	O
an	O
ancestral	O
alpha-fodrin-like	B-GENE
gene	I-GENE
.	O

Immunologically	O
reactive	O
insulin	B-GENE
levels	O
were	O
determined	O
in	O
freely-moving	O
normal	O
rats	O
offered	O
three	O
different	O
test-meals	O
.	O

Transcriptional	O
blockade	O
was	O
reversed	O
by	O
co-transfections	O
of	O
a	O
wild-type	B-GENE
SRF	I-GENE
expression	O
vector	O
,	O
but	O
was	O
not	O
rescued	O
by	O
the	O
expression	O
of	O
other	O
myogenic	O
factors	O
,	O
such	O
as	O
MyoD	B-GENE
and	O
Mef-2C	B-GENE
.	O

The	O
significance	O
of	O
structural	O
integrity	O
of	O
lymphoid	O
tissue	O
for	O
antibody	O
production	O
in	O
culture	O
in	O
vivo	O
.	O

Displacement	O
thresholds	O
of	O
peripheral	O
sites	O
in	O
monocular	O
human	O
vision	O
were	O
obtained	O
.	O

Losartan	O
Intervention	O
For	O
Endpoint	O
.	O

In	O
the	O
evening	O
,	O
the	O
amplitude	O
of	O
the	O
responses	O
to	O
both	O
O2	O
and	O
CO2	O
increased	O
but	O
the	O
increase	O
in	O
CO2	O
sensitivity	O
was	O
proportionally	O
more	O
important	O
.	O

The	O
lethal	O
toxicity	O
of	O
inorganic	O
(	O
HgCl2	O
)	O
and	O
organic	O
(	O
CH3HgCl	O
)	O
mercury	O
chloride	O
was	O
compared	O
for	O
Coturnix	O
(	O
Japanese	O
quail	O
,	O
Coturnix	O
japonica	O
)	O
of	O
different	O
ages	O
from	O
hatch	O
through	O
adulthood	O
by	O
single-dose	O
acute	O
oral	O
and	O
intramuscular	O
injections	O
and	O
by	O
a	O
5-d	O
dietary	O
trial	O
.	O

Distal	O
tubular	O
acidification	O
and	O
the	O
threshold	O
for	O
proximal	O
tubular	O
bicarbonate	O
reabsorption	O
were	O
normal	O
,	O
as	O
was	O
urine	O
concentrating	O
capacity	O
.	O

By	O
negatively	O
regulating	O
GRK-mediated	O
receptor	O
phosphorylation	O
,	O
beta-arrestin-mediated	O
processes	O
such	O
as	O
Src	B-GENE
recruitment	O
and	O
clathrin-mediated	O
internalization	O
,	O
which	O
are	O
required	O
for	O
GPCR-mediated	O
ERK	B-GENE
activation	O
,	O
are	O
inhibited	O
,	O
thus	O
dampening	O
further	O
ERK	B-GENE
activation	O
.	O

Of	O
the	O
patients	O
in	O
each	O
regimen	O
who	O
reached	O
study	O
end	O
points	O
,	O
17	O
of	O
29	O
(	O
59%	O
)	O
were	O
in	O
regimen	O
A	O
,	O
11	O
of	O
20	O
(	O
55%	O
)	O
were	O
in	O
regimen	O
B	O
,	O
and	O
28	O
of	O
43	O
(	O
65%	O
)	O
were	O
in	O
regimen	O
C	O
met	O
the	O
treatment	O
success	O
criterion	O
.	O

The	O
patients	O
who	O
presented	O
with	O
mucocutaneous	O
disease	O
also	O
had	O
low	O
CD4+	B-GENE
T	O
lymphocyte	O
counts	O
,	O
and	O
most	O
of	O
them	O
had	O
AIDS	O
defining	O
illnesses	O
.	O

The	O
results	O
indicate	O
that	O
the	O
relationship	O
between	O
comprehension	O
and	O
production	O
is	O
different	O
at	O
different	O
stages	O
in	O
development	O
.	O

C	O
.	O
D2-Chr	O
4	O
congenic	O
strains	O
harboring	O
DBA	B-GENE
/	I-GENE
2	I-GENE
alleles	I-GENE
associated	O
with	O
the	O
Pctr1	B-GENE
locus	I-GENE
contained	O
DBA	B-GENE
/	I-GENE
2	I-GENE
"resistant"	I-GENE
alleles	I-GENE
of	O
the	O
CDK4	B-GENE
/	I-GENE
CDK6	I-GENE
inhibitors	O
p16	B-GENE
and	O
p15	B-GENE
.	O

We	O
previously	O
showed	O
that	O
this	O
proteolysis	O
1	O
)	O
can	O
be	O
acutely	O
promoted	O
by	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
2	O
)	O
requires	O
a	O
metalloprotease	B-GENE
activity	O
,	O
3	O
)	O
generates	O
both	O
shed	O
GHBP	B-GENE
and	O
a	O
membrane-associated	B-GENE
GHR	I-GENE
transmembrane	I-GENE
/	I-GENE
cytoplasmic	I-GENE
domain	I-GENE
remnant	O
,	O
and	O
4	O
)	O
results	O
in	O
down-regulation	O
of	O
GHR	B-GENE
abundance	O
and	O
GH	B-GENE
signaling	O
.	O

Finally	O
,	O
Cas	B-GENE
existed	O
mainly	O
in	O
cytosol	O
and	O
membrane	O
cytoskeleton	O
fractions	O
in	O
the	O
resting	O
state	O
,	O
and	O
remained	O
unchanged	O
during	O
platelet	O
aggregation	O
,	O
when	O
FAK	B-GENE
translocated	O
to	O
the	O
cytoskeletal	O
fraction	O
.	O

On	O
the	O
basis	O
of	O
serum	B-GENE
alpha1AT	I-GENE
quantitation	O
,	O
newborn	O
infants	O
may	O
be	O
separated	O
into	O
two	O
groups	O
,	O
characterized	O
respectively	O
by	O
concentrations	O
above	O
or	O
below	O
150	O
mg%	O
.	O

Elimination	O
of	O
bagassosis	O
in	O
Louisiana	O
paper	O
manufacturing	O
plant	O
workers	O
.	O

The	O
present	O
data	O
also	O
suggest	O
that	O
when	O
compared	O
to	O
the	O
systemic	O
vascular	O
bed	O
,	O
the	O
pulmonary	O
vascular	O
bed	O
is	O
less	O
responsive	O
to	O
bolus	O
administration	O
of	O
ET-1	B-GENE
.	O

Intracavitary	O
irradiation	O
was	O
carried	O
out	O
with	O
a	O
microSelectron	O
HDR	O
afterloading	O
device	O
and	O
usually	O
22	O
.	O
5	O
Gy	O
was	O
given	O
in	O
three	O
fractions	O
repeated	O
weekly	O
.	O

The	O
POEMS	O
syndrome	O
(	O
Polyneuropathy	O
,	O
Organomegaly	O
,	O
Endocrinopathy	O
,	O
Monoclonal	O
component	O
,	O
Skin	O
)	O
.	O

Neuronal	O
mechanisms	O
underlying	O
stimulus-response	O
(	O
S-R	O
)	O
associations	O
in	O
S-R	O
compatibility	O
tasks	O
were	O
identified	O
in	O
2	O
experiments	O
with	O
monkeys	O
.	O

Identification	O
of	O
Ste4	B-GENE
as	O
a	O
potential	O
regulator	O
of	O
Byr2	B-GENE
in	O
the	O
sexual	O
response	O
pathway	O
of	O
Schizosaccharomyces	O
pombe	O
.	O

After	O
two	O
successive	O
rounds	O
of	O
selection	O
by	O
focus	O
formation	O
assay	O
,	O
a	O
transforming	B-GENE
ribozyme	I-GENE
(	O
Rz007	B-GENE
)	O
was	O
identified	O
.	O

Analysis	O
of	O
an	O
autopsy	O
population	O
.	O

This	O
work	O
unravels	O
a	O
new	O
model	O
for	O
the	O
ets-1	B-GENE
/	I-GENE
ets-2	I-GENE
gene's	O
evolution	O
,	O
based	O
for	O
the	O
first	O
time	O
on	O
both	O
structural	O
and	O
functional	O
evidences	O
.	O

Molecular	O
cloning	O
and	O
sequencing	O
of	O
a	O
cDNA	O
encoding	O
SR	B-GENE
beta	I-GENE
revealed	O
that	O
SR	B-GENE
beta	I-GENE
is	O
a	O
transmembrane	O
protein	O
and	O
,	O
like	O
SR	B-GENE
alpha	I-GENE
and	O
SRP54	B-GENE
,	O
is	O
a	O
member	O
of	O
the	O
GTPase	B-GENE
superfamily	I-GENE
.	O

The	O
major	O
findings	O
of	O
our	O
studies	O
are	O
as	O
follows	O
:	O
1	O
)	O
There	O
are	O
no	O
detectable	O
signals	O
around	O
GDF-9-deficient	O
follicles	O
for	O
several	O
theca	O
cell	O
layer	O
markers	O
[	O
i	O
.	O
e	O
.	O

W	O
.	O
G	O
.	O

RACK1	B-GENE
,	O
a	O
receptor	O
for	O
activated	B-GENE
C	I-GENE
kinase	I-GENE
and	O
a	O
homolog	O
of	O
the	O
beta	O
subunit	O
of	O
G	B-GENE
proteins	I-GENE
,	O
inhibits	O
activity	O
of	O
src	B-GENE
tyrosine	I-GENE
kinases	I-GENE
and	O
growth	O
of	O
NIH	O
3T3	O
cells	O
.	O

The	O
polyubiquitin	B-GENE
gene	I-GENE
was	O
transcribed	O
throughout	O
the	O
Volvox	O
life	O
cycle	O
with	O
peaks	O
in	O
the	O
1	O
.	O
6-kb	O
mRNA	O
levels	O
during	O
pre-cleavage	O
,	O
cleavage	O
,	O
and	O
post-inversion	O
.	O

DNase	B-GENE
I	I-GENE
and	O
1	O
,	O
10-phenanthroline-copper	O
footprinting	O
of	O
MURA-Mu1	B-GENE
TIR	I-GENE
complexes	I-GENE
indicate	O
that	O
MURA	B-GENE
binds	O
to	O
a	O
conserved	O
approximately	O
32-bp	O
region	O
in	O
the	O
TIR	B-GENE
of	O
Mu1	B-GENE
.	O

We	O
and	O
others	O
have	O
demonstrated	O
that	O
the	O
c-cbl	B-GENE
proto-oncogene	I-GENE
product	I-GENE
is	O
one	O
of	O
the	O
earliest	O
targets	O
of	O
tyrosine	O
phosphorylation	O
upon	O
T	B-GENE
cell	I-GENE
receptor	I-GENE
stimulation	O
.	O

Analysis	O
of	O
the	O
DNA	O
from	O
15	O
cases	O
of	O
sporadic	O
and	O
familial	O
Wilms'	O
tumor	O
did	O
not	O
reveal	O
any	O
changes	O
,	O
indicating	O
that	O
the	O
translocation	O
breakpoint	O
does	O
not	O
reside	O
in	O
this	O
gene	O
.	O

In	O
order	O
to	O
study	O
the	O
structural	O
and	O
functional	O
organization	O
of	O
the	O
eukaryotic	O
nucleolus	O
,	O
we	O
have	O
started	O
to	O
isolate	O
and	O
characterize	O
nucleolar	O
components	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
use	O
of	O
specific	O
antibodies	O
allowed	O
the	O
identification	O
of	O
at	O
least	O
RAR	B-GENE
beta	I-GENE
in	O
some	O
of	O
the	O
DNA-protein	O
complexes	O
,	O
although	O
the	O
four	O
sequences	O
bind	O
single	O
RARs	B-GENE
transfected	O
in	O
COS	O
cells	O
much	O
less	O
efficiently	O
,	O
or	O
not	O
at	O
all	O
,	O
when	O
compared	O
to	O
a	O
canonical	O
RAR	B-GENE
responsive	I-GENE
element	I-GENE
.	O

Although	O
increased	O
expression	O
of	O
the	O
HMG-I	B-GENE
/	I-GENE
Y	I-GENE
proteins	I-GENE
is	O
associated	O
with	O
cellular	O
proliferation	O
,	O
neoplastic	O
transformation	O
,	O
and	O
several	O
human	O
cancers	O
,	O
the	O
role	O
of	O
these	O
proteins	O
in	O
the	O
pathogenesis	O
of	O
malignancy	O
remains	O
unclear	O
.	O

The	O
hydropathy	O
plot	O
revealed	O
a	O
rather	O
hydrophilic	O
N-terminal	O
region	O
and	O
the	O
absence	O
of	O
a	O
hydrophobic	O
signal	O
peptide	O
.	O

These	O
results	O
demonstrate	O
that	O
sequences	O
in	O
the	O
SH2	B-GENE
/	I-GENE
SH3	I-GENE
/	I-GENE
SH2	I-GENE
region	I-GENE
of	O
p120	B-GENE
GAP	I-GENE
are	O
required	O
for	O
full	O
catalytic	O
activity	O
toward	O
Ras	B-GENE
.	O

We	O
have	O
isolated	O
a	O
binding	O
partner	O
for	O
the	O
Fanconi	B-GENE
anemia	I-GENE
group	I-GENE
C	I-GENE
protein	I-GENE
(	O
FANCC	B-GENE
)	O
by	O
yeast	O
two-hybrid	O
screening	O
.	O

The	O
effects	O
of	O
coenzyme	B-GENE
Q10	I-GENE
(	O
CoQ	B-GENE
)	O
and	O
captopril	O
on	O
functional	O
capacity	O
,	O
hemodynamics	O
and	O
survival	O
were	O
studied	O
in	O
154	O
rats	O
that	O
recovered	O
after	O
experimental	O
myocardial	O
infarction	O
.	O

Novel	O
intronic	O
promoter	O
in	O
the	O
rat	B-GENE
ER	I-GENE
alpha	I-GENE
gene	I-GENE
responsible	O
for	O
the	O
transient	O
transcription	O
of	O
a	O
variant	O
receptor	O
.	O

In	O
assays	O
with	O
purified	O
enzymes	O
,	O
wild-type	O
but	O
not	O
PTPS-S19A	B-GENE
was	O
a	O
specific	O
substrate	O
for	O
the	O
cGMP-dependent	B-GENE
protein	I-GENE
kinase	I-GENE
(	I-GENE
cGK	I-GENE
)	I-GENE
type	I-GENE
I	I-GENE
and	I-GENE
II	O
.	O

A	O
decanucleotide	O
promoter	O
sequence	O
homologous	O
to	O
those	O
found	O
in	O
humans	O
and	O
mice	O
was	O
located	O
in	O
the	O
5'	O
untranslated	O
region	O
of	O
one	O
horse	O
gene	O
.	O

Effects	O
of	O
rhG-CSF	B-GENE
on	O
neutrophil	O
functions	O
and	O
survival	O
in	O
sepsis	O
induced	O
diabetic	O
rats	O
.	O

Each	O
of	O
these	O
genes	O
contains	O
a	O
putative	O
upstream	O
ORF	O
,	O
while	O
STA2	B-GENE
has	O
two	O
additional	O
in-frame	O
AUG	O
codons	O
5'	O
to	O
the	O
major	O
cistron	O
.	O

BRCA1	B-GENE
protein	I-GENE
contains	O
an	O
amino-terminal	O
zinc	O
finger	O
motif	O
and	O
a	O
carboxy-terminal	O
acidic	O
region	O
.	O

Eleven	O
patients	O
tested	O
positive	O
for	O
the	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
(	O
HBsAg	B-GENE
)	O
.	O

Gel-mobility	O
shift	O
analysis	O
was	O
also	O
performed	O
for	O
the	O
CCAAT	O
motif	O
at	O
-67	O
.	O

Vesicles	O
could	O
be	O
induced	O
only	O
with	O
multiple	O
exposures	O
to	O
UVA	O
.	O

Hrs	B-GENE
has	O
a	O
FYVE	B-GENE
double	I-GENE
zinc	I-GENE
finger	I-GENE
domain	I-GENE
,	O
which	O
specifically	O
binds	O
phosphatidylinositol	O
(	O
3	O
)	O
-phosphate	O
and	O
is	O
conserved	O
in	O
several	O
proteins	O
involved	O
in	O
vesicular	O
traffic	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
807	O
consecutive	O
patients	O
from	O
the	O
Chilean	O
National	O
Registry	O
of	O
Acute	O
Myocardial	O
Infarction	O
we	O
analyzed	O
the	O
resolution	O
of	O
chest	O
pain	O
and	O
ST	O
segment	O
elevation	O
over	O
50%	O
within	O
the	O
first	O
90	O
min	O
,	O
abrupt	O
CK	O
rise	O
within	O
8	O
h	O
and	O
T	O
wave	O
inversion	O
in	O
infarct	O
related	O
EKG	O
leads	O
within	O
the	O
first	O
24	O
h	O
after	O
thrombolysis	O
.	O

For	O
each	O
night	O
,	O
the	O
diary	O
allowed	O
the	O
subjective	O
measurement	O
of	O
bedtime	O
,	O
wake	O
time	O
,	O
time	O
in	O
bed	O
(	O
TIB	O
)	O
,	O
sleep	O
efficiency	O
,	O
number	O
of	O
minutes	O
of	O
wake	O
after	O
sleep	O
onset	O
(	O
WASO	O
)	O
,	O
alertness	O
on	O
awakening	O
,	O
and	O
percentage	O
of	O
morning	O
needing	O
an	O
alarm	O
(	O
or	O
a	O
person	O
functioning	O
as	O
one	O
)	O
.	O

Mutational	O
analysis	O
of	O
the	O
L1	B-GENE
binding	I-GENE
site	I-GENE
of	O
23S	B-GENE
rRNA	I-GENE
in	I-GENE
Escherichia	I-GENE
coli	I-GENE
.	O

We	O
propose	O
that	O
the	O
reduced	O
responsiveness	O
of	O
CYP3A2	B-GENE
is	O
the	O
result	O
of	O
preferential	O
binding	O
of	O
COUP-TF	B-GENE
at	O
the	O
CYP3A2	B-GENE
DexRE-1	I-GENE
site	I-GENE
.	O

Location	O
and	O
orientation	O
of	O
an	O
activating	O
region	O
in	O
the	O
Escherichia	O
coli	O
transcription	O
factor	O
,	O
FNR	B-GENE
.	O

(	O
iii	O
)	O
The	O
mRNA	O
is	O
not	O
efficiently	O
polyadenylated	O
at	O
sequences	O
in	O
the	O
3'	O
end	O
of	O
the	O
DHFR	B-GENE
cDNA	I-GENE
but	O
rather	O
uses	O
polyadenylation	O
signals	O
downstream	O
from	O
the	O
DHFR	B-GENE
cDNA	I-GENE
.	O

Northern	O
blot	O
analysis	O
with	O
one	O
of	O
the	O
PARNAs	B-GENE
revealed	O
a	O
highly	O
abundant	O
signal	O
of	O
approximately	O
2	O
.	O
0	O
kilobases	O
(	O
kb	O
)	O
present	O
in	O
all	O
cell	O
lines	O
tested	O
.	O

Therefore	O
,	O
the	O
impaired	O
floor	O
plate	O
development	O
in	O
oep	B-GENE
mutants	I-GENE
is	O
not	O
caused	O
by	O
the	O
absence	O
of	O
the	O
floor	B-GENE
plate	I-GENE
inducer	I-GENE
shh	I-GENE
.	O

The	O
cellular	O
sequences	O
5'	O
to	O
the	O
viral	O
integration	O
site	O
exhibited	O
85	O
to	O
97%	O
identity	O
to	O
several	O
sequences	O
belonging	O
to	O
the	O
mouse	B-GENE
L1	I-GENE
family	I-GENE
of	O
long	O
interspersed	O
repetitive	O
sequences	O
.	O

The	O
gene	O
is	O
separated	O
into	O
four	O
exons	O
by	O
three	O
short	O
introns	O
,	O
and	O
the	O
open	O
reading	O
frame	O
consists	O
of	O
6660	O
base	O
pairs	O
(	O
bp	O
)	O
capable	O
of	O
encoding	O
a	O
polypeptide	O
of	O
2220	O
amino	O
acid	O
residues	O
.	O

METHODS	O
:	O
IgG	B-GENE
antibodies	I-GENE
vs	O
HHV-6	O
(	O
anti-HHV-6-IgG	B-GENE
)	O
were	O
determined	O
by	O
indirect	O
immunofluorescence	O
in	O
100	O
IVDA	O
(	O
29	O
seronegative	O
and	O
71	O
seropositive	O
for	O
HIV-1	O
of	O
which	O
45	O
were	O
in	O
stage	O
II	O
and	O
26	O
in	O
IV-C1	O
of	O
CDC	O
)	O
as	O
well	O
as	O
in	O
100	O
healthy	O
subjects	O
of	O
a	O
similar	O
age	O
(	O
control	O
group	O
)	O
.	O

An	O
analysis	O
of	O
sequence	O
of	O
the	O
mutant	B-GENE
recN	I-GENE
gene	I-GENE
revealed	O
a	O
G	O
:	O
C	O
to	O
T	O
:	O
A	O
transversion	O
near	O
the	O
3'	O
end	O
of	O
the	O
coding	O
region	O
.	O

Overexpression	O
of	O
Sed5p	B-GENE
allowed	O
growth	O
in	O
the	O
absence	O
of	O
Vti1p	B-GENE
.	O

Testosterone	O
,	O
free	O
testosterone	O
,	O
non-sex	O
hormone-binding	O
globulin-bound	O
testosterone	O
,	O
and	O
free	O
androgen	O
index	O
:	O
which	O
testosterone	O
measurement	O
is	O
most	O
relevant	O
to	O
reproductive	O
and	O
sexual	O
function	O
in	O
men	O
with	O
epilepsy	O
?	O

Kodak	O
XV-2	O
film	O
is	O
wrapped	O
around	O
a	O
cylindrical	O
water-filled	O
phantom	O
and	O
the	O
dose	O
distribution	O
is	O
recorded	O
.	O

When	O
two-dimensional	O
polyacrylamide	O
gel	O
electrophoretic	O
patterns	O
of	O
[	O
35S	O
]	O
methionine-labeled	O
proteins	O
secreted	O
from	O
cells	O
infected	O
with	O
parental	O
and	O
recombinant	O
viruses	O
were	O
compared	O
,	O
a	O
spot	O
missing	O
from	O
the	O
latter	O
corresponded	O
in	O
molecular	O
weigh	O
and	O
isoelectric	O
point	O
with	O
that	O
predicted	O
from	O
the	O
N1L	B-GENE
ORF	I-GENE
.	O

T	O
cells	O
express	O
two	O
isoforms	O
of	O
S6k1	B-GENE
:	O
a	O
70	B-GENE
kDa	I-GENE
cytoplasmic	I-GENE
kinase	I-GENE
and	O
an	O
85	O
kDa	O
isoform	O
that	O
has	O
a	O
classic	O
nuclear	O
localisation	O
.	O

Western	O
blot	O
analysis	O
showed	O
a	O
rapid	O
corresponding	O
increase	O
in	O
p21WAF1	B-GENE
/	I-GENE
CIP1	I-GENE
protein	I-GENE
,	O
whereas	O
protein	O
levels	O
of	O
another	O
member	O
of	O
the	O
cyclin-dependent	B-GENE
kinase	I-GENE
inhibitor	I-GENE
family	I-GENE
,	O
p27kip1	B-GENE
,	O
were	O
unchanged	O
.	O

C	B-GENE
/	I-GENE
EBPbeta	I-GENE
LIP	I-GENE
overexpressing	O
HC11	O
cells	O
did	O
not	O
express	O
beta-casein	B-GENE
mRNA	I-GENE
(	O
mammary	O
epithelial	O
cell	O
differentiation	O
marker	O
)	O
in	O
response	O
to	O
lactogenic	O
hormones	O
.	O

Effects	O
of	O
beta-adrenergic	B-GENE
receptor	I-GENE
blockade	O
on	O
airway	O
conductance	O
and	O
lung	O
volume	O
in	O
normal	O
and	O
asthmatic	O
subjects	O
.	O

Co-transfection	O
of	O
the	O
Sp1	B-GENE
expression	O
plasmid	O
and	O
the	O
-58	O
promoter	O
construct	O
into	O
Drosophila	O
Schneider	O
cells	O
revealed	O
that	O
Sp1	B-GENE
contributed	O
to	O
the	O
kinase	B-GENE
basal	I-GENE
promoter	I-GENE
activity	O
by	O
binding	O
to	O
the	O
non-consensus	O
site	O
in	O
the	O
-58	O
region	O
.	O

Incidental	O
findings	O
in	O
the	O
epidermis	O
and	O
in	O
the	O
intraepidermal	O
eccrine	O
sweat	O
duct	O
units	O
.	O

Protein	O
sequence	O
analysis	O
reveals	O
that	O
MAN1	B-GENE
shares	O
a	O
conserved	O
globular	O
domain	O
of	O
approximately	O
40	O
amino	O
acids	O
,	O
which	O
we	O
term	O
the	O
LEM	B-GENE
module	I-GENE
,	O
with	O
inner	O
nuclear	O
membrane	O
proteins	O
lamina-associated	B-GENE
polypeptide	I-GENE
2	I-GENE
and	O
emerin	B-GENE
.	O

This	O
shows	O
that	O
the	O
characteristically	O
diffuse	O
banding	O
pattern	O
of	O
plant	O
nuclear	O
proteins	O
interacting	O
with	O
the	O
G-box	O
is	O
also	O
observed	O
in	O
a	O
binding	O
assay	O
using	O
only	O
one	O
recombinant	B-GENE
GBF	I-GENE
.	O

Based	O
on	O
these	O
results	O
and	O
because	O
Cdc68	B-GENE
has	O
been	O
implicated	O
as	O
a	O
regulator	O
of	O
chromatin	O
structure	O
,	O
we	O
postulate	O
that	O
polymerase	B-GENE
alpha	I-GENE
may	O
interact	O
with	O
these	O
proteins	O
to	O
gain	O
access	O
to	O
its	O
template	O
or	O
to	O
origins	O
of	O
replication	O
in	O
vivo	O
.	O

Mutants	O
lacking	O
any	O
tyrosine	O
residues	O
in	O
the	O
cytoplasmic	O
domain	O
maintain	O
their	O
ability	O
to	O
activate	O
STAT5	B-GENE
and	O
STAT1	B-GENE
but	O
cannot	O
activate	O
STAT3	B-GENE
,	O
implying	O
that	O
STAT5	B-GENE
and	O
STAT1	B-GENE
activation	O
does	O
not	O
require	O
receptor	O
tyrosine	O
phosphorylation	O
.	O

Tyrosine	O
112	O
of	O
latent	B-GENE
membrane	I-GENE
protein	I-GENE
2A	I-GENE
is	O
essential	O
for	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
loading	O
and	O
regulation	O
of	O
Epstein-Barr	O
virus	O
latency	O
.	O

The	O
status	O
of	O
education	O
and	O
training	O
programs	O
in	O
speech	O
pathology	O
and	O
audiology--1971-72	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
in	O
the	O
presence	O
of	O
tryptophan	O
the	O
ribosome	O
translating	O
tnaC	B-GENE
blocks	O
Rho's	O
access	O
to	O
the	O
boxA	B-GENE
and	O
rut	B-GENE
sites	I-GENE
,	O
thereby	O
preventing	O
transcription	O
termination	O
.	O

Recently	O
,	O
an	O
alternatively	O
spliced	O
form	O
of	O
c-myb-encoded	B-GENE
mRNA	I-GENE
has	O
been	O
identified	O
in	O
murine	O
cells	O
containing	O
either	O
normal	O
or	O
rearranged	O
c-myb	B-GENE
genes	I-GENE
.	O

A	O
comparative	O
study	O
was	O
undertaken	O
between	O
an	O
enzymatic	O
immunohistochemical	O
technique	O
(	O
EIT	O
)	O
developed	O
for	O
the	O
diagnosis	O
of	O
human	O
trichinellosis	O
and	O
the	O
indirect	O
immunofluorescence	O
test	O
(	O
IIF	O
)	O
,	O
analysing	O
sera	O
from	O
outbreaks	O
of	O
human	O
trichinellosis	O
in	O
Argentina	O
.	O

Endogenous	O
RMP	B-GENE
was	O
immunologically	O
detected	O
interacting	O
with	O
assembled	O
RPB5	B-GENE
in	O
RNA	B-GENE
polymerase	I-GENE
in	O
mammalian	O
cells	O
.	O

Transcriptional	O
activation	O
by	O
thyroid	O
hormone	O
(	O
T3	O
)	O
requires	O
interactions	O
between	O
the	O
T3	B-GENE
receptor	I-GENE
(	O
TR	B-GENE
)	O
and	O
T3	B-GENE
response	I-GENE
elements	I-GENE
(	O
TREs	B-GENE
)	O
composed	O
of	O
two	O
copies	O
of	O
sequences	O
related	O
to	O
AGGTCA	B-GENE
.	O

Fufang	O
wuzi	O
yanzong	O
pills	O
have	O
strong	O
leukogenic	O
effect	O
on	O
cyclophosphamide	O
induced	O
leukopenia	O
in	O
mice	O
.	O

Rhizobium	O
meliloti	O
large	O
plasmid	O
pRmeGR4b	O
carries	O
the	O
nodulation	O
competitiveness	O
locus	O
nfe	B-GENE
responsible	O
for	O
the	O
nodulation	O
efficiency	O
and	O
competitive	O
ability	O
of	O
strain	O
GR4	O
on	O
alfalfa	O
roots	O
.	O

Sp1	B-GENE
binds	O
the	O
CTC	O
repeat	O
with	O
an	O
affinity	O
,	O
KD	O
=	O
0	O
.	O
37	O
nM	O
,	O
at	O
least	O
as	O
high	O
as	O
the	O
consensus	O
GC	O
box	O
.	O

Clinical	O
aspects	O
of	O
early	O
increase	O
in	O
serum	O
gamma-glutamyl	B-GENE
transferase	I-GENE
in	O
cerebral	O
infarction	O
.	O

However	O
,	O
bilateral	O
diffuse	O
pulmonary	O
infiltrations	O
developed	O
21	O
days	O
later	O
.	O

A	O
cause	O
of	O
increase	O
of	O
alkaline	B-GENE
phosphatase	I-GENE
in	O
children	O
.	O

The	O
physical	O
linkage	O
of	O
the	O
FHR2	B-GENE
and	O
the	O
factor	B-GENE
H	I-GENE
genes	I-GENE
provides	O
additional	O
evidence	O
for	O
a	O
close	O
relatedness	O
of	O
complement	B-GENE
factor	I-GENE
H	I-GENE
and	O
the	O
factor	B-GENE
H-related	I-GENE
proteins	I-GENE
.	O

Protein	B-GENE
kinase	I-GENE
A-Ialpha	I-GENE
subunit-directed	O
antisense	O
inhibition	O
of	O
ovarian	O
cancer	O
cell	O
growth	O
:	O
crosstalk	O
with	O
tyrosine	B-GENE
kinase	I-GENE
signaling	O
pathway	O
.	O

BiP670	B-GENE
retains	O
basal	O
and	O
Ca2+	O
ionophore	O
A23187-inducible	O
activities	O
.	O

This	O
is	O
in	O
contrast	O
to	O
PPARgamma2	B-GENE
,	O
which	O
was	O
previously	O
shown	O
to	O
be	O
phosphorylated	O
at	O
a	O
single	O
site	O
in	O
a	O
motif	O
that	O
is	O
not	O
homologous	O
to	O
the	O
sites	O
now	O
described	O
in	O
PPARalpha	B-GENE
.	O

Materials	O
science	O
studies	O
on	O
the	O
soldering	O
of	O
different	O
orthodontic	O
wires	O
.	O

Also	O
,	O
the	O
EWS	B-GENE
protein	I-GENE
stimulates	O
transcription	O
mediated	O
by	O
the	O
COOH-terminal	O
transactivation	O
domain	O
of	O
the	O
cofactor	O
CREB-binding	B-GENE
protein	I-GENE
(	O
CBP	B-GENE
)	O
.	O

This	O
is	O
the	O
first	O
study	O
in	O
which	O
mutation	O
screening	O
has	O
been	O
performed	O
for	O
both	O
the	O
EXT1	B-GENE
and	O
EXT2	B-GENE
genes	I-GENE
prior	O
to	O
any	O
linkage	O
analysis	O
.	O

In	O
a	O
stepwise	O
logistic	O
regression	O
analysis	O
of	O
SPT	O
and	O
RAST	O
data	O
,	O
the	O
occurrence	O
of	O
serum	B-GENE
IgE	I-GENE
antibodies	I-GENE
to	I-GENE
P	I-GENE
.	I-GENE
orbiculare	I-GENE
had	O
the	O
highest	O
explanatory	O
value	O
for	O
current	O
eczema	O
.	O

Group	O
I	O
consisted	O
of	O
six	O
noncholestatic	O
patients	O
;	O
group	O
II	O
consisted	O
of	O
nine	O
mildly	O
cholestatic	O
patients	O
with	O
mild	O
hepatic	O
impairment	O
(	O
conjugated	O
bilirubin	O
,	O
47	O
mumol	O
liter-1	O
;	O
alkaline	B-GENE
phosphatase	I-GENE
,	O
280	O
IU	O
liter-1	O
;	O
gamma-glutamyltranspeptidase	B-GENE
,	O
190	O
IU	O
liter-1	O
)	O
;	O
group	O
III	O
consisted	O
of	O
six	O
benign	O
intrahepatic	O
cholestatic	O
patients	O
with	O
high	O
isolated	O
conjugated	O
hyperbilirubinemia	O
(	O
98	O
.	O
1	O
mumol	O
liter-1	O
)	O
.	O

Genitography	O
in	O
intersexual	O
states	O
.	O

To	O
understand	O
the	O
function	O
of	O
receptor-linked	B-GENE
tyrosine	I-GENE
phosphatases	I-GENE
in	O
neural	O
development	O
,	O
we	O
sought	O
to	O
identify	O
LAR	B-GENE
isoforms	I-GENE
preferentially	O
expressed	O
in	O
the	O
nervous	O
system	O
and	O
cellular	O
processes	O
regulating	O
LAR	B-GENE
alternative	O
splicing	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
pyridinium	O
cross-link	O
excretion	O
and	O
thyroid	O
hormone	O
concentrations	O
.	O

An	O
analysis	O
of	O
the	O
steady	O
state	O
RNA	O
levels	O
in	O
T-lymphoid	O
cell	O
lines	O
showed	O
that	O
at	O
least	O
three	O
different	O
incomplete	O
proviral	O
transcripts	O
and	O
their	O
spliced	O
products	O
made	O
up	O
the	O
majority	O
of	O
expressed	O
RD-114	B-GENE
mRNA	I-GENE
,	O
and	O
further	O
demonstrated	O
that	O
partially	O
deleted	O
proviral	O
loci	O
have	O
the	O
potential	O
to	O
be	O
transcriptionally	O
vigorous	O
in	O
certain	O
feline	O
cell	O
types	O
.	O

The	O
ATR-X	O
syndrome	O
results	O
from	O
mutations	O
of	O
the	O
XH2	B-GENE
gene	I-GENE
,	O
located	O
on	O
the	O
X	O
chromosome	O
(	O
Xq13	O
.	O
3	O
)	O
and	O
coding	O
for	O
a	O
transacting	O
factor	O
which	O
regulates	O
gene	O
expression	O
.	O

MPO	O
was	O
labeled	O
with	O
1	O
mCi	O
125I	O
by	O
a	O
technique	O
of	O
self-labeling	O
in	O
the	O
presence	O
of	O
10	O
(	O
-4	O
)	O
M	O
hydrogen	O
peroxide	O
.	O

These	O
data	O
establish	O
Smd1p	B-GENE
as	O
a	O
required	O
component	O
of	O
the	O
cellular	O
splicing	O
apparatus	O
and	O
a	O
factor	O
in	O
snRNA	O
maturation	O
and	O
stability	O
.	O

Erratum	O
to	O
:	O
corticostriatal	O
and	O
corticosubthalamic	O
input	O
zones	O
from	O
the	O
presupplementary	O
motor	O
area	O
in	O
the	O
macaque	O
monkey	O
:	O
comparison	O
with	O
the	O
input	O
zones	O
from	O
the	O
supplementary	O
motor	O
area	O
.	O

Their	O
use	O
resulted	O
in	O
a	O
sensitivity	O
of	O
73%	O
and	O
a	O
specificity	O
of	O
74%	O
with	O
regard	O
to	O
predictability	O
of	O
ALT	B-GENE
levels	O
increasing	O
during	O
the	O
trial	O
.	O

It	O
contains	O
25	O
exons	O
coding	O
for	O
a	O
4	O
.	O
7kb	O
transcript	O
including	O
large	O
5'-	O
and	O
3'-	O
(	O
1218bp	O
and	O
701bp	O
,	O
respectively	O
)	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
.	O

This	O
repression	O
was	O
mediated	O
through	O
binding	O
to	O
the	O
E2	B-GENE
DNA-binding	I-GENE
site	I-GENE
immediately	O
upstream	O
of	O
the	O
P105	B-GENE
promoter	O
TATA	O
box	O
and	O
could	O
be	O
abrogated	O
by	O
preincubation	O
of	O
the	O
HPV-18	B-GENE
P105	I-GENE
promoter	I-GENE
template	O
with	O
the	O
nuclear	O
extract	O
allowing	O
the	O
formation	O
of	O
the	O
preinitiation	O
complex	O
.	O

These	O
results	O
were	O
corroborated	O
in	O
a	O
subsequent	O
study	O
in	O
which	O
30	O
hypogonadal	O
men	O
were	O
supplemented	O
with	O
SLT	O
5	O
mg	O
three	O
times	O
daily	O
for	O
6	O
months	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
-DEDDDL	B-GENE
sequence	I-GENE
stabilizes	O
GDP	O
binding	O
to	O
Ran	B-GENE
,	O
and	O
that	O
the	O
domain	O
is	O
required	O
for	O
high	O
affinity	O
interaction	O
with	O
a	O
Ran-binding	B-GENE
protein	I-GENE
,	O
HTF9A	B-GENE
/	I-GENE
RanBP1	I-GENE
.	O

We	O
conclude	O
that	O
c-Abl	B-GENE
activates	O
c-myc	B-GENE
transcription	O
indirectly	O
with	O
no	O
requirement	O
for	O
DNA	O
binding	O
by	O
c-Abl	B-GENE
.	O

Differential	O
regulation	O
of	O
the	O
pre-C	O
and	O
pregenomic	O
promoters	O
of	O
human	O
hepatitis	O
B	O
virus	O
by	O
members	O
of	O
the	O
nuclear	B-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

Despite	O
this	O
DNA	O
binding	O
activity	O
,	O
AP-1	B-GENE
reporter	I-GENE
activity	O
was	O
suppressed	O
in	O
these	O
cells	O
.	O

Multiple	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
signaling	O
pathways	O
connect	O
the	O
cot	B-GENE
oncoprotein	I-GENE
to	O
the	O
c-jun	B-GENE
promoter	I-GENE
and	O
to	O
cellular	O
transformation	O
.	O

Inspection	O
of	O
enhancer	O
mutants	O
suggests	O
that	O
trans-activation	O
by	O
hLEF	B-GENE
/	I-GENE
GAL4	I-GENE
is	O
especially	O
dependent	O
on	O
TCF-2	B-GENE
,	O
a	O
distinct	O
T-cell-enriched	O
protein	O
that	O
binds	O
to	O
sequences	O
flanking	O
the	O
hLEF-binding	B-GENE
site	I-GENE
in	O
the	O
enhancer	O
.	O

Mapping	O
features	O
of	O
HIV-1	B-GENE
integrase	I-GENE
near	O
selected	O
sites	O
on	O
viral	O
and	O
target	O
DNA	O
molecules	O
in	O
an	O
active	O
enzyme-DNA	O
complex	O
by	O
photo-cross-linking	O
.	O

Surprisingly	O
,	O
calf	B-GENE
thymus	I-GENE
CstF	I-GENE
contained	O
an	O
additional	O
,	O
novel	O
form	O
of	O
the	O
64-kDa	O
subunit	O
with	O
a	O
molecular	O
mass	O
of	O
70	O
kDa	O
.	O

The	O
circadian	O
rhythm	O
,	O
however	O
,	O
was	O
not	O
affected	O
and	O
the	O
difference	O
between	O
minimum	O
(	O
12	O
.	O
00	O
h	O
)	O
and	O
maximum	O
(	O
18	O
.	O
50	O
h	O
)	O
serum	O
concentrations	O
was	O
31	O
.	O
3%	O
.	O

In	O
vitro	O
DNase	B-GENE
I	I-GENE
footprinting	O
showed	O
that	O
OxyR-C199S	B-GENE
protected	O
Pmom	B-GENE
from	O
-104	O
to	O
-46	O
on	O
the	O
top	O
strand	O
and	O
produced	O
a	O
protection	O
pattern	O
characteristic	O
of	O
reduced	B-GENE
wild-type	I-GENE
OxyR	I-GENE
.	O

Growth	B-GENE
factors	I-GENE
induce	O
the	O
expression	O
of	O
the	O
immediate	B-GENE
early	I-GENE
gene	I-GENE
products	I-GENE
MAP	B-GENE
kinase	I-GENE
phosphatase-1	I-GENE
(	O
MKP-1	B-GENE
)	O
,	O
c-Fos	B-GENE
and	O
c-Jun	B-GENE
.	O

There	O
are	O
regions	O
with	O
long	O
runs	O
of	O
up	O
to	O
45%	O
C	O
or	O
35%	O
G	O
residues	O
.	O

7	O
.	O

Three	O
monopolar	O
electrodes	O
were	O
inserted	O
into	O
the	O
left	O
and	O
right	O
lateral	O
vestibulospinal	O
tract	O
(	O
LVST	O
)	O
and	O
medial	O
vestibulospinal	O
tract	O
(	O
MVST	O
)	O
of	O
the	O
C1	O
segment	O
,	O
to	O
determine	O
the	O
pathway	O
of	O
axons	O
.	O

The	O
corresponding	O
inhibition	O
of	O
acid	B-GENE
phosphatase	I-GENE
activity	O
in	O
control	O
male	O
and	O
female	O
guinea	O
pigs	O
was	O
15	O
.	O
91%	O
and	O
20	O
.	O
33%	O
respectively	O
.	O

It	O
also	O
contains	O
a	O
picornaviral	B-GENE
3C-like	I-GENE
protease	I-GENE
domain	I-GENE
and	O
two	O
papain-like	B-GENE
protease	I-GENE
domains	I-GENE
.	O

It	O
is	O
concluded	O
that	O
stereotypy	O
can	O
be	O
evoked	O
also	O
in	O
the	O
case	O
when	O
the	O
striatal	O
dopaminergic	O
tone	O
is	O
normal	O
or	O
even	O
below	O
normal	O
:	O
it	O
is	O
the	O
equilibrium	O
of	O
the	O
striatal	O
cholinergic-dopaminergic	O
systems	O
which	O
must	O
be	O
shifted	O
towards	O
dopamine	O
,	O
which	O
is	O
necessary	O
for	O
the	O
development	O
of	O
this	O
behavioral	O
manifestation	O
.	O

All	O
other	O
normal	O
and	O
transformed	O
lymphoid	O
and	O
nonlymphoid	O
cell	O
lines	O
and	O
normal	O
tissues	O
were	O
negative	O
for	O
PANG	B-GENE
expression	O
except	O
for	O
the	O
brain	O
,	O
wherein	O
unique	O
4	O
.	O
0-	O
and	O
6	O
.	O
1-kb	O
transcripts	O
were	O
detected	O
.	O

A	O
cDNA	O
,	O
cak1At	B-GENE
,	O
was	O
isolated	O
that	O
suppressed	O
the	O
CAK	B-GENE
mutation	I-GENE
in	O
budding	O
yeast	O
,	O
and	O
it	O
also	O
complemented	O
a	O
fission	B-GENE
yeast	I-GENE
CAK	I-GENE
mutant	I-GENE
.	O
cak1At	B-GENE
encodes	O
a	O
protein	O
related	O
to	O
animal	B-GENE
CAKs	I-GENE
.	O

The	O
main	O
aim	O
of	O
the	O
contribution	O
,	O
which	O
opens	O
an	O
arena	O
for	O
discussion	O
on	O
the	O
Rivista	O
dell'Infermiere	O
is	O
to	O
critically	O
appraise	O
published	O
research	O
works	O
focusing	O
both	O
on	O
strengths	O
and	O
novelty	O
and	O
weaknesses	O
in	O
the	O
hypothesis	O
formulation	O
,	O
methods	O
and	O
instruments	O
used	O
,	O
discussion	O
of	O
results	O
.	O

The	O
result	O
suggests	O
that	O
this	O
non-invasive	O
TTD	O
method	O
is	O
easily	O
available	O
and	O
useful	O
in	O
monitoring	O
the	O
intraoperative	O
cardiac	O
output	O
.	O

The	O
HGF-induced	O
cell	O
motility	O
was	O
mimicked	O
by	O
12-0-tetradecanoyl-phorbol-13-acetate	O
,	O
a	O
protein	B-GENE
kinase	I-GENE
C-activating	O
phorbol	O
ester	O
,	O
but	O
not	O
by	O
Ca2+	O
ionophore	O
.	O

These	O
results	O
demonstrate	O
that	O
a	O
class	O
of	O
proline-rich	O
activator	O
proteins	O
and	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
possess	O
a	O
common	O
structural	O
and	O
functional	O
component	O
which	O
can	O
interact	O
with	O
the	O
same	O
target	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

In	O
this	O
paper	O
,	O
such	O
lesions	O
in	O
two	O
cases	O
were	O
evaluated	O
by	O
ultrasonography	O
.	O

Another	O
mutant	O
,	O
T255A	O
,	O
lost	O
the	O
ability	O
to	O
bind	O
E4orf6	B-GENE
,	O
but	O
unexpectedly	O
,	O
viral	O
late-gene	O
expression	O
was	O
not	O
affected	O
.	O

In	O
addition	O
,	O
they	O
display	O
common	O
features	O
that	O
make	O
them	O
strikingly	O
related	O
to	O
snoRNA	B-GENE
U14	I-GENE
.	O

The	O
second	O
class	O
of	O
cDNA	O
hybridized	O
to	O
a	O
13	O
kb	O
transcript	O
,	O
which	O
was	O
approximately	O
twice	O
as	O
large	O
as	O
the	O
mammalian	B-GENE
lactase	I-GENE
mRNA	I-GENE
.	O

Five	O
modalities	O
of	O
nonpharmacologic	O
approaches	O
are	O
recommended	O
at	O
present	O
for	O
lifestyle	O
modification	O
and	O
control	O
of	O
arterial	O
blood	O
pressure	O
elevation	O
:	O
1	O
)	O
weight	O
reduction	O
to	O
ideal	O
body	O
weight	O
,	O
since	O
it	O
reduces	O
risk	O
of	O
hypertension	O
as	O
well	O
as	O
overall	O
cardiovascular	O
morbidity	O
and	O
mortality	O
;	O
2	O
)	O
dietary	O
sodium	O
restriction	O
to	O
less	O
than	O
2	O
g	O
a	O
day	O
,	O
without	O
assurance	O
that	O
it	O
will	O
normalize	O
arterial	O
pressure	O
although	O
it	O
may	O
help	O
reduce	O
dosage	O
and	O
numbers	O
of	O
prescribed	O
antihypertensive	O
drugs	O
;	O
3	O
)	O
moderation	O
of	O
alcohol	O
consumption	O
to	O
less	O
than	O
1	O
ounce	O
a	O
day	O
;	O
4	O
)	O
a	O
regular	O
isotonic	O
exercise	O
program	O
;	O
and	O
5	O
)	O
cessation	O
of	O
tobacco	O
consumption	O
.	O

The	O
corresponding	O
differences	O
in	O
FVIIa	B-GENE
and	O
PAI-1	B-GENE
were	O
not	O
statistically	O
significant	O
.	O

Deletion	O
mapping	O
of	O
the	O
human	B-GENE
presenilin-1	I-GENE
(	O
PS1	B-GENE
)	O
promoter	O
delineated	O
the	O
most	O
active	O
fragment	O
from	O
-118	O
to	O
+178	O
in	O
relation	O
to	O
the	O
transcription	O
start	O
site	O
mapped	O
in	O
this	O
study	O
,	O
in	O
both	O
human	O
neuroblastoma	O
SK-N-SH	O
and	O
hepatoma	O
HepG2	O
cells	O
.	O

Ariga	O
,	O
Biochem	O
.	O

The	O
feed	O
given	O
to	O
young	O
broiler	O
chickens	O
was	O
contaminated	O
artificially	O
with	O
Salmonella	O
kedougou	O
,	O
a	O
serotype	O
associated	O
with	O
both	O
subclinical	O
infections	O
in	O
commercially	O
reared	O
chickens	O
and	O
food	O
poisoning	O
in	O
humans	O
.	O

Src	B-GENE
homology	I-GENE
(	O
SH	B-GENE
)	O
domain	O
dependent	O
protein-protein	O
interactions	O
are	O
important	O
to	O
tyrosine	B-GENE
kinase	I-GENE
receptor	I-GENE
signal	O
transduction	O
.	O

J	O
.	O

It	O
suggests	O
a	O
sequence	O
of	O
surgical	O
planning	O
that	O
can	O
prevent	O
them	O
and	O
also	O
offers	O
ways	O
of	O
dealing	O
with	O
the	O
problems	O
should	O
they	O
occur	O
.	O

To	O
gain	O
insight	O
into	O
the	O
possible	O
involvement	O
of	O
p21	B-GENE
in	O
liver	O
cell	O
growth	O
,	O
the	O
expression	O
and	O
regulation	O
of	O
the	O
p21	B-GENE
gene	I-GENE
was	O
evaluated	O
in	O
rodent	O
models	O
of	O
liver	O
regeneration	O
and	O
specimens	O
of	O
human	O
liver	O
diseases	O
.	O

In	O
a	O
randomised	O
double-blind	O
study	O
,	O
46	O
first	O
episode	O
schizophrenics	O
were	O
given	O
pimozide	O
or	O
flupenthixol	O
for	O
up	O
to	O
5	O
weeks	O
;	O
the	O
mean	O
daily	O
dose	O
at	O
the	O
end	O
was	O
18	O
.	O
8	O
mg	O
pimozide	O
and	O
20	O
mg	O
flupenthixol	O
.	O

A	O
limited	O
study	O
in	O
a	O
glassware	O
factory	O
(	O
As2O3	O
exposure	O
)	O
involving	O
the	O
measurement	O
of	O
total	O
airborne	O
arsenic	O
,	O
the	O
determination	O
of	O
urinary	O
arsenic	O
,	O
and	O
the	O
evaluation	O
of	O
hand	O
and	O
mouth	O
contamination	O
by	O
arsenic	O
before	O
and	O
after	O
the	O
workshift	O
suggests	O
that	O
the	O
high	O
urinary	O
arsenic	O
levels	O
(	O
300	O
microgram	O
/	O
g	O
creatinine	O
)	O
are	O
likely	O
to	O
be	O
more	O
related	O
to	O
an	O
increased	O
oral	O
intake	O
from	O
contaminated	O
hands	O
than	O
to	O
an	O
increased	O
absorption	O
from	O
the	O
lungs	O
.	O

The	O
enzyme	O
activities	O
studied	O
are	O
important	O
elements	O
in	O
the	O
pathophysiology	O
of	O
dental	O
caries	O
and	O
may	O
even	O
be	O
addressed	O
as	O
virulence	O
factors	O
.	O

A	O
central	O
finding	O
is	O
the	O
identification	O
of	O
a	O
GC-rich	O
sequence	O
in	O
the	O
-99	O
/	O
-91	O
Cp	O
region	O
that	O
is	O
essential	O
for	O
oriPI-EBNA1-independent	O
as	O
well	O
as	O
oriPI-EBNA1-dependent	O
activity	O
of	O
the	O
promoter	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
cyclin	B-GENE
E	I-GENE
,	O
in	O
contrast	O
to	O
cyclin	B-GENE
D1	I-GENE
,	O
was	O
required	O
for	O
the	O
G1	O
/	O
S	O
transition	O
even	O
in	O
cells	O
lacking	O
retinoblastoma	B-GENE
protein	I-GENE
function	O
.	O

In	O
patients	O
resistant	O
to	O
VAD	O
,	O
high-dose	O
therapies	O
with	O
intravenous	O
melphalan	O
,	O
a	O
CBV	O
combination	O
(	O
cyclophosphamide-BCNU-VP-16	O
)	O
or	O
an	O
EDAP	O
regimen	O
(	O
VP-16	O
-platinum	O
)	O
produced	O
responses	O
in	O
about	O
40%	O
of	O
patients	O
.	O

Whereas	O
p82	B-GENE
expression	O
had	O
no	O
effect	O
on	O
ERK2	B-GENE
activation	O
by	O
p126	B-GENE
,	O
p70	B-GENE
completely	O
abrogated	O
this	O
activity	O
.	O

We	O
tested	O
10	O
rats	O
with	O
electrophysiologically	O
guided	O
,	O
ibotenic	O
acid	O
lesions	O
of	O
the	O
PBN	O
(	O
PBNx	O
)	O
to	O
determine	O
whether	O
they	O
could	O
acquire	O
a	O
LiCl-induced	O
CTA	O
to	O
l-alanine	O
(	O
0	O
.	O
3	O
M	O
)	O
or	O
demonstrate	O
a	O
sodium	O
appetite	O
following	O
furosemide	O
treatment	O
and	O
overnight	O
access	O
to	O
sodium	O
deficient	O
chow	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
competition	O
experiments	O
showed	O
that	O
site	O
A	O
is	O
recognized	O
by	O
an	O
NF1	B-GENE
protein	I-GENE
.	O

Drosophila	B-GENE
orthodenticle	I-GENE
(	O
otd	B-GENE
)	O
and	O
murine	B-GENE
Otx	I-GENE
genes	I-GENE
exemplify	O
this	O
,	O
both	O
in	O
terms	O
of	O
expression	O
patterns	O
and	O
mutant	O
phenotypes	O
.	O

The	O
ARG	B-GENE
SH2	B-GENE
domain	I-GENE
exhibited	O
relatively	O
weak	O
affinity	O
for	O
BCR	B-GENE
and	O
was	O
determined	O
to	O
bind	O
about	O
10-fold	O
less	O
strongly	O
than	O
the	O
ABL	B-GENE
SH2	B-GENE
domain	I-GENE
.	O

At	O
an	O
ambient	O
temperature	O
of	O
25	O
degrees	O
C	O
,	O
the	O
responses	O
to	O
spinal	O
cooling	O
are	O
reduced	O
during	O
the	O
dark	O
phase	O
.	O

Time	O
delay	O
effects	O
on	O
the	O
tensile	O
bond	O
strength	O
developed	O
by	O
the	O
Silicoater	O
.	O

Liver	O
TG	O
and	O
serum	O
NEFA	O
concentrations	O
were	O
positively	O
correlated	O
.	O

We	O
show	O
that	O
HRI	B-GENE
and	O
dsRNA-PK	B-GENE
phosphorylate	O
yeast	B-GENE
eIF-2	I-GENE
alpha	I-GENE
in	O
vitro	O
and	O
in	O
vivo	O
and	O
functionally	O
substitute	O
for	O
GCN2	B-GENE
protein	I-GENE
to	O
stimulate	O
GCN4	B-GENE
translation	O
in	O
yeast	O
.	O

Two	O
soybean	O
cDNA	O
clones	O
,	O
SPK-3	B-GENE
and	O
SPK-4	B-GENE
,	O
encoding	O
putative	O
protein	B-GENE
kinases	I-GENE
were	O
isolated	O
and	O
characterized	O
.	O

At	O
60	O
days	O
the	O
amount	O
of	O
gangliosides	O
was	O
on	O
average	O
lower	O
in	O
females	O
than	O
in	O
males	O
,	O
even	O
if	O
with	O
some	O
exception	O
.	O

Mechanism	O
in	O
the	O
sequential	O
control	O
of	O
cell	O
morphology	O
and	O
S	O
phase	O
entry	O
by	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
involves	O
distinct	O
MEK	B-GENE
/	I-GENE
ERK	I-GENE
activations	O
.	O

Eleven	O
strains	O
of	O
Fusarium	O
poae	O
and	O
F	O
.	O
sporotrichioides	O
from	O
the	O
U	O
.	O
S	O
.	O
S	O
.	O
R	O
.	O
and	O
7	O
strains	O
of	O
these	O
species	O
and	O
one	O
of	O
F	O
.	O
sporotrichioides	O
var	O
.	O
tricinctum	O
from	O
U	O
.	O
S	O
.	O
A	O
.	O
and	O
France	O
have	O
been	O
compared	O
as	O
to	O
their	O
capacity	O
to	O
yield	O
T-2	B-GENE
toxin	I-GENE
.	O

In	O
a	O
randomized	O
double-blind	O
cross-over	O
study	O
,	O
the	O
subjects	O
received	O
theophylline	O
5	O
mg	O
.	O
kg-1	O
per	O
day	O
with	O
omeprazole	O
20	O
mg	O
per	O
day	O
or	O
identical	O
placebo	O
during	O
two	O
periods	O
,	O
each	O
of	O
7	O
days	O
,	O
separated	O
by	O
a	O
washout	O
period	O
of	O
7	O
days	O
.	O

This	O
conclusion	O
was	O
confirmed	O
by	O
Northern	O
blotting	O
analysis	O
of	O
the	O
5'-flanking	O
region	O
of	O
CAD	B-GENE
gene	I-GENE
.	O

The	O
ARF	B-GENE
promoter	I-GENE
was	O
also	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
E2F1	B-GENE
expression	O
,	O
in	O
keeping	O
with	O
previous	O
results	O
at	O
the	O
RNA	O
level	O
.	O

Thus	O
,	O
chronic	O
hematocrit	O
decrease	O
induced	O
by	O
H	O
or	O
P	O
resulted	O
in	O
a	O
significant	O
fall	O
in	O
blood	O
pressure	O
compared	O
to	O
control	O
(	O
201	O
+	O
/	O
-	O
3	O
v	O
175	O
+	O
/	O
-	O
4	O
,	O
167	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
,	O
respectively	O
;	O
P	O
<	O
.	O
05	O
)	O
.	O

Radiation	O
therapy	O
was	O
effective	O
in	O
controlling	O
symptomatic	O
metastasis	O
in	O
all	O
three	O
patients	O
.	O

Further	O
analysis	O
of	O
this	O
DNA	O
fragment	O
showed	O
that	O
four	O
genes	O
are	O
present	O
encoding	O
proteins	O
of	O
16	O
,	O
18	O
.	O
5	O
,	O
21	O
and	O
89	O
kDal	O
.	O

Since	O
the	O
integrated	O
13h00-16h00	O
plasma	O
cortisol	O
estimation	O
is	O
cheaper	O
and	O
simpler	O
than	O
the	O
mean	O
13h00-16h00	O
plasma	O
cortisol	O
estimation	O
,	O
we	O
recommend	O
it	O
as	O
an	O
adjunct	O
in	O
the	O
diagnosis	O
of	O
Cushing's	O
syndrome	O
.	O

Using	O
an	O
interspecific	O
backcross	O
panel	O
,	O
we	O
localized	O
both	O
Gng3	B-GENE
and	O
Gng3lg	B-GENE
to	O
the	O
same	O
locus	O
on	O
chromosome	O
19	O
.	O

Brucellosis--1990	O
.	O

An	O
ELISA	O
procedure	O
was	O
developed	O
for	O
monitoring	O
the	O
specific	O
IgE	B-GENE
response	O
in	O
dogs	O
to	O
Dirofilaria	O
immitis	O
infection	O
.	O

The	O
malignity	O
of	O
nevoid	O
lentigo	O
.	O

In	O
adherent	O
macrophages	O
,	O
absence	O
of	O
CD45	B-GENE
led	O
to	O
the	O
hyperphosphorylation	O
and	O
hyperactivation	O
of	O
p56	B-GENE
/	I-GENE
59	I-GENE
(	I-GENE
hck	I-GENE
)	I-GENE
and	O
p53	B-GENE
/	I-GENE
56	I-GENE
(	I-GENE
lyn	I-GENE
)	I-GENE
,	O
but	O
not	O
of	O
p58	B-GENE
(	I-GENE
c-fgr	I-GENE
)	I-GENE
.	O

Additionally	O
,	O
I	B-GENE
kappa	I-GENE
B	I-GENE
beta	I-GENE
,	O
but	O
not	O
I	B-GENE
kappa	I-GENE
B	I-GENE
alpha	I-GENE
,	O
also	O
prevented	O
the	O
binding	O
of	O
Rel	B-GENE
to	O
the	O
kappa	B-GENE
B	I-GENE
site	I-GENE
.	O

Although	O
Pho85	B-GENE
is	O
not	O
essential	O
for	O
viability	O
,	O
Pcl1	B-GENE
,	I-GENE
2-Pho85	I-GENE
kinase	I-GENE
complexes	I-GENE
become	O
essential	O
for	O
Start	O
in	O
the	O
absence	O
of	O
Cln1	B-GENE
,	I-GENE
2-Cdc28	I-GENE
kinases	I-GENE
.	O

Exploratory-motor	O
task	O
to	O
evaluate	O
right	O
frontal	O
lobe	O
damage	O
.	O

Study	O
of	O
the	O
alterations	O
of	O
intestinal	O
absorption	O
,	O
by	O
means	O
of	O
I-131-triolein	O
,	O
in	O
the	O
whole	O
body	O
irradiated	O
rat	O
.	O

Cortisone	O
induced	O
bone	O
changes	O
and	O
its	O
response	O
to	O
lipid	O
clearing	O
agents	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
reliable	O
and	O
culturally	O
meaningful	O
exercise	O
self-efficacy	O
questionnaire	O
for	O
older	O
Mexican	O
American	O
women	O
.	O

Following	O
seizure	O
induction	O
,	O
MABP	O
increased	O
to	O
105	O
mm	O
Hg	O
and	O
brain	O
pHi	O
fell	O
to	O
6	O
.	O
79	O
+	O
/	O
-	O
0	O
.	O
03	O
within	O
15	O
min	O
and	O
remained	O
at	O
this	O
level	O
for	O
1	O
h	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
in	O
the	O
subgroup	O
with	O
normal	O
Ht	O
(	O
<	O
0	O
.	O
45	O
l	O
/	O
l	O
;	O
n	O
=	O
201	O
)	O
there	O
was	O
a	O
significant	O
reduction	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
the	O
mortality	O
after	O
3	O
months	O
(	O
27%	O
and	O
16%	O
,	O
respectively	O
)	O
and	O
an	O
increase	O
of	O
independence	O
at	O
home	O
(	O
35%	O
and	O
48%	O
,	O
respectively	O
)	O
due	O
to	O
a	O
reduction	O
of	O
the	O
viscosity	O
by	O
means	O
of	O
haemodilution	O
with	O
albumin	B-GENE
(	O
a	O
specific	O
viscosity	O
effect	O
in	O
the	O
normovolaemic	O
group	O
)	O
.	O

A	O
stable	O
heterologous	O
cell	O
line	O
containing	O
the	O
mouse	B-GENE
TRH	I-GENE
receptor	I-GENE
was	O
constructed	O
by	O
transfection	O
of	O
nonexcitable	O
293	O
cells	O
,	O
which	O
lack	O
L	O
channel	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
the	O
function	O
of	O
the	O
DS2	B-GENE
may	O
be	O
the	O
protection	O
of	O
the	O
nuclear	O
DNA	O
from	O
desiccation	O
.	O

A	O
recently	O
described	O
protein	O
,	O
metaxin	B-GENE
1	I-GENE
,	O
serves	O
as	O
a	O
component	O
of	O
a	O
preprotein	O
import	O
complex	O
in	O
the	O
outer	O
membrane	O
of	O
the	O
mammalian	O
mitochondrion	O
.	O

Thyrotoxicosis	O
due	O
to	O
amiodarone	O
is	O
difficult	O
to	O
treat	O
and	O
is	O
further	O
complicated	O
by	O
the	O
pro-arrhythmic	O
potential	O
of	O
thyrotoxicosis	O
and	O
the	O
fading	O
antiarrhythmic	O
effect	O
after	O
amiodarone	O
withdrawal	O
.	O

RESULTS	O
:	O
The	O
age	O
distribution	O
was	O
28	O
to	O
83	O
years	O
old	O
(	O
mean	O
was	O
54	O
.	O
1	O
years	O
)	O
.	O

Univariate	O
statistical	O
analysis	O
based	O
on	O
Kaplan-Meier-estimates	O
and	O
Log-Rank-Test	O
showed	O
the	O
following	O
prognostically	O
beneficial	O
factors	O
:	O
Limited	O
disease	O
stage	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
NSE	O
serum	O
level	O
less	O
than	O
25	O
micrograms	O
/	O
l	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
serum	O
alkaline	B-GENE
phosphatase	I-GENE
less	O
than	O
200	O
U	O
/	O
l	O
(	O
p	O
=	O
0	O
.	O
035	O
)	O
,	O
normal	O
serum	O
albumin	B-GENE
(	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
activity	O
index	O
of	O
minimum	O
of	O
70	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

GAP	O
JUNCTIONS	O
IN	O
THE	O
BRAIN	O
:	O
PREFACE	O
.	O

The	O
new	O
semi-synthetic	O
oral	O
cephalosporin	O
,	O
CGP	O
9	O
,	O
000	O
,	O
has	O
been	O
evaluated	O
in	O
a	O
large	O
number	O
of	O
hospitalized	O
patients	O
with	O
urinary	O
infections	O
.	O

Piroxicam	O
produced	O
a	O
lower	O
incidence	O
of	O
gastric	O
ulcers	O
than	O
equivalent	O
doses	O
of	O
indomethacin	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
with	O
each	O
of	O
these	O
sequences	O
demonstrated	O
complexes	O
with	O
mobilities	O
identical	O
to	O
those	O
of	O
the	O
NF-kappa	B-GENE
B	I-GENE
site	I-GENE
from	O
the	O
kappa	B-GENE
light-chain	I-GENE
gene	I-GENE
.	O

Taken	O
together	O
,	O
these	O
findings	O
show	O
that	O
16K	B-GENE
hPRL	I-GENE
inhibits	O
the	O
VEGF-induced	O
Ras	B-GENE
activation	O
;	O
this	O
antagonism	O
represents	O
a	O
novel	O
and	O
potentially	O
important	O
mechanism	O
for	O
the	O
control	O
of	O
angiogenesis	O
.	O

Transfection	O
with	O
a	O
CSF-1R	B-GENE
expression	O
plasmid	O
permitted	O
CSF-1-dependent	O
activation	O
of	O
the	O
signalling	O
pathway	O
targeting	O
an	O
Ets	B-GENE
/	I-GENE
AP1	I-GENE
(	O
activator	B-GENE
protein	I-GENE
1	I-GENE
)	O
element	O
in	O
the	O
uPA	B-GENE
promoter	I-GENE
that	O
has	O
been	O
shown	O
previously	O
to	O
be	O
a	O
target	O
of	O
oncogenic	B-GENE
ras	I-GENE
and	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
pathways	I-GENE
.	O

During	O
the	O
1980's	O
,	O
quantifications	O
of	O
immunoserological	O
testings	O
,	O
especially	O
C	B-GENE
reactive	I-GENE
protein	I-GENE
,	O
rheumatoid	B-GENE
factor	I-GENE
and	O
antistreptolysin	B-GENE
O	I-GENE
,	O
progressed	O
rapidly	O
.	O

It	O
is	O
shown	O
that	O
,	O
for	O
any	O
periodic	O
input	O
,	O
the	O
map	O
representing	O
the	O
relation	O
between	O
input	O
phases	O
at	O
consecutive	O
discharge	O
times	O
can	O
be	O
restricted	O
to	O
a	O
piecewise	O
continuous	O
,	O
orientation	O
preserving	O
circle	O
map	O
.	O

Evidence	O
that	O
therapeutic	O
alterations	O
of	O
a	O
circadian	O
rhythm	O
for	O
gastric	O
emptying	O
response	O
may	O
be	O
possible	O
.	O

It	O
is	O
the	O
human	O
homolog	O
of	O
the	O
mouse	B-GENE
Mx	I-GENE
protein	I-GENE
involved	O
in	O
resistance	O
to	O
influenza	O
virus	O
.	O

Accumulations	O
of	O
Tl+1	O
(	O
202Tl	O
label	O
)	O
were	O
6	O
times	O
those	O
for	O
Ga	O
or	O
In	O
in	O
the	O
brain	O
and	O
muscles	O
,	O
and	O
.	O
1	O
times	O
in	O
plasma	O
.	O

These	O
results	O
indicate	O
that	O
during	O
pregnancy	O
there	O
are	O
increases	O
in	O
bone	O
formation	O
rates	O
contributing	O
to	O
the	O
increases	O
in	O
skeletal	O
mass	O
.	O

CBT	O
is	O
discussed	O
in	O
comparison	O
with	O
the	O
Wisconsin	O
Card	O
Sorting	O
Test	O
as	O
a	O
potential	O
cognitive	O
activation	O
task	O
for	O
functional	O
neuroimaging	O
of	O
the	O
frontal	O
lobes	O
.	O

In	O
a	O
recent	O
measles	O
epidemic	O
in	O
El	O
Paso	O
,	O
TX	O
,	O
120	O
,	O
000	O
records	O
were	O
screened	O
using	O
these	O
criteria	O
,	O
and	O
as	O
a	O
result	O
13	O
,	O
000	O
students	O
were	O
vaccinated	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
the	O
cloning	O
of	O
the	O
germ	O
cell-specific	O
,	O
nuclear	B-GENE
orphan	I-GENE
receptor	I-GENE
germ	I-GENE
cell	I-GENE
nuclear	I-GENE
factor	I-GENE
(	I-GENE
GCNF	I-GENE
)	I-GENE
/	I-GENE
RTR	I-GENE
.	O

(	O
1991	O
)	O
.	O

Appropriate	O
restriction	O
sites	O
allow	O
one	O
to	O
insert	O
virtually	O
any	O
desired	O
cDNA	O
fragment	O
directly	O
behind	O
the	O
epitope-specific	O
sequence	O
and	O
before	O
a	O
long	O
poly	O
(	O
A	O
)	O
tail	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
estrogen-inducible	O
pS2	B-GENE
breast	B-GENE
cancer	I-GENE
marker	I-GENE
gene	I-GENE
by	O
the	O
ERR	B-GENE
family	I-GENE
of	O
orphan	B-GENE
nuclear	I-GENE
receptors	I-GENE
.	O

The	O
promoter	O
activity	O
of	O
the	O
proximal	O
region	O
was	O
found	O
to	O
be	O
restricted	O
to	O
a	O
subset	O
of	O
prestalk	O
cells	O
.	O

Such	O
an	O
increase	O
in	O
the	O
steady-state	O
testicular	B-GENE
TIMP-2	I-GENE
mRNA	I-GENE
level	O
apparently	O
is	O
not	O
the	O
result	O
of	O
an	O
up-regulation	O
by	O
germ	O
cells	O
because	O
germ	O
cells	O
cocultured	O
with	O
Sertoli	O
cells	O
failed	O
to	O
elicit	O
an	O
increase	O
in	O
the	O
Sertoli	O
cell	O
steady-state	O
TIMP-2	B-GENE
mRNA	I-GENE
level	O
.	O

Transgenic	O
mice	O
harboring	O
the	O
rat	B-GENE
TnI-CAT	I-GENE
fusion	I-GENE
gene	I-GENE
expressed	O
the	O
reporter	O
specifically	O
in	O
the	O
skeletal	O
muscle	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
indicate	O
that	O
the	O
C-terminal	O
24	O
amino	O
acids	O
are	O
sufficient	O
for	O
NodO	B-GENE
secretion	O
although	O
the	O
region	O
adjacent	O
to	O
this	O
domain	O
appears	O
to	O
affect	O
secretion	O
efficiency	O
.	O

A	O
rabbit	O
antiserum	O
was	O
raised	O
against	O
a	O
synthetic	O
peptide	O
corresponding	O
to	O
a	O
hydrophilic	O
portion	O
of	O
the	O
translated	O
murine	O
cDNA	O
sequence	O
.	O

Substantial	O
evidence	O
supports	O
a	O
critical	O
role	O
for	O
the	O
activation	O
of	O
the	O
Raf-1	B-GENE
/	I-GENE
MEK	I-GENE
/	I-GENE
mitogen-activated	I-GENE
protein	I-GENE
kinase	I-GENE
pathway	I-GENE
in	O
oncogenic	O
Ras-mediated	O
transformation	O
.	O

The	O
3'	O
fragment	O
was	O
shown	O
to	O
accumulate	O
as	O
full-length	O
mRNA	O
disappeared	O
in	O
actinomycin	O
D-treated	O
cells	O
,	O
indicating	O
a	O
precursor-product	O
relationship	O
.	O

Relation	O
between	O
mixing	O
ratio	O
of	O
raw	O
materials	O
and	O
composition	O
of	O
products	O
in	O
the	O
synthesis	O
of	O
aluminosilicates	O
.	O

I	O
.	O

The	O
purified	O
recombinant	O
enzyme	O
catalyzed	O
specific	O
phosphoryl	O
transfer	O
from	O
ATP	O
to	O
UMP	O
and	O
CMP	O
.	O

The	O
course	O
of	O
endotoxin	B-GENE
fever	O
remained	O
uninfluenced	O
by	O
ALS	O
.	O

The	O
brackets	O
were	O
bonded	O
to	O
100	O
freshly	O
extracted	O
bovine	O
incisors	O
,	O
and	O
,	O
after	O
storage	O
in	O
tap	O
water	O
at	O
room	O
temperature	O
for	O
24	O
hours	O
,	O
they	O
were	O
subsequently	O
tested	O
in	O
a	O
shear	O
mode	O
using	O
a	O
universal	O
testing	O
machine	O
.	O

Potential	O
consensus	O
sequences	O
for	O
early	O
and	O
late	O
regulatory	O
elements	O
were	O
identified	O
.	O

Sequencing	O
of	O
a	O
1	O
.	O
3-kilobase	O
fragment	O
of	O
the	O
5'-flanking	O
region	O
of	O
the	O
TSG6	B-GENE
gene	I-GENE
identified	O
TATA-like	O
and	O
CAAT	O
sequences	O
near	O
the	O
transcription	O
start	O
site	O
.	O

In	O
support	O
of	O
clinical	O
antianginal	O
studies	O
,	O
the	O
vasodilator	O
nicorandil	O
(	O
NIC	O
)	O
was	O
combined	O
with	O
the	O
beta-adrenergic	B-GENE
receptor	I-GENE
antagonists	O
propranolol	O
(	O
PRO	O
)	O
and	O
atenolol	O
(	O
ATN	O
)	O
and	O
with	O
the	O
calcium	O
channel	O
blocker	O
diltiazem	O
(	O
DTZ	O
)	O
to	O
determine	O
their	O
cardiovascular	O
and	O
pharmacokinetic	O
interactions	O
.	O

When	O
the	O
downstream	O
operator	O
was	O
altered	O
,	O
there	O
was	O
a	O
fourfold	O
reduction	O
in	O
reporter	O
enzyme	O
levels	O
.	O

Tyrosine	O
phosphorylated	O
STATs	B-GENE
dimerize	O
and	O
translocate	O
into	O
the	O
nucleus	O
to	O
activate	O
specific	O
genes	O
.	O

The	O
fepA-entD	B-GENE
and	O
fes-entF	B-GENE
operons	I-GENE
in	O
the	O
enterobactin	O
synthesis	O
and	O
transport	O
system	O
are	O
divergently	O
transcribed	O
from	O
overlapping	O
promoters	O
,	O
and	O
both	O
are	O
inhibited	O
by	O
the	O
Fur	B-GENE
repressor	I-GENE
protein	I-GENE
under	O
iron-replete	O
conditions	O
.	O

Results	O
from	O
transient	O
assays	O
using	O
these	O
mutants	O
showed	O
that	O
the	O
DE1	B-GENE
received	O
signals	O
from	O
phytochromes	O
A	O
and	O
B	O
,	O
demonstrating	O
that	O
this	O
element	O
is	O
indeed	O
a	O
light-responsive	O
element	O
.	O

Experiments	O
on	O
23	O
white	O
rats	O
and	O
10	O
guinea	O
pigs	O
have	O
shown	O
that	O
preliminarily	O
indomethacin-induced	O
inhibition	O
of	O
prostaglandins	O
synthesis	O
prevented	O
development	O
of	O
pulmonary	O
oedema	O
,	O
evoked	O
by	O
heterologous	O
serum	O
in	O
rats	O
and	O
by	O
vagotomy	O
in	O
guinea	O
pigs	O
.	O

After	O
1	O
.	O
5	O
years	O
of	O
such	O
photoperiodic	O
control	O
,	O
all	O
ewes	O
were	O
blinded	O
by	O
bilateral	O
orbital	O
enucleation	O
.	O

Refined	O
Cox	O
models	O
using	O
a	O
CD4	B-GENE
count	O
of	O
150	O
/	O
microL	O
rather	O
than	O
200	O
/	O
microL	O
to	O
distinguish	O
I0	O
and	O
I1	O
yielded	O
a	O
simplified	O
model	O
with	O
better	O
fit	O
to	O
the	O
observed	O
data	O
.	O

The	O
RPO1	B-GENE
of	O
LCDV	O
shows	O
the	O
highest	O
similarity	O
to	O
the	O
RPO1	B-GENE
of	O
IIV6	O
and	O
significant	O
lower	O
similarity	O
to	O
the	O
eukaryotic	B-GENE
polymerases	I-GENE
II	I-GENE
and	I-GENE
III	I-GENE
as	O
well	O
as	O
to	O
the	O
archaebacteral	O
subunit	O
.	O

Other	O
assays	O
also	O
distinguished	O
the	O
processive	O
replication	O
of	O
pNeo	O
.	O
Myc-2	O
.	O
4	O
from	O
the	O
dispersive	O
labeling	O
of	O
control	O
plasmids	O
.	O

Next	O
,	O
to	O
identify	O
regions	O
of	O
the	O
promoter	O
involved	O
,	O
we	O
examined	O
a	O
series	O
of	O
tenascin-C	B-GENE
promoter	I-GENE
constructs	I-GENE
with	O
5'	O
deletions	O
and	O
showed	O
that	O
denatured	O
collagen-dependent	B-GENE
promoter	I-GENE
activity	O
was	O
retained	O
by	O
a	O
122-base	O
pair	O
element	O
,	O
located	O
-43	O
to	O
-165	O
bp	O
upstream	O
of	O
the	O
RNA	O
start	O
site	O
.	O

Thus	O
adaptation	O
to	O
continuous	O
mild	O
stress	O
has	O
a	O
potent	O
antiarrhythmic	O
effect	O
which	O
occurs	O
due	O
to	O
the	O
increased	O
vagal	O
tone	O
.	O

Because	O
Trp53	B-GENE
(	O
the	O
mouse	B-GENE
homolog	I-GENE
of	I-GENE
human	I-GENE
TP53	I-GENE
)	O
is	O
located	O
with	O
Tk1	B-GENE
on	O
chromosome	O
11	O
and	O
is	O
critical	O
in	O
regulating	O
cellular	O
responses	O
following	O
exposure	O
to	O
DNA	O
damaging	O
agents	O
,	O
we	O
wanted	O
to	O
determine	O
if	O
these	O
mouse	O
lymphoma	O
cells	O
harbor	O
mutations	O
in	O
Trp53	B-GENE
.	O

We	O
concluded	O
that	O
activation	O
of	O
c-fosER	B-GENE
mediated	O
transcriptional	O
inhibition	O
of	O
p21	B-GENE
(	I-GENE
Cip1	I-GENE
/	I-GENE
WAF1	I-GENE
)	I-GENE
through	O
a	O
previously	O
uncharacterized	O
AP-1	B-GENE
site	I-GENE
,	O
revealing	O
an	O
important	O
role	O
for	O
c-fos	B-GENE
in	O
negative	O
control	O
of	O
cell	O
cycle	O
regulatory	O
genes	O
.	O

On	O
the	O
other	O
hand	O
,	O
phosphatidyl	O
inositol	O
4	O
,	O
5	O
bisphosphate	O
(	O
PIP2	O
)	O
hydrolysis	O
requires	O
direct	O
phosphorylation	O
at	O
tyrosine	O
residue	O
of	O
the	O
PLC-gamma1	B-GENE
isozyme	I-GENE
.	O

In	O
the	O
IA	O
task	O
,	O
post-training	O
intraperitoneal	O
injections	O
of	O
picrotoxin	O
and	O
bicuculline	O
induced	O
a	O
dose-dependent	O
enhancement	O
of	O
retention	O
measured	O
24	O
h	O
after	O
the	O
training	O
,	O
while	O
retention	O
was	O
not	O
affected	O
by	O
bicuculline	O
methiodide	O
(	O
a	O
GABA	B-GENE
receptor	I-GENE
antagonist	O
that	O
does	O
not	O
readily	O
cross	O
the	O
blood-brain	O
barrier	O
)	O
.	O

The	O
actA	B-GENE
gene	I-GENE
is	O
present	O
as	O
a	O
single	O
copy	O
in	O
the	O
genome	O
of	O
A	O
.	O
chrysogenum	O
;	O
and	O
its	O
expression	O
level	O
,	O
opposite	O
to	O
pcbC	B-GENE
and	O
cefEF	B-GENE
cephalosporin	I-GENE
biosynthetic	I-GENE
genes	I-GENE
,	O
was	O
steady	O
during	O
cephalosporin	B-GENE
fermentation	O
,	O
showing	O
a	O
single	O
1	O
.	O
4-kb	O
transcript	O
.	O

The	O
antibody	O
titer	O
of	O
202	O
chickens	O
to	O
SA-11	O
rotavirus	O
was	O
determined	O
by	O
enzyme-linked	O
immunosorbent	O
blocking	O
assay	O
.	O

Therefore	O
,	O
recombinant	O
human	O
Ads	O
that	O
express	O
noninfectious	O
HIV	O
or	O
other	O
microbial	O
proteins	O
are	O
attractive	O
vaccine	O
candidates	O
.	O

Based	O
on	O
a	O
morphological	O
study	O
of	O
the	O
resin-dentine	O
interface	O
,	O
a	O
broad	O
selection	O
of	O
dentine	O
adhesive	O
systems	O
was	O
classified	O
following	O
their	O
adhesion-strategy	O
.	O

Chronic	O
graft-versus-host	O
disease	O
(	O
cGVHD	O
)	O
is	O
a	O
major	O
complication	O
of	O
allogeneic	O
hematopoietic	O
cell	O
transplantation	O
.	O

These	O
women	O
should	O
not	O
be	O
given	O
the	O
current	O
estrogen	O
PPI	O
,	O
which	O
was	O
designed	O
to	O
warn	O
women	O
of	O
the	O
risks	O
of	O
long-term	O
estrogen	O
use	O
;	O
a	O
PPI	O
should	O
be	O
written	O
specifically	O
for	O
patients	O
receiving	O
short	O
courses	O
.	O

For	O
SMX	O
at	O
pH	O
7	O
.	O
0	O
,	O
a	O
1	O
:	O
1	O
complex	O
is	O
formed	O
,	O
but	O
at	O
pH	O
7	O
.	O
5	O
HPCD	O
has	O
little	O
effect	O
on	O
the	O
solubility	O
of	O
the	O
highly	O
ionized	O
SMX	O
,	O
presumably	O
since	O
only	O
un-ionized	O
molecules	O
can	O
form	O
inclusion	O
complexes	O
with	O
the	O
HPCD	O
.	O

With	O
such	O
analysis	O
,	O
one	O
can	O
test	O
hypotheses	O
about	O
the	O
structure	O
of	O
latent	O
variability	O
within	O
a	O
given	O
data	O
set	O
.	O

Here	O
,	O
we	O
propose	O
that	O
an	O
antagonistic	O
,	O
BMP	O
/	O
ALK2	O
/	O
Smad-mediated	O
signaling	O
pathway	O
is	O
active	O
on	O
the	O
right	O
side	O
of	O
the	O
Xenopus	O
embryo	O
.	O

The	O
hsp70	B-GENE
gene	I-GENE
family	I-GENE
of	O
Neurospora	O
crassa	O
:	O
cloning	O
,	O
sequence	O
analysis	O
,	O
expression	O
,	O
and	O
genetic	O
mapping	O
of	O
the	O
major	O
stress-inducible	O
member	O
.	O

The	O
process	O
has	O
been	O
applied	O
to	O
the	O
river	O
reclamation	O
in	O
Yangpu	O
District	O
of	O
Shanghai	O
City	O
,	O
China	O
.	O

FK	O
33-824	O
,	O
a	O
methionine-enkephalin	O
analogue	O
,	O
suppressed	O
plasma	O
ACTH	B-GENE
to	O
85%	O
of	O
basal	O
level	O
,	O
while	O
bromocriptine	O
(	O
CB-154	O
)	O
caused	O
no	O
significant	O
change	O
.	O

Most	O
of	O
the	O
patients	O
had	O
locally	O
advanced	O
lesions	O
(	O
63	O
T3-4	O
:	O
91	O
.	O
5%	O
)	O
according	O
to	O
the	O
adopted	O
TNM	O
system	O
(	O
Lederman-Gadeberg	O
,	O
Sisson-Jesse	O
)	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
SNF2	B-GENE
,	O
SNF5	B-GENE
,	O
and	O
SNF6	B-GENE
function	O
interdependently	O
in	O
transcriptional	O
activation	O
,	O
possibly	O
forming	O
a	O
heteromeric	O
complex	O
.	O

There	O
were	O
5	O
treatments	O
:	O
control	O
(	O
C	O
)	O
;	O
a	O
wooden	O
surround	O
in	O
one	O
rear	O
corner	O
of	O
the	O
cage	O
(	O
S	O
)	O
;	O
a	O
fiberglass	O
rollaway	O
hollow	O
in	O
one	O
rear	O
corner	O
of	O
the	O
cage	O
(	O
H	O
)	O
;	O
a	O
hollow	O
and	O
a	O
surround	O
(	O
H	O
/	O
S	O
)	O
;	O
a	O
nest	O
box	O
attached	O
to	O
the	O
back	O
of	O
the	O
cage	O
,	O
containing	O
a	O
hollow	O
(	O
N	O
)	O
.	O

Sinusoidal	O
oscillations	O
of	O
a	O
gas	O
dilution	O
indicator	O
.	O

Shoulder	O
forearm	O
support	O
for	O
the	O
subluxed	O
shoulder	O
.	O

The	O
effects	O
of	O
glutaraldehyde	O
on	O
dimensions	O
and	O
ultrastructure	O
of	O
microvascular	O
beds	O
in	O
rat	O
mesentery	O
were	O
studied	O
in	O
two	O
kinds	O
of	O
experiment	O
,	O
administering	O
the	O
fixative	O
by	O
intra-arterial	O
perfusion	O
at	O
a	O
pressure	O
of	O
80	O
mm	O
Hg	O
and	O
by	O
superfusion	O
of	O
the	O
exteriorized	O
mesenteric	O
membrane	O
.	O

METHODS	O
:	O
Rats	O
received	O
continuous	O
intragastric	O
infusion	O
of	O
elemental	O
diet	O
or	O
with	O
supplementation	O
of	O
oatbase	O
,	O
Lactobacillus	O
reuteri	O
R2LC	O
,	O
and	O
Lactobacillus	O
plantarum	O
DSM	O
9843	O
,	O
with	O
and	O
without	O
fermentation	O
,	O
from	O
the	O
beginning	O
of	O
the	O
study	O
.	O

The	O
examinations	O
were	O
performed	O
on	O
two	O
groups	O
of	O
20	O
(	O
using	O
AmF	O
/	O
SnF2	O
)	O
-	O
,	O
resp	O
.	O

The	O
Ntl1	B-GENE
gene	I-GENE
is	O
present	O
as	O
a	O
unique	O
copy	O
in	O
the	O
diploid	O
N	O
.	O
plumbaginifolia	O
species	O
.	O

Overexpression	O
of	O
PTTG	B-GENE
in	O
transfected	O
NIH	O
3T3	O
cells	O
also	O
stimulated	O
expression	O
and	O
secretion	O
of	O
basic	B-GENE
fibroblast	I-GENE
growth	I-GENE
factor	I-GENE
,	O
a	O
human	O
pituitary	O
tumor	O
growth-regulating	O
factor	O
.	O

Apropos	O
of	O
a	O
case	O
.	O

After	O
age	O
30	O
,	O
mean	O
hemoglobin	B-GENE
levels	O
for	O
men	O
gradually	O
declined	O
,	O
while	O
those	O
in	O
women	O
rose	O
,	O
so	O
that	O
the	O
sex	O
difference	O
diminished	O
after	O
60	O
years	O
of	O
age	O
.	O

Familial	O
autoimmune	O
hepatitis	O
and	O
C4	B-GENE
deficiency	O
.	O

Biol	O
.	O

Among	O
unusual	O
features	O
,	O
we	O
report	O
numerous	O
large	O
G	O
+	O
C-rich	O
conserved	O
sequences	O
located	O
in	O
the	O
first	O
intron	O
.	O

The	O
Nur77	B-GENE
protein	I-GENE
can	O
act	O
as	O
a	O
potent	O
transcription	O
activator	O
and	O
may	O
function	O
to	O
regulate	O
the	O
expression	O
of	O
downstream	O
genes	O
in	O
response	O
to	O
extracellular	O
stimuli	O
.	O

DNase	B-GENE
I	I-GENE
footprinting	O
with	O
rat	O
liver	O
nuclear	O
extracts	O
identified	O
7	O
major	O
protein-binding	O
domains	O
termed	O
P1	B-GENE
through	O
P7	B-GENE
in	O
a	O
796	O
base	O
pair	O
DNA	O
fragment	O
(	O
base	O
pairs	O
-763	O
to	O
+33	O
)	O
.	O

The	O
observed	O
triplexes	O
depend	O
on	O
the	O
length	O
of	O
the	O
repeat	O
.	O

This	O
element	O
,	O
termed	O
CREsp-a	B-GENE
(	O
TGACCTCA	B-GENE
)	O
,	O
differs	O
by	O
one	O
nucleotide	O
from	O
a	O
palindromic	O
CRE	B-GENE
(	O
CREpal	B-GENE
,	O
TGACGTCA	B-GENE
)	O
,	O
which	O
is	O
known	O
to	O
bind	O
CREB	B-GENE
as	O
a	O
homodimer	O
.	O

Its	O
vasodilatory	O
,	O
anti-vasopressor	O
,	O
and	O
platelet	O
stabilizing	O
effects	O
could	O
be	O
expected	O
to	O
counteract	O
the	O
placental	O
ischemia	O
,	O
hypertension	O
and	O
excessive	O
coagulation	O
that	O
are	O
seen	O
in	O
pre-eclampsia	O
.	O

Transient	O
transfection	O
assays	O
using	O
P19	O
cells	O
revealed	O
that	O
expression	O
of	O
NDRF	B-GENE
/	I-GENE
NeuroD2	I-GENE
increased	O
the	O
transactivation	O
of	O
the	O
rat	B-GENE
insulin	I-GENE
promoter	I-GENE
element	I-GENE
3	I-GENE
(	O
RIPE3	B-GENE
)	O
enhancer	O
up	O
to	O
approximately	O
12-fold	O
and	O
that	O
co-expression	O
of	O
catalytically	O
active	O
form	O
of	O
PKN	B-GENE
,	O
but	O
not	O
kinase-deficient	O
derivative	O
,	O
resulted	O
in	O
a	O
further	O
threefold	O
increase	O
of	O
NDRF	O
/	O
NeuroD2-mediated	O
transcription	O
.	O

Platelet	O
aggregation	O
in	O
response	O
to	O
10	O
micrograms	O
collagen	O
/	O
ml	O
was	O
decreased	O
in	O
parallel	O
after	O
treatment	O
with	O
ASA	O
.	O

Low-dose	O
aspirin	O
and	O
recurrent	O
miscarriage	O
.	O

Arhythmacanthus	O
Yamaguti	O
,	O
1935	O
is	O
maintained	O
as	O
a	O
synonym	O
of	O
Heterosentis	O
because	O
the	O
distinction	O
between	O
two	O
and	O
three	O
hook	O
types	O
is	O
made	O
equivocal	O
when	O
the	O
transition	O
between	O
the	O
apical	O
and	O
subapical	O
hooks	O
is	O
gradual	O
.	O

Autorosette-forming	O
cells	O
are	O
characterized	O
by	O
a	O
high	O
activity	O
of	O
alkaline	B-GENE
and	I-GENE
acid	I-GENE
phosphatases	I-GENE
and	O
low	O
NBT-test	O
values	O
.	O

The	O
spectrum	O
of	O
histologically	O
diagnosed	O
malignant	O
neoplasms	O
in	O
Sabah	O
,	O
1983-1988	O
.	O

Eight	O
recombinant	O
DNA	O
clones	O
of	O
endogenous	O
murine	O
leukemia	O
virus	O
(	O
MuLV	O
)	O
-related	O
DNA	O
sequences	O
have	O
been	O
isolated	O
from	O
a	O
lambdaphage	O
genomic	O
library	O
of	O
Balb	O
/	O
c	O
mouse	O
DNA	O
.	O

A	O
cDNA	O
cloning	O
vector	O
that	O
permits	O
expression	O
of	O
cDNA	O
inserts	O
in	O
mammalian	O
cells	O
.	O

When	O
transiently	O
transfected	O
into	O
K562	O
cells	O
,	O
this	O
Lg	B-GENE
genomic	O
clone	O
is	O
actively	O
transcribed	O
,	O
suggesting	O
that	O
,	O
although	O
it	O
possesses	O
the	O
characteristics	O
of	O
a	O
processed	O
pseudogene	O
,	O
it	O
is	O
likely	O
to	O
correspond	O
to	O
the	O
gene	O
encoding	O
this	O
new	O
ferritin	B-GENE
subunit	I-GENE
.	O

The	O
murine	B-GENE
Htf9-a	I-GENE
/	I-GENE
RanBP1	I-GENE
and	O
Htf9-c	B-GENE
genes	I-GENE
are	O
divergently	O
transcribed	O
from	O
a	O
shared	O
TATA-less	O
promoter	O
.	O

Under	O
these	O
schedules	O
,	O
a	O
reinforced	O
response	O
run	O
consisted	O
of	O
responding	O
between	O
eight	O
and	O
12	O
times	O
on	O
one	O
response	O
key	O
(	O
work	O
key	O
)	O
and	O
then	O
responding	O
once	O
on	O
a	O
second	O
response	O
key	O
(	O
reinforced	O
key	O
)	O
.	O

AIMS	O
:	O
To	O
evaluate	O
the	O
role	O
of	O
environmental	O
intra-uterine	O
factors	O
in	O
determining	O
the	O
birthweights	O
of	O
twins	O
with	O
increased	O
susceptibility	O
to	O
diabetes	O
and	O
discordant	O
for	O
abnormal	O
responses	O
to	O
the	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
and	O
verify	O
the	O
possible	O
association	O
of	O
within-pair	O
birthweight	O
differences	O
and	O
metabolic	O
abnormalities	O
in	O
adult	O
life	O
.	O

Although	O
large	O
epidemiologic	O
studies	O
are	O
best	O
able	O
to	O
identify	O
the	O
relative	O
contributions	O
of	O
specific	O
risk	O
factors	O
while	O
controlling	O
for	O
other	O
risk	O
factors	O
,	O
new	O
studies	O
need	O
to	O
focus	O
on	O
important	O
unresolved	O
questions	O
.	O

Amino	O
acid	O
sequence	O
comparison	O
revealed	O
significant	O
homology	O
between	O
the	O
yeast	B-GENE
and	I-GENE
Escherichia	I-GENE
coli	I-GENE
gamma-glutamyl	I-GENE
kinases	I-GENE
throughout	O
their	O
lengths	O
.	O

Tumours	O
of	O
the	O
cavum	O
oris	O
and	O
oropharynx	O
of	O
T1-stage	O
are	O
possible	O
only	O
in	O
1	O
of	O
3	O
cases	O
.	O

Expression	O
and	O
regulation	O
by	O
interferon	O
of	O
a	O
double-stranded-RNA-specific	B-GENE
adenosine	I-GENE
deaminase	I-GENE
from	O
human	O
cells	O
:	O
evidence	O
for	O
two	O
forms	O
of	O
the	O
deaminase	B-GENE
.	O

The	O
ZNF274	B-GENE
gene	I-GENE
is	O
mapped	O
distal	O
to	O
marker	O
RP	O
S28	O
1	O
in	O
the	O
human	O
chromosome	O
19qter	O
region	O
,	O
by	O
RH	O
mapping	O
.	O

In	O
ICU	O
patients	O
,	O
the	O
LIS	O
related	O
to	O
the	O
postoperative	O
rise	O
in	O
IL-6	B-GENE
level	O
only	O
,	O
even	O
though	O
the	O
rise	O
in	O
plasma	O
concentrations	O
of	O
cytokines	O
interrelated	O
.	O

Gene	O
constructs	O
possessing	O
the	O
complete	B-GENE
tat	I-GENE
,	O
rev	B-GENE
(	O
tat+	B-GENE
rev+	B-GENE
)	O
and	O
env	B-GENE
genes	I-GENE
were	O
transiently	O
expressed	O
in	O
COS-1	O
cells	O
as	O
precursor	B-GENE
SU-TM	I-GENE
(	O
gp160	B-GENE
)	O
,	O
SU	B-GENE
.	I-GENE
TM	I-GENE
(	O
gp120	B-GENE
x	I-GENE
41	I-GENE
)	O
,	O
and	O
nucleolar	B-GENE
rev	I-GENE
protein	I-GENE
.	O

The	O
population	O
studied	O
comprised	O
4472	O
men	O
and	O
5212	O
women	O
aged	O
30-74	O
years	O
,	O
without	O
coronary	O
heart	O
disease	O
,	O
who	O
had	O
CRP	O
measurements	O
in	O
the	O
Third	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
III	O
)	O
.	O

V	O
.	O

Disruption	O
of	O
ARF2	B-GENE
causes	O
no	O
detectable	O
phenotype	O
.	O

The	O
analysis	O
of	O
two	O
distinct	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
pathways	O
shows	O
that	O
stress-activated	B-GENE
protein	I-GENE
kinase-Jun	I-GENE
N-terminal	I-GENE
kinase	I-GENE
activation	O
,	O
resulting	O
in	O
the	O
phosphorylation	O
of	O
ATF-2	B-GENE
,	O
c-Jun	B-GENE
,	O
and	O
JunD	B-GENE
,	O
is	O
required	O
not	O
only	O
for	O
the	O
IL-1-	O
but	O
also	O
for	O
the	O
TPA-dependent	O
induction	O
,	O
while	O
the	O
extracellular	B-GENE
signal-related	I-GENE
kinase	I-GENE
1	I-GENE
(	O
ERK-1	B-GENE
)	O
and	O
ERK-2	B-GENE
activation	O
is	O
involved	O
in	O
the	O
TPA-	O
but	O
not	O
in	O
the	O
IL-1-dependent	O
stimulation	O
of	O
the	O
uPA	B-GENE
enhancer	I-GENE
.	O

The	O
specific	O
electrical	O
resistance	O
of	O
the	O
cerebrospinal	O
fluid	O
was	O
measured	O
by	O
means	O
of	O
conductometry	O
in	O
14	O
cases	O
of	O
meningitis	O
purulenta	O
,	O
17	O
cases	O
of	O
meningitis	O
serosa	O
,	O
10	O
cases	O
of	O
encephalitis	O
and	O
in	O
32	O
control	O
subjects	O
.	O

Incubation	O
of	O
the	O
purified	O
fusion	O
proteins	O
with	O
[	O
gamma-32P	O
]	O
ATP	O
in	O
an	O
in	O
vitro	O
assay	O
showed	O
that	O
both	O
proteins	O
were	O
capable	O
of	O
autophosphorylation	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
resistant	O
genotypes	O
exist	O
among	O
the	O
WAD	O
goat	O
population	O
.	O

Complete	O
nucleotide	O
sequence	O
of	O
the	O
bacteriophage	B-GENE
K1F	I-GENE
tail	I-GENE
gene	I-GENE
encoding	O
endo-N-acylneuraminidase	B-GENE
(	O
endo-N	B-GENE
)	O
and	O
comparison	O
to	O
an	O
endo-N	B-GENE
homolog	I-GENE
in	O
bacteriophage	O
PK1E	O
.	O

In	O
human	O
brain	O
,	O
contactin	B-GENE
was	O
first	O
identified	O
by	O
amino	O
terminal	O
and	O
peptide	O
sequencing	O
of	O
the	O
lentil-lectin-binding	B-GENE
glycoprotein	I-GENE
Gp135	I-GENE
.	O

It	O
was	O
argued	O
that	O
this	O
arose	O
from	O
the	O
possibility	O
that	O
the	O
nature	O
of	O
blue	O
collar	O
jobs	O
was	O
physical	O
,	O
and	O
that	O
loss	O
of	O
myocardial	O
tissue	O
might	O
be	O
expected	O
to	O
more	O
markedly	O
interfere	O
with	O
their	O
work	O
efficiency	O
(	O
on	O
returning	O
to	O
work	O
)	O
than	O
it	O
would	O
the	O
efficiency	O
of	O
the	O
more	O
sedentary	O
jobs	O
of	O
white	O
collar	O
workers	O
.	O

Based	O
on	O
the	O
occurrence	O
of	O
several	O
transcription	O
signals	O
in	O
the	O
Thermus	B-GENE
pyr	I-GENE
promoter	I-GENE
region	I-GENE
and	O
strong	O
amino	O
acid	O
sequence	O
identities	O
(	O
about	O
60%	O
)	O
between	O
Thermus	B-GENE
PyrR	I-GENE
and	O
the	O
PyrR	B-GENE
attenuation	I-GENE
proteins	I-GENE
of	O
two	O
Bacillus	O
sp	O
.	O
,	O
we	O
propose	O
a	O
regulatory	O
mechanism	O
involving	O
transcriptional	O
attenuation	O
to	O
control	O
pyr	B-GENE
gene	I-GENE
expression	O
in	O
Thermus	O
.	O

The	O
sensitivity	O
of	O
human	O
neuroblastoma	O
cells	O
SK-N-SH	O
to	O
undergo	O
apoptosis	O
induced	O
by	O
thapsigargin	O
was	O
examined	O
.	O

Detection	O
of	O
airborne	O
Mycobacterium	O
tuberculosis	O
by	O
air	O
filtration	O
and	O
polymerase	B-GENE
chain	O
reaction	O
.	O

Functional	O
flow	O
was	O
evaluated	O
using	O
laser	O
Doppler	O
flowmetry	O
(	O
LDF	O
)	O
,	O
for	O
which	O
the	O
output	O
signal	O
,	O
blood	O
cell	O
flux	O
(	O
BCF	O
)	O
,	O
is	O
expressed	O
in	O
terms	O
of	O
volts	O
.	O

The	O
bHLH	B-GENE
proteins	I-GENE
function	O
as	O
potent	O
transcriptional	O
activators	O
of	O
tissue-specific	O
genes	O
by	O
forming	O
heterodimers	O
between	O
ubiquitous	O
and	O
cell-restricted	O
family	O
members	O
.	O

Evoked	O
potential	O
and	O
single	O
unit	O
responses	O
to	O
olfactory	O
nerve	O
volleys	O
in	O
the	O
isolated	O
turtle	O
olfactory	O
bulb	O
.	O

Selection	O
was	O
based	O
on	O
expression	O
of	O
an	O
integrated	O
DNA	O
fragment	O
containing	O
the	O
con-10	B-GENE
promoter-regulatory	I-GENE
region	I-GENE
followed	O
by	O
the	O
initial	O
segment	O
of	O
the	O
con-10	B-GENE
open	I-GENE
reading	I-GENE
frame	I-GENE
fused	O
in	O
frame	O
with	O
the	O
bacterial	B-GENE
hygromycin	I-GENE
B	I-GENE
phosphotransferase	I-GENE
structural	I-GENE
gene	I-GENE
(	O
con10'-'hph	B-GENE
)	O
.	O

3	O
Significant	O
reductions	O
in	O
lying	O
mean	O
arterial	O
blood	O
pressure	O
were	O
observed	O
with	O
daily	O
doses	O
of	O
200	O
mg	O
(	O
-	O
9%	O
)	O
,	O
400	O
mg	O
(	O
-	O
10%	O
)	O
and	O
800	O
mg	O
(	O
-	O
14%	O
)	O
,	O
and	O
were	O
associated	O
with	O
significant	O
decreases	O
in	O
heart	O
rate	O
and	O
plasma	B-GENE
renin	I-GENE
activity	O
.	O

The	O
antilog	O
transformation	O
of	O
pH	O
did	O
not	O
improve	O
the	O
results	O
.	O

All	O
33	O
subjects	O
were	O
given	O
psychometric	O
instruments	O
for	O
measuring	O
various	O
components	O
of	O
anger	O
and	O
anxiety	O
:	O
Spielberger's	O
State-Trait	O
Personality	O
Inventory	O
,	O
the	O
Anger	O
Expression	O
Scale	O
,	O
and	O
the	O
State	O
Anger	O
Reaction	O
Scale	O
.	O

The	O
data	O
suggest	O
that	O
like	O
in	O
yeast	O
,	O
in	O
plants	O
a	O
certain	O
subfamily	O
of	O
UBC	B-GENE
is	O
specifically	O
involved	O
in	O
the	O
proteolytic	O
degradation	O
of	O
abnormal	O
proteins	O
as	O
result	O
of	O
stress	O
.	O

1	O
)	O
CFDN	O
,	O
AMPC	O
and	O
MNZ	O
showed	O
a	O
potent	O
antimicrobial	O
activity	O
against	O
H	O
.	O
pylori	O
,	O
and	O
especially	O
,	O
AMPC	O
showed	O
a	O
marked	O
bactericidal	O
activity	O
in	O
a	O
short	O
time	O
.	O

Tributyltin	O
and	O
its	O
breakdown	O
products	O
,	O
mono-	O
and	O
di-butyltin	O
,	O
were	O
determined	O
in	O
water	O
birds	O
collected	O
from	O
Lake	O
Huron	O
(	O
the	O
Great	O
Lakes	O
)	O
,	O
marine	O
coastal	O
United	O
States	O
,	O
and	O
the	O
west	O
coast	O
of	O
British	O
Columbia	O
,	O
Canada	O
.	O

Interleukin-8	B-GENE
(	O
IL-8	B-GENE
)	O
is	O
a	O
potent	O
inflammatory	O
mediator	O
that	O
belongs	O
to	O
the	O
family	O
of	O
C-X-C	B-GENE
chemokines	I-GENE
.	O

This	O
motif	O
,	O
first	O
described	O
for	O
the	O
Drosophila	B-GENE
homeobox	I-GENE
activator	I-GENE
DEAF-1	I-GENE
,	O
identifies	O
an	O
emerging	O
group	O
of	O
metazoan	O
transcriptional	O
modulators	O
.	O

Therefore	O
,	O
PC-PLC	B-GENE
is	O
a	O
component	O
of	O
a	O
signal	O
transduction	O
pathway	O
leading	O
to	O
transcription	O
of	O
c-fos	B-GENE
and	O
junB	B-GENE
that	O
collaborates	O
with	O
c-myc	B-GENE
and	O
is	O
independent	O
of	O
PKC-delta	B-GENE
and	O
Ras	B-GENE
activation	O
.	O

Peripheral	O
and	O
preemptive	O
opioid	O
antinociception	O
in	O
a	O
mouse	O
visceral	O
pain	O
model	O
.	O

G-DNA	B-GENE
is	O
a	O
four-stranded	O
DNA	O
structure	O
with	O
diverse	O
putative	O
biological	O
roles	O
.	O

Mean	O
total	O
lung	O
capacity	O
,	O
functional	O
residual	O
capacity	O
,	O
and	O
residual	O
volume	O
increased	O
significantly	O
,	O
and	O
the	O
mean	O
closing	O
volume	O
,	O
the	O
lung	O
volume	O
above	O
residual	O
volume	O
at	O
which	O
phase	O
IV	O
begins	O
,	O
decreased	O
significantly	O
with	O
11	O
cm	O
H20	O
continuous	O
positive	O
airway	O
pressure	O
;	O
differences	O
at	O
5	O
cm	O
H20	O
were	O
not	O
significant	O
.	O

Negatively	O
supercoiled	O
plasmid	O
pUC19	O
did	O
not	O
compete	O
,	O
whereas	O
an	O
otherwise	O
identical	O
plasmid	O
pUC19	O
(	O
CG	O
)	O
,	O
which	O
contained	O
a	O
(	O
dG-dC	O
)	O
7	O
segment	O
in	O
the	O
Z-form	O
was	O
an	O
excellent	O
competitor	O
.	O

Deletion	O
of	O
the	O
proximal	O
octanucleotide	O
motif	O
from	O
the	O
plasmid	O
containing	O
the	O
-461	O
fragment	O
of	O
the	O
LPL	B-GENE
promoter	I-GENE
,	O
resulted	O
in	O
a	O
79	O
and	O
76%	O
decrease	O
in	O
the	O
level	O
of	O
expression	O
in	O
transfected	O
3T3-L1	O
adipocytes	O
and	O
HepG2	O
hepatocytes	O
,	O
respectively	O
.	O

Whereas	O
MARTA1	B-GENE
is	O
clearly	O
detectable	O
in	O
crude	O
lysates	O
,	O
cytosolic	O
and	O
ribosomal	O
salt-wash	O
fractions	O
,	O
and	O
in	O
nuclear	O
extracts	O
,	O
MARTA2	B-GENE
is	O
preferentially	O
found	O
in	O
the	O
ribosomal	O
salt-wash	O
preparation	O
.	O

Blood	B-GENE
serum	I-GENE
erythropoietin	I-GENE
level	O
and	O
basic	O
hematological	O
indices	O
during	O
the	O
adaptation	O
of	O
healthy	O
newborn	O
infants	O
.	O

Angiotensin	B-GENE
II	I-GENE
induces	O
nuclear	B-GENE
factor	I-GENE
(	I-GENE
NF	I-GENE
)	I-GENE
-kappaB1	I-GENE
isoforms	I-GENE
to	O
bind	O
the	O
angiotensinogen	B-GENE
gene	I-GENE
acute-phase	O
response	O
element	O
:	O
a	O
stimulus-specific	O
pathway	O
for	O
NF-kappaB	B-GENE
activation	O
.	O

SETTING--Women	O
,	O
Infants	O
,	O
and	O
Children	O
clinics	O
in	O
Minneapolis	O
,	O
Minn	O
.	O

The	O
transit	O
time	O
was	O
significantly	O
shortened	O
.	O

Roles	O
of	O
the	O
Candida	B-GENE
albicans	I-GENE
mitogen-activated	I-GENE
protein	I-GENE
kinase	I-GENE
homolog	I-GENE
,	O
Cek1p	B-GENE
,	O
in	O
hyphal	O
development	O
and	O
systemic	O
candidiasis	O
.	O

By	O
using	O
reporter	O
gene	O
constructs	O
,	O
it	O
is	O
shown	O
that	O
upstream	O
sequences	O
of	O
the	O
P1	B-GENE
promoter	I-GENE
contain	O
several	O
regions	O
that	O
modulate	O
the	O
expression	O
either	O
positively	O
or	O
negatively	O
.	O

RESULTS	O
:	O
Using	O
information	O
in	O
the	O
dbEST	O
database	O
of	O
expressed	O
sequence	O
tags	O
,	O
we	O
isolated	O
an	O
Arabidopsis	O
thaliana	O
gene	O
(	O
GCR1	B-GENE
)	O
that	O
encodes	O
a	O
protein	O
with	O
seven	O
predicted	O
membrane-spanning	O
domains	O
and	O
other	O
features	O
characteristic	O
of	O
7TM	B-GENE
receptors	I-GENE
.	O

Gentamicin	O
given	O
by	O
DPI	O
and	O
SVN	O
significantly	O
decreased	O
the	O
sputum	O
Psa	O
density	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
by	O
almost	O
one	O
order	O
of	O
magnitude	O
.	O

The	O
210	O
kDa	O
precursor	O
is	O
converted	O
slowly	O
(	O
t	O
1	O
/	O
2	O
=	O
2	O
h	O
)	O
by	O
proteolytic	O
processing	O
into	O
a	O
125	O
kDa	O
(	O
alpha'	O
)	O
and	O
83	O
kDa	O
(	O
beta'	O
)	O
species	O
.	O

TATA	O
and	O
CCAAT	O
boxes	O
are	O
located	O
34-bp	O
and	O
68-bp	O
,	O
respectively	O
,	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
the	O
5'-untranslated	O
leader	O
is	O
78	O
nucleotides	O
long	O
,	O
and	O
the	O
intronless	O
gene	O
has	O
at	O
least	O
two	O
different	O
polyadenylation	O
sites	O
.	O

We	O
speculate	O
that	O
the	O
human	O
papillomavirus	O
late	O
mRNAs	O
,	O
produced	O
from	O
several	O
hundred	O
copies	O
of	O
the	O
virus	O
genome	O
present	O
in	O
infected	O
cells	O
,	O
compete	O
with	O
the	O
c-fos	B-GENE
mRNAs	I-GENE
for	O
destabilizing	O
cellular	O
factors	O
and	O
that	O
this	O
may	O
lead	O
to	O
elevated	O
Fos	B-GENE
protein	I-GENE
levels	O
in	O
human	O
papillomavirus	O
infected	O
cells	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
gene	O
has	O
significant	O
homology	O
to	O
the	O
interferon	B-GENE
regulatory	I-GENE
factors	I-GENE
(	O
IRFs	B-GENE
)	O
.	O

PET	O
activation	O
studies	O
are	O
performed	O
widely	O
to	O
study	O
human	O
brain	O
function	O
.	O

Deterministic	O
effects	O
.	O

Regulation	O
of	O
mitochondrial	B-GENE
single-stranded	I-GENE
DNA-binding	I-GENE
protein	I-GENE
gene	I-GENE
expression	O
links	O
nuclear	O
and	O
mitochondrial	O
DNA	O
replication	O
in	O
drosophila	O
.	O

In	O
mitogen-stimulated	O
splenocytes	O
,	O
Gfi-1	B-GENE
expression	O
begins	O
to	O
rise	O
at	O
12	O
h	O
after	O
stimulation	O
and	O
reaches	O
very	O
high	O
levels	O
after	O
50	O
h	O
,	O
suggesting	O
that	O
it	O
may	O
be	O
functionally	O
involved	O
in	O
events	O
occurring	O
after	O
the	O
interaction	O
of	O
IL-2	B-GENE
with	O
its	O
receptor	O
,	O
perhaps	O
during	O
the	O
transition	O
from	O
the	O
G1	O
to	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

The	O
LAMMER	B-GENE
protein	B-GENE
kinase	I-GENE
encoded	O
by	O
the	O
Doa	B-GENE
locus	I-GENE
of	O
Drosophila	O
is	O
required	O
in	O
both	O
somatic	O
and	O
germline	O
cells	O
and	O
is	O
expressed	O
as	O
both	O
nuclear	O
and	O
cytoplasmic	O
isoforms	O
throughout	O
development	O
.	O

Several	O
authors	O
have	O
recently	O
reported	O
interference	O
in	O
theophylline	O
analysis	O
by	O
paraxanthine	O
(	O
1	O
,	O
7-dimethylxanthine	O
)	O
,	O
an	O
important	O
metabolite	O
of	O
caffeine	O
.	O

An	O
immunoperoxidase	B-GENE
reaction	O
,	O
PAP	B-GENE
method	O
,	O
with	O
the	O
antiserum	O
of	O
Factor	B-GENE
VIII	I-GENE
as	O
the	O
primary	O
antibody	O
,	O
was	O
carried	O
out	O
in	O
the	O
endometrial	O
biopsies	O
to	O
detect	O
the	O
Factor	B-GENE
VIII	I-GENE
activity	O
in	O
the	O
endometrial	O
endothelium	O
before	O
and	O
after	O
insertion	O
of	O
LNG-IUD-20	O
.	O

Age	O
was	O
categorized	O
into	O
four	O
groups	O
:	O
20-44	O
,	O
45-64	O
,	O
65-74	O
,	O
and	O
75+	O
.	O
RESULTS	O
:	O
At	O
the	O
initiation	O
of	O
dialysis	O
PD	O
patients	O
were	O
approximately	O
6	O
years	O
younger	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
than	O
HD	O
patients	O
.	O

UPMC	O
is	O
not	O
the	O
only	O
organization	O
pursuing	O
controlled	O
NHBC	O
organ	O
procurement	O
,	O
however	O
.	O

Multivariate	O
Cox	O
survival	O
analysis	O
identified	O
baseline	O
EF	O
<	O
or	O
=	O
30%	O
,	O
presence	O
of	O
significant	O
mitral	O
regurgitation	O
(	O
>	O
2+	O
)	O
before	O
ablation	O
,	O
and	O
failure	O
to	O
exhibit	O
improved	O
cardiac	O
performance	O
by	O
1	O
month	O
after	O
ablation	O
as	O
the	O
only	O
independent	O
predictors	O
of	O
death	O
.	O

Functional	O
analysis	O
of	O
DNase-I	B-GENE
hypersensitive	O
sites	O
at	O
the	O
mouse	B-GENE
porphobilinogen	I-GENE
deaminase	I-GENE
gene	I-GENE
locus	I-GENE
.	O

The	O
synthetic	O
DNA	O
sequence	O
was	O
constructed	O
to	O
achieve	O
efficient	O
base	O
pairing	O
with	O
Escherichia	B-GENE
coli	I-GENE
16S	I-GENE
ribosomal	I-GENE
RNA	I-GENE
,	O
avoidance	O
of	O
internal	O
secondary	O
structure	O
,	O
and	O
optimal	O
codon	O
usage	O
for	O
high-level	O
protein	O
expression	O
in	O
accord	O
with	O
the	O
known	O
preferences	O
in	O
E	O
.	O
coli	O
.	O

Similarly	O
,	O
the	O
sequence	O
of	O
the	O
U2	B-GENE
RNA	I-GENE
region	I-GENE
shown	O
to	O
be	O
involved	O
in	O
pre-mRNA	O
branchpoint	O
recognition	O
in	O
yeast	O
,	O
and	O
exactly	O
conserved	O
in	O
metazoan	B-GENE
U2	I-GENE
RNAs	I-GENE
,	O
was	O
totally	O
divergent	O
in	O
trypanosomes	O
.	O

The	O
Ras-related	B-GENE
GTPases	I-GENE
are	O
small	O
,	O
20-	O
to	O
25-kDa	O
proteins	O
which	O
cycle	O
between	O
an	O
inactive	O
GDP-bound	O
form	O
and	O
an	O
active	O
GTP-bound	O
state	O
.	O

Cognitive	O
visual	O
dysfunction	O
in	O
a	O
child	O
with	O
cerebral	O
damage	O
.	O

The	O
most	O
common	O
characteristics	O
of	O
VRE	O
patients	O
were	O
recent	O
prior	O
vancomycin	O
use	O
,	O
recent	O
prior	O
susceptible	O
enterococcal	O
infection	O
,	O
coinfection	O
with	O
other	O
microbial	O
pathogens	O
,	O
and	O
concurrent	O
fungal	O
infection	O
.	O

Northern	O
and	O
Western	O
blot	O
analyses	O
demonstrated	O
that	O
Graf	B-GENE
2	I-GENE
is	O
expressed	O
in	O
several	O
tissues	O
,	O
with	O
the	O
highest	O
expression	O
in	O
skeletal	O
muscle	O
.	O

3D	O
image-processing	O
permits	O
to	O
analyse	O
ultrasound	O
data	O
interactively	O
in	O
three	O
orthogonal	O
planes	O
(	O
section	O
mode	O
)	O
or	O
in	O
realistic	O
3D	O
views	O
(	O
rendering	O
mode	O
)	O
.	O

Lac	O
operators	O
were	O
introduced	O
into	O
several	O
positions	O
within	O
the	O
CAB	B-GENE
promoter	I-GENE
and	O
operator-free	O
plasmid	O
was	O
used	O
as	O
control	O
.	O

c-Fos	B-GENE
transcriptional	O
activity	O
stimulated	O
by	O
H-Ras-activated	B-GENE
protein	I-GENE
kinase	I-GENE
distinct	O
from	O
JNK	B-GENE
and	O
ERK	B-GENE
.	O

However	O
,	O
if	O
EMPD	O
involves	O
the	O
glans	O
penis	O
or	O
perianal	O
area	O
,	O
a	O
search	O
for	O
internal	O
malignancy	O
is	O
still	O
warranted	O
.	O

There	O
was	O
a	O
significant	O
effect	O
of	O
hematocrit	O
on	O
the	O
General	O
Health	O
scale	O
on	O
the	O
SF-36	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
function	O
of	O
the	O
C-terminal	O
tail	O
in	O
telomere	O
maintenance	O
is	O
not	O
mediated	O
through	O
the	O
RAP1	B-GENE
interacting	I-GENE
factor	I-GENE
RIF1	B-GENE
:	O
rap1	B-GENE
alleles	I-GENE
defective	O
in	O
both	O
the	O
C-terminal	O
tail	O
and	O
RIF1	B-GENE
interaction	I-GENE
domains	I-GENE
have	O
additive	O
effects	O
on	O
telomere	O
length	O
.	O

Cloning	O
by	O
complementation	O
and	O
subsequent	O
physical	O
and	O
genetic	O
analysis	O
revealed	O
that	O
it	O
maps	O
to	O
RAF1	B-GENE
.	O

An	O
RNA-binding	B-GENE
protein	I-GENE
gene	I-GENE
(	O
rbp1	B-GENE
)	O
from	O
Drosophila	O
melanogaster	O
,	O
encoding	O
an	O
RNA	O
recognition	O
motif	O
and	O
an	O
Arg-Ser	O
rich	O
(	O
RS	O
)	O
domain	O
,	O
has	O
been	O
characterized	O
.	O

These	O
single	O
mutational	O
defects	O
in	O
the	O
eRF1-eRF3	B-GENE
interaction	O
became	O
evident	O
when	O
either	O
truncated	O
protein	O
eRF3C	B-GENE
or	O
C-terminally	O
altered	O
eRF1	B-GENE
proteins	O
were	O
used	O
for	O
the	O
authentic	O
protein	O
,	O
providing	O
further	O
support	O
for	O
the	O
presence	O
of	O
a	O
C-terminal	O
interaction	O
.	O

Eight-four	O
ACOAs	O
were	O
tested	O
in	O
order	O
to	O
examine	O
the	O
fit	O
of	O
the	O
model	O
to	O
the	O
data	O
by	O
path	O
analysis	O
with	O
LISREL	O
VII	O
.	O

In	O
conclusion	O
,	O
marmoset	B-GENE
monkey	I-GENE
LHR	I-GENE
seems	O
to	O
lack	O
the	O
sequence	O
corresponding	O
to	O
exon	O
10	O
of	O
the	O
LHR	B-GENE
gene	I-GENE
in	O
other	O
mammalian	O
species	O
.	O

By	O
deletion	O
analysis	O
of	O
the	O
MLS1	B-GENE
control	O
region	O
,	O
we	O
identified	O
two	O
sites	O
,	O
UAS1	B-GENE
and	O
UAS2	B-GENE
,	O
as	O
important	O
for	O
efficient	O
derepression	O
of	O
the	O
gene	O
.	O

3'	O
RNA	O
boundary	O
experiments	O
indicate	O
that	O
the	O
5'	O
structure	O
reduces	O
the	O
number	O
of	O
(	O
G	O
/	O
U	O
)	O
AG	O
repeats	O
required	O
for	O
stable	O
TRAP-trp	B-GENE
leader	I-GENE
RNA	I-GENE
association	O
.	O

Human	O
neutrophil	O
response	O
to	O
short-term	O
exposure	O
to	O
F-75	O
cobalt-based	O
alloy	O
.	O

Overexpressing	O
the	O
coactivator	O
,	O
SRC1a	B-GENE
or	O
GRIP1	B-GENE
,	O
further	O
enhances	O
ERRalpha1-induced	O
transcriptional	O
activity	O
.	O

Individuals	O
attending	O
the	O
GUM	O
Department	O
in	O
the	O
Royal	O
Infirmary	O
of	O
Edinburgh	O
between	O
1990	O
and	O
1994	O
with	O
the	O
diagnosis	O
of	O
HIV	O
infection	O
,	O
genital	O
warts	O
,	O
genital	O
herpes	O
,	O
non-specific	O
genital	O
infection	O
(	O
NSGI	O
)	O
,	O
gonorrhoea	O
and	O
syphilis	O
were	O
included	O
in	O
the	O
study	O
.	O

DMI	O
and	O
2-OH-DMI	O
concentrations	O
were	O
determined	O
in	O
a	O
similar	O
group	O
of	O
61	O
DMI-treated	O
patients	O
.	O

In	O
addition	O
,	O
insulin	B-GENE
induced	O
AP-1	B-GENE
DNA	O
binding	O
activity	O
,	O
this	O
effect	O
being	O
totally	O
prevented	O
in	O
the	O
presence	O
of	O
MEK-1	B-GENE
inhibitor	O
.	O

A	O
rate-decreasing	O
dose	O
of	O
physostigmine	O
,	O
an	O
acetylcholinesterase	B-GENE
inhibitor	O
,	O
was	O
studied	O
in	O
combination	O
with	O
the	O
range	O
of	O
atropine	O
doses	O
.	O

(	O
5	O
)	O
An	O
increase	O
in	O
leukocyte-counts	O
occurred	O
on	O
the	O
administration	O
of	O
serum	O
obtained	O
from	O
rabbit	O
during	O
phase-2	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
type	O
of	O
inhibitory	O
domain	O
in	O
the	O
N-terminal	O
60	O
amino	O
acids	O
of	O
IRF-1	B-GENE
which	O
strongly	O
inhibits	O
its	O
transcriptional	O
activity	O
.	O

Similarly	O
,	O
expression	O
of	O
a	O
transiently	O
transfected	O
wild-type	B-GENE
prothymosin	I-GENE
alpha	I-GENE
gene	I-GENE
as	O
the	O
reporter	O
was	O
not	O
affected	O
by	O
a	O
repertoire	O
of	O
myc-derived	B-GENE
genes	I-GENE
,	O
including	O
myc	B-GENE
itself	O
and	O
dominant	O
or	O
recessive	O
negative	O
myc	B-GENE
mutants	I-GENE
.	O

Identification	O
of	O
a	O
novel	O
E2F3	B-GENE
product	I-GENE
suggests	O
a	O
mechanism	O
for	O
determining	O
specificity	O
of	O
repression	O
by	O
Rb	B-GENE
proteins	I-GENE
.	O

In	O
this	O
paper	O
,	O
a	O
comparison	O
between	O
the	O
number	O
and	O
shape	O
of	O
corneal	O
endothelial	O
cells	O
has	O
been	O
performed	O
in	O
25	O
patients	O
before	O
and	O
6	O
months	O
after	O
PRK	O
.	O

Experimental	O
study	O
of	O
ta	O
chengchi	O
tang	O
decoction	O
for	O
relieving	O
lung	O
injury	O
during	O
acute	O
necrotizing	O
pancreatitis	O
The	O
objectives	O
of	O
the	O
study	O
were	O
to	O
investigate	O
the	O
changes	O
of	O
leukocyte	O
adhesiveness	O
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	O
TNF	B-GENE
)	O
in	O
the	O
early	O
stage	O
of	O
acute	O
necrotizing	O
pancreatitis	O
(	O
ANP	O
)	O
,	O
to	O
go	O
further	O
into	O
the	O
relation	O
of	O
those	O
changes	O
to	O
lung	O
injury	O
of	O
ANP	O
,	O
and	O
to	O
evaluate	O
the	O
prohibitive	O
effect	O
of	O
ta	O
chengchi	O
tang	O
Decoction	O
on	O
leukocyte	O
adhesion	O
and	O
TNF	B-GENE
secretion	O
.	O

Processing	O
of	O
the	O
NS3'-5B	B-GENE
polyprotein	I-GENE
was	O
complex	O
and	O
occurred	O
rapidly	O
.	O

Sequential	O
cleavage	O
by	O
metallopeptidases	B-GENE
and	O
proteasomes	O
is	O
involved	O
in	O
processing	O
HIV-1	B-GENE
ENV	I-GENE
epitope	I-GENE
for	O
endogenous	O
MHC	B-GENE
class	I-GENE
I	I-GENE
antigen	I-GENE
presentation	O
.	O

The	O
recombinant	O
enzymes	O
exist	O
as	O
monomers	O
.	O

Identification	O
of	O
a	O
new	O
gene	O
in	O
the	O
streptococcal	O
plasmid	O
pLS1	O
:	O
the	O
rnaI	B-GENE
gene	I-GENE
.	O

We	O
recommend	O
that	O
ovarian	O
stimulation	O
is	O
done	O
only	O
if	O
there	O
is	O
a	O
valid	O
indication	O
after	O
proper	O
assessment	O
of	O
the	O
ovaries	O
,	O
and	O
that	O
women	O
who	O
have	O
had	O
ovarian	O
stimulation	O
are	O
followed	O
for	O
longer	O
than	O
at	O
present	O
.	O

In	O
Experiment	O
1	O
,	O
pups	O
that	O
had	O
received	O
an	O
injection	O
of	O
the	O
noncompetitive	O
N-methyl-D-aspartate	B-GENE
receptor	I-GENE
antagonist	O
MK-801	O
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
either	O
30	O
min	O
before	O
or	O
immediately	O
after	O
conditioning	O
spent	O
less	O
time	O
over	O
the	O
conditioned	O
odor	O
than	O
saline-treated	O
controls	O
.	O

Group	O
A	O
was	O
treated	O
with	O
three	O
or	O
four	O
doses	O
of	O
hepatitis	B-GENE
B	I-GENE
immune	I-GENE
globulin	I-GENE
(	O
HBIG	B-GENE
)	O
in	O
one	O
of	O
three	O
different	O
schedules	O
.	O

The	O
flow	O
rate	O
of	O
phosphate	O
buffered	O
saline	O
through	O
dermis	O
was	O
measured	O
as	O
a	O
function	O
of	O
applied	O
pressure	O
.	O

Vestibular	O
adaptation	O
exercises	O
and	O
recovery	O
:	O
acute	O
stage	O
after	O
acoustic	O
neuroma	O
resection	O
.	O

SEA	O
was	O
recorded	O
with	O
bidirectional	O
filters	O
at	O
25-250	O
HZ	O
and	O
40-250	O
Hz	O
using	O
Simson	O
method	O
.	O

(	O
Cactaceae	O
)	O
waste	O
matter	O
.	O

During	O
chronic	O
treatment	O
,	O
when	O
plasma	O
concentrations	O
fluctuated	O
between	O
23	O
.	O
5	O
ng	O
.	O
ml-1	O
at	O
8	O
h	O
and	O
14	O
ng	O
.	O
ml-1	O
at	O
24	O
h	O
post-dosing	O
,	O
ST	O
segment	O
depression	O
at	O
an	O
individually	O
comparable	O
workload	O
was	O
significantly	O
decreased	O
by	O
28%	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
at	O
both	O
points	O
in	O
time	O
.	O

Both	O
inhaled	O
and	O
superfused	O
isoflurane	O
dilated	O
the	O
baseline	O
vein	O
diameter	O
before	O
stimulation	O
.	O

Immunoblotting	O
of	O
expressed	O
recombinant	O
proteins	O
with	O
the	O
monoclonal	B-GENE
08L	I-GENE
antibody	I-GENE
localized	O
the	O
08L	B-GENE
epitope	O
to	O
the	O
carboxyl	O
end	O
of	O
the	O
protein	O
.	O

Consistently	O
,	O
activation	O
of	O
c-Jun	B-GENE
N-terminal	I-GENE
kinase	I-GENE
downstream	O
of	O
Rho	B-GENE
family	I-GENE
GTP-binding	I-GENE
proteins	I-GENE
was	O
also	O
enhanced	O
when	O
Dbl	B-GENE
was	O
tyrosine-phosphorylated	O
.	O

However	O
,	O
both	O
TPN	O
groups	O
showed	O
a	O
marked	O
increase	O
in	O
activities	O
of	O
liver	B-GENE
lysosomal	I-GENE
enzymes	I-GENE
.	O

267	O
,	O
4870-4877	O
)	O
)	O
indicates	O
an	O
overall	O
identity	O
of	O
58	O
and	O
56%	O
,	O
respectively	O
,	O
with	O
a	O
91	O
and	O
92%	O
identity	O
in	O
the	O
highly	O
conserved	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
.	O

Endo16	B-GENE
transcripts	I-GENE
are	O
confined	O
to	O
the	O
definitive	O
vegetal	O
plate	O
in	O
blastula	O
stage	O
embryos	O
;	O
at	O
gastrula	O
stage	O
this	O
gene	O
is	O
expressed	O
throughout	O
the	O
archenteron	O
,	O
but	O
later	O
only	O
in	O
the	O
midgut	O
.	O

Nuclear	B-GENE
beta	I-GENE
II	I-GENE
PKC	I-GENE
,	O
like	O
p34cdc2	B-GENE
kinase	I-GENE
,	O
may	O
function	O
to	O
regulate	O
nuclear	O
lamina	O
structural	O
stability	O
during	O
cell	O
cycle	O
.	O

When	O
Hy-Vac	O
SPF	O
type	O
V	O
embryos	O
were	O
exposed	O
to	O
either	O
0	O
.	O
20	O
ml	O
50%	O
ethanol	O
in	O
CRS	O
or	O
to	O
0	O
.	O
20	O
ml	O
CRS	O
(	O
controls	O
)	O
,	O
ethanol-treated	O
embryos	O
showed	O
a	O
VSD	O
incidence	O
of	O
34	O
.	O
1%	O
compared	O
with	O
a	O
3	O
.	O
6%	O
incidence	O
in	O
the	O
controls	O
(	O
P	O
=	O
0	O
.	O
0017	O
)	O
.	O

Gains	O
increased	O
3	O
.	O
5%	O
(	O
P	O
less	O
than	O
.	O
10	O
)	O
and	O
feed	O
conversion	O
improved	O
5	O
.	O
9%	O
(	O
P	O
less	O
than	O
.	O
07	O
)	O
in	O
steers	O
fed	O
.	O
28%	O
AS-VFA	O
compared	O
with	O
gain	O
and	O
feed	O
conversion	O
of	O
the	O
control	O
steers	O
.	O

Endocrine	O
cells	O
were	O
studied	O
by	O
means	O
of	O
Grimelius'	O
silver	O
staining	O
and	O
immunostaining	O
for	O
chromogranin	B-GENE
,	O
a	O
general	O
marker	O
of	O
endocrine	O
cells	O
.	O

The	O
gene	O
encoding	O
TRP-2	B-GENE
maps	O
to	O
mouse	O
chromosome	O
14	O
,	O
in	O
the	O
region	O
of	O
the	O
coat	B-GENE
colour	I-GENE
mutation	I-GENE
slaty	I-GENE
.	O

Genetic	O
and	O
molecular	O
data	O
indicate	O
that	O
wild-type	B-GENE
Pan	I-GENE
and	O
CiD	B-GENE
compete	O
for	O
binding	O
to	O
Arm	B-GENE
,	O
leading	O
to	O
a	O
compromised	O
transduction	O
of	O
the	O
Wg	B-GENE
signal	O
in	O
heterozygous	O
ciD	B-GENE
/	I-GENE
+	I-GENE
animals	O
and	O
to	O
a	O
dramatic	O
enhancement	O
of	O
the	O
gain-of-function	O
activity	O
of	O
CiD	B-GENE
in	O
homozygous	O
mutants	O
.	O

Our	O
data	O
therefore	O
indicate	O
that	O
it	O
is	O
possible	O
to	O
engineer	O
the	O
HA	B-GENE
envelope	I-GENE
glycoprotein	I-GENE
by	O
fusing	O
ligands	O
to	O
its	O
amino-terminal	O
end	O
without	O
affecting	O
its	O
fusion	O
activity	O
.	O

Drug	O
and	O
nutrient	O
interactions	O
.	O

The	O
protein	O
first	O
identified	O
by	O
the	O
monoclonal	B-GENE
antibody	I-GENE
Q18	I-GENE
is	O
encoded	O
by	O
a	O
gene	O
located	O
in	O
57A	O
on	O
polytene	O
chromosomes	O
and	O
has	O
been	O
consequently	O
named	O
Hrb57A	B-GENE
.	O

This	O
analysis	O
supports	O
the	O
use	O
of	O
fluticasone	O
propionate	O
88	O
microg	O
twice	O
daily	O
as	O
first-line	O
treatment	O
in	O
patients	O
with	O
persistent	O
asthma	O
previously	O
treated	O
with	O
short-acting	O
beta2-agonist	O
alone	O
.	O

On	O
admission	O
to	O
our	O
department	O
in	O
September	O
,	O
1987	O
,	O
the	O
patient	O
was	O
alert	O
and	O
had	O
spastic	O
paraparesis	O
,	O
the	O
impairment	O
of	O
all	O
sensory	O
modalities	O
below	O
the	O
level	O
of	O
Th	O
10	O
and	O
urinary	O
disturbance	O
.	O

In	O
conclusion	O
,	O
changes	O
in	O
carotid	O
sinus	O
stimulation	O
alters	O
blood	O
flow	O
to	O
the	O
hindlimb	O
through	O
changes	O
in	O
both	O
Pcrit	O
and	O
Ra	O
.	O

This	O
R-domain	O
may	O
modulate	O
the	O
interaction	O
with	O
SRF	B-GENE
,	O
providing	O
a	O
mechanism	O
that	O
would	O
be	O
unique	O
to	O
FLI1	B-GENE
and	O
EWS-FLI1	B-GENE
,	O
thus	O
implicating	O
a	O
novel	O
function	O
for	O
these	O
ETS	B-GENE
transcription	I-GENE
factors	I-GENE
in	O
the	O
regulation	O
of	O
the	O
Egr1	B-GENE
gene	I-GENE
.	O

A	O
new	O
generation	O
of	O
information	O
retrieval	O
tools	O
for	O
biologists	O
:	O
the	O
example	O
of	O
the	O
ExPASy	O
WWW	O
server	O
.	O

Histamine-2	O
blockade	O
in	O
psoriasis	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
the	O
mouse	B-GENE
NMO1	I-GENE
cDNA	I-GENE
,	O
which	O
encodes	O
the	O
NAD	B-GENE
(	I-GENE
P	I-GENE
)	I-GENE
H	I-GENE
:	I-GENE
menadione	I-GENE
oxidoreductase	I-GENE
[	O
also	O
called	O
NAD	B-GENE
(	I-GENE
P	I-GENE
)	I-GENE
H	I-GENE
:	I-GENE
(	I-GENE
quinone	I-GENE
acceptor	I-GENE
)	I-GENE
oxidoreductase	I-GENE
;	I-GENE
quinone	I-GENE
reductase	I-GENE
;	O
azo	B-GENE
dye	I-GENE
reductase	I-GENE
;	O
DT	B-GENE
diaphorase	I-GENE
;	O
EC	B-GENE
1	I-GENE
.	I-GENE
6	I-GENE
.	I-GENE
99	I-GENE
.	I-GENE
2	I-GENE
]	I-GENE
.	O

Type	O
I	O
cysts	O
(	O
with	O
a	O
high	O
K+	O
/	O
Na+	O
ratio	O
)	O
tend	O
to	O
have	O
higher	O
total	O
PSA	B-GENE
than	O
Type	O
II	O
cysts	O
.	O

The	O
presence	O
of	O
local	O
abnormalities	O
in	O
both	O
patients	O
can	O
support	O
the	O
hypothesis	O
that	O
the	O
cortex	O
,	O
especially	O
of	O
the	O
temporal	O
anterior	O
lobe	O
,	O
is	O
involved	O
in	O
the	O
origin	O
of	O
the	O
laughing	O
seizures	O
.	O

In	O
summary	O
,	O
WT1	B-GENE
is	O
enriched	O
by	O
oligo	O
(	O
dT	O
)	O
chromatography	O
,	O
as	O
are	O
U2AF65	B-GENE
,	O
the	O
U5	B-GENE
small	I-GENE
nuclear	I-GENE
RNP-associated	I-GENE
protein	I-GENE
p116	I-GENE
and	O
hnRNP	B-GENE
A1	O
.	O

Predictors	O
of	O
success	O
in	O
pharmacy	O
school	O
:	O
PCAT	O
vs	O
.	O
other	O
admission	O
criteria	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
coimmunoprecipitation	O
studies	O
suggest	O
that	O
homo-	O
and	O
heterodimerization	O
occurs	O
between	O
cKrox	B-GENE
family	I-GENE
members	I-GENE
.	O

A	O
new	O
bioencapsulation	O
technology	O
for	O
microbial	O
inoculants	O
.	O

This	O
indicates	O
that	O
recruitment	O
of	O
large	B-GENE
T	I-GENE
antigen	I-GENE
to	O
the	O
rRNA	O
promoter	O
by	O
SL1	B-GENE
constitutes	O
a	O
crucial	O
step	O
in	O
the	O
activation	O
process	O
.	O

Anatomy	O
of	O
the	O
RNA	O
and	O
gene	O
products	O
of	O
MC29	O
and	O
MH2	O
,	O
two	O
defective	O
avian	O
tumor	O
viruses	O
causing	O
acute	O
leukemia	O
and	O
carcinoma	O
:	O
evidence	O
for	O
a	O
new	O
class	O
of	O
transforming	O
genes	O
.	O

Concomitant	O
chronic	O
lymphocytic	O
leukemia	O
,	O
acute	O
myeloid	O
leukemia	O
,	O
and	O
thrombosis	O
with	O
protein	B-GENE
C	I-GENE
deficiency	O
.	O

NO	O
metabolites	O
were	O
determined	O
by	O
the	O
measurement	O
of	O
nitrate	O
/	O
nitrite	O
(	O
NOx	O
,	O
micromol	O
/	O
mmol	O
creatinine	O
)	O
and	O
cyclic	O
guanosine	O
monophosphate	O
(	O
cGMP	O
,	O
nmol	O
/	O
mmol	O
creatinine	O
)	O
in	O
plasma	O
and	O
urine	O
.	O

The	O
therapeutic	O
protocole	O
used	O
at	O
the	O
Gustave	O
Roussy	O
Institute	O
for	O
invasive	O
epithelioma	O
of	O
the	O
uterine	O
cervix	O
rests	O
,	O
for	O
limited	O
forms	O
(	O
T1B-T2	O
proximal	O
)	O
,	O
on	O
combined	O
radiology	O
and	O
surgery	O
.	O

Thus	O
,	O
NART-R	O
performance	O
may	O
not	O
be	O
a	O
valid	O
estimate	O
of	O
baseline	O
IQ	O
for	O
patients	O
with	O
neurologic	O
disorders	O
with	O
suspected	O
language	O
impairment	O
.	O

Staphylococcal	B-GENE
enterotoxin	I-GENE
A	I-GENE
involvement	O
in	O
the	O
illness	O
of	O
a	O
20-month-old	O
burn	O
patient	O
.	O

Surface	O
spin	O
waves	O
in	O
a	O
Heisenberg	O
ferrimagnet	O
with	O
a	O
single-ion	O
anisotropy	O
(	O
uniaxial	O
and	O
nonuniaxial	O
)	O
.	O

Importantly	O
,	O
concomitant	O
expression	O
of	O
constitutive	O
activated	O
Raf	B-GENE
and	O
V12N38	B-GENE
Ras	I-GENE
results	O
in	O
almost	O
complete	O
loss	O
of	O
TTF-1	B-GENE
activity	O
.	O

Using	O
an	O
audiotape	O
cassette	O
and	O
headphones	O
the	O
duration	O
of	O
the	O
hallucinations	O
decreased	O
significantly	O
.	O

These	O
studies	O
indicate	O
that	O
the	O
acidimetric	O
test	O
was	O
less	O
sensitive	O
than	O
the	O
chromogenic	O
cephalosporin	O
substrates	O
and	O
that	O
nitrocefin	O
and	O
S1	O
could	O
be	O
used	O
to	O
screen	O
for	O
beta-lactamase	B-GENE
production	O
in	O
these	O
tested	O
species	O
.	O

We	O
performed	O
the	O
present	O
study	O
to	O
clarify	O
the	O
relationship	O
between	O
the	O
DOX	O
binding	O
ability	O
(	O
%DB	O
)	O
and	O
the	O
histologic	O
response	O
,	O
rate	O
of	O
decrease	O
in	O
tumor	O
volume	O
of	O
malignant	O
soft	O
tissue	O
tumors	O
after	O
preoperative	O
chemotherapy	O
and	O
prognosis	O
.	O

Gel-shift	O
assays	O
identified	O
two	O
Sp1	B-GENE
binding	I-GENE
sites	I-GENE
within	O
this	O
element	O
.	O

2000	O
update	O
of	O
recommendations	O
for	O
the	O
use	O
of	O
hematopoietic	B-GENE
colony-stimulating	I-GENE
factors	I-GENE
:	O
evidence-based	O
,	O
clinical	O
practice	O
guidelines	O
.	O

The	O
beta	O
chain	O
contains	O
five	O
potential	O
N-linked	O
glycosylation	O
sites	O
,	O
and	O
endoglycosidase	B-GENE
digestion	O
suggested	O
that	O
the	O
beta	O
chain	O
contained	O
multiple	O
complex	O
carbohydrate	O
side	O
chains	O
.	O

Rapid	O
detection	O
of	O
this	O
mutation	O
is	O
achieved	O
by	O
restriction	O
digestion	O
of	O
PCR-amplified	O
genomic	O
DNA	O
;	O
a	O
mismatch	O
primer	O
combined	O
with	O
the	O
point	O
mutation	O
creates	O
a	O
Tru9I	B-GENE
restriction	I-GENE
site	I-GENE
.	O

Transactivation	O
domain	O
is	O
located	O
downstream	O
of	O
the	O
128-amino-acid	B-GENE
runt	I-GENE
homology	I-GENE
region	I-GENE
,	O
referred	O
to	O
as	O
the	O
Runt	B-GENE
domain	I-GENE
.	O

This	O
generally	O
means	O
an	O
energy	O
intake	O
of	O
1	O
.	O
4	O
to	O
1	O
.	O
6	O
times	O
the	O
energy	O
expenditure	O
,	O
with	O
a	O
N	O
intake	O
of	O
250	O
to	O
400	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Mutational	O
analysis	O
showed	O
that	O
the	O
U-box	O
,	O
like	O
the	O
RING	O
finger	O
in	O
other	O
proteins	O
,	O
forms	O
the	O
physical	O
basis	O
for	O
the	O
interaction	O
with	O
E2	B-GENE
enzymes	I-GENE
.	O

Pb	O
foil	O
(	O
0	O
.	O
55	O
gcm-2	O
)	O
provided	O
the	O
best	O
overall	O
improvement	O
.	O

This	O
article	O
reviews	O
recent	O
information	O
on	O
the	O
frequency	O
,	O
characteristics	O
,	O
and	O
possible	O
pathogenic	O
mechanisms	O
of	O
the	O
vasculitides	O
occurring	O
in	O
patients	O
with	O
the	O
main	O
connective	O
tissue	O
diseases	O
.	O

During	O
activity	O
III	O
,	O
one	O
patient	O
developed	O
angina	O
.	O

A	O
4	B-GENE
.	I-GENE
8-kilobase	I-GENE
BamHI-HindIII	I-GENE
fragment	I-GENE
encoding	O
the	O
entire	B-GENE
Neurospora	I-GENE
crassa	I-GENE
CuZn	I-GENE
superoxide	I-GENE
dismutase	I-GENE
gene	I-GENE
(	O
herein	O
designated	O
sod-1	B-GENE
)	O
was	O
isolated	O
from	O
a	O
genomic	O
library	O
using	O
two	O
60-base	O
deoxyoligonucleotide	O
probes	O
corresponding	O
to	O
the	O
published	O
N	O
.	O
crassa	O
amino	O
acid	O
sequence	O
.	O

Eight	O
hr	O
of	O
acidosis	O
caused	O
a	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
decrease	O
in	O
P50	O
in	O
vitro	O
which	O
fell	O
from	O
29	O
.	O
0	O
to	O
24	O
.	O
4	O
torr	O
.	O

Neutron	O
scattering	O
measurements	O
of	O
critical	O
exponents	O
in	O
CsMnBr3	O
:	O
A	O
Z2	O
>	O
=	O
1	O
antiferromagnet	O
.	O

Thus	O
,	O
the	O
B-S	O
mutant	O
does	O
not	O
mimic	O
efficiently	O
the	O
chloroplastic	B-GENE
GAPDHs	I-GENE
,	O
and	O
long-range	O
and	O
/	O
or	O
second-layer	O
effects	O
,	O
not	O
easily	O
predictable	O
from	O
visual	O
inspection	O
of	O
three-dimensional	O
structures	O
,	O
need	O
to	O
be	O
taken	O
into	O
account	O
for	O
designing	O
a	O
true	O
"chloroplastic-like"	O
mutant	O
of	O
cytosolic	B-GENE
GAPDH	I-GENE
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
parCBA	B-GENE
operon	I-GENE
encodes	O
a	O
plasmid	O
partitioning	O
system	O
(	O
M	O
.	O

The	O
oral	O
temperature	O
rose	O
and	O
the	O
serum	B-GENE
creatine	I-GENE
kinase	I-GENE
levels	O
fell	O
only	O
in	O
those	O
patients	O
who	O
were	O
actively	O
warmed	O
.	O

Genome	O
plasticity	O
in	O
the	O
distal	B-GENE
tail	I-GENE
fiber	I-GENE
locus	I-GENE
of	O
the	O
T-even	O
bacteriophage	O
:	O
recombination	O
between	O
conserved	O
motifs	O
swaps	O
adhesin	B-GENE
specificity	O
.	O

Because	O
of	O
its	O
great	O
reliability	O
,	O
conventional	O
arteriography	O
occupies	O
a	O
place	O
of	O
choice	O
among	O
the	O
medical	O
imaging	O
techniques	O
.	O

They	O
were	O
checked	O
for	O
anti-HCV	B-GENE
(	O
anti-C100-3	B-GENE
)	O
with	O
HCV	O
EIA	O
kit	O
(	O
Abbott	O
Lab	O
.	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O

Therefore	O
more	O
active	O
and	O
tolerable	O
salvage	O
regimens	O
are	O
needed	O
.	O

Furthermore	O
,	O
upstream	O
insertion	O
of	O
the	O
GSTP1	B-GENE
silencer	I-GENE
element	I-GENE
failed	O
to	O
inhibit	O
activity	O
of	O
a	O
heterologous	O
promoter	O
in	O
MCF7	O
cells	O
.	O

A	O
variety	O
of	O
professional	O
and	O
self-applied	O
fluoride	O
products	O
are	O
available	O
and	O
new	O
fluoride	O
delivery	O
systems	O
have	O
recently	O
entered	O
the	O
market	O
.	O

These	O
results	O
indicate	O
that	O
K-glypican	B-GENE
is	O
a	O
novel	O
GPI-anchored	B-GENE
HSPG	I-GENE
involved	O
in	O
embryonic	O
development	O
.	O

Serum	O
gastrin	B-GENE
levels	O
did	O
not	O
change	O
in	O
either	O
group	O
;	O
however	O
,	O
background	O
serum	O
gastrin	B-GENE
concentrations	O
were	O
significantly	O
greater	O
for	O
V&P	O
patients	O
than	O
V&A	O
patients	O
throughout	O
the	O
study	O
.	O

These	O
residues	O
,	O
Ile244	O
at	O
the	O
extracellular	O
end	O
of	O
transmembrane	O
helix	O
3	O
,	O
and	O
Tyr318	O
at	O
the	O
COOH-terminal	O
portion	O
of	O
extracellular	O
loop	O
2	O
,	O
are	O
replaced	O
by	O
Leu	O
and	O
Ile	O
in	O
the	O
PTH-1	B-GENE
receptor	I-GENE
,	O
respectively	O
.	O

Lung	O
mesenchyme	O
serves	O
as	O
a	O
'compleat'	O
inducer	O
of	O
lung	O
morphogenesis	O
by	O
secreting	O
soluble	O
peptide	O
growth	O
factors	O
.	O

Viable	O
flap	O
areas	O
were	O
established	O
following	O
vascular	O
pedicle	O
ligation	O
(	O
both	O
vessels	O
or	O
only	O
artery	O
or	O
vein	O
)	O
,	O
on	O
the	O
third	O
day	O
after	O
flap	O
replantation	O
in	O
both	O
island	O
and	O
free	O
flaps	O
.	O

Using	O
backcross	O
analysis	O
,	O
both	O
exons	O
1	O
and	O
4	O
mapped	O
to	O
a	O
proximal	O
region	O
of	O
murine	O
Chromosome	O
4	O
indistinguishable	O
from	O
the	O
vacillans	B-GENE
gene	I-GENE
.	O

It	O
was	O
found	O
that	O
under	O
the	O
selected	O
conditions	O
a	O
linear	O
dependence	O
exists	O
between	O
the	O
betaI%	O
value	O
and	O
lgC	O
within	O
the	O
range	O
of	O
0	O
.	O
5--10	O
mug	O
ruscogenin	O
.	O

Characterization	O
of	O
the	O
transcription	B-GENE
factor	I-GENE
MTF-1	I-GENE
from	O
the	O
Japanese	O
pufferfish	O
(	O
Fugu	O
rubripes	O
)	O
reveals	O
evolutionary	O
conservation	O
of	O
heavy	O
metal	O
stress	O
response	O
.	O

We	O
characterized	O
cDNA	O
clones	O
specific	O
for	O
the	O
extracellular	O
matrix	O
glycoprotein	O
undulin	B-GENE
.	O

Furthermore	O
,	O
no	O
Shine-Dalgarno	O
sequences	O
are	O
present	O
upstream	O
of	O
the	O
presumed	O
translational	O
start	O
codons	O
.	O

Holger	O
v	O
.	O

Tolerance	O
to	O
ADAL-2	O
was	O
similar	O
to	O
that	O
of	O
Vicryl	O
suture	O
and	O
tolerance	O
to	O
ADAL-2	O
was	O
superior	O
to	O
that	O
to	O
Tisuacryl	O
.	O

PKNbeta	B-GENE
had	O
high	O
sequence	O
homology	O
with	O
PKNalpha	B-GENE
,	O
originally	O
isolated	O
PKN	B-GENE
,	O
especially	O
in	O
the	O
repeats	O
of	O
charged	O
amino	O
acid-rich	O
region	O
with	O
leucine-zipper	O
like	O
sequences	O
(	O
CZ	B-GENE
region	I-GENE
/	I-GENE
HR1	I-GENE
)	O
,	O
in	O
the	O
carboxyl-terminal	O
catalytic	O
domain	O
,	O
and	O
in	O
approximately	O
130	O
amino	O
acid	O
stretch	O
(	O
D	B-GENE
region	I-GENE
/	I-GENE
HR2	I-GENE
)	O
,	O
located	O
between	O
CZ	B-GENE
region	I-GENE
/	I-GENE
HR1	I-GENE
and	O
the	O
catalytic	O
domain	O
.	O

Results	O
have	O
surprisingly	O
revealed	O
the	O
presence	O
of	O
three	O
U14	B-GENE
snRNA-homologous	I-GENE
regions	I-GENE
positioned	O
within	O
introns	O
5	O
,	O
6	O
,	O
and	O
8	O
of	O
the	O
mouse	O
cognate	O
hsc70	B-GENE
heat	O
shock	O
gene	O
.	O

[	O
figure	O
:	O
see	O
text	O
]	O
The	O
Stille	O
coupling	O
reaction	O
has	O
been	O
performed	O
in	O
1-butyl-3-methylimidazolium	O
tetrafluoroborate	O
(	O
BMIM	O
BF4	O
)	O
,	O
a	O
room-temperature	O
ionic	O
liquid	O
(	O
RTIL	O
)	O
.	O

In	O
general	O
,	O
the	O
values	O
obtained	O
by	O
the	O
two	O
methods	O
were	O
in	O
agreement	O
for	O
each	O
species	O
of	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
and	O
followed	O
the	O
order	O
:	O
wild	O
type	O
greater	O
than	O
Glu24----Gly	O
greater	O
than	O
Asp27----Gly	O
much	O
greater	O
than	O
Pro7----Thr	O
greater	O
than	O
Tyr29----Gly	O
greater	O
than	O
Leu47----His	O
.	O

The	O
ensembles	O
are	O
considered	O
to	O
be	O
one	O
of	O
the	O
forms	O
of	O
activity	O
of	O
the	O
structured	O
morphofunctional	O
cortical	O
units	O
,	O
i	O
.	O
e	O
.	O
the	O
columns	O
.	O

The	O
mouse	B-GENE
platelet-derived	I-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
PDGF	I-GENE
)	I-GENE
beta-receptor	I-GENE
promoter	I-GENE
contains	O
a	O
CCAAT	O
motif	O
,	O
and	O
NF-Y	B-GENE
plays	O
an	O
essential	O
role	O
in	O
its	O
transcription	O
.	O

Sequence	O
and	O
genetic	O
organization	O
of	O
a	O
Zymomonas	O
mobilis	O
gene	O
cluster	O
that	O
encodes	O
several	O
enzymes	O
of	O
glucose	O
metabolism	O
.	O

The	O
growth-promoting	O
properties	O
of	O
the	O
retroviral	B-GENE
v-erbA	I-GENE
oncogene	I-GENE
,	O
a	O
highly	O
mutated	O
version	O
of	O
the	O
chicken	B-GENE
thyroid	I-GENE
hormone	I-GENE
receptor	I-GENE
(	I-GENE
TR	I-GENE
)	I-GENE
alpha	I-GENE
,	O
have	O
so	O
far	O
exclusively	O
been	O
linked	O
to	O
dominant	O
repression	O
of	O
the	O
antimitogenic	O
roles	O
of	O
TR	B-GENE
and	O
retinoic	B-GENE
acid	I-GENE
receptors	I-GENE
.	O

With	O
a	O
population	O
of	O
853	O
million	O
there	O
should	O
be	O
51	O
,	O
204	O
patients	O
with	O
hemophilia	O
A	O
in	O
India	O
assuming	O
a	O
prevalence	O
of	O
6	O
/	O
100	O
,	O
000	O
population	O
.	O

Restriction	O
enzyme	O
mapping	O
and	O
Southern	O
analysis	O
indicated	O
further	O
that	O
the	O
human	B-GENE
MZF-1	I-GENE
gene	I-GENE
is	O
a	O
single-copy	O
gene	O
.	O

Anti-CRK	B-GENE
antibodies	I-GENE
detect	O
a	O
53kDa	O
protein	O
in	O
extracts	O
of	O
C	O
.	O
fasciculata	O
in	O
agreement	O
with	O
the	O
size	O
predicted	O
from	O
the	O
nucleotide	O
sequence	O
of	O
the	O
cloned	O
gene	O
.	O

To	O
identify	O
critical	O
regions	O
mediating	O
growth	O
signal	O
transduction	O
by	O
hG-CSFR	B-GENE
,	O
deletions	O
or	O
site-directed	O
amino	O
acid	O
substitutions	O
were	O
introduced	O
into	O
the	O
cytoplasmic	O
domain	O
of	O
hG-CSFR	B-GENE
,	O
and	O
the	O
mutant	O
cDNAs	O
were	O
transfected	O
into	O
the	O
murine	B-GENE
interleukin-3	I-GENE
(	O
IL-3	B-GENE
)	O
-dependent	O
Ba	O
/	O
F3	O
and	O
FDCP	O
cell	O
lines	O
.	O

We	O
developed	O
a	O
system	O
for	O
domain	O
shuffling	O
to	O
establish	O
the	O
function	O
of	O
C1	B-GENE
domains	I-GENE
from	O
human	B-GENE
Raf	I-GENE
kinase	I-GENE
and	O
rat	B-GENE
PKC	I-GENE
eta	I-GENE
in	O
yeast	O
.	O

This	O
survey	O
included	O
3000	O
randomly	O
selected	O
Norwegians	O
above	O
18	O
years	O
of	O
age	O
who	O
received	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Core	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
EORTC	O
QLQ-C30	O
(	O
+3	O
)	O
by	O
mail	O
.	O

To	O
isolate	O
this	O
gene	O
,	O
a	O
P-1	O
artificial	O
chromosome	O
(	O
PAC	O
)	O
library	O
was	O
screened	O
with	O
a	O
full	B-GENE
length	I-GENE
UGT2B7	I-GENE
probe	O
and	O
a	O
clone	O
of	O
approximately	O
100	O
kb	O
in	O
length	O
was	O
isolated	O
.	O

Simple	O
method	O
for	O
determination	O
of	O
the	O
cephalosporin	O
DQ-2556	O
in	O
biological	O
fluids	O
by	O
high-performance	O
liquid	O
chromatography	O
.	O

Repair	O
of	O
double-strand	O
breaks	O
(	O
DSBs	O
)	O
in	O
chromosomal	O
DNA	O
by	O
nonhomologous	O
end-joining	O
(	O
NHEJ	O
)	O
is	O
not	O
well	O
characterized	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Two	O
new	O
flavone	O
glucosides	O
,	O
nevadensin	O
5-O-beta-D-glucoside	O
and	O
nevadensin	O
5-O-beta-D-glucosyl	O
(	O
1--	O
>	O
6	O
)	O
beta-D-glucoside	O
,	O
have	O
been	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Lysionotus	O
pauciflorus	O
.	O

Molecule	O
(	O
s	O
)	O
secreted	O
by	O
neuronal	O
cultures	O
contribute	O
to	O
this	O
induction	O
of	O
GLT-1	B-GENE
,	O
but	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathways	O
mediating	O
this	O
regulation	O
.	O

The	O
six	O
commonest	O
causes	O
of	O
death	O
varied	O
in	O
the	O
three	O
ethnic	O
groups	O
.	O

These	O
"nucleocapsid-like"	O
structures	O
were	O
readily	O
purified	O
by	O
density	O
gradient	O
centrifugation	O
.	O

Similar	O
to	O
Hp140	B-GENE
,	O
isolated	O
Hp55	B-GENE
binds	O
DNA	O
with	O
moderate	O
strength	O
and	O
was	O
a	O
specificity	O
for	O
double-stranded	O
primer-template	O
DNA	O
.	O

Montelukast	O
reduces	O
airway	O
eosinophilic	O
inflammation	O
in	O
asthma	O
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

This	O
is	O
particularly	O
intriguing	O
because	O
SKUT-1B-20	O
cells	O
lack	O
the	O
transcription	O
factor	O
Pit-1	B-GENE
.	O

Surprisingly	O
,	O
a	O
C	O
to	O
G	O
transversion	O
at	O
the	O
first	O
residue	O
of	O
the	O
CAT	B-GENE
pentanucleotide	I-GENE
,	O
which	O
severely	O
impairs	O
the	O
activity	O
of	O
both	O
promoters	O
,	O
appears	O
to	O
increase	O
affinity	O
of	O
the	O
CAT	B-GENE
binding	I-GENE
protein	I-GENE
.	O

Using	O
a	O
polymerase	B-GENE
chain	O
reaction-based	O
approach	O
,	O
we	O
cloned	O
a	O
150-base	O
pair	O
fragment	O
of	O
a	O
new	O
sialymotif	O
from	O
human	O
placenta	O
mRNA	O
,	O
which	O
was	O
then	O
used	O
as	O
a	O
probe	O
to	O
clone	O
the	O
complete	O
coding	O
sequence	O
of	O
the	O
corresponding	O
gene	O
from	O
a	O
cDNA	O
library	O
.	O

PULSE	O
is	O
used	O
to	O
set	O
such	O
NMR	O
spectroscopic	O
parameters	O
as	O
the	O
delay	O
and	O
duration	O
of	O
rf	O
transmit	O
and	O
receive	O
gates	O
,	O
rf	O
phase	O
,	O
sampling	O
times	O
,	O
and	O
such	O
imaging	O
parameters	O
as	O
rf	O
pulse	O
shape	O
and	O
gradient	O
waveforms	O
.	O

The	O
biosynthesis	O
and	O
stability	O
of	O
the	O
three	O
mutant	O
proteins	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild-type	B-GENE
erbB	I-GENE
protein	I-GENE
,	O
and	O
all	O
three	O
retained	O
the	O
ability	O
to	O
transform	O
chicken	O
embryo	O
fibroblasts	O
.	O

The	O
results	O
indicate	O
that	O
rep	B-GENE
strongly	O
enhances	O
the	O
function	O
of	O
negative	O
regulatory	O
elements	O
of	O
the	O
LTR	O
.	O

A	O
genetic	O
system	O
was	O
devised	O
to	O
select	O
for	O
pi	B-GENE
protein	I-GENE
mutants	I-GENE
which	O
discriminate	O
between	O
IR	O
and	O
DR	O
(	O
York	O
et	O
al	O
.	O
,	O
Gene	O
(	O
Amst	O
.	O
)	O
116	O
,	O
7-12	O
,	O
1992	O
;	O
York	O
and	O
Filutowicz	O
,	O
J	O
.	O

Mitochondria-lytic	O
action	O
of	O
warfarin	O
in	O
lymphocytes	O
.	O

TT	O
cells	O
,	O
a	O
human	O
MTC	O
cell	O
line	O
expressing	O
MEN	B-GENE
2A	I-GENE
type	I-GENE
RET	I-GENE
,	O
display	O
transcriptionally	B-GENE
active	I-GENE
RelA	I-GENE
(	I-GENE
p65	I-GENE
)	I-GENE
in	O
the	O
nucleus	O
.	O

Zarix	O
expected	O
patient	O
enrollment	O
in	O
Canadian	O
clinical	O
sites	O
to	O
begin	O
in	O
Spring	O
2001	O
[	O
397955	O
]	O
,	O
[	O
405928	O
]	O
.	O

Members	O
of	O
SVA	B-GENE
are	O
also	O
present	O
in	O
the	O
complement	B-GENE
C2	I-GENE
gene	I-GENE
located	O
about	O
20	O
kilobases	O
upstream	O
of	O
RP1	B-GENE
in	O
the	O
HLA	B-GENE
and	O
in	O
the	O
cytochrome	B-GENE
CYP1A1	I-GENE
gene	I-GENE
.	O

The	O
reduced	O
efficiency	O
in	O
the	O
glycosylase	B-GENE
activity	O
is	O
also	O
reflected	O
in	O
a	O
reduced	O
ability	O
of	O
S120K	B-GENE
MutY	I-GENE
to	O
prevent	O
DNA	O
mutations	O
in	O
vivo	O
.	O

The	O
plasma	O
half-life	O
of	O
slow	O
disposition	O
phase	O
t1	O
/	O
2	O
beta	O
,	O
increases	O
from	O
0	O
.	O
26	O
hour	O
in	O
rabbits	O
with	O
normal	O
renal	O
function	O
to	O
5	O
.	O
41	O
hours	O
in	O
rabbits	O
with	O
severe	O
renal	O
impairment	O
.	O

Fermentation	O
process	O
after	O
supplementation	O
of	O
nitrate	O
,	O
nitrite	O
,	O
lactic	O
acid	O
bacteria	O
and	O
formic	O
acid	O
.	O

TOR2	B-GENE
is	O
part	O
of	O
two	O
related	O
signaling	O
pathways	O
coordinating	O
cell	O
growth	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
T-cyt	B-GENE
promoter	I-GENE
,	O
although	O
of	O
bacterial	O
origin	O
is	O
active	O
in	O
planta	O
and	O
the	O
30	B-GENE
bp	I-GENE
cyt-1	I-GENE
element	I-GENE
is	O
located	O
within	O
a	O
region	O
that	O
is	O
essential	O
for	O
T-cyt	B-GENE
promotor	I-GENE
activity	O
in	O
leaf	O
,	O
stem	O
and	O
root	O
cells	O
of	O
tobacco	O
plants	O
.	O

The	O
weak	O
base	O
ketoconazole	O
showed	O
complete	O
dissolution	O
from	O
a	O
tablet	O
formulation	O
in	O
Simulated	O
Gastric	O
Fluid	O
without	O
pepsin	B-GENE
(	O
SGFsp	O
)	O
within	O
30	O
minutes	O
,	O
70%	O
dissolution	O
in	O
2	O
hours	O
under	O
fed	O
state	O
simulated	O
upper	O
jejunal	O
conditions	O
but	O
only	O
6%	O
dissolution	O
in	O
2	O
hours	O
under	O
fasted	O
state	O
conditions	O
.	O

Phosphorylation	O
analyses	O
indicated	O
that	O
inhibition	O
of	O
ERK-1	B-GENE
/	I-GENE
2	I-GENE
decreased	O
okadaic	O
acid-elevated	O
phosphorylation	O
of	O
JunD	B-GENE
and	O
FosB	B-GENE
.	O

This	O
sequenced	O
region	O
of	O
the	O
V	B-GENE
beta	I-GENE
locus	I-GENE
contains	O
an	O
average	O
number	O
of	O
repetitive	O
DNA	O
elements	O
(	O
21	O
Alu	O
,	O
three	O
L1	O
,	O
three	O
MER	O
,	O
and	O
three	O
retrovirus-related	O
elements	O
.	O

A	O
total	O
of	O
174	O
primer	O
pairs	O
gave	O
interpretable	O
banding	O
patterns	O
,	O
137	O
(	O
79%	O
)	O
of	O
which	O
revealed	O
at	O
least	O
two	O
alleles	O
on	O
native	O
polyacrylamide	O
gels	O
.	O

All	O
problems	O
were	O
associated	O
with	O
fractured	O
or	O
lost	O
screws	O
.	O

Following	O
baseline	O
clinical	O
examination	O
and	O
initial	O
periodontal	O
therapy	O
,	O
32	O
patients	O
received	O
mucogingival	O
surgery	O
with	O
free	O
gingival	O
grafts	O
for	O
treatment	O
of	O
insufficient	O
attached	O
gingiva	O
.	O

This	O
effect	O
was	O
not	O
seen	O
in	O
conjunction	O
with	O
oxycodone	O
,	O
a	O
morphine-like	B-GENE
mu-receptor	I-GENE
agonist	O
.	O

RESULTS	O
:	O
Significant	O
changes	O
from	O
pretreatment	O
to	O
posttreatment	O
were	O
observed	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
mechanism	O
of	O
activation	O
of	O
HIF-1alpha	B-GENE
is	O
a	O
multi-step	O
process	O
which	O
includes	O
hypoxia-dependent	O
nuclear	O
import	O
and	O
activation	O
(	O
derepression	O
)	O
of	O
the	O
transactivation	O
domain	O
,	O
resulting	O
in	O
recruitment	O
of	O
the	O
CREB-binding	B-GENE
protein	I-GENE
(	O
CBP	B-GENE
)	O
/	B-GENE
p300	I-GENE
coactivator	I-GENE
.	O

There	O
were	O
15	O
deaths	O
,	O
seven	O
of	O
which	O
were	O
felt	O
to	O
be	O
avoidable	O
.	O

Sequence	O
comparison	O
of	O
cytochromes	B-GENE
bd	I-GENE
and	O
their	O
homologs	O
from	O
various	O
organisms	O
demonstrates	O
that	O
the	O
proteins	O
can	O
be	O
classified	O
into	O
two	O
subfamilies	O
,	O
a	O
proteobacterial	O
type	O
including	O
E	B-GENE
.	I-GENE
coli	I-GENE
bd	I-GENE
and	O
a	O
more	O
widely	O
distributed	O
type	O
including	O
the	O
B	O
.	O
stearothermophilus	O
enzyme	O
,	O
suggesting	O
that	O
the	O
latter	O
type	O
is	O
evolutionarily	O
older	O
.	O

The	O
beta	O
subunit	O
of	O
the	O
heterotrimeric	B-GENE
G	I-GENE
proteins	I-GENE
that	O
transduce	O
signals	O
across	O
the	O
plasma	O
membrane	O
is	O
made	O
up	O
of	O
an	O
amino-terminal	O
alpha-helical	O
segment	O
followed	O
by	O
seven	O
repeating	O
units	O
called	O
WD	O
(	O
Trp-Asp	O
)	O
repeats	O
that	O
occur	O
in	O
about	O
140	O
different	O
proteins	O
.	O

The	O
combination	O
of	O
ifosfamide	O
,	O
epirubicin	O
and	O
etoposide	O
(	O
IEV	O
)	O
is	O
an	O
effective	O
salvage	O
regimen	O
for	O
lymphoproliferative	O
disease	O
.	O

Administration	O
of	O
RIFA	O
at	O
200	O
mg	O
/	O
kg	O
/	O
day	O
in	O
combination	O
with	O
ATO	O
at	O
100	O
mg	O
/	O
kg	O
/	O
day	O
resulted	O
in	O
a	O
marked	O
prolongation	O
of	O
survival	O
compared	O
with	O
that	O
for	O
mice	O
that	O
received	O
ATO	O
or	O
RIFA	O
alone	O
.	O

The	O
patients	O
and	O
their	O
families	O
were	O
closely	O
questioned	O
,	O
and	O
full	O
clinical	O
examination	O
included	O
a	O
test	O
for	O
orthostasia	O
.	O

Thyroid	O
lymphoma	O
and	O
its	O
management	O
.	O

In	O
eukaryotic	O
cells	O
,	O
premature	O
termination	O
of	O
translation	O
at	O
nonsense	O
codons	O
has	O
been	O
implicated	O
as	O
the	O
cause	O
of	O
a	O
variety	O
of	O
posttranscriptional	O
events	O
,	O
including	O
rapid	O
mRNA	O
decay	O
in	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
,	O
altered	O
splice	O
site	O
selection	O
,	O
and	O
exon	O
skipping	O
.	O

The	O
two	O
methods	O
identify	O
the	O
same	O
patients	O
only	O
if	O
micturitional	O
pressures	O
are	O
normal	O
(	O
40	O
to	O
60	O
cmH2O	O
)	O
to	O
high	O
(	O
over	O
60	O
cmH2O	O
)	O
and	O
the	O
Sussett	O
formula	O
is	O
used	O
with	O
a	O
higher	O
(	O
95th	O
centile	O
)	O
cutoff	O
.	O

Thus	O
,	O
the	O
N-Nus	B-GENE
complex	I-GENE
may	O
be	O
affected	O
through	O
contacts	O
with	O
the	O
CTD	O
of	O
the	O
alpha	O
subunit	O
of	O
RNA	B-GENE
polymerase	I-GENE
,	O
as	O
is	O
a	O
group	O
of	O
regulatory	O
proteins	O
that	O
influences	O
initiation	O
of	O
transcription	O
.	O

The	O
highly	O
amyloidogenic	O
42-residue	O
form	O
of	O
Abeta	B-GENE
(	O
Abeta42	B-GENE
)	O
is	O
the	O
first	O
species	O
to	O
be	O
deposited	O
in	O
both	O
sporadic	O
and	O
familial	O
AD	O
.	O

Kaposi's	O
sarcoma-associated	O
herpesvirus	O
viral	B-GENE
interferon	I-GENE
regulatory	I-GENE
factor	I-GENE
confers	O
resistance	O
to	O
the	O
antiproliferative	O
effect	O
of	O
interferon-alpha	B-GENE
.	O

Regulatory	O
motifs	O
for	O
gene	O
expression	O
such	O
as	O
nuclear-factor-kappaB-binding-site-like	B-GENE
sequence	I-GENE
(	O
kappaB	B-GENE
site	I-GENE
)	O
and	O
nuclear-factor-interleukin-6-binding-site-like	B-GENE
sequence	I-GENE
(	O
NF-IL-6	B-GENE
site	I-GENE
)	O
were	O
found	O
in	O
the	O
5'-upstream	O
regulatory	O
region	O
.	O

In	O
vitro	O
DNase	B-GENE
I	I-GENE
footprinting	O
of	O
the	O
200-bp	O
proximal	O
region	O
of	O
the	O
promoter	O
with	O
a	O
murine	O
Hepa	O
1-6	O
cell	O
nuclear	O
extract	O
revealed	O
a	O
clear	O
footprint	O
of	O
a	O
region	O
corresponding	O
to	O
-80	O
to	O
-28	O
bp	O
of	O
the	O
murine	B-GENE
fVII	I-GENE
gene	I-GENE
,	O
suggesting	O
that	O
liver	O
factors	O
interact	O
with	O
this	O
region	O
of	O
the	O
DNA	O
.	O

Nuclear	B-GENE
factor	I-GENE
III	I-GENE
(	O
NFIII	B-GENE
)	O
is	O
a	O
protein	O
from	O
HeLa	O
cells	O
that	O
stimulates	O
the	O
initiation	O
of	O
adenovirus	O
type	O
2	O
(	O
Ad2	O
)	O
DNA	O
replication	O
by	O
binding	O
to	O
a	O
specific	O
nucleotide	O
sequence	O
in	O
the	O
origin	O
,	O
adjacent	O
to	O
the	O
nuclear	B-GENE
factor	I-GENE
I	I-GENE
recognition	I-GENE
site	I-GENE
.	O

We	O
have	O
measured	O
the	O
kinetics	O
of	O
the	O
recovery	O
of	O
mRNA	O
synthesis	O
in	O
the	O
inducible	O
GAL10	B-GENE
and	O
RNR3	B-GENE
genes	I-GENE
after	O
exposure	O
of	O
yeast	O
cells	O
to	O
ultraviolet	O
(	O
UV	O
)	O
radiation	O
.	O

These	O
data	O
define	O
a	O
conserved	O
pathway	O
wherein	O
sequential	O
histone	B-GENE
modifications	O
establish	O
a	O
"histone	O
code"	O
essential	O
for	O
the	O
epigenetic	O
inheritance	O
of	O
heterochromatin	O
assembly	O
.	O

UGA	O
codon	O
position	O
affects	O
the	O
efficiency	O
of	O
selenocysteine	O
incorporation	O
into	O
glutathione	B-GENE
peroxidase-1	I-GENE
.	O

Using	O
the	O
yeast	O
one-hybrid	O
screen	O
with	O
integrated	O
NRE	O
and	O
flanking	O
DNA	O
as	O
bait	O
,	O
the	O
predominant	O
clone	O
obtained	O
was	O
bovine	B-GENE
Nrl	I-GENE
.	O

The	O
regions	O
of	O
the	O
tooth	O
fracture	O
are	O
determined	O
.	O

It	O
consists	O
of	O
2185	O
amino	O
acid	O
residues	O
encoded	O
by	O
a	O
9-kilobase	O
pair	O
mRNA	O
;	O
several	O
splice	O
variants	O
have	O
been	O
detected	O
in	O
human	O
and	O
rat	O
cDNA	O
libraries	O
.	O

A	O
correlation	O
coefficient	O
was	O
used	O
for	O
assessing	O
the	O
similarity	O
of	O
each	O
map	O
pattern	O
with	O
the	O
normal	O
mean	O
IQRST	O
map	O
.	O

Furthermore	O
,	O
this	O
element	O
confers	O
p53	B-GENE
induction	O
to	O
the	O
otherwise	O
nonresponsive	O
adenovirus	O
major	O
late	O
promoter	O
.	O

RESULTS	O
:	O
The	O
diagnostic	O
quality	O
of	O
FDG	O
images	O
was	O
at	O
least	O
as	O
good	O
as	O
that	O
of	O
their	O
Tl-201	O
counterparts	O
,	O
with	O
less	O
liver	O
background	O
in	O
all	O
but	O
one	O
FDG	O
study	O
.	O

Systemic	O
impact	O
of	O
risk-sharing	O
arrangements	O
.	O

By	O
screening	O
a	O
cDNA	O
library	O
with	O
a	O
probe	O
derived	O
from	O
sequences	O
downstream	O
of	O
the	O
p53p2	B-GENE
start	O
site	O
,	O
we	O
have	O
cloned	O
and	O
characterized	O
a	O
cDNA	O
that	O
represents	O
a	O
mRNA	O
that	O
appears	O
to	O
have	O
been	O
initiated	O
from	O
the	O
p53p2	B-GENE
promoter	I-GENE
.	O

Manipulation	O
of	O
the	O
checkpoint	O
regulators	O
involved	O
in	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
may	O
thus	O
provide	O
a	O
novel	O
strategy	O
to	O
cancer	O
therapy	O
.	O

Induction	O
was	O
reversed	O
by	O
coexpression	O
of	O
A-Fos	B-GENE
,	O
a	O
dominant	O
negative	O
to	O
AP-1	B-GENE
.	O

Plasma	B-GENE
leptin	I-GENE
concentrations	O
were	O
higher	O
in	O
women	O
than	O
men	O
,	O
even	O
after	O
the	O
adjustment	O
for	O
differences	O
in	O
fat	O
mass	O
(	O
28	O
+	O
/	O
-	O
3	O
ng	O
/	O
ml	O
for	O
women	O
vs	O
.	O

Conservation	O
of	O
function	O
of	O
Drosophila	B-GENE
melanogaster	I-GENE
abl	I-GENE
and	O
murine	B-GENE
v-abl	I-GENE
proteins	I-GENE
in	O
transformation	O
of	O
mammalian	O
cells	O
.	O

There	O
are	O
,	O
however	O
,	O
several	O
differences	O
between	O
the	O
two	O
new	O
ars	B-GENE
sequences	I-GENE
.	O

These	O
sorting	B-GENE
nexins	I-GENE
also	O
associated	O
with	O
the	O
long	O
isoform	O
of	O
the	O
leptin	B-GENE
receptor	I-GENE
but	O
not	O
with	O
the	O
short	O
and	O
medium	O
isoforms	O
.	O

Molecular	O
cloning	O
of	O
the	O
polypeptide	O
component	O
of	O
the	O
Rel-related	B-GENE
human	I-GENE
p75	I-GENE
nucleoprotein	I-GENE
complex	I-GENE
has	O
revealed	O
its	O
identity	O
with	O
the	O
65-kDa	O
(	O
p65	B-GENE
)	O
subunit	O
of	O
NF-kappa	B-GENE
B	I-GENE
.	O

Following	O
the	O
results	O
of	O
toxicological	O
experiments	O
in	O
the	O
target	O
animals	O
"Toxicological	O
Drinking	O
Water	O
Standards	O
for	O
Animals"	O
can	O
be	O
established	O
.	O

We	O
find	O
that	O
3T1-3T2	O
mixing	O
has	O
a	O
pronounced	O
effect	O
on	O
the	O
line	O
shape	O
and	O
radiative	O
decay	O
rate	O
of	O
emission	O
from	O
the	O
3T2	O
state	O
and	O
that	O
the	O
extent	O
of	O
mixing	O
depends	O
critically	O
on	O
the	O
magnitude	O
of	O
nontetrahedral	O
distortions	O
.	O

This	O
cohort	O
of	O
patients	O
was	O
selected	O
on	O
the	O
basis	O
of	O
clinical	O
stage	O
.	O

Systemic	O
lupus	O
erythematosus	O
was	O
diagnosed	O
.	O

We	O
describe	O
the	O
identification	O
and	O
initial	O
characterization	O
of	O
neurobeachin	B-GENE
,	O
a	O
neuron-specific	O
multidomain	O
protein	O
of	O
327	O
kDa	O
with	O
a	O
high-affinity	O
binding	O
site	O
(	O
K	O
(	O
d	O
)	O
,	O
10	O
nm	O
)	O
for	O
the	O
type	B-GENE
II	I-GENE
regulatory	I-GENE
subunit	I-GENE
of	I-GENE
protein	I-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
RII	I-GENE
)	O
.	O

Senior	O
systems--45	O
;	O
Mental	O
health	O
and	O
illness	O
in	O
old	O
age--3	O
.	O

Intron	O
1	O
is	O
6	O
.	O
5	O
kb	O
long	O
,	O
and	O
the	O
minimal	O
sizes	O
of	O
introns	O
2	O
and	O
3	O
are	O
estimated	O
to	O
be	O
32	O
kb	O
each	O
.	O

In	O
3Y1	O
and	O
3Y1	O
v-crk-transformed	O
fibroblasts	O
,	O
almost	O
all	O
of	O
the	O
total	O
PTP1B	B-GENE
and	O
about	O
40%	O
of	O
total	O
p130	B-GENE
(	I-GENE
Cas	I-GENE
)	I-GENE
co-sediment	O
with	O
membranes	O
composed	O
primarily	O
of	O
endoplasmic	O
reticulum	O
.	O

Several	O
agents	O
have	O
been	O
tried	O
for	O
treatment	O
,	O
often	O
limited	O
by	O
toxic	O
side	O
effects	O
.	O

These	O
studies	O
have	O
shown	O
that	O
the	O
majority	O
of	O
tested	O
staphylococci	O
were	O
resistant	O
to	O
penicillin	O
G	O
,	O
erythromycin	O
,	O
and	O
produced	O
beta-lactamase	B-GENE
.	O

Renal	O
clearance	O
fell	O
from	O
19	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
9	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
group	O
I	O
)	O
to	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
4	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
(	O
group	O
IV	O
)	O
.	O

19-32	O
.	O

Treatment	O
with	O
amphotericin	O
B	O
and	O
flucytosine	O
led	O
to	O
improvement	O
of	O
the	O
symptoms	O
but	O
did	O
not	O
eradicate	O
the	O
micro-organisms	O
from	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

The	O
yeast	O
silent	B-GENE
information	I-GENE
regulator	I-GENE
Sir4p	I-GENE
anchors	O
and	O
partitions	O
plasmids	O
.	O

Antituberculosis	O
agents	O
.	O

A	O
poor	O
correlation	O
was	O
found	O
between	O
a	O
mildly-atypical	O
(	O
inflammatory	O
)	O
cytological	O
result	O
(	O
class	O
2	O
)	O
and	O
a	O
benign	O
histological	O
diagnosis	O
:	O
48%	O
of	O
class-2	O
smears	O
were	O
diagnosed	O
histologically	O
as	O
dysplasia	O
or	O
worse	O
.	O

SRY-related	B-GENE
cDNA	I-GENE
encoding	O
a	O
protein	O
with	O
a	O
high-mobility-group	B-GENE
(	O
HMG	B-GENE
)	O
box	O
and	O
a	O
leucine	O
zipper	O
motif	O
,	O
which	O
was	O
designated	O
SOX-LZ	B-GENE
,	O
was	O
isolated	O
from	O
a	O
rainbow	O
trout	O
testis	O
cDNA	O
library	O
.	O

These	O
results	O
indicate	O
a	O
possible	O
involvement	O
of	O
endogenous	B-GENE
opioid	I-GENE
peptides	I-GENE
in	O
the	O
cardiac	O
effects	O
due	O
to	O
myocardial	O
ischaemia	O
and	O
reperfusion	O
,	O
mediated	O
by	O
opiate	B-GENE
receptors	I-GENE
through	O
opiate	O
antagonism	O
.	O

In	O
addition	O
,	O
a	O
wild-type	O
strain	O
containing	O
a	O
temperature-sensitive	B-GENE
threonyl-tRNA	I-GENE
synthetase	I-GENE
mutation	I-GENE
showed	O
increased	O
thr	B-GENE
operon	I-GENE
expression	O
at	O
the	O
non-permissive	O
temperature	O
,	O
whereas	O
none	O
of	O
the	O
mutants	O
showed	O
any	O
change	O
.	O

Ten	O
patients	O
with	O
advanced	O
,	O
diffuse	O
Hodgkin's	O
and	O
non-Hodgkin's	O
lymphomas	O
responding	O
poorly	O
to	O
the	O
most	O
widely	O
employed	O
primary	O
chemotherapy	O
regimens	O
were	O
treated	O
with	O
a	O
high-dose	O
chemotherapy	O
(	O
HDC	O
)	O
followed	O
by	O
rescue	O
with	O
non-frozen	O
autologous	O
bone	O
marrow	O
infusion	O
(	O
ABMT	O
)	O
.	O

Maternal	O
seizures	O
had	O
occurred	O
during	O
pregnancy	O
in	O
52	O
per	O
cent	O
.	O

All	O
four	O
doubly	O
tyrosine	O
phosphorylated	O
TAM	B-GENE
peptides	I-GENE
cross-compete	O
with	O
each	O
other	O
for	O
binding	O
to	O
the	O
tandem	O
SH2	B-GENE
domains	I-GENE
of	O
ZAP-70	B-GENE
.	O

Axillary	O
nodal	O
status	O
,	O
tumour	O
progesterone	B-GENE
receptor	I-GENE
status	O
,	O
and	O
season	O
of	O
tumour	O
detection	O
significantly	O
influenced	O
survival	O
in	O
both	O
older	O
(	O
greater	O
than	O
50	O
yrs	O
)	O
and	O
younger	O
(	O
less	O
than	O
50	O
yrs	O
)	O
patients	O
.	O

Adjustment	O
for	O
age	O
,	O
total	O
cholesterol	O
,	O
HDL	O
cholesterol	O
,	O
triglycerides	O
,	O
current	O
smoking	O
,	O
and	O
systolic	O
pressure	O
slightly	O
reduced	O
the	O
association	O
between	O
fibrinogen	B-GENE
and	O
atherosclerosis	O
.	O

However	O
,	O
a	O
cosmid	O
clone	O
containing	O
the	O
entire	O
mouse	B-GENE
alpha	I-GENE
1	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
gene	I-GENE
,	O
including	O
3	O
.	O
7	O
kb	O
of	O
5'-	O
and	O
4	O
kb	O
of	O
3'-flanking	O
DNA	O
,	O
was	O
expressed	O
at	O
reduced	O
levels	O
in	O
fibroblasts	O
overexpressing	O
oncogenic	B-GENE
ras	I-GENE
.	O

It	O
is	O
striking	O
that	O
the	O
active	O
CHO	B-GENE
spacer	I-GENE
promoter	I-GENE
violated	O
the	O
otherwise	O
universal	O
rule	O
that	O
metazoan	B-GENE
RNA	I-GENE
polymerase	I-GENE
I	I-GENE
promoters	I-GENE
all	O
have	O
a	O
G	O
residue	O
at	O
position	O
-16	O
.	O

To	O
understand	O
the	O
regulatory	O
mechanism	O
controlling	O
its	O
expression	O
at	O
low	O
temperature	O
,	O
the	O
promoter	O
region	O
has	O
been	O
characterized	O
.	O

2	O
.	O
--concepts	O
of	O
higher	O
nervous	O
function	O
in	O
the	O
USSR	O
.	O

The	O
mature	O
AP-2	B-GENE
mRNA	I-GENE
is	O
spliced	O
from	O
7	O
exons	O
distributed	O
over	O
a	O
region	O
of	O
18	O
kb	O
genomic	O
DNA	O
.	O

Nonsynonymous	O
substitution	O
in	O
abalone	O
sperm	O
fertilization	O
genes	O
exceeds	O
substitution	O
in	O
introns	O
and	O
mitochondrial	O
DNA	O
.	O

The	O
molecular	O
associations	O
dictating	O
INCENP	B-GENE
behavior	O
during	O
mitosis	O
are	O
currently	O
unknown	O
.	O

202-8	O
.	O

There	O
were	O
differences	O
between	O
males	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
for	O
most	O
of	O
the	O
characteristics	O
studied	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
strongyloidiasis	O
was	O
the	O
cause	O
of	O
sudden	O
death	O
.	O

Many	O
canonical	O
TATA	O
sequences	O
are	O
present	O
upstream	O
from	O
these	O
VZV	O
transcriptional	O
start	O
sites	O
but	O
,	O
apparently	O
,	O
are	O
not	O
used	O
.	O

Van	O
der	O
Ende	O
,	O
R	O
.	O

A	O
comparative	O
study	O
of	O
the	O
cortical	O
end	O
of	O
the	O
auditory	O
analyzer	O
during	O
postnatal	O
ontogenesis	O
in	O
lower	O
monkeys	O
and	O
man	O
.	O

Constitutive	O
function	O
of	O
a	O
positively	O
regulated	O
promoter	O
reveals	O
new	O
sequences	O
essential	O
for	O
activity	O
.	O

Analysis	O
in	O
3	O
groups	O
of	O
patients	O
suffering	O
from	O
simple	O
acute	O
and	O
pernicious	O
malarial	O
flare-ups	O
.	O

The	O
mobility	O
shift	O
assay	O
of	O
the	O
65	O
bp	O
(	O
-318	O
/	O
-254	O
)	O
fragment	O
with	O
nuclear	O
extract	O
from	O
the	O
dark-adapted	O
sample	O
showed	O
an	O
additional	O
band	O
,	O
not	O
seen	O
with	O
the	O
light-grown	O
sample	O
.	O

Grasso	O
,	O
and	O
A	O
.	O

Feed	O
intake	O
was	O
not	O
affected	O
by	O
dietary	O
KCl	O
or	O
NaHCO3	O
supplementation	O
,	O
but	O
average	O
daily	O
gain	O
increased	O
with	O
increased	O
K	O
and	O
tended	O
to	O
be	O
reduced	O
by	O
dietary	O
NaHCO3	O
.	O

The	O
high	O
degree	O
of	O
sequence	O
identity	O
(	O
96%	O
)	O
between	O
hydrolase	B-GENE
B	I-GENE
and	I-GENE
C	I-GENE
,	O
particularly	O
in	O
the	O
3'	O
untranslated	O
region	O
,	O
suggests	O
that	O
the	O
genes	O
encoding	O
these	O
two	O
carboxylesterases	B-GENE
evolved	O
by	O
duplication	O
and	O
divergence	O
of	O
a	O
common	O
ancestral	O
gene	O
.	O

Hypotension	O
was	O
produced	O
by	O
head	O
up	O
tilt	O
.	O

Immunodepression	O
was	O
combined	O
with	O
the	O
increase	O
of	O
glucocorticoid	O
activity	O
of	O
adrenal	O
cortex	O
,	O
while	O
no	O
significant	O
changes	O
in	O
thyroid	O
hormones	O
were	O
registered	O
.	O

Determination	O
of	O
potassium	O
iodide	O
in	O
Polish	O
edible	O
salt	O
.	O

Enhanced	O
period-peak	O
analysis	O
of	O
electro-encephalograms	O
using	O
a	O
fast	O
sinc	O
function	O
.	O

These	O
sequence	O
analyses	O
suggest	O
that	O
xIRS-u	B-GENE
is	O
a	O
novel	O
member	O
of	O
the	O
IRS	B-GENE
family	I-GENE
rather	O
than	O
a	O
Xenopus	O
homolog	O
of	O
an	O
existing	O
member	O
.	O

Analysis	O
with	O
additional	O
anti-peptide	O
antibodies	O
specific	O
for	O
alpha	B-GENE
,	I-GENE
beta	I-GENE
,	I-GENE
or	I-GENE
gamma	I-GENE
PKC	I-GENE
indicated	O
that	O
all	O
three	O
types	O
of	O
PKC	B-GENE
are	O
expressed	O
in	O
JK	O
cells	O
;	O
however	O
,	O
JKPE	O
cells	O
lost	O
a	O
major	O
approximately	O
82	O
kDa	O
immunoreactive	O
cytosolic	O
protein	O
detectable	O
with	O
anti-PKC	B-GENE
alpha	I-GENE
antibody	I-GENE
.	O

Reverse	O
transcription	O
(	O
RT	O
)	O
-PCR	O
products	O
were	O
synthesized	O
with	O
two	O
degenerate	O
primers	O
derived	O
from	O
the	O
conserved	O
motifs	O
of	O
various	O
tyrosine	B-GENE
kinases	I-GENE
.	O

The	O
experiment	O
included	O
6	O
male	O
and	O
4	O
female	O
healthy	O
subjects	O
who	O
,	O
during	O
a	O
24-hour	O
stay	O
in	O
the	O
respiration	O
chambers	O
,	O
performed	O
,	O
in	O
the	O
morning	O
and	O
afternoon	O
,	O
15	O
min	O
cycling	O
with	O
the	O
total	O
work	O
of	O
6	O
,	O
750	O
kg	O
m	O
.	O

Mutations	O
in	O
a	O
region	O
located	O
15	O
to	O
30	O
bp	O
downstream	O
from	O
the	O
major	O
transcription	O
start	O
site	O
that	O
shows	O
good	O
homology	O
to	O
a	O
sequence	O
in	O
the	O
first	O
exon	O
of	O
c-fos	B-GENE
implicated	O
as	O
a	O
negative	O
regulatory	O
element	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
basal	O
gene	O
expression	O
but	O
did	O
not	O
affect	O
regulation	O
.	O

After	O
all	O
doses	O
of	O
d-amphetamine	O
,	O
responding	O
occurred	O
largely	O
on	O
the	O
saline	O
key	O
under	O
both	O
schedules	O
.	O

Thrombosis	O
of	O
the	O
renal	O
vein	O
may	O
be	O
dramatic	O
and	O
include	O
renal	O
failure	O
.	O

The	O
experimental	O
group	O
consisted	O
of	O
61	O
examinees	O
class	O
II	O
/	O
2	O
orthodontic	O
anomalies	O
.	O

Many	O
eukaryotic	O
cell	O
surface	O
proteins	O
are	O
anchored	O
in	O
the	O
lipid	O
bilayer	O
through	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
.	O

Contrary	O
to	O
expectations	O
,	O
we	O
find	O
a	O
relatively	O
high	O
level	O
of	O
variation	O
in	O
the	O
stripe	B-GENE
2	I-GENE
enhancer	I-GENE
region	I-GENE
,	O
including	O
point	O
substitutions	O
and	O
insertion	O
/	O
deletions	O
in	O
binding	O
sites	O
,	O
and	O
a	O
comparable	O
level	O
of	O
variation	O
in	O
the	O
other	O
noncoding	O
regions	O
.	O

Thyreoliberin	O
VUFB	O
in	O
thyroid	O
gammagraphy	O
.	O

A	O
soluble	O
62-kDa	O
protein	O
was	O
produced	O
without	O
the	O
proteolytic	O
processing	O
by	O
inserting	O
the	O
coding	O
sequence	O
of	O
amino	O
acids	O
112	O
to	O
660	O
of	O
ORF-2	O
in	O
a	O
baculovirus	O
expression	O
vector	O
and	O
using	O
the	O
corresponding	O
virus	O
to	O
infect	O
Sf9	O
cells	O
.	O

While	O
these	O
findings	O
may	O
reflect	O
the	O
sensitivity	O
of	O
a	O
thick	O
myocardial	O
wall	O
to	O
ischaemia	O
during	O
surgery	O
,	O
the	O
postoperative	O
recovery	O
was	O
not	O
related	O
to	O
the	O
serum	B-GENE
CK-MB	I-GENE
level	O
.	O

Recombinant	B-GENE
erythropoietin	I-GENE
(	O
r-HuEPO	B-GENE
)	O
in	O
the	O
treatment	O
of	O
anemia	O
in	O
multiple	O
myeloma	O
.	O

Model	O
predictions	O
were	O
in	O
accord	O
with	O
the	O
nine-year	O
survival	O
experience	O
of	O
women	O
in	O
the	O
HIP	O
trial	O
,	O
and	O
,	O
with	O
the	O
exception	O
of	O
women	O
40-44	O
years	O
old	O
,	O
with	O
HIP	O
data	O
on	O
18-year	O
survival	O
.	O

Eleven	O
biopsy	O
specimens	O
(	O
five	O
papules	O
and	O
six	O
dusky	O
or	O
crusted	O
lesions	O
)	O
from	O
four	O
patients	O
with	O
pityriasis	O
lichenoides	O
et	O
varioliformis	O
acuta	O
(	O
PLEVA	O
)	O
were	O
studied	O
by	O
direct	O
immunofluorescence	O
and	O
immunoperoxidase	O
technics	O
.	O

Detection	O
of	O
poisoning	O
by	O
Impila	O
(	O
Callilepis	O
laureola	O
)	O
in	O
a	O
mother	O
and	O
child	O
.	O

Screening	O
,	O
counseling	O
,	O
and	O
treatment	O
for	O
alcohol	O
and	O
illicit	O
drug	O
use	O
should	O
be	O
essential	O
components	O
in	O
comprehensive	O
HBP	O
care	O
.	O

Analyses	O
of	O
tyrosine	O
residue-mutated	O
PDGF	B-GENE
receptors	I-GENE
show	O
that	O
Src	B-GENE
homology	I-GENE
2	I-GENE
domain-containing	I-GENE
proteins	I-GENE
including	O
Src	B-GENE
family	I-GENE
kinases	I-GENE
,	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
,	O
the	O
GTPase-activating	B-GENE
protein	I-GENE
of	O
Ras	B-GENE
,	O
the	O
Src	B-GENE
homology	I-GENE
2	I-GENE
domain-containing	I-GENE
phosphatase	I-GENE
SHP-2	B-GENE
,	O
phospholipase	B-GENE
C-gamma	I-GENE
,	O
and	O
Crk	B-GENE
do	O
not	O
play	O
a	O
major	O
role	O
in	O
mediating	O
the	O
PDGF-induced	O
activation	O
of	O
p38	B-GENE
.	O

The	O
serum	O
levels	O
of	O
IgE	B-GENE
,	O
and	O
asIgE	B-GENE
and	O
IgG-4	B-GENE
against	O
14	O
common	O
food	O
allergens	O
were	O
determined	O
.	O

Also	O
,	O
the	O
amplitude	O
of	O
the	O
oscillatory	O
potentials	O
(	O
O1+O2+O3+O4	O
)	O
was	O
significantly	O
reduced	O
in	O
the	O
early	O
postoperative	O
period	O
.	O

Differential	O
expression	O
of	O
the	O
"B"	O
subunit	O
of	O
the	O
vacuolar	B-GENE
H	I-GENE
(	I-GENE
+	I-GENE
)	I-GENE
-ATPase	I-GENE
in	O
bovine	O
tissues	O
.	O

Pediatric	O
medical	O
emergencies	O
in	O
a	O
regional	O
hospital	O
:	O
appropriate	O
locale	O
?	O

CONCLUSION	O
:	O
During	O
chronic	O
treatment	O
,	O
the	O
haemodynamic	O
response	O
to	O
oral	O
cilazapril	O
was	O
attenuated	O
,	O
indicating	O
that	O
continued	O
clinical	O
improvement	O
in	O
patients	O
with	O
CHF	O
on	O
CLZ	O
is	O
independent	O
of	O
to	O
its	O
acute	O
haemodynamic	O
effects	O
.	O

Trichloroethylene	O
,	O
in	O
turn	O
,	O
increased	O
the	O
AUC	O
5	O
.	O
0	O
(	O
1	O
.	O
9-13	O
.	O
4	O
)	O
,	O
25	O
.	O
8	O
(	O
8	O
.	O
2-80	O
.	O
8	O
)	O
and	O
2	O
.	O
9	O
(	O
1	O
.	O
6-5	O
.	O
4	O
)	O
,	O
respectively	O
,	O
whereas	O
the	O
corresponding	O
values	O
for	O
n-hexane	O
were	O
1	O
.	O
9	O
(	O
0	O
.	O
7-5	O
.	O
1	O
)	O
,	O
1	O
.	O
5	O
(	O
0	O
.	O
5-4	O
.	O
6	O
)	O
,	O
and	O
3	O
.	O
2	O
(	O
1	O
.	O
8-5	O
.	O
9	O
)	O
.	O

The	O
interaction	O
of	O
U1-70K	B-GENE
with	O
the	O
SRZ	B-GENE
proteins	I-GENE
is	O
confirmed	O
further	O
in	O
vitro	O
using	O
a	O
blot	O
overlay	O
assay	O
.	O

Analysis	O
of	O
various	O
deletion	O
mutants	O
indicates	O
that	O
the	O
sequence	O
requirements	O
for	O
binding	O
by	O
QBP	B-GENE
in	O
vitro	O
are	O
indistinguishable	O
from	O
those	O
necessary	O
for	O
Q	B-GENE
activity	O
in	O
vivo	O
,	O
strongly	O
suggesting	O
that	O
QBP	B-GENE
is	O
required	O
for	O
the	O
function	O
of	O
this	O
TATA-independent	O
promoter	O
.	O

Common	O
history	O
and	O
prospects	O
in	O
surgical	O
gynecology	O
of	O
the	O
Charite	O
and	O
the	O
Vienna	O
University	O
Clinic	O
.	O

Therefore	O
,	O
we	O
have	O
developed	O
a	O
system	O
to	O
study	O
nuclear	O
targeting	O
in	O
plants	O
and	O
have	O
established	O
that	O
the	O
nuclear	O
transport	O
machinery	O
is	O
similar	O
in	O
monocots	O
and	O
dicots	O
.	O

CONCLUSIONS	O
:	O
Under	O
current	O
immunization	O
practices	O
,	O
the	O
authors	O
estimate	O
that	O
nearly	O
13	O
,	O
000	O
Asian	O
and	O
Pacific	O
Islander	O
children	O
living	O
in	O
the	O
United	O
States	O
today	O
will	O
become	O
infected	O
with	O
HBV	O
in	O
the	O
future	O
,	O
resulting	O
in	O
more	O
than	O
600	O
liver	O
carcinoma	O
deaths	O
.	O

Steroids	O
in	O
germfree	O
and	O
conventional	O
rats	O
.	O

Cardiac	O
output	O
at	O
anaerobic	O
threshold	O
(	O
COAT	O
)	O
<	O
or	O
=	O
7	O
.	O
3	O
L	O
/	O
min	O
was	O
the	O
best	O
cutoff	O
value	O
for	O
identifying	O
multivessel	O
coronary	O
artery	O
disease	O
(	O
relative	O
risk	O
,	O
3	O
.	O
1	O
)	O
.	O

We	O
show	O
that	O
cytR	B-GENE
expression	O
is	O
negatively	O
controlled	O
by	O
the	O
CytR	B-GENE
protein	I-GENE
and	O
positively	O
affected	O
by	O
the	O
cAMP	B-GENE
/	I-GENE
CAP	I-GENE
complex	I-GENE
.	O

The	O
topography	O
and	O
trajectories	O
of	O
the	O
commissural	O
fibers	O
of	O
the	O
superior	O
temporal	O
region	O
(	O
STR	O
)	O
are	O
studied	O
using	O
the	O
autoradiographic	O
technique	O
.	O

SSG1	B-GENE
,	O
a	O
gene	O
encoding	O
a	O
sporulation-specific	B-GENE
1	I-GENE
,	I-GENE
3-beta-glucanase	I-GENE
in	O
Saccharomyces	O
cerevisiae	O
.	O

T4	O
and	O
FT4I	O
followed	O
parallel	O
courses	O
in	O
both	O
groups	O
;	O
during	O
the	O
first	O
45	O
days	O
,	O
however	O
,	O
the	O
values	O
were	O
significantly	O
lower	O
in	O
premature	O
infants	O
under	O
34	O
weeks'	O
EGA	O
than	O
in	O
term	O
infants	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Multiple	O
regression	O
analysis	O
performed	O
between	O
these	O
long-term	O
abiotic	O
factors	O
and	O
nymphal	O
abundance	O
in	O
positive	O
sites	O
showed	O
high	O
relationship	O
(	O
R2	O
coefficients	O
)	O
for	O
every	O
habitat	O
category	O
and	O
explained	O
>	O
50%	O
of	O
the	O
variation	O
in	O
tick	O
abundance	O
.	O

The	O
regulation	O
of	O
PGHS-2	B-GENE
mRNA	I-GENE
and	O
protein	O
was	O
studied	O
in	O
primary	O
cultures	O
of	O
bovine	O
uterine	O
stromal	O
cells	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
;	O
100	O
nM	O
)	O
.	O

When	O
cells	O
were	O
microinjected	O
with	O
TFOs	O
designed	O
to	O
bind	O
to	O
a	O
30-bp	O
polypurine	O
site	O
situated	O
between	O
the	O
two	O
TK	B-GENE
genes	I-GENE
,	O
recombination	O
was	O
observed	O
at	O
frequencies	O
in	O
the	O
range	O
of	O
1%	O
,	O
2	O
,	O
500-fold	O
above	O
the	O
background	O
.	O

Moreover	O
,	O
the	O
ability	O
to	O
selectivity	O
arrest	O
elongation	O
by	O
polIII	B-GENE
at	O
defined	O
positions	O
within	O
the	O
tRNA	B-GENE
gene	I-GENE
transcription	I-GENE
unit	I-GENE
has	O
permitted	O
the	O
identification	O
of	O
discrete	O
functional	O
properties	O
of	O
paused	O
mammalian	B-GENE
polIII	I-GENE
ternary	I-GENE
complexes	I-GENE
.	O

The	O
effect	O
of	O
food	O
on	O
procainamide	O
absorption	O
.	O

Approximately	O
50%	O
of	O
the	O
ribosomal	O
DNA	O
(	O
rDNA	O
)	O
units	O
of	O
Drosophila	O
melanogaster	O
are	O
inactivated	O
by	O
two	O
different	O
28	B-GENE
S	I-GENE
RNA	I-GENE
ribosomal	I-GENE
gene	I-GENE
insertions	O
(	O
type	O
I	O
and	O
type	O
II	O
)	O
.	O

Based	O
on	O
restriction	O
enzyme	O
analysis	O
,	O
Southern	O
blots	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
DNA	O
sequencing	O
,	O
it	O
was	O
confirmed	O
that	O
the	O
three	O
overlapping	O
clones	O
isolated	O
cover	O
the	O
entire	O
cHO-1	B-GENE
gene	I-GENE
,	O
as	O
well	O
as	O
approximately	O
10	O
kb	O
of	O
the	O
flanking	O
regions	O
on	O
both	O
ends	O
.	O

GafChromic	O
(	O
MD-55-2	O
)	O
radiochromic	O
film	O
has	O
become	O
increasingly	O
popular	O
for	O
medical	O
applications	O
and	O
has	O
proven	O
to	O
be	O
useful	O
for	O
brachytherapy	O
dosimetry	O
.	O

The	O
pharmacokinetics	O
of	O
each	O
tetracycline	O
in	O
serum	O
and	O
dermal	O
,	O
suction	O
blister	O
fluid	O
were	O
determined	O
after	O
oral	O
doses	O
of	O
300	O
mg	O
lymecycline	O
or	O
100	O
mg	O
doxycycline	O
on	O
the	O
3rd	O
day	O
.	O

Defects	O
in	O
the	O
Schizosaccharomyces	O
pombe	O
(	O
Sp	O
)	O
cell	O
cycle-controlling	O
genes	O
prevent	O
the	O
cell	O
cycle	O
progression	O
.	O

Problems	O
remain	O
to	O
be	O
resolved	O
in	O
the	O
area	O
of	O
quantitative	O
risk	O
assessment	O
.	O

The	O
binding	O
of	O
transcription	O
factor	O
AP-1	B-GENE
and	O
vitamin	B-GENE
D	I-GENE
receptor	I-GENE
(	O
VDR	B-GENE
)	O
to	O
the	O
composite	O
AP-1	B-GENE
plus	O
vitamin-D-responsive	B-GENE
promoter	I-GENE
region	I-GENE
(	O
AP-1	B-GENE
+	I-GENE
VDRE	I-GENE
)	O
of	O
the	O
human	B-GENE
osteocalcin	I-GENE
gene	I-GENE
was	O
characterized	O
in	O
osteocalcin-producing	O
(	O
MG-63	O
)	O
and	O
non-producing	O
(	O
U2-Os	O
,	O
SaOs-2	O
)	O
human	O
osteosarcoma	O
cell	O
lines	O
.	O

Ultrasound	O
effect	O
on	O
the	O
cytochrome	B-GENE
oxidase	I-GENE
activity	O
.	O

To	O
examine	O
the	O
role	O
of	O
this	O
CE2	B-GENE
element	I-GENE
in	O
regulating	O
Hoxa1	B-GENE
expression	O
in	O
vivo	O
,	O
transgenic	O
mice	O
were	O
generated	O
which	O
express	O
a	O
Hoxa1	B-GENE
beta-galactosidase	B-GENE
reporter	O
gene	O
that	O
contains	O
a	O
mutation	O
in	O
the	O
CE2	B-GENE
element	I-GENE
.	O

We	O
produced	O
transgenic	O
plants	O
expressing	O
the	O
antisense	B-GENE
Arabidopsis	I-GENE
HD	I-GENE
(	O
AtHD1	B-GENE
)	O
gene	O
.	O

To	O
determine	O
the	O
relationship	O
of	O
these	O
viruses	O
,	O
the	O
complete	O
DNA	O
sequence	O
of	O
KV	O
consisting	O
of	O
4754	O
bp	O
was	O
determined	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
cellular	B-GENE
p21ras	I-GENE
protein	I-GENE
in	O
insulin	B-GENE
and	O
insulin-like	B-GENE
growth	I-GENE
factor-I	I-GENE
(	O
IGF-I	B-GENE
)	O
signaling	O
pathways	O
.	O

This	O
effect	O
was	O
abolished	O
once	O
the	O
EM	B-GENE
motif	I-GENE
in	O
the	O
promoter-reporter	O
construct	O
was	O
mutated	O
,	O
thus	O
suggesting	O
that	O
the	O
synergistic	O
transactivation	O
function	O
of	O
the	O
TEF-1-Max	B-GENE
heterotypic	I-GENE
complex	I-GENE
is	O
mediated	O
through	O
binding	O
of	O
the	O
complex	O
to	O
the	O
EM	B-GENE
motif	I-GENE
.	O

A	O
stable	O
interface	O
depends	O
on	O
overall	O
stress	O
and	O
microstress	O
distribution	O
on	O
the	O
bone	O
,	O
particularly	O
trabecular	O
bone	O
.	O

Variation	O
in	O
the	O
temporal-spatial	O
distribution	O
of	O
228Ra	O
and	O
224Ra	O
in	O
the	O
RES	O
and	O
marrow-free	O
skeleton	O
after	O
incorporation	O
of	O
colloidal	O
ThO2	O
.	O

Hypoglycemic	O
and	O
antidiabetic	O
properties	O
.	O

The	O
method	O
is	O
applied	O
to	O
determine	O
aberration	O
constants	O
of	O
a	O
CM300	O
FEG	O
/	O
UT	O
microscope	O
with	O
correction	O
of	O
the	O
three-fold	O
astigmatism	O
.	O

B	B-GENE
cell	I-GENE
antigen	I-GENE
receptor	I-GENE
(	O
BCR	B-GENE
)	O
-induced	O
apoptosis	O
in	O
the	O
WEHI-231	O
B	O
lymphoma	O
cell	O
line	O
can	O
be	O
prevented	O
by	O
engaging	O
CD40	B-GENE
.	O

Gel	O
retardation	O
assays	O
detected	O
ZiaR-dependent	O
complexes	O
forming	O
with	O
the	O
zia	B-GENE
operator-promoter	I-GENE
and	O
ZiaR-DNA	O
binding	O
was	O
enhanced	O
by	O
treatment	O
with	O
a	O
metal-chelator	O
in	O
vitro	O
.	O

Similarly	O
,	O
co-expression	O
of	O
a	O
dominant-negative	O
mutant	O
of	O
p38alpha	B-GENE
,	O
but	O
not	O
of	O
ERK1	B-GENE
,	O
ERK2	B-GENE
,	O
JNK1	B-GENE
,	O
or	O
JNK2	B-GENE
,	O
reduces	O
basal	O
and	O
cadmium-induced	O
pE1-luc	B-GENE
activity	O
.	O

A	O
contiguous	O
and	O
sequentially	O
occupied	O
secondary	O
Fur-binding	B-GENE
site	I-GENE
in	O
entC	B-GENE
was	O
protected	O
at	O
higher	O
Fur	B-GENE
concentrations	O
,	O
extending	O
the	O
protected	O
region	O
to	O
+49	O
,	O
and	O
sequestering	O
the	O
putative	O
Shine-Dalgarno	O
sequence	O
.	O

The	O
biochemistry	O
of	O
amniotic	O
fluid	O
with	O
poor	O
fetal	O
growth	O
.	O

Northern	O
analysis	O
of	O
the	O
3	B-GENE
.	I-GENE
1-kb	I-GENE
PWP2H	I-GENE
cDNA	I-GENE
revealed	O
that	O
a	O
3	O
.	O
3-kb	O
major	O
transcript	O
is	O
ubiquitously	O
expressed	O
in	O
human	O
adult	O
tissues	O
.	O

Application	O
of	O
the	O
2-deoxy-D-glucose	O
method	O
to	O
the	O
coupling	O
of	O
cerebral	O
metabolism	O
and	O
blood	O
flow	O
.	O

Genetic	O
analysis	O
has	O
subsequently	O
identified	O
subpathways	O
of	O
the	O
DNA	O
structure	O
checkpoints	O
,	O
including	O
the	O
reversible	O
arrest	O
of	O
DNA	O
synthesis	O
.	O

One	O
linker-peptide	O
insertion	O
in	O
the	O
RsaA	B-GENE
C	I-GENE
terminus	I-GENE
(	I-GENE
amino	I-GENE
acid	I-GENE
784	I-GENE
)	I-GENE
had	O
no	O
effect	O
on	O
S-layer	O
biogenesis	O
,	O
while	O
another	O
(	O
amino	O
acid	O
907	O
)	O
disrupted	O
secretion	O
of	O
the	O
protein	O
,	O
suggesting	O
that	O
RsaA	B-GENE
possesses	O
a	O
secretion	O
signal	O
lying	O
C	O
terminal	O
to	O
amino	O
acid	O
784	O
,	O
near	O
or	O
including	O
amino	O
acid	O
907	O
.	O

Dipetalonema	O
(	O
Alafilaria	O
)	O
hydrochoerus	O
subgen	O
.	O
et	O
sp	O
.	O
n	O
.	O

The	O
Laser	O
Scanning	O
Ophthalmoscope	O
enables	O
a	O
fundus-based	O
examination	O
and	O
therefore	O
allows	O
exact	O
comparison	O
between	O
morphologic	O
appearance	O
and	O
corresponding	O
function	O
.	O

356	O
,	O
93-98	O
]	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
Case	O
study	O
.	O

Like	O
pineal	O
melatonin	O
,	O
serum	O
melatonin	O
was	O
high	O
at	O
mid-dark	O
and	O
low	O
at	O
mid-light	O
.	O

After	O
an	O
initial	O
titration	O
period	O
and	O
adjustment	O
of	O
the	O
therapeutic	O
dose	O
,	O
the	O
individual	O
doses	O
were	O
from	O
21	O
to	O
500	O
micrograms	O
/	O
24	O
hrs	O
(	O
mean	O
160	O
micrograms	O
/	O
24	O
hrs	O
)	O
.	O

For	O
an	O
unsupervised	O
program	O
,	O
the	O
costs	O
were	O
estimated	O
at	O
$311	O
for	O
the	O
first	O
year	O
and	O
$73	O
for	O
all	O
additional	O
years	O
.	O

The	O
model	O
indicates	O
that	O
a	O
0	O
.	O
076%	O
reduction	O
in	O
cigarette	O
consumption	O
is	O
associated	O
with	O
the	O
availability	O
of	O
nicotine	O
patches	O
after	O
1992	O
.	O

E1	B-GENE
,	O
a	O
DNA	B-GENE
helicase	I-GENE
,	O
collaborates	O
with	O
the	O
HPV	B-GENE
E2	I-GENE
protein	I-GENE
in	O
ori-dependent	O
replication	O
.	O

Tec	B-GENE
kinase	I-GENE
signaling	O
in	O
T	O
cells	O
is	O
regulated	O
by	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
and	O
the	O
Tec	B-GENE
pleckstrin	B-GENE
homology	I-GENE
domain	I-GENE
.	O

Together	O
,	O
our	O
results	O
show	O
that	O
tinman	B-GENE
is	O
controlled	O
by	O
an	O
array	O
of	O
discrete	O
enhancer	O
elements	O
that	O
are	O
activated	O
successively	O
by	O
differential	O
genetic	O
inputs	O
,	O
as	O
well	O
as	O
by	O
closely	O
linked	O
activator	O
and	O
repressor	O
binding	O
sites	O
within	O
an	O
early-acting	O
enhancer	O
,	O
which	O
restrict	O
twist	B-GENE
activity	O
to	O
specific	O
areas	O
within	O
the	O
twist	B-GENE
expression	I-GENE
domain	I-GENE
.	O

Effects	O
of	O
alterations	O
of	O
primer-binding	O
site	O
sequences	O
on	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
.	O

Infant	O
aged	O
3	O
.	O
5	O
years	O
presents	O
persistence	O
of	O
primordial	O
vitreous	O
body	O
with	O
crystalline	O
dislocation	O
in	O
the	O
camera	O
aquosa	O
and	O
secondary	O
buphthalmos	O
of	O
the	O
left	O
eye	O
and	O
microphthalmos	O
with	O
dislocation	O
of	O
the	O
crystalline	O
in	O
the	O
vitreous	O
body	O
of	O
the	O
right	O
eye	O
.	O

The	O
scr	B-GENE
regulon	I-GENE
of	O
pUR400	O
and	O
the	O
chromosomally	B-GENE
encoded	I-GENE
scr	I-GENE
regulon	I-GENE
of	I-GENE
Klebsiella	I-GENE
pneumoniae	I-GENE
KAY2026	I-GENE
are	O
both	O
negatively	O
controlled	O
by	O
a	O
specific	O
repressor	O
(	O
ScrR	B-GENE
)	O
.	O

A	O
215-base-pair	O
(	O
bp	O
)	O
region	O
of	O
the	O
mouse	B-GENE
MOPC	I-GENE
41	I-GENE
kappa	I-GENE
light-chain	I-GENE
immunoglobulin	I-GENE
gene	I-GENE
enhancer	I-GENE
has	O
been	O
analyzed	O
for	O
specific	O
binding	O
of	O
lymphoid	O
and	O
nonlymphoid	O
nuclear	O
factors	O
.	O

These	O
mutants	O
had	O
deletions	O
of	O
the	O
extreme	O
amino-terminal	O
residues	O
as	O
far	O
as	O
amino	O
acid	O
residue	O
30	O
.	O

This	O
transition	O
is	O
regulated	O
positively	O
by	O
G1-specific	B-GENE
cyclin-dependent	I-GENE
kinases	I-GENE
(	O
cdks	B-GENE
)	O
and	O
negatively	O
by	O
the	O
product	O
of	O
the	O
retinoblastoma	B-GENE
tumour	I-GENE
suppressor	I-GENE
gene	I-GENE
,	O
pRb	B-GENE
.	O

She	O
was	O
able	O
to	O
stand	O
unaided	O
by	O
3	O
years	O
of	O
age	O
with	O
then	O
progressive	O
worsening	O
of	O
motor	O
abilities	O
.	O

These	O
RZR	B-GENE
subtypes	O
represent	O
members	O
of	O
a	O
new	O
family	O
of	O
orphan	B-GENE
nuclear	I-GENE
receptors	I-GENE
that	O
most	O
likely	O
regulate	O
specific	O
gene	O
expression	O
.	O

To	O
study	O
the	O
in	O
vivo	O
role	O
of	O
p16	B-GENE
.	I-GENE
7	I-GENE
,	O
a	O
phi29	O
mutant	O
containing	O
a	O
suppressible	O
mutation	O
in	O
gene	B-GENE
16	I-GENE
.	I-GENE
7	I-GENE
was	O
constructed	O
.	O

In	O
an	O
in	O
vitro	O
study	O
,	O
10	O
/	O
0	O
nylon	O
was	O
found	O
to	O
require	O
a	O
significantly	O
lower	O
laser	O
energy	O
density	O
to	O
produce	O
suture	O
lysis	O
following	O
a	O
single	O
shot	O
than	O
either	O
10	O
/	O
0	O
Dacron	O
or	O
10	O
/	O
0	O
prolene	O
.	O

In	O
order	O
to	O
screen	O
for	O
such	O
cofactors	O
,	O
we	O
have	O
used	O
a	O
transcriptionally	O
inactive	O
mutant	O
of	O
Xenopus	B-GENE
MEF2D	I-GENE
in	O
a	O
yeast	O
two-hybrid	O
screen	O
.	O

A	O
decamer	O
sequence	O
,	O
5'-CGA-CCCCUCC-3'	B-GENE
,	O
complementary	O
to	O
a	O
conserved	O
sequence	O
adjacent	O
to	O
the	O
enzymatic	O
cleavage	O
site	O
on	O
the	O
mitochondrial	O
RNA	O
substrate	O
,	O
is	O
present	O
in	O
the	O
RNAase	B-GENE
MRP	I-GENE
RNA	I-GENE
.	O

In	O
vitro	O
translation	O
of	O
RNA	O
synthesized	O
from	O
the	O
cloned	O
cDNAs	O
predicts	O
that	O
P0	B-GENE
transcripts	I-GENE
are	O
translated	O
into	O
a	O
novel	O
12	O
.	O
5-kilodalton	O
protein	O
corresponding	O
to	O
the	O
first	O
open	O
reading	O
frame	O
.	O

In	O
the	O
remaining	O
case	O
,	O
the	O
aneurysm	O
originated	O
from	O
the	O
proximal	O
end	O
of	O
the	O
associated	O
A1	O
fenestration	O
.	O

The	O
diagnosis	O
of	O
amyloidosis	O
was	O
determined	O
from	O
a	O
labial	O
salivary	O
gland	O
biopsy	O
.	O

CASE	O
REPORT	O
:	O
Referred	O
because	O
of	O
a	O
right	O
corneal	O
perforation	O
with	O
cellular	O
reaction	O
in	O
anterior	O
chamber	O
,	O
a	O
patient	O
was	O
sutured	O
and	O
treated	O
with	O
a	O
single	O
intravitreal	O
injection	O
of	O
0	O
.	O
2	O
ml	O
(	O
1	O
mg	O
)	O
Amikacin	O
and	O
0	O
.	O
2	O
ml	O
(	O
1	O
mg	O
)	O
Vancomycin	O
.	O

We	O
further	O
found	O
that	O
KmMig1p	B-GENE
is	O
fully	O
functional	O
when	O
expressed	O
in	O
S	O
.	O
cerevisiae	O
.	O

It	O
has	O
repeatedly	O
been	O
shown	O
that	O
HCMV	B-GENE
IE1	I-GENE
/	I-GENE
IE2	I-GENE
can	O
independently	O
transactivate	O
HIV-1	B-GENE
LTR	I-GENE
.	O

Terbutaline	O
;	O
a	O
beta2-adrenergic	O
agonist	O
,	O
and	O
aminophyllin	O
,	O
a	O
phosphodiesterase	B-GENE
inhibitor	O
,	O
were	O
given	O
separately	O
,	O
or	O
in	O
combination	O
,	O
to	O
rabbit	O
fetuses	O
on	O
the	O
28th	O
day	O
of	O
gestation	O
.	O

Comparison	O
to	O
other	O
coxI	B-GENE
genes	I-GENE
revealed	O
a	O
966-bp	B-GENE
group	I-GENE
I	I-GENE
intron	I-GENE
,	O
which	O
,	O
based	O
on	O
homology	O
with	O
the	O
related	O
yeast	B-GENE
coxI	I-GENE
intron	I-GENE
aI4	I-GENE
,	O
potentially	O
encodes	O
a	O
279-amino-acid	B-GENE
site-specific	I-GENE
DNA	I-GENE
endonuclease	I-GENE
.	O

In	O
conclusion	O
,	O
tube	O
size	O
estimated	O
by	O
Cole's	O
formula	O
tends	O
to	O
be	O
smaller	O
than	O
practically	O
appropriate	O
tube	O
size	O
for	O
pediatric	O
cardiac	O
anesthesia	O
,	O
and	O
therefore	O
we	O
suggest	O
new	O
formula	O
to	O
estimate	O
the	O
tube	O
size	O
.	O

Antipyretic	O
therapy	O
:	O
physiologic	O
rationale	O
,	O
diagnostic	O
implications	O
,	O
and	O
clinical	O
consequences	O
.	O

Upon	O
analysis	O
of	O
the	O
tissue	O
distribution	O
of	O
AAMP	B-GENE
,	O
it	O
was	O
found	O
to	O
be	O
expressed	O
strongly	O
in	O
endothelial	O
cells	O
,	O
cytotrophoblasts	O
,	O
and	O
poorly	O
differentiated	O
colon	O
adenocarcinoma	O
cells	O
found	O
in	O
lymphatics	O
.	O

We	O
propose	O
that	O
noi	B-GENE
/	I-GENE
pax2	I-GENE
.	I-GENE
1	I-GENE
participates	O
in	O
sequential	O
signaling	O
processes	O
as	O
a	O
key	O
integrator	O
of	O
midbrain-hindbrain	O
boundary	O
development	O
.	O

Finally	O
,	O
over	O
a	O
similar	O
range	O
of	O
QO2	O
,	O
oxygen	O
extraction	O
was	O
greater	O
in	O
patients	O
with	O
ARDS	O
compared	O
to	O
patients	O
with	O
non-ARDS	O
respiratory	O
failure	O
(	O
r	O
=	O
-0	O
.	O
67	O
and	O
slope	O
=	O
-0	O
.	O
62	O
vs	O
r	O
=	O
-0	O
.	O
45	O
and	O
slope	O
=	O
-0	O
.	O
35	O
;	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
commercially	O
available	O
intravenous	O
formulation	O
of	O
Cyclosporin	O
A	O
(	O
Sandimmun	O
)	O
,	O
polyoxyethylated	O
castor	O
oil	O
(	O
Cremophor	O
EL	O
)	O
is	O
used	O
as	O
a	O
solubilizing	O
agent	O
.	O

Inhibition	O
of	O
histalog-stimulated	O
gastric	O
secretion	O
by	O
40	O
749	O
RP	O
,	O
a	O
new	O
long-acting	O
gastric	O
antisecretory	O
agent	O
.	O

The	O
HMG	B-GENE
CoA	I-GENE
reductase	I-GENE
inhibitors	O
are	O
the	O
most	O
effective	O
cholesterol-lowering	O
agents	O
currently	O
available	O
.	O

The	O
activity	O
of	O
the	O
EGF	B-GENE
receptor	I-GENE
promoter	I-GENE
can	O
be	O
modulated	O
by	O
E1A	B-GENE
protein	I-GENE
and	O
receptor	O
RNA	O
levels	O
increased	O
by	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
fetal	O
calf	O
serum	O
.	O

Moreover	O
,	O
the	O
observation	O
of	O
enhanced	O
luteal	B-GENE
HSP-27	I-GENE
phosphorylation	O
in	O
vivo	O
,	O
in	O
late	O
pregnancy	O
,	O
when	O
PKC-delta	B-GENE
is	O
abundant	O
and	O
active	O
,	O
suggests	O
that	O
select	O
PKC	B-GENE
family	I-GENE
members	I-GENE
contribute	O
to	O
sHSP	B-GENE
phosphorylation	O
events	O
in	O
vivo	O
.	O

Analysis	O
of	O
the	O
5'	O
flanking	O
region	O
of	O
the	O
gene	O
also	O
revealed	O
the	O
presence	O
of	O
multiple	O
TATA	O
and	O
CAAT	O
sequences	O
.	O

Sural	O
nerve	O
biopsy	O
showed	O
mild	O
thickening	O
of	O
the	O
perineurium	O
,	O
vascular	O
alterations	O
with	O
inflammatory	O
cell	O
infiltration	O
in	O
the	O
perineurium	O
,	O
and	O
remarkable	O
loss	O
of	O
large	O
and	O
small	O
myelinated	O
fibers	O
.	O

Family	O
environment	O
was	O
an	O
important	O
influence	O
on	O
interpersonal	O
relationships	O
,	O
substance	O
use	O
,	O
and	O
social	O
support	O
.	O

Finally	O
,	O
we	O
compared	O
the	O
differential	O
screening	O
techniques	O
in	O
terms	O
of	O
sensitivity	O
,	O
efficiency	O
and	O
occurrence	O
of	O
false	O
positives	O
.	O

There	O
has	O
been	O
similar	O
improvement	O
in	O
treating	O
ampullary	O
and	O
periampullary	O
cancer	O
,	O
gallbladder	O
cancer	O
,	O
or	O
extrahepatic	O
bile	O
duct	O
cancer	O
.	O

Modification	O
of	O
the	O
growth	O
of	O
Tetrahymena	O
by	O
compounds	O
which	O
affect	O
the	O
adrenergic	O
mechanism	O
.	O

Editorial	O
:	O
Low-dose	O
heparin	O
and	O
the	O
prevention	O
of	O
venous	O
thromboembolic	O
disease	O
.	O

These	O
genes	O
were	O
expressed	O
in	O
a	O
Saccharomyces	O
cerevisiae	O
mutant	O
in	O
which	O
the	O
endogenous	B-GENE
ferrochelatase	I-GENE
gene	I-GENE
(	O
HEM15	B-GENE
)	O
had	O
been	O
deleted	O
,	O
and	O
the	O
phenotypes	O
of	O
the	O
transformants	O
were	O
characterized	O
.	O

Lyn	B-GENE
kinase	I-GENE
immunoprecipitated	O
from	O
lysates	O
of	O
irradiated	O
BCP	O
as	O
well	O
as	O
a	O
full-length	B-GENE
glutathione	I-GENE
S-transferase	I-GENE
(	O
GST	B-GENE
)	O
-Lyn	O
fusion	O
protein-phosphorylated	O
recombinant	B-GENE
human	I-GENE
p34cdc2	I-GENE
on	O
tyrosine	O
15	O
.	O

Computer-aided	O
"FRAME"	O
analysis	O
revealed	O
four	O
possible	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
three	O
in	O
one	O
direction	O
and	O
one	O
in	O
the	O
opposite	O
direction	O
.	O

Our	O
observations	O
suggest	O
that	O
members	O
of	O
the	O
HMG-I	B-GENE
family	I-GENE
play	O
an	O
important	O
role	O
in	O
SRF-dependent	O
transcription	O
and	O
that	O
their	O
effect	O
is	O
mediated	O
primarily	O
by	O
a	O
protein-protein	O
interaction	O
.	O

I	O
.	O

The	O
corresponding	O
orifice	O
voltages	O
for	O
the	O
three	O
instruments	O
were	O
20	O
/	O
50	O
/	O
80	O
V	O
(	O
API	O
365	O
)	O
,	O
30	O
/	O
90	O
/	O
130	O
V	O
(	O
API	O
2000	O
)	O
and	O
40	O
/	O
80	O
/	O
120	O
V	O
(	O
API	O
3000	O
)	O
.	O

Schnell	O
,	O
J	O
.	O

Continued	O
development	O
of	O
the	O
rat	O
conditioning	O
paradigm	O
is	O
especially	O
warranted	O
because	O
of	O
the	O
ability	O
to	O
record	O
sympathetic	O
nerve	O
activity	O
in	O
intact	O
,	O
awake	O
subjects	O
and	O
the	O
large	O
number	O
of	O
readily	O
available	O
genetic	O
strains	O
,	O
which	O
model	O
human	O
pathological	O
states	O
.	O

These	O
results	O
with	O
clozapine	O
illustrate	O
that	O
LI	O
is	O
sensitive	O
to	O
antipsychotics	O
which	O
differ	O
in	O
their	O
mode	O
of	O
action	O
and	O
furthermore	O
emphasize	O
the	O
value	O
of	O
LI	O
as	O
a	O
test	O
model	O
for	O
detecting	O
the	O
antipsychotic	O
potential	O
of	O
novel	O
drugs	O
.	O

Patients	O
who	O
have	O
undergone	O
thyroidectomy	O
for	O
thyroid	O
carcinoma	O
are	O
frequently	O
subjected	O
to	O
periods	O
of	O
induced	O
severe	O
hypothyroidism	O
in	O
preparation	O
for	O
131I	O
whole	O
body	O
scanning	O
and	O
measurement	O
of	O
serum	O
TG	O
.	O

In	O
metabolic	O
acidosis	O
there	O
was	O
a	O
marked	O
stimulation	O
when	O
clamped	O
at	O
-10	O
to	O
-100	O
mV	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-GENE
promoter	I-GENE
by	O
the	O
Z	B-GENE
/	I-GENE
c-myb	I-GENE
combination	O
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-GENE
protein	I-GENE
but	O
not	O
the	O
c-myb	B-GENE
protein	I-GENE
.	O

Insulin-like	B-GENE
growth	I-GENE
factor-I	I-GENE
induces	O
bcl-2	B-GENE
promoter	I-GENE
through	O
the	O
transcription	O
factor	O
cAMP-response	B-GENE
element-binding	I-GENE
protein	I-GENE
.	O

METHODS	O
:	O
We	O
determined	O
an	O
odds	O
ratio	O
(	O
OR	O
)	O
,	O
as	O
a	O
measure	O
of	O
the	O
relative	O
risk	O
of	O
being	O
exposed	O
to	O
a	O
potential	O
interaction	O
,	O
comparing	O
the	O
use	O
of	O
the	O
H2-receptor	B-GENE
antagonist	I-GENE
,	O
cimetidine	O
,	O
with	O
that	O
of	O
the	O
noninteracting	O
agents	O
ranitidine	O
,	O
famotidine	O
and	O
nizatidine	O
in	O
users	O
and	O
nonusers	O
of	O
warfarin	O
,	O
phenytoin	O
and	O
theophylline	O
.	O

Long-range	O
comparison	O
of	O
human	B-GENE
and	I-GENE
mouse	I-GENE
SCL	I-GENE
loci	I-GENE
:	O
localized	O
regions	O
of	O
sensitivity	O
to	O
restriction	B-GENE
endonucleases	I-GENE
correspond	O
precisely	O
with	O
peaks	O
of	O
conserved	O
noncoding	O
sequences	O
.	O

In	O
TNF-resistant	O
T24	O
bladder	O
carcinoma	O
cells	O
,	O
TNF	B-GENE
failed	O
to	O
alter	O
EGF-R	B-GENE
tyrosine	B-GENE
protein	I-GENE
kinase	I-GENE
activity	O
although	O
both	O
EGF	B-GENE
and	O
phorbol	O
ester	O
were	O
shown	O
to	O
modulate	O
the	O
enzymatic	O
activity	O
of	O
the	O
receptor	O
in	O
these	O
cells	O
.	O

We	O
isolated	O
a	O
ribosomal	B-GENE
protein	I-GENE
L18	I-GENE
by	O
interaction	O
with	O
PKR	B-GENE
.	O

Sequence	O
determination	O
of	O
isolated	O
peptides	O
suggested	O
that	O
Asn120	O
is	O
glycosylated	O
,	O
Asn65	O
and	O
Asn109	O
glycosylated	O
in	O
some	O
molecules	O
but	O
not	O
in	O
others	O
,	O
and	O
Asn72	O
not	O
glycosylated	O
.	O

Qualitatively	O
,	O
the	O
results	O
are	O
similar	O
for	O
the	O
two	O
species	O
:	O
Both	O
rhesus	O
monkey	O
and	O
man	O
have	O
photopic	O
and	O
scotopic	O
branches	O
,	O
which	O
cross	O
at	O
approximately	O
the	O
same	O
time	O
in	O
the	O
dark	O
and	O
at	O
approximately	O
the	O
same	O
background	O
luminance	O
.	O

Insertional	O
inactivation	O
of	O
sms	B-GENE
led	O
to	O
increased	O
sensitivity	O
to	O
the	O
alkylating	O
agent	O
methylmethane	O
sulfonate	O
,	O
but	O
not	O
to	O
a	O
requirement	O
for	O
serine	O
or	O
other	O
metabolites	O
.	O

Since	O
the	O
5'-flanking	O
region	O
of	O
this	O
gene	O
is	O
likely	O
involved	O
in	O
hormonal	O
regulation	O
of	O
its	O
expression	O
,	O
we	O
have	O
isolated	O
and	O
partially	O
characterized	O
an	O
avian	O
fatty	B-GENE
acid	I-GENE
synthase	I-GENE
gene	O
.	O

Improved	O
cosmesis	O
,	O
extension	O
of	O
the	O
scope	O
of	O
the	O
problems	O
that	O
can	O
be	O
addressed	O
with	O
this	O
repair	O
(	O
including	O
treatment	O
of	O
a	O
distal	O
urethrocutaneous	O
fistula	O
)	O
and	O
the	O
ease	O
with	O
which	O
the	O
Arap	O
procedure	O
can	O
be	O
performed	O
are	O
the	O
advantages	O
that	O
this	O
operation	O
has	O
over	O
other	O
1-stage	O
distal	O
hypospadias	O
repairs	O
.	O

Thirty	O
percent	O
of	O
patients	O
were	O
tapered	O
off	O
all	O
steroids	O
,	O
and	O
the	O
average	O
steroid	O
dose	O
in	O
the	O
group	O
who	O
received	O
steroids	O
was	O
8	O
.	O
6	O
mg	O
of	O
prednisone	O
per	O
day	O
.	O

However	O
,	O
in	O
contrast	O
with	O
previous	O
in	O
vitro	O
cell-free	O
integration	O
studies	O
,	O
alteration	O
of	O
the	O
highly	O
conserved	O
CA	O
dinucleotide	O
resulted	O
in	O
a	O
mutant	O
which	O
still	O
retained	O
40%	O
of	O
wild-type	O
integration	O
activity	O
.	O

Spontaneous	O
recovery	O
occurs	O
within	O
30	O
min	O
to	O
2	O
hrs	O
.	O

A	O
p21	B-GENE
peptide	I-GENE
spanning	O
amino	O
acids	O
139-164	O
was	O
found	O
to	O
bind	O
PCNA	B-GENE
in	O
a	O
filter	O
binding	O
assay	O
and	O
this	O
peptide	O
suppressed	O
recombinant	B-GENE
p21-PCNA	I-GENE
interaction	O
.	O

Molecular	O
characterization	O
of	O
malignant	O
melanoma	O
of	O
soft	O
parts	O
or	O
soft	O
tissue	O
clear	O
cell	O
sarcoma	O
which	O
shares	O
t	O
(	O
12	O
;	O
22	O
)	O
chromosome	O
translocation	O
revealed	O
fusion	O
of	O
EWS	B-GENE
with	O
a	O
transcriptional	O
factor	O
gene	B-GENE
ATF-1	I-GENE
.	O

Thus	O
,	O
these	O
studies	O
on	O
rat	B-GENE
Std	I-GENE
promoter	I-GENE
function	O
indicate	O
that	O
(	O
i	O
)	O
HNF1	B-GENE
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
are	O
responsible	O
for	O
liver	O
specificity	O
of	O
the	O
rat	B-GENE
Std	I-GENE
gene	I-GENE
;	O
(	O
ii	O
)	O
androgenic	O
repression	O
of	O
the	O
gene	O
requires	O
the	O
presence	O
of	O
all	O
of	O
the	O
OCT-1	B-GENE
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
elements	I-GENE
between	O
positions	O
-231	O
and	O
-292	O
;	O
and	O
(	O
iii	O
)	O
AR	B-GENE
may	O
exert	O
its	O
negative	O
regulatory	O
effect	O
indirectly	O
through	O
transcriptional	O
interference	O
of	O
OCT-1	B-GENE
and	O
C	B-GENE
/	I-GENE
EBP	I-GENE
rather	O
than	O
through	O
a	O
direct	O
DNA-AR	B-GENE
interaction	O
.	O

The	O
R	B-GENE
.	I-GENE
meliloti	I-GENE
nifH	I-GENE
promoter	I-GENE
but	O
not	O
the	O
K	B-GENE
.	I-GENE
pneumoniae	I-GENE
nifH	I-GENE
promoter	I-GENE
showed	O
sigma	O
54-dependent	O
methylation	O
protection	O
of	O
guanine	O
residues	O
at	O
-14	O
,	O
-25	O
and	O
-26	O
,	O
the	O
most	O
conserved	O
nucleotides	O
characteristic	O
of	O
sigma	B-GENE
54-dependent	I-GENE
promoters	I-GENE
.	O

Competition	O
EMSA	O
established	O
that	O
constitutively	O
expressed	O
nuclear	O
proteins	O
bound	O
the	O
KCS	B-GENE
element	I-GENE
selectively	O
;	O
KCS	B-GENE
protein	I-GENE
binding	O
activity	O
correlated	O
with	O
promoter	O
activity	O
in	O
the	O
transient	O
transfection	O
reporter	O
assay	O
.	O

CONCLUSION	O
:	O
In	O
Cdks	B-GENE
functioning	O
throughout	O
the	O
cell	O
cycle	O
,	O
tyrosine	O
phosphorylation	O
is	O
inhibitory	O
to	O
the	O
activation	O
of	O
kinase	O
,	O
whereas	O
the	O
phosphorylation	O
of	O
threonine	O
in	O
the	O
T-loop	O
is	O
essential	O
for	O
activation	O
.	O

For	O
the	O
first	O
time	O
we	O
describe	O
deletion	O
and	O
point	O
mutations	O
within	O
the	O
plasma	B-GENE
membrane	I-GENE
family	I-GENE
of	I-GENE
guanylyl	I-GENE
cyclase	I-GENE
receptors	I-GENE
that	O
result	O
in	O
the	O
formation	O
of	O
effective	O
dominant	O
negative	O
proteins	O
.	O

No	O
difference	O
in	O
the	O
clinical	O
acceptability	O
could	O
be	O
ascertained	O
between	O
the	O
two	O
groups	O
.	O

MSSPs	B-GENE
are	O
believed	O
to	O
regulate	O
DNA	O
replication	O
,	O
transcription	O
,	O
apopotosis	O
and	O
cell	O
cycle	O
progression	O
by	O
interacting	O
with	O
the	O
C-MYC	B-GENE
protein	I-GENE
.	O

The	O
clinical	O
picture	O
of	O
the	O
disease	O
was	O
significantly	O
different	O
from	O
anthropogenic	O
cutaneous	O
leishmaniasis	O
caused	O
by	O
L	O
.	O
tropica	O
but	O
similar	O
to	O
cutaneous	O
patterns	O
caused	O
by	O
L	O
.	O
infantum	O
which	O
was	O
a	O
prevalent	O
pattern	O
in	O
the	O
southern	O
France	O
.	O

The	O
human	B-GENE
2'	I-GENE
,	I-GENE
5'-oligoadenylate	I-GENE
(	I-GENE
2-5A	I-GENE
)	I-GENE
synthetases	I-GENE
are	O
members	O
of	O
a	O
family	O
interferon	B-GENE
(	O
IFN	B-GENE
)	O
-inducible	O
anti-viral	B-GENE
proteins	I-GENE
.	O

Taken	O
together	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
existence	O
of	O
an	O
activator	O
,	O
NFE	B-GENE
,	O
which	O
in	O
combination	O
with	O
the	O
p50	B-GENE
and	O
c-Rel	B-GENE
proteins	I-GENE
,	O
are	O
part	O
of	O
the	O
transcription	O
factor	O
machinery	O
that	O
regulates	O
3'	O
enhancer	O
activity	O
,	O
and	O
thus	O
the	O
control	O
of	O
the	O
IgH	B-GENE
locus	I-GENE
in	O
late	O
B	O
lymphocyte	O
development	O
.	O

We	O
show	O
that	O
the	O
mouse	O
genome	O
contains	O
four	O
copies	O
of	O
the	O
ubc-9	B-GENE
gene	I-GENE
.	O

The	O
AtERF	B-GENE
genes	I-GENE
were	O
differentially	O
regulated	O
by	O
ethylene	O
and	O
by	O
abiotic	O
stress	O
conditions	O
,	O
such	O
as	O
wounding	O
,	O
cold	O
,	O
high	O
salinity	O
,	O
or	O
drought	O
,	O
via	O
ETHYLENE-INSENSITIVE2	B-GENE
(	O
EIN2	B-GENE
)	O
-dependent	O
or	O
-independent	O
pathways	O
.	O

In	O
resting	O
3T3	O
cells	O
,	O
jun-D	B-GENE
is	O
expressed	O
at	O
a	O
higher	O
level	O
compared	O
to	O
c-jun	B-GENE
and	O
jun-B	B-GENE
,	O
and	O
its	O
transcription	O
is	O
stimulated	O
only	O
slightly	O
by	O
serum	O
growth	B-GENE
factors	I-GENE
.	O

A	O
method	O
is	O
described	O
for	O
the	O
simultaneous	O
determination	O
of	O
1	O
,	O
alpha-acetylmethadol	O
(	O
LAAM	O
)	O
and	O
five	O
active	O
metabolites--noracetylmethadol	O
,	O
dinoracetylmethadol	O
,	O
methadol	O
,	O
normethadol	O
,	O
and	O
dinormethadol--in	O
biofluids	O
by	O
high-performance	O
liquid	O
chromatography	O
using	O
a	O
normal-phase	O
column	O
and	O
a	O
UV	O
detector	O
at	O
218	O
nm	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
identify	O
neuronal	O
cell	O
cultures	O
that	O
express	O
RC3	B-GENE
/	I-GENE
neurogranin	I-GENE
,	O
to	O
check	O
whether	O
they	O
are	O
sensitive	O
to	O
T3	O
,	O
and	O
to	O
examine	O
the	O
mechanism	O
of	O
regulation	O
.	O

Self-emasculation	O
is	O
the	O
end	O
result	O
of	O
an	O
unusual	O
psychiatric	O
disorder	O
,	O
which	O
initially	O
requires	O
surgical	O
treatment	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
TAFII250	B-GENE
,	O
the	O
largest	O
subunit	O
of	O
TFIID	B-GENE
,	O
contains	O
two	O
tandem	O
bromodomain	O
modules	O
that	O
bind	O
selectively	O
to	O
multiply	O
acetylated	O
histone	B-GENE
H4	I-GENE
peptides	I-GENE
.	O

Reovirus	O
mRNAs	O
are	O
efficiently	O
translated	O
within	O
host	O
cells	O
despite	O
the	O
absence	O
of	O
3'	O
polyadenylated	O
tails	O
.	O

The	O
disturbance	O
of	O
pulmonary	O
gas	O
exchange	O
,	O
as	O
revealed	O
by	O
the	O
high	O
value	O
of	O
AaDO2	O
,	O
existed	O
without	O
left	O
ventricular	O
dysfunction	O
,	O
and	O
AaDO2	O
had	O
no	O
significant	O
relationship	O
with	O
any	O
of	O
the	O
hemodynamic	O
parameters	O
including	O
the	O
difference	O
between	O
plasma	O
colloid	O
osmotic	O
pressure	O
and	O
PCW	O
.	O

Transfection	O
of	O
cDNAs	O
for	O
three	O
mutant	O
enzymes	O
into	O
FPGS-null	O
Chinese	O
hamster	O
ovary	O
cells	O
restored	O
a	O
reduced	O
level	O
of	O
clonal	O
growth	O
,	O
whereas	O
a	O
T339I	O
mutant	O
supported	O
growth	O
at	O
a	O
level	O
comparable	O
to	O
that	O
of	O
the	O
wild-type	O
enzyme	O
.	O

A	O
vector	O
containing	O
a	O
transcriptionally	O
inactive	O
neomycin	B-GENE
phosphotransferase	I-GENE
II	I-GENE
gene	I-GENE
was	O
used	O
to	O
select	O
promoter	O
sequences	O
from	O
a	O
pool	O
of	O
random	O
genomic	O
DNA	O
fragments	O
.	O

None	O
of	O
the	O
measured	O
parameters	O
(	O
heart	O
contents	O
of	O
neutral	O
lipids	O
,	O
total	O
phospholipids	O
,	O
phosphatidylcholine	O
,	O
phosphatidylethanolamine	O
,	O
diphosphatidylglycerol	O
,	O
sphingomyelin	O
and	O
fatty	O
acid	O
composition	O
of	O
each	O
phospholipid	O
class	O
)	O
appeared	O
to	O
be	O
related	O
with	O
the	O
grading	O
of	O
the	O
lesions	O
.	O

In	O
co-transfection	O
studies	O
,	O
the	O
expression	O
of	O
c-Jun	B-GENE
plus	O
c-Fos	B-GENE
enhanced	O
the	O
transactivation	O
of	O
oIFNtau-CAT	B-GENE
but	O
the	O
expression	O
of	O
GATA-1	B-GENE
,	O
GATA-2	B-GENE
or	O
GATA-3	B-GENE
did	O
not	O
.	O

In	O
the	O
DNAs	O
of	O
all	O
Ph1-positive	O
chronic	O
myelocytic	O
leukemia	O
patients	O
studied	O
to	O
date	O
,	O
a	O
breakpoint	O
on	O
chromosome	O
22	O
(	O
the	O
Ph1	O
chromosome	O
)	O
can	O
be	O
demonstrated	O
with	O
a	O
probe	O
from	O
the	O
bcr	O
(	O
breakpoint	O
cluster	O
region	O
)	O
.	O

The	O
bactericidal	O
effect	O
of	O
disinfectants	O
against	O
biofilm	O
cells	O
was	O
found	O
to	O
be	O
considerably	O
enhanced	O
by	O
increasing	O
the	O
concentrations	O
of	O
the	O
disinfectants	O
.	O

Domain	O
II	O
is	O
highly	O
homologous	O
to	O
the	O
LDL	B-GENE
receptor	I-GENE
and	O
contains	O
four	O
repeats	O
with	O
perfect	O
conservation	O
of	O
all	O
6	O
consecutive	O
cysteines	O
.	O

In	O
light	O
of	O
the	O
importance	O
of	O
GnRHR	B-GENE
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
transcriptional	O
regulation	O
of	O
the	O
human	B-GENE
GnRHR	I-GENE
(	O
hGnRHR	B-GENE
)	O
gene	O
become	O
a	O
key	O
issue	O
in	O
understanding	O
human	O
reproduction	O
.	O

Sequencing	O
of	O
a	O
40-kb	O
DNA	O
segment	O
of	O
the	O
FK506	B-GENE
gene	I-GENE
cluster	O
from	O
Streptomyces	O
sp	O
.	O

Thus	O
,	O
replication	O
fork	O
movement	O
near	O
HML	B-GENE
pauses	O
at	O
a	O
silent	O
origin	O
which	O
is	O
competent	O
for	O
replication	O
initiation	O
but	O
kept	O
silent	O
through	O
Orc2p	B-GENE
,	O
a	O
component	O
of	O
the	O
replication	O
initiator	O
.	O

Assessment	O
of	O
nutrient	O
media	O
in	O
the	O
diagnosis	O
of	O
diptheria	O
.	O

Histological	O
changes	O
,	O
including	O
cortical	O
cell	O
involution	O
and	O
hemorrhage	O
occurring	O
during	O
the	O
neonatal	O
period	O
,	O
would	O
seem	O
to	O
have	O
crucial	O
relevance	O
to	O
the	O
remodeling	O
of	O
the	O
adrenal	O
vasculature	O
.	O

The	O
cglIM	B-GENE
gene	I-GENE
is	O
organized	O
in	O
an	O
unusual	O
operon	O
which	O
contains	O
,	O
in	O
addition	O
,	O
two	O
genes	O
encoding	O
stress-sensitive	O
restriction	B-GENE
enzymes	I-GENE
.	O

The	O
Gap69C	B-GENE
is	O
a	O
single-copy	O
gene	O
producing	O
a	O
major	O
2	O
.	O
1-kb	O
mRNA	O
throughout	O
development	O
,	O
but	O
its	O
amount	O
is	O
decreased	O
in	O
larvae	O
.	O

The	O
relationship	O
of	O
the	O
factor	B-GENE
V	I-GENE
Leiden	I-GENE
mutation	I-GENE
or	O
the	O
deletion-deletion	O
polymorphism	O
of	O
the	O
angiotensin	B-GENE
converting	I-GENE
enzyme	I-GENE
to	O
postoperative	O
thromboembolic	O
events	O
following	O
total	O
joint	O
arthroplasty	O
.	O

End-tidal	O
PO2	O
and	O
the	O
ratio	O
of	O
minute	O
ventilation	O
to	O
oxygen	O
consumption	O
(	O
VE	O
/	O
VO2	O
)	O
were	O
lower	O
while	O
PETCO2	O
was	O
higher	O
for	O
Hyp	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
.	O

Considering	O
these	O
sources	O
of	O
error	O
some	O
of	O
the	O
variability	O
in	O
the	O
present	O
investigation	O
might	O
be	O
avoided	O
by	O
systematic	O
instructions	O
.	O

Results	O
obtained	O
for	O
chloramphenicol-containing	O
preparations	O
are	O
presented	O
,	O
and	O
both	O
dissolution	O
curves	O
and	O
cup-plate	O
assays	O
demonstrate	O
that	O
chloramphenicol	O
has	O
far	O
superior	O
release	O
(	O
and	O
hence	O
activity	O
)	O
from	O
creams	O
than	O
from	O
ophthalmic	O
ointments	O
.	O

Diagnosis	O
of	O
prostatic	O
carcinoma	O
:	O
the	O
yield	O
of	O
serum	B-GENE
prostate	I-GENE
specific	I-GENE
antigen	I-GENE
,	O
digital	O
rectal	O
examination	O
and	O
transrectal	O
ultrasonography	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
LvUSF2	B-GENE
is	O
nearly	O
identical	O
to	O
LvUSF1	B-GENE
except	O
at	O
the	O
amino	O
end	O
,	O
where	O
they	O
are	O
sharply	O
divergent	O
.	O

In	O
retrospect	O
,	O
the	O
diagnoses	O
were	O
reconsidered	O
applying	O
strict	O
criteria	O
.	O

A	O
consensus	O
sequence	O
indicates	O
a	O
highly	O
conserved	O
lysine	O
residue	O
,	O
K120	O
of	O
endonuclease	B-GENE
III	I-GENE
or	O
K241	O
of	O
Ogg1	B-GENE
,	O
respectively	O
.	O

Examination	O
of	O
various	O
promoter	O
deletion	O
mutants	O
indicated	O
that	O
SF-1	B-GENE
acts	O
through	O
the	O
proximal	O
promoter	O
region	O
and	O
upstream	O
promoter	O
sequences	O
.	O

The	O
data	O
show	O
conclusively	O
that	O
phosphorylation	O
of	O
His-304	O
is	O
not	O
essential	O
for	O
any	O
of	O
the	O
known	O
functions	O
of	O
A	B-GENE
.	I-GENE
vinelandii	I-GENE
NifL	I-GENE
.	O

The	O
maximal	O
effect	O
was	O
seen	O
at	O
100	O
ng	O
/	O
ml	O
EGF	B-GENE
,	O
with	O
a	O
time	O
lag	O
of	O
about	O
5	O
h	O
.	O

Effects	O
of	O
aerosol-vapor	O
JP-8	O
jet	O
fuel	O
on	O
the	O
functional	O
observational	O
battery	O
,	O
and	O
learning	O
and	O
memory	O
in	O
the	O
rat	O
.	O

The	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
GAL1	I-GENE
and	O
GAL10	B-GENE
genes	I-GENE
are	O
controlled	O
in	O
response	O
to	O
the	O
availability	O
of	O
galactose	O
and	O
glucose	O
by	O
multiple	O
activating	O
and	O
repressing	O
proteins	O
bound	O
at	O
adjacent	O
or	O
overlapping	O
sites	O
in	O
UASG	B-GENE
.	O

These	O
activities	O
are	O
all	O
required	O
for	O
stimulation	O
of	O
cell	O
growth	O
by	O
middle-T	B-GENE
and	O
activate	O
members	O
of	O
the	O
MAP	B-GENE
kinase	I-GENE
family	I-GENE
.	O

When	O
differentiated	O
G0-arrested	O
leaf	O
cells	O
were	O
induced	O
to	O
resume	O
cell	O
division	O
by	O
treatment	O
with	O
plant	O
hormones	O
,	O
cycMs4	B-GENE
transcription	O
was	O
induced	O
before	O
the	O
onset	O
of	O
DNA	O
synthesis	O
.	O

Also	O
,	O
component	O
I	O
significantly	O
correlated	O
with	O
fasting	O
insulin	B-GENE
and	O
VO2	O
max	O
for	O
both	O
sexes	O
and	O
with	O
basal	O
metabolism	O
and	O
HDL-cholesterol	B-GENE
for	O
females	O
and	O
males	O
,	O
respectively	O
.	O

Desmethyltrimebutine	O
was	O
inactive	O
.	O

The	O
antibodies	O
inhibited	O
specifically	O
the	O
transcription	O
of	O
DNA	B-GENE
polymerase	I-GENE
alpha	I-GENE
promoter	O
in	O
vitro	O
.	O

Architecture	O
and	O
anatomy	O
of	O
the	O
genomic	O
locus	O
encoding	O
the	O
human	B-GENE
leukemia-associated	I-GENE
transcription	I-GENE
factor	I-GENE
RUNX1	I-GENE
/	I-GENE
AML1	I-GENE
.	O

RNase	B-GENE
protection	O
experiments	O
confirmed	O
the	O
presence	O
of	O
the	O
GHR1-279	B-GENE
variant	I-GENE
in	O
IM-9	O
cells	O
and	O
human	O
liver	O
.	O

The	O
open	O
reading	O
frames	O
of	O
rbsD	B-GENE
,	O
rbsA	B-GENE
,	O
and	O
rbsC	B-GENE
encode	O
proteins	O
of	O
139	O
,	O
501	O
,	O
and	O
321	O
amino	O
acid	O
residues	O
,	O
respectively	O
.	O

Sucrose-specific	O
regulation	O
of	O
scrB	B-GENE
was	O
also	O
lost	O
upon	O
deletion	O
of	O
4	O
bp	O
of	O
a	O
palindromic	O
sequence	O
(	O
OB	O
)	O
covering	O
positions	O
+6	O
to	O
+21	O
downstream	O
of	O
the	O
scrB	B-GENE
transcriptional	O
start	O
site	O
.	O

High	O
concentrations	O
of	O
tumor-associated	O
trypsin	B-GENE
inhibitor	O
in	O
hemodialyzed	O
patients	O
.	O

A	O
mutation	O
which	O
abrogates	O
the	O
binding	O
of	O
these	O
factors	O
reduces	O
Wp	B-GENE
reporter	I-GENE
activity	O
specifically	O
in	O
B	O
cell	O
lines	O
,	O
whereas	O
a	O
mutation	O
which	O
converts	O
the	O
site	O
to	O
a	O
consensus	O
CREB-binding	B-GENE
sequence	I-GENE
maintains	O
wild-type	O
promoter	O
function	O
.	O

There	O
was	O
a	O
gradual	O
increase	O
in	O
the	O
myocyte	O
diameter	O
according	O
to	O
age	O
in	O
the	O
biopsy	O
and	O
autopsy	O
specimens	O
.	O

Mutation	O
of	O
the	O
Sp1	B-GENE
element	I-GENE
,	O
which	O
abolishes	O
Sp1	B-GENE
binding	O
,	O
results	O
in	O
a	O
6-10-fold	O
reduction	O
in	O
reporter	O
activity	O
.	O

INTERVENTIONS	O
:	O
Subcutaneous	O
tissue	O
PO2	O
and	O
PCO2	O
tensions	O
were	O
measured	O
directly	O
in	O
patients	O
with	O
necrotising	O
fasciitis	O
and	O
in	O
healthy	O
volunteers	O
during	O
normobaric	O
and	O
hyperbaric	O
conditions	O
.	O

Because	O
of	O
the	O
potential	O
implications	O
of	O
these	O
findings	O
in	O
human	O
physiology	O
,	O
we	O
cloned	O
the	O
hPACAP-R	B-GENE
gene	I-GENE
.	O

The	O
Tax	B-GENE
/	I-GENE
IKKgamma	I-GENE
interaction	O
serves	O
to	O
recruit	O
Tax	B-GENE
to	O
the	O
IKK	B-GENE
catalytic	I-GENE
subunits	I-GENE
,	O
IKKalpha	B-GENE
and	O
IKKbeta	B-GENE
,	O
and	O
this	O
recruitment	O
appears	O
to	O
be	O
an	O
essential	O
mechanism	O
by	O
which	O
Tax	B-GENE
stimulates	O
the	O
activity	O
of	O
IKK	B-GENE
.	O

Modifications	O
of	O
the	O
involuntary	O
postcontraction	O
in	O
diseased	O
people	O
.	O

Although	O
noninhibitory	O
fluid	O
had	O
higher	O
mean	O
concentrations	O
of	O
phosphorus	O
and	O
zinc	O
,	O
these	O
differences	O
did	O
not	O
hold	O
after	O
meconium-stained	O
samples	O
were	O
excluded	O
.	O

Normal	O
baseline	O
(	O
day-8	O
)	O
PC	O
levels	O
(	O
86	O
and	O
89%	O
)	O
were	O
markedly	O
reduced	O
in	O
both	O
patients	O
at	O
the	O
time	O
of	O
VOD	O
manifestation	O
on	O
day	O
20	O
and	O
40	O
,	O
respectively	O
(	O
26	O
and	O
31%	O
)	O
.	O

The	O
sequence	O
upstream	O
of	O
the	O
rhlA	B-GENE
promoter	I-GENE
contains	O
two	O
inverted	O
repeats	O
which	O
define	O
putative	O
binding	O
sites	O
for	O
the	O
RhlR	B-GENE
regulator	I-GENE
.	O

In	O
this	O
model	O
,	O
eltoprazine	O
has	O
a	O
very	O
specific	O
anti-aggressive	O
(	O
serenic	O
)	O
profile	O
,	O
inhibiting	O
aggression	O
while	O
social	O
interaction	O
and	O
exploration	O
are	O
not	O
decreased	O
but	O
even	O
enhanced	O
;	O
inactivity	O
,	O
a	O
measure	O
for	O
sedation	O
,	O
is	O
not	O
affected	O
.	O

A	O
second	O
aim	O
was	O
to	O
determine	O
whether	O
the	O
decrease	O
in	O
muscle-tendon	O
unit	O
rest	O
length	O
produced	O
by	O
prolonged	O
immobilisation	O
in	O
a	O
shortened	O
position	O
is	O
mediated	O
primarily	O
by	O
adaptations	O
of	O
the	O
muscle	O
or	O
tendon	O
.	O

Analysis	O
of	O
clearance	O
curve	O
of	O
rose	O
bengal-I-131	O
.	O

Intravenous	O
administration	O
(	O
25	O
mg	O
/	O
kg	O
)	O
of	O
carbonic	B-GENE
anhydrase	I-GENE
inhibitors	O
(	O
acetazolamide	O
,	O
methazolamide	O
,	O
dichlorphenamide	O
,	O
sulthiame	O
)	O
induced	O
an	O
early	O
important	O
rise	O
of	O
cortical	O
p	O
O2	O
,	O
which	O
is	O
not	O
dependent	O
on	O
increase	O
of	O
p	O
O2	O
and	O
p	O
CO2	O
and	O
decrease	O
of	O
pH	O
in	O
arterial	O
blood	O
.	O

Cholinesterase	B-GENE
.	O

RESULTS	O
:	O
Surprisingly	O
,	O
PAF	B-GENE
blockade	O
increased	O
mortality	O
after	O
trauma	O
(	O
5	O
of	O
11	O
WEB-2086	O
animals	O
versus	O
1	O
of	O
9	O
vehicle	O
animals	O
;	O
p	O
=	O
0	O
.	O
15	O
)	O
and	O
depressed	O
cardiac	O
index	O
and	O
O2	O
delivery	O
at	O
72	O
hours	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Moritta	O
)	O
and	O
contains	O
Bis-GMA	O
.	O

Single	O
amino	O
acid	O
substitutions	O
at	O
the	O
acyl-CoA-binding	O
domain	O
interrupt	O
14	O
[	O
C	O
]	O
palmitoyl-CoA	O
binding	O
of	O
ACBP2	B-GENE
,	O
an	O
Arabidopsis	O
acyl-CoA-binding	B-GENE
protein	I-GENE
with	O
ankyrin	B-GENE
repeats	O
.	O

Expression	O
of	O
GlcNAc-TI	B-GENE
mRNA	I-GENE
in	O
tobacco	O
leaves	O
was	O
detected	O
using	O
RT-PCR	O
.	O

At	O
a	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
of	O
60	O
mmHg	O
,	O
C02	O
responsiveness	O
was	O
abolished	O
,	O
but	O
was	O
maintained	O
at	O
higher	O
levels	O
of	O
BP	O
.	O

Both	O
methods	O
were	O
employed	O
for	O
various	O
focal-film	O
distances	O
,	O
image	O
intensifier	O
tube	O
modes	O
and	O
laser	O
printer	O
formats	O
.	O

Colorectal	O
cancer	O
was	O
shown	O
to	O
disproportionately	O
overburden	O
Ashkenazi	O
Jews	O
,	O
who	O
may	O
also	O
be	O
at	O
increased	O
risk	O
for	O
ovarian	O
,	O
pancreatic	O
and	O
stomach	O
cancer	O
,	O
and	O
non-Hodgkin's	O
lymphoma	O
.	O

HIV-1	O
and	O
hepatitis	O
B	O
virus	O
infections	O
in	O
adolescents	O
lodged	O
in	O
security	O
institutes	O
of	O
Buenos	O
Aires	O
.	O

Covalent	O
modification	O
of	O
the	O
transactivator	B-GENE
protein	I-GENE
IE2-p86	I-GENE
of	O
human	O
cytomegalovirus	O
by	O
conjugation	O
to	O
the	O
ubiquitin-homologous	B-GENE
proteins	I-GENE
SUMO-1	B-GENE
and	O
hSMT3b	B-GENE
.	O

The	O
full	O
protocol	O
was	O
completed	O
by	O
33	O
patients	O
(	O
45%	O
of	O
original	O
cohort	O
)	O
.	O

Forskolin	O
significantly	O
enhanced	O
heregulin-stimulated	O
expression	O
of	O
cyclin	B-GENE
D	I-GENE
and	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-GENE
gene	I-GENE
product	I-GENE
.	O

TaqMan	O
analysis	O
of	O
gene	O
expression	O
following	O
chronic	O
FA	O
treatment	O
showed	O
neither	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
leptin	B-GENE
receptor	I-GENE
(	O
Ob-R	B-GENE
)	O
mRNA	O
,	O
nor	O
an	O
increase	O
in	O
the	O
negative	O
regulators	O
of	O
STAT	B-GENE
signalling	O
,	O
SOCS3	B-GENE
(	O
suppressors	B-GENE
of	I-GENE
cytokine	I-GENE
signalling	I-GENE
)	O
or	O
cytokine	B-GENE
inducible	I-GENE
sequence	I-GENE
(	O
CIS	B-GENE
)	O
.	O

It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS-40	B-GENE
behaved	O
as	O
an	O
authentic	O
enhancer	O
for	O
high-level	O
zeta	B-GENE
2	I-GENE
globin	I-GENE
promoter	I-GENE
activity	O
in	O
K562	O
cells	O
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and	O
/	O
or	O
fetal	O
origin	O
.	O

Despite	O
the	O
presence	O
of	O
one	O
additional	O
ribonucleotide	B-GENE
reductase	I-GENE
,	O
the	O
nrdAB-encoded	B-GENE
enzyme	I-GENE
is	O
essential	O
to	O
the	O
aerobic	O
growth	O
of	O
the	O
cell	O
because	O
nrdAB-defective	B-GENE
mutants	I-GENE
of	O
both	O
species	O
are	O
not	O
viable	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O

We	O
studied	O
the	O
human	O
vestibulo-ocular	O
reflex	O
(	O
VOR	O
)	O
in	O
response	O
to	O
head	O
'impulses'	O
:	O
brief	O
,	O
unpredictable	O
,	O
passive	O
,	O
high-acceleration	O
(	O
up	O
to	O
4000	O
degrees	O
/	O
s2	O
)	O
,	O
low-amplitude	O
(	O
20-30	O
degrees	O
)	O
head	O
rotations	O
.	O

A	O
suspected	O
hypothalamic	O
dysfunction	O
and	O
a	O
slightly	O
impaired	O
pituitary	O
function	O
manifested	O
as	O
GH	B-GENE
deficiency	O
were	O
their	O
common	O
endocrinological	O
features	O
.	O

CXCR4	B-GENE
is	O
a	O
chemokine	B-GENE
receptor	I-GENE
and	O
a	O
coreceptor	O
for	O
T-cell-line-tropic	O
(	O
X4	O
)	O
and	O
dual-tropic	O
(	O
R5X4	O
)	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
isolates	O
.	O

Implication	O
of	O
PAF	B-GENE
and	O
acetylhydrolase	B-GENE
(	O
PAF-AH	B-GENE
)	O
activity	O
in	O
periodontal	O
disease	O
.	O

Coactivation	O
of	O
endogenous	O
or	O
exogenous	O
G	B-GENE
(	I-GENE
q	I-GENE
)	I-GENE
-coupled	I-GENE
receptors	I-GENE
with	O
the	O
delta-opioid	B-GENE
receptor	I-GENE
produced	O
strong	O
stimulations	O
of	O
PLCbeta	B-GENE
and	O
such	O
responses	O
could	O
be	O
partially	O
blocked	O
by	O
pertussis	B-GENE
toxin	I-GENE
.	O

CONCLUSION	O
:	O
The	O
results	O
demonstrate	O
that	O
at	O
the	O
site	O
of	O
lumbar	O
disc	O
herniation	O
,	O
inflammatory	O
cytokines	O
such	O
as	O
interleukin-1	B-GENE
alpha	I-GENE
are	O
produced	O
,	O
which	O
increases	O
prostaglandin	O
E2	O
production	O
.	O

Currents	O
aspects	O
of	O
H2	B-GENE
receptor	I-GENE
antagonists	O
in	O
the	O
treatment	O
of	O
ulcers	O
.	O

Here	O
,	O
we	O
report	O
the	O
complete	O
structure	O
of	O
the	O
human	B-GENE
topoisomerase	I-GENE
IIalpha	I-GENE
gene	I-GENE
,	O
which	O
consists	O
of	O
35	O
exons	O
spanning	O
27	O
.	O
5	O
kb	O
.	O

100	O
of	O
the	O
patients	O
who	O
would	O
have	O
died	O
survive	O
.	O

Calcitonin	B-GENE
simultaneously	O
regulates	O
both	O
periosteal	O
hyperostosis	O
and	O
trabecular	O
osteopenia	O
in	O
the	O
spinal	O
hyperostotic	O
mouse	O
(	O
twy	B-GENE
/	I-GENE
twy	I-GENE
)	O
in	O
vivo	O
.	O

SCA	B-GENE
was	O
resistant	O
to	O
inhibitors	O
of	O
serine	O
,	O
aspartyl	O
,	O
and	O
metalloproteases	B-GENE
,	O
but	O
it	O
was	O
sensitive	O
to	O
N-ethylmaleimide	O
.	O

A	O
pyrazolo-quinoline	O
compound	O
,	O
6-methoxy-4-	O
[	O
2-	O
[	O
(	O
2-hydroxyethoxyl	O
)	O
-ethyl	O
]	O
amino	O
]	O
-3-methyl-1M-pyrazo	O
lo	O
[	O
3	O
,	O
4-b	O
]	O
quinoline	O
(	O
SCH	O
51344	O
)	O
,	O
was	O
identified	O
based	O
on	O
its	O
ability	O
to	O
derepress	O
human	O
smooth	O
muscle	O
alpha-actin	B-GENE
promoter	I-GENE
activity	O
in	O
ras-transformed	O
cells	O
.	O

The	O
failures	O
frequently	O
were	O
related	O
to	O
patient	O
intolerance	O
or	O
poor	O
mechanical	O
fit	O
and	O
occurred	O
in	O
the	O
first	O
few	O
days	O
or	O
first	O
few	O
months	O
after	O
insertion	O
.	O

Recovery	O
of	O
radiolabelled	O
BA	O
through	O
urine	O
(	O
28%	O
)	O
and	O
faeces	O
(	O
22%	O
)	O
up	O
to	O
96	O
hrs	O
averaged	O
50%	O
,	O
whereas	O
residual	O
radioactivity	O
in	O
liver	O
and	O
testis	O
experienced	O
a	O
recovery	O
of	O
29%	O
in	O
scorbutic	O
animals	O
.	O

Epstein-Barr	B-GENE
virus	I-GENE
nuclear	I-GENE
protein	I-GENE
2	I-GENE
(	I-GENE
EBNA2	I-GENE
)	I-GENE
binds	O
to	O
a	O
component	O
of	O
the	O
human	B-GENE
SNF-SWI	I-GENE
complex	I-GENE
,	O
hSNF5	B-GENE
/	I-GENE
Ini1	I-GENE
.	O

HIV-1	O
C	O
subtype	O
in	O
IDUs	O
accounted	O
for	O
61	O
.	O
3%	O
.	O

The	O
gene	O
was	O
expressed	O
as	O
an	O
approximately	O
1	O
.	O
5-kb	O
mRNA	O
in	O
most	O
nonlymphoid	O
human	O
cells	O
/	O
tissues	O
including	O
prostate	O
,	O
lung	O
,	O
liver	O
,	O
and	O
colon	O
.	O

METHODS	O
:	O
rHb1	B-GENE
.	I-GENE
1	I-GENE
or	O
human	B-GENE
serum	I-GENE
albumin	I-GENE
was	O
administered	O
intravenously	O
to	O
fasting	O
male	O
volunteers	O
.	O

EsaR	B-GENE
can	O
repress	O
its	O
own	O
expression	O
but	O
seems	O
not	O
to	O
regulate	O
the	O
expression	O
of	O
esaI	B-GENE
.	O

Administration	O
of	O
dexamethasone	O
was	O
associated	O
with	O
progressive	O
rises	O
in	O
plasma	O
17	O
alpha	O
OH	O
progesterone	O
,	O
11	O
beta-desoxycortisol	O
,	O
DHEA	O
sulphate	O
,	O
androstenedione	O
and	O
testosterone	O
,	O
together	O
with	O
increased	O
urinary	O
excretion	O
of	O
androsterone	O
,	O
11	O
beta	O
OH	O
androsterone	O
,	O
etiocholanolone	O
,	O
DHEA	O
,	O
and	O
16	O
alpha	O
OH	O
DHEA	O
.	O

In	O
the	O
course	O
of	O
investigating	O
the	O
mechanisms	O
by	O
which	O
OF5	B-GENE
and	O
OF3	B-GENE
regulated	O
CYP11A1	B-GENE
transcription	O
,	O
we	O
found	O
that	O
OF5	B-GENE
and	O
OF3	B-GENE
bound	O
Sp1	B-GENE
and	O
Sp3	B-GENE
in	O
JEG-3	O
cells	O
.	O

The	O
TEA1	B-GENE
(	O
Ty	B-GENE
enhancer	I-GENE
activator	I-GENE
)	O
gene	O
sequence	O
predicts	O
a	O
protein	O
of	O
86	O
.	O
9	O
kDa	O
whose	O
N	O
terminus	O
contains	O
a	O
zinc	O
cluster	O
and	O
dimerization	O
motif	O
typical	O
of	O
the	O
Gal4-type	B-GENE
family	I-GENE
of	O
DNA-binding	O
proteins	O
.	O

Several	O
secondary	O
structure	O
elements	O
were	O
identified	O
.	O

Streptococcal	O
preparation	O
(	O
OK-432	O
)	O
,	O
a	O
new	O
type	O
of	O
anti-cancer	O
agent	O
,	O
was	O
given	O
to	O
the	O
patients	O
with	O
advanced	O
cancer	O
in	O
combination	O
with	O
Mitomycin-C	O
,	O
5-FU	O
and	O
Cytosine	O
arabinoside	O
.	O

The	O
genomic	O
fragments	O
were	O
fused	O
upstream	O
of	O
the	O
luciferase	B-GENE
reporter	I-GENE
gene	I-GENE
.	O

At	O
1	O
,	O
5	O
,	O
and	O
9	O
months	O
after	O
initial	O
isolation	O
of	O
C	O
.	O
kutscheri	O
from	O
the	O
oral	O
cavity	O
,	O
hamsters	O
were	O
euthanatized	O
,	O
and	O
attempts	O
were	O
made	O
to	O
culture	O
C	O
.	O
kutscheri	O
from	O
13	O
additional	O
sites	O
.	O

Copyright	O
2000	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Incidence	O
rate	O
ranging	O
between	O
122	O
/	O
100	O
,	O
000	O
/	O
year	O
and	O
190	O
/	O
100	O
,	O
000	O
/	O
year	O
were	O
found	O
(	O
minimum	O
,	O
estimated	O
and	O
raw	O
datasets	O
)	O
.	O

An	O
automated	O
method	O
for	O
the	O
quantitative	O
analysis	O
of	O
the	O
polyamines	O
putrescine	O
,	O
spermidine	O
and	O
spermine	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
was	O
used	O
to	O
analyze	O
CSF	O
samples	O
from	O
37	O
patients	O
with	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
tumors	O
and	O
from	O
13	O
patients	O
without	O
tumors	O
.	O

Further	O
studies	O
established	O
that	O
the	O
Ep-induced	O
increase	O
in	O
beta-globin	B-GENE
mRNA	I-GENE
could	O
be	O
inhibited	O
by	O
the	O
tyrosine	B-GENE
kinase	I-GENE
inhibitor	O
genistein	O
and	O
the	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
inhibitor	O
Compound	O
3	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
relationship	O
between	O
estrogenic	O
properties	O
of	O
Tamoxifen	O
and	O
breast	O
cancer	O
management	O
is	O
discussed	O
.	O

Disciplinary	O
action	O
for	O
DNA	O
violation	O
.	O

In	O
PC	O
,	O
rare	O
MNGCs	O
had	O
intranuclear	O
inclusions	O
and	O
grooves	O
.	O

The	O
costs	O
were	O
DM	O
11	O
,	O
562	O
for	O
a	O
PE	O
,	O
DM	O
12	O
,	O
477	O
for	O
a	O
VR	O
and	O
DM	O
7	O
,	O
532	O
for	O
a	O
MR	O
.	O

The	O
provisional	O
reports	O
are	O
based	O
mainly	O
upon	O
macroscopic	O
findings	O
,	O
whereas	O
the	O
final	O
reports	O
include	O
the	O
information	O
provided	O
by	O
supplementary	O
investigations	O
such	O
as	O
microscopy	O
,	O
histochemistry	O
,	O
more	O
rarely	O
electron	O
microscopy	O
,	O
immunohistochemistry	O
and	O
/	O
or	O
microbiology	O
.	O

Cells	O
containing	O
alpha	O
subunits	O
that	O
lacked	O
a	O
distal	B-GENE
domain	O
(	O
term-3	B-GENE
)	O
or	O
had	O
the	O
alternatively	O
spliced	O
alpha-2	B-GENE
distal	I-GENE
domain	I-GENE
showed	O
markedly	O
decreased	O
ability	O
to	O
support	O
tyrosine	O
phosphorylation	O
of	O
Jak-2	B-GENE
and	O
its	O
substrates	O
or	O
to	O
up-regulate	O
CD86	B-GENE
.	O

Consistent	O
with	O
this	O
possibility	O
,	O
a	O
non-MBD	O
region	O
of	O
Bin1	B-GENE
was	O
sufficient	O
to	O
recruit	O
a	O
repression	O
function	O
to	O
DNA	O
that	O
was	O
unrelated	O
to	O
histone	B-GENE
deacetylase	I-GENE
.	O

Abundant	O
infiltration	O
of	O
lymphocytes	O
and	O
plasma	O
cells	O
was	O
also	O
wide-spread	O
beneath	O
the	O
carcinoma	O
in	O
situ	O
,	O
together	O
with	O
the	O
lymphoid	O
follicles	O
.	O

Addition	O
of	O
Rap	O
or	O
KN62	O
after	O
exposure	O
of	O
cells	O
to	O
progesterone	O
agonist	O
Org	O
2058	O
had	O
no	O
effect	O
on	O
induction	O
of	O
CAT	B-GENE
activity	O
.	O

Teicoplanin	O
was	O
given	O
most	O
often	O
because	O
of	O
persistent	O
fever	O
or	O
initial	O
Gram-positive	O
bacteraemia	O
and	O
only	O
one-third	O
of	O
these	O
cases	O
responded	O
.	O

A	O
peculiar	O
people	O
:	O
"the	O
physiological	O
aspects	O
of	O
Mormonism	O
1850-1975	O
.	O
"	O

Two	O
nuclear	O
medicine	O
physicians	O
blinded	O
to	O
the	O
surgical	O
findings	O
interpreted	O
all	O
available	O
images	O
and	O
various	O
Tc-99m	O
MIBI	O
image	O
combinations	O
at	O
15	O
minutes	O
alone	O
;	O
15	O
minutes	O
and	O
2	O
hours	O
,	O
15	O
minutes	O
and	O
4	O
hours	O
;	O
and	O
15	O
minutes	O
and	O
2	O
and	O
4	O
hours	O
each	O
with	O
and	O
without	O
correlative	O
pertechnetate	O
thyroid	O
imaging	O
.	O

Keck	O
,	O
C	O
.	O
J	O
.	O

E2F	B-GENE
-1	I-GENE
is	O
a	O
transcription	O
factor	O
that	O
regulates	O
cell	O
cycle	O
progression	O
into	O
S-phase	O
.	O

L3-L4	O
compressive	O
load	O
was	O
calculated	O
using	O
a	O
model	O
of	O
the	O
anatomy	O
of	O
the	O
trunk	O
musculoskeletal	O
system	O
.	O

Transactivation	O
of	O
oIFNtau	B-GENE
enhancer-reporter	O
constructs	O
was	O
primarily	O
regulated	O
by	O
three	O
regions	O
containing	O
AP-1	B-GENE
site	I-GENE
,	O
GATA	B-GENE
like	O
sequence	O
and	O
site	O
(	O
s	O
)	O
unidentified	O
.	O

Interestingly	O
,	O
continuation	O
of	O
the	O
interferon	B-GENE
therapy	O
in	O
the	O
presence	O
of	O
a	O
mild-to-moderate	O
exacerbation	O
of	O
sarcoidosis	O
may	O
be	O
safe	O
in	O
a	O
minority	O
of	O
patients	O
with	O
noncritical	O
organ	O
involvement	O
.	O

The	O
lengths	O
of	O
the	O
complete	O
polypeptide	O
chain	O
of	O
the	O
recombinant	O
enzyme	O
and	O
its	O
transit	O
peptide	O
are	O
388	O
and	O
53	O
residues	O
,	O
respectively	O
.	O

Transfection	O
analyses	O
indicate	O
that	O
mutation	O
of	O
any	O
one	O
of	O
these	O
TGACCT	B-GENE
motifs	I-GENE
or	O
truncation	O
of	O
the	O
entire	O
HD	B-GENE
PPRE	B-GENE
into	O
a	O
separate	O
DR1	B-GENE
and	O
DR2	B-GENE
element	I-GENE
significantly	O
reduced	O
the	O
transcriptional	O
response	O
of	O
HD	B-GENE
PPRE	B-GENE
to	O
peroxisome	O
proliferators	O
.	O

The	O
amino	O
acid	O
changes	O
D206A	O
and	O
D208A	O
abolish	O
singly	O
or	O
in	O
combination	O
the	O
exonuclease	B-GENE
activity	O
in	O
vivo	O
.	O

Chem	O
.	O

(	O
Emeritus	O
)	O
John	O
Henri	O
Roosegaarde	O
Bisschop	O
.	O

A	O
case	O
of	O
AIDS-related	O
complex	O
(	O
ARC	O
/	O
LAS	O
)	O
in	O
a	O
health	O
worker	O
.	O

There	O
occurred	O
a	O
linear	O
relationship	O
between	O
the	O
drop	O
in	O
glucose-6-phosphatase	B-GENE
dehydrogenase	I-GENE
activity	O
and	O
in	O
vitamin	O
E	O
level	O
,	O
on	O
one	O
hand	O
,	O
and	O
the	O
duration	O
of	O
poisoning	O
with	O
sodium	O
nitrite	O
.	O

A	O
cis-acting	O
DNA	O
element	O
located	O
between	O
TATA	O
box	O
and	O
transcription	O
initiation	O
site	O
is	O
critical	O
in	O
response	O
to	O
regulatory	O
sequences	O
in	O
human	O
angiotensinogen	B-GENE
gene	I-GENE
.	O

Hepatic	O
oxygen	O
supply	O
and	O
selected	O
blood	O
parameters	O
were	O
recorded	O
in	O
fasted	O
male	O
rates	O
given	O
20--30	O
mg	O
/	O
kg	O
Escherichia	B-GENE
coli	I-GENE
endotoxin	I-GENE
intraperitoneally	O
.	O

The	O
addition	O
of	O
culture	O
to	O
the	O
CC	O
and	O
CC	O
:	O
SW	O
by-products	O
resulted	O
in	O
pH	O
values	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
those	O
without	O
culture	O
on	O
Day	O
21	O
,	O
and	O
the	O
15%	O
carbohydrate	O
treatment	O
significantly	O
reduced	O
pH	O
beyond	O
the	O
5%	O
carbohydrate	O
.	O

Branch	O
occlusion	O
of	O
Heubner's	O
artery	O
,	O
or	O
perforators	O
from	O
the	O
proximal	O
anterior	O
or	O
middle	O
cerebral	O
arteries	O
were	O
the	O
posited	O
mechanism	O
of	O
infarction	O
.	O

We	O
propose	O
that	O
Gly84	O
is	O
part	O
of	O
a	O
putative	O
"oxyanion	O
hole"	O
involved	O
in	O
the	O
stabilization	O
of	O
the	O
transition	O
state	O
similar	O
to	O
the	O
C	B-GENE
group	I-GENE
of	O
the	O
esterase	B-GENE
/	I-GENE
lipase	I-GENE
family	I-GENE
.	O

While	O
important	O
for	O
ligand-dependent	O
transactivation	O
,	O
this	O
interaction	O
surface	O
is	O
not	O
directly	O
involved	O
in	O
transrepression	O
of	O
AP-1	B-GENE
activity	O
.	O

To	O
elucidate	O
whether	O
potential	O
endocrine	O
changes	O
resulted	O
from	O
acute	O
hypoxaemia	O
alone	O
,	O
the	O
underlying	O
disease	O
,	O
or	O
unspecific	O
influences	O
connected	O
with	O
the	O
ICU	O
setting	O
,	O
all	O
measurements	O
were	O
compared	O
to	O
those	O
of	O
a	O
completely	O
healthy	O
reference	O
group	O
(	O
REF	O
)	O
with	O
comparable	O
acute	O
experimental	O
hypoxaemia	O
.	O

An	O
integrated	O
RTC	O
algorithm	O
for	O
the	O
urban	O
wastewater	O
system	O
is	O
formulated	O
,	O
the	O
parameters	O
of	O
which	O
are	O
optimized	O
using	O
various	O
global	O
optimization	O
routines	O
.	O

Their	O
function	O
is	O
not	O
only	O
to	O
recruit	O
Pho2	B-GENE
to	O
the	O
promoter	O
but	O
to	O
allow	O
cooperative	O
binding	O
of	O
Pho4	B-GENE
together	O
with	O
Pho2	B-GENE
.	O

EUK-8	O
is	O
a	O
novel	O
,	O
synthetic	O
,	O
low-molecular-weight	O
salen-manganese	O
complex	O
that	O
exhibits	O
both	O
superoxide	B-GENE
dismutase	I-GENE
and	O
catalase	B-GENE
activities	O
in	O
vitro	O
.	O

Ras	B-GENE
p21Val	I-GENE
inhibits	O
myogenesis	O
without	O
altering	O
the	O
DNA	O
binding	O
or	O
transcriptional	O
activities	O
of	O
the	O
myogenic	B-GENE
basic	I-GENE
helix-loop-helix	I-GENE
factors	I-GENE
.	O

The	O
patient	O
underwent	O
two	O
intracytoplasmic	O
sperm	O
injection	O
cycles	O
with	O
thawed	O
epididymal	O
spermatozoa	O
,	O
in	O
which	O
,	O
due	O
to	O
a	O
pharmacist's	O
mistake	O
,	O
ovarian	O
stimulation	O
was	O
carried	O
out	O
by	O
a	O
combination	O
of	O
long-acting	O
gonadotrophin-releasing	B-GENE
hormone	I-GENE
agonist	O
(	O
leuprolide	O
depot	O
)	O
and	O
gonadotrophins	B-GENE
.	O

In	O
F42A-stimulated	O
internalization	O
assays	O
on	O
forskolin-induced	O
YT-1	O
cells	O
,	O
the	O
IL-2R	B-GENE
alpha	I-GENE
chain	I-GENE
is	O
consistently	O
endocytosed	O
together	O
with	O
the	O
IL-2R	B-GENE
beta	I-GENE
subunit	I-GENE
indicating	O
that	O
IL-2R	B-GENE
alpha	I-GENE
is	O
stably	O
associated	O
with	O
the	O
F42A-IL-2R	B-GENE
beta	I-GENE
complex	I-GENE
even	O
though	O
the	O
alpha-subunit	O
contributes	O
little	O
if	O
any	O
affinity	O
to	O
the	O
F42A	B-GENE
binding	O
reaction	O
.	O

These	O
findings	O
suggest	O
that	O
an	O
intracellular	B-GENE
WT1	I-GENE
/	I-GENE
Hsal	I-GENE
2	I-GENE
pathway	O
may	O
play	O
a	O
role	O
in	O
development	O
and	O
hematopoiesis	O
.	O

Adjuvant	O
and	O
neoadjuvant	O
treatment	O
of	O
breast	O
cancer	O
.	O

This	O
was	O
obtained	O
with	O
the	O
thermal	O
neutron	O
fluency	O
2	O
.	O
0	O
x	O
10	O
(	O
10	O
)	O
n	O
/	O
cm2	O
.	O

In	O
contrast	O
to	O
T	O
cells	O
,	O
in	O
fibroblasts	O
PILOT	B-GENE
gene	I-GENE
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	O
by	O
CyA	O
.	O

Similar	O
experiments	O
with	O
TR	B-GENE
support	O
the	O
high	O
affinity	O
of	O
RIP140	B-GENE
to	O
the	O
RXR	B-GENE
subunit	I-GENE
and	O
also	O
suggest	O
that	O
either	O
partner	O
in	O
the	O
TR	B-GENE
/	I-GENE
RXR	I-GENE
heterodimer	I-GENE
can	O
independently	O
respond	O
to	O
ligand	O
.	O

The	O
findings	O
are	O
compatible	O
with	O
the	O
idea	O
that	O
the	O
genes	O
encoding	O
PDGF	B-GENE
receptors	I-GENE
in	O
glioma	O
cells	O
are	O
regulated	O
in	O
concert	O
with	O
other	O
genes	O
,	O
the	O
expression	O
of	O
which	O
may	O
reflect	O
the	O
developmental	O
program	O
of	O
normal	O
glia	O
cell	O
lineages	O
.	O

Current	O
clinical	O
trials	O
should	O
answer	O
the	O
question	O
of	O
which	O
of	O
the	O
therapeutic	O
options	O
impairs	O
quality	O
of	O
life	O
less	O
.	O

Several	O
genes	O
or	O
transcriptional	O
units	O
were	O
identified	O
,	O
including	O
the	O
3'	O
end	O
of	O
ribosomal	B-GENE
s6	I-GENE
kinase	I-GENE
(	O
Rsk3	B-GENE
)	O
;	O
two	O
apparently	O
intronless	O
and	O
ORF-less	O
genes	O
;	O
and	O
Gpr31	B-GENE
,	O
an	O
intronless	O
,	O
putative	O
G-protein	B-GENE
coupled	I-GENE
receptor	I-GENE
.	O

Using	O
gel	O
retardation	O
assays	O
with	O
HepG2	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
a	O
specific	O
protein	O
which	O
bound	O
to	O
the	O
NRE	B-GENE
fragment	O
.	O

Xenopus	B-GENE
homolog	I-GENE
of	I-GENE
the	I-GENE
mos	I-GENE
protooncogene	I-GENE
transforms	O
mammalian	O
fibroblasts	O
and	O
induces	O
maturation	O
of	O
Xenopus	O
oocytes	O
.	O

In	O
contrast	O
,	O
a	O
similar	O
fragment	O
lacking	O
the	O
38-base-pair	O
region	O
had	O
no	O
such	O
stabilizing	O
effect	O
.	O

Here	O
,	O
we	O
describe	O
a	O
tyrosine-phosphorylated	O
nuclear	O
protein	O
,	O
YT521-B	B-GENE
,	O
and	O
show	O
that	O
it	O
interacts	O
with	O
the	O
nuclear	B-GENE
transcriptosomal	I-GENE
component	I-GENE
scaffold	I-GENE
attachment	I-GENE
factor	I-GENE
B	I-GENE
,	O
and	O
the	O
68-kDa	B-GENE
Src	I-GENE
substrate	O
associated	O
during	O
mitosis	O
,	O
Sam68	B-GENE
.	O

The	O
exon	O
:	O
intron	O
structure	O
of	O
chicken	B-GENE
IL8	I-GENE
corresponds	O
almost	O
exactly	O
to	O
that	O
of	O
human	B-GENE
IL8	I-GENE
and	O
differs	O
from	O
those	O
of	O
other	O
known	O
mammalian	B-GENE
CXC	I-GENE
chemokine	I-GENE
genes	I-GENE
.	O

Brain	O
scan	O
with	O
99mTc-labelled	O
macroaggregated	O
albumin	B-GENE
(	O
MAA	O
brain	O
scan	O
)	O
and	O
computed	O
tomography	O
studies	O
(	O
CT	O
)	O
were	O
performed	O
on	O
78	O
patients	O
with	O
intracranial	O
diseases	O
.	O

Procion	O
yellow	O
dye	O
was	O
injected	O
intracellularly	O
into	O
large	O
auditory	O
fibers	O
of	O
goldfish	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
response	O
type	O
of	O
these	O
fibers	O
and	O
their	O
site	O
of	O
termination	O
in	O
the	O
saccular	O
macula	O
.	O

First	O
,	O
each	O
lung	O
was	O
cut	O
into	O
slices	O
,	O
from	O
which	O
primary	O
disectors	O
were	O
sampled	O
systematically	O
with	O
a	O
known	O
sampling	O
fraction	O
.	O

Tumor	O
cells	O
were	O
focally	O
immunoreactive	O
for	O
neuron-specific	B-GENE
enolase	I-GENE
,	O
insulin	B-GENE
,	O
glucagon	B-GENE
and	O
VIP	B-GENE
.	O

Analysis	O
of	O
viral	O
mutants	O
in	O
vivo	O
demonstrated	O
that	O
the	O
NFIII	B-GENE
/	I-GENE
OCT-1	I-GENE
binding	I-GENE
site	I-GENE
and	O
a	O
conserved	O
ATF	B-GENE
motif	I-GENE
were	O
important	O
for	O
efficient	O
viral	O
growth	O
.	O

E1A	B-GENE
autoactivation	O
mediated	O
by	O
these	O
sites	O
was	O
about	O
twofold	O
compared	O
with	O
a	O
ninefold	O
activation	O
described	O
for	O
the	O
complete	O
E1A	B-GENE
promoter	I-GENE
.	O

We	O
report	O
here	O
the	O
molecular	O
cloning	O
of	O
a	O
putative	O
adhesive	O
molecule	O
from	O
P	O
.	O
falciparum	O
that	O
shares	O
both	O
sequence	O
and	O
structural	O
similarities	O
with	O
a	O
sporozoite	O
surface	O
molecule	O
from	O
Plasmodium	O
termed	O
the	O
thrombospondin-related	B-GENE
anonymous	I-GENE
protein	I-GENE
(	O
TRAP	B-GENE
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
with	O
the	O
circumsporozoite	O
(	O
CS	O
)	O
protein	O
.	O

In	O
a	O
second	O
patient	O
the	O
VT	O
became	O
nonsustained	O
.	O

Further	O
,	O
the	O
PIP2	O
content	O
of	O
the	O
85-90	O
kDa	O
protein	O
appeared	O
to	O
decrease	O
with	O
CSF-1	B-GENE
treatment	O
.	O

The	O
epitope-protected	O
lysine	O
(	O
K	O
)	O
was	O
present	O
in	O
a	O
30-aa	B-GENE
TPO	I-GENE
fragment	I-GENE
that	O
,	O
by	O
N-terminal	O
sequencing	O
,	O
was	O
found	O
to	O
be	O
K713	O
.	O

Therefore	O
,	O
magnetic	O
resonance	O
imaging	O
was	O
used	O
to	O
determine	O
liver	O
volume	O
in	O
pediatric	O
and	O
adolescent	O
patients	O
,	O
in	O
whom	O
systemic	O
clearance	O
of	O
three	O
model	O
substrates	O
[	O
lorazepam	O
(	O
0	O
.	O
03	O
mg	O
/	O
kg	O
)	O
,	O
antipyrine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
and	O
indocyanine	O
green	O
(	O
ICG	O
;	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
]	O
was	O
also	O
determined	O
.	O

Northern	O
blotting	O
analysis	O
indicates	O
that	O
expression	O
of	O
the	O
genes	O
corresponding	O
to	O
these	O
clones	O
is	O
confined	O
to	O
pollen	O
tissue	O
.	O

Like	O
scrotal	O
testes	O
,	O
undescended	O
testes	O
were	O
hypointense	O
to	O
fat	O
on	O
sequences	O
with	O
a	O
short	O
repetition	O
time	O
(	O
TR	O
)	O
and	O
echo	O
time	O
(	O
TE	O
)	O
in	O
all	O
cases	O
,	O
and	O
hyperintense	O
or	O
isointense	O
to	O
fat	O
on	O
long	O
TR	O
/	O
TE	O
sequences	O
in	O
all	O
but	O
two	O
cases	O
.	O

Samples	O
from	O
1415	O
neurological	O
patients	O
were	O
used	O
to	O
study	O
the	O
diagnostic	O
value	O
of	O
acid	B-GENE
alpha	I-GENE
1-glycoprotein	I-GENE
in	O
the	O
lumbar	O
cerebrospinal	O
fluid	O
.	O

In	O
addition	O
,	O
a	O
comparison	O
of	O
the	O
hCHLR	B-GENE
gene	I-GENE
sequences	I-GENE
with	O
available	O
databases	O
indicates	O
that	O
a	O
large	O
portion	O
of	O
these	O
genes	O
,	O
including	O
exons	O
encoding	O
two	O
functional	O
domains	O
of	O
the	O
carboxyl-terminal	O
region	O
of	O
these	O
proteins	O
,	O
has	O
been	O
duplicated	O
as	O
part	O
of	O
a	O
larger	O
human	O
telomeric	O
repeat	O
sequence	O
found	O
on	O
many	O
human	O
chromosomes	O
.	O

The	O
pulmonary	O
effects	O
observed	O
,	O
became	O
more	O
pronounced	O
with	O
increasing	O
NO2	O
concentrations	O
(	O
0	O
,	O
25	O
,	O
75	O
,	O
125	O
,	O
175	O
or	O
200	O
ppm	O
,	O
1	O
ppm	O
NO2	O
=	O
1	O
.	O
88	O
mg	O
m-3	O
NO2	O
)	O
and	O
exposure	O
times	O
(	O
5	O
,	O
10	O
,	O
20	O
or	O
30	O
min	O
)	O
.	O

Moreover	O
,	O
increasing	O
the	O
dosage	O
of	O
wild-type	B-GENE
Fus3	I-GENE
intensifies	O
the	O
inhibition	O
of	O
both	O
Ty1	B-GENE
transposition	O
and	O
invasive	O
growth	O
.	O

Type	B-GENE
2	I-GENE
deiodinase	I-GENE
(	O
D2	B-GENE
)	O
catalyzes	O
the	O
5'-deiodination	O
of	O
thyroxine	O
to	O
form	O
3	O
,	O
5	O
,	O
3'-triiodothyronine	O
.	O

Comparison	O
of	O
genomic	O
sequence	O
shows	O
that	O
the	O
ph	B-GENE
locus	I-GENE
has	O
been	O
duplicated	O
,	O
and	O
that	O
it	O
contains	O
proximal	O
and	O
distal	O
transcription	O
units	O
.	O

Pao2	O
increased	O
from	O
15	O
.	O
5	O
+	O
/	O
-	O
5	O
.	O
6	O
kPa	O
(	O
116	O
+	O
/	O
-	O
42	O
mm	O
Hg	O
)	O
to	O
17	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
3	O
kPa	O
(	O
130	O
+	O
/	O
-	O
47	O
mm	O
Hg	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
efficacy	O
and	O
safety	O
of	O
a	O
novel	O
percutaneous	O
anaesthetic	O
preparation	O
based	O
on	O
amethocaine	O
has	O
been	O
investigated	O
in	O
the	O
paediatric	O
clinical	O
environment	O
.	O

Phosphopeptide	O
mapping	O
revealed	O
the	O
same	O
autophosphorylation	O
sites	O
utilized	O
by	O
EGFR-IC	B-GENE
as	O
those	O
identified	O
in	O
wild-type	B-GENE
EGFR	I-GENE
.	O

Cell	O
.	O

The	O
drug	O
sensitivity	O
was	O
100%	O
for	O
vancomycin	O
(	O
VCM	O
)	O
,	O
30%	O
for	O
imipenam	O
(	O
IMP	O
)	O
,	O
31%	O
for	O
minomycin	O
(	O
MINO	O
)	O
,	O
31%	O
for	O
amikacin	O
(	O
AMK	O
)	O
,	O
and	O
7%	O
for	O
fosfomycin	O
(	O
FOM	O
)	O
.	O

Induction	O
of	O
CD86	B-GENE
expression	O
by	O
stimulation	O
of	O
U937	O
cells	O
with	O
IFN-gamma	B-GENE
revealed	O
the	O
presence	O
of	O
two	O
functional	O
GAS	B-GENE
(	O
gamma-interferon	B-GENE
activation	I-GENE
site	I-GENE
)	O
elements	O
.	O

Measurements	O
of	O
perfusion	O
also	O
showed	O
significantly	O
higher	O
values	O
under	O
active	O
therapy	O
.	O

BACKGROUND	O
:	O
It	O
is	O
generally	O
accepted	O
that	O
smoking	O
increases	O
blood	O
pressure	O
and	O
inhibits	O
muscle	O
sympathetic	O
nerve	O
activity	O
(	O
SNA	O
)	O
.	O

Serum	O
and	O
peritoneal	O
dialysis	O
fluid	O
(	O
PDF	O
)	O
were	O
collected	O
for	O
assay	O
throughout	O
the	O
course	O
of	O
the	O
study	O
and	O
for	O
5	O
days	O
thereafter	O
.	O

These	O
results	O
show	O
that	O
Ski	B-GENE
is	O
a	O
component	O
of	O
the	O
HDAC	B-GENE
complex	I-GENE
and	O
that	O
Ski	B-GENE
is	O
required	O
for	O
the	O
transcriptional	O
repression	O
mediated	O
by	O
this	O
complex	O
.	O

Theory	O
and	O
applications	O
of	O
pulse	O
dosing	O
:	O
a	O
summary	O
of	O
the	O
symposium	O
.	O

The	O
structural	O
genes	O
encoding	O
glyceraldehyde-3-phosphate	B-GENE
dehydrogenase	I-GENE
(	O
GAPDH	B-GENE
)	O
,	O
3-phosphoglycerate	B-GENE
kinase	I-GENE
(	O
PGK	B-GENE
)	O
and	O
the	O
N-terminal	O
part	O
of	O
triosephosphate	B-GENE
isomerase	I-GENE
(	O
TIM	B-GENE
)	O
from	O
mesophilic	O
Bacillus	O
megaterium	O
DSM319	O
have	O
been	O
cloned	O
as	O
a	O
gene	O
cluster	O
(	O
gap	B-GENE
operon	I-GENE
)	O
by	O
complementation	O
of	O
an	O
Escherichia	O
coli	O
gap	B-GENE
amber	I-GENE
mutant	I-GENE
.	O

An	O
E	O
box	O
element	O
is	O
required	O
for	O
the	O
expression	O
of	O
the	O
ad4bp	B-GENE
gene	I-GENE
,	O
a	O
mammalian	B-GENE
homologue	I-GENE
of	I-GENE
ftz-f1	I-GENE
gene	I-GENE
,	O
which	O
is	O
essential	O
for	O
adrenal	O
and	O
gonadal	O
development	O
.	O

1-	O
(	O
m-Chlorophenyl	O
)	O
piperazine	O
(	O
mCPP	O
,	O
0	O
.	O
1-3	O
.	O
0	O
mg	O
/	O
kg	O
)	O
and	O
1-	O
(	O
m-trifluoromethylphenyl	O
)	O
piperazine	O
(	O
TFMPP	O
,	O
0	O
.	O
1-3	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
both	O
thought	O
to	O
act	O
primarily	O
at	O
5-HT1	B-GENE
sites	I-GENE
,	O
also	O
decreased	O
responding	O
and	O
this	O
effect	O
was	O
blocked	O
by	O
methysergide	O
and	O
by	O
1-NP	O
,	O
but	O
not	O
by	O
ketanserin	O
.	O

METHOD	O
:	O
The	O
sample	O
of	O
subjects	O
was	O
drawn	O
from	O
the	O
Suffolk	O
County	O
Mental	O
Health	O
Project	O
,	O
a	O
longitudinal	O
epidemiologic	O
study	O
of	O
first-hospitalized	O
subjects	O
with	O
psychotic	O
disorders	O
;	O
the	O
present	O
study	O
focused	O
on	O
patients	O
with	O
schizophrenic	O
disorders	O
.	O

The	O
temporal	O
component	O
lacked	O
a	O
mandibular	O
fossa	O
as	O
well	O
as	O
articular	O
eminence	O
.	O

Ang	B-GENE
II-induced	I-GENE
fibronectin	I-GENE
mRNA	I-GENE
was	O
not	O
affected	O
by	O
PKC	B-GENE
inhibitors	O
or	O
PKC	B-GENE
depletion	O
,	O
whereas	O
specific	O
inhibition	O
of	O
EGF-R	B-GENE
function	O
by	O
a	O
dominant	B-GENE
negative	I-GENE
EGF-R	I-GENE
mutant	I-GENE
and	O
tyrphostin	O
AG1478	O
abolished	O
induction	O
of	O
fibronectin	B-GENE
mRNA	I-GENE
.	O

These	O
fusions	O
are	O
contained	O
on	O
plasmids	O
which	O
have	O
both	O
yeast	O
and	O
E	O
.	O
coli	O
replication	O
origins	O
and	O
selectable	O
markers	O
and	O
,	O
therefore	O
,	O
can	O
be	O
used	O
to	O
transform	O
either	O
yeast	O
or	O
E	O
.	O
coli	O
cells	O
.	O

Furthermore	O
,	O
although	O
the	O
regional	O
distribution	O
of	O
lean	O
tissue	O
mass	O
in	O
the	O
trunk	O
and	O
legs	O
remained	O
fairly	O
constant	O
at	O
different	O
pubertal	O
stages	O
,	O
the	O
regional	O
distribution	O
of	O
fat	O
was	O
altered	O
significantly	O
,	O
becoming	O
more	O
central	O
and	O
less	O
peripheral	O
.	O

Coliphage	B-GENE
186	I-GENE
B	I-GENE
is	O
a	O
72-amino	O
acid	O
protein	O
belonging	O
to	O
the	O
Ogr	B-GENE
family	O
of	O
analogous	O
transcription	O
factors	O
present	O
in	O
P2-like	O
phage	O
,	O
which	O
contain	O
a	O
Cys-X2-Cys-X22-Cys-X4-Cys	O
presumptive	O
zinc-finger	O
motif	O
.	O

In	O
a	O
maxicell	O
system	O
a	O
protein	O
with	O
an	O
approximate	O
molecular	O
weight	O
of	O
36	O
,	O
000	O
was	O
synthesized	O
.	O

Vac1p	B-GENE
was	O
found	O
to	O
bind	O
the	O
Sec1p	B-GENE
homologue	I-GENE
Vps45p	B-GENE
.	O

Interspecific	O
complementation	O
tests	O
showed	O
that	O
the	O
P7	B-GENE
proteins	I-GENE
are	O
unable	O
to	O
complement	O
P1	B-GENE
parA	I-GENE
or	O
parB	B-GENE
mutants	I-GENE
,	O
and	O
the	O
P1	B-GENE
proteins	I-GENE
fail	O
to	O
complement	O
the	O
P7	B-GENE
mutations	I-GENE
.	O

The	O
Aie1	B-GENE
locus	I-GENE
was	O
mapped	O
to	O
mouse	O
chromosome	O
7A2-A3	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
.	O

Effects	O
of	O
point	O
defects	O
on	O
lattice	O
parameters	O
of	O
semiconductors	O
.	O

There	O
was	O
no	O
difference	O
in	O
apnea	O
duration	O
between	O
the	O
supine	O
and	O
prone	O
positions	O
.	O

Cell	O
49	O
,	O
753-761	O
]	O
.	O

Erratum	O
to	O
"Cholesteryl	B-GENE
ester	I-GENE
transfer	I-GENE
protein	I-GENE
and	O
atherosclerosis	O
in	O
Japanese	O
subjects	O
:	O
a	O
study	O
based	O
on	O
coronary	O
angiography"	O
.	O

After	O
PTCA	O
,	O
ejection	O
fraction	O
increased	O
from	O
54	O
+	O
/	O
-	O
8%	O
to	O
59	O
+	O
/	O
-	O
8%	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
regional	O
function	O
improved	O
significantly	O
(	O
maximal	O
standard	O
deviation	O
before	O
PTCA	O
:	O
2	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
8	O
;	O
after	O
PTCA	O
:	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9-	O
segments	O
below	O
the	O
first	O
standard	O
deviation	O
before	O
PTCA	O
:	O
31	O
+	O
/	O
-	O
16	O
;	O
after	O
PTCA	O
:	O
19	O
+	O
/	O
-	O
17	O
)	O
.	O

The	O
concentrations	O
of	O
plasma	O
ACTH	B-GENE
and	O
cortisol	O
increased	O
by	O
40%	O
and	O
60%	O
after	O
MPTP	O
treatment	O
,	O
respectively	O
.	O

This	O
distribution	O
parallels	O
that	O
of	O
the	O
neurotransmitters	O
glutamate	O
and	O
aspartate	O
;	O
however	O
,	O
neither	O
of	O
these	O
excitatory	O
amino	O
acids	O
is	O
a	O
substrate	O
for	O
transport	O
.	O

Only	O
two	O
of	O
the	O
isoforms	O
possess	O
the	O
N-terminal	O
zinc	O
finger	O
domain	O
that	O
is	O
necessary	O
and	O
sufficient	O
for	O
TdT	B-GENE
promoter	I-GENE
binding	O
.	O

RT-PCR	O
indicated	O
that	O
p21	B-GENE
mRNA	I-GENE
was	O
induced	O
1	O
.	O
4-	O
,	O
2	O
.	O
0-	O
,	O
and	O
3	O
.	O
1-fold	O
in	O
the	O
2-day	O
neonatal	O
,	O
7-day	O
neonatal	O
,	O
and	O
adult	O
stages	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
17-day	O
fetal	O
stage	O
.	O

This	O
demonstrates	O
that	O
treatment	O
of	O
the	O
graft	O
recipient	O
for	O
a	O
relatively	O
short	O
period	O
during	O
and	O
after	O
surgery	O
has	O
a	O
favorable	O
effect	O
on	O
the	O
survival	O
of	O
grafted	O
dopaminergic	O
neurons	O
.	O

Three-dimensional	O
structural	O
studies	O
using	O
electron	O
cryomicroscopy	O
showed	O
that	O
the	O
binding	O
of	O
one	O
Fab	B-GENE
(	O
8H2	O
/	O
G5	O
)	O
does	O
not	O
affect	O
the	O
conformation	O
of	O
the	O
capsid	O
,	O
and	O
the	O
efficiency	O
of	O
mRNA	O
production	O
is	O
similar	O
to	O
that	O
of	O
the	O
native	O
subviral	O
particle	O
.	O

Femoral	O
strain	O
adaptation	O
after	O
total	O
hip	O
replacement	O
:	O
a	O
comparison	O
of	O
cemented	O
and	O
porous	O
ingrowth	O
components	O
in	O
canines	O
.	O

The	O
ability	O
of	O
chronic	O
UM-272	O
(	O
dimethylpropranolol	O
)	O
treatment	O
to	O
prevent	O
the	O
induction	O
of	O
reentrant	O
ventricular	O
tachyarrhythmias	O
was	O
assessed	O
in	O
the	O
conscious	O
dog	O
subjected	O
to	O
serial	O
programmed	O
electrical	O
stimulation	O
on	O
days	O
3--5	O
after	O
myocardial	O
infarction	O
.	O

The	O
detectability	O
of	O
the	O
defects	O
in	O
RCA	O
or	O
LAD	O
region	O
was	O
80%	O
in	O
single-position	O
scans	O
in	O
stress	O
studies	O
.	O

MR	O
imaging	O
of	O
traumatic	O
head	O
injuries	O
using	O
FLAIR	O
technique	O
.	O

With	O
0	O
.	O
5	O
vol	O
.	O
-%	O
,	O
the	O
corresponding	O
values	O
were	O
345	O
mumol	O
/	O
1	O
(	O
5	O
.	O
72	O
mg	O
/	O
100	O
ml	O
)	O
and	O
137	O
mumol	O
/	O
1	O
(	O
2	O
.	O
25	O
mg	O
/	O
100	O
ml	O
)	O
respectively	O
.	O

Given	O
its	O
relative	O
longevity	O
on	O
the	O
Web	O
,	O
TIE	O
researchers	O
have	O
been	O
in	O
a	O
unique	O
position	O
to	O
observe	O
trends	O
in	O
telemedicine	O
.	O

She	O
improved	O
with	O
a	O
combination	O
of	O
benzodiazepines	O
and	O
the	O
acetylcholinesterase	B-GENE
inhibitor	O
physostigmine	O
.	O

Platelet	B-GENE
activating	I-GENE
factor	I-GENE
was	O
given	O
in	O
six	O
doses	O
at	O
15	O
minute	O
intervals	O
and	O
airway	O
response	O
measured	O
as	O
change	O
in	O
partial	O
expiratory	O
flow	O
at	O
30%	O
of	O
vital	O
capacity	O
(	O
Vp30	O
)	O
.	O

Those	O
radiological	O
aspects	O
were	O
distributed	O
in	O
two	O
categories	O
:	O
1	O
)	O
type	O
I-presenting	O
variable	O
sinusoidal	O
filling	O
.	O

Since	O
we	O
have	O
observed	O
effects	O
of	O
growth	B-GENE
factors	I-GENE
and	O
cAMP	O
as	O
well	O
as	O
estradiol	O
(	O
E2	O
)	O
on	O
regulation	O
of	O
expression	O
of	O
some	O
genes	O
stimulated	O
by	O
the	O
estrogen	B-GENE
receptor	I-GENE
(	O
ER	B-GENE
)	O
,	O
we	O
have	O
undertaken	O
studies	O
to	O
examine	O
directly	O
whether	O
activators	O
of	O
protein	B-GENE
kinases	I-GENE
can	O
modulate	O
transcriptional	O
activity	O
of	O
the	O
ER	B-GENE
.	O

BCL-2	B-GENE
,	O
an	O
inhibitor	O
of	O
apoptosis	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
,	O
has	O
been	O
reported	O
to	O
prevent	O
oxidative	O
stress-induced	O
cell	O
death	O
.	O

This	O
mechanism	O
is	O
not	O
due	O
to	O
the	O
observed	O
grain	O
boundary	O
precipitates	O
.	O

Mature	B-GENE
tobacco	I-GENE
L12	I-GENE
protein	I-GENE
has	O
44%	O
amino	O
acid	O
identity	O
with	O
ribosomal	B-GENE
protein	I-GENE
L7	I-GENE
/	I-GENE
L12	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
.	O

Taste	O
reactivity	O
tests	O
were	O
used	O
to	O
examine	O
the	O
orofacial	O
responses	O
of	O
alcohol	O
preferring	O
(	O
P	O
)	O
rats	O
and	O
alcohol	O
nonpreferring	O
(	O
NP	O
)	O
rats	O
to	O
the	O
taste	O
of	O
alcohol	O
.	O

On	O
the	O
other	O
side	O
,	O
when	O
the	O
aortic	O
ring	O
was	O
perfused	O
with	O
L-NNA	O
(	O
NO-synthesis	O
inhibitor	O
)	O
or	O
methylene	O
blue	O
(	O
soluble	O
cGMPase	B-GENE
inhibitor	O
)	O
,	O
the	O
changes	O
could	O
be	O
attenuated	O
.	O

Effects	O
of	O
verapamil	O
and	O
propranolol	O
on	O
early	O
afterdepolarizations	O
and	O
ventricular	O
arrhythmias	O
induced	O
by	O
epinephrine	O
in	O
congenital	O
long	O
QT	O
syndrome	O
.	O

This	O
implies	O
that	O
the	O
groups	O
do	O
not	O
just	O
differ	O
along	O
one	O
dimension	O
,	O
but	O
along	O
three	O
dimensions	O
.	O

These	O
results	O
are	O
very	O
useful	O
for	O
deciding	O
on	O
the	O
doses	O
of	O
hormones	O
and	O
the	O
expected	O
serum	O
estradiol	O
level	O
in	O
HRT	O
for	O
Japanese	O
women	O
.	O

Poor	O
response	O
when	O
laboratory	O
recommended	O
range	O
for	O
serum	O
lithium	O
is	O
changed	O
.	O

Hydrocoele	O
is	O
common	O
in	O
men	O
in	O
Wuchereria	O
bancrofti-endemic	O
areas	O
,	O
the	O
treatment	O
for	O
which	O
is	O
currently	O
surgical	O
intervention	O
.	O

Replication	O
of	O
bovine	O
papillomavirus-1	O
(	O
BPV-1	O
)	O
DNA	O
requires	O
two	O
viral	O
gene	O
products	O
,	O
the	O
E1	B-GENE
protein	I-GENE
and	O
the	O
full-length	B-GENE
E2	I-GENE
protein	I-GENE
.	O

We	O
have	O
been	O
able	O
to	O
map	O
specific	O
DNA	O
fragments	O
at	O
the	O
bases	O
of	O
chromatin	O
loops	O
with	O
the	O
help	O
of	O
a	O
novel	O
extraction	O
procedure	O
by	O
using	O
lithium-3'	O
,	O
5'-diiodosalicylate	O
.	O

The	O
gene	B-GENE
encoding	I-GENE
human	I-GENE
tissue-type	I-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
t-PA	B-GENE
)	O
is	O
regulated	O
in	O
a	O
cell-type-specific	O
manner	O
.	O

One	O
month	O
after	O
the	O
DTaP	O
booster	O
vaccination	O
,	O
both	O
groups	O
had	O
6-	O
to	O
40-fold	O
increases	O
in	O
serum	O
antibody	O
concentrations	O
to	O
all	O
antigens	O
tested	O
;	O
the	O
concentrations	O
against	O
the	O
three	O
pertussis	B-GENE
antigens	I-GENE
were	O
higher	O
in	O
the	O
DTaP-primed	O
children	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
iron	O
dependence	O
of	O
transcription	O
and	O
expression	O
of	O
cvaA	B-GENE
,	O
which	O
encodes	O
a	O
transporter	O
accessory	O
protein	O
,	O
and	O
cvi	B-GENE
,	O
encoding	O
the	O
colicin	B-GENE
V	I-GENE
immunity	I-GENE
protein	I-GENE
,	O
was	O
assessed	O
under	O
conditions	O
of	O
iron	O
excess	O
or	O
depletion	O
.	O

Synthetic	O
ligands	O
have	O
been	O
identified	O
that	O
reset	O
and	O
amplify	O
the	O
cycle	O
of	O
pulsatile	O
GH	B-GENE
secretion	O
by	O
interacting	O
with	O
the	O
orphan	B-GENE
GH-secretagogue	I-GENE
receptor	I-GENE
(	O
GHS-R	B-GENE
)	O
.	O

Self-heating	O
after	O
deep	O
hypothermia	O
(	O
20	O
degrees	O
C	O
)	O
causes	O
a	O
considerable	O
increase	O
in	O
the	O
brain	O
tissues	O
glutaminase	B-GENE
activity	O
at	O
all	O
studied	O
incubation	O
temperatures	O
(	O
37	O
,	O
30	O
,	O
20	O
and	O
10	O
degrees	O
C	O
)	O
as	O
compared	O
to	O
control	O
rats	O
and	O
rats	O
under	O
hypothermia	O
.	O

RESULTS	O
:	O
Within	O
7	O
days	O
,	O
all	O
groups	O
re-acquired	O
responding	O
for	O
heroin	O
under	O
CRF	O
at	O
rates	O
similar	O
to	O
their	O
pre-lesion	O
performance	O
.	O

HFA	O
134a	O
had	O
a	O
greater	O
tendency	O
to	O
take	O
up	O
moisture	O
from	O
the	O
environment	O
than	O
did	O
HFA	O
227	O
.	O

We	O
also	O
show	O
that	O
in	O
fusions	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
GAL4	B-GENE
,	O
full	O
activity	O
requires	O
the	O
entire	O
BHV-alpha	B-GENE
TIF	I-GENE
,	O
although	O
both	O
amino	O
and	O
carboxyl	O
termini	O
display	O
some	O
activity	O
on	O
their	O
own	O
.	O

Effects	O
of	O
a	O
booster	O
dose	O
of	O
tetanus	O
toxoid	O
after	O
different	O
primary	O
courses	O
of	O
vaccination	O
:	O
implications	O
on	O
the	O
use	O
of	O
immune	B-GENE
globulin	I-GENE
.	O

In	O
Xenopus	O
,	O
BMPs	B-GENE
act	O
as	O
epidermal	O
inducers	O
and	O
also	O
as	O
negative	O
regulators	O
of	O
neurogenesis	O
.	O

These	O
early	O
structural	O
processes	O
are	O
assumed	O
to	O
be	O
subserved	O
by	O
the	O
anterior	O
parts	O
of	O
the	O
left	O
hemisphere	O
,	O
as	O
event-related	O
brain	O
potentials	O
show	O
this	O
area	O
to	O
be	O
maximally	O
activated	O
when	O
phrase	O
structure	O
violations	O
are	O
processed	O
and	O
as	O
circumscribed	O
lesions	O
in	O
this	O
area	O
lead	O
to	O
an	O
impairment	O
of	O
the	O
on-line	O
structural	O
assignment	O
.	O

Characterization	O
of	O
fus1	B-GENE
of	O
Schizosaccharomyces	O
pombe	O
:	O
a	O
developmentally	O
controlled	O
function	O
needed	O
for	O
conjugation	O
.	O

Southern	O
analysis	O
on	O
genomic	O
DNA	O
isolated	O
from	O
tissues	O
and	O
cell	O
lines	O
from	O
several	O
mouse	O
strains	O
using	O
mCD22	B-GENE
cDNA	I-GENE
demonstrated	O
that	O
the	O
Cd22	B-GENE
locus	I-GENE
encoding	O
mCD22	B-GENE
is	O
a	O
single	O
copy	O
gene	O
of	O
<	O
or	O
=	O
30	O
kb	O
.	O

Importance	O
of	O
determining	O
the	O
blood	O
sulfhydryl	O
groups	O
in	O
fractures	O
of	O
the	O
long	O
tubular	O
bones	O
complicated	O
by	O
infection	O
.	O

Similar	O
observations	O
have	O
been	O
made	O
previously	O
for	O
other	O
genes	O
.	O

A	O
general	O
model	O
for	O
ARE-mediated	O
mRNA	O
degradation	O
involving	O
a	O
potential	O
role	O
for	O
certain	O
heterogeneous	O
nuclear	O
ribonucleoproteins	O
and	O
ARE-binding	O
proteins	O
is	O
proposed	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
DnaA	B-GENE
may	O
contact	O
the	O
beta	O
subunit	O
of	O
RNA	B-GENE
polymerase	I-GENE
during	O
activation	O
of	O
the	O
pR	B-GENE
promoter	I-GENE
.	O

Letter	O
:	O
Salmonella	O
detection	O
.	O

Fourth	O
,	O
the	O
3'-region	O
splice	O
junctions	O
of	O
the	O
MSRs	B-GENE
during	O
latent	O
and	O
productive	O
infection	O
were	O
determined	O
by	O
sequencing	O
RNA-PCR	O
products	O
generated	O
with	O
primers	O
that	O
flank	O
the	O
3'	O
splice	O
region	O
.	O

A	O
neuropsychological	O
test	O
battery	O
was	O
used	O
that	O
contained	O
the	O
Wisconsin	O
card	O
sorting	O
test	O
,	O
Street	O
completion	O
test	O
,	O
Stroop	O
test	O
,	O
a	O
dichotic	O
memory	O
listening	O
test	O
,	O
and	O
a	O
facial	O
recognition	O
test	O
.	O

LON-72	O
(	O
34	O
isolates	O
)	O
,	O
LON-73	O
(	O
1	O
)	O
,	O
LON-71	O
(	O
2	O
)	O
and	O
LON-10	O
(	O
2	O
)	O
were	O
found	O
at	O
altitudes	O
around	O
2000	O
m	O
,	O
3	O
of	O
them	O
in	O
a	O
single	O
village	O
.	O

Treatment	O
of	O
hypertension	O
with	O
a	O
combination	O
of	O
the	O
adrenergic	B-GENE
beta	I-GENE
receptor	I-GENE
blockader	O
,	O
obsidan	O
,	O
and	O
the	O
vasodilator	O
,	O
apressin	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrate	O
that	O
the	O
rat	B-GENE
HDL	I-GENE
receptor	I-GENE
SR-BI	I-GENE
promoter	I-GENE
contains	O
two	O
sterol	B-GENE
response	I-GENE
elements	I-GENE
(	O
pSRE	B-GENE
and	O
dSRE	B-GENE
)	O
through	O
which	O
SREBP-1a	B-GENE
can	O
bind	O
and	O
activate	O
transcription	O
of	O
this	O
gene	O
.	O

Disruption	O
demonstrates	O
that	O
CDC14	B-GENE
is	O
an	O
essential	O
gene	O
.	O

The	O
sites	O
targeted	O
for	O
mutagenesis	O
,	O
residues	O
60	O
,	O
61	O
,	O
and	O
66	O
,	O
are	O
located	O
within	O
a	O
putative	O
helical	O
loop	O
structure	O
which	O
may	O
be	O
involved	O
in	O
substrate	O
recognition	O
by	O
the	O
enzyme	O
.	O

Further	O
support	O
for	O
a	O
direct	O
interaction	O
of	O
Tub4p	B-GENE
,	O
Spc98p	B-GENE
and	O
Spc97p	B-GENE
comes	O
from	O
the	O
toxicity	O
of	O
strong	O
SPC97	B-GENE
overexpression	O
which	O
is	O
suppressed	O
by	O
co-overexpression	O
of	O
TUB4	B-GENE
or	O
SPC98	B-GENE
.	O

The	O
amino	O
acid	O
sequences	O
of	O
the	O
yeast	O
and	O
mammalian	O
mitochondrial	O
targeting	O
sequences	O
are	O
similar	O
but	O
less	O
related	O
than	O
the	O
mature	O
polypeptides	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
SHP-1	B-GENE
,	O
a	O
SH2	B-GENE
domain-containing	I-GENE
protein-tyrosine	I-GENE
phosphatase	I-GENE
,	O
is	O
expressed	O
not	O
only	O
in	O
cells	O
of	O
hematopoietic	O
lineages	O
,	O
but	O
also	O
in	O
many	O
non-hematopoietic	O
cells	O
under	O
the	O
control	O
of	O
an	O
alternative	O
tissue-specific	O
promoter	O
,	O
P1	B-GENE
.	O

Owing	O
to	O
parental	O
attitude	O
,	O
a	O
low	O
protein	O
diet	O
(	O
1-5	O
g	O
/	O
kg	O
)	O
was	O
introduced	O
only	O
late	O
.	O

Current	O
status	O
of	O
telepathology	O
.	O

The	O
Y-type	B-GENE
structural	I-GENE
motif	I-GENE
is	O
also	O
conserved	O
among	O
a	O
number	O
of	O
divergent	O
BiP	B-GENE
mRNAs	I-GENE
.	O

Effects	O
of	O
dioxins	O
on	O
thyroid	O
function	O
in	O
newborn	O
babies	O
.	O

Potentiation	O
of	O
the	O
thrombolytic	O
efficacy	O
of	O
single-chain	B-GENE
urokinase	I-GENE
(	O
Pro-urokinase	B-GENE
)	O
by	O
heparin	O
.	O

Effect	O
of	O
biliary	O
obstruction	O
and	O
cholangitis	O
on	O
serum	B-GENE
SPan-1	I-GENE
level	O
.	O

The	O
overexpressed	O
His6-tagged	B-GENE
GrsA	I-GENE
derivatives	I-GENE
were	O
affinity-purified	O
,	O
and	O
the	O
catalytic	O
properties	O
of	O
the	O
deletion	O
mutants	O
were	O
examined	O
by	O
biochemical	O
studies	O
including	O
ATP-dependent	O
amino	O
acid	O
activation	O
,	O
carboxyl	O
thioester	O
formation	O
,	O
and	O
the	O
ability	O
to	O
racemize	O
the	O
covalently	O
bound	O
phenylalanine	O
from	O
L-	O
to	O
the	O
D-isomer	O
.	O

Induction	O
requires	O
the	O
ACE1	B-GENE
gene	I-GENE
product	I-GENE
,	O
which	O
binds	O
to	O
specific	O
sites	O
in	O
the	O
promoter	O
region	O
of	O
the	O
CUP1	B-GENE
gene	I-GENE
.	O

Fatal	O
encephalitis	O
in	O
a	O
patient	O
with	O
chronic	O
graft-versus-host	O
disease	O
.	O

The	O
need	O
in	O
the	O
small	O
hospital	O
.	O

Mechanical	O
ventilation	O
in	O
control	O
lungs	O
produced	O
a	O
47%	O
decrease	O
in	O
chord	O
compliance	O
,	O
an	O
increase	O
in	O
lung	O
lavage	O
levels	O
of	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	I-GENE
TNF	I-GENE
)	I-GENE
-alpha	I-GENE
(	O
722	O
+	O
/	O
-	O
306	O
pg	O
/	O
ml	O
)	O
,	O
interleukin	B-GENE
(	I-GENE
IL	I-GENE
)	I-GENE
-1beta	I-GENE
(	O
902	O
+	O
/	O
-	O
322	O
pg	O
/	O
ml	O
)	O
,	O
and	O
macrophage	B-GENE
inflammatory	I-GENE
protein-2	I-GENE
(	O
MIP-2	B-GENE
)	O
(	O
363	O
+	O
/	O
-	O
104	O
pg	O
/	O
ml	O
)	O
as	O
compared	O
with	O
low	O
levels	O
of	O
cytokines	O
detected	O
in	O
preventilation	O
data	O
,	O
and	O
no	O
change	O
in	O
percentage	O
of	O
surfactant	O
large	O
aggregates	O
(	O
LA	O
)	O
.	O

Of	O
the	O
compounds	O
tested	O
,	O
alpha-	O
(	O
3-methyl-2-quinoxalinyl	O
)	O
-N-methylnitrone	O
1	O
,	O
4-dioxide	O
(	O
2	O
)	O
was	O
the	O
most	O
active	O
agent	O
in	O
vivo	O
against	O
the	O
gram-negative	O
and	O
the	O
gram-positive	O
organisms	O
.	O

A	O
chromosome	O
transmission	O
fidelity	O
(	O
ctf	O
)	O
mutant	O
,	O
s138	O
,	O
of	O
Saccharomyces	O
cerevisiae	O
was	O
identified	O
by	O
its	O
centromere	O
(	O
CEN	O
)	O
transcriptional	O
readthrough	O
phenotype	O
,	O
suggesting	O
perturbed	O
kinetochore	O
integrity	O
in	O
vivo	O
.	O

Immunohistochemical	O
studies	O
revealed	O
positive	O
staining	O
for	O
S100	B-GENE
protein	I-GENE
in	O
all	O
the	O
granular	O
cell	O
tumors	O
of	O
the	O
adult	O
but	O
in	O
none	O
of	O
the	O
congenital	O
granular	O
cell	O
epulides	O
.	O

In	O
a	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
we	O
compared	O
the	O
efficacy	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
(	O
every	O
8	O
h	O
)	O
calcium	O
heparin	O
to	O
intravenous	O
(	O
IV	O
)	O
sodium	O
heparin	O
in	O
the	O
treatment	O
of	O
proximal	O
deep-vein	O
thrombosis	O
(	O
DVT	O
)	O
.	O

Mean	O
increase	O
of	O
milk	O
protein	O
yield	O
was	O
46	O
g	O
/	O
d	O
with	O
Met	O
plus	O
Lys	O
,	O
and	O
mean	O
increase	O
of	O
true	O
protein	O
content	O
was	O
1	O
.	O
1	O
g	O
/	O
kg	O
of	O
milk	O
.	O

V	O
.	O

Alignment	O
of	O
the	O
amino	O
acid	O
sequences	O
surrounding	O
Tyr-766	O
with	O
corresponding	O
regions	O
of	O
other	O
FGFRs	B-GENE
revealed	O
conserved	O
tyrosine	O
residues	O
in	O
all	O
known	O
members	O
of	O
the	O
FGFR	B-GENE
family	I-GENE
.	O

Mss4	B-GENE
also	O
acts	O
as	O
a	O
relatively	O
inefficient	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
(	O
GEF	B-GENE
)	O
.	O

Treatment	O
of	O
Graves'	O
disease	O
.	O

Some	O
artificial	O
promoter	O
constructs	O
containing	O
multiple	O
Sp1	B-GENE
sites	I-GENE
were	O
highly	O
responsive	O
to	O
ethanol	O
,	O
but	O
others	O
were	O
not	O
,	O
suggesting	O
that	O
the	O
organization	O
of	O
the	O
proximal	O
promoter	O
region	O
was	O
an	O
additional	O
factor	O
that	O
affected	O
the	O
ethanol	O
response	O
.	O

Polysome	B-GENE
and	O
40S	B-GENE
ribosome	I-GENE
fractions	O
were	O
severely	O
decreased	O
in	O
the	O
krr1	B-GENE
mutant	I-GENE
and	O
Kri1p-depleted	O
cells	O
.	O

The	O
alpha	B-GENE
4	I-GENE
gene	I-GENE
5'	O
flanking	O
region	O
acted	O
as	O
a	O
promoter	O
in	O
transfection	O
assays	O
.	O

Atopic	O
allergy	O
and	O
other	O
hypersensitivities	O
.	O

Reaction	O
time	O
(	O
RT	O
)	O
and	O
P300	O
were	O
collected	O
simultaneously	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
persistent	O
oscillation	O
within	O
the	O
ULF	O
band	O
.	O

From	O
March	O
5	O
through	O
October	O
26	O
,	O
1991	O
,	O
eight	O
persons	O
were	O
diagnosed	O
with	O
elevated	O
blood	O
lead	O
levels	O
(	O
BLLs	O
)	O
at	O
a	O
local	O
hospital	O
and	O
were	O
reported	O
to	O
the	O
notifiable	O
disease	O
surveillance	O
system	O
maintained	O
by	O
the	O
Alabama	O
Department	O
of	O
Public	O
Health	O
(	O
ADPH	O
)	O
.	O

Delineating	O
the	O
molecular	O
basis	O
for	O
agonist-induced	O
destabilization	O
of	O
mRNA	O
of	O
G-protein-linked	B-GENE
receptors	I-GENE
that	O
contributes	O
to	O
receptor	O
down-regulation	O
is	O
fundamental	O
to	O
our	O
understanding	O
of	O
long-term	O
regulation	O
of	O
receptors	O
by	O
agonist	O
.	O

The	O
cloned	O
alcR	B-GENE
gene	I-GENE
provided	O
in	O
trans	O
restored	O
these	O
siderophore	O
system	O
activities	O
to	O
the	O
mutants	O
.	O

Amikacin	O
concentrations	O
in	O
serum	O
and	O
blister	O
fluid	O
in	O
healthy	O
volunteers	O
and	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O

We	O
conclude	O
that	O
the	O
gp54	B-GENE
structural	I-GENE
gene	I-GENE
is	O
required	O
for	O
initiation	O
or	O
amplification	O
of	O
the	O
splenic	O
erythroblast	O
hyperplasia	O
which	O
characterizes	O
the	O
preleukemic	O
phase	O
of	O
Rauscher	O
disease	O
.	O

With	O
Sair	O
and	O
So2	O
,	O
mean	O
vital	O
capacity	O
was	O
reduced	O
by	O
44%	O
from	O
control	O
.	O

The	O
bronchial	O
epithelia	O
of	O
all	O
smoke-exposed	O
animals	O
were	O
hyperplastic	O
,	O
and	O
their	O
ultrastructure	O
showed	O
invaginations	O
,	O
tilt	O
of	O
nuclear	O
axes	O
,	O
an	O
increase	O
in	O
the	O
number	O
and	O
size	O
of	O
lysosomes	O
and	O
multivesiculated	O
bodies	O
,	O
and	O
increased	O
numbers	O
of	O
enlarged	O
intramitochondrial	O
granules	O
.	O

Transcription	O
of	O
the	O
first	O
operon	O
coding	O
for	O
m-xylene-degrading	O
enzymes	O
on	O
the	O
TOL	O
plasmid	O
of	O
Pseudomonas	O
putida	O
is	O
activated	O
by	O
the	O
xylR	B-GENE
gene	I-GENE
product	I-GENE
in	O
the	O
presence	O
of	O
m-xylene	O
.	O

Three	O
patients	O
received	O
additional	O
cycles	O
of	O
5-fluorouracil	O
+	O
/	O
-	O
leucovorin	O
as	O
maintenance	O
chemotherapy	O
.	O
RESULTS	O
:	O
Thirty	O
males	O
and	O
21	O
females	O
with	O
a	O
median	O
age	O
of	O
55	O
years	O
(	O
range	O
31--73	O
years	O
)	O
were	O
treated	O
.	O

Epididymal	O
growth	O
was	O
retarded	O
in	O
animals	O
maintained	O
solely	O
on	O
chickpea	O
haulm	O
and	O
improved	O
with	O
supplementation	O
.	O

The	O
mean	O
extracted	O
concentration	O
of	O
flucloxacillin	O
obtained	O
at	O
operation	O
was	O
12	O
.	O
9	O
micrograms	O
/	O
ml	O
(	O
SD	O
5	O
.	O
25	O
)	O
in	O
synovial	O
fluid	O
;	O
2	O
.	O
9	O
micrograms	O
/	O
g	O
(	O
SD	O
3	O
.	O
59	O
)	O
in	O
synovium	O
;	O
2	O
.	O
0	O
micrograms	O
/	O
g	O
(	O
SD	O
1	O
.	O
48	O
)	O
in	O
cancellous	O
bone	O
and	O
1	O
.	O
3	O
micrograms	O
/	O
g	O
(	O
SD	O
1	O
.	O
25	O
)	O
in	O
cortical	O
bone	O
.	O

MDBP	B-GENE
from	O
HeLa	O
and	O
Raji	O
cells	O
formed	O
DNA-protein	O
complexes	O
with	O
X-box	O
oligonucleotides	O
that	O
coelectrophoresed	O
with	O
those	O
containing	O
standard	O
MDBP	B-GENE
sites	I-GENE
.	O

Interestingly	O
,	O
segment	O
nesting	O
differentially	O
increases	O
the	O
copy	O
number	O
of	O
genes	O
encoded	O
by	O
segment	O
W	O
,	O
suggesting	O
that	O
the	O
unusual	O
genomic	O
organization	O
of	O
PDVs	O
may	O
be	O
directly	O
linked	O
to	O
the	O
unique	O
functions	O
of	O
this	O
virus	O
in	O
its	O
obligate	O
mutualistic	O
association	O
with	O
parasitic	O
wasps	O
.	O

Molecular	O
mimicry	O
of	O
human	O
cytokine	O
and	O
cytokine	O
response	O
pathway	O
genes	O
by	O
KSHV	O
.	O

The	O
insulin	B-GENE
therapy	O
regimen	O
did	O
not	O
affect	O
the	O
evolution	O
of	O
the	O
patients	O
and	O
no	O
significant	O
relationship	O
existed	O
between	O
the	O
age	O
at	O
diagnosis	O
,	O
duration	O
of	O
diabetes	O
,	O
daily	O
insulin	B-GENE
dosage	O
or	O
metabolic	O
control	O
and	O
height	O
or	O
BMI	O
.	O

Cutis	O
aplasia	O
.	O

As	O
in	O
mammals	O
,	O
considerable	O
nucleotide	O
diversity	O
was	O
observed	O
at	O
the	O
junctions	O
of	O
the	O
variable	O
,	O
diversity	O
,	O
and	O
joining	O
elements	O
in	O
chicken	B-GENE
TCR	I-GENE
beta	I-GENE
cDNAs	I-GENE
.	O

Two	O
alternatively	O
spliced	O
5'	O
UTRs	O
,	O
designated	O
type	O
I	O
and	O
type	O
II	O
,	O
of	O
222	O
and	O
115	O
bp	O
,	O
respectively	O
,	O
were	O
found	O
associated	O
with	O
PFP	B-GENE
.	O

Our	O
data	O
,	O
combined	O
with	O
those	O
of	O
Hershey	O
and	O
co-workers	O
,	O
suggest	O
that	O
mammalian	B-GENE
eIF3	I-GENE
is	O
composed	O
of	O
at	O
least	O
10	O
subunits	O
:	O
p170	B-GENE
,	O
p116	B-GENE
(	O
hPrt1	B-GENE
)	O
,	O
p110	B-GENE
,	O
p66	B-GENE
,	O
p48	B-GENE
,	O
p47	B-GENE
,	O
p44	B-GENE
,	O
p40	B-GENE
,	O
p36	B-GENE
,	O
and	O
p35	B-GENE
.	O

A	O
controlled	O
trial	O
of	O
recombinant	B-GENE
human	I-GENE
granulocyte-macrophage	I-GENE
colony-stimulating	I-GENE
factor	I-GENE
after	O
total	O
body	O
irradiation	O
,	O
high-dose	O
chemotherapy	O
,	O
and	O
autologous	O
bone	O
marrow	O
transplantation	O
for	O
acute	O
lymphoblastic	O
leukemia	O
or	O
malignant	O
lymphoma	O
.	O

The	O
development	O
of	O
a	O
data	O
base	O
is	O
described	O
which	O
can	O
be	O
used	O
as	O
common	O
reference	O
for	O
ECG	O
computer	O
programs	O
analyzing	O
12	O
or	O
15	O
simultaneously	O
recorded	O
leads	O
.	O

However	O
,	O
we	O
did	O
detect	O
lot-to-lot	O
variation	O
and	O
differences	O
in	O
performance	O
between	O
narrow	O
bandpass	O
and	O
wide	O
bandpass	O
spectrophotometers	O
.	O

The	O
ability	O
of	O
sodium	O
phenobarbital	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
sodium	O
barbital	O
(	O
80	O
mg	O
/	O
kg	O
)	O
to	O
produce	O
a	O
taste	O
aversion	O
in	O
23	O
hr	O
fluid	O
deprived	O
rats	O
was	O
examined	O
using	O
a	O
discrimination	O
or	O
two	O
bottle	O
taste	O
aversion	O
task	O
(	O
0	O
.	O
125%	O
sodium	O
saccharin	O
solution	O
or	O
water	O
)	O
.	O

Study	O
on	O
the	O
evagination	O
of	O
Cysticercus	O
pisiformis	O
.	O

Gaucher's	O
disease	O
is	O
a	O
rare	O
metabolic	O
disorder	O
characterized	O
by	O
the	O
lack	O
of	O
beta-glucocerebrosidase	B-GENE
enzyme	I-GENE
.	O

In	O
order	O
to	O
infer	O
shape	O
from	O
contour	O
,	O
the	O
human	O
visual	O
system	O
must	O
selectively	O
integrate	O
fragments	O
projecting	O
from	O
a	O
common	O
object	O
while	O
keeping	O
fragments	O
from	O
different	O
objects	O
separate	O
.	O

Simultaneous	O
right	O
and	O
left	O
adrenal	O
and	O
peripheral	O
blood	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
oestrone	O
(	O
E1	O
)	O
and	O
oestradiol	O
(	O
E2	O
)	O
.	O

The	O
NIT2	B-GENE
protein	I-GENE
is	O
localised	O
in	O
nuclei	O
and	O
could	O
not	O
be	O
detected	O
in	O
the	O
cytoplasmic	O
fraction	O
of	O
cells	O
subjected	O
to	O
nitrogen	O
derepression	O
or	O
nitrogen	O
repression	O
,	O
indicating	O
that	O
the	O
nuclear	O
import	O
of	O
NIT2	B-GENE
is	O
not	O
regulated	O
.	O

Prostaglandins	O
F	O
(	O
PGF	O
)	O
were	O
measured	O
in	O
uterine	O
vein	O
,	O
ovarian	O
artery	O
,	O
and	O
jugular	O
vein	O
plasma	O
and	O
in	O
the	O
endometrial	O
tissues	O
at	O
various	O
times	O
during	O
the	O
bovine	O
estrous	O
cycle	O
,	O
and	O
were	O
compared	O
to	O
peripheral	O
plasma	O
progesterone	O
levels	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
trials	O
comparing	O
children	O
undergoing	O
systematic	O
therapy	O
focusing	O
on	O
the	O
family	O
in	O
conjunction	O
with	O
asthma	O
medication	O
,	O
with	O
children	O
taking	O
asthma	O
medication	O
only	O
.	O

All	O
numbers	O
refer	O
to	O
nucleotide	O
positions	O
on	O
the	O
wild-type	O
HIV-1	O
transcript	O
.	O

Promoter	O
analysis	O
demonstrated	O
that	O
the	O
sequence	O
identical	O
to	O
consensus	B-GENE
cAMP-responsive	I-GENE
element	I-GENE
(	O
CRE	B-GENE
)	O
located	O
at	O
-481	O
of	O
the	O
SMemb	B-GENE
promoter	I-GENE
was	O
critical	O
for	O
Hex	B-GENE
responsiveness	O
.	O

PLUS-3	O
is	O
a	O
new	O
Swedish	O
protocol	O
of	O
natural	O
speech	O
in	O
3-year-old	O
children	O
.	O

Transfection	O
of	O
increasing	O
amounts	O
of	O
delta5ERalpha	B-GENE
expression	O
vector	O
into	O
[	O
ERalpha+	O
]	O
OS	O
cells	O
resulted	O
in	O
potentiation	O
of	O
E2-stimulated	O
ERELuc	B-GENE
activity	O
in	O
a	O
synergistic	O
,	O
dose-dependent	O
manner	O
.	O

Specialist	O
in	O
family	O
practice--prototype	O
of	O
a	O
doctor	O
.	O

The	O
effect	O
of	O
low	O
dosage	O
radiation	O
on	O
metabolism	O
and	O
function	O
of	O
the	O
rat	O
kidney	O
damaged	O
by	O
ischemia	O
.	O

By	O
introducing	O
a	O
series	O
of	O
deletions	O
in	O
the	O
vimentin	B-GENE
promoter	O
,	O
we	O
further	O
restrict	O
these	O
sequences	O
to	O
30	O
base	O
pairs	O
,	O
located	O
between	O
241	O
and	O
210	O
base	O
pairs	O
upstream	O
of	O
the	O
mRNA	O
cap	O
site	O
.	O

Transformation	O
of	O
the	O
sconC3	B-GENE
mutant	I-GENE
with	O
sconB+	B-GENE
restores	O
the	O
wild-type	O
phenotype	O
.	O

We	O
have	O
attempted	O
to	O
clone	O
two	O
recessive	O
extragenic	O
suppressors	O
of	O
such	O
ts	O
mutants	O
(	O
sdp1	O
for	O
mutation	B-GENE
pol3-14	I-GENE
and	O
sdp5-1	O
for	O
mutation	B-GENE
pol3-11	I-GENE
)	O
by	O
transforming	O
thermoresistant	O
haploid	O
strains	O
pol3-14	B-GENE
sdp1	I-GENE
and	O
pol3-11	B-GENE
sdp5-1	I-GENE
with	O
wild-type	O
genomic	O
libraries	O
in	O
singlecopy	O
or	O
multicopy	O
vectors	O
.	O

Alternative	O
splicing	O
of	O
CDC25B	B-GENE
may	O
therefore	O
contribute	O
to	O
the	O
control	O
of	O
cell	O
proliferation	O
.	O

After	O
i	O
.	O
v	O
.	O
administration	O
of	O
500	O
mg	O
acetazolamide	O
and	O
disinfection	O
of	O
the	O
conjunctiva	O
,	O
50	O
micrograms	O
rt-PA	O
in	O
0	O
.	O
1	O
ml	O
(	O
BSS	O
)	O
and	O
0	O
.	O
5	O
ml	O
SF6	O
were	O
injected	O
intravitreally	O
.	O

Of	O
202	O
initially	O
seronegative	O
caretakers	O
(	O
observed	O
for	O
an	O
average	O
of	O
305	O
days	O
per	O
woman	O
)	O
,	O
19	O
seroconverted	O
,	O
for	O
an	O
annual	O
seroconversion	O
rate	O
of	O
11	O
percent	O
.	O

Enhancer	O
and	O
promoter	O
elements	O
directing	O
activation	O
and	O
glucocorticoid	O
repression	O
of	O
the	O
alpha	B-GENE
1-fetoprotein	I-GENE
gene	I-GENE
in	O
hepatocytes	O
.	O

The	O
terminator	O
region	O
supported	O
termination	O
of	O
transcripts	O
initiated	O
by	O
RNA	B-GENE
polymerase	I-GENE
I	I-GENE
in	O
vivo	O
.	O

The	O
level	O
of	O
the	O
SUP4A53T61	B-GENE
transcript	I-GENE
was	O
threefold	O
higher	O
in	O
the	O
tap1-1	B-GENE
mutant	I-GENE
than	O
in	O
the	O
wild	O
type	O
.	O

However	O
,	O
for	O
the	O
evaluable	O
cases	O
,	O
the	O
performances	O
of	O
the	O
CD3500	O
and	O
the	O
STKS	O
were	O
broadly	O
similar	O
and	O
generally	O
correlated	O
well	O
with	O
the	O
manual	O
reference	O
procedure	O
.	O

The	O
application	O
of	O
ultrafiltration	O
to	O
sample	O
preparation	O
in	O
the	O
detection	O
and	O
quantification	O
of	O
ethylene	O
glycol	O
in	O
plasma	O
by	O
gas	O
chromatography	O
is	O
described	O
.	O

Familial	O
juvenile	O
nephronophthisis	O
.	O

A	O
note	O
on	O
some	O
consequences	O
of	O
UV	O
vision	O
in	O
birds	O
.	O

Biol	O
.	O

The	O
data	O
indicates	O
the	O
presence	O
of	O
5-HT2	B-GENE
serotonergic	I-GENE
receptors	I-GENE
in	O
the	O
bronchial	O
artery	O
of	O
these	O
species	O
.	O

There	O
are	O
no	O
introns	O
within	O
the	O
gene	O
,	O
which	O
contains	O
a	O
9360-bp	O
open	O
reading	O
frame	O
and	O
encodes	O
a	O
377-kDa	O
protein	O
.	O

At	O
4	O
wk	O
however	O
,	O
tumor	O
relapse	O
was	O
noted	O
in	O
6	O
of	O
7	O
group	O
4	O
responders	O
,	O
10	O
of	O
12	O
in	O
group	O
5	O
,	O
13	O
of	O
16	O
in	O
group	O
7	O
,	O
but	O
only	O
4	O
of	O
19	O
group	O
8	O
responders	O
(	O
p	O
less	O
than	O
.	O
001	O
group	O
8	O
versus	O
4	O
,	O
5	O
,	O
7	O
)	O
.	O

This	O
study	O
shows	O
that	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
is	O
the	O
predominant	O
C	B-GENE
/	I-GENE
EBP	I-GENE
isoform	I-GENE
found	O
in	O
activated	O
stellate	O
cells	O
and	O
that	O
increased	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
protein	I-GENE
and	O
C	B-GENE
/	I-GENE
EBPbeta	I-GENE
binding	O
to	O
a	O
proximal	O
C	B-GENE
/	I-GENE
EBP	I-GENE
binding	I-GENE
site	I-GENE
in	O
the	O
promoter	O
mediates	O
the	O
activating	O
effect	O
of	O
acetaldehyde	O
.	O

The	O
mean	O
thickness	O
of	O
the	O
visceral	O
peritoneum	O
was	O
comparable	O
in	O
both	O
groups	O
of	O
animals	O
,	O
but	O
,	O
macroscopically	O
,	O
more	O
severe	O
fibrosis	O
was	O
found	O
in	O
the	O
peritoneum	O
of	O
rats	O
exposed	O
to	O
CAPD	O
3	O
as	O
compared	O
with	O
animals	O
treated	O
with	O
CAPD	O
3	O
Balance	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Hence	O
temperature	O
and	O
virF	B-GENE
are	O
both	O
required	O
for	O
the	O
induction	O
of	O
the	O
yop	B-GENE
regulon	I-GENE
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
the	O
recently	O
identified	O
isoforms	O
Vav2	B-GENE
and	O
Vav3	B-GENE
,	O
which	O
are	O
broadly	O
expressed	O
,	O
can	O
couple	O
with	O
similar	O
classes	O
of	O
receptors	O
,	O
nor	O
is	O
it	O
known	O
whether	O
all	O
Vav	B-GENE
isoforms	I-GENE
possess	O
identical	O
functional	O
activities	O
.	O

Lymphatics	O
in	O
the	O
aorta	O
of	O
rats	O
treated	O
with	O
a	O
soy-bean	O
oil	O
extract	O
(	O
lipofundin	O
)	O
.	O

Two	O
distinct	O
recessive	O
susceptibility	O
loci	O
for	O
vasculitis	O
were	O
mapped	O
on	O
chromosome	O
(	O
Chr	O
)	O
4	O
at	O
D4Mit89	B-GENE
and	O
D4Mit147	B-GENE
in	O
both	O
progenies	O
.	O

These	O
cell	O
lines	O
,	O
selected	O
for	O
the	O
ability	O
to	O
support	O
the	O
replication	O
of	O
a	O
temperature-sensitive	O
VP5	B-GENE
mutant	I-GENE
,	O
were	O
used	O
to	O
isolate	O
VP5	B-GENE
and	O
VP23	B-GENE
null	O
mutants	O
.	O

The	O
toxicological	O
evaluation	O
of	O
chlorofluorocarbon	O
22	O
(	O
CFC	O
22	O
)	O
.	O

Resolution	O
of	O
thermographic	O
asymmetry	O
and	O
/	O
or	O
decrease	O
in	O
Delta	O
T	O
was	O
demonstrated	O
in	O
approximately	O
81%	O
of	O
the	O
post-treatment	O
population	O
.	O

The	O
cochlear	O
compromise	O
.	O

The	O
Cut9	B-GENE
subunit	I-GENE
is	O
likely	O
to	O
be	O
a	O
target	O
for	O
regulating	O
APC	B-GENE
/	I-GENE
cyclosome	I-GENE
function	O
through	O
protein-protein	O
interactions	O
and	O
phosphorylation	O
.	O

Bacteria	O
can	O
also	O
cause	O
a	O
labyrinthitis	O
acting	O
directly	O
on	O
the	O
inner	O
ear	O
:	O
among	O
these	O
,	O
Treponemas	O
Pallidum	O
,	O
a	O
spirochaete	O
which	O
causes	O
syphilis	O
and	O
Borrelia	O
Burgdorferi	O
,	O
a	O
spirochaete	O
that	O
causes	O
Lyme	O
Disease	O
,	O
must	O
be	O
mentioned	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
two	O
recombination-	O
and	O
repair-defective	O
mutations	O
,	O
rad1	B-GENE
and	O
rad52	B-GENE
,	O
on	O
direct	O
repeat	O
recombination	O
in	O
transcriptionally	O
active	O
and	O
inactive	O
sequences	O
.	O

The	O
following	O
markers	O
were	O
looked	O
for	O
in	O
the	O
serum	O
,	O
skin	O
and	O
liver	O
of	O
all	O
patients	O
with	O
chronic	O
hepatitis	O
:	O
HBV	O
(	O
HBs	O
Ag	O
and	O
HBe	O
Ag	O
,	O
anti-HBs	B-GENE
,	O
anti-HBe	B-GENE
and	O
anti-HBc	B-GENE
in	O
the	O
serum	O
,	O
HBs	O
and	O
HBc	O
Ag	O
in	O
the	O
liver	O
)	O
;	O
non-A	O
non-B	O
(	O
non-A	O
,	O
non-B	O
Ag	O
and	O
antibody	O
,	O
anti	B-GENE
non-A	I-GENE
non-Bc	I-GENE
in	O
the	O
serum	O
,	O
non-A	O
,	O
non-Bc	O
Ag	O
in	O
the	O
liver	O
)	O
.	O

The	O
harpin-encoding	O
hrpZ	B-GENE
gene	I-GENE
is	O
located	O
in	O
an	O
operon	O
that	O
also	O
encodes	O
Hrp	B-GENE
secretion	I-GENE
pathway	I-GENE
components	I-GENE
and	O
is	O
part	O
of	O
the	O
functional	O
cluster	O
of	O
hrp	B-GENE
genes	I-GENE
carried	O
on	O
cosmid	O
pHIR11	O
that	O
enables	O
saprophytic	O
bacteria	O
like	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
fluorescens	O
to	O
elicit	O
the	O
HR	O
in	O
tobacco	O
leaves	O
.	O

Lactation	O
of	O
baboons	O
fed	O
a	O
low	O
protein	O
maintenance	O
diet	O
.	O

We	O
present	O
here	O
a	O
detailed	O
genomic	O
sequencing	O
analysis	O
of	O
the	O
cytosine	O
methylation	O
patterns	O
of	O
the	O
transposase	O
binding	O
sites	O
within	O
both	O
Ac	B-GENE
ends	O
in	O
the	O
wx-m9	B-GENE
:	O
:	O
Ac	B-GENE
allele	I-GENE
,	O
where	O
Ac	B-GENE
is	O
inserted	O
into	O
the	O
tenth	O
exon	O
of	O
the	O
Waxy	B-GENE
gene	I-GENE
.	O

During	O
an	O
8-wk	O
follow-up	O
,	O
parasites	O
reappeared	O
in	O
10	O
patients	O
,	O
5	O
after	O
each	O
drug	O
,	O
between	O
1	O
and	O
7	O
wk	O
after	O
treatment	O
.	O

Expression	O
of	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
type	I-GENE
2	I-GENE
US3	I-GENE
affects	O
the	O
Cdc42	B-GENE
/	I-GENE
Rac	I-GENE
pathway	O
and	O
attenuates	O
c-Jun	B-GENE
N-terminal	I-GENE
kinase	I-GENE
activation	O
.	O

Pure	O
T1	O
and	O
dual-T1	O
images	O
were	O
visually	O
evaluated	O
for	O
image	O
quality	O
(	O
IQ	O
)	O
on	O
a	O
five-point	O
scale	O
(	O
0	O
=	O
unacceptable	O
to	O
4	O
=	O
excellent	O
)	O
.	O

Changing	O
and	O
predicting	O
doses	O
of	O
Cs137	O
irradiation	O
.	O

Thus	O
,	O
the	O
positive	O
effect	O
of	O
NS1	B-GENE
on	O
the	O
steady-state	O
levels	O
of	O
P4	B-GENE
transcripts	I-GENE
depends	O
on	O
the	O
amplification	O
of	O
gene	O
copy	O
number	O
and	O
the	O
integrity	O
of	O
the	O
terminal	O
repeats	O
.	O

However	O
,	O
the	O
requirement	O
of	O
rev3	B-GENE
for	O
the	O
production	O
of	O
G	O
.	O
C--	O
>	O
T	O
.	O
A	O
transversions	O
by	O
the	O
rad18	B-GENE
mutator	I-GENE
,	O
which	O
induces	O
only	O
these	O
substitutions	O
,	O
was	O
similar	O
to	O
that	O
for	O
rad6-mediated	O
G	O
.	O
C--	O
>	O
T	O
.	O
A	O
transversion	O
.	O

All	O
clones	O
and	O
strains	O
produced	O
have	O
been	O
deposited	O
in	O
the	O
EUROFAN	O
genetic	O
stock	O
centre	O
(	O
EUROSCARF	O
,	O
Frankfurt	O
)	O
.	O

METHODS	O
:	O
The	O
passive	O
and	O
active	O
transport	O
of	O
fluorescein	O
through	O
the	O
BRB	O
was	O
quantitated	O
by	O
vitreous	O
fluorometry	O
.	O

As	O
a	O
result	O
,	O
the	O
subendocardial	O
/	O
subepicardial	O
blood	O
flow	O
ratio	O
(	O
ENDO	O
/	O
EPI	O
)	O
increased	O
from	O
0	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
09	O
during	O
control	O
stenosis	O
to	O
0	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
13	O
after	O
ITF	O
1129	O
(	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
i	O
.	O
v	O
.	O
)	O
and	O
to	O
0	O
.	O
81	O
+	O
/	O
-	O
0	O
.	O
12	O
after	O
NTG	O
.	O

The	O
risk	O
factors	O
for	O
hematuria	O
in	O
patients	O
with	O
renal	O
hypouricemia	O
are	O
the	O
elevation	O
of	O
urinary	O
urate	O
concentration	O
and	O
the	O
subtypes	O
of	O
Post	O
and	O
Secretion	O
.	O

Results	O
demonstrated	O
that	O
the	O
presence	O
of	O
myofibroblasts	O
varied	O
considerably	O
from	O
case	O
to	O
case	O
and	O
was	O
always	O
related	O
to	O
smooth	O
muscle	O
cell	O
dispersion	O
,	O
which	O
occurred	O
around	O
medium-sized	O
damaged	O
portal	O
vein	O
branches	O
.	O

Serum	B-GENE
insulin-like	I-GENE
growth	I-GENE
factor	I-GENE
I	I-GENE
(	O
IGF-I	B-GENE
)	O
SD	O
score	O
increased	O
from	O
-2	O
.	O
2	O
and	O
-4	O
.	O
2	O
in	O
men	O
and	O
women	O
,	O
respectively	O
,	O
to	O
1	O
.	O
8	O
and	O
-0	O
.	O
9	O
at	O
6	O
months	O
and	O
0	O
.	O
8	O
and	O
-0	O
.	O
7	O
at	O
12	O
months	O
.	O

The	O
N1	O
and	O
P2	O
were	O
comparable	O
in	O
amplitude	O
and	O
both	O
had	O
prolonged	O
refractory	O
periods	O
.	O

These	O
human	O
IFN-beta-transformed	O
cell	O
populations	O
have	O
acquired	O
a	O
low	O
,	O
constitutive	O
production	O
of	O
human	B-GENE
IFN	I-GENE
,	O
while	O
replicating	O
at	O
a	O
rate	O
similar	O
to	O
that	O
of	O
untransformed	O
cells	O
and	O
of	O
cells	O
transformed	O
with	O
the	O
control	O
vector	O
carrying	O
a	O
human	B-GENE
IFN-beta	I-GENE
sequence	I-GENE
encoding	O
an	O
inactive	O
,	O
mutated	O
protein	O
.	O

Thirty-five	O
strains	O
of	O
Legionnaires'	O
disease	O
bacteria	O
were	O
shown	O
to	O
belong	O
in	O
four	O
distinct	O
serologic	O
groups	O
on	O
the	O
basis	O
of	O
findings	O
obtained	O
with	O
direct	O
fluorescent	O
antibody	O
testing	O
.	O

An	O
additional	O
advantage	O
is	O
that	O
the	O
resin	O
can	O
be	O
removed	O
and	O
the	O
immunoperoxidase	O
technique	O
carried	O
out	O
on	O
thin	O
sections	O
.	O

CONCLUSIONS	O
:	O
A	O
50-mg	O
daily	O
dose	O
of	O
bicalutamide	O
is	O
sufficient	O
when	O
given	O
in	O
combination	O
with	O
an	O
agent	O
,	O
such	O
as	O
a	O
LHRH-A	O
,	O
that	O
lowers	O
serum	O
testosterone	O
,	O
but	O
higher	O
doses	O
of	O
bicalutamide	O
may	O
be	O
needed	O
when	O
the	O
drug	O
is	O
given	O
as	O
monotherapy	O
.	O

The	O
alternative	O
exon	O
introduces	O
the	O
novel	O
carboxyl	O
terminus	O
and	O
a	O
new	O
translation	O
stop	O
signal	O
,	O
while	O
simultaneously	O
converting	O
the	O
coding	O
sequence	O
for	O
40	O
carboxyl-terminal	O
residues	O
in	O
CeCAT	B-GENE
alpha	I-GENE
into	O
3'-untranslated	O
nucleotides	O
.	O

Studies	O
on	O
alcoholic	O
liver	O
injury	O
.	O

However	O
,	O
the	O
serum	B-GENE
TNF-a	I-GENE
concentration	O
decreased	O
significantly	O
in	O
patients	O
receiving	O
pentoxifylline	O
(	O
basal	O
623+	O
/	O
-366	O
pg	O
/	O
ml	O
;	O
6th	O
month	O
562+	O
/	O
-358	O
pg	O
/	O
ml	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
the	O
control	O
group	O
.	O

While	O
no	O
significant	O
differences	O
in	O
the	O
tensile	O
responses	O
or	O
failure	O
characteristics	O
were	O
noted	O
for	O
irradiated	O
and	O
nonirradiated	O
grafts	O
in	O
the	O
drip	O
,	O
in	O
the	O
bath	O
environment	O
the	O
nonirradiated	O
tissues	O
had	O
greater	O
strength	O
and	O
modulus	O
.	O

Isolation	O
of	O
Proteus	O
vulgaris	O
MC-63	O
from	O
carcinoma	O
63	O
and	O
its	O
antitumor	O
effect	O
on	O
Crocker	O
sarcoma	O
180	O
and	O
Ehrlich	O
carcinoma	O
.	O

Pretreatment	O
of	O
cells	O
with	O
the	O
mitogen-activated	B-GENE
protein-extracellular	I-GENE
signal-regulated	I-GENE
kinase	I-GENE
kinase	I-GENE
(	O
MEK	B-GENE
)	O
inhibitor	O
U0126	O
inhibited	O
S6K2	B-GENE
activation	O
to	O
a	O
greater	O
extent	O
than	O
S6K1	B-GENE
.	O

No	O
symptomatic	O
abnormality	O
has	O
been	O
noted	O
in	O
the	O
neonatal	O
period	O
except	O
periventricular	O
calcifications	O
.	O

The	O
differences	O
were	O
as	O
follows	O
:	O
for	O
overall	O
response	O
rate	O
p	O
=	O
0	O
.	O
004	O
;	O
power	O
(	O
for	O
p	O
=	O
0	O
.	O
05	O
)	O
85%	O
;	O
for	O
survival	O
p	O
=	O
0	O
.	O
09	O
;	O
for	O
grade	O
IV	O
granulocytopenia	O
p	O
=	O
0	O
.	O
3	O
;	O
and	O
for	O
febrile	O
neutropenia	O
p	O
=	O
0	O
.	O
61	O
.	O

The	O
N-terminal	O
amino	O
acid	O
sequence	O
of	O
Mop	B-GENE
has	O
sequence	O
homology	O
with	O
DNA	O
binding	O
proteins	O
.	O

A	O
catalytic	O
domain	O
of	O
eukaryotic	B-GENE
DNA	I-GENE
topoisomerase	I-GENE
I	O
.	O

Nutritional	O
status	O
in	O
adults	O
on	O
an	O
alternative	O
or	O
traditional	O
diet	O
BACKGROUND	O
:	O
Plant	O
food	O
lacks	O
vitamin	O
B12	O
,	O
vitamin	O
D	O
and	O
higher	O
n-3	O
polyunsaturated	O
fatty	O
acids	O
.	O

Thus	O
,	O
the	O
effects	O
of	O
father	O
absence	O
under	O
routine	O
conditions	O
in	O
relatively	O
healthy	O
samples	O
may	O
exert	O
no	O
significant	O
effects	O
independent	O
of	O
intervening	O
family	O
stressors	O
or	O
maternal	O
psychopathology	O
.	O

Common	O
foot	O
pathologies	O
are	O
heel	O
pain	O
,	O
metatarsalgia	O
,	O
hammertoes	O
and	O
clawtoes	O
,	O
bunions	O
,	O
hallux	O
rigidus	O
,	O
corns	O
and	O
calluses	O
,	O
nail	O
pathologies	O
,	O
arthritis	O
,	O
and	O
neuropathies	O
.	O

Using	O
an	O
oligomer	O
duplex	O
5'-A	B-GENE
(	I-GENE
GGGTTA	I-GENE
)	I-GENE
(	I-GENE
5	I-GENE
)	I-GENE
-3'	I-GENE
/	I-GENE
5'-	I-GENE
(	I-GENE
TAACCC	I-GENE
)	I-GENE
(	I-GENE
5	I-GENE
)	I-GENE
T-3'	I-GENE
as	O
a	O
template-primer	O
,	O
we	O
show	O
that	O
both	O
the	O
Klenow	B-GENE
fragment	I-GENE
of	I-GENE
Escherichia	I-GENE
coli	I-GENE
DNA	I-GENE
polymerase	I-GENE
I	I-GENE
and	O
HIV	B-GENE
reverse	I-GENE
transcriptase	I-GENE
could	O
expand	O
telomere	O
DNA	O
sequences	O
as	O
well	O
,	O
giving	O
products	O
greater	O
than	O
the	O
size	O
of	O
the	O
template	O
DNA	O
.	O

VIII	O
in	O
doses	O
2-3	O
times	O
higher	O
than	O
usually	O
used	O
in	O
haemophiliacs	O
without	O
inhibitor	O
were	O
successful	O
.	O

Endotoxemia	O
induced	O
by	O
gram-negative	O
bacteria	O
leads	O
to	O
endotoxic	O
shock	O
pathogenetically	O
stemming	O
from	O
the	O
integral	O
component	O
of	O
the	O
bacterial	O
wall--lipid	O
A	O
.	O

Constitutive	O
phosphorylation	O
of	O
the	O
CD30v	B-GENE
protein	I-GENE
was	O
demonstrated	O
by	O
in	O
vitro	O
labeling	O
with	O
[	O
32P	O
]	O
.	O

Baseline	O
BMD	O
values	O
were	O
significantly	O
lower	O
in	O
the	O
oligo-amenorrheic	O
group	O
than	O
in	O
the	O
two	O
others	O
at	O
the	O
level	O
of	O
lumbar	O
spine	O
(	O
anteroposterior	O
view	O
:	O
0	O
.	O
941+	O
/	O
-0	O
.	O
039	O
in	O
oligo-amenorrheic	O
vs	O
1	O
.	O
077+	O
/	O
-0	O
.	O
029	O
or	O
1	O
.	O
051	O
+	O
/	O
-0	O
.	O
017	O
g	O
x	O
cm	O
(	O
-2	O
)	O
,	O
P	O
<	O
0	O
.	O
005	O
,	O
in	O
the	O
eumenorrheic	O
and	O
contraceptive	O
user	O
groups	O
,	O
respectively	O
)	O
but	O
not	O
in	O
weight-bearing	O
bone	O
such	O
as	O
proximal	O
and	O
midshaft	O
femur	O
.	O

Antithrombin	B-GENE
III	I-GENE
(	O
AT	B-GENE
III	I-GENE
)	O
is	O
a	O
plasma	O
protein	O
which	O
acts	O
as	O
the	O
principal	O
inhibitor	O
of	O
thrombin	B-GENE
and	O
is	O
a	O
major	O
modulator	O
of	O
intravascular	O
coagulation	O
.	O

The	O
effects	O
of	O
cardioselective	O
beta-1	O
adrenergic	O
agonist	O
,	O
1-	O
(	O
4-hydroxyphenoxy	O
)	O
-isopropylamino-2-propanol	O
)	O
,	O
i	O
.	O
e	O
.	O
,	O
prenalterol	O
,	O
were	O
examined	O
on	O
direct	O
and	O
continuous	O
measurements	O
of	O
left	O
ventricular	O
(	O
LV	O
)	O
pressure	O
,	O
diameter	O
,	O
dP	O
/	O
dt	O
,	O
velocity	O
of	O
shortening	O
,	O
arterial	O
pressure	O
,	O
iliac	O
blood	O
flow	O
and	O
heart	O
rate	O
in	O
10	O
conscious	O
dogs	O
.	O

These	O
defects	O
no	O
doubt	O
impair	O
the	O
folding	O
and	O
configuration	O
necessary	O
for	O
normal	O
processing	O
of	O
the	O
AVP	B-GENE
gene	I-GENE
precursor	I-GENE
.	O

The	O
results	O
presented	O
here	O
show	O
that	O
AR1	B-GENE
of	O
the	O
promoter-proximal	O
CAP	B-GENE
subunit	I-GENE
was	O
required	O
for	O
papBA	B-GENE
transcription	O
even	O
in	O
the	O
absence	O
of	O
the	O
histone-like	B-GENE
protein	I-GENE
H-NS	B-GENE
.	O

In	O
Ka13	O
cells	O
,	O
CoCl	O
(	O
2	O
)	O
stimulated	O
expression	O
of	O
a	O
luciferase	B-GENE
reporter	I-GENE
gene	I-GENE
under	O
the	O
control	O
of	O
a	O
15-kilobase	B-GENE
pair	I-GENE
mouse	I-GENE
ho-1	I-GENE
promoter	I-GENE
(	O
pHO15luc	B-GENE
)	O
.	O

Hybridization	O
data	O
indicate	O
that	O
6F6	B-GENE
.	I-GENE
2	I-GENE
corresponds	O
to	O
the	O
previously	O
characterized	O
m6F6	B-GENE
cDNA	I-GENE
clone	I-GENE
and	O
that	O
6F6	B-GENE
.	I-GENE
1	I-GENE
and	O
6F6	B-GENE
.	I-GENE
3	I-GENE
,	O
but	O
not	O
6F6	B-GENE
.	I-GENE
2	I-GENE
,	O
are	O
adjacent	O
to	O
alpha-type	B-GENE
genes	I-GENE
.	O

Neither	O
ethanol	O
nor	O
estrogen	O
has	O
been	O
shown	O
to	O
cause	O
UROD-deficiency	O
in	O
animals	O
.	O

The	O
test	O
was	O
not	O
performed	O
in	O
3923	O
patients	O
because	O
of	O
contraindications	O
.	O

The	O
viral	B-GENE
oncoprotein	I-GENE
E1A	I-GENE
inhibits	O
NFAT-dependent	O
transactivation	O
in	O
a	O
p300-dependent	O
manner	O
.	O

EEG	O
theta	O
waves	O
and	O
psychological	O
phenomena	O
:	O
a	O
review	O
and	O
analysis	O
.	O

Correlation	O
between	O
intraocular	O
involvement	O
and	O
systemic	O
outcome	O
was	O
poor	O
.	O

Health	O
:	O
an	O
integrative	O
reticulum	O
.	O

Genomic	O
DNA	O
clones	O
containing	O
the	O
T-cell-specific	B-GENE
human	I-GENE
MAL	I-GENE
gene	I-GENE
were	O
isolated	O
.	O

Hematopoietic	B-GENE
growth	I-GENE
factors	I-GENE
have	O
already	O
had	O
an	O
enormous	O
impact	O
on	O
transfusion	O
practice	O
by	O
eliminating	O
or	O
reducing	O
the	O
need	O
for	O
red	O
blood	O
cell	O
transfusions	O
in	O
a	O
variety	O
of	O
anemic	O
states	O
characterized	O
by	O
an	O
absolute	O
or	O
relative	O
decrease	O
in	O
erythropoietin	B-GENE
.	O

Increased	O
blood	O
pressure	O
during	O
CyA	O
treatment	O
was	O
independent	O
of	O
circulating	O
ET-1	B-GENE
levels	O
.	O

An	O
NF1-related	B-GENE
vitellogenin	I-GENE
activator	I-GENE
element	I-GENE
mediates	O
transcription	O
from	O
the	O
estrogen-regulated	O
Xenopus	B-GENE
laevis	I-GENE
vitellogenin	I-GENE
promoter	I-GENE
.	O

Engagement	O
of	O
human	B-GENE
CD2	I-GENE
by	O
mitogenic	O
pairs	O
of	O
anti-CD2	B-GENE
mAb	I-GENE
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
number	O
of	O
intracellular	O
proteins	O
including	O
a	O
120	O
kDa	O
phosphoprotein	O
that	O
we	O
identify	O
as	O
the	O
proto-oncogene	B-GENE
c-Cbl	I-GENE
.	O

As	O
an	O
extension	O
of	O
our	O
structural	O
characterization	O
of	O
the	O
exon-intron	O
organization	O
of	O
the	O
mouse	B-GENE
Pkr	I-GENE
gene	I-GENE
,	O
we	O
now	O
have	O
isolated	O
and	O
characterized	O
the	O
mouse	B-GENE
Pkr	I-GENE
promoter	I-GENE
region	I-GENE
required	O
for	O
IFN-inducible	O
transcription	O
.	O

Therefore	O
the	O
binding	O
sites	O
for	O
liver-enriched	O
factors	O
,	O
present	O
in	O
the	O
hamster	B-GENE
CYP7A1	I-GENE
proximal	I-GENE
promoter	I-GENE
in	O
close	O
vicinity	O
and	O
conserved	O
between	O
species	O
,	O
constitute	O
a	O
regulatory	O
unit	O
important	O
for	O
basal	O
hepatic	O
expression	O
and	O
tissue	O
restriction	O
of	O
the	O
action	O
of	O
hormones	O
such	O
as	O
insulin	B-GENE
.	O

I	O
.	O

Although	O
antisperm	B-GENE
antibodies	I-GENE
are	O
associated	O
with	O
infertility	O
,	O
many	O
hospital	O
laboratories	O
do	O
not	O
test	O
for	O
these	O
antibodies	O
.	O

We	O
demonstrated	O
that	O
,	O
under	O
serum-starved	O
conditions	O
,	O
KMS-11	O
and	O
OPM-2	O
cells	O
express	O
appreciable	O
levels	O
of	O
phosphorylated	O
FGFR3	B-GENE
mutants	I-GENE
indicating	O
a	O
constitutive	O
activation	O
of	O
the	O
Y373C	B-GENE
and	O
K650E	B-GENE
receptors	I-GENE
;	O
the	O
addition	O
of	O
the	O
aFGF	B-GENE
ligand	I-GENE
further	O
increased	O
the	O
level	O
of	O
receptor	O
phosphorylation	O
.	O

Is	O
desensitization'	O
for	O
ragweed	O
hay	O
fever	O
immunologically	O
specific	O
?	O

Here	O
we	O
show	O
that	O
calpeptin	B-GENE
inhibits	O
tyrosine	B-GENE
phosphatases	I-GENE
,	O
enhancing	O
tyrosine	O
phosphorylation	O
particularly	O
of	O
paxillin	B-GENE
.	O

We	O
show	O
here	O
that	O
the	O
LIM	B-GENE
domain	I-GENE
homeobox	B-GENE
protein	I-GENE
isl-1	B-GENE
activates	O
the	O
rat	B-GENE
amylin	I-GENE
promoter	I-GENE
in	O
both	O
fibroblast	O
and	O
islet	O
cell	O
lines	O
.	O

The	O
ability	O
of	O
spt2	B-GENE
mutations	I-GENE
to	O
suppress	O
the	O
transcriptional	O
interference	O
caused	O
by	O
the	O
delta	B-GENE
promoter	I-GENE
insertion	I-GENE
his-4-912	I-GENE
delta	I-GENE
correlates	O
with	O
an	O
increase	O
in	O
wild-type	B-GENE
HIS4	I-GENE
mRNA	I-GENE
levels	O
.	O

The	O
Pro-258--	O
>	O
Leu	O
(	O
P258L	O
)	O
mutation	O
caused	O
constitutive	O
receptor	O
signaling	O
that	O
was	O
equivalent	O
to	O
about	O
45%	O
of	O
the	O
maximum	O
level	O
observed	O
in	O
wild-type	O
cells	O
stimulated	O
with	O
alpha-factor	B-GENE
.	O

The	O
proportion	O
of	O
the	O
biopsies	O
found	O
to	O
be	O
seropositive	O
for	O
HBs	O
antigen	O
was	O
27	O
.	O
9%	O
,	O
and	O
these	O
showed	O
either	O
MGN	O
or	O
MPGN	O
pattern	O
.	O

A	O
sterol-regulated	B-GENE
protease	I-GENE
initiates	O
release	O
of	O
the	O
NH2-terminal	O
segments	O
of	O
sterol	B-GENE
regulatory	I-GENE
element-binding	I-GENE
proteins	I-GENE
(	O
SREBPs	B-GENE
)	O
from	O
cell	O
membranes	O
,	O
thereby	O
allowing	O
them	O
to	O
enter	O
the	O
nucleus	O
and	O
to	O
stimulate	O
transcription	O
of	O
genes	O
involved	O
in	O
the	O
uptake	O
and	O
synthesis	O
of	O
cholesterol	O
and	O
fatty	O
acids	O
.	O

Initial	O
experience	O
with	O
a	O
microprocessor	O
controlled	O
current	O
based	O
defibrillator	O
.	O

The	O
following	O
technique	O
describes	O
a	O
modification	O
to	O
a	O
bar	O
superstructure	O
that	O
provided	O
the	O
advantages	O
of	O
convenience	O
,	O
security	O
,	O
and	O
consistent	O
positioning	O
even	O
though	O
one	O
implant	O
was	O
lost	O
and	O
the	O
angulation	O
of	O
implants	O
limited	O
accuracy	O
.	O

Cell	O
survival	O
by	O
Epo	B-GENE
did	O
not	O
require	O
activation	O
of	O
other	O
known	O
signaling	O
pathways	O
including	O
PI-3	B-GENE
kinase	I-GENE
,	O
PLC-gamma	B-GENE
,	O
Ras	B-GENE
or	O
Stats	B-GENE
.	O

Phase	O
II	O
study	O
of	O
paclitaxel	O
and	O
oral	O
etoposide	O
in	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
non-small	O
cell	O
lung	O
cancer	O
.	O

After	O
termination	O
of	O
medication	O
the	O
animals	O
were	O
kindled	O
electrically	O
in	O
the	O
nucleus	O
amygdala	O
.	O

Account	O
was	O
taken	O
of	O
noncellular	O
and	O
nonhuman	O
elements	O
in	O
the	O
smears	O
;	O
they	O
included	O
mucus	O
,	O
Charcot-Layden	O
crystals	O
,	O
pollen	O
grains	O
,	O
vegetal	O
fragments	O
and	O
fungi	O
.	O

We	O
have	O
now	O
identified	O
,	O
after	O
21	O
serial	O
undiluted	O
passages	O
of	O
MHV	O
,	O
a	O
small	B-GENE
DI	I-GENE
RNA	I-GENE
,	O
DIssF	B-GENE
,	O
which	O
is	O
efficiently	O
packaged	O
into	O
virions	O
.	O

No	O
homology	O
was	O
found	O
between	O
RNA14	B-GENE
and	O
RNA15	B-GENE
or	O
between	O
RNA14	B-GENE
and	O
other	O
proteins	O
contained	O
in	O
data	O
banks	O
.	O

Physical	O
principles	O
in	O
therapeutic	O
apheresis	O
.	O

E2F	B-GENE
is	O
a	O
heterodimeric	O
complex	O
consisting	O
of	O
E2F	B-GENE
family	I-GENE
members	I-GENE
(	I-GENE
1-5	I-GENE
)	I-GENE
and	O
DP	B-GENE
proteins	I-GENE
(	I-GENE
1-3	I-GENE
)	I-GENE
.	O

We	O
screened	O
a	O
K562	O
cDNA	O
library	O
and	O
identified	O
novel	O
transcripts	O
,	O
MZF1B	B-GENE
and	O
MZF1C	B-GENE
.	O

Ischemic	O
stroke	O
due	O
to	O
protein	B-GENE
C	I-GENE
deficiency	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
pre-treatment	O
with	O
coenzyme	O
Q10	O
may	O
play	O
a	O
protective	O
role	O
during	O
routine	O
vascular	O
procedures	O
requiring	O
abdominal	O
aortic	O
cross	O
clamping	O
by	O
attenuating	O
the	O
degree	O
of	O
peroxidative	O
damage	O
.	O

The	O
kinase	B-GENE
is	O
essential	O
in	O
vivo	O
for	O
normal	O
phosphorylation	O
of	O
the	O
CTD	O
and	O
for	O
normal	O
growth	O
and	O
differentiation	O
.	O

The	O
hit1-1	B-GENE
mutation	O
caused	O
a	O
defect	O
in	O
synthesis	O
of	O
a	O
74-kD	B-GENE
heat	I-GENE
shock	I-GENE
protein	I-GENE
.	O

A	O
new	O
DNA	B-GENE
repair	I-GENE
gene	I-GENE
from	I-GENE
Schizosaccharomyces	I-GENE
pombe	I-GENE
with	O
homology	O
to	O
RecA	B-GENE
was	O
identified	O
and	O
characterized	O
.	O

Recombinant	O
,	O
bacterially	O
expressed	O
PIP5KIalpha	B-GENE
possessed	O
PIP5K	B-GENE
activity	O
and	O
was	O
immunoreactive	O
with	O
erythroid	B-GENE
PIP5KI	I-GENE
antibodies	I-GENE
.	O

After	O
transfection	O
,	O
specific	O
TSH	B-GENE
beta	I-GENE
promoter	I-GENE
activity	O
was	O
evident	O
in	O
both	O
TRH-responsive	O
pituitary-derived	O
GH3	O
and	O
primary	O
pituitary	O
cell	O
cultures	O
.	O

The	O
results	O
show	O
that	O
ROS	O
production	O
by	O
viable	O
spermatozoa	O
is	O
highly	O
correlated	O
with	O
the	O
concentration	O
of	O
PMN	B-GENE
elastase	I-GENE
and	O
the	O
number	O
of	O
both	O
peroxidase-positive	O
and	O
round	O
cells	O
.	O

Recombinant	O
unr	B-GENE
acts	O
synergistically	O
with	O
recombinant	O
PTB	B-GENE
to	O
stimulate	O
translation	O
dependent	O
on	O
the	O
rhinovirus	O
IRES	O
.	O

GATA-1	B-GENE
mRNA	I-GENE
was	O
present	O
in	O
equivalent	O
levels	O
in	O
both	O
erythroid	O
cell	O
lines	O
,	O
but	O
at	O
a	O
low	O
level	O
in	O
FDC-P1	O
cells	O
.	O

DNA	O
sequence	O
and	O
evolution	O
of	O
the	O
CPS	B-GENE
domain	I-GENE
of	O
the	O
Syrian	B-GENE
hamster	I-GENE
multifunctional	I-GENE
protein	I-GENE
CAD	I-GENE
.	O

The	O
short-term	O
synthesis	O
and	O
infant-regulated	O
removal	O
of	O
milk	O
in	O
lactating	O
women	O
.	O

Together	O
,	O
these	O
data	O
support	O
a	O
model	O
in	O
which	O
Tax	B-GENE
anchors	O
CBP	B-GENE
to	O
the	O
HTLV-1	B-GENE
promoter	I-GENE
,	O
with	O
strong	O
transcriptional	O
activation	O
resulting	O
from	O
the	O
CBP-associated	O
activities	O
of	O
nucleosome	O
remodeling	O
and	O
recruitment	O
of	O
the	O
general	O
transcription	O
machinery	O
.	O

ORF	B-GENE
E8	I-GENE
colinear	O
with	O
ORF	B-GENE
E6	I-GENE
,	O
which	O
could	O
generate	O
a	O
50-amino-acid	O
protein	O
with	O
a	O
hydrophobic	O
segment	O
,	O
did	O
not	O
transform	O
cells	O
when	O
cloned	O
into	O
the	O
pZipNeo	O
vector	O
.	O

Rep-Rep	B-GENE
protein	I-GENE
interaction	O
was	O
confirmed	O
in	O
vitro	O
through	O
coimmunoprecipitation	O
experiments	O
with	O
a	O
bacterially	O
expressed	O
maltose-binding	B-GENE
protein-Rep78	I-GENE
fusion	I-GENE
protein	I-GENE
in	O
combination	O
with	O
[	O
35S	O
]	O
methionine-labeled	O
Rep78	B-GENE
synthesized	O
in	O
a	O
coupled	O
in	O
vitro	O
transcription-translation	O
system	O
.	O

The	O
repression	O
domain	O
,	O
and	O
indeed	O
the	O
entire	O
Cdc68	B-GENE
protein	I-GENE
,	O
is	O
highly	O
conserved	O
,	O
as	O
shown	O
by	O
the	O
sequence	O
of	O
the	O
Cdc68	B-GENE
functional	I-GENE
homolog	I-GENE
from	O
the	O
yeast	O
Kluyveromyces	O
lactis	O
and	O
by	O
database	O
searches	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
adapter	O
Gab1	B-GENE
may	O
redirect	O
c-Met	B-GENE
signaling	O
through	O
PI3K	B-GENE
away	O
from	O
a	O
c-Akt	B-GENE
/	I-GENE
Pak1	I-GENE
cell	O
survival	O
pathway	O
.	O

(	O
2	O
)	O
Erythroid	O
32D	O
Epo1	B-GENE
cells	O
showed	O
a	O
lower	O
level	O
of	O
bulk	O
PKC	B-GENE
catalytic	O
activity	O
,	O
lacked	O
the	O
expression	O
of	O
epsilon	B-GENE
and	O
eta	B-GENE
PKC	I-GENE
isoforms	I-GENE
,	O
and	O
showed	O
a	O
weak	O
or	O
absent	O
upregulation	O
of	O
the	O
remaining	O
isoforms	O
,	O
except	O
betaI	B-GENE
,	O
upon	O
readdition	O
of	O
Epo	B-GENE
to	O
growth	O
factor-starved	O
cells	O
.	O

Downstream	O
of	O
the	O
G-A	O
anastomosis	O
,	O
the	O
RD	O
,	O
CC	O
,	O
E	O
(	O
p	O
)	O
and	O
loop	O
areas	O
were	O
significantly	O
different	O
from	O
REF	O
,	O
but	O
significantly	O
different	O
from	O
A-A	O
.	O

Secretion	O
in	O
milk	O
and	O
transplacental	O
transfer	O
of	O
two	O
iodized	O
oils	O
,	O
Lipiodol	O
UF	O
and	O
Oriodol	O
,	O
in	O
rabbits	O
.	O

Catecholamines	O
and	O
aversive	O
learning	O
:	O
a	O
review	O
.	O

S6K2	B-GENE
is	O
highly	O
homologous	O
to	O
S6K1	B-GENE
in	O
the	O
core	B-GENE
kinase	I-GENE
and	O
linker	O
regulatory	O
domains	O
but	O
differs	O
from	O
S6K1	B-GENE
in	O
the	O
N-	O
and	O
C-terminal	O
regions	O
and	O
is	O
differently	O
localized	O
primarily	O
to	O
the	O
nucleus	O
because	O
of	O
a	O
C-terminal	O
nuclear	O
localization	O
signal	O
unique	O
to	O
S6K2	B-GENE
.	O

LMP2A	B-GENE
enhances	O
Lyn	B-GENE
and	O
Syk	B-GENE
ubiquitination	O
in	O
vivo	O
in	O
a	O
fashion	O
that	O
depends	O
on	O
the	O
activity	O
of	O
Nedd4	B-GENE
family	O
members	O
and	O
correlates	O
with	O
destabilization	O
of	O
the	O
Lyn	B-GENE
tyrosine	I-GENE
kinase	I-GENE
.	O

Amyloid	B-GENE
beta-protein	I-GENE
(	O
Abeta	B-GENE
)	O
is	O
the	O
main	O
constituent	O
of	O
amyloid	O
fibrils	O
found	O
in	O
senile	O
plaques	O
and	O
cerebral	O
vessels	O
in	O
Alzheimer's	O
disease	O
(	O
AD	O
)	O
and	O
is	O
derived	O
by	O
proteolysis	O
from	O
the	O
beta-amyloid	B-GENE
precursor	I-GENE
protein	I-GENE
(	O
APP	B-GENE
)	O
.	O

Drug	O
interactions	O
have	O
been	O
found	O
with	O
drugs	O
that	O
compete	O
for	O
the	O
same	O
CYP450	B-GENE
isoenzymes	I-GENE
as	O
statins	B-GENE
.	O

The	O
Clb5	B-GENE
kinase	I-GENE
,	O
which	O
promotes	O
S	O
phase	O
,	O
remains	O
active	O
during	O
the	O
G2-phase	O
arrest	O
of	O
cells	O
of	O
the	O
parental	O
strain	O
,	O
but	O
its	O
activity	O
declines	O
rapidly	O
in	O
sim	B-GENE
mutants	I-GENE
.	O

The	O
mean	O
marginal	O
discrepancy	O
of	O
provisional	O
restorations	O
was	O
compared	O
for	O
restorations	O
fabricated	O
from	O
stone	O
,	O
low-viscosity	O
poly	O
(	O
vinyl	O
siloxane	O
)	O
,	O
and	O
medium-viscosity	O
poly	O
(	O
vinyl	O
siloxane	O
)	O
.	O

A	O
site-directed	O
R618K	B-GENE
mutation	I-GENE
in	O
the	O
Stat5	B-GENE
SH2	B-GENE
domain	I-GENE
abolished	O
the	O
phosphorylation	O
by	O
Jak2	B-GENE
,	O
while	O
deletion	O
of	O
the	O
C	O
terminus	O
led	O
to	O
Stat5	B-GENE
hyperphosphorylation	O
.	O

Another	O
putative	O
HNF3	B-GENE
site	I-GENE
in	O
close	O
apposition	O
to	O
a	O
NF1	B-GENE
/	I-GENE
CTF	I-GENE
site	I-GENE
was	O
localized	O
upstream	O
of	O
the	O
silencer-like	B-GENE
element	I-GENE
.	O

In	O
patients	O
with	O
complete	O
or	O
partial	O
remission	O
of	O
the	O
tumor	O
,	O
the	O
neopterine	O
excretion	O
dropped	O
to	O
normal	O
values	O
.	O

The	O
child	O
left	O
behind	O
.	O

With	O
respect	O
to	O
the	O
distribution	O
of	O
active	O
MREs	B-GENE
over	O
the	O
promoter	O
region	O
,	O
the	O
hMT-IIA	B-GENE
gene	I-GENE
is	O
largely	O
different	O
from	O
the	O
mouse	O
metallothionein-I	B-GENE
gene	I-GENE
,	O
suggesting	O
that	O
MRE	B-GENE
arrangement	O
is	O
not	O
an	O
important	O
factor	O
for	O
metal	O
regulation	O
.	O

Electrocardiograms	O
of	O
the	O
month	O
.	O

Symposium	O
on	O
presenile	O
spongy	O
encephalopathies	O
.	O

The	O
hIGF-I	B-GENE
gene	I-GENE
has	O
two	O
promoters	O
,	O
P1	O
and	O
P2	O
.	O

In	O
this	O
animal	O
,	O
infected	O
with	O
what	O
was	O
judged	O
previously	O
to	O
be	O
the	O
less	O
virulent	O
of	O
the	O
two	O
T	O
.	O
cruzi	O
stocks	O
used	O
(	O
'strain	O
7'	O
)	O
,	O
there	O
was	O
severe	O
myocarditis	O
,	O
with	O
myofibre	O
degeneration	O
,	O
and	O
lesions	O
of	O
the	O
oesophagus	O
.	O

Five	O
families	O
of	O
Ashkenazi	O
Jewish	O
descent	O
carried	O
the	O
185delAG	O
mutation	O
and	O
shared	O
the	O
same	O
haplotype	O
at	O
eight	O
polymorphic	O
markers	O
spanning	O
approximately	O
850	O
kb	O
at	O
BRCA1	B-GENE
.	O

3	O
)	O
and	O
one	O
distal	O
(	O
-11	O
.	O
8	O
/	O
-10	O
.	O
9	O
)	O
,	O
presented	O
an	O
enhancer	O
activity	O
in	O
pituitary	O
cells	O
when	O
placed	O
upstream	O
of	O
the	O
SV40	O
promoter	O
.	O

RESULTS	O
:	O
There	O
is	O
a	O
considerable	O
amount	O
of	O
variation	O
between	O
the	O
results	O
of	O
TRA1	O
and	O
TRA2	O
and	O
between	O
the	O
results	O
of	O
both	O
TRA's	O
and	O
the	O
door-to-door	O
survey	O
.	O

Clinical	O
use	O
of	O
absorbable	O
polyglycolic	O
acid	O
suture	O
in	O
Blalock-Taussig's	O
operation	O
.	O

The	O
standard	O
dosage	O
of	O
anti-D	B-GENE
currently	O
given	O
at	O
all	O
gestational	O
ages	O
is	O
1	O
ampoule	O
containing	O
125	O
micrograms	O
of	O
anti-D	B-GENE
.	O

3'-Methyl	O
,	O
8-methyl	O
,	O
and	O
8-phenyl	O
derivatives	O
of	O
5	O
,	O
9-dimethyl-6	O
,	O
7-benzomorphans	O
.	O

Mean	O
ROI-A	O
/	O
B	O
ratio	O
was	O
49	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
7%	O
in	O
the	O
diabetic	O
group	O
,	O
significantly	O
lower	O
than	O
the	O
57	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
6%	O
at	O
the	O
nondiabetic	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

Recovery	O
of	O
carbimazole-induced	O
agranulocytosis	O
following	O
recombinant	B-GENE
granulocyte-macrophage	I-GENE
colony	I-GENE
stimulating	I-GENE
factor	I-GENE
(	O
rhGM-CSF	B-GENE
)	O
administration	O
.	O

This	O
locus	O
maps	O
approximately	O
160	O
kbp	O
from	O
the	O
genes	O
encoding	O
cytadherence-associated	O
proteins	O
HMW1	B-GENE
and	O
HMW3	B-GENE
,	O
and	O
yet	O
insertions	O
therein	O
result	O
in	O
loss	O
of	O
these	O
proteins	O
and	O
a	O
hemadsorption-negative	O
(	O
HA-	O
)	O
phenotype	O
,	O
prompting	O
the	O
designation	O
cytadherence-regulatory	B-GENE
locus	I-GENE
(	O
crl	B-GENE
)	O
.	O

The	O
effect	O
of	O
diffusion	O
limitation	O
was	O
quantified	O
in	O
terms	O
of	O
the	O
ratio	O
O2	O
uptake	O
/	O
O2	O
requirement	O
(	O
=	O
fraction	O
of	O
cross-sectional	O
area	O
supplied	O
with	O
O2	O
)	O
,	O
assuming	O
local	O
O2	O
requirement	O
per	O
unit	O
volume	O
to	O
be	O
constant	O
and	O
independent	O
of	O
PO2	O
at	O
PO2	O
greater	O
than	O
0	O
.	O

Analysis	O
of	O
intragenic	O
revertants	O
shows	O
that	O
this	O
function	O
depends	O
on	O
the	O
amino	O
acid	O
preceding	O
the	O
first	O
cysteine	O
residue	O
of	O
the	O
DNA-binding	O
domain	O
of	O
Hap1p	B-GENE
.	O

Here	O
we	O
investigate	O
the	O
role	O
of	O
c-Cbl	B-GENE
in	O
development	O
and	O
homeostasis	O
in	O
mice	O
by	O
targeted	O
disruption	O
of	O
the	O
c-Cbl	B-GENE
locus	I-GENE
.	O
c-Cbl-deficient	O
mice	O
were	O
viable	O
,	O
fertile	O
,	O
and	O
outwardly	O
normal	O
in	O
appearance	O
.	O

Acoust	O
.	O

The	O
modification	O
of	O
P32	O
uptake	O
into	O
the	O
Jensen	O
sarcoma	O
in	O
vitro	O
by	O
adding	O
of	O
peroxide	O
to	O
the	O
nutritive	O
medium	O
.	O

Detailed	O
molecular	O
organization	O
of	O
the	O
coding	O
and	O
upstream	O
regulatory	O
regions	O
of	O
the	O
murine	O
homeodomain-containing	O
gene	O
,	O
Msx-1	B-GENE
,	O
is	O
reported	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
mammalian	B-GENE
AMP-activated	I-GENE
protein	I-GENE
kinase	I-GENE
(	O
AMPK	B-GENE
)	O
plays	O
a	O
role	O
in	O
protecting	O
cells	O
from	O
stresses	O
that	O
cause	O
ATP	O
depletion	O
by	O
switching	O
off	O
ATP-consuming	O
biosynthetic	O
pathways	O
.	O

Studies	O
are	O
necessary	O
to	O
assess	O
the	O
source	O
of	O
contamination	O
and	O
potential	O
role	O
of	O
MRSA-contaminated	O
milk	O
in	O
the	O
transmission	O
of	O
MRSA	O
to	O
neonates	O
.	O

A	O
suspected	O
new	O
storage	O
disease	O
in	O
cattle	O
.	O

Reduced	O
NK	O
activity	O
correlates	O
with	O
active	O
disease	O
in	O
HIV-	O
patients	O
with	O
multidrug-resistant	O
pulmonary	O
tuberculosis	O
.	O

These	O
results	O
indicate	O
that	O
evaluation	O
of	O
exposure	O
to	O
S	O
.	O
neurona	O
by	O
WB	O
analysis	O
of	O
serum	O
may	O
be	O
misleading	O
in	O
young	O
horses	O
.	O

Because	O
of	O
the	O
probable	O
causal	O
relationship	O
between	O
constitutive	O
p210	B-GENE
(	I-GENE
bcr	I-GENE
/	I-GENE
abl	I-GENE
)	I-GENE
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
activity	O
and	O
manifestations	O
of	O
chronic-phase	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
;	O
myeloid	O
expansion	O
)	O
,	O
a	O
key	O
goal	O
is	O
to	O
identify	O
relevant	O
p210	B-GENE
substrates	O
in	O
primary	O
chronic-phase	O
CML	O
hematopoietic	O
progenitor	O
cells	O
.	O

The	O
PC2	B-GENE
protein	I-GENE
also	O
shows	O
great	O
similarity	O
to	O
the	O
incomplete	O
NH2-terminal	O
sequence	O
of	O
the	O
human	B-GENE
furin	I-GENE
gene	I-GENE
product	I-GENE
,	O
a	O
putative	O
membrane-inserted	O
receptor-like	O
molecule	O
.	O

Difficulties	O
bound	O
to	O
measuring	O
of	O
sputum	O
viscosity	O
.	O

Whether	O
or	O
not	O
there	O
are	O
sequences	O
conferring	O
cAMP	O
responsiveness	O
which	O
are	O
common	O
both	O
to	O
P-450scc	B-GENE
and	O
the	O
other	O
steroidogenic	O
P-450	B-GENE
genes	I-GENE
remains	O
to	O
be	O
established	O
.	O

We	O
have	O
also	O
tested	O
Src	B-GENE
SH2	I-GENE
mutants	I-GENE
for	O
their	O
binding	O
properties	O
and	O
have	O
interpreted	O
our	O
results	O
in	O
light	O
of	O
the	O
recent	O
crystal	O
structure	O
solution	O
for	O
the	O
Src	B-GENE
SH2	I-GENE
domain	I-GENE
.	O

This	O
protein	O
encoded	O
by	O
this	O
cDNA	O
,	O
which	O
we	O
have	O
termed	O
p150TSP	B-GENE
(	O
for	O
TPR-containing	B-GENE
,	I-GENE
SH2-binding	I-GENE
phosphoprotein	I-GENE
)	O
,	O
is	O
located	O
predominantly	O
in	O
the	O
nucleus	O
and	O
is	O
highly	O
conserved	O
in	O
evolution	O
.	O

We	O
linked	O
hypersensitivity	B-GENE
site	I-GENE
2	I-GENE
(	O
HS2	B-GENE
)	O
from	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
to	O
a	O
A	B-GENE
gamma-globin	I-GENE
gene	O
(	O
A	B-GENE
gamma*	I-GENE
)	O
mutationally	O
marked	O
to	O
allow	O
its	O
transcript	O
to	O
be	O
distinguished	O
from	O
endogenous	O
gamma-globin	B-GENE
mRNA	O
.	O

In	O
controls	O
,	O
only	O
modest	O
differences	O
were	O
observed	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
sequence	O
match	O
between	O
enhancers	O
and	O
certain	O
promoter	O
elements	O
is	O
critical	O
.	O

A	O
conserved	O
role	O
for	O
L1	B-GENE
as	O
a	O
transmembrane	O
link	O
between	O
neuronal	O
adhesion	O
and	O
membrane	O
cytoskeleton	O
assembly	O
.	O

The	O
most	O
frequent	O
causes	O
of	O
the	O
meningitis	O
was	O
the	O
external	O
ventricular	O
drainage	O
(	O
14	O
.	O
8%	O
)	O
,	O
post-neurosurgical	O
(	O
0	O
.	O
8%	O
)	O
and	O
head	O
injury	O
(	O
0	O
.	O
0007%	O
)	O
.	O

Cicatricial	O
pemphigoid	O
is	O
an	O
autoimmune	O
systemic	O
disease	O
characterized	O
by	O
chronic	O
conjunctival	O
cicatrization	O
.	O

1	O
.	O

We	O
conclude	O
that	O
the	O
alpha-subunit	O
of	O
the	O
telomere-binding	B-GENE
protein	I-GENE
,	O
like	O
many	O
transcription	O
factors	O
,	O
has	O
separable	O
DNA-binding	O
and	O
protein-protein	O
interaction	O
domains	O
.	O

In	O
the	O
electrophoresis	O
mobility	O
shift	O
assay	O
using	O
nuclear	O
extracts	O
of	O
the	O
myogenic	O
cells	O
,	O
MyoD	B-GENE
and	O
myogenin	B-GENE
bound	O
to	O
the	O
right	O
E-box	O
in	O
the	O
enhancer	O
region	O
of	O
the	O
MCK	B-GENE
gene	I-GENE
even	O
in	O
the	O
presence	O
of	O
BMP-2	B-GENE
.	O

The	O
reduced	O
rate	O
of	O
F	O
absorption	O
and	O
slower	O
rise	O
in	O
plasma	O
F	O
concentration	O
accompanying	O
delayed	O
gastric	O
emptying	O
indicate	O
that	O
passage	O
of	O
F	O
into	O
the	O
small	O
intestine	O
is	O
the	O
major	O
factor	O
in	O
rapid	O
F	O
absorption	O
.	O

1	O
,	O
3-bis	O
(	O
2-chloroethyl	O
)	O
-1-nitrosourea	O
(	O
bcnu	O
)	O
and	O
other	O
nitrosoureas	O
in	O
cancer	O
treatment	O
:	O
a	O
review	O
.	O

9	O
,	O
1498-1506	O
)	O
.	O

Therefore	O
,	O
to	O
understand	O
how	O
ErbB1	B-GENE
/	I-GENE
ErbB2	I-GENE
signaling	O
contributes	O
to	O
this	O
process	O
,	O
we	O
used	O
the	O
ErbB	B-GENE
kinase	I-GENE
inhibitor	O
AG1478in	O
ErbB2-dependent	O
BT-474	O
and	O
SKBR-3	O
human	O
breast	O
cancer	O
cells	O
.	O

Infants	O
who	O
died	O
in	O
the	O
first	O
12	O
hours	O
from	O
'IVH	O
only'	O
had	O
suffered	O
severe	O
birth	O
asphyxia	O
but	O
in	O
those	O
who	O
died	O
later	O
the	O
main	O
symptom	O
was	O
recurrent	O
apnoea	O
.	O

Various	O
treatment	O
modalities	O
are	O
reviewed	O
in	O
the	O
context	O
of	O
the	O
psychology	O
as	O
well	O
as	O
the	O
physiology	O
of	O
severe	O
intractable	O
pain	O
.	O

When	O
vascular	O
pressure	O
(	O
Pvas	O
)	O
was	O
raised	O
abruptly	O
from	O
-5	O
to	O
+25	O
cmH2O	O
by	O
air	O
inflation	O
for	O
60	O
min	O
,	O
Px	O
(	O
f	O
)	O
became	O
abruptly	O
less	O
negative	O
,	O
then	O
remained	O
stable	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
beta-catenin	B-GENE
interacted	O
directly	O
with	O
the	O
RA	B-GENE
receptor	I-GENE
(	O
RAR	B-GENE
)	O
in	O
a	O
retinoid-dependent	O
manner	O
,	O
but	O
not	O
with	O
the	O
retinoid	B-GENE
X	I-GENE
receptor	I-GENE
(	O
RXR	B-GENE
)	O
,	O
and	O
RAR	B-GENE
competed	O
with	O
TCF	B-GENE
for	O
beta-catenin	B-GENE
binding	O
.	O

Measurement	O
of	O
anti-HCV	B-GENE
IgM	I-GENE
antibodies	I-GENE
with	O
an	O
experimental	O
kit	O
.	O

In	O
three	O
cases	O
(	O
21	O
.	O
4%	O
)	O
,	O
the	O
MR	O
imaging	O
was	O
interpreted	O
as	O
negative	O
,	O
but	O
microscopic	O
tumor	O
was	O
shown	O
around	O
seroma	O
on	O
reexcision	O
.	O

In	O
both	O
settings	O
,	O
it	O
can	O
be	O
phosphorylated	O
by	O
cyclin	B-GENE
D-dependent	I-GENE
kinases	I-GENE
,	O
suggesting	O
that	O
its	O
transcriptional	O
activity	O
may	O
normally	O
be	O
regulated	O
through	O
such	O
mechanisms	O
.	O

Protein	B-GENE
phosphatase	I-GENE
2A	I-GENE
is	O
a	O
critical	O
regulator	O
of	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
zeta	I-GENE
signaling	O
targeted	O
by	O
SV40	B-GENE
small	I-GENE
t	I-GENE
to	O
promote	O
cell	O
growth	O
and	O
NF-kappaB	B-GENE
activation	O
.	O

The	O
homology	O
to	O
v-mil	B-GENE
starts	O
within	O
the	O
coding	O
sequence	O
of	O
exon	O
1	O
and	O
ends	O
within	O
the	O
3'	O
untranslated	O
region	O
of	O
exon	O
11	O
,	O
12	O
nucleotides	O
downstream	O
from	O
the	O
nonsense	O
codon	O
terminating	O
the	O
large	O
open	O
reading	O
frame	O
shared	O
between	O
c-mil	B-GENE
and	O
v-mil	B-GENE
.	O

DESIGN	O
:	O
Retrospective	O
study	O
.	O

The	O
R2	O
between	O
MFI	O
of	O
fresh	O
and	O
frozen	O
muscle	O
was	O
0	O
.	O
94	O
and	O
0	O
.	O
92	O
for	O
lamb	O
and	O
pork	O
longissimus	O
,	O
respectively	O
.	O

Riboflavin	O
did	O
not	O
affect	O
the	O
percentage	O
of	O
aflatoxin-treated	O
animals	O
with	O
abnormal	O
urinary	O
excretion	O
patterns	O
,	O
but	O
did	O
increase	O
the	O
magnitude	O
of	O
the	O
disturbances	O
in	O
elimination	O
of	O
kynurenic	O
and	O
xanthurenic	O
acids	O
.	O

The	O
spectrum	O
of	O
age-associated	O
brain	O
abnormalities	O
:	O
their	O
measurement	O
and	O
histopathological	O
correlates	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
explored	O
in	O
some	O
detail	O
,	O
specifically	O
as	O
it	O
relates	O
to	O
reticuloendothelial	O
system	O
(	O
RES	O
)	O
Fc	B-GENE
receptor	I-GENE
blockade	O
and	O
suppression	O
of	O
antiplatelet	O
antibody	O
synthesis	O
.	O

During	O
this	O
period	O
,	O
administration	O
of	O
additional	O
exogenous	B-GENE
PRL	I-GENE
did	O
not	O
stimulate	O
further	O
activation	O
(	O
binding	O
)	O
of	O
the	O
Stat	B-GENE
factors	I-GENE
.	O

Differential	O
screening	O
of	O
mitochondrial	O
cDNA	O
libraries	O
from	O
male-fertile	O
and	O
cytoplasmic	O
male-sterile	O
sugar-beet	O
reveals	O
genome	O
rearrangements	O
at	O
atp6	B-GENE
and	O
atpA	B-GENE
loci	I-GENE
.	O

ALT	B-GENE
levels	O
in	O
responders	O
were	O
lowered	O
by	O
46%	O
and	O
AST	B-GENE
levels	O
were	O
lowered	O
by	O
35%	O
after	O
12	O
weeks	O
of	O
vitamin	O
E	O
treatment	O
.	O

No	O
patient	O
had	O
a	O
history	O
of	O
excess	O
alcohol	O
intake	O
,	O
or	O
prolonged	O
intake	O
of	O
hepatotoxic	O
drugs	O
and	O
steroids	O
,	O
and	O
were	O
not	O
obese	O
or	O
malnourished	O
.	O

Chaperones	B-GENE
/	I-GENE
HSPs	I-GENE
thus	O
play	O
important	O
roles	O
within	O
cell	O
cycle	O
processes	O
.	O

Experiences	O
with	O
the	O
clinical	O
and	O
experimental	O
use	O
of	O
Urat-I	O
lithotriptor	O
.	O

Under	O
resting	O
conditions	O
,	O
activity	O
levels	O
of	O
cardiac	O
vagal	O
and	O
sympathetic	O
outflows	O
are	O
not	O
related	O
across	O
young	O
,	O
healthy	O
human	O
subjects	O
and	O
peripheral	O
interaction	O
is	O
not	O
manifest	O
between	O
the	O
autonomic	O
divisions	O
.	O

The	O
distal	O
portion	O
of	O
the	O
rat	B-GENE
insulin	I-GENE
I	I-GENE
gene	I-GENE
5'-flanking	I-GENE
DNA	I-GENE
contains	O
two	O
sequence	O
elements	O
,	O
the	O
Far	B-GENE
and	O
FLAT	B-GENE
elements	I-GENE
,	O
that	O
can	O
function	O
in	O
combination	O
,	O
but	O
not	O
separately	O
,	O
as	O
a	O
beta-cell-specific	O
transcriptional	O
enhancer	O
.	O

This	O
study	O
describes	O
a	O
new	O
MADS	B-GENE
box	I-GENE
gene	I-GENE
,	O
nmhC5	B-GENE
,	O
which	O
along	O
with	O
nmh7	B-GENE
(	O
J	O
.	O

To	O
explore	O
the	O
functional	O
significance	O
of	O
these	O
subdomains	O
in	O
PRL	B-GENE
binding	O
and	O
signal	O
transduction	O
,	O
deletion	O
mutants	O
of	O
S1	B-GENE
or	O
/	O
and	O
S2	B-GENE
subdomains	I-GENE
were	O
constructed	O
.	O

A	O
second	O
large	O
group	O
of	O
disorders	O
in	O
pregnancy	O
is	O
caused	O
by	O
effects	O
of	O
infections	O
of	O
the	O
mother	O
without	O
pathogens	O
being	O
transmitted	O
to	O
the	O
embryo	O
or	O
the	O
placenta	O
.	O

Melatonin	O
and	O
seasonality	O
:	O
filling	O
the	O
gap	O
.	O

Hantaan	O
virus	O
.	O

Our	O
laboratory	O
has	O
recently	O
identified	O
two	O
phosducin-like	B-GENE
orphan	I-GENE
proteins	I-GENE
(	O
PhLOP1	B-GENE
and	O
PhLOP2	B-GENE
)	O
that	O
lack	O
the	O
ability	O
to	O
interact	O
with	O
Gbetagamma	B-GENE
.	O

In	O
18%	O
lymphography	O
was	O
clearly	O
positive	O
and	O
CT	O
negative	O
.	O

Surprisingly	O
,	O
double	O
mutants	O
of	O
the	O
shy2-1D	B-GENE
mutant	I-GENE
with	O
the	O
phytochrome-deficient	O
mutants	O
hy2	B-GENE
,	O
hy3	B-GENE
(	I-GENE
phyB-1	I-GENE
)	I-GENE
and	O
fre1-1	B-GENE
(	I-GENE
phyA-201	I-GENE
)	I-GENE
showed	O
reduced	O
photomorphogenic	O
response	O
in	O
darkness	O
with	O
a	O
longer	O
hypocotyl	O
,	O
a	O
longer	O
inflorescence	O
stem	O
,	O
and	O
a	O
lower	O
level	O
expression	O
of	O
the	O
CAB	B-GENE
gene	I-GENE
than	O
the	O
shy2-1D	B-GENE
single	I-GENE
mutant	I-GENE
.	O

1	O
.	O

Validation	O
of	O
the	O
survey	O
of	O
work	O
styles	O
:	O
a	O
profile	O
measure	O
of	O
the	O
type	O
A	O
behaviour	O
pattern	O
.	O

During	O
the	O
CR	O
/	O
PP	O
diet	O
only	O
the	O
HS	O
subjects	O
did	O
not	O
show	O
the	O
stress-induced	O
rise	O
in	O
depression	O
,	O
decline	O
in	O
vigour	O
and	O
cortisol	O
elevation	O
that	O
they	O
showed	O
after	O
the	O
PR	O
/	O
CP	O
diet	O
.	O

Overexpression	O
of	O
RORgamma	B-GENE
has	O
been	O
shown	O
to	O
inhibit	O
T	O
cell	O
receptor-mediated	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
and	O
to	O
repress	O
the	O
induction	O
of	O
Fas-ligand	B-GENE
and	O
interleukin	B-GENE
2	I-GENE
.	O

Circularized	B-GENE
Ac	I-GENE
/	I-GENE
Ds	I-GENE
transposons	I-GENE
:	O
formation	O
,	O
structure	O
and	O
fate	O
.	O

Since	O
the	O
latter	O
is	O
very	O
small	O
for	O
physiological	O
flows	O
,	O
the	O
result	O
is	O
that	O
alpha	O
<	O
1	O
even	O
at	O
relatively	O
high	O
values	O
of	O
the	O
Reynolds	O
number	O
(	O
i	O
.	O
e	O
.	O
,	O
for	O
non-negligible	O
inertia	O
)	O
and	O
we	O
validate	O
our	O
perturbation	O
theory	O
results	O
by	O
comparison	O
with	O
a	O
numerical	O
integration	O
of	O
the	O
full	O
model	O
.	O

In	O
cases	O
of	O
1	O
degrees	O
HPT	O
,	O
the	O
plasma	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D	O
level	O
rose	O
significantly	O
in	O
all	O
cases	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
although	O
the	O
pattern	O
of	O
the	O
increase	O
was	O
not	O
uniform	O
.	O

The	O
study	O
enrolled	O
994	O
people	O
co-infected	O
with	O
CMV	O
and	O
HIV	O
,	O
with	O
at	O
least	O
one	O
CD4	B-GENE
count	O
recorded	O
<	O
100	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
l	O
.	O

UK's	O
biotechnology	O
lacking	O
specialists	O
.	O

Expression	O
of	O
a	O
dominant-negative	B-GENE
ras	I-GENE
gene	I-GENE
also	O
blocks	O
TIS10	B-GENE
/	I-GENE
PGS2	I-GENE
induction	O
by	O
v-src	B-GENE
.	O

High-affinity	O
binding	O
sites	O
for	O
both	O
GR	B-GENE
and	O
AP-1	B-GENE
nucleoproteins	I-GENE
were	O
identified	O
at	O
adjacent	O
elements	O
within	O
the	O
nGRE	B-GENE
.	O

A	O
significant	O
herd	O
X	O
period	O
interaction	O
existed	O
for	O
liver	O
TG	O
and	O
serum	O
dextran	O
precipitable	O
cholesterol	O
concentrations	O
.	O

The	O
nucleotide	O
sequence	O
of	O
3874	O
bp	O
of	O
cloned	O
R	O
.	O
sphaeroides	O
chromosomal	O
DNA	O
,	O
including	O
the	O
three	O
structural	O
genes	O
fbcF	B-GENE
,	O
fbcB	B-GENE
and	O
fbcC	B-GENE
has	O
been	O
determined	O
.	O

We	O
obtained	O
quantitative	O
evidence	O
on	O
the	O
coding	O
of	O
interaural	O
time	O
differences	O
(	O
ITDs	O
)	O
of	O
click	O
stimuli	O
by	O
40	O
single	O
neurons	O
in	O
the	O
auditory	O
cortex	O
of	O
anesthetized	O
albino	O
rats	O
.	O

Renal	O
cell	O
carcinoma	O
in	O
children	O
:	O
a	O
single	O
institution's	O
experience	O
.	O

What	O
to	O
look	O
for	O
during	O
a	O
compliance	O
review	O
:	O
10	O
common	O
mistakes	O
made	O
by	O
SNFs	O
.	O

NH2-	O
and	O
COOH-terminal	O
deletion	O
analysis	O
revealed	O
that	O
both	O
the	O
PH	B-GENE
and	O
putative	O
guanine	B-GENE
nucleotide	I-GENE
exchange	I-GENE
factor	I-GENE
domains	I-GENE
are	O
required	O
,	O
but	O
the	O
zinc	O
butterfly	O
is	O
dispensable	O
,	O
for	O
transformation	O
.	O

Following	O
chondroitinase	B-GENE
AC	I-GENE
and	O
ABC	B-GENE
digestion	O
,	O
staining	O
reactions	O
suggested	O
that	O
the	O
highest	O
levels	O
of	O
dermatan	O
sulfate	O
were	O
in	O
the	O
diabetes	O
resistant	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
compared	O
to	O
diabetic	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
compared	O
to	O
diabetes	O
prone	O
)	O
and	O
the	O
highest	O
levels	O
of	O
chondroitin	O
sulfates	O
were	O
in	O
the	O
diabetes	O
prone	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

In	O
this	O
paper	O
we	O
report	O
that	O
ligand	O
binding	O
induced	O
tyrosine	O
phosphorylation	O
in	O
BaF3	O
cells	O
engineered	O
to	O
express	O
the	O
murine	B-GENE
Mpl	I-GENE
receptor	I-GENE
(	O
BaF3	B-GENE
/	I-GENE
mMpl	I-GENE
)	O
.	O

New	O
and	O
successful	O
steps	O
have	O
been	O
made	O
in	O
immunodiagnostics	O
,	O
immunotherapy	O
,	O
and	O
immunoprophylaxis	O
of	O
immunologically	O
conditioned	O
infertility	O
.	O

Localization	O
of	O
the	O
intronless	O
gene	O
coding	O
for	O
calmodulin-like	B-GENE
protein	I-GENE
CLP	B-GENE
to	O
human	O
chromosome	O
10p13-ter	O
.	O

Sequence	O
comparison	O
between	O
the	O
translated	O
ORF	O
and	O
a	O
protein	O
database	O
reveal	O
between	O
26	O
.	O
5	O
and	O
23	O
.	O
4%	O
aa	O
sequence	O
homology	O
to	O
bacterial	B-GENE
transmembrane	I-GENE
(	I-GENE
TM	I-GENE
)	I-GENE
proteins	I-GENE
including	O
those	O
mediating	O
chloramphenicol	O
(	O
Cm	O
)	O
and	O
tetracycline	O
(	O
Tc	O
)	O
resistance	O
and	O
an	O
arabinose-proton	O
symport	O
protein	O
.	O

Uroflowmetry	O
can	O
detect	O
dysuria	O
,	O
which	O
may	O
be	O
poorly	O
perceived	O
or	O
even	O
unknown	O
to	O
the	O
subjects	O
themselves	O
.	O

Removal	O
of	O
lipid	O
fractions	O
of	O
plant	O
extractions	O
with	O
hexane	O
is	O
recommended	O
to	O
avoid	O
damage	O
to	O
the	O
HPLC	O
column	O
.	O

However	O
,	O
the	O
signaling	O
cascade	O
utilized	O
by	O
the	O
urokinase	B-GENE
receptor	I-GENE
is	O
only	O
incompletely	O
understood	O
.	O

Substrate	O
specificity	O
of	O
the	O
RNase	B-GENE
activity	O
of	O
yeast	B-GENE
RNA	I-GENE
polymerase	I-GENE
III	I-GENE
.	O

Despite	O
its	O
requirement	O
for	O
enhancer-dependent	O
splicing	O
activity	O
in	O
vitro	O
,	O
the	O
dU2AF38	B-GENE
RS	I-GENE
domain	I-GENE
was	O
also	O
inessential	O
in	O
vivo	O
.	O

The	O
rear	O
silver	O
liquid	O
chamber	O
was	O
threefold	O
thick	O
to	O
17	O
MeV	O
protons	O
in	O
water	O
and	O
it	O
efficiently	O
produced	O
either	O
13N	O
by	O
the	O
16O	O
(	O
p	O
,	O
alpha	O
)	O
13N	O
reaction	O
or	O
[	O
18F	O
]	O
fluoride	O
ion	O
by	O
the	O
18O	O
(	O
p	O
,	O
n	O
)	O
18F	O
reaction	O
.	O

Furthermore	O
,	O
analysis	O
of	O
deletion	O
promoter-reporter	O
constructs	O
found	O
that	O
the	O
basal	O
activity	O
of	O
P2	O
resided	O
in	O
the	O
proximal	O
region	O
of	O
P2	O
.	O

We	O
introduced	O
the	O
gel	O
technique	O
as	O
a	O
routine	O
assay	O
for	O
antibody	O
detection	O
and	O
identification	O
in	O
1993	O
.	O

Their	O
conduction	O
velocity	O
ranged	O
from	O
0	O
.	O
23	O
to	O
0	O
.	O
98	O
m	O
/	O
sec	O
(	O
group	O
C	O
)	O
.	O

Similar	O
results	O
were	O
seen	O
on	O
Western	O
blots	O
of	O
Autographa	O
californica	O
MNPV	O
(	O
AcMNPV	O
)	O
-infected	O
Spodoptera	O
frugiperda	O
cells	O
.	O

Fasting	O
gastrin	B-GENE
levels	O
(	O
normal	O
range	O
:	O
25-110	O
mU	O
/	O
L	O
)	O
varied	O
from	O
48	O
.	O
78	O
mU	O
/	O
L-168	O
.	O
20	O
(	O
mean	O
:	O
85	O
.	O
23	O
mU	O
/	O
L	O
)	O
.	O

CONCLUSION	O
:	O
Sonographic	O
angiography	O
has	O
a	O
possible	O
role	O
in	O
the	O
detection	O
of	O
small	O
nodules	O
in	O
patients	O
with	O
CRF	O
.	O

To	O
examine	O
transcriptional	O
regulation	O
of	O
the	O
rat	B-GENE
eIF4E	I-GENE
gene	I-GENE
,	O
2	O
.	O
1	O
kB	O
of	O
the	O
rat	B-GENE
eIF4E	I-GENE
promoter	I-GENE
region	I-GENE
was	O
cloned	O
and	O
the	O
contribution	O
of	O
specific	O
elements	O
in	O
regulating	O
transcription	O
was	O
determined	O
in	O
primary	O
cultures	O
of	O
rat	O
cardiocytes	O
and	O
in	O
a	O
murine	O
C	O
(	O
2	O
)	O
C	O
(	O
12	O
)	O
myoblast	O
cell	O
line	O
.	O

Cytochrome	B-GENE
b	I-GENE
in	O
human	B-GENE
complex	I-GENE
II	I-GENE
(	O
succinate-ubiquinone	B-GENE
oxidoreductase	I-GENE
)	O
:	O
cDNA	O
cloning	O
of	O
the	O
components	O
in	O
liver	O
mitochondria	O
and	O
chromosome	O
assignment	O
of	O
the	O
genes	O
for	O
the	O
large	O
(	O
SDHC	B-GENE
)	O
and	O
small	O
(	O
SDHD	B-GENE
)	O
subunits	O
to	O
1q21	O
and	O
11q23	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
new	O
member	O
of	O
the	O
rat	B-GENE
placental	I-GENE
prolactin	I-GENE
(	O
PRL	B-GENE
)	O
family	O
,	O
PRL-like	B-GENE
protein	I-GENE
H	O
.	O

During	O
latency	O
,	O
more	O
than	O
1%	O
of	O
neurons	O
in	O
ganglia	O
that	O
innervate	O
the	O
footpad	O
expressed	O
beta-galactosidase	B-GENE
,	O
with	O
the	O
number	O
of	O
positive	O
cells	O
remaining	O
constant	O
for	O
at	O
least	O
5	O
months	O
.	O

Using	O
a	O
novel	O
method	O
combining	O
chromatin	O
immunoprecipitation	O
and	O
genomic	O
array	O
hybridization	O
,	O
we	O
have	O
identified	O
a	O
460-kb	B-GENE
CENP-A-binding	I-GENE
DNA	I-GENE
domain	I-GENE
of	O
a	O
neocentromere	O
derived	O
from	O
the	O
20p12	O
region	O
of	O
an	O
invdup	O
(	O
20p	O
)	O
human	O
marker	O
chromosome	O
.	O

The	O
effects	O
of	O
oral	O
vanadyl	O
sulfate	O
(	O
VOSO4	O
)	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
on	O
anthropometry	O
,	O
body	O
composition	O
,	O
and	O
performance	O
were	O
investigated	O
in	O
a	O
12-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
involving	O
weight-training	O
volunteers	O
.	O

A	O
new	O
instrument	O
has	O
been	O
designed	O
for	O
freeze-fracturing	O
of	O
biological	O
material	O
in	O
ultra	O
high	O
vacuum	O
.	O

Ang	B-GENE
II	I-GENE
significantly	O
induced	O
Ang2	B-GENE
mRNA	I-GENE
accumulations	O
without	O
affecting	O
Ang1	B-GENE
or	O
Tie2	B-GENE
expression	O
,	O
which	O
was	O
inhibited	O
by	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
inhibitors	O
and	O
by	O
intracellular	O
Ca	O
(	O
2+	O
)	O
chelating	O
agents	O
.	O

Antibodies	O
against	O
this	O
purified	O
protein	O
localize	O
RIM1	B-GENE
to	O
mitochondria	O
.	O

RESULTS	O
:	O
Of	O
the	O
29	O
patients	O
who	O
received	O
concurrent	O
chemotherapy	O
and	O
G-CSF	B-GENE
,	O
ten	O
(	O
34%	O
;	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
17	O
.	O
9	O
to	O
54	O
.	O
3%	O
)	O
were	O
believed	O
to	O
have	O
clinically	O
significant	O
bleomycin	O
toxicity	O
.	O

The	O
growth	O
of	O
Aer	O
.	O
hydrophila	O
in	O
filter-sterilized	O
lettuce	O
extract	O
was	O
completely	O
inhibited	O
by	O
0	O
.	O
1%	O
(	O
v	O
/	O
v	O
)	O
BMC	O
whereas	O
that	O
of	O
Ps	O
.	O
fluorescens	O
was	O
not	O
significantly	O
affected	O
by	O
1%	O
(	O
v	O
/	O
v	O
)	O
BMC	O
.	O

Crystal	O
structure	O
of	O
an	O
oligomer	O
of	O
proteolytic	B-GENE
zymogens	I-GENE
:	O
detailed	O
conformational	O
analysis	O
of	O
the	O
bovine	O
ternary	O
complex	O
and	O
implications	O
for	O
their	O
activation	O
.	O

MSMS	O
Council	O
hears	O
new	O
public	O
health	O
director	O
.	O

Maize	B-GENE
rbcS	I-GENE
promoter	I-GENE
activity	O
depends	O
on	O
sequence	O
elements	O
not	O
found	O
in	O
dicot	B-GENE
rbcS	I-GENE
promoters	I-GENE
.	O

COUP	B-GENE
transcription	I-GENE
factor	I-GENE
is	O
a	O
member	O
of	O
the	O
steroid	B-GENE
receptor	I-GENE
superfamily	I-GENE
.	O

When	O
a	O
plateau	O
of	O
enhancement	O
was	O
reached	O
,	O
a	O
single	O
lesion	O
in	O
each	O
patient	O
was	O
imaged	O
using	O
five	O
different	O
continuous	O
scanning	O
modes	O
,	O
fundamental	O
grey	O
scale	O
(	O
FGS	O
)	O
;	O
fundamental	O
colour	O
Doppler	O
(	O
FCD	O
)	O
;	O
fundamental	O
power	O
Doppler	O
(	O
FPD	O
)	O
;	O
second	O
harmonic	O
grey	O
scale	O
(	O
HGS	O
)	O
;	O
and	O
pulse	O
inversion	O
mode	O
(	O
Pim	O
)	O
using	O
an	O
HDI5000	O
scanner	O
and	O
C5-2	O
probe	O
(	O
ATL	O
,	O
Bothell	O
,	O
WA	O
)	O
.	O

Cat	B-GENE
proteins	I-GENE
are	O
tyrosine-phosphorylated	O
when	O
co-expressed	O
in	O
cells	O
with	O
the	O
focal	B-GENE
adhesion	I-GENE
kinase	I-GENE
Fak	B-GENE
and	O
Src	B-GENE
.	O

Less	O
antibacterial	O
activity	O
was	O
shown	O
toward	O
the	O
Gram-negative	O
bacilli	O
,	O
i	O
.	O
e	O
.	O
,	O
Pseudomonas	O
,	O
Klebsiella-Enterobacter	O
,	O
Shigella	O
,	O
Escherichia	O
coli	O
,	O
Serratia	O
marcescens	O
and	O
Proteus	O
.	O

From	O
Pap	O
to	O
ApUp	O
.	O

This	O
transcriptional	O
regulation	O
occurs	O
through	O
modulation	O
of	O
the	O
forkhead	B-GENE
transcription	I-GENE
factor	I-GENE
FKHR-L1	B-GENE
,	O
and	O
IL-3	B-GENE
inhibited	O
FKHR-L1	B-GENE
activity	O
in	O
a	O
PI3K-dependent	O
manner	O
.	O

Utero-placental	O
blood	O
flow	O
and	O
the	O
effect	O
of	O
beta	B-GENE
2-adrenoceptor	I-GENE
stimulating	O
drugs	O
.	O

Intron	O
8	O
harbored	O
a	O
strong	O
erythroid-specific	O
enhancer	O
activity	O
which	O
was	O
orientation-dependent	O
.	O

Dermoid	O
cyst	O
in	O
a	O
free	O
skin	O
flap	O
as	O
the	O
complication	O
after	O
treatment	O
of	O
recurring	O
hernia	O
.	O

Hodgkin's	O
disease	O
.	O

The	O
relationship	O
between	O
the	O
rare	O
complications	O
mentioned	O
above	O
and	O
the	O
pathophysiology	O
of	O
Bartter's	O
syndrome	O
is	O
still	O
obscure	O
.	O

Examination	O
of	O
the	O
mitochondrial	B-GENE
bc1	I-GENE
complex	I-GENE
crystal	I-GENE
structure	I-GENE
[	O
Zhang	O
,	O
Z	O
.	O
,	O
Huang	O
,	O
L	O
.	O
,	O
Shulmeister	O
,	O
V	O
.	O

Sequence	O
analysis	O
of	O
the	O
sMtCK	B-GENE
genomic	I-GENE
upstream	I-GENE
sequences	I-GENE
reveals	O
a	O
typical	O
TATAA	O
box	O
within	O
the	O
80	O
base	O
pairs	O
(	O
bp	O
)	O
that	O
,	O
by	O
transfection	O
experiments	O
,	O
are	O
sufficient	O
to	O
promote	O
expression	O
of	O
chimeric	O
plasmids	O
with	O
the	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
reporter	I-GENE
.	O

Gonadal	O
dysfunction	O
in	O
patients	O
with	O
ataxia	O
telangiectasia	O
.	O

The	O
MAP	B-GENE
kinase	I-GENE
cascade	I-GENE
is	O
highly	O
conserved	O
in	O
all	O
eukaryotes	O
and	O
involved	O
in	O
numerous	O
cellular	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
indicate	O
that	O
inhibition	O
of	O
p27	B-GENE
(	I-GENE
KIP1	I-GENE
)	I-GENE
transcription	O
through	O
PI3K-induced	B-GENE
FKHR-L1	I-GENE
phosphorylation	O
provides	O
a	O
novel	O
mechanism	O
of	O
regulating	O
cytokine-mediated	O
survival	O
and	O
proliferation	O
.	O

The	O
effects	O
of	O
c-myc	B-GENE
were	O
further	O
dissected	O
by	O
showing	O
that	O
c-myc	B-GENE
can	O
inhibit	O
differentiation	O
independently	O
of	O
Id	B-GENE
,	O
a	O
negative	O
regulator	O
of	O
muscle	O
differentiation	O
.	O

Statement	O
of	O
the	O
American	O
Academy	O
of	O
Implant	O
Dentistry	O
.	O

The	O
NAUSICAA	O
system	O
gives	O
a	O
good	O
knowledge	O
of	O
LET	O
spectra	O
for	O
the	O
first	O
time	O
in	O
space	O
dosimetry	O
.	O

Other	O
adverse	O
events	O
with	O
incidences	O
significantly	O
higher	O
than	O
with	O
placebo	O
were	O
dizziness	O
,	O
constipation	O
,	O
sweating	O
,	O
nervousness	O
,	O
and	O
abnormal	O
ejaculation	O
.	O

Bacillus	O
cereus	O
cross-infection	O
in	O
a	O
maternity-unit	O
.	O

The	O
effect	O
of	O
smoking	O
was	O
not	O
examined	O
in	O
this	O
study	O
,	O
as	O
such	O
data	O
were	O
not	O
available	O
.	O

The	O
S229A	O
variant	O
can	O
better	O
flip	O
modified	O
bases	O
but	O
does	O
not	O
tightly	O
lock	O
the	O
flipped	O
base	O
into	O
the	O
adenine-binding	O
pocket	O
,	O
suggesting	O
that	O
Ser229	O
could	O
form	O
a	O
contact	O
to	O
the	O
flipped	O
adenine	O
.	O

Dynamics	O
of	O
hospital	O
stay	O
in	O
peptic	O
ulcer	O
patients	O
.	O

Characterization	O
and	O
hormonal	O
regulation	O
of	O
the	O
promoter	O
of	O
the	O
rat	B-GENE
prostaglandin	I-GENE
endoperoxide	I-GENE
synthase	I-GENE
2	I-GENE
gene	I-GENE
in	O
granulosa	O
cells	O
.	O

Cerebral	O
flow	O
and	O
resistance	O
showed	O
minor	O
reductions	O
with	O
HD	O
.	O

Losses	O
of	O
dichlofluanid	O
(	O
54%	O
)	O
,	O
chlozolinate	O
(	O
22%	O
)	O
,	O
and	O
etridiazole	O
(	O
40%	O
)	O
,	O
previously	O
reported	O
to	O
occur	O
during	O
ambient	O
processing	O
of	O
apples	O
,	O
were	O
reduced	O
to	O
barely	O
significant	O
levels	O
(	O
10	O
,	O
17	O
,	O
and	O
14%	O
,	O
respectively	O
)	O
by	O
cryogenic	O
processing	O
.	O

Further	O
studies	O
of	O
mandibular	O
movement	O
at	O
initial	O
tooth	O
contact	O
.	O

Serum	O
concentrations	O
of	O
E2	O
and	O
TBOH	O
were	O
measured	O
on	O
d	O
0	O
,	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
13	O
,	O
21	O
,	O
28	O
,	O
42	O
,	O
56	O
,	O
84	O
,	O
112	O
,	O
and	O
140	O
in	O
finishing	O
heifers	O
administered	O
the	O
following	O
treatments	O
:	O
1	O
)	O
control	O
;	O
2	O
)	O
MGA	O
,	O
.	O
5	O
mg	O
per	O
heifer	O
daily	O
;	O
3	O
)	O
Revalor-H	O
(	O
140	O
mg	O
TBA	O
+	O
14	O
mg	O
E2	O
)	O
;	O
4	O
)	O
Revalor-H	O
+	O
MGA	O
;	O
5	O
)	O
Finaplix-H	O
(	O
200	O
mg	O
TBA	O
)	O
;	O
and	O
6	O
)	O
Finaplix-H	O
+	O
MGA	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
the	O
dsRNA	O
binding	O
domains	O
may	O
be	O
composed	O
of	O
two	O
separate	O
functional	O
subdomains	O
.	O

The	O
molecular	O
basis	O
for	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	O
lineage	O
and	O
mechanisms	O
by	O
which	O
eosinophil-specific	O
genes	O
are	O
expressed	O
and	O
regulated	O
during	O
differentiation	O
is	O
unknown	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
these	O
elements	O
are	O
required	O
for	O
promoter	O
activity	O
,	O
we	O
compared	O
the	O
reporter	O
expression	O
activity	O
of	O
segments	O
containing	O
mutations	O
of	O
these	O
elements	O
with	O
activity	O
of	O
the	O
parent	B-GENE
Hlx	I-GENE
promoter	I-GENE
sequence	I-GENE
.	O

2	O
:	O
The	O
dynamic	O
moduli	O
of	O
microcrystalline	B-GENE
cellulose	I-GENE
.	O

N-Substituted	O
trimethylsilylcarbamates	O
were	O
tested	O
as	O
derivatizing	O
reagents	O
for	O
gas	O
chromatographic	O
analysis	O
.	O

Glomerular	O
lesions	O
in	O
renal	O
allografts	O
.	O

At	O
the	O
genomic	O
level	O
,	O
the	O
sequences	O
of	O
two	O
members	O
of	O
this	O
family	O
are	O
known	O
in	O
the	O
rat	O
Rattus	O
norvegicus	O
:	O
the	O
VCSA1	B-GENE
gene	I-GENE
,	O
encoding	O
the	O
prohormone-like	B-GENE
polypeptide	I-GENE
SMR1	I-GENE
,	O
and	O
the	O
VCSB1	B-GENE
gene	I-GENE
,	O
encoding	O
a	O
salivary	O
Pro-rich	O
polypeptide	O
.	O

Angiotensin	B-GENE
effect	O
in	O
the	O
human	O
kidney	O
.	O

The	O
RNA	O
genome	O
of	O
rabbit	O
hemorrhagic	O
disease	O
virus	O
(	O
RHDV	O
)	O
was	O
molecularly	O
cloned	O
.	O

We	O
have	O
introduced	O
a	O
mutation	O
(	O
Ser36	O
--	O
>	O
Asn	O
)	O
into	O
this	O
domain	O
of	O
p190	B-GENE
that	O
decreased	O
its	O
ability	O
to	O
bind	O
guanine	O
nucleotide	O
when	O
expressed	O
as	O
a	O
hemagglutinin	B-GENE
(	O
HA	B-GENE
)	O
-tagged	O
protein	O
in	O
COS	O
cells	O
.	O

Increased	O
p53	B-GENE
activity	O
induced	O
by	O
OP	O
is	O
not	O
due	O
to	O
elevated	O
p53	B-GENE
mRNA	I-GENE
nor	O
to	O
protein	O
levels	O
.	O

In	O
an	O
ongoing	O
study	O
the	O
performance	O
of	O
the	O
SMSP	O
is	O
being	O
compared	O
with	O
that	O
of	O
the	O
Mini	O
Speech	O
Processor	O
(	O
MSP	O
)	O
.	O

Tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
(	O
TNF	B-GENE
)	O
is	O
reported	O
to	O
cause	O
a	O
shock	O
syndrome	O
similar	O
to	O
that	O
produced	O
by	O
endotoxin	B-GENE
(	O
LPS	B-GENE
)	O
.	O

Phylogenetic	O
analyses	O
of	O
19	O
amino	O
acid	O
sequences	O
of	O
6	O
related	O
protein	O
types	O
indicate	O
that	O
actin-associated	O
proteins	O
related	O
to	O
gelsolin	B-GENE
are	O
monophyletic	O
to	O
a	O
common	O
ancestor	O
and	O
include	O
flightless	B-GENE
proteins	I-GENE
.	O

Whereas	O
the	O
mutant	O
enzymes	O
terminate	O
normally	O
at	O
the	O
late	O
terminator	O
in	O
T7	O
DNA	O
(	O
T	O
(	O
phi	O
)	O
)	O
and	O
rrnB	O
T2	O
,	O
they	O
fail	O
to	O
terminate	O
at	O
one	O
of	O
the	O
termination	O
sites	O
of	O
rrnB	O
T1	O
,	O
and	O
also	O
fail	O
to	O
recognize	O
the	O
PTH	B-GENE
and	O
CJ	O
signals	O
.	O

Anoxia	O
was	O
introduced	O
by	O
perfusing	O
the	O
gill	O
with	O
water	O
deprived	O
of	O
oxygen	O
or	O
by	O
halting	O
the	O
water	O
flow	O
to	O
the	O
gill	O
.	O

Alternative	O
splicing	O
of	O
ClC-6	B-GENE
(	O
a	O
member	O
of	O
the	O
CIC	B-GENE
chloride-channel	I-GENE
family	I-GENE
)	O
transcripts	O
generates	O
three	O
truncated	O
isoforms	O
one	O
of	O
which	O
,	O
ClC-6c	B-GENE
,	O
is	O
kidney-specific	O
.	O

Strategies	O
for	O
blood	O
screening	O
for	O
the	O
hepatitis	O
C	O
virus	O
and	O
for	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
high	O
risk	O
groups	O
.	O

We	O
purified	O
both	O
proteins	O
from	O
human	O
platelet	O
membranes	O
using	O
DEAE-Sepharose	O
chromatography	O
followed	O
by	O
mAb	B-GENE
F11	I-GENE
affinity	O
chromatography	O
.	O

The	O
evaluation	O
of	O
amniotic	O
fluid	O
delta	O
OD450	O
is	O
considered	O
to	O
be	O
the	O
cornerstone	O
of	O
clinical	O
management	O
.	O

5	O
)	O
Before	O
and	O
ten	O
days	O
after	O
DOTC	O
infusion	O
,	O
laboratory	O
tests	O
for	O
liver	O
and	O
renal	O
functions	O
and	O
blood	O
were	O
performed	O
.	O

A	O
recombinant	O
with	O
a	O
5'	O
end	O
from	O
src	B-GENE
and	O
a	O
3'	O
end	O
from	O
ros	B-GENE
,	O
called	O
SRC	B-GENE
x	O
ROS	B-GENE
,	O
transformed	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
to	O
a	O
spindle	O
shape	O
morphology	O
,	O
mimicking	O
that	O
of	O
UR2	B-GENE
.	O

After	O
one	O
accommodation	O
night	O
,	O
sleep	O
EEG	O
recordings	O
were	O
performed	O
during	O
three	O
consecutive	O
nights	O
in	O
ten	O
drug-free	O
inpatients	O
presenting	O
generalized	O
anxiety	O
disorder	O
(	O
GAD	O
)	O
with	O
significant	O
depression	O
,	O
compared	O
with	O
a	O
age-	O
and	O
sex-matched	O
group	O
of	O
patients	O
with	O
GAD	O
and	O
a	O
group	O
of	O
primary	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
patients	O
.	O

S6	B-GENE
kinase	I-GENE
activation	O
requires	O
displacement	O
of	O
this	O
inhibitory	O
segment	O
,	O
which	O
is	O
proposed	O
to	O
occur	O
consequent	O
to	O
its	O
multiple	O
phosphorylation	O
.	O

Thus	O
,	O
the	O
PCE	B-GENE
binds	O
a	O
Pbx	B-GENE
dimer	I-GENE
partner	I-GENE
that	O
behaves	O
unlike	O
Class	B-GENE
I	I-GENE
Hox	I-GENE
proteins	I-GENE
.	O

Most	O
recently	O
,	O
the	O
use	O
of	O
the	O
product	O
of	O
brain	O
weight	O
and	O
clearance	O
has	O
been	O
proposed	O
.	O

Purified	B-GENE
P7	I-GENE
could	O
be	O
assembled	O
onto	O
particles	O
lacking	O
P7	B-GENE
and	O
particles	O
lacking	O
both	O
P2	B-GENE
(	O
RNA	B-GENE
polymerase	I-GENE
)	O
and	O
P7	O
.	O

Deletion	O
analyses	O
of	O
the	O
pCD41	B-GENE
ORF-A	I-GENE
and	O
the	O
use	O
of	O
promoter	O
constructs	O
further	O
mapped	O
an	O
internal	O
functional	O
promoter	O
within	O
the	O
pCD41	B-GENE
sequence	I-GENE
that	O
can	O
direct	O
the	O
synthesis	O
of	O
the	O
trans-activating	O
protein	O
.	O

Reproductive	O
period	O
affects	O
water	O
intake	O
in	O
heat-stressed	O
dehydrated	O
goats	O
.	O

Our	O
data	O
suggest	O
that	O
trans-activation	O
from	O
the	O
prothymosin	B-GENE
intron	I-GENE
enhancer	I-GENE
is	O
a	O
faithful	O
reflection	O
of	O
the	O
transforming	O
properties	O
of	O
the	O
Myc	B-GENE
protein	I-GENE
.	O

The	O
mRNA	O
expression	O
of	O
RFX1	B-GENE
,	O
RFX2	B-GENE
,	O
and	O
RFX3	B-GENE
was	O
detected	O
ubiquitously	O
,	O
but	O
in	O
transient-transfection	O
assays	O
,	O
multimerized	B-GENE
RFX	I-GENE
binding	I-GENE
sites	I-GENE
in	O
front	O
of	O
a	O
basal	O
promoter	O
efficiently	O
functioned	O
in	O
a	O
tissue-	O
and	O
lineage-specific	O
manner	O
.	O

To	O
study	O
the	O
role	O
of	O
heavy	B-GENE
chain	I-GENE
motifs	I-GENE
in	O
substrate	O
recognition	O
,	O
secreted	O
variants	O
of	O
recombinant	B-GENE
bovine	I-GENE
proenteropeptidase	I-GENE
were	O
constructed	O
by	O
replacing	O
the	O
transmembrane	O
domain	O
with	O
a	O
signal	O
peptide	O
.	O

The	O
centromedial	O
amygdala	O
and	O
gastric	O
pathology	O
in	O
rats	O
.	O

The	O
p53-homolog	B-GENE
p73beta	B-GENE
also	O
activated	O
the	O
PIG3	B-GENE
promoter	I-GENE
,	O
but	O
in	O
contrast	O
to	O
p53	B-GENE
,	O
the	O
proline-rich	O
domain	O
of	O
p73beta	B-GENE
(	I-GENE
residues	I-GENE
81-113	I-GENE
)	I-GENE
was	O
dispensable	O
to	O
induce	O
the	O
PIG3	B-GENE
promoter	I-GENE
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
m-Staf	B-GENE
is	O
highly	O
homologous	O
to	O
that	O
of	O
Staf	B-GENE
,	O
another	O
selenocysteine	B-GENE
tRNA	I-GENE
gene	I-GENE
transcription	I-GENE
activating	I-GENE
factor	I-GENE
of	O
Xenopus	O
laevis	O
.	O

The	O
DRF-2	B-GENE
nuclear	I-GENE
protein	I-GENE
has	O
characteristics	O
similar	O
to	O
those	O
of	O
the	O
muscle-specific	O
regulatory	O
factor	O
,	O
MEF-2	B-GENE
(	O
Buskin	O
and	O
Hauschka	O
1989	O
;	O
Gossett	O
et	O
al	O
.	O
,	O
1989	O
)	O
.	O

Pulmonary	O
vein	O
varix	O
in	O
association	O
with	O
bilateral	O
pulmonary	O
vein	O
stenosis	O
.	O

RESULTS	O
:	O
At	O
the	O
beginning	O
of	O
the	O
QA	O
/	O
QI	O
process	O
,	O
monitoring	O
of	O
blood	O
administration	O
practices	O
revealed	O
that	O
a	O
variance	O
from	O
institutional	O
blood	O
administration	O
policy	O
occurred	O
during	O
50	O
percent	O
of	O
blood	O
and	O
component	O
transfusions	O
.	O

TNFalpha	B-GENE
and	O
IL-6	B-GENE
levels	O
were	O
determined	O
in	O
the	O
culture	O
supernatants	O
.	O

The	O
human	B-GENE
papillomavirus	I-GENE
type	I-GENE
16	I-GENE
E7	I-GENE
protein	I-GENE
complements	O
adenovirus	B-GENE
type	I-GENE
5	I-GENE
E1A	I-GENE
amino-terminus-dependent	O
transactivation	O
of	O
adenovirus	O
type	O
5	O
early	O
genes	O
and	O
increases	O
ATF	B-GENE
and	O
Oct-1	B-GENE
DNA	O
binding	O
activity	O
.	O

In	O
two	O
further	O
cases	O
(	O
one	O
type	O
I	O
and	O
one	O
type	O
III	O
SMA	O
)	O
,	O
de	O
novo	O
deletions	O
of	O
only	O
one	O
copy	O
of	O
Ag1-CA	B-GENE
and	O
C212	B-GENE
were	O
found	O
.	O

In	O
supine	O
position	O
,	O
plasma	O
ANP	B-GENE
levels	O
ranged	O
from	O
12	O
pg	O
/	O
ml	O
to	O
51	O
.	O
5	O
pg	O
/	O
ml	O
,	O
with	O
an	O
average	O
level	O
of	O
35	O
.	O
3	O
+	O
/	O
-	O
11	O
.	O
5	O
pg	O
/	O
ml	O
.	O

NIK-244	O
suppressed	O
coronary	O
ligation-	O
and	O
digitalis-induced	O
arrhythmias	O
,	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentrations	O
for	O
arrhythmias	O
induced	O
by	O
24-h	O
and	O
48-h	O
coronary	O
ligation	O
and	O
digitalis	O
were	O
0	O
.	O
41	O
+	O
/	O
-	O
0	O
.	O
10	O
(	O
by	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
0	O
.	O
70	O
+	O
/	O
-	O
0	O
.	O
13	O
(	O
by	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
and	O
0	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
08	O
(	O
by	O
0	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
microgram	O
/	O
ml	O
,	O
respectively	O
(	O
mean	O
+	O
/	O
-	O
SD	O
of	O
the	O
mean	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
5'	O
external	O
transcribed	O
spacer	O
(	O
ETS	O
)	O
region	O
of	O
the	O
pre-rRNA	O
in	O
Saccharomyces	O
cerevisiae	O
contains	O
a	O
sequence	O
with	O
10	O
bp	O
of	O
perfect	O
complementarity	O
to	O
the	O
U3	B-GENE
snoRNA	I-GENE
.	O

This	O
constitutes	O
evidence	O
for	O
an	O
in	O
vivo	O
role	O
of	O
SRC-1	B-GENE
in	O
dimerization-induced	O
activation	O
by	O
OR1	B-GENE
/	I-GENE
RXRalpha	I-GENE
.	O

To	O
further	O
define	O
the	O
structural	O
requirements	O
for	O
ZAP-70	B-GENE
interaction	O
with	O
the	O
TCR	B-GENE
,	O
we	O
developed	O
a	O
binding	O
assay	O
using	O
immobilized	O
glutathione	B-GENE
S-transferase	I-GENE
fusion	I-GENE
proteins	I-GENE
containing	O
the	O
NH2-	O
and	O
/	O
or	O
COOH-terminal	B-GENE
SH2	I-GENE
domains	I-GENE
of	O
ZAP-70	B-GENE
,	O
and	O
soluble	O
synthetic	O
peptides	O
with	O
the	O
sequence	O
of	O
the	O
cytoplasmic	O
region	O
of	O
the	O
TCR	B-GENE
zeta	I-GENE
chain	I-GENE
(	O
TCR	B-GENE
zeta	I-GENE
cyt	I-GENE
)	O
or	O
individual	O
TCR	B-GENE
zeta	I-GENE
and	O
CD3	B-GENE
epsilon	I-GENE
TAM	I-GENE
motifs	I-GENE
.	O

The	O
inspiratory	O
oxygen	O
concentration	O
needed	O
(	O
FiO2	O
)	O
and	O
the	O
Horowitz	O
quotient	O
differed	O
in	O
a	O
highly	O
significant	O
manner	O
beginning	O
on	O
the	O
1st	O
day	O
after	O
trauma	O
.	O

The	O
sera	O
and	O
nasal	O
secretions	O
of	O
142	O
patients	O
,	O
who	O
were	O
positive	O
in	O
HD	O
or	O
mites	O
skin	O
test	O
,	O
were	O
subjected	O
to	O
a	O
radioallergosorbent	O
test	O
(	O
RAST	O
)	O
for	O
estimating	O
the	O
specific	O
IgE	B-GENE
antibody	I-GENE
activity	O
to	O
mites	O
.	O

This	O
organization	O
suggests	O
that	O
duplication	O
events	O
that	O
have	O
generated	O
the	O
primate	B-GENE
FUT3-FUT5-FUT6	I-GENE
cluster	I-GENE
might	O
have	O
occurred	O
through	O
a	O
long-interspersed-nuclear-element-based	O
mechanism	O
of	O
unequal	O
crossing	O
over	O
,	O
as	O
described	O
for	O
the	O
globin	B-GENE
cluster	I-GENE
.	O

Structure	O
determination	O
of	O
an	O
adsorbate-induced	O
multilayer	O
reconstruction	O
:	O
(	O
1	O
x	O
2	O
)	O
-H	O
/	O
Ni	O
(	O
110	O
)	O
.	O

BACKGROUND	O
:	O
In	O
the	O
ubiquitin-dependent	O
proteolysis	O
pathway	O
,	O
a	O
ubiquitin	B-GENE
ligase	I-GENE
(	O
E3	B-GENE
)	O
is	O
responsible	O
for	O
substrate	O
selectivity	O
and	O
timing	O
of	O
degradation	O
.	O

The	O
initial	O
phase	O
of	O
increased	O
vascular	O
permeability	O
in	O
the	O
peritoneal	O
cavity	O
and	O
LTB4	O
production	O
was	O
dose	O
dependently	O
inhibited	O
by	O
the	O
5-LO	O
inhibitors	O
phenidone	O
,	O
BW	O
A4C	O
,	O
A63162	O
,	O
and	O
ICI	O
207	O
968	O
but	O
not	O
by	O
dexamethasone	O
or	O
colchicine	O
.	O

Circulatory	O
arrest	O
in	O
the	O
operating	O
room	O
.	O

This	O
study	O
is	O
a	O
further	O
and	O
more	O
extensive	O
validation	O
of	O
the	O
clinician	O
rated	O
NIMH-LCM-p	O
.	O

The	O
Mean	O
was	O
74	O
,	O
3	O
+	O
/	O
-	O
53	O
,	O
6	O
micrograms	O
J	O
/	O
g	O
Cr	O
,	O
the	O
Median	O
61	O
micrograms	O
J	O
/	O
g	O
Cr	O
.	O

Left	O
atrial	O
volumes	O
were	O
greater	O
in	O
old	O
compared	O
with	O
young	O
subjects	O
(	O
maximal	O
:	O
31	O
+	O
/	O
-	O
10	O
cm3	O
/	O
m2	O
vs	O
24	O
+	O
/	O
-	O
8	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
02	O
;	O
at	O
onset	O
of	O
atrial	O
systole	O
:	O
23	O
+	O
/	O
-	O
8	O
cm3	O
/	O
m2	O
vs	O
15	O
+	O
/	O
-	O
5	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
0002	O
;	O
minimal	O
:	O
13	O
+	O
/	O
-	O
5	O
cm3	O
/	O
m2	O
vs	O
9	O
+	O
/	O
-	O
4	O
cm3	O
/	O
m2	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

This	O
article	O
describes	O
the	O
collaborative	O
care	O
of	O
the	O
woman	O
participating	O
in	O
maternal	O
blood	O
donation	O
for	O
intrauterine	O
transfusion	O
.	O

Gestational	O
trophoblastic	O
diseases	O
:	O
recent	O
advances	O
in	O
the	O
understanding	O
of	O
cytogenetics	O
,	O
histopathology	O
,	O
and	O
natural	O
history	O
.	O

A	O
genetic	O
screen	O
applied	O
to	O
mutants	O
in	O
the	O
branch	O
site	O
region	O
shows	O
that	O
all	O
positions	O
in	O
the	O
conserved	O
TACTAAC	O
sequence	O
are	O
important	O
for	O
intron	O
recognition	O
.	O

A	O
global	O
response	O
rate	O
was	O
17%	O
(	O
95%	O
confidence	O
interval	O
(	O
95%	O
CI	O
)	O
:	O
2%-32%	O
)	O
and	O
the	O
median	O
overall	O
survival	O
was	O
12	O
months	O
.	O

The	O
system	O
consisted	O
of	O
the	O
intact	O
canine	O
heart	O
connected	O
to	O
a	O
microcomputer	O
that	O
operated	O
as	O
the	O
modulated	O
parasystolic	O
pacemaker	O
.	O

Immunological	O
and	O
biochemical	O
characterization	O
of	O
streptococcal	B-GENE
pyrogenic	I-GENE
exotoxins	I-GENE
I	I-GENE
and	I-GENE
J	I-GENE
(	O
SPE-I	B-GENE
and	O
SPE-J	B-GENE
)	O
from	O
Streptococcus	O
pyogenes	O
.	O

Patients	O
with	O
an	O
enzymatic	O
activity	O
below	O
X--1	O
manifested	O
a	O
decrease	O
of	O
the	O
content	O
of	O
IgA	B-GENE
,	O
IgG	B-GENE
,	O
IgM	B-GENE
,	O
T	O
and	O
B	O
lymphocytes	O
,	O
and	O
of	O
phagocytic	O
activity	O
of	O
neutrophils	O
as	O
compared	O
to	O
patients	O
exhibiting	O
a	O
high	O
enzymatic	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
the	O
combined	O
treatment	O
with	O
a	O
thromboxane	B-GENE
synthetase	I-GENE
inhibitor	O
and	O
a	O
thromboxane	B-GENE
receptor	I-GENE
antagonist	O
provides	O
a	O
better	O
protection	O
against	O
digoxin	O
intoxication	O
than	O
with	O
either	O
agent	O
alone	O
.	O

RESULTS	O
:	O
Cholinergic	O
nerves	O
are	O
mainly	O
involved	O
in	O
the	O
regulation	O
of	O
enteric	O
nerve	O
responses	O
to	O
EFS	O
in	O
the	O
normal	O
IAS	O
.	O

These	O
are	O
the	O
long	B-GENE
terminal	I-GENE
repeat	I-GENE
(	I-GENE
LTR	I-GENE
)	I-GENE
promoter	I-GENE
,	O
which	O
regulates	O
expression	O
of	O
the	O
viral	O
structural	O
proteins	O
,	O
and	O
a	O
second	O
internal	O
promoter	O
,	O
located	O
towards	O
the	O
3'	O
end	O
of	O
the	O
env	B-GENE
gene	I-GENE
,	O
that	O
directs	O
expression	O
of	O
the	O
viral	O
auxiliary	O
proteins	O
.	O

The	O
1	O
.	O
1-	O
and	O
1	O
.	O
3-kb	O
mRNA	O
species	O
were	O
found	O
only	O
in	O
the	O
heart	O
,	O
and	O
the	O
2	O
.	O
6-kb	O
species	O
was	O
found	O
in	O
the	O
heart	O
,	O
kidney	O
and	O
brain	O
,	O
but	O
not	O
in	O
skeletal	O
muscle	O
or	O
liver	O
.	O

It	O
has	O
been	O
reported	O
that	O
rat	O
blood	O
chloroform	O
levels	O
were	O
significantly	O
decreased	O
after	O
treatment	O
with	O
ClO2	O
.	O

A	O
DNA	O
motif	O
related	O
to	O
the	O
cAMP-responsive	B-GENE
element	I-GENE
and	O
an	O
exon-located	B-GENE
activator	I-GENE
protein-2	I-GENE
binding	I-GENE
site	I-GENE
in	O
the	O
human	B-GENE
tissue-type	I-GENE
plasminogen	I-GENE
activator	I-GENE
gene	I-GENE
promoter	I-GENE
cooperate	O
in	O
basal	O
expression	O
and	O
convey	O
activation	O
by	O
phorbol	O
ester	O
and	O
cAMP	O
.	O

To	O
facilitate	O
the	O
availability	O
of	O
important	O
new	O
therapeutic	O
agents	O
,	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
in	O
the	O
mid-1970s	O
began	O
assigning	O
therapeutic	O
ratings	O
to	O
investigational	O
new	O
drugs	O
and	O
holding	O
end-of-phase	O
II	O
conferences	O
with	O
drug	O
sponsors	O
.	O

Band	O
structure	O
effects	O
of	O
transport	O
properties	O
in	O
icosahedral	O
quasicrystals	O
.	O

Each	O
dietary	O
treatment	O
was	O
fed	O
to	O
six	O
pen	O
replicates	O
of	O
five	O
chicks	O
per	O
pen	O
for	O
21	O
d	O
.	O

Repression	O
of	O
glucocorticoid	O
receptor-mediated	O
transcriptional	O
activation	O
by	O
unliganded	O
thyroid	B-GENE
hormone	I-GENE
receptor	I-GENE
(	O
TR	B-GENE
)	O
is	O
TR	B-GENE
isoform-specific	O
.	O

cDNA	O
encoding	O
a	O
functional	O
feline	B-GENE
liver	I-GENE
/	I-GENE
bone	I-GENE
/	I-GENE
kidney-type	I-GENE
alkaline	I-GENE
phosphatase	I-GENE
.	O

Goodpasture's-like	O
syndrome	O
and	O
effect	O
of	O
extracorporeal	O
membrane	O
oxygenator	O
support	O
.	O

RNase	B-GENE
protection	O
assays	O
revealed	O
a	O
correlation	O
between	O
the	O
levels	O
of	O
dorsal	O
and	O
ventral	O
skin	O
expression	O
with	O
pigmentation	O
/	O
phaeomelanin	O
phenotypes	O
.	O

Because	O
chromosome	O
X	O
is	O
frequently	O
involved	O
in	O
structural	O
alterations	O
in	O
neoplastic	O
Syrian	O
hamster	O
cells	O
transformed	O
by	O
chemical	O
carcinogens	O
and	O
oncogenic	O
viruses	O
,	O
the	O
localization	O
of	O
the	O
cph	B-GENE
locus	I-GENE
on	O
this	O
chromosome	O
supports	O
the	O
notion	O
that	O
the	O
cph	B-GENE
oncogene	I-GENE
plays	O
a	O
role	O
in	O
the	O
malignant	O
conversion	O
of	O
chemically	O
transformed	O
hamster	O
fibroblasts	O
.	O

In	O
this	O
paper	O
,	O
the	O
current	O
status	O
of	O
the	O
understanding	O
of	O
the	O
interaction	O
mechanisms	O
of	O
ultrasound	O
with	O
biological	O
media	O
and	O
the	O
factors	O
that	O
govern	O
different	O
biological	O
effects	O
are	O
surveyed	O
.	O

Most	O
of	O
the	O
phenomena	O
of	O
azotaemic	O
osteodystrophy	O
are	O
encountered	O
in	O
simple	O
vitamin	O
D	O
deficiency	O
;	O
as	O
in	O
that	O
condition	O
,	O
deficiency	O
of	O
1	O
,	O
25-dihydroxycholecalciferol	O
may	O
be	O
of	O
primary	O
significance	O
in	O
causing	O
secondary	O
hyperparathyroidism	O
in	O
renal	O
failure	O
.	O

A	O
G22V	B-GENE
mutant	I-GENE
of	O
M-Ras	B-GENE
was	O
constitutively	O
active	O
and	O
its	O
expression	O
in	O
an	O
interleukin-3	B-GENE
(	O
IL-3	B-GENE
)	O
-dependent	O
mast	O
cell	O
/	O
megakaryocyte	O
cell	O
line	O
resulted	O
in	O
increased	O
survival	O
in	O
the	O
absence	O
of	O
IL-3	B-GENE
,	O
increased	O
growth	O
in	O
IL-4	B-GENE
,	O
and	O
,	O
at	O
high	O
expression	O
levels	O
,	O
in	O
factor-independent	O
growth	O
.	O

Diabetes	O
care	O
:	O
a	O
guideline	O
to	O
the	O
facilities	O
needed	O
to	O
support	O
internationally	O
endorsed	O
standards	O
.	O

However	O
,	O
the	O
N63S	O
mutation	O
in	O
the	O
wild-type	B-GENE
VP5	I-GENE
background	O
increased	O
the	O
interaction	O
,	O
as	O
judged	O
by	O
the	O
beta-galactosidase	B-GENE
activity	O
,	O
by	O
a	O
factor	O
of	O
9	O
relative	O
to	O
when	O
the	O
PR7	O
mutation	O
was	O
present	O
.	O

The	O
possibility	O
of	O
a	O
hereditary	O
disorder	O
leading	O
to	O
a	O
minor	O
defect	O
in	O
elastic	O
fibre	O
structure	O
which	O
could	O
be	O
responsible	O
for	O
the	O
spontaneous	O
lesions	O
is	O
discussed	O
.	O

The	O
binding	O
of	O
PH	B-GENE
domains	I-GENE
to	O
Gbetagamma	B-GENE
was	O
inhibited	O
by	O
preincubation	O
of	O
Gbetagamma	B-GENE
with	O
the	O
GDP-bound	O
but	O
not	O
the	O
GTP-bound	O
form	O
of	O
Gialpha	B-GENE
.	O

It	O
was	O
shown	O
that	O
estradiol	O
concentrations	O
obtained	O
after	O
estradiol	O
valerate	O
and	O
micronized	O
estradiol	O
ingestion	O
were	O
dependent	O
on	O
the	O
patient's	O
age	O
as	O
well	O
as	O
on	O
the	O
constitutional	O
type	O
.	O

False	O
positive	O
amniotic	B-GENE
fluid	I-GENE
alpha	I-GENE
fetoprotein	I-GENE
levels	O
resulting	O
from	O
contamination	O
with	O
fetal	O
blood	O
:	O
results	O
of	O
an	O
experiment	O
.	O

Piperacillin-tazobactam	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
gram-negative	O
,	O
gram-positive	O
,	O
aerobic	O
,	O
and	O
anaerobic	O
bacteria	O
.	O

Identification	O
of	O
RNase	B-GENE
T	I-GENE
as	O
a	O
high-copy	O
suppressor	O
of	O
the	O
UV	O
sensitivity	O
associated	O
with	O
single-strand	B-GENE
DNA	I-GENE
exonuclease	I-GENE
deficiency	O
in	O
Escherichia	O
coli	O
.	O

All	O
patients	O
had	O
elevated	O
levels	O
of	O
serum	B-GENE
IgE	I-GENE
antibodies	I-GENE
to	O
the	O
crude	O
soybean	O
extract	O
;	O
binding	O
values	O
ranged	O
from	O
2	O
.	O
3	O
to	O
28	O
.	O
1	O
times	O
that	O
of	O
a	O
negative	O
control	O
serum	O
.	O

The	O
gene	O
includes	O
three	O
exons	O
and	O
two	O
introns	O
within	O
1	O
.	O
6	O
kilobases	O
of	O
DNA	O
,	O
and	O
the	O
entire	O
open	O
reading	O
frame	O
for	O
glycoprotein	B-GENE
IX	I-GENE
is	O
included	O
within	O
the	O
third	O
exon	O
.	O

DNA	B-GENE
polymerase	I-GENE
E	I-GENE
,	O
DNA	B-GENE
ligase	I-GENE
III	I-GENE
and	O
a	O
DNA	B-GENE
structure-specific	I-GENE
endonuclease	I-GENE
co-purify	O
with	O
the	O
five	O
polypeptide	O
complex	O
.	O

Yeast	B-GENE
U1	I-GENE
snRNP	I-GENE
therefore	O
contains	O
16	O
different	O
proteins	O
,	O
including	O
seven	O
snRNP	B-GENE
core	I-GENE
proteins	I-GENE
,	O
three	O
homologues	O
of	O
the	O
metazoan	B-GENE
U1	I-GENE
snRNP-specific	I-GENE
proteins	I-GENE
,	O
and	O
six	O
yeast-specific	B-GENE
U1	I-GENE
snRNP	I-GENE
proteins	I-GENE
.	O

Strontium	O
chloride	O
Sr	O
89	O
is	O
costly	O
,	O
but	O
preliminary	O
analysis	O
indicates	O
that	O
it	O
may	O
reduce	O
management	O
expenditures	O
overall	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Measurement	O
of	O
magnesium	O
absorption	O
in	O
man	O
using	O
stable	O
26Mg	O
as	O
a	O
tracer	O
.	O

On	O
the	O
basis	O
of	O
this	O
anatomic	O
concept	O
,	O
the	O
brachioplasty	O
procedure	O
was	O
modified	O
to	O
provide	O
secure	O
anchoring	O
of	O
the	O
arm	O
flap	O
to	O
the	O
axillary	O
fascia	O
along	O
with	O
strong	O
superficial	O
fascial	O
system	O
repair	O
of	O
incisions	O
,	O
reducing	O
the	O
risk	O
of	O
widening	O
or	O
migration	O
of	O
scars	O
and	O
unnatural	O
contours	O
.	O

The	O
frameshift	O
initiated	O
by	O
ADEx2	O
is	O
believed	O
to	O
alter	O
the	O
regular	O
coding	O
sequence	O
,	O
acting	O
as	O
a	O
loss-of-function	O
ASIP	B-GENE
mutation	I-GENE
.	O

Distant	O
spread	O
was	O
found	O
in	O
46	O
patients	O
(	O
34%	O
)	O
,	O
42	O
of	O
whom	O
had	O
serum	O
Tg	O
greater	O
than	O
10	O
micrograms	O
/	O
l	O
.	O

METHODS	O
:	O
Out	O
of	O
171	O
patients	O
receiving	O
anticoagulation	O
between	O
July	O
1992	O
and	O
December	O
1993	O
,	O
83	O
patients	O
with	O
hemispheric	O
embolisms	O
received	O
heparin	O
within	O
72	O
hours	O
from	O
onset	O
(	O
activated	O
partial	O
thromboplastin	B-GENE
time	O
[	O
aPTT	O
]	O
1	O
.	O
5	O
times	O
control	O
value	O
)	O
.	O

These	O
probable	O
border	O
sequences	O
are	O
closely	O
related	O
to	O
those	O
of	O
other	O
known	O
T-regions	O
and	O
define	O
a	O
second	O
T-region	O
of	O
pTiChry5	O
,	O
called	O
T-right	O
(	O
TR	O
)	O
,	O
that	O
confers	O
production	O
of	O
the	O
Amadoriopines	O
.	O

Open	O
reading	O
frames	O
in	O
a	O
4556	O
nucleotide	O
sequence	O
within	O
MDV-1	B-GENE
BamHI-D	I-GENE
DNA	I-GENE
fragment	I-GENE
:	O
evidence	O
for	O
splicing	O
of	O
mRNA	O
from	O
a	O
new	O
viral	O
glycoprotein	O
gene	O
.	O

The	O
structural	O
changes	O
in	O
intra-acinar	O
artery	O
manifested	O
mainly	O
by	O
an	O
increase	O
in	O
number	O
of	O
muscular	O
artery	O
resulting	O
from	O
muscularization	O
of	O
precursor	O
cells	O
(	O
pericytes	O
and	O
intermediate	O
cells	O
)	O
located	O
within	O
partially	O
muscular	O
and	O
nonmuscular	O
arterial	O
wall	O
to	O
smooth	O
muscle	O
cell	O
,	O
and	O
by	O
the	O
medial	O
wall	O
thickened	O
due	O
to	O
hypertrophy	O
and	O
hyperplasia	O
of	O
smooth	O
muscle	O
cells	O
as	O
well	O
as	O
accumulation	O
of	O
a	O
large	O
amount	O
of	O
collagen	B-GENE
,	O
especially	O
the	O
type	B-GENE
1	I-GENE
collagen	I-GENE
.	O

In	O
subjects	O
(	O
n	O
=	O
5	O
)	O
with	O
quadriplegia	O
and	O
reduced	O
sympathetic	O
tone	O
secondary	O
to	O
cervical	O
cord	O
trauma	O
,	O
TcpO2	O
at	O
42	O
degrees	O
C	O
and	O
vasodilation	O
index	O
were	O
increased	O
(	O
45	O
.	O
0	O
mmHg	O
and	O
0	O
.	O
61	O
)	O
;	O
TcpO2	O
at	O
45	O
degrees	O
C	O
did	O
not	O
change	O
.	O

Letter	O
:	O
Is	O
actinic	O
(	O
solar	O
)	O
damage	O
the	O
provoking	O
cause	O
of	O
'post-inflammatory	O
elastolysis	O
and	O
cutis	O
laxa	O
(	O
PECL	O
)	O
'	O
?	O

The	O
size	O
discrepancy	O
is	O
not	O
due	O
to	O
glycosylation	O
or	O
phosphorylation	O
of	O
Ag35	B-GENE
but	O
may	O
result	O
from	O
a	O
proline-rich	O
sequence	O
which	O
occurs	O
in	O
this	O
polypeptide	O
.	O

The	O
criterion	O
was	O
reached	O
after	O
two	O
sessions	O
and	O
generalization	O
to	O
a	O
variety	O
of	O
pills	O
and	O
capsules	O
occurred	O
.	O

Moreover	O
,	O
LD50	O
in	O
mice	O
of	O
RP-170	O
(	O
4	O
.	O
3	O
g	O
/	O
kg	O
on	O
i	O
.	O
v	O
.	O
)	O
was	O
increased	O
to	O
5	O
.	O
2	O
g	O
/	O
kg	O
by	O
oral	O
administration	O
.	O

The	O
co-existence	O
of	O
TE	B-GENE
domains	I-GENE
within	O
modular	O
PKSs	B-GENE
along	O
with	O
physically	O
separated	O
,	O
monofunctional	O
TEs	B-GENE
(	O
TE	B-GENE
IIs	I-GENE
)	O
has	O
been	O
reported	O
for	O
a	O
number	O
of	O
modular	O
polyketide	O
and	O
non-ribosomal	B-GENE
peptide	I-GENE
synthases	I-GENE
(	O
NRPS	B-GENE
)	O
.	O

The	O
complete	O
circular	O
TTV	O
genome	O
contained	O
a	O
novel	O
sequence	O
of	O
113	O
nt	O
(	O
nt	O
3740	O
to	O
3852	O
[	O
=	O
0	O
]	O
)	O
in	O
between	O
the	O
known	O
3'-	O
and	O
5'-end	O
arms	O
,	O
forming	O
a	O
117-nt	O
GC-rich	O
stretch	O
(	O
GC	O
content	O
,	O
90	O
.	O
6%	O
at	O
nt	O
3736	O
to	O
3852	O
)	O
.	O

SNAP-23	B-GENE
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
vesicle	O
trafficking	O
in	O
mammalian	O
cells	O
.	O

Recombinant	O
plasmid	O
pFV100	O
was	O
subsequently	O
isolated	O
by	O
its	O
ability	O
to	O
complement	O
B-band	O
expression	O
in	O
ge6	B-GENE
.	O

Surprisingly	O
,	O
there	O
is	O
no	O
sequence	O
homology	O
between	O
this	O
region	O
of	O
Ly-6E	B-GENE
and	O
the	O
established	O
consensus	O
for	O
the	O
interferon-stimulated	B-GENE
response	I-GENE
element	I-GENE
,	O
which	O
has	O
been	O
shown	O
functionally	O
important	O
to	O
all	O
previously	O
characterized	O
alpha	B-GENE
/	I-GENE
beta	I-GENE
interferon-inducible	I-GENE
promoters	I-GENE
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	B-GENE
mutant	I-GENE
Lg3	I-GENE
allele	I-GENE
is	O
believed	O
to	O
cause	O
the	O
phenotype	O
.	O

Expression	O
of	O
the	O
dibasic	O
proprotein	O
processing	O
enzyme	O
furin	B-GENE
is	O
directed	O
by	O
multiple	O
promoters	O
.	O

Structural	O
changes	O
in	O
the	O
kinetically	O
more	O
damaged	O
E44D	O
mutant	O
detected	O
in	O
(	O
1	O
)	O
H-	O
(	O
15	O
)	O
N	O
HSQC	O
spectra	O
were	O
largely	O
limited	O
to	O
the	O
loop	O
I-helix	O
I	O
motif	O
,	O
suggesting	O
that	O
Glu-44	O
stabilizes	O
the	O
active	O
site	O
region	O
.	O

A	O
motif	O
(	O
TGATGTCA	B-GENE
)	O
which	O
matches	O
a	O
CREB	B-GENE
site	I-GENE
and	O
is	O
similar	O
to	O
an	O
AP-1	B-GENE
site	I-GENE
is	O
embedded	O
within	O
ER2	B-GENE
.	O

Between	O
1967	O
and	O
1994	O
,	O
495	O
patients	O
underwent	O
surgery	O
for	O
primary	O
PTC	O
at	O
the	O
Department	O
of	O
Surgery	O
,	O
Helsinki	O
University	O
Central	O
Hospital	O
.	O

According	O
to	O
the	O
literature	O
,	O
second	O
malignant	O
epithelial	O
tumours	O
are	O
,	O
in	O
contrast	O
to	O
mesenchymal	O
tumours	O
such	O
as	O
osteosarcoma	O
,	O
very	O
rare	O
in	O
retinoblastoma	O
survivors	O
.	O

In	O
patients	O
,	O
the	O
effect	O
of	O
CCK-PZ	O
on	O
the	O
movement	O
of	O
the	O
terminal	O
part	O
of	O
the	O
bile	O
duct	O
was	O
measured	O
with	O
a	O
pressure	O
sensor	O
using	O
a	O
duodenofiberscope	O
.	O

Intestinal	O
adaptation	O
(	O
first	O
of	O
two	O
parts	O
)	O
.	O

Their	O
chemical	O
structures	O
were	O
elucidated	O
as	O
1	O
alpha	O
,	O
2	O
alpha-diacetoxy-8	O
beta-isobutanoyloxy-	O
9	O
alpha-benzoyloxy-13-	O
(	O
alpha-methyl	O
)	O
butanoyloxy-4	O
beta	O
,	O
6	O
beta-dihydroxy-beta-dihydroagarofuran	O
(	O
1	O
)	O
,	O
1	O
alpha	O
,	O
2	O
alpha-diacetoxy-8	O
beta-	O
(	O
beta-	O
furancarbonyloxy	O
)	O
-9	O
alpha-benzoyloxy-13-isobutanoyloxy-4	O
beta	O
,	O
6	O
beta-dihydroxy-beta-dihydroagarofuran	O
(	O
2	O
)	O
and	O
1	O
alpha	O
,	O
6	O
beta	O
,	O
8	O
alpha	O
,	O
13-tetraacetoxy-9	O
alpha-benzoyloxy-2	O
alpha-hydroxy-beta-dihydroagarofuran	O
(	O
3	O
)	O
mainly	O
by	O
analyses	O
NMR	O
and	O
MS	O
spectral	O
data	O
.	O

Tissue	O
samples	O
were	O
obtained	O
either	O
from	O
rats	O
that	O
had	O
been	O
exposed	O
to	O
opiate	O
withdrawal	O
following	O
a	O
seven	O
day	O
morphine	O
infusion	O
or	O
sham	O
treated	O
control	O
subjects	O
.	O

The	O
optimal	O
sequence	O
for	O
interaction	O
with	O
mu	B-GENE
2	I-GENE
and	O
with	O
AP-2	B-GENE
has	O
tyrosine	O
as	O
an	O
anchor	O
and	O
prefers	O
arginine	O
at	O
position	O
Y	O
+	O
2	O
and	O
leucine	O
at	O
position	O
Y	O
+	O
3	O
.	O

Unlike	O
most	O
other	O
small	B-GENE
G	I-GENE
proteins	I-GENE
which	O
are	O
expressed	O
ubiquitously	O
,	O
TTF	B-GENE
was	O
transcribed	O
only	O
in	O
hemopoietic	O
cells	O
as	O
a	O
2	O
.	O
2	O
kb	O
transcript	O
.	O

The	O
generally	O
adopted	O
criteria	O
enabling	O
to	O
classify	O
the	O
examined	O
persons	O
into	O
the	O
following	O
3	O
groups	O
have	O
been	O
used	O
:	O
(	O
a	O
)	O
diseased	O
of	O
BEN	O
;	O
(	O
b	O
)	O
suspect	O
to	O
be	O
diseased	O
of	O
BEN	O
,	O
and	O
(	O
c	O
)	O
individuals	O
without	O
signs	O
of	O
a	O
renal	O
disease	O
.	O

Nhp2p	B-GENE
is	O
a	O
highly	O
basic	O
protein	O
that	O
belongs	O
to	O
a	O
family	O
of	O
putative	O
RNA-binding	B-GENE
proteins	I-GENE
.	O

No	O
changes	O
were	O
evident	O
in	O
the	O
FR-task	O
performance	O
of	O
controls	O
that	O
received	O
daily	O
saline	O
injections	O
.	O

Of	O
165	O
women	O
with	O
non-malignant	O
diagnoses	O
26	O
(	O
16%	O
)	O
had	O
CA	B-GENE
125	I-GENE
levels	O
in	O
excess	O
of	O
35	O
U	O
/	O
ml	O
and	O
8	O
(	O
5%	O
)	O
greater	O
than	O
65	O
U	O
/	O
ml	O
.	O

P-CIP1	B-GENE
,	O
a	O
novel	O
protein	O
that	O
interacts	O
with	O
the	O
cytosolic	O
domain	O
of	O
peptidylglycine	B-GENE
alpha-amidating	I-GENE
monooxygenase	I-GENE
,	O
is	O
associated	O
with	O
endosomes	O
.	O

Contagious	O
bovine	O
pleuropneumonia	O
is	O
a	O
major	O
threat	O
for	O
cattle	O
in	O
Africa	O
.	O

However	O
,	O
a	O
10--15%	O
lengthening	O
of	O
the	O
partial	O
thromboplastin	B-GENE
time	O
is	O
evident	O
after	O
24	O
hours	O
of	O
storage	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
investigated	O
the	O
regulatory	O
mechanism	O
for	O
CD95L	B-GENE
expression	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
randomised	O
controlled	O
trials	O
comparing	O
IUSs	O
with	O
other	O
forms	O
of	O
reversible	O
contraceptives	O
and	O
reporting	O
on	O
pre-determined	O
outcomes	O
in	O
women	O
of	O
reproductive	O
years	O
.	O

The	O
experimental	O
design	O
incorporated	O
a	O
multiple	O
regression	O
model	O
,	O
sequential	O
treatments	O
and	O
a	O
proportional	O
end	O
point	O
(	O
95%	O
)	O
for	O
protection	O
time	O
.	O

In	O
conclusion	O
,	O
we	O
observed	O
a	O
great	O
regeneration	O
ability	O
following	O
mechanical	O
injury	O
in	O
the	O
nasal	O
mucosa	O
.	O

Infect	O
.	O

Full-length	B-GENE
FLAP	I-GENE
clones	O
were	O
isolated	O
from	O
a	O
mouse	O
skeletal	O
muscle	O
cDNA	O
library	O
.	O

Liver	O
dysfunction	O
in	O
the	O
presence	O
of	O
different	O
adverse	O
reactions	O
presented	O
with	O
a	O
higher	O
activity	O
in	O
the	O
blood	O
serum	O
of	O
indicator	O
liver	O
enzymes	O
and	O
its	O
impaired	O
protein-forming	O
function	O
.	O

Regulation	O
of	O
the	O
Raf	B-GENE
kinase	I-GENE
in	O
T	O
cells	O
differs	O
from	O
findings	O
with	O
a	O
variety	O
of	O
cell	O
lines	O
that	O
the	O
catalytic	B-GENE
domain	I-GENE
of	I-GENE
Raf	I-GENE
(	O
Raf	B-GENE
(	I-GENE
delta26-303	I-GENE
)	O
)	O
shows	O
no	O
activity	O
.	O

The	O
experience	O
of	O
the	O
lateral	O
rhinotomy	O
approach	O
in	O
transsphenoidal	O
surgery	O
of	O
acromegaly	O
has	O
been	O
favourable	O
.	O

Perceptual	O
learning	O
for	O
a	O
pattern	O
discrimination	O
task	O
.	O

BACKGROUND	O
:	O
Measurement	O
of	O
stereoacuity	O
at	O
varying	O
distances	O
,	O
by	O
real	O
or	O
simulated	O
depth	O
stereoacuity	O
tests	O
,	O
is	O
helpful	O
in	O
the	O
evaluation	O
of	O
patients	O
with	O
binocular	O
imbalance	O
or	O
strabismus	O
.	O

A	O
comparison	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
T	O
.	O
thermophilus	O
enzyme	O
with	O
that	O
of	O
the	O
Escherichia	O
coli	O
enzyme	O
showed	O
(	O
i	O
)	O
a	O
37%	O
overall	O
similarity	O
;	O
(	O
ii	O
)	O
the	O
conservation	O
of	O
the	O
Ser	O
residue	O
,	O
which	O
is	O
known	O
to	O
be	O
phosphorylated	O
in	O
the	O
E	O
.	O
coli	O
enzyme	O
,	O
and	O
of	O
the	O
surrounding	O
sequence	O
;	O
and	O
(	O
iii	O
)	O
the	O
presence	O
of	O
141	O
extra	O
residues	O
at	O
the	O
C	O
terminus	O
of	O
the	O
T	O
.	O
thermophilus	O
enzyme	O
.	O

The	O
range	O
of	O
serum	O
concentrations	O
,	O
mean	O
values	O
,	O
median	O
values	O
,	O
and	O
standard	O
deviations	O
for	O
each	O
analyte	O
are	O
reported	O
for	O
males	O
and	O
females	O
and	O
for	O
three	O
age	O
groups	O
(	O
25-44	O
,	O
45-59	O
,	O
60-70	O
)	O
.	O

Therapeutic	O
effects	O
of	O
cefpirome	O
(	O
HR	O
810	O
)	O
on	O
experimental	O
mixed	O
infections	O
with	O
Enterococcus	O
faecalis	O
and	O
Escherichia	O
coli	O
in	O
mice	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
mouse	B-GENE
HO-1	I-GENE
gene	I-GENE
is	O
identical	O
to	O
that	O
of	O
p32	B-GENE
,	O
initially	O
identified	O
as	O
a	O
stress-induced	O
protein	O
in	O
mouse	O
BALBc	O
/	O
3T3	O
cells	O
.	O

This	O
is	O
a	O
challenging	O
task	O
insofar	O
as	O
direct	O
measures	O
of	O
ISF	O
glucose	O
are	O
not	O
readily	O
available	O
.	O

These	O
results	O
suggest	O
that	O
both	O
transcription	O
activators	O
depend	O
on	O
or	O
interact	O
with	O
different	O
subunits	O
of	O
RNA	B-GENE
polymerase	I-GENE
,	O
although	O
their	O
role	O
in	O
formation	O
of	O
proper	O
DNA	O
geometry	O
may	O
also	O
be	O
crucial	O
.	O

Inhibition	O
assays	O
performed	O
with	O
over	O
30	O
different	O
natural	O
and	O
synthetic	O
sialylated	O
and	O
/	O
or	O
sulfated	O
compounds	O
are	O
utilized	O
to	O
define	O
in	O
greater	O
detail	O
specific	O
structural	O
features	O
involved	O
in	O
oligosaccharide-protein	O
binding	O
.	O

Molecular	O
cloning	O
of	O
a	O
cDNA	O
encoding	O
rat	B-GENE
NADH-cytochrome	I-GENE
b5	I-GENE
reductase	I-GENE
and	O
the	O
corresponding	O
gene	O
.	O

Pyrethroid	O
insecticides	O
are	O
widely	O
used	O
in	O
agriculture	O
and	O
private	O
households	O
.	O

We	O
also	O
localized	O
the	O
Fra-2	B-GENE
phosphorylation	I-GENE
sites	I-GENE
by	O
MAPK	B-GENE
to	O
three	O
threonine	O
and	O
three	O
serine	O
residues	O
in	O
the	O
COOH-terminal	O
region	O
by	O
means	O
of	O
site-directed	O
mutagenesis	O
and	O
showed	O
that	O
the	O
threonine	O
residues	O
were	O
more	O
susceptible	O
to	O
MAPK	B-GENE
.	O

Deletion	O
mapping	O
studies	O
revealed	O
that	O
the	O
upstream	O
DNA	O
sequences	O
up	O
to	O
-86	O
were	O
sufficient	O
for	O
the	O
optimal	O
basal	O
level	O
transcription	O
in	O
HeLa	O
cells	O
and	O
also	O
for	O
the	O
EIA-induced	O
transcription	O
.	O

The	O
QT	O
interval	O
was	O
related	O
to	O
various	O
components	O
of	O
the	O
insulin	B-GENE
resistance	O
syndrome	O
,	O
including	O
BP	O
and	O
insulin	B-GENE
sensitivity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
nebulized	O
ipratropium	O
in	O
patients	O
with	O
acute	O
asthma	O
in	O
order	O
to	O
determine	O
whether	O
it	O
augments	O
the	O
bronchodilator	O
effect	O
of	O
a	O
beta	O
agonist	O
drug	O
.	O

Intravenous	O
injections	O
of	O
SG-75	O
(	O
0	O
.	O
03-1	O
mg	O
/	O
kg	O
)	O
decreased	O
systemic	O
blood	O
pressure	O
(	O
SBP	O
)	O
and	O
increased	O
peripheral	O
(	O
coronary	O
,	O
renal	O
,	O
mesenteric	O
and	O
femoral	O
)	O
blood	O
flow	O
(	O
PBF	O
)	O
dose-dependently	O
.	O

Ongoing	O
and	O
future	O
investigations	O
may	O
better	O
define	O
the	O
optimal	O
approach	O
for	O
local	O
control	O
,	O
the	O
optimal	O
duration	O
of	O
maintenance	O
chemotherapy	O
,	O
and	O
the	O
possible	O
role	O
of	O
biologic	O
response	O
modifiers	O
and	O
growth	B-GENE
factors	I-GENE
in	O
further	O
improving	O
the	O
outcome	O
for	O
patients	O
with	O
this	O
disease	O
.	O

Effects	O
of	O
long-term	O
parenteral	O
nutrition	O
on	O
gastrin	B-GENE
release	O
in	O
dogs	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
SGC1	B-GENE
gene	I-GENE
product	I-GENE
includes	O
a	O
region	O
with	O
substantial	O
similarity	O
to	O
the	O
basic-helix-loop-helix	O
domain	O
of	O
the	O
Myc	B-GENE
family	I-GENE
of	O
DNA-binding	O
proteins	O
.	O

Evidence	O
suggests	O
that	O
PHACES	O
syndrome	O
is	O
not	O
a	O
random	O
association	O
but	O
a	O
true	O
phakomatosis	O
;	O
further	O
studies	O
are	O
awaited	O
to	O
shed	O
light	O
on	O
a	O
possible	O
genetic	O
background	O
.	O

To	O
discern	O
whether	O
these	O
disorders	O
of	O
GnRH	B-GENE
deficiency	O
are	O
associated	O
with	O
altered	O
melatonin	O
secretion	O
profiles	O
,	O
we	O
compared	O
untreated	O
young	O
males	O
IGD	O
(	O
n	O
=	O
7	O
)	O
and	O
DP	O
(	O
n	O
=	O
7	O
)	O
to	O
normal	O
pubertal	O
male	O
controls	O
(	O
n	O
=	O
6	O
)	O
.	O

Monitoring	O
patients	O
with	O
acute	O
leukemia	O
for	O
IL-1	B-GENE
and	O
TNF	B-GENE
levels	O
throughout	O
the	O
clinical	O
course	O
of	O
disease	O
may	O
help	O
clarify	O
the	O
causes	O
of	O
febrile	O
episodes	O
.	O

Virol	O
.	O

The	O
P131	B-GENE
ORF	I-GENE
is	O
followed	O
in-frame	O
by	O
a	O
second	O
ORF	O
which	O
is	O
probably	O
expressed	O
by	O
partial	O
readthrough	O
of	O
the	O
UGA	O
termination	O
codon	O
of	O
the	O
P131	B-GENE
ORF	I-GENE
to	O
produce	O
a	O
polypeptide	O
of	O
M	O
(	O
r	O
)	O
191044	O
(	O
P191	B-GENE
)	O
.	O

The	O
CANNTG	B-GENE
motifs	I-GENE
were	O
found	O
to	O
bind	O
MyoD	B-GENE
and	O
myogenin	B-GENE
fusion	I-GENE
proteins	I-GENE
and	O
to	O
interact	O
with	O
proteins	O
in	O
nuclear	O
extracts	O
from	O
cultured	O
myotubes	O
.	O

Baseline	O
data	O
were	O
obtained	O
from	O
10	O
adults	O
.	O

D3S1261	B-GENE
is	O
physically	O
located	O
at	O
or	O
near	O
the	O
MITF	B-GENE
locus	I-GENE
,	O
while	O
D3S2465	B-GENE
and	O
D3S1766	B-GENE
are	O
flanking	O
the	O
locus	O
at	O
about	O
17	O
.	O
5	O
cM	O
genetic	O
distance	O
each	O
side	O
.	O

CyIIa	B-GENE
transcription	O
follows	O
,	O
and	O
is	O
therefore	O
downstream	O
of	O
,	O
the	O
initial	O
specification	O
of	O
these	O
embryonic	O
domains	O
.	O

Determination	O
of	O
diquat	O
in	O
biological	O
materials	O
by	O
electron	O
spin	O
resonance	O
spectroscopy	O
.	O

As	O
no	O
complete	O
PPARgamma	B-GENE
antagonists	O
have	O
been	O
described	O
hitherto	O
,	O
we	O
have	O
constructed	O
a	O
dominant-negative	O
mutant	O
receptor	O
to	O
inhibit	O
wild-type	O
PPARgamma	B-GENE
action	O
.	O

The	O
present	O
investigation	O
conducted	O
in	O
a	O
population	O
of	O
258	O
dentally	O
aware	O
individuals	O
in	O
the	O
age	O
range	O
20-69	O
years	O
,	O
was	O
initiated	O
to	O
elucidate	O
the	O
relationship	O
between	O
tobacco	O
smoking	O
and	O
supragingival	O
calculus	O
,	O
taking	O
into	O
account	O
possible	O
confounding	O
factors	O
such	O
as	O
age	O
,	O
gender	O
,	O
oral	O
hygiene	O
and	O
gingival	O
inflammation	O
.	O

PCNA	B-GENE
mRNA	I-GENE
has	O
a	O
3'UTR	O
antisense	O
to	O
yellow	O
crescent	O
RNA	O
and	O
is	O
localized	O
in	O
ascidian	O
eggs	O
and	O
embryos	O
.	O

Anti-PTB	B-GENE
antibodies	I-GENE
did	O
not	O
inhibit	O
the	O
binding	O
of	O
PTB	B-GENE
to	O
RNA	O
because	O
they	O
were	O
able	O
to	O
supershift	O
RNA-PTB	B-GENE
complexes	I-GENE
.	O

Influence	O
of	O
different	O
methods	O
of	O
chemical	O
disinfection	O
on	O
the	O
physical	O
properties	O
of	O
type	O
IV	O
and	O
V	O
gypsum	O
dies	O
Several	O
instruments	O
and	O
materials	O
frequently	O
used	O
in	O
prosthodontics--such	O
as	O
stone	O
casts	O
,	O
dental	O
impressions	O
,	O
interocclusal	O
records--are	O
classified	O
,	O
by	O
the	O
dental	O
literature	O
,	O
as	O
vehicles	O
of	O
transmission	O
of	O
infectious	O
diseases	O
to	O
those	O
who	O
handle	O
them	O
.	O

Spectrophotometric	O
microanalysis	O
of	O
ethylenediaminotetracetic	O
acid	O
in	O
pharmaceutical	O
preparations	O
.	O

The	O
measurement	O
of	O
the	O
areas	O
of	O
fibrin	B-GENE
,	O
of	O
tissue	O
and	O
fibrinolysis	O
,	O
at	O
the	O
above	O
mentioned	O
times	O
,	O
has	O
been	O
effected	O
at	O
standard	O
magnification	O
(	O
15	O
X	O
)	O
by	O
an	O
image	O
analyser	O
(	O
Videoplan	O
)	O
scale	O
1	O
:	O
8	O
.	O

Pacing	O
the	O
Roux	O
limb	O
abolished	O
the	O
ectopic	O
pacemakers	O
,	O
restored	O
the	O
slow	O
emptying	O
of	O
liquids	O
to	O
the	O
more	O
rapid	O
rate	O
found	O
in	O
the	O
Billroth	O
dogs	O
(	O
t1	O
/	O
2	O
:	O
paced	O
Roux	O
,	O
72	O
+	O
/	O
-	O
15	O
minutes	O
;	O
Billroth	O
,	O
43	O
+	O
/	O
-	O
9	O
minutes	O
;	O
p	O
greater	O
than	O
0	O
.	O
05	O
)	O
and	O
did	O
not	O
change	O
emptying	O
of	O
solids	O
.	O

Staining	O
with	O
IF	B-GENE
MoAB	O
alone	O
of	O
BAL	O
fluid	O
only	O
seemed	O
to	O
be	O
even	O
more	O
sensitive	O
than	O
silver	O
methenamine	O
staining	O
of	O
BAL	O
,	O
TBB	O
and	O
brushing	O
material	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
the	O
Glc7-Reg1	B-GENE
phosphatase	I-GENE
and	O
the	O
Snf1-Snf4	B-GENE
kinase	I-GENE
in	O
the	O
regulation	O
of	O
INO1	B-GENE
transcription	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
effects	O
of	O
social	O
isolation	O
on	O
morphine-induced	O
locomotor	O
activity	O
were	O
compared	O
in	O
:	O
(	O
i	O
)	O
animals	O
with	O
an	O
intact	O
hypothalamo-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
;	O
(	O
ii	O
)	O
animals	O
in	O
which	O
stress-induced	O
corticosterone	O
secretion	O
was	O
blocked	O
by	O
adrenalectomy	O
.	O

Effects	O
of	O
intramammary	O
endotoxin	O
infusion	O
on	O
milking-induced	O
oxytocin	B-GENE
release	O
.	O

255-61	O
.	O

Drug	O
and	O
personnel	O
costs	O
were	O
reduced	O
when	O
batch	O
manufacturing	O
with	O
40-mL	O
multidose	O
vials	O
was	O
compared	O
with	O
extemporaneous	O
compounding	O
with	O
unit-dose	O
vials	O
.	O

The	O
MSL	B-GENE
complex	I-GENE
is	O
specifically	O
localized	O
on	O
the	O
male	O
X	O
chromosome	O
to	O
increase	O
its	O
expression	O
approximately	O
2-fold	O
.	O

Transfer	O
also	O
correlated	O
inversely	O
with	O
gastric	O
juice	O
pH	O
(	O
r	O
=	O
-0	O
.	O
619	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

In	O
several	O
cases	O
of	O
definite	O
SjS	O
,	O
labial	O
salivary	O
gland	O
examinations	O
after	O
more	O
than	O
a	O
one	O
year	O
interval	O
were	O
performed	O
on	O
two	O
occasions	O
,	O
and	O
the	O
clinical	O
and	O
histopathological	O
changes	O
were	O
investigated	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
CAP1	B-GENE
is	O
involved	O
in	O
multidrug	O
resistance	O
and	O
oxidative	O
stress	O
response	O
in	O
C	O
.	O
albicans	O
.	O

Sequence	O
analysis	O
and	O
identification	O
of	O
two	O
hyp	B-GENE
regulatory	I-GENE
mutants	I-GENE
.	O

Acute	O
pancreatitis	O
is	O
a	O
rather	O
common	O
abdominal	O
disorder	O
.	O

Using	O
Scheffe's	O
procedure	O
as	O
an	O
illustration	O
,	O
comparisons	O
are	O
made	O
to	O
usual	O
sample	O
size	O
methods	O
that	O
incorrectly	O
ignore	O
the	O
stochastic	O
nature	O
of	O
S2p	O
.	O

Refugees	O
living	O
in	O
Lund	O
and	O
repatriated	O
to	O
Chile	O
considered	O
their	O
health	O
as	O
bad	O
in	O
a	O
higher	O
proportion	O
than	O
their	O
Swedish	O
counterparts	O
,	O
with	O
an	O
odds	O
ratio	O
of	O
3	O
.	O
48	O
(	O
2	O
.	O
03-5	O
.	O
66	O
)	O
and	O
4	O
.	O
78	O
(	O
2	O
.	O
1-10	O
.	O
25	O
)	O
respectively	O
.	O

Recently	O
,	O
cell-surface	O
TRAIL	B-GENE
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
activated	O
human	O
and	O
mouse	O
T	O
lymphocytes	O
,	O
raising	O
the	O
possibility	O
that	O
TRAIL	B-GENE
might	O
be	O
involved	O
in	O
T	O
cell-mediated	O
cytotoxicity	O
and	O
/	O
or	O
immune	O
regulation	O
.	O

Classical	O
ligand-activated	B-GENE
nuclear	I-GENE
receptors	I-GENE
(	O
e	O
.	O
g	O
.	O
thyroid	B-GENE
hormone	I-GENE
receptor	I-GENE
,	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
)	O
,	O
orphan	B-GENE
nuclear	I-GENE
receptors	I-GENE
(	O
e	O
.	O
g	O
.	O

Therefore	O
the	O
procedure	O
of	O
Lich-Gregoir	O
is	O
not	O
to	O
be	O
recommended	O
in	O
adults	O
.	O

In	O
the	O
posthospital	O
phase	O
of	O
AMI	O
,	O
as	O
well	O
as	O
in	O
CCHD	O
,	O
the	O
occurrence	O
of	O
high-grade	O
VPBs	O
usually	O
indicates	O
more	O
advanced	O
degrees	O
of	O
both	O
coronary	O
and	O
left	O
ventricular	O
disease	O
as	O
well	O
as	O
the	O
possibility	O
of	O
cardiac	O
and	O
/	O
or	O
sudden	O
death	O
.	O

Activities	O
of	O
hepatic	O
cytochrome	O
P-450-dependent	O
metabolizing	O
enzymes	O
such	O
as	O
aminopyrine-	B-GENE
and	I-GENE
TMO	I-GENE
N-demethylase	I-GENE
and	O
aniline	B-GENE
hydroxylase	I-GENE
activity	O
were	O
decreased	O
by	O
pretreatment	O
of	O
rats	O
with	O
cimetidine	O
,	O
whereas	O
in	O
the	O
rats	O
pretreated	O
with	O
ranitidine	O
,	O
these	O
enzyme	O
activities	O
were	O
not	O
changed	O
.	O

Kinetics	O
of	O
calcium	O
metabolism	O
.	O

However	O
,	O
essential	O
contrast	O
differences	O
existing	O
between	O
the	O
FSE	O
sequences	O
and	O
their	O
routine	O
asymmetric	O
dual	O
SE	O
counterpart	O
can	O
be	O
identified	O
.	O

Management	O
of	O
postvitrectomy	O
diabetic	O
vitreous	O
hemorrhage	O
with	O
tissue	B-GENE
plasminogen	I-GENE
activator	I-GENE
(	O
t-PA	B-GENE
)	O
and	O
volume	O
homeostatic	O
fluid-fluid	O
exchanger	O
.	O

After	O
peripheral	O
administration	O
of	O
both	O
CRF	B-GENE
and	O
TRH	B-GENE
,	O
ACTH	B-GENE
levels	O
were	O
significantly	O
higher	O
on	O
the	O
tumor	O
side	O
in	O
all	O
patients	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
This	O
study	O
is	O
a	O
retrospective	O
cohort	O
study	O
of	O
all	O
children	O
with	O
cancer	O
admitted	O
to	O
a	O
single	O
institution	O
with	O
fever	O
and	O
neutropenia	O
(	O
defined	O
as	O
an	O
absolute	O
neutrophil	O
count	O
<	O
500	O
cells	O
/	O
mm3	O
)	O
in	O
a	O
1-year	O
period	O
.	O

The	O
leader	O
sequence	O
of	O
the	O
isolated	O
cDNA	O
clone	O
contains	O
several	O
small	O
open	O
reading	O
frames	O
upstream	O
of	O
the	O
initiation	O
codon	O
of	O
the	O
largest	O
open	O
reading	O
frame	O
coding	O
for	O
the	O
homeodomain	O
protein	O
.	O

The	O
foregoing	O
results	O
show	O
that	O
CXD	O
has	O
high	O
efficacy	O
and	O
safety	O
and	O
it	O
can	O
be	O
said	O
that	O
it	O
is	O
a	O
drug	O
required	O
in	O
the	O
pediatric	O
field	O
.	O

Three	O
mutants	O
were	O
isolated	O
from	O
the	O
widely	O
used	O
strain	O
,	O
PAO1	O
.	O

No	O
anisotropism	O
was	O
recorded	O
in	O
a	O
tetrahydrofuran	O
solution	O
.	O

This	O
c-Jun	B-GENE
activity	O
is	O
inhibited	O
by	O
c-Fos	B-GENE
,	O
another	O
protooncoprotein	O
that	O
can	O
dimerize	O
with	O
c-Jun	B-GENE
to	O
form	O
the	O
transcription	O
factor	O
AP-1	B-GENE
.	O

The	O
moduli	O
of	O
elasticity	O
of	O
the	O
gray	O
and	O
white	O
matter	O
were	O
3	O
.	O
4+	O
/	O
-1	O
.	O
4	O
kPa	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
and	O
3	O
.	O
4+	O
/	O
-0	O
.	O
9	O
kPa	O
in	O
the	O
axial	O
section	O
,	O
3+	O
/	O
-0	O
.	O
3	O
kPa	O
and	O
3	O
.	O
5+	O
/	O
-0	O
.	O
5	O
kPa	O
in	O
the	O
frontal	O
section	O
,	O
and	O
3	O
.	O
5+	O
/	O
-0	O
.	O
9	O
kPa	O
and	O
2	O
.	O
8+	O
/	O
-0	O
.	O
4	O
kPa	O
in	O
the	O
sagittal	O
section	O
,	O
respectively	O
.	O

The	O
NF1	B-GENE
locus	I-GENE
encodes	O
a	O
protein	O
functionally	O
related	O
to	O
mammalian	B-GENE
GAP	I-GENE
and	O
yeast	B-GENE
IRA	I-GENE
proteins	I-GENE
.	O

In	O
the	O
second	O
experiment	O
,	O
a	O
stable	O
nickel	O
isotope	O
,	O
61Ni	O
,	O
was	O
given	O
in	O
drinking	O
water	O
to	O
20	O
nickel-sensitized	O
women	O
and	O
20	O
age-matched	O
controls	O
,	O
both	O
groups	O
having	O
vesicular	O
hand	O
eczema	O
of	O
the	O
pompholyx	O
type	O
.	O

Subsequent	O
to	O
their	O
secretion	O
,	O
the	O
IGF-II	B-GENE
in	O
xz97	O
and	O
G11	O
cells	O
accumulated	O
in	O
the	O
conditioned	O
medium	O
mostly	O
as	O
two	O
partially	O
processed	O
species	O
with	O
appMr	O
,	O
of	O
17K	O
and	O
14K	O
,	O
respectively	O
.	O

Five-year	O
prospective	O
study	O
of	O
peripheral	O
white	O
blood	O
cells	O
in	O
infectious	O
mononucleosis	O
.	O

Cold	O
cardioplegia	O
was	O
administered	O
at	O
45	O
mm	O
Hg	O
every	O
20	O
minutes	O
for	O
2	O
hours	O
.	O

Experimental	O
data	O
showed	O
that	O
these	O
abnormal	O
proteins	O
are	O
constitutively	O
localized	O
in	O
the	O
nucleus	O
,	O
have	O
lost	O
the	O
transcriptional	O
repressor	O
functions	O
typical	O
of	O
normal	O
NF-kappa	B-GENE
B2p52	I-GENE
and	O
may	O
be	O
capable	O
of	O
transactivation	O
activity	O
.	O

Ultrastructure	O
of	O
the	O
heart	O
muscle	O
in	O
experimental	O
myocardial	O
infarct	O
following	O
physical	O
training	O
.	O

By	O
using	O
lacZ	B-GENE
fusions	I-GENE
,	O
it	O
was	O
possible	O
to	O
localize	O
the	O
DNA	O
sequences	O
required	O
to	O
mediate	O
nitrate	O
repression	O
to	O
the	O
pfl	B-GENE
promoter-regulatory	I-GENE
region	I-GENE
.	O

MVR	O
typing	O
of	O
rare-length	O
alleles	O
indicates	O
that	O
they	O
are	O
comprised	O
of	O
disorganized	O
sequences	O
,	O
although	O
they	O
usually	O
bear	O
a	O
resemblance	O
to	O
one	O
of	O
the	O
common	O
alleles	O
at	O
the	O
5'-most	O
end	O
.	O

Splicing	O
of	O
the	O
K-SAM	B-GENE
alternative	O
exon	O
of	O
the	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
2	I-GENE
gene	I-GENE
is	O
heavily	O
dependent	O
on	O
the	O
U-rich	O
sequence	O
IAS1	B-GENE
lying	O
immediately	O
downstream	O
from	O
its	O
5'	O
splice	O
site	O
.	O

Biochemical	O
examinations	O
of	O
calcium-phosphorus	O
metabolism	O
included	O
ions	O
and	O
PTH	B-GENE
concentrations	O
in	O
blood	O
serum	O
,	O
and	O
the	O
activity	O
of	O
bone	O
isoenzyme	O
of	O
AP	B-GENE
.	O

Changes	O
in	O
prognosis	O
of	O
twin	O
births	O
over	O
20	O
years	O
.	O

Losses	O
during	O
the	O
complete	O
procedure	O
are	O
corrected	O
for	O
using	O
radioactive	O
estrogen	O
conjugates	O
during	O
the	O
first	O
steps	O
and	O
later	O
by	O
adding	O
deuterated	O
internal	O
standards	O
of	O
all	O
compounds	O
measured	O
(	O
matairesinol	O
,	O
enterodiol	O
,	O
enterolactone	O
,	O
daidzein	O
,	O
O-desmethylangolensin	O
,	O
equol	O
,	O
and	O
genistein	O
)	O
.	O

Altogether	O
,	O
these	O
data	O
suggest	O
that	O
Ypt51p	B-GENE
,	O
Ypt52p	B-GENE
,	O
and	O
Ypt53p	B-GENE
are	O
required	O
for	O
transport	O
in	O
the	O
endocytic	O
pathway	O
and	O
for	O
correct	O
sorting	O
of	O
vacuolar	B-GENE
hydrolases	I-GENE
suggesting	O
a	O
possible	O
intersection	O
of	O
the	O
endocytic	O
with	O
the	O
vacuolar	O
sorting	O
pathway	O
.	O

Regionalization	O
of	O
drug	O
delivery	O
is	O
a	O
potential	O
method	O
to	O
avoid	O
this	O
problem	O
.	O

Restriction	O
mapping	O
analysis	O
localized	O
this	O
cDNA	O
to	O
the	O
HHV-6A	B-GENE
(	I-GENE
U1102	I-GENE
)	I-GENE
genomic	I-GENE
BamHI	I-GENE
G	I-GENE
fragment	I-GENE
,	O
at	O
the	O
right	O
end	O
of	O
the	O
unique	O
long	O
segment	O
of	O
the	O
genome	O
and	O
to	O
the	O
SalI	B-GENE
L	I-GENE
and	O
SalI	B-GENE
O	I-GENE
fragments	I-GENE
within	O
the	O
left	O
and	O
right	O
terminal	O
direct	O
repeat	O
regions	O
,	O
respectively	O
.	O

Fowlpox	O
virus	O
encodes	O
nonessential	O
homologs	O
of	O
cellular	B-GENE
alpha-SNAP	I-GENE
,	O
PC-1	B-GENE
,	O
and	O
an	O
orphan	O
human	O
homolog	O
of	O
a	O
secreted	O
nematode	O
protein	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
temporal	O
characteristics	O
and	O
the	O
spatial	O
mapping	O
of	O
the	O
independent	O
components	O
identified	O
by	O
ICA	O
when	O
the	O
subject	O
performs	O
a	O
finger-tapping	O
task	O
.	O

CONCLUSIONS	O
:	O
Physiologic	O
pacing	O
provides	O
little	O
benefit	O
over	O
ventricular	O
pacing	O
for	O
the	O
prevention	O
of	O
stroke	O
or	O
death	O
due	O
to	O
cardiovascular	O
causes	O
.	O

Antiviral	O
agents	O
.	O

The	O
maintenance	O
of	O
increased	O
myocardial	O
capillary	O
density	O
required	O
a	O
similar	O
amount	O
of	O
exercise	O
,	O
and	O
at	O
least	O
1	O
h	O
of	O
exercise	O
once	O
a	O
week	O
was	O
necessary	O
to	O
maintain	O
the	O
enlargement	O
of	O
ECA	O
.	O
20	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O
Brandt's	O
double	O
cuff-tubes	O
(	O
G2	O
)	O
succeed	O
in	O
avoiding	O
uncontrolled	O
increase	O
of	O
cuff-pressure	O
during	O
anaesthesia	O
with	O
N2O	O
.	O

The	O
effects	O
produced	O
by	O
oral	O
administration	O
of	O
500	O
mg	O
/	O
kg	O
p-xylene	O
or	O
toluene	O
lasted	O
at	O
least	O
8	O
hr	O
,	O
while	O
the	O
effect	O
of	O
inhaled	O
p-xylene	O
dissipated	O
within	O
75	O
min	O
of	O
removal	O
from	O
the	O
exposure	O
.	O

One	O
of	O
these	O
factors	O
,	O
IRF-2	B-GENE
,	O
was	O
initially	O
cloned	O
as	O
an	O
antagonistic	O
counterpart	O
to	O
IRF-1	B-GENE
with	O
oncogenic	O
potential	O
.	O

This	O
combined	O
intravenous	O
anaesthetic	O
regimen	O
gave	O
good	O
anaesthesia	O
and	O
analgesia	O
to	O
pigs	O
for	O
up	O
to	O
2	O
h	O
as	O
monitored	O
by	O
clinical	O
signs	O
.	O

Serum	O
E2	O
concentrations	O
increased	O
numerically	O
two-	O
to	O
threefold	O
from	O
d	O
56	O
to	O
140	O
in	O
controls	O
fed	O
MGA	O
,	O
compared	O
with	O
controls	O
not	O
fed	O
MGA	O
.	O

The	O
coding	O
sequences	O
of	O
the	O
Crry	B-GENE
gene	I-GENE
encompass	O
over	O
25	O
kb	O
of	O
DNA	O
,	O
whereas	O
the	O
Crry-ps	B-GENE
sequences	I-GENE
are	O
included	O
within	O
a	O
single	O
5	B-GENE
.	I-GENE
6-kb	I-GENE
Eco-R1	I-GENE
fragment	I-GENE
.	O

A	O
note	O
on	O
the	O
phase-plane	O
technique	O
representation	O
of	O
cardiac	O
action	O
potentials	O
.	O

Prevention	O
of	O
acute	O
paraquat	O
toxicity	O
in	O
rats	O
by	O
superoxide	B-GENE
dismutase	I-GENE
.	O

The	O
amino	O
acid	O
sequence	O
was	O
determined	O
to	O
be	O
residues	O
716-724	O
and	O
hence	O
lysine	O
residue	O
721	O
is	O
located	O
within	O
the	O
ATP-binding	O
site	O
.	O

Thus	O
,	O
hGRbeta	B-GENE
potentially	O
functions	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
hGRalpha	B-GENE
activity	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
RSTD	O
predicts	O
coronary	O
anatomy	O
during	O
acute	O
coronary	O
occlusion	O
.	O

Alignment	O
of	O
the	O
cervical	O
spine	O
,	O
vertebral	O
abnormalities	O
,	O
and	O
disc	O
changes	O
also	O
were	O
evaluated	O
.	O

CONCLUSION	O
:	O
Intravenous	O
diazepam	O
administration	O
before	O
EGD	O
produces	O
a	O
significant	O
fall	O
in	O
SpO2	O
during	O
the	O
procedure	O
,	O
and	O
so	O
should	O
be	O
avoided	O
;	O
continuous	O
monitoring	O
of	O
SpO2	O
should	O
be	O
done	O
during	O
EGD	O
.	O

There	O
are	O
two	O
immunogenic	O
sites	O
on	O
the	O
type	B-GENE
A	I-GENE
influenza	I-GENE
A	I-GENE
/	I-GENE
Japan	I-GENE
/	I-GENE
57	I-GENE
(	I-GENE
H2N2	I-GENE
)	I-GENE
hemagglutinin	I-GENE
(	O
HA	B-GENE
)	O
that	O
can	O
be	O
recognized	O
by	O
class	B-GENE
I	I-GENE
major	I-GENE
histocompatibility	I-GENE
complex	I-GENE
(	O
MHC	B-GENE
)	O
,	O
H-2Kd-restricted	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O

However	O
,	O
after	O
PRK	O
at	O
5	O
weeks	O
of	O
age	O
,	O
partial	O
retreatment	O
may	O
be	O
necessary	O
due	O
to	O
regression	O
of	O
the	O
PRK	O
effect	O
.	O

One	O
maternal	O
death	O
,	O
reduced	O
body	O
weight	O
,	O
and	O
reduced	O
weight	O
gain	O
were	O
noted	O
at	O
the	O
high	O
dose	O
;	O
confirmed	O
pregnancy	O
rates	O
were	O
84	O
to	O
100%	O
for	O
each	O
group	O
.	O

Entry	O
of	O
yeast	O
cells	O
into	O
the	O
mitotic	O
cell	O
cycle	O
(	O
Start	O
)	O
involves	O
a	O
form	O
of	O
the	O
CDC28	B-GENE
kinase	I-GENE
that	O
associates	O
with	O
G1-specific	O
cyclins	B-GENE
encoded	O
by	O
CLN1	B-GENE
and	O
CLN2	B-GENE
(	O
ref	O
.	O

The	O
tip	O
of	O
the	O
button	O
caused	O
a	O
perforation	O
of	O
the	O
posterior	O
stomach	O
wall	O
,	O
leading	O
to	O
death	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
STAT	B-GENE
activation	O
in	O
a	O
panel	O
of	O
rodent	O
fibroblast	O
cell	O
lines	O
stably	O
transformed	O
by	O
diverse	O
viral	O
oncoproteins	O
.	O

Comparison	O
with	O
the	O
crystal	O
structure	O
of	O
Desulfovibrio	O
gigas	O
,	O
Dg	O
,	O
Fd	O
(	O
Kissinger	O
et	O
al	O
.	O
,	O
1991	O
)	O
reveals	O
a	O
very	O
similar	O
folding	O
topology	O
,	O
although	O
several	O
secondary	O
structural	O
elements	O
are	O
extended	O
in	O
Pf	O
relative	O
to	O
Dg	O
Fd	O
.	O

Thus	O
,	O
elongin	B-GENE
C	I-GENE
is	O
found	O
to	O
oligomerize	O
in	O
solution	O
and	O
to	O
undergo	O
significant	O
structural	O
rearrangements	O
upon	O
binding	O
of	O
two	O
different	O
partner	O
proteins	O
.	O

The	O
gene	B-GENE
lac-1	I-GENE
,	O
encoding	O
the	O
enzyme	O
laccase	B-GENE
,	O
is	O
the	O
best	O
characterized	O
of	O
a	O
number	O
of	O
genes	O
in	O
the	O
chestnut	O
blight	O
fungus	O
,	O
Cryphonectria	O
parasitica	O
,	O
that	O
are	O
repressed	O
by	O
hypoviruses	O
,	O
a	O
group	O
of	O
virulence-attenuating	O
mycoviruses	O
.	O
lac-1	B-GENE
has	O
also	O
been	O
shown	O
to	O
be	O
transcriptionally	O
activated	O
by	O
low	O
concentrations	O
of	O
the	O
translational	O
inhibitor	O
cycloheximide	O
(	O
CHX	O
)	O
and	O
by	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

4	O
.	O

Using	O
sequence	O
information	O
from	O
human	B-GENE
BMAL1	I-GENE
(	O
hBMAL1	B-GENE
)	O
cDNAs	O
previously	O
reported	O
by	O
our	O
laboratory	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
cDNAs	O
encoding	O
three	O
splice	O
variants	O
of	O
the	O
mouse	B-GENE
BMAL1	I-GENE
(	O
mBMAL1	B-GENE
)	O
gene	O
.	O

In	O
support	O
of	O
a	O
role	O
at	O
the	O
spindle	O
,	O
two-hybrid	O
library	O
screening	O
with	O
HEF1	B-GENE
identifies	O
the	O
human	O
homolog	O
of	O
the	O
G2	B-GENE
/	I-GENE
M	I-GENE
spindle-regulatory	I-GENE
protein	I-GENE
Dim1p	I-GENE
as	O
a	O
specific	O
interactor	O
with	O
a	O
region	O
of	O
HEF1	B-GENE
encompassed	O
in	O
p55	B-GENE
(	I-GENE
HEF1	I-GENE
)	I-GENE
.	O

An	O
endogenous	O
mammalian	O
regulator	O
of	O
this	O
process	O
,	O
named	O
Usurpin	B-GENE
,	O
has	O
been	O
identified	O
(	O
aliases	O
for	O
Usurpin	B-GENE
include	O
CASH	B-GENE
,	O
Casper	B-GENE
,	O
CLARP	B-GENE
,	O
FLAME-1	B-GENE
,	O
FLIP	B-GENE
,	O
I-FLICE	B-GENE
and	O
MRIT	B-GENE
)	O
.	O

In	O
a	O
similar	O
fashion	O
to	O
adipose	O
stromal	O
cells	O
,	O
serum	O
potentiated	O
the	O
response	O
to	O
dexamethasone	O
but	O
had	O
no	O
effect	O
on	O
phorbol	O
ester-stimulated	O
activity	O
.	O

Although	O
MAP	B-GENE
(	I-GENE
mitogen-activated	I-GENE
protein	I-GENE
)	I-GENE
kinases	I-GENE
are	O
implicated	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
in	O
many	O
cell	O
types	O
,	O
the	O
role	O
of	O
MAP	B-GENE
kinases	I-GENE
in	O
cardiac	O
hypertrophy	O
remains	O
unclear	O
.	O

AGO1	B-GENE
is	O
similar	O
to	O
QDE-2	B-GENE
required	O
for	O
quelling	O
and	O
RDE-1	B-GENE
required	O
for	O
RNAi	O
.	O

METHODS	O
:	O
Fifty-eight	O
patients	O
who	O
underwent	O
a	O
curative	O
hepatic	O
resection	O
for	O
HCC	O
and	O
whose	O
preoperative	O
AFP	B-GENE
levels	O
were	O
>	O
100	O
ng	O
/	O
ml	O
,	O
were	O
selected	O
for	O
this	O
study	O
.	O

Significant	O
alterations	O
in	O
the	O
vasectomized	O
rats	O
from	O
sham	O
rats	O
included	O
:	O
testicular	O
and	O
epididymal	O
hypertrophy	O
,	O
formation	O
of	O
pathologic	O
vas	O
deferens	O
granulomas	O
,	O
decreased	O
total	O
serum	O
protein	O
,	O
lowered	O
alpha-globulin	B-GENE
levels	O
as	O
shown	O
by	O
serum	O
electrophoresis	O
,	O
and	O
increased	O
sperm	O
agglutinin	O
antibody	O
titers	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
hormone	O
receptor	O
status	O
between	O
the	O
cases	O
without	O
lymph	O
node	O
metastases	O
and	O
with	O
lymph	O
node	O
metastases	O
,	O
'clandestine'	O
or	O
macrometastases	O
.	O

It	O
may	O
be	O
time	O
to	O
reevaluate	O
the	O
dichotomy	O
between	O
AD	O
and	O
VaD	O
.	O

Comparative	O
mapping	O
of	O
the	O
Brassica	B-GENE
S	I-GENE
locus	I-GENE
region	I-GENE
and	O
its	O
homeolog	O
in	O
Arabidopsis	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
individual	O
members	O
of	O
one	O
subfamily	O
of	O
KRAB	B-GENE
zinc	I-GENE
finger	I-GENE
genes	I-GENE
is	O
restricted	O
to	O
specific	O
hematopoietic	O
cell	O
lineages	O
.	O

Two	O
of	O
the	O
ORFs	O
are	O
completely	O
internal	O
to	O
longer	O
ones	O
and	O
a	O
third	O
is	O
partially	O
embedded	O
in	O
G2850	B-GENE
.	O

Fast	O
goal-directed	O
voluntary	O
movements	O
of	O
the	O
human	O
upper	O
extremity	O
are	O
known	O
to	O
be	O
associated	O
with	O
three	O
distinct	O
bursts	O
of	O
EMG	O
activity	O
in	O
antagonistic	O
muscles	O
.	O

A	O
5-month-old	O
infant	O
with	O
persistent	O
congenital	O
stridor	O
and	O
acute	O
respiratory	O
distress	O
is	O
presented	O
.	O

Nevertheless	O
,	O
antibodies	O
directed	O
against	O
an	O
epitope-tagged	O
version	O
of	O
Prp42p	B-GENE
specifically	O
precipitate	O
U1	B-GENE
snRNA	I-GENE
from	O
yeast	O
extracts	O
.	O

They	O
lack	O
a	O
predicted	O
single	O
stranded	O
(	O
ss	O
)	O
DNA	O
binding	O
motif	O
that	O
is	O
unique	O
the	O
large	O
terminase	B-GENE
proteins	I-GENE
in	O
T4	B-GENE
gp17	I-GENE
,	O
and	O
that	O
has	O
been	O
implicated	O
in	O
recognizing	O
ssDNA	O
regions	O
in	O
replicating	O
and	O
recombining	O
T4DNA	O
destined	O
to	O
be	O
packaged	O
.	O

The	O
Tullio	O
phenomenon	O
,	O
fistula	O
test	O
,	O
and	O
Hennebert's	O
sign	O
:	O
clinical	O
significance	O
.	O

The	O
ORF3	O
mutant	O
produced	O
reduced	O
levels	O
of	O
tabtoxin	B-GENE
,	O
indicating	O
that	O
ORF3	O
may	O
have	O
a	O
role	O
in	O
T	B-GENE
beta	I-GENE
L	I-GENE
biosynthesis	O
.	O

No	O
significant	O
differences	O
existed	O
between	O
the	O
two	O
age	O
groups	O
in	O
baseline	O
characteristics	O
,	O
including	O
treatment	O
protocol	O
,	O
performance	O
status	O
,	O
and	O
serum	B-GENE
lactate	I-GENE
dehydrogenase	I-GENE
(	O
LDH	B-GENE
)	O
level	O
.	O

Interferon	B-GENE
stimulated	I-GENE
gene	I-GENE
factor	I-GENE
3	I-GENE
(	O
ISGF3	B-GENE
)	O
is	O
a	O
trimeric	O
transcription	O
factor	O
activated	O
on	O
treatment	O
of	O
cells	O
with	O
interferon-alpha	B-GENE
and	I-GENE
beta	I-GENE
(	O
type	B-GENE
I	I-GENE
IFNs	I-GENE
)	O
.	O

Although	O
heart	O
rate	O
and	O
diastolic	O
pressure	O
rose	O
in	O
some	O
degree	O
1	O
min	O
after	O
intubation	O
,	O
free	O
and	O
total	O
CA	O
concentrations	O
did	O
not	O
increase	O
during	O
study	O
period	O
.	O

Biol	O
.	O

Activation	O
of	O
c-fos	B-GENE
gene	I-GENE
expression	O
by	O
a	O
kinase-deficient	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
.	O

Fifty	O
six	O
young	O
patients	O
(	O
age	O
<	O
45	O
yr	O
)	O
with	O
doppler-proven	O
DVT	O
were	O
investigated	O
for	O
the	O
presence	O
of	O
resistance	O
to	O
activated	B-GENE
protein	I-GENE
C	I-GENE
(	O
APC-R	B-GENE
)	O
,	O
lupus	O
anticoagulant	O
(	O
LA	O
)	O
,	O
anticardiolipin	B-GENE
antibodies	I-GENE
and	O
deficiencies	O
of	O
protein	B-GENE
C	I-GENE
,	O
protein	B-GENE
S	I-GENE
,	O
ATIII	B-GENE
activities	O
.	O

The	O
effects	O
of	O
procedural	O
variations	O
on	O
lateralized	O
Stroop	O
effects	O
.	O

Host	O
lipids	O
in	O
tuberculous	O
infection	O
.	O

However	O
,	O
in	O
those	O
studies	O
due	O
to	O
the	O
presence	O
of	O
thiol	O
agents	O
in	O
the	O
PKC	B-GENE
preparations	O
,	O
the	O
sensitive	O
reaction	O
of	O
BPO	O
with	O
redox-active	O
cysteine	O
residues	O
in	O
PKC	B-GENE
was	O
not	O
observed	O
.	O

Increasing	O
the	O
cut-off	O
point	O
to	O
3	O
positive	O
responses	O
decreased	O
the	O
sensitivity	O
to	O
81%	O
and	O
increased	O
the	O
specificity	O
to	O
94%	O
.	O

Recently	O
,	O
extremely	O
high	O
levels	O
of	O
endothelin-1	B-GENE
(	O
ET-1	B-GENE
)	O
were	O
detected	O
in	O
the	O
pericardial	O
fluid	O
of	O
patients	O
undergoing	O
cardiac	O
surgery	O
.	O

The	O
3'	O
stem-loop	O
is	O
highly	O
divergent	O
in	O
structure	O
among	O
species	O
and	O
lies	O
immediately	O
upstream	O
of	O
the	O
binding	O
site	O
for	O
Sm	B-GENE
proteins	I-GENE
.	O

The	O
C-terminal	O
domains	O
(	O
CTDs	O
)	O
of	O
the	O
RPase	B-GENE
beta	I-GENE
subunit	I-GENE
and	O
DNA	B-GENE
primase	I-GENE
(	O
dnaG	B-GENE
protein	I-GENE
)	O
were	O
not	O
only	O
strongly	O
homologous	O
to	O
each	O
other	O
but	O
also	O
considerably	O
homologous	O
to	O
the	O
RPase	B-GENE
alpha	I-GENE
,	O
suggesting	O
that	O
an	O
alpha	O
subunit-like	O
enzyme	O
must	O
have	O
been	O
commonly	O
ancestral	O
to	O
core	B-GENE
enzyme	I-GENE
subunits	I-GENE
and	O
primase	B-GENE
.	O

In	O
these	O
cases	O
,	O
asbestos	O
or	O
erionite-tissue	O
burden	O
followed	O
by	O
fibrosis	O
was	O
frequently	O
observed	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
amphotericin	O
B	O
oral	O
suspension	O
(	O
ABOS	O
)	O
for	O
the	O
treatment	O
of	O
fluconazole	O
refractory	O
oral	O
candidiasis	O
in	O
persons	O
with	O
HIV	O
infection	O
.	O

Chlamydial	O
agents	O
were	O
isolated	O
from	O
the	O
semen	O
near	O
the	O
end	O
of	O
the	O
chlamydemic	O
phase	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
how	O
couplers	O
and	O
their	O
placement	O
affect	O
the	O
ALGO2	O
click	O
spectral	O
properties	O
.	O

III	O
.	O

The	O
arrangement	O
of	O
these	O
cutoff-levels	O
leads	O
to	O
a	O
sensitivity	O
of	O
85%	O
at	O
a	O
specificity	O
of	O
55%	O
for	O
Protein	B-GENE
S100	I-GENE
when	O
measured	O
by	O
RIA	O
,	O
and	O
to	O
a	O
sensitivity	O
of	O
77%	O
at	O
a	O
specificity	O
of	O
61%	O
when	O
measured	O
by	O
LIA	O
.	O

In	O
memory	O
of	O
Magdelaine	O
Comtesse	O
.	O

In	O
the	O
absence	O
of	O
Swi4	B-GENE
and	O
Swi6	B-GENE
cell	O
viability	O
is	O
lost	O
,	O
but	O
can	O
be	O
regained	O
by	O
ectopic	O
expression	O
of	O
the	O
G1	B-GENE
cyclin	I-GENE
encoding	I-GENE
genes	I-GENE
,	O
CLN1	B-GENE
or	O
CLN2	B-GENE
.	O

The	O
study	O
made	O
to	O
define	O
the	O
ability	O
of	O
lipid	B-GENE
A	I-GENE
monoclonal	I-GENE
antibodies	I-GENE
to	O
correct	O
hemodynamic	O
disturbances	O
due	O
to	O
endotoxemia	O
in	O
dog	O
experiments	O
showed	O
the	O
efficacy	O
of	O
the	O
antibodies	O
administration	O
.	O

Data	O
on	O
prosthesis	O
use	O
are	O
encouraging	O
,	O
although	O
a	O
follow-up	O
study	O
is	O
required	O
to	O
determine	O
the	O
functional	O
outcome	O
for	O
prosthesis	O
users	O
and	O
non-users	O
.	O

HBx	B-GENE
strongly	O
elevates	O
levels	O
of	O
GTP-bound	O
Ras	B-GENE
,	O
activated	O
and	O
phosphorylated	O
Raf	B-GENE
,	O
and	O
tyrosine-phosphorylated	O
and	O
activated	O
MAP	B-GENE
kinase	I-GENE
.	O

These	O
studies	O
indicate	O
that	O
in	O
vitro	O
and	O
in	O
vivo	O
electrical	O
stimulation	O
generate	O
reactive	O
oxygen	O
species	O
and	O
affect	O
SOD	B-GENE
activity	O
,	O
which	O
in	O
part	O
are	O
responsible	O
for	O
decreased	O
sperm	O
motion	O
and	O
viability	O
.	O

In	O
addition	O
,	O
the	O
DNA-binding	O
experiments	O
show	O
that	O
either	O
one	O
of	O
the	O
two	O
MADS	B-GENE
domains	I-GENE
of	O
a	O
dimer	O
can	O
be	O
sufficient	O
to	O
confer	O
a	O
particular	O
DNA-binding	O
specificity	O
to	O
the	O
complex	O
and	O
that	O
sequences	O
outside	O
the	O
amino-terminal	O
basic	O
region	O
of	O
the	O
MADS	B-GENE
domain	O
can	O
,	O
in	O
some	O
cases	O
,	O
contribute	O
to	O
the	O
DNA-binding	O
specificity	O
of	O
the	O
proteins	O
.	O

Finally	O
,	O
the	O
mechanism	O
of	O
ASK1	B-GENE
activation	O
involves	O
,	O
in	O
part	O
,	O
homo-oligomerization	O
.	O

A	O
third	O
one	O
is	O
homologous	O
in	O
half	O
of	O
its	O
length	O
to	O
the	O
prokaryotic	B-GENE
hydantoinase	I-GENE
HyuA	B-GENE
and	O
in	O
the	O
other	O
half	O
to	O
hydatoinase	B-GENE
HyuB	B-GENE
.	O

One	O
of	O
the	O
most	O
relevant	O
aspects	O
in	O
achieving	O
the	O
consistent	O
survival	O
of	O
an	O
animal	O
undergoing	O
the	O
experimental	O
implantation	O
of	O
a	O
total	O
artificial	O
heart	O
is	O
obviously	O
related	O
to	O
the	O
correct	O
anatomic	O
placement	O
of	O
prosthetic	O
ventricles	O
inside	O
the	O
chest	O
.	O

In	O
addition	O
serum	B-GENE
IgE	I-GENE
concentrations	O
were	O
not	O
statistically	O
different	O
.	O

Our	O
results	O
demonstrate	O
that	O
distinct	O
cytoplasmic	O
domains	O
of	O
these	O
cytokine	B-GENE
receptors	I-GENE
elicit	O
convergent	O
signaling	O
pathways	O
and	O
provide	O
evidence	O
that	O
beta	B-GENE
c	I-GENE
and	O
IL-2R	B-GENE
beta	I-GENE
function	O
as	O
a	O
complete	O
signal	O
transducer	O
.	O

H-7	O
,	O
which	O
specifically	O
,	O
although	O
weakly	O
,	O
inhibited	O
PKC	B-GENE
activation	O
,	O
had	O
no	O
effect	O
on	O
tyrosine	O
phosphorylation	O
and	O
PtdIns	O
(	O
3	O
,	O
4	O
)	O
P2	O
production	O
.	O

CONCLUSION	O
:	O
Extrusion	O
cooking	O
is	O
effective	O
for	O
the	O
inactivation	O
of	O
DON	O
but	O
is	O
of	O
limited	O
value	O
for	O
AFB1	O
,	O
even	O
if	O
metabisulphite	O
is	O
added	O
.	O

Efforts	O
were	O
made	O
to	O
determine	O
the	O
amount	O
of	O
time	O
required	O
for	O
kidney	O
lesions	O
to	O
develop	O
and	O
,	O
if	O
possible	O
,	O
to	O
delineate	O
the	O
potential	O
site	O
of	O
action	O
of	O
PBB	O
.	O

In	O
summary	O
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
activation	O
of	O
NO	O
production	O
mediates	O
apoptosis	O
after	O
TG	O
exposure	O
in	O
JT	O
/	O
Neo	O
cells	O
.	O

All	O
carcasses	O
resulted	O
in	O
contamination	O
with	O
aerobic	O
mesophilic	O
bacteria	O
in	O
the	O
range	O
from	O
6	O
x	O
10	O
(	O
3	O
)	O
to	O
1	O
.	O
2	O
x	O
10	O
(	O
6	O
)	O
CFU	O
/	O
ml	O
liquid	O
washed	O
,	O
and	O
94%	O
them	O
with	O
sporulate	O
bacteria	O
,	O
the	O
threshold	O
being	O
under	O
100	O
CFU	O
/	O
ml	O
(	O
Figure	O
1	O
)	O
.	O

Saccharomyces	O
cerevisiae	O
contains	O
four	O
known	O
acyl-CoA	B-GENE
synthetases	I-GENE
(	O
fatty	B-GENE
acid	I-GENE
activation	I-GENE
proteins	I-GENE
,	O
Faaps	B-GENE
)	O
.	O

Specific	O
requirements	O
for	O
branched-chain	O
amino	O
acids	O
,	O
glutamine	O
,	O
and	O
arginine	O
are	O
evaluated	O
.	O

The	O
corn	O
and	O
mineral	O
oil	O
emulsions	O
were	O
almost	O
as	O
effective	O
as	O
milk	O
but	O
less	O
effective	O
than	O
sucrose	O
(	O
0	O
.	O
3M	O
)	O
in	O
stimulating	O
ingestion	O
.	O

In	O
both	O
shoots	O
and	O
roots	O
,	O
GT-2	B-GENE
protein	I-GENE
is	O
undetectable	O
in	O
meristematic	O
tissue	O
but	O
becomes	O
expressed	O
at	O
later	O
stages	O
of	O
cellular	O
development	O
,	O
consistent	O
with	O
a	O
role	O
in	O
contributing	O
to	O
the	O
pattern	O
of	O
phytochrome	B-GENE
A	I-GENE
gene	I-GENE
expression	O
.	O

The	O
calcium	O
requirement	O
for	O
hypothermic	O
storage	O
of	O
the	O
cardiac	O
explant	O
.	O

A	O
cDNA	O
library	O
of	O
tumour	O
cells	O
was	O
screened	O
with	O
an	O
interleukin	B-GENE
2	I-GENE
gene-specific	O
probe	O
.	O

An	O
element	O
within	O
the	O
5'	O
untranslated	O
region	O
of	O
human	B-GENE
Hsp70	I-GENE
mRNA	I-GENE
which	O
acts	O
as	O
a	O
general	O
enhancer	O
of	O
mRNA	O
translation	O
.	O

The	O
ARX2	O
procedure	O
models	O
the	O
recorded	O
signal	O
as	O
the	O
sum	O
of	O
three	O
signals	O
:	O
(	O
a	O
)	O
the	O
background	O
EEG	O
activity	O
,	O
modelled	O
as	O
an	O
autoregressive	O
process	O
driven	O
by	O
a	O
white	O
noise	O
;	O
(	O
b	O
)	O
a	O
filtered	O
version	O
of	O
a	O
reference	O
signal	O
carrying	O
the	O
average	O
information	O
contained	O
in	O
each	O
sweep	O
;	O
(	O
c	O
)	O
a	O
signal	O
due	O
to	O
the	O
ocular	O
artefact	O
propagation	O
.	O

Diagnosis	O
and	O
treatment	O
of	O
insulin-secreting	O
tumours	O
.	O

The	O
coordinated	O
expression	O
of	O
CD4	B-GENE
and	O
CD8	B-GENE
during	O
T-cell	O
development	O
is	O
tightly	O
coupled	O
with	O
the	O
maturation	O
state	O
of	O
the	O
T	O
cell	O
.	O

In	O
contrast	O
,	O
recent	O
evidence	O
suggests	O
that	O
children	O
with	O
sickle-hemoglobin	B-GENE
C	I-GENE
disease	O
do	O
not	O
develop	O
functional	O
asplenia	O
before	O
3	O
to	O
4	O
years	O
of	O
age	O
and	O
thus	O
may	O
not	O
benefit	O
from	O
penicillin	O
prophylaxis	O
.	O

Contraction	O
of	O
the	O
tracheal	O
muscle	O
and	O
the	O
activity	O
of	O
stretch	O
receptors	O
in	O
the	O
trachea	O
.	O

Imaging	O
of	O
D2	B-GENE
dopamine	I-GENE
receptor	I-GENE
.	O

Modification	O
of	O
enteral	O
resorption	O
by	O
cytostatic	O
therapy	O
.	O

This	O
mutation	O
no	O
longer	O
repressed	O
the	O
HPV-11	O
upstream	O
regulatory	O
region-controlled	O
reporter	O
expression	O
.	O

The	O
production	O
of	O
ceramide	O
is	O
emerging	O
as	O
a	O
fixture	O
of	O
programmed	O
cell	O
death	O
.	O

Foveating	O
saccades	O
,	O
therefore	O
,	O
can	O
be	O
distinguished	O
from	O
other	O
FEMs	O
on	O
the	O
basis	O
of	O
speed	O
.	O

RESULTS	O
:	O
In	O
the	O
AGA	O
group	O
,	O
both	O
fetal	O
and	O
maternal	O
serum	O
prolactin	B-GENE
concentration	O
increased	O
significantly	O
with	O
gestation	O
(	O
P	O
<	O
0	O
.	O
001	O
and	O
P	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Colorimetric	O
determination	O
of	O
urinary	O
iron	O
,	O
chelated	O
with	O
deferoxamine	O
B	O
,	O
using	O
a	O
single	O
reagent	O
.	O

We	O
hypothesize	O
that	O
proprioception	O
may	O
be	O
used	O
to	O
calibrate	O
the	O
efference	O
copy	O
during	O
development	O
and	O
in	O
response	O
to	O
perturbations	O
by	O
signaling	O
potential	O
mismatches	O
between	O
eye	O
movement	O
information	O
derived	O
from	O
the	O
efferent	O
command	O
and	O
the	O
actual	O
motion	O
of	O
the	O
eye	O
transduced	O
by	O
the	O
proprioceptive	O
organs	O
.	O

The	O
maps	O
of	O
Case	O
2	O
showed	O
that	O
a	O
maximum	O
first	O
appeared	O
on	O
the	O
upper	O
right	O
back	O
and	O
then	O
moved	O
down	O
the	O
right	O
side	O
of	O
the	O
posterior	O
thorax	O
.	O

Assembly	O
of	O
a	O
complex	O
between	O
FAK	B-GENE
and	O
Src	B-GENE
kinases	I-GENE
may	O
serve	O
to	O
regulate	O
the	O
subcellular	O
localization	O
and	O
the	O
enzymatic	O
activity	O
of	O
members	O
of	O
the	O
Src	B-GENE
family	I-GENE
of	O
kinases	B-GENE
.	O

Naphthalene	O
and	O
paradichlorobenzene	O
in	O
clinical	O
toxicology	O
.	O

Role	O
of	O
the	O
transcription	O
start	O
site	O
core	O
region	O
and	O
transcription	B-GENE
factor	I-GENE
YY1	I-GENE
in	O
Rous	B-GENE
sarcoma	I-GENE
virus	I-GENE
long	I-GENE
terminal	I-GENE
repeat	I-GENE
promoter	I-GENE
activity	O
.	O

Some	O
8	O
.	O
8	O
kb	O
of	O
the	O
Lactobacillus	O
sake	O
plasmid	O
pCIM1	O
was	O
sequenced	O
,	O
revealing	O
eight	O
tightly	O
clustered	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
downstream	O
from	O
lasA	B-GENE
,	O
which	O
encodes	O
pre-lactocin	B-GENE
S	O
.	O

These	O
overall	O
results	O
indicate	O
that	O
there	O
is	O
generally	O
one	O
PERV	O
copy	O
per	O
integration	O
site	O
.	O

Until	O
now	O
,	O
each	O
of	O
these	O
loci	O
was	O
considered	O
to	O
contain	O
three	O
genes	O
(	O
for	O
regulator	B-GENE
,	O
permease	B-GENE
and	O
alpha-glucosidase	B-GENE
)	O
,	O
but	O
a	O
fourth	O
gene	O
,	O
presumably	O
an	O
extra	O
alpha-glucosidase	B-GENE
gene	I-GENE
,	O
was	O
found	O
at	O
MAL1	B-GENE
adjacent	O
to	O
the	O
usual	O
cluster	O
of	O
three	O
genes	O
.	O

In	O
patients	O
with	O
type	O
II	O
tumors	O
,	O
the	O
pattern	O
of	O
lymphatic	O
spread	O
was	O
primarily	O
directed	O
toward	O
the	O
paracardial	O
,	O
lesser	O
curvature	O
,	O
and	O
left	O
gastric	O
artery	O
nodes	O
;	O
esophagectomy	O
offered	O
no	O
survival	O
benefit	O
over	O
extended	O
gastrectomy	O
in	O
these	O
patients	O
.	O

INF-alpha	B-GENE
therapy	O
has	O
been	O
a	O
major	O
development	O
in	O
the	O
treatment	O
of	O
CML	O
.	O

On	O
the	O
transport	O
of	O
mucus	O
and	O
its	O
rheologic	O
simulants	O
in	O
ciliated	O
systems	O
.	O

The	O
cAMP-dependent	O
mitogenic	O
pathway	O
is	O
unique	O
as	O
it	O
is	O
independent	O
of	O
mitogen-activated	B-GENE
protein	I-GENE
kinase	I-GENE
activation	O
and	O
differs	O
from	O
growth	O
factor-dependent	O
pathways	O
at	O
the	O
level	O
of	O
the	O
expression	O
of	O
several	O
protooncogenes	O
/	O
transcription	O
factors	O
.	O

If	O
NCR-sensitive	O
gene	O
expression	O
occurs	O
exclusively	O
by	O
this	O
pathway	O
,	O
as	O
has	O
been	O
thought	O
to	O
be	O
the	O
case	O
,	O
then	O
the	O
NCR	O
sensitivity	O
of	O
a	O
gene's	O
expression	O
should	O
be	O
abolished	O
by	O
a	O
ure2	B-GENE
delta	I-GENE
mutation	I-GENE
.	O

These	O
data	O
show	O
that	O
heterologous	O
virus	O
RNAs	O
(	O
BSMV	O
)	O
can	O
serve	O
as	O
primer	O
donors	O
for	O
MStV	O
mRNA	O
capped	O
RNA-primed	O
transcription	O
in	O
doubly	O
infected	O
plants	O
.	O

With	O
certain	O
exceptions	O
the	O
method	O
was	O
considered	O
suitable	O
in	O
the	O
routine	O
intravenous	O
cholangiography	O
.	O

CDDP	O
is	O
active	O
as	O
a	O
single	O
agent	O
in	O
non-Hodgkin's	O
lymphoma	O
.	O

Four	O
possible	O
isoforms	O
(	O
hGli2	B-GENE
alpha	I-GENE
,	I-GENE
beta	I-GENE
,	I-GENE
gamma	I-GENE
,	I-GENE
and	I-GENE
delta	I-GENE
)	O
are	O
formed	O
by	O
combinations	O
of	O
two	O
independent	O
alternative	O
splicings	O
,	O
and	O
all	O
the	O
isoforms	O
could	O
bind	O
to	O
a	O
DNA	O
motif	O
,	O
TRE2S	B-GENE
,	O
in	O
the	O
LTR	O
.	O

When	O
the	O
E1A	B-GENE
N-terminus	I-GENE
is	O
used	O
as	O
a	O
competitor	O
in	O
squelshing	O
experiments	O
it	O
abolishes	O
CBP-induced	O
activation	O
of	O
E2F1	B-GENE
/	I-GENE
DP1	I-GENE
,	O
whereas	O
an	O
E1A	B-GENE
mutant	I-GENE
lacking	O
CBP	B-GENE
binding	O
ability	O
fails	O
to	O
do	O
so	O
.	O

Specialized	O
actin	B-GENE
tails	O
that	O
propel	O
IEV	O
particles	O
to	O
the	O
periphery	O
and	O
virus-tipped	O
microvilli	O
(	O
both	O
common	O
in	O
wild-type-infected	O
cells	O
)	O
were	O
absent	O
in	O
cells	O
infected	O
with	O
vA33delta	O
.	O

(	O
1996a	O
)	O
Biochemistry	O
35	O
,	O
1589-1598	O
]	O
.	O

Schwab	O
and	O
England	O
ADL	O
scores	O
in	O
the	O
"off"	O
state	O
were	O
improved	O
by	O
18%	O
and	O
in	O
the	O
"on"	O
state	O
the	O
scores	O
declined	O
by	O
2%	O
.	O

TGF	B-GENE
beta	I-GENE
1	I-GENE
expression	O
is	O
largely	O
governed	O
by	O
three	O
AP-1	B-GENE
binding	I-GENE
sites	I-GENE
located	O
in	O
two	O
different	O
promoters	O
of	O
this	O
gene	O
.	O

The	O
pyramidal	O
tract	O
and	O
Mesencephalic	O
Reticular	O
Formation	O
(	O
MRF	O
)	O
were	O
stimulated	O
before	O
and	O
after	O
the	O
transection	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
EF	O
between	O
the	O
two	O
studies	O
,	O
both	O
at	O
rest	O
(	O
56	O
.	O
0	O
+	O
/	O
-	O
13	O
.	O
8%	O
vs	O
58	O
.	O
2	O
+	O
/	O
-	O
11	O
.	O
7%	O
,	O
p	O
=	O
NS	O
)	O
and	O
with	O
exercise	O
(	O
51	O
.	O
1	O
+	O
/	O
-	O
17	O
.	O
6%	O
vs	O
54	O
.	O
3	O
+	O
/	O
-	O
17	O
.	O
6%	O
,	O
p	O
=	O
NS	O
)	O
and	O
a	O
highly	O
significant	O
correlation	O
was	O
shown	O
between	O
the	O
two	O
groups	O
of	O
values	O
(	O
rest	O
r	O
=	O
0	O
.	O
90	O
,	O
exercise	O
r	O
=	O
0	O
.	O
93	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Serum	O
levels	O
of	O
testosterone	O
also	O
showed	O
no	O
significant	O
changes	O
by	O
exposure	O
to	O
p	O
,	O
p'-DDE	O
under	O
the	O
conditions	O
of	O
this	O
study	O
.	O

Effects	O
of	O
repeated	O
exposures	O
of	O
hydrogen	O
sulphide	O
on	O
rat	O
hippocampal	O
EEG	O
.	O

CONCLUSIONS	O
:	O
ChromaFlo-enhanced	O
IVUS	O
demonstrates	O
colorized	O
blood	O
flow	O
inside	O
the	O
vessel	O
lumen	O
,	O
which	O
is	O
helpful	O
in	O
distinguishing	O
echolucent	O
disease	O
from	O
luminal	O
blood	O
flow	O
and	O
can	O
also	O
be	O
used	O
to	O
perform	O
peripheral	O
interventions	O
in	O
patients	O
with	O
renal	O
failure	O
or	O
allergy	O
,	O
avoiding	O
the	O
use	O
of	O
contrast	O
media	O
.	O

Disruption	O
of	O
microtubules	O
did	O
not	O
affect	O
the	O
fidelity	O
or	O
kinetics	O
of	O
vacuolar	O
protein	O
sorting	O
,	O
indicating	O
that	O
Vps1p	B-GENE
function	O
is	O
not	O
dependent	O
on	O
microtubules	O
.	O

Transcription	O
start	O
sites	O
of	O
the	O
plastid	O
ACCase	B-GENE
genes	I-GENE
were	O
estimated	O
from	O
the	O
longest	O
cDNA	O
clones	O
obtained	O
by	O
5'-RACE	O
(	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
)	O
.	O

MKK3	B-GENE
autophosphorylation	O
and	O
activation	O
of	O
p38	B-GENE
was	O
also	O
observed	O
following	O
coexpression	O
of	O
MKK3	B-GENE
with	O
MEKK3	B-GENE
,	O
but	O
not	O
with	O
MEKK2	B-GENE
.	O

Oxygen	O
profiles	O
calculated	O
for	O
the	O
Krogh	O
model	O
with	O
excentric	O
diffusion	O
were	O
similar	O
to	O
those	O
derived	O
for	O
the	O
two	O
models	O
of	O
concentric	O
diffusion	O
.	O

We	O
investigate	O
the	O
reaction	O
kinetics	O
of	O
small	O
spherical	O
particles	O
with	O
inertia	O
,	O
obeying	O
coalescence	O
type	O
of	O
reaction	O
,	O
B+B--	O
>	O
B	O
,	O
and	O
being	O
advected	O
by	O
hydrodynamical	O
flows	O
with	O
time-periodic	O
forcing	O
.	O

These	O
striations	O
were	O
caused	O
by	O
contact	O
between	O
the	O
sharp	O
edge	O
of	O
the	O
upper	O
canine	O
and	O
the	O
P3	O
during	O
honing	O
(	O
canine	O
/	O
premolar	O
complex	O
)	O
.	O

At	O
the	O
very	O
high	O
dose	O
levels	O
used	O
,	O
sodium	O
saccharin	O
and	O
sodium	O
cyclamate	O
were	O
weak	O
solitary	O
carcinogens	O
producing	O
4	O
/	O
253	O
and	O
3	O
/	O
228	O
bladder	O
tumours	O
respectively	O
,	O
and	O
the	O
first	O
of	O
these	O
tumours	O
did	O
not	O
appear	O
for	O
more	O
than	O
80	O
weeks	O
.	O

Our	O
analysis	O
of	O
nonsense	O
mutations	O
indicates	O
that	O
the	O
C	O
terminus	O
of	O
eIF2Bepsilon	B-GENE
(	I-GENE
residues	I-GENE
518	I-GENE
to	I-GENE
712	I-GENE
)	I-GENE
is	O
required	O
for	O
both	O
catalytic	O
activity	O
and	O
interaction	O
with	O
eIF2	B-GENE
.	O

This	O
study	O
demonstrates	O
that	O
inducible	O
expression	O
in	O
response	O
to	O
either	O
PMA	O
or	O
TPO	B-GENE
is	O
mediated	O
through	O
the	O
Ets	B-GENE
site	I-GENE
in	O
the	O
proximal	O
promoter	O
of	O
GPIX	B-GENE
and	O
is	O
dependent	O
upon	O
the	O
upstream	O
activation	O
of	O
MAPK	B-GENE
/	I-GENE
extracellular	I-GENE
signal-regulated	I-GENE
kinase	I-GENE
.	O

While	O
these	O
results	O
are	O
consistent	O
with	O
previously	O
reported	O
effects	O
of	O
the	O
C-terminal	O
domain	O
on	O
nucleotide	O
binding	O
,	O
they	O
also	O
demonstrate	O
that	O
interactions	O
with	O
the	O
N-terminal	O
domains	O
are	O
necessary	O
to	O
inhibit	O
proton	O
transport	O
.	O

In	O
contrast	O
,	O
the	O
loss	O
of	O
MAD2	B-GENE
staining	O
in	O
meiosis	O
was	O
not	O
correlated	O
with	O
initial	O
microtubule	O
attachment	O
but	O
was	O
correlated	O
with	O
a	O
measure	O
of	O
tension	O
:	O
the	O
distance	O
between	O
homologous	O
or	O
sister	O
kinetochores	O
(	O
in	O
meiosis	O
I	O
and	O
II	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
Rac1	B-GENE
activation	O
of	O
JNK	B-GENE
or	O
SRF	B-GENE
,	O
or	O
induction	O
of	O
lamellipodia	O
,	O
was	O
neither	O
necessary	O
nor	O
sufficient	O
for	O
Rac1	B-GENE
transforming	O
activity	O
.	O

It	O
is	O
suggested	O
that	O
the	O
observed	O
clinical	O
phenomena	O
in	O
response	O
to	O
morphine	O
can	O
be	O
explained	O
by	O
differences	O
in	O
expression	O
and	O
sensitivity	O
of	O
some	O
opioid	B-GENE
receptor	I-GENE
subtypes	O
in	O
migraine	O
.	O

Aggravating	O
process	O
induced	O
by	O
indomethacin	O
on	O
chronic	O
gastric	O
lesion	O
in	O
rat	O
.	O

These	O
protective	O
influences	O
were	O
observed	O
throughout	O
the	O
range	O
of	O
filling	O
pressures	O
measured	O
,	O
from	O
0	O
to	O
30	O
mmHg	O
.	O

The	O
levels	O
of	O
galactosyltransferase	B-GENE
activity	O
in	O
sera	O
from	O
normal	O
children	O
and	O
patients	O
with	O
cystic	O
fibrosis	O
.	O

SSF	O
experiments	O
were	O
carried	O
out	O
in	O
bench-scale	O
bioreactors	O
(	O
equipped	O
with	O
CO2	O
and	O
volatile	O
organic	O
traps	O
)	O
containing	O
a	O
mixture	O
of	O
lignocellulosic	O
materials	O
and	O
a	O
radiolabeled	O
pesticide	O
.	O

Since	O
CENP-B	B-GENE
gene	I-GENE
is	O
conserved	O
in	O
mammalian	O
species	O
and	O
CENP-B	B-GENE
boxes	I-GENE
are	O
found	O
also	O
in	O
mouse	O
centromere	O
satellite	O
DNA	O
(	O
minor	O
satellite	O
)	O
,	O
this	O
sequence-specific	O
DNA-protein	O
interaction	O
may	O
be	O
important	O
for	O
some	O
kind	O
of	O
common	O
centromere	O
function	O
.	O

(	O
1989	O
)	O
,	O
which	O
is	O
identical	O
to	O
the	O
SSC1	B-GENE
gene	I-GENE
(	O
Smith	O
et	O
al	O
.	O
,	O
1988	O
)	O
.	O

The	O
paper	O
is	O
concerned	O
with	O
the	O
data	O
on	O
change	O
in	O
the	O
blood	O
level	O
of	O
ACTH	B-GENE
,	O
STH	B-GENE
,	I-GENE
TSH	I-GENE
,	O
cortisol	O
,	O
T3	O
,	O
insulin	B-GENE
,	O
C-peptide	B-GENE
during	O
a	O
25-minute	O
session	O
of	O
respiration	O
using	O
a	O
gaseous	O
hypoxic	O
mixture	O
with	O
10%	O
oxygen	O
(	O
GHM-10	O
)	O
.	O

Testing	O
blood	O
donors	O
for	O
non-A	O
,	O
non-B	O
hepatitis	O
:	O
irrational	O
,	O
perhaps	O
,	O
but	O
inescapable	O
.	O

Raes	O
,	O
P	O
.	O

Blocked	O
shift	O
/	O
supershift	O
analysis	O
indicates	O
that	O
Fos	B-GENE
family	I-GENE
member	O
proteins	O
especially	O
Fra-1	B-GENE
and	O
Fra-2	B-GENE
are	O
related	O
to	O
progression	O
and	O
no	O
changes	O
found	O
in	O
the	O
Jun	B-GENE
family	I-GENE
member	O
proteins	O
although	O
they	O
are	O
present	O
in	O
the	O
AP-1	B-GENE
/	I-GENE
DNA	I-GENE
binding	I-GENE
complex	I-GENE
.	O

A	O
strong	O
trithorax	B-GENE
binding	I-GENE
site	I-GENE
was	O
found	O
at	O
the	O
cytological	O
location	O
of	O
the	O
fork	B-GENE
head	I-GENE
gene	I-GENE
,	O
a	O
region-specific	O
homeotic	B-GENE
gene	I-GENE
not	O
located	O
within	O
a	O
homeotic	B-GENE
complex	I-GENE
.	O

To	O
investigate	O
the	O
regulation	O
of	O
Spec	B-GENE
gene	I-GENE
activity	O
,	O
the	O
region	O
around	O
the	O
Spec1	B-GENE
transcriptional	I-GENE
initiation	I-GENE
site	I-GENE
was	O
analyzed	O
for	O
sites	O
of	O
protein-DNA	O
interaction	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
Sp1	B-GENE
and	O
Sp3	B-GENE
as	O
major	O
factors	O
binding	O
to	O
the	O
Sp1	B-GENE
sites	I-GENE
of	O
the	O
p21	B-GENE
/	I-GENE
WAF1	I-GENE
/	I-GENE
Cip1	I-GENE
promoter	I-GENE
in	O
MG63	O
cells	O
through	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
showed	O
that	O
TSA	O
treatment	O
did	O
not	O
change	O
their	O
binding	O
activities	O
.	O

Experience	O
with	O
the	O
restoration	O
of	O
agglutination	O
properties	O
of	O
non-agglutinating	O
dysenterial	O
cultures	O
with	O
the	O
use	O
of	O
Rzhaninov's	O
method	O
.	O

Vitiligo	O
in	O
diabetes	O
mellitus	O
.	O

It	O
is	O
possible	O
that	O
the	O
telomeres	O
of	O
the	O
two	O
nuclei	O
have	O
different	O
functions	O
.	O

Therefore	O
,	O
we	O
studied	O
ninety	O
coagulopathic	O
patients	O
with	O
the	O
aim	O
of	O
determining	O
the	O
prevalence	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
antibodies	O
using	O
the	O
ELISA	O
and	O
RIBA	O
methods	O
.	O

Direct	O
superoxide	O
scavenging	O
activity	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
:	O
determination	O
by	O
electron	O
spin	O
resonance	O
using	O
the	O
spin	O
trap	O
method	O
.	O

Low	O
affinity	O
binding	O
of	O
Rab6A-GTP	B-GENE
was	O
also	O
observed	O
(	O
K	O
(	O
d	O
)	O
=	O
16	O
&mgr	O
;	O
m	O
)	O
,	O
whereas	O
Rab1B	B-GENE
,	I-GENE
-5	I-GENE
,	I-GENE
-7	I-GENE
,	I-GENE
-8	I-GENE
,	I-GENE
or	I-GENE
-11A	I-GENE
did	O
not	O
bind	O
.	O

CM-ACO3	B-GENE
is	O
expressed	O
in	O
flowers	O
and	O
is	O
not	O
induced	O
by	O
any	O
of	O
the	O
stimuli	O
tested	O
.	O

The	O
contribution	O
of	O
skin	O
flow	O
to	O
the	O
changes	O
in	O
760-800	O
nm	O
absorption	O
was	O
investigated	O
by	O
simultaneous	O
measurement	O
of	O
skin	O
flow	O
by	O
laser	O
flow	O
Doppler	O
and	O
NIR	O
recordings	O
during	O
hot	O
water	O
immersion	O
.	O

PCR	O
analysis	O
indicates	O
that	O
this	O
new	O
beta-adducin	B-GENE
isoform	I-GENE
is	O
expressed	O
in	O
fetal	O
brain	O
and	O
liver	O
,	O
bone	O
marrow	O
,	O
and	O
NT-2	O
(	O
neuroepithelial	O
)	O
cells	O
,	O
but	O
is	O
not	O
detected	O
in	O
several	O
other	O
tissues	O
.	O

Both	O
PPC-1	O
and	O
ALVA-31	O
cells	O
display	O
tumorigenesis	O
and	O
invasiveness	O
in	O
nude	O
mice	O
,	O
whereas	O
LNCap	O
cells	O
exhibit	O
a	O
less	O
malignant	O
phenotype	O
,	O
suggesting	O
a	O
correlation	O
between	O
CD44	B-GENE
variant	I-GENE
(	O
CD44v	B-GENE
)	O
expression	O
and	O
aggressive	O
prostate	O
tumor	O
behavior	O
.	O

The	O
mMIWC1	B-GENE
promoter	I-GENE
was	O
identified	O
and	O
contained	O
TATA	O
,	O
CAAT	O
,	O
GATA	B-GENE
,	O
and	O
AP-2	B-GENE
elements	I-GENE
;	O
primer	O
extension	O
revealed	O
mMIWC	B-GENE
transcription	O
initiation	O
at	O
621	O
bp	O
upstream	O
from	O
the	O
mMIWC1	B-GENE
translational	O
initiation	O
site	O
.	O

RESULTS	O
:	O
CK-MB	B-GENE
elevation	O
was	O
detected	O
in	O
313	O
patients	O
(	O
18	O
.	O
7%	O
)	O
,	O
with	O
1-3x	O
in	O
12	O
.	O
8%	O
,	O
3-5x	O
in	O
3	O
.	O
5%	O
and	O
>	O
5x	O
normal	O
in	O
2	O
.	O
4%	O
of	O
patients	O
.	O

In	O
similar	O
transient	O
transfection	O
experiments	O
in	O
HeLa	O
cells	O
,	O
overexpression	O
of	O
the	O
wt	B-GENE
human	I-GENE
retinoblastoma	I-GENE
susceptibility	I-GENE
gene	I-GENE
product	I-GENE
,	O
RB	B-GENE
,	O
was	O
found	O
to	O
repress	O
the	O
serum-induced	O
IL-6	B-GENE
(	O
-225	O
to	O
+13	O
)	O
,	O
c-fos	B-GENE
(	O
-711	O
to	O
+42	O
)	O
,	O
and	O
beta-actin	B-GENE
(	O
-3400	O
to	O
+912	O
)	O
promoters	O
but	O
not	O
the	O
PRV-induced	O
IL-6	B-GENE
(	O
-110	O
to	O
+13	O
)	O
or	O
the	O
serum-induced	O
MHC	B-GENE
(	O
-528	O
to	O
-38	O
)	O
promoters	O
.	O

This	O
gene	O
joins	O
the	O
group	O
of	O
genes	O
whose	O
members	O
are	O
rapidly	O
transcribed	O
in	O
response	O
to	O
insulin	B-GENE
and	O
other	O
mitogens	O
.	O

The	O
deleted	O
nucleotide	O
sequence	O
corresponded	O
to	O
sequences	O
that	O
,	O
by	O
analogy	O
to	O
the	O
organization	O
of	O
the	O
type	B-GENE
I	I-GENE
collagen	I-GENE
genes	I-GENE
,	O
should	O
be	O
precisely	O
encoded	O
by	O
exon	O
41	O
of	O
the	O
COL3A1	B-GENE
gene	I-GENE
.	O

A	O
highly	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
presence	O
of	O
fibrinolytic	O
degradation	O
products	O
(	O
FDP	O
)	O
and	O
the	O
incidence	O
of	O
nephropathy	O
and	O
renal	O
insufficiency	O
,	O
as	O
well	O
as	O
between	O
the	O
presence	O
of	O
fibrin	B-GENE
monomers	I-GENE
(	O
Godal's	O
ethanol-gelification	O
test	O
)	O
and	O
the	O
evolutive	O
signs	O
of	O
the	O
primary	O
disease	O
(	O
fever	O
,	O
accelerated	O
ESR	O
)	O
.	O

The	O
perifascicular	O
connective	O
tissue	O
sheath	O
is	O
important	O
in	O
organising	O
the	O
contraction	O
of	O
the	O
myocardium	O
by	O
preventing	O
lateral	O
spread	O
of	O
conduction	O
and	O
by	O
permitting	O
transmission	O
of	O
the	O
impulse	O
only	O
at	O
the	O
termination	O
of	O
the	O
purkinje	O
fibre	O
.	O

Neurospora	O
crassa	O
CYT-18	B-GENE
,	O
can	O
rescue	O
the	O
exonic	O
trap	O
and	O
intron	O
mutants	O
which	O
cause	O
a	O
structural	O
defect	O
.	O

During	O
the	O
past	O
decade	O
,	O
different	O
types	O
of	O
endogenous	O
retroviral	O
sequences	O
have	O
been	O
defined	O
in	O
the	O
human	O
genome	O
usually	O
by	O
low	O
stringency	O
hybridization	O
employing	O
DNA	O
probes	O
of	O
evolutionary	O
conserved	O
animal	O
retrovirus	O
genes	O
.	O

Previous	O
work	O
showed	O
that	O
repA	B-GENE
(	O
initiator	B-GENE
protein	I-GENE
)	O
expression	O
requires	O
tap	B-GENE
(	O
leader	B-GENE
peptide	I-GENE
)	O
translation	O
.	O

In	O
addition	O
,	O
IgM	B-GENE
can	O
be	O
absent	O
in	O
children	O
with	O
congenital	O
toxoplasmosis	O
or	O
subjects	O
with	O
secondary	O
reactivation	O
.	O

The	O
high	O
level	O
of	O
transformation-associated	O
deletions	O
in	O
the	O
human	O
YACs	O
was	O
reduced	O
over	O
10-fold	O
when	O
the	O
host	O
was	O
a	O
recombination-deficient	O
strain	O
deleted	O
for	O
the	O
RAD52	B-GENE
gene	I-GENE
.	O

Notably	O
,	O
SRF	B-GENE
has	O
been	O
found	O
to	O
be	O
a	O
key	O
regulator	O
of	O
members	O
of	O
a	O
class	O
of	O
cellular	O
response	O
genes	O
termed	O
immediate-early	B-GENE
genes	I-GENE
(	O
IEGs	B-GENE
)	O
,	O
many	O
of	O
which	O
are	O
believed	O
to	O
be	O
involved	O
in	O
regulating	O
cell	O
growth	O
and	O
differentiation	O
.	O

Total	O
body	O
water	O
,	O
rhodanide	O
space	O
and	O
I-131-albumin	B-GENE
space	O
under	O
the	O
acute	O
effect	O
of	O
furosemide	O
.	O

Furthermore	O
,	O
an	O
upstream	O
element	O
,	O
collagen	B-GENE
element	I-GENE
I	I-GENE
(	I-GENE
-370	I-GENE
/	I-GENE
-344	I-GENE
)	I-GENE
,	O
which	O
shares	O
homology	O
with	O
the	O
LAP	B-GENE
binding	O
cis-element	O
of	O
the	O
albumin	B-GENE
promoter	I-GENE
(	O
9	O
of	O
13	O
bp	O
)	O
is	O
described	O
.	O

Cut-off	O
levels	O
that	O
define	O
abnormality	O
are	O
rather	O
arbitrary	O
and	O
this	O
decreases	O
the	O
specificity	O
of	O
the	O
test	O
in	O
apparently	O
healthy	O
patients	O
.	O

The	O
Oct-3	B-GENE
/	I-GENE
4	I-GENE
gene	I-GENE
product	I-GENE
,	O
which	O
belongs	O
to	O
the	O
POU	B-GENE
family	I-GENE
of	I-GENE
transcription	I-GENE
factors	I-GENE
,	O
is	O
a	O
good	O
candidate	O
for	O
regulating	O
initial	O
differentiation	O
decisions	O
.	O

Fatal	O
apneusis	O
was	O
observed	O
under	O
following	O
conditions	O
:	O
(	O
1	O
)	O
Persistent	O
apnea	O
was	O
produced	O
after	O
a	O
single	O
KA	O
microinjection	O
in	O
one	O
side	O
of	O
the	O
VRG-Apa	O
(	O
5	O
animals	O
)	O
.	O

Value	O
of	O
Normotest	O
and	O
antithrombin	B-GENE
3	I-GENE
in	O
the	O
assessment	O
of	O
liver	O
function	O
.	O

Orthop	O
.	O

Recombinant	B-GENE
Ffh	I-GENE
has	O
a	O
melting	O
point	O
of	O
tm	O
=	O
89	O
degreesC	O
.	O

In	O
a	O
similar	O
experiment	O
,	O
simultaneous	O
nitrofurazone	O
administration	O
and	O
S	O
.	O
enteritidis	O
challenge	O
resulted	O
in	O
no	O
significant	O
differences	O
in	O
S	O
.	O
enteritidis	O
isolation	O
frequency	O
.	O

The	O
front	O
(	O
F	O
)	O
interaction	O
occurs	O
ahead	O
of	O
the	O
growing	O
end	O
of	O
RNA	O
.	O

Normocapnic	O
(	O
PACO2	O
=	O
40	O
mm	O
Hg	O
)	O
ventilatory	O
drive	O
increased	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
six	O
subjects	O
(	O
Type	O
1	O
response	O
)	O
and	O
decreased	O
substantially	O
in	O
the	O
others	O
(	O
Type	O
2	O
response	O
)	O
;	O
with	O
hypercapnia	O
,	O
the	O
changes	O
in	O
drive	O
were	O
attenuated	O
in	O
both	O
groups	O
.	O

MOP5	B-GENE
contained	O
the	O
characteristic	O
PAS	B-GENE
domain	I-GENE
and	O
a	O
variable	O
C	O
terminus	O
;	O
it	O
is	O
possible	O
that	O
the	O
cDNA	O
contains	O
a	O
bHLH	B-GENE
domain	O
,	O
but	O
the	O
entire	O
open	O
reading	O
frame	O
has	O
yet	O
to	O
be	O
completed	O
.	O

Sequence	O
analysis	O
of	O
the	O
5'	O
flanking	O
region	O
revealed	O
several	O
GC	O
boxes	O
but	O
no	O
identifiable	O
TATA	O
box	O
.	O

Drug	O
use	O
in	O
trauma	O
victims	O
.	O

Haycocknema	O
perplexum	O
n	O
.	O
g	O
.	O
,	O
n	O
.	O
sp	O
.	O

It	O
applies	O
Udry's	O
biosocial	O
perspective	O
,	O
which	O
attempts	O
to	O
reconcile	O
the	O
biological	O
and	O
sociological	O
models	O
of	O
premarital	O
sexual	O
and	O
reproductive	O
behaviour	O
.	O

We	O
conclude	O
that	O
(	O
i	O
)	O
we	O
have	O
identified	O
several	O
candidate	O
latency	O
genes	O
of	O
murine	O
gammaHV68	O
,	O
(	O
ii	O
)	O
expression	O
of	O
genes	O
during	O
latency	O
may	O
be	O
different	O
in	O
different	O
organs	O
,	O
consistent	O
with	O
multiple	O
latency	O
programs	O
and	O
/	O
or	O
multiple	O
cellular	O
sites	O
of	O
latency	O
,	O
and	O
(	O
iii	O
)	O
regions	O
of	O
the	O
viral	O
genome	O
(	O
v-bcl-2	B-GENE
gene	I-GENE
,	O
v-GCR	B-GENE
gene	I-GENE
,	O
and	O
gene	B-GENE
73	I-GENE
)	O
are	O
transcribed	O
during	O
latency	O
with	O
both	O
gammaHV68	O
and	O
primate	O
gammaherpesviruses	O
.	O

Co-immunoprecipitation	O
and	O
DNA	O
affinity	O
chromatography	O
prove	O
that	O
Sp1	B-GENE
heterodimerizes	O
with	O
ZBP-89	B-GENE
when	O
bound	O
to	O
the	O
silencer	O
element	O
to	O
yield	O
a	O
DNA-protein	O
complex	O
whose	O
mobility	O
is	O
indistinguishable	O
from	O
that	O
displayed	O
by	O
HeLa	O
nuclear	O
extract	O
in	O
band	O
shift	O
assays	O
.	O

The	O
location	O
of	O
multiple	O
GRK2	B-GENE
and	O
GRK5	B-GENE
phosphoacceptor	I-GENE
sites	I-GENE
at	O
the	O
extreme	O
carboxyl	O
terminus	O
of	O
the	O
beta2AR	B-GENE
is	O
highly	O
reminiscent	O
of	O
GRK1-mediated	O
phosphorylation	O
of	O
rhodopsin	B-GENE
.	O

Immobilization	O
of	O
the	O
fracture	O
in	O
a	O
collar	O
and	O
cuff	O
sling	O
was	O
as	O
effective	O
as	O
more	O
elaborate	O
methods	O
.	O

Focused	O
beams	O
of	O
classical	O
light	O
ablate	O
elements	O
of	O
the	O
cell	O
division	O
machinery	O
and	O
switch	O
the	O
beating	O
of	O
hearts	O
on	O
a	O
cellular	O
basis	O
.	O

In	O
Exp	O
.	O

This	O
last	O
region	O
contains	O
two	O
sites	O
that	O
bind	O
Ets-related	B-GENE
proteins	I-GENE
present	O
in	O
liver	O
nuclear	O
extracts	O
as	O
well	O
as	O
recombinant	B-GENE
purified	I-GENE
Ets-1	I-GENE
protein	I-GENE
.	O

Sequence	O
analysis	O
of	O
the	O
promoter	O
region	O
showed	O
no	O
TATA	O
box	O
but	O
identified	O
consensus	O
binding	O
motifs	O
for	O
Sp1	B-GENE
,	O
CREB	B-GENE
,	O
and	O
half	O
sites	O
of	O
the	O
estrogen	B-GENE
receptor	I-GENE
binding	I-GENE
site	I-GENE
.	O

The	O
problem	O
of	O
disablement	O
due	O
to	O
pulmonary	O
tuberculosis	O
,	O
on	O
the	O
basis	O
of	O
an	O
analysis	O
of	O
the	O
history	O
of	O
395	O
cases	O
as	O
observed	O
in	O
Gdansk	O
in	O
the	O
years	O
1946-1965	O
.	O

Cytohesin-1	B-GENE
,	O
a	O
protein	O
abundant	O
in	O
cells	O
of	O
the	O
immune	O
system	O
,	O
has	O
been	O
proposed	O
to	O
be	O
a	O
human	O
homolog	O
of	O
the	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
Sec7	I-GENE
gene	I-GENE
product	I-GENE
,	O
which	O
is	O
crucial	O
in	O
protein	O
transport	O
.	O

Also	O
in	O
the	O
spectrum	O
of	O
mutants	O
with	O
TGN	O
sorting	O
defects	O
are	O
isolates	O
with	O
mutations	O
in	O
the	O
following	O
:	O
RIC1	B-GENE
,	O
encoding	O
a	O
product	O
originally	O
proposed	O
to	O
participate	O
in	O
ribosome	O
biogenesis	O
;	O
LUV1	B-GENE
,	O
encoding	O
a	O
product	O
potentially	O
involved	O
in	O
vacuole	O
and	O
microtubule	O
organization	O
;	O
and	O
INP53	B-GENE
,	O
encoding	O
a	O
synaptojanin-like	B-GENE
inositol	I-GENE
polyphosphate	I-GENE
5-phosphatase	I-GENE
.	O

Transcriptional	O
activation	O
by	O
the	O
HIV-1	B-GENE
Tat	I-GENE
protein	I-GENE
requires	O
specific	O
residues	O
in	O
the	O
hexanucleotide	O
loop	O
and	O
trinucleotide	O
bulge	O
of	O
the	O
TAR	B-GENE
RNA	I-GENE
stem-loop	O
structure	O
found	O
in	O
the	O
5'-untranslated	O
leader	O
of	O
all	O
viral	O
transcripts	O
.	O

Ligand-independent	O
activation	O
of	O
platelet-derived	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
is	O
a	O
necessary	O
intermediate	O
in	O
lysophosphatidic	O
,	O
acid-stimulated	O
mitogenic	O
activity	O
in	O
L	O
cells	O
.	O

The	O
general	O
transcription	B-GENE
factor	I-GENE
IIA	I-GENE
(	O
TFIIA	B-GENE
)	O
interacts	O
with	O
the	O
TATA	B-GENE
binding	I-GENE
protein	I-GENE
(	O
TBP	B-GENE
)	O
and	O
promoter	O
DNA	O
to	O
mediate	O
transcription	O
activation	O
in	O
vitro	O
.	O

Since	O
August	O
1994	O
,	O
the	O
ENRP	O
has	O
retained	O
70	O
.	O
3	O
metric	O
tons	O
of	O
TP	O
that	O
otherwise	O
would	O
have	O
entered	O
the	O
Everglades	O
.	O

These	O
findings	O
suggest	O
a	O
functional	O
cross-talk	O
between	O
RB	B-GENE
protein	I-GENE
and	O
p21ras	B-GENE
,	O
which	O
balances	O
the	O
cell	O
phenotype	O
between	O
normal	O
and	O
transformed	O
states	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
tissue-restricted	O
transcription	O
factors	O
including	O
PU	B-GENE
.	I-GENE
1	I-GENE
and	O
PU	B-GENE
.	I-GENE
1	I-GENE
interaction	I-GENE
partner	I-GENE
(	O
PIP	B-GENE
)	O
function	O
synergistically	O
with	O
c-Fos	B-GENE
plus	O
c-Jun	B-GENE
to	O
stimulate	O
the	O
kappaE3'-enhancer	B-GENE
in	O
3T3	O
cells	O
.	O

The	O
origins	O
of	O
reflected	O
light	O
changes	O
associated	O
with	O
neuronal	O
activity	O
(	O
optical	O
signals	O
)	O
were	O
investigated	O
in	O
rat	O
somatosensory	O
cortex	O
with	O
optical	O
imaging	O
,	O
microspectrophotometry	O
,	O
and	O
laser-Doppler	O
flowmetry	O
,	O
and	O
dynamic	O
changes	O
in	O
local	O
hemoglobin	B-GENE
concentration	O
and	O
oxygenation	O
were	O
focused	O
on	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
was	O
performed	O
using	O
eyestalk	O
complementary	O
DNA	O
of	O
the	O
sand	O
shrimp	O
Metapenaeus	O
ensis	O
.	O

This	O
reveals	O
a	O
new	O
test	O
for	O
short	O
saphenous	O
incompetence	O
and	O
shows	O
that	O
14	O
per	O
cent	O
of	O
varices	O
stem	O
from	O
a	O
saphenopopliteal	O
reflux	O
.	O

These	O
observations	O
,	O
together	O
with	O
the	O
occurrence	O
of	O
putative	O
4'-phosphopantetheine-attachment	O
sites	O
and	O
a	O
putative	O
thioesterase	B-GENE
site	I-GENE
,	O
are	O
discussed	O
with	O
reference	O
to	O
the	O
reaction	O
sequence	O
leading	O
to	O
production	O
of	O
the	O
ACV	B-GENE
tripeptide	I-GENE
.	O

Examination	O
of	O
DNA	O
:	O
protein	O
binding	O
complexes	O
by	O
gel-shift	O
analysis	O
indicated	O
that	O
nuclear	O
factors	O
from	O
both	O
proliferative	O
and	O
growth-arrested	O
cells	O
bound	O
to	O
the	O
DNA	O
fragment	O
spanning	O
-949-	O
-722	O
bp	O
.	O

The	O
pharmacokinetic	O
patterns	O
of	O
estradiol	O
(	O
CAS	O
50-28-2	O
)	O
and	O
of	O
estrone	O
(	O
CAS	O
53-16-7	O
)	O
were	O
investigated	O
in	O
18	O
women	O
in	O
natural	O
or	O
surgical	O
menopause	O
during	O
the	O
application	O
of	O
a	O
new	O
estradiol	O
transdermal	O
patch	O
with	O
active	O
matrix	O
and	O
without	O
absorption	O
enhancers	O
designed	O
for	O
epicutaneous	O
applications	O
of	O
7	O
days	O
(	O
hereinafter	O
called	O
"patch	O
7D"	O
)	O
.	O

A	O
striking	O
finding	O
in	O
all	O
of	O
the	O
studies	O
was	O
a	O
positive	O
correlation	O
between	O
PI	O
ACTH	B-GENE
and	O
MSH	B-GENE
contents	O
.	O

The	O
capacity	O
to	O
repair	O
8-OxoG	O
has	O
been	O
measured	O
in	O
cell-free	O
extracts	O
of	O
wild-type	O
and	O
ogg1	B-GENE
strains	O
using	O
a	O
34mer	O
DNA	O
fragment	O
containing	O
a	O
single	O
8-OxoG	O
residue	O
paired	O
with	O
a	O
cytosine	O
(	O
8-OxoG	O
/	O
C	O
)	O
as	O
a	O
substrate	O
.	O

The	O
maximum	O
stress	O
due	O
to	O
the	O
hygroscopic	O
examination	O
of	O
the	O
composite	O
was	O
0	O
.	O
74	O
kg	O
/	O
mm2	O
at	O
equilibrium	O
of	O
the	O
water	O
absorbed	O
of	O
the	O
composite	O
.	O

VirD2	B-GENE
is	O
one	O
of	O
the	O
key	O
Agrobacterium	O
tumefaciens	O
proteins	O
involved	O
in	O
T-DNA	O
processing	O
and	O
transfer	O
.	O

The	O
dnaK	B-GENE
operon	I-GENE
of	I-GENE
Bacillus	I-GENE
subtilis	I-GENE
is	O
heptacistronic	O
.	O

NIRS	O
was	O
used	O
for	O
the	O
quantitative	O
measurement	O
of	O
muscle	O
O	O
(	O
2	O
)	O
consumption	O
(	O
mV	O
.	O
O	O
(	O
2	O
)	O
)	O
and	O
forearm	O
blood	O
flow	O
(	O
FBF	O
)	O
in	O
78	O
healthy	O
subjects	O
.	O

Alterations	O
in	O
DNase	B-GENE
I	I-GENE
reactivity	O
of	O
the	O
GC-response	O
element	O
region	O
suggest	O
that	O
GC	B-GENE
receptor-GC	I-GENE
complexes	I-GENE
may	O
associate	O
,	O
in	O
a	O
transient	O
manner	O
,	O
with	O
the	O
promoter	O
in	O
the	O
actively	O
transcribing	O
control	O
state	O
.	O

Reconstitution	O
of	O
complexes	O
containing	O
p62	B-GENE
and	O
the	O
src	B-GENE
family	I-GENE
kinase	I-GENE
p59fyn	B-GENE
in	O
HeLa	O
cells	O
demonstrated	O
that	O
complex	O
formation	O
resulted	O
in	O
tyrosine	O
phosphorylation	O
of	O
p62	B-GENE
and	O
was	O
mediated	O
by	O
both	O
the	O
SH3	B-GENE
and	O
SH2	B-GENE
domains	I-GENE
of	O
p59fyn	B-GENE
.	O

Sixteen	O
out	O
of	O
52	O
seropositive	O
MS	O
patients	O
(	O
30	O
.	O
8%	O
)	O
showed	O
intrathecal	O
synthesis	O
of	O
C	B-GENE
.	I-GENE
pneumoniae-specific	I-GENE
IgG	I-GENE
but	O
only	O
one	O
of	O
43	O
seropositive	O
controls	O
(	O
2	O
.	O
3%	O
)	O
.	O

The	O
N-terminus	O
of	O
another	O
open	O
reading	O
frame	O
was	O
found	O
3'	O
from	O
nifA	B-GENE
and	O
tentatively	O
identified	O
as	O
nifB	B-GENE
by	O
amino	O
acid	O
sequence	O
comparison	O
.	O

Phosphatidylinositol	B-GENE
3-kinase	I-GENE
requirement	O
in	O
activation	O
of	O
the	O
ras	B-GENE
/	I-GENE
C-raf-1	I-GENE
/	I-GENE
MEK	I-GENE
/	I-GENE
ERK	I-GENE
and	O
p70	B-GENE
(	I-GENE
s6k	I-GENE
)	I-GENE
signaling	O
cascade	O
by	O
the	O
insulinomimetic	O
agent	O
vanadyl	O
sulfate	O
.	O

Cortical	O
dysplasias	O
,	O
genetics	O
,	O
and	O
epileptogenesis	O
.	O

In	O
addition	O
to	O
homologues	O
of	O
the	O
human	B-GENE
genes	I-GENE
PSMB5	I-GENE
through	O
PSMB9	B-GENE
,	O
two	O
new	O
genes	O
,	O
PSMB11	B-GENE
and	O
PSMB12	B-GENE
,	O
have	O
been	O
found	O
for	O
which	O
there	O
are	O
no	O
known	O
corresponding	O
genes	O
in	O
humans	O
.	O

We	O
conclude	O
that	O
the	O
conservation	O
of	O
nucleotides	O
154	O
to	O
156	O
is	O
likely	O
to	O
be	O
a	O
consequence	O
of	O
their	O
role	O
as	O
a	O
sequence-specific	O
recognition	O
element	O
for	O
the	O
SRP54	B-GENE
protein	I-GENE
.	O

The	O
genetic	O
basis	O
for	O
the	O
expression	O
of	O
a	O
latent	O
VH	B-GENE
allotype	I-GENE
in	O
the	O
rabbit	O
was	O
investigated	O
.	O

Open	O
head-brain	O
injuries	O
.	O

Administration	O
of	O
a	O
second	O
dose	O
of	O
vaccine	O
during	O
the	O
outbreak	O
was	O
not	O
protective	O
.	O

Clipping	O
resulted	O
in	O
a	O
serious	O
mislocalization	O
of	O
the	O
position	O
of	O
the	O
peak	O
of	O
the	O
epicortical	O
potential	O
field	O
.	O

Unexpectedly	O
,	O
Arg1-expressing	O
COS1	O
cells	O
showed	O
no	O
significant	O
proteinase	B-GENE
activity	O
to	O
various	O
synthesized	O
substrates	O
under	O
neutral	O
or	O
acidic	O
conditions	O
in	O
this	O
study	O
.	O

In	O
the	O
duodenum	O
a	O
small	O
part	O
of	O
the	O
administered	O
dose	O
was	O
transformed	O
to	O
3H-alpha-acetyldigoxin	O
.	O

Effects	O
of	O
a	O
perfluorochemical	O
blood	O
substitute	O
on	O
diazepam	O
binding	O
by	O
human	B-GENE
albumin	I-GENE
.	O

These	O
findings	O
suggest	O
one	O
potential	O
mechanism	O
for	O
direct	O
recruitment	O
of	O
distal	O
regulatory	O
regions	O
of	O
the	O
globin	B-GENE
loci	I-GENE
to	O
the	O
individual	O
promoters	O
.	O

GETS-1	B-GENE
is	O
expressed	O
in	O
many	O
tissues	O
,	O
but	O
is	O
enriched	O
in	O
retina	O
and	O
brain	O
.	O

A	O
second	O
isotype	O
of	O
Raja	B-GENE
immunoglobulin	I-GENE
heavy	I-GENE
chain	I-GENE
genes	I-GENE
has	O
been	O
detected	O
by	O
screening	O
a	O
spleen	O
cDNA	O
library	O
with	O
homologous	O
Raja	O
VH-	O
and	O
CH1-specific	O
probes	O
complementing	O
the	O
respective	O
regions	O
of	O
the	O
mu-like	B-GENE
isotype	I-GENE
.	O

Thereafter	O
,	O
the	O
aggregation	O
rose	O
to	O
the	O
initial	O
100%	O
value	O
4	O
h	O
after	O
drug	O
application	O
and	O
remained	O
at	O
this	O
level	O
during	O
the	O
observation	O
period	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Lack	O
of	O
cyclin	B-GENE
D-Cdk	I-GENE
complexes	I-GENE
in	O
Rb-negative	O
cells	O
correlates	O
with	O
high	O
levels	O
of	O
p16INK4	B-GENE
/	I-GENE
MTS1	I-GENE
tumour	I-GENE
suppressor	I-GENE
gene	I-GENE
product	I-GENE
.	O

At	O
the	O
time	O
of	O
the	O
seizure	O
,	O
the	O
patient	O
was	O
asked	O
to	O
read	O
a	O
test	O
phrase	O
aloud	O
until	O
it	O
was	O
read	O
correctly	O
and	O
clearly	O
.	O

Two	O
new	O
artifacts	O
in	O
automated	O
coagulation	O
testing	O
.	O

This	O
study	O
examines	O
the	O
cooperative	O
effects	O
of	O
a	O
human	O
estrogen	B-GENE
receptor-alpha	I-GENE
(	O
ERalpha	B-GENE
)	O
isoform	O
on	O
estrogen	B-GENE
(	O
E2	B-GENE
)	O
-mediated	O
gene	O
activation	O
in	O
U2-OS	O
osteosarcoma	O
cells	O
.	O

Three	O
mog-1	B-GENE
alleles	I-GENE
possess	O
premature	O
stop	O
codons	O
and	O
are	O
likely	O
to	O
be	O
null	O
alleles	O
,	O
and	O
one	O
is	O
a	O
missense	O
mutation	O
and	O
is	O
likely	O
to	O
retain	O
residual	O
activity	O
.	O
mog-1	B-GENE
mRNA	I-GENE
is	O
expressed	O
in	O
both	O
germ	O
line	O
and	O
somatic	O
tissues	O
and	O
appears	O
to	O
be	O
ubiquitous	O
.	O

The	O
distribution	O
of	O
cryptosporidia	O
in	O
the	O
intestine	O
and	O
number	O
of	O
cryptosporidia	O
per	O
ileal	O
villus	O
on	O
different	O
DPI	O
were	O
also	O
estimated	O
for	O
detailed	O
characterization	O
of	O
the	O
infection	O
in	O
kids	O
as	O
a	O
model	O
for	O
experimental	O
cryptosporidiosis	O
.	O

Marked	O
hemolysis	O
significantly	O
increased	O
plasma	O
values	O
of	O
potassium	O
,	O
phosphorus	O
,	O
total	O
protein	O
,	O
and	O
aspartate	B-GENE
aminotransferase	I-GENE
.	O

The	O
regurgitation	O
of	O
large	O
vitreous	O
injections	O
.	O

Assessment	O
of	O
the	O
carcinogenicity	O
of	O
non-nutritive	O
sweetners	O
II	O
:	O
Cyclamates	O
and	O
cyclohexylamine	O
.	O

Blood	O
from	O
dams	O
was	O
collected	O
prior	O
to	O
inoculation	O
and	O
at	O
time	O
of	O
necropsy	O
for	O
measurement	O
of	O
IgM	B-GENE
and	O
IgG	B-GENE
antibodies	I-GENE
to	O
M	O
.	O
pulmonis	O
.	O

We	O
conclude	O
that	O
CPET	O
is	O
a	O
useful	O
investigation	O
in	O
the	O
management	O
of	O
patients	O
with	O
cardiopulmonary	O
disease	O
and	O
complements	O
the	O
various	O
other	O
investigations	O
offered	O
by	O
a	O
pulmonary	O
function	O
laboratory	O
.	O

Effects	O
of	O
cisapride	O
on	O
upper-gastrointestinal	O
motility	O
and	O
digestive	O
hormones	O
.	O

The	O
cDNAs	O
cross-hybridize	O
with	O
genomic	O
sequences	O
in	O
rat	O
,	O
human	O
,	O
and	O
chicken	O
DNA	O
,	O
but	O
not	O
with	O
DNA	O
from	O
frog	O
,	O
Drosophila	O
,	O
or	O
sea	O
urchin	O
.	O

Trials	O
of	O
sevine	O
activity	O
against	O
mosquito	O
larvae	O
.	O

Immediately	O
before	O
surgery	O
patients	O
received	O
either	O
intravenous	O
hydrocortisone	O
100	O
mg	O
or	O
placebo	O
in	O
random	O
,	O
double-blind	O
order	O
.	O

In	O
HeLa	O
cells	O
,	O
the	O
JNKK2-JNK1	B-GENE
fusion	I-GENE
protein	I-GENE
showed	O
significant	O
JNK	B-GENE
activity	O
,	O
which	O
was	O
comparable	O
with	O
that	O
of	O
JNK1	B-GENE
activated	O
by	O
many	O
stimuli	O
and	O
activators	O
,	O
including	O
EGF	B-GENE
,	O
TNF-alpha	B-GENE
,	O
anisomycin	O
,	O
UV	O
irradiation	O
,	O
MEKK1	B-GENE
,	O
and	O
small	B-GENE
GTP	I-GENE
binding	I-GENE
proteins	I-GENE
Rac1	I-GENE
and	O
Cdc42Hs	B-GENE
.	O

In	O
some	O
early	O
B	O
cells	O
and	O
Abelson	O
murine	O
leukemia	O
virus-transformed	O
pre-B-cell	O
lines	O
,	O
LT	B-GENE
mRNA	I-GENE
is	O
constitutively	O
expressed	O
.	O

Substitution	O
of	O
bulky	O
hydrophobic	O
residues	O
with	O
charged	O
residues	O
within	O
PEP1	B-GENE
affects	O
the	O
fusion	O
activity	O
of	O
the	O
S	B-GENE
protein	I-GENE
without	O
affecting	O
processing	O
and	O
surface	O
expression	O
.	O

The	O
dying	O
tTG-transfected	O
cells	O
exhibit	O
both	O
cytoplasmic	O
and	O
nuclear	O
changes	O
characteristic	O
of	O
cells	O
undergoing	O
apoptosis	O
.	O

Roizman	O
,	O
J	O
.	O

In	O
this	O
study	O
,	O
a	O
common	O
mechanism	O
has	O
been	O
identified	O
to	O
coordinate	O
the	O
growth-	O
and	O
FC-dependent	O
expression	O
of	O
caveolin	B-GENE
.	O

There	O
are	O
four	O
polyglutamine	O
motifs	O
interspersed	O
with	O
histidine-rich	O
regions	O
.	O

SL1	B-GENE
trans-splicing	O
specified	O
by	O
AU-rich	O
synthetic	O
RNA	O
inserted	O
at	O
the	O
5'	O
end	O
of	O
Caenorhabditis	O
elegans	O
pre-mRNA	O
.	O

When	O
CSF	O
[	O
HCO3-	O
]	O
is	O
shown	O
as	O
a	O
function	O
of	O
CSF	O
PCO2	O
the	O
data	O
of	O
K-depleted	O
rats	O
are	O
no	O
longer	O
displaced	O
when	O
compared	O
to	O
controls	O
but	O
still	O
have	O
a	O
significantly	O
greater	O
slope	O
(	O
1	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
23	O
vs	O
.	O

The	O
patient	O
with	O
a	O
prolonged	O
fever	O
caused	O
by	O
dissecting	O
aneurysm	O
of	O
the	O
aorta	O
in	O
whom	O
pleuropneumonia	O
masked	O
the	O
real	O
diseases	O
has	O
been	O
presented	O
.	O

The	O
low	O
number	O
of	O
false	O
positives	O
indicates	O
that	O
our	O
scheme	O
would	O
not	O
confuse	O
the	O
radiologist	O
by	O
suggesting	O
normal	O
regions	O
as	O
suspicious	O
.	O

ENV	B-GENE
also	O
was	O
secreted	O
from	O
P	O
.	O
pastoris	O
using	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
alpha-factor	I-GENE
prepro	I-GENE
secretion	I-GENE
leader	I-GENE
and	O
the	O
S	B-GENE
.	I-GENE
cerevisiae	I-GENE
invertase	I-GENE
signal	I-GENE
sequence	I-GENE
.	O

Androgens	O
and	O
growth	O
.	O

Arterial	O
blood	O
gas	O
tensions	O
were	O
similar	O
across	O
all	O
ventilation	O
modes	O
.	O

Accordingly	O
,	O
no	O
Ha-ras	B-GENE
codon	I-GENE
12	I-GENE
mutations	O
are	O
found	O
in	O
the	O
EtNU-induced	O
mammary	O
tumors	O
.	O

The	O
sequence	O
and	O
isolated	O
cDNAs	O
will	O
provide	O
useful	O
reagents	O
for	O
studying	O
the	O
expression	O
of	O
Brca1	B-GENE
in	O
the	O
mouse	O
,	O
and	O
for	O
testing	O
the	O
importance	O
of	O
the	O
evolutionarily	O
conserved	O
domains	O
.	O

Functional	O
postnatal	O
development	O
of	O
the	O
rat	O
primary	O
visual	O
cortex	O
and	O
the	O
role	O
of	O
visual	O
experience	O
:	O
dark	O
rearing	O
and	O
monocular	O
deprivation	O
.	O

The	O
patients	O
in	O
one	O
group	O
had	O
intrauterine	O
catheters	O
inserted	O
and	O
oxytocin	O
was	O
titrated	O
to	O
achieve	O
the	O
75th	O
percentile	O
of	O
uterine	O
activity	O
observed	O
in	O
spontaneous	O
normal	O
labour	O
according	O
to	O
parity	O
.	O

A	O
mouse	B-GENE
brain	I-GENE
beta-spectrin	I-GENE
of	O
cDNA	O
was	O
identified	O
within	O
a	O
lambda	O
Gt11	O
expression	O
library	O
using	O
an	O
antibody	O
which	O
specifically	O
binds	O
with	O
the	O
235	B-GENE
kDa	I-GENE
spectrin	I-GENE
beta-subunit	I-GENE
.	O

Renal	O
and	O
extrarenal	O
arterial	O
fibromuscular	O
hyperplasia	O
with	O
hypertension	O
.	O

Antibodies	O
specific	O
to	O
rE12	B-GENE
and	O
rNFIL-6	B-GENE
disrupt	O
nucleoprotein	O
complexes	O
with	O
these	O
DNA-binding	O
sites	O
,	O
confirming	O
the	O
interaction	O
of	O
native	O
in	O
vivo	O
factors	O
.	O

The	O
other	O
transmembrane	O
regions	O
as	O
well	O
as	O
the	O
nucleoplasmic	O
domain	O
are	O
not	O
required	O
for	O
sorting	O
.	O

The	O
major	O
pathological	O
findings	O
of	O
the	O
placenta	O
were	O
prematuration	O
and	O
hypoplasia	O
.	O

Viral	O
genomic	O
RNA	O
for	O
these	O
reactions	O
was	O
obtained	O
directly	O
from	O
fecal	O
specimens	O
of	O
infected	O
infant	O
rats	O
.	O

In	O
two	O
experiments	O
,	O
neonatal	O
female	O
BALB	O
/	O
cCrgl	O
or	O
BALB	O
/	O
cfC3HCrgl	O
mice	O
were	O
given	O
subcutaneous	O
injections	O
of	O
5	O
micrograms	O
17	O
beta-estradiol	O
or	O
sesame	O
oil	O
for	O
the	O
first	O
3	O
days	O
of	O
life	O
and	O
were	O
ovariectomized	O
at	O
60	O
days	O
of	O
age	O
,	O
at	O
which	O
time	O
vaginal	O
concretions	O
(	O
Experiments	O
I	O
and	O
II	O
)	O
or	O
silica	O
(	O
Experiment	O
II	O
)	O
were	O
implanted	O
intravaginally	O
.	O

Evaluation	O
of	O
human	O
and	O
bovine	O
modified-hemoglobin	O
solution	O
as	O
oxygen-carrying	O
fluid	O
for	O
blood	O
volume	O
replacement	O
.	O

Human	B-GENE
thyroid	I-GENE
stimulator	I-GENE
(	O
HTS	B-GENE
)	O
in	O
thyroid	O
diseases	O
.	O

Substituting	O
a	O
Ser	O
for	O
Gly69	O
or	O
a	O
Glu	O
for	O
Lys	O
71	O
in	O
the	O
conserved	O
TGEK	B-GENE
tetrapeptide	I-GENE
in	O
finger	O
II	O
of	O
TFIIIA	B-GENE
resulted	O
in	O
the	O
loss	O
of	O
DNA	O
binding	O
.	O

Plasma	O
thrombomodulin	B-GENE
:	O
a	O
marker	O
for	O
microvascular	O
complications	O
in	O
diabetes	O
mellitus	O
.	O

Thus	O
,	O
the	O
L45	B-GENE
sequence	I-GENE
between	O
kinase	B-GENE
subdomains	I-GENE
IV	I-GENE
and	I-GENE
V	I-GENE
specifies	O
TGF-beta	B-GENE
responsiveness	O
of	O
the	O
type	B-GENE
I	I-GENE
receptor	I-GENE
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
a	O
region	O
encoding	O
a	O
lipase	B-GENE
operon	I-GENE
and	O
a	O
putative	O
,	O
previously	O
uncharacterized	O
metalloprotease	B-GENE
of	I-GENE
Vibrio	I-GENE
cholerae	I-GENE
O1	I-GENE
.	O

Epitopes	O
of	O
adhesion-perturbing	O
monoclonal	O
antibodies	O
map	O
within	O
a	O
predicted	O
alpha-helical	O
domain	O
of	O
the	O
integrin	B-GENE
beta	I-GENE
1	I-GENE
subunit	I-GENE
.	O

In	O
addition	O
,	O
the	O
transcription	O
of	O
c-IAP2	B-GENE
promoter	I-GENE
was	O
strongly	O
up-regulated	O
when	O
CD40	B-GENE
or	O
Epstein-Barr	B-GENE
virus	I-GENE
latent	I-GENE
membrane	I-GENE
protein	I-GENE
1	I-GENE
was	O
overexpressed	O
.	O

A	O
local	O
,	O
high-density	O
,	O
single-nucleotide	O
polymorphism	O
map	O
used	O
to	O
clone	O
Caenorhabditis	B-GENE
elegans	I-GENE
cdf-1	I-GENE
.	O

Tiaprofenic	O
acid	O
overdose	O
.	O

PURPOSE	O
:	O
Previous	O
WR-2721	O
human	O
pharmacokinetic	O
studies	O
were	O
limited	O
to	O
plasma	O
levels	O
in	O
patients	O
receiving	O
platinum-based	O
compounds	O
,	O
and	O
none	O
includes	O
the	O
effects	O
of	O
WR-2721	O
on	O
endogenous	O
thiols	O
.	O

Fentanyl	O
,	O
a	O
prototypic	O
mu-opiate	B-GENE
receptor	I-GENE
agonist	O
,	O
has	O
been	O
previously	O
shown	O
to	O
produce	O
a	O
syndrome	O
characterized	O
by	O
marked	O
analgesia	O
and	O
locomotor	O
stimulation	O
as	O
well	O
as	O
tachycardia	O
,	O
tachypnoea	O
and	O
behavioural	O
arousal	O
.	O

CONCLUSIONS	O
:	O
In	O
our	O
patients	O
and	O
within	O
the	O
range	O
of	O
treatment	O
variables	O
studied	O
,	O
age	O
,	O
Karnofsky	O
index	O
,	O
and	O
graft-versus-host	O
disease	O
are	O
the	O
most	O
important	O
factors	O
related	O
with	O
early	O
mortality	O
.	O

Once	O
P-450scc	B-GENE
mRNA	I-GENE
is	O
induced	O
as	O
a	O
consequence	O
of	O
the	O
LH	B-GENE
/	I-GENE
hCG	I-GENE
surge	O
it	O
is	O
constitutively	O
maintained	O
by	O
luteinized	O
cells	O
in	O
vivo	O
(	O
0-4	O
days	O
)	O
and	O
in	O
vitro	O
(	O
0-9	O
days	O
)	O
in	O
the	O
absence	O
of	O
gonadotropins	B-GENE
,	O
is	O
susceptible	O
to	O
modulation	O
by	O
prolactin	B-GENE
and	O
is	O
no	O
longer	O
regulated	O
by	O
cAMP	O
.	O

Effects	O
of	O
3'	O
terminus	O
modifications	O
on	O
mRNA	O
functional	O
decay	O
during	O
in	O
vitro	O
protein	O
synthesis	O
.	O

A	O
positive	O
correlation	O
between	O
serum	B-GENE
myoglobin	I-GENE
and	O
CA	B-GENE
III	I-GENE
concentrations	O
(	O
rs	O
=	O
0	O
.	O
933	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
was	O
observed	O
in	O
hemodialyzed	O
patients	O
with	O
chronic	O
renal	O
failure	O
.	O

The	O
maximum	O
period	O
of	O
treatment	O
was	O
73	O
(	O
oral	O
)	O
,	O
73	O
(	O
intraperitoneal	O
)	O
or	O
75	O
(	O
dermal	O
)	O
weeks	O
.	O

Sequence	O
analysis	O
of	O
the	O
47-kilodalton	B-GENE
major	I-GENE
integral	I-GENE
membrane	I-GENE
immunogen	I-GENE
of	I-GENE
Treponema	I-GENE
pallidum	I-GENE
.	O

By	O
using	O
total-protein	O
extracts	O
from	O
mycelia	O
grown	O
under	O
penicillin	O
producing	O
conditions	O
we	O
have	O
detected	O
a	O
DNA-binding	O
activity	O
that	O
specifically	O
shifts	O
a	O
promoter	O
fragment	O
located	O
between	O
-654	O
and	O
-455	O
(	O
relative	O
to	O
IPNS	B-GENE
tsp	I-GENE
)	O
.	O

The	O
RF	O
values	O
correlated	O
well	O
with	O
the	O
angiographic	O
semiquantitative	O
scale	O
of	O
severity	O
of	O
aortal	O
insufficiency	O
(	O
r	O
=	O
0	O
.	O
805	O
;	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
although	O
they	O
enabled	O
the	O
authors	O
only	O
to	O
make	O
a	O
partial	O
differentiation	O
of	O
haemodynamically	O
severe	O
regurgitations	O
and	O
mild	O
or	O
insignificant	O
ones	O
.	O

Effect	O
of	O
alcohol	O
on	O
minimal	O
effective	O
nCPAP	O
pressure	O
.	O

Hb	B-GENE
levels	O
remained	O
adequate	O
(	O
Hb	B-GENE
=	O
10	O
.	O
68	O
+	O
/	O
-	O
0	O
.	O
77	O
g	O
/	O
dl	O
)	O
after	O
14	O
.	O
6	O
+	O
/	O
-	O
7	O
.	O
64	O
months	O
.	O

Their	O
numbers	O
have	O
regularly	O
increased	O
since	O
the	O
mid-1970s	O
.	O

An	O
unusual	O
cysteine	O
triplet	O
conserved	O
in	O
the	O
sequences	O
of	O
TB	B-GENE
domains	I-GENE
is	O
localized	O
to	O
the	O
hydrophobic	O
core	O
,	O
at	O
the	O
C-terminus	O
of	O
an	O
alpha-helix	O
.	O

BIM	O
130	O
.	O

The	O
results	O
corroborate	O
the	O
idea	O
that	O
the	O
structure	O
of	O
relaxation	O
curves	O
contains	O
information	O
on	O
the	O
distance	O
scale	O
and	O
on	O
the	O
architecture	O
of	O
the	O
pore	O
space	O
,	O
even	O
if	O
it	O
is	O
difficult	O
to	O
extract	O
it	O
without	O
ambiguities	O
.	O

Prostate	B-GENE
specific	I-GENE
antigen	I-GENE
shows	O
the	O
metastatic	O
cases	O
better	O
[	O
correction	O
of	O
worse	O
]	O
than	O
prostatic	B-GENE
acid	I-GENE
phosphatase	I-GENE
.	O

An	O
industry-wide	O
retrospective	O
cohort	O
mortality	O
study	O
was	O
conducted	O
on	O
6	O
,	O
152	O
chemical	O
workers	O
(	O
2	O
,	O
460	O
exposed	O
and	O
3	O
,	O
692	O
nonexposed	O
)	O
engaged	O
in	O
chloromethyl	O
ether	O
manufacture	O
at	O
7	O
major	O
U	O
.	O
S	O
.	O
companies	O
between	O
1948	O
and	O
1980	O
.	O

The	O
cwg2-1	B-GENE
mutation	I-GENE
was	O
identified	O
as	O
a	O
guanine	O
to	O
adenine	O
substitution	O
at	O
nucleotide	O
604	O
of	O
the	O
coding	O
region	O
,	O
originating	O
the	O
change	O
A202T	O
in	O
the	O
cwg2p	B-GENE
.	O

Closure	O
of	O
an	O
open	O
high	O
below-knee	O
guillotine	O
amputation	O
wound	O
using	O
a	O
skin-stretching	O
device	O
.	O

